{"idx": 0, "sentence": "糖尿病足部溃烂、肿胀，脓性分泌物较多，医嘱：建议做血管的CTA检查（CT血管造影），如果血管特别不好，那截肢的可能性会更高。", "ner": [[25, 27, "Anatomy"], [44, 46, "Anatomy"], [52, 54, "Operation"], [0, 3, "Disease"], [3, 7, "Symptom"], [8, 10, "Symptom"], [11, 18, "Symptom"], [28, 41, "Test"]], "rel": []}
{"idx": 1, "sentence": "患者七十七岁且患有心脏病，糖尿病13年并发糖尿病足，左脚肢端变黑已经全部截掉，16年五月发现右脚的两个脚趾变黑，现在在医院就诊，因脚部供血不达标不能手术。医嘱：考虑糖尿病下肢血管病变，先要做个血管造影，必要时开通闭塞血管。 ", "ner": [[9, 12, "Disease"], [13, 16, "Disease"], [21, 25, "Disease"], [36, 38, "Operation"], [96, 100, "Test"], [28, 32, "Symptom"], [51, 55, "Symptom"], [26, 28, "Anatomy"], [46, 48, "Anatomy"], [16, 19, "Duration"], [65, 67, "Anatomy"], [108, 110, "Anatomy"], [82, 91, "Disease"]], "rel": [[21, 25, "Disease", 13, 16, "Disease", "Disease_Disease"], [96, 100, "Test", 21, 25, "Disease", "Test_Disease"], [36, 38, "Operation", 21, 25, "Disease", "Operation_Disease"], [51, 55, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [26, 28, "Anatomy", 21, 25, "Disease", "Anatomy_Disease"], [46, 48, "Anatomy", 21, 25, "Disease", "Anatomy_Disease"], [65, 67, "Anatomy", 21, 25, "Disease", "Anatomy_Disease"], [82, 91, "Disease", 13, 16, "Disease", "Disease_Disease"]]}
{"idx": 2, "sentence": "糖尿病30年，最近将近两个月有一个脚趾溃烂，外用药治疗，也没见好转还继续加重，目前四个脚趾逢都有溃烂，去当地医院也没有好的办法，做了腿的B超，说动脉血管堵塞，患者感觉脚麻木特别难受，每天夜晚不能入睡，血液检查总胆固醇和甘油三酯都高，右足背动脉栓塞，医嘱：复查一下下肢动脉CTA检查（CT血管造影），动脉堵塞，建议截肢手术。", "ner": [[0, 3, "Disease"], [17, 21, "Symptom"], [66, 67, "Anatomy"], [68, 70, "Test"], [83, 86, "Symptom"], [100, 104, "Test"], [104, 108, "Test_items"], [109, 113, "Test_items"], [156, 160, "Operation"], [9, 14, "Duration"], [114, 115, "Test_Value"], [72, 78, "Disease"], [149, 153, "Disease"], [48, 50, "Symptom"], [41, 46, "Anatomy"], [3, 6, "Duration"], [116, 123, "Disease"], [131, 148, "Test"]], "rel": [[104, 108, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [109, 113, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [100, 104, "Test", 0, 3, "Disease", "Test_Disease"], [83, 86, "Symptom", 72, 78, "Disease", "Symptom_Disease"], [156, 160, "Operation", 72, 78, "Disease", "Operation_Disease"], [72, 78, "Disease", 0, 3, "Disease", "Disease_Disease"], [68, 70, "Test", 72, 78, "Disease", "Test_Disease"], [17, 21, "Symptom", 72, 78, "Disease", "Symptom_Disease"], [131, 148, "Test", 72, 78, "Disease", "Test_Disease"], [48, 50, "Symptom", 72, 78, "Disease", "Symptom_Disease"], [48, 50, "Symptom", 149, 153, "Disease", "Symptom_Disease"], [83, 86, "Symptom", 149, 153, "Disease", "Symptom_Disease"], [17, 21, "Symptom", 149, 153, "Disease", "Symptom_Disease"], [68, 70, "Test", 149, 153, "Disease", "Test_Disease"], [131, 148, "Test", 149, 153, "Disease", "Test_Disease"]]}
{"idx": 3, "sentence": "患者男，66岁，2012年1月发病，右脚趾溃烂，确诊为双下肢血管闭塞，做了右下肢血管支架手术。过去半年了，但是脚趾溃烂处伤口愈合较差。医嘱：做截趾清创术让既有的足部感染不再继续加重。", "ner": [[49, 51, "Duration"], [71, 76, "Operation"], [80, 84, "Symptom"], [55, 66, "Symptom"], [37, 46, "Operation"], [27, 34, "Disease"], [18, 23, "Symptom"]], "rel": [[55, 66, "Symptom", 27, 34, "Disease", "Symptom_Disease"], [80, 84, "Symptom", 27, 34, "Disease", "Symptom_Disease"], [37, 46, "Operation", 27, 34, "Disease", "Operation_Disease"], [71, 76, "Operation", 27, 34, "Disease", "Operation_Disease"], [18, 23, "Symptom", 27, 34, "Disease", "Symptom_Disease"]]}
{"idx": 4, "sentence": "父亲今年83岁，已经有30年的糖尿病史了。三个月前在医院做了左大脚趾截肢手术，足部感染，拍片说血液只循环到大腿根部。医嘱：B超提示下肢动脉血管硬化，保后半只脚的话需要反复清创。", "ner": [[61, 63, "Test"], [85, 87, "Operation"], [47, 57, "Test_Value"], [34, 38, "Operation"], [30, 34, "Anatomy"], [39, 43, "Symptom"], [11, 14, "Duration"], [65, 73, "Disease"], [78, 79, "Anatomy"]], "rel": [[39, 43, "Symptom", 65, 73, "Disease", "Symptom_Disease"], [61, 63, "Test", 65, 73, "Disease", "Test_Disease"], [34, 38, "Operation", 65, 73, "Disease", "Operation_Disease"], [85, 87, "Operation", 65, 73, "Disease", "Operation_Disease"]]}
{"idx": 5, "sentence": "糖尿病并发糖尿病足，足部溃疡面很大很深，右脚第四趾有个洞直通脚面上的溃疡洞，溃疡面积大概5cm*5cm，现在，脚面上溃疡的洞已经长出肉芽，但是血糖升高，而且右脚大拇趾出现红肿，脚趾皮肤变成紫红色。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [15, 19, "Level"], [42, 51, "Level"], [71, 73, "Test_items"], [73, 75, "Test_Value"], [10, 12, "Anatomy"], [25, 37, "Symptom"], [12, 15, "Symptom"], [58, 68, "Symptom"], [83, 87, "Symptom"], [38, 42, "Symptom"], [92, 97, "Symptom"], [20, 25, "Anatomy"], [55, 58, "Anatomy"], [78, 83, "Anatomy"], [88, 92, "Anatomy"]], "rel": [[71, 73, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [10, 12, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [12, 15, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [38, 42, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [25, 37, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [83, 87, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [92, 97, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [58, 68, "Symptom", 5, 9, "Disease", "Symptom_Disease"]]}
{"idx": 6, "sentence": "患者今年3月份开始足部溃烂，刺痛，逐渐加重，旁边脚趾溃烂，肿胀肢端变黑。自行测空腹血糖，半个月前8.4，服药二甲双胍0.75g，一个星期前9.4，用药0.75g，昨天05/09血糖10.6，二甲双胍1.5g。右侧肢体脑血栓后遗症多年，近一年活动不便，长期卧床。医嘱：有下肢缺血，做个双下肢动脉CTA检查（CT血管造影），看看能不能做手术。目前找用上阿司匹林，西洛他唑。", "ner": [[108, 114, "Disease"], [9, 13, "Symptom"], [14, 16, "Symptom"], [24, 28, "Symptom"], [120, 124, "Symptom"], [69, 72, "Test_Value"], [90, 94, "Test_Value"], [48, 51, "Test_Value"], [54, 58, "Drug"], [174, 178, "Drug"], [179, 183, "Drug"], [58, 63, "Amount"], [75, 80, "Amount"], [104, 108, "Anatomy"], [114, 116, "Duration"], [41, 43, "Test_items"], [95, 99, "Drug"], [99, 103, "Amount"], [125, 129, "Symptom"], [88, 90, "Test_items"], [29, 31, "Symptom"], [31, 35, "Symptom"], [141, 159, "Test"], [134, 138, "Symptom"]], "rel": [[58, 63, "Amount", 54, 58, "Drug", "Amount_Drug"], [104, 108, "Anatomy", 108, 114, "Disease", "Anatomy_Disease"]]}
{"idx": 7, "sentence": "糖尿病足4期或5期，病人想保守治疗，鞋不合脚，把脚指头磨坏了然后外皮长好了，里面的脓性分泌物较多，到医院后外科介入，放掉了浓血，现在每天在清创。医嘱：肢端变黑，坏死组织增多，慢性水肿，足部溃烂，应该进行截肢手术。", "ner": [[41, 48, "Symptom"], [75, 79, "Symptom"], [80, 86, "Symptom"], [87, 91, "Symptom"], [92, 96, "Symptom"], [101, 105, "Operation"], [24, 27, "Anatomy"], [21, 22, "Anatomy"], [66, 68, "Frequency"], [0, 4, "Disease"], [69, 71, "Operation"]], "rel": [[101, 105, "Operation", 0, 4, "Disease", "Operation_Disease"], [69, 71, "Operation", 0, 4, "Disease", "Operation_Disease"], [41, 48, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [75, 79, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [80, 86, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [92, 96, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [21, 22, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [24, 27, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 8, "sentence": "患者71岁，有10年以上糖尿病史并发糖尿病足，之前口服二甲双胍和格列齐特，14年12月开始胰岛素，血糖控制较好，但由患者自行减少剂量，血糖一度失控，15年5月~9月空腹血糖平均10以上，高时超过20，15年9月摔伤脑部少量出血抽搐水肿在当地三甲医院住院，期间内分泌科会诊调胰岛素剂量和用药，血糖指标控制，近4个月均在4~9范围。但于15年11月发现糖尿病足病情，右脚跟出现一个5cm直径黑点淤血，足部溃烂，间歇性跛行，医院对淤血部位进行剪除死皮坏肉处理，并进行消炎，辅以医院自制皮肤促皮肤愈合生长药膏包扎治疗，截止目前，该患处平均4天在该医院进行一次换药包扎，病变处得到控制，但未见明显好转，中心部呈现0.8cm直径创面，伤口愈合较差。16年3月，患者右脚中指出现约0.3cm淤血黑点，同样包扎处理，未见控制，目前右脚中指指甲溃烂脱落。医嘱：目前看创面感染，在内科情况控制好的情况下，针对这种伤口，通常采用红紗条换药处理，用时大概1个月左右。", "ner": [[12, 15, "Disease"], [18, 22, "Disease"], [7, 12, "Duration"], [27, 31, "Drug"], [32, 36, "Drug"], [45, 48, "Drug"], [49, 51, "Test_items"], [67, 69, "Test_items"], [82, 86, "Test_items"], [86, 92, "Test_Value"], [95, 99, "Test_Value"], [136, 139, "Drug"], [145, 147, "Test_items"], [158, 163, "Test_Value"], [174, 178, "Disease"], [198, 202, "Symptom"], [203, 208, "Symptom"], [235, 250, "Drug"], [218, 226, "Treatment"], [181, 184, "Anatomy"], [326, 330, "Anatomy"], [107, 109, "Anatomy"], [374, 378, "Symptom"], [413, 420, "Duration"], [230, 232, "Method"], [277, 279, "Method"], [193, 197, "Symptom"], [188, 193, "Level"], [109, 113, "Symptom"], [113, 117, "Symptom"], [361, 367, "Symptom"], [338, 342, "Symptom"], [332, 338, "Level"], [301, 308, "Level"], [403, 406, "Method"], [357, 361, "Anatomy"], [263, 267, "Frequency"], [311, 317, "Symptom"]], "rel": [[27, 31, "Drug", 12, 15, "Disease", "Drug_Disease"], [32, 36, "Drug", 12, 15, "Disease", "Drug_Disease"], [45, 48, "Drug", 12, 15, "Disease", "Drug_Disease"], [235, 250, "Drug", 18, 22, "Disease", "Drug_Disease"], [193, 197, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [198, 202, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [338, 342, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [203, 208, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [361, 367, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [374, 378, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [18, 22, "Disease", 12, 15, "Disease", "Disease_Disease"], [181, 184, "Anatomy", 174, 178, "Disease", "Anatomy_Disease"], [326, 330, "Anatomy", 174, 178, "Disease", "Anatomy_Disease"], [413, 420, "Duration", 403, 406, "Method", "Duration_Drug"], [49, 51, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [263, 267, "Duration", 277, 279, "Method", "Frequency_Drug"], [218, 226, "Treatment", 174, 178, "Disease", "Treatment_Disease"], [311, 317, "Symptom", 18, 22, "Disease", "Symptom_Disease"]]}
{"idx": 9, "sentence": "糖尿病10年病龄，一直药物控制，1月23日因高烧40度住院，发现肺部轻微感染，诊断为肺炎并治疗，当时检测血糖数值达到二十多，用胰岛素三天未下降，三天后血糖开始下降，开始出现糖尿病足并发症，肢端皮肤变成紫红色，1月28日医院因疫情严重被要求出院，回家继续输液治疗，每日输头孢他啶，近两天血糖有所控制，已控制到正常范围内，脚部未进一步病变，从前天开始有刺痛感觉，在病变之前肢端变黑，指甲变厚，先足部皮肤变红，目前在家输液头孢他啶，脚指甲上有水疱。注射用头孢他啶1.0g一天三支共3克氯化钠静脉输入。医嘱：加用前列地尔，甲钴胺，改善循环的中药（丹参），还要根据分泌物培养结果输消炎药，另外局部换药。", "ner": [[0, 3, "Disease"], [42, 44, "Disease"], [86, 90, "Disease"], [22, 27, "Symptom"], [94, 103, "Symptom"], [174, 178, "Symptom"], [184, 188, "Symptom"], [189, 193, "Symptom"], [194, 201, "Symptom"], [213, 220, "Symptom"], [52, 54, "Test_items"], [58, 61, "Test_Value"], [63, 66, "Drug"], [69, 71, "Test_Value"], [75, 77, "Test_items"], [79, 81, "Test_Value"], [134, 138, "Drug"], [142, 144, "Test_items"], [153, 157, "Test_Value"], [159, 161, "Anatomy"], [126, 128, "Method"], [206, 208, "Method"], [208, 212, "Drug"], [221, 223, "Method"], [224, 228, "Drug"], [228, 232, "Amount"], [232, 236, "Frequency"], [239, 242, "Drug"], [242, 246, "Method"], [257, 260, "Drug"], [252, 256, "Drug"], [269, 271, "Drug"], [32, 38, "Symptom"], [3, 8, "Duration"], [131, 133, "Frequency"]], "rel": [[22, 27, "Symptom", 42, 44, "Disease", "Symptom_Disease"], [32, 38, "Symptom", 42, 44, "Disease", "Symptom_Disease"], [94, 103, "Symptom", 86, 90, "Disease", "Symptom_Disease"], [174, 178, "Symptom", 86, 90, "Disease", "Symptom_Disease"], [184, 188, "Symptom", 86, 90, "Disease", "Symptom_Disease"], [189, 193, "Symptom", 86, 90, "Disease", "Symptom_Disease"], [194, 201, "Symptom", 86, 90, "Disease", "Symptom_Disease"], [213, 220, "Symptom", 86, 90, "Disease", "Symptom_Disease"], [52, 54, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [63, 66, "Drug", 0, 3, "Disease", "Drug_Disease"], [134, 138, "Drug", 42, 44, "Disease", "Drug_Disease"], [232, 236, "Frequency", 224, 228, "Drug", "Frequency_Drug"], [228, 232, "Amount", 224, 228, "Drug", "Amount_Drug"], [159, 161, "Anatomy", 86, 90, "Disease", "Anatomy_Disease"], [242, 246, "Method", 239, 242, "Drug", "Method_Drug"], [206, 208, "Method", 208, 212, "Drug", "Method_Drug"], [221, 223, "Method", 224, 228, "Drug", "Method_Drug"], [131, 133, "Frequency", 134, 138, "Drug", "Frequency_Drug"], [252, 256, "Drug", 86, 90, "Disease", "Drug_Disease"], [257, 260, "Drug", 86, 90, "Disease", "Drug_Disease"], [269, 271, "Drug", 86, 90, "Disease", "Drug_Disease"]]}
{"idx": 10, "sentence": "糖尿病足，足部溃烂，医嘱：下肢血管彩超检查一下，目前创面用药可以，检查与创面治疗同步，抬高患肢，爱可欣银愈生物凝胶敷料，降糖药外敷。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [48, 59, "Drug"], [63, 65, "Method"], [43, 47, "Treatment"], [13, 19, "Test"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [63, 65, "Method", 48, 59, "Drug", "Method_Drug"], [13, 19, "Test", 0, 4, "Disease", "Test_Disease"]]}
{"idx": 11, "sentence": "20年前查出糖尿病，血糖波动动10上下，3年前发现双足趾肢端变黑、肿胀，半年前发生脑血栓，经对症治疗好转，检查超声示左侧胫后右侧胫前动脉狭窄严重曾用诺和龙和格华止等，足部刺痛，间歇性跛行。", "ner": [[6, 9, "Disease"], [10, 12, "Test_items"], [15, 19, "Test_Value"], [41, 44, "Disease"], [74, 77, "Drug"], [78, 81, "Drug"], [83, 87, "Symptom"], [88, 93, "Symptom"], [55, 57, "Test"], [0, 4, "Duration"], [20, 23, "Duration"], [36, 39, "Duration"], [66, 70, "Disease"], [28, 32, "Symptom"], [33, 35, "Symptom"], [25, 28, "Anatomy"], [58, 62, "Anatomy"], [62, 66, "Anatomy"]], "rel": [[74, 77, "Drug", 6, 9, "Disease", "Drug_Disease"], [78, 81, "Drug", 6, 9, "Disease", "Drug_Disease"], [66, 70, "Disease", 6, 9, "Disease", "Disease_Disease"], [83, 87, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [88, 93, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [62, 66, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"], [58, 62, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"], [55, 57, "Test", 66, 70, "Disease", "Test_Disease"], [33, 35, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 66, 70, "Disease", "Symptom_Disease"]]}
{"idx": 12, "sentence": "患有糖尿病20多年，糖尿病足有11年，第一次是在医院治疗，后续糖尿病足有炎症时在家通过服用消炎药消炎。这次发病足部刺痛有一个多月，肿胀有四天。空腹血糖13多。用药：二甲双胍每天一颗，胰岛素诺和灵R，早上32个单位，晚上15个单位", "ner": [[2, 5, "Disease"], [10, 14, "Disease"], [31, 35, "Disease"], [43, 45, "Method"], [55, 59, "Symptom"], [65, 67, "Symptom"], [60, 64, "Duration"], [68, 70, "Duration"], [75, 77, "Test_Value"], [82, 86, "Drug"], [91, 98, "Drug"], [99, 106, "Amount"], [107, 114, "Amount"], [15, 18, "Duration"], [5, 9, "Duration"], [36, 38, "Symptom"], [86, 88, "Frequency"], [88, 90, "Amount"], [71, 75, "Test_items"]], "rel": [[10, 14, "Disease", 2, 5, "Disease", "Disease_Disease"], [55, 59, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [65, 67, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [73, 75, "Test_items", 2, 5, "Disease", "Test_items_Disease"], [107, 114, "Amount", 91, 98, "Drug", "Amount_Drug"], [99, 106, "Amount", 91, 98, "Drug", "Amount_Drug"], [36, 38, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [86, 88, "Frequency", 82, 86, "Drug", "Frequency_Drug"], [88, 90, "Amount", 82, 86, "Drug", "Amount_Drug"]]}
{"idx": 13, "sentence": "患糖尿病已经24年并发糖尿病足，2008年我母亲右脚大脚趾变黑，截肢后其它两个脚趾变黑，右腿膝盖下面放了支架，腿部血管暂时改善，去年开始右脚出现窦道，足部溃烂，现在窦道肢端变黑，还伴有灼痛，疼得动弹不了，而且患者开始发烧。医嘱：目前看来是支架或支架下方腿部血管又堵塞了，造成了足趾坏死和足部溃烂。目前应打通血管，有血液供应后，再对溃烂伤口进行处理。", "ner": [[1, 4, "Disease"], [11, 15, "Disease"], [27, 31, "Symptom"], [32, 34, "Operation"], [39, 43, "Symptom"], [72, 74, "Symptom"], [75, 79, "Symptom"], [82, 88, "Symptom"], [92, 94, "Symptom"], [108, 110, "Symptom"], [138, 142, "Symptom"], [143, 147, "Symptom"], [165, 167, "Symptom"], [24, 26, "Anatomy"], [44, 48, "Anatomy"], [55, 59, "Anatomy"], [68, 70, "Anatomy"], [6, 9, "Duration"], [126, 130, "Anatomy"], [153, 155, "Anatomy"], [131, 133, "Symptom"]], "rel": [[32, 34, "Operation", 11, 15, "Disease", "Operation_Disease"], [27, 31, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [72, 74, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [75, 79, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [82, 88, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [92, 94, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [108, 110, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [11, 15, "Disease", 1, 4, "Disease", "Disease_Disease"], [24, 26, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"], [138, 142, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [143, 147, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [165, 167, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [131, 133, "Symptom", 11, 15, "Disease", "Symptom_Disease"]]}
{"idx": 14, "sentence": "糖尿病并发糖尿病足，足部溃烂严重。目前生命体征是平稳的，希望保住患足。医嘱：加强换药，促进血液循环，促进愈合。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [10, 14, "Symptom"], [33, 34, "Anatomy"], [14, 16, "Level"]], "rel": [[5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [10, 14, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [33, 34, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 15, "sentence": "糖尿病10年现并发糖尿病足，目前足部溃疡和腿部溃烂越来越严重。医嘱：处置建议：建议：1.查一次甲状腺功能和甲状腺抗体。2.小腿部位的病变很像皮肤病，请皮肤科看一下。3.胰岛素继续用。", "ner": [[0, 3, "Disease"], [3, 6, "Duration"], [9, 13, "Disease"], [16, 20, "Symptom"], [21, 25, "Symptom"], [28, 30, "Level"], [47, 52, "Test"], [53, 58, "Test_items"], [61, 65, "Anatomy"], [70, 73, "Disease"], [84, 87, "Drug"]], "rel": [[9, 13, "Disease", 0, 3, "Disease", "Disease_Disease"], [16, 20, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [84, 87, "Drug", 0, 3, "Disease", "Drug_Disease"], [47, 52, "Test", 0, 3, "Disease", "Test_Disease"], [53, 58, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [61, 65, "Anatomy", 70, 73, "Disease", "Anatomy_Disease"]]}
{"idx": 16, "sentence": "糖尿病足坏疽，处置建议：控制血糖，抗感染，住院手术治疗。", "ner": [[0, 4, "Disease"], [4, 6, "Symptom"], [18, 20, "Symptom"], [14, 16, "Test_items"]], "rel": [[4, 6, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 17, "sentence": "糖尿病足，足部溃烂，医嘱：控制血糖，抗足部感染，做下肢血管B超检查，看看血管情况。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [19, 23, "Symptom"], [36, 38, "Anatomy"], [15, 17, "Test_items"], [25, 31, "Test"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [19, 23, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [36, 38, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [25, 31, "Test", 0, 4, "Disease", "Test_Disease"]]}
{"idx": 18, "sentence": "糖尿病并发糖尿病足，截肢脚指头一个，因脚指毛细血管堵塞伤口愈合较差。医嘱：建议局部应用VSD敷料，一边冲洗一边吸引，控制血糖，抗凝降脂治疗，阿司匹林肠溶片，瑞舒伐他汀钙。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [10, 12, "Operation"], [12, 15, "Anatomy"], [19, 21, "Anatomy"], [70, 77, "Drug"], [78, 84, "Drug"], [27, 33, "Symptom"], [43, 48, "Treatment"], [21, 27, "Disease"], [60, 62, "Test_items"]], "rel": [[5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [10, 12, "Operation", 5, 9, "Disease", "Operation_Disease"], [27, 33, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [70, 77, "Drug", 5, 9, "Disease", "Drug_Disease"], [43, 48, "Treatment", 5, 9, "Disease", "Treatment_Disease"], [12, 15, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [21, 27, "Disease", 5, 9, "Disease", "Disease_Disease"], [27, 33, "Symptom", 21, 27, "Disease", "Symptom_Disease"], [19, 21, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [10, 12, "Operation", 21, 27, "Disease", "Operation_Disease"], [43, 48, "Treatment", 21, 27, "Disease", "Treatment_Disease"], [70, 77, "Drug", 21, 27, "Disease", "Drug_Disease"], [78, 84, "Drug", 5, 9, "Disease", "Drug_Disease"], [78, 84, "Drug", 21, 27, "Disease", "Drug_Disease"]]}
{"idx": 19, "sentence": "糖尿病足，看着挺严重的，脚拇趾坏死，脚肿胀，肢端皮肤变成紫红色。医嘱：考虑缺血性坏疽，建议积极完善双下肢血管造影检查，如果血管闭塞的建议首先积极开通血管阻塞。", "ner": [[0, 4, "Disease"], [8, 10, "Level"], [12, 17, "Symptom"], [18, 21, "Symptom"], [22, 31, "Symptom"], [37, 42, "Symptom"], [61, 65, "Disease"], [49, 58, "Test"], [74, 78, "Symptom"]], "rel": [[12, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 21, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [22, 31, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [37, 42, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [61, 65, "Disease", 0, 4, "Disease", "Disease_Disease"], [49, 58, "Test", 61, 65, "Disease", "Test_Disease"], [74, 78, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [74, 78, "Symptom", 61, 65, "Disease", "Symptom_Disease"]]}
{"idx": 20, "sentence": "足部刺痛，脚趾肿胀，肢端变黑，用药：木丹颗粒，甲钴胺片。医嘱：考虑糖尿病足，下肢动脉硬化闭塞。可采用介入微创手术开通血管，保肢或减少截肢平面。", "ner": [[0, 4, "Symptom"], [5, 9, "Symptom"], [10, 14, "Symptom"], [18, 22, "Drug"], [23, 27, "Drug"], [33, 37, "Disease"], [50, 56, "Operation"], [58, 60, "Anatomy"], [38, 46, "Disease"]], "rel": [[0, 4, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [5, 9, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [18, 22, "Drug", 33, 37, "Disease", "Drug_Disease"], [23, 27, "Drug", 33, 37, "Disease", "Drug_Disease"], [58, 60, "Anatomy", 38, 46, "Disease", "Anatomy_Disease"], [38, 46, "Disease", 33, 37, "Disease", "Disease_Disease"], [50, 56, "Operation", 38, 46, "Disease", "Operation_Disease"], [5, 9, "Symptom", 38, 46, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 38, 46, "Disease", "Symptom_Disease"], [18, 22, "Drug", 38, 46, "Disease", "Drug_Disease"], [23, 27, "Drug", 38, 46, "Disease", "Drug_Disease"], [50, 56, "Operation", 33, 37, "Disease", "Operation_Disease"]]}
{"idx": 21, "sentence": "目前患者肾功能衰竭、尿毒症，透析四年，糖尿病足，左脚溃烂肢端变黑，足部刺痛，右脚也向溃烂发展。医嘱：如果血管闭塞严重，身体状况允许可以再做动脉介入治疗开通，如果通了保肢希望大大增加，如不行，可以加强口服药物，加用中药口服改善侧肢循环，局部换药暂时以干燥为主。", "ner": [[4, 9, "Disease"], [10, 13, "Disease"], [14, 16, "Treatment"], [16, 18, "Duration"], [19, 23, "Disease"], [24, 28, "Symptom"], [28, 32, "Symptom"], [33, 37, "Symptom"], [42, 44, "Symptom"], [38, 40, "Anatomy"], [52, 56, "Disease"], [69, 75, "Operation"], [99, 101, "Method"], [108, 110, "Method"], [112, 114, "Anatomy"], [117, 121, "Method"]], "rel": [[52, 56, "Disease", 19, 23, "Disease", "Disease_Disease"], [4, 9, "Disease", 10, 13, "Disease", "Disease_Disease"], [24, 28, "Symptom", 19, 23, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 19, 23, "Disease", "Symptom_Disease"], [33, 37, "Symptom", 19, 23, "Disease", "Symptom_Disease"], [14, 16, "Treatment", 10, 13, "Disease", "Treatment_Disease"], [42, 44, "Symptom", 19, 23, "Disease", "Symptom_Disease"], [38, 40, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [69, 75, "Operation", 52, 56, "Disease", "Operation_Disease"], [24, 28, "Symptom", 52, 56, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 52, 56, "Disease", "Symptom_Disease"], [42, 44, "Symptom", 52, 56, "Disease", "Symptom_Disease"], [69, 75, "Operation", 19, 23, "Disease", "Operation_Disease"]]}
{"idx": 22, "sentence": "糖尿病并发糖尿病足，右脚大脚趾感染，肌肉坏死，脚趾中心溃烂，现已做过清创手术。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [18, 22, "Symptom"], [23, 29, "Symptom"], [34, 38, "Operation"], [10, 12, "Anatomy"], [12, 17, "Symptom"]], "rel": [[34, 38, "Operation", 5, 9, "Disease", "Operation_Disease"], [5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [10, 12, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [18, 22, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [23, 29, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [12, 17, "Symptom", 5, 9, "Disease", "Symptom_Disease"]]}
{"idx": 23, "sentence": "糖尿病足导致足部溃烂，现在中间三个脚趾，开始内部溃烂。医嘱：全身基础疾病多，年龄大，确实不好处理，截肢对患者打击也大，创面也不一定能愈合。", "ner": [[0, 4, "Disease"], [6, 10, "Symptom"], [17, 19, "Anatomy"], [24, 26, "Symptom"], [49, 51, "Operation"]], "rel": [[6, 10, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [17, 19, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [49, 51, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 24, "sentence": "糖尿病20年，五个月前左足部溃烂，目前伤口愈合较差，半个月前右脚又破了，现在足部刺痛，近几个月一直涂抹消炎药治疗。医嘱：根据病情，可能需要血管介入和骨膜搬运手术，b超检查不准，还是建议CT下肢血管造影。", "ner": [[0, 3, "Disease"], [3, 6, "Duration"], [11, 16, "Symptom"], [19, 25, "Symptom"], [30, 32, "Anatomy"], [38, 42, "Symptom"], [43, 47, "Duration"], [49, 51, "Method"], [69, 73, "Operation"], [74, 80, "Operation"], [81, 85, "Test"], [92, 100, "Test"]], "rel": []}
{"idx": 25, "sentence": "过年疫情期间，做透析感染了新冠病毒，在治疗新冠期间，糖尿病的没控制好，引发了糖尿病足，并引发了脑梗心梗，足部溃烂，肢端皮肤变成紫红色，伤口化脓。医嘱：在药物治疗无效的情况下，结合病情考虑介入治疗和手术治疗。", "ner": [[8, 10, "Treatment"], [26, 29, "Disease"], [21, 23, "Disease"], [38, 42, "Disease"], [47, 49, "Disease"], [49, 51, "Disease"], [52, 56, "Symptom"], [57, 66, "Symptom"], [67, 71, "Symptom"], [93, 97, "Operation"]], "rel": [[38, 42, "Disease", 26, 29, "Disease", "Disease_Disease"], [47, 49, "Disease", 26, 29, "Disease", "Disease_Disease"], [49, 51, "Disease", 26, 29, "Disease", "Disease_Disease"], [93, 97, "Operation", 38, 42, "Disease", "Operation_Disease"], [52, 56, "Symptom", 38, 42, "Disease", "Symptom_Disease"], [57, 66, "Symptom", 38, 42, "Disease", "Symptom_Disease"], [67, 71, "Symptom", 38, 42, "Disease", "Symptom_Disease"]]}
{"idx": 26, "sentence": "糖尿病并发糖尿病足病情加重，足部溃烂到现在已经快两个月，内分泌科住院治疗，出院一周左右伤口继续发炎、肿胀、伤口化脓并肢端变黑。医嘱：目前来看保肢希望大。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [11, 13, "Level"], [14, 18, "Symptom"], [23, 27, "Duration"], [47, 49, "Symptom"], [50, 52, "Symptom"], [53, 57, "Symptom"], [58, 62, "Symptom"]], "rel": [[14, 18, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [47, 49, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [50, 52, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [53, 57, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [58, 62, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"]]}
{"idx": 27, "sentence": "糖尿病，17年出现糖尿病视网膜病变，双眼眼底血管新增，做过两次激光，双眼白内障术后左脚小趾碰破一小块皮，因防控没去医院处理，然后足部感染。于3月5日住院，血色素66，红细胞2.1，血清肌酐500多，血尿素氮34，住院后第三天做了一次ct血管造影，造影后进行一次床旁血滤，间隔2天又做一次透析。医嘱：足部情况可以做保肢治疗。", "ner": [[0, 3, "Disease"], [9, 17, "Disease"], [36, 39, "Disease"], [34, 36, "Anatomy"], [41, 45, "Anatomy"], [18, 22, "Anatomy"], [22, 24, "Anatomy"], [64, 68, "Symptom"], [77, 80, "Test_items"], [80, 82, "Test_Value"], [83, 86, "Test_items"], [86, 89, "Test_Value"], [90, 94, "Test_items"], [94, 98, "Test_Value"], [99, 103, "Test_items"], [103, 105, "Test_Value"], [116, 122, "Test"], [130, 134, "Treatment"], [143, 145, "Treatment"], [149, 151, "Anatomy"]], "rel": [[36, 39, "Disease", 9, 17, "Disease", "Disease_Disease"], [9, 17, "Disease", 0, 3, "Disease", "Disease_Disease"], [34, 36, "Anatomy", 36, 39, "Disease", "Anatomy_Disease"], [18, 22, "Anatomy", 9, 17, "Disease", "Anatomy_Disease"], [77, 80, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [83, 86, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [90, 94, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [99, 103, "Test_items", 0, 3, "Disease", "Test_items_Disease"]]}
{"idx": 28, "sentence": "糖尿病足，糖尿病足部溃烂，医嘱：建议检查下肢动脉彩超并测压，了解下肢动脉情况，必要时可以介入治疗。糖尿病足大部分情况是中小动脉的闭塞，如果成功开通血管的话，可以有效避免截肢，恢复肢体活力，提高生活质量。", "ner": [[0, 4, "Disease"], [8, 12, "Symptom"], [5, 8, "Disease"], [20, 26, "Test"], [27, 29, "Test"], [32, 36, "Anatomy"], [49, 53, "Disease"], [59, 66, "Disease"], [84, 86, "Operation"], [44, 48, "Operation"]], "rel": [[59, 66, "Disease", 49, 53, "Disease", "Disease_Disease"], [20, 26, "Test", 49, 53, "Disease", "Test_Disease"], [27, 29, "Test", 49, 53, "Disease", "Test_Disease"], [8, 12, "Symptom", 49, 53, "Disease", "Symptom_Disease"], [44, 48, "Operation", 49, 53, "Disease", "Operation_Disease"], [84, 86, "Operation", 49, 53, "Disease", "Operation_Disease"], [0, 4, "Disease", 5, 8, "Disease", "Disease_Disease"], [20, 26, "Test", 59, 66, "Disease", "Test_Disease"], [27, 29, "Test", 59, 66, "Disease", "Test_Disease"], [8, 12, "Symptom", 59, 66, "Disease", "Symptom_Disease"], [32, 36, "Anatomy", 59, 66, "Disease", "Anatomy_Disease"], [44, 48, "Operation", 59, 66, "Disease", "Operation_Disease"], [84, 86, "Operation", 59, 66, "Disease", "Operation_Disease"]]}
{"idx": 29, "sentence": "患2型糖尿病20年并发糖尿病足，曾服用二甲双胍片等降糖药治疗，现应用精蛋白生物合成人胰岛素50注射液早30，晚32联合利格列汀片。三个月前左足趾溃烂，足部刺痛影响睡眠。另患有冠心病缺血性心肌病15年，间断口服速效救心丸，高血压15年最高160／90，服用替米沙坦片，慢性支气管炎五年。医嘱：足趾溃烂疼痛的根本原因在于糖尿病的慢性动脉闭塞症。仅靠曲马多之类的止疼药无济于事。建议：1.可以加用西洛他唑片50毫克/片，每天2-3次，每次50毫克。2.有条件的话，可以从股动脉注射前列地尔注射液，每次10微克（这个治疗方法有风险，但效果很好）。3.血管外科做下肢血管介入。", "ner": [[11, 15, "Disease"], [6, 9, "Duration"], [19, 24, "Drug"], [34, 50, "Drug"], [50, 53, "Amount"], [54, 57, "Amount"], [59, 64, "Drug"], [75, 79, "Symptom"], [87, 90, "Disease"], [90, 96, "Disease"], [96, 99, "Duration"], [102, 104, "Method"], [104, 109, "Drug"], [110, 113, "Disease"], [113, 116, "Duration"], [118, 124, "Test_Value"], [127, 132, "Drug"], [125, 127, "Method"], [133, 139, "Disease"], [139, 141, "Duration"], [158, 161, "Disease"], [162, 169, "Disease"], [149, 151, "Symptom"], [172, 175, "Drug"], [195, 200, "Drug"], [207, 213, "Frequency"], [214, 220, "Amount"], [232, 235, "Anatomy"], [235, 237, "Method"], [237, 244, "Drug"], [245, 251, "Amount"], [145, 149, "Symptom"], [69, 74, "Symptom"], [276, 282, "Operation"], [1, 6, "Disease"]], "rel": [[162, 169, "Disease", 158, 161, "Disease", "Disease_Disease"], [104, 109, "Drug", 87, 90, "Disease", "Drug_Disease"], [127, 132, "Drug", 110, 113, "Disease", "Drug_Disease"], [50, 53, "Amount", 34, 50, "Drug", "Amount_Drug"], [54, 57, "Amount", 34, 50, "Drug", "Amount_Drug"], [214, 220, "Amount", 195, 200, "Drug", "Amount_Drug"], [207, 213, "Frequency", 195, 200, "Drug", "Frequency_Drug"], [235, 237, "Method", 237, 244, "Drug", "Method_Drug"], [125, 127, "Method", 127, 132, "Drug", "Method_Drug"], [102, 104, "Method", 104, 109, "Drug", "Method_Drug"], [75, 79, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [69, 74, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [276, 282, "Operation", 162, 169, "Disease", "Operation_Disease"], [145, 149, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [149, 151, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [145, 149, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [149, 151, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [69, 74, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [195, 200, "Drug", 11, 15, "Disease", "Drug_Disease"], [195, 200, "Drug", 162, 169, "Disease", "Drug_Disease"], [237, 244, "Drug", 11, 15, "Disease", "Drug_Disease"], [237, 244, "Drug", 162, 169, "Disease", "Drug_Disease"], [104, 109, "Drug", 90, 96, "Disease", "Drug_Disease"], [245, 251, "Amount", 237, 244, "Drug", "Amount_Drug"], [276, 282, "Operation", 11, 15, "Disease", "Operation_Disease"], [19, 24, "Drug", 1, 6, "Disease", "Drug_Disease"], [34, 50, "Drug", 1, 6, "Disease", "Drug_Disease"], [59, 64, "Drug", 1, 6, "Disease", "Drug_Disease"], [11, 15, "Disease", 1, 6, "Disease", "Disease_Disease"]]}
{"idx": 30, "sentence": "糖尿病并发糖尿病足右脚做了清创，现在左脚起水疱，伤口化脓，在医院住了一个月的院，现在在家打阿莫西林、丹参。医嘱：如果水泡不增大，不要刺破，脓性分泌物较多，可用碘伏消毒清洗创面。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [13, 15, "Operation"], [9, 11, "Anatomy"], [18, 20, "Anatomy"], [24, 28, "Symptom"], [20, 23, "Symptom"], [45, 49, "Drug"], [50, 52, "Drug"], [69, 76, "Symptom"], [79, 81, "Drug"], [44, 45, "Method"]], "rel": [[5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [9, 11, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [18, 20, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [20, 23, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [24, 28, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [69, 76, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [13, 15, "Operation", 5, 9, "Disease", "Operation_Disease"], [44, 45, "Method", 45, 49, "Drug", "Method_Drug"], [44, 45, "Method", 50, 52, "Drug", "Method_Drug"], [45, 49, "Drug", 5, 9, "Disease", "Drug_Disease"], [50, 52, "Drug", 5, 9, "Disease", "Drug_Disease"]]}
{"idx": 31, "sentence": "患者今年81岁，糖尿病二十多年了，现在血糖是9左右，现在每天都在注射胰岛素。近几年每年右脚都会起水疱，水疱磨破后开始溃烂，到现在肢端变黑且脚面溃烂。老人感觉不到足部刺痛，大小便困难，腹部肿胀，插尿管后也没有排除很多尿液，身体有浮肿的现象。医嘱：控制足部感染关健是处理好创面，外用磺胺嘧啶银换药。", "ner": [[8, 11, "Disease"], [11, 15, "Duration"], [19, 21, "Test_items"], [22, 23, "Test_Value"], [32, 34, "Method"], [34, 37, "Drug"], [38, 41, "Duration"], [28, 30, "Frequency"], [43, 45, "Anatomy"], [47, 50, "Symptom"], [58, 60, "Symptom"], [64, 68, "Symptom"], [69, 73, "Symptom"], [80, 84, "Symptom"], [85, 90, "Symptom"], [91, 95, "Symptom"], [113, 115, "Symptom"], [137, 139, "Method"], [124, 128, "Symptom"], [139, 144, "Drug"]], "rel": [[28, 30, "Frequency", 34, 37, "Drug", "Frequency_Drug"], [32, 34, "Method", 34, 37, "Drug", "Method_Drug"], [19, 21, "Test_items", 8, 11, "Disease", "Test_items_Disease"], [137, 139, "Method", 139, 144, "Drug", "Method_Drug"]]}
{"idx": 32, "sentence": "糖尿病15年左右，脚底刺伤，打了破伤风及吃消炎药，后足部感染，伤口化脓，入院做了二次清创手术，未见好转，现在血管有些堵塞。医嘱：目前第一二足趾坏死，不过有希望不截肢，通过治疗将坏死转变为干性坏死，前提是血供改善和感染得到控制，需要做下肢CTA（CT血管造影）。", "ner": [[0, 3, "Disease"], [3, 8, "Duration"], [14, 15, "Method"], [16, 19, "Drug"], [26, 30, "Symptom"], [31, 35, "Symptom"], [42, 46, "Operation"], [54, 56, "Anatomy"], [66, 73, "Symptom"], [80, 82, "Operation"], [116, 129, "Test"], [58, 60, "Symptom"], [88, 90, "Symptom"], [93, 97, "Symptom"]], "rel": [[14, 15, "Method", 16, 19, "Drug", "Method_Drug"]]}
{"idx": 33, "sentence": "糖尿病足患者今年66岁，足部大拇趾部位有水疱，之后有脓性分泌物较多，三个月左右结痂至今。", "ner": [[0, 4, "Disease"], [12, 17, "Anatomy"], [26, 33, "Symptom"], [34, 39, "Duration"], [19, 22, "Symptom"]], "rel": [[26, 33, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [12, 17, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [19, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 34, "sentence": "洗脚后脚趾上皮破损，后创口变大，医院初诊为典型糖尿病足，后坐多普勒彩超检查，发现下肢血管不同程度堵塞，建议住院采取措施疏通血管。", "ner": [[5, 9, "Symptom"], [11, 15, "Symptom"], [23, 27, "Disease"], [3, 5, "Anatomy"], [30, 35, "Test"], [40, 44, "Anatomy"], [61, 63, "Anatomy"], [48, 50, "Symptom"]], "rel": [[11, 15, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [5, 9, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [3, 5, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"], [30, 35, "Test", 23, 27, "Disease", "Test_Disease"], [48, 50, "Symptom", 23, 27, "Disease", "Symptom_Disease"]]}
{"idx": 35, "sentence": "2007年查出高血压并服药（倍他洛克、压氏达、马来酸依那普利、阿司匹林），2020年7月血压正常，停药，监测至今，血压正常；去年10月体检查出高血糖，服药（格列吡嗪缓释片），2021年01月份，脚趾有水疱，脚趾发黑、足部刺痛，输液治疗。医嘱：目前足趾干性坏疽，符合糖尿病足诊断。首先考虑下肢动脉硬化闭塞症引起的远端肢体缺血。建议完善CT血管造影，至于药物，目前西洛他唑口服，但最终改善血管缺血还是考虑介入手术。", "ner": [[7, 10, "Disease"], [14, 18, "Drug"], [19, 22, "Drug"], [23, 30, "Drug"], [31, 35, "Drug"], [44, 46, "Test_items"], [57, 59, "Test_items"], [71, 74, "Disease"], [78, 85, "Drug"], [97, 99, "Anatomy"], [99, 102, "Symptom"], [103, 107, "Symptom"], [108, 112, "Symptom"], [113, 115, "Method"], [123, 129, "Symptom"], [132, 136, "Disease"], [155, 161, "Symptom"], [166, 172, "Test"], [180, 184, "Drug"], [184, 186, "Method"], [200, 204, "Operation"], [143, 152, "Disease"], [192, 196, "Symptom"]], "rel": [[14, 18, "Drug", 7, 10, "Disease", "Drug_Disease"], [19, 22, "Drug", 7, 10, "Disease", "Drug_Disease"], [23, 30, "Drug", 7, 10, "Disease", "Drug_Disease"], [31, 35, "Drug", 7, 10, "Disease", "Drug_Disease"], [78, 85, "Drug", 71, 74, "Disease", "Drug_Disease"], [180, 184, "Drug", 145, 152, "Disease", "Drug_Disease"], [97, 99, "Anatomy", 132, 136, "Disease", "Anatomy_Disease"], [184, 186, "Method", 180, 184, "Drug", "Method_Drug"], [166, 172, "Test", 143, 152, "Disease", "Test_Disease"], [200, 204, "Operation", 143, 152, "Disease", "Operation_Disease"], [166, 172, "Test", 132, 136, "Disease", "Test_Disease"], [99, 102, "Symptom", 132, 136, "Disease", "Symptom_Disease"], [103, 107, "Symptom", 132, 136, "Disease", "Symptom_Disease"], [123, 129, "Symptom", 132, 136, "Disease", "Symptom_Disease"], [108, 112, "Symptom", 132, 136, "Disease", "Symptom_Disease"], [99, 102, "Symptom", 143, 152, "Disease", "Symptom_Disease"], [103, 107, "Symptom", 143, 152, "Disease", "Symptom_Disease"], [155, 161, "Symptom", 143, 152, "Disease", "Symptom_Disease"], [123, 129, "Symptom", 143, 152, "Disease", "Symptom_Disease"], [200, 204, "Operation", 132, 136, "Disease", "Operation_Disease"], [180, 184, "Drug", 132, 136, "Disease", "Drug_Disease"], [57, 59, "Test_items", 7, 10, "Disease", "Test_items_Disease"], [192, 196, "Symptom", 143, 152, "Disease", "Symptom_Disease"], [192, 196, "Symptom", 132, 136, "Disease", "Symptom_Disease"], [155, 161, "Symptom", 132, 136, "Disease", "Symptom_Disease"]]}
{"idx": 36, "sentence": "患者糖尿病、尿毒症，脚肿，消肿之后脚部出现坏痕，腿部溃烂。医嘱：下肢血管有闭塞的情况，容易激发下肢感染，不容易好。", "ner": [[2, 5, "Disease"], [6, 9, "Disease"], [10, 12, "Symptom"], [19, 23, "Symptom"], [24, 28, "Symptom"], [47, 51, "Symptom"], [32, 36, "Anatomy"], [17, 19, "Anatomy"], [37, 39, "Symptom"]], "rel": []}
{"idx": 37, "sentence": "糖尿病10多年，左腿在10年前股骨头摔骨折。今年2月份，左脚小脚趾溃烂，目前已坏疽。做了彩超看到下肢多阶段闭塞，已经堵到大腿根部，医生建议保守治疗，输液消炎，吃扩血管增加侧支循环的药，或者从大腿根部截肢。", "ner": [[0, 3, "Disease"], [3, 7, "Duration"], [8, 10, "Anatomy"], [19, 21, "Disease"], [15, 18, "Anatomy"], [30, 35, "Symptom"], [28, 30, "Anatomy"], [39, 41, "Symptom"], [44, 46, "Test"], [60, 64, "Anatomy"], [74, 76, "Method"], [79, 80, "Method"], [95, 99, "Anatomy"], [99, 101, "Operation"], [48, 55, "Disease"]], "rel": [[15, 18, "Anatomy", 19, 21, "Disease", "Anatomy_Disease"], [44, 46, "Test", 48, 55, "Disease", "Test_Disease"], [48, 55, "Disease", 0, 3, "Disease", "Disease_Disease"], [99, 101, "Operation", 48, 55, "Disease", "Operation_Disease"], [30, 35, "Symptom", 48, 55, "Disease", "Symptom_Disease"], [39, 41, "Symptom", 48, 55, "Disease", "Symptom_Disease"], [95, 99, "Anatomy", 48, 55, "Disease", "Anatomy_Disease"]]}
{"idx": 38, "sentence": "糖尿病十多年并发糖尿病足，近一年多足部红肿、足部溃烂，糖尿病足坏疽、下肢动脉硬化闭塞症。医嘱：肾功能允许下，查下肢血管CTA评估血管，然后才能考虑是否有介入/截肢等手术方案机会；但若临床医生和家属共同评估觉得手术风险大于获益情况下，那只能选择维持现状治疗（但没有特效治疗能长期控制进展和疼痛）。", "ner": [[0, 3, "Disease"], [3, 6, "Duration"], [8, 12, "Disease"], [13, 17, "Duration"], [17, 21, "Symptom"], [22, 26, "Symptom"], [27, 31, "Disease"], [31, 33, "Symptom"], [47, 48, "Anatomy"], [64, 66, "Anatomy"], [76, 78, "Operation"], [79, 81, "Operation"], [34, 43, "Disease"], [55, 62, "Test"], [143, 145, "Symptom"]], "rel": [[8, 12, "Disease", 0, 3, "Disease", "Disease_Disease"], [76, 78, "Operation", 8, 12, "Disease", "Operation_Disease"], [79, 81, "Operation", 8, 12, "Disease", "Operation_Disease"], [17, 21, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [22, 26, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [31, 33, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [34, 43, "Disease", 8, 12, "Disease", "Disease_Disease"], [55, 62, "Test", 34, 43, "Disease", "Test_Disease"], [55, 62, "Test", 8, 12, "Disease", "Test_Disease"], [17, 21, "Symptom", 34, 43, "Disease", "Symptom_Disease"], [22, 26, "Symptom", 34, 43, "Disease", "Symptom_Disease"], [31, 33, "Symptom", 34, 43, "Disease", "Symptom_Disease"], [76, 78, "Operation", 34, 43, "Disease", "Operation_Disease"], [79, 81, "Operation", 34, 43, "Disease", "Operation_Disease"], [64, 66, "Anatomy", 34, 43, "Disease", "Anatomy_Disease"], [143, 145, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [143, 145, "Symptom", 34, 43, "Disease", "Symptom_Disease"]]}
{"idx": 39, "sentence": "长期糖尿病，尿酸高并发糖尿病足，10天前泡脚之后肿胀，足部溃烂，左足坏疽伴足背感染进展。", "ner": [[2, 5, "Disease"], [0, 2, "Duration"], [6, 8, "Test_items"], [8, 9, "Test_Value"], [11, 15, "Disease"], [24, 26, "Symptom"], [27, 31, "Symptom"], [32, 36, "Symptom"], [37, 41, "Symptom"]], "rel": [[11, 15, "Disease", 2, 5, "Disease", "Disease_Disease"], [6, 8, "Test_items", 2, 5, "Disease", "Test_items_Disease"], [37, 41, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [32, 36, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [27, 31, "Symptom", 11, 15, "Disease", "Symptom_Disease"]]}
{"idx": 40, "sentence": "糖尿病足部溃烂，医嘱：糖尿病足患者足部感染延肌间隙扩大，溃疡深度已经到跖骨头，外侧肌腱暴露。保肢治疗难度大。但是，考虑患者年纪仅57岁，需要进一步完善CT血管造影检查，如果血供正常，可以尝试积极清创修复，尽可能的降低截肢平面。", "ner": [[0, 3, "Disease"], [3, 7, "Symptom"], [11, 15, "Disease"], [17, 21, "Symptom"], [21, 27, "Symptom"], [39, 45, "Symptom"], [75, 81, "Test"], [97, 99, "Operation"], [35, 38, "Anatomy"]], "rel": [[11, 15, "Disease", 0, 3, "Disease", "Disease_Disease"], [3, 7, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [17, 21, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [21, 27, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [39, 45, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [97, 99, "Operation", 11, 15, "Disease", "Operation_Disease"], [75, 81, "Test", 11, 15, "Disease", "Test_Disease"]]}
{"idx": 41, "sentence": "糖尿病足肢端变黑，医嘱：先评估血管情况，做下肢动脉CT血管造影，结合血管介入治疗加胫骨骨搬运手术改善足部血液循环，争取保留还没变黑的肢体。", "ner": [[0, 4, "Disease"], [4, 8, "Symptom"], [15, 17, "Anatomy"], [34, 40, "Operation"], [41, 48, "Operation"], [50, 52, "Anatomy"], [21, 31, "Test"], [66, 68, "Anatomy"]], "rel": [[4, 8, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [50, 52, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [34, 40, "Operation", 0, 4, "Disease", "Operation_Disease"], [41, 48, "Operation", 0, 4, "Disease", "Operation_Disease"], [21, 31, "Test", 0, 4, "Disease", "Test_Disease"]]}
{"idx": 42, "sentence": "糖尿病并发糖尿病足，剪破了皮就开始足部溃烂，已经1个多月了，目前肿胀。医嘱：第二足趾需要切除手术，如果不及时治疗，还可能会影响到其他足趾，甚至向足背发展。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [17, 21, "Symptom"], [24, 28, "Duration"], [32, 34, "Symptom"], [38, 42, "Anatomy"], [44, 48, "Operation"], [66, 68, "Anatomy"], [72, 74, "Anatomy"]], "rel": [[5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [17, 21, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [32, 34, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [44, 48, "Operation", 5, 9, "Disease", "Operation_Disease"], [38, 42, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [66, 68, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [72, 74, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 43, "sentence": "糖尿病足，脚趾发黑、坏死、刺痛难忍、血糖偏高，72周岁。医嘱：需要尽快截肢手术。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 12, "Symptom"], [13, 17, "Symptom"], [18, 20, "Test_items"], [20, 22, "Test_Value"], [35, 39, "Operation"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 12, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [13, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [35, 39, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 44, "sentence": "患者59岁，患糖尿病5年，7月初洗脚时足部感染，7月20日在地方医院住院治疗，目前血糖血压都已控制稳定，右足已慢慢恢复，但左足伤口目前仍隔天换药，外科大夫看没有明显好转，建议做植皮手术。糖尿病足可以首先考虑进行局部清创，清创表面干性痂皮后，使用密闭式负压吸引装置使创面的坏死组织得到充分引流后，使用高张盐水行创面浸泡、去腐生肌药物及生长因子凝胶换药会取得明显效果。", "ner": [[7, 10, "Disease"], [10, 12, "Duration"], [19, 23, "Symptom"], [41, 43, "Test_items"], [43, 45, "Test_items"], [49, 51, "Test_Value"], [52, 54, "Anatomy"], [61, 63, "Anatomy"], [68, 70, "Frequency"], [88, 92, "Operation"], [93, 97, "Disease"], [107, 109, "Operation"], [122, 131, "Treatment"], [149, 153, "Drug"], [156, 158, "Method"], [159, 165, "Drug"], [166, 172, "Drug"], [143, 145, "Treatment"]], "rel": [[41, 43, "Test_items", 7, 10, "Disease", "Test_items_Disease"], [43, 45, "Test_items", 7, 10, "Disease", "Test_items_Disease"], [93, 97, "Disease", 7, 10, "Disease", "Disease_Disease"], [88, 92, "Operation", 93, 97, "Disease", "Operation_Disease"], [107, 109, "Operation", 93, 97, "Disease", "Operation_Disease"], [122, 131, "Treatment", 93, 97, "Disease", "Treatment_Disease"], [156, 158, "Method", 149, 153, "Drug", "Method_Drug"], [149, 153, "Drug", 93, 97, "Disease", "Drug_Disease"], [159, 165, "Drug", 93, 97, "Disease", "Drug_Disease"], [166, 172, "Drug", 93, 97, "Disease", "Drug_Disease"], [19, 23, "Symptom", 93, 97, "Disease", "Symptom_Disease"], [143, 145, "Treatment", 93, 97, "Disease", "Treatment_Disease"]]}
{"idx": 45, "sentence": "糖尿病足，足部肿胀，刺痛，肢端皮肤变成紫红色，下肢CT血管造影检查，根据脚的颜色，考虑下肢动脉血管闭塞。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 12, "Symptom"], [13, 22, "Symptom"], [36, 37, "Anatomy"], [43, 51, "Disease"], [23, 31, "Test"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 12, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [13, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [43, 51, "Disease", 0, 4, "Disease", "Disease_Disease"], [23, 31, "Test", 43, 51, "Disease", "Test_Disease"], [5, 9, "Symptom", 43, 51, "Disease", "Symptom_Disease"], [13, 22, "Symptom", 43, 51, "Disease", "Symptom_Disease"], [23, 31, "Test", 0, 4, "Disease", "Test_Disease"], [36, 37, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 46, "sentence": "88年身体开始消瘦、多汗等症状，95年确诊糖尿病，确诊后盲目就诊和听信偏方，没有及时打胰岛素，到07年开始打胰岛素控制血糖，13年9月肾出现问题，确诊为糖尿病肾病，20年9月底右侧小脚趾溃烂，当时用碘伏等进行消毒（无明显效果），20年10月底右侧小脚趾变黑，肢端皮肤变成紫红色。医嘱：用改善微循环的药物，局部换药，定期复查。", "ner": [[7, 9, "Symptom"], [10, 12, "Symptom"], [21, 24, "Disease"], [43, 46, "Drug"], [42, 43, "Method"], [54, 57, "Drug"], [53, 54, "Method"], [59, 61, "Test_items"], [67, 68, "Anatomy"], [76, 81, "Disease"], [90, 95, "Symptom"], [99, 101, "Drug"], [123, 128, "Symptom"], [129, 138, "Symptom"]], "rel": [[10, 12, "Symptom", 21, 24, "Disease", "Symptom_Disease"], [7, 9, "Symptom", 21, 24, "Disease", "Symptom_Disease"], [59, 61, "Test_items", 21, 24, "Disease", "Test_items_Disease"], [54, 57, "Drug", 21, 24, "Disease", "Drug_Disease"], [53, 54, "Method", 54, 57, "Drug", "Method_Drug"], [67, 68, "Anatomy", 76, 81, "Disease", "Anatomy_Disease"], [76, 81, "Disease", 21, 24, "Disease", "Disease_Disease"]]}
{"idx": 47, "sentence": "糖尿病史15年，去年脚指头烫伤，还有一小伤口不断的往外渗血，伤口愈合较差。医嘱：考虑糖尿病足，缺血足，合并慢性骨髓炎可能。医嘱：1.强调心脑血管风险: 患者糖尿病伴多并发症，应详细评估系统并发症尤其是心脑血管，预防冠心病、脑卒中发生。2. 建议患者评估CT血管造影（动脉CTA)、患足X线平片（骨CT重建），明确缺血和骨髓炎病情，以制定后续治疗方案。", "ner": [[4, 7, "Duration"], [10, 13, "Anatomy"], [22, 29, "Symptom"], [30, 36, "Symptom"], [42, 46, "Disease"], [53, 58, "Disease"], [68, 72, "Anatomy"], [78, 81, "Disease"], [100, 104, "Anatomy"], [107, 110, "Disease"], [111, 114, "Disease"], [126, 139, "Test"], [140, 153, "Test"], [159, 162, "Disease"], [156, 158, "Disease"], [47, 50, "Disease"]], "rel": [[22, 29, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [30, 36, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [10, 13, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [68, 72, "Anatomy", 107, 110, "Disease", "Anatomy_Disease"], [42, 46, "Disease", 78, 81, "Disease", "Disease_Disease"], [107, 110, "Disease", 78, 81, "Disease", "Disease_Disease"], [126, 139, "Test", 42, 46, "Disease", "Test_Disease"], [140, 153, "Test", 53, 58, "Disease", "Test_Disease"], [111, 114, "Disease", 78, 81, "Disease", "Disease_Disease"], [47, 50, "Disease", 42, 46, "Disease", "Disease_Disease"]]}
{"idx": 48, "sentence": "韩某，72岁。两个月前，不慎碰伤左足第二足趾，在当地诊所换药处理后，足趾溃疡、伤口愈合较差且疼痛难忍。经省某三甲医院确诊为“糖尿病，糖尿病足坏死”后给予积极治疗，但左足溃疡及刺痛仍无法控制。入院查体:血压170/100mmHg，精神差，双肺呼吸音粗。双侧腘动脉搏动减弱，胫后动脉搏动未触及。双足未见汗毛生长，左足皮肤颜色发暗，皮温较右侧升高，可触及轻度指凹性水肿。左足第二肢端变黑、肢端发凉感，可见多发溃疡面，伴脓血性分泌物。查空腹血糖8.59mmol/L、餐后2h血糖16.6mmol/L。入院诊断:Ⅱ型糖尿病，糖尿病足，高血压病2级(极高危)。入院治疗:给予胰岛素注射积极控制血糖，中西医结合药物降压、调脂，抗菌消炎，利湿解毒等综合治疗。治疗2周后，患者疼痛控制，血糖较为稳定，左足指凹性水肿消失，左足坏死分界尚不清晰，溃疡分泌物减少。继续改善供血，控制血糖及感染综合治疗，继续治疗2周后，坏死组织分界清楚，符合手术指征，行左足坏死足趾清除术，术后16天伤口自然愈合，患者出院。", "ner": [[16, 22, "Anatomy"], [34, 38, "Symptom"], [39, 45, "Symptom"], [66, 70, "Disease"], [82, 86, "Symptom"], [87, 89, "Symptom"], [100, 102, "Test_items"], [102, 113, "Test_Value"], [114, 117, "Symptom"], [118, 124, "Symptom"], [127, 134, "Symptom"], [135, 144, "Symptom"], [147, 153, "Symptom"], [163, 170, "Symptom"], [191, 196, "Symptom"], [199, 204, "Symptom"], [205, 212, "Symptom"], [216, 218, "Test_items"], [218, 228, "Test_Value"], [233, 235, "Test_items"], [235, 245, "Test_Value"], [257, 261, "Disease"], [262, 266, "Disease"], [281, 284, "Drug"], [284, 286, "Method"], [290, 292, "Test_items"], [334, 336, "Test_items"], [156, 162, "Symptom"], [154, 156, "Anatomy"], [343, 348, "Symptom"], [176, 181, "Symptom"], [174, 176, "Level"], [184, 190, "Symptom"], [182, 184, "Anatomy"], [379, 381, "Test_items"], [416, 423, "Operation"], [70, 72, "Symptom"], [62, 65, "Disease"], [251, 256, "Disease"], [341, 343, "Anatomy"], [351, 353, "Anatomy"], [46, 50, "Symptom"]], "rel": [[34, 38, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [46, 50, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [39, 45, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [70, 72, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [82, 86, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [87, 89, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [114, 117, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [118, 124, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [127, 134, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [135, 144, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [147, 153, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [156, 162, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [163, 170, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [176, 181, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [184, 190, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [191, 196, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [199, 204, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [205, 212, "Symptom", 66, 70, "Disease", "Symptom_Disease"], [281, 284, "Drug", 62, 65, "Disease", "Drug_Disease"], [284, 286, "Method", 281, 284, "Drug", "Method_Drug"], [216, 218, "Test_items", 62, 65, "Disease", "Test_items_Disease"], [66, 70, "Disease", 62, 65, "Disease", "Disease_Disease"], [416, 423, "Operation", 66, 70, "Disease", "Operation_Disease"], [154, 156, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"], [16, 22, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"], [100, 102, "Test_items", 62, 65, "Disease", "Test_items_Disease"]]}
{"idx": 49, "sentence": "糖尿病，脚趾受伤伤口愈合较差，血糖控制不好。医嘱：糖尿病合并糖尿病足，建议正规医院系统检查应用胰岛素强化降糖，血管介入科和外科就诊，解决血管问题必要时外科手术治疗，避免严重感染败血症危及生命。", "ner": [[0, 3, "Disease"], [4, 6, "Anatomy"], [8, 14, "Symptom"], [15, 17, "Test_items"], [25, 28, "Disease"], [30, 34, "Disease"], [47, 50, "Drug"], [68, 70, "Anatomy"], [84, 86, "Level"], [88, 91, "Disease"]], "rel": [[30, 34, "Disease", 0, 3, "Disease", "Disease_Disease"], [47, 50, "Drug", 0, 3, "Disease", "Drug_Disease"], [8, 14, "Symptom", 30, 34, "Disease", "Symptom_Disease"], [4, 6, "Anatomy", 30, 34, "Disease", "Anatomy_Disease"], [15, 17, "Test_items", 0, 3, "Disease", "Test_items_Disease"]]}
{"idx": 50, "sentence": "糖尿病足，肢端变黑、刺痛难忍。医嘱：第一足趾已经坏死，很难保肢。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 14, "Symptom"], [24, 26, "Symptom"], [18, 22, "Anatomy"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 22, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 51, "sentence": "病人足部感染严重，后转到手足病科。医师建议截肢。医嘱：建议先完善血管检查，如血管彩超，CT血管造影，了解血流情况。足部予聚维酮碘换药处理。", "ner": [[2, 6, "Symptom"], [6, 8, "Level"], [21, 23, "Operation"], [38, 42, "Test"], [43, 49, "Test"], [57, 59, "Anatomy"], [60, 64, "Drug"]], "rel": []}
{"idx": 52, "sentence": "糖尿病足患者于2月前出现右足趾肿胀、刺痛，足部溃烂、伤口愈合较差，在当地医院检查诊治，诊断右下肢动脉硬化闭塞症。医嘱：彩超报告很清楚，右侧股动脉到小腿的动脉闭塞了，足趾缺血严重，可以考虑开通手术（球囊扩张及支架植入）。", "ner": [[0, 4, "Disease"], [12, 17, "Symptom"], [18, 20, "Symptom"], [21, 25, "Symptom"], [26, 32, "Symptom"], [59, 61, "Test"], [67, 72, "Anatomy"], [73, 78, "Anatomy"], [93, 108, "Operation"], [45, 55, "Disease"], [86, 88, "Level"], [78, 80, "Symptom"], [82, 86, "Symptom"]], "rel": [[12, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [26, 32, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [45, 55, "Disease", 0, 4, "Disease", "Disease_Disease"], [93, 108, "Operation", 45, 55, "Disease", "Operation_Disease"], [12, 17, "Symptom", 45, 55, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 45, 55, "Disease", "Symptom_Disease"], [26, 32, "Symptom", 45, 55, "Disease", "Symptom_Disease"], [59, 61, "Test", 45, 55, "Disease", "Test_Disease"], [73, 78, "Anatomy", 45, 55, "Disease", "Anatomy_Disease"], [67, 72, "Anatomy", 45, 55, "Disease", "Anatomy_Disease"], [93, 108, "Operation", 0, 4, "Disease", "Operation_Disease"], [78, 80, "Symptom", 45, 55, "Disease", "Symptom_Disease"], [82, 86, "Symptom", 45, 55, "Disease", "Symptom_Disease"], [82, 86, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 53, "sentence": "20年糖尿病并发糖尿病足，现在足部溃烂，伤口愈合较差，血糖近一个月控制在7点左右。医嘱：建议口服迈之灵片和贝前列腺素钠片。", "ner": [[3, 6, "Disease"], [0, 3, "Duration"], [8, 12, "Disease"], [15, 19, "Symptom"], [20, 26, "Symptom"], [27, 29, "Test_items"], [29, 33, "Duration"], [36, 38, "Test_Value"], [46, 48, "Method"], [48, 52, "Drug"], [53, 60, "Drug"]], "rel": [[8, 12, "Disease", 3, 6, "Disease", "Disease_Disease"], [15, 19, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [20, 26, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [27, 29, "Test_items", 3, 6, "Disease", "Test_items_Disease"], [48, 52, "Drug", 8, 12, "Disease", "Drug_Disease"], [53, 60, "Drug", 8, 12, "Disease", "Drug_Disease"], [46, 48, "Method", 48, 52, "Drug", "Method_Drug"], [46, 48, "Method", 53, 60, "Drug", "Method_Drug"]]}
{"idx": 54, "sentence": "2020年发现脚面脚底有大水疱，到中医院就诊开甘草油和聚维酮碘消毒加外敷症状有所改善，后因药物缺货中断改为当地医院的一种自制纱条，近两日发现肢端变黑。医嘱：糖尿病足，下肢坏死，足趾坏疽，建议进一步完善血管检查，必要时CTA检查（CT血管造影）。", "ner": [[7, 9, "Anatomy"], [9, 11, "Anatomy"], [12, 15, "Symptom"], [23, 26, "Drug"], [27, 31, "Drug"], [34, 36, "Method"], [70, 74, "Symptom"], [78, 82, "Disease"], [83, 87, "Symptom"], [88, 92, "Symptom"], [100, 102, "Anatomy"], [108, 121, "Test"], [60, 64, "Treatment"]], "rel": [[108, 121, "Test", 78, 82, "Disease", "Test_Disease"], [12, 15, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [83, 87, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [88, 92, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [70, 74, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [9, 11, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"], [7, 9, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"], [34, 36, "Method", 23, 26, "Drug", "Method_Drug"], [34, 36, "Method", 27, 31, "Drug", "Method_Drug"]]}
{"idx": 55, "sentence": "发现糖尿病足，趾端出现坏疽3月余，肢端皮肤变成紫红色。医嘱：下肢动脉硬化闭塞症伴足趾坏死，CT显示下肢股浅动脉闭塞，建议尽早行下肢动脉腔内介入治疗，然后局部坏死组织清创，促进创面愈合。", "ner": [[2, 6, "Disease"], [7, 13, "Symptom"], [13, 16, "Duration"], [17, 26, "Symptom"], [40, 44, "Symptom"], [45, 47, "Test"], [82, 84, "Operation"], [63, 73, "Operation"], [30, 39, "Disease"], [49, 57, "Disease"]], "rel": [[40, 44, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [7, 13, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [17, 26, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [82, 84, "Operation", 2, 6, "Disease", "Operation_Disease"], [63, 73, "Operation", 30, 39, "Disease", "Operation_Disease"], [30, 39, "Disease", 2, 6, "Disease", "Disease_Disease"], [49, 57, "Disease", 2, 6, "Disease", "Disease_Disease"], [7, 13, "Symptom", 30, 39, "Disease", "Symptom_Disease"], [40, 44, "Symptom", 30, 39, "Disease", "Symptom_Disease"], [17, 26, "Symptom", 30, 39, "Disease", "Symptom_Disease"], [82, 84, "Operation", 30, 39, "Disease", "Operation_Disease"], [63, 73, "Operation", 2, 6, "Disease", "Operation_Disease"], [45, 47, "Test", 30, 39, "Disease", "Test_Disease"], [45, 47, "Test", 2, 6, "Disease", "Test_Disease"]]}
{"idx": 56, "sentence": "糖尿病足，右脚第四足趾溃疡，趾端出现坏疽，2020年12月31日做完右腿介入球囊扩张手术，目前脚趾未有改善，寻求治疗方案，可提供近期下肢CTA血管造型、右脚X光。", "ner": [[0, 4, "Disease"], [11, 13, "Symptom"], [18, 20, "Symptom"], [14, 16, "Anatomy"], [5, 11, "Anatomy"], [36, 44, "Operation"], [47, 49, "Anatomy"], [78, 80, "Test"], [34, 36, "Anatomy"], [66, 75, "Test"], [76, 78, "Anatomy"]], "rel": [[11, 13, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [5, 11, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [14, 16, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [47, 49, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [36, 44, "Operation", 0, 4, "Disease", "Operation_Disease"], [78, 80, "Test", 0, 4, "Disease", "Test_Disease"], [66, 75, "Test", 0, 4, "Disease", "Test_Disease"], [34, 36, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [76, 78, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [78, 80, "Test", 0, 4, "Disease", "Test_Disease"]]}
{"idx": 57, "sentence": "糖尿病足已截肢，医嘱：伤口内还有一些足部感染、坏死组织，伤口干净后再次缝合一下。", "ner": [[0, 4, "Disease"], [5, 7, "Operation"], [18, 22, "Symptom"], [23, 25, "Symptom"]], "rel": [[5, 7, "Operation", 0, 4, "Disease", "Operation_Disease"], [18, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [23, 25, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 58, "sentence": "糖尿病并发糖尿病足：足部溃烂，足部肿胀。每天是吃2次药，晚上打1次长效胰岛素，住院时血糖达到16，使用短效的胰岛素。医嘱：控制血糖，观察双下肢伤口愈合情况。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [10, 14, "Symptom"], [15, 19, "Symptom"], [20, 26, "Frequency"], [28, 33, "Frequency"], [35, 38, "Drug"], [42, 44, "Test_items"], [46, 48, "Test_Value"], [54, 57, "Drug"], [68, 71, "Anatomy"], [63, 65, "Test_items"]], "rel": [[10, 14, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [15, 19, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [28, 33, "Frequency", 35, 38, "Drug", "Frequency_Drug"], [42, 44, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [35, 38, "Drug", 0, 3, "Disease", "Drug_Disease"]]}
{"idx": 59, "sentence": "足部溃烂，肢端发凉感，感染不断蔓延，糖尿病足。医嘱：下肢坏死，足部感染如果并发毒血症的话，会导致全身的感染，那治疗起来非常麻烦，危险性很大，需要截肢手术。", "ner": [[0, 4, "Symptom"], [5, 10, "Symptom"], [11, 13, "Symptom"], [18, 22, "Disease"], [26, 30, "Symptom"], [31, 35, "Symptom"], [39, 42, "Disease"], [51, 53, "Symptom"], [48, 50, "Anatomy"], [72, 76, "Operation"]], "rel": [[11, 13, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [5, 10, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [0, 4, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [26, 30, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 18, 22, "Disease", "Symptom_Disease"], [39, 42, "Disease", 18, 22, "Disease", "Disease_Disease"], [48, 50, "Anatomy", 39, 42, "Disease", "Anatomy_Disease"], [72, 76, "Operation", 18, 22, "Disease", "Operation_Disease"]]}
{"idx": 60, "sentence": "2017年11月确诊尿毒症，并开始透析，右脚因为糖尿病足，肢端变黑、足部坏死于2019年11月实行截肢手术，保留小腿部分，现安假肢可以活动。2021年1月足趾变黑，刺痛。", "ner": [[10, 13, "Disease"], [17, 19, "Treatment"], [20, 22, "Anatomy"], [24, 28, "Disease"], [29, 33, "Symptom"], [34, 38, "Symptom"], [49, 53, "Operation"], [56, 58, "Anatomy"], [77, 81, "Symptom"], [82, 84, "Symptom"]], "rel": [[17, 19, "Treatment", 10, 13, "Disease", "Treatment_Disease"], [20, 22, "Anatomy", 24, 28, "Disease", "Anatomy_Disease"], [34, 38, "Symptom", 24, 28, "Disease", "Symptom_Disease"], [29, 33, "Symptom", 24, 28, "Disease", "Symptom_Disease"], [82, 84, "Symptom", 24, 28, "Disease", "Symptom_Disease"], [77, 81, "Symptom", 24, 28, "Disease", "Symptom_Disease"]]}
{"idx": 61, "sentence": "多年糖尿病足，左脚五个脚趾发黑向脚掌扩展，足部刺痛。", "ner": [[2, 6, "Disease"], [13, 15, "Symptom"], [21, 25, "Symptom"], [7, 13, "Anatomy"], [16, 18, "Anatomy"]], "rel": [[7, 13, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [13, 15, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [16, 18, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 62, "sentence": "糖尿病足患者脚趾溃烂，1月底住院进行血糖控制，目前肢端皮肤变成紫红色，两个脚趾感觉减退。后面转院后医生建议截肢，将坏死部分吸出来。", "ner": [[0, 4, "Disease"], [6, 10, "Symptom"], [25, 34, "Symptom"], [39, 43, "Symptom"], [35, 39, "Anatomy"], [53, 55, "Operation"], [18, 20, "Test_items"]], "rel": [[39, 43, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [6, 10, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [25, 34, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [53, 55, "Operation", 0, 4, "Disease", "Operation_Disease"], [35, 39, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 63, "sentence": "糖尿病足，肢端皮肤变成紫红色，血糖最高达30，右下肢动脉堵塞，肢端变黑，足部感染。10.16日进行右下肢动脉介入支架手术，手术顺利，小腿动脉恢复通畅。但肢端变黑情况并未改善，足部溃烂，由于基础疾病比较多，糖尿病，高血压，糖尿病肾病（目前采用腹透透析），双腿下肢静脉堵塞（四月加了支架和滤网），心梗，心肌缺血（八月中山一院CCU住院半个月），脑梗，血管钙化，心衰。医嘱：这样的基础疾病，目前这样的创面，确实截肢是一个选择，但风险需要麻醉科，骨科，心脏科共同评估和家属理解。", "ner": [[0, 4, "Disease"], [5, 14, "Symptom"], [15, 17, "Test_items"], [20, 22, "Test_Value"], [31, 35, "Symptom"], [36, 40, "Symptom"], [49, 52, "Anatomy"], [52, 60, "Operation"], [66, 70, "Anatomy"], [76, 80, "Symptom"], [87, 91, "Symptom"], [102, 105, "Disease"], [106, 109, "Disease"], [110, 115, "Disease"], [120, 124, "Treatment"], [146, 148, "Disease"], [149, 153, "Disease"], [170, 172, "Disease"], [173, 177, "Disease"], [178, 180, "Disease"], [202, 204, "Operation"], [23, 30, "Disease"], [126, 134, "Disease"]], "rel": [[15, 17, "Test_items", 102, 105, "Disease", "Test_items_Disease"], [110, 115, "Disease", 102, 105, "Disease", "Disease_Disease"], [120, 124, "Treatment", 110, 115, "Disease", "Treatment_Disease"], [202, 204, "Operation", 0, 4, "Disease", "Operation_Disease"], [0, 4, "Disease", 102, 105, "Disease", "Disease_Disease"], [5, 14, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [36, 40, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [5, 14, "Symptom", 23, 30, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 23, 30, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 23, 30, "Disease", "Symptom_Disease"], [36, 40, "Symptom", 23, 30, "Disease", "Symptom_Disease"], [5, 14, "Symptom", 126, 134, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 126, 134, "Disease", "Symptom_Disease"], [36, 40, "Symptom", 126, 134, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 126, 134, "Disease", "Symptom_Disease"], [23, 30, "Disease", 0, 4, "Disease", "Disease_Disease"], [126, 134, "Disease", 0, 4, "Disease", "Disease_Disease"], [202, 204, "Operation", 23, 30, "Disease", "Operation_Disease"], [202, 204, "Operation", 126, 134, "Disease", "Operation_Disease"]]}
{"idx": 64, "sentence": "糖尿病30年，足部感染，刺痛，无法行走，足部溃烂。", "ner": [[0, 3, "Disease"], [3, 6, "Anatomy"], [7, 11, "Symptom"], [12, 14, "Symptom"], [15, 19, "Symptom"], [20, 24, "Symptom"]], "rel": []}
{"idx": 65, "sentence": "糖尿病引起血管病变，糖尿病足，足部溃烂，近一个月内出现足部刺痛。医嘱：下肢缺血性病变，必要的开通下肢血管以及膝下血管，去除足趾坏死组织。", "ner": [[0, 3, "Disease"], [10, 14, "Disease"], [15, 19, "Symptom"], [27, 31, "Symptom"], [61, 63, "Anatomy"], [48, 52, "Anatomy"], [54, 58, "Anatomy"], [5, 9, "Disease"], [35, 42, "Disease"]], "rel": [[15, 19, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [27, 31, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [61, 63, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [10, 14, "Disease", 0, 3, "Disease", "Disease_Disease"], [5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [35, 42, "Disease", 0, 3, "Disease", "Disease_Disease"]]}
{"idx": 66, "sentence": "糖尿病足，右脚脚趾溃烂。医嘱：截掉脚趾创面，要控制好血糖，如果下肢的动脉有问题，也要提前解除动脉狭窄，还可能出现脚趾坏死，甚至截肢，目前就是上面说的这些方法，减少出现再次坏死风险。", "ner": [[0, 4, "Disease"], [7, 11, "Symptom"], [5, 7, "Anatomy"], [15, 17, "Operation"], [26, 28, "Test_items"], [17, 19, "Anatomy"], [31, 36, "Anatomy"], [46, 50, "Disease"], [56, 60, "Symptom"], [63, 65, "Operation"]], "rel": [[46, 50, "Disease", 0, 4, "Disease", "Disease_Disease"], [15, 17, "Operation", 0, 4, "Disease", "Operation_Disease"], [63, 65, "Operation", 0, 4, "Disease", "Operation_Disease"], [5, 7, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [17, 19, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [7, 11, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [56, 60, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [31, 36, "Anatomy", 46, 50, "Disease", "Anatomy_Disease"], [7, 11, "Symptom", 46, 50, "Disease", "Symptom_Disease"], [56, 60, "Symptom", 46, 50, "Disease", "Symptom_Disease"], [63, 65, "Operation", 46, 50, "Disease", "Operation_Disease"], [15, 17, "Operation", 46, 50, "Disease", "Operation_Disease"]]}
{"idx": 67, "sentence": "糖尿病足，右脚红肿之后足趾溃烂，医嘱：要做清创手术，右脚脚底脚背都需破开，小拇趾截除，手术需分2-3次。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [11, 15, "Symptom"], [21, 25, "Operation"], [26, 28, "Anatomy"], [28, 30, "Anatomy"], [30, 32, "Anatomy"], [37, 40, "Anatomy"], [40, 42, "Operation"]], "rel": [[40, 42, "Operation", 0, 4, "Disease", "Operation_Disease"], [21, 25, "Operation", 0, 4, "Disease", "Operation_Disease"], [5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [11, 15, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [26, 28, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [28, 30, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [30, 32, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [37, 40, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 68, "sentence": "一个月前，左脚大拇趾出水泡,挑破后肿胀,后脚趾变黑，于5月16日就诊糖尿病足科，目测诊断为糖尿病足。先做一个下肢CTA（CT血管造影）。", "ner": [[5, 10, "Anatomy"], [11, 13, "Symptom"], [17, 19, "Symptom"], [20, 25, "Symptom"], [45, 49, "Disease"], [54, 67, "Test"]], "rel": [[11, 13, "Symptom", 45, 49, "Disease", "Symptom_Disease"], [17, 19, "Symptom", 45, 49, "Disease", "Symptom_Disease"], [20, 25, "Symptom", 45, 49, "Disease", "Symptom_Disease"], [5, 10, "Anatomy", 45, 49, "Disease", "Anatomy_Disease"], [54, 67, "Test", 45, 49, "Disease", "Test_Disease"]]}
{"idx": 69, "sentence": "糖尿病足患者于2020年12月右下肢肿胀、刺痛，足趾变黑进入医院血管外科，确诊双下肢动脉粥样硬化。选择保守治疗，脚部溶栓消肿后出院。于2021年1月29日，病情加重住院，2月2日进行脊髓电极置入术。2月19日出院，出院时右下肢有消肿迹象，但脚趾坏死，肢端变黑迹象。医嘱：不能保住坏死趾头，尽快检测血管情况，行手术治疗。", "ner": [[15, 20, "Symptom"], [21, 23, "Symptom"], [24, 28, "Symptom"], [56, 58, "Anatomy"], [91, 98, "Operation"], [110, 113, "Anatomy"], [120, 124, "Symptom"], [125, 129, "Symptom"], [141, 143, "Anatomy"], [148, 150, "Anatomy"], [0, 4, "Disease"], [39, 48, "Disease"]], "rel": [[15, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [21, 23, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [24, 28, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [120, 124, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [125, 129, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [56, 58, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [148, 150, "Anatomy", 39, 48, "Disease", "Anatomy_Disease"], [91, 98, "Operation", 0, 4, "Disease", "Operation_Disease"], [15, 20, "Symptom", 39, 48, "Disease", "Symptom_Disease"], [24, 28, "Symptom", 39, 48, "Disease", "Symptom_Disease"], [125, 129, "Symptom", 39, 48, "Disease", "Symptom_Disease"], [120, 124, "Symptom", 39, 48, "Disease", "Symptom_Disease"], [141, 143, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [110, 113, "Anatomy", 39, 48, "Disease", "Anatomy_Disease"]]}
{"idx": 70, "sentence": "患者于半年前出现肢端发凉感，灼痛，皮肤色素沉着，其后出现足趾发黑，足部溃破，予控制血糖，中草药物治疗，效果不好。近日去医院住院治疗，检查诊断双下肢动脉硬化闭塞症。医嘱：您的情况主要缺血导致的，应该尽快开通闭塞的血管，才能保住腿。", "ner": [[8, 13, "Symptom"], [14, 16, "Symptom"], [17, 23, "Symptom"], [28, 32, "Symptom"], [33, 37, "Symptom"], [112, 113, "Anatomy"], [70, 80, "Disease"], [41, 43, "Test_items"], [105, 107, "Anatomy"], [90, 92, "Symptom"]], "rel": [[8, 13, "Symptom", 70, 80, "Disease", "Symptom_Disease"], [33, 37, "Symptom", 70, 80, "Disease", "Symptom_Disease"], [17, 23, "Symptom", 70, 80, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 70, 80, "Disease", "Symptom_Disease"], [112, 113, "Anatomy", 70, 80, "Disease", "Anatomy_Disease"], [90, 92, "Symptom", 70, 80, "Disease", "Symptom_Disease"], [105, 107, "Anatomy", 70, 80, "Disease", "Anatomy_Disease"]]}
{"idx": 71, "sentence": "拇趾长水泡，伤口愈合较差，大面积肢端变黑，确诊糖尿病足病，输液用的消炎和扩血管的药物，吃的降糖的药，足部感染，诊断双下肢动脉硬化闭塞，做了疏通血管的手术。医嘱：加强营养，多吃蛋白一类食物，控制血糖用胰岛素。每天局部换药。全身用改善血流的药物，如前列地尔，己酮可可碱等，抗菌素等。", "ner": [[3, 5, "Symptom"], [6, 12, "Symptom"], [0, 2, "Anatomy"], [13, 16, "Level"], [23, 27, "Disease"], [29, 31, "Method"], [43, 44, "Method"], [50, 54, "Symptom"], [69, 76, "Operation"], [99, 102, "Drug"], [110, 112, "Anatomy"], [122, 126, "Drug"], [127, 132, "Drug"], [134, 137, "Drug"], [16, 20, "Symptom"], [96, 98, "Test_items"], [57, 66, "Disease"], [103, 105, "Frequency"], [80, 84, "Treatment"]], "rel": [[6, 12, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [3, 5, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [50, 54, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [122, 126, "Drug", 23, 27, "Disease", "Drug_Disease"], [127, 132, "Drug", 23, 27, "Disease", "Drug_Disease"], [134, 137, "Drug", 23, 27, "Disease", "Drug_Disease"], [69, 76, "Operation", 57, 66, "Disease", "Operation_Disease"], [57, 66, "Disease", 23, 27, "Disease", "Disease_Disease"], [3, 5, "Symptom", 57, 66, "Disease", "Symptom_Disease"], [6, 12, "Symptom", 57, 66, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 57, 66, "Disease", "Symptom_Disease"], [50, 54, "Symptom", 57, 66, "Disease", "Symptom_Disease"], [69, 76, "Operation", 23, 27, "Disease", "Operation_Disease"], [122, 126, "Drug", 57, 66, "Disease", "Drug_Disease"], [127, 132, "Drug", 57, 66, "Disease", "Drug_Disease"], [134, 137, "Drug", 57, 66, "Disease", "Drug_Disease"], [80, 84, "Treatment", 23, 27, "Disease", "Treatment_Disease"], [80, 84, "Treatment", 57, 66, "Disease", "Treatment_Disease"]]}
{"idx": 72, "sentence": "老人患有糖尿病，大拇趾砸伤，最近两天疼痛的厉害，到医院就诊后一直在点促进血液循环的药，右脚脚背开始消肿，肢端皮肤变成紫红色。但今晚五点不小心将脚部划伤，结果晚上脚趾发黑，脓性分泌物较多，足部溃烂，疼痛加剧。医嘱：下肢血管存在闭塞，普通的内科治疗效果欠佳，建议您到血管外科就诊，进行创口清理和血管干预，效果会好很多。", "ner": [[4, 7, "Disease"], [8, 11, "Anatomy"], [52, 61, "Symptom"], [43, 47, "Anatomy"], [71, 73, "Anatomy"], [80, 84, "Symptom"], [85, 92, "Symptom"], [93, 97, "Symptom"], [98, 102, "Symptom"], [106, 110, "Anatomy"], [112, 114, "Symptom"]], "rel": []}
{"idx": 73, "sentence": "71岁，女性，17年糖尿病史，血糖控制一直不好。6月中旬剪趾甲，不小心剪破，7月7日，脚趾发黑。头孢西丁钠及银杏达莫静脉滴注2周后，脚趾发黑、坏疽。现口服头孢、贝前列素钠片，甲钴铵静脉滴注银杏达莫；白天口服降糖药和胰岛素控制。医嘱：干性坏疽不用去截，否则伤口可能会不愈合甚至继续向近端腐烂。不过，有必要查下肢CTA（CT血管造影）了解腿部供血情况。", "ner": [[7, 10, "Anatomy"], [15, 17, "Test_items"], [43, 47, "Symptom"], [48, 53, "Drug"], [54, 58, "Drug"], [58, 62, "Method"], [66, 70, "Symptom"], [71, 73, "Symptom"], [75, 77, "Method"], [77, 79, "Drug"], [80, 86, "Drug"], [87, 90, "Drug"], [90, 94, "Method"], [94, 98, "Drug"], [101, 103, "Method"], [107, 110, "Drug"], [116, 120, "Symptom"], [132, 135, "Symptom"], [139, 144, "Symptom"], [167, 169, "Anatomy"], [152, 165, "Test"]], "rel": [[58, 62, "Method", 54, 58, "Drug", "Method_Drug"], [58, 62, "Method", 48, 53, "Drug", "Method_Drug"], [75, 77, "Method", 77, 79, "Drug", "Method_Drug"], [75, 77, "Method", 80, 86, "Drug", "Method_Drug"], [75, 77, "Method", 87, 90, "Drug", "Method_Drug"], [90, 94, "Method", 94, 98, "Drug", "Method_Drug"], [101, 103, "Method", 107, 110, "Drug", "Method_Drug"]]}
{"idx": 74, "sentence": "糖尿病足，脚底伤口愈合较差，医嘱：如果伤口基本愈合了，再来门诊复查，订制一双糖尿病足特制鞋子，预防足溃烂复发。", "ner": [[0, 4, "Disease"], [5, 13, "Symptom"], [38, 42, "Disease"], [49, 52, "Symptom"]], "rel": [[5, 13, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [49, 52, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 75, "sentence": "糖尿病足左脚溃烂，糖尿病引起血管病变，下肢动脉硬化闭塞症。医嘱：建议住院，必要时手术干预。", "ner": [[0, 4, "Disease"], [4, 8, "Symptom"], [9, 12, "Disease"], [19, 28, "Disease"], [14, 18, "Disease"]], "rel": [[19, 28, "Disease", 0, 4, "Disease", "Disease_Disease"], [0, 4, "Disease", 9, 12, "Disease", "Disease_Disease"], [4, 8, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [4, 8, "Symptom", 19, 28, "Disease", "Symptom_Disease"], [14, 18, "Disease", 9, 12, "Disease", "Disease_Disease"]]}
{"idx": 76, "sentence": "糖尿病10年左右并发糖尿病足，一直注射胰岛素，控制不理想，足部溃烂，肢端变黑。医嘱：截肢可能是最好的选择，而且要高位截，最佳位置应该是在膝关节以上，这样能够确保长好。", "ner": [[0, 3, "Disease"], [3, 8, "Duration"], [10, 14, "Disease"], [19, 22, "Drug"], [17, 19, "Method"], [15, 17, "Duration"], [29, 33, "Symptom"], [34, 38, "Symptom"], [42, 44, "Operation"], [68, 71, "Anatomy"]], "rel": [[10, 14, "Disease", 0, 3, "Disease", "Disease_Disease"], [17, 19, "Method", 19, 22, "Drug", "Method_Drug"], [34, 38, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [29, 33, "Symptom", 10, 14, "Disease", "Symptom_Disease"], [42, 44, "Operation", 10, 14, "Disease", "Operation_Disease"], [19, 22, "Drug", 0, 3, "Disease", "Drug_Disease"]]}
{"idx": 77, "sentence": "泡脚引起的足部感染，医嘱：糖尿病足各并下肢动脉硬化闭塞症明确，建议进行下肢血管介入治疗。", "ner": [[5, 9, "Symptom"], [13, 17, "Disease"], [19, 28, "Disease"], [35, 43, "Operation"]], "rel": [[19, 28, "Disease", 13, 17, "Disease", "Disease_Disease"], [5, 9, "Symptom", 13, 17, "Disease", "Symptom_Disease"], [35, 43, "Operation", 19, 28, "Disease", "Operation_Disease"], [5, 9, "Symptom", 19, 28, "Disease", "Symptom_Disease"], [35, 43, "Operation", 13, 17, "Disease", "Operation_Disease"]]}
{"idx": 78, "sentence": "病历概要：糖尿病足右足远端干性坏死近一月，综合病情考虑下肢血管闭塞远端缺血引起可能性大。处置建议：建议CTA检查（CT血管造影）明确血管病变，药物以控制基础病、抗血小板、降脂、扩管为主，清淡饮食、戒烟。", "ner": [[5, 9, "Disease"], [9, 13, "Anatomy"], [13, 17, "Symptom"], [17, 20, "Duration"], [51, 64, "Test"], [66, 68, "Anatomy"], [93, 97, "Treatment"], [98, 100, "Treatment"], [27, 33, "Disease"], [33, 37, "Symptom"]], "rel": [[9, 13, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [93, 97, "Treatment", 27, 33, "Disease", "Treatment_Disease"], [98, 100, "Treatment", 27, 33, "Disease", "Treatment_Disease"], [66, 68, "Anatomy", 27, 33, "Disease", "Anatomy_Disease"], [51, 64, "Test", 27, 33, "Disease", "Test_Disease"], [51, 64, "Test", 5, 9, "Disease", "Test_Disease"], [13, 17, "Symptom", 27, 33, "Disease", "Symptom_Disease"], [93, 97, "Treatment", 5, 9, "Disease", "Treatment_Disease"], [98, 100, "Treatment", 5, 9, "Disease", "Treatment_Disease"], [33, 37, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [33, 37, "Symptom", 27, 33, "Disease", "Symptom_Disease"]]}
{"idx": 79, "sentence": "糖尿病足情况严重，足部坏死组织增多。足部溃疡，肢端变黑。医嘱：重度缺血，足部坏疽，需要截肢来挽救生命。", "ner": [[0, 4, "Disease"], [6, 8, "Level"], [18, 22, "Symptom"], [23, 27, "Symptom"], [31, 33, "Level"], [36, 40, "Symptom"], [43, 45, "Operation"], [9, 17, "Symptom"]], "rel": [[9, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [23, 27, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [36, 40, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [43, 45, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 80, "sentence": "糖尿病足，肢端变黑、足趾坏疽，下肢动脉闭塞长度达到18.5厘米。医嘱：左足趾坏疽，CTA（CT血管造影）提示下肢动脉多发狭窄闭塞，建议介入手术开通患肢动脉血供。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 14, "Symptom"], [25, 31, "Test_Value"], [21, 23, "Test_items"], [35, 40, "Symptom"], [41, 52, "Test"], [15, 21, "Disease"], [54, 64, "Disease"], [67, 71, "Operation"], [75, 77, "Anatomy"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [35, 40, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [15, 21, "Disease", 0, 4, "Disease", "Disease_Disease"], [54, 64, "Disease", 0, 4, "Disease", "Disease_Disease"], [41, 52, "Test", 15, 21, "Disease", "Test_Disease"], [67, 71, "Operation", 15, 21, "Disease", "Operation_Disease"], [75, 77, "Anatomy", 15, 21, "Disease", "Anatomy_Disease"], [41, 52, "Test", 0, 4, "Disease", "Test_Disease"], [41, 52, "Test", 54, 64, "Disease", "Test_Disease"], [10, 14, "Symptom", 15, 21, "Disease", "Symptom_Disease"], [5, 9, "Symptom", 15, 21, "Disease", "Symptom_Disease"], [35, 40, "Symptom", 15, 21, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 54, 64, "Disease", "Symptom_Disease"], [5, 9, "Symptom", 54, 64, "Disease", "Symptom_Disease"], [35, 40, "Symptom", 54, 64, "Disease", "Symptom_Disease"], [75, 77, "Anatomy", 54, 64, "Disease", "Anatomy_Disease"], [67, 71, "Operation", 54, 64, "Disease", "Operation_Disease"], [67, 71, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 81, "sentence": "糖尿病足，足部溃烂，医嘱：足部感染，下肢动脉硬化闭塞。碘伏、酒精消毒创面后，雷夫奴尔溶液湿敷，每日二次，建议到我院门诊就诊，进一步治疗。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [13, 17, "Symptom"], [27, 29, "Drug"], [30, 32, "Drug"], [38, 44, "Drug"], [44, 46, "Method"], [47, 51, "Frequency"], [18, 26, "Disease"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [13, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [44, 46, "Method", 38, 44, "Drug", "Method_Drug"], [47, 51, "Frequency", 38, 44, "Drug", "Frequency_Drug"], [18, 26, "Disease", 0, 4, "Disease", "Disease_Disease"], [5, 9, "Symptom", 18, 26, "Disease", "Symptom_Disease"], [13, 17, "Symptom", 18, 26, "Disease", "Symptom_Disease"], [38, 44, "Drug", 0, 4, "Disease", "Drug_Disease"], [38, 44, "Drug", 18, 26, "Disease", "Drug_Disease"]]}
{"idx": 82, "sentence": "2020年10月开始右脚拇趾溃烂颜色苍白，足部开始疼痛不已，其中糖尿病足发展迅速，肢端变黑，右脚拇趾已全黑，大拇指半个黑掉，足根部溃烂，用碘伏每日冲洗伤口，刺痛非常。", "ner": [[10, 14, "Anatomy"], [14, 16, "Symptom"], [16, 20, "Symptom"], [25, 29, "Symptom"], [21, 23, "Anatomy"], [32, 36, "Disease"], [41, 45, "Symptom"], [46, 50, "Anatomy"], [62, 67, "Symptom"], [69, 71, "Drug"], [78, 80, "Symptom"], [71, 73, "Frequency"], [73, 75, "Method"], [54, 57, "Anatomy"], [51, 53, "Symptom"], [59, 60, "Symptom"]], "rel": [[14, 16, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [62, 67, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [41, 45, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [25, 29, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [78, 80, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [21, 23, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"], [73, 75, "Method", 69, 71, "Drug", "Method_Drug"], [71, 73, "Frequency", 69, 71, "Drug", "Frequency_Drug"], [59, 60, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [51, 53, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [46, 50, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"], [54, 57, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"]]}
{"idx": 83, "sentence": "糖尿病足，出现较深创口，肿胀。医嘱：糖尿病足，足部溃烂，控制血糖8-10mmol/L水平，彻底清创，每日换药，抗感染治疗。", "ner": [[0, 4, "Disease"], [12, 14, "Symptom"], [18, 22, "Disease"], [23, 27, "Symptom"], [30, 32, "Test_items"], [32, 42, "Test_Value"], [47, 49, "Operation"], [50, 52, "Frequency"]], "rel": [[12, 14, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [23, 27, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [47, 49, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 84, "sentence": "糖尿病足，足部肿胀、脓性分泌物较多，肢端变黑。医嘱：变黑坏死组织需要截肢。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 17, "Symptom"], [18, 22, "Symptom"], [34, 36, "Operation"], [26, 28, "Symptom"], [28, 30, "Symptom"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [26, 28, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [28, 30, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [34, 36, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 85, "sentence": "20年前确诊糖尿病，药物治疗，血糖控制不佳。1月前出现右足趾溃烂、肢端变黑，伤口愈合较差，直至出现骨外露。医嘱：从脚的发展和目前的情况，建议截肢手术，不建议勉强做开通，否则可能导致感染性休克有生命危险。", "ner": [[0, 4, "Duration"], [6, 9, "Disease"], [15, 17, "Test_items"], [27, 32, "Symptom"], [33, 37, "Symptom"], [38, 44, "Symptom"], [57, 58, "Anatomy"], [70, 74, "Operation"], [90, 95, "Disease"], [47, 52, "Symptom"]], "rel": [[15, 17, "Test_items", 6, 9, "Disease", "Test_items_Disease"]]}
{"idx": 86, "sentence": "多年糖尿病史，去年才开始打胰岛素，血糖稍有控制，糖尿病足综合症：患足麻木，足部刺痛、灼痛，间歇性跛行，下肢无力。医嘱：从临床症状上推测糖尿病足，建议完善一下下肢血管动脉血管超声检查，至于药物治疗，需要明确病情后会给您一个建议。", "ner": [[12, 13, "Method"], [13, 16, "Drug"], [17, 19, "Test_items"], [24, 31, "Disease"], [32, 36, "Symptom"], [37, 41, "Symptom"], [42, 44, "Symptom"], [45, 50, "Symptom"], [51, 55, "Symptom"], [67, 71, "Disease"], [78, 90, "Test"]], "rel": [[78, 90, "Test", 67, 71, "Disease", "Test_Disease"], [32, 36, "Symptom", 67, 71, "Disease", "Symptom_Disease"], [37, 41, "Symptom", 67, 71, "Disease", "Symptom_Disease"], [42, 44, "Symptom", 67, 71, "Disease", "Symptom_Disease"], [45, 50, "Symptom", 67, 71, "Disease", "Symptom_Disease"], [51, 55, "Symptom", 67, 71, "Disease", "Symptom_Disease"], [12, 13, "Method", 13, 16, "Drug", "Method_Drug"], [78, 90, "Test", 24, 31, "Disease", "Test_Disease"], [32, 36, "Symptom", 24, 31, "Disease", "Symptom_Disease"], [37, 41, "Symptom", 24, 31, "Disease", "Symptom_Disease"], [42, 44, "Symptom", 24, 31, "Disease", "Symptom_Disease"], [45, 50, "Symptom", 24, 31, "Disease", "Symptom_Disease"], [51, 55, "Symptom", 24, 31, "Disease", "Symptom_Disease"]]}
{"idx": 87, "sentence": "脚底龟裂引起的糖尿病足，坏死组织增多，医嘱：糖尿病足合并坏死性筋膜炎，建议尽快转院手术。", "ner": [[7, 11, "Disease"], [22, 26, "Disease"], [28, 34, "Disease"], [0, 4, "Reason"]], "rel": [[0, 4, "Reason", 7, 11, "Disease", "Reason_Disease"]]}
{"idx": 88, "sentence": "患者于1月前出现右足皮肤溃破，伴肢端变黑，去医院做检查提示右腘动脉狭窄，诊断糖尿病足，予抗生素及防止血栓药物输液治疗，目前坏死扩散严重。医嘱：严重的糖尿病足，估计内科保守效果不佳，应该考虑行脊髓电刺激手术，可以极大改善下肢血供，促进伤口愈合。", "ner": [[16, 20, "Symptom"], [10, 14, "Symptom"], [8, 10, "Anatomy"], [29, 35, "Disease"], [38, 42, "Disease"], [74, 78, "Disease"], [71, 73, "Level"], [95, 102, "Operation"], [109, 111, "Anatomy"], [65, 67, "Level"], [54, 56, "Method"]], "rel": [[29, 35, "Disease", 38, 42, "Disease", "Disease_Disease"], [8, 10, "Anatomy", 38, 42, "Disease", "Anatomy_Disease"], [95, 102, "Operation", 38, 42, "Disease", "Operation_Disease"], [10, 14, "Symptom", 38, 42, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 38, 42, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 29, 35, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 29, 35, "Disease", "Symptom_Disease"], [109, 111, "Anatomy", 29, 35, "Disease", "Anatomy_Disease"]]}
{"idx": 89, "sentence": "糖尿病足并感染，足底溃烂严重，有臭味，血糖13-15；心脏等功能正常，轻度肾炎。医嘱：完善BR（血液常规检查），PCT（降钙素原检查），CRP（C反应蛋白检查项目），ESR（红细胞沉降率检查），双下肢CTA检查（CT血管造影），创面分泌物细菌培养及药敏（药物敏感试验）。住院可以住足踝外科，也可以住内分泌科，方便控制血糖和感染。", "ner": [[0, 4, "Disease"], [8, 12, "Symptom"], [12, 14, "Level"], [15, 18, "Symptom"], [19, 21, "Test_items"], [21, 26, "Test_Value"], [27, 29, "Anatomy"], [35, 37, "Level"], [37, 39, "Disease"], [45, 55, "Test"], [56, 67, "Test"], [68, 82, "Test"], [83, 96, "Test"], [97, 113, "Test"], [114, 134, "Test"], [158, 160, "Test_items"], [5, 7, "Symptom"], [161, 163, "Symptom"]], "rel": [[8, 12, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [97, 113, "Test", 0, 4, "Disease", "Test_Disease"], [45, 55, "Test", 0, 4, "Disease", "Test_Disease"], [56, 67, "Test", 0, 4, "Disease", "Test_Disease"], [68, 82, "Test", 0, 4, "Disease", "Test_Disease"], [114, 134, "Test", 0, 4, "Disease", "Test_Disease"], [83, 96, "Test", 0, 4, "Disease", "Test_Disease"], [5, 7, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [15, 18, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 90, "sentence": "血糖长期不稳定，糖尿病足治疗目前两只脚下肢大血管己放入支架通至脚扳处，但是末梢脚趾介入无法到，现在脚趾变黑，医院让病人回家自行换药，肢端皮肤变成紫红色，足部刺痛。医嘱：典型的缺血性糖尿病足，也是最严重和危险的一种类型。治疗：只有下肢血管疏通才能缓解症状和后期治疗足部创面，否则真没有太多的好办法。", "ner": [[0, 2, "Test_items"], [8, 12, "Disease"], [31, 33, "Anatomy"], [16, 24, "Anatomy"], [37, 41, "Anatomy"], [49, 53, "Symptom"], [66, 75, "Symptom"], [76, 80, "Symptom"], [90, 94, "Disease"], [114, 118, "Anatomy"], [2, 4, "Duration"], [131, 133, "Anatomy"]], "rel": [[49, 53, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [76, 80, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [66, 75, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [37, 41, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [31, 33, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [131, 133, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 91, "sentence": "患者男78岁，长期患有糖尿病并发糖尿病足，从10年一只脚后跟磨破以后，伤口愈合较差，去医院查看，医生使用中草药及消炎药进行治疗。到2011年上半年，发现相应的脚出现了3个脚趾变黑，检查发现是这只小腿血管堵塞，做了相依的疏通手术，手术后病人感觉疼痛消失，可简单活动，出院。但过一段时间，动手术的这只脚其中的两个脚趾已经下垂，肢端变黑，去医院进行截肢（截掉脚部食指和中指），手术后，恢复程度一直很慢，脚面一直也没有消除肿胀，用大量的消炎药和中药进行热敷，效果一般，但期间的血糖指标正常。医嘱：1）你爸第一次截趾后，创面愈合慢，仍需进一步的消炎和局部换药。可以根据创面的细菌培养结果来选择抗生素，局部和全身使用并重。2）另一只脚也发生坏疽，当然需要截肢。截肢前可通过介入治疗或血管搭桥来改善血流，使截肢平面尽可能降低，最大限度保全肢体的功能。", "ner": [[11, 14, "Disease"], [16, 20, "Disease"], [7, 9, "Duration"], [27, 30, "Anatomy"], [35, 41, "Symptom"], [79, 80, "Anatomy"], [85, 87, "Anatomy"], [87, 89, "Symptom"], [109, 113, "Operation"], [148, 149, "Anatomy"], [154, 156, "Anatomy"], [158, 160, "Symptom"], [161, 165, "Symptom"], [171, 173, "Operation"], [176, 180, "Anatomy"], [181, 183, "Anatomy"], [198, 200, "Anatomy"], [234, 236, "Test_items"], [314, 316, "Symptom"], [321, 323, "Operation"], [324, 326, "Operation"], [330, 334, "Operation"], [335, 339, "Operation"], [362, 364, "Anatomy"], [222, 224, "Treatment"], [174, 176, "Operation"], [97, 103, "Disease"], [255, 260, "Symptom"], [251, 253, "Operation"]], "rel": [[16, 20, "Disease", 11, 14, "Disease", "Disease_Disease"], [314, 316, "Symptom", 16, 20, "Disease", "Symptom_Disease"], [161, 165, "Symptom", 16, 20, "Disease", "Symptom_Disease"], [35, 41, "Symptom", 16, 20, "Disease", "Symptom_Disease"], [87, 89, "Symptom", 16, 20, "Disease", "Symptom_Disease"], [255, 260, "Symptom", 16, 20, "Disease", "Symptom_Disease"], [158, 160, "Symptom", 16, 20, "Disease", "Symptom_Disease"], [35, 41, "Symptom", 97, 103, "Disease", "Symptom_Disease"], [87, 89, "Symptom", 97, 103, "Disease", "Symptom_Disease"], [158, 160, "Symptom", 97, 103, "Disease", "Symptom_Disease"], [161, 165, "Symptom", 97, 103, "Disease", "Symptom_Disease"], [255, 260, "Symptom", 97, 103, "Disease", "Symptom_Disease"], [314, 316, "Symptom", 97, 103, "Disease", "Symptom_Disease"], [27, 30, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [85, 87, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [79, 80, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [176, 180, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [181, 183, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [198, 200, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [362, 364, "Anatomy", 97, 103, "Disease", "Anatomy_Disease"], [222, 224, "Treatment", 97, 103, "Disease", "Treatment_Disease"], [222, 224, "Treatment", 16, 20, "Disease", "Treatment_Disease"], [97, 103, "Disease", 16, 20, "Disease", "Disease_Disease"], [109, 113, "Operation", 16, 20, "Disease", "Operation_Disease"], [174, 176, "Operation", 16, 20, "Disease", "Operation_Disease"], [171, 173, "Operation", 16, 20, "Disease", "Operation_Disease"], [251, 253, "Operation", 16, 20, "Disease", "Operation_Disease"], [330, 334, "Operation", 16, 20, "Disease", "Operation_Disease"], [335, 339, "Operation", 97, 103, "Disease", "Operation_Disease"], [109, 113, "Operation", 97, 103, "Disease", "Operation_Disease"], [174, 176, "Operation", 97, 103, "Disease", "Operation_Disease"], [171, 173, "Operation", 97, 103, "Disease", "Operation_Disease"], [251, 253, "Operation", 97, 103, "Disease", "Operation_Disease"], [330, 334, "Operation", 97, 103, "Disease", "Operation_Disease"], [335, 339, "Operation", 16, 20, "Disease", "Operation_Disease"]]}
{"idx": 92, "sentence": "糖尿病20多年并发糖尿病足，脚上长水疱，现在餐前血糖8，餐后血糖9.5，长期打胰岛素，早上18，晚上15。医嘱：CTA（CT血管造影）的结果显示膝关节下病变，药物治疗就行。", "ner": [[0, 3, "Disease"], [3, 7, "Duration"], [9, 13, "Disease"], [16, 19, "Symptom"], [14, 16, "Anatomy"], [32, 35, "Test_Value"], [26, 27, "Test_Value"], [39, 42, "Drug"], [38, 39, "Method"], [36, 38, "Duration"], [43, 47, "Amount"], [48, 52, "Amount"], [56, 67, "Test"], [22, 26, "Test_items"], [28, 32, "Test_items"], [72, 78, "Disease"]], "rel": [[9, 13, "Disease", 0, 3, "Disease", "Disease_Disease"], [16, 19, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [14, 16, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [28, 32, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [22, 26, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [38, 39, "Method", 39, 42, "Drug", "Method_Drug"], [43, 47, "Amount", 39, 42, "Drug", "Amount_Drug"], [48, 52, "Amount", 39, 42, "Drug", "Amount_Drug"], [56, 67, "Test", 9, 13, "Disease", "Test_Disease"], [39, 42, "Drug", 0, 3, "Disease", "Drug_Disease"], [72, 78, "Disease", 0, 3, "Disease", "Disease_Disease"]]}
{"idx": 93, "sentence": "糖尿病足，脚步伤口发炎发烧不退，肢端皮肤变成紫红色，外科医生对脚部伤口进行一次简单包扎，透明油性敷料。医嘱：足部坏死组织没有增加因为血运不是完全闭塞，持续的发烧就说明足部感染没有控制住。", "ner": [[0, 4, "Disease"], [7, 11, "Symptom"], [11, 15, "Symptom"], [16, 25, "Symptom"], [31, 33, "Anatomy"], [41, 43, "Treatment"], [54, 56, "Anatomy"], [83, 87, "Disease"], [78, 80, "Symptom"], [72, 74, "Symptom"], [44, 50, "Treatment"]], "rel": [[7, 11, "Symptom", 83, 87, "Disease", "Symptom_Disease"], [11, 15, "Symptom", 83, 87, "Disease", "Symptom_Disease"], [16, 25, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [31, 33, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [54, 56, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [54, 56, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [72, 74, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [44, 50, "Treatment", 0, 4, "Disease", "Treatment_Disease"]]}
{"idx": 94, "sentence": "糖尿病足，足部溃烂部分进行了清理，每天饭前20分钟打胰岛素、早12个、中午14个、晚12个，睡前9点打长效胰岛素6个；用消炎最好的头孢药；口服药：琥珀酸亚铁片、维生素C、谷维素。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [17, 25, "Frequency"], [25, 26, "Method"], [26, 29, "Drug"], [30, 34, "Amount"], [35, 40, "Amount"], [41, 45, "Amount"], [50, 51, "Method"], [56, 58, "Amount"], [65, 68, "Drug"], [73, 79, "Drug"], [80, 84, "Drug"], [85, 88, "Drug"], [51, 56, "Drug"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [25, 26, "Method", 26, 29, "Drug", "Method_Drug"], [50, 51, "Method", 51, 56, "Drug", "Method_Drug"], [30, 34, "Amount", 26, 29, "Drug", "Amount_Drug"], [35, 40, "Amount", 26, 29, "Drug", "Amount_Drug"], [41, 45, "Amount", 26, 29, "Drug", "Amount_Drug"], [56, 58, "Amount", 51, 56, "Drug", "Amount_Drug"], [17, 25, "Frequency", 26, 29, "Drug", "Frequency_Drug"], [65, 68, "Drug", 0, 4, "Disease", "Drug_Disease"], [73, 79, "Drug", 0, 4, "Disease", "Drug_Disease"], [80, 84, "Drug", 0, 4, "Disease", "Drug_Disease"], [85, 88, "Drug", 0, 4, "Disease", "Drug_Disease"]]}
{"idx": 95, "sentence": "糖尿病足，足部血液流通不畅，伤口愈合较差，空腹血糖5.6餐前血糖8.6。医嘱：控制血糖，控制足部感染而迁延不愈合，可以用点表皮生长因子。", "ner": [[0, 4, "Disease"], [14, 20, "Symptom"], [21, 25, "Test_items"], [25, 28, "Test_Value"], [28, 32, "Test_items"], [32, 35, "Test_Value"], [41, 43, "Test_items"], [46, 50, "Disease"], [61, 67, "Drug"], [5, 13, "Symptom"]], "rel": [[46, 50, "Disease", 0, 4, "Disease", "Disease_Disease"], [14, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [41, 43, "Test_items", 0, 4, "Disease", "Test_items_Disease"], [61, 67, "Drug", 46, 50, "Disease", "Drug_Disease"], [5, 13, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [61, 67, "Drug", 0, 4, "Disease", "Drug_Disease"]]}
{"idx": 96, "sentence": "糖尿病足，血糖高，自己一直没注意，上个月严重了，脚趾变黑，足部刺痛，去医院就诊，血压高180 心率快120  发烧38.5  内分泌住七天，注射胰岛素，消炎，降压 现在心率100以下，餐前血糖七点多 餐后血糖八到十四浮动  骨外科建议截肢在大腿，想问问您有能有更好的办法。医嘱：建议手术，微创治疗应该可以。", "ner": [[0, 4, "Disease"], [5, 7, "Test_items"], [7, 8, "Test_Value"], [20, 22, "Level"], [24, 28, "Symptom"], [29, 33, "Symptom"], [40, 42, "Test_items"], [42, 43, "Test_Value"], [43, 46, "Test_Value"], [47, 49, "Test_items"], [49, 53, "Test_Value"], [55, 57, "Symptom"], [57, 61, "Test_Value"], [72, 75, "Drug"], [70, 72, "Method"], [84, 86, "Test_items"], [86, 91, "Test_Value"], [92, 96, "Test_items"], [96, 99, "Test_Value"], [100, 104, "Test_items"], [104, 110, "Test_Value"], [117, 119, "Operation"], [120, 122, "Anatomy"], [144, 148, "Operation"]], "rel": [[24, 28, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [29, 33, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [70, 72, "Method", 72, 75, "Drug", "Method_Drug"], [117, 119, "Operation", 0, 4, "Disease", "Operation_Disease"], [144, 148, "Operation", 0, 4, "Disease", "Operation_Disease"], [55, 57, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 97, "sentence": "糖尿病足，一个月前脚趾溃烂，起初不疼，最近溃烂部位开始疼，足部刺痛，脚趾中间是放了加了碘酒的。医嘱：做手术需要下肢血管cta及心肺肾功能检验结果。", "ner": [[0, 4, "Disease"], [9, 13, "Symptom"], [29, 33, "Symptom"], [21, 25, "Anatomy"], [34, 36, "Anatomy"], [43, 45, "Drug"], [55, 62, "Test"], [63, 70, "Test"]], "rel": [[55, 62, "Test", 0, 4, "Disease", "Test_Disease"], [63, 70, "Test", 0, 4, "Disease", "Test_Disease"], [9, 13, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [29, 33, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [34, 36, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 98, "sentence": "患糖尿病已经接近20年，糖尿病足，有心脏病，高血压等并发症。从2003年左右开始患足麻木，最近3到4年每次走路疼痛难忍，描述肢端灼痛，每次出去走一趟，回来就要用手搓半天才缓解。而且肢端皮肤变成紫红色，睡觉的时候不疼。目前在注射胰岛素，血糖控制的不错。", "ner": [[1, 4, "Disease"], [6, 11, "Duration"], [12, 16, "Disease"], [18, 21, "Disease"], [22, 25, "Disease"], [41, 44, "Symptom"], [55, 59, "Symptom"], [62, 66, "Symptom"], [80, 81, "Anatomy"], [90, 99, "Symptom"], [111, 113, "Method"], [113, 116, "Drug"], [117, 119, "Test_items"], [100, 107, "Symptom"]], "rel": [[12, 16, "Disease", 1, 4, "Disease", "Disease_Disease"], [18, 21, "Disease", 1, 4, "Disease", "Disease_Disease"], [22, 25, "Disease", 1, 4, "Disease", "Disease_Disease"], [111, 113, "Method", 113, 116, "Drug", "Method_Drug"], [117, 119, "Test_items", 1, 4, "Disease", "Test_items_Disease"], [100, 107, "Symptom", 12, 16, "Disease", "Symptom_Disease"], [41, 44, "Symptom", 12, 16, "Disease", "Symptom_Disease"], [55, 59, "Symptom", 12, 16, "Disease", "Symptom_Disease"], [62, 66, "Symptom", 12, 16, "Disease", "Symptom_Disease"], [90, 99, "Symptom", 12, 16, "Disease", "Symptom_Disease"], [113, 116, "Drug", 1, 4, "Disease", "Drug_Disease"]]}
{"idx": 99, "sentence": "糖尿病足，患足足背、食趾有散在多发溃疡面，足部溃疡，表面干燥无分泌物，肢端皮肤变成紫红色，轻微浮肿。医嘱：可以用点抗生素，加强换药和观察。", "ner": [[0, 4, "Disease"], [13, 20, "Symptom"], [21, 25, "Symptom"], [26, 34, "Symptom"], [35, 44, "Symptom"], [45, 49, "Symptom"], [7, 9, "Anatomy"], [10, 12, "Anatomy"]], "rel": [[13, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [26, 34, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [35, 44, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [45, 49, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 100, "sentence": "糖尿病足，足部溃烂，肿胀，指头溃烂。长期糖尿病，尿酸。医嘱：缺血感染糖尿病足，建议住院治疗。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 12, "Symptom"], [13, 17, "Symptom"], [20, 23, "Disease"], [18, 20, "Duration"], [30, 32, "Reason"], [34, 38, "Disease"], [24, 26, "Test_items"]], "rel": [[30, 32, "Reason", 34, 38, "Disease", "Reason_Disease"], [34, 38, "Disease", 20, 23, "Disease", "Disease_Disease"], [13, 17, "Symptom", 34, 38, "Disease", "Symptom_Disease"], [10, 12, "Symptom", 34, 38, "Disease", "Symptom_Disease"], [5, 9, "Symptom", 34, 38, "Disease", "Symptom_Disease"]]}
{"idx": 101, "sentence": "糖尿病伴有多种并发症，目前糖尿病足严重，手指脚趾变黑剧烈疼痛。", "ner": [[0, 3, "Disease"], [13, 17, "Disease"], [20, 26, "Symptom"], [26, 30, "Symptom"], [17, 19, "Level"]], "rel": [[13, 17, "Disease", 0, 3, "Disease", "Disease_Disease"], [20, 26, "Symptom", 13, 17, "Disease", "Symptom_Disease"], [26, 30, "Symptom", 13, 17, "Disease", "Symptom_Disease"]]}
{"idx": 102, "sentence": "发现间歇性跛行，9月检查双下肢CTA，双下肢动脉闭塞，其中，左肢膝盖以上大动脉闭塞情况严重，小腿有一根小动脉能见血流。而右肢大动脉相对好一些，但小腿小动脉都闭塞。医院血管外科左肢介入手术放置2个支架，右肢放了1个支架。12月天气变冷，右脚大脚趾、二脚趾、四脚趾皮肤变紫红色，且大脚趾、二脚趾变紫处触碰疼痛，1月份大脚趾、二脚趾发展为自主无规律疼痛，晚上睡觉也疼。1月下旬入靖江市人民医院，用前列地尔、硫辛酸输液，略有好转，但仍有间歇性休息痛，疼痛时间十几秒、几十秒消失，且大脚趾、二脚趾不固定。", "ner": [[2, 7, "Symptom"], [12, 18, "Test"], [30, 39, "Anatomy"], [43, 45, "Level"], [46, 48, "Anatomy"], [51, 54, "Anatomy"], [60, 65, "Anatomy"], [72, 77, "Anatomy"], [87, 93, "Operation"], [117, 122, "Anatomy"], [123, 126, "Anatomy"], [127, 130, "Anatomy"], [130, 136, "Symptom"], [138, 141, "Anatomy"], [142, 145, "Anatomy"], [145, 152, "Symptom"], [156, 159, "Anatomy"], [160, 163, "Anatomy"], [166, 173, "Symptom"], [195, 199, "Drug"], [200, 203, "Drug"], [203, 205, "Method"], [214, 220, "Symptom"], [236, 239, "Anatomy"], [240, 243, "Anatomy"], [19, 26, "Disease"], [78, 80, "Symptom"]], "rel": [[12, 18, "Test", 19, 26, "Disease", "Test_Disease"], [87, 93, "Operation", 19, 26, "Disease", "Operation_Disease"], [2, 7, "Symptom", 19, 26, "Disease", "Symptom_Disease"], [130, 136, "Symptom", 19, 26, "Disease", "Symptom_Disease"], [145, 152, "Symptom", 19, 26, "Disease", "Symptom_Disease"], [166, 173, "Symptom", 19, 26, "Disease", "Symptom_Disease"], [214, 220, "Symptom", 19, 26, "Disease", "Symptom_Disease"], [72, 77, "Anatomy", 19, 26, "Disease", "Anatomy_Disease"], [60, 65, "Anatomy", 19, 26, "Disease", "Anatomy_Disease"], [203, 205, "Method", 195, 199, "Drug", "Method_Drug"], [203, 205, "Method", 200, 203, "Drug", "Method_Drug"], [30, 39, "Anatomy", 19, 26, "Disease", "Anatomy_Disease"], [51, 54, "Anatomy", 19, 26, "Disease", "Anatomy_Disease"], [195, 199, "Drug", 19, 26, "Disease", "Drug_Disease"], [200, 203, "Drug", 19, 26, "Disease", "Drug_Disease"], [78, 80, "Symptom", 19, 26, "Disease", "Symptom_Disease"]]}
{"idx": 103, "sentence": "糖尿病足，去年10月份右脚小趾坏死组织增多，今年4月左脚跟坏死，右脚俩个脚趾截掉，左脚肢端变黑，而且面积还在扩大，近期发高烧，脓性分泌物较多。糖尿病30年病程，透析5年，医嘱：缺血比较重，如果有机会介入，建议介入手术尝试开通一下血管。但是，总体来说，截肢风险比较大，先处理创面，清创引流，减压。", "ner": [[0, 4, "Disease"], [11, 15, "Anatomy"], [26, 29, "Anatomy"], [32, 38, "Anatomy"], [38, 40, "Operation"], [41, 47, "Symptom"], [59, 62, "Symptom"], [63, 70, "Symptom"], [71, 74, "Disease"], [74, 79, "Duration"], [80, 82, "Treatment"], [82, 84, "Duration"], [104, 108, "Operation"], [125, 127, "Operation"], [139, 141, "Operation"], [144, 146, "Treatment"], [141, 143, "Treatment"], [88, 90, "Symptom"], [114, 116, "Anatomy"]], "rel": [[41, 47, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [63, 70, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [59, 62, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [104, 108, "Operation", 0, 4, "Disease", "Operation_Disease"], [125, 127, "Operation", 0, 4, "Disease", "Operation_Disease"], [0, 4, "Disease", 71, 74, "Disease", "Disease_Disease"], [26, 29, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [11, 15, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [32, 38, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [139, 141, "Operation", 0, 4, "Disease", "Operation_Disease"], [141, 143, "Treatment", 0, 4, "Disease", "Treatment_Disease"], [144, 146, "Treatment", 0, 4, "Disease", "Treatment_Disease"], [88, 90, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [38, 40, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 104, "sentence": "三个月以前足部溃烂了，现在脚趾头上有两个洞，伤口愈合较差。医嘱：糖尿病足，是否合并骨质破坏和下肢缺血还需要进一步检查。如果足部感染未能控制、下肢血供不够，是无法愈合的。", "ner": [[13, 17, "Anatomy"], [22, 28, "Symptom"], [32, 36, "Disease"], [5, 9, "Symptom"], [41, 45, "Symptom"], [46, 50, "Symptom"], [61, 65, "Disease"], [70, 76, "Symptom"]], "rel": [[5, 9, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [22, 28, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [41, 45, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [46, 50, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [70, 76, "Symptom", 32, 36, "Disease", "Symptom_Disease"], [61, 65, "Disease", 32, 36, "Disease", "Disease_Disease"], [13, 17, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"]]}
{"idx": 105, "sentence": "糖尿病足，左脚小指和四指肢端变黑，脚面溃烂，现在脚面溃烂还没好，特别是夜里有时疼得睡不着，就诊后略有缓解，伤口愈合较差。医嘱：介入手术治疗。", "ner": [[0, 4, "Disease"], [5, 9, "Anatomy"], [10, 12, "Anatomy"], [12, 16, "Symptom"], [17, 21, "Symptom"], [24, 26, "Anatomy"], [53, 59, "Symptom"], [63, 67, "Operation"]], "rel": [[12, 16, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [17, 21, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [53, 59, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [5, 9, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [10, 12, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [24, 26, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [63, 67, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 106, "sentence": "家族遗传高血压，脑梗恢复期，因血糖控制不稳导致糖尿病足，患处比原来有加重，出院2个月左右，现医院建议截肢。足后跟溃疡形成，伴有下肢缺血。需要处理血管，并清理足部溃疡，坏死组织增多，如果坏死范围深及跟骨，后期可能需要皮瓣修复伤口。保肢治疗有希望，直接截肢有点可惜。", "ner": [[4, 7, "Disease"], [8, 10, "Disease"], [15, 17, "Test_items"], [23, 27, "Disease"], [33, 36, "Level"], [50, 52, "Operation"], [53, 56, "Anatomy"], [56, 60, "Symptom"], [63, 67, "Symptom"], [72, 74, "Anatomy"], [78, 80, "Anatomy"], [98, 100, "Anatomy"], [124, 126, "Operation"], [107, 109, "Anatomy"]], "rel": [[63, 67, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [56, 60, "Symptom", 23, 27, "Disease", "Symptom_Disease"], [53, 56, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"], [78, 80, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"], [50, 52, "Operation", 23, 27, "Disease", "Operation_Disease"], [98, 100, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"]]}
{"idx": 107, "sentence": "2021年6月上旬发现左脚脚底溃疡，足温发热，后来发展为全身发热，于6月16号住院至今，脚底发臭、脓性分泌物较多，于7月29号在蚌埠医学院第一附属医院实施了胫骨横向搬移手术，但是至今脚底每天还是有脓液渗出。医嘱：综合您足部照片及下肢血管CTA检查判断，糖尿病足的发生与感染及下肢缺血有关。虽然当地医院做个胫骨横向骨搬移及创面骨水泥植入，但是效果并不好。单从创面看，任然有脓液流出，即局部感染存在，没有彻底清创。建议：立即拆除骨水泥，清除创面里坏死组织，再评估血管，是否可以通过介入方法改善血供。如果感染继续进展，创面更深入坏死，恐怕只能截肢了。", "ner": [[13, 17, "Symptom"], [11, 13, "Anatomy"], [18, 22, "Symptom"], [28, 32, "Symptom"], [44, 48, "Symptom"], [49, 56, "Symptom"], [78, 86, "Operation"], [91, 93, "Anatomy"], [93, 95, "Frequency"], [97, 102, "Symptom"], [109, 111, "Anatomy"], [114, 123, "Test"], [126, 130, "Disease"], [134, 136, "Reason"], [137, 141, "Reason"], [152, 159, "Operation"], [160, 167, "Operation"], [184, 189, "Symptom"], [191, 195, "Symptom"], [202, 204, "Operation"], [268, 270, "Operation"], [238, 240, "Operation"], [249, 251, "Symptom"]], "rel": [[78, 86, "Operation", 126, 130, "Disease", "Operation_Disease"], [160, 167, "Operation", 126, 130, "Disease", "Operation_Disease"], [202, 204, "Operation", 126, 130, "Disease", "Operation_Disease"], [238, 240, "Operation", 126, 130, "Disease", "Operation_Disease"], [268, 270, "Operation", 126, 130, "Disease", "Operation_Disease"], [44, 48, "Symptom", 126, 130, "Disease", "Symptom_Disease"], [49, 56, "Symptom", 126, 130, "Disease", "Symptom_Disease"], [97, 102, "Symptom", 126, 130, "Disease", "Symptom_Disease"], [13, 17, "Symptom", 126, 130, "Disease", "Symptom_Disease"], [18, 22, "Symptom", 126, 130, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 126, 130, "Disease", "Symptom_Disease"], [91, 93, "Anatomy", 126, 130, "Disease", "Anatomy_Disease"], [11, 13, "Anatomy", 126, 130, "Disease", "Anatomy_Disease"], [109, 111, "Anatomy", 126, 130, "Disease", "Anatomy_Disease"], [114, 123, "Test", 126, 130, "Disease", "Test_Disease"], [134, 136, "Reason", 126, 130, "Disease", "Reason_Disease"], [137, 141, "Reason", 126, 130, "Disease", "Reason_Disease"]]}
{"idx": 108, "sentence": "糖尿病20多年，一直服用二甲双胍，格列吡嗪每日三次每次一粒。近一年又加服用阿卡波糖每日三次每次一粒。近半年突发糖尿病足，伤口愈合较差，在小诊所打针无效果后现住院治疗，足部做了微创清理小手术。住院初次开始注射胰岛素，检查出肾功能出现问题，右眼底有水肿，眼睛之前都做过白内障手术，其中右眼刚打过激光。医嘱：情况了解，糖尿病并发糖尿病足，医生建议使用前列地尔治疗很好，该药对下肢血管有扩张，疏通，修复作用，能使糖尿病足局部血供应增加，帮助创伤愈合，一般使用10天右。入院检查肾功能，眼底问题，从糖尿病治疗方面来看注射胰岛素是对你最好治疗，胰岛素对肝功能，肾功能没有副作用，对眼底视网膜病变有改善作用，医生治疗，建议还是不错的。化验报告有大量蛋白尿，己并发糖尿病肾病，要认真治疗，可增加减少蛋白尿排出药物，己经住院医师都会选用。", "ner": [[0, 3, "Disease"], [3, 7, "Duration"], [12, 16, "Drug"], [10, 12, "Method"], [8, 10, "Duration"], [17, 21, "Drug"], [21, 25, "Frequency"], [25, 29, "Amount"], [35, 37, "Method"], [37, 41, "Drug"], [41, 45, "Frequency"], [45, 49, "Amount"], [55, 59, "Disease"], [60, 66, "Symptom"], [83, 85, "Anatomy"], [87, 94, "Operation"], [101, 103, "Method"], [103, 106, "Drug"], [110, 111, "Anatomy"], [118, 121, "Anatomy"], [122, 124, "Symptom"], [125, 127, "Anatomy"], [132, 137, "Operation"], [140, 142, "Anatomy"], [145, 147, "Treatment"], [156, 159, "Disease"], [161, 165, "Disease"], [172, 176, "Drug"], [184, 188, "Anatomy"], [202, 206, "Disease"], [225, 229, "Duration"], [234, 235, "Anatomy"], [238, 240, "Anatomy"], [244, 247, "Disease"], [253, 255, "Method"], [255, 258, "Drug"], [266, 269, "Drug"], [270, 271, "Anatomy"], [274, 275, "Anatomy"], [284, 291, "Disease"], [317, 320, "Symptom"], [324, 329, "Disease"], [341, 344, "Symptom"]], "rel": [[55, 59, "Disease", 0, 3, "Disease", "Disease_Disease"], [324, 329, "Disease", 0, 3, "Disease", "Disease_Disease"], [284, 291, "Disease", 0, 3, "Disease", "Disease_Disease"], [10, 12, "Method", 12, 16, "Drug", "Method_Drug"], [10, 12, "Method", 17, 21, "Drug", "Method_Drug"], [35, 37, "Method", 37, 41, "Drug", "Method_Drug"], [101, 103, "Method", 103, 106, "Drug", "Method_Drug"], [21, 25, "Frequency", 17, 21, "Drug", "Frequency_Drug"], [21, 25, "Frequency", 12, 16, "Drug", "Frequency_Drug"], [41, 45, "Frequency", 37, 41, "Drug", "Frequency_Drug"], [25, 29, "Amount", 12, 16, "Drug", "Amount_Drug"], [25, 29, "Amount", 17, 21, "Drug", "Amount_Drug"], [45, 49, "Amount", 37, 41, "Drug", "Amount_Drug"], [60, 66, "Symptom", 55, 59, "Disease", "Symptom_Disease"], [87, 94, "Operation", 55, 59, "Disease", "Operation_Disease"], [83, 85, "Anatomy", 55, 59, "Disease", "Anatomy_Disease"], [274, 275, "Anatomy", 324, 329, "Disease", "Anatomy_Disease"], [317, 320, "Symptom", 324, 329, "Disease", "Symptom_Disease"], [12, 16, "Drug", 0, 3, "Disease", "Drug_Disease"], [17, 21, "Drug", 0, 3, "Disease", "Drug_Disease"], [37, 41, "Drug", 0, 3, "Disease", "Drug_Disease"], [103, 106, "Drug", 0, 3, "Disease", "Drug_Disease"], [122, 124, "Symptom", 284, 291, "Disease", "Symptom_Disease"], [172, 176, "Drug", 161, 165, "Disease", "Drug_Disease"], [118, 121, "Anatomy", 284, 291, "Disease", "Anatomy_Disease"], [140, 142, "Anatomy", 284, 291, "Disease", "Anatomy_Disease"], [238, 240, "Anatomy", 284, 291, "Disease", "Anatomy_Disease"]]}
{"idx": 109, "sentence": "糖尿病足,开始脚趾变黑，足部溃疡，1个星期发展到脚掌。医嘱：患者诊断是糖尿病足，下肢动脉硬化闭塞症合并左足坏疽。那么这样1个病人，现在这个足部坏疽的很重，足部坏死组织增多已达足心深部，变性坏死的组织是无法恢复的。建议完善下肢的动脉粥样CT，存在脓肿，应该切开引流，可以用普朗特凝胶敷料外用抗菌，如果坏死这个继续蔓延的话，那么这个病人就需要截肢处理。", "ner": [[0, 4, "Disease"], [7, 11, "Symptom"], [12, 16, "Symptom"], [24, 26, "Anatomy"], [35, 39, "Disease"], [40, 49, "Disease"], [51, 55, "Symptom"], [69, 73, "Symptom"], [77, 79, "Anatomy"], [87, 89, "Anatomy"], [110, 119, "Test"], [120, 124, "Symptom"], [135, 142, "Treatment"], [169, 171, "Operation"], [129, 131, "Treatment"]], "rel": [[7, 11, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [12, 16, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [69, 73, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [120, 124, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [110, 119, "Test", 40, 49, "Disease", "Test_Disease"], [40, 49, "Disease", 0, 4, "Disease", "Disease_Disease"], [77, 79, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [169, 171, "Operation", 40, 49, "Disease", "Operation_Disease"], [135, 142, "Treatment", 0, 4, "Disease", "Treatment_Disease"], [110, 119, "Test", 0, 4, "Disease", "Test_Disease"], [7, 11, "Symptom", 40, 49, "Disease", "Symptom_Disease"], [12, 16, "Symptom", 40, 49, "Disease", "Symptom_Disease"], [51, 55, "Symptom", 40, 49, "Disease", "Symptom_Disease"], [69, 73, "Symptom", 40, 49, "Disease", "Symptom_Disease"], [120, 124, "Symptom", 40, 49, "Disease", "Symptom_Disease"], [87, 89, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [24, 26, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [169, 171, "Operation", 0, 4, "Disease", "Operation_Disease"], [129, 131, "Treatment", 0, 4, "Disease", "Treatment_Disease"], [129, 131, "Treatment", 40, 49, "Disease", "Treatment_Disease"]]}
{"idx": 110, "sentence": "糖尿病足，尿毒症，糖尿病病足伤口愈合较差，脓性分泌物较多，渗水之后开始肢端变黑 并没有好转无法自愈 现在吃当地医院开的贝前列素钠 抹的药膏。病历概要：糖尿病，下肢动脉闭塞。处置建议：当地医院完善下肢动脉检查后决定进一步方案。", "ner": [[0, 4, "Disease"], [5, 8, "Disease"], [9, 12, "Disease"], [12, 20, "Symptom"], [21, 28, "Symptom"], [35, 39, "Symptom"], [59, 64, "Drug"], [52, 53, "Method"], [65, 66, "Method"], [75, 78, "Disease"], [79, 85, "Disease"], [97, 103, "Test"]], "rel": [[0, 4, "Disease", 75, 78, "Disease", "Disease_Disease"], [12, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [21, 28, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [35, 39, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [52, 53, "Method", 59, 64, "Drug", "Method_Drug"], [97, 103, "Test", 79, 85, "Disease", "Test_Disease"], [97, 103, "Test", 0, 4, "Disease", "Test_Disease"], [12, 20, "Symptom", 79, 85, "Disease", "Symptom_Disease"], [21, 28, "Symptom", 79, 85, "Disease", "Symptom_Disease"], [35, 39, "Symptom", 79, 85, "Disease", "Symptom_Disease"], [59, 64, "Drug", 79, 85, "Disease", "Drug_Disease"], [59, 64, "Drug", 0, 4, "Disease", "Drug_Disease"], [79, 85, "Disease", 75, 78, "Disease", "Disease_Disease"]]}
{"idx": 111, "sentence": "糖尿病足，患者男性，80岁，糖尿病史40年，四个月前干活时不慎擦破左足趾3.4。县医院住院治疗三个月余，脚趾坏死三个，脚背皮肤颜色发紫。医嘱：三个趾头需要截肢，不知道足背动脉搏动或者说血管供血情况，但治疗难度大，需要综合治疗，内科药物，局部换药，血管介入治疗改善供血，甚至截肢。", "ner": [[0, 4, "Disease"], [18, 21, "Duration"], [33, 36, "Anatomy"], [52, 54, "Anatomy"], [59, 67, "Symptom"], [73, 75, "Anatomy"], [77, 79, "Operation"], [83, 87, "Anatomy"], [92, 94, "Anatomy"], [136, 138, "Operation"], [123, 129, "Operation"]], "rel": [[59, 67, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [52, 54, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [73, 75, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [77, 79, "Operation", 0, 4, "Disease", "Operation_Disease"], [123, 129, "Operation", 0, 4, "Disease", "Operation_Disease"], [33, 36, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 112, "sentence": "糖尿病6年，血糖未控制好，导致足部感染，疼痛无法行走，过去两年期间有过两次足部切开手术。这次病情加重，这边医院处理不了，建议转入上级医院治疗。医嘱：根据它这个图片看，应该是足部感染严重的。然后足底部这个地方需要进行1个切开引流血管的问题，因为CT的描述不是很清楚，不是很好判断，但是感染很重，首先要切开引流。", "ner": [[0, 3, "Disease"], [3, 5, "Duration"], [6, 8, "Test_items"], [20, 22, "Symptom"], [37, 43, "Operation"], [90, 93, "Level"], [96, 99, "Anatomy"], [113, 115, "Anatomy"], [121, 123, "Test"], [141, 143, "Symptom"], [86, 90, "Disease"], [15, 19, "Disease"], [151, 153, "Treatment"]], "rel": [[6, 8, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [20, 22, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [141, 143, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [96, 99, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"], [151, 153, "Treatment", 15, 19, "Disease", "Treatment_Disease"]]}
{"idx": 113, "sentence": "糖尿病15年，糖尿病足，足部感染，足面红肿，没有疼痛。病历概要：糖尿病足，足趾坏疽。处置建议：建议抗感染治疗后截趾。", "ner": [[0, 3, "Disease"], [3, 6, "Duration"], [7, 11, "Disease"], [12, 16, "Symptom"], [17, 21, "Symptom"], [22, 26, "Symptom"], [32, 36, "Disease"], [37, 41, "Symptom"], [55, 57, "Operation"]], "rel": [[7, 11, "Disease", 0, 3, "Disease", "Disease_Disease"], [12, 16, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [17, 21, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [22, 26, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [37, 41, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [55, 57, "Operation", 7, 11, "Disease", "Operation_Disease"]]}
{"idx": 114, "sentence": "患者是81岁患者糖尿病足，然后来院的时候足底的皮肤坏死，足部溃烂.经过几个月的治疗，现在足底的皮肤已经基本愈合，只是脚后跟有一处伤口愈合较差，然后足部远端有一处小的创面没有长上.目前的话，继续局部换药，深部可以用庆大霉素，b12做湿敷，然后等这个创面变成从三维变成二维，然后只剩皮肤没长的时候，可以应用表皮生长因子凝胶。处置建议：继续换药治疗，足跟注意减张。", "ner": [[8, 12, "Disease"], [28, 32, "Symptom"], [20, 27, "Symptom"], [44, 49, "Anatomy"], [58, 61, "Anatomy"], [64, 70, "Symptom"], [73, 77, "Anatomy"], [115, 117, "Method"], [151, 159, "Drug"], [172, 174, "Anatomy"], [106, 114, "Drug"]], "rel": [[20, 27, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [64, 70, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [111, 114, "Drug", 8, 12, "Disease", "Drug_Disease"], [106, 110, "Drug", 8, 12, "Disease", "Drug_Disease"], [172, 174, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [106, 114, "Drug", 115, 117, "Method", "Method_Drug"], [58, 61, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [73, 77, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 115, "sentence": "患者于2月前因外伤后出现右足趾伤口不愈合并有下肢颜色改变，后在住院检查为糖尿病足及下肢血管闭塞，行介入手术治疗，效果不佳，后于2月2日，转院至郑州大学附属第一医院治疗，再次行介入手术，并行右足第二趾截肢术，术后效果未达预期，今切口愈合不佳，并有踇趾及中趾部分坏疽，今患者家属咨询可有好的治疗方案。医嘱：保肢难度大，大概率是要截肢的。", "ner": [[12, 15, "Anatomy"], [15, 20, "Symptom"], [22, 28, "Symptom"], [36, 40, "Disease"], [41, 47, "Disease"], [49, 53, "Operation"], [87, 91, "Operation"], [94, 102, "Operation"], [113, 119, "Symptom"], [122, 124, "Anatomy"], [125, 127, "Anatomy"], [127, 131, "Symptom"], [162, 164, "Operation"]], "rel": [[49, 53, "Operation", 41, 47, "Disease", "Operation_Disease"], [94, 102, "Operation", 41, 47, "Disease", "Operation_Disease"], [162, 164, "Operation", 41, 47, "Disease", "Operation_Disease"], [15, 20, "Symptom", 36, 40, "Disease", "Symptom_Disease"], [113, 119, "Symptom", 36, 40, "Disease", "Symptom_Disease"], [127, 131, "Symptom", 36, 40, "Disease", "Symptom_Disease"], [22, 28, "Symptom", 36, 40, "Disease", "Symptom_Disease"], [41, 47, "Disease", 36, 40, "Disease", "Disease_Disease"], [12, 15, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [125, 127, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [122, 124, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [15, 20, "Symptom", 41, 47, "Disease", "Symptom_Disease"], [22, 28, "Symptom", 41, 47, "Disease", "Symptom_Disease"], [113, 119, "Symptom", 41, 47, "Disease", "Symptom_Disease"], [127, 131, "Symptom", 41, 47, "Disease", "Symptom_Disease"], [49, 53, "Operation", 36, 40, "Disease", "Operation_Disease"], [94, 102, "Operation", 36, 40, "Disease", "Operation_Disease"], [162, 164, "Operation", 36, 40, "Disease", "Operation_Disease"]]}
{"idx": 116, "sentence": "糖尿病足，左脚肿胀，足趾坏死，CT和造影都做了，脚有所缓轻，但45趾间有炎症。医嘱：控制好血糖后清创，去除坏死足趾，创面肉芽新鲜后植皮。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [10, 14, "Symptom"], [15, 17, "Test"], [18, 20, "Test"], [24, 25, "Anatomy"], [35, 38, "Symptom"], [33, 34, "Anatomy"], [45, 47, "Test_items"], [48, 50, "Operation"], [55, 57, "Anatomy"], [65, 67, "Operation"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [15, 17, "Test", 0, 4, "Disease", "Test_Disease"], [18, 20, "Test", 0, 4, "Disease", "Test_Disease"], [24, 25, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [48, 50, "Operation", 0, 4, "Disease", "Operation_Disease"], [65, 67, "Operation", 0, 4, "Disease", "Operation_Disease"], [35, 38, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [55, 57, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [33, 34, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 117, "sentence": "糖尿病足，今年83岁，已经有30年的糖尿病史了。三个月前在滨州医学院附属医院，做了左大脚趾截肢手术。术后恢复不好。现在县医院输液治疗。拍片说血液只循环到大腿根部。医嘱：保肢还是截肢，往往取决于两个方面：1、足部感染破坏的程度2、下肢缺血的程度。", "ner": [[0, 4, "Disease"], [14, 17, "Duration"], [45, 49, "Operation"], [62, 64, "Method"], [67, 69, "Test"], [70, 80, "Symptom"], [103, 107, "Symptom"], [114, 118, "Symptom"], [41, 45, "Anatomy"], [88, 90, "Operation"]], "rel": [[70, 80, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [114, 118, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [103, 107, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [45, 49, "Operation", 0, 4, "Disease", "Operation_Disease"], [67, 69, "Test", 0, 4, "Disease", "Test_Disease"], [88, 90, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 118, "sentence": "糖尿病足早期主要表现在，因为下肢的血供不好，出现皮肤变成暗紫色，皮肤颜色的变化。第二方面，因为糖尿病影响下肢的神经，会出现足部感觉异常，比如有些人足部麻木。第三方面因为神经的损伤，它会出现足部肌肉病变，足部肌肉病变导致足部畸形，所以糖尿病患者早期，逐渐出现皮肤颜色改变，足部感觉的异常，甚至足部行走畸形等一系列问题，所以大家一日出现这方面问题，一定要去重视。", "ner": [[0, 4, "Disease"], [14, 21, "Symptom"], [24, 31, "Symptom"], [47, 50, "Disease"], [73, 77, "Symptom"], [84, 86, "Anatomy"], [94, 100, "Symptom"], [109, 113, "Symptom"], [101, 107, "Symptom"], [128, 134, "Symptom"], [135, 142, "Symptom"], [61, 67, "Symptom"], [145, 151, "Symptom"], [32, 39, "Symptom"], [52, 57, "Anatomy"]], "rel": [[14, 21, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [24, 31, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [61, 67, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [73, 77, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [94, 100, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [101, 107, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [109, 113, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [135, 142, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [145, 151, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [0, 4, "Disease", 47, 50, "Disease", "Disease_Disease"], [32, 39, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [128, 134, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 119, "sentence": "糖尿病足，吃了那些药，病情没有缓解，足部刺痛，脚趾头加重肿胀。医嘱：糖尿病足实际上是末梢血管闭塞了，导致营养不良引起足趾坏死。止痛，局部外涂抗炎药，高压氧舱治疗，明显坏死，只能截肢手术坏死足跖。", "ner": [[0, 4, "Disease"], [18, 22, "Symptom"], [23, 30, "Symptom"], [34, 38, "Disease"], [58, 62, "Symptom"], [88, 92, "Operation"], [94, 96, "Anatomy"], [68, 70, "Method"], [74, 80, "Treatment"], [42, 46, "Anatomy"], [46, 48, "Symptom"]], "rel": [[18, 22, "Symptom", 34, 38, "Disease", "Symptom_Disease"], [23, 30, "Symptom", 34, 38, "Disease", "Symptom_Disease"], [58, 62, "Symptom", 34, 38, "Disease", "Symptom_Disease"], [74, 80, "Treatment", 34, 38, "Disease", "Treatment_Disease"], [88, 92, "Operation", 34, 38, "Disease", "Operation_Disease"], [94, 96, "Anatomy", 34, 38, "Disease", "Anatomy_Disease"], [46, 48, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 120, "sentence": "糖尿病足，患足足趾坏死，足部感染，病人痛苦，存在诱发心脑血管疾病风险。处置建议：建议积极治疗缓解病人痛苦，再次评估缺血程度，必要时介入治疗。缺血改善或不缺血情况下截趾清创+抗炎治疗。配合局部换药，负压封闭引流等，促进愈合。", "ner": [[0, 4, "Disease"], [7, 11, "Symptom"], [6, 7, "Anatomy"], [12, 16, "Symptom"], [26, 32, "Disease"], [65, 69, "Operation"], [81, 83, "Operation"], [83, 85, "Operation"], [98, 104, "Treatment"]], "rel": [[6, 7, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [7, 11, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [12, 16, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [65, 69, "Operation", 0, 4, "Disease", "Operation_Disease"], [81, 83, "Operation", 0, 4, "Disease", "Operation_Disease"], [83, 85, "Operation", 0, 4, "Disease", "Operation_Disease"], [98, 104, "Treatment", 0, 4, "Disease", "Treatment_Disease"], [26, 32, "Disease", 0, 4, "Disease", "Disease_Disease"]]}
{"idx": 121, "sentence": "糖尿病30年，糖尿病足双脚感染、足部溃疡，现在基本就不能下地行走了，坐轮椅，脓性分泌物较多，起疖子，感染。医嘱：双下肢CTA检查。", "ner": [[0, 3, "Disease"], [3, 6, "Duration"], [7, 11, "Disease"], [11, 15, "Symptom"], [16, 20, "Symptom"], [38, 45, "Symptom"], [46, 49, "Symptom"], [50, 52, "Symptom"], [56, 64, "Test"]], "rel": [[11, 15, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [38, 45, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [46, 49, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [50, 52, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [56, 64, "Test", 7, 11, "Disease", "Test_Disease"], [7, 11, "Disease", 0, 3, "Disease", "Disease_Disease"]]}
{"idx": 122, "sentence": "糖尿病足，足部感染，去年九月脚趾甲溃烂，去医院检查无果而终，也没有做任何处理，回到家中碘伏消毒，随后指甲脱落，去边12月足趾变黑，1月摔了跤，急救送到医院，因血糖高，酮酸中毒，住院1周，脚步指头变黑，脚底板有一个血块，但现在发展有一半血泡，医院要求截肢，但因岁数大，每日打胰岛素，饭量、大小便目前正常，可以吃头孢呋辛脂，一天两次 一次0.5。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [14, 19, "Symptom"], [43, 45, "Drug"], [50, 52, "Anatomy"], [60, 64, "Symptom"], [79, 81, "Test_items"], [81, 82, "Test_Value"], [83, 85, "Test_items"], [95, 99, "Symptom"], [100, 108, "Symptom"], [114, 119, "Symptom"], [124, 126, "Operation"], [135, 136, "Method"], [136, 139, "Drug"], [154, 159, "Drug"], [153, 154, "Method"], [160, 164, "Frequency"], [165, 170, "Amount"], [85, 87, "Test_Value"]], "rel": [[14, 19, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [60, 64, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [114, 119, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [100, 108, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [95, 99, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [124, 126, "Operation", 0, 4, "Disease", "Operation_Disease"], [154, 159, "Drug", 0, 4, "Disease", "Drug_Disease"], [153, 154, "Method", 154, 159, "Drug", "Method_Drug"], [160, 164, "Frequency", 154, 159, "Drug", "Frequency_Drug"], [165, 170, "Amount", 160, 164, "Frequency", "Amount_Drug"], [135, 136, "Method", 136, 139, "Drug", "Method_Drug"], [50, 52, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 123, "sentence": "多年糖尿病导致糖尿病足，今年一月因行走导致右脚大脚趾骨处水泡，足部溃烂，伤口愈合较差。现患足部浮肿，足部皮肤紫红色。", "ner": [[2, 5, "Disease"], [7, 11, "Disease"], [21, 27, "Anatomy"], [28, 30, "Symptom"], [31, 35, "Symptom"], [36, 42, "Symptom"], [44, 49, "Symptom"], [50, 57, "Symptom"]], "rel": [[7, 11, "Disease", 2, 5, "Disease", "Disease_Disease"], [28, 30, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [36, 42, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [44, 49, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [50, 57, "Symptom", 7, 11, "Disease", "Symptom_Disease"], [21, 27, "Anatomy", 7, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 124, "sentence": "糖尿病足，足部坏疽合并足部感染，血管情况不明。建议立即到糖尿病足专科就诊清创引流控制感染、控制血糖等综合治疗，同时评估下肢血管情况、全身心肾状况，为下一步治疗做准备。", "ner": [[0, 4, "Disease"], [5, 9, "Symptom"], [11, 15, "Symptom"], [16, 18, "Anatomy"], [36, 38, "Operation"], [47, 49, "Test_items"], [59, 63, "Anatomy"], [66, 70, "Anatomy"], [38, 40, "Treatment"]], "rel": [[5, 9, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [11, 15, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [36, 38, "Operation", 0, 4, "Disease", "Operation_Disease"], [38, 40, "Treatment", 0, 4, "Disease", "Treatment_Disease"]]}
{"idx": 125, "sentence": "糖尿病20余年，血糖不稳定。近半年开始出现脚趾头坏死情况。医嘱：沟通说明主要治疗方案，说明患者已有截肢治疗指征。", "ner": [[0, 3, "Disease"], [3, 7, "Duration"], [8, 10, "Test_items"], [21, 26, "Symptom"], [49, 53, "Operation"]], "rel": [[8, 10, "Test_items", 0, 3, "Disease", "Test_items_Disease"]]}
{"idx": 126, "sentence": "病历概要，糖尿病，糖尿病足。病情：糖尿病11年史，每天打胰岛素。血糖控制在6.7左右。高血压15年史，今天147/77。冠心病6年史。脊髓型颈椎病半身不遂，卧床不起一年多时间，半年前脚开始起干皮，最近脚更严重了，足部溃烂，处置建议：脚有伤口时不能洗脚，伤口可以用碘伏消毒，然后敷上康复新液，有条件伤口处无菌纱布包裹，现在不能洗脚，没有伤口处的其他部分可以用干净毛巾擦脚。足部伤口有脓液渗出，需要到医院就诊清创换药。", "ner": [[5, 8, "Disease"], [9, 13, "Disease"], [17, 20, "Disease"], [20, 24, "Duration"], [25, 27, "Frequency"], [27, 28, "Method"], [28, 31, "Drug"], [32, 34, "Test_items"], [37, 42, "Test_Value"], [43, 46, "Disease"], [46, 50, "Duration"], [53, 59, "Test_Value"], [60, 63, "Disease"], [63, 66, "Duration"], [67, 73, "Disease"], [73, 77, "Symptom"], [82, 85, "Duration"], [78, 82, "Symptom"], [91, 92, "Anatomy"], [100, 101, "Anatomy"], [101, 104, "Level"], [106, 110, "Symptom"], [116, 117, "Anatomy"], [131, 133, "Drug"], [140, 144, "Drug"], [138, 139, "Method"], [151, 157, "Treatment"], [189, 194, "Symptom"], [202, 204, "Operation"], [94, 97, "Symptom"]], "rel": [[9, 13, "Disease", 5, 8, "Disease", "Disease_Disease"], [25, 27, "Frequency", 28, 31, "Drug", "Frequency_Drug"], [73, 77, "Symptom", 67, 73, "Disease", "Symptom_Disease"], [78, 82, "Symptom", 67, 73, "Disease", "Symptom_Disease"], [106, 110, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [189, 194, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [94, 97, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [32, 34, "Test_items", 5, 8, "Disease", "Test_items_Disease"], [91, 92, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [189, 194, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [138, 139, "Method", 140, 144, "Drug", "Method_Drug"], [27, 28, "Method", 28, 31, "Drug", "Method_Drug"], [151, 157, "Treatment", 9, 13, "Disease", "Treatment_Disease"], [202, 204, "Operation", 9, 13, "Disease", "Operation_Disease"], [140, 144, "Drug", 9, 13, "Disease", "Drug_Disease"]]}
{"idx": 127, "sentence": "糖尿病并发糖尿病足，左足溃烂到现在已经四个月了，在人民医院做CTA左腿动脉显影不清楚，考虑下肢动脉闭塞，医生说要打通血管，上支架。医嘱：只有下肢血管重建手术把血管打通，然后才能争取保肢。但风险很大、截肢或其他更严重后果仍然存在。脚面脓性分泌物较多，看创面有新鲜肉芽，但足溃疡仍存在，伤口愈合较差。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [10, 14, "Symptom"], [17, 22, "Duration"], [30, 33, "Test"], [33, 37, "Anatomy"], [45, 51, "Disease"], [70, 78, "Operation"], [58, 60, "Anatomy"], [79, 81, "Anatomy"], [99, 101, "Operation"], [114, 123, "Symptom"], [134, 137, "Symptom"], [141, 147, "Symptom"]], "rel": [[5, 9, "Disease", 0, 3, "Disease", "Disease_Disease"], [45, 51, "Disease", 5, 9, "Disease", "Disease_Disease"], [10, 14, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [114, 123, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [134, 137, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [141, 147, "Symptom", 5, 9, "Disease", "Symptom_Disease"], [70, 78, "Operation", 45, 51, "Disease", "Operation_Disease"], [99, 101, "Operation", 5, 9, "Disease", "Operation_Disease"], [58, 60, "Anatomy", 45, 51, "Disease", "Anatomy_Disease"], [33, 37, "Anatomy", 45, 51, "Disease", "Anatomy_Disease"], [30, 33, "Test", 45, 51, "Disease", "Test_Disease"], [30, 33, "Test", 5, 9, "Disease", "Test_Disease"], [10, 14, "Symptom", 45, 51, "Disease", "Symptom_Disease"], [114, 123, "Symptom", 45, 51, "Disease", "Symptom_Disease"], [134, 137, "Symptom", 45, 51, "Disease", "Symptom_Disease"], [141, 147, "Symptom", 45, 51, "Disease", "Symptom_Disease"], [99, 101, "Operation", 45, 51, "Disease", "Operation_Disease"], [70, 78, "Operation", 5, 9, "Disease", "Operation_Disease"]]}
{"idx": 128, "sentence": "做的下肢CTA，下肢血管闭塞，出院后一个星期，脚有病变，大夫给开的药，沙格雷脂，一直在用，但是控制不住，慢慢变大，到现在有将近四个月的时间了，足部脓性分泌物较多。医嘱：这种足很难保住，考虑截肢，血管闭塞的足预后很差，足部有脓的部位需要彻底清创，但打开后因为没有血流很难愈合。", "ner": [[2, 7, "Test"], [8, 14, "Disease"], [23, 24, "Anatomy"], [35, 39, "Drug"], [61, 66, "Duration"], [71, 80, "Symptom"], [86, 87, "Anatomy"], [94, 96, "Operation"], [102, 103, "Anatomy"], [119, 121, "Operation"], [108, 110, "Anatomy"]], "rel": [[2, 7, "Test", 8, 14, "Disease", "Test_Disease"], [94, 96, "Operation", 8, 14, "Disease", "Operation_Disease"], [23, 24, "Anatomy", 8, 14, "Disease", "Anatomy_Disease"], [71, 80, "Symptom", 8, 14, "Disease", "Symptom_Disease"], [35, 39, "Drug", 8, 14, "Disease", "Drug_Disease"], [86, 87, "Anatomy", 8, 14, "Disease", "Anatomy_Disease"], [108, 110, "Anatomy", 8, 14, "Disease", "Anatomy_Disease"], [119, 121, "Operation", 8, 14, "Disease", "Operation_Disease"]]}
{"idx": 129, "sentence": "患者64岁，20多年糖尿病史，长期注射胰岛素，血糖控制在9-11间；高血压，长期服药。今年初做CTA报告称双下肢动脉闭塞，足部皮肤呈较深的紫褐色，左足尤为严重，行动困难，双足疼痛剧烈。今年3月份在医院介入科诊断为双下肢动脉闭塞症，行导管介入手术欲通开堵塞血管，未成功。医嘱：从下肢CTA检查的资料来看，应当有希望开通闭塞的血管。建议先找水平高的医生先行介入治疗，如果仍然不能成功，可以做搭桥治疗，如果身体条件许可，搭桥成功率应当非常高。", "ner": [[6, 10, "Duration"], [15, 17, "Duration"], [17, 19, "Method"], [19, 22, "Drug"], [23, 25, "Test_items"], [28, 32, "Test_Value"], [34, 37, "Disease"], [47, 50, "Test"], [53, 60, "Disease"], [61, 72, "Symptom"], [73, 75, "Anatomy"], [77, 79, "Level"], [85, 91, "Symptom"], [80, 84, "Symptom"], [106, 114, "Disease"], [116, 122, "Operation"], [127, 129, "Anatomy"], [138, 145, "Test"], [161, 163, "Anatomy"], [176, 180, "Operation"], [193, 197, "Operation"], [207, 209, "Operation"]], "rel": [[61, 72, "Symptom", 106, 114, "Disease", "Symptom_Disease"], [80, 84, "Symptom", 106, 114, "Disease", "Symptom_Disease"], [85, 91, "Symptom", 106, 114, "Disease", "Symptom_Disease"], [138, 145, "Test", 106, 114, "Disease", "Test_Disease"], [127, 129, "Anatomy", 106, 114, "Disease", "Anatomy_Disease"], [17, 19, "Method", 19, 22, "Drug", "Method_Drug"], [47, 50, "Test", 53, 60, "Disease", "Test_Disease"], [80, 84, "Symptom", 53, 60, "Disease", "Symptom_Disease"], [85, 91, "Symptom", 53, 60, "Disease", "Symptom_Disease"], [61, 72, "Symptom", 53, 60, "Disease", "Symptom_Disease"], [116, 122, "Operation", 53, 60, "Disease", "Operation_Disease"], [193, 197, "Operation", 53, 60, "Disease", "Operation_Disease"], [207, 209, "Operation", 53, 60, "Disease", "Operation_Disease"], [176, 180, "Operation", 53, 60, "Disease", "Operation_Disease"], [116, 122, "Operation", 106, 114, "Disease", "Operation_Disease"], [193, 197, "Operation", 106, 114, "Disease", "Operation_Disease"], [176, 180, "Operation", 106, 114, "Disease", "Operation_Disease"], [207, 209, "Operation", 106, 114, "Disease", "Operation_Disease"]]}
{"idx": 130, "sentence": "糖尿病足是下肢动脉闭塞的特殊类型，它是由糖尿病神经病变，血管病变和感染导致的足部感染，足部溃疡和小腿及足部坏死，治疗困难，不易康复，50%需截肢处理。通常的表现为病变肢体发凉、足部麻木、行走困难至数百米后患肢疼痛、臀部和下肢酸胀，乏力，休息数分钟后症状缓解，冬天症状较夏天重。随着病情的进展和患肢缺血加重，在安静状态下足趾、足部或小腿也会出现持续性的疼痛，在夜间更为剧烈，甚至足趾发黑溃烂，肌肉萎缩。一日出现症状，及时就医。通过CTA检查即可明确诊断。", "ner": [[0, 4, "Disease"], [5, 11, "Disease"], [20, 27, "Reason"], [28, 32, "Reason"], [33, 35, "Reason"], [38, 42, "Symptom"], [43, 47, "Symptom"], [48, 55, "Symptom"], [70, 72, "Operation"], [81, 87, "Symptom"], [88, 92, "Symptom"], [93, 106, "Symptom"], [107, 114, "Symptom"], [115, 117, "Symptom"], [159, 161, "Anatomy"], [162, 164, "Anatomy"], [165, 167, "Anatomy"], [171, 177, "Symptom"], [183, 185, "Level"], [188, 194, "Symptom"], [195, 199, "Symptom"], [214, 219, "Test"]], "rel": [[5, 11, "Disease", 0, 4, "Disease", "Disease_Disease"], [20, 27, "Reason", 0, 4, "Disease", "Reason_Disease"], [28, 32, "Reason", 0, 4, "Disease", "Reason_Disease"], [33, 35, "Reason", 0, 4, "Disease", "Reason_Disease"], [43, 47, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [38, 42, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [48, 55, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [81, 87, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [88, 92, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [93, 106, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [107, 114, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [115, 117, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [171, 177, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [188, 194, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [195, 199, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [214, 219, "Test", 0, 4, "Disease", "Test_Disease"], [70, 72, "Operation", 0, 4, "Disease", "Operation_Disease"], [159, 161, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [162, 164, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [38, 42, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [43, 47, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [48, 55, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [81, 87, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [88, 92, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [93, 106, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [107, 114, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [115, 117, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [188, 194, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [195, 199, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [171, 177, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [214, 219, "Test", 5, 11, "Disease", "Test_Disease"], [165, 167, "Anatomy", 5, 11, "Disease", "Anatomy_Disease"], [70, 72, "Operation", 5, 11, "Disease", "Operation_Disease"]]}
{"idx": 131, "sentence": "控制血压、血糖，调整血脂于正常水平，戒烟，口服前列地尔、阿司匹林等扩血管药物，注意肢体保温。如症状明显，建议及早就医。在所有的治疗选择中，介入治疗能快速开通阻塞的血管，恢复下肢血流。介入治疗优势:是目前唯一微创的下肢动脉硬化闭塞症及糖尿病足的治疗方式。具有快速缓解症状、不开刀、微创、术后恢复快的特点。其主要方法是运用细导丝打通血管，之后运用球囊进行扩张，必要时使用支架进行辅助，使血管恢复血供。术后注意事项:按时服用抗血小板和抗凝药物，定期复查，戒烟、控制血糖血压和血脂，适度多锻炼。对于已经足部坏死的肢体，通过医疗手段是不能使其恢复活性，截肢不可避免。我们的终极目的是维持血运通畅，减轻症状，尽可能减少截肢的发生或截肢的程度。", "ner": [[2, 4, "Test_items"], [5, 7, "Test_items"], [10, 12, "Test_items"], [13, 17, "Test_Value"], [18, 20, "Treatment"], [21, 23, "Method"], [23, 27, "Drug"], [28, 32, "Drug"], [69, 73, "Operation"], [81, 83, "Anatomy"], [86, 88, "Anatomy"], [91, 95, "Operation"], [106, 115, "Disease"], [116, 120, "Disease"], [164, 166, "Anatomy"], [191, 193, "Anatomy"], [224, 226, "Treatment"], [229, 231, "Test_items"], [231, 233, "Test_items"], [234, 236, "Test_items"], [237, 242, "Treatment"], [247, 251, "Symptom"], [252, 254, "Anatomy"], [271, 273, "Operation"], [303, 305, "Operation"], [309, 311, "Operation"]], "rel": [[247, 251, "Symptom", 116, 120, "Disease", "Symptom_Disease"], [106, 115, "Disease", 116, 120, "Disease", "Disease_Disease"], [18, 20, "Treatment", 116, 120, "Disease", "Treatment_Disease"], [237, 242, "Treatment", 116, 120, "Disease", "Treatment_Disease"], [81, 83, "Anatomy", 106, 115, "Disease", "Anatomy_Disease"], [86, 88, "Anatomy", 106, 115, "Disease", "Anatomy_Disease"], [271, 273, "Operation", 116, 120, "Disease", "Operation_Disease"], [21, 23, "Method", 23, 27, "Drug", "Method_Drug"], [21, 23, "Method", 28, 32, "Drug", "Method_Drug"], [69, 73, "Operation", 116, 120, "Disease", "Operation_Disease"], [69, 73, "Operation", 106, 115, "Disease", "Operation_Disease"], [271, 273, "Operation", 106, 115, "Disease", "Operation_Disease"], [247, 251, "Symptom", 106, 115, "Disease", "Symptom_Disease"], [18, 20, "Treatment", 106, 115, "Disease", "Treatment_Disease"], [237, 242, "Treatment", 106, 115, "Disease", "Treatment_Disease"], [23, 27, "Drug", 106, 115, "Disease", "Drug_Disease"], [23, 27, "Drug", 116, 120, "Disease", "Drug_Disease"], [28, 32, "Drug", 106, 115, "Disease", "Drug_Disease"], [28, 32, "Drug", 116, 120, "Disease", "Drug_Disease"]]}
{"idx": 132, "sentence": "糖尿病后用药一年余,后打胰岛素至今已三个多月,09年底,双腿脚发凉，足部麻木,时有抽筋和脚面足趾刺痛,凉已延至膝上,左小腿有红斑3块(指盖大小),右脚二趾侧长一似鸡眼样硬块,足部刺痛。近期血压:130~150/50~65mmHg,血糖空腹:5.0,餐后2h血糖:7.0左右,糖化血红蛋白:6.5~7.5%,诊断:1、09年底,64排CT:双下肢动脉硬化斑块形成，轻度狭窄。双侧胫后动脉闭塞（管腔节段性狭窄）。2、神经源性损害，（符合多发性周围神经病变）。3、糖尿病周围神经病。4.糖尿病足前期。", "ner": [[0, 3, "Disease"], [6, 9, "Duration"], [11, 12, "Method"], [12, 15, "Drug"], [17, 22, "Duration"], [28, 33, "Symptom"], [34, 38, "Symptom"], [41, 43, "Symptom"], [44, 50, "Symptom"], [55, 57, "Anatomy"], [61, 64, "Symptom"], [58, 61, "Anatomy"], [87, 91, "Symptom"], [78, 86, "Symptom"], [94, 96, "Test_items"], [97, 114, "Test_Value"], [115, 119, "Test_items"], [120, 123, "Test_Value"], [124, 130, "Test_items"], [131, 136, "Test_Value"], [137, 143, "Test_items"], [144, 152, "Test_Value"], [169, 180, "Symptom"], [181, 185, "Symptom"], [186, 203, "Disease"], [229, 237, "Disease"], [240, 244, "Disease"], [163, 168, "Test"], [73, 78, "Anatomy"], [216, 225, "Disease"]], "rel": [[186, 203, "Disease", 240, 244, "Disease", "Disease_Disease"], [240, 244, "Disease", 0, 3, "Disease", "Disease_Disease"], [229, 237, "Disease", 0, 3, "Disease", "Disease_Disease"], [28, 33, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [34, 38, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [41, 43, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [44, 50, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [61, 64, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [78, 86, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [169, 180, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [181, 185, "Symptom", 186, 203, "Disease", "Symptom_Disease"], [28, 33, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [61, 64, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [44, 50, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [41, 43, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [34, 38, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [78, 86, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [169, 180, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [181, 185, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [34, 38, "Symptom", 229, 237, "Disease", "Symptom_Disease"], [44, 50, "Symptom", 229, 237, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 229, 237, "Disease", "Symptom_Disease"], [58, 61, "Anatomy", 186, 203, "Disease", "Anatomy_Disease"], [163, 168, "Test", 186, 203, "Disease", "Test_Disease"], [163, 168, "Test", 240, 244, "Disease", "Test_Disease"], [11, 12, "Method", 12, 15, "Drug", "Method_Drug"], [12, 15, "Drug", 0, 3, "Disease", "Drug_Disease"], [94, 96, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [115, 119, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [124, 130, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [137, 143, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [73, 78, "Anatomy", 240, 244, "Disease", "Anatomy_Disease"], [216, 225, "Disease", 0, 3, "Disease", "Disease_Disease"]]}
{"idx": 133, "sentence": "在医院做的骨搬移手术不成功，手术期间患者吃不下饭，有胃潴留和胃炎伴糜烂，脚部疼痛难忍，无法治疗了才出院回家休养 。慢性疾病：1998年确诊为糖尿病 (2021-06-08填写)医嘱：病历概要：糖尿病足合并缺血，足趾坏疽，创面不愈合，疼痛明显。处置建议：疾病发展到这个阶段，单纯口服抗凝和扩血管药物已经无法起到太大作用，对于缓解疼痛或者促进创面愈合，血管介入治疗可能是唯一选择，否则只能截肢。", "ner": [[5, 10, "Operation"], [30, 35, "Symptom"], [26, 29, "Symptom"], [36, 42, "Symptom"], [70, 73, "Disease"], [96, 100, "Disease"], [102, 104, "Symptom"], [105, 109, "Symptom"], [110, 115, "Symptom"], [116, 120, "Symptom"], [138, 140, "Method"], [174, 180, "Operation"], [192, 194, "Operation"]], "rel": [[36, 42, "Symptom", 96, 100, "Disease", "Symptom_Disease"], [102, 104, "Symptom", 96, 100, "Disease", "Symptom_Disease"], [105, 109, "Symptom", 96, 100, "Disease", "Symptom_Disease"], [110, 115, "Symptom", 96, 100, "Disease", "Symptom_Disease"], [116, 120, "Symptom", 96, 100, "Disease", "Symptom_Disease"], [192, 194, "Operation", 96, 100, "Disease", "Operation_Disease"], [5, 10, "Operation", 96, 100, "Disease", "Operation_Disease"], [174, 180, "Operation", 96, 100, "Disease", "Operation_Disease"], [96, 100, "Disease", 70, 73, "Disease", "Disease_Disease"]]}
{"idx": 134, "sentence": "糖尿病足，腿血管闭塞，静息痛，下足部坏死，血糖控制还好，右眼失明，有三高，右腿血液不通畅，右脚第四趾头干了以后自然脱落，其它脚趾也出现干枯，脚背也出现干枯，同时伴有疼痛。医嘱：血管堵了得通血管，足部刺痛和肢端变黑都主要是缺血引起来的", "ner": [[0, 4, "Disease"], [5, 10, "Disease"], [11, 14, "Symptom"], [15, 20, "Symptom"], [21, 23, "Test_items"], [28, 32, "Symptom"], [37, 44, "Symptom"], [45, 51, "Anatomy"], [65, 69, "Symptom"], [62, 64, "Anatomy"], [70, 72, "Anatomy"], [73, 77, "Symptom"], [80, 84, "Symptom"], [88, 90, "Anatomy"], [94, 96, "Anatomy"], [97, 101, "Symptom"], [102, 106, "Symptom"], [110, 112, "Symptom"]], "rel": [[11, 14, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [15, 20, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [65, 69, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [37, 44, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [80, 84, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [97, 101, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [102, 106, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [110, 112, "Symptom", 5, 10, "Disease", "Symptom_Disease"], [11, 14, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [15, 20, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [37, 44, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [65, 69, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [80, 84, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [102, 106, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [110, 112, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [45, 51, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [62, 64, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [70, 72, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [94, 96, "Anatomy", 5, 10, "Disease", "Anatomy_Disease"]]}
{"idx": 135, "sentence": "糖尿病足合并下肢动脉栓塞、脑梗，医嘱：足趾溃疡。处置建议：查下肢CTA进一步明确足部供血。", "ner": [[0, 4, "Disease"], [6, 12, "Disease"], [13, 15, "Disease"], [19, 23, "Symptom"], [30, 35, "Test"], [40, 42, "Anatomy"]], "rel": [[19, 23, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [19, 23, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [30, 35, "Test", 6, 12, "Disease", "Test_Disease"], [30, 35, "Test", 0, 4, "Disease", "Test_Disease"], [6, 12, "Disease", 0, 4, "Disease", "Disease_Disease"]]}
{"idx": 136, "sentence": "患者女，70岁。1、患糖尿病20多年，高血压40年；2、96年左侧股骨颈摔折，已缺血性坏死；3、2011年5月发现乳腺小叶癌；4、糖尿病足坏疽（干性）下肢动脉血管闭塞很严重。1、2011年5月21日，在四平市第一医院外科手术，截掉左脚第二趾；又作了乳腺手术，放疗一个月。这期间用抗菌消炎药，用头孢替唑，血管扩张药和微循环药，用前列地尔，低分子量肝素钙，银杏达莫，输血宁，口服抗凝药等。3、足趾伤口愈合较差，又很疼痛，但脚的颜色较好，不那么青紫。这时，大夫给往创口涂敷美宝（MEBO），出现炎症、汾泌物浓水等。又滴注奥扎格雷，出现眼底出血。4、2011年8月8日，在四平市中心医院作介入治疗，因血管堵塞严重导丝无法通过而介入治疗失败。又失血较多，有1200ML多，给予两次输血，计800ML。用药：凯时（前列地尔），低分子肝素钙，银杏达莫，抗菌消炎药，抗凝药 培达，补血药 力蜚能等；还用中药调理。但脚趾不封口，也未恶化发展。5、2011年10月20日，到2012年1月中旬，脚趾仍不封口，但也不那麽疼。1月20日，脚又开始疼，可能与天气冷有关，一天比一天利害，开始恶化。3月13日，住进第一医院，又转入中心医院。但越治越恶化，第三、足趾变黑变细，缺血坏死，现又波及到其余趾。医嘱：双下肢股动脉以下狭窄闭塞严重，但流出道还有，应该可以通过介入手段或手术来改善下肢血供，坏死足趾没办法救活，但可以降低截肢平面。", "ner": [[11, 14, "Disease"], [14, 18, "Duration"], [40, 45, "Symptom"], [31, 38, "Disease"], [57, 62, "Disease"], [65, 69, "Disease"], [69, 75, "Symptom"], [75, 83, "Disease"], [83, 86, "Level"], [113, 115, "Operation"], [115, 120, "Anatomy"], [124, 128, "Operation"], [146, 150, "Drug"], [163, 167, "Drug"], [168, 175, "Drug"], [176, 180, "Drug"], [181, 184, "Drug"], [185, 187, "Method"], [194, 202, "Symptom"], [205, 207, "Symptom"], [231, 233, "Method"], [233, 241, "Drug"], [247, 252, "Symptom"], [255, 257, "Method"], [257, 261, "Drug"], [264, 268, "Symptom"], [244, 246, "Symptom"], [290, 294, "Operation"], [296, 298, "Anatomy"], [300, 302, "Level"], [309, 313, "Operation"], [348, 356, "Drug"], [357, 363, "Drug"], [364, 368, "Drug"], [379, 381, "Drug"], [386, 389, "Drug"], [399, 401, "Anatomy"], [437, 439, "Anatomy"], [457, 458, "Anatomy"], [516, 522, "Symptom"], [523, 527, "Symptom"], [535, 536, "Anatomy"], [568, 570, "Operation"], [578, 580, "Anatomy"], [585, 587, "Anatomy"], [540, 546, "Anatomy"], [552, 554, "Level"], [548, 550, "Symptom"], [550, 552, "Symptom"]], "rel": [[69, 75, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [40, 45, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [194, 202, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [205, 207, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [244, 246, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [247, 252, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [264, 268, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [516, 522, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [523, 527, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [40, 45, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [194, 202, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [205, 207, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [244, 246, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [247, 252, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [264, 268, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [516, 522, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [523, 527, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [115, 120, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"], [296, 298, "Anatomy", 75, 83, "Disease", "Anatomy_Disease"], [399, 401, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"], [457, 458, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"], [535, 536, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"], [540, 546, "Anatomy", 75, 83, "Disease", "Anatomy_Disease"], [585, 587, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"], [578, 580, "Anatomy", 75, 83, "Disease", "Anatomy_Disease"], [163, 167, "Drug", 65, 69, "Disease", "Drug_Disease"], [168, 175, "Drug", 65, 69, "Disease", "Drug_Disease"], [176, 180, "Drug", 65, 69, "Disease", "Drug_Disease"], [181, 184, "Drug", 65, 69, "Disease", "Drug_Disease"], [146, 150, "Drug", 65, 69, "Disease", "Drug_Disease"], [233, 241, "Drug", 65, 69, "Disease", "Drug_Disease"], [257, 261, "Drug", 65, 69, "Disease", "Drug_Disease"], [348, 356, "Drug", 65, 69, "Disease", "Drug_Disease"], [379, 381, "Drug", 65, 69, "Disease", "Drug_Disease"], [357, 363, "Drug", 65, 69, "Disease", "Drug_Disease"], [146, 150, "Drug", 75, 83, "Disease", "Drug_Disease"], [163, 167, "Drug", 75, 83, "Disease", "Drug_Disease"], [168, 175, "Drug", 75, 83, "Disease", "Drug_Disease"], [176, 180, "Drug", 75, 83, "Disease", "Drug_Disease"], [181, 184, "Drug", 75, 83, "Disease", "Drug_Disease"], [257, 261, "Drug", 75, 83, "Disease", "Drug_Disease"], [348, 356, "Drug", 75, 83, "Disease", "Drug_Disease"], [357, 363, "Drug", 75, 83, "Disease", "Drug_Disease"], [379, 381, "Drug", 75, 83, "Disease", "Drug_Disease"], [124, 128, "Operation", 57, 62, "Disease", "Operation_Disease"], [290, 294, "Operation", 75, 83, "Disease", "Operation_Disease"], [290, 294, "Operation", 65, 69, "Disease", "Operation_Disease"], [568, 570, "Operation", 65, 69, "Disease", "Operation_Disease"], [568, 570, "Operation", 75, 83, "Disease", "Operation_Disease"], [231, 233, "Method", 233, 241, "Drug", "Method_Drug"], [255, 257, "Method", 257, 261, "Drug", "Method_Drug"], [185, 187, "Method", 379, 381, "Drug", "Method_Drug"], [113, 115, "Operation", 75, 83, "Disease", "Operation_Disease"], [113, 115, "Operation", 65, 69, "Disease", "Operation_Disease"], [548, 550, "Symptom", 65, 69, "Disease", "Symptom_Disease"], [548, 550, "Symptom", 75, 83, "Disease", "Symptom_Disease"], [550, 552, "Symptom", 40, 45, "Symptom", "Symptom_Disease"], [550, 552, "Symptom", 65, 69, "Disease", "Symptom_Disease"]]}
{"idx": 137, "sentence": "糖尿病足合并下肢动脉绝大部分闭塞。2016年3月份左下肢踝骨处出现溃烂，先前没太注意，后持续溃烂，用的偏方涂抹于患处，后伤口长时间未痊愈，经大夫，建议去医院拍了一个下肢彩超，确诊为1：双侧下肢动脉主干硬化2：左侧股浅,腘窝动脉管腔闭塞3：左下肢动脉主干频谱均呈单相。医嘱：你的情况考虑下肢动脉硬化闭塞 建议完善CTA后 制定开通手术方案", "ner": [[0, 4, "Disease"], [25, 31, "Anatomy"], [33, 35, "Symptom"], [46, 48, "Symptom"], [53, 55, "Method"], [82, 86, "Test"], [92, 102, "Disease"], [119, 132, "Symptom"], [155, 158, "Test"], [142, 150, "Disease"], [6, 10, "Anatomy"], [14, 16, "Symptom"], [104, 117, "Symptom"]], "rel": [[82, 86, "Test", 0, 4, "Disease", "Test_Disease"], [155, 158, "Test", 0, 4, "Disease", "Test_Disease"], [82, 86, "Test", 142, 150, "Disease", "Test_Disease"], [155, 158, "Test", 142, 150, "Disease", "Test_Disease"], [142, 150, "Disease", 0, 4, "Disease", "Disease_Disease"], [25, 31, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [6, 10, "Anatomy", 142, 150, "Disease", "Anatomy_Disease"], [14, 16, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [104, 117, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [119, 132, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [14, 16, "Symptom", 142, 150, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 142, 150, "Disease", "Symptom_Disease"], [104, 117, "Symptom", 142, 150, "Disease", "Symptom_Disease"], [119, 132, "Symptom", 142, 150, "Disease", "Symptom_Disease"], [92, 102, "Disease", 0, 4, "Disease", "Disease_Disease"]]}
{"idx": 138, "sentence": "糖尿病足左下肢动脉血管闭塞，患者男，65岁，糖尿病10年，血糖控制欠佳，餐前血糖14、餐后血糖19与2010年因急性左髂动脉急性栓塞行介入治疗后，栓子脱落远端下肢动脉，左下肢高位截肢。现2011年CTA造影示右下肢胫前动脉多发性血管壁钙化，远端见少了造影剂断续通过。胫后动脉显影良好通畅，但是与腘动脉分叉处狭窄明显但仍见造影剂通过，远端血管良好未见明显狭窄。症状下肢体温发冷，足背动脉波动消失，活动后踇趾皮肤变成紫红色。现血糖控制，餐后血糖10，餐前血糖7左右。医嘱：应考虑先做介入手术治疗，如远期效果不佳可考虑搭桥手术，胫前动脉及腓动脉打通可行性不大，狭窄处理成功率比较高。", "ner": [[0, 4, "Disease"], [4, 13, "Disease"], [22, 25, "Disease"], [25, 28, "Duration"], [29, 31, "Test_items"], [36, 40, "Test_items"], [40, 42, "Test_Value"], [43, 47, "Test_items"], [47, 49, "Test_Value"], [56, 66, "Disease"], [67, 71, "Operation"], [79, 83, "Anatomy"], [84, 87, "Anatomy"], [89, 91, "Operation"], [98, 103, "Test"], [104, 119, "Disease"], [133, 137, "Anatomy"], [147, 150, "Anatomy"], [168, 170, "Anatomy"], [181, 187, "Symptom"], [188, 196, "Symptom"], [200, 209, "Symptom"], [211, 213, "Test_items"], [216, 220, "Test_items"], [220, 222, "Test_Value"], [223, 227, "Test_items"], [227, 228, "Test_Value"], [239, 243, "Operation"], [256, 260, "Operation"], [261, 265, "Anatomy"], [266, 269, "Anatomy"], [176, 178, "Symptom"], [153, 155, "Symptom"], [277, 279, "Symptom"]], "rel": [[181, 187, "Symptom", 4, 13, "Disease", "Symptom_Disease"], [188, 196, "Symptom", 4, 13, "Disease", "Symptom_Disease"], [200, 209, "Symptom", 4, 13, "Disease", "Symptom_Disease"], [181, 187, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [188, 196, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [200, 209, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [79, 83, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [84, 87, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [147, 150, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [168, 170, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [133, 137, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [261, 265, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [266, 269, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [29, 31, "Test_items", 22, 25, "Disease", "Test_items_Disease"], [43, 47, "Test_items", 22, 25, "Disease", "Test_items_Disease"], [36, 40, "Test_items", 22, 25, "Disease", "Test_items_Disease"], [67, 71, "Operation", 0, 4, "Disease", "Operation_Disease"], [239, 243, "Operation", 0, 4, "Disease", "Operation_Disease"], [89, 91, "Operation", 0, 4, "Disease", "Operation_Disease"], [67, 71, "Operation", 4, 13, "Disease", "Operation_Disease"], [239, 243, "Operation", 4, 13, "Disease", "Operation_Disease"], [256, 260, "Operation", 4, 13, "Disease", "Operation_Disease"], [89, 91, "Operation", 4, 13, "Disease", "Operation_Disease"], [104, 119, "Disease", 4, 13, "Disease", "Disease_Disease"], [56, 66, "Disease", 4, 13, "Disease", "Disease_Disease"], [4, 13, "Disease", 0, 4, "Disease", "Disease_Disease"], [0, 4, "Disease", 22, 25, "Disease", "Disease_Disease"], [98, 103, "Test", 104, 119, "Disease", "Test_Disease"], [176, 178, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [176, 178, "Symptom", 4, 13, "Disease", "Symptom_Disease"]]}
{"idx": 139, "sentence": "糖尿病足，现在左脚第五趾与第四趾中间足趾溃烂，前些天左脚与左腿肿胀，点滴凯时十余天减轻。左脚疼痛厉害。今天请沈阳盛京医院介入科医生手术，发现穿刺点硬化钙化严重，针都顶弯了，大夫不敢强行尝试。想求助了解下那位医生还有方案。这次做不了恶化后只有截肢，医生说小腿血管不好，弄不好都会高位截。医嘱：左腿已经做多次介入治疗，建议坚持口服药物治疗，并坚持走路锻炼，或者经常平卧位活动踝关节和膝关节有利于建立侧支循环。", "ner": [[0, 4, "Disease"], [7, 12, "Anatomy"], [13, 16, "Anatomy"], [18, 22, "Symptom"], [31, 33, "Symptom"], [26, 28, "Anatomy"], [29, 31, "Anatomy"], [36, 38, "Drug"], [38, 41, "Duration"], [34, 36, "Method"], [44, 48, "Symptom"], [48, 50, "Level"], [77, 79, "Duration"], [120, 122, "Operation"], [126, 130, "Anatomy"], [145, 147, "Anatomy"], [152, 156, "Operation"], [161, 163, "Method"], [169, 175, "Treatment"], [180, 192, "Treatment"], [73, 75, "Symptom"], [75, 77, "Symptom"]], "rel": [[18, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [31, 33, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [44, 48, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [7, 12, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [13, 16, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [26, 28, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [120, 122, "Operation", 0, 4, "Disease", "Operation_Disease"], [152, 156, "Operation", 0, 4, "Disease", "Operation_Disease"], [36, 38, "Drug", 0, 4, "Disease", "Drug_Disease"], [34, 36, "Method", 36, 38, "Drug", "Method_Drug"], [73, 75, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [75, 77, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 140, "sentence": "糖尿病足，下肢动脉狭窄，疼痛难忍，脚趾发黑。医嘱：调整全身机体等状态，争取为清创保肢做准备。单纯创面而言，在有血供基础上，建议彻底清创去除坏死组织，然后尝试封闭长好创面。若创面血供不够，建议血管介入治疗改善血供。若血供尚可，建议手术彻底清创。", "ner": [[0, 4, "Disease"], [12, 16, "Symptom"], [5, 11, "Disease"], [17, 21, "Symptom"], [38, 40, "Operation"], [65, 67, "Operation"], [95, 97, "Anatomy"], [97, 101, "Operation"], [118, 120, "Operation"]], "rel": [[12, 16, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [17, 21, "Symptom", 5, 11, "Disease", "Symptom_Disease"], [12, 16, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [17, 21, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [5, 11, "Disease", 0, 4, "Disease", "Disease_Disease"], [38, 40, "Operation", 5, 11, "Disease", "Operation_Disease"], [38, 40, "Operation", 0, 4, "Disease", "Operation_Disease"], [95, 97, "Anatomy", 5, 11, "Disease", "Anatomy_Disease"], [97, 101, "Operation", 5, 11, "Disease", "Operation_Disease"], [97, 101, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 141, "sentence": "糖尿病足，做血管ct显示下肢血管堵塞了，已经做了小脚趾截肢，术后不愈合6月初入院，心血管外科说疏通不了，于6月19日做了小脚趾切除，打了9天氯化钠引流，6月28日，进行清创手术，伤口愈合较差，又切除了一点，现在进行第二次氯化钠引流，说7天后打开伤口还不愈合就没有办法了，请医生给看看还有什么办法可以疏通血管，我们准备去协和做手术糖尿病足半年，右脚小脚趾伤口长时间不愈合，准备做胫骨横向搬移手术。2019年12月伤口愈合，2020年12月伤口走坏了。医嘱：建议拍脚的片子和核磁，看看创面底下骨髓炎的情况，目前创面清洗保持干净。", "ner": [[0, 4, "Disease"], [6, 10, "Test"], [12, 16, "Anatomy"], [24, 27, "Anatomy"], [27, 29, "Operation"], [60, 63, "Anatomy"], [70, 73, "Drug"], [73, 75, "Treatment"], [84, 88, "Operation"], [68, 70, "Duration"], [89, 95, "Symptom"], [110, 113, "Drug"], [113, 115, "Treatment"], [151, 153, "Anatomy"], [164, 168, "Disease"], [168, 170, "Duration"], [171, 176, "Anatomy"], [176, 184, "Symptom"], [188, 196, "Operation"], [229, 234, "Test"], [235, 237, "Test"], [244, 247, "Disease"]], "rel": [[89, 95, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [176, 184, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [6, 10, "Test", 0, 4, "Disease", "Test_Disease"], [235, 237, "Test", 244, 247, "Disease", "Test_Disease"], [229, 234, "Test", 244, 247, "Disease", "Test_Disease"], [24, 27, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [171, 176, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [73, 75, "Treatment", 0, 4, "Disease", "Treatment_Disease"], [84, 88, "Operation", 0, 4, "Disease", "Operation_Disease"], [188, 196, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 142, "sentence": "2型糖尿病患者于8年前偶测血糖时发现血糖升高，最高空腹血糖达19 mmo/L，曾行“口服葡萄糖耐量试验”检查明确诊断为“2型糖尿病”，自行予以“格列美脲1mg”或“诺和灵70/30 18u早 12u晚”交替管理血糖，平素未规律监测血糖。2月前偶然发现足溃疡，皮温稍高，伴头晕、肢体麻木不适，眼底出血，曾就诊于我院，诊断为“2型糖尿病肾病、糖尿病足、糖尿病周围血管病、糖尿病周围神经病、糖尿病视网膜病变、白内障;高血压3级 极高危组；高血压性心脏病”，予管理血糖、血压、换药处理，好转后出院，出院后自行换药，发现溃烂处较前加重，今为进一步诊治遂来我院。", "ner": [[0, 5, "Disease"], [13, 15, "Test_items"], [18, 20, "Test_items"], [20, 22, "Test_Value"], [25, 29, "Test_items"], [30, 38, "Test_Value"], [44, 51, "Test"], [60, 65, "Disease"], [72, 76, "Drug"], [76, 79, "Amount"], [82, 90, "Drug"], [91, 95, "Amount"], [96, 100, "Amount"], [105, 107, "Test_items"], [115, 117, "Test_items"], [125, 128, "Symptom"], [129, 133, "Symptom"], [135, 137, "Symptom"], [138, 144, "Symptom"], [145, 149, "Symptom"], [161, 168, "Disease"], [169, 173, "Disease"], [174, 182, "Disease"], [183, 191, "Disease"], [192, 200, "Disease"], [201, 204, "Disease"], [205, 208, "Disease"], [208, 210, "Level"], [216, 223, "Disease"], [228, 230, "Test_items"], [231, 233, "Test_items"], [260, 262, "Level"]], "rel": [[161, 168, "Disease", 0, 5, "Disease", "Disease_Disease"], [169, 173, "Disease", 0, 5, "Disease", "Disease_Disease"], [174, 182, "Disease", 0, 5, "Disease", "Disease_Disease"], [183, 191, "Disease", 0, 5, "Disease", "Disease_Disease"], [192, 200, "Disease", 0, 5, "Disease", "Disease_Disease"], [201, 204, "Disease", 0, 5, "Disease", "Disease_Disease"], [216, 223, "Disease", 205, 208, "Disease", "Disease_Disease"], [228, 230, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [231, 233, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [231, 233, "Test_items", 205, 208, "Disease", "Test_items_Disease"], [25, 29, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [44, 51, "Test", 0, 5, "Disease", "Test_Disease"], [72, 76, "Drug", 0, 5, "Disease", "Drug_Disease"], [82, 90, "Drug", 0, 5, "Disease", "Drug_Disease"], [76, 79, "Amount", 72, 76, "Drug", "Amount_Drug"], [91, 95, "Amount", 82, 90, "Drug", "Amount_Drug"], [96, 100, "Amount", 82, 90, "Drug", "Amount_Drug"], [125, 128, "Symptom", 169, 173, "Disease", "Symptom_Disease"], [129, 133, "Symptom", 169, 173, "Disease", "Symptom_Disease"], [138, 144, "Symptom", 183, 191, "Disease", "Symptom_Disease"], [138, 144, "Symptom", 169, 173, "Disease", "Symptom_Disease"], [145, 149, "Symptom", 192, 200, "Disease", "Symptom_Disease"], [135, 137, "Symptom", 174, 182, "Disease", "Symptom_Disease"], [135, 137, "Symptom", 205, 208, "Disease", "Symptom_Disease"]]}
{"idx": 143, "sentence": "十年血糖高，现肢端变黑，脚趾灼痛，去医院就诊 糖高25  血压高180 心率快120 发烧38.5  内分泌住七天，注射胰岛素，消炎，降压 现在心率100以下，餐前血糖七点多 餐后血糖八到十四浮动。双下肢动脉闭塞，足趾坏疽，我科可以通过多种治疗方法：加压灌注、手术清创等治疗方案保肢。", "ner": [[2, 4, "Test_items"], [4, 5, "Test_Value"], [7, 11, "Symptom"], [0, 2, "Duration"], [12, 16, "Symptom"], [23, 24, "Test_items"], [24, 27, "Test_Value"], [29, 31, "Test_items"], [31, 35, "Test_Value"], [36, 38, "Test_items"], [38, 42, "Test_Value"], [45, 49, "Test_Value"], [43, 45, "Symptom"], [60, 63, "Drug"], [58, 60, "Method"], [72, 74, "Test_items"], [74, 79, "Test_Value"], [80, 84, "Test_items"], [84, 87, "Test_Value"], [88, 92, "Test_items"], [92, 98, "Test_Value"], [99, 106, "Disease"], [107, 111, "Symptom"], [125, 129, "Treatment"], [132, 134, "Operation"]], "rel": [[7, 11, "Symptom", 99, 106, "Disease", "Symptom_Disease"], [12, 16, "Symptom", 99, 106, "Disease", "Symptom_Disease"], [107, 111, "Symptom", 99, 106, "Disease", "Symptom_Disease"], [125, 129, "Treatment", 99, 106, "Disease", "Treatment_Disease"], [132, 134, "Operation", 99, 106, "Disease", "Operation_Disease"], [58, 60, "Method", 60, 63, "Drug", "Method_Drug"]]}
{"idx": 144, "sentence": "出现糖尿病足的症状，间歇性跛行，足部刺痛，冬天病情开始恶化，脚趾开始发红，冰凉，并伴有疼痛，感染延肌间隙扩大。", "ner": [[2, 6, "Disease"], [10, 15, "Symptom"], [16, 20, "Symptom"], [30, 32, "Anatomy"], [34, 36, "Symptom"], [37, 39, "Symptom"], [41, 45, "Symptom"], [46, 54, "Symptom"]], "rel": [[10, 15, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [34, 36, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [37, 39, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [41, 45, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [46, 54, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 2, 6, "Disease", "Symptom_Disease"], [30, 32, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 145, "sentence": "糖尿病足，脓性分泌物及坏死组织增多，医嘱：您好，糖尿病足治疗首要是要加强控制血糖，根据您的描述，目前处于急性感染期，首选胰岛素治疗控制血糖，目标控制空腹血糖：5-7mmol/L，餐后2h血糖：6-8mmol/L，须尽快将血糖控制好；其次，继续全身抗感染治疗，可以继续静脉输液抗感染，疗程用足；第三，坚持局部换药，糖尿病足一般有创口小，里面损伤大的特点，清创换药，有条件可做双下肢动静脉彩超明确下肢血管有无硬化、狭窄、阻塞等情况，必要时可能需要外科手术治疗；最后，目前尽量避免下地活动，要保持伤口外观干洁。糖尿病足进展快，治疗难度大，疗程长。", "ner": [[0, 4, "Disease"], [5, 17, "Symptom"], [24, 28, "Disease"], [38, 40, "Test_items"], [60, 63, "Drug"], [67, 69, "Test_items"], [74, 78, "Test_items"], [79, 88, "Test_Value"], [89, 95, "Test_items"], [96, 105, "Test_Value"], [110, 112, "Test_items"], [133, 137, "Method"], [156, 160, "Disease"], [176, 178, "Operation"], [186, 194, "Test"], [196, 200, "Anatomy"], [252, 256, "Disease"], [202, 204, "Symptom"], [205, 207, "Symptom"], [208, 210, "Symptom"]], "rel": [[5, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [176, 178, "Operation", 0, 4, "Disease", "Operation_Disease"], [186, 194, "Test", 0, 4, "Disease", "Test_Disease"], [202, 204, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [205, 207, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [208, 210, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 146, "sentence": "1.患糖尿病10多年，空腹血糖8.4-9.3，2010年轻度脑卒中，用药后无复发。2.现在症状表现为：日常脚后跟持续疼痛，静卧时脚后跟至脚掌或脚后跟至膝盖时足部刺痛。站立更觉疼痛。病人晨起静走，觉运动之后似乎疼痛更甚。", "ner": [[3, 6, "Disease"], [6, 10, "Duration"], [11, 15, "Test_items"], [15, 22, "Test_Value"], [30, 33, "Disease"], [28, 30, "Level"], [53, 60, "Symptom"], [78, 82, "Symptom"], [87, 89, "Symptom"], [104, 106, "Symptom"], [64, 67, "Anatomy"], [68, 70, "Anatomy"], [71, 74, "Anatomy"], [75, 77, "Anatomy"]], "rel": [[11, 15, "Test_items", 3, 6, "Disease", "Test_items_Disease"]]}
{"idx": 147, "sentence": "最近4个多月了大脚趾已经坏死现在脚掌趾有脓性分泌物及坏死组织增多，曾经治疗情况和效果：治疗效果不好动脉已经基本栓塞股动脉触摸感觉减退或缺失。", "ner": [[2, 6, "Duration"], [7, 14, "Symptom"], [20, 32, "Symptom"], [16, 19, "Anatomy"], [49, 51, "Anatomy"], [55, 57, "Symptom"], [57, 60, "Anatomy"], [60, 69, "Symptom"]], "rel": []}
{"idx": 148, "sentence": "遗传糖尿病史，现糖尿病足足部感染，半个月未见好转，阿卡波糖片 依帕司他片 氨路地平片 缬沙坦胶囊", "ner": [[8, 12, "Disease"], [12, 16, "Symptom"], [25, 30, "Drug"], [31, 36, "Drug"], [37, 42, "Drug"], [43, 48, "Drug"]], "rel": [[12, 16, "Symptom", 8, 12, "Disease", "Symptom_Disease"], [31, 36, "Drug", 8, 12, "Disease", "Drug_Disease"]]}
{"idx": 149, "sentence": "糖尿病足俩小脚趾溃疡，后截掉俩脚趾。后没治愈五趾全阶。先近两个月，伤口仍发炎", "ner": [[0, 4, "Disease"], [4, 10, "Symptom"], [12, 14, "Operation"], [14, 17, "Anatomy"], [22, 24, "Anatomy"], [33, 38, "Symptom"]], "rel": [[4, 10, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [33, 38, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [12, 14, "Operation", 0, 4, "Disease", "Operation_Disease"], [14, 17, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [22, 24, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 150, "sentence": "患者类风湿病20余年病史，于8月29日发烧以及小腿出现皮疹磨损状，糖尿病足，8月31日送院，送院当天腿部恶化程度已经十分严重，验血血糖高达36，后入院，胰岛素控制血糖以及控制感染，目前血糖在4~9之间波动，胰岛素视情况注射。入院后各项检查，蛋白较低，腿部血管b超无异常，内脏肝功能有损害和轻微肾结石，控制好血糖后准备清创手术。9月11日第一次清创手术，感染病灶已侵犯深部肌肉组织，还需要多次清创。医嘱：血管情况好，可以考虑先保肢。需要手术清创才能治愈。", "ner": [[2, 6, "Disease"], [6, 10, "Duration"], [19, 21, "Symptom"], [23, 32, "Symptom"], [33, 37, "Disease"], [50, 52, "Anatomy"], [58, 62, "Level"], [63, 65, "Test"], [65, 67, "Test_items"], [67, 71, "Test_Value"], [76, 79, "Drug"], [81, 83, "Test_items"], [87, 89, "Symptom"], [92, 94, "Test_items"], [95, 100, "Test_Value"], [103, 106, "Drug"], [109, 111, "Method"], [120, 122, "Test_items"], [122, 124, "Test_Value"], [125, 131, "Test"], [135, 137, "Anatomy"], [137, 143, "Symptom"], [144, 149, "Disease"], [153, 155, "Test_items"], [158, 162, "Operation"], [171, 175, "Operation"], [176, 189, "Symptom"], [219, 221, "Operation"], [195, 197, "Operation"], [201, 203, "Anatomy"]], "rel": [[19, 21, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [23, 32, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [87, 89, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [176, 189, "Symptom", 33, 37, "Disease", "Symptom_Disease"], [125, 131, "Test", 33, 37, "Disease", "Test_Disease"], [195, 197, "Operation", 33, 37, "Disease", "Operation_Disease"], [158, 162, "Operation", 33, 37, "Disease", "Operation_Disease"], [109, 111, "Method", 103, 106, "Drug", "Method_Drug"]]}
{"idx": 151, "sentence": "摔跤后脚指头出现口子，脓性分泌物较多，大夫按糖尿病足治疗，消炎降糖药", "ner": [[3, 10, "Symptom"], [11, 18, "Symptom"], [22, 26, "Disease"]], "rel": [[3, 10, "Symptom", 22, 26, "Disease", "Symptom_Disease"], [11, 18, "Symptom", 22, 26, "Disease", "Symptom_Disease"]]}
{"idx": 152, "sentence": "右足小姆指红肿，有点溃疡。发病时间有20多天。糖尿病是在社区医院，特殊门诊，每天打胰岛素和吃二甲双胍。血糖空腹一般在7，左右。糖化血红蛋白6.9。可乐必妥1天两次。一次1粒，3天", "ner": [[0, 7, "Symptom"], [10, 12, "Symptom"], [18, 22, "Duration"], [23, 26, "Disease"], [38, 40, "Frequency"], [40, 41, "Method"], [41, 44, "Drug"], [45, 46, "Method"], [46, 50, "Drug"], [51, 53, "Test_items"], [58, 59, "Test_Value"], [63, 69, "Test_items"], [69, 72, "Test_Value"], [73, 77, "Drug"], [77, 81, "Frequency"], [82, 86, "Amount"], [87, 89, "Duration"]], "rel": [[41, 44, "Drug", 23, 26, "Disease", "Drug_Disease"], [46, 50, "Drug", 23, 26, "Disease", "Drug_Disease"], [51, 53, "Test_items", 23, 26, "Disease", "Test_items_Disease"], [63, 69, "Test_items", 23, 26, "Disease", "Test_items_Disease"], [38, 40, "Frequency", 41, 44, "Drug", "Frequency_Drug"], [38, 40, "Frequency", 46, 50, "Drug", "Frequency_Drug"], [77, 81, "Frequency", 73, 77, "Drug", "Frequency_Drug"], [40, 41, "Method", 41, 44, "Drug", "Method_Drug"], [45, 46, "Method", 46, 50, "Drug", "Method_Drug"], [82, 86, "Amount", 73, 77, "Drug", "Amount_Drug"]]}
{"idx": 153, "sentence": "我爷爷糖尿病十多年，之前饮食控制差，所以血糖也没控制好，右脚一个小伤口烂了大约半年才到医院就诊，目前双脚感染病灶已侵犯深部肌肉组织，足部刺痛难忍。", "ner": [[3, 6, "Disease"], [6, 9, "Duration"], [20, 22, "Test_items"], [28, 30, "Anatomy"], [50, 65, "Symptom"], [66, 72, "Symptom"], [37, 41, "Duration"], [12, 16, "Treatment"]], "rel": [[20, 22, "Test_items", 3, 6, "Disease", "Test_items_Disease"], [12, 16, "Treatment", 3, 6, "Disease", "Treatment_Disease"]]}
{"idx": 154, "sentence": "糖尿病足，医生说伤到骨头了，脓性分泌物较多，第二趾已截掉。", "ner": [[0, 4, "Disease"], [14, 21, "Symptom"], [22, 25, "Anatomy"], [26, 28, "Operation"], [8, 12, "Symptom"]], "rel": [[8, 12, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [14, 21, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [22, 25, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [26, 28, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 155, "sentence": "糖尿病足，在3个月前开始发病，前期脚肿，后过了一个月中指出现溃疡，并有灼痛。在德州市人民医院控制了血糖，并处理了伤口，进行了消炎，脓性分泌物较多，在进行各种检查后发现右腿血管不通，最后在右腿动脉加入了支架。加入支架后脚有一定好转，但中指已经基本坏死，肢端变黑。脚底板处血脉仍不完全通畅。医生在脚底板处切开一个长度约4CM，深度约5㎜的口，血液才有流出。现已进行敷药处理。打胰岛素控制血糖，一天打两次，白天24个单位，晚上21个单位。", "ner": [[0, 4, "Disease"], [17, 19, "Symptom"], [35, 37, "Symptom"], [49, 51, "Test_items"], [65, 72, "Symptom"], [83, 89, "Symptom"], [93, 97, "Anatomy"], [108, 109, "Anatomy"], [125, 129, "Symptom"], [116, 124, "Symptom"], [130, 142, "Symptom"], [146, 149, "Anatomy"], [156, 160, "Level"], [163, 166, "Level"], [185, 186, "Method"], [186, 189, "Drug"], [191, 193, "Test_items"], [194, 199, "Frequency"], [200, 207, "Amount"], [208, 215, "Amount"], [30, 32, "Symptom"], [26, 28, "Anatomy"]], "rel": [[17, 19, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [35, 37, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [30, 32, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [65, 72, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [83, 89, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [116, 124, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [125, 129, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [130, 142, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [26, 28, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [108, 109, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [146, 149, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [194, 199, "Frequency", 186, 189, "Drug", "Frequency_Drug"], [185, 186, "Method", 186, 189, "Drug", "Method_Drug"], [200, 207, "Amount", 186, 189, "Drug", "Amount_Drug"], [208, 215, "Amount", 186, 189, "Drug", "Amount_Drug"]]}
{"idx": 156, "sentence": "患糖尿病多年，从2018年开始脚底板和脚趾感染延肌间隙扩大。现在早晚两次打甘舒霖16个单位，血糖一直控制的不算太好，前两天血糖达到12点多，配合吃了二甲双胍，这两天血糖达到8点多。", "ner": [[1, 4, "Disease"], [4, 6, "Duration"], [21, 29, "Symptom"], [32, 36, "Frequency"], [36, 37, "Method"], [37, 40, "Drug"], [15, 18, "Anatomy"], [19, 21, "Anatomy"], [40, 45, "Amount"], [46, 48, "Test_items"], [61, 63, "Test_items"], [65, 69, "Test_Value"], [74, 78, "Drug"], [72, 73, "Method"], [82, 84, "Test_items"], [86, 89, "Test_Value"]], "rel": [[46, 48, "Test_items", 1, 4, "Disease", "Test_items_Disease"], [74, 78, "Drug", 1, 4, "Disease", "Drug_Disease"], [37, 40, "Drug", 1, 4, "Disease", "Drug_Disease"], [32, 36, "Frequency", 37, 40, "Drug", "Frequency_Drug"], [36, 37, "Method", 37, 40, "Drug", "Method_Drug"], [72, 73, "Method", 74, 78, "Drug", "Method_Drug"], [40, 45, "Amount", 37, 40, "Drug", "Amount_Drug"]]}
{"idx": 157, "sentence": "2019年6月脑梗后，糖尿病足从慢慢色素沉着，现在双脚脚趾头溃疡。", "ner": [[7, 9, "Disease"], [11, 15, "Disease"], [18, 22, "Symptom"], [27, 32, "Symptom"], [25, 27, "Anatomy"]], "rel": [[18, 22, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [27, 32, "Symptom", 11, 15, "Disease", "Symptom_Disease"], [25, 27, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"]]}
{"idx": 158, "sentence": "2021年6月15号住院。治疗糖尿病足。出院后未见改善。左脚病足大脚趾加重，肢端变黑，破皮，脓性分泌物较多，患者灼痛感较大。", "ner": [[15, 19, "Disease"], [38, 42, "Symptom"], [35, 37, "Level"], [43, 45, "Symptom"], [46, 53, "Symptom"], [56, 59, "Symptom"], [59, 61, "Level"], [32, 35, "Anatomy"], [28, 30, "Anatomy"]], "rel": [[38, 42, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [43, 45, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [46, 53, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [56, 59, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [28, 30, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"], [32, 35, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"]]}
{"idx": 159, "sentence": "糖尿病史17年，脚疼灼痛住院10天，感染病灶已侵犯深部肌肉组织，脓性分泌物较多。住院时医生把伤口切开挤脓，目前一直有足部刺痛。这几天疼痛和肿加重，吃了一个礼拜头孢消炎也未见好转。又开了阿莫西林，还是肿疼。", "ner": [[4, 7, "Duration"], [8, 12, "Symptom"], [14, 17, "Duration"], [32, 39, "Symptom"], [58, 62, "Symptom"], [66, 68, "Symptom"], [69, 70, "Symptom"], [70, 72, "Level"], [79, 81, "Drug"], [75, 79, "Duration"], [73, 74, "Method"], [92, 96, "Drug"], [99, 101, "Symptom"], [18, 31, "Symptom"]], "rel": [[73, 74, "Method", 79, 81, "Drug", "Method_Drug"]]}
{"idx": 160, "sentence": "糖尿病足患者发现足溃疡，多发性脓灶，色素沉着，在当地医院住院20多天，做过彩超检查，足部动脉静脉化，输液用药为疏血通、前列地尔、甲钴胺，经过治疗足部颜色接近正常，输液后，治疗17天后足部下午有水肿、次日清晨消失，足部仅清创，现出院回家。糖尿病史10多年。", "ner": [[0, 4, "Disease"], [8, 11, "Symptom"], [12, 17, "Symptom"], [18, 22, "Symptom"], [30, 34, "Duration"], [37, 41, "Test"], [42, 49, "Symptom"], [55, 58, "Drug"], [59, 63, "Drug"], [64, 67, "Drug"], [106, 108, "Anatomy"], [109, 111, "Operation"], [96, 98, "Symptom"], [91, 93, "Anatomy"], [50, 52, "Method"], [72, 74, "Anatomy"]], "rel": [[8, 11, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [12, 17, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [42, 49, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [96, 98, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [91, 93, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [55, 58, "Drug", 0, 4, "Disease", "Drug_Disease"], [59, 63, "Drug", 0, 4, "Disease", "Drug_Disease"], [64, 67, "Drug", 0, 4, "Disease", "Drug_Disease"], [109, 111, "Operation", 0, 4, "Disease", "Operation_Disease"]]}
{"idx": 161, "sentence": "患者1个月前，右足无明显诱因出现溃烂，不伴疼痛及瘙痒，有少许渗液，随时间推移，逐渐扩大，期间自行换药处理，1周前，其溃烂处，渗液明显增大，仍不伴疼痛及瘙痒，无发热、恶心及乏力等不适症状，自行换药，无明显效果，现为求治疗，就诊于我科门诊，以“糖尿病足”收治入院。   患者近期，精神、食欲可，夜间睡眠佳，大小便正常，体重及体力无明显变化。", "ner": [[7, 9, "Anatomy"], [16, 18, "Symptom"], [62, 64, "Symptom"], [64, 68, "Level"], [120, 124, "Disease"], [21, 23, "Symptom"], [24, 26, "Symptom"], [72, 74, "Symptom"], [75, 77, "Symptom"], [79, 81, "Symptom"], [82, 84, "Symptom"], [85, 87, "Symptom"], [30, 32, "Symptom"]], "rel": [[16, 18, "Symptom", 120, 124, "Disease", "Symptom_Disease"], [21, 23, "Symptom", 120, 124, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 120, 124, "Disease", "Symptom_Disease"], [30, 32, "Symptom", 120, 124, "Disease", "Symptom_Disease"], [7, 9, "Anatomy", 120, 124, "Disease", "Anatomy_Disease"]]}
{"idx": 162, "sentence": "患者2月前出现右足皮肤溃烂，至当地医院住院治疗后好转不明显，无四肢麻木，无发热咳嗽，无心慌胸闷，无恶心呕吐，为进一步治疗门诊以“糖尿病足”收入我科。    起病以来，精神、饮食、睡眠可，大小便如常，体力下降，体重无明显改变。", "ner": [[7, 13, "Symptom"], [31, 35, "Symptom"], [37, 39, "Symptom"], [39, 41, "Symptom"], [64, 68, "Disease"], [43, 45, "Symptom"], [45, 47, "Symptom"], [49, 51, "Symptom"], [51, 53, "Symptom"], [99, 103, "Symptom"]], "rel": [[7, 13, "Symptom", 64, 68, "Disease", "Symptom_Disease"]]}
{"idx": 163, "sentence": "患者8月余前开始出现行走后左下肢疼痛，休息后可缓解，不伴下肢肿胀、局部皮温皮色改变等不适，患者未重视，未行进一步检查治疗。2月余前上述症状较前明显加重，左小腿及以下部分冰冷、皮色暗红，左足部分足趾发黑、渗液，不伴发热、咳嗽咳痰、心慌胸闷胸痛等不适，欲行进一步诊治来我院，以“1.双下肢动脉硬化闭塞症; 2.左足感染”收治。    起病以来，精神饮食睡眠欠佳，大小便如常，体力下降，体重未见明显改变。", "ner": [[13, 18, "Symptom"], [28, 32, "Symptom"], [33, 41, "Symptom"], [71, 75, "Level"], [84, 86, "Symptom"], [87, 91, "Symptom"], [94, 100, "Symptom"], [101, 103, "Symptom"], [106, 108, "Symptom"], [114, 116, "Symptom"], [116, 118, "Symptom"], [118, 120, "Symptom"], [109, 111, "Symptom"], [111, 113, "Symptom"], [139, 149, "Disease"], [153, 157, "Disease"], [92, 94, "Anatomy"], [76, 84, "Anatomy"], [170, 178, "Symptom"], [185, 189, "Symptom"]], "rel": [[13, 18, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [33, 41, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [84, 86, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [94, 100, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [101, 103, "Symptom", 139, 149, "Disease", "Symptom_Disease"], [153, 157, "Disease", 139, 149, "Disease", "Disease_Disease"]]}
{"idx": 164, "sentence": "患者诉今年2月份左足第五足趾行走时疼痛，未行特殊处理，自己在家中泡脚后，修剪趾甲，不慎剪破后，皮肤发黑，就诊我科门诊，建议住院治疗，患者未治疗。于2021年4月份就诊宜昌市中心医院，左足创面行换药治疗，创面逐渐愈合。近几日，患者于家中泡脚后，发现左足红肿，第5足趾颜色暗紫，行走疼痛，现为求进一步治疗，就诊我科门诊，门诊以“2型糖尿病病足”收治入院。自起病以来，患者神志清楚，精神饮食睡眠欠佳，二便正常，体力下降，体重正常。", "ner": [[17, 19, "Symptom"], [8, 14, "Anatomy"], [47, 51, "Symptom"], [91, 93, "Anatomy"], [123, 127, "Symptom"], [132, 136, "Symptom"], [128, 132, "Anatomy"], [137, 141, "Symptom"], [162, 169, "Disease"], [188, 196, "Symptom"], [202, 206, "Symptom"]], "rel": [[17, 19, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [47, 51, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [123, 127, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [132, 136, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [137, 141, "Symptom", 162, 169, "Disease", "Symptom_Disease"], [8, 14, "Anatomy", 162, 169, "Disease", "Anatomy_Disease"], [91, 93, "Anatomy", 162, 169, "Disease", "Anatomy_Disease"], [128, 132, "Anatomy", 162, 169, "Disease", "Anatomy_Disease"]]}
{"idx": 165, "sentence": "患者20年前患者偶测血糖升高，最高血糖达20.0mmol/L，既往曾明确诊断为“2型糖尿病”，长期行“精蛋白生物合成人胰岛素30R早餐前24u，晚餐前14u”管理血糖，3月前患者右足小趾出现水泡，随之皮肤溃烂，长期在“宜昌市中心医院”换药治疗，情况无好转，目前空腹血糖控制在8mmol/L左右，餐后血糖控制在9-10mmol/L左右，且诉时有低血糖发生，今为进一步调整血糖及换药治疗，门诊以“2型糖尿病 糖尿病足”收住院。起病以来，患者精神、饮食、睡眠可，大便、小便正常，体力下降，体重下降，约10公斤。", "ner": [[10, 12, "Test_items"], [17, 19, "Test_items"], [20, 30, "Test_Value"], [40, 45, "Disease"], [81, 83, "Test_items"], [51, 65, "Drug"], [65, 71, "Amount"], [72, 78, "Amount"], [95, 97, "Symptom"], [89, 93, "Anatomy"], [100, 104, "Symptom"], [130, 134, "Test_items"], [137, 146, "Test_Value"], [147, 151, "Test_items"], [154, 166, "Test_Value"], [171, 174, "Disease"], [184, 186, "Test_items"], [196, 201, "Disease"], [202, 206, "Disease"], [236, 240, "Symptom"], [241, 245, "Symptom"], [12, 14, "Test_Value"], [246, 251, "Test_Value"]], "rel": [[95, 97, "Symptom", 202, 206, "Disease", "Symptom_Disease"], [100, 104, "Symptom", 202, 206, "Disease", "Symptom_Disease"], [236, 240, "Symptom", 40, 45, "Disease", "Symptom_Disease"], [241, 245, "Symptom", 40, 45, "Disease", "Symptom_Disease"], [10, 12, "Test_items", 40, 45, "Disease", "Test_items_Disease"], [130, 134, "Test_items", 40, 45, "Disease", "Test_items_Disease"], [147, 151, "Test_items", 40, 45, "Disease", "Test_items_Disease"], [51, 65, "Drug", 40, 45, "Disease", "Drug_Disease"], [65, 71, "Amount", 51, 65, "Drug", "Amount_Drug"], [72, 78, "Amount", 51, 65, "Drug", "Amount_Drug"], [202, 206, "Disease", 40, 45, "Disease", "Disease_Disease"], [89, 93, "Anatomy", 202, 206, "Disease", "Anatomy_Disease"], [171, 174, "Disease", 40, 45, "Disease", "Disease_Disease"]]}
{"idx": 166, "sentence": "患者诉4月前因“右足第二足趾皮肤溃烂”，于2021年06月23日就诊我科，多次行手术清创，于2021年8月18日在腰麻下行“右小腿截肢术”，术后患者病情平稳，恢复可，现为患者办理周转入院，门诊以“右足糖尿病足”收治入院。自起病以来，患者神志清楚，精神可，食欲差，小便如常，便秘，体重正常，体力下降。", "ner": [[14, 18, "Symptom"], [8, 14, "Anatomy"], [42, 44, "Operation"], [62, 68, "Operation"], [100, 104, "Disease"], [98, 100, "Anatomy"], [127, 130, "Symptom"], [136, 138, "Symptom"], [144, 148, "Symptom"]], "rel": [[14, 18, "Symptom", 100, 104, "Disease", "Symptom_Disease"], [8, 14, "Anatomy", 100, 104, "Disease", "Anatomy_Disease"], [98, 100, "Anatomy", 100, 104, "Disease", "Anatomy_Disease"], [62, 68, "Operation", 100, 104, "Disease", "Operation_Disease"], [42, 44, "Operation", 100, 104, "Disease", "Operation_Disease"]]}
{"idx": 167, "sentence": "患者于3天前在外钓鱼时双足被阳光暴晒约2小时余，当时无明显不适，回到家后发现双足红肿，脚趾逐渐出现水疱。在家行换药治疗，随时间推移，创面红肿，疼痛剧烈，并发现左足足趾发黑，水疱呈黑色。未见明显好转。为求进一步治疗以“糖尿病足”收入住院。    患者受伤以来，神志清、精神可，饮食、睡眠可，大小便正常，面颈部、胸前疼痛，无体重改变", "ner": [[11, 13, "Anatomy"], [18, 23, "Duration"], [38, 42, "Symptom"], [43, 45, "Anatomy"], [49, 51, "Symptom"], [66, 70, "Symptom"], [71, 75, "Symptom"], [81, 85, "Symptom"], [86, 91, "Symptom"], [79, 81, "Anatomy"], [108, 112, "Disease"], [150, 158, "Symptom"]], "rel": [[38, 42, "Symptom", 108, 112, "Disease", "Symptom_Disease"], [71, 75, "Symptom", 108, 112, "Disease", "Symptom_Disease"], [49, 51, "Symptom", 108, 112, "Disease", "Symptom_Disease"], [81, 85, "Symptom", 108, 112, "Disease", "Symptom_Disease"], [86, 91, "Symptom", 108, 112, "Disease", "Symptom_Disease"], [66, 70, "Symptom", 108, 112, "Disease", "Symptom_Disease"], [11, 13, "Anatomy", 108, 112, "Disease", "Anatomy_Disease"], [43, 45, "Anatomy", 108, 112, "Disease", "Anatomy_Disease"], [79, 81, "Anatomy", 108, 112, "Disease", "Anatomy_Disease"]]}
{"idx": 168, "sentence": "患者2月前出现右足皮肤溃烂，至当地医院住院治疗后好转不明显，无四肢麻木，无发热咳嗽，无心慌胸闷，无恶心呕吐，为进一步治疗门诊以“糖尿病足”收入我科。    起病以来，精神、饮食、睡眠可，大小便如常，体力下降，体重无明显改变。", "ner": [[9, 13, "Symptom"], [7, 9, "Anatomy"], [31, 35, "Symptom"], [37, 39, "Symptom"], [39, 41, "Symptom"], [43, 45, "Symptom"], [45, 47, "Symptom"], [49, 51, "Symptom"], [51, 53, "Symptom"], [64, 68, "Disease"], [99, 103, "Symptom"]], "rel": [[9, 13, "Symptom", 64, 68, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 64, 68, "Disease", "Symptom_Disease"], [7, 9, "Anatomy", 64, 68, "Disease", "Anatomy_Disease"]]}
{"idx": 169, "sentence": "患者诉10年前发现血糖升高，当时无多饮、多尿、多食等不适，完善OGTT明确诊断为“2型糖尿病”，目前予“门冬胰岛素30注射液早餐前10U，晚餐前6U皮下注射”控制血糖，半年前患者左足出现溃烂、部分流脓，伴有左足疼痛、麻木不适，于当地医院予换药后左足溃烂无明显好转，现左足已发坏死、发黑，为求进一步诊治，来我院就诊，门诊以“2型糖尿病”收住我科。起病以来，精神，饮食、睡眠可，大小便正常，体力体重无明显下降。", "ner": [[9, 11, "Test_items"], [11, 13, "Test_Value"], [17, 19, "Symptom"], [20, 22, "Symptom"], [23, 25, "Symptom"], [31, 35, "Test"], [41, 46, "Disease"], [52, 62, "Drug"], [62, 68, "Amount"], [69, 74, "Amount"], [74, 78, "Method"], [81, 83, "Test_items"], [89, 95, "Symptom"], [96, 100, "Symptom"], [103, 107, "Symptom"], [108, 112, "Symptom"], [122, 126, "Symptom"], [140, 142, "Symptom"], [133, 135, "Anatomy"], [161, 166, "Disease"], [137, 139, "Symptom"]], "rel": [[17, 19, "Symptom", 41, 46, "Disease", "Symptom_Disease"], [20, 22, "Symptom", 41, 46, "Disease", "Symptom_Disease"], [23, 25, "Symptom", 41, 46, "Disease", "Symptom_Disease"], [133, 135, "Anatomy", 161, 166, "Disease", "Anatomy_Disease"], [62, 68, "Amount", 52, 62, "Drug", "Amount_Drug"], [69, 74, "Amount", 52, 62, "Drug", "Amount_Drug"], [9, 11, "Test_items", 41, 46, "Disease", "Test_items_Disease"], [74, 78, "Method", 52, 62, "Drug", "Method_Drug"], [31, 35, "Test", 41, 46, "Disease", "Test_Disease"]]}
{"idx": 170, "sentence": "患者家属诉2021年9月左右发现患者左小腿至脚跟无明显诱因出现皮肤凹陷，随着时间推移，去年11月份出现左小腿疼痛加剧，近3月左小腿肿胀明显，脚后跟出现大片皮肤坏死，坏死痂皮覆盖，无局部渗液，无明显异味，就诊于当阳市长坂坡医院，予以清创包扎治疗。现患者为求进一步治疗，就诊我院。    自起病以来，患者神志清楚，精神食欲可，尿频，大便正常，体重正常，体力下降。发现左下肢皮肤溃烂半年余", "ner": [[18, 21, "Anatomy"], [22, 24, "Anatomy"], [31, 35, "Symptom"], [54, 58, "Symptom"], [65, 69, "Symptom"], [62, 65, "Anatomy"], [51, 54, "Anatomy"], [77, 81, "Symptom"], [75, 77, "Level"], [70, 73, "Anatomy"], [82, 88, "Symptom"], [90, 94, "Symptom"], [96, 100, "Symptom"], [115, 117, "Operation"], [161, 163, "Symptom"], [174, 178, "Symptom"], [184, 188, "Symptom"], [188, 191, "Duration"], [181, 184, "Anatomy"]], "rel": []}
{"idx": 171, "sentence": "患者13余年前发现血糖升高，具体血糖水平不详。无明显口干多饮多尿，后进一步检查确诊为“2型糖尿病”，先后口服降糖药物治疗，现家属已自行停用降糖药物，血糖未规律检测。1月前患者左足出现溃烂、部分流脓，伴有左足疼痛、麻木不适，未予特殊处理，现为求进一步诊治，来我院就诊，门诊以“2型糖尿病”收住我科。起病以来，精神、饮食、睡眠可，大便干结，小便正常，体力下降，体重无明显下降。", "ner": [[9, 11, "Test_items"], [11, 13, "Test_Value"], [16, 18, "Test_items"], [26, 28, "Symptom"], [28, 30, "Symptom"], [30, 32, "Symptom"], [43, 48, "Disease"], [52, 54, "Method"], [74, 76, "Test_items"], [91, 93, "Symptom"], [87, 89, "Anatomy"], [94, 98, "Symptom"], [101, 105, "Symptom"], [106, 110, "Symptom"], [137, 142, "Disease"], [163, 167, "Symptom"], [173, 177, "Symptom"]], "rel": [[9, 11, "Test_items", 43, 48, "Disease", "Test_items_Disease"], [173, 177, "Symptom", 43, 48, "Disease", "Symptom_Disease"]]}
{"idx": 172, "sentence": "患者于26年前体检发现血糖升高，查空腹血糖9.5mmol/L，伴口干、多饮、多尿、多食，尿量与饮水量平行，进一步检查确诊为2型糖尿病，予二甲双胍片控制血糖。10余年前因血糖控制不佳改为胰岛素治疗，曾在我科住院诊断为“2型糖尿病并视网膜病变、骨密度减低、周围神经病变、大血管病变、肾病”，现予“门冬胰岛素早6U，中6U，晚4U+德谷胰岛素28U睡前皮下注射”管理血糖治疗，平素查餐前血糖约8.5mmol/l，餐后未监测。4月前患者右足中趾无明显诱因出现皮肤破损，未特殊处理，至今无明显好转，今为进一步诊治来我院，门诊以“2型糖尿病”收治我科。起病以来，患者精神、饮食、睡眠一般，大便如常，小便次数增多，体力、体重下降。", "ner": [[11, 13, "Test_items"], [13, 15, "Test_Value"], [17, 21, "Test_items"], [21, 30, "Test_Value"], [32, 34, "Symptom"], [35, 37, "Symptom"], [38, 40, "Symptom"], [41, 43, "Symptom"], [44, 52, "Symptom"], [61, 66, "Disease"], [68, 73, "Drug"], [75, 77, "Test_items"], [84, 86, "Test_items"], [92, 95, "Drug"], [108, 113, "Disease"], [120, 125, "Symptom"], [139, 141, "Disease"], [146, 151, "Drug"], [151, 154, "Amount"], [155, 158, "Amount"], [159, 162, "Amount"], [163, 168, "Drug"], [168, 171, "Amount"], [173, 177, "Method"], [180, 182, "Test_items"], [188, 192, "Test_items"], [192, 202, "Test_Value"], [214, 218, "Anatomy"], [225, 229, "Symptom"], [259, 264, "Disease"], [293, 299, "Symptom"], [300, 307, "Symptom"], [114, 119, "Disease"], [126, 132, "Disease"], [133, 138, "Disease"]], "rel": [[32, 34, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [44, 52, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [41, 43, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [38, 40, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [35, 37, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [120, 125, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [293, 299, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [300, 307, "Symptom", 61, 66, "Disease", "Symptom_Disease"], [11, 13, "Test_items", 61, 66, "Disease", "Test_items_Disease"], [17, 21, "Test_items", 61, 66, "Disease", "Test_items_Disease"], [188, 192, "Test_items", 61, 66, "Disease", "Test_items_Disease"], [146, 151, "Drug", 61, 66, "Disease", "Drug_Disease"], [68, 73, "Drug", 61, 66, "Disease", "Drug_Disease"], [92, 95, "Drug", 61, 66, "Disease", "Drug_Disease"], [173, 177, "Method", 163, 168, "Drug", "Method_Drug"], [173, 177, "Method", 146, 151, "Drug", "Method_Drug"], [151, 154, "Amount", 146, 151, "Drug", "Amount_Drug"], [155, 158, "Amount", 146, 151, "Drug", "Amount_Drug"], [159, 162, "Amount", 146, 151, "Drug", "Amount_Drug"], [168, 171, "Amount", 163, 168, "Drug", "Amount_Drug"], [139, 141, "Disease", 108, 113, "Disease", "Disease_Disease"], [163, 168, "Drug", 61, 66, "Disease", "Drug_Disease"], [114, 119, "Disease", 61, 66, "Disease", "Disease_Disease"], [126, 132, "Disease", 61, 66, "Disease", "Disease_Disease"], [133, 138, "Disease", 61, 66, "Disease", "Disease_Disease"]]}
{"idx": 173, "sentence": "患者8年前体检时发现血糖升高，于中心医院住院明确诊断为“2型糖尿病”，长期予“二甲双胍、阿卡波糖、格列美脲”管理血糖，在家未规律监测血糖，偶测空腹血糖13.0mmol/l左右，无明显口干、多饮、多尿及体重减轻等，1月前患者左下肢蚊虫叮咬搔抓后出现多处溃烂，随后出现下肢及足部红肿热痛，曾于外院抗感染治疗，下肢红肿溃烂稍好转，但仍有下肢红肿，今为求进一步诊治，门诊以“2型糖尿病足”收入我科住院。     起病以来，患者精神饮食睡眠可，大小便正常，体力稍下降，体重无明显改变。", "ner": [[10, 12, "Test_items"], [12, 14, "Test_Value"], [28, 33, "Disease"], [39, 43, "Drug"], [44, 48, "Drug"], [49, 53, "Drug"], [56, 58, "Test_items"], [66, 68, "Test_items"], [71, 75, "Test_items"], [75, 87, "Test_Value"], [91, 93, "Symptom"], [94, 96, "Symptom"], [97, 99, "Symptom"], [100, 104, "Symptom"], [111, 114, "Anatomy"], [123, 127, "Symptom"], [132, 134, "Anatomy"], [135, 137, "Anatomy"], [137, 141, "Symptom"], [152, 158, "Symptom"], [165, 169, "Symptom"], [183, 189, "Disease"], [223, 228, "Symptom"]], "rel": [[91, 93, "Symptom", 28, 33, "Disease", "Symptom_Disease"], [94, 96, "Symptom", 28, 33, "Disease", "Symptom_Disease"], [97, 99, "Symptom", 28, 33, "Disease", "Symptom_Disease"], [100, 104, "Symptom", 28, 33, "Disease", "Symptom_Disease"], [223, 228, "Symptom", 28, 33, "Disease", "Symptom_Disease"], [183, 189, "Disease", 28, 33, "Disease", "Disease_Disease"], [135, 137, "Anatomy", 183, 189, "Disease", "Anatomy_Disease"], [123, 127, "Symptom", 183, 189, "Disease", "Symptom_Disease"], [152, 158, "Symptom", 183, 189, "Disease", "Symptom_Disease"], [137, 141, "Symptom", 183, 189, "Disease", "Symptom_Disease"], [165, 169, "Symptom", 183, 189, "Disease", "Symptom_Disease"], [39, 43, "Drug", 28, 33, "Disease", "Drug_Disease"], [44, 48, "Drug", 28, 33, "Disease", "Drug_Disease"], [49, 53, "Drug", 28, 33, "Disease", "Drug_Disease"], [56, 58, "Test_items", 28, 33, "Disease", "Test_items_Disease"], [71, 75, "Test_items", 28, 33, "Disease", "Test_items_Disease"]]}
{"idx": 174, "sentence": "患者1月前出现右足疼痛不适，足趾局部渗液、红肿，在家行换药、消毒处理，效果欠佳，右足多趾局部发黑伴渗液，右足跟部溃疡形成伴渗出，右足疼痛加重，伴双足间歇性麻木不适，无低热盗汗，偶有胸闷气短，活动后加重，为求进一步诊治，今日来我院门诊就诊，门诊以“糖尿病足”收入我科。   起病以来，患者精神饮食睡眠差，大小便如常，体力体重未见明显变化。", "ner": [[7, 13, "Symptom"], [21, 23, "Symptom"], [14, 20, "Symptom"], [64, 70, "Symptom"], [72, 81, "Symptom"], [83, 85, "Symptom"], [85, 87, "Symptom"], [90, 94, "Symptom"], [123, 127, "Disease"], [143, 150, "Symptom"], [52, 63, "Symptom"], [40, 51, "Symptom"]], "rel": [[7, 13, "Symptom", 123, 127, "Disease", "Symptom_Disease"], [14, 20, "Symptom", 123, 127, "Disease", "Symptom_Disease"], [21, 23, "Symptom", 123, 127, "Disease", "Symptom_Disease"], [40, 51, "Symptom", 123, 127, "Disease", "Symptom_Disease"], [52, 63, "Symptom", 123, 127, "Disease", "Symptom_Disease"], [64, 70, "Symptom", 123, 127, "Disease", "Symptom_Disease"], [72, 81, "Symptom", 123, 127, "Disease", "Symptom_Disease"]]}
{"idx": 175, "sentence": "患者10余年前因视力下降就诊发现血糖升高，空腹血糖29mmol/l，完善相关检查，诊断为“2型糖尿病”，先后给予口服降糖药物及胰岛素降糖治疗，目前降糖方案为“门冬胰岛素早8u，晚6U餐前皮下注射”，未规律监测血糖；2月余前因烤火致左足烫伤，于葛洲坝中心医院就诊予以“烫伤膏”外敷换药，现伤口大小约3cm*2cm，无红肿化脓、渗血渗液不适，今为求进一步诊治，遂至我院就诊，门诊以“2型糖尿病”收入我科住院治疗。起病以来，患者精神、饮食、睡眠可，大便干结，尿少，体力下降，体重无明显变化。", "ner": [[16, 18, "Test_items"], [18, 20, "Test_Value"], [21, 25, "Test_items"], [25, 33, "Test_Value"], [45, 50, "Disease"], [56, 58, "Method"], [63, 66, "Drug"], [79, 84, "Drug"], [84, 87, "Amount"], [88, 91, "Amount"], [93, 97, "Method"], [104, 106, "Test_items"], [133, 136, "Drug"], [137, 139, "Method"], [147, 155, "Level"], [157, 161, "Symptom"], [162, 168, "Symptom"], [189, 194, "Disease"], [221, 225, "Symptom"], [226, 228, "Symptom"], [229, 233, "Symptom"]], "rel": [[16, 18, "Test_items", 45, 50, "Disease", "Test_items_Disease"], [21, 25, "Test_items", 45, 50, "Disease", "Test_items_Disease"], [63, 66, "Drug", 45, 50, "Disease", "Drug_Disease"], [79, 84, "Drug", 45, 50, "Disease", "Drug_Disease"], [93, 97, "Method", 79, 84, "Drug", "Method_Drug"], [137, 139, "Method", 133, 136, "Drug", "Method_Drug"], [229, 233, "Symptom", 45, 50, "Disease", "Symptom_Disease"], [84, 87, "Amount", 79, 84, "Drug", "Amount_Drug"], [88, 91, "Amount", 79, 84, "Drug", "Amount_Drug"]]}
{"idx": 176, "sentence": "患者于3月余前发现左足无明显原因溃烂，当时未做特殊处理，随时间推移，左足伤口逐渐增大，伴渗液，无发热、恶心、呕吐等不适。遂至宜昌中心医院行抗感染输液治疗（具体不详），左足应用外用药物治疗（具体不详），无好转。2020-02-19于我科住院治疗， 2020-03-02在神经阻滞麻醉下行“左足踇趾清创+负压吸引术”，术后给予抗感染、换药等治疗。患者左足创面较前稍有好转，患者为医保患者，住院满2个月，给予办理周转后，继续以“2型糖尿病足”收住入院。     起病以来，患者精神、饮食、睡眠欠佳，大小便通畅，大便失禁。", "ner": [[16, 18, "Symptom"], [9, 11, "Anatomy"], [34, 36, "Anatomy"], [44, 46, "Symptom"], [48, 50, "Symptom"], [51, 53, "Symptom"], [54, 56, "Symptom"], [83, 85, "Anatomy"], [143, 149, "Operation"], [150, 155, "Treatment"], [173, 175, "Anatomy"], [211, 217, "Disease"], [235, 245, "Symptom"], [252, 256, "Symptom"]], "rel": [[16, 18, "Symptom", 211, 217, "Disease", "Symptom_Disease"], [44, 46, "Symptom", 211, 217, "Disease", "Symptom_Disease"], [9, 11, "Anatomy", 211, 217, "Disease", "Anatomy_Disease"], [143, 149, "Operation", 211, 217, "Disease", "Operation_Disease"], [150, 155, "Treatment", 211, 217, "Disease", "Treatment_Disease"]]}
{"idx": 177, "sentence": "患者于3年前发现血糖升高，无多饮、多尿、多食等不适，完善OGTT诊断为“2型糖尿病”，目前予以“门冬胰岛素30 22u早餐前+二甲双胍 500mg tid+阿卡波糖 50mg tid”控制血糖，自行在家监测空腹血糖波动在8-11mmol/L，2月前患者因左足第二足趾溃烂伴双下肢麻木在我院住院，诊断为“1.2型糖尿病足伴足趾感染及溃烂 2.2型糖尿病性肾病; 3.2型糖尿病性周围神经病; 4.2型糖尿病性周围血管病变; 5.2型糖尿病性视网膜病变”，经管理血糖、营养神经、清洗换药等处理后创口愈合好转出院，1月前患者出现左侧足趾疼痛紫绀，足趾发冷，双下肢麻木，今为求进一步诊治，遂来我院门诊就诊，门诊以“2型糖尿病足”收入我科住院。     起病以来，患者精神、饮食、睡眠可，大小便正常，体力、体重无明显改变。", "ner": [[8, 10, "Test_items"], [10, 12, "Test_Value"], [14, 16, "Symptom"], [17, 19, "Symptom"], [20, 22, "Symptom"], [28, 32, "Test"], [36, 41, "Disease"], [48, 55, "Drug"], [56, 62, "Amount"], [63, 67, "Drug"], [68, 73, "Amount"], [74, 77, "Frequency"], [78, 82, "Drug"], [83, 87, "Amount"], [88, 91, "Frequency"], [94, 96, "Test_items"], [103, 107, "Test_items"], [110, 120, "Test_Value"], [127, 129, "Anatomy"], [129, 135, "Symptom"], [136, 141, "Symptom"], [153, 159, "Disease"], [160, 164, "Disease"], [165, 167, "Symptom"], [170, 178, "Disease"], [182, 193, "Disease"], [197, 209, "Disease"], [213, 224, "Disease"], [265, 269, "Symptom"], [270, 274, "Symptom"], [275, 280, "Symptom"], [261, 265, "Anatomy"], [229, 231, "Test_items"], [234, 236, "Anatomy"], [303, 309, "Disease"]], "rel": [[8, 10, "Test_items", 36, 41, "Disease", "Test_items_Disease"], [103, 107, "Test_items", 36, 41, "Disease", "Test_items_Disease"], [14, 16, "Symptom", 36, 41, "Disease", "Symptom_Disease"], [17, 19, "Symptom", 36, 41, "Disease", "Symptom_Disease"], [20, 22, "Symptom", 36, 41, "Disease", "Symptom_Disease"], [48, 55, "Drug", 36, 41, "Disease", "Drug_Disease"], [78, 82, "Drug", 36, 41, "Disease", "Drug_Disease"], [63, 67, "Drug", 36, 41, "Disease", "Drug_Disease"], [56, 62, "Amount", 48, 55, "Drug", "Amount_Drug"], [68, 73, "Amount", 63, 67, "Drug", "Amount_Drug"], [83, 87, "Amount", 78, 82, "Drug", "Amount_Drug"], [88, 91, "Frequency", 78, 82, "Drug", "Frequency_Drug"], [74, 77, "Frequency", 63, 67, "Drug", "Frequency_Drug"], [28, 32, "Test", 36, 41, "Disease", "Test_Disease"], [129, 135, "Symptom", 153, 159, "Disease", "Symptom_Disease"], [165, 167, "Symptom", 153, 159, "Disease", "Symptom_Disease"], [136, 141, "Symptom", 153, 159, "Disease", "Symptom_Disease"], [265, 269, "Symptom", 153, 159, "Disease", "Symptom_Disease"], [270, 274, "Symptom", 153, 159, "Disease", "Symptom_Disease"], [275, 280, "Symptom", 153, 159, "Disease", "Symptom_Disease"], [160, 164, "Disease", 153, 159, "Disease", "Disease_Disease"], [170, 178, "Disease", 36, 41, "Disease", "Disease_Disease"], [182, 193, "Disease", 36, 41, "Disease", "Disease_Disease"], [153, 159, "Disease", 36, 41, "Disease", "Disease_Disease"], [197, 209, "Disease", 36, 41, "Disease", "Disease_Disease"], [213, 224, "Disease", 36, 41, "Disease", "Disease_Disease"], [261, 265, "Anatomy", 153, 159, "Disease", "Anatomy_Disease"], [127, 129, "Anatomy", 153, 159, "Disease", "Anatomy_Disease"], [234, 236, "Anatomy", 182, 193, "Disease", "Anatomy_Disease"]]}
{"idx": 178, "sentence": "患者于6月前发现左足第2足趾无明显原因溃烂，当时未做特殊处理，随时间推移，左足足趾伤口逐渐增大，伴渗液，无发热、恶心、呕吐等不适。左足应用外用药物治疗，无好转，2月前在宜昌市第一人民医院行左足半足截除，左足半足截肢伤口愈合慢，皮瓣未完全闭合，患者家属为求进一步治疗，遂来我院，门诊以“2型糖尿病足”收住入院。 起病以来，患者精神、饮食、睡眠欠佳，大小便通畅，大便失禁。", "ner": [[19, 21, "Symptom"], [37, 41, "Anatomy"], [8, 14, "Anatomy"], [45, 47, "Level"], [49, 51, "Symptom"], [53, 55, "Symptom"], [56, 58, "Symptom"], [59, 61, "Symptom"], [65, 67, "Anatomy"], [98, 100, "Operation"], [105, 107, "Operation"], [94, 98, "Anatomy"], [101, 105, "Anatomy"], [113, 115, "Anatomy"], [142, 148, "Disease"], [162, 172, "Symptom"], [179, 183, "Symptom"]], "rel": [[19, 21, "Symptom", 142, 148, "Disease", "Symptom_Disease"], [49, 51, "Symptom", 142, 148, "Disease", "Symptom_Disease"], [105, 107, "Operation", 142, 148, "Disease", "Operation_Disease"], [98, 100, "Operation", 142, 148, "Disease", "Operation_Disease"], [8, 14, "Anatomy", 142, 148, "Disease", "Anatomy_Disease"], [37, 41, "Anatomy", 142, 148, "Disease", "Anatomy_Disease"], [65, 67, "Anatomy", 142, 148, "Disease", "Anatomy_Disease"], [101, 105, "Anatomy", 142, 148, "Disease", "Anatomy_Disease"]]}
{"idx": 179, "sentence": "患者于18年前因体检时发现血糖升高，当时查空腹血糖12mmol/L，伴口干、多饮、多尿及体重下降，后进一步检查确诊为“2型糖尿病”，目前给予“阿卡波糖50mg 三餐嚼服”管理血糖，未控制饮食及监测血糖，具体血糖监测不详，近1月来患者右足皮肤溃烂，伴局部红肿及轻微疼痛，无明显口干、多饮、多尿，伴视物模糊、泡沫尿，自行换药后无明显好转，今为求进一步治疗来我院，门诊以“2型糖尿病 糖尿病足”收治我科。 起病以来，精神、饮食、睡眠可，大小便如常，体力、体重无明显改变。", "ner": [[13, 15, "Test_items"], [15, 17, "Test_Value"], [21, 25, "Test_items"], [25, 33, "Test_Value"], [35, 37, "Symptom"], [38, 40, "Symptom"], [41, 43, "Symptom"], [44, 48, "Symptom"], [59, 64, "Disease"], [71, 75, "Drug"], [75, 79, "Amount"], [80, 82, "Frequency"], [82, 84, "Method"], [87, 89, "Test_items"], [98, 100, "Test_items"], [91, 95, "Treatment"], [103, 105, "Test_items"], [116, 122, "Symptom"], [124, 128, "Symptom"], [129, 133, "Symptom"], [137, 139, "Symptom"], [140, 142, "Symptom"], [143, 145, "Symptom"], [147, 151, "Symptom"], [152, 155, "Symptom"], [183, 188, "Disease"], [189, 193, "Disease"]], "rel": [[13, 15, "Test_items", 59, 64, "Disease", "Test_items_Disease"], [21, 25, "Test_items", 59, 64, "Disease", "Test_items_Disease"], [44, 48, "Symptom", 59, 64, "Disease", "Symptom_Disease"], [41, 43, "Symptom", 59, 64, "Disease", "Symptom_Disease"], [38, 40, "Symptom", 59, 64, "Disease", "Symptom_Disease"], [35, 37, "Symptom", 59, 64, "Disease", "Symptom_Disease"], [71, 75, "Drug", 59, 64, "Disease", "Drug_Disease"], [91, 95, "Treatment", 59, 64, "Disease", "Treatment_Disease"], [82, 84, "Method", 71, 75, "Drug", "Method_Drug"], [75, 79, "Amount", 71, 75, "Drug", "Amount_Drug"], [80, 82, "Frequency", 71, 75, "Drug", "Frequency_Drug"], [189, 193, "Disease", 59, 64, "Disease", "Disease_Disease"], [116, 122, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [124, 128, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [129, 133, "Symptom", 189, 193, "Disease", "Symptom_Disease"]]}
{"idx": 180, "sentence": "患者20年前因口干多饮多尿发现血糖升高，后多次查血糖＞7mmol/L，进一步检查确诊为“2型糖尿病”，病初给予口服降糖治疗，10年前调整降糖方案为“诺和灵30R早12U 晚10U 餐前皮下注射”管理血糖，具体血糖控制不详，半月前患者出现右足皮肤溃烂，至当地医院住院治疗后好转不明显，为进一步治疗门诊以“糖尿病足”收入我科。起病以来，精神、饮食、睡眠可，大小便如常，体力下降，体重无明显改变。", "ner": [[7, 9, "Symptom"], [9, 11, "Symptom"], [11, 13, "Symptom"], [15, 17, "Test_items"], [17, 19, "Test_Value"], [24, 26, "Test_items"], [26, 34, "Test_Value"], [44, 49, "Disease"], [55, 57, "Method"], [74, 80, "Drug"], [80, 84, "Amount"], [85, 89, "Amount"], [92, 96, "Method"], [99, 101, "Test_items"], [104, 106, "Test_items"], [118, 124, "Symptom"], [151, 155, "Disease"], [182, 186, "Symptom"]], "rel": [[11, 13, "Symptom", 44, 49, "Disease", "Symptom_Disease"], [9, 11, "Symptom", 44, 49, "Disease", "Symptom_Disease"], [7, 9, "Symptom", 44, 49, "Disease", "Symptom_Disease"], [15, 17, "Test_items", 44, 49, "Disease", "Test_items_Disease"], [74, 80, "Drug", 44, 49, "Disease", "Drug_Disease"], [80, 84, "Amount", 74, 80, "Drug", "Amount_Drug"], [85, 89, "Amount", 74, 80, "Drug", "Amount_Drug"], [92, 96, "Method", 74, 80, "Drug", "Method_Drug"], [118, 124, "Symptom", 151, 155, "Disease", "Symptom_Disease"], [182, 186, "Symptom", 44, 49, "Disease", "Symptom_Disease"], [151, 155, "Disease", 44, 49, "Disease", "Disease_Disease"]]}
{"idx": 181, "sentence": "患者于3月前发现右足第2趾及左足第3趾远端自行涂抹鸡眼膏至皮肤溃烂并渗液，无发热、头晕、恶心及呕吐等全身不适症状，随时间推移逐渐皮肤发黑，干痂形成。2月前右足背红肿明显，活动障碍，在当地诊所行抗感染输液治疗（具体不详）未见明显好转。来我院后右足第2趾发黑行截趾术。现创面仍未愈合，以“糖尿病足”收住入院。", "ner": [[8, 13, "Anatomy"], [14, 21, "Anatomy"], [23, 25, "Method"], [25, 28, "Drug"], [29, 33, "Symptom"], [34, 36, "Symptom"], [38, 40, "Symptom"], [41, 43, "Symptom"], [44, 46, "Symptom"], [47, 49, "Symptom"], [64, 68, "Symptom"], [69, 73, "Symptom"], [77, 82, "Symptom"], [85, 89, "Symptom"], [99, 101, "Method"], [128, 131, "Operation"], [142, 146, "Disease"], [120, 127, "Symptom"]], "rel": [[14, 21, "Anatomy", 142, 146, "Disease", "Anatomy_Disease"], [8, 13, "Anatomy", 142, 146, "Disease", "Anatomy_Disease"], [29, 33, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [34, 36, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [64, 68, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [69, 73, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [77, 82, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [85, 89, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [120, 127, "Symptom", 142, 146, "Disease", "Symptom_Disease"], [128, 131, "Operation", 142, 146, "Disease", "Operation_Disease"], [23, 25, "Method", 25, 28, "Drug", "Method_Drug"]]}
{"idx": 182, "sentence": "患者于6年前出现口干、多饮、多尿不适，伴乏力、消瘦，体重减轻约10千克，无多食易饥，无头昏，无心慌、胸闷，无腹痛、腹泻等不适，在当地医院就诊，行血糖等相关检查，诊断为2型糖尿病，给予胰岛素及口服药降糖，具体不详，后自行停用胰岛素及口服药，血糖未正规监测，症状时有反复，逐渐出现视物模糊、手足麻木疼痛、皮肤瘙痒等不适。2021年出现左小腿外侧溃烂，2021年3月于我科住院诊断为：2型糖尿病足 2型糖尿病性酮症 2型糖尿病伴血糖控制不佳 2型糖尿病性视网膜病变 2型糖尿病性周围血管病变；给予甘舒霖R+甘精胰岛素、阿卡波糖、吡格列酮二甲双胍降糖治疗；后自行停药，目前口服二甲双胍降糖。出院后双腿持续溃烂渗液，自行碘伏涂抹，近1月患者双下肢乏力疼痛较前加重，伴间断双下肢水肿，为求诊治就诊我院，为求进一步诊治，门诊查新冠肺炎核酸阴性，结合患者症状及流行病学史，排除新冠肺炎后以“2型糖尿病足病”收住我科。发病以来，精神饮食睡眠欠佳，体力下降，体重减轻约10千克，小便如上述，大便次数增多。", "ner": [[8, 10, "Symptom"], [11, 13, "Symptom"], [14, 16, "Symptom"], [20, 22, "Symptom"], [23, 25, "Symptom"], [26, 30, "Symptom"], [30, 35, "Test_Value"], [37, 41, "Symptom"], [43, 45, "Symptom"], [47, 49, "Symptom"], [50, 52, "Symptom"], [54, 56, "Symptom"], [57, 59, "Symptom"], [72, 74, "Test_items"], [83, 88, "Disease"], [91, 94, "Drug"], [111, 114, "Drug"], [119, 121, "Test_items"], [138, 142, "Symptom"], [143, 149, "Symptom"], [150, 154, "Symptom"], [165, 172, "Symptom"], [189, 195, "Disease"], [196, 204, "Disease"], [205, 210, "Disease"], [211, 213, "Test_items"], [218, 229, "Disease"], [230, 242, "Disease"], [245, 249, "Drug"], [250, 255, "Drug"], [256, 260, "Drug"], [261, 269, "Drug"], [282, 284, "Method"], [284, 288, "Drug"], [294, 300, "Symptom"], [300, 302, "Symptom"], [305, 307, "Drug"], [307, 309, "Method"], [315, 320, "Symptom"], [320, 322, "Symptom"], [324, 326, "Level"], [328, 335, "Symptom"], [356, 362, "Test_items"], [362, 364, "Test_Value"], [380, 384, "Disease"], [387, 394, "Disease"], [405, 413, "Symptom"], [414, 418, "Symptom"], [419, 423, "Symptom"], [423, 428, "Test_Value"], [435, 441, "Symptom"], [429, 434, "Symptom"]], "rel": [[8, 10, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [11, 13, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [14, 16, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [20, 22, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [23, 25, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [26, 30, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [37, 41, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [72, 74, "Test_items", 83, 88, "Disease", "Test_items_Disease"], [356, 362, "Test_items", 380, 384, "Disease", "Test_items_Disease"], [138, 142, "Symptom", 218, 229, "Disease", "Symptom_Disease"], [143, 149, "Symptom", 230, 242, "Disease", "Symptom_Disease"], [150, 154, "Symptom", 230, 242, "Disease", "Symptom_Disease"], [165, 172, "Symptom", 189, 195, "Disease", "Symptom_Disease"], [294, 300, "Symptom", 189, 195, "Disease", "Symptom_Disease"], [300, 302, "Symptom", 189, 195, "Disease", "Symptom_Disease"], [328, 335, "Symptom", 189, 195, "Disease", "Symptom_Disease"], [315, 320, "Symptom", 189, 195, "Disease", "Symptom_Disease"], [320, 322, "Symptom", 189, 195, "Disease", "Symptom_Disease"], [414, 418, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [307, 309, "Method", 305, 307, "Drug", "Method_Drug"], [282, 284, "Method", 284, 288, "Drug", "Method_Drug"], [91, 94, "Drug", 83, 88, "Disease", "Drug_Disease"], [245, 249, "Drug", 83, 88, "Disease", "Drug_Disease"], [250, 255, "Drug", 83, 88, "Disease", "Drug_Disease"], [256, 260, "Drug", 83, 88, "Disease", "Drug_Disease"], [261, 269, "Drug", 83, 88, "Disease", "Drug_Disease"], [284, 288, "Drug", 83, 88, "Disease", "Drug_Disease"], [189, 195, "Disease", 83, 88, "Disease", "Disease_Disease"], [196, 204, "Disease", 83, 88, "Disease", "Disease_Disease"], [218, 229, "Disease", 83, 88, "Disease", "Disease_Disease"], [230, 242, "Disease", 83, 88, "Disease", "Disease_Disease"], [387, 394, "Disease", 83, 88, "Disease", "Disease_Disease"]]}
{"idx": 183, "sentence": "患者2月前无明显诱因出现右足背及踝部皮肤变黑坏死，未特殊治疗，后坏死逐渐溃烂流脓，来我院门诊就诊，经冲洗换药及口服抗炎药物治疗后未见明显好转，现因疼痛难忍遂来我院就诊，经体检后遂以“1.右糖尿病足; 2.右足软组织感染; 3.右糖尿病性下肢溃疡; 4.糖尿病; 5.高血压; 6.哮喘；7.便秘”收入院。患者精神尚可，饮食、睡眠欠佳，小便夜尿频繁，大便干结便秘，近期体重体力无明显变化。", "ner": [[18, 22, "Symptom"], [22, 24, "Symptom"], [16, 18, "Anatomy"], [12, 15, "Anatomy"], [36, 40, "Symptom"], [32, 34, "Symptom"], [50, 52, "Treatment"], [55, 57, "Method"], [73, 77, "Symptom"], [93, 98, "Disease"], [102, 109, "Disease"], [113, 122, "Disease"], [126, 129, "Disease"], [133, 136, "Disease"], [140, 142, "Disease"], [145, 147, "Disease"], [159, 166, "Symptom"], [167, 173, "Symptom"], [174, 180, "Symptom"]], "rel": [[12, 15, "Anatomy", 93, 98, "Disease", "Anatomy_Disease"], [16, 18, "Anatomy", 93, 98, "Disease", "Anatomy_Disease"], [18, 22, "Symptom", 93, 98, "Disease", "Symptom_Disease"], [22, 24, "Symptom", 93, 98, "Disease", "Symptom_Disease"], [36, 40, "Symptom", 93, 98, "Disease", "Symptom_Disease"], [73, 77, "Symptom", 93, 98, "Disease", "Symptom_Disease"], [167, 173, "Symptom", 126, 129, "Disease", "Symptom_Disease"], [50, 52, "Treatment", 93, 98, "Disease", "Treatment_Disease"], [93, 98, "Disease", 126, 129, "Disease", "Disease_Disease"], [113, 122, "Disease", 126, 129, "Disease", "Disease_Disease"], [102, 109, "Disease", 126, 129, "Disease", "Disease_Disease"], [174, 180, "Symptom", 145, 147, "Disease", "Symptom_Disease"]]}
{"idx": 184, "sentence": "患者20余年前因视物黑点就诊，发现血糖升高，空腹血糖9mmol/l，完善相关检查，诊断为“2型糖尿病”，先后给予口服降糖药物及胰岛素降糖治疗，曾多次在我科住院完善检查诊断为“2型糖尿病性周围血管病变、周围神经病、视网膜病变、肾病”，目前降糖方案为“精蛋白生物合成人胰岛素30R早22u-晚22u”，平素血糖控制尚可。半月前无明显诱因出现右足第2趾溃烂，在当地诊所给予头孢及甲硝唑静滴5天后继续口服头孢类消炎药3天，治疗效果不佳，今为求进一步诊治来我院就诊，门诊以“2型糖尿病足”收入我科住院治疗。起病以来，患者精神、饮食、睡眠可，大小便正常，体力、体重无明显变化。", "ner": [[8, 12, "Symptom"], [17, 19, "Test_items"], [19, 21, "Test_Value"], [22, 26, "Test_items"], [26, 33, "Test_Value"], [45, 50, "Disease"], [56, 58, "Method"], [63, 66, "Drug"], [87, 99, "Disease"], [100, 105, "Disease"], [106, 111, "Disease"], [112, 114, "Disease"], [124, 138, "Drug"], [138, 142, "Amount"], [143, 147, "Amount"], [151, 153, "Test_items"], [168, 173, "Anatomy"], [173, 175, "Symptom"], [183, 185, "Drug"], [186, 189, "Drug"], [189, 191, "Method"], [232, 238, "Disease"], [198, 204, "Drug"], [191, 193, "Duration"], [204, 206, "Duration"], [196, 198, "Method"]], "rel": [[8, 12, "Symptom", 106, 111, "Disease", "Symptom_Disease"], [17, 19, "Test_items", 45, 50, "Disease", "Test_items_Disease"], [22, 26, "Test_items", 45, 50, "Disease", "Test_items_Disease"], [63, 66, "Drug", 45, 50, "Disease", "Drug_Disease"], [124, 138, "Drug", 45, 50, "Disease", "Drug_Disease"], [183, 185, "Drug", 232, 238, "Disease", "Drug_Disease"], [186, 189, "Drug", 232, 238, "Disease", "Drug_Disease"], [198, 204, "Drug", 232, 238, "Disease", "Drug_Disease"], [168, 173, "Anatomy", 232, 238, "Disease", "Anatomy_Disease"], [173, 175, "Symptom", 232, 238, "Disease", "Symptom_Disease"], [138, 142, "Amount", 124, 138, "Drug", "Amount_Drug"], [143, 147, "Amount", 124, 138, "Drug", "Amount_Drug"], [189, 191, "Method", 186, 189, "Drug", "Method_Drug"], [189, 191, "Method", 183, 185, "Drug", "Method_Drug"], [232, 238, "Disease", 45, 50, "Disease", "Disease_Disease"], [87, 99, "Disease", 45, 50, "Disease", "Disease_Disease"], [100, 105, "Disease", 45, 50, "Disease", "Disease_Disease"], [106, 111, "Disease", 45, 50, "Disease", "Disease_Disease"], [112, 114, "Disease", 45, 50, "Disease", "Disease_Disease"], [196, 198, "Method", 198, 204, "Drug", "Method_Drug"]]}
{"idx": 185, "sentence": "患者5年前出现口干、多饮、多尿，当地诊断为“2型糖尿病”，未规范治疗，1月前出现左小腿红肿溃烂，伴视物模糊，给予药物治疗（阿卡波糖、吡格列酮二甲双胍、甘精胰岛素、甘舒霖），血糖控制较差，无恶心、呕吐，无意识障碍，无大小便失禁，在家未给予特殊治疗，今到我院就诊，门诊查手指血糖示：29.6mmol/L", "ner": [[7, 9, "Symptom"], [10, 12, "Symptom"], [13, 15, "Symptom"], [22, 27, "Disease"], [40, 47, "Symptom"], [49, 53, "Symptom"], [61, 65, "Drug"], [66, 74, "Drug"], [75, 80, "Drug"], [81, 84, "Drug"], [86, 88, "Test_items"], [94, 96, "Symptom"], [97, 99, "Symptom"], [101, 105, "Symptom"], [107, 112, "Symptom"], [133, 137, "Test_items"], [139, 149, "Test_Value"]], "rel": [[7, 9, "Symptom", 22, 27, "Disease", "Symptom_Disease"], [10, 12, "Symptom", 22, 27, "Disease", "Symptom_Disease"], [13, 15, "Symptom", 22, 27, "Disease", "Symptom_Disease"], [61, 65, "Drug", 22, 27, "Disease", "Drug_Disease"], [81, 84, "Drug", 22, 27, "Disease", "Drug_Disease"], [75, 80, "Drug", 22, 27, "Disease", "Drug_Disease"], [66, 74, "Drug", 22, 27, "Disease", "Drug_Disease"], [133, 137, "Test_items", 22, 27, "Disease", "Test_items_Disease"], [86, 88, "Test_items", 22, 27, "Disease", "Test_items_Disease"]]}
{"idx": 186, "sentence": "患者诉，半月前无意间发现右足足趾趾蹼溃烂，未行治疗，右足逐渐红肿，10月3号患者感发热，自行外用退烧药。于2021年10月7号就诊于葛洲坝中心医院内分泌科，行抗感染，创面换药对症治疗，效果不佳，现为求进一步在治疗，就我科门诊，门诊以“右足糖尿病足”收治入院。     自起病以来，患者间断发热，最高体温38°，精神食欲欠佳，二便正常，体重体力无明显下降。", "ner": [[16, 20, "Symptom"], [12, 16, "Anatomy"], [26, 28, "Anatomy"], [30, 32, "Symptom"], [41, 43, "Symptom"], [46, 48, "Method"], [117, 123, "Disease"], [142, 146, "Symptom"], [147, 151, "Test_items"], [151, 154, "Test_Value"], [155, 161, "Symptom"]], "rel": [[16, 20, "Symptom", 117, 123, "Disease", "Symptom_Disease"], [30, 32, "Symptom", 117, 123, "Disease", "Symptom_Disease"], [12, 16, "Anatomy", 117, 123, "Disease", "Anatomy_Disease"], [26, 28, "Anatomy", 117, 123, "Disease", "Anatomy_Disease"]]}
{"idx": 187, "sentence": "患者7年余前体检查血糖高，具体不详，未行糖耐量试验于当地医院开始加用口服药物降糖，具体药物不详，血糖控制情况不详。1周前自行剪趾后出现右足中趾皮肤溃烂，逐渐出现皮肤溃疡伴右足红肿，右足趾化脓，无发热，伴乏力、纳差不适，今为求进一步诊治来我院，门诊以“2型糖尿病足”收入我科。此次起病以来，患者精神、饮食、睡眠一般，大小便如常，体力下降，体重无明显变化。", "ner": [[9, 11, "Test_items"], [11, 12, "Test_Value"], [20, 25, "Test"], [48, 50, "Test_items"], [71, 75, "Symptom"], [67, 71, "Anatomy"], [80, 84, "Symptom"], [85, 89, "Symptom"], [90, 95, "Symptom"], [97, 99, "Symptom"], [101, 103, "Symptom"], [104, 108, "Symptom"], [125, 131, "Disease"], [163, 167, "Symptom"]], "rel": [[71, 75, "Symptom", 125, 131, "Disease", "Symptom_Disease"], [80, 84, "Symptom", 125, 131, "Disease", "Symptom_Disease"], [85, 89, "Symptom", 125, 131, "Disease", "Symptom_Disease"], [90, 95, "Symptom", 125, 131, "Disease", "Symptom_Disease"]]}
{"idx": 188, "sentence": "患者于20余年前体检发现血糖升高，曾住院行OGTT试验、胰岛素+C肽确诊为“2型糖尿病”，行胰岛素及口服药物治疗，其后多次住院完善相关检查后诊断为2型糖尿病伴多个并发症、2型糖尿病性周围血管病、2型糖尿病性周围神经病现予“德谷胰岛素注射液+阿卡波糖”皮下注射治疗，自诉血糖控制欠佳。1周前可能右足趾磨损后出现右足第二足趾溃烂，伴局部渗液，测餐后血糖波动在20-26mmol/L，为进一步治疗来我院，予门诊以“糖尿病足”收入我科。     起病以来，患者精神、食欲、睡眠可，大小便正常，体重较前无明显改变、体力较前下降。", "ner": [[12, 14, "Test_items"], [14, 16, "Test_Value"], [21, 27, "Test"], [28, 34, "Test"], [38, 43, "Disease"], [46, 49, "Drug"], [73, 78, "Disease"], [85, 96, "Disease"], [97, 108, "Disease"], [111, 119, "Drug"], [120, 124, "Drug"], [125, 129, "Method"], [134, 136, "Test_items"], [146, 149, "Anatomy"], [154, 162, "Symptom"], [164, 168, "Symptom"], [170, 174, "Test_items"], [177, 188, "Test_Value"], [204, 208, "Disease"], [252, 258, "Symptom"]], "rel": [[21, 27, "Test", 38, 43, "Disease", "Test_Disease"], [28, 34, "Test", 38, 43, "Disease", "Test_Disease"], [125, 129, "Method", 120, 124, "Drug", "Method_Drug"], [125, 129, "Method", 111, 119, "Drug", "Method_Drug"], [46, 49, "Drug", 38, 43, "Disease", "Drug_Disease"], [111, 119, "Drug", 38, 43, "Disease", "Drug_Disease"], [120, 124, "Drug", 38, 43, "Disease", "Drug_Disease"], [12, 14, "Test_items", 38, 43, "Disease", "Test_items_Disease"], [170, 174, "Test_items", 38, 43, "Disease", "Test_items_Disease"], [154, 162, "Symptom", 204, 208, "Disease", "Symptom_Disease"], [164, 168, "Symptom", 204, 208, "Disease", "Symptom_Disease"], [252, 258, "Symptom", 38, 43, "Disease", "Symptom_Disease"], [85, 96, "Disease", 38, 43, "Disease", "Disease_Disease"], [97, 108, "Disease", 38, 43, "Disease", "Disease_Disease"], [204, 208, "Disease", 38, 43, "Disease", "Disease_Disease"], [146, 149, "Anatomy", 204, 208, "Disease", "Anatomy_Disease"]]}
{"idx": 189, "sentence": "患者2月余前无意间发现左足踇趾一“血疱”，后血疱溃烂，遂至当地卫生院行抗感染及创面换药治疗（具体不详），未见明显好转。后左足逐渐红肿，踇趾逐渐发黑坏死，伴有渗液，不伴疼痛，无发热。2021-11-11于我科住院治疗，于2021-11-17、2021-11-24、2021-12-01在腰麻下行“左足清创探查术+vsd术”，2021年12月8日在神经阻滞麻醉下行左足清创术+局部皮瓣修复术+VSD术。术后予以给予持续负压引流、抗感染等治疗。现为求进一步在治疗，就诊于我科门诊，门诊以“左足2型糖尿病足”收治入院。      自起病以来，患者精神食欲欠佳，二便正常，体重体力无明显下降。", "ner": [[22, 26, "Symptom"], [11, 15, "Anatomy"], [17, 19, "Symptom"], [60, 62, "Anatomy"], [64, 66, "Symptom"], [71, 73, "Symptom"], [73, 75, "Symptom"], [67, 69, "Anatomy"], [78, 80, "Symptom"], [83, 85, "Symptom"], [87, 89, "Symptom"], [147, 154, "Operation"], [155, 159, "Operation"], [180, 185, "Operation"], [186, 193, "Operation"], [194, 198, "Operation"], [207, 211, "Treatment"], [241, 249, "Disease"], [269, 275, "Symptom"]], "rel": [[17, 19, "Symptom", 241, 249, "Disease", "Symptom_Disease"], [22, 26, "Symptom", 241, 249, "Disease", "Symptom_Disease"], [64, 66, "Symptom", 241, 249, "Disease", "Symptom_Disease"], [78, 80, "Symptom", 241, 249, "Disease", "Symptom_Disease"], [73, 75, "Symptom", 241, 249, "Disease", "Symptom_Disease"], [71, 73, "Symptom", 241, 249, "Disease", "Symptom_Disease"], [11, 15, "Anatomy", 241, 249, "Disease", "Anatomy_Disease"], [60, 62, "Anatomy", 241, 249, "Disease", "Anatomy_Disease"], [67, 69, "Anatomy", 241, 249, "Disease", "Anatomy_Disease"], [207, 211, "Treatment", 241, 249, "Disease", "Treatment_Disease"], [147, 154, "Operation", 241, 249, "Disease", "Operation_Disease"], [180, 185, "Operation", 241, 249, "Disease", "Operation_Disease"], [186, 193, "Operation", 241, 249, "Disease", "Operation_Disease"], [194, 198, "Operation", 241, 249, "Disease", "Operation_Disease"], [155, 159, "Operation", 241, 249, "Disease", "Operation_Disease"]]}
{"idx": 190, "sentence": "患者诉10年余前发现血糖升高，当时无多饮、多尿、多食等不适，完善OGTT明确诊断为“2型糖尿病”，目前予“门冬胰岛素注射液早7U、中6U、晚6u餐前皮下注射、德谷胰岛素16u睡前皮下注射”控制血糖，血糖控制欠佳，空腹12mmol/L左右。1月前患者右足出现溃烂、部分流脓，伴疼痛、麻木不适，病后未行特殊处理，今为求进一步诊治，来我院就诊，门诊以“2型糖尿病”收住我科。    起病以来，精神，饮食、睡眠可，大小便正常，体力体重无明显下降。", "ner": [[10, 12, "Test_items"], [12, 14, "Test_Value"], [18, 20, "Symptom"], [21, 23, "Symptom"], [24, 26, "Symptom"], [32, 36, "Test"], [42, 47, "Disease"], [53, 61, "Drug"], [61, 64, "Amount"], [65, 68, "Amount"], [69, 72, "Amount"], [74, 78, "Method"], [79, 84, "Drug"], [84, 87, "Amount"], [89, 93, "Method"], [96, 98, "Test_items"], [99, 101, "Test_items"], [108, 118, "Test_Value"], [124, 126, "Anatomy"], [128, 130, "Symptom"], [131, 135, "Symptom"], [137, 139, "Symptom"], [140, 144, "Symptom"], [173, 178, "Disease"]], "rel": [[32, 36, "Test", 42, 47, "Disease", "Test_Disease"], [10, 12, "Test_items", 42, 47, "Disease", "Test_items_Disease"], [53, 61, "Drug", 42, 47, "Disease", "Drug_Disease"], [79, 84, "Drug", 42, 47, "Disease", "Drug_Disease"], [18, 20, "Symptom", 42, 47, "Disease", "Symptom_Disease"], [21, 23, "Symptom", 42, 47, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 42, 47, "Disease", "Symptom_Disease"], [84, 87, "Amount", 79, 84, "Drug", "Amount_Drug"], [61, 64, "Amount", 53, 61, "Drug", "Amount_Drug"], [65, 68, "Amount", 53, 61, "Drug", "Amount_Drug"], [69, 72, "Amount", 53, 61, "Drug", "Amount_Drug"], [89, 93, "Method", 79, 84, "Drug", "Method_Drug"], [74, 78, "Method", 53, 61, "Drug", "Method_Drug"]]}
{"idx": 191, "sentence": "患者于1年前不慎发现左踝部皮肤溃烂，伴渗液，无发热，无明显疼痛，自行于家中外涂“碘伏”治疗，随时间推移，溃烂面积逐渐增大加深，仍无明显疼痛。遂至“宜昌市家和医院”就诊，于2021-09行“左足清创术+皮瓣转移术”（具体不详）。现患者左足伤口仍未愈合，左足外踝创面较大，可见骨外露。患者为求进一步治疗，来我科门诊就诊，以“左足糖尿病足”收住入院。起病以来，患者精神、饮食一般，睡眠欠佳，大便少，小便正常，体力、体重下降。", "ner": [[13, 17, "Symptom"], [19, 21, "Symptom"], [23, 25, "Symptom"], [29, 31, "Symptom"], [10, 13, "Anatomy"], [37, 39, "Method"], [40, 42, "Drug"], [58, 62, "Level"], [67, 69, "Symptom"], [94, 99, "Operation"], [100, 105, "Operation"], [116, 124, "Symptom"], [136, 139, "Symptom"], [125, 129, "Anatomy"], [160, 166, "Disease"], [187, 191, "Symptom"], [192, 195, "Symptom"], [201, 208, "Symptom"]], "rel": [[13, 17, "Symptom", 160, 166, "Disease", "Symptom_Disease"], [19, 21, "Symptom", 160, 166, "Disease", "Symptom_Disease"], [29, 31, "Symptom", 160, 166, "Disease", "Symptom_Disease"], [136, 139, "Symptom", 160, 166, "Disease", "Symptom_Disease"], [116, 124, "Symptom", 160, 166, "Disease", "Symptom_Disease"], [10, 13, "Anatomy", 160, 166, "Disease", "Anatomy_Disease"], [125, 129, "Anatomy", 160, 166, "Disease", "Anatomy_Disease"], [94, 99, "Operation", 160, 166, "Disease", "Operation_Disease"], [100, 105, "Operation", 160, 166, "Disease", "Operation_Disease"], [37, 39, "Method", 40, 42, "Drug", "Method_Drug"]]}
{"idx": 192, "sentence": "患者于半年前无明显诱因渐出现多尿、口干，伴多饮，无明显多食及体重下降，未予重视，1月前因烫伤后出现左下肢红肿，伴疼痛及肢体麻木，继而出现水泡，自行挑破后出现外用“紫草油”涂擦创面，于我科就诊完善相关检查考虑为“2型糖尿病足”，予以抗感染及磺胺嘧啶银外敷及对症处理稍好转后出院，病程中再次出现大踇趾趾跟处皮肤溃烂伴流脓，1周前开始出现发热，于当地诊所就诊予以“青霉素”静滴3天后症状缓解，现左足仍有红肿伴疼痛不适，为进一步治疗门诊以“2型糖尿病足”收住我科。起病以来，患者精神、食欲、睡眠一般，小便多，大便如常，体力下降，体重无明显改变。", "ner": [[14, 16, "Symptom"], [17, 19, "Symptom"], [21, 23, "Symptom"], [27, 29, "Symptom"], [30, 34, "Symptom"], [49, 54, "Symptom"], [56, 58, "Symptom"], [59, 63, "Symptom"], [68, 70, "Symptom"], [81, 84, "Drug"], [85, 87, "Method"], [105, 111, "Disease"], [119, 124, "Drug"], [124, 126, "Method"], [151, 155, "Symptom"], [145, 151, "Anatomy"], [156, 158, "Symptom"], [166, 168, "Symptom"], [179, 182, "Drug"], [183, 185, "Method"], [185, 187, "Duration"], [198, 200, "Symptom"], [201, 205, "Symptom"], [194, 196, "Anatomy"], [216, 222, "Disease"], [255, 259, "Symptom"]], "rel": [[49, 54, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [56, 58, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [59, 63, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [68, 70, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [151, 155, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [156, 158, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [198, 200, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [201, 205, "Symptom", 105, 111, "Disease", "Symptom_Disease"], [119, 124, "Drug", 105, 111, "Disease", "Drug_Disease"], [85, 87, "Method", 81, 84, "Drug", "Method_Drug"], [124, 126, "Method", 119, 124, "Drug", "Method_Drug"], [183, 185, "Method", 179, 182, "Drug", "Method_Drug"], [194, 196, "Anatomy", 105, 111, "Disease", "Anatomy_Disease"], [145, 151, "Anatomy", 105, 111, "Disease", "Anatomy_Disease"]]}
{"idx": 193, "sentence": "患者于3年余前无明显诱因出现烦渴、多饮、小便增多、消瘦，于2020年5月份左右来我院就诊，诊断“2型糖尿病”，目前给予口服“二甲双胍肠溶片，阿卡波糖片”控制血糖，平素血糖控制情况不详；3天前因左足外踝处瘙痒不适后不慎抓伤，逐渐局部出现水泡，并溃烂后自己在家用碘伏涂抹，溃烂面积渐扩大，周围皮肤发红肿胀，诊所查餐后血糖17.5mmol/l", "ner": [[14, 16, "Symptom"], [17, 19, "Symptom"], [20, 24, "Symptom"], [25, 27, "Symptom"], [48, 53, "Disease"], [59, 61, "Method"], [62, 69, "Drug"], [70, 75, "Drug"], [78, 80, "Test_items"], [83, 85, "Test_items"], [101, 105, "Symptom"], [96, 101, "Anatomy"], [113, 119, "Symptom"], [121, 123, "Symptom"], [129, 131, "Drug"], [131, 133, "Method"], [142, 150, "Symptom"], [154, 158, "Test_items"], [158, 168, "Test_Value"]], "rel": [[14, 16, "Symptom", 48, 53, "Disease", "Symptom_Disease"], [17, 19, "Symptom", 48, 53, "Disease", "Symptom_Disease"], [20, 24, "Symptom", 48, 53, "Disease", "Symptom_Disease"], [25, 27, "Symptom", 48, 53, "Disease", "Symptom_Disease"], [62, 69, "Drug", 48, 53, "Disease", "Drug_Disease"], [70, 75, "Drug", 48, 53, "Disease", "Drug_Disease"], [83, 85, "Test_items", 48, 53, "Disease", "Test_items_Disease"], [59, 61, "Method", 62, 69, "Drug", "Method_Drug"], [59, 61, "Method", 70, 75, "Drug", "Method_Drug"], [154, 158, "Test_items", 83, 85, "Test_items", "Test_items_Disease"], [131, 133, "Method", 129, 131, "Drug", "Method_Drug"]]}
{"idx": 194, "sentence": "患者于2月余前无明显原因及诱因出现左足及左小腿皮肤溃烂，伴流液疼痛，起始为左足小拇指皮肤变黑、干枯，后逐渐蔓延至左足及左小腿，局部组织溃烂、坏死，疼痛尚可忍受，无畏寒、发热、抽搐等症，起病后曾到中医院就诊，给予中药治疗（具体不详），上述症状无明显好转，疼痛难以忍受，遂于今日来我院就诊，门诊遂以“2型糖尿病”收住院。", "ner": [[17, 19, "Anatomy"], [20, 23, "Anatomy"], [23, 27, "Symptom"], [29, 31, "Symptom"], [31, 33, "Symptom"], [42, 46, "Symptom"], [47, 49, "Symptom"], [37, 42, "Anatomy"], [56, 58, "Anatomy"], [59, 62, "Anatomy"], [63, 69, "Symptom"], [70, 72, "Symptom"], [73, 75, "Symptom"], [75, 79, "Level"], [81, 83, "Symptom"], [84, 86, "Symptom"], [87, 89, "Symptom"], [126, 128, "Symptom"], [128, 132, "Level"], [147, 153, "Disease"]], "rel": []}
{"idx": 195, "sentence": "患者于8年前开始出现口干、多饮、多尿不适，伴乏力、消瘦，无多食易饥，无头昏，无心慌、胸闷，无腹痛、腹泻等不适，曾在当地镇卫生院就诊，行血糖等相关检查，诊断为“2型糖尿病”，给予口服药降糖，血糖未正规监测，症状时有反复，并出现双下肢麻木疼痛不适，半月前患者出现左足趾溃烂，自行口服阿莫西林无明显好转，于今日来我院门诊就诊，为求进一步诊治，在核酸检测门诊完善新冠肺炎核酸检测，排除新冠肺炎后，门诊以“2型糖尿病”收入院。         发病以来，精神欠佳，糖尿病饮食，睡眠欠佳，体力下降，体重变化不详，小便如上述，大便正常。", "ner": [[10, 12, "Symptom"], [13, 15, "Symptom"], [16, 20, "Symptom"], [22, 24, "Symptom"], [25, 27, "Symptom"], [29, 33, "Symptom"], [35, 37, "Symptom"], [39, 41, "Symptom"], [42, 44, "Symptom"], [46, 48, "Symptom"], [49, 51, "Symptom"], [67, 69, "Test_items"], [79, 84, "Disease"], [94, 96, "Test_items"], [112, 117, "Symptom"], [117, 121, "Symptom"], [129, 134, "Symptom"], [137, 139, "Method"], [139, 143, "Drug"], [177, 185, "Test"], [188, 192, "Disease"], [198, 203, "Disease"], [222, 226, "Symptom"], [233, 237, "Symptom"], [238, 242, "Symptom"]], "rel": [[10, 12, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [13, 15, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [22, 24, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [25, 27, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [29, 33, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [238, 242, "Symptom", 79, 84, "Disease", "Symptom_Disease"], [67, 69, "Test_items", 79, 84, "Disease", "Test_items_Disease"], [137, 139, "Method", 139, 143, "Drug", "Method_Drug"], [177, 185, "Test", 188, 192, "Disease", "Test_Disease"]]}
{"idx": 196, "sentence": "患者于12年前出现口干、多饮、多尿不适，伴乏力、消瘦，伴多食易饥，体重减轻约15千克，无头昏，无心慌、胸闷，无腹痛、腹泻等不适，曾在我院就诊，行血糖等相关检查，诊断为2型糖尿病，给予口服药二甲双胍降糖，血糖未正规监测，症状时有反复，10年前患者因血糖控制不佳调整为胰岛素（甘舒霖30R 目前为早7u 晚7u餐前半小时皮下注射）降糖，近年来患者出现视物模糊、手足麻木、皮肤瘙痒不适，1月余前患者左足第二趾无明显诱因开始出现渗液、流脓，皮肤颜色改变，伴脚趾肿胀、疼痛，现患者为求进一步诊治，于今日来我院门诊就诊，门诊查新冠肺炎核酸阴性，结合患者症状及流行病学史，排除新冠肺炎后以“2型糖尿病“收入我科。         发病以来，精神、饮食尚可，睡眠佳，体力稍下降，体重变化不详，小便如上述，大便正常。", "ner": [[9, 11, "Symptom"], [12, 14, "Symptom"], [15, 19, "Symptom"], [21, 23, "Symptom"], [24, 26, "Symptom"], [28, 32, "Symptom"], [33, 37, "Symptom"], [37, 42, "Test_Value"], [44, 46, "Symptom"], [48, 50, "Symptom"], [51, 53, "Symptom"], [55, 57, "Symptom"], [58, 60, "Symptom"], [72, 74, "Test_items"], [83, 88, "Disease"], [94, 98, "Drug"], [101, 103, "Test_items"], [123, 125, "Test_items"], [132, 135, "Drug"], [136, 142, "Drug"], [146, 149, "Amount"], [150, 153, "Amount"], [158, 162, "Method"], [173, 177, "Symptom"], [178, 182, "Symptom"], [183, 189, "Symptom"], [196, 201, "Anatomy"], [210, 212, "Symptom"], [213, 215, "Symptom"], [216, 222, "Symptom"], [224, 228, "Symptom"], [229, 231, "Symptom"], [257, 263, "Test_items"], [263, 265, "Test_Value"], [281, 285, "Disease"], [288, 293, "Disease"], [325, 330, "Symptom"]], "rel": [[9, 11, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [12, 14, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [15, 19, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [21, 23, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [33, 37, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [325, 330, "Symptom", 83, 88, "Disease", "Symptom_Disease"], [72, 74, "Test_items", 83, 88, "Disease", "Test_items_Disease"], [94, 98, "Drug", 83, 88, "Disease", "Drug_Disease"], [132, 135, "Drug", 83, 88, "Disease", "Drug_Disease"], [136, 142, "Drug", 83, 88, "Disease", "Drug_Disease"], [146, 149, "Amount", 136, 142, "Drug", "Amount_Drug"], [150, 153, "Amount", 136, 142, "Drug", "Amount_Drug"], [158, 162, "Method", 136, 142, "Drug", "Method_Drug"]]}
{"idx": 197, "sentence": "患者20年前无明显诱因逐渐起病出现口干、多饮、多尿，无明显消瘦，病后就诊我院，诊断“糖尿病”并长期“诺和锐30R胰岛素、阿卡波糖胶囊”降糖治疗，血糖控制较差。病情进展逐渐出现四肢麻木、双眼视力下降。半月前起病出现左足皮肤溃烂、流水。今为求进一步检查及治疗，来我院就诊，骨外科予以左足溃疡清创后以“2型糖尿病足”收住我科。", "ner": [[17, 19, "Symptom"], [20, 22, "Symptom"], [23, 25, "Symptom"], [29, 31, "Symptom"], [42, 45, "Disease"], [50, 59, "Drug"], [60, 66, "Drug"], [72, 74, "Test_items"], [87, 91, "Symptom"], [92, 98, "Symptom"], [108, 112, "Symptom"], [113, 115, "Symptom"], [106, 108, "Anatomy"], [139, 145, "Operation"], [148, 154, "Disease"]], "rel": [[17, 19, "Symptom", 42, 45, "Disease", "Symptom_Disease"], [20, 22, "Symptom", 42, 45, "Disease", "Symptom_Disease"], [23, 25, "Symptom", 42, 45, "Disease", "Symptom_Disease"], [29, 31, "Symptom", 42, 45, "Disease", "Symptom_Disease"], [87, 91, "Symptom", 148, 154, "Disease", "Symptom_Disease"], [113, 115, "Symptom", 148, 154, "Disease", "Symptom_Disease"], [108, 112, "Symptom", 148, 154, "Disease", "Symptom_Disease"], [92, 98, "Symptom", 148, 154, "Disease", "Symptom_Disease"], [50, 59, "Drug", 42, 45, "Disease", "Drug_Disease"], [60, 66, "Drug", 42, 45, "Disease", "Drug_Disease"], [106, 108, "Anatomy", 148, 154, "Disease", "Anatomy_Disease"], [72, 74, "Test_items", 42, 45, "Disease", "Test_items_Disease"], [139, 145, "Operation", 148, 154, "Disease", "Operation_Disease"], [148, 154, "Disease", 42, 45, "Disease", "Disease_Disease"]]}
{"idx": 198, "sentence": "患者于20余年前出现口干、多饮、多尿不适，伴乏力、消瘦，体重减轻约20千克，无多食易饥，无头昏，无心慌、胸闷，无腹痛、腹泻等不适，曾在我院就诊，行血糖等相关检查，诊断为2型糖尿病，给予口服药二甲双胍片降糖，血糖未正规监测，症状时有反复，逐渐出现视物模糊、手足麻木疼痛、皮肤瘙痒不适，4年前上述症状加重，出现双侧足部及右小腿溃破，左足第三趾及右足小拇指溃烂、自行脱落，发病后在夷陵区时作霖医院住院治疗，行右足小拇指截肢术，2018年3月在我院住院，诊断为“2型糖尿病足病并感染 足部多处骨髓炎 2型糖尿病  2型糖尿病性周围神经病 糖尿病周围血管病变 糖尿病肾病 贫血”，行左小腿截肢术，建议患者予胰岛素降糖，患者表示拒绝，出院后口服格列美脲片 2mg 1次/日口服；在家自测空腹血糖波动在8-10mmol/L左右。2个月前出现左膝关节处溃烂，在家自行换药处理，半月前出现记忆力明显减退，无明显乏力，无吐词不清，无头晕、头痛，无咳嗽、咳痰，无恶心、呕吐，无腹痛，在我院门诊查头颅CT提示：1.左侧基底节区、辐射冠区多发腔隙性脑梗塞，部分软化灶；若症状不缓解，建议MRI检查。2.脑白质变性，脑萎缩。附见", "ner": [[10, 12, "Symptom"], [13, 15, "Symptom"], [16, 20, "Symptom"], [22, 24, "Symptom"], [25, 27, "Symptom"], [28, 32, "Symptom"], [32, 37, "Test_Value"], [39, 43, "Symptom"], [45, 47, "Symptom"], [49, 51, "Symptom"], [52, 54, "Symptom"], [56, 58, "Symptom"], [59, 61, "Symptom"], [73, 75, "Test_items"], [84, 89, "Disease"], [95, 100, "Drug"], [103, 105, "Test_items"], [122, 126, "Symptom"], [127, 133, "Symptom"], [134, 140, "Symptom"], [148, 150, "Level"], [153, 157, "Anatomy"], [158, 161, "Anatomy"], [161, 163, "Symptom"], [175, 177, "Symptom"], [178, 182, "Symptom"], [164, 169, "Anatomy"], [170, 175, "Anatomy"], [201, 209, "Operation"], [227, 234, "Disease"], [235, 237, "Symptom"], [246, 251, "Disease"], [253, 264, "Disease"], [265, 274, "Disease"], [275, 280, "Disease"], [281, 283, "Disease"], [286, 292, "Operation"], [298, 301, "Drug"], [316, 321, "Drug"], [322, 325, "Amount"], [326, 330, "Frequency"], [330, 332, "Method"], [337, 341, "Test_items"], [344, 356, "Test_Value"], [363, 370, "Symptom"], [385, 392, "Symptom"], [396, 398, "Symptom"], [400, 404, "Symptom"], [406, 408, "Symptom"], [409, 411, "Symptom"], [413, 415, "Symptom"], [416, 418, "Symptom"], [420, 422, "Symptom"], [423, 425, "Symptom"], [427, 429, "Symptom"], [436, 440, "Test"], [445, 451, "Anatomy"], [452, 456, "Anatomy"], [456, 464, "Disease"], [465, 470, "Symptom"], [480, 485, "Test"], [494, 497, "Disease"], [488, 493, "Symptom"], [242, 245, "Disease"], [237, 240, "Anatomy"]], "rel": [[10, 12, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [13, 15, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [22, 24, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [25, 27, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [39, 43, "Symptom", 84, 89, "Disease", "Symptom_Disease"], [127, 133, "Symptom", 253, 264, "Disease", "Symptom_Disease"], [134, 140, "Symptom", 253, 264, "Disease", "Symptom_Disease"], [161, 163, "Symptom", 227, 234, "Disease", "Symptom_Disease"], [175, 177, "Symptom", 227, 234, "Disease", "Symptom_Disease"], [178, 182, "Symptom", 227, 234, "Disease", "Symptom_Disease"], [235, 237, "Symptom", 227, 234, "Disease", "Symptom_Disease"], [363, 370, "Symptom", 227, 234, "Disease", "Symptom_Disease"], [127, 133, "Symptom", 127, 133, "Symptom", "Symptom_Disease"], [385, 392, "Symptom", 456, 464, "Disease", "Symptom_Disease"], [400, 404, "Symptom", 456, 464, "Disease", "Symptom_Disease"], [436, 440, "Test", 456, 464, "Disease", "Test_Disease"], [480, 485, "Test", 456, 464, "Disease", "Test_Disease"], [445, 451, "Anatomy", 456, 464, "Disease", "Anatomy_Disease"], [452, 456, "Anatomy", 456, 464, "Disease", "Anatomy_Disease"], [153, 157, "Anatomy", 227, 234, "Disease", "Anatomy_Disease"], [158, 161, "Anatomy", 265, 274, "Disease", "Anatomy_Disease"], [164, 169, "Anatomy", 227, 234, "Disease", "Anatomy_Disease"], [170, 175, "Anatomy", 227, 234, "Disease", "Anatomy_Disease"], [161, 163, "Symptom", 265, 274, "Disease", "Symptom_Disease"], [175, 177, "Symptom", 265, 274, "Disease", "Symptom_Disease"], [178, 182, "Symptom", 265, 274, "Disease", "Symptom_Disease"], [235, 237, "Symptom", 265, 274, "Disease", "Symptom_Disease"], [201, 209, "Operation", 227, 234, "Disease", "Operation_Disease"], [286, 292, "Operation", 227, 234, "Disease", "Operation_Disease"], [286, 292, "Operation", 265, 274, "Disease", "Operation_Disease"], [201, 209, "Operation", 265, 274, "Disease", "Operation_Disease"], [95, 100, "Drug", 84, 89, "Disease", "Drug_Disease"], [316, 321, "Drug", 84, 89, "Disease", "Drug_Disease"], [298, 301, "Drug", 84, 89, "Disease", "Drug_Disease"], [330, 332, "Method", 316, 321, "Drug", "Method_Drug"], [322, 325, "Amount", 316, 321, "Drug", "Amount_Drug"], [326, 330, "Frequency", 316, 321, "Drug", "Frequency_Drug"], [337, 341, "Test_items", 84, 89, "Disease", "Test_items_Disease"], [73, 75, "Test_items", 84, 89, "Disease", "Test_items_Disease"], [227, 234, "Disease", 84, 89, "Disease", "Disease_Disease"], [242, 245, "Disease", 84, 89, "Disease", "Disease_Disease"], [253, 264, "Disease", 84, 89, "Disease", "Disease_Disease"], [265, 274, "Disease", 84, 89, "Disease", "Disease_Disease"], [275, 280, "Disease", 84, 89, "Disease", "Disease_Disease"], [281, 283, "Disease", 84, 89, "Disease", "Disease_Disease"], [237, 240, "Anatomy", 227, 234, "Disease", "Anatomy_Disease"]]}
{"idx": 199, "sentence": "患者于2018年4月因“右足拇趾皮肤溃烂”在我院住院，查血糖高，无口干、多饮、多尿等不适，经检查诊断为“2型糖尿病足并右足拇趾软组织感染 2型糖尿病性周围神经病变 2型糖尿病性大血管病变”，予降糖（甘舒霖30R、阿卡波糖、二甲双胍）、抗感染、营养神经、换药等治疗后好转，但出院后患者自行停用胰岛素，改用中药治疗，血糖未正规监测，逐渐出现视物模糊、手足麻木疼痛、皮肤瘙痒、腹泻便秘交替等不适；2021年7月患者再次因呕吐、腹泻在我院住院诊断为“2型糖尿病伴多个并发症 2型糖尿病性周围神经病 2型糖尿病性视网膜病变 2型糖尿病性周围血管病变 2型糖尿病性胃肠自主神经病变 2型糖尿病性肾病 2型糖尿病伴血糖控制不佳 2.急性胃肠炎 3.低钾血症 4.高血压病3级 极高危组”，给予疗：诺和锐30笔芯 早8u、中6u、晚4u 皮下注射降糖治疗；患者出院后改为诺和锐30（早10u 晚8u）皮下注射降糖，血糖控制不佳。昨日下午患者出现恶心呕吐，呕吐物为胃内食物残渣，伴腹泻，解10余次水样便，无呕血、黑便，无明显心慌、胸闷、气喘，伴畏寒、发热，无咳嗽、咳痰，急来我院就诊，急诊完善新冠肺炎核酸检测，因患者病", "ner": [[12, 16, "Anatomy"], [16, 20, "Symptom"], [28, 30, "Test_items"], [30, 31, "Test_Value"], [33, 35, "Symptom"], [36, 38, "Symptom"], [39, 41, "Symptom"], [52, 58, "Disease"], [59, 68, "Disease"], [69, 81, "Disease"], [82, 93, "Disease"], [99, 105, "Drug"], [106, 110, "Drug"], [111, 115, "Drug"], [123, 125, "Anatomy"], [145, 148, "Drug"], [156, 158, "Test_items"], [168, 172, "Symptom"], [173, 179, "Symptom"], [180, 184, "Symptom"], [185, 191, "Symptom"], [207, 209, "Symptom"], [210, 212, "Symptom"], [221, 226, "Disease"], [233, 244, "Disease"], [245, 256, "Disease"], [257, 269, "Disease"], [270, 284, "Disease"], [285, 293, "Disease"], [294, 299, "Disease"], [300, 302, "Test_items"], [309, 314, "Disease"], [317, 321, "Disease"], [324, 328, "Disease"], [349, 352, "Amount"], [353, 356, "Amount"], [357, 360, "Amount"], [361, 365, "Method"], [341, 348, "Drug"], [377, 382, "Drug"], [383, 387, "Amount"], [388, 391, "Amount"], [392, 396, "Method"], [399, 401, "Test_items"], [414, 416, "Symptom"], [416, 418, "Symptom"], [431, 433, "Symptom"], [434, 442, "Symptom"], [444, 446, "Symptom"], [447, 449, "Symptom"], [453, 455, "Symptom"], [456, 458, "Symptom"], [459, 461, "Symptom"], [463, 465, "Symptom"], [466, 468, "Symptom"], [470, 472, "Symptom"], [473, 475, "Symptom"], [487, 495, "Test"]], "rel": [[28, 30, "Test_items", 221, 226, "Disease", "Test_items_Disease"], [12, 16, "Anatomy", 52, 58, "Disease", "Anatomy_Disease"], [123, 125, "Anatomy", 69, 81, "Disease", "Anatomy_Disease"], [99, 105, "Drug", 221, 226, "Disease", "Drug_Disease"], [111, 115, "Drug", 221, 226, "Disease", "Drug_Disease"], [106, 110, "Drug", 221, 226, "Disease", "Drug_Disease"], [145, 148, "Drug", 221, 226, "Disease", "Drug_Disease"], [341, 348, "Drug", 221, 226, "Disease", "Drug_Disease"], [377, 382, "Drug", 221, 226, "Disease", "Drug_Disease"], [357, 360, "Amount", 341, 348, "Drug", "Amount_Drug"], [353, 356, "Amount", 341, 348, "Drug", "Amount_Drug"], [349, 352, "Amount", 341, 348, "Drug", "Amount_Drug"], [388, 391, "Amount", 377, 382, "Drug", "Amount_Drug"], [383, 387, "Amount", 377, 382, "Drug", "Amount_Drug"], [392, 396, "Method", 377, 382, "Drug", "Method_Drug"], [361, 365, "Method", 341, 348, "Drug", "Method_Drug"], [16, 20, "Symptom", 52, 58, "Disease", "Symptom_Disease"], [39, 41, "Symptom", 221, 226, "Disease", "Symptom_Disease"], [36, 38, "Symptom", 221, 226, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 221, 226, "Disease", "Symptom_Disease"], [173, 179, "Symptom", 233, 244, "Disease", "Symptom_Disease"], [180, 184, "Symptom", 233, 244, "Disease", "Symptom_Disease"], [168, 172, "Symptom", 245, 256, "Disease", "Symptom_Disease"], [207, 209, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [210, 212, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [185, 191, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [414, 416, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [434, 442, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [52, 58, "Disease", 221, 226, "Disease", "Disease_Disease"], [82, 93, "Disease", 221, 226, "Disease", "Disease_Disease"], [69, 81, "Disease", 221, 226, "Disease", "Disease_Disease"], [59, 68, "Disease", 52, 58, "Disease", "Disease_Disease"], [233, 244, "Disease", 221, 226, "Disease", "Disease_Disease"], [245, 256, "Disease", 221, 226, "Disease", "Disease_Disease"], [257, 269, "Disease", 221, 226, "Disease", "Disease_Disease"], [270, 284, "Disease", 221, 226, "Disease", "Disease_Disease"], [285, 293, "Disease", 221, 226, "Disease", "Disease_Disease"], [185, 191, "Symptom", 270, 284, "Disease", "Symptom_Disease"], [210, 212, "Symptom", 270, 284, "Disease", "Symptom_Disease"], [207, 209, "Symptom", 270, 284, "Disease", "Symptom_Disease"], [414, 416, "Symptom", 270, 284, "Disease", "Symptom_Disease"], [434, 442, "Symptom", 270, 284, "Disease", "Symptom_Disease"]]}
{"idx": 200, "sentence": "患者15年前无明显诱因出现口干、多饮，每日饮水约3000ml，尿多，多食易饥，体重下降，伴肢软乏力，后在外院住院治疗（具体不详），诊断为'2型糖尿病'，现皮下注射甘舒霖胰岛素30R-早晚各20u/16u控制血糖，平素未正规监测血糖；2月前患者发现右足溃烂，难以愈合，口干、多饮，伴双手指麻木、疼痛，活动不利，肢软乏力，无言语不利，无口角歪斜，无恶寒、发热，无头昏、头痛，无心悸、胸闷，无恶心、呕吐，无皮肤瘙痒，现患者为求系统治疗，于今日入我院，门诊以'消渴'收入院；入院时症见:患者右足溃烂，难以愈合，口干、多饮，伴双手指麻木、疼痛，活动不利，肢软乏力，无言语不利，无口角歪斜，无恶寒、发热，无头昏、头痛，无心悸、胸闷，无恶心、呕吐，无皮肤瘙痒；起病以来，患者神志清楚，精神萎靡，纳差，夜尿2-3次/晚，大便干结，夜寐欠安，体力明显下降，体重无明显改变。", "ner": [[13, 15, "Symptom"], [16, 18, "Symptom"], [31, 33, "Symptom"], [34, 38, "Symptom"], [39, 43, "Symptom"], [45, 49, "Symptom"], [69, 74, "Disease"], [77, 81, "Method"], [81, 90, "Drug"], [91, 101, "Amount"], [103, 105, "Test_items"], [113, 115, "Test_items"], [123, 127, "Symptom"], [128, 132, "Symptom"], [133, 135, "Symptom"], [136, 138, "Symptom"], [140, 145, "Symptom"], [146, 148, "Symptom"], [149, 153, "Symptom"], [154, 158, "Symptom"], [160, 164, "Symptom"], [166, 170, "Symptom"], [172, 174, "Symptom"], [175, 177, "Symptom"], [179, 181, "Symptom"], [182, 184, "Symptom"], [186, 188, "Symptom"], [189, 191, "Symptom"], [193, 195, "Symptom"], [196, 198, "Symptom"], [200, 204, "Symptom"], [226, 228, "Disease"], [241, 245, "Symptom"], [246, 250, "Symptom"], [251, 253, "Symptom"], [254, 256, "Symptom"], [258, 263, "Symptom"], [264, 266, "Symptom"], [267, 271, "Symptom"], [272, 276, "Symptom"], [278, 282, "Symptom"], [284, 288, "Symptom"], [290, 292, "Symptom"], [293, 295, "Symptom"], [297, 299, "Symptom"], [300, 302, "Symptom"], [304, 306, "Symptom"], [307, 309, "Symptom"], [311, 313, "Symptom"], [314, 316, "Symptom"], [318, 322, "Symptom"], [335, 339, "Symptom"], [340, 342, "Symptom"], [343, 351, "Symptom"], [352, 356, "Symptom"], [357, 361, "Symptom"], [362, 368, "Symptom"]], "rel": [[13, 15, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [16, 18, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [31, 33, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [34, 38, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [39, 43, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [45, 49, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [362, 368, "Symptom", 69, 74, "Disease", "Symptom_Disease"], [251, 253, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [254, 256, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [362, 368, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [31, 33, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [34, 38, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [39, 43, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [45, 49, "Symptom", 226, 228, "Disease", "Symptom_Disease"], [226, 228, "Disease", 69, 74, "Disease", "Disease_Disease"], [81, 90, "Drug", 69, 74, "Disease", "Drug_Disease"], [91, 101, "Amount", 81, 90, "Drug", "Amount_Drug"], [77, 81, "Method", 69, 74, "Disease", "Method_Drug"], [103, 105, "Test_items", 69, 74, "Disease", "Test_items_Disease"]]}
{"idx": 201, "sentence": "患者诉10年余前发现血糖升高，当时无多饮、多尿、多食等不适，完善检查明确诊断为“2型糖尿病足、2型糖尿病性周围神经病;、2型糖尿病性周围血管病变”，目前予“门冬30胰岛素注射液早22U、中8U、晚10u餐前皮下注射”控制血糖，血糖控制欠佳，空腹12mmol/L左右。4月前患者右足出现溃烂、部分流脓，伴疼痛、麻木不适后就诊我院血管外科完善下肢血管CTA后予2022.3.10局麻下行右下肢动脉支架植入术", "ner": [[10, 12, "Test_items"], [12, 14, "Test_Value"], [18, 20, "Symptom"], [21, 23, "Symptom"], [24, 26, "Symptom"], [40, 46, "Disease"], [47, 58, "Disease"], [60, 72, "Disease"], [78, 88, "Drug"], [88, 92, "Amount"], [93, 96, "Amount"], [97, 101, "Amount"], [103, 107, "Method"], [110, 112, "Test_items"], [113, 115, "Test_items"], [122, 132, "Test_Value"], [142, 144, "Symptom"], [138, 140, "Anatomy"], [145, 149, "Symptom"], [151, 153, "Symptom"], [154, 158, "Symptom"], [169, 176, "Test"], [191, 201, "Operation"]], "rel": [[142, 144, "Symptom", 40, 46, "Disease", "Symptom_Disease"], [145, 149, "Symptom", 40, 46, "Disease", "Symptom_Disease"], [151, 153, "Symptom", 40, 46, "Disease", "Symptom_Disease"], [154, 158, "Symptom", 40, 46, "Disease", "Symptom_Disease"], [142, 144, "Symptom", 60, 72, "Disease", "Symptom_Disease"], [145, 149, "Symptom", 60, 72, "Disease", "Symptom_Disease"], [151, 153, "Symptom", 60, 72, "Disease", "Symptom_Disease"], [154, 158, "Symptom", 60, 72, "Disease", "Symptom_Disease"], [138, 140, "Anatomy", 40, 46, "Disease", "Anatomy_Disease"], [169, 176, "Test", 40, 46, "Disease", "Test_Disease"], [169, 176, "Test", 60, 72, "Disease", "Test_Disease"], [88, 92, "Amount", 78, 88, "Drug", "Amount_Drug"], [93, 96, "Amount", 78, 88, "Drug", "Amount_Drug"], [97, 101, "Amount", 78, 88, "Drug", "Amount_Drug"], [103, 107, "Method", 78, 88, "Drug", "Method_Drug"], [191, 201, "Operation", 40, 46, "Disease", "Operation_Disease"], [191, 201, "Operation", 60, 72, "Disease", "Operation_Disease"]]}
{"idx": 202, "sentence": "患者20年前无明显诱因出现口干、多饮、多尿症状，饮食量稍增加，不伴消瘦，起病后曾多次在县人民医院及我院住院治疗，诊断为“糖尿病”，长期予以甘舒霖30R注射液、阿卡波糖胶囊协同降糖治疗。患病期间视物模糊，四肢疼痛麻木、针刺感等症状，经检查确诊为糖尿病周围神经病变、糖尿病视网膜病变。近1周来，再发口干、多饮、多尿症状，下肢时有疼痛麻木针刺，且右足拇趾处有溃烂，少许渗液。为求诊治，遂来我院，门诊以“消渴病”收入我科。本次起病来，患者神清，精神差，纳差，饮水量稍多，大便干结，小便量多，睡眠差。体力下降，体重无明显减轻。   入院证见:口干多饮，小便频，大便干结，睡眠差。   自起病来，睡眠差，饮食清淡，大便干结，小便如上述。体力体重无明显下降。", "ner": [[13, 15, "Symptom"], [16, 18, "Symptom"], [19, 21, "Symptom"], [24, 30, "Symptom"], [33, 35, "Symptom"], [60, 63, "Disease"], [69, 78, "Drug"], [79, 85, "Drug"], [96, 100, "Symptom"], [101, 107, "Symptom"], [108, 111, "Symptom"], [121, 130, "Disease"], [131, 139, "Disease"], [147, 149, "Symptom"], [150, 152, "Symptom"], [153, 155, "Symptom"], [158, 160, "Anatomy"], [162, 168, "Symptom"], [176, 178, "Symptom"], [179, 183, "Symptom"], [170, 175, "Anatomy"], [198, 201, "Disease"], [218, 221, "Symptom"], [222, 224, "Symptom"], [225, 230, "Symptom"], [231, 235, "Symptom"], [236, 240, "Symptom"], [241, 244, "Symptom"], [245, 249, "Symptom"], [268, 270, "Symptom"], [271, 274, "Symptom"], [275, 279, "Symptom"], [280, 283, "Symptom"], [292, 295, "Symptom"], [301, 305, "Symptom"], [266, 268, "Symptom"]], "rel": [[13, 15, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [16, 18, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [19, 21, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [96, 100, "Symptom", 131, 139, "Disease", "Symptom_Disease"], [101, 107, "Symptom", 121, 130, "Disease", "Symptom_Disease"], [108, 111, "Symptom", 121, 130, "Disease", "Symptom_Disease"], [162, 168, "Symptom", 121, 130, "Disease", "Symptom_Disease"], [266, 268, "Symptom", 198, 201, "Disease", "Symptom_Disease"], [268, 270, "Symptom", 198, 201, "Disease", "Symptom_Disease"], [271, 274, "Symptom", 198, 201, "Disease", "Symptom_Disease"], [245, 249, "Symptom", 245, 249, "Symptom", "Symptom_Disease"], [245, 249, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [245, 249, "Symptom", 198, 201, "Disease", "Symptom_Disease"], [121, 130, "Disease", 60, 63, "Disease", "Disease_Disease"], [131, 139, "Disease", 60, 63, "Disease", "Disease_Disease"], [198, 201, "Disease", 60, 63, "Disease", "Disease_Disease"], [79, 85, "Drug", 60, 63, "Disease", "Drug_Disease"], [69, 78, "Drug", 60, 63, "Disease", "Drug_Disease"]]}
{"idx": 203, "sentence": "患者于5年前无明显诱因开始出现口干、多饮、多尿不适，伴乏力，无体重减轻，无多食易饥，无头昏，无心慌、胸闷，无腹痛、腹泻等不适，2022年1月因“右足皮肤溃烂”于我科住院诊断为：1.2型糖尿病足伴感染 2型糖尿病性周围神经病 2型糖尿病伴血糖控制不佳 2.高脂血症；给予诺和锐30笔芯三餐前皮下注射，二甲双胍、阿卡波糖口服降糖治疗，出院后自行改为18u 16u早晚皮下注射降糖。1周前患者出现发热（最高体温39℃），伴咳嗽，无明显咳痰，伴全身乏力不适，于分乡卫生院输液（具体不详）治疗，现仍稍许咳嗽，无气喘，近4天出现右足跟部溃烂渗液加重，无明显疼痛，上诉创面逐渐增大，为求诊治就诊我院，查新冠肺炎核酸阴性，结合患者症状及流行病学史，排除新冠肺炎后以“2型糖尿病足”收住我科。         发病以来，患者精神欠佳，饮食可，睡眠可，体力下降，小便如上述，大便正常。", "ner": [[15, 17, "Symptom"], [18, 20, "Symptom"], [21, 23, "Symptom"], [27, 29, "Symptom"], [31, 35, "Symptom"], [37, 41, "Symptom"], [43, 45, "Symptom"], [47, 49, "Symptom"], [50, 52, "Symptom"], [54, 56, "Symptom"], [57, 59, "Symptom"], [72, 78, "Symptom"], [90, 96, "Disease"], [97, 99, "Symptom"], [100, 111, "Disease"], [112, 117, "Disease"], [118, 120, "Test_items"], [127, 131, "Disease"], [134, 141, "Drug"], [144, 148, "Method"], [149, 153, "Drug"], [154, 158, "Drug"], [181, 185, "Method"], [172, 175, "Amount"], [176, 179, "Amount"], [195, 197, "Symptom"], [198, 202, "Test_items"], [202, 205, "Test_Value"], [208, 210, "Symptom"], [214, 216, "Symptom"], [218, 224, "Symptom"], [231, 233, "Method"], [244, 248, "Symptom"], [250, 252, "Symptom"], [262, 266, "Symptom"], [258, 262, "Anatomy"], [266, 268, "Level"], [272, 274, "Symptom"], [281, 283, "Level"], [294, 300, "Test_items"], [300, 302, "Test_Value"], [318, 322, "Disease"], [325, 331, "Disease"], [353, 357, "Symptom"], [366, 370, "Symptom"]], "rel": [[15, 17, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [18, 20, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [21, 23, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [27, 29, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [31, 35, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [37, 41, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [72, 78, "Symptom", 90, 96, "Disease", "Symptom_Disease"], [97, 99, "Symptom", 90, 96, "Disease", "Symptom_Disease"], [262, 266, "Symptom", 90, 96, "Disease", "Symptom_Disease"], [272, 274, "Symptom", 90, 96, "Disease", "Symptom_Disease"], [134, 141, "Drug", 112, 117, "Disease", "Drug_Disease"], [149, 153, "Drug", 112, 117, "Disease", "Drug_Disease"], [154, 158, "Drug", 112, 117, "Disease", "Drug_Disease"], [144, 148, "Method", 134, 141, "Drug", "Method_Drug"], [258, 262, "Anatomy", 90, 96, "Disease", "Anatomy_Disease"], [294, 300, "Test_items", 318, 322, "Disease", "Test_items_Disease"], [118, 120, "Test_items", 112, 117, "Disease", "Test_items_Disease"], [366, 370, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [100, 111, "Disease", 112, 117, "Disease", "Disease_Disease"], [90, 96, "Disease", 112, 117, "Disease", "Disease_Disease"], [198, 202, "Test_items", 318, 322, "Disease", "Test_items_Disease"]]}
{"idx": 204, "sentence": "：{患者11年前起无明显诱因出现反复口干多饮，昼夜饮水量可达2升，伴小便量及次数相应增多，食欲增加，体重略有减轻。无明显视力下降，皮肤瘙痒症状，无咳嗽、咯血，发热、盗汗，无腹痛、腹泻等症。曾来我查行糖耐量试验等检查后确诊为“2型糖尿病”，长期口服降糖药（格列美脲、二甲双胍片），血糖控制不佳。2月来患者渐感双足麻木、刺痛感，伴视力下降、头晕、上腹隐痛、烧心不适。今为求进一步诊治前来我院，门诊以“糖尿病”收入院。}   起病以来，患者精神、饮食、睡眠尚可，大便未见明显异常，小便多，2年来体重明显下降约40斤，体力下降。", "ner": [[18, 20, "Symptom"], [20, 22, "Symptom"], [34, 44, "Symptom"], [45, 49, "Symptom"], [50, 56, "Symptom"], [60, 64, "Symptom"], [65, 69, "Symptom"], [73, 75, "Symptom"], [76, 78, "Symptom"], [79, 81, "Symptom"], [82, 84, "Symptom"], [86, 88, "Symptom"], [89, 91, "Symptom"], [99, 104, "Test"], [112, 117, "Disease"], [121, 123, "Method"], [127, 131, "Drug"], [132, 137, "Drug"], [139, 141, "Test_items"], [153, 157, "Symptom"], [158, 161, "Symptom"], [163, 167, "Symptom"], [168, 170, "Symptom"], [171, 175, "Symptom"], [176, 180, "Symptom"], [198, 201, "Disease"], [237, 240, "Symptom"], [255, 259, "Symptom"], [244, 254, "Symptom"], [241, 244, "Duration"]], "rel": [[18, 20, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [20, 22, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [34, 44, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [45, 49, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [50, 56, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [237, 240, "Symptom", 112, 117, "Disease", "Symptom_Disease"], [132, 137, "Drug", 112, 117, "Disease", "Drug_Disease"], [127, 131, "Drug", 112, 117, "Disease", "Drug_Disease"], [139, 141, "Test_items", 112, 117, "Disease", "Test_items_Disease"], [121, 123, "Method", 127, 131, "Drug", "Method_Drug"], [121, 123, "Method", 132, 137, "Drug", "Method_Drug"], [255, 259, "Symptom", 112, 117, "Disease", "Symptom_Disease"]]}
{"idx": 205, "sentence": "患者于12年前无明显诱因开始出现口干、多饮、多尿不适，伴乏力、消瘦，无多食易饥，无头昏，无心慌、胸闷，无腹痛、腹泻等不适，2015年2月在我院就诊，行血糖等相关检查，诊断为“1型糖尿病并酮症酸中毒，糖尿病肾损害，高渗性昏迷，高乳酸血症，急性肾功能衰竭”，给予“甘舒霖R+甘舒霖N”降糖，但出院后间断停用胰岛素，血糖未正规监测，症状时有反复，伴视物模糊、手足麻木疼痛、皮肤瘙痒不适；2020年1月因双足皮肤溃烂在我院住院诊断为“1型糖尿病性足病 1型糖尿病性下肢感染 1型糖尿病性肾病 1型糖尿病性周围神经病 1型糖尿病性周围血管病变 2.中度贫血 3.低蛋白血症 4.低钾血症”，给予诺和锐笔芯 6u三餐前皮下注射+甘精胰岛素8u 睡前皮下注射，抗感染、伤口换药等治疗后好转出院。2个月前出现双下肢水肿，逐渐出现全身水肿，伴腹胀，伴心慌、胸闷、气喘，无恶心、呕吐，无腹泻，无咳嗽、咳痰，尿量无明显减少，伴泡沫尿，无尿频、尿急、尿痛。为求诊治，昨日来我院门诊就诊，门诊查血常规示：WBC 5.8×10^9/L、RBC 4.09×10^12/L、HGB830 g/L、PLT 244×10^9/L、L1.", "ner": [[16, 18, "Symptom"], [19, 21, "Symptom"], [22, 24, "Symptom"], [28, 30, "Symptom"], [31, 33, "Symptom"], [35, 39, "Symptom"], [41, 43, "Symptom"], [45, 47, "Symptom"], [48, 50, "Symptom"], [52, 54, "Symptom"], [55, 57, "Symptom"], [75, 77, "Test_items"], [87, 92, "Disease"], [93, 98, "Disease"], [99, 105, "Disease"], [106, 111, "Disease"], [112, 117, "Disease"], [118, 125, "Disease"], [130, 134, "Drug"], [135, 139, "Drug"], [151, 154, "Drug"], [155, 157, "Test_items"], [171, 175, "Symptom"], [176, 182, "Symptom"], [183, 187, "Symptom"], [198, 204, "Symptom"], [213, 221, "Disease"], [222, 232, "Disease"], [233, 241, "Disease"], [242, 253, "Disease"], [254, 266, "Disease"], [269, 273, "Disease"], [276, 281, "Disease"], [284, 288, "Disease"], [292, 297, "Drug"], [298, 300, "Amount"], [303, 307, "Method"], [308, 313, "Drug"], [313, 315, "Amount"], [318, 322, "Method"], [346, 351, "Symptom"], [356, 360, "Symptom"], [362, 364, "Symptom"], [366, 368, "Symptom"], [369, 371, "Symptom"], [372, 374, "Symptom"], [376, 378, "Symptom"], [379, 381, "Symptom"], [383, 385, "Symptom"], [387, 389, "Symptom"], [390, 392, "Symptom"], [402, 405, "Symptom"], [407, 409, "Symptom"], [410, 412, "Symptom"], [413, 415, "Symptom"], [434, 437, "Test"], [439, 442, "Test_items"], [443, 453, "Test_Value"], [454, 457, "Test_items"], [458, 470, "Test_Value"], [471, 474, "Test_items"], [474, 481, "Test_Value"], [482, 485, "Test_items"], [486, 496, "Test_Value"], [497, 499, "Test_items"]], "rel": [[16, 18, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [31, 33, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [35, 39, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [19, 21, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [22, 24, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [28, 30, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [176, 182, "Symptom", 242, 253, "Disease", "Symptom_Disease"], [183, 187, "Symptom", 242, 253, "Disease", "Symptom_Disease"], [198, 204, "Symptom", 213, 221, "Disease", "Symptom_Disease"], [198, 204, "Symptom", 254, 266, "Disease", "Symptom_Disease"], [346, 351, "Symptom", 213, 221, "Disease", "Symptom_Disease"], [356, 360, "Symptom", 254, 266, "Disease", "Symptom_Disease"], [402, 405, "Symptom", 233, 241, "Disease", "Symptom_Disease"], [407, 409, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [410, 412, "Symptom", 87, 92, "Disease", "Symptom_Disease"], [413, 415, "Symptom", 118, 125, "Disease", "Symptom_Disease"], [99, 105, "Disease", 87, 92, "Disease", "Disease_Disease"], [213, 221, "Disease", 87, 92, "Disease", "Disease_Disease"], [222, 232, "Disease", 87, 92, "Disease", "Disease_Disease"], [233, 241, "Disease", 87, 92, "Disease", "Disease_Disease"], [242, 253, "Disease", 87, 92, "Disease", "Disease_Disease"], [254, 266, "Disease", 87, 92, "Disease", "Disease_Disease"], [118, 125, "Disease", 87, 92, "Disease", "Disease_Disease"], [75, 77, "Test_items", 87, 92, "Disease", "Test_items_Disease"], [439, 442, "Test_items", 87, 92, "Disease", "Test_items_Disease"], [454, 457, "Test_items", 87, 92, "Disease", "Test_items_Disease"], [471, 474, "Test_items", 87, 92, "Disease", "Test_items_Disease"], [482, 485, "Test_items", 87, 92, "Disease", "Test_items_Disease"], [497, 499, "Test_items", 87, 92, "Disease", "Test_items_Disease"], [130, 134, "Drug", 87, 92, "Disease", "Drug_Disease"], [135, 139, "Drug", 87, 92, "Disease", "Drug_Disease"], [151, 154, "Drug", 87, 92, "Disease", "Drug_Disease"], [292, 297, "Drug", 87, 92, "Disease", "Drug_Disease"], [308, 313, "Drug", 87, 92, "Disease", "Drug_Disease"], [313, 315, "Amount", 308, 313, "Drug", "Amount_Drug"], [298, 300, "Amount", 292, 297, "Drug", "Amount_Drug"], [318, 322, "Method", 308, 313, "Drug", "Method_Drug"], [303, 307, "Method", 292, 297, "Drug", "Method_Drug"], [434, 437, "Test", 87, 92, "Disease", "Test_Disease"]]}
{"idx": 206, "sentence": "：{患者自10年前无明显诱因出现下肢皮肤溃烂疼痛，以右下肢为重，曾在我院皮肤科诊治，后发现血糖高，确诊为：2型糖尿病，长期坚持口服二甲双胍格列本脲片1粒，每日2次，罗格列酮片4mg，每日1次，未合理控制饮食及定期监测血糖，长期使用百多邦及湿润烧伤膏自行换药处理，下肢皮肤溃烂基本愈合，但易反复，后在我院内分泌科住院诊断为“1、2型糖尿病性坏疽；2、2型糖尿病并大血管病变、末梢神经病变；3、高血压病3级 极高危组；4、慢性胃炎；”换用“门冬胰岛素30R胰岛素注射液”餐前皮下注射调控血糖，给予营养神经、改善循环、对症支持等治疗，患者下肢皮肤溃烂改善出院，出院仍未定期监测血糖。近1月左下肢皮肤溃烂加重伴疼痛，局部有少量黄色脓液渗出，伴双下肢乏力，四肢末端痛温觉减退，时有双下肢水肿，多晨轻暮重，劳累时感胸闷气促，无发热寒战，无咳嗽、胸痛，无腹痛腹泻等不适。起病后未行特殊不适，今由家人送人我院就诊，门诊以“2型糖尿病伴多个并发症”收入我科。} 起病以来，患者精神、饮食、睡眠欠佳，大小便未见明显异常，体力下降，体重无明显下降。", "ner": [[16, 24, "Symptom"], [26, 29, "Anatomy"], [45, 47, "Test_items"], [47, 48, "Test_Value"], [53, 58, "Disease"], [63, 65, "Method"], [65, 74, "Drug"], [74, 76, "Amount"], [77, 81, "Frequency"], [82, 87, "Drug"], [87, 90, "Amount"], [91, 95, "Frequency"], [99, 103, "Treatment"], [108, 110, "Test_items"], [115, 118, "Drug"], [119, 124, "Drug"], [131, 135, "Anatomy"], [163, 171, "Disease"], [174, 179, "Disease"], [180, 185, "Disease"], [186, 192, "Disease"], [195, 199, "Disease"], [209, 213, "Disease"], [218, 232, "Drug"], [235, 239, "Method"], [241, 243, "Test_items"], [248, 250, "Anatomy"], [266, 270, "Anatomy"], [285, 287, "Test_items"], [291, 298, "Symptom"], [298, 300, "Level"], [301, 303, "Symptom"], [307, 315, "Symptom"], [317, 322, "Symptom"], [323, 332, "Symptom"], [335, 340, "Symptom"], [357, 359, "Symptom"], [359, 361, "Symptom"], [351, 353, "Symptom"], [353, 355, "Symptom"], [363, 365, "Symptom"], [366, 368, "Symptom"], [370, 372, "Symptom"], [372, 374, "Symptom"], [403, 408, "Disease"], [429, 439, "Symptom"], [450, 454, "Symptom"]], "rel": [[16, 24, "Symptom", 163, 171, "Disease", "Symptom_Disease"], [291, 298, "Symptom", 163, 171, "Disease", "Symptom_Disease"], [301, 303, "Symptom", 163, 171, "Disease", "Symptom_Disease"], [307, 315, "Symptom", 163, 171, "Disease", "Symptom_Disease"], [317, 322, "Symptom", 186, 192, "Disease", "Symptom_Disease"], [323, 332, "Symptom", 186, 192, "Disease", "Symptom_Disease"], [335, 340, "Symptom", 180, 185, "Disease", "Symptom_Disease"], [450, 454, "Symptom", 174, 179, "Disease", "Symptom_Disease"], [248, 250, "Anatomy", 186, 192, "Disease", "Anatomy_Disease"], [45, 47, "Test_items", 174, 179, "Disease", "Test_items_Disease"], [63, 65, "Method", 65, 74, "Drug", "Method_Drug"], [74, 76, "Amount", 65, 74, "Drug", "Amount_Drug"], [87, 90, "Amount", 82, 87, "Drug", "Amount_Drug"], [235, 239, "Method", 218, 232, "Drug", "Method_Drug"], [77, 81, "Frequency", 65, 74, "Drug", "Frequency_Drug"], [91, 95, "Frequency", 82, 87, "Drug", "Frequency_Drug"], [65, 74, "Drug", 174, 179, "Disease", "Drug_Disease"], [82, 87, "Drug", 174, 179, "Disease", "Drug_Disease"], [115, 118, "Drug", 163, 171, "Disease", "Drug_Disease"], [119, 124, "Drug", 163, 171, "Disease", "Drug_Disease"], [218, 232, "Drug", 174, 179, "Disease", "Drug_Disease"], [99, 103, "Treatment", 174, 179, "Disease", "Treatment_Disease"], [180, 185, "Disease", 174, 179, "Disease", "Disease_Disease"], [186, 192, "Disease", 174, 179, "Disease", "Disease_Disease"], [163, 171, "Disease", 174, 179, "Disease", "Disease_Disease"]]}
{"idx": 207, "sentence": "糖尿病足患者出现感觉异常，右侧足趾溃烂末梢感觉，足溃疡，右侧足趾溃烂末梢感觉，足部感觉减退或消失，神经传导功能异常，感觉迟钝或丧失，麻木，感觉检查：神清，右侧指甲脱落，甲床少量渗液，压痛，无明显红肿。否认高血压、糖尿病及心脏病等特殊病史。否认药敏史。发病前14天内无CV肺炎高风险地区及境外归国人员、无症状感染者、CV肺炎疑似、确诊病例有接触史；居住小区无CV病毒感染者，否认家庭中有聚集性发病，随机手指毛细血糖：6.2mmol/l。", "ner": [[0, 4, "Disease"], [8, 12, "Symptom"], [13, 19, "Symptom"], [24, 27, "Symptom"], [28, 34, "Symptom"], [39, 48, "Symptom"], [49, 57, "Symptom"], [58, 65, "Symptom"], [66, 68, "Symptom"], [77, 83, "Symptom"], [84, 90, "Symptom"], [91, 93, "Symptom"], [97, 99, "Symptom"], [102, 105, "Disease"], [106, 109, "Disease"], [110, 113, "Disease"], [133, 137, "Disease"], [157, 161, "Disease"], [200, 206, "Test_items"], [207, 216, "Test_Value"]], "rel": [[8, 12, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [13, 19, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [24, 27, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [39, 48, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [49, 57, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [58, 65, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [66, 68, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [77, 83, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [84, 90, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [91, 93, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [97, 99, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [0, 4, "Disease", 106, 109, "Disease", "Disease_Disease"], [200, 206, "Test_items", 106, 109, "Disease", "Test_items_Disease"]]}
{"idx": 208, "sentence": "糖尿病足患者左足坏疽疼痛1月余，仍诉左足疼痛，夜间较重，足部刺痛、灼痛", "ner": [[0, 4, "Disease"], [6, 10, "Symptom"], [10, 12, "Symptom"], [12, 15, "Duration"], [18, 22, "Symptom"], [28, 32, "Symptom"], [33, 35, "Symptom"]], "rel": [[6, 10, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [10, 12, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [18, 22, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 0, 4, "Disease", "Symptom_Disease"]]}
{"idx": 209, "sentence": "糖尿病周围神经病患者伴多个并发症于20余年前因体检发现血糖升高，多次在当地医院就诊，明确诊断为“2型糖尿病、糖尿病周围神经病变”，目前使用“门冬胰岛素注射液早10U晚10U”管理血糖治疗至今。1个多月前无明显诱因出现双足部皮肤变黑，麻木，疼痛，感觉异常。", "ner": [[0, 8, "Disease"], [27, 29, "Test_items"], [29, 31, "Test_Value"], [48, 53, "Disease"], [54, 63, "Disease"], [70, 78, "Drug"], [78, 82, "Amount"], [82, 86, "Amount"], [89, 91, "Test_items"], [111, 115, "Symptom"], [108, 111, "Anatomy"], [116, 118, "Symptom"], [119, 121, "Symptom"], [122, 126, "Symptom"]], "rel": [[54, 63, "Disease", 48, 53, "Disease", "Disease_Disease"], [0, 8, "Disease", 48, 53, "Disease", "Disease_Disease"], [70, 78, "Drug", 48, 53, "Disease", "Drug_Disease"], [82, 86, "Amount", 70, 78, "Drug", "Amount_Drug"], [78, 82, "Amount", 70, 78, "Drug", "Amount_Drug"], [27, 29, "Test_items", 48, 53, "Disease", "Test_items_Disease"], [122, 126, "Symptom", 0, 8, "Disease", "Symptom_Disease"], [119, 121, "Symptom", 0, 8, "Disease", "Symptom_Disease"], [116, 118, "Symptom", 0, 8, "Disease", "Symptom_Disease"]]}
{"idx": 210, "sentence": "糖尿病三年了，最开始是脚疼痛发热，理疗了2个月没有好，后面去查血糖，发现是糖尿病 现在血糖控制的还可以 但是双脚发热 麻木 疼痛 明显感觉小腿经络扯着痛 现在还感觉后背也发热 屁股也发热 目前脚还没有伤口 也没有变形 就是疼痛灼热感 影响睡眠，彩超已排除大血管病变，建议要排除内分泌、神经内科、风湿免疫科等方面的情况，必要时检查或复查足部核磁。", "ner": [[0, 3, "Disease"], [3, 5, "Duration"], [11, 12, "Anatomy"], [12, 16, "Symptom"], [31, 33, "Test_items"], [20, 23, "Duration"], [37, 40, "Disease"], [43, 45, "Test_items"], [54, 58, "Symptom"], [59, 61, "Symptom"], [62, 64, "Symptom"], [69, 76, "Symptom"], [82, 87, "Symptom"], [88, 93, "Symptom"], [96, 97, "Anatomy"], [106, 108, "Symptom"], [111, 116, "Symptom"], [122, 124, "Test"], [127, 132, "Disease"], [167, 171, "Test"]], "rel": [[122, 124, "Test", 127, 132, "Disease", "Test_Disease"], [43, 45, "Test_items", 37, 40, "Disease", "Test_items_Disease"], [167, 171, "Test", 127, 132, "Disease", "Test_Disease"]]}
{"idx": 211, "sentence": "糖尿病，病历概要：化疗后坏疽持续疼痛 干燥周围皮肤变黑 手脚麻痹 口腔溃疡 皮肤过敏 心率加快 骨髓抑制IV度 血小板降低 白细胞减少（2022-07-20填写）请问医生我妈妈现在坏疽很疼痛 21号第二次化疗 担心化疗会影响双脚使其恶化 现在不知道应该住院治疗坏疽还是怎么办（2022-07-20填写）医生你好 妈妈二次化疗后坏疽疼痛严重 手脚麻痹坏疽周围变黑 干燥 不知道怎么处理 继续化疗是否会恶化脚步问题导致截肢 能有什么办法缓解坏疽恶化（2022-07-20填写）医生你好 我妈妈在住院 医师说做动脉旋切球囊扩张手术（2022-07-29填写）请问做完之后会有什么情况发生，是不是坏疽的地方会潮湿然后会恶化 因为血运到了，那样就必须清创。严重可能需要截肢（2022-07-29填写）处置建议：已经做过血运重建，效果不好，脚趾仍然疼痛严重。如果再次做血运重建，不管方法如何更新，效果也是短暂，无法避免因疼痛需要截除大脚趾，并且只截大脚趾创面愈合可能性也很小。所以建议直接截除大脚趾，继续吃抗血小板抗凝药，继续吃加巴喷丁。只要不疼痛，局部感染，一般局部换药，即使创面不愈合，也不影响寿命。", "ner": [[0, 3, "Disease"], [19, 21, "Symptom"], [21, 27, "Symptom"], [28, 32, "Symptom"], [33, 37, "Symptom"], [38, 42, "Symptom"], [43, 47, "Symptom"], [48, 55, "Symptom"], [56, 61, "Symptom"], [62, 67, "Symptom"], [92, 95, "Symptom"], [112, 114, "Anatomy"], [90, 92, "Disease"], [130, 132, "Disease"], [163, 165, "Disease"], [165, 167, "Symptom"], [167, 169, "Level"], [170, 174, "Symptom"], [174, 180, "Symptom"], [181, 183, "Symptom"], [207, 209, "Operation"], [218, 220, "Disease"], [220, 222, "Level"], [252, 262, "Operation"], [320, 322, "Operation"], [300, 302, "Symptom"], [329, 331, "Operation"], [368, 370, "Symptom"], [364, 366, "Anatomy"], [370, 372, "Level"], [404, 406, "Symptom"], [408, 410, "Operation"], [410, 413, "Anatomy"], [418, 421, "Anatomy"], [438, 440, "Operation"], [440, 443, "Anatomy"], [457, 458, "Method"], [458, 462, "Drug"], [446, 447, "Method"], [465, 468, "Symptom"], [469, 473, "Symptom"], [14, 18, "Symptom"], [12, 14, "Disease"]], "rel": [[14, 18, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [19, 21, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [21, 27, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [28, 32, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [92, 95, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [165, 167, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [174, 180, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [469, 473, "Symptom", 12, 14, "Disease", "Symptom_Disease"], [207, 209, "Operation", 12, 14, "Disease", "Operation_Disease"], [252, 262, "Operation", 12, 14, "Disease", "Operation_Disease"], [320, 322, "Operation", 12, 14, "Disease", "Operation_Disease"], [408, 410, "Operation", 12, 14, "Disease", "Operation_Disease"], [364, 366, "Anatomy", 12, 14, "Disease", "Anatomy_Disease"], [418, 421, "Anatomy", 12, 14, "Disease", "Anatomy_Disease"], [457, 458, "Method", 458, 462, "Drug", "Method_Drug"], [12, 14, "Disease", 0, 3, "Disease", "Disease_Disease"]]}
{"idx": 212, "sentence": "2型糖尿病10余年，患者于2月前，出现脚背上皮肤瘙痒，有铜钱块儿大小皮肤表面溃烂瘙痒，一直不好。既往糖尿病，予以长效胰岛素及阿卡波糖对症治疗，糖化血红蛋白6.2，左右腿上皮肤瘙痒多年（冬季尤为明显） ，皮肤颜色已经变暗。最近双脚脚面瘙痒溃烂大约半年，我们当地医院叫去伤口处理中心抹药，不从根部解决问题。脚皮肤溃烂，瘙痒2个月", "ner": [[0, 5, "Disease"], [5, 9, "Duration"], [19, 22, "Anatomy"], [22, 26, "Symptom"], [34, 42, "Symptom"], [50, 53, "Disease"], [56, 61, "Drug"], [62, 66, "Drug"], [71, 77, "Test_items"], [77, 80, "Test_Value"], [81, 85, "Anatomy"], [85, 89, "Symptom"], [89, 91, "Duration"], [43, 47, "Symptom"], [101, 109, "Symptom"], [114, 120, "Symptom"], [112, 114, "Anatomy"], [120, 124, "Duration"], [152, 156, "Symptom"], [151, 152, "Anatomy"], [157, 159, "Symptom"], [159, 162, "Duration"]], "rel": [[56, 61, "Drug", 50, 53, "Disease", "Drug_Disease"], [62, 66, "Drug", 50, 53, "Disease", "Drug_Disease"], [71, 77, "Test_items", 50, 53, "Disease", "Test_items_Disease"]]}
{"idx": 213, "sentence": "双足皮肤多处色素沉着玩块。腓肠肌及双足趾问肌轻度萎缩,看毛儿乎完全脱落，双足足弓严重塌陷,踝关节内翻点击查看畸形,以左足为著左足底有一直径约3.0 cmx3.0cm的圆形溃疡.深度约0.5cm,周边角化明显,无明显感染征象(图1)正常。0.9。明显减退神经元性损害，神经传导速度降低。双下肢动泳多普勒:双下肢动手无异常，足背动脉和轻后动抹血流增快:左足足底压力测定:中足塌陷,下沉和弧形底:X线摄片:左足跖跐关节脱位,部分跖骨头骨密度增加,右侧跖附关节轻度脱位:3维CT:证实X线检查结果(图2-4):双足MRI扫插:跖骨,跳骨存在碎骨片及部分骨吸收，左足贴跗关节,舟棚关节脱位，周围软组织肿胀,诊断为DCN(进展期)清创,换药,抗感染;全接触石膏减压治疗4月后糖尿病足病减压鞋维持治疗:常规降血糖:甲钴胺0.5 mg 次/d,依帕司他50 mg3次/d,阿仑膦酸钠片70 mg1次/周尽可能减少运动,走路穿减压鞋。强化糖尿病及神经病变治疗，创面愈合，拟进一步行矫形手术治疗。患者男性，38岁，因血糖升高14年，反复双足皮肤溃烂2年加重半年入院。患者于14年前体检发现空腹血糖12mmol/L，口服葡萄糖耐量试验（OGTT）2h血糖25 mmol/L，糖化血红蛋白（HbA1c）12.5%，确诊为2型糖尿病（T2DM）。予以胰岛素强化治疗后改为口服降糖药治疗，平素仅间断自购降糖药物治疗。有饮酒史，每周约500ml，无吸烟史。4年来患者反复出现双足麻木、针刺感、烧灼感，持续数年后症状消失，其间下肢出现反复发作性溃疡，继出现双足肿胀、畸形及左足底溃烂。", "ner": [[0, 12, "Symptom"], [13, 16, "Anatomy"], [17, 22, "Anatomy"], [22, 26, "Symptom"], [31, 35, "Symptom"], [38, 44, "Symptom"], [36, 38, "Anatomy"], [45, 50, "Symptom"], [58, 60, "Anatomy"], [62, 65, "Anatomy"], [67, 82, "Level"], [83, 87, "Symptom"], [88, 96, "Level"], [97, 103, "Symptom"], [107, 109, "Symptom"], [124, 132, "Symptom"], [133, 141, "Symptom"], [142, 150, "Test"], [151, 154, "Anatomy"], [160, 164, "Anatomy"], [176, 182, "Test"], [174, 176, "Anatomy"], [183, 187, "Symptom"], [188, 190, "Symptom"], [191, 194, "Symptom"], [195, 199, "Test"], [200, 208, "Symptom"], [211, 219, "Symptom"], [220, 230, "Symptom"], [231, 235, "Test"], [238, 242, "Test"], [251, 256, "Test"], [259, 269, "Symptom"], [272, 275, "Symptom"], [276, 282, "Symptom"], [283, 289, "Symptom"], [292, 297, "Symptom"], [301, 304, "Disease"], [309, 311, "Operation"], [319, 328, "Treatment"], [331, 336, "Disease"], [336, 339, "Treatment"], [347, 349, "Test_items"], [350, 353, "Drug"], [353, 359, "Amount"], [360, 363, "Frequency"], [364, 368, "Drug"], [368, 373, "Amount"], [373, 377, "Frequency"], [378, 384, "Drug"], [384, 389, "Amount"], [390, 393, "Frequency"], [401, 407, "Treatment"], [410, 413, "Disease"], [414, 418, "Disease"], [431, 435, "Operation"], [448, 450, "Test_items"], [450, 452, "Test_Value"], [452, 455, "Duration"], [460, 464, "Symptom"], [458, 460, "Anatomy"], [484, 488, "Test_items"], [488, 496, "Test_Value"], [499, 512, "Test"], [512, 516, "Test_items"], [516, 525, "Test_Value"], [526, 539, "Test_items"], [539, 544, "Test_Value"], [548, 559, "Disease"], [562, 565, "Drug"], [572, 574, "Method"], [599, 601, "Frequency"], [622, 626, "Symptom"], [627, 630, "Symptom"], [631, 634, "Symptom"], [651, 658, "Symptom"], [647, 649, "Anatomy"], [662, 666, "Symptom"], [667, 669, "Symptom"], [670, 675, "Symptom"]], "rel": [[0, 12, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [22, 26, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [38, 44, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [45, 50, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [83, 87, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [107, 109, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [133, 141, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [124, 132, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [460, 464, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [622, 626, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [627, 630, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [631, 634, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [651, 658, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [662, 666, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [667, 669, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [670, 675, "Symptom", 331, 336, "Disease", "Symptom_Disease"], [622, 626, "Symptom", 414, 418, "Disease", "Symptom_Disease"], [627, 630, "Symptom", 414, 418, "Disease", "Symptom_Disease"], [631, 634, "Symptom", 414, 418, "Disease", "Symptom_Disease"], [309, 311, "Operation", 331, 336, "Disease", "Operation_Disease"], [431, 435, "Operation", 331, 336, "Disease", "Operation_Disease"], [458, 460, "Anatomy", 331, 336, "Disease", "Anatomy_Disease"], [512, 516, "Test_items", 548, 559, "Disease", "Test_items_Disease"], [526, 539, "Test_items", 548, 559, "Disease", "Test_items_Disease"], [448, 450, "Test_items", 548, 559, "Disease", "Test_items_Disease"], [484, 488, "Test_items", 548, 559, "Disease", "Test_items_Disease"], [350, 353, "Drug", 414, 418, "Disease", "Drug_Disease"], [364, 368, "Drug", 414, 418, "Disease", "Drug_Disease"], [562, 565, "Drug", 548, 559, "Disease", "Drug_Disease"], [353, 359, "Amount", 350, 353, "Drug", "Amount_Drug"], [384, 389, "Amount", 378, 384, "Drug", "Amount_Drug"], [368, 373, "Amount", 364, 368, "Drug", "Amount_Drug"], [373, 377, "Frequency", 364, 368, "Drug", "Frequency_Drug"], [390, 393, "Frequency", 378, 384, "Drug", "Frequency_Drug"], [360, 363, "Frequency", 347, 349, "Test_items", "Frequency_Drug"], [319, 328, "Treatment", 331, 336, "Disease", "Treatment_Disease"], [336, 339, "Treatment", 331, 336, "Disease", "Treatment_Disease"], [401, 407, "Treatment", 331, 336, "Disease", "Treatment_Disease"], [331, 336, "Disease", 548, 559, "Disease", "Disease_Disease"], [414, 418, "Disease", 548, 559, "Disease", "Disease_Disease"], [142, 150, "Test", 331, 336, "Disease", "Test_Disease"], [176, 182, "Test", 331, 336, "Disease", "Test_Disease"], [195, 199, "Test", 331, 336, "Disease", "Test_Disease"], [231, 235, "Test", 331, 336, "Disease", "Test_Disease"], [238, 242, "Test", 331, 336, "Disease", "Test_Disease"], [251, 256, "Test", 331, 336, "Disease", "Test_Disease"], [124, 132, "Symptom", 414, 418, "Disease", "Symptom_Disease"], [133, 141, "Symptom", 414, 418, "Disease", "Symptom_Disease"]]}
{"idx": 214, "sentence": "主诉：左足部冰凉麻木伴痛觉敏感4 个月。现病史   4 个月前无明显诱因出现左足冰凉麻木，当水溅到左足部或衣服拂过左足部时出现足部刺痛。诉经常感到患足无知觉或僵硬。在外院接受理疗、非类固醇类抗炎药治疗无效，为求进一步治疗来我院就诊。既往史  糖尿病史17年，一直服用二甲双胍。查体   常规检查无异常，专科检查：双足肤色肉眼观正常，皮肤温度正常，动脉搏动良好。双足轻触觉正常。用别针刺左足部做针刺试验时，患者迅速缩回足部，诉针刺时足部出现难以忍受的烧灼痛。", "ner": [[11, 15, "Symptom"], [15, 19, "Duration"], [38, 42, "Symptom"], [42, 44, "Symptom"], [8, 10, "Symptom"], [3, 8, "Symptom"], [49, 52, "Anatomy"], [57, 60, "Anatomy"], [63, 67, "Symptom"], [74, 75, "Anatomy"], [75, 78, "Symptom"], [79, 81, "Symptom"], [87, 89, "Treatment"], [125, 128, "Duration"], [133, 137, "Drug"], [156, 158, "Anatomy"], [180, 182, "Anatomy"], [173, 175, "Anatomy"], [166, 168, "Anatomy"], [192, 195, "Anatomy"], [196, 200, "Test"], [215, 217, "Anatomy"], [219, 224, "Level"], [224, 227, "Symptom"], [208, 210, "Anatomy"]], "rel": []}
{"idx": 215, "sentence": "患者于2018年4月因“右足拇趾皮肤溃烂”在我院住院，查血糖高，无口干、多饮、多尿等不适，经检查诊断为“2型糖尿病足并右足拇趾软组织感染 2型糖尿病性周围神经病变 2型糖尿病性大血管病变”，予降糖（甘舒霖30R、阿卡波糖、二甲双胍）、抗感染、营养神经、换药等治疗后好转，但出院后患者自行停用胰岛素，改用中药治疗，血糖未正规监测，逐渐出现视物模糊、手足麻木疼痛、皮肤瘙痒、腹泻便秘交替等不适；2021年7月患者再次因呕吐、腹泻在我院住院诊断为“2型糖尿病伴多个并发症 2型糖尿病性周围神经病 2型糖尿病性视网膜病变 2型糖尿病性周围血管病变 2型糖尿病性胃肠自主神经病变 2型糖尿病性肾病 2型糖尿病伴血糖控制不佳 2.急性胃肠炎 3.低钾血症 4.高血压病3级 极高危组”，给予诺和锐30笔芯 早8u、中6u、晚4u 皮下注射降糖治疗；患者出院后改为诺和锐30（早10u 晚8u）皮下注射降糖，血糖控制不佳。2022年6月20日患者再次因恶心、呕吐在我院住院，诊断为“2型糖尿病性肾病 2型糖尿病性周围神经病 2型糖尿病性视网膜病变 2型糖尿病性周围血管病变 ”，给予诺和锐30 早10u 中8u 晚", "ner": [[12, 16, "Anatomy"], [16, 20, "Symptom"], [28, 30, "Test_items"], [30, 31, "Test_Value"], [33, 35, "Symptom"], [36, 38, "Symptom"], [39, 41, "Symptom"], [52, 58, "Disease"], [59, 68, "Disease"], [69, 81, "Disease"], [82, 93, "Disease"], [99, 105, "Drug"], [106, 110, "Drug"], [111, 115, "Drug"], [123, 125, "Anatomy"], [145, 148, "Drug"], [156, 158, "Test_items"], [168, 172, "Symptom"], [173, 179, "Symptom"], [180, 184, "Symptom"], [185, 191, "Symptom"], [207, 209, "Symptom"], [210, 212, "Symptom"], [221, 226, "Disease"], [232, 244, "Disease"], [245, 256, "Disease"], [257, 269, "Disease"], [270, 284, "Disease"], [285, 293, "Disease"], [294, 299, "Disease"], [300, 302, "Test_items"], [309, 314, "Disease"], [317, 321, "Disease"], [324, 328, "Disease"], [339, 346, "Drug"], [347, 350, "Amount"], [351, 354, "Amount"], [355, 358, "Amount"], [359, 363, "Method"], [375, 380, "Drug"], [381, 385, "Amount"], [386, 389, "Amount"], [390, 394, "Method"], [397, 399, "Test_items"], [419, 421, "Symptom"], [422, 424, "Symptom"], [434, 442, "Disease"], [443, 454, "Disease"], [455, 466, "Disease"], [467, 479, "Disease"], [484, 489, "Drug"], [490, 494, "Amount"], [495, 498, "Amount"]], "rel": [[52, 58, "Disease", 221, 226, "Disease", "Disease_Disease"], [82, 93, "Disease", 221, 226, "Disease", "Disease_Disease"], [69, 81, "Disease", 221, 226, "Disease", "Disease_Disease"], [59, 68, "Disease", 52, 58, "Disease", "Disease_Disease"], [232, 244, "Disease", 221, 226, "Disease", "Disease_Disease"], [245, 256, "Disease", 221, 226, "Disease", "Disease_Disease"], [257, 269, "Disease", 221, 226, "Disease", "Disease_Disease"], [270, 284, "Disease", 221, 226, "Disease", "Disease_Disease"], [285, 293, "Disease", 221, 226, "Disease", "Disease_Disease"], [99, 105, "Drug", 221, 226, "Disease", "Drug_Disease"], [106, 110, "Drug", 221, 226, "Disease", "Drug_Disease"], [111, 115, "Drug", 221, 226, "Disease", "Drug_Disease"], [145, 148, "Drug", 221, 226, "Disease", "Drug_Disease"], [339, 346, "Drug", 221, 226, "Disease", "Drug_Disease"], [375, 380, "Drug", 221, 226, "Disease", "Drug_Disease"], [12, 16, "Anatomy", 52, 58, "Disease", "Anatomy_Disease"], [123, 125, "Anatomy", 69, 81, "Disease", "Anatomy_Disease"], [156, 158, "Test_items", 221, 226, "Disease", "Test_items_Disease"], [347, 350, "Amount", 339, 346, "Drug", "Amount_Drug"], [351, 354, "Amount", 339, 346, "Drug", "Amount_Drug"], [355, 358, "Amount", 339, 346, "Drug", "Amount_Drug"], [381, 385, "Amount", 375, 380, "Drug", "Amount_Drug"], [386, 389, "Amount", 375, 380, "Drug", "Amount_Drug"], [390, 394, "Method", 375, 380, "Drug", "Method_Drug"], [359, 363, "Method", 339, 346, "Drug", "Method_Drug"], [16, 20, "Symptom", 52, 58, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 221, 226, "Disease", "Symptom_Disease"], [36, 38, "Symptom", 221, 226, "Disease", "Symptom_Disease"], [39, 41, "Symptom", 221, 226, "Disease", "Symptom_Disease"], [173, 179, "Symptom", 232, 244, "Disease", "Symptom_Disease"], [180, 184, "Symptom", 232, 244, "Disease", "Symptom_Disease"], [185, 191, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [168, 172, "Symptom", 245, 256, "Disease", "Symptom_Disease"], [207, 209, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [210, 212, "Symptom", 309, 314, "Disease", "Symptom_Disease"], [185, 191, "Symptom", 270, 284, "Disease", "Symptom_Disease"], [210, 212, "Symptom", 270, 284, "Disease", "Symptom_Disease"], [207, 209, "Symptom", 270, 284, "Disease", "Symptom_Disease"]]}
{"idx": 216, "sentence": "患者，男，58岁，四川攀枝花人，因出现多饮、多食、多尿、消瘦，血糖高，诊断为糖尿病，平素靠药物治疗，但血糖控制差，半月来右足溃烂、恶臭，在当地卫生院予以治疗，效果不佳，于2010年5月\"糖尿病、糖尿病足\"入院治疗。入院时神志清楚，T37.3℃，P92次/min，R18次/min，BP140/80mmHg，患者双下肢凹陷性水肿，左足I°，右足Ⅱ°，两足皮温升高，足背动脉搏动减弱，右足第三、四趾足底溃烂，足背皮下积液，足弓内侧发黑、恶臭，入院后予以改善微循环、抗炎、降糖、清创换药、加强血糖监测等处理。血常规示：白细胞22.3×109/L;尿常规示尿糖+++;脓液培养：粪肠球菌;血培养：无细菌生长。5月21日在全麻下行右小腿中上段截肢术，术中见下肢血管均有血栓，部分血管内见脓栓。术后生命体征平稳，继续予以补液、抗炎、降糖等治疗。5月24日T39.5℃，血培养：无细菌生长;5月25日患者右下肢残端皮肤肌肉呈烧焦状，可触及捻发感，诊断为气性坏疽，进行隔离，同时通知相关科室做好隔离。给予高压氧治疗。26日在全麻下行右小腿截肢术后右大腿中段再截肢术，术中切口未缝合，后生命体征平稳，予以补液、抗炎、降糖、吸氧、高压氧等治疗，每日清创。27日换药中见肌肉血供差，呈熟肉状。29日体温、血糖降至正常，肌肉血供较好。31日伤口肉芽组织培养：无细菌生长。6月5日在全麻下行残端清创术，予以大跨度试行缝合。26日在全麻下行残端修整术，缝合切口。7月19日伤口愈合良好，出院。", "ner": [[19, 21, "Symptom"], [22, 24, "Symptom"], [25, 27, "Symptom"], [28, 30, "Symptom"], [31, 33, "Test_items"], [33, 34, "Test_Value"], [38, 41, "Disease"], [51, 53, "Test_items"], [60, 64, "Symptom"], [65, 67, "Symptom"], [93, 96, "Disease"], [97, 101, "Disease"], [115, 116, "Test_items"], [116, 121, "Test_Value"], [122, 123, "Test_items"], [123, 130, "Test_Value"], [131, 132, "Test_items"], [132, 139, "Test_Value"], [140, 142, "Test_items"], [142, 152, "Test_Value"], [158, 163, "Symptom"], [155, 158, "Anatomy"], [164, 166, "Anatomy"], [169, 171, "Anatomy"], [166, 168, "Level"], [171, 173, "Level"], [176, 180, "Symptom"], [174, 176, "Anatomy"], [181, 189, "Symptom"], [197, 201, "Symptom"], [190, 197, "Anatomy"], [204, 208, "Symptom"], [202, 204, "Anatomy"], [209, 215, "Symptom"], [216, 218, "Symptom"], [236, 238, "Operation"], [243, 245, "Test_items"], [251, 254, "Test"], [256, 259, "Test_items"], [259, 269, "Test_Value"], [270, 273, "Test"], [274, 276, "Test_items"], [276, 279, "Test_Value"], [310, 319, "Operation"], [323, 327, "Anatomy"], [329, 331, "Symptom"], [334, 336, "Anatomy"], [338, 340, "Symptom"], [371, 372, "Test_items"], [372, 377, "Test_Value"], [395, 398, "Anatomy"], [398, 408, "Symptom"], [412, 415, "Symptom"], [419, 423, "Disease"], [444, 449, "Treatment"], [458, 464, "Operation"], [465, 470, "Anatomy"], [471, 474, "Operation"], [502, 504, "Treatment"], [505, 508, "Treatment"], [514, 516, "Operation"], [524, 529, "Symptom"], [530, 534, "Symptom"], [538, 540, "Test_items"], [541, 543, "Test_items"], [545, 547, "Test_Value"], [582, 587, "Operation"], [606, 611, "Operation"]], "rel": [[19, 21, "Symptom", 38, 41, "Disease", "Symptom_Disease"], [22, 24, "Symptom", 38, 41, "Disease", "Symptom_Disease"], [25, 27, "Symptom", 38, 41, "Disease", "Symptom_Disease"], [28, 30, "Symptom", 38, 41, "Disease", "Symptom_Disease"], [60, 64, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [65, 67, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [158, 163, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [176, 180, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [181, 189, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [197, 201, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [204, 208, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [209, 215, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [329, 331, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [338, 340, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [398, 408, "Symptom", 419, 423, "Disease", "Symptom_Disease"], [412, 415, "Symptom", 419, 423, "Disease", "Symptom_Disease"], [524, 529, "Symptom", 419, 423, "Disease", "Symptom_Disease"], [530, 534, "Symptom", 419, 423, "Disease", "Symptom_Disease"], [514, 516, "Operation", 419, 423, "Disease", "Operation_Disease"], [458, 464, "Operation", 419, 423, "Disease", "Operation_Disease"], [471, 474, "Operation", 419, 423, "Disease", "Operation_Disease"], [236, 238, "Operation", 97, 101, "Disease", "Operation_Disease"], [310, 319, "Operation", 97, 101, "Disease", "Operation_Disease"], [471, 474, "Operation", 97, 101, "Disease", "Operation_Disease"], [444, 449, "Treatment", 419, 423, "Disease", "Treatment_Disease"], [502, 504, "Treatment", 419, 423, "Disease", "Treatment_Disease"], [505, 508, "Treatment", 419, 423, "Disease", "Treatment_Disease"], [541, 543, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [115, 116, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [122, 123, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [131, 132, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [140, 142, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [256, 259, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [274, 276, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [251, 254, "Test", 38, 41, "Disease", "Test_Disease"], [270, 273, "Test", 38, 41, "Disease", "Test_Disease"], [164, 166, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [169, 171, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [190, 197, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [174, 176, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [202, 204, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [155, 158, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [395, 398, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [538, 540, "Test_items", 93, 96, "Disease", "Test_items_Disease"]]}
{"idx": 217, "sentence": "男性,68岁,退休，右足疼痛伴足趾坏死2个月。【现病史】患者于2个月前，在无明显诱因的情况下，出现右足疼痛、发凉，右足第4趾逐渐发黑坏死。逐来我院就诊，门诊查彩超示双下肢动脉闭塞（胫后动脉、足背动脉闭塞），门诊以下肢动脉闭塞症伴右糖尿病足为诊断收入院治疗。病来无发热，无寒颤，无心悸气短、无胸腹痛、二便正常。【既往史】身体健康状况一般，否认肝炎、结核等传染病史。糖尿病病史20年（使用胰岛素治疗中）", "ner": [[10, 14, "Symptom"], [15, 19, "Symptom"], [19, 22, "Duration"], [49, 53, "Symptom"], [54, 56, "Symptom"], [64, 66, "Symptom"], [66, 68, "Symptom"], [57, 62, "Anatomy"], [79, 81, "Test"], [82, 89, "Disease"], [106, 113, "Disease"], [114, 119, "Disease"], [131, 133, "Symptom"], [135, 137, "Symptom"], [139, 141, "Symptom"], [141, 143, "Symptom"], [145, 148, "Symptom"], [170, 172, "Disease"], [173, 175, "Disease"], [181, 184, "Disease"], [192, 195, "Drug"], [90, 94, "Anatomy"], [95, 99, "Anatomy"], [99, 101, "Symptom"]], "rel": [[10, 14, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [10, 14, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [15, 19, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [15, 19, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [15, 19, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [49, 53, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [49, 53, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [49, 53, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [54, 56, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [54, 56, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [54, 56, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [64, 66, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [64, 66, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [64, 66, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [66, 68, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [66, 68, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [66, 68, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [99, 101, "Symptom", 82, 89, "Disease", "Symptom_Disease"], [99, 101, "Symptom", 114, 119, "Disease", "Symptom_Disease"], [99, 101, "Symptom", 106, 113, "Disease", "Symptom_Disease"], [57, 62, "Anatomy", 114, 119, "Disease", "Anatomy_Disease"], [90, 94, "Anatomy", 82, 89, "Disease", "Anatomy_Disease"], [90, 94, "Anatomy", 106, 113, "Disease", "Anatomy_Disease"], [95, 99, "Anatomy", 82, 89, "Disease", "Anatomy_Disease"], [95, 99, "Anatomy", 106, 113, "Disease", "Anatomy_Disease"], [114, 119, "Disease", 181, 184, "Disease", "Disease_Disease"], [82, 89, "Disease", 181, 184, "Disease", "Disease_Disease"], [106, 113, "Disease", 181, 184, "Disease", "Disease_Disease"], [192, 195, "Drug", 181, 184, "Disease", "Drug_Disease"], [79, 81, "Test", 82, 89, "Disease", "Test_Disease"], [79, 81, "Test", 106, 113, "Disease", "Test_Disease"], [79, 81, "Test", 114, 119, "Disease", "Test_Disease"]]}
{"idx": 218, "sentence": "发现血糖升高10余年，右足底红肿热痛溃破5天入院。患者于十年前发现血糖高，给予胰岛素降糖，配合二甲双胍和阿卡波糖口服 ，一直治疗病情稳定，一月前因右足第四趾坏死，在当地乡镇卫生院手术切除 ，术后一直愈合不好，近5天来出现右足底红肿热痛，溃破流液 ，伴有发热，今日来诊，门诊以“2型糖尿病 糖尿病足病”收入院。", "ner": [[2, 4, "Test_items"], [4, 6, "Test_Value"], [6, 10, "Duration"], [11, 14, "Anatomy"], [14, 16, "Symptom"], [16, 18, "Symptom"], [18, 20, "Symptom"], [20, 22, "Duration"], [33, 35, "Test_items"], [35, 36, "Test_Value"], [39, 42, "Drug"], [47, 51, "Drug"], [52, 56, "Drug"], [73, 80, "Symptom"], [99, 103, "Symptom"], [110, 113, "Anatomy"], [113, 115, "Symptom"], [115, 117, "Symptom"], [118, 120, "Symptom"], [120, 122, "Symptom"], [126, 128, "Symptom"], [138, 143, "Disease"], [144, 149, "Disease"]], "rel": [[2, 4, "Test_items", 138, 143, "Disease", "Test_items_Disease"], [144, 149, "Disease", 138, 143, "Disease", "Disease_Disease"], [14, 16, "Symptom", 144, 149, "Disease", "Symptom_Disease"], [16, 18, "Symptom", 144, 149, "Disease", "Symptom_Disease"], [18, 20, "Symptom", 144, 149, "Disease", "Symptom_Disease"], [73, 80, "Symptom", 144, 149, "Disease", "Symptom_Disease"], [99, 103, "Symptom", 144, 149, "Disease", "Symptom_Disease"], [120, 122, "Symptom", 144, 149, "Disease", "Symptom_Disease"], [11, 14, "Anatomy", 144, 149, "Disease", "Anatomy_Disease"], [39, 42, "Drug", 138, 143, "Disease", "Drug_Disease"], [47, 51, "Drug", 138, 143, "Disease", "Drug_Disease"], [52, 56, "Drug", 138, 143, "Disease", "Drug_Disease"]]}
{"idx": 219, "sentence": "女性,73岁,农民，口干多饮20余年，右足拇指红肿五天。患者20年前出现多尿、多饮，测血糖明显升高，诊断为\"糖尿病\"，平素以\"格列苯脲 2.5mg bid、二甲双胍 0.25g bid\"等药物治疗。一月前出现反复低血糖，后停用降糖药物。五天前患者右足拇指出现红肿，有疼痛，于当地诊所外敷以及口服抗生素治疗后症状较前加重，拇趾出现溃烂，足面红肿面积扩大，今来本院门诊，以\"糖尿病，糖尿病足\"收住院。发病以来，神清，精神可，无心慌多汗，时有胸闷，无胸痛，无呕吐腹痛，无畏寒发热，无头昏头痛，视物模糊，双足麻木，食纳睡眠可，大小便正常。平素健康状况一般 ，否认肝炎、结核等传染病史，否认高血压、癫痫等慢性病史，有子宫切除手术史，有胆囊切除手术史，左手外伤史，否认食物、药物过敏史，预防接种史不详。专科检查WC 86cm ：BMI 23.833 kg/m2 双足背动脉搏动微弱，左足部皮温低，右足足面红肿，有疼痛，拇趾外出红肿，第一关节处有大小约1*2cm大小的胼胝，周围红肿明显，有大小约4*7cm的不规则水泡,局部有脓性渗出。趾腹处有波动感。", "ner": [[10, 12, "Symptom"], [12, 14, "Symptom"], [14, 18, "Duration"], [19, 25, "Symptom"], [25, 27, "Duration"], [36, 38, "Symptom"], [39, 41, "Symptom"], [43, 45, "Test_items"], [47, 49, "Test_Value"], [54, 57, "Disease"], [63, 67, "Drug"], [68, 73, "Amount"], [74, 77, "Frequency"], [78, 82, "Drug"], [83, 88, "Amount"], [89, 92, "Frequency"], [106, 109, "Disease"], [129, 131, "Symptom"], [133, 135, "Symptom"], [123, 127, "Anatomy"], [141, 143, "Method"], [145, 147, "Method"], [160, 162, "Anatomy"], [164, 166, "Symptom"], [167, 175, "Symptom"], [185, 188, "Disease"], [189, 193, "Disease"], [211, 213, "Symptom"], [213, 215, "Symptom"], [218, 220, "Symptom"], [222, 224, "Symptom"], [226, 228, "Symptom"], [228, 230, "Symptom"], [232, 234, "Symptom"], [234, 236, "Symptom"], [238, 240, "Symptom"], [240, 242, "Symptom"], [243, 247, "Symptom"], [248, 252, "Symptom"], [277, 279, "Disease"], [280, 282, "Disease"], [290, 293, "Disease"], [294, 296, "Disease"], [349, 351, "Test_items"], [352, 356, "Test_Value"], [358, 361, "Test_items"], [362, 374, "Test_Value"], [375, 384, "Symptom"], [385, 391, "Symptom"], [392, 398, "Symptom"], [400, 402, "Symptom"], [403, 409, "Symptom"], [410, 414, "Anatomy"], [418, 426, "Level"], [432, 436, "Symptom"], [438, 446, "Level"], [447, 452, "Symptom"], [456, 460, "Symptom"], [465, 468, "Symptom"], [461, 464, "Anatomy"], [427, 429, "Disease"]], "rel": [[10, 12, "Symptom", 54, 57, "Disease", "Symptom_Disease"], [12, 14, "Symptom", 54, 57, "Disease", "Symptom_Disease"], [36, 38, "Symptom", 54, 57, "Disease", "Symptom_Disease"], [78, 82, "Drug", 54, 57, "Disease", "Drug_Disease"], [63, 67, "Drug", 54, 57, "Disease", "Drug_Disease"], [43, 45, "Test_items", 54, 57, "Disease", "Test_items_Disease"], [68, 73, "Amount", 63, 67, "Drug", "Amount_Drug"], [83, 88, "Amount", 78, 82, "Drug", "Amount_Drug"], [74, 77, "Frequency", 63, 67, "Drug", "Frequency_Drug"], [89, 92, "Frequency", 78, 82, "Drug", "Frequency_Drug"], [129, 131, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [133, 135, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [164, 166, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [243, 247, "Symptom", 243, 247, "Symptom", "Symptom_Disease"], [243, 247, "Symptom", 54, 57, "Disease", "Symptom_Disease"], [248, 252, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [375, 384, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [385, 391, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [392, 398, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [400, 402, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [403, 409, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [465, 468, "Symptom", 189, 193, "Disease", "Symptom_Disease"], [461, 464, "Anatomy", 189, 193, "Disease", "Anatomy_Disease"], [160, 162, "Anatomy", 189, 193, "Disease", "Anatomy_Disease"], [123, 127, "Anatomy", 189, 193, "Disease", "Anatomy_Disease"], [189, 193, "Disease", 54, 57, "Disease", "Disease_Disease"], [432, 436, "Symptom", 427, 429, "Disease", "Symptom_Disease"], [447, 452, "Symptom", 427, 429, "Disease", "Symptom_Disease"], [456, 460, "Symptom", 427, 429, "Disease", "Symptom_Disease"], [427, 429, "Disease", 189, 193, "Disease", "Disease_Disease"]]}
{"idx": 220, "sentence": "糖尿病15年，右小腿及足部疼痛3个月，溃烂20天。该患者于15年前无明显诱因发现体重下降，进食量明显多于正常，到医院检测血糖发现高于正常，之后连续检测几次空腹及餐后血糖均明显增高，确诊为2型糖尿病。口服二甲双胍片控制血糖，自诉血糖控制尚可，空腹血糖在6.2~8.0mmol/L之间波动。3个月前无明显诱因出现右小腿及足部疼痛，呈持续性刺痛伴瘙痒感，疼痛较重，影响睡眠及饮食，曾去蛟河市医院就诊，疑诊为“带状疱疹”，给予黄柏洗剂及阿昔洛韦乳膏外用，效果不佳。20天前，疼痛部位出现溃烂，由于未予处理及护理不当，溃烂处逐渐出现感染，疼痛加重，局部肿胀、渗液、夜间疼痛加重，另患者彻夜难眠，为求进一步诊疗，今日来诊，门诊检查发现右足拇趾尖端发黑，以“糖尿病足”收入院。病程中患者无明显四肢麻木、视物模糊及泡沫尿，3个月来患者体重下降约10kg，饮食、睡眠差，大小便基本正常。", "ner": [[0, 3, "Disease"], [3, 6, "Duration"], [7, 10, "Anatomy"], [11, 13, "Anatomy"], [13, 15, "Symptom"], [15, 18, "Duration"], [19, 21, "Symptom"], [21, 24, "Duration"], [40, 44, "Symptom"], [45, 54, "Symptom"], [60, 62, "Test_items"], [64, 68, "Test_Value"], [82, 84, "Test_items"], [87, 89, "Test_Value"], [93, 98, "Disease"], [99, 101, "Method"], [101, 106, "Drug"], [108, 110, "Test_items"], [113, 115, "Test_items"], [120, 124, "Test_items"], [125, 138, "Test_Value"], [154, 157, "Anatomy"], [158, 160, "Anatomy"], [160, 162, "Symptom"], [164, 169, "Symptom"], [170, 173, "Symptom"], [201, 205, "Disease"], [209, 213, "Drug"], [214, 220, "Drug"], [220, 222, "Method"], [239, 241, "Symptom"], [261, 263, "Symptom"], [269, 273, "Symptom"], [274, 276, "Symptom"], [315, 319, "Symptom"], [311, 315, "Anatomy"], [322, 326, "Disease"], [339, 343, "Symptom"], [344, 348, "Symptom"], [349, 352, "Symptom"], [359, 363, "Symptom"], [369, 375, "Symptom"], [363, 368, "Test_Value"], [264, 266, "Symptom"], [279, 281, "Symptom"], [266, 268, "Level"], [281, 283, "Level"], [174, 176, "Symptom"], [176, 178, "Level"]], "rel": [[40, 44, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [45, 54, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [13, 15, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [19, 21, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [160, 162, "Symptom", 201, 205, "Disease", "Symptom_Disease"], [164, 169, "Symptom", 201, 205, "Disease", "Symptom_Disease"], [170, 173, "Symptom", 201, 205, "Disease", "Symptom_Disease"], [261, 263, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [264, 266, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [269, 273, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [274, 276, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [339, 343, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [164, 169, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [170, 173, "Symptom", 322, 326, "Disease", "Symptom_Disease"], [11, 13, "Anatomy", 322, 326, "Disease", "Anatomy_Disease"], [311, 315, "Anatomy", 322, 326, "Disease", "Anatomy_Disease"], [101, 106, "Drug", 0, 3, "Disease", "Drug_Disease"], [214, 220, "Drug", 201, 205, "Disease", "Drug_Disease"], [209, 213, "Drug", 201, 205, "Disease", "Drug_Disease"], [220, 222, "Method", 214, 220, "Drug", "Method_Drug"], [220, 222, "Method", 209, 213, "Drug", "Method_Drug"], [99, 101, "Method", 101, 106, "Drug", "Method_Drug"], [82, 84, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [120, 124, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [19, 21, "Symptom", 322, 326, "Disease", "Symptom_Disease"]]}
{"idx": 221, "sentence": "既往诊断Ⅱ型糖尿病13年。血压128/84mmHgBMI23.13kg/m2，腰围92cm，伸舌稍左偏，左侧鼻唇沟变浅，右侧肢体肌力4级，左侧肌力5级。空腹血糖11.6mmol/L，餐后2小时血糖14.5mmol/L，甘油三酯2.1mmol/L，高密度脂蛋白胆固醇HDL-C1.5mmol/L，低密度脂蛋白胆固醇LDL-C2.97mmol/L，尿糖2+，肌酐（Cr）82.9μmol/L，多普勒彩超提示：双侧颈总动脉软斑形成，左侧颈总动脉，左侧颈内动脉混合斑形成,双下肢动脉硬化。应用诺和锐胰岛素泵治疗基础率28u，早5u中5u晚5u，血糖控制不佳。诊断为糖尿病视网膜病变，糖尿病肾病，糖尿病周围神经病变，糖尿病性胃肠功能紊乱，糖尿病足，糖尿病下肢血管病变。", "ner": [[4, 9, "Disease"], [9, 12, "Duration"], [13, 15, "Test_items"], [15, 25, "Test_Value"], [25, 28, "Test_items"], [28, 38, "Test_Value"], [39, 41, "Test_items"], [41, 45, "Test_Value"], [46, 51, "Symptom"], [52, 59, "Symptom"], [60, 64, "Anatomy"], [64, 66, "Test_items"], [66, 68, "Test_Value"], [71, 73, "Test_items"], [73, 75, "Test_Value"], [76, 80, "Test_items"], [80, 90, "Test_Value"], [91, 98, "Test_items"], [98, 108, "Test_Value"], [109, 113, "Test_items"], [113, 122, "Test_Value"], [123, 137, "Test_items"], [137, 146, "Test_Value"], [147, 161, "Test_items"], [161, 171, "Test_Value"], [172, 174, "Test_items"], [174, 176, "Test_Value"], [177, 183, "Test_items"], [183, 193, "Test_Value"], [194, 199, "Test"], [202, 212, "Symptom"], [213, 219, "Anatomy"], [220, 226, "Anatomy"], [226, 231, "Symptom"], [232, 239, "Disease"], [242, 248, "Drug"], [254, 257, "Amount"], [258, 261, "Amount"], [261, 264, "Amount"], [264, 267, "Amount"], [268, 270, "Test_items"], [278, 286, "Disease"], [287, 292, "Disease"], [293, 302, "Disease"], [303, 313, "Disease"], [314, 318, "Disease"], [319, 328, "Disease"]], "rel": [[76, 80, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [91, 98, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [109, 113, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [123, 137, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [147, 161, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [172, 174, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [177, 183, "Test_items", 4, 9, "Disease", "Test_items_Disease"], [194, 199, "Test", 232, 239, "Disease", "Test_Disease"], [194, 199, "Test", 314, 318, "Disease", "Test_Disease"], [194, 199, "Test", 319, 328, "Disease", "Test_Disease"], [213, 219, "Anatomy", 232, 239, "Disease", "Anatomy_Disease"], [220, 226, "Anatomy", 232, 239, "Disease", "Anatomy_Disease"], [242, 248, "Drug", 4, 9, "Disease", "Drug_Disease"], [254, 257, "Amount", 242, 248, "Drug", "Amount_Drug"], [258, 261, "Amount", 242, 248, "Drug", "Amount_Drug"], [261, 264, "Amount", 242, 248, "Drug", "Amount_Drug"], [264, 267, "Amount", 242, 248, "Drug", "Amount_Drug"], [232, 239, "Disease", 4, 9, "Disease", "Disease_Disease"], [287, 292, "Disease", 4, 9, "Disease", "Disease_Disease"], [293, 302, "Disease", 4, 9, "Disease", "Disease_Disease"], [303, 313, "Disease", 4, 9, "Disease", "Disease_Disease"], [314, 318, "Disease", 4, 9, "Disease", "Disease_Disease"], [278, 286, "Disease", 4, 9, "Disease", "Disease_Disease"], [319, 328, "Disease", 4, 9, "Disease", "Disease_Disease"], [268, 270, "Test_items", 4, 9, "Disease", "Test_items_Disease"]]}
{"idx": 222, "sentence": "男，43岁，因左足后跟外侧无明显诱因出现溃烂来笔者科室治疗。溃烂约3cm×3cm×3cm，基底苍白伴坏死组织紧密附着，有明显渗出及异臭味，触痛不明显，双侧足背动脉搏动有力，双下肢血管彩超：双下肢动脉闭塞2级，行左足溃疡清创术后创面缩小好转出院。患者出院后因左足溃烂加重（图1），创面疼痛，发热，体温最高达39℃，伴畏寒、寒颤，以“左足后跟外侧溃烂5周，加重伴发热4d”再次收治入本院。患者糖尿病史7年余", "ner": [[7, 13, "Anatomy"], [20, 22, "Symptom"], [30, 32, "Symptom"], [32, 44, "Level"], [45, 49, "Symptom"], [50, 58, "Symptom"], [62, 64, "Symptom"], [65, 68, "Symptom"], [69, 74, "Symptom"], [75, 85, "Symptom"], [86, 93, "Test"], [94, 101, "Disease"], [105, 112, "Operation"], [128, 132, "Symptom"], [132, 134, "Level"], [139, 143, "Symptom"], [147, 149, "Test_items"], [152, 155, "Test_Value"], [157, 159, "Symptom"], [160, 162, "Symptom"], [165, 171, "Anatomy"], [171, 173, "Symptom"], [173, 175, "Duration"], [179, 181, "Symptom"], [181, 183, "Duration"], [198, 201, "Duration"]], "rel": [[20, 22, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [62, 64, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [65, 68, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [50, 58, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [45, 49, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [69, 74, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [128, 132, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [139, 143, "Symptom", 94, 101, "Disease", "Symptom_Disease"], [105, 112, "Operation", 94, 101, "Disease", "Operation_Disease"], [86, 93, "Test", 94, 101, "Disease", "Test_Disease"]]}
{"idx": 223, "sentence": "患者男，62岁，因“双下肢多处皮肤溃烂一月”入院。【现病史】1月前出现双下肢多处皮肤溃烂，家属自行外购药膏涂抹，部分表浅、小创面愈合，留有色素沉着。但右足足背、左足外踝、左小腿屈侧溃烂面积大，创面深，伴臭味。【查体】检查：静脉血糖28.1mmol/L，糖化血红蛋白9.7%，尿素氮25.3mmol/L，肌酐192.9μmmol/L，C反应蛋白141.9mg/L，血浆白蛋白28g/L左右，血红蛋白120g/L左右。双下肢血管彩超示双侧下肢动脉硬化伴斑块形成，管腔内血流连续完整。左踝关节正侧位片提示骨质有破坏。家属拒绝截肢治疗。【诊治经过】治疗：给予前列地尔10μg入壶qd；硫辛酸，0.3g静点qd；美罗培南1.0g静点bid；丹红30毫升静点qd；每日碘伏消毒创面一次，十天后右足背创面愈合。由于入院时血糖很高，采用小剂量静脉滴注胰岛素，控制稳定后改为皮下四次注射，随着血糖好转停用了基础胰岛素，空腹在5-7mmol/L，餐后2小时在7-10mmol/L。十天前经我院外科医生会诊清创后建议0.9%盐水250毫升+庆大霉素40万单位+普通胰岛素注射液400单位每日湿敷。十天后患者外踝肉芽组织非常新鲜，面积略有所缩小；足跟处这块不行，面积较大，颜色发黑。", "ner": [[10, 13, "Anatomy"], [15, 19, "Symptom"], [19, 21, "Duration"], [35, 38, "Anatomy"], [40, 44, "Symptom"], [53, 55, "Method"], [69, 73, "Symptom"], [75, 79, "Anatomy"], [80, 84, "Anatomy"], [85, 90, "Anatomy"], [90, 95, "Symptom"], [101, 103, "Symptom"], [96, 99, "Symptom"], [111, 115, "Test_items"], [115, 125, "Test_Value"], [126, 132, "Test_items"], [132, 136, "Test_Value"], [137, 140, "Test_items"], [140, 150, "Test_Value"], [151, 153, "Test_items"], [153, 165, "Test_Value"], [166, 171, "Test_items"], [171, 180, "Test_Value"], [181, 186, "Test_items"], [186, 191, "Test_Value"], [194, 198, "Test_items"], [198, 204, "Test_Value"], [207, 214, "Test"], [215, 223, "Disease"], [224, 228, "Symptom"], [239, 243, "Anatomy"], [249, 254, "Symptom"], [259, 261, "Operation"], [275, 279, "Drug"], [279, 283, "Amount"], [283, 285, "Method"], [285, 287, "Frequency"], [288, 291, "Drug"], [292, 296, "Amount"], [298, 300, "Frequency"], [301, 305, "Drug"], [305, 309, "Amount"], [296, 298, "Method"], [309, 311, "Method"], [311, 314, "Frequency"], [315, 317, "Drug"], [317, 321, "Amount"], [321, 323, "Method"], [323, 325, "Frequency"], [328, 330, "Drug"], [340, 343, "Anatomy"], [353, 355, "Test_items"], [355, 357, "Test_Value"], [360, 367, "Method"], [367, 370, "Drug"], [380, 382, "Frequency"], [382, 384, "Method"], [387, 389, "Test_items"], [394, 399, "Drug"], [403, 412, "Test_Value"], [419, 429, "Test_Value"], [442, 444, "Operation"], [447, 453, "Drug"], [453, 458, "Amount"], [459, 463, "Drug"], [463, 468, "Amount"], [477, 482, "Amount"], [482, 484, "Frequency"], [484, 486, "Method"], [492, 494, "Anatomy"], [511, 514, "Anatomy"], [524, 528, "Symptom"], [469, 477, "Drug"], [326, 328, "Frequency"]], "rel": [[15, 19, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [69, 73, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [101, 103, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [224, 228, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [90, 95, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [96, 99, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [249, 254, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [524, 528, "Symptom", 215, 223, "Disease", "Symptom_Disease"], [10, 13, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [35, 38, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [85, 90, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [80, 84, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [239, 243, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [259, 261, "Operation", 215, 223, "Disease", "Operation_Disease"], [492, 494, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [442, 444, "Operation", 215, 223, "Disease", "Operation_Disease"], [275, 279, "Drug", 215, 223, "Disease", "Drug_Disease"], [288, 291, "Drug", 215, 223, "Disease", "Drug_Disease"], [301, 305, "Drug", 215, 223, "Disease", "Drug_Disease"], [315, 317, "Drug", 215, 223, "Disease", "Drug_Disease"], [459, 463, "Drug", 215, 223, "Disease", "Drug_Disease"], [511, 514, "Anatomy", 215, 223, "Disease", "Anatomy_Disease"], [283, 285, "Method", 275, 279, "Drug", "Method_Drug"], [309, 311, "Method", 301, 305, "Drug", "Method_Drug"], [296, 298, "Method", 288, 291, "Drug", "Method_Drug"], [321, 323, "Method", 315, 317, "Drug", "Method_Drug"], [360, 367, "Method", 367, 370, "Drug", "Method_Drug"], [382, 384, "Method", 367, 370, "Drug", "Method_Drug"], [484, 486, "Method", 469, 477, "Drug", "Method_Drug"], [484, 486, "Method", 459, 463, "Drug", "Method_Drug"], [484, 486, "Method", 447, 453, "Drug", "Method_Drug"], [285, 287, "Frequency", 275, 279, "Drug", "Frequency_Drug"], [298, 300, "Frequency", 288, 291, "Drug", "Frequency_Drug"], [311, 314, "Frequency", 301, 305, "Drug", "Frequency_Drug"], [323, 325, "Frequency", 315, 317, "Drug", "Frequency_Drug"], [326, 328, "Frequency", 328, 330, "Drug", "Frequency_Drug"], [380, 382, "Frequency", 367, 370, "Drug", "Frequency_Drug"], [482, 484, "Frequency", 469, 477, "Drug", "Frequency_Drug"], [482, 484, "Frequency", 459, 463, "Drug", "Frequency_Drug"], [482, 484, "Frequency", 447, 453, "Drug", "Frequency_Drug"], [279, 283, "Amount", 275, 279, "Drug", "Amount_Drug"], [292, 296, "Amount", 288, 291, "Drug", "Amount_Drug"], [305, 309, "Amount", 301, 305, "Drug", "Amount_Drug"], [317, 321, "Amount", 315, 317, "Drug", "Amount_Drug"], [463, 468, "Amount", 459, 463, "Drug", "Amount_Drug"], [477, 482, "Amount", 469, 477, "Drug", "Amount_Drug"], [453, 458, "Amount", 447, 453, "Drug", "Amount_Drug"]]}
{"idx": 224, "sentence": "患者男性，78岁，\"双下肢行走无力2年，右足趾发凉疼痛、溃破发黑2月\"入院。【现病史】患者2型糖尿病病史16年，使用胰岛素控制血糖10年，近1月血糖控制不稳定；【既往史】高血压、冠状动脉粥样硬化性心脏病病史20年。【辅助检查】肢动脉彩色多普勒显示：双侧股总、股浅及股深动脉管壁散在粥样硬化斑块样回声，管腔尚通畅；双侧腘动脉未见明显狭窄；右侧胫前动脉和胫后动脉闭塞，右侧腓动脉弥漫性狭窄50%~90%.静态踝肱比（RestAnkleBrachialIndex,rABI）显示：左侧0.75,右侧0.32.下肢动脉造影显示：右侧胫前动脉、胫后动脉及腓动脉闭塞，远端可见紊乱的侧支**足背动脉（图1左）", "ner": [[10, 17, "Symptom"], [17, 19, "Duration"], [23, 25, "Symptom"], [25, 27, "Symptom"], [20, 23, "Anatomy"], [28, 30, "Symptom"], [30, 32, "Symptom"], [32, 34, "Duration"], [45, 50, "Disease"], [52, 55, "Duration"], [58, 61, "Drug"], [63, 65, "Test_items"], [65, 68, "Duration"], [72, 74, "Test_items"], [85, 88, "Disease"], [89, 101, "Disease"], [113, 121, "Test"], [138, 149, "Symptom"], [124, 138, "Anatomy"], [156, 161, "Anatomy"], [165, 167, "Symptom"], [182, 187, "Anatomy"], [187, 192, "Symptom"], [192, 199, "Level"], [251, 257, "Test"], [289, 293, "Anatomy"], [103, 106, "Duration"], [179, 181, "Symptom"], [275, 277, "Symptom"], [168, 174, "Anatomy"], [175, 179, "Anatomy"], [260, 266, "Anatomy"], [267, 271, "Anatomy"], [272, 275, "Anatomy"], [200, 234, "Test_items"], [237, 243, "Test_Value"], [244, 250, "Test_Value"]], "rel": [[58, 61, "Drug", 45, 50, "Disease", "Drug_Disease"], [63, 65, "Test_items", 58, 61, "Drug", "Test_items_Disease"], [200, 234, "Test_items", 85, 88, "Disease", "Test_Disease"]]}
{"idx": 225, "sentence": "患者一月前在家烫脚时,致右足底皮肤形成一个大水泡，当即疼痛厉害，无出血,在家用卫生纸包扎伤口后，未送入院救治，一月来伤肢胀痛，一直未就诊。近十天右足低成溃疡，症状加重。遂来我院要求治疗。门诊拟“糖尿病足”收入住院。入院时患者神清,精神差，急性痛苦面容，大小便未解,右下肢行走疼痛.【既往史】患者有“糖尿病”史10年余，近几年一直在家吃药治疗，血糖控制情况不详。【辅助检查】血分析:WBC：17.0×109/L，RBC：4.22×1012/L，HGB:138g/L；尿分析：蛋白质（-）潜血（-）葡萄糖（+-）；大便常规：未见异常；空腹血糖：23.6mmol/L。", "ner": [[12, 15, "Anatomy"], [21, 24, "Symptom"], [27, 29, "Symptom"], [29, 31, "Level"], [58, 62, "Symptom"], [76, 78, "Symptom"], [72, 74, "Anatomy"], [81, 83, "Level"], [97, 101, "Disease"], [115, 118, "Symptom"], [119, 123, "Symptom"], [132, 139, "Symptom"], [149, 152, "Disease"], [154, 158, "Duration"], [171, 173, "Test_items"], [186, 189, "Test"], [190, 193, "Test_items"], [194, 204, "Test_Value"], [205, 208, "Test_items"], [209, 220, "Test_Value"], [221, 224, "Test_items"], [225, 231, "Test_Value"], [232, 235, "Test"], [236, 239, "Test_items"], [242, 244, "Test_items"], [247, 250, "Test_items"], [255, 259, "Test"], [265, 269, "Test_items"], [270, 280, "Test_Value"]], "rel": [[21, 24, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [27, 29, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [58, 62, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [132, 139, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [119, 123, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [76, 78, "Symptom", 97, 101, "Disease", "Symptom_Disease"], [12, 15, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [72, 74, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [171, 173, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [190, 193, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [205, 208, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [221, 224, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [236, 239, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [242, 244, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [247, 250, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [265, 269, "Test_items", 149, 152, "Disease", "Test_items_Disease"], [186, 189, "Test", 149, 152, "Disease", "Test_Disease"], [232, 235, "Test", 149, 152, "Disease", "Test_Disease"], [255, 259, "Test", 149, 152, "Disease", "Test_Disease"], [97, 101, "Disease", 149, 152, "Disease", "Disease_Disease"]]}
{"idx": 226, "sentence": "【一般资料】 患者男性，60岁，本地农民【主诉】 因“右足部溃烂不愈2周”入院。【既往病史】 既往有高血压病史10年，最高血压170/100mmHg，未进行正规降压治疗；糖尿病史10余年，未控制血糖。【查体】 入院检查：T36.7℃，P80次/min，BP150/90mmHg，心界向左下扩大，律齐，无杂音。【专科检查】 右足肿胀，足背动脉搏动消失，皮温低，痛觉迟钝，足背前侧见约10cm×9cm大小的皮肤灰白**域，有两条长分别为2cm和1.5cm的裂口，伴有灰褐色的渗液，恶臭味，右足第3趾皮肤发黑，足趾屈伸活动尚可。【辅助检查】 血常规：WBC10.6×109/L，NETU70.4%，随机血糖20.7mmmoL/L，糖化血红蛋白13.0%；DR胸片：高血压病心脏表现；DR右足正侧位未见骨质异常；心脏B超：左室增大，二尖瓣及主动脉瓣轻度关闭不全；右下肢血管动静脉B超示：右下肢胭动脉、胫后动脉血栓形成，深静脉血流通畅；右下肢动脉血管CTA示：右胭动脉自膝上动脉分叉部起管腔狭窄，止于胫后动脉与腓动脉分叉部，管腔见血栓填充，该部分尤其分支膝上动脉及腓肠动脉代偿供血，胫后动脉及腓动脉于踝关节上方层面闭塞。", "ner": [[27, 32, "Symptom"], [32, 34, "Symptom"], [34, 36, "Duration"], [55, 58, "Duration"], [59, 63, "Test_items"], [63, 74, "Test_Value"], [89, 93, "Duration"], [110, 111, "Test_items"], [111, 116, "Test_Value"], [117, 118, "Test_items"], [118, 125, "Test_Value"], [126, 128, "Test_items"], [128, 138, "Test_Value"], [139, 146, "Symptom"], [147, 149, "Symptom"], [150, 153, "Symptom"], [161, 165, "Symptom"], [166, 174, "Symptom"], [175, 178, "Symptom"], [179, 183, "Symptom"], [184, 188, "Anatomy"], [189, 200, "Level"], [201, 205, "Symptom"], [216, 219, "Test_Value"], [220, 225, "Test_Value"], [231, 237, "Symptom"], [238, 241, "Symptom"], [247, 251, "Symptom"], [242, 247, "Anatomy"], [268, 271, "Test"], [252, 254, "Anatomy"], [272, 275, "Test_items"], [275, 285, "Test_Value"], [286, 290, "Test_items"], [290, 295, "Test_Value"], [296, 300, "Test_items"], [300, 311, "Test_Value"], [312, 318, "Test_items"], [318, 323, "Test_Value"], [324, 328, "Test"], [329, 333, "Disease"], [333, 335, "Anatomy"], [338, 340, "Test"], [340, 342, "Anatomy"], [352, 356, "Test"], [357, 361, "Symptom"], [362, 376, "Symptom"], [377, 388, "Test"], [97, 99, "Test_items"], [389, 404, "Symptom"], [405, 408, "Anatomy"], [413, 423, "Test"], [425, 442, "Symptom"], [445, 449, "Anatomy"], [450, 456, "Anatomy"], [460, 464, "Symptom"], [457, 459, "Anatomy"], [470, 485, "Symptom"], [486, 504, "Symptom"]], "rel": [[59, 63, "Test_items", 329, 333, "Disease", "Test_items_Disease"], [126, 128, "Test_items", 329, 333, "Disease", "Test_items_Disease"]]}
{"idx": 227, "sentence": "男性，59岁，因糖尿病16年，右足红肿10d于2009年6月19日入院。无高血压、冠心病、脑梗死既往病史，吸烟30年。入院后查体及检查：体温38.6℃。急性病容，心率102次/min。双下肢可见皮肤色素沉着斑，右足红肿，局部皮温高，右足第2、4足趾皮肤暗黑，第3趾坏疽，双足背动脉搏动弱（图1）。血红蛋白102g/L（正常参考值120~160g/L，下同），白细胞22.9 X 109/L（4 X 109~10 X 109），中性粒细胞83%（50%~75%），血小板324X109/L（100X109~300X109），血糖24.6mmol/L，HbA1C11.2%。心电图基本正常。踝肱指数（ABI）：左侧0.92~1.08（0.9~1.3），右侧0.50~0.67。DSA血管造影：右侧股浅动脉中段中鄄重度狭窄，股深动脉血管尚畅；腘动脉管腔无狭窄，胫前动脉多发狭窄，腓动脉和胫后动脉不显影。眼底：视网膜病变3期。足部分泌物多次培养：变形杆菌、表皮葡萄球菌、金黄色葡萄球菌。入院后诊断：2型糖尿病，足溃疡并感染（Wagner4级），下肢血管病变，周围神经病变，肾病，视网膜病变，轻度贫血。", "ner": [[8, 11, "Disease"], [11, 14, "Duration"], [15, 19, "Symptom"], [19, 22, "Duration"], [37, 40, "Disease"], [41, 44, "Disease"], [45, 48, "Disease"], [55, 58, "Duration"], [68, 70, "Test_items"], [70, 75, "Test_Value"], [76, 80, "Symptom"], [81, 83, "Test_items"], [83, 91, "Test_Value"], [92, 95, "Anatomy"], [97, 104, "Symptom"], [105, 109, "Symptom"], [110, 115, "Symptom"], [124, 128, "Symptom"], [116, 124, "Anatomy"], [132, 134, "Symptom"], [129, 132, "Anatomy"], [135, 143, "Symptom"], [148, 152, "Test_items"], [152, 158, "Test_Value"], [164, 174, "Test_Value"], [179, 182, "Test_items"], [182, 194, "Test_Value"], [195, 211, "Test_Value"], [213, 218, "Test_items"], [218, 221, "Test_Value"], [222, 229, "Test_Value"], [231, 234, "Test_items"], [234, 243, "Test_Value"], [244, 259, "Test_Value"], [261, 263, "Test_items"], [263, 273, "Test_Value"], [274, 279, "Test_items"], [279, 284, "Test_Value"], [293, 302, "Test_items"], [305, 314, "Test_Value"], [315, 322, "Test_Value"], [326, 335, "Test_Value"], [336, 343, "Test"], [285, 288, "Test"], [377, 385, "Symptom"], [386, 397, "Symptom"], [401, 406, "Disease"], [409, 411, "Anatomy"], [344, 358, "Symptom"], [359, 365, "Anatomy"], [368, 373, "Anatomy"], [374, 376, "Symptom"], [445, 450, "Disease"], [451, 454, "Symptom"], [455, 457, "Symptom"], [468, 474, "Disease"], [475, 481, "Disease"], [482, 484, "Disease"], [485, 490, "Disease"], [491, 493, "Level"], [493, 495, "Disease"]], "rel": [[97, 104, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [105, 109, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [76, 80, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [15, 19, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [110, 115, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [124, 128, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [132, 134, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [135, 143, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [344, 358, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [374, 376, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [377, 385, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [386, 397, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [451, 454, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [455, 457, "Symptom", 468, 474, "Disease", "Symptom_Disease"], [92, 95, "Anatomy", 468, 474, "Disease", "Anatomy_Disease"], [359, 365, "Anatomy", 468, 474, "Disease", "Anatomy_Disease"], [368, 373, "Anatomy", 468, 474, "Disease", "Anatomy_Disease"], [148, 152, "Test_items", 445, 450, "Disease", "Test_items_Disease"], [179, 182, "Test_items", 445, 450, "Disease", "Test_items_Disease"], [231, 234, "Test_items", 445, 450, "Disease", "Test_items_Disease"], [261, 263, "Test_items", 445, 450, "Disease", "Test_items_Disease"], [274, 279, "Test_items", 445, 450, "Disease", "Test_items_Disease"], [293, 302, "Test_items", 468, 474, "Disease", "Test_items_Disease"], [336, 343, "Test", 468, 474, "Disease", "Test_Disease"], [401, 406, "Disease", 445, 450, "Disease", "Disease_Disease"], [468, 474, "Disease", 445, 450, "Disease", "Disease_Disease"], [475, 481, "Disease", 445, 450, "Disease", "Disease_Disease"], [482, 484, "Disease", 445, 450, "Disease", "Disease_Disease"]]}
{"idx": 228, "sentence": "男性，59岁，因高血糖6年，右第2趾发黑、外踝溃烂1个月余于2010年5月6日入院。既往有高血压、血脂异常、脑梗死病史，遗有右侧肢体活动障碍。2007年曾行左下肢血管搭桥手术。吸烟、饮酒30年。入院后查体及检查：神志清，右上肢肌力2级，肌张力增强，右手呈痉挛状。右下肢肌力3级，感觉减退。双下肢无水肿，双足皮温低，足背动脉搏动减弱。左足第2趾缺如；右足外踝3cmX2cm溃疡，表面少许硬痂，第 2 趾发黑,周围皮肤红肿（ 图 2） 。 足部分泌物多次培养：不动杆菌、金黄色葡萄球菌。血白细胞 5. 8 X 109 / L，血红蛋白119 g / L，HbA1c 8. 1% 。 踝肱指数：左胫后动脉0. 62,左足背动 脉未探及；右侧动脉血管未探及。DSA造影示：右侧股浅动脉多发狭窄、闭塞，腘动脉中度狭窄，胫前动脉、胫后动脉起始部中度狭窄-闭塞，全程断续显影，腓动脉管壁不整，血流速度慢，远端足部动脉弓延迟显影。 眼底：视网膜病变。 入院后诊断为2型糖尿病、足坏疽（ Wagner 4 级） 、下肢动脉闭塞症、神经病变、高血压病、脑梗死后遗症、左下肢动脉搭桥术后、右髋关节骨折术后。", "ner": [[8, 11, "Disease"], [11, 13, "Duration"], [14, 20, "Symptom"], [21, 25, "Symptom"], [25, 29, "Duration"], [45, 48, "Disease"], [54, 57, "Disease"], [49, 53, "Disease"], [62, 70, "Symptom"], [78, 87, "Operation"], [93, 96, "Duration"], [110, 113, "Anatomy"], [113, 115, "Test_items"], [115, 117, "Test_Value"], [118, 123, "Symptom"], [124, 130, "Symptom"], [131, 134, "Anatomy"], [134, 136, "Test_items"], [136, 138, "Test_Value"], [139, 143, "Symptom"], [144, 147, "Anatomy"], [148, 150, "Symptom"], [151, 156, "Symptom"], [157, 165, "Symptom"], [166, 171, "Anatomy"], [174, 178, "Anatomy"], [178, 185, "Level"], [185, 187, "Symptom"], [188, 194, "Symptom"], [195, 202, "Symptom"], [203, 209, "Symptom"], [218, 220, "Anatomy"], [241, 245, "Test_items"], [246, 260, "Test_Value"], [261, 265, "Test_items"], [265, 274, "Test_Value"], [275, 280, "Test_items"], [281, 286, "Test_Value"], [305, 311, "Anatomy"], [315, 321, "Anatomy"], [325, 330, "Test"], [332, 342, "Symptom"], [343, 345, "Symptom"], [346, 353, "Symptom"], [354, 358, "Anatomy"], [359, 363, "Anatomy"], [366, 368, "Level"], [368, 370, "Symptom"], [371, 373, "Symptom"], [374, 380, "Symptom"], [381, 388, "Symptom"], [389, 394, "Symptom"], [395, 406, "Symptom"], [408, 410, "Anatomy"], [411, 416, "Disease"], [424, 429, "Disease"], [430, 433, "Disease"], [448, 455, "Disease"], [456, 460, "Disease"], [461, 465, "Disease"], [466, 472, "Disease"], [473, 481, "Operation"], [483, 490, "Operation"], [289, 293, "Test_items"], [294, 304, "Test_Value"]], "rel": [[14, 20, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [14, 20, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [21, 25, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [62, 70, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [118, 123, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [139, 143, "Symptom", 456, 460, "Disease", "Symptom_Disease"], [148, 150, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [151, 156, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [151, 156, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [157, 165, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [157, 165, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [185, 187, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [188, 194, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [195, 202, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [203, 209, "Symptom", 430, 433, "Disease", "Symptom_Disease"], [332, 342, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [368, 370, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [346, 353, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [343, 345, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [374, 380, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [381, 388, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [389, 394, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [395, 406, "Symptom", 448, 455, "Disease", "Symptom_Disease"], [131, 134, "Anatomy", 448, 455, "Disease", "Anatomy_Disease"], [144, 147, "Anatomy", 448, 455, "Disease", "Anatomy_Disease"], [166, 171, "Anatomy", 430, 433, "Disease", "Anatomy_Disease"], [174, 178, "Anatomy", 430, 433, "Disease", "Anatomy_Disease"], [218, 220, "Anatomy", 430, 433, "Disease", "Anatomy_Disease"], [315, 321, "Anatomy", 448, 455, "Disease", "Anatomy_Disease"], [305, 311, "Anatomy", 448, 455, "Disease", "Anatomy_Disease"], [354, 358, "Anatomy", 448, 455, "Disease", "Anatomy_Disease"], [359, 363, "Anatomy", 448, 455, "Disease", "Anatomy_Disease"], [408, 410, "Anatomy", 411, 416, "Disease", "Anatomy_Disease"], [325, 330, "Test", 448, 455, "Disease", "Test_Disease"], [473, 481, "Operation", 448, 455, "Disease", "Operation_Disease"], [261, 265, "Test_items", 424, 429, "Disease", "Test_items_Disease"], [241, 245, "Test_items", 424, 429, "Disease", "Test_items_Disease"], [275, 280, "Test_items", 424, 429, "Disease", "Test_items_Disease"], [78, 87, "Operation", 448, 455, "Disease", "Operation_Disease"], [411, 416, "Disease", 424, 429, "Disease", "Disease_Disease"], [448, 455, "Disease", 424, 429, "Disease", "Disease_Disease"], [456, 460, "Disease", 424, 429, "Disease", "Disease_Disease"], [430, 433, "Disease", 424, 429, "Disease", "Disease_Disease"], [289, 293, "Test_items", 45, 48, "Disease", "Test_items_Disease"]]}
{"idx": 229, "sentence": "女性，57岁，因糖尿病12年，左足溃烂2周于2010年7月28日入院。既往有高血压病史，无吸烟史。入院后查体及检查：双下肢轻度浮肿。左前足肿胀明显，第3趾明显溃烂，趾背部皮肤缺损，残存皮肤发紫，足底跖趾关节处溃烂，向足背部贯通，第2、4跖趾关节处皮肤溃烂，可见异常分泌物（图3）。左足明显触压痛。白细胞5.9X109/L，血红蛋白101g/L，HbA1C11.0%，血沉50mm/h（0~15）。踝肱指数：左侧0.93~1.07，右侧0.93~1.06。双下肢磁共振示：双下肢动脉多发狭窄并左下肢静脉早期显影。入院后诊断为糖尿病、足溃疡并感染（Wanger3级）、神经病变、高血压病、下肢血管病变、贫血。", "ner": [[8, 11, "Disease"], [11, 14, "Duration"], [15, 19, "Symptom"], [19, 21, "Duration"], [58, 65, "Symptom"], [66, 71, "Symptom"], [74, 77, "Anatomy"], [79, 81, "Symptom"], [82, 89, "Symptom"], [92, 96, "Symptom"], [97, 106, "Symptom"], [108, 111, "Anatomy"], [114, 122, "Anatomy"], [123, 127, "Symptom"], [144, 147, "Symptom"], [140, 142, "Anatomy"], [148, 151, "Test_items"], [151, 160, "Test_Value"], [161, 165, "Test_items"], [165, 171, "Test_Value"], [172, 177, "Test_items"], [177, 182, "Test_Value"], [183, 185, "Test_items"], [185, 191, "Test_Value"], [192, 196, "Test_Value"], [227, 233, "Test"], [235, 244, "Symptom"], [245, 254, "Symptom"], [261, 264, "Disease"], [269, 271, "Symptom"], [265, 268, "Symptom"], [282, 286, "Disease"], [287, 291, "Disease"], [292, 298, "Disease"], [299, 301, "Disease"], [198, 202, "Test_items"], [203, 214, "Test_Value"], [215, 226, "Test_Value"]], "rel": [[15, 19, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [58, 65, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [66, 71, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [79, 81, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [82, 89, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [92, 96, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [97, 106, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [123, 127, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [144, 147, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [235, 244, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [269, 271, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [265, 268, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [245, 254, "Symptom", 292, 298, "Disease", "Symptom_Disease"], [148, 151, "Test_items", 261, 264, "Disease", "Test_items_Disease"], [161, 165, "Test_items", 261, 264, "Disease", "Test_items_Disease"], [172, 177, "Test_items", 261, 264, "Disease", "Test_items_Disease"], [183, 185, "Test_items", 261, 264, "Disease", "Test_items_Disease"], [227, 233, "Test", 292, 298, "Disease", "Test_Disease"], [292, 298, "Disease", 261, 264, "Disease", "Disease_Disease"], [282, 286, "Disease", 261, 264, "Disease", "Disease_Disease"], [287, 291, "Disease", 261, 264, "Disease", "Disease_Disease"], [198, 202, "Test_items", 287, 291, "Disease", "Test_items_Disease"]]}
{"idx": 230, "sentence": "女性，67岁，因血糖升高30年，右足溃烂2周于2010年8月10日入院。既往有冠心病史，否认高血压病、脑梗死病史。有青链霉素过敏史。否认烟酒史。入院后查体及检查：急性病容，轻度贫血貌，体温37.3℃。双下肢轻度水肿，左足背动脉搏动正常，右足背部可见大小约10cmX6cm大小创面，上覆坏死脂肪及肌腱组织，第4趾坏疽，右足周围组织红肿至踝上约10cm。血白细胞15.5X109/L，血红蛋白80g/L，血小板411.1X109/L，中性粒细胞83.7%，HbA1C10.9%，超敏C反应蛋白12.73mg/L（0~3.0），血清铁3.9μmol/L（10.7~26.9），血沉82mm/h，尿A/C466mg/g（<30），血钠132mmol/L（135~145），血氯93mmol/L（96~108）。踝肱指数：左侧0.94，右侧有伤口未测。下肢核磁造影：双侧下肢动脉多发狭窄改变，以双侧小腿动脉为著，右足软组织染色并静脉回流提前，考虑感染性病变可能。多次足溃疡处分泌物培养：铜绿假单胞菌、摩氏摩根菌、肺炎克雷伯杆菌、不动杆菌。入院后诊断为糖尿病、足溃疡并感染（Wagner4级）、神经病变、视网膜病变、下肢动脉闭塞症、冠心病、糖尿病神经源性膀胱、贫血。使用胰岛素控制血糖；静脉点滴头孢替安、盐酸莫西沙星、甲硝唑抗染；退热、导尿、输注红细胞悬液等对症处理；足溃疡清创引流（图4）。", "ner": [[8, 10, "Test_items"], [10, 12, "Test_Value"], [12, 15, "Duration"], [16, 20, "Symptom"], [20, 22, "Duration"], [46, 50, "Disease"], [51, 54, "Disease"], [81, 85, "Symptom"], [86, 91, "Symptom"], [92, 94, "Test_items"], [94, 99, "Test_Value"], [100, 107, "Symptom"], [108, 113, "Anatomy"], [118, 122, "Anatomy"], [124, 135, "Level"], [147, 149, "Anatomy"], [152, 155, "Anatomy"], [155, 157, "Symptom"], [158, 166, "Symptom"], [167, 169, "Anatomy"], [169, 174, "Level"], [175, 179, "Test_items"], [179, 189, "Test_Value"], [190, 194, "Test_items"], [194, 199, "Test_Value"], [200, 203, "Test_items"], [203, 214, "Test_Value"], [215, 220, "Test_items"], [220, 225, "Test_Value"], [226, 231, "Test_items"], [231, 236, "Test_Value"], [237, 244, "Test_items"], [244, 253, "Test_Value"], [254, 259, "Test_Value"], [261, 264, "Test_items"], [264, 273, "Test_Value"], [274, 283, "Test_Value"], [285, 287, "Test_items"], [287, 293, "Test_Value"], [294, 298, "Test_items"], [298, 305, "Test_Value"], [306, 309, "Test_Value"], [311, 313, "Test_items"], [313, 322, "Test_Value"], [323, 330, "Test_Value"], [332, 334, "Test_items"], [334, 342, "Test_Value"], [343, 349, "Test_Value"], [351, 355, "Test_items"], [356, 362, "Test_Value"], [371, 377, "Test"], [378, 390, "Symptom"], [392, 398, "Anatomy"], [401, 408, "Symptom"], [409, 415, "Symptom"], [418, 423, "Symptom"], [428, 429, "Anatomy"], [470, 473, "Disease"], [474, 477, "Symptom"], [478, 480, "Symptom"], [491, 495, "Disease"], [496, 501, "Disease"], [502, 509, "Disease"], [510, 513, "Disease"], [514, 523, "Disease"], [524, 526, "Disease"], [529, 532, "Drug"], [534, 536, "Test_items"], [537, 541, "Method"], [541, 545, "Drug"], [546, 552, "Drug"], [553, 556, "Drug"], [565, 572, "Treatment"], [562, 564, "Treatment"], [578, 581, "Symptom"], [581, 583, "Operation"], [583, 585, "Treatment"]], "rel": [[8, 10, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [175, 179, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [190, 194, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [200, 203, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [215, 220, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [226, 231, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [237, 244, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [261, 264, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [285, 287, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [294, 298, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [311, 313, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [332, 334, "Test_items", 470, 473, "Disease", "Test_items_Disease"], [351, 355, "Test_items", 46, 50, "Disease", "Test_items_Disease"], [86, 91, "Symptom", 524, 526, "Disease", "Symptom_Disease"], [81, 85, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [16, 20, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [100, 107, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [155, 157, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [158, 166, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [378, 390, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [401, 408, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [409, 415, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [418, 423, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [474, 477, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [478, 480, "Symptom", 502, 509, "Disease", "Symptom_Disease"], [392, 398, "Anatomy", 502, 509, "Disease", "Anatomy_Disease"], [541, 545, "Drug", 502, 509, "Disease", "Drug_Disease"], [546, 552, "Drug", 502, 509, "Disease", "Drug_Disease"], [529, 532, "Drug", 470, 473, "Disease", "Drug_Disease"], [553, 556, "Drug", 502, 509, "Disease", "Drug_Disease"], [562, 564, "Treatment", 514, 523, "Disease", "Treatment_Disease"], [565, 572, "Treatment", 524, 526, "Disease", "Treatment_Disease"], [583, 585, "Treatment", 502, 509, "Disease", "Treatment_Disease"], [581, 583, "Operation", 502, 509, "Disease", "Operation_Disease"], [502, 509, "Disease", 470, 473, "Disease", "Disease_Disease"], [496, 501, "Disease", 470, 473, "Disease", "Disease_Disease"], [491, 495, "Disease", 470, 473, "Disease", "Disease_Disease"], [514, 523, "Disease", 470, 473, "Disease", "Disease_Disease"]]}
{"idx": 231, "sentence": "74岁的李伯患糖尿病10年了，一次他不小心擦伤左脚趾皮肤，由于不痛不痒，李伯并没在意。然而过了一段时间，伤口开始化脓溃疡，并且发黑，发出腐臭气味。医生诊断为糖尿病足坏痘，建议截肢。听闻要截肢，李伯痛不欲生，这个消息带给他的痛苦甚至远甚于当年获悉自己被诊断为糖尿病。后来，他的子女在网上查到了济南糖尿病医院，抱着后的希望，来到我院治疗。经过我院医生的诊治，终用“捷生保足疗法保住了他的双腿，治好了他的糖尿病足", "ner": [[7, 10, "Disease"], [10, 13, "Duration"], [56, 60, "Symptom"], [63, 65, "Symptom"], [68, 72, "Symptom"], [78, 82, "Disease"], [87, 89, "Operation"], [93, 95, "Operation"], [128, 131, "Disease"], [199, 203, "Disease"], [191, 193, "Anatomy"], [180, 186, "Treatment"], [23, 26, "Anatomy"]], "rel": [[56, 60, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [63, 65, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [68, 72, "Symptom", 78, 82, "Disease", "Symptom_Disease"], [87, 89, "Operation", 78, 82, "Disease", "Operation_Disease"], [180, 186, "Treatment", 78, 82, "Disease", "Treatment_Disease"], [78, 82, "Disease", 7, 10, "Disease", "Disease_Disease"], [23, 26, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"]]}
{"idx": 232, "sentence": "人自欣老人92岁高龄，本应享受安乐的晚年，却被糖尿病足折磨得寝食不安，为了治好自己的糖尿病足，他辗转郑州各大医院，病情却并没有得到改善，反而愈演愈烈，终出现第三四五趾溃疡部位出现脓性分沙物，并伴有臭味，左足背侧红肿，伴色素沉着，终得到的各医院的诊治结果却都是截肢。后来，他在网络上看到了济南糖尿病医院能不截肢治疗糖尿病足，便在子女的陪伴下前来治疗。济南糖尿病医院的专家为他采用了“捷生”保足疗法，不截肢治好了他的糖尿病足。", "ner": [[23, 27, "Disease"], [42, 46, "Disease"], [78, 83, "Anatomy"], [89, 94, "Symptom"], [98, 100, "Symptom"], [101, 107, "Symptom"], [109, 113, "Symptom"], [129, 131, "Operation"], [156, 160, "Disease"], [189, 197, "Treatment"], [152, 154, "Operation"], [199, 201, "Operation"], [206, 210, "Disease"]], "rel": [[189, 197, "Treatment", 206, 210, "Disease", "Treatment_Disease"], [89, 94, "Symptom", 206, 210, "Disease", "Symptom_Disease"], [98, 100, "Symptom", 206, 210, "Disease", "Symptom_Disease"], [101, 107, "Symptom", 206, 210, "Disease", "Symptom_Disease"], [109, 113, "Symptom", 206, 210, "Disease", "Symptom_Disease"], [152, 154, "Operation", 206, 210, "Disease", "Operation_Disease"], [78, 83, "Anatomy", 206, 210, "Disease", "Anatomy_Disease"], [206, 210, "Disease", 23, 27, "Disease", "Disease_Disease"]]}
{"idx": 233, "sentence": "75岁的张桂兰老人，患有糖尿病多年，发现左脚跨趾出现溃疡后，在当地医院做了相关检查，并接受了相关治疗，好转后出院，后来左脚海趾又一次出现了溃疡。为求治好，患者的儿女带患者去了北京、上海等多家大医院，可治疗效果都不佳，很多医院都让截肢，可老人一想到要截肢，就说还不如死了算了。后来患者的儿子上网看到济南糖尿病医院的“捷生”保足疗法能不截肢治疗糖尿病足，便带着他一起来我院接受治疗。我院专家采用“捷生”保足疗法治好了老人的糖尿病足，保住了他的腿", "ner": [[12, 15, "Disease"], [26, 28, "Symptom"], [20, 24, "Anatomy"], [59, 63, "Anatomy"], [69, 71, "Symptom"], [114, 116, "Operation"], [124, 126, "Operation"], [156, 164, "Treatment"], [166, 168, "Operation"], [170, 174, "Disease"], [195, 203, "Treatment"], [209, 213, "Disease"], [219, 220, "Anatomy"]], "rel": [[20, 24, "Anatomy", 170, 174, "Disease", "Anatomy_Disease"], [59, 63, "Anatomy", 170, 174, "Disease", "Anatomy_Disease"], [124, 126, "Operation", 170, 174, "Disease", "Operation_Disease"], [156, 164, "Treatment", 170, 174, "Disease", "Treatment_Disease"], [26, 28, "Symptom", 170, 174, "Disease", "Symptom_Disease"], [170, 174, "Disease", 12, 15, "Disease", "Disease_Disease"]]}
{"idx": 234, "sentence": "62岁的糖尿病患者王大爷患有足癣20多年，先是脚趾间起了很痒的水疱，痒得让人忍不住去抓，抓破了水疱就开始流脓溃烂，并且伴随着发烧症状。到医院检查，医生确诊王大爷得了糖尿病，引发的脚部溃烂经久不愈。在北京世纪坛医院，王江宁教授通过检查，为王大爷制定了一个完整的治疗方案，经过对血糖的控制医疗和坚持换药，目前王大爷的脚部溃烂得到了很好的控制.免除了截肢的痛苦。", "ner": [[4, 7, "Disease"], [14, 16, "Disease"], [16, 20, "Duration"], [31, 33, "Symptom"], [23, 25, "Anatomy"], [47, 49, "Symptom"], [52, 56, "Symptom"], [62, 64, "Symptom"], [82, 85, "Disease"], [89, 93, "Symptom"], [93, 97, "Symptom"], [137, 139, "Test_items"], [156, 160, "Symptom"], [172, 174, "Operation"]], "rel": [[137, 139, "Test_items", 82, 85, "Disease", "Test_items_Disease"]]}
{"idx": 235, "sentence": "患者，杨XX，女，56岁，（石家庄市桥西区振二街）（病历号：40828）。主因口渴、多饮、消瘦8年，左足跟坏疽3个月于2009-02-12-15：30住院治疗。患者于2001年前出现口渴多饮、消瘦，查血糖升高诊断为“2型糖尿病”。口服多种药物，血糖控制不佳。2年前左足小趾因溃烂、坏疽，小趾脱落。曾注射“普通胰岛素”，血糖控制不佳，后自行停用。2年来，患者不规律应用降糖药，伴有口渴多饮，尿频。3个月前，患者不慎扭伤左足，左足底出现红肿疼痛，自用红花油涂擦后，足底红肿好转，左足跟出现红肿疼痛，水泡形成，渐致左足跟溃疡。在我院查下肢彩超：左股浅动脉狭窄。给予降糖、消炎、股动脉注射及换药治疗，患者血糖稳定，病情好转后出院。出院后患者自行停用胰岛素，双下肢疼痛，尤以左下肢为重，左足跟开始发黑坏死。入院时症见口渴多饮，双下肢疼痛，左足疼痛较重，夜间加重，行走困难，夜不能寐，左足根溃烂发黑，口渴多饮，二便正常。查体：T36.0℃  P90次/分  BP 130／80mmHg，消瘦体型，左足跟处约2.5×4.0㎝黑色坏疽，坏疽皮肤呈硬痂，周围有少许分泌物渗出。左腘动脉、踝动脉、足背动脉搏动消失。辅助检查：随机血糖22.4 mmol/L；尿微量白蛋白26.3mg/L；糖化血红蛋白14.1%。", "ner": [[39, 41, "Symptom"], [42, 44, "Symptom"], [45, 47, "Symptom"], [47, 49, "Duration"], [50, 55, "Symptom"], [55, 58, "Duration"], [91, 93, "Symptom"], [93, 95, "Symptom"], [96, 98, "Symptom"], [100, 102, "Test_items"], [102, 104, "Test_Value"], [108, 113, "Disease"], [122, 124, "Test_items"], [132, 136, "Anatomy"], [137, 139, "Symptom"], [140, 142, "Symptom"], [143, 147, "Symptom"], [152, 157, "Drug"], [149, 151, "Method"], [159, 161, "Test_items"], [189, 191, "Symptom"], [191, 193, "Symptom"], [194, 196, "Symptom"], [208, 210, "Anatomy"], [211, 214, "Anatomy"], [223, 226, "Drug"], [230, 232, "Anatomy"], [237, 240, "Anatomy"], [216, 220, "Symptom"], [242, 246, "Symptom"], [247, 249, "Symptom"], [254, 259, "Symptom"], [264, 268, "Test"], [269, 276, "Symptom"], [285, 288, "Anatomy"], [288, 290, "Method"], [298, 300, "Test_items"], [320, 323, "Drug"], [324, 329, "Symptom"], [332, 335, "Anatomy"], [338, 341, "Anatomy"], [343, 347, "Symptom"], [353, 355, "Symptom"], [355, 357, "Symptom"], [358, 363, "Symptom"], [364, 368, "Symptom"], [368, 370, "Level"], [336, 337, "Level"], [373, 375, "Level"], [376, 380, "Symptom"], [389, 393, "Symptom"], [386, 389, "Anatomy"], [394, 396, "Symptom"], [396, 398, "Symptom"], [407, 408, "Test_items"], [408, 413, "Test_Value"], [415, 416, "Test_items"], [416, 421, "Test_Value"], [422, 425, "Test_items"], [426, 436, "Test_Value"], [437, 439, "Symptom"], [442, 445, "Anatomy"], [446, 455, "Level"], [455, 459, "Symptom"], [460, 467, "Symptom"], [471, 478, "Symptom"], [492, 496, "Symptom"], [479, 483, "Anatomy"], [484, 487, "Anatomy"], [488, 492, "Anatomy"], [502, 506, "Test_items"], [506, 517, "Test_Value"], [518, 524, "Test_items"], [524, 532, "Test_Value"], [533, 539, "Test_items"], [539, 544, "Test_Value"], [115, 117, "Method"]], "rel": [[152, 157, "Drug", 108, 113, "Disease", "Drug_Disease"], [320, 323, "Drug", 108, 113, "Disease", "Drug_Disease"], [100, 102, "Test_items", 108, 113, "Disease", "Test_items_Disease"], [502, 506, "Test_items", 108, 113, "Disease", "Test_items_Disease"], [518, 524, "Test_items", 108, 113, "Disease", "Test_items_Disease"], [533, 539, "Test_items", 108, 113, "Disease", "Test_items_Disease"], [39, 41, "Symptom", 108, 113, "Disease", "Symptom_Disease"], [42, 44, "Symptom", 108, 113, "Disease", "Symptom_Disease"], [45, 47, "Symptom", 108, 113, "Disease", "Symptom_Disease"], [194, 196, "Symptom", 108, 113, "Disease", "Symptom_Disease"]]}
{"idx": 236, "sentence": "糖尿病足是糖尿病的一种慢性严重并发症，早期清创或许可以保全病足，但是如果治疗不及时，后期只能截肢。82岁的秦爷爷曾经就因为患糖尿病足被多家医院建议截肢。秦爷爷患糖尿病将近20年，长期血糖控制不好使他患上了糖尿病足，并且患肢处皮肤发黑、溃烂。而糖尿病足患者足部一旦溃烂，伤口很难愈合，对于年岁较大的秦爷爷更是如此，行动不便，只能卧床生活,饱受病痛折磨。", "ner": [[0, 4, "Disease"], [5, 8, "Disease"], [21, 23, "Operation"], [30, 31, "Anatomy"], [46, 48, "Operation"], [62, 66, "Disease"], [73, 75, "Operation"], [80, 83, "Disease"], [83, 88, "Duration"], [91, 93, "Test_items"], [102, 106, "Disease"], [112, 116, "Symptom"], [117, 119, "Symptom"], [121, 125, "Disease"], [127, 129, "Anatomy"], [131, 133, "Symptom"], [134, 140, "Symptom"]], "rel": [[112, 116, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [117, 119, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [134, 140, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [91, 93, "Test_items", 5, 8, "Disease", "Test_items_Disease"], [21, 23, "Operation", 0, 4, "Disease", "Operation_Disease"], [46, 48, "Operation", 0, 4, "Disease", "Operation_Disease"], [127, 129, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [30, 31, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [0, 4, "Disease", 5, 8, "Disease", "Disease_Disease"]]}
{"idx": 237, "sentence": "患者，梁某某，男，62岁，以“左足糖尿病足感染2月余”就诊于伤口造口门诊，就诊时左足伴有严重臭味，有大量黄色渗液。既往有糖尿病病史7年余，平时口服降糖药物，血糖控制不佳。一年前，因糖尿病足并发感染在西安行手术治疗。", "ner": [[17, 21, "Disease"], [21, 23, "Symptom"], [15, 17, "Anatomy"], [23, 26, "Duration"], [44, 48, "Symptom"], [40, 42, "Anatomy"], [50, 56, "Symptom"], [60, 63, "Disease"], [65, 68, "Duration"], [71, 73, "Method"], [78, 80, "Test_items"], [90, 94, "Disease"], [96, 98, "Symptom"]], "rel": [[21, 23, "Symptom", 17, 21, "Disease", "Symptom_Disease"], [44, 48, "Symptom", 17, 21, "Disease", "Symptom_Disease"], [50, 56, "Symptom", 17, 21, "Disease", "Symptom_Disease"], [40, 42, "Anatomy", 17, 21, "Disease", "Anatomy_Disease"], [17, 21, "Disease", 60, 63, "Disease", "Disease_Disease"], [78, 80, "Test_items", 60, 63, "Disease", "Test_items_Disease"]]}
{"idx": 238, "sentence": "主诉：血糖升高10年余、双足溃烂6月余出现糖尿病足溃烂发黑及就诊史：患糖尿病10年，在这期间未规律服用降糖药物、也未顶底检测血糖，在一次晚上泡脚时左侧足背外侧被烫出直径约1.5cn水泡，水泡破裂逐渐出现皮肤溃烂发红现象，伴有脓性分泌物未给予重视。1个月之后右足跟部逐渐溃烂、在当地卫生院行外涂药物涂抹治疗，效果不佳，皮肤溃烂逐渐加重，之后就诊于当地某医院烧烫伤科，住院给予清创及药物治疗，效果不加，病情一直控住不住，被当地医院建议截肢治疗，为了进一步的能不截肢治疗而转入商丘五院足病科，通过综合、系统、规范化治疗后患者保守不截肢康复。", "ner": [[3, 5, "Test_items"], [5, 7, "Test_Value"], [7, 11, "Duration"], [12, 16, "Symptom"], [16, 19, "Duration"], [21, 25, "Disease"], [25, 27, "Symptom"], [27, 29, "Symptom"], [35, 38, "Disease"], [38, 41, "Duration"], [62, 64, "Test_items"], [90, 92, "Symptom"], [82, 90, "Level"], [73, 79, "Anatomy"], [101, 107, "Symptom"], [112, 117, "Symptom"], [128, 132, "Anatomy"], [134, 136, "Symptom"], [148, 150, "Method"], [158, 162, "Symptom"], [164, 166, "Level"], [186, 188, "Operation"], [215, 217, "Operation"], [228, 230, "Operation"], [262, 264, "Operation"]], "rel": [[12, 16, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [25, 27, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [27, 29, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [90, 92, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [112, 117, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [101, 107, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [158, 162, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [21, 25, "Disease", 35, 38, "Disease", "Disease_Disease"], [3, 5, "Test_items", 35, 38, "Disease", "Test_items_Disease"], [73, 79, "Anatomy", 21, 25, "Disease", "Anatomy_Disease"], [128, 132, "Anatomy", 21, 25, "Disease", "Anatomy_Disease"], [186, 188, "Operation", 21, 25, "Disease", "Operation_Disease"], [215, 217, "Operation", 21, 25, "Disease", "Operation_Disease"]]}
{"idx": 239, "sentence": "肖某某 性别：女 年龄：52岁 籍贯：内蒙古主诉：发现足溃烂伴血糖高2月余出现糖尿病足溃烂发黑及就诊史：右足足趾先是出现水泡并逐渐溃烂，发现病情逐渐加重就去当地医院进行诊断检查才发现自己血糖高，经在当地医院诊断为2型糖尿病，足部溃烂诊断为并发症糖尿病足，在当地医院就诊一周病情没有得到有效控制，为求进一步治疗，而转入商丘五院足病科，通过综合、系统、规范化治疗后患者保守不截肢康复。", "ner": [[27, 30, "Symptom"], [31, 33, "Test_items"], [33, 34, "Test_Value"], [34, 37, "Duration"], [39, 43, "Disease"], [52, 56, "Anatomy"], [60, 62, "Symptom"], [65, 67, "Symptom"], [74, 76, "Level"], [93, 95, "Test_items"], [95, 96, "Test_Value"], [106, 111, "Disease"], [112, 116, "Symptom"], [122, 126, "Disease"], [185, 187, "Operation"], [43, 45, "Symptom"], [45, 47, "Symptom"]], "rel": [[27, 30, "Symptom", 122, 126, "Disease", "Symptom_Disease"], [60, 62, "Symptom", 122, 126, "Disease", "Symptom_Disease"], [65, 67, "Symptom", 122, 126, "Disease", "Symptom_Disease"], [112, 116, "Symptom", 122, 126, "Disease", "Symptom_Disease"], [122, 126, "Disease", 106, 111, "Disease", "Disease_Disease"], [185, 187, "Operation", 122, 126, "Disease", "Operation_Disease"], [52, 56, "Anatomy", 122, 126, "Disease", "Anatomy_Disease"], [31, 33, "Test_items", 106, 111, "Disease", "Test_items_Disease"], [45, 47, "Symptom", 39, 43, "Disease", "Symptom_Disease"]]}
{"idx": 240, "sentence": "孔某某 性别：男 年龄：64 籍贯：河南信阳主诉：左足小脚趾及足背溃烂发黑1月余出现糖尿病足溃烂发黑及就诊史：病人在干农活时不慎将左足第4、5足趾间隙根部，当时只是皮皮肤擦伤，未见出血、并未在意，期间出现间断疼痛、发痒约10天后脚趾远端发黑伴坏死，在当地某医院经过一段时间治疗后，效果不佳，被医生建议截肢治疗，为求进一步保守不截肢治疗好，而转入商丘五院足病科，通过综合、系统、规范化治疗后患者保守不截肢康复。", "ner": [[25, 30, "Anatomy"], [31, 33, "Anatomy"], [37, 40, "Duration"], [42, 46, "Disease"], [65, 77, "Anatomy"], [102, 106, "Symptom"], [107, 109, "Symptom"], [114, 118, "Anatomy"], [118, 120, "Symptom"], [121, 123, "Symptom"], [150, 152, "Operation"], [163, 165, "Operation"], [199, 201, "Operation"], [33, 35, "Symptom"], [35, 37, "Symptom"], [46, 48, "Symptom"], [48, 50, "Symptom"]], "rel": [[102, 106, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [118, 120, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [121, 123, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [107, 109, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [25, 30, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [31, 33, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [114, 118, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [65, 77, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [199, 201, "Operation", 42, 46, "Disease", "Operation_Disease"], [33, 35, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [35, 37, "Symptom", 42, 46, "Disease", "Symptom_Disease"]]}
{"idx": 241, "sentence": "男 年龄：61 籍贯：加拿大华侨主诉：糖尿病史20余年 左足趾溃烂发黑坏死2月余出现糖尿病足溃烂发黑及就诊史：在患糖尿病20年期间，间断治疗，血糖控制不佳，出现左足趾溃烂，呈进行式发展，足趾逐渐变黑，在加拿大温哥华某家医院就诊，患者拒绝高位截肢，为求进一步能不截肢治疗，而转入商丘五院足病科，通过综合、系统、规范化治疗后患者保守不截肢康复。", "ner": [[23, 27, "Duration"], [28, 31, "Anatomy"], [31, 33, "Symptom"], [33, 35, "Symptom"], [35, 37, "Symptom"], [37, 40, "Duration"], [42, 46, "Disease"], [46, 48, "Symptom"], [48, 50, "Symptom"], [57, 60, "Disease"], [60, 63, "Duration"], [71, 73, "Test_items"], [80, 85, "Symptom"], [93, 95, "Anatomy"], [97, 99, "Symptom"], [120, 122, "Operation"], [130, 132, "Operation"], [165, 167, "Operation"]], "rel": [[31, 33, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [33, 35, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [35, 37, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [80, 85, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [97, 99, "Symptom", 42, 46, "Disease", "Symptom_Disease"], [42, 46, "Disease", 57, 60, "Disease", "Disease_Disease"], [28, 31, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [93, 95, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [130, 132, "Operation", 42, 46, "Disease", "Operation_Disease"]]}
{"idx": 242, "sentence": "患者男性， 61岁，以“发现血糖升高12 年，左足第五趾关节处及足底溃疡1 个月”为主诉由某三。入院查体: 体温36.3℃，脉搏100次/分，呼吸20 次/分，血压145/90 mmHg，一般情况可，车推入病房。颈静脉无充盈，颈软，无抵抗。听诊双下肺少量湿公式音，未闻及干性公式音。心音可，律齐，未闻及早搏，心脏各瓣膜听诊区未闻及杂音。腹部查体未见明显异常。双足背凹陷性水肿。左下肢足较右侧明显肿胀，疼痛，湿度、皮肤感觉明显减退。双公式窝动脉搏动稍弱、双足背动脉搏动弱。双下肢肌张力、肌力5级。左足皮温高。病理征（-） 。左足第五趾关节处部可见一个约2 cm×2 cm×4 cm的腔洞。上下贯通，有溃烂面，周围皮肤红肿，可见脓性分泌物，探及一脓腔，内有脓性分泌物，与第五趾关节处创口贯穿。左足底有一大小约3 cm×3 cm的溃烂面，有2 cm×2 cm的引流口，脓性分泌物排出。入院后查血常规示，白细胞（WBC）为10.8×109/L，余基本上正常。心电图示窦性心动过速。入院诊断为: ① 2 型糖尿病合并足病3~4级；② 糖尿病视网膜病变。", "ner": [[14, 16, "Test_items"], [16, 18, "Test_Value"], [18, 22, "Duration"], [23, 31, "Anatomy"], [32, 34, "Anatomy"], [34, 36, "Symptom"], [36, 40, "Duration"], [54, 56, "Test_items"], [56, 61, "Test_Value"], [62, 64, "Test_items"], [64, 70, "Test_Value"], [71, 73, "Test_items"], [73, 79, "Test_Value"], [80, 82, "Test_items"], [82, 93, "Test_Value"], [106, 112, "Symptom"], [113, 115, "Symptom"], [117, 119, "Symptom"], [122, 131, "Symptom"], [154, 159, "Anatomy"], [168, 170, "Anatomy"], [179, 187, "Symptom"], [197, 199, "Symptom"], [200, 202, "Symptom"], [188, 192, "Anatomy"], [206, 214, "Symptom"], [215, 225, "Symptom"], [226, 234, "Symptom"], [235, 238, "Anatomy"], [242, 244, "Test_items"], [238, 241, "Test_items"], [244, 246, "Test_Value"], [247, 252, "Symptom"], [261, 269, "Anatomy"], [274, 289, "Level"], [305, 309, "Symptom"], [321, 323, "Symptom"], [333, 339, "Anatomy"], [344, 347, "Anatomy"], [351, 361, "Level"], [367, 376, "Level"], [325, 331, "Symptom"], [393, 396, "Test"], [398, 406, "Test_items"], [407, 417, "Test_Value"], [425, 428, "Test"], [429, 435, "Symptom"], [445, 451, "Disease"], [453, 455, "Disease"], [462, 470, "Disease"]], "rel": [[34, 36, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [179, 187, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [197, 199, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [200, 202, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [206, 214, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [215, 225, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [226, 234, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [305, 309, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [321, 323, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [325, 331, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [247, 252, "Symptom", 453, 455, "Disease", "Symptom_Disease"], [393, 396, "Test", 445, 451, "Disease", "Test_Disease"], [398, 406, "Test_items", 445, 451, "Disease", "Test_items_Disease"], [14, 16, "Test_items", 445, 451, "Disease", "Test_items_Disease"], [23, 31, "Anatomy", 453, 455, "Disease", "Anatomy_Disease"], [32, 34, "Anatomy", 453, 455, "Disease", "Anatomy_Disease"], [188, 192, "Anatomy", 453, 455, "Disease", "Anatomy_Disease"], [333, 339, "Anatomy", 453, 455, "Disease", "Anatomy_Disease"], [344, 347, "Anatomy", 453, 455, "Disease", "Anatomy_Disease"], [453, 455, "Disease", 445, 451, "Disease", "Disease_Disease"], [462, 470, "Disease", 445, 451, "Disease", "Disease_Disease"]]}
{"idx": 243, "sentence": "患者男，43 岁，因左足后跟外侧无明显诱因出现破溃来笔者科室治疗，破溃约3 cm ×3 cm ×3 cm，基底苍白伴坏死组织紧密附着，有明显渗出及异臭味，触痛不明显，双侧足背动脉搏动有力，双下肢血管彩超：双下肢动脉闭塞2 级，行左足溃疡清创术后创面缩小好转出院。患者出院后因左足破溃加重（图1），创面疼痛，发热，体温最高达39℃，伴畏寒、寒战，以“左足后跟外侧破溃5 周，加重伴发热4 d”再次收治入本院。", "ner": [[10, 16, "Anatomy"], [23, 25, "Symptom"], [33, 35, "Symptom"], [35, 52, "Level"], [53, 57, "Symptom"], [58, 66, "Symptom"], [70, 72, "Symptom"], [73, 76, "Symptom"], [77, 82, "Symptom"], [83, 89, "Anatomy"], [94, 101, "Test"], [102, 109, "Disease"], [114, 121, "Operation"], [137, 141, "Symptom"], [141, 143, "Level"], [150, 152, "Symptom"], [153, 155, "Symptom"], [156, 158, "Test_items"], [161, 164, "Test_Value"], [166, 168, "Symptom"], [169, 171, "Symptom"], [174, 180, "Anatomy"], [180, 182, "Symptom"], [182, 185, "Duration"], [186, 188, "Level"], [189, 191, "Symptom"], [191, 194, "Duration"]], "rel": [[23, 25, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [53, 57, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [58, 66, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [70, 72, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [73, 76, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [77, 82, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [137, 141, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [150, 152, "Symptom", 102, 109, "Disease", "Symptom_Disease"], [10, 16, "Anatomy", 102, 109, "Disease", "Anatomy_Disease"], [83, 89, "Anatomy", 102, 109, "Disease", "Anatomy_Disease"], [174, 180, "Anatomy", 102, 109, "Disease", "Anatomy_Disease"], [94, 101, "Test", 102, 109, "Disease", "Test_Disease"], [114, 121, "Operation", 102, 109, "Disease", "Operation_Disease"]]}
{"idx": 244, "sentence": "李女士，女，58岁，糖尿病史10年，平时口服降糖药二甲双胍和格列齐特，血糖控制不是太好，空腹血糖7.5mmol/L左右，一周前去田里劳动时不小心足底被一根木刺扎到，伤口并不深，也没怎么流血，回家后自行用酒精擦了擦，想着过几天不就好了，未做其他特殊处理。但情况继续恶化，三天后足底刺伤处出现了红肿，然后又化脓感染，在当地卫生院外科切开引流，换药两次，仍无好转，足部发出阵阵臭味，她也听说糖尿病人足部溃烂，严重时需要截肢！李女士十分害怕，最终决定前往市级医院，住进内分泌科治疗。入院后医生马上给她上了胰岛素泵，积极控制血糖、改善循环，每日清创换药，经过综合治疗，住院20多天伤口才逐渐愈合而出院。", "ner": [[14, 17, "Duration"], [20, 22, "Method"], [25, 29, "Drug"], [30, 34, "Drug"], [35, 37, "Test_items"], [44, 48, "Test_items"], [48, 57, "Test_Value"], [72, 74, "Anatomy"], [101, 103, "Drug"], [103, 104, "Method"], [105, 106, "Method"], [137, 139, "Anatomy"], [145, 147, "Symptom"], [151, 155, "Symptom"], [179, 181, "Anatomy"], [185, 187, "Symptom"], [196, 200, "Symptom"], [206, 208, "Operation"], [248, 252, "Method"], [257, 259, "Test_items"], [267, 269, "Operation"], [166, 168, "Treatment"]], "rel": [[20, 22, "Method", 25, 29, "Drug", "Method_Drug"], [20, 22, "Method", 30, 34, "Drug", "Method_Drug"], [103, 104, "Method", 101, 103, "Drug", "Method_Drug"]]}
{"idx": 245, "sentence": "周某，男，57岁，2022年9月22日初诊。右踝关节及双小腿中段后侧皮肤破溃、久不收口2月余。患者自诉既往有“糖尿病”病史20余年。2月余前无明显诱因出现双足、踝关节红肿疼痛、皮肤破溃，有渗出，曾到多家医院外科治疗，诊断为“糖尿病足”，予清创、换药、输液抗感染等治疗，双足红肿疼痛改善，但右踝关节皮肤破溃、久不收口，疗效不佳。期间患者在家自行做艾灸治疗，不慎烫伤致双小腿中段后侧皮肤破溃，久不愈合。患者经过之前治疗疗效欠佳，抱着试一试的心态来到我院寻求中药治疗。2022年9月22日患者来到针灸科门诊要求口服中药治疗。", "ner": [[22, 26, "Anatomy"], [27, 34, "Anatomy"], [34, 38, "Symptom"], [39, 43, "Symptom"], [43, 46, "Duration"], [55, 58, "Disease"], [61, 65, "Duration"], [77, 79, "Anatomy"], [80, 83, "Anatomy"], [83, 85, "Symptom"], [85, 87, "Symptom"], [88, 92, "Symptom"], [94, 96, "Symptom"], [112, 116, "Disease"], [119, 121, "Operation"], [125, 127, "Method"], [134, 136, "Anatomy"], [136, 138, "Symptom"], [138, 140, "Symptom"], [144, 148, "Anatomy"], [148, 152, "Symptom"], [153, 157, "Symptom"], [172, 176, "Treatment"], [182, 189, "Anatomy"], [189, 193, "Symptom"], [194, 198, "Symptom"], [252, 254, "Method"]], "rel": [[34, 38, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [39, 43, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [83, 85, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [85, 87, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [94, 96, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [22, 26, "Anatomy", 112, 116, "Disease", "Anatomy_Disease"], [80, 83, "Anatomy", 112, 116, "Disease", "Anatomy_Disease"], [77, 79, "Anatomy", 112, 116, "Disease", "Anatomy_Disease"], [112, 116, "Disease", 55, 58, "Disease", "Disease_Disease"], [119, 121, "Operation", 112, 116, "Disease", "Operation_Disease"]]}
{"idx": 246, "sentence": "患者7年前出现右足疼痛，呈间歇性跛行，未予重视，疼痛逐渐加重，出现静息痛，尤以夜间为甚，就诊于当地医院，诊断为下肢动脉硬化闭塞症，予以扩血管及活血化瘀中药治疗，疼痛未见缓解。3个月前疼痛明显加重，彻夜不得安眠，且右足踇趾破溃，伴有低热、口干欲饮，便秘溲赤，遂来我院就诊。既往糖尿病病史30余年，空腹血糖最高时达15.7mmol/L，口服盐酸二甲双胍片0.75g bid，空腹血糖控制不佳。查体：右足趾紫红，踇趾趾端可见一约1.5cm*0.7cm大小的溃疡，疮面暗红，肉色不鲜，可见少量黄色脓性分泌物，疮周红肿，右足皮温增高，足背动脉搏动未触及。舌质暗红，少苔，脉细数。辅助检查：双下肢动脉彩超示双下肢动脉粥样硬化。CTA报告双下肢动脉多发钙化斑，管腔不同程度狭窄，右侧足背动脉闭塞。", "ner": [[7, 11, "Symptom"], [13, 18, "Symptom"], [24, 26, "Symptom"], [33, 36, "Symptom"], [55, 64, "Disease"], [68, 70, "Anatomy"], [80, 82, "Symptom"], [91, 93, "Symptom"], [95, 97, "Level"], [28, 30, "Level"], [106, 112, "Symptom"], [115, 117, "Symptom"], [118, 122, "Symptom"], [123, 127, "Symptom"], [137, 140, "Disease"], [147, 151, "Test_items"], [155, 165, "Test_Value"], [166, 168, "Method"], [168, 175, "Drug"], [175, 180, "Amount"], [181, 184, "Frequency"], [185, 189, "Test_items"], [142, 146, "Duration"], [197, 202, "Symptom"], [203, 207, "Anatomy"], [210, 224, "Level"], [225, 227, "Symptom"], [228, 232, "Symptom"], [233, 237, "Symptom"], [240, 249, "Symptom"], [250, 254, "Symptom"], [255, 261, "Symptom"], [262, 271, "Symptom"], [272, 276, "Symptom"], [277, 279, "Symptom"], [280, 283, "Symptom"], [289, 296, "Test"], [307, 310, "Test"], [323, 331, "Symptom"], [332, 340, "Disease"], [297, 306, "Symptom"], [312, 322, "Symptom"]], "rel": [[7, 11, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [13, 18, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [24, 26, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [33, 36, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [106, 112, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [197, 202, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [225, 227, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [228, 232, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [233, 237, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [240, 249, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [250, 254, "Symptom", 250, 254, "Symptom", "Symptom_Disease"], [250, 254, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [255, 261, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [262, 271, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [323, 331, "Symptom", 55, 64, "Disease", "Symptom_Disease"], [297, 306, "Disease", 55, 64, "Disease", "Disease_Disease"], [312, 322, "Disease", 55, 64, "Disease", "Disease_Disease"], [332, 340, "Disease", 55, 64, "Disease", "Disease_Disease"], [166, 168, "Method", 168, 175, "Drug", "Method_Drug"], [175, 180, "Amount", 168, 175, "Drug", "Amount_Drug"], [181, 184, "Frequency", 168, 175, "Drug", "Frequency_Drug"], [68, 70, "Anatomy", 55, 64, "Disease", "Anatomy_Disease"], [307, 310, "Test", 55, 64, "Disease", "Test_Disease"], [289, 296, "Test", 55, 64, "Disease", "Test_Disease"], [307, 310, "Test", 332, 340, "Disease", "Test_Disease"], [289, 296, "Test", 332, 340, "Disease", "Test_Disease"]]}
{"idx": 247, "sentence": "73岁的蒋前进（化名）爷爷从年初开始就不能正常行走，他的双腿经常胀痛、发凉，走起路来一瘸一拐。上周，蒋爷爷的病情加重，双腿疼痛连止疼药都无法缓解，并且右脚第三第四足趾皮肤发紫，第五足趾皮肤则已经发黑，出现少许渗液。家人将他送至长沙市中心医院（南华大学附属长沙中心医院）外周血管介入科就诊。长沙市中心医院（南华大学附属长沙中心医院）外周血管介入科主任、主任医师赵扬程接诊并详细了解病史，考虑患者足趾发紫、发黑、溃烂是由于下肢动脉硬化性闭塞导致肢体缺血引起的。赵扬程解释，肢体动脉硬化性闭塞症是中老年常见的周围血管疾病，以下肢最为常见。下肢动脉硬化性闭塞症是由于下肢动脉粥样硬化斑块形成，引起下肢动脉狭窄、闭塞，进而导致肢体慢性缺血。该病的早期症状不明显，随着病情的发展，症状由下肢发凉、麻木转变为肢体疼痛、行走间歇跛行，直到最后产生坏疽和溃疡，导致肢端坏死。讲解病情后，赵扬程建议患者入院接受治疗。", "ner": [[28, 30, "Anatomy"], [32, 34, "Symptom"], [35, 37, "Symptom"], [56, 58, "Level"], [59, 63, "Symptom"], [75, 83, "Anatomy"], [83, 87, "Symptom"], [97, 99, "Symptom"], [102, 106, "Symptom"], [88, 94, "Anatomy"], [196, 200, "Symptom"], [201, 203, "Symptom"], [204, 206, "Symptom"], [209, 218, "Disease"], [220, 224, "Symptom"], [234, 244, "Disease"], [259, 261, "Anatomy"], [266, 276, "Disease"], [279, 289, "Reason"], [294, 300, "Symptom"], [301, 303, "Symptom"], [308, 314, "Symptom"], [337, 341, "Symptom"], [342, 344, "Symptom"], [347, 351, "Symptom"], [354, 358, "Symptom"], [365, 367, "Symptom"], [368, 370, "Symptom"], [373, 377, "Symptom"]], "rel": [[32, 34, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [35, 37, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [59, 63, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [83, 87, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [97, 99, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [102, 106, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [196, 200, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [204, 206, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [220, 224, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [294, 300, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [301, 303, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [308, 314, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [337, 341, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [342, 344, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [347, 351, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [354, 358, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [365, 367, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [368, 370, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [373, 377, "Symptom", 209, 218, "Disease", "Symptom_Disease"], [259, 261, "Anatomy", 209, 218, "Disease", "Anatomy_Disease"], [28, 30, "Anatomy", 209, 218, "Disease", "Anatomy_Disease"], [279, 289, "Reason", 209, 218, "Disease", "Reason_Disease"]]}
{"idx": 248, "sentence": "中国成人2型糖尿病胰岛素促泌剂应用的专家共识", "ner": [[4, 8, "Disease"], [9, 14, "Drug"]], "rel": [[9, 14, "Drug", 4, 8, "Disease", "Drug_Disease"]]}
{"idx": 249, "sentence": "随着社会经济的发展，糖尿病患病率逐渐增加，已成为严重的世界性问题。糖尿病特别是其慢性并发症影响患者的生活质量，甚至威胁患者的生命，给社会、家庭以及患者带来沉重的经济负担。中国的流行病学调查显示，中国20岁以上人群2型糖尿病患病率达9.7%；且近2/3的患者HbA1c得不到有效控制(HbA1c≤7%)；60.7%的患者因未被诊断而无法及早进行有效的治疗和指导。", "ner": [[10, 12, "Disease"], [33, 35, "Disease"], [128, 132, "Test_items"], [141, 145, "Test_items"], [146, 148, "Test_Value"], [106, 110, "Disease"]], "rel": [[128, 132, "Test_items", 106, 110, "Disease", "Test_items_Disease"], [141, 145, "Test_items", 106, 110, "Disease", "Test_items_Disease"]]}
{"idx": 250, "sentence": "中国成人2型糖尿病发生的病理生理特点与欧美国家存在差异，β细胞胰岛素分泌功能下降比胰岛素敏感性降低更明显，且糖尿病肾病发生率更高(2c级，2b级)。因此根据中国2型糖尿病患者自身特点，进行合理的降糖治疗，努力控制其他多种血管病变危险因素，降低血管并发症风险和提高患者生活质量是目前亟需解决的问题。尽管随着糖尿病防治进展，新降糖药物不断问世，而多数权威指南仍将胰岛素促泌剂作为成人2型糖尿病治疗的一线药物。英国糖尿病前瞻性研究(UKPDS)及其后续研究与糖尿病和心血管疾病行动(ADVANCE)等多个大型临床研究证实，磺脲类促泌剂或以其为基础的降糖治疗可显著提高2型糖尿病患者的血糖达标率，降低糖尿病血管并发症风险(1b级)。由于胰岛素促泌剂的发展，其种类逐渐增多，为了针对中国成人2型糖尿病患者的自身特点，更有效指导临床正确使用胰岛素促泌剂，中华医学会内分泌分会组织专家对胰岛素促泌剂在中国成人2型糖尿病的临床应用进行了多次认真的讨论并达成了共识。", "ner": [[4, 8, "Disease"], [28, 51, "Pathogenesis"], [54, 58, "Disease"], [57, 57, "Anatomy"], [80, 84, "Disease"], [110, 113, "Disease"], [121, 122, "Anatomy"], [152, 154, "Disease"], [179, 184, "Drug"], [189, 193, "Disease"], [204, 206, "Disease"], [226, 228, "Disease"], [230, 234, "Disease"], [230, 232, "Anatomy"], [258, 263, "Drug"], [280, 284, "Disease"], [296, 298, "Disease"], [299, 300, "Anatomy"], [314, 319, "Drug"], [364, 369, "Drug"], [340, 344, "Disease"], [386, 391, "Drug"], [397, 401, "Disease"], [110, 111, "Anatomy"], [288, 289, "Test_items"]], "rel": [[28, 51, "Pathogenesis", 4, 8, "Disease", "Pathogenesis_Disease"], [57, 57, "Anatomy", 54, 58, "Disease", "Anatomy_Disease"], [121, 122, "Anatomy", 80, 84, "Disease", "Anatomy_Disease"], [110, 111, "Anatomy", 110, 113, "Disease", "Anatomy_Disease"], [179, 184, "Drug", 189, 193, "Disease", "Drug_Disease"], [230, 232, "Anatomy", 230, 234, "Disease", "Anatomy_Disease"], [258, 263, "Drug", 280, 284, "Disease", "Drug_Disease"], [288, 289, "Test_items", 280, 284, "Disease", "Test_items_Disease"], [299, 300, "Anatomy", 296, 298, "Disease", "Anatomy_Disease"], [314, 319, "Drug", 340, 344, "Disease", "Drug_Disease"], [364, 369, "Drug", 397, 401, "Disease", "Drug_Disease"], [386, 391, "Drug", 397, 401, "Disease", "Drug_Disease"]]}
{"idx": 251, "sentence": "共识中的证据等级根据牛津循证医学中心的标准分类如(表1)。", "ner": [], "rel": []}
{"idx": 252, "sentence": "糖尿病发病机制与中国2型糖尿病患者特点", "ner": [[0, 2, "Disease"], [10, 14, "Disease"]], "rel": []}
{"idx": 253, "sentence": "胰岛素抵抗和β细胞胰岛素分泌缺陷是2型糖尿病发病的两大因素，胰岛素抵抗常常是2型糖尿病发生的始动因素，但如果β细胞胰岛素分泌功能保持其代偿能力，2型糖尿病并不会发生，因此，β细胞胰岛素分泌功能缺陷是2型糖尿病发病病的中心环节之一(5级)。", "ner": [[0, 4, "Pathogenesis"], [6, 15, "Pathogenesis"], [17, 21, "Disease"], [30, 34, "Reason"], [38, 42, "Disease"], [72, 76, "Disease"], [86, 97, "Pathogenesis"], [99, 103, "Disease"]], "rel": [[0, 4, "Pathogenesis", 17, 21, "Disease", "Pathogenesis_Disease"], [6, 15, "Pathogenesis", 17, 21, "Disease", "Pathogenesis_Disease"], [30, 34, "Reason", 38, 42, "Disease", "Reason_Disease"], [86, 97, "Pathogenesis", 99, 103, "Disease", "Pathogenesis_Disease"]]}
{"idx": 254, "sentence": "事实上在糖尿病诊断前约10~15年，β细胞胰岛素分泌功能已开始逐渐下降(2b级)。", "ner": [[4, 6, "Disease"], [18, 34, "Pathogenesis"]], "rel": [[18, 34, "Pathogenesis", 4, 6, "Disease", "Pathogenesis_Disease"]]}
{"idx": 255, "sentence": "在中国新诊断2型糖尿病患者中，胰岛素抵抗为主、胰岛素分泌缺陷为主以及胰岛素分泌缺陷伴胰岛素抵抗的患者各占约1/3(2c级)。对中国新诊断2型糖尿病患者的调查发现，随着空腹血糖水平增高，患者胰岛素分泌功能的下降较胰岛素敏感性降低更明显，且非肥胖(体重指数<24kg/m2)的2型糖尿病患者胰岛素分泌功能更差(2c级)。", "ner": [[6, 10, "Disease"], [15, 19, "Pathogenesis"], [23, 29, "Pathogenesis"], [34, 40, "Pathogenesis"], [42, 46, "Pathogenesis"], [68, 72, "Disease"], [83, 90, "Pathogenesis"], [94, 115, "Pathogenesis"], [119, 120, "Disease"], [136, 140, "Disease"], [143, 151, "Pathogenesis"]], "rel": [[15, 19, "Pathogenesis", 6, 10, "Disease", "Pathogenesis_Disease"], [23, 29, "Pathogenesis", 6, 10, "Disease", "Pathogenesis_Disease"], [34, 40, "Pathogenesis", 6, 10, "Disease", "Pathogenesis_Disease"], [42, 46, "Pathogenesis", 6, 10, "Disease", "Pathogenesis_Disease"], [83, 90, "Pathogenesis", 68, 72, "Disease", "Pathogenesis_Disease"], [94, 115, "Pathogenesis", 68, 72, "Disease", "Pathogenesis_Disease"], [143, 151, "Pathogenesis", 136, 140, "Disease", "Pathogenesis_Disease"]]}
{"idx": 256, "sentence": "因此中国2型糖尿病患者更应关注β细胞胰岛素分泌功能的异常。", "ner": [[4, 8, "Disease"], [15, 27, "Pathogenesis"]], "rel": [[15, 27, "Pathogenesis", 4, 8, "Disease", "Pathogenesis_Disease"]]}
{"idx": 257, "sentence": "胰岛素促泌剂的分类", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 258, "sentence": "目前国内常用的胰岛素促泌剂分为磺脲类和格列奈类。", "ner": [[7, 12, "Drug"], [15, 17, "Drug"], [19, 22, "Drug"]], "rel": []}
{"idx": 259, "sentence": "磺脲类促泌剂包括半衰期较短的短效促泌剂(如：格列吡嗪和格列喹酮)和半衰期较长的中长效促泌剂(如普通剂型的格列美脲、格列本脲和格列齐特，以及改良剂型的格列吡嗪控释片和格列齐特缓释片)。", "ner": [[0, 5, "Drug"], [14, 18, "Drug"], [22, 25, "Drug"], [27, 30, "Drug"], [39, 44, "Drug"], [52, 55, "Drug"], [57, 60, "Drug"], [62, 65, "Drug"], [74, 80, "Drug"], [82, 88, "Drug"]], "rel": []}
{"idx": 260, "sentence": "格列奈类促泌剂半衰期较短，包括瑞格列奈和那格列奈。", "ner": [[0, 6, "Drug"], [15, 18, "Drug"], [20, 23, "Drug"]], "rel": []}
{"idx": 261, "sentence": "常用的各种胰岛素促泌剂的药理特点如下(表2)。", "ner": [[5, 10, "Drug"]], "rel": []}
{"idx": 262, "sentence": "胰岛素促泌剂的降糖机制", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 263, "sentence": "一、促胰岛素分泌作用", "ner": [], "rel": []}
{"idx": 264, "sentence": "现有胰岛素促泌剂均通过与胰岛β细胞膜ATP依赖钾(KATP)通道的磺脲类受体(SUR)-1结合，促使KATP通道关闭，从而刺激内源性胰岛素分泌。", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 265, "sentence": "促胰岛素分泌的差异取决于不同药物的药代动力学特性、与SUR一1结合的亲和力以及解离速度。", "ner": [], "rel": []}
{"idx": 266, "sentence": "KATP通道也存在于其他许多组织，包括大脑、心机和血管平滑肌细胞。", "ner": [], "rel": []}
{"idx": 267, "sentence": "不同组织的SUR存在差异，且胰岛素促泌剂会与β细胞不同分子量的SUR受体结合，这些是其产生药效学差异的原因(5级)。", "ner": [[14, 19, "Drug"]], "rel": []}
{"idx": 268, "sentence": "二、部分胰岛素增敏作用", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 269, "sentence": "近年采用葡萄糖钳夹技术研究发现，磺脲类促泌剂可使人体外周葡萄糖利用增加10%~52%(平均29%)，但大多数学者认为，此作用可能主要是继发于葡萄糖毒性作用的改善", "ner": [[16, 21, "Drug"]], "rel": []}
{"idx": 270, "sentence": "三、其他降糖机制", "ner": [], "rel": []}
{"idx": 271, "sentence": "磺脲类促泌剂还可以通过其他机制降低血糖。", "ner": [[0, 5, "Drug"], [17, 18, "Test_items"]], "rel": []}
{"idx": 272, "sentence": "Simonson等和Best等证明了磺脲类促泌剂降低空腹血糖的作用还与其抑制基础肝糖的生成密切相关(5级)。", "ner": [[26, 29, "Test_items"], [18, 23, "Drug"]], "rel": []}
{"idx": 273, "sentence": "胰岛素促泌剂的临床效果", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 274, "sentence": "一、降糖效果", "ner": [], "rel": []}
{"idx": 275, "sentence": "胰岛素促泌剂降糖作用强，且降糖作用在常规剂量内呈剂量依赖性，除那格列奈外单药治疗一般可平均降低HbA1c2%左右，甚至降低2%以上(5级)；且患者基线HbA1c越高，服用胰岛素促泌剂治疗后HbA1c的降低幅度越大(2b级)。", "ner": [[0, 5, "Drug"], [75, 79, "Test_items"], [80, 81, "Test_Value"], [85, 90, "Drug"], [94, 98, "Test_items"], [100, 105, "Test_Value"], [47, 51, "Test_items"], [52, 55, "Test_Value"], [59, 64, "Test_Value"], [31, 34, "Drug"]], "rel": []}
{"idx": 276, "sentence": "1.磺脲类促泌剂：磺脲类促泌剂是一类应用时间长、降糖疗效肯定、安全性高的降糖药物。", "ner": [[2, 7, "Drug"], [9, 14, "Drug"]], "rel": []}
{"idx": 277, "sentence": "(1)短效促泌剂：短效磺脲类及格列奈类促泌剂半衰期短，作用迅速，主要降低2型糖尿病患者餐后血糖，主要包括：格列喹酮和格列吡嗪、瑞格列奈和那格列奈等。", "ner": [[3, 7, "Drug"], [9, 13, "Drug"], [15, 21, "Drug"], [36, 40, "Disease"], [53, 56, "Drug"], [58, 61, "Drug"], [63, 66, "Drug"], [68, 71, "Drug"], [43, 46, "Test_items"]], "rel": [[9, 13, "Drug", 36, 40, "Disease", "Drug_Disease"], [15, 21, "Drug", 36, 40, "Disease", "Drug_Disease"], [43, 46, "Test_items", 36, 40, "Disease", "Test_items_Disease"], [68, 71, "Drug", 36, 40, "Disease", "Drug_Disease"], [53, 56, "Drug", 36, 40, "Disease", "Drug_Disease"], [58, 61, "Drug", 36, 40, "Disease", "Drug_Disease"], [63, 66, "Drug", 36, 40, "Disease", "Drug_Disease"]]}
{"idx": 278, "sentence": "(2)中长效促泌剂：中长效磺脲类促泌剂半衰期长，作用较持久，明显降低2型糖尿病患者空腹和餐后血糖。包括自身半衰期较长的普通剂型磺脲类促泌剂，如格列本脲和格列美脲，以及剂型改良后的缓控释制剂，如格列齐特缓释片、格列吡嗪控释片。格列本脲与β细胞膜SUR亲和力强，降糖疗效强，但低血糖的发生率高(1a级)。格列美脲与β细胞膜SUR结合及解离的速度较格列本脲为快，低血糖发生率有所降低(2b级)；且在血糖控制相同的情况下格列美脲较格列本脲治疗时的空腹及餐后胰岛素和C肽水平为低(2b级)。格列吡嗪控释片通过胃肠道治疗系统(GITS)技术实现控释，格列齐特缓释片采用以亲水性羟丙甲纤维素为基质的缓释技术，可保持全天血药浓度平稳。其活性成分的释放更符合2型糖尿病患者24h血糖变化特点，低血糖尤其是严重低血糖的发生更少(4级)。", "ner": [[343, 347, "ADE"], [337, 339, "ADE"], [327, 331, "Test_items"], [3, 8, "Drug"], [10, 18, "Drug"], [34, 38, "Disease"], [41, 47, "Test_items"], [59, 68, "Drug"], [71, 74, "Drug"], [76, 79, "Drug"], [96, 102, "Drug"], [104, 110, "Drug"], [112, 115, "Drug"], [136, 138, "ADE"], [150, 153, "Drug"], [171, 174, "Drug"], [178, 180, "ADE"], [196, 197, "Test_items"], [206, 209, "Drug"], [211, 214, "Drug"], [269, 275, "Drug"], [320, 324, "Disease"], [240, 246, "Drug"], [219, 226, "Test_items"], [228, 231, "Test_items"]], "rel": [[327, 331, "Test_items", 320, 324, "Disease", "Test_items_Disease"], [10, 18, "Drug", 34, 38, "Disease", "Drug_Disease"], [41, 47, "Test_items", 34, 38, "Disease", "Test_items_Disease"], [136, 138, "ADE", 112, 115, "Drug", "ADE_Drug"], [178, 180, "ADE", 150, 153, "Drug", "ADE_Drug"], [178, 180, "ADE", 171, 174, "Drug", "ADE_Drug"]]}
{"idx": 279, "sentence": "2.格列奈类促泌剂：格列奈类促泌剂直接刺激胰岛β细胞分泌胰岛素，其最大特点是改善早相分泌，起效快、作用时间短，以降低餐后血糖为主，且低血糖风险小、受肾功能影响小(3b级)。一般需1日多次服用。", "ner": [[2, 8, "Drug"], [10, 16, "Drug"], [58, 61, "Test_items"], [66, 68, "ADE"], [89, 92, "Frequency"]], "rel": [[66, 68, "ADE", 10, 16, "Drug", "ADE_Drug"], [89, 92, "Frequency", 10, 16, "Drug", "Frequency_Drug"]]}
{"idx": 280, "sentence": "二、减少或延缓微血管及大血管并发症发生和发展的效果", "ner": [[11, 16, "Disease"], [7, 9, "Anatomy"], [11, 13, "Anatomy"]], "rel": [[7, 9, "Anatomy", 11, 16, "Disease", "Anatomy_Disease"], [11, 13, "Anatomy", 11, 16, "Disease", "Anatomy_Disease"]]}
{"idx": 281, "sentence": "2.大血管并发症：对新诊断的2型糖尿病患者，UKPDS以格列本脲和氯磺丙脲为基础的降糖治疗，其后续研究5年随访未显示明显的大血管获益，10年随访心肌梗死风险下降15%(P=0.01，1b级)。对病程较长且合并心血管高危因素的患者，ADVANCE发现以格列齐特缓释片为基础的降糖治疗5年，HbA1c降至6.5%时，心血管死亡相对风险下降12%(P=0.12，1b级)。对伴有持续性微量白蛋白尿的非超重2型糖尿病患者，Steno-2研究结果显示，采用以格列齐特为基础的降糖治疗，结合多因素强化干预，心血管疾病相对风险下降53%(P=0.008，1b级)。对UKPDS和ADVANCE等研究的meta分析结果显示，以氯磺丙脲、格列本脲和格列齐特缓释片为基础的降糖治疗可使2型糖尿病患者非致死性心肌梗死风险显著降低17%、冠心病风险显著降低15%(1a级)。", "ner": [[2, 4, "Anatomy"], [14, 18, "Disease"], [28, 31, "Drug"], [33, 36, "Drug"], [72, 75, "Disease"], [72, 73, "Anatomy"], [125, 131, "Drug"], [143, 147, "Test_items"], [148, 153, "Test_Value"], [156, 158, "Anatomy"], [189, 190, "Level"], [191, 194, "Disease"], [197, 198, "Disease"], [199, 203, "Disease"], [224, 227, "Drug"], [247, 251, "Disease"], [247, 249, "Anatomy"], [305, 308, "Drug"], [310, 313, "Drug"], [315, 321, "Drug"], [332, 336, "Disease"], [339, 346, "Disease"], [343, 344, "Anatomy"], [357, 359, "Disease"], [140, 141, "Duration"]], "rel": [[2, 4, "Anatomy", 14, 18, "Disease", "Anatomy_Disease"], [28, 31, "Drug", 14, 18, "Disease", "Drug_Disease"], [33, 36, "Drug", 14, 18, "Disease", "Drug_Disease"], [72, 73, "Anatomy", 72, 75, "Disease", "Anatomy_Disease"], [140, 141, "Duration", 125, 131, "Drug", "Duration_Drug"], [224, 227, "Drug", 199, 203, "Disease", "Drug_Disease"], [247, 249, "Anatomy", 247, 251, "Disease", "Anatomy_Disease"], [305, 308, "Drug", 332, 336, "Disease", "Drug_Disease"], [310, 313, "Drug", 332, 336, "Disease", "Drug_Disease"], [315, 321, "Drug", 332, 336, "Disease", "Drug_Disease"], [343, 344, "Anatomy", 339, 346, "Disease", "Anatomy_Disease"]]}
{"idx": 282, "sentence": "三、降低全因死亡的效果", "ner": [], "rel": []}
{"idx": 283, "sentence": "由于糖尿病使心脏病或卒中风险加倍，多数医生和患者非常关注心脑血管疾病，而糖尿病导致死亡的其他因素却较少受到关注。近期的一项研究显示，40%的糖尿病患者死于非心血管疾病，包括肾病、感染、癌症、老年痴呆症、慢性阻塞性肺疾病、神经系统疾病等，提示关注糖尿病患者全因死亡非常重要(2b级)。", "ner": [[2, 4, "Disease"], [6, 8, "Disease"], [6, 7, "Anatomy"], [10, 11, "Disease"], [28, 33, "Disease"], [28, 31, "Anatomy"], [36, 38, "Disease"], [70, 72, "Disease"], [78, 82, "Disease"], [78, 80, "Anatomy"], [86, 87, "Disease"], [86, 86, "Anatomy"], [89, 90, "Disease"], [92, 93, "Disease"], [95, 99, "Disease"], [101, 108, "Disease"], [106, 106, "Anatomy"], [110, 115, "Disease"], [110, 111, "Anatomy"], [122, 124, "Disease"]], "rel": [[6, 7, "Anatomy", 6, 8, "Disease", "Anatomy_Disease"], [28, 31, "Anatomy", 28, 33, "Disease", "Anatomy_Disease"], [78, 80, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"], [86, 86, "Anatomy", 86, 87, "Disease", "Anatomy_Disease"], [106, 106, "Anatomy", 101, 108, "Disease", "Anatomy_Disease"], [110, 111, "Anatomy", 110, 115, "Disease", "Anatomy_Disease"]]}
{"idx": 284, "sentence": "ADVANCE显示以格列齐特缓释片为基础的强化降糖治疗组，随访5年，，全因死亡有降低的趋势(1b级)。", "ner": [[10, 16, "Drug"]], "rel": []}
{"idx": 285, "sentence": "UKPDS试验后继续10年的随访结果显示：格列本脲和氯磺丙脲治疗组的患者，全因死亡风险下降13%(P=0.007，1b级)。", "ner": [[21, 24, "Drug"], [26, 29, "Drug"]], "rel": []}
{"idx": 286, "sentence": "安全性", "ner": [], "rel": []}
{"idx": 287, "sentence": "一、低血糖风险", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 288, "sentence": "磺脲类促泌剂可导致低血糖的发生，但剂型改良后的缓释、控释制剂、格列奈类及格列美脲低血糖发生率相对较低。GUIDE研究结果显示，在血糖水平控制相似的情况下，不同磺脲类促泌剂所致低血糖发生风险不同(1b级)。ADVANCE以格列齐特缓释片为基础的降糖治疗严重低血糖年发生率仅为UKPDS采用格列本脲和氯磺丙脲为基础的降糖治疗的1/4(1b级)。因此，应根据不同胰岛素促泌剂的特点及糖尿病患者的血糖谱选择合适的胰岛素促泌剂，从而在保证降糖疗效的同时降低低血糖发生风险。", "ner": [[0, 5, "Drug"], [9, 11, "ADE"], [31, 34, "Drug"], [36, 39, "Drug"], [40, 42, "ADE"], [64, 65, "Test_items"], [79, 84, "Drug"], [87, 89, "ADE"], [110, 116, "Drug"], [125, 129, "ADE"], [143, 146, "Drug"], [148, 151, "Drug"], [178, 183, "Drug"], [188, 190, "Disease"], [202, 207, "Drug"], [194, 195, "Test_items"], [223, 225, "ADE"]], "rel": [[9, 11, "ADE", 0, 5, "Drug", "ADE_Drug"], [40, 42, "ADE", 36, 39, "Drug", "ADE_Drug"], [87, 89, "ADE", 79, 84, "Drug", "ADE_Drug"], [125, 129, "ADE", 110, 116, "Drug", "ADE_Drug"], [178, 183, "Drug", 188, 190, "Disease", "Drug_Disease"], [194, 195, "Test_items", 188, 190, "Disease", "Test_items_Disease"], [223, 225, "ADE", 202, 207, "Drug", "ADE_Drug"]]}
{"idx": 289, "sentence": "二、对体重的影响", "ner": [], "rel": []}
{"idx": 290, "sentence": "肥胖是多种慢性疾病特别是心脑血管疾病发生、进展的危险因素，因此应该高度重视。一般认为磺脲类药物治疗可引起体重增加。", "ner": [[0, 1, "Disease"], [12, 17, "Disease"], [12, 15, "Anatomy"], [42, 46, "Drug"], [52, 55, "ADE"]], "rel": [[12, 15, "Anatomy", 12, 17, "Disease", "Anatomy_Disease"], [52, 55, "ADE", 42, 46, "Drug", "ADE_Drug"]]}
{"idx": 291, "sentence": "UKPDS表明，以格列本脲为基础的降糖治疗，患者体重增加1.7kg(1b级)。", "ner": [[9, 12, "Drug"], [24, 27, "ADE"]], "rel": [[24, 27, "ADE", 9, 12, "Drug", "ADE_Drug"]]}
{"idx": 292, "sentence": "而ADVANCE以格列齐特缓释片为基础的联合降糖治疗，随访5年，平均体重并未增加(1b级)。", "ner": [[9, 15, "Drug"]], "rel": []}
{"idx": 293, "sentence": "剂型改良后的磺脲类促泌剂、格列奈类及格列美脲对体重影响较小。", "ner": [[6, 11, "Drug"], [13, 16, "Drug"], [18, 21, "Drug"]], "rel": []}
{"idx": 294, "sentence": "三、对β细胞功能的影响", "ner": [], "rel": []}
{"idx": 295, "sentence": "UKPDS的结果显示，接受格列本脲和氯磺丙脲治疗的患者β细胞胰岛素分泌功能有下降趋势，但与采用二甲双胍治疗和单纯饮食控制相似(2b级)。糖尿病进展实验(ADOPT)对比了3种不同类型降糖药物(罗格列酮、格列本脲和二甲双胍)在新诊断2型糖尿病患者中的疗效，对该研究分析发现，格列本脲组在治疗早期对β细胞胰岛素分泌功能显著优于罗格列酮和二甲双胍(2b级)。", "ner": [[13, 16, "Drug"], [18, 21, "Drug"], [47, 50, "Drug"], [68, 70, "Disease"], [96, 99, "Drug"], [101, 104, "Drug"], [106, 109, "Drug"], [115, 119, "Disease"], [136, 139, "Drug"], [161, 164, "Drug"], [166, 169, "Drug"]], "rel": [[96, 99, "Drug", 115, 119, "Disease", "Drug_Disease"], [101, 104, "Drug", 115, 119, "Disease", "Drug_Disease"], [106, 109, "Drug", 115, 119, "Disease", "Drug_Disease"]]}
{"idx": 296, "sentence": "因此，磺脲类胰岛素促泌剂并不加速β细胞胰岛素分泌功能的衰竭。", "ner": [[3, 11, "Drug"]], "rel": []}
{"idx": 297, "sentence": "四、肿瘤风险", "ner": [], "rel": []}
{"idx": 298, "sentence": "研究表明2型糖尿病患者的肿瘤风险增加，目前没有胰岛素促泌剂增加肿瘤风险的确切证据。", "ner": [[4, 8, "Disease"], [23, 28, "Drug"]], "rel": [[23, 28, "Drug", 4, 8, "Disease", "Drug_Disease"]]}
{"idx": 299, "sentence": "近期发表的ADVANCE亚组分析显示，以格列齐特缓释片为基础的降糖治疗，并不增加患者肿瘤风险(2b级)。", "ner": [[20, 26, "Drug"]], "rel": []}
{"idx": 300, "sentence": "五、心血管风险", "ner": [], "rel": []}
{"idx": 301, "sentence": "美国大学组糖尿病研究项目(UGDP)研究提出，甲苯磺丁脲可能增加2型糖尿病患者心血管死亡风险。", "ner": [[5, 7, "Disease"], [39, 45, "ADE"], [32, 36, "Disease"], [23, 27, "Drug"]], "rel": [[23, 27, "Drug", 32, 36, "Disease", "Drug_Disease"]]}
{"idx": 302, "sentence": "但UKPDS、ADOPT及ADVANCE并未发现格列本脲和格列齐特缓释片增加心血管风险(1b级，2b级)。", "ner": [[24, 27, "Drug"], [29, 35, "Drug"]], "rel": []}
{"idx": 303, "sentence": "六、其他不良反应", "ner": [], "rel": []}
{"idx": 304, "sentence": "胰岛素促泌剂其他少见不良反应包括头晕、乏力、头痛、皮疹、恶心和胃肠道不良反应(呕吐、腹痛、腹泻等)。", "ner": [[0, 5, "Drug"], [16, 17, "ADE"], [19, 20, "ADE"], [22, 23, "ADE"], [25, 26, "ADE"], [28, 29, "ADE"], [31, 37, "ADE"], [39, 40, "ADE"], [42, 43, "ADE"], [45, 46, "ADE"]], "rel": [[16, 17, "ADE", 0, 5, "Drug", "ADE_Drug"], [19, 20, "ADE", 0, 5, "Drug", "ADE_Drug"], [22, 23, "ADE", 0, 5, "Drug", "ADE_Drug"], [25, 26, "ADE", 0, 5, "Drug", "ADE_Drug"], [28, 29, "ADE", 0, 5, "Drug", "ADE_Drug"], [31, 37, "ADE", 0, 5, "Drug", "ADE_Drug"], [39, 40, "ADE", 0, 5, "Drug", "ADE_Drug"], [42, 43, "ADE", 0, 5, "Drug", "ADE_Drug"], [45, 46, "ADE", 0, 5, "Drug", "ADE_Drug"]]}
{"idx": 305, "sentence": "一般对症处理和调理药物剂量后上述症状可以缓解或消失。", "ner": [], "rel": []}
{"idx": 306, "sentence": "新型的如格列美脲、格列奈类及剂型改良后的磺脲类促泌剂，这些情况更少见。", "ner": [[4, 7, "Drug"], [9, 12, "Drug"], [20, 25, "Drug"]], "rel": []}
{"idx": 307, "sentence": "胰岛素促泌剂用药原则", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 308, "sentence": "一、胰岛素促泌剂总的用药原则", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 309, "sentence": "1.胰岛素促泌剂的适应证：胰岛素促泌剂可作为2型糖尿病患者的一线用药。一般而言，有一定β细胞功能、无胰岛素促泌剂使用禁忌的2型糖尿病患者可考虑选用胰岛素促泌剂，为不适合使用二甲双胍的2型糖尿病患者的治疗首选，或其他口服降糖药物治疗血糖控制不佳的2型糖尿病患者联合用药方案首选(5级)。", "ner": [[2, 7, "Drug"], [13, 18, "Drug"], [22, 26, "Disease"], [50, 55, "Drug"], [73, 78, "Drug"], [86, 89, "Drug"], [91, 95, "Disease"], [122, 126, "Disease"], [115, 116, "Test_items"], [107, 108, "Method"], [61, 65, "Disease"], [117, 120, "Test_Value"]], "rel": [[13, 18, "Drug", 22, 26, "Disease", "Drug_Disease"], [50, 55, "Drug", 61, 65, "Disease", "Drug_Disease"], [73, 78, "Drug", 61, 65, "Disease", "Drug_Disease"], [86, 89, "Drug", 91, 95, "Disease", "Drug_Disease"], [115, 116, "Test_items", 122, 126, "Disease", "Test_items_Disease"]]}
{"idx": 310, "sentence": "2.胰岛素促泌剂的禁忌证：药物过敏、1型糖尿病、糖尿病酮症酸中毒、高糖性高渗透压综合征、严重肝或肾损伤和哺乳期患者等。", "ner": [[2, 7, "Drug"], [13, 16, "Disease"], [18, 22, "Disease"], [24, 31, "Disease"], [33, 42, "Disease"], [44, 50, "Disease"], [46, 46, "Anatomy"], [48, 48, "Anatomy"]], "rel": [[46, 46, "Anatomy", 44, 50, "Disease", "Anatomy_Disease"], [48, 48, "Anatomy", 44, 50, "Disease", "Anatomy_Disease"]]}
{"idx": 311, "sentence": "3.胰岛素促泌剂的联合用药原则：2型糖尿病患者，若胰岛素促泌剂单药治疗血糖控制不佳，应与其他降糖药物如双胍类、α-糖苷酶抑制剂或噻唑烷二酮类药物联用。", "ner": [[64, 71, "Drug"], [55, 62, "Drug"], [51, 53, "Drug"], [35, 36, "Test_items"], [37, 40, "Test_Value"], [16, 20, "Disease"], [25, 30, "Drug"], [2, 7, "Drug"]], "rel": [[64, 71, "Drug", 16, 20, "Disease", "Drug_Disease"], [55, 62, "Drug", 16, 20, "Disease", "Drug_Disease"], [51, 53, "Drug", 16, 20, "Disease", "Drug_Disease"], [35, 36, "Test_items", 16, 20, "Disease", "Test_items_Disease"], [25, 30, "Drug", 16, 20, "Disease", "Drug_Disease"]]}
{"idx": 312, "sentence": "联合治疗时应注意以下事项：(1)应选择作用机制互补的降糖药物(5级)；(2)一般联合2种药物，最多可联用3种药物，若血糖仍得不到有效控制，应及时启动胰岛素治疗(5级)；(3)联合用药应考虑价效因素，尽量减轻患者经济负担；(4)磺脲类促泌剂与格列奈类促泌剂虽然在分子结构和作用靶位上存在不同，但两者合用的临床证据尚不充分，一般不推荐两者联用。", "ner": [[58, 59, "Test_items"], [61, 67, "Test_Value"], [74, 76, "Drug"], [113, 118, "Drug"], [120, 126, "Drug"]], "rel": []}
{"idx": 313, "sentence": "二、不同血糖谱的选药原则", "ner": [[4, 5, "Test_items"]], "rel": []}
{"idx": 314, "sentence": "在选择胰岛素促泌剂治疗时，可根据患者血糖选择不同类型胰岛素促泌剂(5级)：(1)以餐后血糖(PPG)升高为主者，宜选择格列吡嗪、格列奈类促泌剂；(2)以空腹血糖(FPG)升高为主者，宜选择依从性好、低血糖发生风险低的中长效磺脲类促泌剂；(3)餐后血糖和空腹血糖均升高者，宜选择依从性好、低血糖发生风险低的中长效磺脲类促泌剂。", "ner": [[3, 8, "Drug"], [18, 19, "Test_items"], [26, 31, "Drug"], [41, 49, "Test_items"], [50, 51, "Test_Value"], [59, 62, "Drug"], [64, 70, "Drug"], [76, 84, "Test_items"], [85, 86, "Test_Value"], [99, 101, "ADE"], [108, 116, "Drug"], [121, 124, "Test_items"], [126, 129, "Test_items"], [131, 132, "Test_Value"], [143, 145, "ADE"], [152, 160, "Drug"]], "rel": [[99, 101, "ADE", 108, 116, "Drug", "ADE_Drug"], [143, 145, "ADE", 152, 160, "Drug", "ADE_Drug"]]}
{"idx": 315, "sentence": "三、老年糖尿病患者(≥65岁)", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 316, "sentence": "老年患者应根据脏器功能、认知功能以级预期寿命选择不同胰岛素促泌剂治疗，但总体而言，治疗措施应尽量简单易行，并充分考虑肝肾功能减退程度(5级)。若患者既往有严重低血糖史、合并其他严重疾病、预期生存期较短，宜选择作用时间较短的格列奈类促泌剂；若患者脏器功能和认知能力良好、预期生存期较长，可选择低血糖少等安全性较好的磺脲类促泌剂。", "ner": [[77, 78, "Level"], [79, 81, "Disease"], [111, 117, "Drug"], [145, 147, "ADE"], [156, 161, "Drug"], [26, 31, "Drug"]], "rel": [[145, 147, "ADE", 156, 161, "Drug", "ADE_Drug"]]}
{"idx": 317, "sentence": "四、低血糖高危险人群", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 318, "sentence": "糖尿病病程长(>15年)、有“无感知”低血糖病史、存在肝肾功能不全或全天血糖波动较大并反复出现低血糖症状的患者给予胰岛素促泌剂治疗时，应选择格列奈类促泌剂或低血糖风险较低的磺脲类促泌剂(1b级，5级)；一般应小剂量开始使用。", "ner": [[0, 2, "Disease"], [19, 21, "Disease"], [27, 32, "Disease"], [27, 27, "Anatomy"], [28, 28, "Anatomy"], [36, 37, "Test_items"], [38, 41, "Test_Value"], [47, 49, "Disease"], [57, 63, "Drug"], [70, 76, "Drug"], [78, 80, "ADE"], [86, 91, "Drug"]], "rel": [[70, 76, "Drug", 0, 2, "Disease", "Drug_Disease"], [36, 37, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [57, 63, "Drug", 0, 2, "Disease", "Drug_Disease"], [27, 27, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [28, 28, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [78, 80, "ADE", 70, 76, "Drug", "ADE_Drug"]]}
{"idx": 319, "sentence": "五、其他情况", "ner": [], "rel": []}
{"idx": 320, "sentence": "目前关于妊娠期糖尿病或妊娠期显性糖尿病或孕前2型糖尿病患者妊娠期间及哺乳期使用胰岛素促泌剂的临床证据尚不太充分，一般情况下国内不推荐孕妇及哺乳期患者应用胰岛素促泌剂治疗。", "ner": [[4, 9, "Disease"], [11, 18, "Disease"], [20, 26, "Disease"], [39, 44, "Drug"], [76, 81, "Drug"]], "rel": []}
{"idx": 321, "sentence": "对伴有中度肾功能不全患者，应首选胰岛素，也可选择经肾排泄少的胰岛素促泌剂，如瑞格列奈或格列喹酮，并根据肾功能水平适当降低胰岛素促泌剂的使用剂量。", "ner": [[3, 9, "Disease"], [3, 4, "Level"], [5, 5, "Anatomy"], [16, 18, "Drug"], [30, 35, "Drug"], [38, 41, "Drug"], [43, 46, "Drug"], [60, 65, "Drug"]], "rel": [[5, 5, "Anatomy", 3, 9, "Disease", "Anatomy_Disease"], [16, 18, "Drug", 3, 9, "Disease", "Drug_Disease"], [30, 35, "Drug", 3, 9, "Disease", "Drug_Disease"], [38, 41, "Drug", 3, 9, "Disease", "Drug_Disease"], [43, 46, "Drug", 3, 9, "Disease", "Drug_Disease"], [60, 65, "Drug", 3, 9, "Disease", "Drug_Disease"]]}
{"idx": 322, "sentence": "对短期接受胰岛素强化治疗后的患者，可选择胰岛素促泌剂治疗。", "ner": [[5, 7, "Drug"], [20, 25, "Drug"]], "rel": []}
{"idx": 323, "sentence": "对依从性差的患者，尤其是在中国农村地区的患者，宜选择低血糖风险低、对体重影响小及廉价的1日1次磺脲类促泌剂(4级)。", "ner": [[26, 28, "ADE"], [43, 46, "Frequency"], [47, 52, "Drug"]], "rel": [[26, 28, "ADE", 47, 52, "Drug", "ADE_Drug"], [43, 46, "Frequency", 47, 52, "Drug", "Frequency_Drug"]]}
{"idx": 324, "sentence": "总结", "ner": [], "rel": []}
{"idx": 325, "sentence": "迄今为止，胰岛素促泌剂在2型糖尿病治疗中仍占据不可或缺的地位，为多数权威2型糖尿病防治指南中的一线降糖药物。中国成人2型糖尿病患者体重指数较低、糖尿病肾病发生率较高且β细胞胰岛素分泌功能比胰岛素敏感性降低更明显，胰岛素促泌剂更符合中国成人2型糖尿病患者特点。", "ner": [[5, 10, "Drug"], [12, 16, "Disease"], [36, 40, "Disease"], [58, 62, "Disease"], [72, 76, "Disease"], [75, 75, "Anatomy"], [83, 104, "Pathogenesis"], [106, 111, "Drug"], [119, 123, "Disease"]], "rel": [[5, 10, "Drug", 12, 16, "Disease", "Drug_Disease"], [75, 75, "Anatomy", 72, 76, "Disease", "Anatomy_Disease"], [83, 104, "Pathogenesis", 72, 76, "Disease", "Pathogenesis_Disease"], [106, 111, "Drug", 119, 123, "Disease", "Drug_Disease"]]}
{"idx": 326, "sentence": "磺脲类药物，经长时间应用及大型临床研究证实，降糖疗效肯定且降HbA1c作用强、安全性高，可减少微血管并发症的发生，早期使用还可减少大血管并发症和全因死亡的发生。", "ner": [[0, 4, "Drug"], [30, 34, "Test_items"], [47, 49, "Anatomy"], [65, 67, "Anatomy"]], "rel": []}
{"idx": 327, "sentence": "格列奈类有效降低餐后血糖，在中国也广泛使用。", "ner": [[0, 3, "Drug"], [8, 11, "Test_items"]], "rel": []}
{"idx": 328, "sentence": "由于患者的耐受性、依从性及经济条件差别较大，因此，在临床实践中应根据患者特点，选用合适的胰岛素促泌剂。", "ner": [[44, 49, "Drug"]], "rel": []}
{"idx": 329, "sentence": "1.微血管并发症：UKPDS证实，以氯磺丙脲、格列本脲为基础的降糖治疗，可减少新诊断2型糖尿病患者的微血管复合终点风险25%(P=0.0099)，其中视网膜病变风险下降29%(P=0.0031，1b级)；9年随防时微量白蛋白尿和大量白蛋白尿发生的相对风险分别下降24%(P=0.00062)和33%(P=0.026，1b级)。ADVANCE对病程较长，合并心血管高危因素的2型糖尿病患者采用以格列齐特缓释片为基础的降糖治疗，主要微血管事件减少14%(P=0.01)，肾脏事件减少21%(P=0.006，1b级)。", "ner": [[18, 21, "Drug"], [23, 26, "Drug"], [42, 46, "Disease"], [50, 52, "Anatomy"], [75, 79, "Disease"], [75, 77, "Anatomy"], [107, 108, "Level"], [109, 112, "Disease"], [114, 115, "Level"], [116, 119, "Disease"], [178, 180, "Anatomy"], [186, 190, "Disease"], [196, 202, "Drug"], [214, 218, "Disease"], [214, 216, "Anatomy"], [233, 236, "Disease"], [233, 234, "Anatomy"], [2, 4, "Anatomy"]], "rel": [[18, 21, "Drug", 42, 46, "Disease", "Drug_Disease"], [23, 26, "Drug", 42, 46, "Disease", "Drug_Disease"], [50, 52, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [2, 4, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [75, 77, "Anatomy", 75, 79, "Disease", "Anatomy_Disease"], [178, 180, "Anatomy", 186, 190, "Disease", "Anatomy_Disease"], [196, 202, "Drug", 186, 190, "Disease", "Drug_Disease"], [214, 216, "Anatomy", 214, 218, "Disease", "Anatomy_Disease"], [233, 234, "Anatomy", 233, 236, "Disease", "Anatomy_Disease"]]}
{"idx": 330, "sentence": "优化的降糖治疗不仅只针对胰岛素分泌缺陷，还应同时关注其他发病机制(如胰岛素抵抗、能量摄取等)。胰岛素促泌剂与其他作用机制互补的药物联用，可多方面干预糖尿病发病环节，使患者血糖得到长期、有效、平稳及安全的控制。", "ner": [[12, 18, "Pathogenesis"], [34, 38, "Pathogenesis"], [40, 43, "Pathogenesis"], [47, 52, "Drug"], [74, 76, "Disease"], [85, 86, "Test_items"]], "rel": [[47, 52, "Drug", 74, 76, "Disease", "Drug_Disease"], [85, 86, "Test_items", 74, 76, "Disease", "Test_items_Disease"]]}
{"idx": 331, "sentence": "糖尿病周围神经病诊断和治疗共识", "ner": [[0, 7, "Disease"], [3, 6, "Anatomy"]], "rel": [[3, 6, "Anatomy", 0, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 332, "sentence": "糖尿病周围神经病(diabetic peripheral neuropathy，DPN)是糖尿病的常见并发症，临床表现包括多种类型，其中以远端对称性多发性周围神经病(distal symmetric polyneuropathy，DSPN)和自主神经病最为常见。", "ner": [[0, 43, "Disease"], [3, 6, "Anatomy"], [45, 47, "Disease"], [69, 119, "Disease"], [121, 125, "Disease"], [77, 80, "Anatomy"], [121, 124, "Anatomy"]], "rel": [[3, 6, "Anatomy", 0, 43, "Disease", "Anatomy_Disease"], [77, 80, "Anatomy", 69, 119, "Disease", "Anatomy_Disease"], [121, 124, "Anatomy", 121, 125, "Disease", "Anatomy_Disease"]]}
{"idx": 333, "sentence": "早期识别和治疗DPN，对于改善患者预后具有重要意义。", "ner": [[7, 9, "Disease"]], "rel": []}
{"idx": 334, "sentence": "一、临床症状和体征", "ner": [], "rel": []}
{"idx": 335, "sentence": "通过详细的病史询问和体格检查，寻找周围神经受累的证据是诊断DPN的第一步。", "ner": [[10, 13, "Test"], [17, 20, "Anatomy"], [29, 31, "Disease"]], "rel": [[10, 13, "Test", 29, 31, "Disease", "Test_Disease"], [17, 20, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"]]}
{"idx": 336, "sentence": "(一)病史", "ner": [], "rel": []}
{"idx": 337, "sentence": "肢体麻木、疼痛等感觉异常为DPN的常见主诉。", "ner": [[0, 3, "Symptom"], [5, 6, "Symptom"], [8, 11, "Symptom"], [13, 15, "Disease"]], "rel": [[0, 3, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [5, 6, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [8, 11, "Symptom", 13, 15, "Disease", "Symptom_Disease"]]}
{"idx": 338, "sentence": "临床医生应详细追问感觉异常的性质、分布范围和发生发展的规律，同时明确感觉障碍是否符合周围神经分布以及肢体疼痛是否符合神经痛的特点。", "ner": [[9, 12, "Symptom"], [34, 37, "Symptom"], [42, 45, "Anatomy"], [50, 53, "Symptom"], [58, 60, "Symptom"]], "rel": []}
{"idx": 339, "sentence": "应注意询问是否有排汗异常、腹泻、便秘、性功能障碍等症状，从而了解有无自主神经受累。", "ner": [[8, 11, "Symptom"], [13, 14, "Symptom"], [16, 17, "Symptom"], [19, 23, "Symptom"], [34, 37, "Anatomy"]], "rel": []}
{"idx": 340, "sentence": "糖尿病患者出现肢体肌肉无力和萎缩通常相对较晚。", "ner": [[0, 2, "Disease"], [7, 12, "Symptom"], [14, 15, "Symptom"]], "rel": [[7, 12, "Symptom", 0, 2, "Disease", "Symptom_Disease"], [14, 15, "Symptom", 0, 2, "Disease", "Symptom_Disease"]]}
{"idx": 341, "sentence": "(二)体格检查", "ner": [[3, 6, "Test"]], "rel": []}
{"idx": 342, "sentence": "1.感觉检查：应仔细检查患者有无振动觉、痛觉、触压觉、温度觉减退以及痛觉过敏，DPN的感觉障碍通常以下肢远端更为明显，严重者可有感觉共济失调。", "ner": [[2, 5, "Test"], [16, 31, "Symptom"], [34, 37, "Symptom"], [39, 41, "Disease"], [43, 46, "Symptom"], [50, 53, "Anatomy"], [54, 57, "Level"], [59, 60, "Level"], [64, 69, "Symptom"]], "rel": [[2, 5, "Test", 39, 41, "Disease", "Test_Disease"], [16, 31, "Symptom", 39, 41, "Disease", "Symptom_Disease"], [34, 37, "Symptom", 39, 41, "Disease", "Symptom_Disease"], [43, 46, "Symptom", 39, 41, "Disease", "Symptom_Disease"], [64, 69, "Symptom", 39, 41, "Disease", "Symptom_Disease"], [50, 53, "Anatomy", 39, 41, "Disease", "Anatomy_Disease"]]}
{"idx": 343, "sentence": "2.运动检查：患者可有足部或手部小肌肉的无力和萎缩，但通常出现较晚。", "ner": [[2, 5, "Test"], [11, 21, "Symptom"], [23, 24, "Symptom"]], "rel": []}
{"idx": 344, "sentence": "3.腱反射检查：通常可出现腱反射减低或消失，尤以跟腱反射为著，是诊断DPN的主要体征之一。", "ner": [[2, 6, "Test"], [13, 20, "Symptom"], [22, 29, "Symptom"], [34, 36, "Disease"]], "rel": [[2, 6, "Test", 34, 36, "Disease", "Test_Disease"], [13, 20, "Symptom", 34, 36, "Disease", "Symptom_Disease"], [22, 29, "Symptom", 34, 36, "Disease", "Symptom_Disease"]]}
{"idx": 345, "sentence": "4.自主神经功能检查：注意有无足部皮肤发凉、干燥以及变薄、溃疡，注意患者卧位和立位的血压和心率变化等。", "ner": [[2, 9, "Test"], [15, 20, "Symptom"], [22, 23, "Symptom"], [26, 27, "Symptom"], [29, 30, "Symptom"], [42, 43, "Test"], [45, 46, "Test"]], "rel": []}
{"idx": 346, "sentence": "(三)注意事项", "ner": [], "rel": []}
{"idx": 347, "sentence": "1.应重视下肢的感觉障碍和腱反射检查。", "ner": [[13, 17, "Test"], [5, 11, "Disease"], [5, 6, "Anatomy"]], "rel": [[5, 6, "Anatomy", 5, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 348, "sentence": "2.询问患者有无偏食、饮酒史、药物或毒物接触史以及家族史等，从而有助于对病因进行鉴别。", "ner": [[8, 9, "Reason"], [11, 13, "Reason"], [15, 22, "Reason"], [25, 27, "Reason"]], "rel": []}
{"idx": 349, "sentence": "3.中枢神经系统感觉通路病变、功能性疾病或内外科相关疾病也可有感觉异常或某些自主神经症状(如性功能障碍、便秘、排尿困难等)，详细的病史询问和体格检查是鉴别DPN与其他疾病的关键。", "ner": [[2, 13, "Disease"], [31, 34, "Symptom"], [38, 43, "Symptom"], [46, 50, "Symptom"], [52, 53, "Symptom"], [55, 58, "Symptom"], [77, 79, "Disease"]], "rel": [[31, 34, "Symptom", 2, 13, "Disease", "Symptom_Disease"], [38, 43, "Symptom", 2, 13, "Disease", "Symptom_Disease"], [46, 50, "Symptom", 2, 13, "Disease", "Symptom_Disease"], [52, 53, "Symptom", 2, 13, "Disease", "Symptom_Disease"], [55, 58, "Symptom", 2, 13, "Disease", "Symptom_Disease"], [31, 34, "Symptom", 77, 79, "Disease", "Symptom_Disease"], [38, 43, "Symptom", 77, 79, "Disease", "Symptom_Disease"], [46, 50, "Symptom", 77, 79, "Disease", "Symptom_Disease"], [52, 53, "Symptom", 77, 79, "Disease", "Symptom_Disease"], [55, 58, "Symptom", 77, 79, "Disease", "Symptom_Disease"]]}
{"idx": 350, "sentence": "二、辅助检查", "ner": [[2, 5, "Test"]], "rel": []}
{"idx": 351, "sentence": "(一)生化检查", "ner": [[3, 6, "Test"]], "rel": []}
{"idx": 352, "sentence": "1.血糖相关检查：对于周围神经病患者，应常规进行空腹血糖、葡萄糖负荷后2h血糖和糖化血红蛋白测定，明确患者有无糖尿病。", "ner": [[2, 7, "Test"], [11, 15, "Disease"], [11, 14, "Anatomy"], [24, 27, "Test_items"], [29, 38, "Test_items"], [40, 45, "Test_items"], [55, 57, "Disease"]], "rel": [[2, 7, "Test", 11, 15, "Disease", "Test_Disease"], [2, 7, "Test", 55, 57, "Disease", "Test_Disease"], [11, 14, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"], [24, 27, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [29, 38, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [40, 45, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [24, 27, "Test_items", 55, 57, "Disease", "Test_items_Disease"], [29, 38, "Test_items", 55, 57, "Disease", "Test_items_Disease"], [40, 45, "Test_items", 55, 57, "Disease", "Test_items_Disease"]]}
{"idx": 353, "sentence": "2.根据患者临床表现的差异，可选择不同的化验检查进行鉴别，如：血常规、肝肾功能、肿瘤筛查、免疫指标、免疫固定电泳、甲状腺功能、叶酸和维生素B12检测等，必要时可进行毒物筛查、腰椎穿刺脑脊液检查等。", "ner": [[20, 23, "Test"], [31, 33, "Test"], [35, 38, "Test"], [40, 43, "Test"], [45, 48, "Test"], [50, 55, "Test"], [57, 61, "Test"], [63, 73, "Test"], [82, 85, "Test"], [87, 95, "Test"]], "rel": []}
{"idx": 354, "sentence": "(二)神经电生理检查。", "ner": [[3, 9, "Test"]], "rel": []}
{"idx": 355, "sentence": "神经电生理检查能够确认周围神经病变，并辅助判断其类型以及严重程度；对于无症状的糖尿病患者，电生理检查有助于发现其亚临床周围神经病变。", "ner": [[0, 6, "Test"], [11, 16, "Disease"], [11, 14, "Anatomy"], [39, 41, "Disease"], [45, 49, "Test"], [56, 64, "Disease"], [59, 62, "Anatomy"]], "rel": [[0, 6, "Test", 11, 16, "Disease", "Test_Disease"], [11, 14, "Anatomy", 11, 16, "Disease", "Anatomy_Disease"], [45, 49, "Test", 39, 41, "Disease", "Test_Disease"], [45, 49, "Test", 56, 64, "Disease", "Test_Disease"], [59, 62, "Anatomy", 56, 64, "Disease", "Anatomy_Disease"]]}
{"idx": 356, "sentence": "当病史和体检已经能够明确周围神经病变及其类型时，神经电生理检查并非必需。", "ner": [[12, 17, "Disease"], [12, 15, "Anatomy"], [24, 30, "Test"]], "rel": [[12, 15, "Anatomy", 12, 17, "Disease", "Anatomy_Disease"], [24, 30, "Test", 12, 17, "Disease", "Test_Disease"]]}
{"idx": 357, "sentence": "1.神经传导测定：神经传导测定在DPN的诊断中具有重要作用。感觉和运动神经传导测定应至少包括上、下肢各2条神经。①感觉神经传导测定：主要表现为感觉神经动作电位波幅降低，下肢远端更为明显，传导速度相对正常，符合长度依赖性轴索性周围神经病的特点。当存在嵌压性周围神经病时，跨嵌压部位的感觉神经传导速度可有减慢。在以自主神经表现为主者，感觉传导可以正常。感觉神经传导测定有助于发现亚临床病变。2运动神经传导测定：远端运动潜伏期和神经传导速度早期通常正常，一般无运动神经部分传导阻滞或异常波形离散，后期可出现复合肌肉动作电位波幅降低，传导速度轻度减慢。在单神经病或腰骶丛病变时，受累神经的复合肌肉动作电位波幅可以明显降低，传导速度也可有轻微减慢。在合并嵌压性周围神经病者，跨嵌压部位传导速度可明显减慢。", "ner": [[2, 7, "Test"], [9, 14, "Test"], [16, 18, "Disease"], [30, 40, "Test"], [57, 64, "Test"], [104, 116, "Disease"], [112, 115, "Anatomy"], [124, 131, "Disease"], [127, 130, "Anatomy"], [155, 158, "Anatomy"], [174, 181, "Test"], [194, 201, "Test"], [273, 276, "Disease"], [278, 282, "Disease"], [274, 275, "Anatomy"], [278, 280, "Anatomy"], [322, 329, "Disease"], [325, 328, "Anatomy"], [290, 297, "Test_items"], [298, 305, "Test_Value"], [307, 310, "Test_items"], [316, 317, "Test_Value"], [314, 315, "Level"], [287, 288, "Anatomy"], [71, 78, "Test_items"], [79, 82, "Test_Value"], [84, 87, "Anatomy"], [93, 96, "Test_items"], [97, 100, "Test_Value"], [140, 147, "Test_items"], [150, 151, "Test_Value"], [203, 216, "Test_items"], [221, 222, "Test_Value"], [250, 257, "Test_items"], [258, 261, "Test_Value"], [263, 266, "Test_items"], [269, 270, "Test_Value"], [267, 268, "Level"], [337, 340, "Test_items"], [344, 345, "Test_Value"], [165, 168, "Test"], [171, 172, "Test_Value"]], "rel": [[2, 7, "Test", 16, 18, "Disease", "Test_Disease"], [9, 14, "Test", 16, 18, "Disease", "Test_Disease"], [57, 64, "Test", 104, 116, "Disease", "Test_Disease"], [112, 115, "Anatomy", 104, 116, "Disease", "Anatomy_Disease"], [71, 78, "Test_items", 104, 116, "Disease", "Test_items_Disease"], [93, 96, "Test_items", 104, 116, "Disease", "Test_items_Disease"], [84, 87, "Anatomy", 104, 116, "Disease", "Anatomy_Disease"], [127, 130, "Anatomy", 124, 131, "Disease", "Anatomy_Disease"], [140, 147, "Test_items", 124, 131, "Disease", "Test_items_Disease"], [274, 275, "Anatomy", 273, 276, "Disease", "Anatomy_Disease"], [287, 288, "Anatomy", 273, 276, "Disease", "Anatomy_Disease"], [290, 297, "Test_items", 273, 276, "Disease", "Test_items_Disease"], [307, 310, "Test_items", 273, 276, "Disease", "Test_items_Disease"], [278, 280, "Anatomy", 278, 282, "Disease", "Anatomy_Disease"], [287, 288, "Anatomy", 278, 282, "Disease", "Anatomy_Disease"], [290, 297, "Test_items", 278, 282, "Disease", "Test_items_Disease"], [307, 310, "Test_items", 278, 282, "Disease", "Test_items_Disease"], [325, 328, "Anatomy", 322, 329, "Disease", "Anatomy_Disease"], [337, 340, "Test_items", 322, 329, "Disease", "Test_items_Disease"]]}
{"idx": 358, "sentence": "2.针极肌电图检查：①针极肌电图检查可见异常自发电位，运动单位电位时限增宽、波幅增高，大力收缩时运动单位募集减少。②针极肌电图能够证实运动神经轴索损害，发现亚临床病变，并协助不同神经病变分布类型的定位。③在以自主神经或感觉神经受累为主的周围神经病变，针电极检测的阳性率较低。", "ner": [[2, 8, "Test"], [11, 17, "Test"], [20, 25, "Test_Value"], [27, 41, "Test_Value"], [43, 55, "Test_Value"], [58, 62, "Test"], [67, 74, "Disease"], [89, 92, "Disease"], [89, 90, "Anatomy"], [104, 107, "Anatomy"], [109, 112, "Anatomy"], [118, 123, "Disease"], [118, 121, "Anatomy"], [125, 129, "Test"], [67, 70, "Anatomy"], [71, 72, "Anatomy"], [131, 135, "Test_Value"]], "rel": [[58, 62, "Test", 89, 92, "Disease", "Test_Disease"], [58, 62, "Test", 67, 74, "Disease", "Test_Disease"], [67, 70, "Anatomy", 67, 74, "Disease", "Anatomy_Disease"], [71, 72, "Anatomy", 67, 74, "Disease", "Anatomy_Disease"], [89, 90, "Anatomy", 89, 92, "Disease", "Anatomy_Disease"], [104, 107, "Anatomy", 118, 123, "Disease", "Anatomy_Disease"], [109, 112, "Anatomy", 118, 123, "Disease", "Anatomy_Disease"], [118, 121, "Anatomy", 118, 123, "Disease", "Anatomy_Disease"], [125, 129, "Test", 118, 123, "Disease", "Test_Disease"]]}
{"idx": 359, "sentence": "3.F波和H反射：可有潜伏期延长，以下肢神经为著。", "ner": [[2, 3, "Test"], [5, 7, "Test"], [11, 15, "Test_Value"], [18, 21, "Anatomy"]], "rel": []}
{"idx": 360, "sentence": "4.皮肤交感反应测定：有助于发现交感神经通路的异常。", "ner": [[2, 9, "Test"], [16, 19, "Anatomy"]], "rel": []}
{"idx": 361, "sentence": "表现为潜伏期延长，波幅降低或引不出波形。", "ner": [[3, 7, "Test_Value"], [9, 18, "Test_Value"]], "rel": []}
{"idx": 362, "sentence": "5.定量感觉测定：可以定量评估深感觉和痛温觉的异常，常用于DPN的临床研究；对于痛觉纤维的评估，有助于小纤维神经病变的判断，对糖尿病自主神经病的诊断有辅助作用。", "ner": [[2, 7, "Test"], [29, 31, "Disease"], [51, 57, "Disease"], [51, 55, "Anatomy"], [63, 70, "Disease"], [66, 69, "Anatomy"]], "rel": [[2, 7, "Test", 29, 31, "Disease", "Test_Disease"], [2, 7, "Test", 51, 57, "Disease", "Test_Disease"], [2, 7, "Test", 63, 70, "Disease", "Test_Disease"], [51, 55, "Anatomy", 51, 57, "Disease", "Anatomy_Disease"], [66, 69, "Anatomy", 63, 70, "Disease", "Anatomy_Disease"]]}
{"idx": 363, "sentence": "6.其他：心率变异度测定可反映副交感神经的功能，是诊断小纤维受累为主周围神经病变的主要方法之一。", "ner": [[5, 11, "Test"], [27, 29, "Anatomy"], [34, 39, "Disease"], [34, 37, "Anatomy"]], "rel": [[5, 11, "Test", 34, 39, "Disease", "Test_Disease"], [27, 29, "Anatomy", 34, 39, "Disease", "Anatomy_Disease"], [34, 37, "Anatomy", 34, 39, "Disease", "Anatomy_Disease"]]}
{"idx": 364, "sentence": "痛觉诱发电位也可以评估痛觉通路的异常，目前主要用于临床研究。", "ner": [[0, 5, "Test"]], "rel": []}
{"idx": 365, "sentence": "(三)影像学检查", "ner": [[3, 7, "Test"]], "rel": []}
{"idx": 366, "sentence": "对于神经根或丛病变者，可选择影像学检查排除脊柱与椎管内病变和盆腔内占位性病变。", "ner": [[2, 8, "Disease"], [2, 6, "Anatomy"], [14, 18, "Test"], [21, 28, "Disease"], [21, 22, "Anatomy"], [30, 37, "Disease"], [30, 32, "Anatomy"], [24, 26, "Anatomy"]], "rel": [[2, 6, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [14, 18, "Test", 2, 8, "Disease", "Test_Disease"], [14, 18, "Test", 21, 28, "Disease", "Test_Disease"], [14, 18, "Test", 30, 37, "Disease", "Test_Disease"], [21, 22, "Anatomy", 21, 28, "Disease", "Anatomy_Disease"], [24, 26, "Anatomy", 21, 28, "Disease", "Anatomy_Disease"], [30, 32, "Anatomy", 30, 37, "Disease", "Anatomy_Disease"]]}
{"idx": 367, "sentence": "(四)神经或皮肤活体组织检查", "ner": [[3, 13, "Test"]], "rel": []}
{"idx": 368, "sentence": "皮肤活体组织检查有助于小纤维神经病的诊断，在糖尿病自主神经病的诊断中具有一定价值。神经活体组织检查主要用于鉴别其他疾病，并非诊断DPN的常规手段，仅在病因诊断困难的情况下根据病情选择。", "ner": [[0, 7, "Test"], [11, 16, "Disease"], [11, 15, "Anatomy"], [22, 29, "Disease"], [25, 28, "Anatomy"], [41, 48, "Test"], [64, 66, "Disease"]], "rel": [[0, 7, "Test", 11, 16, "Disease", "Test_Disease"], [0, 7, "Test", 22, 29, "Disease", "Test_Disease"], [11, 15, "Anatomy", 11, 16, "Disease", "Anatomy_Disease"], [25, 28, "Anatomy", 22, 29, "Disease", "Anatomy_Disease"], [41, 48, "Test", 64, 66, "Disease", "Test_Disease"]]}
{"idx": 369, "sentence": "(五)其他自主神经功能的测定", "ner": [[5, 13, "Test"]], "rel": []}
{"idx": 370, "sentence": "不同的自主神经功能有相应的检测方法，如测定卧位和立位或Valsalva试验引起的血压变化和心率变化，可以反映心脏自主神经功能；B超检测膀胱残余尿和尿动力学测定有助于排尿困难的鉴别诊断。", "ner": [[27, 36, "Test"], [63, 64, "Test"], [73, 78, "Test"], [82, 85, "Disease"], [40, 41, "Test"], [45, 46, "Test"], [67, 71, "Test_items"]], "rel": [[63, 64, "Test", 82, 85, "Disease", "Test_Disease"], [73, 78, "Test", 82, 85, "Disease", "Test_Disease"], [67, 71, "Test_items", 82, 85, "Disease", "Test_items_Disease"]]}
{"idx": 371, "sentence": "三、糖尿病周围神经病的诊断标准", "ner": [[2, 9, "Disease"], [5, 8, "Anatomy"]], "rel": [[5, 8, "Anatomy", 2, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 372, "sentence": "(一)糖尿病周围神经病诊断的基本条件", "ner": [[3, 10, "Disease"], [6, 9, "Anatomy"]], "rel": [[6, 9, "Anatomy", 3, 10, "Disease", "Anatomy_Disease"]]}
{"idx": 373, "sentence": "1.明确患有糖尿病。", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 374, "sentence": "2.存在周围神经病变的临床和(或)电生理的证据。", "ner": [[4, 9, "Disease"], [4, 7, "Anatomy"]], "rel": [[4, 7, "Anatomy", 4, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 375, "sentence": "3.排除导致周围神经病变的其他原因。", "ner": [[6, 11, "Disease"], [6, 9, "Anatomy"]], "rel": [[6, 9, "Anatomy", 6, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 376, "sentence": "(二)糖尿病周围神经病的分类", "ner": [[3, 10, "Disease"], [6, 9, "Anatomy"]], "rel": [[6, 9, "Anatomy", 3, 10, "Disease", "Anatomy_Disease"]]}
{"idx": 377, "sentence": "糖尿病周围神经病有多种分类方法。按照周围神经受累的分布，可以分为多发性对称性周围神经病和局灶性非对称性周围神经病‘。", "ner": [[0, 7, "Disease"], [3, 6, "Anatomy"], [18, 21, "Anatomy"], [32, 42, "Disease"], [44, 55, "Disease"], [38, 41, "Anatomy"], [51, 54, "Anatomy"]], "rel": [[3, 6, "Anatomy", 0, 7, "Disease", "Anatomy_Disease"], [18, 21, "Anatomy", 32, 42, "Disease", "Anatomy_Disease"], [18, 21, "Anatomy", 44, 55, "Disease", "Anatomy_Disease"], [38, 41, "Anatomy", 32, 42, "Disease", "Anatomy_Disease"], [51, 54, "Anatomy", 44, 55, "Disease", "Anatomy_Disease"]]}
{"idx": 378, "sentence": "1.远端对称性多发性周围神经病：是DPN最常见的类型。主要表现为隐袭起病，缓慢发展，临床表现对称，多以肢体远端感觉异常为首发症状，可呈现手套.袜套样感觉障碍，早期即可有腱反射减低，尤以双下肢为著，可伴有自主神经受损表现。", "ner": [[2, 14, "Disease"], [10, 13, "Anatomy"], [17, 19, "Disease"], [51, 58, "Symptom"], [68, 77, "Symptom"], [84, 88, "Symptom"], [92, 94, "Anatomy"], [101, 106, "Disease"], [101, 104, "Anatomy"]], "rel": [[10, 13, "Anatomy", 2, 14, "Disease", "Anatomy_Disease"], [101, 104, "Anatomy", 101, 106, "Disease", "Anatomy_Disease"]]}
{"idx": 379, "sentence": "早期肌无力和肌萎缩通常不明显。", "ner": [[2, 4, "Symptom"], [6, 8, "Symptom"], [11, 13, "Level"]], "rel": []}
{"idx": 380, "sentence": "2.糖尿病自主神经病：以自主神经病变为首发症状，一般隐袭起病，缓慢发展，表现有排汗异常、胃肠道症状、性功能减退、排尿困难、直立性低血压以及静息时心动过速等。由于小纤维受累，发生心绞痛或心肌梗死时可无心前区疼痛的表现，发生严重心律失常时猝死的风险增加。", "ner": [[2, 9, "Disease"], [5, 8, "Anatomy"], [12, 17, "Disease"], [12, 15, "Anatomy"], [39, 42, "Symptom"], [44, 48, "Symptom"], [50, 54, "Symptom"], [56, 59, "Symptom"], [61, 66, "Symptom"], [69, 75, "Symptom"], [80, 82, "Anatomy"], [88, 90, "Disease"], [92, 95, "Disease"], [99, 103, "Symptom"], [110, 115, "Disease"], [110, 111, "Level"], [112, 112, "Anatomy"], [117, 118, "Disease"], [88, 88, "Anatomy"], [92, 93, "Anatomy"]], "rel": [[5, 8, "Anatomy", 2, 9, "Disease", "Anatomy_Disease"], [39, 42, "Symptom", 2, 9, "Disease", "Symptom_Disease"], [44, 48, "Symptom", 2, 9, "Disease", "Symptom_Disease"], [50, 54, "Symptom", 2, 9, "Disease", "Symptom_Disease"], [56, 59, "Symptom", 2, 9, "Disease", "Symptom_Disease"], [61, 66, "Symptom", 2, 9, "Disease", "Symptom_Disease"], [69, 75, "Symptom", 2, 9, "Disease", "Symptom_Disease"], [12, 15, "Anatomy", 12, 17, "Disease", "Anatomy_Disease"], [80, 82, "Anatomy", 88, 90, "Disease", "Anatomy_Disease"], [80, 82, "Anatomy", 92, 95, "Disease", "Anatomy_Disease"], [88, 88, "Anatomy", 88, 90, "Disease", "Anatomy_Disease"], [92, 93, "Anatomy", 92, 95, "Disease", "Anatomy_Disease"], [112, 112, "Anatomy", 110, 115, "Disease", "Anatomy_Disease"]]}
{"idx": 381, "sentence": "3.糖尿病单神经病或多发单神经病：以正中神经、尺神经、腓总神经受累多见，常隐袭发病，也有急性起病者。", "ner": [[2, 8, "Disease"], [6, 7, "Anatomy"], [10, 15, "Disease"], [13, 14, "Anatomy"], [18, 21, "Anatomy"], [23, 25, "Anatomy"], [27, 30, "Anatomy"]], "rel": [[6, 7, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [18, 21, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [23, 25, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [27, 30, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [13, 14, "Anatomy", 10, 15, "Disease", "Anatomy_Disease"], [18, 21, "Anatomy", 10, 15, "Disease", "Anatomy_Disease"], [23, 25, "Anatomy", 10, 15, "Disease", "Anatomy_Disease"], [27, 30, "Anatomy", 10, 15, "Disease", "Anatomy_Disease"]]}
{"idx": 382, "sentence": "主要表现为神经支配区域的感觉和运动功能障碍。", "ner": [[5, 20, "Symptom"]], "rel": []}
{"idx": 383, "sentence": "在神经走行易受嵌压部位(如腕管、肘管、腓骨小头处)更容易受累。", "ner": [[1, 2, "Anatomy"], [13, 14, "Anatomy"], [16, 17, "Anatomy"], [19, 23, "Anatomy"]], "rel": []}
{"idx": 384, "sentence": "脑神经亦可受累，如动眼神经、外展神经、面神经等，通常为急性起病。", "ner": [[0, 2, "Anatomy"], [9, 12, "Anatomy"], [14, 17, "Anatomy"], [19, 21, "Anatomy"]], "rel": []}
{"idx": 385, "sentence": "4.糖尿病神经根神经丛病：也称糖尿病性肌萎缩或痛性肌萎缩，为少见的糖尿病并发症，常见于腰骶神经根神经丛分布区。急性或亚急性起病，表现为受累神经支配区的疼痛和感觉障碍，相继出现肌肉无力和萎缩，以下肢近端为主，可以单侧或双侧受累，诊断时需要首先除外其他原因的神经根或神经丛病变。", "ner": [[2, 11, "Disease"], [5, 7, "Anatomy"], [8, 10, "Anatomy"], [15, 21, "Disease"], [23, 27, "Disease"], [19, 19, "Anatomy"], [25, 25, "Anatomy"], [33, 35, "Disease"], [43, 53, "Anatomy"], [67, 81, "Symptom"], [87, 93, "Symptom"], [96, 99, "Anatomy"], [127, 135, "Disease"], [127, 129, "Anatomy"], [131, 133, "Anatomy"]], "rel": [[5, 7, "Anatomy", 2, 11, "Disease", "Anatomy_Disease"], [8, 10, "Anatomy", 2, 11, "Disease", "Anatomy_Disease"], [43, 53, "Anatomy", 2, 11, "Disease", "Anatomy_Disease"], [19, 19, "Anatomy", 15, 21, "Disease", "Anatomy_Disease"], [43, 53, "Anatomy", 15, 21, "Disease", "Anatomy_Disease"], [25, 25, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"], [43, 53, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"], [43, 53, "Anatomy", 33, 35, "Disease", "Anatomy_Disease"], [127, 129, "Anatomy", 127, 135, "Disease", "Anatomy_Disease"], [131, 133, "Anatomy", 127, 135, "Disease", "Anatomy_Disease"]]}
{"idx": 386, "sentence": "5.其他糖尿病相关周围神经病：糖尿病前周围神经病是糖耐量异常或空腹血糖受损相关的周围神经病，临床特点和DPN相似。", "ner": [[4, 6, "Disease"], [9, 13, "Disease"], [9, 12, "Anatomy"], [25, 29, "Pathogenesis"], [31, 36, "Pathogenesis"], [40, 44, "Disease"], [40, 43, "Anatomy"], [51, 53, "Disease"], [15, 23, "Disease"], [19, 22, "Anatomy"]], "rel": [[9, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [25, 29, "Pathogenesis", 40, 44, "Disease", "Pathogenesis_Disease"], [25, 29, "Pathogenesis", 15, 23, "Disease", "Pathogenesis_Disease"], [31, 36, "Pathogenesis", 40, 44, "Disease", "Pathogenesis_Disease"], [31, 36, "Pathogenesis", 15, 23, "Disease", "Pathogenesis_Disease"], [40, 43, "Anatomy", 40, 44, "Disease", "Anatomy_Disease"], [19, 22, "Anatomy", 15, 23, "Disease", "Anatomy_Disease"]]}
{"idx": 387, "sentence": "糖尿病治疗相关的周围神经病较为少见。", "ner": [[0, 2, "Disease"], [8, 12, "Disease"], [8, 11, "Anatomy"]], "rel": [[8, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 388, "sentence": "通常在采用胰岛素或其他方法过于快速地控制血糖后出现，主要表现为急性远端对称性神经痛，疼痛往往较为难治，部分患者在1—2年后可自发缓解。", "ner": [[5, 7, "Drug"], [20, 21, "Test_items"], [31, 40, "Symptom"], [42, 43, "Symptom"], [56, 59, "Duration"]], "rel": []}
{"idx": 389, "sentence": "四、鉴别诊断", "ner": [], "rel": []}
{"idx": 390, "sentence": "在DPN诊断过程中，需要与多种其他病因导致的周围神经病进行鉴别，特别是当临床存在明显的肢体无力或神经电生理显示传导速度明显减慢时，诊断DPN应该慎重。临床常需要与其鉴别的疾病包括：慢性炎性脱髓鞘性多发性神经根周围神经病、营养缺乏、中毒、异常球蛋白血症、肝功能不全、肾功能不全、甲状腺功能减退、恶性肿瘤、结缔组织病、感染性疾病以及遗传病等。", "ner": [[1, 3, "Disease"], [22, 26, "Disease"], [22, 25, "Anatomy"], [40, 46, "Symptom"], [40, 41, "Level"], [48, 52, "Test"], [55, 62, "Test_Value"], [67, 69, "Disease"], [90, 108, "Disease"], [101, 107, "Anatomy"], [110, 113, "Disease"], [115, 116, "Disease"], [118, 124, "Disease"], [126, 130, "Disease"], [132, 136, "Disease"], [138, 144, "Disease"], [146, 149, "Disease"], [151, 155, "Disease"], [157, 161, "Disease"], [164, 166, "Disease"], [126, 126, "Anatomy"], [132, 132, "Anatomy"], [138, 140, "Anatomy"], [151, 154, "Anatomy"]], "rel": [[22, 25, "Anatomy", 22, 26, "Disease", "Anatomy_Disease"], [40, 46, "Symptom", 22, 26, "Disease", "Symptom_Disease"], [48, 52, "Test", 22, 26, "Disease", "Test_Disease"], [40, 46, "Symptom", 67, 69, "Disease", "Symptom_Disease"], [48, 52, "Test", 67, 69, "Disease", "Test_Disease"], [101, 107, "Anatomy", 90, 108, "Disease", "Anatomy_Disease"], [126, 126, "Anatomy", 126, 130, "Disease", "Anatomy_Disease"], [132, 132, "Anatomy", 132, 136, "Disease", "Anatomy_Disease"], [138, 140, "Anatomy", 138, 144, "Disease", "Anatomy_Disease"], [151, 154, "Anatomy", 151, 155, "Disease", "Anatomy_Disease"]]}
{"idx": 391, "sentence": "DPN为排除性诊断，但临床表现典型时，通常不需要进行各种复杂的检查。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 392, "sentence": "五、糖尿病周围神经病的治疗", "ner": [[2, 9, "Disease"], [5, 8, "Anatomy"]], "rel": [[5, 8, "Anatomy", 2, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 393, "sentence": "(一)病因治疗", "ner": [], "rel": []}
{"idx": 394, "sentence": "积极控制血糖和糖化血红蛋白水平，保持血糖稳定。", "ner": [[4, 5, "Test_items"], [7, 12, "Test_items"], [18, 19, "Test_items"]], "rel": []}
{"idx": 395, "sentence": "建议将糖化血红蛋白控制在7%以内，但具体控制程度应个体化。", "ner": [[3, 8, "Test_items"], [12, 15, "Test_Value"]], "rel": []}
{"idx": 396, "sentence": "(二)针对发病机制的治疗", "ner": [], "rel": []}
{"idx": 397, "sentence": "目前有多种药物在临床上用于DPN的治疗，包括具有抗氧化应激作用的药物(如α-硫辛酸)，改善代谢紊乱类药物(如醛糖还原酶抑制剂)以及各种改善微循环的药物等。但是，临床研究显示当DPN发生后，目前尚无药物能够逆转周围神经病变的进展。", "ner": [[13, 15, "Disease"], [36, 40, "Drug"], [54, 61, "Drug"], [87, 89, "Disease"], [104, 109, "Disease"], [104, 107, "Anatomy"]], "rel": [[36, 40, "Drug", 13, 15, "Disease", "Drug_Disease"], [54, 61, "Drug", 13, 15, "Disease", "Drug_Disease"], [104, 107, "Anatomy", 104, 109, "Disease", "Anatomy_Disease"]]}
{"idx": 398, "sentence": "(三)神经营养修复药物", "ner": [[3, 10, "Drug"]], "rel": []}
{"idx": 399, "sentence": "临床可选择多种B族维生素类(如硫胺素和甲钴胺等)作为针对神经营养修复的辅助治疗药物。", "ner": [[7, 11, "Drug"], [15, 17, "Drug"], [19, 21, "Drug"]], "rel": []}
{"idx": 400, "sentence": "(四)对症治疗", "ner": [], "rel": []}
{"idx": 401, "sentence": "神经痛是影响DPN患者生活质量的主要因素之一，临床有多种药物可以改善患者神经痛的症状，如阿米替林、加巴喷丁、普瑞巴林、度洛西汀、文拉法辛等，具体参见中华医学会神经病学分会制定的痛性周围神经病的诊断和治疗共识。对于自主神经病变引起各系统受累的症状，可根据情况分别治疗，如胃肠道排空功能减退者，可适当选择胃肠动力药物，需注意降糖药的使用，防止低血糖的发生；对于存在明显直立性低血压者，可使用弹力袜，但需注意下肢的血液循环情况。", "ner": [[0, 2, "Symptom"], [6, 8, "Disease"], [36, 38, "Symptom"], [44, 47, "Drug"], [49, 52, "Drug"], [54, 57, "Drug"], [59, 62, "Drug"], [64, 67, "Drug"], [79, 81, "Disease"], [88, 94, "Disease"], [90, 93, "Anatomy"], [106, 111, "Disease"], [106, 109, "Anatomy"], [134, 142, "Disease"], [134, 134, "Anatomy"], [135, 136, "Anatomy"], [169, 171, "ADE"], [180, 181, "Level"], [182, 187, "Disease"], [193, 195, "Treatment"], [201, 202, "Anatomy"], [79, 80, "Anatomy"]], "rel": [[0, 2, "Symptom", 6, 8, "Disease", "Symptom_Disease"], [44, 47, "Drug", 88, 94, "Disease", "Drug_Disease"], [49, 52, "Drug", 88, 94, "Disease", "Drug_Disease"], [54, 57, "Drug", 88, 94, "Disease", "Drug_Disease"], [59, 62, "Drug", 88, 94, "Disease", "Drug_Disease"], [64, 67, "Drug", 88, 94, "Disease", "Drug_Disease"], [79, 80, "Anatomy", 79, 81, "Disease", "Anatomy_Disease"], [90, 93, "Anatomy", 88, 94, "Disease", "Anatomy_Disease"], [106, 109, "Anatomy", 106, 111, "Disease", "Anatomy_Disease"], [134, 134, "Anatomy", 134, 142, "Disease", "Anatomy_Disease"], [135, 136, "Anatomy", 134, 142, "Disease", "Anatomy_Disease"], [193, 195, "Treatment", 182, 187, "Disease", "Treatment_Disease"], [201, 202, "Anatomy", 182, 187, "Disease", "Anatomy_Disease"]]}
{"idx": 402, "sentence": "应避免使用可能加重自主神经病症状的药物。", "ner": [[9, 13, "Disease"], [9, 12, "Anatomy"]], "rel": [[9, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 403, "sentence": "(五)预防", "ner": [], "rel": []}
{"idx": 404, "sentence": "加强健康教育，提高患者自我护理能力。积极控制高血压和高脂血症，改变生活方式，控制体重，避免吸烟和过度饮酒。早期发现空腹血糖受损以及糖耐量异常的患者，并进行积极干预。", "ner": [[0, 5, "Treatment"], [7, 16, "Treatment"], [22, 24, "Disease"], [26, 29, "Disease"], [31, 36, "Treatment"], [38, 41, "Treatment"], [43, 51, "Treatment"], [57, 62, "Pathogenesis"], [65, 69, "Pathogenesis"]], "rel": [[31, 36, "Treatment", 22, 24, "Disease", "Treatment_Disease"], [38, 41, "Treatment", 22, 24, "Disease", "Treatment_Disease"], [43, 51, "Treatment", 22, 24, "Disease", "Treatment_Disease"], [31, 36, "Treatment", 26, 29, "Disease", "Treatment_Disease"], [38, 41, "Treatment", 26, 29, "Disease", "Treatment_Disease"], [43, 51, "Treatment", 26, 29, "Disease", "Treatment_Disease"]]}
{"idx": 405, "sentence": "基于胰高血糖素样肽1降糖药物的临床应用共识 ", "ner": [[2, 13, "Drug"]], "rel": []}
{"idx": 406, "sentence": "自从2005年国际上第一个肠促胰素类药上市以来，此类药物的研究和临床应用有了飞速的发展。目前在我国已经上市2种胰高血糖素样肽1(GLP-1)受体激动剂和5种二肽基肽酶Ⅳ(DPP-4)抑制剂，为了便于使用者全面和快速地了解此类药物的基本知识以及在我国的临床研究和应用情况，中华医学会糖尿病学分会达成以下共识。", "ner": [[13, 18, "Drug"], [140, 142, "Disease"], [55, 74, "Drug"], [78, 93, "Drug"]], "rel": [[55, 74, "Drug", 140, 142, "Disease", "Drug_Disease"], [78, 93, "Drug", 140, 142, "Disease", "Drug_Disease"]]}
{"idx": 407, "sentence": "—、肠促胰素类药物的发现和发展 ", "ner": [[2, 8, "Drug"]], "rel": []}
{"idx": 408, "sentence": "胃肠道是机体重要的内分泌器官，肠道内分泌细胞在代谢调节中的作用日益受到重视。", "ner": [], "rel": []}
{"idx": 409, "sentence": "二十世纪初期，人们发现营养物质摄入后，从肠道分泌的某种激素可以刺激胰岛素分泌从而产生降低血糖的作用。", "ner": [[44, 45, "Test_items"]], "rel": []}
{"idx": 410, "sentence": "1929年，中国学者冯德培、侯祥川、林可胜教授在国际上率先发现并命名了肠抑胃素(enterogastrone)。", "ner": [], "rel": []}
{"idx": 411, "sentence": "同年，Zunz和LaBarre教授发现在狗身上应用这种物质后可引发低血糖，进而将该物质命名为\"肠促胰素\"(incretin)。", "ner": [[33, 35, "Disease"]], "rel": []}
{"idx": 412, "sentence": "1969年，Unger和Eisentraut等首先以“肠-胰岛轴”来描述肠道与胰岛之间的关联，提示这样一个系统能够整合从肠道到胰岛细胞之间的营养、神经和激素信号，从而调控胰岛素、胰高糖素、生长抑素或胰多肽的分泌。", "ner": [], "rel": []}
{"idx": 413, "sentence": "营养物质尤其是碳水化合物可刺激这类激素的释放，当血糖升高时刺激胰岛素释放。", "ner": [[24, 25, "Test_items"], [26, 27, "Test_Value"]], "rel": []}
{"idx": 414, "sentence": "Elrick等发现，在血糖变化水平相同的情况下，与静脉注射葡萄糖相比，口服葡萄糖可引起更多的胰岛素分泌，这种现象被称为“肠促胰素效应”。", "ner": [[25, 28, "Method"], [29, 31, "Drug"], [35, 36, "Method"], [37, 39, "Drug"]], "rel": [[25, 28, "Method", 29, 31, "Drug", "Method_Drug"], [35, 36, "Method", 37, 39, "Drug", "Method_Drug"]]}
{"idx": 415, "sentence": "人体内主要有两种肠促胰素：葡萄糖依赖性胰岛素释放肽(GIP)和GLP-I。", "ner": [], "rel": []}
{"idx": 416, "sentence": "GIP早在1930年被发现，是第一个被发现的肠促胰素，它是从猪小肠提取物中分离出来的物质，由于其具有抑制胃酸和胃蛋白酵分泌的作用，早期被命名为抑胃肽。", "ner": [], "rel": []}
{"idx": 417, "sentence": "但在1973年，Pederson等学者发现它在狗、大鼠乃至人体内呈现出葡萄糖依赖性刺激胰岛素释放的特性，即被更名为葡萄糖依赖性胰岛素释放肽。", "ner": [], "rel": []}
{"idx": 418, "sentence": "1986至1987年间，Drucker等和Orskov等分别在对哺乳动物胰高糖素原基因的克隆和序列测定过程中，发现第二个可以刺激胰岛素释放的肠促胰素，即GLP-1。", "ner": [[32, 50, "Test"]], "rel": []}
{"idx": 419, "sentence": "肠促胰素引起的胰岛素分泌能力约占全部胰岛素分泌量的50%-70%，而且肠促素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。GIP是人17号常染色体长臂基因编码的具有42个氨基酸的肽类物质，在碳水化合物和脂类刺激下，主要由十二指肠和空肠近端的K细胞分泌。GIP与胰腺β细胞上的特异性受体结合，促进胰岛素分泌。但2型糖尿病患者的循环CIP水平正常或升高，同时GIP对β细胞的促胰岛素分泌作用显著降低，对a细胞也没有作用，因而限制了其临床应用。GLP-1是人2号常染色体长臂的胰高血糖素原基因编码，而后经修饰的具有30个氨基酸的肠肽类激素，在食物的刺激下由回肠和结肠的L细胞分泌释放入血，从而发挥葡萄糖依赖性促进胰岛素的合成和分泌、抑制β细胞凋亡、抑制胰高糖素分泌等生理作用。1993年，在Nauck等发表的文章中，提示对磺脲类药物不能有效控制的2型糖尿病患者，持续静脉输注CLP-1后，能够显著降低血糖；当血糖达到正常水平时，持续输注GLP-1并未继续刺激胰岛素分泌、血糖呈稳定状态，进一步表明了GLP-1的葡萄糖浓度依赖性降糖的特征。", "ner": [[65, 66, "Test_items"], [73, 75, "Disease"], [175, 179, "Disease"], [379, 383, "Drug"], [391, 395, "Disease"], [418, 419, "Test_items"], [453, 454, "Test_items"], [456, 459, "Test_Value"]], "rel": [[65, 66, "Test_items", 73, 75, "Disease", "Test_items_Disease"], [379, 383, "Drug", 391, 395, "Disease", "Drug_Disease"], [418, 419, "Test_items", 391, 395, "Disease", "Test_items_Disease"]]}
{"idx": 420, "sentence": "此外，研究还发现肠促胰素，尤其是GLP-1可抑制胰腺α细胞分泌胰高糖素，并有减轻体重、改善β细胞功能和在动物模型中增加β细胞量的作用，可对2型糖尿病患者的代谢异常进行多方面的调控。", "ner": [[69, 73, "Disease"]], "rel": []}
{"idx": 421, "sentence": "二、作用机制", "ner": [], "rel": []}
{"idx": 422, "sentence": "GLP-1通过与其广泛存在于器官上的特异受体相结合，从而发挥相应的作用。", "ner": [], "rel": []}
{"idx": 423, "sentence": "目前明确存在GLP-1受体的器官包括胰岛细胞、胃肠、肺、脑、肾脏、下丘脑、心血管系统等。", "ner": [], "rel": []}
{"idx": 424, "sentence": "另外，肝脏、脂肪组织和骨骼肌也可能存在GLP-1受体。", "ner": [], "rel": []}
{"idx": 425, "sentence": "不像其他胰岛素促泌剂通过KATP通道释放胰岛素,GLP-1还通过刺激胰岛素前体基因表达面合成胰岛素。", "ner": [[4, 9, "Drug"]], "rel": []}
{"idx": 426, "sentence": "这个效应主要是通过GLP-1与β细胞的GLP-1受体结合后激活了cAMP依赖的PKA信号通路。", "ner": [], "rel": []}
{"idx": 427, "sentence": "另外，GLP-1也可以通过抑制胰岛α细胞释放胰高糖素而降低血糖。", "ner": [[29, 30, "Test_items"]], "rel": []}
{"idx": 428, "sentence": "这个机制尚不明确，可能是通过存在于α细胞上的GLP-1受体直接作用或间接通过刺激分泌的胰岛素和生长抑素的旁路效应。", "ner": [], "rel": []}
{"idx": 429, "sentence": "在临床前研究中发现，GLP-1对胰腺的作用还包括保护β细胞、增加β细胞量(可能是通过促进β细胞分化、增殖、抑制细胞凋亡通路)。", "ner": [], "rel": []}
{"idx": 430, "sentence": "GLP-1除了对胰腺作用外，还通过与存在于其他脏器上的特异受体结合发挥胰腺外作用，其胰腺外作用可能通盖多个方面：", "ner": [], "rel": []}
{"idx": 431, "sentence": "1.作用于胃肠道，延缓胃挂空和肠道蠕动的作用，并可以抑制胃酸和五肽胃泌素分泌，从而减少餐后血糖波动和减轻体重。", "ner": [[50, 53, "Symptom"], [43, 46, "Test_items"], [47, 48, "Test_Value"]], "rel": []}
{"idx": 432, "sentence": "2.作用于中枢神经系统，发挥抑制食欲、增加饱感等作用.从而达到减少摄食的目的。", "ner": [], "rel": []}
{"idx": 433, "sentence": "3.作用于心血管系统，降低收缩压、改善心肌缺血和心肌收缩功能。", "ner": [[13, 15, "Test"], [19, 22, "Disease"], [19, 20, "Anatomy"]], "rel": [[19, 20, "Anatomy", 19, 22, "Disease", "Anatomy_Disease"]]}
{"idx": 434, "sentence": "4.作用于肝、肾，抑制肝脏葡萄糖生成、降低肝酶、降低血脂，改善肝功能。", "ner": [[26, 27, "Test"]], "rel": []}
{"idx": 435, "sentence": "5.增加肥胖者的钠排泄、减少H+分泌、降低肾小球高滤过，从而对肾脏可能起到保护作用。", "ner": [[4, 5, "Disease"]], "rel": []}
{"idx": 436, "sentence": "三、药物分类", "ner": [], "rel": []}
{"idx": 437, "sentence": "目前有两大类药物：分别为GLP-1受体激动剂和DPP-4抑制剂。", "ner": [[12, 21, "Drug"], [23, 30, "Drug"]], "rel": []}
{"idx": 438, "sentence": "CLP-1受体激动剂通过模拟天然CLP-1激活GLP-1受体而发挥作用，且不容易被DPP-4快速降解，延长了半衰期，增加了活性GLP-1在体内的浓度。", "ner": [[0, 9, "Drug"]], "rel": []}
{"idx": 439, "sentence": "GLP-1受体激动剂主要通过外源性补充GLP-1以使体内的GLP-1水平达到药理浓度而发挥作用，其降糖效果显著，降低HbA1c幅度约0.8%~1.5%。", "ner": [[0, 9, "Drug"], [58, 62, "Test_items"], [66, 74, "Test_Value"]], "rel": []}
{"idx": 440, "sentence": "目前，在中国上市的GLP-1受体激动剂有两种：一种是短效GLP-1受体激动剂艾塞那肽(exenatide，商品名百泌达)，是两栖动物美洲毒蜥唾液中多肽exendin-4的人工合成多肽，其与人GLP-1的同源性为53%；另一种是长效人GLP-1类似物利拉鲁肽(liraglutide，商品名诺和力)，通过对人GLP-1分子结构局部修饰加工而成，与GLP-1的同源性为97%。", "ner": [[9, 18, "Drug"], [113, 147, "Drug"], [26, 59, "Drug"]], "rel": []}
{"idx": 441, "sentence": "另外，根据降糖作用时间长短，可以把GPL-I受体激动剂分为短效和长效制剂，短效制剂对延迟胃排空作用较强，餐后血糖降低明显，长效制剂对延迟胃排空作用较弱，但通过刺激胰岛素分泌和抑制胰高糖素分泌，对空腹血糖降低明显。短效制剂有艾塞那肽，每天注射两次；利司那肽(lixisenatide)，每天一次。", "ner": [[17, 26, "Drug"], [52, 55, "Test_items"], [56, 59, "Test_Value"], [97, 100, "Test_items"], [101, 104, "Test_Value"], [111, 114, "Drug"], [116, 121, "Frequency"], [123, 140, "Drug"], [142, 145, "Frequency"]], "rel": [[116, 121, "Frequency", 111, 114, "Drug", "Frequency_Drug"], [142, 145, "Frequency", 123, 140, "Drug", "Frequency_Drug"]]}
{"idx": 442, "sentence": "长效制剂有利拉鲁肽，每天一次；艾塞那肽周制剂，每周一次；阿必鲁肽(albiglutide)，每周一次；dulaglutide，每周一次。", "ner": [[5, 8, "Drug"], [10, 13, "Frequency"], [15, 21, "Drug"], [23, 26, "Frequency"], [28, 44, "Drug"], [46, 49, "Frequency"], [51, 61, "Drug"], [63, 66, "Frequency"]], "rel": [[10, 13, "Frequency", 5, 8, "Drug", "Frequency_Drug"], [23, 26, "Frequency", 15, 21, "Drug", "Frequency_Drug"], [46, 49, "Frequency", 28, 44, "Drug", "Frequency_Drug"], [63, 66, "Frequency", 51, 61, "Drug", "Frequency_Drug"]]}
{"idx": 443, "sentence": "DPP-4抑制剂通过阻止DPP-4酶降解体内CLP-1，使得CLP-1在生理浓度范围内有一定程度的升高，其降低HbA1c幅度约为0.4%~1.0%。", "ner": [[0, 7, "Drug"], [55, 59, "Test_items"], [64, 72, "Test_Value"]], "rel": []}
{"idx": 444, "sentence": "目前在中国已上市的DPP-4抑制剂药物有西格列汀(sitagliptin,商品名捷诺维)、沙格列汀(saxagliptin，商品名安立泽)、维格列汀(vildagliptin，商品名佳维乐)、利格列汀(linagliptin，商品名欧唐宁)和阿格列汀(alogliptin，商品名尼欣那)。", "ner": [[9, 18, "Drug"], [20, 43, "Drug"], [45, 68, "Drug"], [70, 94, "Drug"], [96, 119, "Drug"], [121, 143, "Drug"]], "rel": []}
{"idx": 445, "sentence": "四、临床应用", "ner": [], "rel": []}
{"idx": 446, "sentence": "(一)GLP-1受体激动剂", "ner": [[3, 12, "Drug"]], "rel": []}
{"idx": 447, "sentence": "CLP-1受体激动剂不但具有显著的降糖效果，还同时兼有低血糖发生率低的优点。", "ner": [[0, 9, "Drug"]], "rel": []}
{"idx": 448, "sentence": "另外具有降低体重、收缩压，改善血脂紊乱的作用。", "ner": [[4, 7, "Symptom"], [9, 11, "Test"], [15, 16, "Test"], [17, 18, "Test_Value"]], "rel": []}
{"idx": 449, "sentence": "1.CLP-1受体激动剂的临床疗效", "ner": [[2, 11, "Drug"]], "rel": []}
{"idx": 450, "sentence": "目前国内上市的GLP-1受体激动剂为艾塞那肽和利拉鲁肽，均需皮下注射。包括我国2型糖尿病患者在内的临床试验显示艾塞那肽可以使HbA1c降低0.8%，利拉鲁肽的疗效和格列美脲相当。", "ner": [[7, 16, "Drug"], [18, 21, "Drug"], [23, 26, "Drug"], [30, 33, "Method"], [39, 43, "Disease"], [55, 58, "Drug"], [62, 66, "Test_items"], [67, 72, "Test_Value"], [74, 77, "Drug"], [82, 85, "Drug"]], "rel": [[30, 33, "Method", 18, 21, "Drug", "Method_Drug"], [30, 33, "Method", 23, 26, "Drug", "Method_Drug"], [55, 58, "Drug", 39, 43, "Disease", "Drug_Disease"], [62, 66, "Test_items", 39, 43, "Disease", "Test_items_Disease"], [74, 77, "Drug", 39, 43, "Disease", "Drug_Disease"], [82, 85, "Drug", 39, 43, "Disease", "Drug_Disease"]]}
{"idx": 451, "sentence": "2.GLP-1受体激动剂的适应证", "ner": [[2, 11, "Drug"]], "rel": []}
{"idx": 452, "sentence": "GLP-1受体激动剂适用于成人2型糖尿病患者。艾塞那肽是在国内最早上市的GLP-1受体激动剂，用于改善2型糖尿病患者的血糖控制，适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者(表1)。", "ner": [[0, 9, "Drug"], [15, 19, "Disease"], [23, 26, "Drug"], [36, 45, "Drug"], [51, 55, "Disease"], [69, 72, "Drug"], [74, 76, "Drug"], [80, 83, "Drug"], [86, 88, "Drug"], [91, 92, "Test_items"], [94, 97, "Test_Value"]], "rel": [[0, 9, "Drug", 15, 19, "Disease", "Drug_Disease"], [23, 26, "Drug", 51, 55, "Disease", "Drug_Disease"], [91, 92, "Test_items", 51, 55, "Disease", "Test_items_Disease"], [69, 72, "Drug", 51, 55, "Disease", "Drug_Disease"], [74, 76, "Drug", 51, 55, "Disease", "Drug_Disease"], [80, 83, "Drug", 51, 55, "Disease", "Drug_Disease"], [86, 88, "Drug", 51, 55, "Disease", "Drug_Disease"]]}
{"idx": 453, "sentence": "在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类、以及基础胰岛素联合使用等。", "ner": [[4, 7, "Drug"], [11, 16, "Drug"], [18, 21, "Drug"], [24, 26, "Drug"], [28, 31, "Drug"], [34, 39, "Drug"], [43, 47, "Drug"]], "rel": []}
{"idx": 454, "sentence": "利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用(表1)。", "ner": [[0, 3, "Drug"], [12, 15, "Drug"], [17, 21, "Drug"], [32, 33, "Test_items"], [35, 38, "Test_Value"], [44, 47, "Drug"], [49, 53, "Drug"]], "rel": []}
{"idx": 455, "sentence": "在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍合用磺脲类或与二甲双胍合用噻唑烷二酮类或与胰岛素联合应用的适应证等。", "ner": [[4, 7, "Drug"], [23, 26, "Drug"], [29, 31, "Drug"], [34, 37, "Drug"], [40, 45, "Drug"], [48, 50, "Drug"]], "rel": []}
{"idx": 456, "sentence": "3.GLP-1受体激动剂的不良反应及注意事项", "ner": [[2, 11, "Drug"]], "rel": []}
{"idx": 457, "sentence": "(1)不良反应：GLP-1受体激动剂的主要不良反应为恶心、呕吐、腹泻、消化不良、食欲下降、低血糖等。", "ner": [[8, 17, "Drug"], [26, 27, "ADE"], [29, 30, "ADE"], [32, 33, "ADE"], [35, 38, "ADE"], [40, 43, "ADE"], [45, 47, "ADE"]], "rel": [[26, 27, "ADE", 8, 17, "Drug", "ADE_Drug"], [29, 30, "ADE", 8, 17, "Drug", "ADE_Drug"], [32, 33, "ADE", 8, 17, "Drug", "ADE_Drug"], [35, 38, "ADE", 8, 17, "Drug", "ADE_Drug"], [40, 43, "ADE", 8, 17, "Drug", "ADE_Drug"], [45, 47, "ADE", 8, 17, "Drug", "ADE_Drug"]]}
{"idx": 458, "sentence": "罕见的不良反应包括胰腺炎、皮疹等。", "ner": [[9, 11, "ADE"], [13, 14, "ADE"]], "rel": []}
{"idx": 459, "sentence": "详细信息请参考各种GLP-1受体激动剂的说明书。", "ner": [[9, 18, "Drug"]], "rel": []}
{"idx": 460, "sentence": "(2)注意事项", "ner": [], "rel": []}
{"idx": 461, "sentence": "①GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。", "ner": [[1, 10, "Drug"], [15, 17, "Drug"], [23, 27, "Disease"], [31, 38, "Disease"]], "rel": [[15, 17, "Drug", 23, 27, "Disease", "Drug_Disease"], [15, 17, "Drug", 31, 38, "Disease", "Drug_Disease"]]}
{"idx": 462, "sentence": "②严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。", "ner": [[3, 7, "Disease"], [1, 2, "Level"], [3, 3, "Anatomy"], [4, 5, "Anatomy"]], "rel": [[3, 3, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"], [4, 5, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 463, "sentence": "③艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，应当告知患者急性胰腺炎的特征性症状。", "ner": [[1, 4, "Drug"], [6, 9, "Drug"], [16, 20, "ADE"], [32, 36, "Disease"], [34, 35, "Anatomy"], [18, 19, "Anatomy"]], "rel": [[16, 20, "ADE", 1, 4, "Drug", "ADE_Drug"], [16, 20, "ADE", 6, 9, "Drug", "ADE_Drug"], [34, 35, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"]]}
{"idx": 464, "sentence": "如果怀疑发生了腹腺炎，应该立即停用。", "ner": [[7, 9, "Disease"], [7, 8, "Anatomy"]], "rel": [[7, 8, "Anatomy", 7, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 465, "sentence": "⑤艾塞那肽有罕见肾功能改变报告，不推荐艾塞那肽用于终末期肾病或严重肾功能不全(肌酐清除率<30ml/min)的患者；利拉鲁肽由于经验有限，不推荐利拉鲁肽用于肾脏终末期患者。", "ner": [[1, 4, "Drug"], [19, 22, "Drug"], [25, 29, "Disease"], [28, 28, "Anatomy"], [31, 37, "Disease"], [33, 33, "Anatomy"], [39, 43, "Test_items"], [44, 52, "Test_Value"], [58, 61, "Drug"], [72, 75, "Drug"], [78, 82, "Disease"], [78, 79, "Anatomy"], [8, 12, "ADE"]], "rel": [[8, 12, "ADE", 1, 4, "Drug", "ADE_Drug"], [28, 28, "Anatomy", 25, 29, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 31, 37, "Disease", "Anatomy_Disease"], [39, 43, "Test_items", 31, 37, "Disease", "Test_items_Disease"], [78, 79, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"]]}
{"idx": 466, "sentence": "⑥利拉鲁肽在纽约心脏病学会(NYHA)分级Ⅰ-Ⅱ级的充血性心力衰竭的患者中的治疗经验有限，尚无在Ⅲ-Ⅳ级充血性心力衰竭患者中的应用经验。", "ner": [[1, 4, "Drug"], [8, 10, "Disease"], [8, 9, "Anatomy"], [55, 55, "Anatomy"], [26, 32, "Disease"], [29, 29, "Anatomy"], [52, 58, "Disease"]], "rel": [[1, 4, "Drug", 26, 32, "Disease", "Drug_Disease"], [8, 9, "Anatomy", 8, 10, "Disease", "Anatomy_Disease"], [55, 55, "Anatomy", 52, 58, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 26, 32, "Disease", "Anatomy_Disease"]]}
{"idx": 467, "sentence": "⑦利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者(MEN2)。", "ner": [[1, 4, "Drug"], [10, 20, "Disease"], [10, 12, "Anatomy"], [32, 52, "Disease"]], "rel": [[10, 12, "Anatomy", 10, 20, "Disease", "Anatomy_Disease"]]}
{"idx": 468, "sentence": "4.禁忌证", "ner": [], "rel": []}
{"idx": 469, "sentence": "GLP-1受体激动剂禁用于对该类产品活性成分或任何其他辅料过敏者。", "ner": [[0, 9, "Drug"], [29, 30, "ADE"]], "rel": [[29, 30, "ADE", 0, 9, "Drug", "ADE_Drug"]]}
{"idx": 470, "sentence": "(二)DPP-4抑制剂", "ner": [[3, 10, "Drug"]], "rel": []}
{"idx": 471, "sentence": "DPP-4抑制剂可抑制DPP-4活性，有效减少GLP-1的失活，在生理范围内增加有活性的GLP-1水平，以葡萄糖浓度依赖的方式促进胰岛素释放，并降低胰高糖素水平，发挥降低糖化血红蛋白(HbA1c)、空腹血糖及餐后血糖的作用。最近临床试验的研究结果证实了阿格列汀和沙格列汀对心血管疾病(CVD)的长期良好安全性。", "ner": [[0, 7, "Drug"], [99, 102, "Test_items"], [104, 107, "Test_items"], [126, 129, "Drug"], [131, 134, "Drug"], [136, 145, "Disease"], [136, 138, "Anatomy"], [85, 97, "Test_items"]], "rel": [[126, 129, "Drug", 136, 145, "Disease", "Drug_Disease"], [131, 134, "Drug", 136, 145, "Disease", "Drug_Disease"], [136, 138, "Anatomy", 136, 145, "Disease", "Anatomy_Disease"]]}
{"idx": 472, "sentence": "1.DPP-4抑制剂的临床疗效(表2)", "ner": [[2, 9, "Drug"]], "rel": []}
{"idx": 473, "sentence": "DPP-4抑制剂国内注册研究的主要疗效见表1。此外，在以二甲双胍为基础治疗，再加用DPP-4抑制剂与其他多种降糖药物，包括磺脲类、噻唑烷二酮类的许多对比研究中，显示DPP-4抑制剂在降低HbA1c方面，与对照药的疗效相当。在中国2型尿病人群的对比研究中维格列汀与阿卡波糖降低HbA1c的作用相似。", "ner": [[0, 7, "Drug"], [28, 31, "Drug"], [41, 48, "Drug"], [61, 63, "Drug"], [65, 70, "Drug"], [82, 89, "Drug"], [93, 97, "Test_items"], [114, 117, "Disease"], [126, 129, "Drug"], [131, 134, "Drug"], [137, 141, "Test_items"]], "rel": [[126, 129, "Drug", 114, 117, "Disease", "Drug_Disease"], [131, 134, "Drug", 114, 117, "Disease", "Drug_Disease"], [137, 141, "Test_items", 114, 117, "Disease", "Test_items_Disease"]]}
{"idx": 474, "sentence": "需要注意的是DPP-4抑制剂降低HbA1c程度与基线HbA1c水平有一定的关系，即基线HbA1c水平高的降低幅度明显。", "ner": [[6, 13, "Drug"], [41, 49, "Test_items"], [16, 20, "Test_items"], [24, 32, "Test_items"], [50, 50, "Test_Value"]], "rel": []}
{"idx": 475, "sentence": "2.DPP-4抑制剂的适应证", "ner": [[2, 9, "Drug"]], "rel": []}
{"idx": 476, "sentence": "DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制(表2)。", "ner": [[0, 7, "Drug"], [13, 17, "Disease"], [42, 45, "Drug"], [49, 52, "Treatment"], [54, 55, "Treatment"], [63, 66, "Drug"], [80, 83, "Drug"], [85, 88, "Drug"], [91, 92, "Treatment"], [94, 95, "Treatment"], [111, 114, "Drug"], [115, 116, "Test_items"], [117, 120, "Test_Value"], [123, 126, "Drug"], [132, 135, "Drug"], [137, 140, "Drug"], [167, 170, "Drug"], [162, 163, "Test_items"], [176, 179, "Drug"], [183, 186, "Treatment"], [188, 189, "Treatment"], [192, 195, "Drug"], [197, 201, "Drug"], [208, 209, "Test_items"], [75, 76, "Test_items"], [21, 22, "Test_items"]], "rel": [[0, 7, "Drug", 13, 17, "Disease", "Drug_Disease"], [21, 22, "Test_items", 13, 17, "Disease", "Test_items_Disease"]]}
{"idx": 477, "sentence": "3.DPP-4抑制剂的不良反应和注意事项", "ner": [[2, 9, "Drug"]], "rel": []}
{"idx": 478, "sentence": "(1)不良反应", "ner": [], "rel": []}
{"idx": 479, "sentence": "DPP-4抑制剂的主要不良反应有鼻咽炎，头痛、上呼吸道感染、低血糖等，低血糖的发生率比磺脲类低。其他一些很少见的不良反应有超敏反应、血管神经性水肿、肝酶升高、腹泻、咳嗽、淋巴细胞绝对计数降低等。最近完成的临床研究结果显示，沙格列汀可明显增加心力衰竭住院的风险，但不增加相关的死亡率。", "ner": [[0, 7, "Drug"], [16, 18, "ADE"], [20, 21, "ADE"], [23, 28, "ADE"], [30, 32, "ADE"], [35, 37, "ADE"], [43, 45, "Drug"], [61, 64, "ADE"], [66, 72, "ADE"], [74, 77, "ADE"], [79, 80, "ADE"], [82, 83, "ADE"], [85, 94, "ADE"], [111, 114, "Reason"], [120, 123, "Disease"], [120, 120, "Anatomy"]], "rel": [[16, 18, "ADE", 0, 7, "Drug", "ADE_Drug"], [20, 21, "ADE", 0, 7, "Drug", "ADE_Drug"], [23, 28, "ADE", 0, 7, "Drug", "ADE_Drug"], [30, 32, "ADE", 0, 7, "Drug", "ADE_Drug"], [35, 37, "ADE", 43, 45, "Drug", "ADE_Drug"], [111, 114, "Reason", 120, 123, "Disease", "Reason_Disease"], [120, 120, "Anatomy", 120, 123, "Disease", "Anatomy_Disease"]]}
{"idx": 480, "sentence": "详细信息请参考各种DPP-4抑制剂的说明书。", "ner": [[9, 16, "Drug"]], "rel": []}
{"idx": 481, "sentence": "(2)注意事项", "ner": [], "rel": []}
{"idx": 482, "sentence": "①DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。", "ner": [[1, 8, "Drug"], [13, 17, "Disease"], [19, 26, "Disease"]], "rel": []}
{"idx": 483, "sentence": "②DPP-4抑制剂在肾功能不全患者中的应用：", "ner": [[1, 8, "Drug"], [10, 14, "Disease"], [10, 10, "Anatomy"]], "rel": [[1, 8, "Drug", 10, 14, "Disease", "Drug_Disease"], [10, 10, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"]]}
{"idx": 484, "sentence": "a.西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病的患者时需要根据肌酐清除率调整剂量。", "ner": [[2, 5, "Drug"], [15, 23, "Disease"], [19, 19, "Anatomy"], [30, 34, "Disease"], [33, 33, "Anatomy"], [43, 47, "Test_items"], [27, 28, "Treatment"]], "rel": [[2, 5, "Drug", 15, 23, "Disease", "Drug_Disease"], [2, 5, "Drug", 30, 34, "Disease", "Drug_Disease"], [19, 19, "Anatomy", 15, 23, "Disease", "Anatomy_Disease"], [43, 47, "Test_items", 15, 23, "Disease", "Test_items_Disease"], [33, 33, "Anatomy", 30, 34, "Disease", "Anatomy_Disease"], [43, 47, "Test_items", 30, 34, "Disease", "Test_items_Disease"], [27, 28, "Treatment", 30, 34, "Disease", "Treatment_Disease"]]}
{"idx": 485, "sentence": "b.维格列汀均在中度或重度肾功能不全患者或需要接受血液透析治疗的终末期肾脏疾病(ESRD)患者中的应用经验有限，因此不推荐此类者使用。", "ner": [[2, 5, "Drug"], [13, 17, "Disease"], [32, 44, "Disease"], [35, 36, "Anatomy"], [8, 12, "Level"], [13, 13, "Anatomy"], [25, 28, "Treatment"]], "rel": [[13, 13, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"], [35, 36, "Anatomy", 32, 44, "Disease", "Anatomy_Disease"], [25, 28, "Treatment", 32, 44, "Disease", "Treatment_Disease"]]}
{"idx": 486, "sentence": "c.沙格列汀在轻度肾功能不全的患者中无需调整剂量。中重度肾功能不全的患者应将剂量调整为2.5mg，每日1次。在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用。", "ner": [[2, 5, "Drug"], [9, 13, "Disease"], [7, 8, "Level"], [9, 9, "Anatomy"], [28, 32, "Disease"], [25, 27, "Level"], [28, 28, "Anatomy"], [43, 47, "Amount"], [49, 52, "Frequency"], [57, 61, "Disease"], [55, 56, "Level"], [57, 57, "Anatomy"]], "rel": [[2, 5, "Drug", 9, 13, "Disease", "Drug_Disease"], [9, 9, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [28, 28, "Anatomy", 28, 32, "Disease", "Anatomy_Disease"], [57, 57, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"]]}
{"idx": 487, "sentence": "d.利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量。", "ner": [[2, 5, "Drug"], [20, 24, "Disease"], [20, 20, "Anatomy"]], "rel": [[2, 5, "Drug", 20, 24, "Disease", "Drug_Disease"], [20, 20, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"]]}
{"idx": 488, "sentence": "e.阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。", "ner": [[2, 5, "Drug"], [9, 13, "Disease"], [7, 8, "Level"], [9, 9, "Anatomy"], [31, 34, "Disease"], [29, 30, "Level"], [31, 31, "Anatomy"], [36, 43, "Disease"], [39, 39, "Anatomy"], [52, 59, "Amount"], [22, 27, "Amount"]], "rel": [[2, 5, "Drug", 9, 13, "Disease", "Drug_Disease"], [2, 5, "Drug", 31, 34, "Disease", "Drug_Disease"], [2, 5, "Drug", 36, 43, "Disease", "Drug_Disease"], [22, 27, "Amount", 2, 5, "Drug", "Amount_Drug"], [52, 59, "Amount", 2, 5, "Drug", "Amount_Drug"], [9, 9, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [31, 31, "Anatomy", 31, 34, "Disease", "Anatomy_Disease"], [39, 39, "Anatomy", 36, 43, "Disease", "Anatomy_Disease"]]}
{"idx": 489, "sentence": "推荐在开始使用阿格列汀前评估肾功能并定期复查。", "ner": [[7, 10, "Drug"], [14, 16, "Test"]], "rel": []}
{"idx": 490, "sentence": "③DPP-4抑制剂在肝功能不全患者中的应用", "ner": [[1, 8, "Drug"], [10, 14, "Disease"], [10, 10, "Anatomy"]], "rel": [[1, 8, "Drug", 10, 14, "Disease", "Drug_Disease"], [10, 10, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"]]}
{"idx": 491, "sentence": "a.西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整；尚无严重肝功能不全患者使用的临床经验。", "ner": [[2, 5, "Drug"], [13, 17, "Disease"], [8, 12, "Level"], [13, 13, "Anatomy"], [36, 40, "Disease"], [34, 35, "Level"], [36, 36, "Anatomy"]], "rel": [[2, 5, "Drug", 13, 17, "Disease", "Drug_Disease"], [13, 13, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"], [36, 36, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"]]}
{"idx": 492, "sentence": "b.维格列汀不推荐用于开始给药前血清谷丙转氨酵或谷草转氨酶大于正常上限3倍的患者；罕见有肝功能障碍(包括肝炎)报告，需要进行定期检测肝酶；", "ner": [[2, 5, "Drug"], [16, 22, "Test_items"], [24, 28, "Test_items"], [29, 36, "Test_Value"], [44, 48, "ADE"], [52, 53, "ADE"], [64, 67, "Test"]], "rel": [[44, 48, "ADE", 2, 5, "Drug", "ADE_Drug"], [52, 53, "ADE", 2, 5, "Drug", "ADE_Drug"]]}
{"idx": 493, "sentence": "对于用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用。", "ner": [[7, 10, "ADE"], [14, 16, "Test"]], "rel": []}
{"idx": 494, "sentence": "c.沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者。", "ner": [[2, 5, "Drug"], [10, 14, "Disease"], [8, 9, "Level"], [10, 10, "Anatomy"], [30, 34, "Disease"], [28, 29, "Level"], [30, 30, "Anatomy"]], "rel": [[2, 5, "Drug", 10, 14, "Disease", "Drug_Disease"], [10, 10, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [30, 30, "Anatomy", 30, 34, "Disease", "Anatomy_Disease"]]}
{"idx": 495, "sentence": "d.利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量。", "ner": [[2, 5, "Drug"], [11, 15, "Disease"], [11, 11, "Anatomy"]], "rel": [[2, 5, "Drug", 11, 15, "Disease", "Drug_Disease"], [11, 11, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"]]}
{"idx": 496, "sentence": "e.阿格列汀在肝功能检查结果异常的患者中应慎重使用。如果患者报告发生可能提示肝损伤的症状，迅速进行肝功能检查。如果患者出现具有临床意义的肝酶升高，和肝功能检查异常结果持续或恶化，应停用阿格列汀。", "ner": [[2, 5, "Drug"], [7, 9, "Test"], [38, 40, "Disease"], [49, 51, "Test"], [68, 69, "Test"], [70, 71, "Test_Value"], [74, 76, "Test"], [92, 95, "Drug"], [38, 38, "Anatomy"], [79, 87, "Test_Value"], [14, 15, "Test_Value"]], "rel": [[38, 38, "Anatomy", 38, 40, "Disease", "Anatomy_Disease"], [49, 51, "Test", 38, 40, "Disease", "Test_Disease"]]}
{"idx": 497, "sentence": "如果未发现引起肝功能检查异常的其他原因，不要在此类患者中再次使用阿格列汀。", "ner": [[7, 9, "Test"], [32, 35, "Drug"], [12, 13, "Test_Value"]], "rel": []}
{"idx": 498, "sentence": "④超敏反应", "ner": [[1, 4, "ADE"]], "rel": []}
{"idx": 499, "sentence": "a.西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和脱性皮肤损害，包括Stevens-Johnson综合征。如怀疑发生超敏反应，应停止使用。", "ner": [[2, 5, "Drug"], [13, 18, "ADE"], [22, 25, "ADE"], [27, 31, "ADE"], [33, 38, "ADE"], [42, 59, "ADE"], [66, 69, "ADE"]], "rel": [[13, 18, "ADE", 2, 5, "Drug", "ADE_Drug"], [22, 25, "ADE", 2, 5, "Drug", "ADE_Drug"], [27, 31, "ADE", 2, 5, "Drug", "ADE_Drug"], [33, 38, "ADE", 2, 5, "Drug", "ADE_Drug"], [42, 59, "ADE", 2, 5, "Drug", "ADE_Drug"]]}
{"idx": 500, "sentence": "b.维格列汀和沙格列汀在对猴子进行的毒理学研究中，出现四肢皮肤的损伤报告，尽管未在临床中观察到皮肤损伤的发生率升高，但在合并有糖尿病皮肤并发症的患者中经验有限。", "ner": [[2, 5, "Drug"], [7, 10, "Drug"], [47, 50, "ADE"], [27, 33, "ADE"], [63, 70, "Disease"], [66, 67, "Anatomy"]], "rel": [[2, 5, "Drug", 63, 70, "Disease", "Drug_Disease"], [27, 33, "ADE", 2, 5, "Drug", "ADE_Drug"], [47, 50, "ADE", 2, 5, "Drug", "ADE_Drug"], [7, 10, "Drug", 63, 70, "Disease", "Drug_Disease"], [27, 33, "ADE", 7, 10, "Drug", "ADE_Drug"], [47, 50, "ADE", 7, 10, "Drug", "ADE_Drug"], [66, 67, "Anatomy", 63, 70, "Disease", "Anatomy_Disease"]]}
{"idx": 501, "sentence": "建议观察皮肤病变，如水疱、皮疹或溃疡等情况。", "ner": [[4, 7, "Disease"], [4, 5, "Anatomy"], [10, 11, "Disease"], [13, 14, "Disease"], [16, 17, "Disease"]], "rel": [[4, 5, "Anatomy", 4, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 502, "sentence": "c.阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应，停用阿格列汀。", "ner": [[2, 5, "Drug"], [26, 31, "ADE"], [35, 38, "Drug"], [12, 19, "ADE"]], "rel": [[12, 19, "ADE", 2, 5, "Drug", "ADE_Drug"], [26, 31, "ADE", 35, 38, "Drug", "ADE_Drug"]]}
{"idx": 503, "sentence": "d.沙格列汀和阿格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)。如果疑有沙格列汀严重超敏反应，则停止使用，评估是否还存在其他可能的原因，并改用别的方案治疗糖尿病。", "ner": [[2, 5, "Drug"], [17, 22, "ADE"], [26, 31, "ADE"], [33, 37, "ADE"], [44, 47, "Drug"], [48, 53, "ADE"], [85, 87, "Disease"], [7, 10, "Drug"]], "rel": [[17, 22, "ADE", 2, 5, "Drug", "ADE_Drug"], [26, 31, "ADE", 2, 5, "Drug", "ADE_Drug"], [33, 37, "ADE", 2, 5, "Drug", "ADE_Drug"], [17, 22, "ADE", 7, 10, "Drug", "ADE_Drug"], [26, 31, "ADE", 7, 10, "Drug", "ADE_Drug"], [33, 37, "ADE", 7, 10, "Drug", "ADE_Drug"], [48, 53, "ADE", 44, 47, "Drug", "ADE_Drug"], [44, 47, "Drug", 85, 87, "Disease", "Drug_Disease"]]}
{"idx": 504, "sentence": "e.利格列汀治疗的临床研究中报告的其他不良反应有高敏反应(例如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应)。", "ner": [[2, 5, "Drug"], [24, 27, "ADE"], [31, 33, "ADE"], [35, 39, "ADE"], [41, 46, "ADE"], [48, 54, "ADE"]], "rel": [[24, 27, "ADE", 2, 5, "Drug", "ADE_Drug"], [31, 33, "ADE", 2, 5, "Drug", "ADE_Drug"], [35, 39, "ADE", 2, 5, "Drug", "ADE_Drug"], [41, 46, "ADE", 2, 5, "Drug", "ADE_Drug"], [48, 54, "ADE", 2, 5, "Drug", "ADE_Drug"]]}
{"idx": 505, "sentence": "⑤沙格列汀及维格列汀含有乳糖，罕见的半乳糖不耐受遗传疾病、Lapp乳糖酶缺乏症或葡萄糖-半乳糖吸收不良患者不得服用。", "ner": [[1, 4, "Drug"], [6, 9, "Drug"], [18, 27, "Disease"], [29, 38, "Disease"], [40, 50, "Disease"]], "rel": []}
{"idx": 506, "sentence": "⑥维格列汀和沙格列汀在纽约心功能分级(NYHA)为Ⅰ-Ⅱ级的充血性心力衰竭的患者中经验有限，此类患者中慎用；尚未在Ⅲ-Ⅳ级充血性心力衰竭的患者中进行临床试验，不推荐在此类患者中使用。", "ner": [[1, 4, "Drug"], [6, 9, "Drug"], [33, 33, "Anatomy"], [57, 67, "Disease"], [64, 64, "Anatomy"], [30, 36, "Disease"]], "rel": [[1, 4, "Drug", 30, 36, "Disease", "Drug_Disease"], [6, 9, "Drug", 30, 36, "Disease", "Drug_Disease"], [33, 33, "Anatomy", 30, 36, "Disease", "Anatomy_Disease"], [64, 64, "Anatomy", 57, 67, "Disease", "Anatomy_Disease"]]}
{"idx": 507, "sentence": "⑦药物相互作用：西格列汀在与磺脲类药物合用时低血糖风险增加，需适当减少磺脉类药物的剂量。利格列汀在与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类药物的剂量。沙格列汀的代谢主要由CYP3A4/5介导。沙格列汀的主要代谢产物也是DPP-4抑制剂，其抑制活性作用是沙格列汀的二分之一。因此，CYP3A4/5强抑制剂和强诱导剂能改变沙格列汀及其代谢物的药代动力学。与强效CYP3A4/5抑制剂(如酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那书和泰利霉素)合用时，应将沙格列汀的剂量限制为2.5mg/d。", "ner": [[8, 11, "Drug"], [14, 18, "Drug"], [22, 24, "ADE"], [35, 39, "Drug"], [44, 47, "Drug"], [50, 52, "Drug"], [54, 56, "Drug"], [60, 62, "ADE"], [73, 75, "Drug"], [77, 81, "Drug"], [86, 89, "Drug"], [107, 110, "Drug"], [137, 140, "Drug"], [170, 173, "Drug"], [187, 199, "Drug"], [202, 204, "Drug"], [206, 209, "Drug"], [211, 214, "Drug"], [216, 219, "Drug"], [221, 224, "Drug"], [226, 229, "Drug"], [231, 234, "Drug"], [236, 239, "Drug"], [241, 244, "Drug"], [246, 249, "Drug"], [257, 260, "Drug"], [150, 166, "Drug"], [267, 273, "Amount"]], "rel": [[22, 24, "ADE", 8, 11, "Drug", "ADE_Drug"], [22, 24, "ADE", 14, 18, "Drug", "ADE_Drug"], [60, 62, "ADE", 44, 47, "Drug", "ADE_Drug"], [60, 62, "ADE", 50, 52, "Drug", "ADE_Drug"], [60, 62, "ADE", 54, 56, "Drug", "ADE_Drug"], [267, 273, "Amount", 257, 260, "Drug", "Amount_Drug"]]}
{"idx": 508, "sentence": "4.DPP-4抑制剂的禁忌证", "ner": [[2, 9, "Drug"]], "rel": []}
{"idx": 509, "sentence": "已知对药物或药物中任何一成分过敏者禁用。", "ner": [[14, 15, "ADE"]], "rel": []}
{"idx": 510, "sentence": "五、小结", "ner": [], "rel": []}
{"idx": 511, "sentence": "基于GLP-1类降糖药物的应用是2型糖尿病治疗中的一个重要发展，其药物作用的特点弥补了传统降糖药物治疗中的一些不足之处。多项研究结果显示CLP-1受体激动剂具有葡萄糖浓度依赖性降低血糖作用的特点，低血糖发生率低，还可减轻体重、降低收缩压、减少心血管疾病危险因素。", "ner": [[2, 11, "Drug"], [16, 20, "Disease"], [68, 77, "Drug"], [90, 91, "Test_items"], [98, 100, "ADE"], [108, 111, "Symptom"], [115, 117, "Test"], [121, 125, "Disease"], [121, 123, "Anatomy"]], "rel": [[2, 11, "Drug", 16, 20, "Disease", "Drug_Disease"], [98, 100, "ADE", 68, 77, "Drug", "ADE_Drug"], [121, 123, "Anatomy", 121, 125, "Disease", "Anatomy_Disease"]]}
{"idx": 512, "sentence": "目前GLP-1受体激动剂艾塞那肽和利拉鲁肽在国内均被批准可在一种口服药(二甲双胍或磺脲类)治疗失效后开始使用，艾塞那肽还可在二甲双胍与磺脲类联合治疗失效后开始使用。", "ner": [[2, 11, "Drug"], [12, 15, "Drug"], [17, 20, "Drug"], [32, 33, "Method"], [36, 39, "Drug"], [41, 43, "Drug"], [55, 58, "Drug"], [62, 65, "Drug"], [67, 69, "Drug"]], "rel": []}
{"idx": 513, "sentence": "这为我国2型糖尿病忠者降糖治疗提供了一种新的选择。", "ner": [[4, 8, "Disease"]], "rel": []}
{"idx": 514, "sentence": "DPP-4抑制剂均为口服制剂，使用方便，也具有葡萄糖浓度依赖性降低血糖作用，低血糖发生率低，对体重的影响小，已有报告阿格列汀和沙格列汀对CVD的长期安全性良好，胃肠道不良反应少。目前DPP-4抑制剂在国内被批准用于单药或与二甲双胍或与磺脲类联合治疗。综上所述，作为新一类2型糖尿病的治疗药物，基于GLP-1的降糖药物为临床控制糖尿病提供了新的治疗手段。", "ner": [[0, 7, "Drug"], [10, 11, "Method"], [33, 34, "Test_items"], [38, 40, "ADE"], [58, 61, "Drug"], [63, 66, "Drug"], [68, 70, "Disease"], [91, 98, "Drug"], [111, 114, "Drug"], [117, 119, "Drug"], [135, 139, "Disease"], [148, 157, "Drug"], [163, 165, "Disease"], [80, 86, "ADE"]], "rel": [[10, 11, "Method", 0, 7, "Drug", "Method_Drug"], [38, 40, "ADE", 0, 7, "Drug", "ADE_Drug"], [58, 61, "Drug", 68, 70, "Disease", "Drug_Disease"], [80, 86, "ADE", 58, 61, "Drug", "ADE_Drug"], [63, 66, "Drug", 68, 70, "Disease", "Drug_Disease"], [80, 86, "ADE", 63, 66, "Drug", "ADE_Drug"], [148, 157, "Drug", 163, 165, "Disease", "Drug_Disease"]]}
{"idx": 515, "sentence": "④GLP-1受体激动剂在与磺脲类药物合用时低血糖发生率升高，适当减少磺脲类药物的剂量可减少低血糖风险。在联合使用GLP-1受体激动剂与磺脲类药物时，应告知患者在驾驶或操作机械时采取必要措施防止发生低血糖。", "ner": [[1, 10, "Drug"], [13, 17, "Drug"], [21, 23, "ADE"], [34, 38, "Drug"], [45, 47, "ADE"], [56, 65, "Drug"], [67, 71, "Drug"], [98, 100, "ADE"]], "rel": [[21, 23, "ADE", 1, 10, "Drug", "ADE_Drug"], [21, 23, "ADE", 13, 17, "Drug", "ADE_Drug"], [45, 47, "ADE", 34, 38, "Drug", "ADE_Drug"], [98, 100, "ADE", 56, 65, "Drug", "ADE_Drug"], [98, 100, "ADE", 67, 71, "Drug", "ADE_Drug"]]}
{"idx": 516, "sentence": "二甲双胍临床应用专家共识", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 517, "sentence": "二甲双胍自1957年问世，应用于临床已有50多年的历史，是当前全球应用最广泛的口服降糖药之一。近年来有许多种新型降糖药物上市，但二甲双胍仍是在全球使用量迅速增加的经典口服降糖药物。二甲双胍具有良好的单药/联合治疗的疗效和安全性证据，以及良好的卫生经济学效益证据。无论对于血糖控制，还是糖尿病心血管并发症的预防，其都有明确的临床证据。", "ner": [[0, 3, "Drug"], [64, 67, "Drug"], [90, 93, "Drug"], [142, 144, "Disease"], [135, 136, "Test_items"], [145, 147, "Anatomy"]], "rel": [[135, 136, "Test_items", 142, 144, "Disease", "Test_items_Disease"], [145, 147, "Anatomy", 142, 144, "Disease", "Anatomy_Disease"]]}
{"idx": 518, "sentence": "因此，该药已成为全球控制糖尿病的核心药物。", "ner": [[12, 14, "Disease"]], "rel": []}
{"idx": 519, "sentence": "二甲双胍在我国已经有近20年的使用经验。1995年，FDA正式批准二甲双胍用于治疗T2DM，2004年欧盟正式批准二甲双胍用于治疗10岁以上的儿童T2DM。国内外主要糖尿病指南均建议：无论患者超重与否，除非有肾损害的证据或风险，否则均应从开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了二甲双胍在糖尿病治疗中的“基石“地位。然而,在临床工作中，仍有部分医生和患者对二甲双胍的使用(有效性、剂量、用法、安全性、疗效与体重的关系等)存在误区，如因担心胃肠道反应未能发挥二甲双胍的剂量优势：因担心其损害肝肾功能和引起乳酸酸中毒等，使一些原本可从二甲双胍治疗中获益的患者错失治疗良机，为此，我们组织内分泌临床专家、药学专家共同制定《二甲双胍临床应用专家共识》，以指导临床医生和患者正确认识并合理使用二甲双胍。", "ner": [[0, 3, "Drug"], [41, 44, "Disease"], [73, 76, "Disease"], [57, 60, "Drug"], [83, 85, "Disease"], [124, 127, "Drug"], [144, 147, "Drug"], [153, 156, "Drug"], [158, 160, "Disease"], [192, 195, "Drug"], [233, 237, "ADE"], [242, 245, "Drug"], [256, 261, "ADE"], [265, 269, "ADE"], [279, 282, "Drug"], [322, 325, "Drug"], [355, 358, "Drug"], [33, 36, "Drug"], [96, 97, "Disease"], [104, 106, "Disease"], [104, 104, "Anatomy"]], "rel": [[33, 36, "Drug", 41, 44, "Disease", "Drug_Disease"], [57, 60, "Drug", 73, 76, "Disease", "Drug_Disease"], [124, 127, "Drug", 83, 85, "Disease", "Drug_Disease"], [144, 147, "Drug", 83, 85, "Disease", "Drug_Disease"], [153, 156, "Drug", 158, 160, "Disease", "Drug_Disease"], [233, 237, "ADE", 242, 245, "Drug", "ADE_Drug"], [256, 261, "ADE", 279, 282, "Drug", "ADE_Drug"], [265, 269, "ADE", 279, 282, "Drug", "ADE_Drug"], [104, 104, "Anatomy", 104, 106, "Disease", "Anatomy_Disease"]]}
{"idx": 520, "sentence": "循证医学证据分级、常见缩略语及主要推荐意见见表1~3。", "ner": [], "rel": []}
{"idx": 521, "sentence": "一、临床地位与使用时机", "ner": [], "rel": []}
{"idx": 522, "sentence": "1.治疗T2DM的一线首选用药：二甲双胍具有可靠的短期和长期降糖疗效，单独使用可有效降低T2DM患者的FPG、PPG，可使HbA1c下降1%~2%，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的降糖疗效显著强于其他口服降糖药。二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(Ⅰ级)。联合胰岛素可降低血糖、改善血脂，同时减轻胰岛素引起的体重增加，减少胰岛素用量。该药具有心血管保护作用，是目前唯一被糖尿病指南推荐为有明确心血管获益证据的降糖药物。二甲双胍的长期治疗与新诊断的T2DM患者及已经发生了心血管疾病的T2DM患者的心血管疾病发生风险下降相关(Ⅰ级)。二甲双胍具有良好的安全性和耐受性，低血糖的发生率低，胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症和乳酸酸中毒的风险。", "ner": [[4, 7, "Disease"], [16, 19, "Drug"], [51, 53, "Test_items"], [55, 57, "Test_items"], [61, 65, "Test_items"], [44, 47, "Disease"], [88, 92, "Test_items"], [124, 128, "Test_items"], [166, 169, "Drug"], [200, 201, "Test_items"], [211, 213, "Drug"], [217, 218, "Test_items"], [222, 223, "Test"], [229, 231, "Drug"], [242, 244, "Drug"], [66, 72, "Test_Value"], [93, 98, "Test_Value"], [235, 238, "ADE"], [140, 147, "Amount"], [186, 187, "Method"], [160, 161, "Method"], [266, 268, "Disease"], [290, 293, "Drug"], [304, 307, "Disease"], [347, 350, "Drug"], [364, 366, "ADE"], [373, 377, "ADE"], [387, 390, "ADE"], [399, 403, "Disease"], [405, 409, "Disease"], [316, 320, "Disease"], [316, 318, "Anatomy"], [329, 333, "Disease"], [329, 331, "Anatomy"], [81, 84, "Disease"], [322, 325, "Disease"]], "rel": [[16, 19, "Drug", 4, 7, "Disease", "Drug_Disease"], [51, 53, "Test_items", 44, 47, "Disease", "Test_items_Disease"], [55, 57, "Test_items", 44, 47, "Disease", "Test_items_Disease"], [61, 65, "Test_items", 44, 47, "Disease", "Test_items_Disease"], [88, 92, "Test_items", 81, 84, "Disease", "Test_items_Disease"], [235, 238, "ADE", 229, 231, "Drug", "ADE_Drug"], [290, 293, "Drug", 304, 307, "Disease", "Drug_Disease"], [364, 366, "ADE", 347, 350, "Drug", "ADE_Drug"], [373, 377, "ADE", 347, 350, "Drug", "ADE_Drug"], [316, 318, "Anatomy", 316, 320, "Disease", "Anatomy_Disease"], [329, 331, "Anatomy", 329, 333, "Disease", "Anatomy_Disease"]]}
{"idx": 523, "sentence": "与其他降糖药物相比，具有更好的成本效益比(Ⅰ级)。", "ner": [], "rel": []}
{"idx": 524, "sentence": "如无禁忌症，二甲双胍是T2DM药物治疗的首选药物，且应一直保留在糖尿病治疗方案中。", "ner": [[11, 14, "Disease"], [32, 34, "Disease"], [6, 9, "Drug"]], "rel": [[6, 9, "Drug", 11, 14, "Disease", "Drug_Disease"]]}
{"idx": 525, "sentence": "2.超重或肥胖T2DM患者的首选用药：回顾性和前瞻性的临床研究结果均显示，二甲双胍在正常体重、超重、肥胖的T2DM患者中的疗效相当，", "ner": [[7, 10, "Disease"], [53, 56, "Disease"], [37, 40, "Drug"], [2, 3, "Disease"], [5, 6, "Disease"], [47, 48, "Disease"], [50, 51, "Disease"]], "rel": [[37, 40, "Drug", 53, 56, "Disease", "Drug_Disease"]]}
{"idx": 526, "sentence": "因此，体重不是使用二甲双胍治疗与否的决定因素(Ⅰ级)。无论对于超重患者还是体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。", "ner": [[9, 12, "Drug"], [31, 32, "Disease"], [50, 52, "Disease"], [65, 68, "Disease"], [58, 61, "Drug"]], "rel": [[58, 61, "Drug", 65, 68, "Disease", "Drug_Disease"]]}
{"idx": 527, "sentence": "3.对于糖尿病的预防作用：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。二甲双胍能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。但在我国预防糖尿病尚不是二甲双胍的适应证。DPP研究显示，二甲双胍干预治疗3年可使糖尿病的发生率降低31%，且在中年腹型肥胖的患者中干预效果最佳(Ⅰ级)。IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低发生糖尿病的危险(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好选择生活方式干预，对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。", "ner": [[4, 6, "Disease"], [13, 16, "Drug"], [27, 29, "Disease"], [33, 35, "Disease"], [42, 45, "Drug"], [61, 64, "Disease"], [92, 94, "Disease"], [98, 101, "Drug"], [127, 129, "Disease"], [115, 118, "Drug"], [144, 147, "Disease"], [172, 175, "Drug"], [198, 200, "Disease"], [219, 222, "Disease"], [230, 232, "Disease"], [257, 258, "Disease"], [265, 268, "Drug"], [246, 248, "Disease"], [52, 56, "Disease"], [182, 187, "Treatment"]], "rel": [[13, 16, "Drug", 27, 29, "Disease", "Drug_Disease"], [13, 16, "Drug", 33, 35, "Disease", "Drug_Disease"], [42, 45, "Drug", 52, 56, "Disease", "Drug_Disease"], [42, 45, "Drug", 61, 64, "Disease", "Drug_Disease"], [98, 101, "Drug", 92, 94, "Disease", "Drug_Disease"], [115, 118, "Drug", 127, 129, "Disease", "Drug_Disease"], [115, 118, "Drug", 144, 147, "Disease", "Drug_Disease"], [172, 175, "Drug", 198, 200, "Disease", "Drug_Disease"], [182, 187, "Treatment", 198, 200, "Disease", "Treatment_Disease"], [265, 268, "Drug", 230, 232, "Disease", "Drug_Disease"], [265, 268, "Drug", 257, 258, "Disease", "Drug_Disease"], [265, 268, "Drug", 246, 248, "Disease", "Drug_Disease"]]}
{"idx": 528, "sentence": "DPP研究随访显示，生活方式干预组和二甲双胍治疗组与安慰剂组相比，10年内糖尿病病发生率分别降低了34%和18%(Ⅰ级)。", "ner": [[18, 21, "Drug"], [37, 39, "Disease"], [10, 15, "Treatment"]], "rel": [[18, 21, "Drug", 37, 39, "Disease", "Drug_Disease"], [10, 15, "Treatment", 37, 39, "Disease", "Treatment_Disease"]]}
{"idx": 529, "sentence": "二、作用机制", "ner": [], "rel": []}
{"idx": 530, "sentence": "1.二甲双胍的降糖作用机制：二甲双胍治疗糖尿病的作用机制包括(1)通过直接抑制肝脏的糖异生降低FPG；(2)通过提高外周组织(肌肉、脂肪)对葡萄糖的摄取和利用，降低PPG；(3)减少小肠内葡萄糖吸收；(4)通过抑制线粒体复合物Ⅰ和线粒体氧化磷酸化，减少ATP合成，激活AMPK，促进脂肪酸进入线粒体进行脂肪酸β氧化，减少脂肪合成，从而减轻IR；(5)改善IS，提高胰岛β细胞对血糖的应答；(6)升高GLP-1水平。", "ner": [[2, 5, "Drug"], [20, 22, "Disease"], [14, 17, "Drug"], [47, 49, "Test_items"], [82, 84, "Test_items"], [188, 189, "Test_items"], [169, 170, "Pathogenesis"], [199, 203, "Test_items"]], "rel": [[14, 17, "Drug", 20, 22, "Disease", "Drug_Disease"], [47, 49, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [82, 84, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [188, 189, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [199, 203, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [169, 170, "Pathogenesis", 20, 22, "Disease", "Pathogenesis_Disease"]]}
{"idx": 531, "sentence": "2.二甲双胍是一种胰岛素增敏剂：《Joslin糖尿病学》将二甲双胍归为增敏剂一类。IR是T2DM的主要病理生理特征之一。", "ner": [[2, 5, "Drug"], [23, 25, "Disease"], [29, 32, "Drug"], [44, 47, "Disease"], [9, 14, "Drug"], [41, 42, "Pathogenesis"]], "rel": [[29, 32, "Drug", 23, 25, "Disease", "Drug_Disease"], [41, 42, "Pathogenesis", 44, 47, "Disease", "Pathogenesis_Disease"]]}
{"idx": 532, "sentence": "机体在IR的代偿反应是分泌更多的胰岛素，以维持正常的糖代谢。", "ner": [[3, 4, "Pathogenesis"]], "rel": []}
{"idx": 533, "sentence": "胰岛素增敏剂通过改善IR，增加胰岛素刺激的葡萄糖利用，减少脂肪酸氧化代谢，抑制肝糖输出。", "ner": [[0, 5, "Drug"], [10, 11, "Pathogenesis"]], "rel": []}
{"idx": 534, "sentence": "二甲双胍通过抑制肝糖原分解，降低肝糖异生，增强胰岛素与外周组织胰岛素受体的亲合力，促进葡萄糖的摄取和利用，改善组织对胰岛素的敏感性。", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 535, "sentence": "三、剂量与临床疗效", "ner": [], "rel": []}
{"idx": 536, "sentence": "1.最小、最大及最佳使用剂量：二甲双胍的降糖效果与剂量(500~2000mg/d)呈正相关。500mg/d二甲双胍可降低HbA1c0.6%(减去安慰剂效应后，以下同)，2000mg/d可降低HbA1c2%，且胃肠道反应与1000或1500mg/d差异无统计学意义(Ⅰ级)。UKPDS研究中二甲双胍强化治疗剂量中位数达到2550mg/d，缓释剂型推荐最大用量为2000mg/d，普通片推荐成人最大剂量为2550mg/d。二甲双胍起效的最小推荐剂量500mg/d，成人最大量2550mg/d，最佳有效剂量2000mg/d。", "ner": [[15, 18, "Drug"], [46, 52, "Amount"], [53, 56, "Drug"], [60, 64, "Test_items"], [84, 91, "Amount"], [104, 108, "ADE"], [144, 147, "Drug"], [159, 166, "Amount"], [179, 186, "Amount"], [200, 207, "Amount"], [222, 228, "Amount"], [235, 242, "Amount"], [250, 257, "Amount"], [110, 122, "Amount"], [95, 99, "Test_items"], [209, 212, "Drug"], [65, 68, "Test_Value"], [100, 101, "Test_Value"], [28, 39, "Amount"]], "rel": [[28, 39, "Amount", 15, 18, "Drug", "Amount_Drug"], [46, 52, "Amount", 53, 56, "Drug", "Amount_Drug"], [84, 91, "Amount", 53, 56, "Drug", "Amount_Drug"], [110, 122, "Amount", 53, 56, "Drug", "Amount_Drug"], [104, 108, "ADE", 53, 56, "Drug", "ADE_Drug"], [159, 166, "Amount", 144, 147, "Drug", "Amount_Drug"], [179, 186, "Amount", 144, 147, "Drug", "Amount_Drug"], [200, 207, "Amount", 144, 147, "Drug", "Amount_Drug"], [222, 228, "Amount", 209, 212, "Drug", "Amount_Drug"], [235, 242, "Amount", 209, 212, "Drug", "Amount_Drug"], [250, 257, "Amount", 209, 212, "Drug", "Amount_Drug"]]}
{"idx": 537, "sentence": "2.剂量调整原则：二甲双胍的剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000mg/d，1~2周后加量至1000mg/d，继续1~2周加量1次。最佳剂量为2000mg/d(1000mg，2次/d或2000mg/d，3次/d)。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案：建议起始500mg，2次/d，如无明显胃肠道不良反应，2周后可增加至1000mg，2次/d可根据患者状况个体化治疗，每日总剂量1500~2550mg，分2~3次服用。老年人及肝肾功能不全的患者需要调整剂量，具体调整方法详见“四”中，二甲双胍在特殊人群的使用。", "ner": [[9, 12, "Drug"], [39, 45, "Amount"], [47, 55, "Amount"], [65, 72, "Amount"], [90, 97, "Amount"], [99, 104, "Amount"], [106, 109, "Frequency"], [111, 118, "Amount"], [120, 123, "Frequency"], [126, 129, "Drug"], [132, 141, "Method"], [147, 150, "Frequency"], [194, 198, "Amount"], [200, 203, "Frequency"], [224, 229, "Amount"], [231, 234, "Frequency"], [209, 215, "ADE"], [152, 161, "Method"], [253, 263, "Amount"], [265, 269, "Frequency"], [277, 282, "Disease"], [306, 309, "Drug"], [277, 277, "Anatomy"], [278, 278, "Anatomy"]], "rel": [[132, 141, "Method", 126, 129, "Drug", "Method_Drug"], [152, 161, "Method", 126, 129, "Drug", "Method_Drug"], [147, 150, "Frequency", 126, 129, "Drug", "Frequency_Drug"], [277, 277, "Anatomy", 277, 282, "Disease", "Anatomy_Disease"], [278, 278, "Anatomy", 277, 282, "Disease", "Anatomy_Disease"]]}
{"idx": 538, "sentence": "3.剂型：目前国内外主要有单一成分的二甲双胍普通片(250mg/片，500mg/片或850rag/片)、二甲双胍缓释片或胶囊(500mg/片或500mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药[如磺脲类药物或DPP-4抑制剂]组成的复方制剂。", "ner": [[110, 115, "Drug"], [129, 133, "Drug"], [135, 142, "Drug"], [122, 123, "Method"], [18, 24, "Drug"], [52, 61, "Drug"], [81, 90, "Drug"]], "rel": [[122, 123, "Method", 129, 133, "Drug", "Method_Drug"], [122, 123, "Method", 135, 142, "Drug", "Method_Drug"]]}
{"idx": 539, "sentence": "4.不同剂型的疗效区别：(1)各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同。", "ner": [], "rel": []}
{"idx": 540, "sentence": "普通片剂在胃内崩解释放；肠溶片在从胃排空到肠道后崩解释放；缓释片和缓释胶囊在肠道内缓慢地溶出、释放；肠溶胶囊在肠道内溶出、释放；(2)普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之。", "ner": [], "rel": []}
{"idx": 541, "sentence": "因每种制剂给药后血药浓度峰值、达峰时间、表观半衰期等参数存在一定的差异，所以多剂量给药后的达稳时间也不一致；(3)缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；(4)合格的药物制剂，在相同的给药剂量下，各种剂型间应具有生物等效性；(5)不同剂型的临床疗效是否一致，尚需更多的大样本临床研究证实。", "ner": [[87, 91, "ADE"]], "rel": []}
{"idx": 542, "sentence": "5.单药治疗的降糖疗效：一项双盲、安慰剂对照、剂量效应研究显示，在减去安慰剂效应后，不同剂量的二甲双胍单药治疗可使FPG降低1.05~4.33mmol/L，HbA1c下降0.9%~2.o%。另有研究显示，二甲双胍可使PPG降低2.58mmol/L。中国新诊断T2DM患者中，二甲双胍可使HbA1c降低1.8%(可能含安慰剂效应)(Ⅰ级)。在新诊断的经过短期胰岛素治疗后的中国T2DM患者中开展的随机分组、前瞻性对照研究结果显示，二甲双胍(2000mg/d)的疗效与甘精胰岛素的降糖疗效相当。", "ner": [[47, 50, "Drug"], [57, 59, "Test_items"], [60, 76, "Test_Value"], [78, 82, "Test_items"], [83, 93, "Test_Value"], [102, 105, "Drug"], [108, 110, "Test_items"], [111, 122, "Test_Value"], [129, 132, "Disease"], [137, 140, "Drug"], [143, 147, "Test_items"], [148, 153, "Test_Value"], [187, 190, "Disease"], [178, 180, "Drug"], [214, 217, "Drug"], [232, 236, "Drug"], [219, 226, "Amount"]], "rel": [[137, 140, "Drug", 129, 132, "Disease", "Drug_Disease"], [143, 147, "Test_items", 129, 132, "Disease", "Test_items_Disease"], [178, 180, "Drug", 187, 190, "Disease", "Drug_Disease"], [219, 226, "Amount", 214, 217, "Drug", "Amount_Drug"]]}
{"idx": 543, "sentence": "6.联合磺脲类药物的疗效：二甲双胍可改善IR，降低肝糖输出，磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM的病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c。针对磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时可更好地控制FPG(Ⅰ级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降幅(1.7%)显著高于二甲双胍联合阿卡波糖治疗组的HbA1c降幅(0.9%)，且两组间低血糖、体重增加无差异无统计学意义。另有随机、双盲、双模拟、平行对照研究显示，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂与相同剂量的格列本脲相比，降糖效果相当，但低血糖发生的风险显著减低。", "ner": [[65, 68, "Disease"], [13, 16, "Drug"], [30, 34, "Drug"], [4, 8, "Drug"], [97, 100, "Drug"], [103, 106, "Drug"], [113, 116, "Drug"], [120, 123, "Drug"], [131, 133, "Test_items"], [135, 139, "Test_items"], [143, 147, "Drug"], [148, 149, "Test_items"], [164, 167, "Drug"], [169, 176, "Drug"], [181, 182, "Test_items"], [187, 191, "Test_items"], [192, 196, "Test_Value"], [210, 213, "Drug"], [226, 229, "Drug"], [257, 259, "Test_items"], [292, 295, "Drug"], [298, 301, "Drug"], [306, 310, "Test_items"], [311, 318, "Test_Value"], [323, 326, "Drug"], [329, 332, "Drug"], [337, 341, "Test_items"], [342, 349, "Test_Value"], [355, 357, "ADE"], [395, 398, "Drug"], [407, 410, "Drug"], [441, 443, "ADE"], [426, 429, "Drug"], [20, 21, "Pathogenesis"], [268, 271, "Disease"], [359, 362, "ADE"], [150, 153, "Test_Value"]], "rel": [[13, 16, "Drug", 65, 68, "Disease", "Drug_Disease"], [30, 34, "Drug", 65, 68, "Disease", "Drug_Disease"], [20, 21, "Pathogenesis", 65, 68, "Disease", "Pathogenesis_Disease"], [292, 295, "Drug", 268, 271, "Disease", "Drug_Disease"], [359, 362, "ADE", 292, 295, "Drug", "ADE_Drug"], [355, 357, "ADE", 292, 295, "Drug", "ADE_Drug"], [298, 301, "Drug", 268, 271, "Disease", "Drug_Disease"], [359, 362, "ADE", 298, 301, "Drug", "ADE_Drug"], [355, 357, "ADE", 298, 301, "Drug", "ADE_Drug"], [306, 310, "Test_items", 268, 271, "Disease", "Test_items_Disease"], [323, 326, "Drug", 268, 271, "Disease", "Drug_Disease"], [359, 362, "ADE", 323, 326, "Drug", "ADE_Drug"], [355, 357, "ADE", 323, 326, "Drug", "ADE_Drug"], [329, 332, "Drug", 268, 271, "Disease", "Drug_Disease"], [359, 362, "ADE", 329, 332, "Drug", "ADE_Drug"], [355, 357, "ADE", 329, 332, "Drug", "ADE_Drug"], [337, 341, "Test_items", 268, 271, "Disease", "Test_items_Disease"], [441, 443, "ADE", 395, 398, "Drug", "ADE_Drug"], [441, 443, "ADE", 407, 410, "Drug", "ADE_Drug"], [441, 443, "ADE", 426, 429, "Drug", "ADE_Drug"]]}
{"idx": 544, "sentence": "7.联合噻唑烷二酮类药物的疗效：对于严重IR，二甲双胍联合噻唑烷二酮类药物能更好地降低HbA1c，显著改善胰岛功能和IR，且有剂量依赖性趋势，但不良反应(体重增加、升高LDL-C)高于二甲双胍单用组；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著，故在IR严重，且排除两药的使用禁忌时，可考虑二甲双胍联合噻唑烷二酮类药物的治疗方案(Ⅰ级)。", "ner": [[23, 26, "Drug"], [43, 47, "Test_items"], [77, 80, "ADE"], [82, 88, "ADE"], [29, 36, "Drug"], [92, 95, "Drug"], [100, 113, "Drug"], [117, 120, "Drug"], [58, 59, "Pathogenesis"], [20, 21, "Pathogenesis"], [4, 11, "Drug"], [130, 134, "Test_items"], [136, 138, "Test_items"], [165, 168, "Drug"], [171, 178, "Drug"], [145, 146, "Pathogenesis"]], "rel": [[77, 80, "ADE", 23, 26, "Drug", "ADE_Drug"], [82, 88, "ADE", 23, 26, "Drug", "ADE_Drug"], [77, 80, "ADE", 29, 36, "Drug", "ADE_Drug"], [77, 80, "ADE", 92, 95, "Drug", "ADE_Drug"], [82, 88, "ADE", 29, 36, "Drug", "ADE_Drug"], [82, 88, "ADE", 92, 95, "Drug", "ADE_Drug"]]}
{"idx": 545, "sentence": "8.联合格列奈类药物的疗效：格列奈类药物属于短效促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生率差异无统计学意义。那格列奈联用二甲双胍和格列齐特联用二甲双胍的降糖强度差异无统计学意义，但低血糖事件更少(Ⅰ级)。故在二甲双胍联合磺脲类且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。", "ner": [[4, 9, "Drug"], [14, 19, "Drug"], [22, 30, "Drug"], [33, 36, "Drug"], [51, 52, "Test_items"], [58, 62, "Test_items"], [74, 77, "Disease"], [81, 84, "Drug"], [86, 89, "Drug"], [95, 98, "Drug"], [105, 109, "Test_items"], [112, 114, "ADE"], [127, 130, "Drug"], [133, 136, "Drug"], [138, 141, "Drug"], [144, 147, "Drug"], [163, 165, "ADE"], [177, 180, "Drug"], [183, 185, "Drug"], [187, 189, "ADE"], [203, 206, "Drug"], [209, 214, "Drug"], [53, 56, "Test_Value"], [65, 71, "Test_Value"]], "rel": [[51, 52, "Test_items", 74, 77, "Disease", "Test_items_Disease"], [58, 62, "Test_items", 74, 77, "Disease", "Test_items_Disease"], [105, 109, "Test_items", 74, 77, "Disease", "Test_items_Disease"], [95, 98, "Drug", 74, 77, "Disease", "Drug_Disease"], [86, 89, "Drug", 74, 77, "Disease", "Drug_Disease"], [81, 84, "Drug", 74, 77, "Disease", "Drug_Disease"], [112, 114, "ADE", 81, 84, "Drug", "ADE_Drug"], [112, 114, "ADE", 86, 89, "Drug", "ADE_Drug"], [112, 114, "ADE", 95, 98, "Drug", "ADE_Drug"], [163, 165, "ADE", 127, 130, "Drug", "ADE_Drug"], [163, 165, "ADE", 133, 136, "Drug", "ADE_Drug"], [163, 165, "ADE", 138, 141, "Drug", "ADE_Drug"], [163, 165, "ADE", 144, 147, "Drug", "ADE_Drug"], [187, 189, "ADE", 177, 180, "Drug", "ADE_Drug"], [187, 189, "ADE", 183, 185, "Drug", "ADE_Drug"], [187, 189, "ADE", 203, 206, "Drug", "ADE_Drug"], [187, 189, "ADE", 209, 214, "Drug", "ADE_Drug"]]}
{"idx": 546, "sentence": "另有研究显示，在二甲双胍的基础上加用米格列奈，可进一步降低HbA1c、FPG和PPG，并提高达标率，而不良事件的发生率差异无统计学意义。", "ner": [[8, 11, "Drug"], [18, 21, "Drug"], [29, 33, "Test_items"], [35, 37, "Test_items"], [39, 41, "Test_items"]], "rel": []}
{"idx": 547, "sentence": "9.联合α糖苷酶抑制剂的疗效：二甲双胍与α糖苷酶抑制剂联合，可兼顺FPG和PPG，超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好地控制HbA1c、FPG和体重。一项在中国T2DM人群中的对照研究显示，二甲双胍和阿卡波糖联用的降糖效果劣于二甲双胍和磺脲类联用。", "ner": [[4, 10, "Drug"], [41, 42, "Disease"], [15, 18, "Drug"], [20, 26, "Drug"], [33, 35, "Test_items"], [37, 39, "Test_items"], [51, 54, "Drug"], [63, 66, "Drug"], [44, 47, "Disease"], [73, 77, "Test_items"], [79, 81, "Test_items"], [106, 109, "Drug"], [111, 114, "Drug"], [124, 127, "Drug"], [129, 131, "Drug"], [91, 94, "Disease"]], "rel": [[51, 54, "Drug", 41, 42, "Disease", "Drug_Disease"], [63, 66, "Drug", 41, 42, "Disease", "Drug_Disease"], [73, 77, "Test_items", 41, 42, "Disease", "Test_items_Disease"], [79, 81, "Test_items", 41, 42, "Disease", "Test_items_Disease"], [51, 54, "Drug", 44, 47, "Disease", "Drug_Disease"], [63, 66, "Drug", 44, 47, "Disease", "Drug_Disease"], [79, 81, "Test_items", 44, 47, "Disease", "Test_items_Disease"], [73, 77, "Test_items", 44, 47, "Disease", "Test_items_Disease"], [106, 109, "Drug", 91, 94, "Disease", "Drug_Disease"], [111, 114, "Drug", 91, 94, "Disease", "Drug_Disease"], [124, 127, "Drug", 91, 94, "Disease", "Drug_Disease"], [129, 131, "Drug", 91, 94, "Disease", "Drug_Disease"]]}
{"idx": 548, "sentence": "这两种药物都有一定的胃肠道不良反应，联合应用有可能增加胃肠不适。", "ner": [[10, 16, "ADE"], [27, 30, "ADE"]], "rel": []}
{"idx": 549, "sentence": "10.联合DPP-4抑制剂的疗效：二甲双胍联合DPP-4抑制剂在降低FPG、HbA1c、体重的幅度均强于两药单用，但是对心血管危险因素、低血糖、胃肠道作用差异无统计学意义，二甲双胍联合DPP-4抑制剂的疗效与二甲双胍联合磺脲类药物的疗效相当，但体重增加和低血糖发生的风险低于二甲双胍联合磺脲类药物，由于DPP-4抑制剂上市时间较短，关于二甲双胍和DPP-4抑制剂的联合用药的疗效和安全性，还需要更多的研究验证。", "ner": [[5, 12, "Drug"], [17, 20, "Drug"], [23, 30, "Drug"], [34, 36, "Test_items"], [38, 42, "Test_items"], [68, 70, "ADE"], [86, 89, "Drug"], [92, 99, "Drug"], [104, 107, "Drug"], [110, 114, "Drug"], [137, 140, "Drug"], [143, 147, "Drug"], [151, 158, "Drug"], [168, 171, "Drug"], [173, 180, "Drug"], [127, 129, "ADE"], [72, 76, "ADE"], [122, 125, "ADE"]], "rel": [[68, 70, "ADE", 17, 20, "Drug", "ADE_Drug"], [72, 76, "ADE", 17, 20, "Drug", "ADE_Drug"], [68, 70, "ADE", 23, 30, "Drug", "ADE_Drug"], [72, 76, "ADE", 23, 30, "Drug", "ADE_Drug"], [122, 125, "ADE", 86, 89, "Drug", "ADE_Drug"], [127, 129, "ADE", 86, 89, "Drug", "ADE_Drug"], [122, 125, "ADE", 92, 99, "Drug", "ADE_Drug"], [127, 129, "ADE", 92, 99, "Drug", "ADE_Drug"], [122, 125, "ADE", 104, 107, "Drug", "ADE_Drug"], [127, 129, "ADE", 104, 107, "Drug", "ADE_Drug"], [122, 125, "ADE", 110, 114, "Drug", "ADE_Drug"], [127, 129, "ADE", 110, 114, "Drug", "ADE_Drug"], [122, 125, "ADE", 137, 140, "Drug", "ADE_Drug"], [127, 129, "ADE", 137, 140, "Drug", "ADE_Drug"], [122, 125, "ADE", 143, 147, "Drug", "ADE_Drug"], [127, 129, "ADE", 143, 147, "Drug", "ADE_Drug"]]}
{"idx": 550, "sentence": "11.联合GLP-1受体激动剂的疗效：目前中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG、HbA1c，血糖达标率更高：改善胰岛素β细胞功能：改善IR，降低体重和SBP，无严重低血糖事件(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍相比降糖疗效相当，体重和血压显著降低，低血糖发生风险显著减少。", "ner": [[47, 50, "Drug"], [53, 56, "Drug"], [81, 83, "Test_items"], [85, 89, "Test_items"], [91, 92, "Test_items"], [127, 129, "ADE"], [140, 143, "Disease"], [163, 166, "Drug"], [42, 45, "Drug"], [169, 172, "Drug"], [174, 177, "Drug"], [180, 183, "Drug"], [203, 205, "ADE"], [28, 37, "Drug"], [64, 73, "Drug"], [5, 14, "Drug"], [112, 113, "Pathogenesis"], [93, 97, "Test_Value"]], "rel": [[127, 129, "ADE", 53, 56, "Drug", "ADE_Drug"], [127, 129, "ADE", 64, 73, "Drug", "ADE_Drug"], [163, 166, "Drug", 140, 143, "Disease", "Drug_Disease"], [169, 172, "Drug", 140, 143, "Disease", "Drug_Disease"], [174, 177, "Drug", 140, 143, "Disease", "Drug_Disease"], [180, 183, "Drug", 140, 143, "Disease", "Drug_Disease"], [203, 205, "ADE", 163, 166, "Drug", "ADE_Drug"], [203, 205, "ADE", 169, 172, "Drug", "ADE_Drug"], [203, 205, "ADE", 174, 177, "Drug", "ADE_Drug"], [203, 205, "ADE", 180, 183, "Drug", "ADE_Drug"]]}
{"idx": 551, "sentence": "但患者对利拉鲁肽联合二甲双胍治疗所导致的不良反应的耐受性更差。", "ner": [[4, 7, "Drug"], [10, 13, "Drug"]], "rel": []}
{"idx": 552, "sentence": "12.联合胰岛素的疗效：二甲双胍可增强肝脏和肌肉组织的IR，因此在开始胰岛素治疗的同时应该继续维持二甲双胍治疗。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量，还可减少使用胰岛素之后出现的体重增加(Ⅰ级)，一项随机对照研究人组了接受胰岛素单药治疗但HbA1c≥7.0%的T2DM患者，受试者随机接受胰岛素单药(n=31)或胰岛素联合二甲双胍(n=27)治疗4个月。结果显示，二甲双胍联合胰岛素治疗，在保证相同降精疗效的同时，可减少胰岛素用量，从而降低低血糖的发生风险。Yki-Jarvinen等将96例接受磺脲类药物治疗血糖控制不佳的T2DM患者，随机分为睡前胰岛素+二甲双胍+安慰剂组、睡前胰岛素+格列本脲+安慰剂组、睡前胰岛素+二甲双胍+格列本脲和睡前胰岛素+清晨胰岛素组。治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组的体重均有所增加，且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大，每日胰岛素用量最少，低血糖的发生率最低。", "ner": [[5, 7, "Drug"], [12, 15, "Drug"], [35, 37, "Drug"], [49, 52, "Drug"], [57, 59, "Drug"], [67, 70, "Drug"], [73, 75, "Drug"], [82, 86, "Test_items"], [90, 92, "Drug"], [102, 104, "Drug"], [110, 113, "ADE"], [151, 154, "Disease"], [132, 134, "Drug"], [140, 144, "Test_items"], [145, 149, "Test_Value"], [165, 167, "Drug"], [177, 179, "Drug"], [182, 185, "Drug"], [203, 206, "Drug"], [209, 211, "Drug"], [231, 233, "Drug"], [241, 243, "ADE"], [283, 286, "Disease"], [276, 277, "Test_items"], [269, 273, "Drug"], [296, 298, "Drug"], [300, 303, "Drug"], [312, 314, "Drug"], [316, 319, "Drug"], [328, 330, "Drug"], [332, 335, "Drug"], [337, 340, "Drug"], [344, 346, "Drug"], [350, 352, "Drug"], [27, 28, "Pathogenesis"], [363, 365, "Drug"], [367, 370, "Drug"], [385, 391, "ADE"], [403, 405, "Drug"], [407, 410, "Drug"], [412, 416, "Test_items"], [424, 426, "Drug"], [432, 434, "ADE"]], "rel": [[110, 113, "ADE", 102, 104, "Drug", "ADE_Drug"], [132, 134, "Drug", 151, 154, "Disease", "Drug_Disease"], [165, 167, "Drug", 151, 154, "Disease", "Drug_Disease"], [177, 179, "Drug", 151, 154, "Disease", "Drug_Disease"], [182, 185, "Drug", 151, 154, "Disease", "Drug_Disease"], [140, 144, "Test_items", 151, 154, "Disease", "Test_items_Disease"], [241, 243, "ADE", 203, 206, "Drug", "ADE_Drug"], [241, 243, "ADE", 209, 211, "Drug", "ADE_Drug"], [241, 243, "ADE", 231, 233, "Drug", "ADE_Drug"], [276, 277, "Test_items", 283, 286, "Disease", "Test_items_Disease"], [269, 273, "Drug", 283, 286, "Disease", "Drug_Disease"], [296, 298, "Drug", 283, 286, "Disease", "Drug_Disease"], [300, 303, "Drug", 283, 286, "Disease", "Drug_Disease"], [312, 314, "Drug", 283, 286, "Disease", "Drug_Disease"], [316, 319, "Drug", 283, 286, "Disease", "Drug_Disease"], [328, 330, "Drug", 283, 286, "Disease", "Drug_Disease"], [332, 335, "Drug", 283, 286, "Disease", "Drug_Disease"], [337, 340, "Drug", 283, 286, "Disease", "Drug_Disease"], [344, 346, "Drug", 283, 286, "Disease", "Drug_Disease"], [350, 352, "Drug", 283, 286, "Disease", "Drug_Disease"], [432, 434, "ADE", 403, 405, "Drug", "ADE_Drug"], [432, 434, "ADE", 407, 410, "Drug", "ADE_Drug"], [432, 434, "ADE", 424, 426, "Drug", "ADE_Drug"]]}
{"idx": 553, "sentence": "13.应尽早足量使用以维持更长的达标时间：在500~2000mg剂量范围，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本效益比(Ⅰ级)。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下。", "ner": [[37, 40, "Drug"], [22, 31, "Amount"], [62, 65, "Drug"], [96, 99, "Disease"], [104, 107, "Drug"], [109, 116, "Amount"], [134, 138, "Test_items"], [144, 147, "Test_Value"]], "rel": [[22, 31, "Amount", 37, 40, "Drug", "Amount_Drug"], [104, 107, "Drug", 96, 99, "Disease", "Drug_Disease"], [134, 138, "Test_items", 96, 99, "Disease", "Test_items_Disease"], [109, 116, "Amount", 104, 107, "Drug", "Amount_Drug"]]}
{"idx": 554, "sentence": "在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周。", "ner": [[19, 22, "Drug"], [24, 30, "Amount"], [39, 42, "Drug"], [44, 51, "Amount"], [63, 67, "Test_items"], [73, 76, "Test_Value"]], "rel": [[24, 30, "Amount", 19, 22, "Drug", "Amount_Drug"], [44, 51, "Amount", 39, 42, "Drug", "Amount_Drug"]]}
{"idx": 555, "sentence": "因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可以使血糖控制尽早达标，且可使血糖得到更长时间的良好控制，如果出现可耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换其他降糖药。", "ner": [[34, 37, "Drug"], [24, 31, "Amount"], [57, 58, "Test_items"], [45, 46, "Test_items"]], "rel": [[24, 31, "Amount", 34, 37, "Drug", "Amount_Drug"]]}
{"idx": 556, "sentence": "14.用于正在接受胰岛素治疗的T1DM患者：对于T1DM患者可联用二甲双胍。临床研究发现其不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C；对于单用胰岛索治疗血糖控不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。中国T1DM诊治指南也支持T1DM在使用胰岛素治疗的前提下联用二甲双胍。", "ner": [[15, 18, "Disease"], [9, 11, "Drug"], [24, 27, "Disease"], [33, 36, "Drug"], [50, 52, "Drug"], [63, 64, "Test"], [71, 72, "Test_items"], [80, 84, "Test_items"], [90, 92, "Drug"], [95, 96, "Test_items"], [108, 111, "Drug"], [116, 118, "Drug"], [129, 131, "Drug"], [136, 141, "ADE"], [145, 148, "Disease"], [156, 159, "Disease"], [163, 165, "Drug"], [174, 177, "Drug"]], "rel": [[9, 11, "Drug", 15, 18, "Disease", "Drug_Disease"], [33, 36, "Drug", 24, 27, "Disease", "Drug_Disease"], [50, 52, "Drug", 24, 27, "Disease", "Drug_Disease"], [63, 64, "Test", 24, 27, "Disease", "Test_Disease"], [71, 72, "Test_items", 24, 27, "Disease", "Test_items_Disease"], [80, 84, "Test_items", 24, 27, "Disease", "Test_items_Disease"], [136, 141, "ADE", 129, 131, "Drug", "ADE_Drug"], [163, 165, "Drug", 156, 159, "Disease", "Drug_Disease"], [174, 177, "Drug", 156, 159, "Disease", "Drug_Disease"]]}
{"idx": 557, "sentence": "15.减重效果：二甲双胍具有控制体重的作用。研究表明，新诊断T2DM患者二甲双胍单药治疗16周，可使正常(BMI18.5~23.9kg/m2)、超重(BMI24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81及2.92kg(Ⅰ级)，磺脲类、格列酮类和胰岛素治疗伴有体重增加，以二甲双胍为基础的联合治疗减轻上述药物对体重增加的影响。", "ner": [[8, 11, "Drug"], [30, 33, "Disease"], [36, 39, "Drug"], [72, 73, "Disease"], [94, 95, "Disease"], [170, 173, "ADE"], [154, 156, "Drug"], [158, 161, "Drug"], [163, 165, "Drug"], [176, 179, "Drug"], [195, 198, "ADE"]], "rel": [[36, 39, "Drug", 30, 33, "Disease", "Drug_Disease"], [170, 173, "ADE", 154, 156, "Drug", "ADE_Drug"], [170, 173, "ADE", 158, 161, "Drug", "ADE_Drug"], [170, 173, "ADE", 163, 165, "Drug", "ADE_Drug"]]}
{"idx": 558, "sentence": "HOME研究证实，以二甲双胍为基础联合胰岛素治疗，体重少增加2.28~3.85kg。", "ner": [[10, 13, "Drug"], [19, 21, "Drug"]], "rel": []}
{"idx": 559, "sentence": "四、特殊人群用药", "ner": [], "rel": []}
{"idx": 560, "sentence": "1.心力衰竭患者使用注意事项：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证，但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。2014年ADA糖尿病指南也指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者(Ⅴ级)。", "ner": [[2, 5, "Disease"], [22, 33, "Disease"], [35, 38, "Drug"], [55, 58, "Drug"], [65, 68, "Disease"], [74, 77, "Disease"], [95, 97, "Disease"], [112, 115, "Drug"], [124, 126, "Disease"], [2, 2, "Anatomy"], [25, 25, "Anatomy"], [65, 65, "Anatomy"], [74, 74, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [25, 25, "Anatomy", 22, 33, "Disease", "Anatomy_Disease"], [65, 65, "Anatomy", 65, 68, "Disease", "Anatomy_Disease"], [74, 74, "Anatomy", 74, 77, "Disease", "Anatomy_Disease"], [112, 115, "Drug", 95, 97, "Disease", "Drug_Disease"], [112, 115, "Drug", 124, 126, "Disease", "Drug_Disease"]]}
{"idx": 561, "sentence": "2.65岁以上老年患者使用注意事项：2013年IDF老年糖尿病指南和中国老年糖尿病诊疗措施专家共识都把二甲双胍作为一线首选用药，对二甲双胍的使用没有具体年龄限制。老年糖尿病患者合理应用二甲双胍治疗可以达到良好的降糖效果，较少的低血糖风险对老年人有一定益处，但需要定期监测肾功能(3~6个月检查1次)。", "ner": [[28, 30, "Disease"], [38, 40, "Disease"], [51, 54, "Drug"], [65, 68, "Drug"], [83, 85, "Disease"], [92, 95, "Drug"], [113, 115, "ADE"]], "rel": [[51, 54, "Drug", 28, 30, "Disease", "Drug_Disease"], [51, 54, "Drug", 38, 40, "Disease", "Drug_Disease"], [92, 95, "Drug", 83, 85, "Disease", "Drug_Disease"], [113, 115, "ADE", 92, 95, "Drug", "ADE_Drug"]]}
{"idx": 562, "sentence": "80岁以上患者[eGFR<45ml/(min·1.73m2)除外]，如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍可取得良好的效果(Ⅰ级)。", "ner": [[60, 63, "Drug"], [8, 11, "Test_items"], [12, 28, "Test_Value"]], "rel": []}
{"idx": 563, "sentence": "因此，年龄并非二甲双胍治疗的禁忌，但需要监测肾功能。", "ner": [[7, 10, "Drug"]], "rel": []}
{"idx": 564, "sentence": "老年患者的eGFR在45~60ml/(min·1.73ml2)者，应减少剂量，如果eGFR<45ml/(min·1.73m2)则不能使用]。", "ner": [[5, 8, "Test_items"], [10, 30, "Test_Value"], [41, 44, "Test_items"], [45, 62, "Test_Value"]], "rel": []}
{"idx": 565, "sentence": "适合我国CKD患者的eGFR评估公式为：cG FR[ml/(min·1.73m2)]=175×Scr-1.234(mg/dI)×年龄-0.179(女性X0.79)。", "ner": [[4, 6, "Disease"], [20, 24, "Test_items"]], "rel": []}
{"idx": 566, "sentence": "3.儿童和青少年糖尿病及糖尿病前期患儿使用注意事项：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，应立即开始给予生活方式干预，不达标者以二甲双胍作为起始治疗药物。10岁及以上的糖尿病前期(IFG或lGT)患儿经3个月有效的生活方式干预(饮食控制、150min/周运动，减轻体重5%~10%)后，代谢异常指标仍无法逆转，建议使用二甲双胍治疗，起始剂量500mg，3次/d，最大剂量2000mg/d(V级)。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的儿童。", "ner": [[8, 10, "Disease"], [29, 31, "Drug"], [59, 64, "Treatment"], [71, 74, "Drug"], [12, 16, "Disease"], [91, 95, "Disease"], [121, 124, "Treatment"], [126, 135, "Treatment"], [137, 146, "Treatment"], [166, 169, "Drug"], [177, 181, "Amount"], [183, 186, "Frequency"], [192, 199, "Amount"], [97, 99, "Disease"], [101, 103, "Disease"], [45, 48, "Disease"], [114, 119, "Treatment"], [205, 208, "Drug"], [239, 246, "Amount"], [219, 222, "Disease"]], "rel": [[59, 64, "Treatment", 45, 48, "Disease", "Treatment_Disease"], [71, 74, "Drug", 45, 48, "Disease", "Drug_Disease"], [121, 124, "Treatment", 91, 95, "Disease", "Treatment_Disease"], [126, 135, "Treatment", 91, 95, "Disease", "Treatment_Disease"], [137, 146, "Treatment", 91, 95, "Disease", "Treatment_Disease"], [166, 169, "Drug", 91, 95, "Disease", "Drug_Disease"], [114, 119, "Treatment", 91, 95, "Disease", "Treatment_Disease"], [121, 124, "Treatment", 97, 99, "Disease", "Treatment_Disease"], [121, 124, "Treatment", 101, 103, "Disease", "Treatment_Disease"], [126, 135, "Treatment", 97, 99, "Disease", "Treatment_Disease"], [126, 135, "Treatment", 101, 103, "Disease", "Treatment_Disease"], [137, 146, "Treatment", 97, 99, "Disease", "Treatment_Disease"], [137, 146, "Treatment", 101, 103, "Disease", "Treatment_Disease"], [192, 199, "Amount", 166, 169, "Drug", "Amount_Drug"], [183, 186, "Frequency", 166, 169, "Drug", "Frequency_Drug"], [166, 169, "Drug", 97, 99, "Disease", "Drug_Disease"], [166, 169, "Drug", 101, 103, "Disease", "Drug_Disease"], [177, 181, "Amount", 166, 169, "Drug", "Amount_Drug"], [114, 119, "Treatment", 97, 99, "Disease", "Treatment_Disease"], [114, 119, "Treatment", 101, 103, "Disease", "Treatment_Disease"], [239, 246, "Amount", 205, 208, "Drug", "Amount_Drug"], [205, 208, "Drug", 219, 222, "Disease", "Drug_Disease"]]}
{"idx": 567, "sentence": "4.妊娠期糖尿病(GDM)患者使用注意事项：有GDM史的患者发现为糖尿病前期时，应接受生活方式干预或二甲双胍以预防糖尿病。患者一旦妊娠，建议改用胰岛素治疗(V级)。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率。在控制孕妇体重和治疗IR方面有优势，孕早期口服二甲双胍没有增加胎儿重大畸形和新生儿并发症的风险，二甲双胍在FDA妊娠期用药分级中为B类药物。", "ner": [[23, 25, "Disease"], [33, 37, "Disease"], [57, 59, "Disease"], [43, 48, "Treatment"], [50, 53, "Drug"], [72, 74, "Drug"], [82, 85, "Drug"], [89, 92, "Disease"], [104, 106, "Disease"], [135, 138, "Drug"], [122, 123, "Pathogenesis"], [160, 163, "Drug"], [133, 134, "Method"], [2, 12, "Disease"]], "rel": [[43, 48, "Treatment", 33, 37, "Disease", "Treatment_Disease"], [50, 53, "Drug", 33, 37, "Disease", "Drug_Disease"], [82, 85, "Drug", 89, 92, "Disease", "Drug_Disease"], [82, 85, "Drug", 104, 106, "Disease", "Drug_Disease"], [133, 134, "Method", 135, 138, "Drug", "Method_Drug"]]}
{"idx": 568, "sentence": "但我国药监部门尚未批准二甲双胍用于妊娠期妇女。", "ner": [[11, 14, "Drug"]], "rel": []}
{"idx": 569, "sentence": "5.肝功能不全的T2DM患者使用注意事项：二甲双胍不经过肝脏代谢，无肝脏毒性。", "ner": [[2, 6, "Disease"], [8, 11, "Disease"], [21, 24, "Drug"], [2, 2, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [21, 24, "Drug", 8, 11, "Disease", "Drug_Disease"]]}
{"idx": 570, "sentence": "目前肝功能不全患者使用二甲双胍的临床资料较少。", "ner": [[2, 6, "Disease"], [11, 14, "Drug"], [2, 2, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [11, 14, "Drug", 2, 6, "Disease", "Drug_Disease"]]}
{"idx": 571, "sentence": "肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限时应避免使用，血清转氨酶轻度升高的患者使用时应密切监测肝功能。", "ner": [[22, 26, "Test_items"], [42, 46, "Test_items"], [27, 34, "Test_Value"], [47, 50, "Test_Value"]], "rel": []}
{"idx": 572, "sentence": "7.造影或全麻术前患者使用注意事项：肾功能正常患者，造影前不必停用二甲双胍，但使用对比剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用对比剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。", "ner": [[33, 36, "Drug"], [79, 83, "Disease"], [109, 112, "Drug"], [5, 7, "Operation"], [79, 79, "Anatomy"], [94, 98, "Operation"]], "rel": [[79, 79, "Anatomy", 79, 83, "Disease", "Anatomy_Disease"], [94, 98, "Operation", 79, 83, "Disease", "Operation_Disease"], [109, 112, "Drug", 79, 83, "Disease", "Drug_Disease"]]}
{"idx": 573, "sentence": "五、安全性", "ner": [], "rel": []}
{"idx": 574, "sentence": "1.禁忌证：(1)血清肌酐水平，男≥132μmol/L(1.5mg/dl)女≥124μmol/L(1.4mg/dl)，或eGFR<45ml/(min·1.73m2)禁用；(2)需要药物治疗的CHF和其他严重心、肺疾患；(3)严重感染和外伤、外科大手术、临床有低血压和缺氧等；(4)已知对盐酸二甲双胍过敏；(5)急、慢性代谢性酸中毒，包括有或无昏迷的糖尿病酮症酸中毒；(6)酗酒者；(7)接受血管内注射碘化对比剂者，应暂时停用；(8)维生素B12、叶酸缺乏未纠正者。", "ner": [[9, 14, "Test_items"], [60, 63, "Test_items"], [64, 81, "Test_Value"], [95, 97, "Disease"], [129, 131, "ADE"], [155, 164, "Disease"], [143, 148, "Drug"], [174, 181, "Disease"], [103, 103, "Anatomy"], [105, 105, "Anatomy"], [17, 36, "Test_Value"], [38, 57, "Test_Value"], [133, 134, "ADE"], [114, 115, "Disease"], [112, 113, "Level"], [117, 118, "Disease"], [103, 107, "Disease"], [101, 102, "Level"], [149, 150, "ADE"], [200, 204, "Drug"], [195, 199, "Method"], [216, 226, "Disease"]], "rel": [[149, 150, "ADE", 143, 148, "Drug", "ADE_Drug"], [103, 103, "Anatomy", 103, 107, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 103, 107, "Disease", "Anatomy_Disease"], [195, 199, "Method", 200, 204, "Drug", "Method_Drug"]]}
{"idx": 575, "sentence": "2.常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。", "ner": [[17, 18, "ADE"], [20, 21, "ADE"], [23, 24, "ADE"], [26, 27, "ADE"], [29, 30, "ADE"], [32, 35, "ADE"], [37, 40, "ADE"], [42, 43, "ADE"]], "rel": []}
{"idx": 576, "sentence": "这些不良反应的发生常见于药物治疗的早期，", "ner": [], "rel": []}
{"idx": 577, "sentence": "绝大多数患者可耐受。", "ner": [], "rel": []}
{"idx": 578, "sentence": "随着治疗时间的延长，上述不良反应可基本消失。", "ner": [], "rel": []}
{"idx": 579, "sentence": "小剂量开始，逐渐增加剂量是减少治疗初期不良反应发生的有效方法。", "ner": [], "rel": []}
{"idx": 580, "sentence": "3.胃肠道反应与剂量的关系及处理原则：二甲双胍引起的胃肠道反应发生多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。国外报道，即使二甲双胍较大剂量(1000mg/d)起始治疗，其胃肠道反应发生率为28%，在1000mg增至2000mg/d时胃肠道反应差异无统计学意义。", "ner": [[2, 6, "ADE"], [19, 22, "Drug"], [26, 30, "ADE"], [88, 91, "Drug"], [97, 104, "Amount"], [112, 116, "ADE"], [143, 147, "ADE"], [126, 141, "Amount"]], "rel": [[26, 30, "ADE", 19, 22, "Drug", "ADE_Drug"], [97, 104, "Amount", 88, 91, "Drug", "Amount_Drug"], [112, 116, "ADE", 88, 91, "Drug", "ADE_Drug"], [143, 147, "ADE", 88, 91, "Drug", "ADE_Drug"], [126, 141, "Amount", 88, 91, "Drug", "Amount_Drug"]]}
{"idx": 581, "sentence": "国内报道，二甲双胍的胃肠道反应发生率为15%(Ⅰ级)，如果增加剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量，缓释制剂也可减少患者的胃肠道症状。", "ner": [[5, 8, "Drug"], [10, 14, "ADE"], [36, 42, "ADE"], [79, 83, "ADE"]], "rel": [[10, 14, "ADE", 5, 8, "Drug", "ADE_Drug"]]}
{"idx": 582, "sentence": "4.对维生素B12的吸收的影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。其机制可能与以下因素有关(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。", "ner": [[41, 44, "Drug"], [142, 145, "Drug"], [190, 193, "Drug"], [198, 205, "ADE"], [215, 222, "Disease"], [48, 58, "ADE"], [184, 185, "Drug"]], "rel": [[48, 58, "ADE", 41, 44, "Drug", "ADE_Drug"], [198, 205, "ADE", 190, 193, "Drug", "ADE_Drug"]]}
{"idx": 583, "sentence": "建议在长期使用二甲双胍治疗患者中适当补充维生素B12。", "ner": [[7, 10, "Drug"], [20, 25, "Drug"]], "rel": []}
{"idx": 584, "sentence": "不建议在服用二甲双胍的患者中常规监测维生素B12的水平。", "ner": [[6, 9, "Drug"], [16, 26, "Test_items"]], "rel": []}
{"idx": 585, "sentence": "5.是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争P450酶，在体内也不降解，面是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此二甲双胍无肝毒性，推荐剂量范围内用药的肝功能正常者，不会造成肝损害。但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。", "ner": [[9, 12, "Drug"], [47, 50, "Drug"], [57, 61, "Test_items"], [76, 79, "Drug"], [91, 94, "Drug"], [109, 112, "Drug"], [124, 127, "Drug"], [211, 214, "Drug"], [241, 243, "Disease"], [254, 257, "Drug"], [246, 250, "Disease"], [265, 269, "Disease"], [241, 241, "Anatomy"], [246, 246, "Anatomy"], [265, 265, "Anatomy"], [63, 66, "Test_Value"]], "rel": [[241, 241, "Anatomy", 241, 243, "Disease", "Anatomy_Disease"], [254, 257, "Drug", 246, 250, "Disease", "Drug_Disease"], [246, 246, "Anatomy", 246, 250, "Disease", "Anatomy_Disease"], [265, 265, "Anatomy", 265, 269, "Disease", "Anatomy_Disease"]]}
{"idx": 586, "sentence": "6.二甲双胍与乳酸酸中毒：目前尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝肾功能正常患者长期应用不增加乳酸酸中毒风险。COSMIC研究显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗差异无统计学意义(Ⅰ级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因二甲双胍直接以原形经肾脏排泄，因此有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用。", "ner": [[2, 5, "Drug"], [7, 11, "Disease"], [24, 27, "Drug"], [32, 36, "Disease"], [55, 59, "Disease"], [76, 79, "Drug"], [81, 85, "ADE"], [128, 131, "Drug"], [135, 139, "Disease"], [144, 147, "Drug"], [150, 154, "ADE"], [172, 175, "Drug"], [190, 194, "Disease"], [199, 202, "Drug"], [218, 222, "ADE"], [228, 232, "Disease"], [234, 237, "Test_items"], [238, 255, "Test_Value"], [258, 261, "Disease"], [190, 190, "Anatomy"], [228, 228, "Anatomy"], [163, 164, "Method"]], "rel": [[81, 85, "ADE", 76, 79, "Drug", "ADE_Drug"], [150, 154, "ADE", 144, 147, "Drug", "ADE_Drug"], [190, 190, "Anatomy", 190, 194, "Disease", "Anatomy_Disease"], [218, 222, "ADE", 199, 202, "Drug", "ADE_Drug"], [234, 237, "Test_items", 228, 232, "Disease", "Test_items_Disease"], [228, 228, "Anatomy", 228, 232, "Disease", "Anatomy_Disease"]]}
{"idx": 587, "sentence": "7.与非降糖药物的相互作用：(1)使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，其影响肾功能或二甲双胍分布，应密切监测血糖并调整二甲双胍和/或相互作用的剂量；(2)同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物需密切监测血糖。而在这些药物停用后，要密切注意低血糖的发生：合并服用氯磺丙脲的患者在换用二甲双胍的最初2周要密切监测血糖，氯磺丙脲在体内有较长潜留，易发生低血糖；(3)二甲双胍有增加华法林的抗凝血倾向；(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。", "ner": [[19, 22, "Drug"], [24, 26, "Drug"], [28, 29, "Drug"], [31, 35, "Drug"], [37, 39, "Drug"], [41, 42, "Drug"], [44, 47, "Drug"], [49, 52, "Drug"], [54, 59, "Drug"], [61, 64, "Drug"], [86, 89, "Drug"], [98, 99, "Test_items"], [103, 106, "Drug"], [125, 129, "Drug"], [137, 141, "Drug"], [143, 145, "Drug"], [147, 151, "Drug"], [153, 155, "Drug"], [163, 165, "Drug"], [167, 169, "Drug"], [171, 176, "Drug"], [178, 185, "Drug"], [187, 189, "Drug"], [194, 195, "Test_items"], [206, 207, "Test_items"], [224, 226, "Disease"], [235, 238, "Drug"], [245, 248, "Drug"], [259, 260, "Test_items"], [262, 265, "Drug"], [278, 280, "ADE"], [285, 288, "Drug"], [312, 314, "Drug"], [316, 317, "Drug"], [319, 320, "Drug"], [323, 326, "Drug"], [292, 294, "Drug"], [157, 161, "Drug"], [157, 158, "Method"], [196, 197, "Test_Value"], [133, 135, "Drug"]], "rel": [[278, 280, "ADE", 262, 265, "Drug", "ADE_Drug"], [157, 158, "Method", 157, 161, "Drug", "Method_Drug"]]}
{"idx": 588, "sentence": "六、心血管益处", "ner": [], "rel": []}
{"idx": 589, "sentence": "1.心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用(Ⅰ级)。UKPDS显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%，心肌梗死风险下降39%；UKPDS10年随访显示，二甲双胍治疗组大血管并发症及死亡风险的获益具有延续效应，且降低死亡和心肌梗死的作用优于磺脲类和胰岛素。", "ner": [[20, 22, "Disease"], [10, 13, "Drug"], [25, 27, "Disease"], [31, 32, "Pathogenesis"], [85, 88, "Disease"], [78, 81, "Drug"], [83, 84, "Disease"], [106, 109, "Disease"], [131, 134, "Drug"], [138, 140, "Anatomy"], [165, 168, "Disease"], [174, 176, "Drug"], [178, 180, "Drug"], [106, 107, "Anatomy"], [165, 166, "Anatomy"]], "rel": [[10, 13, "Drug", 20, 22, "Disease", "Drug_Disease"], [31, 32, "Pathogenesis", 20, 22, "Disease", "Pathogenesis_Disease"], [10, 13, "Drug", 25, 27, "Disease", "Drug_Disease"], [31, 32, "Pathogenesis", 25, 27, "Disease", "Pathogenesis_Disease"], [78, 81, "Drug", 85, 88, "Disease", "Drug_Disease"], [138, 140, "Anatomy", 85, 88, "Disease", "Anatomy_Disease"], [78, 81, "Drug", 83, 84, "Disease", "Drug_Disease"], [138, 140, "Anatomy", 83, 84, "Disease", "Anatomy_Disease"], [106, 107, "Anatomy", 106, 109, "Disease", "Anatomy_Disease"], [165, 166, "Anatomy", 165, 168, "Disease", "Anatomy_Disease"]]}
{"idx": 590, "sentence": "REACH研究结果提示，二甲双胍治疗2年，全因死亡相对风险下降24%，HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险，中国SPREAD研究结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。", "ner": [[12, 15, "Drug"], [46, 49, "Drug"], [52, 54, "Drug"], [58, 60, "Drug"], [65, 69, "Disease"], [91, 93, "Disease"], [97, 100, "Disease"], [105, 108, "Drug"], [113, 116, "Drug"], [65, 67, "Anatomy"]], "rel": [[65, 67, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"]]}
{"idx": 591, "sentence": "二甲双胍是目前唯一被2013AACE指南推荐有心血管获益证据的降糖药物。", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 592, "sentence": "2.心血管保护作用机制：二甲双胍可能通过减少心血管疾病的危险因素而达到心血管保护。心血管疾病的危险因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制危险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。", "ner": [[12, 15, "Drug"], [22, 26, "Disease"], [35, 37, "Anatomy"], [41, 45, "Disease"], [53, 56, "Disease"], [58, 59, "Disease"], [61, 62, "Disease"], [64, 66, "Disease"], [68, 72, "Disease"], [95, 98, "Drug"], [110, 111, "Test_items"], [115, 119, "Disease"], [121, 122, "Disease"], [141, 142, "Test"], [149, 150, "Test_items"], [152, 156, "Test_items"], [158, 159, "Test_items"], [164, 168, "Test_items"], [182, 185, "Drug"], [22, 24, "Anatomy"], [41, 43, "Anatomy"]], "rel": [[12, 15, "Drug", 22, 26, "Disease", "Drug_Disease"], [22, 24, "Anatomy", 22, 26, "Disease", "Anatomy_Disease"], [35, 37, "Anatomy", 22, 26, "Disease", "Anatomy_Disease"], [41, 43, "Anatomy", 41, 45, "Disease", "Anatomy_Disease"], [95, 98, "Drug", 115, 119, "Disease", "Drug_Disease"], [95, 98, "Drug", 121, 122, "Disease", "Drug_Disease"]]}
{"idx": 593, "sentence": "七、降糖外益处", "ner": [], "rel": []}
{"idx": 594, "sentence": "1.在改善血脂方面的作用：二甲双胍能够改善脂肪的合成与代谢。多项研究显示，二甲双胍治疗T2DM患者，可降低患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。", "ner": [[5, 6, "Test"], [13, 16, "Drug"], [43, 46, "Disease"], [37, 40, "Drug"], [57, 58, "Test_items"], [60, 64, "Test_items"], [66, 67, "Test_items"], [73, 77, "Test_items"], [78, 82, "Test_Value"]], "rel": [[37, 40, "Drug", 43, 46, "Disease", "Drug_Disease"], [57, 58, "Test_items", 43, 46, "Disease", "Test_items_Disease"], [60, 64, "Test_items", 43, 46, "Disease", "Test_items_Disease"], [66, 67, "Test_items", 43, 46, "Disease", "Test_items_Disease"], [73, 77, "Test_items", 43, 46, "Disease", "Test_items_Disease"]]}
{"idx": 595, "sentence": "2.在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出：除非存在明显的肝损害(如血清转氨大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，否则NAFLD患者可安全使用胰岛素增敏剂(二甲双胍和噻唑烷二酮类)等药物(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况，所有研究均显示HOMA-IR明显改善，13项研究显示血清酶学(谷丙转氨酶、谷草转氨酶)明显下降；5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有改善。", "ner": [[5, 9, "Disease"], [26, 28, "Disease"], [30, 34, "Disease"], [41, 49, "Disease"], [75, 77, "Disease"], [80, 83, "Test_items"], [95, 99, "Disease"], [101, 107, "Disease"], [114, 118, "Disease"], [126, 131, "Drug"], [133, 136, "Drug"], [138, 143, "Drug"], [169, 173, "Disease"], [164, 167, "Drug"], [187, 188, "Disease"], [224, 227, "Test"], [229, 233, "Test_items"], [235, 239, "Test_items"], [28, 28, "Anatomy"], [33, 33, "Anatomy"], [48, 48, "Anatomy"], [75, 75, "Anatomy"], [95, 95, "Anatomy"], [105, 105, "Anatomy"], [84, 92, "Test_Value"], [241, 244, "Test_Value"]], "rel": [[28, 28, "Anatomy", 26, 28, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 30, 34, "Disease", "Anatomy_Disease"], [48, 48, "Anatomy", 41, 49, "Disease", "Anatomy_Disease"], [75, 75, "Anatomy", 75, 77, "Disease", "Anatomy_Disease"], [80, 83, "Test_items", 75, 77, "Disease", "Test_items_Disease"], [95, 95, "Anatomy", 95, 99, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 101, 107, "Disease", "Anatomy_Disease"], [126, 131, "Drug", 114, 118, "Disease", "Drug_Disease"], [133, 136, "Drug", 114, 118, "Disease", "Drug_Disease"], [138, 143, "Drug", 114, 118, "Disease", "Drug_Disease"], [164, 167, "Drug", 169, 173, "Disease", "Drug_Disease"]]}
{"idx": 596, "sentence": "3.在治疗PCOS方面的作用：PCOS不是二甲双胍的适应证，但国内外应用二甲双胍治疗PCOS已有十余年的历史。美国内分泌学会推荐二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。循证医学证据表明二甲双胍可降低血浆胰岛素水平，增加IS，降低雄激素水平，提高雌二醇水平，改善PCOS患者的多毛症，使月经规律，诱导排卵，PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分二次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。", "ner": [[5, 8, "Disease"], [15, 18, "Disease"], [21, 24, "Drug"], [36, 39, "Drug"], [42, 45, "Disease"], [71, 74, "Disease"], [77, 80, "Disease"], [82, 84, "Disease"], [64, 67, "Drug"], [88, 93, "Treatment"], [113, 115, "Drug"], [142, 145, "Drug"], [151, 155, "Test_items"], [164, 166, "Test_items"], [172, 174, "Test_items"], [180, 183, "Disease"], [187, 189, "Disease"], [202, 205, "Disease"], [210, 216, "Amount"], [220, 228, "Amount"], [230, 239, "Amount"], [241, 243, "Frequency"], [244, 250, "Method"]], "rel": [[36, 39, "Drug", 42, 45, "Disease", "Drug_Disease"], [64, 67, "Drug", 71, 74, "Disease", "Drug_Disease"], [88, 93, "Treatment", 71, 74, "Disease", "Treatment_Disease"], [64, 67, "Drug", 77, 80, "Disease", "Drug_Disease"], [88, 93, "Treatment", 77, 80, "Disease", "Treatment_Disease"], [64, 67, "Drug", 82, 84, "Disease", "Drug_Disease"], [88, 93, "Treatment", 82, 84, "Disease", "Treatment_Disease"], [142, 145, "Drug", 202, 205, "Disease", "Drug_Disease"], [210, 216, "Amount", 142, 145, "Drug", "Amount_Drug"], [220, 228, "Amount", 142, 145, "Drug", "Amount_Drug"], [230, 239, "Amount", 142, 145, "Drug", "Amount_Drug"], [241, 243, "Frequency", 142, 145, "Drug", "Frequency_Drug"], [244, 250, "Method", 142, 145, "Drug", "Method_Drug"]]}
{"idx": 597, "sentence": "国外甚至用到2500mg/d，安全性依然良好。", "ner": [[6, 13, "Amount"]], "rel": []}
{"idx": 598, "sentence": "4.抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的危险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激(AMPK)通路。", "ner": [[8, 10, "Disease"], [20, 22, "Disease"], [24, 26, "Disease"], [28, 31, "Disease"], [33, 37, "Disease"], [52, 55, "Drug"], [20, 21, "Anatomy"], [24, 25, "Anatomy"], [28, 30, "Anatomy"], [33, 36, "Anatomy"]], "rel": [[20, 21, "Anatomy", 20, 22, "Disease", "Anatomy_Disease"], [24, 25, "Anatomy", 24, 26, "Disease", "Anatomy_Disease"], [28, 30, "Anatomy", 28, 31, "Disease", "Anatomy_Disease"], [33, 36, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"]]}
{"idx": 599, "sentence": "而AMPK通路的激活除了影响代谢外，也可能抑制肿瘤的发生和发展。", "ner": [], "rel": []}
{"idx": 600, "sentence": "英国一项大型病例对照研究显示，二甲双胍治疗与癌症的危险性下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势(Ⅱ级)。", "ner": [[15, 18, "Drug"], [58, 61, "Drug"]], "rel": []}
{"idx": 601, "sentence": "6.肾功能不全的T2DM患者使用注意事项：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。", "ner": [[2, 6, "Disease"], [8, 11, "Disease"], [21, 24, "Drug"], [51, 54, "Drug"], [45, 47, "Disease"], [2, 2, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [21, 24, "Drug", 8, 11, "Disease", "Drug_Disease"]]}
{"idx": 602, "sentence": "建议根据eGFR的水平调整二甲双胍的使用。", "ner": [[4, 7, "Test_items"], [13, 16, "Drug"]], "rel": []}
{"idx": 603, "sentence": "患者eGFR≥60ml/(min·1.73m2)无需减量，eGFR 45~60ml/(min·1.73m2)时减量，当eGFR<45ml/(min·1.73m2)时停用(V级)。", "ner": [[2, 5, "Test_items"], [6, 23, "Test_Value"], [29, 32, "Test_items"], [34, 53, "Test_Value"], [59, 62, "Test_items"], [63, 80, "Test_Value"]], "rel": []}
{"idx": 604, "sentence": "中国2型糖尿病合并血脂异常防治专家共识(2017年修订版)", "ner": [[2, 6, "Disease"], [9, 10, "Test"], [11, 12, "Test_Value"]], "rel": [[9, 10, "Test", 2, 6, "Disease", "Test_Disease"]]}
{"idx": 605, "sentence": "一、前言", "ner": [], "rel": []}
{"idx": 606, "sentence": "2型糖尿病(T2DM)患者合并血脂异常，可进一步增加大血管和微血管并发症的风险。为了进一步做好T2DM患者的血脂管理工作，中华医学会内分泌学分会曾于2011年颁布了《中国2型糖尿病合并血脂异常防治专家共识》。近年来，一系列新研究结果的发表、新指南的颁布，促使了血脂异常管理理念进一步发展。为了进一步优化我国T2DM患者的血脂管理，为临床医生提供更为科学合理的诊疗建议，中华医学会内分泌学分会根据中国患者的疾病特点，参考国内外新的循证证据和指南，对2011年版的《中国2型糖尿病合并血脂异常防治专家共识》进行修订，以更好地规范我国T2DM患者的血脂管理，预防动脉粥样硬化性心直管疾病(ASCVD)的发生。", "ner": [[0, 10, "Disease"], [47, 50, "Disease"], [54, 55, "Test"], [85, 89, "Disease"], [153, 156, "Disease"], [160, 161, "Test"], [15, 16, "Test"], [17, 18, "Test_Value"], [92, 93, "Test"], [94, 95, "Test_Value"], [130, 131, "Test"], [132, 133, "Test_Value"], [233, 237, "Disease"], [240, 241, "Test"], [242, 243, "Test_Value"], [264, 267, "Disease"], [278, 296, "Disease"], [271, 272, "Test"], [26, 28, "Anatomy"], [30, 32, "Anatomy"], [285, 287, "Anatomy"]], "rel": [[15, 16, "Test", 0, 10, "Disease", "Test_Disease"], [26, 28, "Anatomy", 0, 10, "Disease", "Anatomy_Disease"], [30, 32, "Anatomy", 0, 10, "Disease", "Anatomy_Disease"], [54, 55, "Test", 47, 50, "Disease", "Test_Disease"], [92, 93, "Test", 85, 89, "Disease", "Test_Disease"], [160, 161, "Test", 153, 156, "Disease", "Test_Disease"], [240, 241, "Test", 233, 237, "Disease", "Test_Disease"], [271, 272, "Test", 264, 267, "Disease", "Test_Disease"], [285, 287, "Anatomy", 278, 296, "Disease", "Anatomy_Disease"]]}
{"idx": 607, "sentence": "相较于2011版《专家共识》，本共识中我们对下列内容进行了更新：(1)血脂异常特点及流行病学中补充了中国血脂研究的数据。(2)对于国外指南建议非空腹血脂监测，本共识未做推荐。(3)ASCVD危险度评估和治疗目标中更新危险因素。(4)对T2DM患者的血脂管理的流程图进行合并，更简单明了，易于操作。(5)基于疗效、耐受性及治疗费用的考虑，中国证据显示中等强度他汀类药物治疗适合于我国多数T2DM合并血脂异常患者。(6)经过中等强度的他汀类药物治疗后非高密度脂蛋白胆固醉(non-HDL-C)仍不达标者，特别是三酰甘油(TG)≥2.3mmol/L，可在他汀类药物治疗基础上加用贝特类药物，如非诺贝特或苯扎贝特，或高纯度鱼油。(7)胆固醇吸收抑制剂依折麦布和人类前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂可作为他汀不耐受或单药治疗低密度脂蛋白胆固醇(LDL-C)不能达标时的联合用药。(8)对于T2DM患者特殊情况下的血脂管理，如合并肝病或肝功能异常、合并慢性肾脏病(CKD)、老年T2DM时的处理进行了更新。(9)评价了长期服用他汀类药物对血糖影响和增加新发糖尿病风险的获益和风险。", "ner": [[35, 36, "Test"], [37, 38, "Test_Value"], [52, 53, "Test"], [71, 77, "Test"], [90, 94, "Disease"], [117, 120, "Disease"], [124, 125, "Test"], [174, 182, "Drug"], [192, 195, "Disease"], [198, 199, "Test"], [200, 201, "Test_Value"], [210, 219, "Drug"], [223, 243, "Test_items"], [253, 260, "Test_items"], [261, 270, "Test_Value"], [274, 278, "Drug"], [286, 290, "Drug"], [293, 296, "Drug"], [298, 301, "Drug"], [304, 308, "Drug"], [395, 398, "Disease"], [407, 408, "Test"], [418, 422, "Disease"], [439, 442, "Disease"], [326, 349, "Drug"], [363, 378, "Test_items"], [415, 416, "Disease"], [426, 435, "Disease"], [415, 415, "Anatomy"], [418, 418, "Anatomy"], [428, 429, "Anatomy"], [245, 247, "Test_Value"], [313, 320, "Drug"], [321, 324, "Drug"], [379, 382, "Test_Value"], [476, 480, "ADE"], [468, 472, "ADE"], [463, 467, "Drug"]], "rel": [[124, 125, "Test", 117, 120, "Disease", "Test_Disease"], [174, 182, "Drug", 192, 195, "Disease", "Drug_Disease"], [198, 199, "Test", 192, 195, "Disease", "Test_Disease"], [407, 408, "Test", 395, 398, "Disease", "Test_Disease"], [407, 408, "Test", 415, 416, "Disease", "Test_Disease"], [407, 408, "Test", 418, 422, "Disease", "Test_Disease"], [407, 408, "Test", 426, 435, "Disease", "Test_Disease"], [407, 408, "Test", 439, 442, "Disease", "Test_Disease"], [418, 418, "Anatomy", 418, 422, "Disease", "Anatomy_Disease"], [415, 415, "Anatomy", 415, 416, "Disease", "Anatomy_Disease"], [428, 429, "Anatomy", 426, 435, "Disease", "Anatomy_Disease"], [476, 480, "ADE", 463, 467, "Drug", "ADE_Drug"], [468, 472, "ADE", 463, 467, "Drug", "ADE_Drug"]]}
{"idx": 608, "sentence": "(10)本共识增加T2DM患者常用药物对血脂的影响。", "ner": [[20, 21, "Test"], [9, 12, "Disease"]], "rel": [[20, 21, "Test", 9, 12, "Disease", "Test_Disease"]]}
{"idx": 609, "sentence": "为了便于读者了解某一项诊疗措施的价值和证据等级，本共识制订了分级体系(附表1)，用来阐明和编纂各项建议的证据。", "ner": [], "rel": []}
{"idx": 610, "sentence": "二、T2DM患者的血脂异常特点及流行病学", "ner": [[2, 5, "Disease"], [9, 10, "Test"], [11, 12, "Test_Value"]], "rel": [[9, 10, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 611, "sentence": "推荐1：T2DM患者的血脂诸以混合型血脂紊乱多见，其特征性的血脂谱包括：(1)空腹和餐后TG水平升高.即使在空腹血糖和TG水平控制正常后往往还存在餐后高TG血症；(2)HDL-C水平降低；(3)血清总胆固醇(TC)水平和LDL-C正常或轻度升商，且LDL-C发生质变，小而致密的LDL-C水平升高；(4)富含TG脂蛋白的载脂蛋白(apo)B-100和apoB-48水平升高，apo-CⅢ水平升高，apo-CII/apo-CIII以及apo-CIII/apo-E的比值升高。", "ner": [[4, 7, "Disease"], [11, 12, "Test"], [15, 21, "Test_Value"], [30, 31, "Test"], [75, 79, "Disease"], [124, 128, "Test_items"], [48, 49, "Test_Value"], [54, 57, "Test_items"], [59, 62, "Test_items"], [84, 90, "Test_items"], [91, 92, "Test_Value"], [97, 114, "Test_items"], [115, 121, "Test_Value"], [146, 147, "Test_Value"], [152, 183, "Test_items"], [184, 185, "Test_Value"], [187, 194, "Test_items"], [195, 196, "Test_Value"], [198, 232, "Test_items"], [233, 234, "Test_Value"], [39, 47, "Test_items"], [134, 145, "Test_items"], [63, 66, "Test_Value"]], "rel": [[11, 12, "Test", 4, 7, "Disease", "Test_Disease"], [39, 47, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [54, 57, "Test_items", 75, 79, "Disease", "Test_items_Disease"], [59, 62, "Test_items", 75, 79, "Disease", "Test_items_Disease"]]}
{"idx": 612, "sentence": "推荐2：中国T2DM患者合并血脂异常的比例高，治疗率、达标率低，临床上应加强对T2DM患者的血脂管理。", "ner": [[6, 9, "Disease"], [14, 15, "Test"], [16, 17, "Test_Value"], [39, 42, "Disease"], [46, 47, "Test"]], "rel": [[14, 15, "Test", 6, 9, "Disease", "Test_Disease"], [46, 47, "Test", 39, 42, "Disease", "Test_Disease"]]}
{"idx": 613, "sentence": "T2DM是危害人类健康的主要疾病之一，是ASCVD的独立危险因素。T2DM患者血脂异常的发生率明显高于非糖尿病患者，是T2DM患者心血管并发症发生率增加的重要危险因素。英国前瞻性糖尿病研究(UKPDS)的结果显示，血脂异常是T2DM患者发生致死性和非致死性心肌梗死的首要危险因素。", "ner": [[20, 24, "Disease"], [0, 3, "Disease"], [33, 36, "Disease"], [39, 40, "Test"], [41, 42, "Test_Value"], [59, 62, "Disease"], [107, 108, "Test"], [109, 110, "Test_Value"], [112, 115, "Disease"], [120, 131, "Disease"], [128, 129, "Anatomy"], [89, 91, "Disease"], [52, 54, "Disease"], [65, 67, "Anatomy"]], "rel": [[39, 40, "Test", 33, 36, "Disease", "Test_Disease"], [39, 40, "Test", 52, 54, "Disease", "Test_Disease"], [65, 67, "Anatomy", 59, 62, "Disease", "Anatomy_Disease"], [107, 108, "Test", 112, 115, "Disease", "Test_Disease"], [107, 108, "Test", 120, 131, "Disease", "Test_Disease"], [128, 129, "Anatomy", 120, 131, "Disease", "Anatomy_Disease"]]}
{"idx": 614, "sentence": "T2DM患者的脂代谢异常与胰岛素抵抗和腹型肥胖等代谢综合因素有关。导致患者血脂异常的主要原因是由于胰岛素作用不足、胰岛素抵抗等所致的极低密度脂蛋白(VLDL)、TG的产生过多和清除缺陷。T2DM患者的血脂谱以混合型血脂紊乱多见，其特征性的血脂谱包括：空腹和餐后TC水平升高，即使在空腹血糖和TG水平控制正常后往往还存在餐后高TG血症；HDL-C水平降低；血清TC水平和LDL-C正常或轻度升高，且LDL-C发生质变，小而致密的LDL-C水平升高。", "ner": [[0, 3, "Disease"], [7, 11, "Pathogenesis"], [66, 78, "Test_items"], [80, 81, "Test_items"], [93, 96, "Disease"], [161, 165, "Disease"], [184, 188, "Test_items"], [198, 202, "Test_items"], [37, 38, "Test"], [39, 40, "Test_Value"], [13, 17, "Pathogenesis"], [19, 22, "Reason"], [57, 61, "Pathogenesis"], [100, 102, "Test"], [104, 110, "Test_Value"], [119, 121, "Test"], [125, 133, "Test_items"], [134, 135, "Test_Value"], [140, 143, "Test_items"], [145, 148, "Test_items"], [167, 173, "Test_items"], [174, 175, "Test_Value"], [177, 182, "Test_items"], [189, 195, "Test_Value"], [220, 221, "Test_Value"], [49, 55, "Pathogenesis"], [149, 152, "Test_Value"], [208, 219, "Test_items"]], "rel": [[7, 11, "Pathogenesis", 0, 3, "Disease", "Pathogenesis_Disease"], [13, 17, "Pathogenesis", 0, 3, "Disease", "Pathogenesis_Disease"], [19, 22, "Reason", 0, 3, "Disease", "Reason_Disease"], [57, 61, "Pathogenesis", 93, 96, "Disease", "Pathogenesis_Disease"], [100, 102, "Test", 93, 96, "Disease", "Test_Disease"], [125, 133, "Test_items", 161, 165, "Disease", "Test_items_Disease"], [140, 143, "Test_items", 161, 165, "Disease", "Test_items_Disease"], [145, 148, "Test_items", 161, 165, "Disease", "Test_items_Disease"]]}
{"idx": 615, "sentence": "富含TG脂蛋白(triglyceride- rich lipoprotein) 的apoB-100和apoB-48水平升高，apo- CIII水平升高，apo-CII/apo-CIII以及apo-CIII/apo-E的比值升高。", "ner": [[0, 58, "Test_items"], [59, 60, "Test_Value"], [62, 72, "Test_items"], [73, 74, "Test_Value"], [111, 112, "Test_Value"], [76, 110, "Test_items"]], "rel": []}
{"idx": 616, "sentence": "中国人群血脂控制现状不容乐观，据研究显示，我国人群血清总胆固醇及低密度脂蛋白胆固醇水平增高，如无有效的干预措施，在不久的将来，动脉硬化性心血管疾病的患病率将飞速增长。CCMR-3B研究对全国104家医院的25817例中国T2DM门诊患者进行了调查，结果发现42%的T2DM忠者合并血脂异常，其中仅有55%的患者接受了调脂治疗。", "ner": [[4, 5, "Test"], [63, 72, "Disease"], [110, 113, "Disease"], [132, 135, "Disease"], [140, 141, "Test"], [25, 42, "Test_items"], [43, 44, "Test_Value"], [142, 143, "Test_Value"], [68, 70, "Anatomy"]], "rel": [[4, 5, "Test", 63, 72, "Disease", "Test_Disease"], [25, 42, "Test_items", 63, 72, "Disease", "Test_items_Disease"], [68, 70, "Anatomy", 63, 72, "Disease", "Anatomy_Disease"], [140, 141, "Test", 132, 135, "Disease", "Test_Disease"]]}
{"idx": 617, "sentence": "此外，该研究中TC<4.5mmol/L、TG<1.5mmol/L、LDL-C<2.6mmol/L和HDL-C>1.04mmol/L的患者比例分别为36.1%、46.6%、42.9%和71.9%，四项指标均达标的患者比例仅为12%。", "ner": [[7, 8, "Test_items"], [9, 18, "Test_Value"], [20, 21, "Test_items"], [22, 31, "Test_Value"], [33, 37, "Test_items"], [38, 47, "Test_Value"], [49, 53, "Test_items"], [54, 64, "Test_Value"]], "rel": []}
{"idx": 618, "sentence": "CCMR-3B研究真实地反映了当前我国T2DM患者血脂异常患病及控制情况，并提示临床上应加强对T2DM患者的血脂管理。", "ner": [[19, 22, "Disease"], [25, 26, "Test"], [27, 28, "Test_Value"], [54, 55, "Test"], [47, 50, "Disease"]], "rel": [[25, 26, "Test", 19, 22, "Disease", "Test_Disease"], [54, 55, "Test", 47, 50, "Disease", "Test_Disease"]]}
{"idx": 619, "sentence": " ", "ner": [], "rel": []}
{"idx": 620, "sentence": "三、T2DM者血脂检测时机及监测频率", "ner": [[7, 10, "Test"], [2, 5, "Disease"]], "rel": [[7, 10, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 621, "sentence": "推荐3：在确诊T2DM的同时均应检测患者的空血脂(包括TG、TC、HDL-C和LDL-C)(推荐；E级证据)。", "ner": [[7, 10, "Disease"], [21, 23, "Test"], [27, 28, "Test_items"], [30, 31, "Test_items"], [33, 37, "Test_items"], [39, 43, "Test_items"]], "rel": [[21, 23, "Test", 7, 10, "Disease", "Test_Disease"], [27, 28, "Test_items", 7, 10, "Disease", "Test_items_Disease"], [30, 31, "Test_items", 7, 10, "Disease", "Test_items_Disease"], [33, 37, "Test_items", 7, 10, "Disease", "Test_items_Disease"], [39, 43, "Test_items", 7, 10, "Disease", "Test_items_Disease"]]}
{"idx": 622, "sentence": "推荐4：对于血脂位于正常范围内的患者，如果无其他心血管风险。在T2DM治疗过程中每年至少要进行1次血脂谱的检测：如果伴有多重心血管风险因素，则在诊断T2DM后每3个月监测血脂谱1次。对于合井血脂谱异常的T2DM患者，则在起始生活方式干预和药物治疗，以及药物剂量调整期间每1~3个月监测1次血脂谱，此后则建议每3~12个月监测1次血脂谱。", "ner": [[6, 7, "Test"], [31, 34, "Disease"], [74, 77, "Disease"], [85, 86, "Test"], [101, 104, "Disease"], [144, 146, "Test"], [164, 166, "Test"], [112, 117, "Treatment"], [98, 99, "Test_Value"], [95, 97, "Test"], [10, 13, "Test_Value"]], "rel": [[85, 86, "Test", 74, 77, "Disease", "Test_Disease"], [95, 97, "Test", 101, 104, "Disease", "Test_Disease"], [144, 146, "Test", 101, 104, "Disease", "Test_Disease"], [164, 166, "Test", 101, 104, "Disease", "Test_Disease"], [112, 117, "Treatment", 101, 104, "Disease", "Treatment_Disease"]]}
{"idx": 623, "sentence": "由于血脂异常通常没有明显症状，往往通过体检或发生了心脑血管事件后才得以发现，因而及早发现T2DM患者合并血脂异常，并给予早期干预，可防治动脉粥样硬化、减少心脑血管事件、降低死亡率。", "ner": [[2, 3, "Test"], [4, 5, "Test_Value"], [25, 30, "Disease"], [25, 28, "Anatomy"], [44, 47, "Disease"], [52, 53, "Test"], [68, 73, "Disease"], [77, 82, "Disease"], [77, 80, "Anatomy"], [54, 55, "Test_Value"]], "rel": [[25, 28, "Anatomy", 25, 30, "Disease", "Anatomy_Disease"], [52, 53, "Test", 44, 47, "Disease", "Test_Disease"], [77, 80, "Anatomy", 77, 82, "Disease", "Anatomy_Disease"]]}
{"idx": 624, "sentence": "为了及早发现T2DM患者的血脂异常，在确诊T2DM的同时均应检测患者的空腹血脂谱(包括TG、TC、HDL-C和LDL-C)(推荐；E级证据)，根据基线血脂水平以制定相应的监测策略(图1)：对于血脂位于正常范围内的患者，如果无其他心血管风险，在T2DM治疗过程中每年至少要进行1次血脂谱的检测；如果伴有多重心血管风险因素(男性≥40岁或绝经期后女性、吸烟、肥胖和早发缺血性心血管病家族史等).则在诊断T2DM后每3个月监测血脂谱1次。对于合并血脂谱异常的T2DM患者，则在起始生活方式干预和药物治疗，以及药物剂量调整期间每4~12周监测1次血脂谱，此后则建议每3~12个月监测1次血脂谱。", "ner": [[35, 39, "Test"], [6, 9, "Disease"], [21, 24, "Disease"], [75, 76, "Test"], [55, 59, "Test_items"], [49, 53, "Test_items"], [46, 47, "Test_items"], [43, 44, "Test_items"], [15, 16, "Test_Value"], [13, 14, "Test"], [96, 97, "Test"], [121, 124, "Disease"], [139, 140, "Test"], [180, 188, "Disease"], [185, 187, "Anatomy"], [199, 202, "Disease"], [220, 222, "Test"], [226, 229, "Disease"], [269, 271, "Test"], [289, 291, "Test"], [100, 103, "Test_Value"], [237, 242, "Treatment"], [177, 178, "Disease"]], "rel": [[35, 39, "Test", 21, 24, "Disease", "Test_Disease"], [13, 14, "Test", 6, 9, "Disease", "Test_Disease"], [43, 44, "Test_items", 21, 24, "Disease", "Test_items_Disease"], [46, 47, "Test_items", 21, 24, "Disease", "Test_items_Disease"], [49, 53, "Test_items", 21, 24, "Disease", "Test_items_Disease"], [55, 59, "Test_items", 21, 24, "Disease", "Test_items_Disease"], [75, 76, "Test", 21, 24, "Disease", "Test_Disease"], [139, 140, "Test", 121, 124, "Disease", "Test_Disease"], [185, 187, "Anatomy", 180, 188, "Disease", "Anatomy_Disease"], [220, 222, "Test", 226, 229, "Disease", "Test_Disease"], [237, 242, "Treatment", 226, 229, "Disease", "Treatment_Disease"], [269, 271, "Test", 226, 229, "Disease", "Test_Disease"], [289, 291, "Test", 226, 229, "Disease", "Test_Disease"]]}
{"idx": 625, "sentence": "鉴于有关血脂控制目标和心血管风险分层、血脂治疗等研究数据均基本来自于空腹血脂监测，目前亦缺乏非空腹血脂监测的中国人群的研究数据，因此目前暂不宜在我国临床工作中推广非空腹血脂监测，仍应继续采用空腹血脂监测。", "ner": [[4, 5, "Test"], [19, 20, "Test"], [34, 39, "Test"], [46, 52, "Test"], [81, 87, "Test"], [95, 100, "Test"]], "rel": []}
{"idx": 626, "sentence": "建议采取以下措施可提高标本采集的质量：(1)受试者准备：采集标本前受试者处于稳定代谢状态，至少2周内保持非高脂饮食习惯和稳定体重。", "ner": [], "rel": []}
{"idx": 627, "sentence": "(2)采集标本前受试者24小时内不进行剧烈身体活动、避免情绪紧张、饮酒、饮咖啡等。", "ner": [[28, 31, "Symptom"]], "rel": []}
{"idx": 628, "sentence": "(3)采集标本前受试者禁食约12小时。", "ner": [], "rel": []}
{"idx": 629, "sentence": "(4)除特殊情况外，受试者可取坐位或半卧位接受采血，采血前至少休息5min。", "ner": [], "rel": []}
{"idx": 630, "sentence": "(5)静脉穿刺时止血带使用不超过1min。", "ner": [], "rel": []}
{"idx": 631, "sentence": "(6)血液标本保持密封，避免震荡，及时送检。", "ner": [], "rel": []}
{"idx": 632, "sentence": "床疾患等进行综合评估，并根据评估结果制定相应的血脂管理目标和治疗措施(推荐；C级证据)。值得关注的是，虽然T2DM患者的血脂谱特征是LDL-C正常或轻度升高，但小而致密的LDL颗粒数量增加。事实上，小而密LDL颗粒更容易被氧化形成过氧化脂质，易通过非受体通路摄取，被单核-巨噬细胞的清道夫受体识别、吞噬，形成泡沫细胞，促进ASCVD的发生，具有很强的致ASCVD作用。UKPDS研究结果也显示，LDL-C是T2DM患者发生冠心病和心肌梗死的首要预测因素，LDL-C每上升1mmo/L，冠脉事件发生率增加57%。胆固醇治疗试验(CTT)协作组的meta分析结果也显示，LDL-C每降低1.0mmol/L分别显著下降主要血管事件、血管性死亡和缺血性卒中事件风险达21%、13%和21%。由此证明，T2DM患者降低LDL-C心血管获益确切。低HDL-C水平往往与TG水平升高相关，也是T2DM患者常见的血脂异常。", "ner": [[23, 24, "Test"], [60, 62, "Test"], [66, 70, "Test_items"], [53, 56, "Disease"], [161, 165, "Disease"], [176, 180, "Disease"], [197, 201, "Test_items"], [211, 213, "Disease"], [215, 218, "Disease"], [203, 206, "Disease"], [227, 231, "Test_items"], [242, 245, "Disease"], [283, 287, "Test_items"], [354, 358, "Test_items"], [378, 379, "Test_items"], [398, 399, "Test"], [400, 401, "Test_Value"], [346, 349, "Disease"], [389, 392, "Disease"], [71, 77, "Test_Value"], [368, 374, "Test_items"], [378, 381, "Test_items"], [308, 311, "Disease"], [308, 309, "Anatomy"], [313, 317, "Disease"], [319, 323, "Disease"], [80, 91, "Test_items"], [92, 93, "Test_Value"], [99, 119, "Pathogenesis"], [121, 130, "Pathogenesis"], [132, 157, "Pathogenesis"], [215, 216, "Anatomy"], [232, 240, "Test_Value"], [242, 243, "Anatomy"], [288, 299, "Test_Value"], [382, 383, "Test_Value"], [367, 367, "Test_Value"]], "rel": [[60, 62, "Test", 53, 56, "Disease", "Test_Disease"], [66, 70, "Test_items", 53, 56, "Disease", "Test_items_Disease"], [80, 91, "Test_items", 53, 56, "Disease", "Test_items_Disease"], [99, 119, "Pathogenesis", 161, 165, "Disease", "Pathogenesis_Disease"], [121, 130, "Pathogenesis", 161, 165, "Disease", "Pathogenesis_Disease"], [132, 157, "Pathogenesis", 161, 165, "Disease", "Pathogenesis_Disease"], [197, 201, "Test_items", 203, 206, "Disease", "Test_items_Disease"], [197, 201, "Test_items", 211, 213, "Disease", "Test_items_Disease"], [197, 201, "Test_items", 215, 218, "Disease", "Test_items_Disease"], [215, 216, "Anatomy", 215, 218, "Disease", "Anatomy_Disease"], [227, 231, "Test_items", 242, 245, "Disease", "Test_items_Disease"], [242, 243, "Anatomy", 242, 245, "Disease", "Anatomy_Disease"], [283, 287, "Test_items", 308, 311, "Disease", "Test_items_Disease"], [283, 287, "Test_items", 313, 317, "Disease", "Test_items_Disease"], [283, 287, "Test_items", 319, 323, "Disease", "Test_items_Disease"], [354, 358, "Test_items", 346, 349, "Disease", "Test_items_Disease"], [398, 399, "Test", 389, 392, "Disease", "Test_Disease"], [368, 374, "Test_items", 389, 392, "Disease", "Test_items_Disease"], [378, 381, "Test_items", 389, 392, "Disease", "Test_items_Disease"], [308, 309, "Anatomy", 308, 311, "Disease", "Anatomy_Disease"]]}
{"idx": 633, "sentence": "而靶向升高HDL-C治疗药物的证证远远不如他汀类药物充分。", "ner": [[21, 25, "Drug"], [1, 13, "Drug"]], "rel": []}
{"idx": 634, "sentence": "因此，当前各糖尿病指南中虽然建议T2DM患者需全面控制血脂，但LDL-C仍是首要的", "ner": [[31, 35, "Test_items"], [27, 28, "Test"], [6, 8, "Disease"], [16, 19, "Disease"]], "rel": [[31, 35, "Test_items", 16, 19, "Disease", "Test_items_Disease"], [27, 28, "Test", 16, 19, "Disease", "Test_Disease"]]}
{"idx": 635, "sentence": "降脂治疗目标(表1)。", "ner": [], "rel": []}
{"idx": 636, "sentence": "四、T2DM患者的ASCVD危险度评估和治疗目标 ", "ner": [[2, 5, "Disease"], [9, 13, "Disease"]], "rel": []}
{"idx": 637, "sentence": "推荐5：T2DM患者ASCVD高危人群调脂的主要目标为LDL-C<2.6mmol/L，次要目标Non-HDL-C<3.4mmol/L，其他目标TG<1.7mmo/L。", "ner": [[4, 7, "Disease"], [10, 14, "Disease"], [27, 31, "Test_items"], [32, 41, "Test_Value"], [47, 55, "Test_items"], [56, 65, "Test_Value"], [71, 72, "Test_items"], [73, 81, "Test_Value"]], "rel": [[27, 31, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [47, 55, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [71, 72, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [27, 31, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [47, 55, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [71, 72, "Test_items", 10, 14, "Disease", "Test_items_Disease"]]}
{"idx": 638, "sentence": " ", "ner": [], "rel": []}
{"idx": 639, "sentence": "推荐6：T2DM患者ASCVD极高危人群调脂的主要目标为LDL-C<1.8mmol/L，次要目标Non-HDL-C<2.6mmol/L，其他目标TG<1.7mmol/L。", "ner": [[4, 7, "Disease"], [10, 14, "Disease"], [28, 32, "Test_items"], [33, 42, "Test_Value"], [48, 56, "Test_items"], [57, 66, "Test_Value"], [72, 73, "Test_items"], [74, 83, "Test_Value"]], "rel": [[28, 32, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [48, 56, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [72, 73, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [28, 32, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [48, 56, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [72, 73, "Test_items", 10, 14, "Disease", "Test_items_Disease"]]}
{"idx": 640, "sentence": " ", "ner": [], "rel": []}
{"idx": 641, "sentence": "基于ASCVD危险程度的分层管理策略是当前血脂管理的总体趋势，因此，全面评估ASCVD危险度是T2DM患者进行血脂管理的前提。在确诊T2DM后，应对患者的血脂水平、所具有的心血管危险因素及临床疾患等进行综合评估，并根据评定结果指定相应的血脂管理目标和治疗措施（推荐：C级证据）。值得关注的是，虽然T2DM患者的血脂谱特征是LDL-C正常或轻度升高，但小而致密的LDL颗粒数量增加。事实上，小而密LDL颗粒更容易被氧化形成过氧化脂质，易通过非受体通路摄取，被单核-巨噬细胞的清道夫受体识别、吞噬，形成泡沫细胞，促进ASCVD的发生，具有很强的致ASCVD作用。UKPDS研究结果也显示，LDL-C是T2DM患者发生冠心病和心肌梗死的首要预测因素，LDL-C每上升1mmol/L，冠脉事件发生率增加57%。胆固醇治疗试验（CTT）协作组的meta分析结果也显示，LDL-C每降低1.0mmol/L分别显著下降主要血管事件、心血管死亡和缺血性卒中事件风险达21%、13%和21%。由此证明，T2DDM患者降低LDL-C心血管获益确切。低HDL-C水平往往与TG水平升高相关，也是T2DM患者常见的血脂异常。而靶向升高HDL-C治疗药物的循证证据远远不如他汀类药物充分。因此，当前各糖尿病指南中虽然建议T2DM患者全面控制血脂，但LDL-C仍是首要的降脂治疗目标（表1）。", "ner": [[2, 6, "Disease"], [21, 22, "Test"], [38, 42, "Disease"], [47, 50, "Disease"], [55, 56, "Test"], [66, 69, "Disease"], [77, 80, "Test"], [86, 88, "Anatomy"], [148, 151, "Disease"], [155, 157, "Test"], [161, 165, "Test_items"], [166, 172, "Test_Value"], [175, 184, "Test_items"], [185, 188, "Test_Value"], [256, 260, "Disease"], [271, 275, "Disease"], [194, 214, "Reason"], [216, 225, "Reason"], [227, 252, "Reason"], [292, 296, "Test_items"], [298, 301, "Disease"], [306, 308, "Disease"], [310, 313, "Disease"], [310, 311, "Anatomy"], [322, 326, "Test_items"], [328, 336, "Test_Value"], [338, 341, "Disease"], [338, 339, "Anatomy"], [379, 383, "Test_items"], [385, 395, "Test_Value"], [404, 407, "Disease"], [404, 405, "Anatomy"], [409, 413, "Disease"], [409, 411, "Anatomy"], [415, 419, "Disease"], [442, 446, "Disease"], [451, 455, "Test_items"], [465, 469, "Test_items"], [464, 464, "Test_Value"], [475, 478, "Test_items"], [479, 480, "Test_Value"], [486, 489, "Disease"], [495, 496, "Test"], [497, 498, "Test_Value"], [503, 504, "Test_Value"], [505, 509, "Test_items"], [523, 527, "Drug"], [537, 539, "Disease"], [547, 550, "Disease"], [557, 558, "Test"], [561, 565, "Test_items"]], "rel": [[21, 22, "Test", 2, 6, "Disease", "Test_Disease"], [55, 56, "Test", 38, 42, "Disease", "Test_Disease"], [55, 56, "Test", 47, 50, "Disease", "Test_Disease"], [77, 80, "Test", 66, 69, "Disease", "Test_Disease"], [86, 88, "Anatomy", 66, 69, "Disease", "Anatomy_Disease"], [155, 157, "Test", 148, 151, "Disease", "Test_Disease"], [161, 165, "Test_items", 148, 151, "Disease", "Test_items_Disease"], [175, 184, "Test_items", 148, 151, "Disease", "Test_items_Disease"], [194, 214, "Reason", 256, 260, "Disease", "Reason_Disease"], [216, 225, "Reason", 256, 260, "Disease", "Reason_Disease"], [227, 252, "Reason", 256, 260, "Disease", "Reason_Disease"], [292, 296, "Test_items", 298, 301, "Disease", "Test_items_Disease"], [292, 296, "Test_items", 306, 308, "Disease", "Test_items_Disease"], [292, 296, "Test_items", 310, 313, "Disease", "Test_items_Disease"], [310, 311, "Anatomy", 310, 313, "Disease", "Anatomy_Disease"], [322, 326, "Test_items", 338, 341, "Disease", "Test_items_Disease"], [338, 339, "Anatomy", 338, 341, "Disease", "Anatomy_Disease"], [379, 383, "Test_items", 404, 407, "Disease", "Test_items_Disease"], [379, 383, "Test_items", 409, 413, "Disease", "Test_items_Disease"], [379, 383, "Test_items", 415, 419, "Disease", "Test_items_Disease"], [404, 405, "Anatomy", 404, 407, "Disease", "Anatomy_Disease"], [409, 411, "Anatomy", 409, 413, "Disease", "Anatomy_Disease"], [451, 455, "Test_items", 442, 446, "Disease", "Test_items_Disease"], [465, 469, "Test_items", 486, 489, "Disease", "Test_items_Disease"], [475, 478, "Test_items", 486, 489, "Disease", "Test_items_Disease"], [495, 496, "Test", 486, 489, "Disease", "Test_Disease"], [557, 558, "Test", 547, 550, "Disease", "Test_Disease"], [561, 565, "Test_items", 547, 550, "Disease", "Test_items_Disease"]]}
{"idx": 642, "sentence": "五、T2DM合并血脂异常患者的血脂管理", "ner": [[2, 5, "Disease"], [8, 9, "Test"], [10, 11, "Test_Value"], [15, 16, "Test"]], "rel": [[8, 9, "Test", 2, 5, "Disease", "Test_Disease"], [15, 16, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 643, "sentence": "(一)T2DM患者的血脂管理流程", "ner": [[3, 6, "Disease"], [10, 11, "Test"]], "rel": [[10, 11, "Test", 3, 6, "Disease", "Test_Disease"]]}
{"idx": 644, "sentence": "推荐7：所有T2DM合并血脂异常患者均应进行生活方式干预，在此基础上血脂仍未达标者接受中等强度的他汀类药物治疗。若他汀类药物不耐受，则换用另一种他汀类药物、减低他汀剂量或给药频次、或小剂量他汀合用胆固醇吸收抑制剂依折麦布或PCSK9抑制剂。若LDL-C未达到预期目标，则进一步强化调整生活方式，并中等强度他汀合用胆固醇吸收抑制剂折麦布或PCSK9抑制剂。若他汀治疗前TG>5.6hmol/L，服用降TG药物(如贝特类或高纯度鱼油)，以减少发生急性胰腺炎的风险；若他汀治疗后TG≥2.3mmol/L，可在他汀类药物治疗基上合用贝特类或高纯度鱼油。", "ner": [[6, 9, "Disease"], [12, 13, "Test"], [14, 15, "Test_Value"], [22, 27, "Treatment"], [34, 35, "Test"], [43, 52, "Drug"], [57, 61, "Drug"], [111, 118, "Drug"], [121, 125, "Test_items"], [168, 175, "Drug"], [178, 179, "Drug"], [183, 184, "Test_items"], [185, 194, "Test_Value"], [198, 202, "Drug"], [205, 207, "Drug"], [209, 213, "Drug"], [221, 225, "Disease"], [223, 224, "Anatomy"], [231, 232, "Drug"], [236, 237, "Test_items"], [238, 247, "Test_Value"], [251, 255, "Drug"], [262, 264, "Drug"], [266, 270, "Drug"], [72, 76, "Drug"], [80, 81, "Drug"], [94, 95, "Drug"], [98, 105, "Drug"], [106, 109, "Drug"], [37, 39, "Test_Value"], [126, 132, "Test_Value"], [140, 145, "Treatment"], [148, 153, "Drug"], [156, 163, "Drug"], [164, 166, "Drug"], [62, 64, "ADE"]], "rel": [[12, 13, "Test", 6, 9, "Disease", "Test_Disease"], [22, 27, "Treatment", 6, 9, "Disease", "Treatment_Disease"], [34, 35, "Test", 6, 9, "Disease", "Test_Disease"], [43, 52, "Drug", 6, 9, "Disease", "Drug_Disease"], [62, 64, "ADE", 57, 61, "Drug", "ADE_Drug"], [178, 179, "Drug", 221, 225, "Disease", "Drug_Disease"], [183, 184, "Test_items", 221, 225, "Disease", "Test_items_Disease"], [198, 202, "Drug", 221, 225, "Disease", "Drug_Disease"], [205, 207, "Drug", 221, 225, "Disease", "Drug_Disease"], [209, 213, "Drug", 221, 225, "Disease", "Drug_Disease"], [223, 224, "Anatomy", 221, 225, "Disease", "Anatomy_Disease"]]}
{"idx": 645, "sentence": "T2DM患者的血脂管理需基于其血脂异常情况及心血管危险程度，确定个体化的治疗目标及措施(图2)。", "ner": [[0, 3, "Disease"], [7, 8, "Test"], [15, 16, "Test"], [17, 18, "Test_Value"], [23, 24, "Anatomy"]], "rel": [[7, 8, "Test", 0, 3, "Disease", "Test_Disease"], [15, 16, "Test", 0, 3, "Disease", "Test_Disease"], [23, 24, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"]]}
{"idx": 646, "sentence": "(二)生活方式干顶", "ner": [[3, 8, "Treatment"]], "rel": []}
{"idx": 647, "sentence": "推荐8：T2DM患者的血脂管理均应以生活方式干预为基础，并贯穿T2DM治疗的全过程(推荐；A级证据)。", "ner": [[4, 7, "Disease"], [11, 12, "Test"], [18, 23, "Treatment"], [31, 34, "Disease"]], "rel": [[18, 23, "Treatment", 4, 7, "Disease", "Treatment_Disease"], [11, 12, "Test", 4, 7, "Disease", "Test_Disease"]]}
{"idx": 648, "sentence": "T2DM患者的血脂管理均应以生活方式干预为基础(表2)，并贯穿T2DM治疗的全过程(推荐；A级证据)。生活方式干预不仅有助于降低胆固醇水平，还可对血压、血糖以及整体心血管健康状况产生有益的影响，因此是糖尿病患者血脂管理的基础。一些轻度血脂异常的T2DM患者，经有效生活方式干预可将其血脂参数控制在理想范围。", "ner": [[0, 3, "Disease"], [7, 8, "Test"], [14, 19, "Treatment"], [31, 34, "Disease"], [64, 68, "Test_items"], [76, 77, "Test_items"], [100, 102, "Disease"], [105, 106, "Test"], [117, 118, "Test"], [119, 120, "Test_Value"], [122, 125, "Disease"], [141, 144, "Test"], [51, 56, "Treatment"], [73, 74, "Test_items"]], "rel": [[14, 19, "Treatment", 0, 3, "Disease", "Treatment_Disease"], [7, 8, "Test", 0, 3, "Disease", "Test_Disease"], [64, 68, "Test_items", 100, 102, "Disease", "Test_items_Disease"], [76, 77, "Test_items", 100, 102, "Disease", "Test_items_Disease"], [51, 56, "Treatment", 100, 102, "Disease", "Treatment_Disease"], [105, 106, "Test", 100, 102, "Disease", "Test_Disease"], [73, 74, "Test_items", 100, 102, "Disease", "Test_items_Disease"], [117, 118, "Test", 122, 125, "Disease", "Test_Disease"], [141, 144, "Test", 122, 125, "Disease", "Test_Disease"]]}
{"idx": 649, "sentence": "但经过积极生活方式干预仍不能改善血脂参数的患者，则需加用调脂药物治疗，而积极的生活方式干预有助于减少用药剂量。", "ner": [[16, 19, "Test_items"], [28, 31, "Drug"], [5, 10, "Treatment"], [39, 44, "Treatment"]], "rel": []}
{"idx": 650, "sentence": "(三)调脂药物治疗", "ner": [[3, 6, "Drug"]], "rel": []}
{"idx": 651, "sentence": "既往的研究已充分证实，合并血脂异常可进一步增加T2DM患者的大血管和微血管并发症风险。因此，T2DM患者除了重视血糖控制外，还应重视血脂管理。经过积极的生活方式干预仍不能改善血脂水平者(基于ASCVD危险程度制定的目标)，需加用调脂药物治疗。", "ner": [[13, 14, "Test"], [15, 16, "Test_Value"], [23, 26, "Disease"], [30, 32, "Anatomy"], [34, 36, "Anatomy"], [56, 57, "Test_items"], [46, 49, "Disease"], [66, 67, "Test"], [87, 90, "Test"], [95, 99, "Disease"], [114, 117, "Drug"], [76, 81, "Treatment"]], "rel": [[13, 14, "Test", 23, 26, "Disease", "Test_Disease"], [30, 32, "Anatomy", 23, 26, "Disease", "Anatomy_Disease"], [34, 36, "Anatomy", 23, 26, "Disease", "Anatomy_Disease"], [56, 57, "Test_items", 46, 49, "Disease", "Test_items_Disease"], [66, 67, "Test", 46, 49, "Disease", "Test_Disease"], [87, 90, "Test", 95, 99, "Disease", "Test_Disease"], [76, 81, "Treatment", 95, 99, "Disease", "Treatment_Disease"], [114, 117, "Drug", 95, 99, "Disease", "Drug_Disease"]]}
{"idx": 652, "sentence": "目前常用的调脂药物包括：他汀类药物、贝特类药物，胆固醇吸收抑制剂，烟酸类等(表3)。", "ner": [[5, 8, "Drug"], [12, 16, "Drug"], [18, 22, "Drug"], [24, 31, "Drug"], [33, 35, "Drug"]], "rel": []}
{"idx": 653, "sentence": "1.降胆固醇治疗", "ner": [[3, 5, "Test_items"]], "rel": []}
{"idx": 654, "sentence": "推荐9：对于绝大多数T2DM患者，中等强度他汀(可使LDL-C水平降低30%~50%)是可选的降胆固醇治疗药物(推荐；A级证据)。", "ner": [[10, 13, "Disease"], [17, 22, "Drug"], [26, 32, "Test_items"], [33, 41, "Test_Value"], [47, 54, "Drug"]], "rel": [[17, 22, "Drug", 10, 13, "Disease", "Drug_Disease"], [47, 54, "Drug", 10, 13, "Disease", "Drug_Disease"], [26, 32, "Test_items", 10, 13, "Disease", "Test_items_Disease"]]}
{"idx": 655, "sentence": "在目前临床常用的降胆固醇治疗药物中，他汀类药物是具有最充分随机化临床研究(RCT)证据的显著改善患者预后的词脂药物。特别是，斯堪地那维亚辛伐他汀生存研究(4S)、心脏保护研究(HPS)、协作阿托伐他汀糖尿病研究(CARDS)、CTT协作组进行的一项meta分析等多项研究均证实他汀拥有充分的循证证据证明可显著降低T2DM患者心血管疾病风险(附表2)，被各糖尿病指南推荐为首选的降胆固醇治疗药物。", "ner": [[8, 15, "Drug"], [18, 22, "Drug"], [53, 56, "Drug"], [100, 102, "Disease"], [138, 139, "Drug"], [156, 159, "Disease"], [162, 166, "Disease"], [162, 164, "Anatomy"], [177, 179, "Disease"], [188, 195, "Drug"], [95, 99, "Drug"], [68, 71, "Drug"]], "rel": [[95, 99, "Drug", 100, 102, "Disease", "Drug_Disease"], [68, 71, "Drug", 100, 102, "Disease", "Drug_Disease"], [138, 139, "Drug", 156, 159, "Disease", "Drug_Disease"], [138, 139, "Drug", 162, 166, "Disease", "Drug_Disease"], [162, 164, "Anatomy", 162, 166, "Disease", "Anatomy_Disease"], [188, 195, "Drug", 177, 179, "Disease", "Drug_Disease"]]}
{"idx": 656, "sentence": "临床上选择他汀类药物剂量，在LDL-C达标的前提下，还需考虑安全性、耐受性和治疗费用。对于绝大多数T2DM患者，中等强度他汀(可使LDL-C水平降低30%~50%)是可选的降胆固醉治疗药物(推荐；A级证据)。中国胆固醇教育计划专家建议中指出：与白种人比较，我国人群平均胆固醇水平较低。中国国家糖尿病和代谢紊乱研究表明，中国居民的平均LDL-C水平为2.68mmol/L，明显低于欧美国家。因此，大多数中国患者经过中等强度他汀类药物治疗即可使LDL-C达标。此外，中国患者对于高强度他汀类药物治疗的耐受性也较差，发生肝毒性、肌肉毒性的风险明显高于欧美患者。基于疗效、耐受性及治疗费用的考虑，中等强度他汀类药物治疗适合于我国多数T2DM合并血脂异常患者，推荐临床选择效价比高的中等强度他汀，如辛伐他汀20~40mg、匹伐他汀2~4mg、阿托伐他汀10~20mg等。", "ner": [[5, 9, "Drug"], [14, 18, "Test_items"], [49, 52, "Disease"], [56, 61, "Drug"], [65, 71, "Test_items"], [72, 80, "Test_Value"], [86, 93, "Drug"], [106, 108, "Test_items"], [134, 138, "Test_items"], [146, 148, "Disease"], [150, 153, "Disease"], [166, 172, "Test_items"], [174, 183, "Test_Value"], [206, 214, "Drug"], [220, 224, "Test_items"], [237, 244, "Drug"], [294, 302, "Drug"], [312, 315, "Disease"], [318, 319, "Test"], [320, 321, "Test_Value"], [257, 259, "ADE"], [261, 264, "ADE"], [336, 341, "Drug"], [344, 347, "Drug"], [348, 354, "Amount"], [356, 359, "Drug"], [360, 364, "Amount"], [366, 370, "Drug"], [371, 377, "Amount"], [225, 226, "Test_Value"], [139, 140, "Test_Value"], [19, 20, "Test_items"]], "rel": [[56, 61, "Drug", 49, 52, "Disease", "Drug_Disease"], [86, 93, "Drug", 49, 52, "Disease", "Drug_Disease"], [65, 71, "Test_items", 49, 52, "Disease", "Test_items_Disease"], [166, 172, "Test_items", 146, 148, "Disease", "Test_items_Disease"], [166, 172, "Test_items", 150, 153, "Disease", "Test_items_Disease"], [257, 259, "ADE", 237, 244, "Drug", "ADE_Drug"], [261, 264, "ADE", 237, 244, "Drug", "ADE_Drug"], [294, 302, "Drug", 312, 315, "Disease", "Drug_Disease"], [318, 319, "Test", 312, 315, "Disease", "Test_Disease"], [336, 341, "Drug", 312, 315, "Disease", "Drug_Disease"], [344, 347, "Drug", 312, 315, "Disease", "Drug_Disease"], [356, 359, "Drug", 312, 315, "Disease", "Drug_Disease"], [366, 370, "Drug", 312, 315, "Disease", "Drug_Disease"], [348, 354, "Amount", 344, 347, "Drug", "Amount_Drug"], [360, 364, "Amount", 356, 359, "Drug", "Amount_Drug"], [371, 377, "Amount", 366, 370, "Drug", "Amount_Drug"]]}
{"idx": 657, "sentence": "对于其基线LDL-C水平如何，均应在生活方式干预的基础上使用中等强度他汀(推荐；B级证据)。对于无ASCVD，且不合并其他心血管危险因素的T2DM患者，如果LDL-C≥2.6mmo/L，也应在生活方式干预的基础上使用中等强度他汀(推荐；A级证据)。", "ner": [[5, 11, "Test_items"], [30, 35, "Drug"], [49, 53, "Disease"], [69, 72, "Disease"], [78, 82, "Test_items"], [83, 91, "Test_Value"], [108, 113, "Drug"], [18, 23, "Treatment"], [96, 101, "Treatment"]], "rel": [[78, 82, "Test_items", 69, 72, "Disease", "Test_items_Disease"], [96, 101, "Treatment", 69, 72, "Disease", "Treatment_Disease"], [108, 113, "Drug", 69, 72, "Disease", "Drug_Disease"]]}
{"idx": 658, "sentence": "若出现他汀类药物不耐受情况，可换用另一种他汀类药物，减低剂量或给药频次或加用非他汀类的降LDL-C药物依折麦布。", "ner": [[3, 7, "Drug"], [20, 24, "Drug"], [38, 50, "Drug"], [51, 54, "Drug"]], "rel": []}
{"idx": 659, "sentence": "若血脂未达预期目标，则在强化生活方式干预的同时，合用胆固醇吸收抑制剂依折麦布或PCSK9抑制剂。", "ner": [[1, 2, "Test"], [39, 46, "Drug"], [3, 8, "Test_Value"], [14, 19, "Treatment"], [26, 33, "Drug"], [34, 37, "Drug"]], "rel": []}
{"idx": 660, "sentence": "极高危的T2DM患者，除非存在禁忌证，无论", "ner": [[4, 7, "Disease"]], "rel": []}
{"idx": 661, "sentence": "2.降TG治疗", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 662, "sentence": "推荐10：如果患者TG>5.6mmol/L时，可在生活方式干预的基础上首选隆TG药物治疗(如贝特类，或高纯度鱼油)，以减少发生急性胰腺炎的风险(推荐；C级证据)。", "ner": [[9, 10, "Test_items"], [11, 20, "Test_Value"], [37, 41, "Drug"], [46, 48, "Drug"], [51, 55, "Drug"], [63, 67, "Disease"], [65, 66, "Anatomy"], [25, 30, "Treatment"]], "rel": [[9, 10, "Test_items", 63, 67, "Disease", "Test_items_Disease"], [37, 41, "Drug", 63, 67, "Disease", "Drug_Disease"], [46, 48, "Drug", 63, 67, "Disease", "Drug_Disease"], [51, 55, "Drug", 63, 67, "Disease", "Drug_Disease"], [65, 66, "Anatomy", 63, 67, "Disease", "Anatomy_Disease"], [25, 30, "Treatment", 63, 67, "Disease", "Treatment_Disease"]]}
{"idx": 663, "sentence": "经过中等强度的他汀类药物治疗后non-HDL-C仍不达标者，特别是TG≥2.3mmo/L，可在他汀类药物治疗基础上加用贝特类药物(建议；B级证据)。", "ner": [[2, 11, "Drug"], [15, 23, "Test_items"], [33, 34, "Test_items"], [35, 43, "Test_Value"], [47, 51, "Drug"], [59, 63, "Drug"], [25, 27, "Test_Value"]], "rel": []}
{"idx": 664, "sentence": "高TG血症可引发急性胰腺炎，因此若患者TG>5.6mmol/L时，可在生活方式干预的基础上首选降TG药物治疗(如贝特类，或高纯度鱼油0.5~1.0g/次)，以减少发生急性胰腺炎的风险(推荐；C级证据)。", "ner": [[0, 4, "Reason"], [8, 12, "Disease"], [10, 11, "Anatomy"], [19, 20, "Test_items"], [21, 30, "Test_Value"], [47, 51, "Drug"], [56, 58, "Drug"], [61, 65, "Drug"], [66, 75, "Amount"], [83, 87, "Disease"], [85, 86, "Anatomy"], [35, 40, "Treatment"]], "rel": [[0, 4, "Reason", 8, 12, "Disease", "Reason_Disease"], [10, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [19, 20, "Test_items", 83, 87, "Disease", "Test_items_Disease"], [47, 51, "Drug", 83, 87, "Disease", "Drug_Disease"], [56, 58, "Drug", 83, 87, "Disease", "Drug_Disease"], [66, 75, "Amount", 61, 65, "Drug", "Amount_Drug"], [61, 65, "Drug", 83, 87, "Disease", "Drug_Disease"], [85, 86, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [35, 40, "Treatment", 83, 87, "Disease", "Treatment_Disease"]]}
{"idx": 665, "sentence": "前瞻性流行病学研究和meta分析均证实，高TG水平与ASCVD发生相关，与T2DM患者的大血管和微血管事件的剩留风险相关。多项RCT也检验了此类药物预防CHD的作用。非诺贝特干预及减少糖尿病心脏事件研究(FIELD)和糖尿病患者心血管风险干预研究(ACCORD)的亚组分析均提示在高TG/低HDL-C的糖尿病患者中，非诺贝特治疗可使ASCVD风险减少30%左右。Meta分析表明，贝特类药物可使CHD风险降低约25%，CHD死亡率降低约10%。苯扎贝特心肌梗死预防研究(BIP)和苯扎贝特冠状动脉粥样硬化干预研究(BECAIT)证实，苯扎贝特治疗可以缓解ASCVD的进展。因此，经过中等强度的他汀类药物治疗后non-HDL-C仍不达标者，特别是TG≥2.3mmol/L，可在他汀类药物治疗基础上加用贝特类药物(建议；B级证据)，如非诺贝特或苯扎贝特，或高纯度鱼油。但在老年、严重肝肾疾病、甲状腺功能减退等特殊情况者，应慎用他汀联合贝特类药物，并严密监测和随访，一旦出现异常，及时停药。", "ner": [[26, 30, "Disease"], [37, 40, "Disease"], [44, 52, "Disease"], [44, 46, "Anatomy"], [48, 50, "Anatomy"], [76, 78, "Disease"], [92, 94, "Disease"], [95, 98, "Disease"], [95, 96, "Anatomy"], [109, 111, "Disease"], [141, 142, "Test_items"], [145, 149, "Test_items"], [151, 153, "Disease"], [166, 170, "Disease"], [190, 194, "Drug"], [197, 199, "Disease"], [209, 211, "Disease"], [226, 229, "Disease"], [226, 227, "Anatomy"], [244, 251, "Disease"], [277, 281, "Disease"], [291, 300, "Drug"], [304, 312, "Test_items"], [322, 323, "Test_items"], [324, 333, "Test_Value"], [337, 341, "Drug"], [349, 353, "Drug"], [365, 368, "Drug"], [370, 373, "Drug"], [376, 380, "Drug"], [384, 392, "Disease"], [394, 400, "Disease"], [20, 24, "Reason"], [83, 86, "Drug"], [114, 116, "Anatomy"], [140, 140, "Test_Value"], [144, 144, "Test_Value"], [158, 161, "Drug"], [222, 225, "Drug"], [240, 243, "Drug"], [267, 270, "Drug"], [314, 316, "Test_Value"], [244, 247, "Anatomy"], [411, 412, "Drug"], [415, 419, "Drug"], [389, 389, "Anatomy"], [390, 390, "Anatomy"], [394, 396, "Anatomy"]], "rel": [[20, 24, "Reason", 26, 30, "Disease", "Reason_Disease"], [20, 24, "Reason", 37, 40, "Disease", "Reason_Disease"], [44, 46, "Anatomy", 44, 52, "Disease", "Anatomy_Disease"], [48, 50, "Anatomy", 44, 52, "Disease", "Anatomy_Disease"], [20, 24, "Reason", 44, 52, "Disease", "Reason_Disease"], [83, 86, "Drug", 92, 94, "Disease", "Drug_Disease"], [95, 96, "Anatomy", 95, 98, "Disease", "Anatomy_Disease"], [83, 86, "Drug", 95, 98, "Disease", "Drug_Disease"], [114, 116, "Anatomy", 109, 111, "Disease", "Anatomy_Disease"], [141, 142, "Test_items", 151, 153, "Disease", "Test_items_Disease"], [145, 149, "Test_items", 151, 153, "Disease", "Test_items_Disease"], [158, 161, "Drug", 151, 153, "Disease", "Drug_Disease"], [158, 161, "Drug", 166, 170, "Disease", "Drug_Disease"], [190, 194, "Drug", 197, 199, "Disease", "Drug_Disease"], [226, 227, "Anatomy", 226, 229, "Disease", "Anatomy_Disease"], [222, 225, "Drug", 226, 229, "Disease", "Drug_Disease"], [240, 243, "Drug", 244, 251, "Disease", "Drug_Disease"], [244, 247, "Anatomy", 244, 251, "Disease", "Anatomy_Disease"], [267, 270, "Drug", 277, 281, "Disease", "Drug_Disease"], [411, 412, "Drug", 384, 392, "Disease", "Drug_Disease"], [415, 419, "Drug", 384, 392, "Disease", "Drug_Disease"], [389, 389, "Anatomy", 384, 392, "Disease", "Anatomy_Disease"], [390, 390, "Anatomy", 384, 392, "Disease", "Anatomy_Disease"], [394, 396, "Anatomy", 394, 400, "Disease", "Anatomy_Disease"], [411, 412, "Drug", 394, 400, "Disease", "Drug_Disease"], [415, 419, "Drug", 394, 400, "Disease", "Drug_Disease"]]}
{"idx": 666, "sentence": "3.其他药物", "ner": [], "rel": []}
{"idx": 667, "sentence": "推荐11：胆固醇吸收抑制剂依折麦布和PCSK9抑制剂可作为他汀不耐受或单药治疗LDL-C不能达标时的联合用药(建议；A级证据)。", "ner": [[18, 25, "Drug"], [39, 43, "Test_items"], [29, 30, "Drug"], [44, 47, "Test_Value"], [5, 12, "Drug"], [13, 16, "Drug"], [31, 33, "ADE"]], "rel": [[31, 33, "ADE", 29, 30, "Drug", "ADE_Drug"]]}
{"idx": 668, "sentence": "在T2DM患者中进行的终止糖尿病患者动脉粥样硬化研究(SANDS)、依折麦布/辛伐他汀疗效国际试验(IMPROVE-IT)研究显示，选择性胆固醇吸收抑制剂依折麦布联合他汀治疗进一步降低主要心血管终点事件风险(HR：0.936，P=0.016)，且安全性良好。PCSK9抑制剂是一类新型的降胆固醇治疗药物，Meta分析结果显示，PCSK9抑制剂可降低心肌梗死(OR：0.49，P=0.03)和全因死亡率(OR：0.45，P=0.015)。胆固醇吸收抑制剂依折麦布和PCSK9抑制剂可作为他汀不耐受或单药治疗LDL-C不能达标时的联合用药(建议；A级证据)，但其长期以及在糖尿病患者中的疗效和安全性仍有待进一步的探讨。", "ner": [[1, 4, "Disease"], [13, 15, "Disease"], [18, 23, "Disease"], [83, 84, "Drug"], [129, 136, "Drug"], [143, 150, "Drug"], [163, 170, "Drug"], [174, 177, "Disease"], [174, 175, "Anatomy"], [231, 238, "Drug"], [252, 256, "Test_items"], [284, 286, "Disease"], [34, 37, "Drug"], [39, 42, "Drug"], [66, 76, "Drug"], [77, 80, "Drug"], [94, 100, "Disease"], [94, 96, "Anatomy"], [218, 225, "Drug"], [226, 229, "Drug"], [242, 243, "Drug"], [244, 246, "ADE"], [257, 260, "Test_Value"], [18, 19, "Anatomy"]], "rel": [[34, 37, "Drug", 13, 15, "Disease", "Drug_Disease"], [39, 42, "Drug", 13, 15, "Disease", "Drug_Disease"], [34, 37, "Drug", 18, 23, "Disease", "Drug_Disease"], [39, 42, "Drug", 18, 23, "Disease", "Drug_Disease"], [83, 84, "Drug", 94, 100, "Disease", "Drug_Disease"], [163, 170, "Drug", 174, 177, "Disease", "Drug_Disease"], [174, 175, "Anatomy", 174, 177, "Disease", "Anatomy_Disease"], [231, 238, "Drug", 284, 286, "Disease", "Drug_Disease"], [252, 256, "Test_items", 284, 286, "Disease", "Test_items_Disease"], [218, 225, "Drug", 284, 286, "Disease", "Drug_Disease"], [226, 229, "Drug", 284, 286, "Disease", "Drug_Disease"], [242, 243, "Drug", 284, 286, "Disease", "Drug_Disease"], [66, 76, "Drug", 94, 100, "Disease", "Drug_Disease"], [77, 80, "Drug", 94, 100, "Disease", "Drug_Disease"], [94, 96, "Anatomy", 94, 100, "Disease", "Anatomy_Disease"], [244, 246, "ADE", 242, 243, "Drug", "ADE_Drug"]]}
{"idx": 669, "sentence": "Meta分析证明.烟酸单药或联合他汀治疗可有效改善糖尿病患者的血脂异常，但长期治疗可升高空腹血糖(+0.085mmo/L，P<0.05)。此外，目前没有确切证据证明烟酸用于糖尿病患者中可降低心血管事件风险，而烟酸与他汀联合的终点事件研究——干预对全球卫生健康的影响研究(AIM-HIGH)，因可能增加缺血性卒中风险(1.6%对0.9%)而提前终止。因此，不推荐T2DM合并血脂异常患者使用烟酸。", "ner": [[16, 17, "Drug"], [25, 27, "Disease"], [31, 32, "Test"], [33, 34, "Test_Value"], [44, 47, "Test_items"], [49, 59, "Test_Value"], [82, 83, "Drug"], [86, 88, "Disease"], [95, 99, "Disease"], [95, 97, "Anatomy"], [104, 105, "Drug"], [107, 108, "Drug"], [150, 154, "ADE"], [180, 183, "Disease"], [186, 187, "Test"], [188, 189, "Test_Value"], [194, 195, "Drug"], [9, 10, "Drug"]], "rel": [[16, 17, "Drug", 25, 27, "Disease", "Drug_Disease"], [9, 10, "Drug", 25, 27, "Disease", "Drug_Disease"], [31, 32, "Test", 25, 27, "Disease", "Test_Disease"], [44, 47, "Test_items", 25, 27, "Disease", "Test_items_Disease"], [82, 83, "Drug", 86, 88, "Disease", "Drug_Disease"], [82, 83, "Drug", 95, 99, "Disease", "Drug_Disease"], [95, 97, "Anatomy", 95, 99, "Disease", "Anatomy_Disease"], [150, 154, "ADE", 104, 105, "Drug", "ADE_Drug"], [150, 154, "ADE", 107, 108, "Drug", "ADE_Drug"], [186, 187, "Test", 180, 183, "Disease", "Test_Disease"], [194, 195, "Drug", 180, 183, "Disease", "Drug_Disease"]]}
{"idx": 670, "sentence": "(四)长期维持治疗", "ner": [], "rel": []}
{"idx": 671, "sentence": "推荐12：T2DM血脂异常患者的调脂治疗在血脂达标后，仍需长期维持治疗(推荐；A级证据)。T2DM血脂异常患者的调脂治疗在血脂达标后，仍需长期维持治疗(推荐；A级证据)。已有证据表明，长期调脂治疗可给患者带来更大的获益。由于炎症和不稳定状态会持续一段时间，如T2DM患者发生了急性冠状动脉综合征(ACS)事件后，他汀类药物强化治疗应至少坚持2年，此后用有效剂量长期治疗。而在治疗期间，需对T2DM患者加强健康教育与管理，强调血脂异常的危害、达标及长期治疗的获益等.提高患者长期治疗依从性。", "ner": [[5, 8, "Disease"], [9, 10, "Test"], [11, 12, "Test_Value"], [21, 22, "Test"], [45, 48, "Disease"], [49, 50, "Test"], [51, 52, "Test_Value"], [61, 62, "Test"], [129, 132, "Disease"], [138, 151, "Disease"], [156, 160, "Drug"], [194, 197, "Disease"], [212, 213, "Test"], [214, 215, "Test_Value"], [23, 24, "Test_Value"], [63, 64, "Test_Value"], [140, 143, "Anatomy"], [170, 171, "Duration"]], "rel": [[9, 10, "Test", 5, 8, "Disease", "Test_Disease"], [21, 22, "Test", 5, 8, "Disease", "Test_Disease"], [49, 50, "Test", 45, 48, "Disease", "Test_Disease"], [61, 62, "Test", 45, 48, "Disease", "Test_Disease"], [156, 160, "Drug", 129, 132, "Disease", "Drug_Disease"], [140, 143, "Anatomy", 138, 151, "Disease", "Anatomy_Disease"], [156, 160, "Drug", 138, 151, "Disease", "Drug_Disease"], [170, 171, "Duration", 156, 160, "Drug", "Duration_Drug"], [212, 213, "Test", 194, 197, "Disease", "Test_Disease"]]}
{"idx": 672, "sentence": "(五)提高患者治疗依从性", "ner": [], "rel": []}
{"idx": 673, "sentence": "T2DM患者往往需要长期降胆固醇治疗，而不依从用药占据治疗失败的30%~50%，并导致各种不良后果，包括增加住院率和医疗费用等。因此，在T2DM患者就诊时应评估其生活方式干预及药物治疗的依从性，发现其(可能)存在的问题、障碍或不良反应，并将血脂水平及控制目标等信息持续向惠者反馈。必要时组建多学科治疗团队，包括内分泌代谢病科医师、心血管病科医师、脑血管病科医师、营养专家、运动医学专家、护师、药剂师等，以帮助患者解决依从性问题。", "ner": [[0, 3, "Disease"], [13, 15, "Test_items"], [68, 71, "Disease"], [120, 123, "Test_items"], [173, 176, "Disease"], [165, 168, "Disease"], [165, 167, "Anatomy"], [173, 175, "Anatomy"], [81, 86, "Treatment"], [155, 160, "Disease"]], "rel": [[13, 15, "Test_items", 0, 3, "Disease", "Test_items_Disease"], [81, 86, "Treatment", 68, 71, "Disease", "Treatment_Disease"], [120, 123, "Test_items", 68, 71, "Disease", "Test_items_Disease"], [173, 175, "Anatomy", 173, 176, "Disease", "Anatomy_Disease"], [165, 167, "Anatomy", 165, 168, "Disease", "Anatomy_Disease"]]}
{"idx": 674, "sentence": "六、T2DM患者特殊情况下的血脂管理", "ner": [[2, 5, "Disease"], [14, 15, "Test"]], "rel": [[14, 15, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 675, "sentence": "(一)T2DM合并肝病或肝功能异常", "ner": [[3, 6, "Disease"], [9, 10, "Disease"], [12, 16, "Disease"], [9, 9, "Anatomy"], [12, 12, "Anatomy"]], "rel": [[9, 9, "Anatomy", 9, 10, "Disease", "Anatomy_Disease"], [12, 12, "Anatomy", 12, 16, "Disease", "Anatomy_Disease"]]}
{"idx": 676, "sentence": "推荐13：当血清丙氨酸氨基转移酶(ALT)或天门冬氨酸氨基转移酶(AST)<2.5x正常上限值(ULN)，同时总胆红素(TBil)正常，可观察，无需调整剂量；如血清ALT或AST2.5~3.0xULN时，可减量；如血清ALT或AST≥3.0xULN时，应停药；当ALT恢复正常时，可酌情再次加量或换药。", "ner": [[6, 20, "Test_items"], [22, 36, "Test_items"], [37, 51, "Test_Value"], [55, 64, "Test_items"], [65, 66, "Test_Value"], [89, 99, "Test_Value"], [80, 88, "Test_items"], [107, 115, "Test_items"], [116, 123, "Test_Value"], [131, 133, "Test_items"], [136, 137, "Test_Value"]], "rel": []}
{"idx": 677, "sentence": "1.T2DM合并慢性肝炎、非酒精性脂肪性肝病、非酒精性脂肪性肝炎(NASH)、代偿期肝硬化患者在无肝功能不全征象时可安全使用他汀类药，通常无需减小剂量。在糖尿病前期/T2DM患者以及活检证实的NASH患者中采用他汀类药物治疗是安全的。考虑到他们心血管疾病的高风险，对这类人群应该鼓励服用他汀类药物治疗。他汀类药物与治疗感染(如乙型和丙型肝炎)的药物同时使用时，应了解两类药物之间的相互作用，如果存在药物的相互作用，应更换一种与治疗感染无相互影响的他汀类药物或者限制其在最低的剂量使用。", "ner": [[2, 5, "Disease"], [8, 11, "Disease"], [10, 10, "Anatomy"], [13, 21, "Disease"], [20, 20, "Anatomy"], [23, 37, "Disease"], [30, 30, "Anatomy"], [39, 44, "Disease"], [42, 42, "Anatomy"], [49, 53, "Disease"], [49, 49, "Anatomy"], [62, 65, "Drug"], [77, 81, "Disease"], [83, 86, "Disease"], [96, 99, "Disease"], [105, 109, "Drug"], [122, 126, "Disease"], [122, 124, "Anatomy"], [143, 147, "Drug"], [151, 155, "Drug"], [163, 169, "Disease"], [223, 227, "Drug"], [159, 160, "Disease"], [215, 216, "Disease"]], "rel": [[62, 65, "Drug", 2, 5, "Disease", "Drug_Disease"], [10, 10, "Anatomy", 8, 11, "Disease", "Anatomy_Disease"], [62, 65, "Drug", 8, 11, "Disease", "Drug_Disease"], [20, 20, "Anatomy", 13, 21, "Disease", "Anatomy_Disease"], [62, 65, "Drug", 13, 21, "Disease", "Drug_Disease"], [30, 30, "Anatomy", 23, 37, "Disease", "Anatomy_Disease"], [62, 65, "Drug", 23, 37, "Disease", "Drug_Disease"], [42, 42, "Anatomy", 39, 44, "Disease", "Anatomy_Disease"], [62, 65, "Drug", 39, 44, "Disease", "Drug_Disease"], [49, 49, "Anatomy", 49, 53, "Disease", "Anatomy_Disease"], [105, 109, "Drug", 77, 81, "Disease", "Drug_Disease"], [105, 109, "Drug", 83, 86, "Disease", "Drug_Disease"], [105, 109, "Drug", 96, 99, "Disease", "Drug_Disease"], [122, 124, "Anatomy", 122, 126, "Disease", "Anatomy_Disease"], [143, 147, "Drug", 122, 126, "Disease", "Drug_Disease"], [151, 155, "Drug", 163, 169, "Disease", "Drug_Disease"], [151, 155, "Drug", 159, 160, "Disease", "Drug_Disease"], [223, 227, "Drug", 215, 216, "Disease", "Drug_Disease"]]}
{"idx": 678, "sentence": "2.他汀类药物本身可引起肝功能受损，主要表现为转氨酵升高，发生率约0.5%~3.0%，常见于开始用药或增大剂量的12周内，且呈剂量依赖性，极少引起肝衰竭；当血清ALT或AST<2.5xULN，同时TBil正常，可观察，无需调整剂量；如血清ALT或AST2.5~3.0xULN时可减量；如血清ALT或AST≥3.0xULN时应停药：当ALT恢复正常时.可酌情再次加量或换药。", "ner": [[2, 6, "Drug"], [12, 16, "ADE"], [23, 25, "Test_items"], [26, 27, "Test_Value"], [73, 75, "ADE"], [78, 86, "Test_items"], [87, 94, "Test_Value"], [98, 101, "Test_items"], [102, 103, "Test_Value"], [117, 125, "Test_items"], [126, 136, "Test_Value"], [152, 159, "Test_Value"], [166, 168, "Test_items"], [171, 172, "Test_Value"], [56, 58, "Duration"], [143, 151, "Test_items"]], "rel": [[12, 16, "ADE", 2, 6, "Drug", "ADE_Drug"], [73, 75, "ADE", 2, 6, "Drug", "ADE_Drug"], [56, 58, "Duration", 2, 6, "Drug", "Duration_Drug"]]}
{"idx": 679, "sentence": "3.失代偿性肝硬化及急性肝功能哀竭是他汀类药物应用禁忌证。", "ner": [[2, 8, "Disease"], [10, 16, "Disease"], [18, 22, "Drug"], [6, 6, "Anatomy"], [12, 12, "Anatomy"]], "rel": [[6, 6, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [18, 22, "Drug", 2, 8, "Disease", "Drug_Disease"], [12, 12, "Anatomy", 10, 16, "Disease", "Anatomy_Disease"], [18, 22, "Drug", 10, 16, "Disease", "Drug_Disease"]]}
{"idx": 680, "sentence": "(二)T2DM合并CKD", "ner": [[3, 6, "Disease"], [9, 11, "Disease"]], "rel": []}
{"idx": 681, "sentence": "推荐14：当合并CKDI~2期，他汀类药物的使用无须减量；当合并CKD3期，除普伐他汀限制使用，阿托伐他汀、辛伐他汀、氟伐他汀、瑞舒伐他汀均无须减量：当合并CKD4期，阿托伐他汀可无须减量，辛伐他汀应减量使用，而氟伐他汀、瑞舒伐他汀、普伐他汀均应限制使用；当合并CKD5期，透析前使用他汀治疗的患者，他汀类药物慎续用；不推荐在此期起始他汀治疗。", "ner": [], "rel": []}
{"idx": 682, "sentence": "Meta分析结果显示他汀对肾功能无不良影响，在患者可耐受的前提下，推荐T2DM合并CKD患者在血脂异常时应接受他汀治疗。", "ner": [], "rel": []}
{"idx": 683, "sentence": "当合并CKDI~2期，他汀类药物的使用无须减量(图3)；当合并CKD3期，除普伐他汀限制使用，阿托伐他汀、辛伐他汀、氟伐他汀、瑞舒伐他汀均无须减量；当合并CKD4期，阿托伐他汀可无须减量，辛伐他汀应减量使用，而氟伐他汀、瑞舒伐他汀、普伐他汀均应限制使用；当合并CKD5期，透析前使用他汀治疗的患者.他汀类药物谨慎续用；不推荐在此期起始他汀治疗。", "ner": [[11, 15, "Drug"], [3, 9, "Disease"], [31, 35, "Disease"], [38, 41, "Drug"], [47, 51, "Drug"], [53, 56, "Drug"], [58, 61, "Drug"], [63, 67, "Drug"], [77, 81, "Disease"], [83, 87, "Drug"], [94, 97, "Drug"], [105, 108, "Drug"], [110, 114, "Drug"], [116, 119, "Drug"], [130, 134, "Disease"], [141, 142, "Drug"], [149, 153, "Drug"], [167, 168, "Drug"], [136, 137, "Treatment"]], "rel": [[11, 15, "Drug", 3, 9, "Disease", "Drug_Disease"], [47, 51, "Drug", 31, 35, "Disease", "Drug_Disease"], [53, 56, "Drug", 31, 35, "Disease", "Drug_Disease"], [58, 61, "Drug", 31, 35, "Disease", "Drug_Disease"], [63, 67, "Drug", 31, 35, "Disease", "Drug_Disease"], [83, 87, "Drug", 77, 81, "Disease", "Drug_Disease"], [94, 97, "Drug", 77, 81, "Disease", "Drug_Disease"], [141, 142, "Drug", 130, 134, "Disease", "Drug_Disease"], [136, 137, "Treatment", 130, 134, "Disease", "Treatment_Disease"]]}
{"idx": 684, "sentence": "CKD患者是他汀引起肌病的高危人群，尤其是在肾功能进行性减退或肾小球滤过率(glomerular filtration rale，GFR)<30ml·min-1·1.73m2)时，并且发病风险与他汀剂量密切相关，故应避免大剂量应用。", "ner": [[0, 2, "Disease"], [6, 7, "Drug"], [10, 11, "ADE"], [69, 86, "Test_Value"], [97, 98, "Drug"], [22, 29, "Pathogenesis"], [31, 68, "Test_items"]], "rel": [[6, 7, "Drug", 0, 2, "Disease", "Drug_Disease"], [22, 29, "Pathogenesis", 0, 2, "Disease", "Pathogenesis_Disease"], [31, 68, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [10, 11, "ADE", 6, 7, "Drug", "ADE_Drug"]]}
{"idx": 685, "sentence": "中等强度他汀治疗LDL-C不能达标时，推荐联合应用依折麦布。", "ner": [[0, 5, "Drug"], [8, 12, "Test_items"], [25, 28, "Drug"], [13, 16, "Test_items"]], "rel": []}
{"idx": 686, "sentence": "(三)老年T2DM", "ner": [[3, 8, "Disease"]], "rel": []}
{"idx": 687, "sentence": "老年人大多有不同程度的肝肾功能减退，或常患多种慢性疾病，需服用多种药物，需注意药物间的相互作用和不良反应；调脂药物剂量的选择需要个体化，起始剂量不宜太大；当老年患者年龄>75岁时，不推荐高强度他汀治疗，推荐中等强度他汀治疗，并根据治疗效果调整调脂药物剂量和监测肝肾功能、肌酸激酶。", "ner": [[11, 16, "Disease"], [53, 56, "Drug"], [93, 97, "Drug"], [103, 108, "Drug"], [121, 124, "Drug"], [135, 138, "Test_items"], [130, 133, "Test"], [12, 12, "Anatomy"], [11, 11, "Anatomy"]], "rel": [[11, 11, "Anatomy", 11, 16, "Disease", "Anatomy_Disease"], [12, 12, "Anatomy", 11, 16, "Disease", "Anatomy_Disease"], [53, 56, "Drug", 11, 16, "Disease", "Drug_Disease"], [103, 108, "Drug", 11, 16, "Disease", "Drug_Disease"], [121, 124, "Drug", 11, 16, "Disease", "Drug_Disease"], [130, 133, "Test", 11, 16, "Disease", "Test_Disease"], [135, 138, "Test_items", 11, 16, "Disease", "Test_items_Disease"]]}
{"idx": 688, "sentence": "七、T2DM患者血脂管理中药物不良事件的监测和处理", "ner": [[2, 5, "Disease"], [8, 9, "Test"]], "rel": [[8, 9, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 689, "sentence": "推荐15：大多数患者对他汀类的耐受性良好。", "ner": [[11, 13, "Drug"]], "rel": []}
{"idx": 690, "sentence": "推荐16：在服用他汀类药物期间出现肌肉不适或无力症状以及排褐色尿时，应及时监测肌酸激酵(CK)，注意排除甲状腺功能低下、过度运动等导致的肌肉症状和/或肌酶升高。如果发生或高度怀疑肌炎，应立即停止他汀治疗。", "ner": [[8, 12, "Drug"], [17, 20, "ADE"], [22, 23, "ADE"], [28, 31, "ADE"], [39, 46, "Test_items"], [89, 90, "ADE"], [97, 98, "Drug"], [52, 58, "Disease"], [68, 69, "Anatomy"], [75, 76, "Test_items"], [77, 78, "Test_Value"], [52, 54, "Anatomy"]], "rel": [[17, 20, "ADE", 8, 12, "Drug", "ADE_Drug"], [22, 23, "ADE", 8, 12, "Drug", "ADE_Drug"], [28, 31, "ADE", 8, 12, "Drug", "ADE_Drug"], [89, 90, "ADE", 97, 98, "Drug", "ADE_Drug"], [52, 54, "Anatomy", 52, 58, "Disease", "Anatomy_Disease"], [68, 69, "Anatomy", 52, 58, "Disease", "Anatomy_Disease"], [75, 76, "Test_items", 52, 58, "Disease", "Test_items_Disease"]]}
{"idx": 691, "sentence": "推荐17：长期服用他汀类药物可能引起血糖异常和增加新发糖尿病的风险。", "ner": [[9, 13, "Drug"], [18, 21, "ADE"], [25, 29, "ADE"]], "rel": [[18, 21, "ADE", 9, 13, "Drug", "ADE_Drug"], [25, 29, "ADE", 9, 13, "Drug", "ADE_Drug"]]}
{"idx": 692, "sentence": "推荐18：Meta分析和中国多中心研究数据显示，他汀与非诺贝特联用，可进一步改善血脂谱、显著提高血脂达标率，且耐受性良好。", "ner": [[24, 25, "Drug"], [27, 30, "Drug"], [40, 42, "Test"], [48, 49, "Test"]], "rel": []}
{"idx": 693, "sentence": "因此，可使用他汀与非诺贝特合用，避免与吉非贝齐合用，应用时应加强临床监测，警惕不良反应的发生。", "ner": [[6, 7, "Drug"], [9, 12, "Drug"], [19, 22, "Drug"]], "rel": []}
{"idx": 694, "sentence": "使用调脂药过程，尤其联合用药者应密切监测安全性，特别在高龄、低体重、多系统疾病、同时使用多种药物、围手术期等患者更应加强监测。", "ner": [[2, 4, "Drug"]], "rel": []}
{"idx": 695, "sentence": "大多数患者对他汀类的耐受性良好。常见不良反应包括头痛、失眠、抑郁、以及消化不良、腹泻、腹痛、恶心等消化道症状，通常较轻且短暂.常不需要特殊治疗。", "ner": [[6, 8, "Drug"], [24, 25, "ADE"], [27, 28, "ADE"], [30, 31, "ADE"], [35, 38, "ADE"], [40, 41, "ADE"], [43, 44, "ADE"], [46, 47, "ADE"]], "rel": [[24, 25, "ADE", 6, 8, "Drug", "ADE_Drug"], [27, 28, "ADE", 6, 8, "Drug", "ADE_Drug"], [30, 31, "ADE", 6, 8, "Drug", "ADE_Drug"], [35, 38, "ADE", 6, 8, "Drug", "ADE_Drug"], [40, 41, "ADE", 6, 8, "Drug", "ADE_Drug"], [43, 44, "ADE", 6, 8, "Drug", "ADE_Drug"], [46, 47, "ADE", 6, 8, "Drug", "ADE_Drug"]]}
{"idx": 696, "sentence": "但仍有极少数病例发生肝脏转氨酶如ALT和AST升高，且呈剂量依赖性。", "ner": [[10, 14, "Test_items"], [23, 24, "Test_Value"], [16, 18, "Test_items"], [20, 22, "Test_items"]], "rel": []}
{"idx": 697, "sentence": "因此建议在治疗前和开始治疗后4-8周复查肝功能，如无异常，则逐步调整为6-12个月复查1次；如AST或ALT超过3倍正常上限值，应暂停给药，且仍需每周复查肝功能，直至恢复正常。", "ner": [[54, 62, "Test_Value"], [20, 22, "Test"], [47, 49, "Test_items"], [51, 53, "Test_items"], [77, 79, "Test"]], "rel": []}
{"idx": 698, "sentence": "轻度的肝酶升高小于正常值上限2.5倍并不是治疗的禁忌证，患者可以继续服用他汀，部分患者升高的ALT可能今自行下降。", "ner": [[3, 4, "Test"], [5, 6, "Test_Value"], [7, 17, "Test_Value"], [36, 37, "Drug"], [46, 48, "Test_items"], [52, 55, "Test_Value"]], "rel": []}
{"idx": 699, "sentence": "用药过程仅有血CK升高而不伴肌痛或肌无力等其他肌损伤证据，则不考虑他汀所致肌损伤。在服用他汀类药物期间出现肌肉不适或无力症状以及排褐色尿时，应及时检测CK，注意排除甲状腺功能低下、过度运动等导致的肌肉症状和(或)肌酶升高。如果发生或高度怀疑肌炎，应立即停止他汀治疗。如果患者有肌肉触痛、压痛或疼痛，CK不升高或中度升高(3~10xULN)，应进行随访、每周检测CK水平，直至排除了药物作用；如肌肉症状恶化，应及时停药。如果患者有肌肉触痛、压痛或疼痛，且连续检测CK呈进行性升高，应慎重考虑减少他汀剂量或暂时停药。然后决定是否或何时再开始他汀类药物治疗。一旦患者发生横纹肌溶解，应停止他汀类药物治疗，必要时住院进行静脉内水化治疗。", "ner": [[6, 8, "Test_items"], [9, 10, "Test_Value"], [14, 15, "ADE"], [17, 19, "ADE"], [33, 34, "Drug"], [37, 39, "ADE"], [44, 48, "Drug"], [53, 56, "ADE"], [58, 59, "ADE"], [64, 67, "ADE"], [23, 25, "ADE"], [75, 76, "Test_Value"], [82, 88, "Disease"], [82, 84, "Anatomy"], [98, 99, "Anatomy"], [106, 107, "Test_items"], [108, 109, "Test_Value"], [120, 121, "ADE"], [128, 129, "Drug"], [138, 141, "Symptom"], [143, 144, "Symptom"], [146, 147, "Symptom"], [149, 150, "Test_items"], [151, 153, "Test_Value"], [155, 168, "Test_Value"], [180, 181, "Test_items"], [214, 217, "ADE"], [219, 220, "ADE"], [222, 223, "ADE"], [230, 231, "Test_items"], [233, 237, "Test_Value"], [246, 247, "Drug"], [268, 272, "Drug"], [282, 286, "ADE"], [291, 295, "Drug"]], "rel": [[37, 39, "ADE", 33, 34, "Drug", "ADE_Drug"], [53, 56, "ADE", 44, 48, "Drug", "ADE_Drug"], [58, 59, "ADE", 44, 48, "Drug", "ADE_Drug"], [64, 67, "ADE", 44, 48, "Drug", "ADE_Drug"], [82, 84, "Anatomy", 82, 88, "Disease", "Anatomy_Disease"], [98, 99, "Anatomy", 82, 88, "Disease", "Anatomy_Disease"], [106, 107, "Test_items", 82, 88, "Disease", "Test_items_Disease"], [120, 121, "ADE", 128, 129, "Drug", "ADE_Drug"], [214, 217, "ADE", 246, 247, "Drug", "ADE_Drug"], [219, 220, "ADE", 246, 247, "Drug", "ADE_Drug"], [222, 223, "ADE", 246, 247, "Drug", "ADE_Drug"], [282, 286, "ADE", 291, 295, "Drug", "ADE_Drug"]]}
{"idx": 700, "sentence": "长期服用他汀类药物可能引起血糖异常和增加新发糖尿病的风险。对13项随机对照临床研究进行的meta分析中，他汀治疗组新发糖尿病风险增加9%。关于他汀类药物的类效应的研究发现，阿托伐他汀、瑞舒伐他汀、辛伐他汀、氟伐他汀在正常人和T2DM患者中都具有类似的对血糖调控的不良影响，而匹伐他汀和普伐他汀对血糖调节具有较中性的作用。目前发现他汀引发新发糖尿病的可能机制有：增加其他致糖尿病的危险因素、损伤胰岛β细胞、降低胰岛素敏感性等。一个遗传学随机试验发现他汀类药物通过抑制HMG-CoA还原酶活性，可引起体重增加，从而增加新发糖尿病的风险。在另一项meta分析中，高剂量他汀治疗比中等剂量他汀增加新发糖尿病的风险12%，提示他汀引发新发糖尿病与剂量相关。但他汀对心血管疾病的总体益处与新发糖尿病风险之比是9：1，他汀类药物对心血管疾病的保护作用远大于新发糖尿病风险。使用中等强度他汀不仅有效降低心脑血管事件，同时安全性和耐受性良好。现有数据表明，如果有在使用他汀类出现血糖不良反应，通常反应小且可通过调整血糖控制方案减弱该反应。而他汀减少有糖尿病风险患者的心血管事件的获益已得到充分肯定。因此，T2DM患者使用他汀治疗期间，着重于通过减轻体重或降糖药物来控制血糖和HbA1c，并提供适当的饮食与运动建议。", "ner": [[4, 8, "Drug"], [20, 24, "ADE"], [52, 53, "Drug"], [57, 61, "ADE"], [71, 75, "Drug"], [86, 90, "Drug"], [92, 96, "Drug"], [98, 101, "Drug"], [103, 106, "Drug"], [112, 115, "Disease"], [126, 127, "Test_items"], [137, 140, "Drug"], [142, 145, "Drug"], [147, 148, "Test_items"], [164, 165, "Drug"], [168, 172, "ADE"], [180, 192, "ADE"], [194, 200, "ADE"], [202, 209, "ADE"], [223, 227, "Drug"], [257, 261, "ADE"], [294, 298, "ADE"], [308, 309, "Drug"], [312, 316, "ADE"], [324, 325, "Drug"], [327, 331, "Disease"], [338, 342, "ADE"], [352, 356, "Drug"], [358, 362, "Disease"], [371, 375, "ADE"], [381, 386, "Drug"], [393, 398, "Disease"], [425, 427, "Drug"], [448, 449, "Test_items"], [461, 462, "Drug"], [466, 468, "Disease"], [474, 478, "Disease"], [493, 496, "Disease"], [501, 502, "Drug"], [525, 526, "Test_items"], [528, 532, "Test_items"], [518, 520, "Drug"], [358, 360, "Anatomy"], [327, 329, "Anatomy"], [393, 396, "Anatomy"], [474, 476, "Anatomy"], [13, 16, "ADE"], [248, 251, "ADE"], [281, 282, "Drug"], [290, 291, "Drug"], [430, 435, "ADE"], [513, 516, "Treatment"]], "rel": [[13, 16, "ADE", 4, 8, "Drug", "ADE_Drug"], [20, 24, "ADE", 4, 8, "Drug", "ADE_Drug"], [57, 61, "ADE", 52, 53, "Drug", "ADE_Drug"], [71, 75, "Drug", 112, 115, "Disease", "Drug_Disease"], [86, 90, "Drug", 112, 115, "Disease", "Drug_Disease"], [92, 96, "Drug", 112, 115, "Disease", "Drug_Disease"], [98, 101, "Drug", 112, 115, "Disease", "Drug_Disease"], [103, 106, "Drug", 112, 115, "Disease", "Drug_Disease"], [137, 140, "Drug", 112, 115, "Disease", "Drug_Disease"], [142, 145, "Drug", 112, 115, "Disease", "Drug_Disease"], [126, 127, "Test_items", 112, 115, "Disease", "Test_items_Disease"], [147, 148, "Test_items", 112, 115, "Disease", "Test_items_Disease"], [168, 172, "ADE", 164, 165, "Drug", "ADE_Drug"], [248, 251, "ADE", 223, 227, "Drug", "ADE_Drug"], [257, 261, "ADE", 223, 227, "Drug", "ADE_Drug"], [294, 298, "ADE", 281, 282, "Drug", "ADE_Drug"], [294, 298, "ADE", 290, 291, "Drug", "ADE_Drug"], [312, 316, "ADE", 308, 309, "Drug", "ADE_Drug"], [338, 342, "ADE", 324, 325, "Drug", "ADE_Drug"], [324, 325, "Drug", 327, 331, "Disease", "Drug_Disease"], [327, 329, "Anatomy", 327, 331, "Disease", "Anatomy_Disease"], [352, 356, "Drug", 358, 362, "Disease", "Drug_Disease"], [358, 360, "Anatomy", 358, 362, "Disease", "Anatomy_Disease"], [381, 386, "Drug", 393, 398, "Disease", "Drug_Disease"], [393, 396, "Anatomy", 393, 398, "Disease", "Anatomy_Disease"], [430, 435, "ADE", 425, 427, "Drug", "ADE_Drug"], [461, 462, "Drug", 466, 468, "Disease", "Drug_Disease"], [461, 462, "Drug", 474, 478, "Disease", "Drug_Disease"], [474, 476, "Anatomy", 474, 478, "Disease", "Anatomy_Disease"], [501, 502, "Drug", 493, 496, "Disease", "Drug_Disease"], [518, 520, "Drug", 493, 496, "Disease", "Drug_Disease"], [525, 526, "Test_items", 493, 496, "Disease", "Test_items_Disease"], [528, 532, "Test_items", 493, 496, "Disease", "Test_items_Disease"], [513, 516, "Treatment", 493, 496, "Disease", "Treatment_Disease"]]}
{"idx": 701, "sentence": " ", "ner": [], "rel": []}
{"idx": 702, "sentence": "贝特类最常见的不良反应为胃肠道不适，多为轻微的恶心、腹泻和腹胀等。另外，偶见皮肤强痒、荨麻疹、皮疹、脱发、头痛、失眠和性欲减退等。长期服用贝特类时，需要警惕药物引起的肝、肾功能损害，因此在治疗开始后半个月应该监测肝、肾功能；个别患者服药后可能发生药物性横纹肌溶解症，若有上述症状，则应该立即检测血CK水平。另外，贝特类可使胆结石的发生率升高，个别患者服药后白细胞、红细胞和嗜酸性粒细胞可能减少，因此若有相应的症状和体征，应该进行相应的监测。", "ner": [[0, 2, "Drug"], [12, 16, "ADE"], [20, 24, "ADE"], [26, 27, "ADE"], [29, 30, "ADE"], [38, 41, "ADE"], [43, 45, "ADE"], [47, 48, "ADE"], [50, 51, "ADE"], [53, 54, "ADE"], [56, 57, "ADE"], [59, 62, "ADE"], [69, 71, "Drug"], [83, 89, "ADE"], [106, 110, "Test"], [99, 101, "Duration"], [123, 131, "ADE"], [147, 151, "Test_items"], [156, 158, "Drug"], [161, 169, "ADE"], [178, 195, "ADE"]], "rel": [[12, 16, "ADE", 0, 2, "Drug", "ADE_Drug"], [20, 24, "ADE", 0, 2, "Drug", "ADE_Drug"], [26, 27, "ADE", 0, 2, "Drug", "ADE_Drug"], [29, 30, "ADE", 0, 2, "Drug", "ADE_Drug"], [83, 89, "ADE", 69, 71, "Drug", "ADE_Drug"], [99, 101, "Duration", 69, 71, "Drug", "Duration_Drug"], [123, 131, "ADE", 69, 71, "Drug", "ADE_Drug"], [161, 169, "ADE", 156, 158, "Drug", "ADE_Drug"], [178, 195, "ADE", 156, 158, "Drug", "ADE_Drug"]]}
{"idx": 703, "sentence": "烟酸可导致糖代谢异常或糖耐量恶化，一般不推荐在糖尿病患者中使用。若必须使用，应该定期监测血糖水平。", "ner": [[0, 1, "Drug"], [5, 9, "ADE"], [11, 15, "ADE"], [23, 25, "Disease"], [44, 45, "Test_items"]], "rel": [[5, 9, "ADE", 0, 1, "Drug", "ADE_Drug"], [11, 15, "ADE", 0, 1, "Drug", "ADE_Drug"], [44, 45, "Test_items", 23, 25, "Disease", "Test_items_Disease"]]}
{"idx": 704, "sentence": "T2DM患者常为混合型血脂异常，临床可能需要他汀类与贝特类药物联合应用，两药联用可能会增加不良反应的几率。Meta分析共纳人13项非诺贝特他汀联用随机对照临床研究中的7712例受试者数据，结果显示，联合治疗组尽管肝酶升高发生率有所升高，但因肝功能异常停药的患者比例并未增加，且CK升高、因肌病停药发生率在联合治疗组和单药组间无统计学差异，说明他汀与非诺贝特联用耐受性良好。", "ner": [[0, 3, "Disease"], [8, 14, "Disease"], [22, 24, "Drug"], [26, 30, "Drug"], [106, 109, "ADE"], [138, 139, "Test_items"], [140, 141, "Test_Value"], [144, 145, "Disease"], [144, 144, "Anatomy"], [171, 172, "Drug"], [174, 177, "Drug"], [65, 68, "Drug"], [69, 70, "Drug"]], "rel": [[22, 24, "Drug", 0, 3, "Disease", "Drug_Disease"], [26, 30, "Drug", 0, 3, "Disease", "Drug_Disease"], [22, 24, "Drug", 8, 14, "Disease", "Drug_Disease"], [26, 30, "Drug", 8, 14, "Disease", "Drug_Disease"], [106, 109, "ADE", 65, 68, "Drug", "ADE_Drug"], [106, 109, "ADE", 69, 70, "Drug", "ADE_Drug"], [144, 144, "Anatomy", 144, 145, "Disease", "Anatomy_Disease"]]}
{"idx": 705, "sentence": "中国多中心研究数据显示，他汀与非诺贝特联用，可进一步改善血脂谱、显著提高血脂达标率，且耐受性良好。", "ner": [[12, 13, "Drug"], [15, 18, "Drug"], [28, 30, "Test"], [34, 40, "Test_Value"], [36, 37, "Test"]], "rel": []}
{"idx": 706, "sentence": "因此，可使用他汀与非诺贝特合用，避免与吉非贝齐合用，应用时应加强临床监测，警惕不良反应的发生。", "ner": [[6, 7, "Drug"], [9, 12, "Drug"], [19, 22, "Drug"]], "rel": []}
{"idx": 707, "sentence": "八、T2DM患者常用药物对血脂的影响", "ner": [[2, 5, "Disease"], [13, 14, "Test"]], "rel": [[13, 14, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 708, "sentence": "推荐19：在临床中，T2DM患者一些常用的药物会影响患者的血脂水平，临床医师在处方药物时应该考虑到这些潜在的药物作用。", "ner": [[10, 13, "Disease"], [29, 30, "Test"]], "rel": [[29, 30, "Test", 10, 13, "Disease", "Test_Disease"]]}
{"idx": 709, "sentence": "在临床中，T2DM患者一些常用的药物会影响患者的血脂水平，可能会对患ASCVD的风险产生影响。有些药物对血脂的影响可能显著，但大多数影响较小(附表5)。当T2DM患者同时服用多种药物时，其累积效应不容忽视。", "ner": [[5, 8, "Disease"], [24, 25, "Test"], [34, 38, "Disease"], [52, 53, "Test"], [77, 80, "Disease"]], "rel": [[24, 25, "Test", 5, 8, "Disease", "Test_Disease"], [24, 25, "Test", 34, 38, "Disease", "Test_Disease"]]}
{"idx": 710, "sentence": "因此，临床医师在处方药物时，应该考虑到这些潜在的药物作用，以免使患者承受不必要的风险。", "ner": [], "rel": []}
{"idx": 711, "sentence": "九、T2DM患者的血脂异常预防策略 ", "ner": [[2, 5, "Disease"], [9, 10, "Test"], [11, 12, "Test_Value"]], "rel": [[9, 10, "Test", 2, 5, "Disease", "Test_Disease"]]}
{"idx": 712, "sentence": "推荐20：治疗性生活方式改变不仅是治疗T2DM患者血脂异常的基础，更是预防T2DM患者血脂异常的根本手段。 ", "ner": [[5, 13, "Treatment"], [19, 22, "Disease"], [25, 26, "Test"], [27, 28, "Test_Value"], [37, 40, "Disease"], [43, 44, "Test"], [45, 46, "Test_Value"]], "rel": [[5, 13, "Treatment", 19, 22, "Disease", "Treatment_Disease"], [25, 26, "Test", 19, 22, "Disease", "Test_Disease"], [43, 44, "Test", 37, 40, "Disease", "Test_Disease"]]}
{"idx": 713, "sentence": "治疗性生活方式改变不仅是治疗T2DM患者血脂异常的基础，更是预防T2DM患者血脂异常的根本手段。因此，应教育患者调整饮食结构，并提倡健康生活方式。调整饮食结构包括控制总热量、减少饱和脂肪酸的摄入、增加不饱和脂肪酸的摄入、控制胆固醇的摄入、增加富含维生素、纤维等食物。", "ner": [[0, 8, "Treatment"], [14, 17, "Disease"], [20, 21, "Test"], [22, 23, "Test_Value"], [32, 35, "Disease"], [38, 39, "Test"], [40, 41, "Test_Value"], [56, 61, "Treatment"], [64, 71, "Treatment"], [73, 78, "Treatment"], [81, 85, "Treatment"], [87, 96, "Treatment"], [98, 108, "Treatment"], [110, 117, "Treatment"], [119, 131, "Treatment"]], "rel": [[0, 8, "Treatment", 14, 17, "Disease", "Treatment_Disease"], [20, 21, "Test", 14, 17, "Disease", "Test_Disease"], [38, 39, "Test", 32, 35, "Disease", "Test_Disease"]]}
{"idx": 714, "sentence": "健康生活方式包括减肥、戒烟、控制酒精、限制食盐、坚持有氧运动、注重心理健康、保持乐观达的生活态度等。", "ner": [[0, 5, "Treatment"], [8, 9, "Treatment"], [11, 12, "Treatment"], [14, 17, "Treatment"], [19, 22, "Treatment"], [24, 29, "Treatment"], [31, 36, "Treatment"], [38, 47, "Treatment"]], "rel": []}
{"idx": 715, "sentence": "这些均可以有效预防T2DM患者的血脂异常。", "ner": [[9, 12, "Disease"], [16, 17, "Test"], [18, 19, "Test_Value"]], "rel": [[16, 17, "Test", 9, 12, "Disease", "Test_Disease"]]}
{"idx": 716, "sentence": " ", "ner": [], "rel": []}
{"idx": 717, "sentence": "十、总结 ", "ner": [], "rel": []}
{"idx": 718, "sentence": "总之，遵循专家共识中血脂异常的个体化处理原则，确定T2DM患者调脂治疗的具体目标值，选用合适的调脂药物、剂量及疗程，是改善T2DM伴血脂代谢异常患者临床预后的关键所在。", "ner": [], "rel": []}
{"idx": 719, "sentence": "他汀类药物是首选的降脂药物，在兼顾疗效、安全及费用的基础上可选用中等强度他汀，适合大部分T2DM合并血脂异常患者降脂治疗。", "ner": [], "rel": []}
{"idx": 720, "sentence": "若血脂未达预期目标，则在强化生活方式干预的同时，加用其他非他汀类药物如贝特类药物或依折麦布。", "ner": [], "rel": []}
{"idx": 721, "sentence": "血脂达标后，仍需长期维持治疗。", "ner": [], "rel": []}
{"idx": 722, "sentence": "治疗性生活方式改变不仅是治疗T2DM患者血脂异常的基础，更是预防T2DM患者血脂异常的根本手段。", "ner": [], "rel": []}
{"idx": 723, "sentence": " ", "ner": [], "rel": []}
{"idx": 724, "sentence": "围术期血糖管理专家共识(快捷版)", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 725, "sentence": "血糖异常增高是围术期的常见问题。一方面，手术创伤应激诱发机体分泌儿茶酚胺、皮质醇和炎性介质等胰岛素拮抗因子，促使血糖增高。另一方面，合并糖尿病、代谢综合征等胰岛素抵抗或胰岛素分泌障碍疾病的患者更容易发生围术期高血糖。另外，围术期经常使用的激素、含糖营养液等进一步增加了高血糖的风险。值得注意的是，长时间禁食和不恰当的降糖治疗也有引起患者低血糖和血糖剧烈波动的可能。", "ner": [[0, 1, "Test_items"], [2, 5, "Test_Value"], [20, 23, "Reason"], [24, 52, "Pathogenesis"], [56, 57, "Test_items"], [58, 59, "Test_Value"], [68, 70, "Disease"], [72, 76, "Disease"], [101, 106, "Disease"], [119, 120, "Reason"], [122, 126, "Reason"], [134, 136, "Disease"], [148, 152, "Reason"], [154, 161, "Reason"], [168, 170, "Disease"], [172, 173, "Test_items"], [174, 177, "Test_Value"], [78, 82, "Disease"], [84, 92, "Disease"]], "rel": [[119, 120, "Reason", 134, 136, "Disease", "Reason_Disease"], [122, 126, "Reason", 134, 136, "Disease", "Reason_Disease"], [148, 152, "Reason", 168, 170, "Disease", "Reason_Disease"], [154, 161, "Reason", 168, 170, "Disease", "Reason_Disease"], [172, 173, "Test_items", 168, 170, "Disease", "Test_items_Disease"]]}
{"idx": 726, "sentence": "大量证据表明，围术期血糖异常(包括高血糖、低血糖和血糖波动)增加手术患者的死亡率，增加感染伤口不愈合以及心脑血管事件等并发症的发生率，延长住院时间，影响远期预后。", "ner": [[10, 11, "Test_items"], [12, 13, "Test_Value"], [17, 19, "Disease"], [21, 23, "Disease"], [25, 26, "Test_items"], [27, 28, "Test_Value"], [43, 44, "ADE"], [45, 49, "ADE"], [52, 57, "ADE"]], "rel": [[10, 11, "Test_items", 17, 19, "Disease", "Test_items_Disease"], [10, 11, "Test_items", 21, 23, "Disease", "Test_items_Disease"]]}
{"idx": 727, "sentence": "合理的血糖监测和调控是围术期管理的重要组成部分，应当得到重视。", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 728, "sentence": "据此，中华医学会麻醉学分会于2014年组织专家组起草和制订了《围术期血糖管理专家共识》，本文是在此基础上进一步修订的2015年快捷版本。", "ner": [[34, 35, "Test_items"]], "rel": []}
{"idx": 729, "sentence": "围术期血糖管理的基本原则", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 730, "sentence": "识别围术期血糖异常的高危人群围术期血糖异常以高血糖为主，可分为合并糖尿病的高血糖和应激性高血糖两类(stress-induced hyperglycemia)。一般手术围术期高血糖以合并糖尿病者居多。目前我国糖尿病患病率逐年增高，合并糖尿病的外科手术患者也日趋增多，其中相当比例的患者术前并未得到正确诊断和有效控制。有国外研究报道，择期手术中10%以上的患者合并隐匿性糖尿病。与普通人群相比，合并糖尿病尤其是未发现、未治疗的糖尿病患者血糖升高更加显著，围术期死亡率和并发症发生率更高，应当在术前加以识别。", "ner": [[5, 6, "Test_items"], [7, 8, "Test_Value"], [17, 18, "Test_items"], [22, 24, "Disease"], [33, 35, "Disease"], [37, 39, "Disease"], [41, 46, "Disease"], [50, 77, "Disease"], [84, 89, "Disease"], [93, 95, "Disease"], [104, 106, "Disease"], [117, 119, "Disease"], [181, 186, "Disease"], [198, 200, "Disease"], [212, 214, "Disease"], [217, 218, "Test_items"], [219, 220, "Test_Value"], [19, 20, "Test_Value"]], "rel": [[17, 18, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [17, 18, "Test_items", 33, 35, "Disease", "Test_items_Disease"], [17, 18, "Test_items", 37, 39, "Disease", "Test_items_Disease"], [17, 18, "Test_items", 41, 46, "Disease", "Test_items_Disease"], [17, 18, "Test_items", 50, 77, "Disease", "Test_items_Disease"], [217, 218, "Test_items", 198, 200, "Disease", "Test_items_Disease"], [217, 218, "Test_items", 212, 214, "Disease", "Test_items_Disease"]]}
{"idx": 731, "sentence": "而单纯由于应激导致血糖显著增高者往往提示手术应激很强，或合并感染、败血症等并发症，可能为危重患者。", "ner": [[5, 6, "Reason"], [9, 10, "Test_items"], [11, 14, "Test_Value"], [20, 23, "Reason"], [30, 31, "Disease"], [33, 35, "Disease"]], "rel": []}
{"idx": 732, "sentence": "合理的血糖控制目标大量循证医学证据表明，血糖控制有利于减少外科重症患者术后感染等并发症，但控制过于严格(如降至“正常”范围)则增加低血糖风险，对降低总死亡率并无益处。", "ner": [[3, 4, "Test_items"], [20, 21, "Test_items"], [65, 67, "ADE"], [35, 38, "ADE"]], "rel": []}
{"idx": 733, "sentence": "尽管目前的结论主要来源于对ICU重症患者以及体外循环心脏手术患者的研究，对一般外科手术患者的理想血糖值尚缺乏高级别的研究证据，但采用适当宽松的血糖控制目标已得到了广泛的共识。", "ner": [[71, 72, "Test_items"], [48, 49, "Test_items"], [23, 29, "Operation"]], "rel": []}
{"idx": 734, "sentence": "围术期血糖管理的要点围术期血糖管理的要点在于控制高血糖，同时避免发生低血糖，维持血糖平稳。因禁食、降糖方案未及时调整或降糖治疗中断等因素造成的围术期血糖波动比稳定的高血糖危害更大。", "ner": [[3, 4, "Test_items"], [13, 14, "Test_items"], [24, 26, "Disease"], [34, 36, "Disease"], [40, 41, "Test_items"], [46, 47, "Treatment"], [74, 75, "Test_items"], [76, 80, "Test_Value"], [82, 84, "Disease"]], "rel": [[3, 4, "Test_items", 24, 26, "Disease", "Test_items_Disease"], [3, 4, "Test_items", 34, 36, "Disease", "Test_items_Disease"], [13, 14, "Test_items", 24, 26, "Disease", "Test_items_Disease"], [13, 14, "Test_items", 34, 36, "Disease", "Test_items_Disease"], [40, 41, "Test_items", 24, 26, "Disease", "Test_items_Disease"], [40, 41, "Test_items", 34, 36, "Disease", "Test_items_Disease"], [46, 47, "Treatment", 82, 84, "Disease", "Treatment_Disease"], [74, 75, "Test_items", 82, 84, "Disease", "Test_items_Disease"]]}
{"idx": 735, "sentence": "严密的血糖监测、及时调整降糖治疗方案是保持围术期血糖平稳的关键。", "ner": [[3, 4, "Test_items"], [24, 25, "Test_items"], [26, 27, "Test_Value"]], "rel": []}
{"idx": 736, "sentence": "应根据患者术前血糖水平、治疗方案、有无并发症、手术类型等进行全面评估，制定个体化的管理方案。", "ner": [[7, 8, "Test_items"]], "rel": []}
{"idx": 737, "sentence": "血糖术前评估与术前准备", "ner": [[0, 1, "Test_items"]], "rel": []}
{"idx": 738, "sentence": "术前评估", "ner": [], "rel": []}
{"idx": 739, "sentence": "1.糖化血红蛋白HbA1c反映采血前三个月的平均血糖水平，可用于术前筛查糖尿病和评价血糖控制效果。对既往无糖尿病病史者，如果年龄≥45岁或体重指数BMI≥25kg/m2，同时合并高血压、高血脂、心血管疾病、糖尿病家族史等高危因素，行心脏外科、神经外科、骨科、创伤外科、器官移植等高危手术者，推荐术前筛查HbA1c；HbA1c≥6.5%即可诊断糖尿病。既往已有明确糖尿病病史的患者，HbA1c≤7%提示血糖控制满意，围术期风险较低；HbA1c>8.5%者建议考虑推迟择期手术。单纯应激性高血糖者HbA1c正常。", "ner": [[2, 12, "Test_items"], [15, 16, "Test"], [24, 25, "Test_items"], [36, 38, "Disease"], [42, 43, "Test_items"], [89, 91, "Disease"], [93, 95, "Disease"], [97, 101, "Disease"], [97, 99, "Anatomy"], [103, 105, "Disease"], [134, 137, "Operation"], [151, 155, "Test_items"], [157, 161, "Test_items"], [162, 166, "Test_Value"], [171, 173, "Disease"], [181, 183, "Disease"], [190, 194, "Test_items"], [195, 197, "Test_Value"], [200, 201, "Test_items"], [202, 205, "Test_Value"], [215, 219, "Test_items"], [220, 224, "Test_Value"], [239, 244, "Disease"], [246, 250, "Test_items"], [251, 252, "Test_Value"], [53, 55, "Disease"]], "rel": [[2, 12, "Test_items", 36, 38, "Disease", "Test_items_Disease"], [15, 16, "Test", 36, 38, "Disease", "Test_Disease"], [24, 25, "Test_items", 36, 38, "Disease", "Test_items_Disease"], [42, 43, "Test_items", 36, 38, "Disease", "Test_items_Disease"], [97, 99, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [134, 137, "Operation", 171, 173, "Disease", "Operation_Disease"], [151, 155, "Test_items", 171, 173, "Disease", "Test_items_Disease"], [157, 161, "Test_items", 171, 173, "Disease", "Test_items_Disease"], [190, 194, "Test_items", 181, 183, "Disease", "Test_items_Disease"], [200, 201, "Test_items", 181, 183, "Disease", "Test_items_Disease"], [215, 219, "Test_items", 181, 183, "Disease", "Test_items_Disease"], [246, 250, "Test_items", 239, 244, "Disease", "Test_items_Disease"]]}
{"idx": 740, "sentence": "注意贫血、近期输血等因素可能干扰HbA1c测量的准确性。", "ner": [[2, 3, "Disease"], [7, 8, "Treatment"], [16, 20, "Test_items"]], "rel": []}
{"idx": 741, "sentence": "2.对合并糖尿病的患者，术前还应了解糖尿病类型、病程、目前的治疗方案、低血糖发作情况，特别是有无糖尿病并发症。合并糖尿病酮症酸中毒、高渗综合症是非急诊手术的禁忌。病程长的糖尿病患者可能并发冠心病等心脑血管疾病，且心肌缺血症状往往不典型、容易漏诊，应引起警惕。", "ner": [[5, 7, "Disease"], [18, 20, "Disease"], [35, 37, "Disease"], [48, 50, "Disease"], [57, 64, "Disease"], [66, 70, "Disease"], [85, 87, "Disease"], [94, 96, "Disease"], [98, 103, "Disease"], [98, 101, "Anatomy"], [106, 109, "Disease"], [106, 107, "Anatomy"]], "rel": [[98, 101, "Anatomy", 98, 103, "Disease", "Anatomy_Disease"], [106, 107, "Anatomy", 106, 109, "Disease", "Anatomy_Disease"]]}
{"idx": 742, "sentence": "3.手术类型与围术期高血糖风险相关。手术越大、应激越强，血糖增高越明显。与区域麻醉比较，全身麻醉特别是吸入性麻醉药刺激血糖升高的作用更显著，但目前并没有证据证明糖尿病患者必须首选区域麻醉。", "ner": [[7, 12, "Disease"], [18, 21, "Reason"], [23, 26, "Reason"], [28, 29, "Test_items"], [30, 31, "Test_Value"], [37, 40, "Operation"], [44, 47, "Operation"], [89, 92, "Operation"], [51, 56, "Drug"], [59, 60, "Test_items"], [61, 62, "Test_Value"], [80, 82, "Disease"]], "rel": [[37, 40, "Operation", 80, 82, "Disease", "Operation_Disease"], [44, 47, "Operation", 80, 82, "Disease", "Operation_Disease"], [89, 92, "Operation", 80, 82, "Disease", "Operation_Disease"], [51, 56, "Drug", 80, 82, "Disease", "Drug_Disease"], [59, 60, "Test_items", 80, 82, "Disease", "Test_items_Disease"]]}
{"idx": 743, "sentence": "术前准备", "ner": [], "rel": []}
{"idx": 744, "sentence": "胰岛素是围术期唯一安全的降糖药物。", "ner": [[0, 2, "Drug"]], "rel": []}
{"idx": 745, "sentence": "术前应将原有降糖方案过渡至胰岛素，并根据禁食情况减去控制餐后血糖的胰岛素剂量。", "ner": [[13, 15, "Drug"], [33, 35, "Drug"], [20, 21, "Treatment"], [28, 31, "Test_items"]], "rel": []}
{"idx": 746, "sentence": "1.糖尿病患者手术当日停用口服降糖药和非胰岛素注射剂。磺脲类和格列奈类口服降糖药可能造成低血糖，术前应停用至少24小时；二甲双胍有引起乳酸酸中毒的风险，肾功能不全者术前停用24~48小时。", "ner": [[2, 4, "Disease"], [13, 14, "Method"], [19, 25, "Drug"], [27, 29, "Drug"], [31, 39, "Drug"], [35, 36, "Method"], [44, 46, "ADE"], [60, 63, "Drug"], [67, 71, "ADE"], [76, 80, "Disease"], [76, 76, "Anatomy"]], "rel": [[19, 25, "Drug", 2, 4, "Disease", "Drug_Disease"], [44, 46, "ADE", 27, 29, "Drug", "ADE_Drug"], [35, 36, "Method", 31, 39, "Drug", "Method_Drug"], [44, 46, "ADE", 31, 39, "Drug", "ADE_Drug"], [67, 71, "ADE", 60, 63, "Drug", "ADE_Drug"], [76, 76, "Anatomy", 76, 80, "Disease", "Anatomy_Disease"]]}
{"idx": 747, "sentence": "停药期间监测血糖，使用常规胰岛素控制血糖水平。", "ner": [[6, 7, "Test_items"], [11, 15, "Drug"], [18, 19, "Test_items"]], "rel": []}
{"idx": 748, "sentence": "术前住院时间超过3天的患者可在入院后即换用短效胰岛素皮下注射控制血糖，术前调整到适合的剂量。", "ner": [[21, 25, "Drug"], [26, 29, "Method"], [32, 33, "Test_items"]], "rel": [[26, 29, "Method", 21, 25, "Drug", "Method_Drug"]]}
{"idx": 749, "sentence": "无需禁食水的短小局麻手术可保留口服降糖药。", "ner": [[2, 4, "Treatment"], [8, 11, "Operation"], [15, 16, "Method"]], "rel": []}
{"idx": 750, "sentence": "2.入院前长期胰岛素治疗者，方案多为控制基础血糖的中长效胰岛素联合控制餐后血糖的短效胰岛素皮下注射。长时间大手术、术后无法恢复进食的糖尿病患者，手术日换用短效胰岛素持续静脉泵注控制血糖。短小门诊手术者，手术当日可保留中长效胰岛素，剂量不变或减少1/3~1/2，停用餐前短效胰岛素。", "ner": [[7, 9, "Drug"], [20, 23, "Test_items"], [25, 30, "Drug"], [35, 38, "Test_items"], [40, 44, "Drug"], [45, 48, "Method"], [66, 68, "Disease"], [77, 81, "Drug"], [82, 83, "Duration"], [84, 87, "Method"], [90, 91, "Test_items"], [108, 113, "Drug"], [115, 128, "Amount"], [134, 138, "Drug"]], "rel": [[45, 48, "Method", 25, 30, "Drug", "Method_Drug"], [45, 48, "Method", 40, 44, "Drug", "Method_Drug"], [90, 91, "Test_items", 66, 68, "Disease", "Test_items_Disease"], [77, 81, "Drug", 66, 68, "Disease", "Drug_Disease"], [82, 83, "Duration", 77, 81, "Drug", "Duration_Drug"], [84, 87, "Method", 77, 81, "Drug", "Method_Drug"], [115, 128, "Amount", 108, 113, "Drug", "Amount_Drug"]]}
{"idx": 751, "sentence": "3.术前控制餐前血糖≤140mg/dl(7.8mmol/L)，餐后血糖≤180mg/dl(10.0mmol/L)。", "ner": [[6, 9, "Test_items"], [10, 29, "Test_Value"], [31, 34, "Test_items"], [35, 55, "Test_Value"]], "rel": []}
{"idx": 752, "sentence": "手术风险越高，术前血糖控制达标的重要性越强。", "ner": [[9, 10, "Test_items"]], "rel": []}
{"idx": 753, "sentence": "另一方面，术前血糖长期显著增高者，围术期血糖不宜下降过快。", "ner": [[7, 8, "Test_items"], [9, 14, "Test_Value"], [20, 21, "Test_items"], [24, 27, "Test_Value"]], "rel": []}
{"idx": 754, "sentence": "因此，应当综合评估风险，合理选择手术时机，可适当放宽术前血糖目标上限至空腹≤180mg/dl(10mmol/L)，随机或餐后2小时≤216mg/dl(12mmol/L)。", "ner": [[28, 29, "Test_items"], [37, 55, "Test_Value"], [57, 64, "Test_items"], [65, 83, "Test_Value"], [35, 36, "Test_items"]], "rel": []}
{"idx": 755, "sentence": "4.避免术前不必要的长时间禁食，糖尿病患者择期手术应安排在当日第一台进行。禁食期间注意血糖监测，必要时输注含糖液体。由于术前精神紧张应激，手术患者发生低血糖的风险低于普通住院患者。", "ner": [[13, 14, "Treatment"], [16, 18, "Disease"], [37, 38, "Treatment"], [43, 44, "Test_items"], [51, 52, "Method"], [53, 56, "Drug"], [62, 67, "Reason"], [75, 77, "Disease"]], "rel": [[13, 14, "Treatment", 16, 18, "Disease", "Treatment_Disease"], [51, 52, "Method", 53, 56, "Drug", "Method_Drug"], [62, 67, "Reason", 75, 77, "Disease", "Reason_Disease"]]}
{"idx": 756, "sentence": "围术期血糖监测和控制目标", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 757, "sentence": "围术期血糖测量方法床旁快速血糖仪测量指血(毛细血管血)血糖用于血流动力学稳定的患者。血糖仪需定期校准。严重低血糖时血糖仪所测得的数值可能偏高，应与中心实验室测量的静脉血结果进行对照。动脉或静脉血气分析是围术期血糖监测的金标准。在低血压、组织低灌注、贫血以及高血脂、高胆红素血症等代谢异常的情况下，指血血糖准确性下降，应使用动脉血气监测血糖。", "ner": [[3, 4, "Test_items"], [13, 14, "Test_items"], [18, 28, "Test_items"], [42, 43, "Test_items"], [51, 52, "Level"], [167, 168, "Test_items"], [53, 55, "Disease"], [57, 58, "Test_items"], [68, 69, "Test_Value"], [91, 99, "Test"], [104, 105, "Test_items"], [114, 116, "Symptom"], [118, 122, "Symptom"], [124, 125, "Disease"], [128, 130, "Disease"], [132, 137, "Disease"], [148, 151, "Test_items"], [152, 156, "Test_Value"], [161, 164, "Test"]], "rel": [[167, 168, "Test_items", 124, 125, "Disease", "Test_items_Disease"], [167, 168, "Test_items", 128, 130, "Disease", "Test_items_Disease"], [167, 168, "Test_items", 132, 137, "Disease", "Test_items_Disease"], [57, 58, "Test_items", 53, 55, "Disease", "Test_items_Disease"], [148, 151, "Test_items", 124, 125, "Disease", "Test_items_Disease"], [161, 164, "Test", 124, 125, "Disease", "Test_Disease"], [148, 151, "Test_items", 128, 130, "Disease", "Test_items_Disease"], [161, 164, "Test", 128, 130, "Disease", "Test_Disease"], [148, 151, "Test_items", 132, 137, "Disease", "Test_items_Disease"], [161, 164, "Test", 132, 137, "Disease", "Test_Disease"]]}
{"idx": 758, "sentence": "生理情况下，动脉血糖较毛细血管血糖高0.3mmol/L。", "ner": [[6, 9, "Test_items"], [11, 16, "Test_items"], [17, 26, "Test_Value"]], "rel": []}
{"idx": 759, "sentence": "围术期血糖监测频率正常饮食的患者监测空腹血糖、三餐后血糖和睡前血糖。禁食患者每4~6小时监测一次血糖。术中血糖波动风险高，低血糖表现难以发现，应1~2小时监测一次血糖。危重患者、大手术或持续静脉输注胰岛素的患者，每0.5~1小时监测一次。体外循环手术中，降温复温期间血糖波动大，每15分钟监测一次。血糖≤70mg/dl(3.9mmol/L)时每5~15分钟监测一次直至低血糖得到纠正。", "ner": [[3, 4, "Test_items"], [18, 21, "Test_items"], [23, 27, "Test_items"], [29, 32, "Test_items"], [34, 35, "Treatment"], [48, 49, "Test_items"], [53, 54, "Test_items"], [55, 56, "Test_Value"], [61, 63, "Disease"], [81, 82, "Test_items"], [93, 94, "Duration"], [95, 98, "Method"], [99, 101, "Drug"], [119, 124, "Operation"], [133, 134, "Test_items"], [135, 137, "Test_Value"], [149, 150, "Test_items"], [151, 169, "Test_Value"], [184, 186, "Disease"]], "rel": [[53, 54, "Test_items", 61, 63, "Disease", "Test_items_Disease"], [81, 82, "Test_items", 61, 63, "Disease", "Test_items_Disease"], [93, 94, "Duration", 99, 101, "Drug", "Duration_Drug"], [95, 98, "Method", 99, 101, "Drug", "Method_Drug"], [149, 150, "Test_items", 184, 186, "Disease", "Test_items_Disease"]]}
{"idx": 760, "sentence": "病情稳定的门诊手术患者，如手术时间≤2小时，在入院后和离院前分别监测一次血糖。", "ner": [[36, 37, "Test_items"]], "rel": []}
{"idx": 761, "sentence": "围术期血糖控制目标", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 762, "sentence": "1.推荐围术期血糖控制在140mg/dl(7.8mmol/L)~180mg/dl(10.0mmol/L)，不建议控制过严。", "ner": [[7, 8, "Test_items"], [12, 51, "Test_Value"]], "rel": []}
{"idx": 763, "sentence": "正常饮食的患者控制餐前血糖≤140mg/dl(7.8mmol/L)，餐后血糖≤180mg/dl(10.0mmol/L)。", "ner": [[9, 12, "Test_items"], [13, 32, "Test_Value"], [34, 37, "Test_items"], [38, 58, "Test_Value"]], "rel": []}
{"idx": 764, "sentence": "2.术后ICU住院时间≥3d的危重患者，推荐血糖目标值≤150mg/dl(8.4mmol/L)。", "ner": [[22, 23, "Test_items"], [27, 46, "Test_Value"]], "rel": []}
{"idx": 765, "sentence": "3.根据患者手术类型、术前血糖水平、脏器功能，建立围术期血糖控制的个体化目标。整形手术对伤口愈合要求高，血糖目标降低至108mg/dl(6.0mmol/L)~144mg/dl(8.0mmol/L)有利于减少术后伤口感染。脑血管疾病患者对低血糖耐受差，血糖目标值可适当放宽至≤214mg/dl(12.0mmol/L)。", "ner": [[13, 14, "Test_items"], [28, 29, "Test_items"], [39, 42, "Operation"], [52, 53, "Test_items"], [59, 97, "Test_Value"], [105, 108, "ADE"], [110, 114, "Disease"], [110, 112, "Anatomy"], [118, 120, "Disease"], [125, 126, "Test_items"], [136, 156, "Test_Value"]], "rel": [[110, 112, "Anatomy", 110, 114, "Disease", "Anatomy_Disease"], [125, 126, "Test_items", 110, 114, "Disease", "Test_items_Disease"]]}
{"idx": 766, "sentence": "高龄、有严重合并症、频繁发作低血糖的患者，血糖目标值也可适当放宽。", "ner": [[14, 16, "Disease"], [21, 22, "Test_items"]], "rel": [[21, 22, "Test_items", 14, 16, "Disease", "Test_items_Disease"]]}
{"idx": 767, "sentence": "原则上血糖最高不宜超过250mg/dl(13.9mmol/L)。", "ner": [[3, 4, "Test_items"], [5, 30, "Test_Value"]], "rel": []}
{"idx": 768, "sentence": "血糖管理实施方案", "ner": [[0, 1, "Test_items"]], "rel": []}
{"idx": 769, "sentence": "高血糖", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 770, "sentence": "1.糖尿病患者围术期需要输注葡萄糖者，建议液体中按糖(g)：胰岛素(U)=3~4：1的比例加用胰岛素中和。肠内外营养的患者应注意营养液中的糖负荷，选用糖尿病专用型制剂，适当降低糖与脂肪的比例，缓慢输注，通过降低糖类总量、减慢吸收速度，降低血糖峰值，减少血糖波动。", "ner": [[2, 4, "Disease"], [12, 13, "Method"], [14, 16, "Drug"], [25, 35, "Drug"], [37, 41, "Amount"], [47, 49, "Drug"], [75, 77, "Disease"], [119, 120, "Test_items"], [126, 127, "Test_items"], [128, 129, "Test_Value"]], "rel": [[14, 16, "Drug", 2, 4, "Disease", "Drug_Disease"], [12, 13, "Method", 14, 16, "Drug", "Method_Drug"], [37, 41, "Amount", 25, 35, "Drug", "Amount_Drug"], [119, 120, "Test_items", 75, 77, "Disease", "Test_items_Disease"], [126, 127, "Test_items", 75, 77, "Disease", "Test_items_Disease"]]}
{"idx": 771, "sentence": "2.尽量避免引起血糖升高的其他因素。", "ner": [[8, 9, "Test_items"], [10, 11, "Test_Value"]], "rel": []}
{"idx": 772, "sentence": "地塞米松常用于预防术后恶心呕吐，可升高血糖水平。", "ner": [[0, 3, "Drug"], [11, 12, "ADE"], [13, 14, "ADE"], [19, 20, "Test_items"]], "rel": []}
{"idx": 773, "sentence": "使用其他糖皮质激素、儿茶酚胺类药物、生长抑素和免疫抑制剂也可能造成血糖增高。", "ner": [[4, 8, "Drug"], [10, 16, "Drug"], [18, 21, "Drug"], [23, 27, "Drug"], [33, 34, "Test_items"], [35, 36, "Test_Value"]], "rel": []}
{"idx": 774, "sentence": "3.血糖>180mg/dl(10.0mmol/L)开始胰岛素治疗。静脉给胰岛素起效快，方便滴定剂量，术中和术后ICU期间适宜静脉给药。持续静脉泵注胰岛素有利于减少血糖波动，糖尿病患者以及术前已经使用静脉胰岛素的患者术中首选持续静脉泵注胰岛素。应激性高血糖的患者可选择单次或间断静脉推注胰岛素，如血糖仍高，则予持续泵注。通常使用短效胰岛素加入生理盐水，浓度1U/ml配泵，参照患者的血糖水平、术前胰岛素用量、手术刺激大小等因素来确定胰岛素的用量，密切监测，根据血糖升降适当调整泵速，注意个体化给药，避免发生低血糖。", "ner": [[2, 3, "Test_items"], [4, 24, "Test_Value"], [27, 29, "Drug"], [33, 34, "Method"], [36, 38, "Drug"], [62, 65, "Method"], [67, 68, "Duration"], [69, 72, "Method"], [73, 75, "Drug"], [81, 82, "Test_items"], [83, 84, "Test_Value"], [86, 88, "Disease"], [99, 100, "Method"], [101, 103, "Drug"], [111, 112, "Duration"], [113, 116, "Method"], [117, 119, "Drug"], [121, 126, "Disease"], [133, 137, "Frequency"], [138, 141, "Method"], [142, 144, "Drug"], [147, 148, "Test_items"], [149, 150, "Test_Value"], [154, 155, "Duration"], [156, 157, "Method"], [163, 167, "Drug"], [170, 173, "Drug"], [175, 181, "Amount"], [190, 191, "Test_items"], [197, 199, "Drug"], [215, 217, "Drug"], [229, 230, "Test_items"], [231, 232, "Test_Value"], [252, 254, "ADE"]], "rel": [[33, 34, "Method", 36, 38, "Drug", "Method_Drug"], [62, 65, "Method", 36, 38, "Drug", "Method_Drug"], [67, 68, "Duration", 73, 75, "Drug", "Duration_Drug"], [69, 72, "Method", 73, 75, "Drug", "Method_Drug"], [81, 82, "Test_items", 86, 88, "Disease", "Test_items_Disease"], [101, 103, "Drug", 86, 88, "Disease", "Drug_Disease"], [117, 119, "Drug", 86, 88, "Disease", "Drug_Disease"], [99, 100, "Method", 101, 103, "Drug", "Method_Drug"], [111, 112, "Duration", 117, 119, "Drug", "Duration_Drug"], [113, 116, "Method", 117, 119, "Drug", "Method_Drug"], [142, 144, "Drug", 121, 126, "Disease", "Drug_Disease"], [147, 148, "Test_items", 121, 126, "Disease", "Test_items_Disease"], [133, 137, "Frequency", 142, 144, "Drug", "Frequency_Drug"], [138, 141, "Method", 142, 144, "Drug", "Method_Drug"], [154, 155, "Duration", 142, 144, "Drug", "Duration_Drug"], [156, 157, "Method", 142, 144, "Drug", "Method_Drug"], [175, 181, "Amount", 163, 167, "Drug", "Amount_Drug"], [175, 181, "Amount", 170, 173, "Drug", "Amount_Drug"]]}
{"idx": 775, "sentence": "胰岛素皮下注射适合病情稳定的非重症患者，常用于术前术后过渡；注意避免短时问内反复给药造成降糖药效叠加。", "ner": [[0, 2, "Drug"], [3, 6, "Method"]], "rel": [[3, 6, "Method", 0, 2, "Drug", "Method_Drug"]]}
{"idx": 776, "sentence": "4.严重高血糖可能造成渗透性利尿，引起高渗性脱水和低钾血症，应注意维持水电解质平衡。术中由于多数患者血糖水平增高，一般输注无糖液体。术后和过长时间的手术当中，为了减少酮体合成和酸中毒风险，在血糖<250mg/dl(13.9mmol/L)的前提下，静脉泵注胰岛素的同时可泵注加入中和比例胰岛素的含糖液体，根据测得的血糖水平调节泵速。胰岛素+糖双泵同时输注有利于减少血糖波动，但可能促使钾向细胞内转移，进一步加重低钾血症。因此，持续静脉泵注胰岛素时应注意监测血钾，可预防性补钾。", "ner": [[2, 3, "Level"], [4, 6, "Disease"], [11, 15, "Symptom"], [19, 23, "Disease"], [25, 28, "Disease"], [50, 51, "Test_items"], [54, 55, "Test_Value"], [59, 60, "Method"], [83, 86, "ADE"], [88, 90, "ADE"], [95, 96, "Test_items"], [97, 117, "Test_Value"], [123, 126, "Method"], [127, 129, "Drug"], [134, 135, "Method"], [142, 144, "Drug"], [156, 157, "Test_items"], [165, 167, "Drug"], [181, 182, "Test_items"], [183, 184, "Test_Value"], [191, 197, "Pathogenesis"], [202, 203, "Level"], [204, 207, "Disease"], [212, 213, "Duration"], [214, 217, "Method"], [218, 220, "Drug"], [227, 228, "Test_items"]], "rel": [[11, 15, "Symptom", 4, 6, "Disease", "Symptom_Disease"], [123, 126, "Method", 127, 129, "Drug", "Method_Drug"], [134, 135, "Method", 142, 144, "Drug", "Method_Drug"], [181, 182, "Test_items", 204, 207, "Disease", "Test_items_Disease"], [191, 197, "Pathogenesis", 204, 207, "Disease", "Pathogenesis_Disease"], [212, 213, "Duration", 218, 220, "Drug", "Duration_Drug"], [214, 217, "Method", 218, 220, "Drug", "Method_Drug"]]}
{"idx": 777, "sentence": "低血糖", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 778, "sentence": "1.低血糖的危害超过高血糖。", "ner": [[2, 4, "Disease"], [10, 12, "Disease"]], "rel": []}
{"idx": 779, "sentence": "血糖≤50mg/dl(2.8mmol/L)时出现认知功能障碍，长时间≤40mg/dl(2.2mmol/L)的严重低血糖可造成脑死亡。", "ner": [[0, 1, "Test_items"], [2, 20, "Test_Value"], [34, 52, "Test_Value"], [54, 55, "Level"], [56, 58, "Disease"], [24, 29, "Disease"], [62, 64, "Disease"], [62, 62, "Anatomy"]], "rel": [[0, 1, "Test_items", 24, 29, "Disease", "Test_items_Disease"], [62, 62, "Anatomy", 62, 64, "Disease", "Anatomy_Disease"]]}
{"idx": 780, "sentence": "发生一次低血糖围术期死亡率即可增加。", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 781, "sentence": "2.低血糖重在预防和及时发现。", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 782, "sentence": "衰弱、严重感染、肝肾功能不全的患者低血糖风险增加。长期未得到有效控制的糖尿病患者可能在正常的血糖水平即发生低血糖反应。脑损伤患者难以耐受100mg/dl(5.6mmol/L)以下的血糖水平。", "ner": [[68, 88, "Test_Value"], [0, 1, "Reason"], [3, 6, "Reason"], [8, 13, "Reason"], [17, 19, "Disease"], [35, 37, "Disease"], [46, 47, "Test_items"], [53, 55, "Disease"], [59, 61, "Disease"], [59, 59, "Anatomy"], [90, 91, "Test_items"]], "rel": [[0, 1, "Reason", 17, 19, "Disease", "Reason_Disease"], [3, 6, "Reason", 17, 19, "Disease", "Reason_Disease"], [8, 13, "Reason", 17, 19, "Disease", "Reason_Disease"], [46, 47, "Test_items", 35, 37, "Disease", "Test_items_Disease"], [46, 47, "Test_items", 53, 55, "Disease", "Test_items_Disease"], [90, 91, "Test_items", 59, 61, "Disease", "Test_items_Disease"], [59, 59, "Anatomy", 59, 61, "Disease", "Anatomy_Disease"]]}
{"idx": 783, "sentence": "需要警惕的是，全麻镇静患者的低血糖症状可能被掩盖，不易及时发现。", "ner": [[14, 16, "Disease"], [7, 8, "Operation"]], "rel": []}
{"idx": 784, "sentence": "3.静脉输注胰岛素的患者血糖≤100mg/dl(5.6mmol/L)应重新评估，调整泵速。血糖≤70mg/dl(3.9mmol/L)立即停用胰岛素，开始升血糖处理。可进食的清醒患者立即口服10~25g快速吸收的碳水化合物(如含糖饮料)，不能口服的静脉推注50%葡萄糖20~50rnl，之后持续静脉点滴5%或10%葡萄糖维持血糖，每5~15分钟监测一次直至血糖≥100mg/dl(5.6mmol/L)。", "ner": [[2, 5, "Method"], [6, 8, "Drug"], [12, 13, "Test_items"], [14, 32, "Test_Value"], [45, 46, "Test_items"], [47, 65, "Test_Value"], [70, 72, "Drug"], [77, 78, "Test_items"], [92, 93, "Method"], [94, 99, "Amount"], [120, 121, "Method"], [123, 126, "Method"], [127, 132, "Drug"], [133, 140, "Amount"], [144, 145, "Duration"], [146, 149, "Method"], [150, 158, "Drug"], [161, 162, "Test_items"], [177, 178, "Test_items"], [179, 198, "Test_Value"]], "rel": [[2, 5, "Method", 6, 8, "Drug", "Method_Drug"], [133, 140, "Amount", 127, 132, "Drug", "Amount_Drug"], [144, 145, "Duration", 150, 158, "Drug", "Duration_Drug"], [146, 149, "Method", 150, 158, "Drug", "Method_Drug"]]}
{"idx": 785, "sentence": "仔细筛查引起低血糖的可能原因。", "ner": [[6, 8, "ADE"]], "rel": []}
{"idx": 786, "sentence": "血糖术后管理", "ner": [[0, 1, "Test_items"]], "rel": []}
{"idx": 787, "sentence": "术后早期管理", "ner": [], "rel": []}
{"idx": 788, "sentence": "1.术后因疼痛应激、感染、肠内外营养液输注，是血糖波动的高危时期，也是血糖管理的重要时期。", "ner": [[5, 8, "Symptom"], [10, 11, "Disease"], [13, 18, "Drug"], [19, 20, "Method"], [23, 24, "Test_items"], [25, 26, "Test_Value"], [35, 36, "Test_items"]], "rel": [[19, 20, "Method", 13, 18, "Drug", "Method_Drug"]]}
{"idx": 789, "sentence": "2.术中持续静脉泵注胰岛素者，建议术后继续泵注24小时以上。机械通气和应用血管活性药物的ICU患者容易出现血糖波动，胰岛素应静脉泵注。", "ner": [[4, 5, "Duration"], [6, 9, "Method"], [10, 12, "Drug"], [21, 22, "Method"], [23, 28, "Duration"], [30, 33, "Treatment"], [37, 42, "Drug"], [53, 54, "Test_items"], [55, 56, "Test_Value"], [58, 60, "Drug"], [62, 65, "Method"]], "rel": [[4, 5, "Duration", 10, 12, "Drug", "Duration_Drug"], [6, 9, "Method", 10, 12, "Drug", "Method_Drug"], [23, 28, "Duration", 10, 12, "Drug", "Duration_Drug"], [21, 22, "Method", 10, 12, "Drug", "Method_Drug"], [62, 65, "Method", 58, 60, "Drug", "Method_Drug"]]}
{"idx": 790, "sentence": "3.病情稳定后过渡到皮下注射胰岛素。根据过渡前静脉泵速推算皮下胰岛素剂量。皮下注射和静脉泵注应有2小时左右的重叠，便于平稳过渡。", "ner": [[10, 13, "Method"], [14, 16, "Drug"], [23, 25, "Method"], [31, 33, "Drug"], [37, 40, "Method"], [42, 44, "Method"], [48, 50, "Duration"]], "rel": [[10, 13, "Method", 14, 16, "Drug", "Method_Drug"], [23, 25, "Method", 31, 33, "Drug", "Method_Drug"]]}
{"idx": 791, "sentence": "积极预防术后恶心呕吐，尽早恢复正常饮食，根据进食情况逐步增加餐前短效胰岛素剂量。", "ner": [[6, 7, "ADE"], [8, 9, "ADE"], [32, 36, "Drug"]], "rel": []}
{"idx": 792, "sentence": "出院前准备", "ner": [], "rel": []}
{"idx": 793, "sentence": "1.长期胰岛素治疗的患者在出院前1~2天恢复原有方案。", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 794, "sentence": "2.饮食正常规律、器官功能稳定后，如无禁忌证，可恢复口服降糖药。", "ner": [[26, 27, "Method"]], "rel": []}
{"idx": 795, "sentence": "二甲双胍在肾功能稳定后加用，并且不早于术后48小时。", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 796, "sentence": "3.对于围术期新发现的糖尿病患者以及调整了治疗方案的患者，应进行出院前宣教，安排内分泌科随诊。", "ner": [[11, 13, "Disease"]], "rel": []}
{"idx": 797, "sentence": "4.门诊手术术后监测直至排除低血糖风险后方可离院。皮下注射速效胰岛素1.5小时内、常规胰岛素3~4小时内有发生低血糖的危险。", "ner": [[14, 16, "ADE"], [25, 28, "Method"], [29, 33, "Drug"], [41, 45, "Drug"], [55, 57, "ADE"], [34, 38, "Duration"], [46, 50, "Duration"]], "rel": [[25, 28, "Method", 29, 33, "Drug", "Method_Drug"], [25, 28, "Method", 41, 45, "Drug", "Method_Drug"], [55, 57, "ADE", 29, 33, "Drug", "ADE_Drug"], [34, 38, "Duration", 29, 33, "Drug", "Duration_Drug"], [55, 57, "ADE", 41, 45, "Drug", "ADE_Drug"], [46, 50, "Duration", 41, 45, "Drug", "Duration_Drug"]]}
{"idx": 798, "sentence": "离院途中应随身携带含糖饮料。", "ner": [], "rel": []}
{"idx": 799, "sentence": "常规降糖治疗需推迟到恢复正常饮食以后。", "ner": [], "rel": []}
{"idx": 800, "sentence": "小结", "ner": [], "rel": []}
{"idx": 801, "sentence": "围术期血糖管理对于减少血糖异常相关的并发症、促进患者术后快速康复、改善手术患者预后具有重要意义。术前筛查糖化血红蛋白有助于识别围术期高血糖相关不良事件的高危人群。“合理、有效、安全”是血糖管理的宗旨，围术期血糖目标值定为140mg/dl(7.8mmol/L)~180mg/dl(10.0mmol/L)兼顾了血糖管理的有效性和安全性，较为合理。血糖>180mg/dl(10.0mmol/L)即可启动胰岛素治疗，短效胰岛素持续静脉泵注便于及时调整剂量，减少血糖波动，是高危患者围术期血糖控制的首选方案。", "ner": [[3, 4, "Test_items"], [11, 12, "Test_items"], [13, 14, "Test_Value"], [52, 57, "Test_items"], [66, 68, "Disease"], [92, 93, "Test_items"], [103, 104, "Test_items"], [110, 149, "Test_Value"], [153, 154, "Test_items"], [171, 172, "Test_items"], [173, 193, "Test_Value"], [198, 200, "Drug"], [204, 208, "Drug"], [209, 210, "Duration"], [211, 214, "Method"], [226, 227, "Test_items"], [228, 229, "Test_Value"], [239, 240, "Test_items"]], "rel": [[52, 57, "Test_items", 66, 68, "Disease", "Test_items_Disease"], [209, 210, "Duration", 204, 208, "Drug", "Duration_Drug"], [211, 214, "Method", 204, 208, "Drug", "Method_Drug"]]}
{"idx": 802, "sentence": "严密监测血糖，个体化管理，方可实现围术期平稳过渡。", "ner": [[4, 5, "Test_items"]], "rel": []}
{"idx": 803, "sentence": "2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识", "ner": [[0, 4, "Disease"], [7, 18, "Disease"], [7, 8, "Anatomy"], [14, 16, "Anatomy"]], "rel": [[7, 8, "Anatomy", 7, 18, "Disease", "Anatomy_Disease"], [14, 16, "Anatomy", 7, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 804, "sentence": "随着经济高速发展、生活方式改变及人口老龄化，我国糖尿病患病率呈快速上升趋势。2007~2008年流行病学调查显示，我国20岁以上成人糖尿病患病率为9.7%。2010年流行病学调查显示，我国18岁以上成人糖尿病患病率为11.6%。在我国糖尿病患者中，90%以上为2型糖尿病(T2DM)。动脉粥样硬化性心血管疾病(ASCVD)包括冠心病、缺血性卒中及外周动脉疾病。T2DM与ASCVD关系密切，两者共存可进一步增加心血管事件和死亡风险，半数以上糖尿病患者的死亡与ASCVD相关。近年来，随着临床研究证据的不断积累和更新，关于降糖药物与T2DM患者心血管结局之间的关系也日益明确。因此，合理规范应用降糖药物对于T2DM合并ASCVD患者显得尤为重要。", "ner": [[24, 26, "Disease"], [66, 68, "Disease"], [101, 103, "Disease"], [117, 119, "Disease"], [130, 140, "Disease"], [142, 160, "Disease"], [142, 143, "Anatomy"], [149, 151, "Anatomy"], [163, 165, "Disease"], [167, 171, "Disease"], [173, 178, "Disease"], [173, 176, "Anatomy"], [180, 183, "Disease"], [185, 189, "Disease"], [220, 222, "Disease"], [229, 233, "Disease"], [265, 268, "Disease"], [302, 305, "Disease"], [308, 312, "Disease"], [205, 209, "Disease"], [205, 207, "Anatomy"], [271, 273, "Anatomy"]], "rel": [[142, 143, "Anatomy", 142, 160, "Disease", "Anatomy_Disease"], [149, 151, "Anatomy", 142, 160, "Disease", "Anatomy_Disease"], [173, 176, "Anatomy", 173, 178, "Disease", "Anatomy_Disease"], [271, 273, "Anatomy", 265, 268, "Disease", "Anatomy_Disease"], [205, 207, "Anatomy", 205, 209, "Disease", "Anatomy_Disease"]]}
{"idx": 805, "sentence": "为了指导我国临床医师对T2DM合并ASCVD患者进行规范化管理，并且充分了解T2DM合并ASCVD患者的综合管理策略、降糖治疗原则、血糖控制目标及常用降糖药物合理应用，由我国内分泌科、心内科、肾内科及临床流行病学专家联合制定了本共识。", "ner": [[11, 14, "Disease"], [17, 21, "Disease"], [38, 41, "Disease"], [44, 48, "Disease"], [66, 67, "Test_items"]], "rel": [[66, 67, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [66, 67, "Test_items", 44, 48, "Disease", "Test_items_Disease"]]}
{"idx": 806, "sentence": "一、T2DM合并ASCVD的流行病学", "ner": [[2, 5, "Disease"], [8, 12, "Disease"]], "rel": []}
{"idx": 807, "sentence": "2006年中国心脏调查发现，52.9%的冠心病住院患者合并糖尿病。另一方面，在全国三甲医院住院T2DM患者中，17.1%合并心血管疾病，13.2%合并脑血管疾病。", "ner": [[20, 22, "Disease"], [29, 31, "Disease"], [47, 50, "Disease"], [62, 66, "Disease"], [62, 64, "Anatomy"], [75, 79, "Disease"], [75, 77, "Anatomy"]], "rel": [[62, 64, "Anatomy", 62, 66, "Disease", "Anatomy_Disease"], [75, 77, "Anatomy", 75, 79, "Disease", "Anatomy_Disease"]]}
{"idx": 808, "sentence": "在我国大型城市住院T2DM患者中，25.1%合并冠心病，17.3%合并脑血管疾病。", "ner": [[9, 12, "Disease"], [24, 26, "Disease"], [35, 39, "Disease"], [35, 37, "Anatomy"]], "rel": [[35, 37, "Anatomy", 35, 39, "Disease", "Anatomy_Disease"]]}
{"idx": 809, "sentence": "中国“3B”研究显示，门诊就诊的T2DM患者中，14.6%合并心血管疾病，10.1%合并包括缺血性卒中在内的脑血管疾病。", "ner": [[16, 19, "Disease"], [31, 35, "Disease"], [31, 33, "Anatomy"], [46, 50, "Disease"], [54, 58, "Disease"], [54, 56, "Anatomy"]], "rel": [[31, 33, "Anatomy", 31, 35, "Disease", "Anatomy_Disease"], [54, 56, "Anatomy", 54, 58, "Disease", "Anatomy_Disease"]]}
{"idx": 810, "sentence": "上述研究数据表明，我国T2DM患者合并ASCVD的情况非常普遍，已日益成为糖尿病管理的一个巨大挑战，值得临床医生给予高度重视。", "ner": [[11, 14, "Disease"], [19, 23, "Disease"], [37, 39, "Disease"]], "rel": []}
{"idx": 811, "sentence": "二、T2DM患者中ASCVD危险因素的综合管理", "ner": [[2, 5, "Disease"], [9, 13, "Disease"]], "rel": []}
{"idx": 812, "sentence": "除高血糖外，T2DM患者往往合并有高血压、血脂异常、肥胖等多重心血管危险因素。因此，对于大多数T2DM患者，特别是合并ASCVD的患者，应采取综合管理策略，在控制血糖的同时，全面管理好各种心血管危险因素，具体措施包括生活方式干预、降压、调脂、抗血小板治疗、减重等，以期最大程度降低心血管事件和死亡风险。", "ner": [[6, 9, "Disease"], [17, 19, "Disease"], [21, 24, "Disease"], [26, 27, "Disease"], [47, 50, "Disease"], [59, 63, "Disease"], [81, 82, "Test_items"], [108, 113, "Treatment"], [115, 116, "Treatment"], [118, 119, "Treatment"], [121, 126, "Treatment"], [128, 129, "Treatment"], [140, 144, "Disease"], [140, 142, "Anatomy"], [1, 3, "Disease"], [31, 33, "Anatomy"]], "rel": [[31, 33, "Anatomy", 6, 9, "Disease", "Anatomy_Disease"], [81, 82, "Test_items", 47, 50, "Disease", "Test_items_Disease"], [81, 82, "Test_items", 59, 63, "Disease", "Test_items_Disease"], [140, 142, "Anatomy", 140, 144, "Disease", "Anatomy_Disease"]]}
{"idx": 813, "sentence": "(一)生活方式干预", "ner": [[3, 8, "Treatment"]], "rel": []}
{"idx": 814, "sentence": "对于所有T2DM合并ASCVD患者，生活方式干预应作为综合管理策略的基础性措施，并贯穿于综合治疗的全过程。", "ner": [[4, 7, "Disease"], [10, 14, "Disease"], [18, 23, "Treatment"]], "rel": [[18, 23, "Treatment", 4, 7, "Disease", "Treatment_Disease"], [18, 23, "Treatment", 10, 14, "Disease", "Treatment_Disease"]]}
{"idx": 815, "sentence": "生活方式干预包括健康教育、戒烟限酒、限盐(<6g/d)、合理饮食、规律运动、注意保持心理平衡等。", "ner": [[0, 5, "Treatment"], [8, 11, "Treatment"], [13, 14, "Treatment"], [28, 31, "Treatment"], [33, 36, "Treatment"], [38, 45, "Treatment"], [18, 26, "Treatment"], [15, 16, "Treatment"]], "rel": []}
{"idx": 816, "sentence": "(二)降压治疗", "ner": [], "rel": []}
{"idx": 817, "sentence": "高血压与高血糖并存可使ASCVD发生和发展风险显著增加，从而增加T2DM患者的病死率。研究显示，控制高血压可显著降低ASCVD发生和发展的风险，降压治疗的心血管获益主要源自血压控制本身。因此，对于大多数T2DM合并高血压患者，血压控制目标为<140/80mmHg；对于年轻、没有并发症、合并白蛋白尿或糖尿病慢性肾脏病(CKD)患者，可将收缩压控制在<130mmHg。", "ner": [[0, 2, "Disease"], [4, 6, "Disease"], [11, 15, "Disease"], [32, 35, "Disease"], [50, 52, "Disease"], [58, 62, "Disease"], [101, 104, "Disease"], [107, 109, "Disease"], [120, 130, "Test_Value"], [145, 148, "Disease"], [150, 162, "Disease"], [86, 87, "Test"], [113, 114, "Test"], [168, 170, "Test"], [174, 181, "Test_Value"], [155, 156, "Anatomy"], [77, 79, "Anatomy"]], "rel": [[77, 79, "Anatomy", 50, 52, "Disease", "Anatomy_Disease"], [86, 87, "Test", 50, 52, "Disease", "Test_Disease"], [113, 114, "Test", 101, 104, "Disease", "Test_Disease"], [113, 114, "Test", 107, 109, "Disease", "Test_Disease"], [168, 170, "Test", 145, 148, "Disease", "Test_Disease"], [168, 170, "Test", 150, 162, "Disease", "Test_Disease"], [155, 156, "Anatomy", 150, 162, "Disease", "Anatomy_Disease"]]}
{"idx": 818, "sentence": "选择降压药物时，应综合考虑疗效、心肾保护作用、安全性、依从性、对代谢的影响等因素。", "ner": [], "rel": []}
{"idx": 819, "sentence": "大多数患者需要至少两种不同作用机制的降压药物的联合治疗。", "ner": [], "rel": []}
{"idx": 820, "sentence": "(三)调脂治疗", "ner": [], "rel": []}
{"idx": 821, "sentence": "T2DM患者通常合并多项血脂异常，主要表现为TG升高、LDL-C升高及HDL-C降低、三者均与T2DM患者ASCVD发生风险增高相关。T2DM合并ASCVD患者属于极高危人群，调脂治疗的首要干预靶点IDL-C目标值为<1.8mmol/L，次要干预靶点非HDL-C目标值为<2.6mmol/L，为了达到上述目标-应首选他汀类药物。经他汀类治疗后，如非HDL-C仍不能达到目标值.可在他汀类基础上加用贝特类、高纯度鱼油制剂。对于严重高TG血症(空腹TG≥5.7mmol/L)患者，应首先考虑使用贝特类、高纯度鱼油制剂或烟酸类药物治疗，以预防急性胰腺炎的发生。", "ner": [[0, 3, "Disease"], [12, 15, "Disease"], [22, 23, "Test_items"], [27, 31, "Test_items"], [35, 39, "Test_items"], [24, 25, "Test_Value"], [32, 33, "Test_Value"], [40, 41, "Test_Value"], [47, 50, "Disease"], [53, 57, "Disease"], [67, 70, "Disease"], [73, 77, "Disease"], [99, 103, "Test_items"], [108, 117, "Test_Value"], [125, 130, "Test_items"], [135, 144, "Test_Value"], [158, 162, "Drug"], [165, 167, "Drug"], [173, 178, "Test_items"], [180, 186, "Test_Value"], [190, 192, "Drug"], [198, 200, "Drug"], [202, 208, "Drug"], [214, 218, "Disease"], [212, 213, "Level"], [220, 223, "Test_items"], [224, 233, "Test_Value"], [245, 247, "Drug"], [249, 255, "Drug"], [257, 261, "Drug"], [268, 272, "Disease"], [270, 271, "Anatomy"]], "rel": [[22, 23, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [27, 31, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [35, 39, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [99, 103, "Test_items", 67, 70, "Disease", "Test_items_Disease"], [125, 130, "Test_items", 67, 70, "Disease", "Test_items_Disease"], [158, 162, "Drug", 67, 70, "Disease", "Drug_Disease"], [99, 103, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [125, 130, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [158, 162, "Drug", 73, 77, "Disease", "Drug_Disease"], [220, 223, "Test_items", 214, 218, "Disease", "Test_items_Disease"], [245, 247, "Drug", 214, 218, "Disease", "Drug_Disease"], [249, 255, "Drug", 214, 218, "Disease", "Drug_Disease"], [257, 261, "Drug", 214, 218, "Disease", "Drug_Disease"], [270, 271, "Anatomy", 268, 272, "Disease", "Anatomy_Disease"]]}
{"idx": 822, "sentence": "(四)抗血小板治疗", "ner": [], "rel": []}
{"idx": 823, "sentence": "T2DM患者的高凝血状态是发生心血管事件的重要原因之一。在ASCVD或伴有心血管高危因素的患者中，阿司匹林可有效预防卒中、心肌梗死等心脑血管事件。对于T2DM合并ASCVD患者应常规使用阿司匹林作为二级预防措施，最佳剂量为75~150mg/d；对于阿司匹林过敏或不耐受的患者，可考虑使用氯吡格雷(75mg/d)作为替代治疗。对于急性冠状动脉综合征(ACS)患者，可使用阿司匹林和氯吡格雷双联抗血小板治疗1年。", "ner": [[0, 3, "Disease"], [15, 19, "Disease"], [7, 11, "Reason"], [15, 17, "Anatomy"], [29, 33, "Disease"], [49, 52, "Drug"], [58, 59, "Disease"], [61, 64, "Disease"], [66, 71, "Disease"], [61, 62, "Anatomy"], [66, 69, "Anatomy"], [75, 78, "Disease"], [81, 85, "Disease"], [93, 96, "Drug"], [111, 120, "Amount"], [124, 127, "Drug"], [128, 129, "ADE"], [131, 133, "ADE"], [143, 146, "Drug"], [148, 153, "Amount"], [164, 177, "Disease"], [166, 169, "Anatomy"], [184, 187, "Drug"], [189, 192, "Drug"], [201, 202, "Duration"]], "rel": [[7, 11, "Reason", 15, 19, "Disease", "Reason_Disease"], [15, 17, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"], [49, 52, "Drug", 58, 59, "Disease", "Drug_Disease"], [49, 52, "Drug", 61, 64, "Disease", "Drug_Disease"], [49, 52, "Drug", 66, 71, "Disease", "Drug_Disease"], [61, 62, "Anatomy", 61, 64, "Disease", "Anatomy_Disease"], [66, 69, "Anatomy", 66, 71, "Disease", "Anatomy_Disease"], [93, 96, "Drug", 75, 78, "Disease", "Drug_Disease"], [93, 96, "Drug", 81, 85, "Disease", "Drug_Disease"], [111, 120, "Amount", 93, 96, "Drug", "Amount_Drug"], [128, 129, "ADE", 124, 127, "Drug", "ADE_Drug"], [131, 133, "ADE", 124, 127, "Drug", "ADE_Drug"], [148, 153, "Amount", 143, 146, "Drug", "Amount_Drug"], [166, 169, "Anatomy", 164, 177, "Disease", "Anatomy_Disease"], [184, 187, "Drug", 164, 177, "Disease", "Drug_Disease"], [189, 192, "Drug", 164, 177, "Disease", "Drug_Disease"], [201, 202, "Duration", 184, 187, "Drug", "Duration_Drug"], [201, 202, "Duration", 189, 192, "Drug", "Duration_Drug"]]}
{"idx": 824, "sentence": "(五)体重管理", "ner": [[3, 6, "Treatment"]], "rel": []}
{"idx": 825, "sentence": "超重或肥胖、腹型肥胖可增加胰岛素抵抗(IR)，使ASCVD发生风险显著增加。体重控制目标包括体重指数(BMI)<24kg/m2和腰围(WC)达标(男<90cm，女<85cm)。不同降糖药对体重和内脏脂肪的影响存在差异，胰岛素、磺脲类药物(SUs)及噻唑烷二酮类(TZDs)可导致体重增加；二甲双胍可减轻体重，对内脏脂肪的影响尚不明确；胰升糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂既可减轻体重，又可减少内脏脂肪。因此，对于合并超重或肥胖(尤其是腹型肥胖)的T2DM患者，应优先考虑使用兼具减轻体重和减少内脏脂防的降糖药物。", "ner": [[6, 9, "Disease"], [0, 1, "Reason"], [3, 4, "Reason"], [13, 21, "Pathogenesis"], [24, 28, "Disease"], [64, 69, "Test"], [70, 86, "Test_Value"], [38, 41, "Treatment"], [109, 111, "Drug"], [113, 122, "Drug"], [124, 135, "Drug"], [139, 142, "ADE"], [144, 147, "Drug"], [167, 185, "Drug"], [187, 209, "Drug"], [233, 234, "Disease"], [236, 237, "Disease"], [242, 245, "Disease"], [248, 251, "Disease"]], "rel": [[0, 1, "Reason", 24, 28, "Disease", "Reason_Disease"], [3, 4, "Reason", 24, 28, "Disease", "Reason_Disease"], [13, 21, "Pathogenesis", 24, 28, "Disease", "Pathogenesis_Disease"], [139, 142, "ADE", 109, 111, "Drug", "ADE_Drug"], [139, 142, "ADE", 113, 122, "Drug", "ADE_Drug"], [139, 142, "ADE", 124, 135, "Drug", "ADE_Drug"]]}
{"idx": 826, "sentence": "(六)血糖管理", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 827, "sentence": "糖尿病是ASCVD的独立危险因素，不同类型的高血糖状态，包括空腹血糖(FPG)、餐后血糖(PPG)以及HbA1c的升高，均是ASCVD的危险因素。因此，血糖管理是T2DM合并ASCVD患者综合管理策略中的重要组成部分，以下将对此进行详细阐述。", "ner": [[0, 2, "Disease"], [4, 8, "Disease"], [22, 24, "Disease"], [30, 38, "Test_items"], [40, 48, "Test_items"], [51, 55, "Test_items"], [57, 58, "Test_Value"], [62, 66, "Disease"], [76, 77, "Test_items"], [81, 84, "Disease"], [87, 91, "Disease"]], "rel": [[30, 38, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [40, 48, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [51, 55, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [76, 77, "Test_items", 81, 84, "Disease", "Test_items_Disease"], [76, 77, "Test_items", 87, 91, "Disease", "Test_items_Disease"]]}
{"idx": 828, "sentence": "三、T2DM合并ASCVD患者的血糖管理策略和控制目标", "ner": [[2, 5, "Disease"], [8, 12, "Disease"], [16, 17, "Test_items"]], "rel": [[16, 17, "Test_items", 2, 5, "Disease", "Test_items_Disease"], [16, 17, "Test_items", 8, 12, "Disease", "Test_items_Disease"]]}
{"idx": 829, "sentence": "对于T2DM合并ASCVD患者，血糖管理的总原则是必须兼顾降糖有效性和心血管安全性，并且优先考虑选择具有心血管获益证据的降糖药物。英国糖尿病前瞻性研究(UKPDS)及其后续的10年随访研究显示，在新诊断的T2DM患者中，严格血糖控制(HbA1c<7.0%)对降低心血管事件的远期风险非常重要。然而，退伍军人糖尿病研究(VADT)、控制糖尿病患者心血管风险行动研究(ACCORD)、糖尿病与血管疾病行动研究(AD-VANCE)等随机对照临床试验(RCTs)均显示，在年龄较大、病程较长或合并ASCVD的T2DM患者中，强化降糖治疗并不能显著降低心血管事件风险。此外，对于合并ASCVD的T2DM患者，一旦发生低血糖还可能诱发心律失常、心肌梗死、卒中、猝死等。", "ner": [[2, 5, "Disease"], [8, 12, "Disease"], [16, 17, "Test_items"], [67, 69, "Disease"], [102, 105, "Disease"], [112, 113, "Test_items"], [117, 121, "Test_items"], [122, 126, "Test_Value"], [131, 135, "Disease"], [131, 133, "Anatomy"], [153, 155, "Disease"], [167, 169, "Disease"], [190, 192, "Disease"], [194, 197, "Disease"], [194, 195, "Anatomy"], [244, 248, "Disease"], [250, 253, "Disease"], [271, 275, "Disease"], [271, 273, "Anatomy"], [286, 290, "Disease"], [292, 295, "Disease"], [303, 305, "Reason"], [311, 314, "Disease"], [316, 319, "Disease"], [316, 317, "Anatomy"], [321, 322, "Disease"], [324, 325, "Disease"], [172, 174, "Anatomy"], [311, 311, "Anatomy"]], "rel": [[16, 17, "Test_items", 2, 5, "Disease", "Test_items_Disease"], [16, 17, "Test_items", 8, 12, "Disease", "Test_items_Disease"], [112, 113, "Test_items", 102, 105, "Disease", "Test_items_Disease"], [117, 121, "Test_items", 102, 105, "Disease", "Test_items_Disease"], [131, 133, "Anatomy", 131, 135, "Disease", "Anatomy_Disease"], [172, 174, "Anatomy", 167, 169, "Disease", "Anatomy_Disease"], [194, 195, "Anatomy", 194, 197, "Disease", "Anatomy_Disease"], [271, 273, "Anatomy", 271, 275, "Disease", "Anatomy_Disease"], [303, 305, "Reason", 311, 314, "Disease", "Reason_Disease"], [303, 305, "Reason", 316, 319, "Disease", "Reason_Disease"], [303, 305, "Reason", 321, 322, "Disease", "Reason_Disease"], [303, 305, "Reason", 324, 325, "Disease", "Reason_Disease"], [311, 311, "Anatomy", 311, 314, "Disease", "Anatomy_Disease"], [316, 317, "Anatomy", 316, 319, "Disease", "Anatomy_Disease"]]}
{"idx": 830, "sentence": "因此，对于这类患者而言，降糖治疗的安全性可能比降糖疗效更为重要，应尽量在避免低血糖的前提下使血糖控制达标。", "ner": [[46, 47, "Test_items"], [48, 51, "Test_Value"]], "rel": []}
{"idx": 831, "sentence": "本共识建议，T2DM合并ASCVD患者的血糖控制目标应该遵循个体化原则-综合考虑患者的年龄、糖尿病病程、ASCVD病史、其他并发症或合并症、低血糖风险等因素，充分平衡严格血糖控制的利弊得失。", "ner": [[6, 9, "Disease"], [12, 16, "Disease"], [20, 21, "Test_items"], [46, 48, "Disease"], [52, 56, "Disease"], [70, 72, "Disease"], [85, 86, "Test_items"]], "rel": [[20, 21, "Test_items", 6, 9, "Disease", "Test_items_Disease"], [20, 21, "Test_items", 12, 16, "Disease", "Test_items_Disease"]]}
{"idx": 832, "sentence": "基于现有的循证医学证据，本共识推荐T2DM合并ASCVD患者的血控制目标如下：", "ner": [[17, 20, "Disease"], [23, 27, "Disease"]], "rel": []}
{"idx": 833, "sentence": "1.对于大多数患者，HbA1c目标应控制在<7.0%。", "ner": [[10, 14, "Test_items"], [21, 25, "Test_Value"]], "rel": []}
{"idx": 834, "sentence": "2.对于年龄较大、糖尿病病程较长、存在低血糖高危因素的患者，HbA1c目标应控制在<7.5%或<8.0%.", "ner": [[9, 11, "Disease"], [19, 21, "Disease"], [30, 34, "Test_items"], [41, 51, "Test_Value"]], "rel": [[30, 34, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [30, 34, "Test_items", 19, 21, "Disease", "Test_items_Disease"]]}
{"idx": 835, "sentence": "3.对于慢性疾病终末期患者，如纽约心脏学会(NYHA)心功能Ⅲ-IV级、终末期肾病、恶性肿瘤伴有转移、中重度认知功能障碍等，HbA1c控制目标可适当放宽至<8.5%。", "ner": [[27, 34, "Disease"], [36, 40, "Disease"], [42, 49, "Disease"], [51, 59, "Disease"], [62, 66, "Test_items"], [77, 81, "Test_Value"]], "rel": [[62, 66, "Test_items", 27, 34, "Disease", "Test_items_Disease"], [62, 66, "Test_items", 36, 40, "Disease", "Test_items_Disease"], [62, 66, "Test_items", 42, 49, "Disease", "Test_items_Disease"], [62, 66, "Test_items", 51, 59, "Disease", "Test_items_Disease"]]}
{"idx": 836, "sentence": "四、T2DM合并ASCVD患者的降糖药物治疗", "ner": [[2, 5, "Disease"], [8, 12, "Disease"]], "rel": []}
{"idx": 837, "sentence": "(一)降糖药物的心血管安全性评价", "ner": [], "rel": []}
{"idx": 838, "sentence": "2008年，美国食品药品监督管理局(FDA)发布了强制性指导意见，要求所有新批准上市的降糖药都必须进行心血管安全性评估。", "ner": [], "rel": []}
{"idx": 839, "sentence": "根据这一要求.目前全球已开展了一系列新型降糖药物的心血管结局研究(CVOT)。", "ner": [], "rel": []}
{"idx": 840, "sentence": "传统降糖药物由于不受这条强制性要求的制约，故缺少CVOT证据，其心血管安全性评估通常基于针对降糖治疗策略的大型RCT数据或基于针对降糖疗效的多项RCTs荟萃分析结果。", "ner": [], "rel": []}
{"idx": 841, "sentence": "根据目前已有的CVOT证据(表1)，本共识将降糖药物的心血管安全性分为获益、中性及其他3大类。", "ner": [], "rel": []}
{"idx": 842, "sentence": "1.具有心血管获益证据的降糖药物", "ner": [], "rel": []}
{"idx": 843, "sentence": "目前，明确具有心血管获益的降糖药物包括二甲双胍、恩格列净及利拉鲁肽。二甲双胍是T2DM降糖治疗的一线药物，其心血管安全性证据来自UKPDS及其后续的10年随访研究。UKPDS研究纳人1704例合并超重或肥胖的新诊断T2DM患者，随机分为给予传统治疗(饮食控制为主，n=411)、二甲双胍强化降糖治疗(n=342)或其他药物(SUs或胰岛素)强化降糖治疗(n=951)，中位随访时间为10.7年。结果显示，与传统治疗相比，二甲双胍可显著降低心血管事件风险，其中心肌梗死风险下降39%(P=0.010)，心血管事件复合终点(心肌梗死、猝死、心绞痛、卒中或周围血管疾病)风险下降30%(P=0.020)；二甲双胍与其他药物的两种强化降糖治疗方案之间相比，心血管事件风险差异无统计学意义。UKPDS研究结束后继续随访10年仍发现，二甲双胍的心血管获益具有延续效应，与传统治疗相比，其心肌梗死风险下降33%(P=0.005)。", "ner": [[19, 22, "Drug"], [24, 27, "Drug"], [29, 32, "Drug"], [34, 37, "Drug"], [39, 42, "Disease"], [98, 99, "Disease"], [101, 102, "Disease"], [107, 110, "Disease"], [125, 128, "Treatment"], [139, 142, "Drug"], [162, 164, "Drug"], [166, 168, "Drug"], [210, 213, "Drug"], [219, 223, "Disease"], [219, 221, "Anatomy"], [229, 232, "Disease"], [229, 230, "Anatomy"], [250, 254, "Disease"], [250, 252, "Anatomy"], [260, 263, "Disease"], [260, 261, "Anatomy"], [265, 266, "Disease"], [268, 270, "Disease"], [268, 268, "Anatomy"], [272, 273, "Disease"], [275, 280, "Disease"], [275, 278, "Anatomy"], [299, 302, "Drug"], [324, 328, "Disease"], [324, 326, "Anatomy"], [361, 364, "Drug"], [387, 390, "Disease"], [387, 388, "Anatomy"]], "rel": [[34, 37, "Drug", 39, 42, "Disease", "Drug_Disease"], [125, 128, "Treatment", 107, 110, "Disease", "Treatment_Disease"], [139, 142, "Drug", 107, 110, "Disease", "Drug_Disease"], [162, 164, "Drug", 107, 110, "Disease", "Drug_Disease"], [166, 168, "Drug", 107, 110, "Disease", "Drug_Disease"], [219, 221, "Anatomy", 219, 223, "Disease", "Anatomy_Disease"], [229, 230, "Anatomy", 229, 232, "Disease", "Anatomy_Disease"], [250, 252, "Anatomy", 250, 254, "Disease", "Anatomy_Disease"], [260, 261, "Anatomy", 260, 263, "Disease", "Anatomy_Disease"], [268, 268, "Anatomy", 268, 270, "Disease", "Anatomy_Disease"], [275, 278, "Anatomy", 275, 280, "Disease", "Anatomy_Disease"], [324, 326, "Anatomy", 324, 328, "Disease", "Anatomy_Disease"], [387, 388, "Anatomy", 387, 390, "Disease", "Anatomy_Disease"]]}
{"idx": 844, "sentence": "SGLT-2抑制剂恩格列净是第一个通过CVOT证实具有明确心血管获益的新型降糖药物，但目前尚未在我国上市。恩格列净心血管事件结局(EM-PA-REG OUTCOME)研究纳入7020例伴有心血管疾病的T2DM患者，中位随访时间为3.1年。结果显示，在常规治疗基础上，与安慰剂相比，恩格列净可显著降低3终点的主要心血管不良事件(3终点MACE，包括心血管死亡、非致死性心肌梗死或非致死性卒中)风险14%(P=0.04)，降低心血管死亡风险38%(P<0.001)，降低心力衰竭住院风险35%(P=0.002)。", "ner": [[0, 12, "Drug"], [53, 56, "Drug"], [57, 61, "Disease"], [57, 59, "Anatomy"], [94, 98, "Disease"], [94, 96, "Anatomy"], [100, 103, "Disease"], [140, 143, "Drug"], [179, 186, "Disease"], [183, 184, "Anatomy"], [188, 193, "Disease"], [233, 236, "Disease"], [233, 233, "Anatomy"], [173, 177, "Disease"], [173, 175, "Anatomy"]], "rel": [[57, 59, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"], [94, 96, "Anatomy", 94, 98, "Disease", "Anatomy_Disease"], [183, 184, "Anatomy", 179, 186, "Disease", "Anatomy_Disease"], [233, 233, "Anatomy", 233, 236, "Disease", "Anatomy_Disease"], [173, 175, "Anatomy", 173, 177, "Disease", "Anatomy_Disease"]]}
{"idx": 845, "sentence": "GLP-1受体激动剂利拉鲁肽是目前在中国上市的降糖药物中唯一被CVOT证实具有心血管获益的降糖药物。利拉鲁肽在糖尿病患者中的心血管结局评估(LEADER)研究纳入9340例伴有心血管疾或心血管危险因素的T2DM患者，其中81.3%的患者既往有心血管病史(包括心肌梗死、卒中或短暂性脑缺血发作、曾行血运重建术、冠状动脉或颈动脉或下肢动脉狭窄≥50%)，中位随访时间为3.8年。结果显示，在常规治疗基础上，与安慰剂相比利拉鲁肽可使3终点MACE风险降低13%(P<0.001)-心血管死亡风险降低22%(P=0.007)，扩展的心血管事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建、不稳定性心绞痛住院或心力衰竭住院)风险降低12%(P=0.005)，且不增加心力衰竭住院风险。", "ner": [[0, 13, "Drug"], [50, 53, "Drug"], [55, 57, "Disease"], [88, 91, "Disease"], [88, 90, "Anatomy"], [101, 104, "Disease"], [129, 132, "Disease"], [129, 130, "Anatomy"], [134, 135, "Disease"], [137, 144, "Disease"], [140, 140, "Anatomy"], [148, 152, "Operation"], [154, 168, "Disease"], [154, 157, "Anatomy"], [159, 161, "Anatomy"], [163, 166, "Anatomy"], [169, 172, "Level"], [207, 210, "Drug"], [262, 266, "Disease"], [262, 264, "Anatomy"], [237, 241, "Disease"], [237, 239, "Anatomy"], [272, 276, "Disease"], [272, 274, "Anatomy"], [278, 285, "Disease"], [282, 283, "Anatomy"], [287, 292, "Disease"], [294, 297, "Operation"], [299, 305, "Disease"], [303, 303, "Anatomy"], [309, 312, "Disease"], [309, 309, "Anatomy"], [337, 340, "Disease"], [337, 337, "Anatomy"], [62, 64, "Anatomy"], [93, 95, "Anatomy"]], "rel": [[50, 53, "Drug", 55, 57, "Disease", "Drug_Disease"], [62, 64, "Anatomy", 55, 57, "Disease", "Anatomy_Disease"], [88, 90, "Anatomy", 88, 91, "Disease", "Anatomy_Disease"], [93, 95, "Anatomy", 101, 104, "Disease", "Anatomy_Disease"], [129, 130, "Anatomy", 129, 132, "Disease", "Anatomy_Disease"], [140, 140, "Anatomy", 137, 144, "Disease", "Anatomy_Disease"], [154, 157, "Anatomy", 154, 168, "Disease", "Anatomy_Disease"], [159, 161, "Anatomy", 154, 168, "Disease", "Anatomy_Disease"], [163, 166, "Anatomy", 154, 168, "Disease", "Anatomy_Disease"], [262, 264, "Anatomy", 262, 266, "Disease", "Anatomy_Disease"], [237, 239, "Anatomy", 237, 241, "Disease", "Anatomy_Disease"], [272, 274, "Anatomy", 272, 276, "Disease", "Anatomy_Disease"], [282, 283, "Anatomy", 278, 285, "Disease", "Anatomy_Disease"], [303, 303, "Anatomy", 299, 305, "Disease", "Anatomy_Disease"], [309, 309, "Anatomy", 309, 312, "Disease", "Anatomy_Disease"], [337, 337, "Anatomy", 337, 340, "Disease", "Anatomy_Disease"]]}
{"idx": 846, "sentence": "EMPA-REG OUTCOME和LEADER均为大型、多中心、随机、双盲、安慰剂对照的CVOT，这两项研究分别为恩格列净和利拉鲁肽的心血管保护作用提供了可靠证据，对于T2DM合并ASCVD患者的降糖治疗策略制定具有里程碑意义。", "ner": [[57, 60, "Drug"], [62, 65, "Drug"], [84, 87, "Disease"], [90, 94, "Disease"]], "rel": [[57, 60, "Drug", 84, 87, "Disease", "Drug_Disease"], [57, 60, "Drug", 90, 94, "Disease", "Drug_Disease"], [62, 65, "Drug", 84, 87, "Disease", "Drug_Disease"], [62, 65, "Drug", 90, 94, "Disease", "Drug_Disease"]]}
{"idx": 847, "sentence": "2.具有心血管效应为中性证据的降糖药物", "ner": [], "rel": []}
{"idx": 848, "sentence": "在T2DM患者中CVOT证实心血管效应为中性的降糖药物包括罗格列酮、吡格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽。", "ner": [[1, 4, "Disease"], [29, 32, "Drug"], [34, 37, "Drug"], [39, 43, "Drug"], [45, 48, "Drug"], [50, 53, "Drug"], [55, 58, "Drug"], [60, 63, "Drug"], [14, 16, "Anatomy"]], "rel": [[14, 16, "Anatomy", 1, 4, "Disease", "Anatomy_Disease"], [29, 32, "Drug", 1, 4, "Disease", "Drug_Disease"], [34, 37, "Drug", 1, 4, "Disease", "Drug_Disease"], [39, 43, "Drug", 1, 4, "Disease", "Drug_Disease"], [45, 48, "Drug", 1, 4, "Disease", "Drug_Disease"], [50, 53, "Drug", 1, 4, "Disease", "Drug_Disease"], [55, 58, "Drug", 1, 4, "Disease", "Drug_Disease"], [60, 63, "Drug", 1, 4, "Disease", "Drug_Disease"]]}
{"idx": 849, "sentence": "评估罗格列酮对糖尿病患者心血管结局和血糖控制影响(RECORD)研究是一项开放标签的RCT研究，4447例二甲双胍或SUs单药治疗血糖控制不佳的T2DM患者随机分为两组：在原有治疗基础上联合罗格列酮或在原有治疗基础上联合SUs或双胍类，平均随访时间为5.5年。结果显示与二甲双胍联合SUs治疗组相比，罗格列酮联合二甲双胍或SUs组的首要心血管终点事件(心血管疾病住院或心血管死亡)风险达到非劣效性标准(HR为0.99.95%CI为0.85~1.16)；心力衰竭住院或死亡的相对风险显著增加(HR2.10，95%CI 1.35~3.27)", "ner": [[2, 5, "Drug"], [7, 9, "Disease"], [18, 19, "Test_items"], [53, 56, "Drug"], [58, 60, "Drug"], [65, 66, "Test_items"], [72, 75, "Disease"], [95, 98, "Drug"], [110, 112, "Drug"], [114, 116, "Drug"], [135, 138, "Drug"], [141, 143, "Drug"], [150, 153, "Drug"], [156, 159, "Drug"], [161, 163, "Drug"], [176, 180, "Disease"], [184, 188, "Disease"], [226, 229, "Disease"], [176, 178, "Anatomy"], [226, 226, "Anatomy"], [184, 186, "Anatomy"], [67, 70, "Test_Value"], [12, 14, "Anatomy"]], "rel": [[2, 5, "Drug", 7, 9, "Disease", "Drug_Disease"], [12, 14, "Anatomy", 7, 9, "Disease", "Anatomy_Disease"], [18, 19, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [53, 56, "Drug", 72, 75, "Disease", "Drug_Disease"], [58, 60, "Drug", 72, 75, "Disease", "Drug_Disease"], [65, 66, "Test_items", 72, 75, "Disease", "Test_items_Disease"], [176, 178, "Anatomy", 176, 180, "Disease", "Anatomy_Disease"], [184, 186, "Anatomy", 184, 188, "Disease", "Anatomy_Disease"], [226, 226, "Anatomy", 226, 229, "Disease", "Anatomy_Disease"]]}
{"idx": 850, "sentence": "吡格列酮对大血管事件影响的前瞻性临床试验(PROactive)是一项随机、双盲、安慰剂对照的临床研究，在5238例伴有心血管疾病的T2DM患者中评估吡格列酮的心血管安全性。受试者在常规治疗基础上联合吡格列酮或安慰剂治疗，平均随访时间为34.5个月。结果显示，与安慰剂组相比，吡格列酮组的首要复合事件终点(全因死亡、非致死性心肌梗死、卒中、ACS、冠状动脉或下肢动脉的血运重建、踝关节以上的下肢截肢)风险差异无统计学意义(HR 0.90，95%CI 0.80~1.02，P=0.095)，主要次级终点(全因死亡、非致死性心肌梗死或卒中)相对风险下降16%(P=0.027)。", "ner": [[0, 3, "Drug"], [5, 9, "Disease"], [5, 7, "Anatomy"], [59, 63, "Disease"], [59, 61, "Anatomy"], [65, 68, "Disease"], [74, 77, "Drug"], [99, 102, "Drug"], [137, 140, "Drug"], [157, 164, "Disease"], [161, 162, "Anatomy"], [166, 167, "Disease"], [169, 171, "Disease"], [173, 186, "Operation"], [188, 197, "Operation"], [255, 262, "Disease"], [259, 260, "Anatomy"], [264, 265, "Disease"], [79, 81, "Anatomy"]], "rel": [[0, 3, "Drug", 5, 9, "Disease", "Drug_Disease"], [5, 7, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"], [59, 61, "Anatomy", 59, 63, "Disease", "Anatomy_Disease"], [74, 77, "Drug", 59, 63, "Disease", "Drug_Disease"], [79, 81, "Anatomy", 59, 63, "Disease", "Anatomy_Disease"], [74, 77, "Drug", 65, 68, "Disease", "Drug_Disease"], [79, 81, "Anatomy", 65, 68, "Disease", "Anatomy_Disease"], [161, 162, "Anatomy", 157, 164, "Disease", "Anatomy_Disease"], [259, 260, "Anatomy", 255, 262, "Disease", "Anatomy_Disease"]]}
{"idx": 851, "sentence": "PROactive研究结束后继续随访7.8年发现，两组间在首要终点和主要次级终点方面比较，差异均无统计学意义。", "ner": [], "rel": []}
{"idx": 852, "sentence": "甘精胰岛素初始干预转归(ORIGIN)研究采用随机、双盲、2×2析因设计，纳入12537例有心血管高危因素的IFG、IGT或T2DM患者，随机分为甘精胰岛素或常规治疗，中位随访时间为6.2年。", "ner": [[0, 4, "Drug"], [54, 56, "Disease"], [58, 60, "Disease"], [62, 65, "Disease"], [73, 77, "Drug"], [46, 48, "Anatomy"]], "rel": [[46, 48, "Anatomy", 54, 56, "Disease", "Anatomy_Disease"], [73, 77, "Drug", 54, 56, "Disease", "Drug_Disease"], [46, 48, "Anatomy", 58, 60, "Disease", "Anatomy_Disease"], [73, 77, "Drug", 58, 60, "Disease", "Drug_Disease"], [46, 48, "Anatomy", 62, 65, "Disease", "Anatomy_Disease"], [73, 77, "Drug", 62, 65, "Disease", "Drug_Disease"]]}
{"idx": 853, "sentence": "结果显示，与常规治疗组相比，甘精胰岛素治疗组3终点MACE的风险差异无统计学意义(HR 1.02，95%CI 0.94~1.11，P=0.63)。", "ner": [[14, 18, "Drug"]], "rel": []}
{"idx": 854, "sentence": "在二肽基肽酶4(DPP-4)抑制剂中进行的3项随机、双盲、安慰剂对照的CVOT均显示，DPP-4抑制剂既不增加也不降低心血管事件发生风险。评估T2DM患者中西格列汀心血管安全性(TECOS)研究纳入14671例有心血管病史的T2DM患者，中位随访时间为3年。结果显示，在常规降糖治疗基上，与安慰剂组相比，西格列汀组首要心血管事件复合终点(3终点MACE+不稳定型心绞痛住院)的风险达到非劣效性标准(HR 0.98，95%CI 0.88~1.09)。且不增加心力衰竭住院风险。评价沙格列汀在糖尿病患者中的心血管结局(SAVOR-TIMI53)研究纳入16492例伴有心血管疾病或心血管危险因素的T2DM患者，中位随访时间为2.1年。结果显示，在常规降糖治疗基础上，与安慰剂组相比，沙格列汀组3终点MACE的风险达到非劣效性标准(HR 1.00，95%CI 0.89~1.12)，但心力衰竭住院相对风险增加27%(P=0.007)。阿格列汀与标准治疗在T2DM合并ACS患者中心血管结局比较(EXAMINE)研究在5380例既往15~90d内发生过ACS的T2DM患者中评估阿格列汀的心血管安全性，中位随访时间为18个月。", "ner": [[1, 16, "Drug"], [43, 50, "Drug"], [59, 63, "Disease"], [59, 61, "Anatomy"], [71, 74, "Disease"], [78, 81, "Drug"], [106, 109, "Disease"], [106, 108, "Anatomy"], [112, 115, "Disease"], [152, 155, "Drug"], [159, 163, "Disease"], [159, 161, "Anatomy"], [177, 183, "Disease"], [181, 181, "Anatomy"], [228, 231, "Disease"], [228, 228, "Anatomy"], [239, 242, "Drug"], [244, 246, "Disease"], [282, 286, "Disease"], [282, 284, "Anatomy"], [296, 299, "Disease"], [339, 342, "Drug"], [389, 392, "Disease"], [389, 389, "Anatomy"], [414, 417, "Drug"], [424, 427, "Disease"], [430, 432, "Disease"], [472, 474, "Disease"], [476, 479, "Disease"], [485, 488, "Drug"]], "rel": [[43, 50, "Drug", 59, 63, "Disease", "Drug_Disease"], [59, 61, "Anatomy", 59, 63, "Disease", "Anatomy_Disease"], [78, 81, "Drug", 71, 74, "Disease", "Drug_Disease"], [106, 108, "Anatomy", 106, 109, "Disease", "Anatomy_Disease"], [152, 155, "Drug", 159, 163, "Disease", "Drug_Disease"], [159, 161, "Anatomy", 159, 163, "Disease", "Anatomy_Disease"], [181, 181, "Anatomy", 177, 183, "Disease", "Anatomy_Disease"], [228, 228, "Anatomy", 228, 231, "Disease", "Anatomy_Disease"], [239, 242, "Drug", 244, 246, "Disease", "Drug_Disease"], [282, 284, "Anatomy", 282, 286, "Disease", "Anatomy_Disease"], [389, 389, "Anatomy", 389, 392, "Disease", "Anatomy_Disease"], [414, 417, "Drug", 424, 427, "Disease", "Drug_Disease"], [414, 417, "Drug", 430, 432, "Disease", "Drug_Disease"], [485, 488, "Drug", 472, 474, "Disease", "Drug_Disease"], [485, 488, "Drug", 476, 479, "Disease", "Drug_Disease"]]}
{"idx": 855, "sentence": "结果显示，在常规降糖治疗基上，与安慰剂组相比，阿格列汀组3终点MACE的风险达到非劣效性标准(HR 0.96，单侧重复CI上限1.16)。", "ner": [[23, 26, "Drug"]], "rel": []}
{"idx": 856, "sentence": "利司那肽治疗T2DM合并ACS患者的心血管事件评估(ELIXA)研究是一项随机、双盲、安慰剂对照的临床试验，纳入6068例在既往180d内发生过ACS的T2DM患者，中位随访时间为25个月。结果显示，在常规降糖治疗基础上，与安慰剂组相比，利司那肽组首要心血管事件复合终点(3终点MACE+不稳定性心绞痛住院)的风险达到非劣效性标准( HR 1.02，95%CI 0.89~1.17)，且不增加心力衰竭住院风险。", "ner": [[0, 3, "Drug"], [6, 9, "Disease"], [12, 14, "Disease"], [18, 22, "Disease"], [18, 20, "Anatomy"], [72, 74, "Disease"], [76, 79, "Disease"], [119, 122, "Drug"], [126, 130, "Disease"], [126, 128, "Anatomy"], [144, 150, "Disease"], [148, 148, "Anatomy"], [196, 199, "Disease"], [196, 196, "Anatomy"]], "rel": [[0, 3, "Drug", 6, 9, "Disease", "Drug_Disease"], [0, 3, "Drug", 12, 14, "Disease", "Drug_Disease"], [18, 20, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"], [119, 122, "Drug", 126, 130, "Disease", "Drug_Disease"], [126, 128, "Anatomy", 126, 130, "Disease", "Anatomy_Disease"], [148, 148, "Anatomy", 144, 150, "Disease", "Anatomy_Disease"], [196, 196, "Anatomy", 196, 199, "Disease", "Anatomy_Disease"]]}
{"idx": 857, "sentence": "上述研究数据表明，罗格列酮、毗格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽的心血管效应为中性，既不增加也不降低心血管事件发生风险。", "ner": [[9, 12, "Drug"], [14, 17, "Drug"], [19, 23, "Drug"], [25, 28, "Drug"], [30, 33, "Drug"], [35, 38, "Drug"], [40, 43, "Drug"], [62, 66, "Disease"], [62, 64, "Anatomy"]], "rel": [[62, 64, "Anatomy", 62, 66, "Disease", "Anatomy_Disease"]]}
{"idx": 858, "sentence": "3.其他降糖药物", "ner": [], "rel": []}
{"idx": 859, "sentence": "(1)目前缺少在T2DM患者中评估心血管安全性的CVOT证据的降糖药物", "ner": [[8, 11, "Disease"], [17, 19, "Anatomy"]], "rel": [[17, 19, "Anatomy", 8, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 860, "sentence": "对于那些未进行CVOT的传统降糖药物而言，其心血管安全性证据主要源自针对降糖治疗策略的RCT研究数据或基于针对降糖疗效的多项RCTs的荟萃分析结果，这些药物包括SUs、格列奈类、维格列汀及大部分胰岛素制剂。", "ner": [[80, 82, "Drug"], [84, 87, "Drug"], [89, 92, "Drug"], [97, 101, "Drug"]], "rel": []}
{"idx": 861, "sentence": "47项RCTs研究的荟萃分析显示，与安慰剂或活性对照药相比，SUs不增加T2DM患者全因死亡、心血管死亡、心肌梗死及卒中的风险.。", "ner": [[30, 32, "Drug"], [36, 39, "Disease"], [47, 51, "Disease"], [53, 56, "Disease"], [58, 59, "Disease"], [47, 49, "Anatomy"], [53, 54, "Anatomy"]], "rel": [[30, 32, "Drug", 36, 39, "Disease", "Drug_Disease"], [47, 49, "Anatomy", 47, 51, "Disease", "Anatomy_Disease"], [53, 54, "Anatomy", 53, 56, "Disease", "Anatomy_Disease"]]}
{"idx": 862, "sentence": "那格列奈和缬沙坦在IGT人群中的结局研究(NAVIGATOR)显示，在有心血管事件病史或心血管危险因素的IGT患者中，与安慰剂相比，那格列奈治疗5年后，首要心血管事件复合终点(3终点MACE+心力衰竭住院)风险差异无统计学意义( HR 0.94，95%CI 0.82~1.09，P=0.43)。", "ner": [[0, 3, "Drug"], [5, 7, "Drug"], [9, 11, "Disease"], [36, 40, "Disease"], [36, 38, "Anatomy"], [52, 54, "Disease"], [66, 69, "Drug"], [72, 73, "Duration"], [78, 82, "Disease"], [78, 80, "Anatomy"], [96, 99, "Disease"], [96, 96, "Anatomy"]], "rel": [[0, 3, "Drug", 9, 11, "Disease", "Drug_Disease"], [5, 7, "Drug", 9, 11, "Disease", "Drug_Disease"], [36, 38, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [72, 73, "Duration", 66, 69, "Drug", "Duration_Drug"], [78, 80, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"], [96, 96, "Anatomy", 96, 99, "Disease", "Anatomy_Disease"]]}
{"idx": 863, "sentence": "25项Ⅲ期临床试验的荟萃分析显示，与安慰剂或活性对照药相比，维格列汀不增加T2DM患者心脑血管事件风险，其中50mg/d组的相对风险为0.88(95%CI 0.37~2.11)、100mg/d组的相对风险0.84(95%CI 0.62~1.14).。", "ner": [[30, 33, "Drug"], [37, 40, "Disease"], [43, 48, "Disease"], [43, 46, "Anatomy"], [54, 59, "Amount"], [89, 95, "Amount"]], "rel": [[54, 59, "Amount", 30, 33, "Drug", "Amount_Drug"], [89, 95, "Amount", 30, 33, "Drug", "Amount_Drug"], [30, 33, "Drug", 37, 40, "Disease", "Drug_Disease"], [43, 46, "Anatomy", 43, 48, "Disease", "Anatomy_Disease"]]}
{"idx": 864, "sentence": "T2DM心血管结局(HEART2D)研究显示，在急性心肌梗死后的T2DM患者中，餐时胰岛素或基础胰岛素治疗2.7年后，首要心血管事件复合终点(3终点MACE+冠状动脉血运重建或ACS住院)的风险相似( HR 0.98，95%CI 0.88~1.21)。事后亚组分析提示，在年龄>65.7岁亚组中，与基础胰岛素组相比，餐时胰岛素组首次心血管事件的发生风险更低(HR 0.69，95%CI 0.49~0.96)，表现为发生比例更低、时间更晚。", "ner": [[0, 3, "Disease"], [24, 29, "Disease"], [26, 27, "Anatomy"], [32, 35, "Disease"], [40, 44, "Drug"], [46, 50, "Drug"], [53, 56, "Duration"], [4, 6, "Anatomy"], [61, 65, "Disease"], [61, 63, "Anatomy"], [79, 86, "Operation"], [88, 90, "Disease"], [149, 153, "Drug"], [158, 162, "Drug"], [166, 170, "Disease"], [166, 168, "Anatomy"]], "rel": [[4, 6, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [26, 27, "Anatomy", 24, 29, "Disease", "Anatomy_Disease"], [40, 44, "Drug", 32, 35, "Disease", "Drug_Disease"], [46, 50, "Drug", 32, 35, "Disease", "Drug_Disease"], [53, 56, "Duration", 40, 44, "Drug", "Duration_Drug"], [53, 56, "Duration", 46, 50, "Drug", "Duration_Drug"], [61, 63, "Anatomy", 61, 65, "Disease", "Anatomy_Disease"], [166, 168, "Anatomy", 166, 170, "Disease", "Anatomy_Disease"]]}
{"idx": 865, "sentence": "(2)CVOT尚在进行中的降糖药物", "ner": [], "rel": []}
{"idx": 866, "sentence": "目前，正在进行CVOT的降糖药物包括阿卡波糖、利格列汀、艾塞那肽(周制剂)、度拉唐肽、阿必鲁肽、达格列净、坎格列净及德谷胰岛素。", "ner": [[18, 21, "Drug"], [23, 26, "Drug"], [28, 36, "Drug"], [38, 41, "Drug"], [43, 46, "Drug"], [48, 51, "Drug"], [53, 56, "Drug"], [58, 62, "Drug"]], "rel": []}
{"idx": 867, "sentence": "(二)降糖药物的用药原则", "ner": [], "rel": []}
{"idx": 868, "sentence": "降糖治疗的目标不仅仅是单纯控制血糖，更重要的是减少糖尿病并发症（特别是心血管事件）、降低死亡风险，从而改善患者的远期预后。生活方式干预是T2DM患者降糖治疗的基础性措施，应贯穿于降糖治疗的始终。如果单纯生活方式干预不能使血糖达标，应开始药物治疗。对于合并ASCVD的T2DM患者，尤应注意心血管安全性问题，并且优先考虑选择具有心血管获益证据的降糖药物。", "ner": [[15, 16, "Test_items"], [25, 27, "Disease"], [35, 39, "Disease"], [35, 37, "Anatomy"], [61, 66, "Treatment"], [68, 71, "Disease"], [101, 106, "Treatment"], [110, 111, "Test_items"], [112, 113, "Test_Value"], [127, 131, "Disease"], [133, 136, "Disease"]], "rel": [[35, 37, "Anatomy", 35, 39, "Disease", "Anatomy_Disease"], [61, 66, "Treatment", 68, 71, "Disease", "Treatment_Disease"]]}
{"idx": 869, "sentence": "1.一线治疗", "ner": [], "rel": []}
{"idx": 870, "sentence": "大多数国内外指南均推荐二甲双胍作为T2DM", "ner": [[11, 14, "Drug"], [17, 20, "Disease"]], "rel": [[11, 14, "Drug", 17, 20, "Disease", "Drug_Disease"]]}
{"idx": 871, "sentence": "患者单药治疗的一线首选药物和联合治疗的基本用药，如无禁忌证且能够耐受，二甲双胍应一直保留在T2DM患者的降糖治疗方案中。", "ner": [[35, 38, "Drug"], [45, 48, "Disease"]], "rel": [[35, 38, "Drug", 45, 48, "Disease", "Drug_Disease"]]}
{"idx": 872, "sentence": "若存在禁忌证或无法耐受，建议视患者的具体情况考虑选择具有心血管保护或中性的降糖药物.", "ner": [], "rel": []}
{"idx": 873, "sentence": "2.联合治疗", "ner": [], "rel": []}
{"idx": 874, "sentence": "若一线降药物单药治疗3个月不能使血糖控制达标，需考虑两种降糖药物联合治疗。根据患者的不同情况，选择个体化的联合用药方案。对于T2DM合并ASCVD患者，可优先考虑联合具有明确心血管获益证据的降常药物(如利拉鲁肽或恩格列净)治疗，", "ner": [[16, 17, "Test_items"], [18, 21, "Test_Value"], [62, 65, "Disease"], [68, 72, "Disease"], [101, 104, "Drug"], [106, 109, "Drug"]], "rel": [[101, 104, "Drug", 62, 65, "Disease", "Drug_Disease"], [106, 109, "Drug", 62, 65, "Disease", "Drug_Disease"], [101, 104, "Drug", 68, 72, "Disease", "Drug_Disease"], [106, 109, "Drug", 68, 72, "Disease", "Drug_Disease"]]}
{"idx": 875, "sentence": "以最大限度降低患者心血管事件和死亡的风险。", "ner": [[9, 13, "Disease"], [9, 11, "Anatomy"]], "rel": [[9, 11, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 876, "sentence": "若两种降糖药物联合治疗3个月不能使患者血糖控制达标，可考虑联合第3种降糖药物或者联合胰岛素治疗.。", "ner": [[19, 20, "Test_items"], [21, 24, "Test_Value"], [42, 44, "Drug"]], "rel": []}
{"idx": 877, "sentence": "(三)降糖治疗的药物选择", "ner": [], "rel": []}
{"idx": 878, "sentence": "1.非胰岛素降糖药", "ner": [[3, 5, "Drug"]], "rel": []}
{"idx": 879, "sentence": "表2总结了常用非胰岛素降糖药的作用机制、使用方法、降糖疗效、低血糖风险、对体重的影响、注意事项等主要信息。", "ner": [[8, 10, "Drug"], [30, 32, "ADE"]], "rel": []}
{"idx": 880, "sentence": "(四)其他特殊情况", "ner": [], "rel": []}
{"idx": 881, "sentence": "1.ASCVD急性期", "ner": [[2, 9, "Disease"]], "rel": []}
{"idx": 882, "sentence": "对于处在ASCVD急性期(如ACS、缺血性卒中急性期、冠状动脉血运重建围手术期等)的T2DM患者，其降糖治疗方案需要充分考虑疾病特点、机体应激状况以及严格降糖治疗的获益/风险比。对于合并ACS的患者，若血糖>10.0mmol/L，可采用以胰岛素为基础的降糖治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免发生低血糖。对于接受经皮冠状动脉介人治疗(PCI)的患者，使用对比剂前可以不停用二甲双胍，但应密切监测肾功能，造影后应连续两日检验血清肌酐(Scr)。若Scr值比造影前上升26.5μmol/L，则应考虑对比剂肾病发生，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可重新开始二甲双胍治疗。", "ner": [[4, 11, "Disease"], [14, 16, "Disease"], [18, 25, "Disease"], [27, 34, "Operation"], [42, 45, "Disease"], [93, 95, "Disease"], [101, 102, "Test_items"], [103, 113, "Test_Value"], [119, 121, "Drug"], [134, 135, "Test_items"], [141, 154, "Test_Value"], [164, 166, "ADE"], [172, 186, "Operation"], [193, 195, "Drug"], [202, 205, "Drug"], [213, 215, "Test"], [217, 218, "Test"], [227, 235, "Test_items"], [238, 240, "Test_items"], [246, 257, "Test_Value"], [243, 244, "Test"], [263, 265, "Drug"], [266, 267, "Disease"], [266, 266, "Anatomy"], [276, 279, "Drug"], [283, 285, "Test"], [286, 292, "Test_Value"], [300, 303, "Drug"]], "rel": [[27, 34, "Operation", 4, 11, "Disease", "Operation_Disease"], [101, 102, "Test_items", 93, 95, "Disease", "Test_items_Disease"], [119, 121, "Drug", 93, 95, "Disease", "Drug_Disease"], [134, 135, "Test_items", 93, 95, "Disease", "Test_items_Disease"], [238, 240, "Test_items", 266, 267, "Disease", "Test_items_Disease"], [243, 244, "Test", 266, 267, "Disease", "Test_Disease"], [263, 265, "Drug", 266, 267, "Disease", "Drug_Disease"], [266, 266, "Anatomy", 266, 267, "Disease", "Anatomy_Disease"], [283, 285, "Test", 266, 267, "Disease", "Test_Disease"], [300, 303, "Drug", 266, 267, "Disease", "Drug_Disease"]]}
{"idx": 883, "sentence": "目前尚无充分的证据提示，不同降糖药物对接受PCI治疗患者的预后存在不同的影响。", "ner": [[21, 23, "Operation"]], "rel": []}
{"idx": 884, "sentence": "对于接受冠状动脉旁路移植术(CABG)的患者，围手术期不", "ner": [[4, 18, "Operation"]], "rel": []}
{"idx": 885, "sentence": "推荐口服降糖药，应使用胰岛素治疗。", "ner": [[11, 13, "Drug"], [2, 3, "Method"]], "rel": []}
{"idx": 886, "sentence": "2.心力衰竭", "ner": [[2, 5, "Disease"], [2, 2, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 887, "sentence": "T2DM和ASCVD患者常合并心力衰竭。对于合并心力衰竭的T2DM患者，制定降糖治疗方案时，应关注某些降糖药物对心力衰竭的潜在不良影响。", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [15, 18, "Disease"], [15, 15, "Anatomy"], [24, 27, "Disease"], [24, 24, "Anatomy"], [29, 32, "Disease"], [56, 59, "Disease"], [56, 56, "Anatomy"]], "rel": [[15, 15, "Anatomy", 15, 18, "Disease", "Anatomy_Disease"], [24, 24, "Anatomy", 24, 27, "Disease", "Anatomy_Disease"], [56, 56, "Anatomy", 56, 59, "Disease", "Anatomy_Disease"]]}
{"idx": 888, "sentence": "二甲双胍：在定期检查心、肾功能的情况下，稳定期的慢性心力衰竭患者可以服用二甲双胍，但因存在乳酸性酸中毒的潜在风险，急性、病情不稳定或住院的心力衰竭患者禁用。", "ner": [[0, 3, "Drug"], [10, 14, "Test"], [24, 29, "Disease"], [26, 26, "Anatomy"], [36, 39, "Drug"], [45, 50, "Disease"], [69, 72, "Disease"], [69, 69, "Anatomy"]], "rel": [[10, 14, "Test", 24, 29, "Disease", "Test_Disease"], [26, 26, "Anatomy", 24, 29, "Disease", "Anatomy_Disease"], [36, 39, "Drug", 24, 29, "Disease", "Drug_Disease"], [69, 69, "Anatomy", 69, 72, "Disease", "Anatomy_Disease"]]}
{"idx": 889, "sentence": "TZDs：可引起水钠潴留和血容量扩张，诱发或加重心力衰竭，故急性心力衰竭、NYHA心功能Ⅱ~IV级的慢性心力衰竭患者禁用。", "ner": [[0, 3, "Drug"], [8, 11, "ADE"], [13, 17, "ADE"], [30, 35, "Disease"], [32, 32, "Anatomy"], [37, 48, "Disease"], [50, 55, "Disease"], [52, 52, "Anatomy"], [19, 27, "ADE"]], "rel": [[8, 11, "ADE", 0, 3, "Drug", "ADE_Drug"], [13, 17, "ADE", 0, 3, "Drug", "ADE_Drug"], [19, 27, "ADE", 0, 3, "Drug", "ADE_Drug"], [32, 32, "Anatomy", 30, 35, "Disease", "Anatomy_Disease"], [52, 52, "Anatomy", 50, 55, "Disease", "Anatomy_Disease"]]}
{"idx": 890, "sentence": "DPP-4抑制剂：SAVOR-TIMI53研究显示，对于伴有心血管事件病史或心血管危险因素的T2DM患者，沙格列汀可增加心力衰竭住院风险。EXAMINE研究事后分析显示，对于无心力衰竭病史、近期发生过ACS的T2DM患者，阿格列汀增加心力衰竭住院风险( HR 1.76，P=0.026)。", "ner": [[0, 7, "Drug"], [30, 34, "Disease"], [30, 32, "Anatomy"], [38, 40, "Anatomy"], [46, 49, "Disease"], [53, 56, "Drug"], [60, 63, "Disease"], [60, 60, "Anatomy"], [88, 91, "Disease"], [88, 88, "Anatomy"], [100, 102, "Disease"], [104, 107, "Disease"], [111, 114, "Drug"], [117, 120, "Disease"], [117, 117, "Anatomy"]], "rel": [[30, 32, "Anatomy", 30, 34, "Disease", "Anatomy_Disease"], [38, 40, "Anatomy", 46, 49, "Disease", "Anatomy_Disease"], [53, 56, "Drug", 46, 49, "Disease", "Drug_Disease"], [60, 60, "Anatomy", 60, 63, "Disease", "Anatomy_Disease"], [88, 88, "Anatomy", 88, 91, "Disease", "Anatomy_Disease"], [111, 114, "Drug", 100, 102, "Disease", "Drug_Disease"], [111, 114, "Drug", 104, 107, "Disease", "Drug_Disease"], [117, 117, "Anatomy", 117, 120, "Disease", "Anatomy_Disease"]]}
{"idx": 891, "sentence": "2015年4月，美国FDA对沙格列汀和阿格列汀提出警示，要求在说明书中增加对心力衰竭风险的标示。TECOS研究显示，在有心血管病史的T2DM患者中，西格列汀不增加心力衰竭住院风险，维格列汀的相关研究证据尚不充分.。", "ner": [[14, 17, "Drug"], [19, 22, "Drug"], [38, 41, "Disease"], [38, 38, "Anatomy"], [60, 63, "Disease"], [60, 62, "Anatomy"], [66, 69, "Disease"], [74, 77, "Drug"], [81, 84, "Disease"], [81, 81, "Anatomy"], [90, 93, "Drug"]], "rel": [[14, 17, "Drug", 38, 41, "Disease", "Drug_Disease"], [19, 22, "Drug", 38, 41, "Disease", "Drug_Disease"], [38, 38, "Anatomy", 38, 41, "Disease", "Anatomy_Disease"], [60, 62, "Anatomy", 60, 63, "Disease", "Anatomy_Disease"], [74, 77, "Drug", 66, 69, "Disease", "Drug_Disease"], [90, 93, "Drug", 66, 69, "Disease", "Drug_Disease"], [81, 81, "Anatomy", 81, 84, "Disease", "Anatomy_Disease"]]}
{"idx": 892, "sentence": "GLP-1受体激动剂：LEADER和ELIXA研究显示，在心血管事件高危的T2DM患者中利拉鲁肽和利司那肽治疗不增加心力衰竭住院风险。", "ner": [[0, 9, "Drug"], [29, 33, "Disease"], [29, 31, "Anatomy"], [37, 40, "Disease"], [44, 47, "Drug"], [49, 52, "Drug"], [58, 61, "Disease"], [58, 58, "Anatomy"]], "rel": [[29, 31, "Anatomy", 29, 33, "Disease", "Anatomy_Disease"], [44, 47, "Drug", 37, 40, "Disease", "Drug_Disease"], [49, 52, "Drug", 37, 40, "Disease", "Drug_Disease"], [58, 58, "Anatomy", 58, 61, "Disease", "Anatomy_Disease"]]}
{"idx": 893, "sentence": "SGLT-2抑制剂：EMPA-REG OUTCOME研究显示，在伴有心血管疾病的T2DM患者中，恩格列净可降低心力衰竭住院风险。", "ner": [[0, 8, "Drug"], [34, 38, "Disease"], [34, 36, "Anatomy"], [40, 43, "Disease"], [48, 51, "Drug"], [55, 58, "Disease"], [55, 55, "Anatomy"]], "rel": [[34, 36, "Anatomy", 34, 38, "Disease", "Anatomy_Disease"], [48, 51, "Drug", 40, 43, "Disease", "Drug_Disease"], [55, 55, "Anatomy", 55, 58, "Disease", "Anatomy_Disease"]]}
{"idx": 894, "sentence": "胰岛素：胰岛素治疗不增加心力衰竭患者的死亡风险。ORIGIN研究显示，在有心血管高危因素的糖代谢异常患者中，与二甲双胍或SUs相比，甘精膝岛素治疗不增加心力衰竭住院风险。", "ner": [[0, 2, "Drug"], [4, 6, "Drug"], [12, 15, "Disease"], [12, 12, "Anatomy"], [45, 49, "Disease"], [55, 58, "Drug"], [60, 62, "Drug"], [66, 70, "Drug"], [76, 79, "Disease"], [76, 76, "Anatomy"]], "rel": [[12, 12, "Anatomy", 12, 15, "Disease", "Anatomy_Disease"], [76, 76, "Anatomy", 76, 79, "Disease", "Anatomy_Disease"]]}
{"idx": 895, "sentence": "其他降糖药物在心力衰竭患者中应用的安全性尚待进一步评估。", "ner": [[7, 10, "Disease"], [7, 7, "Anatomy"]], "rel": [[7, 7, "Anatomy", 7, 10, "Disease", "Anatomy_Disease"]]}
{"idx": 896, "sentence": "3.低血糖", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 897, "sentence": "低血糖对心血管系统具有显著的不良影响.其短期风险包括诱发心律失常、心血管事件，长期风险为认知障碍和痴呆，严重低血糖甚至可导致患者猝死。因此，对于合并ASCVD的T2DM患者，在降糖治疗过程中尤其应尽量避免出现低血糖。胰岛素和胰岛素促泌剂均可引起低血糖，与SUs相比，格列奈类药物的低血糖风险相对较低。二甲双胍、a-糖苷酶抑制剂、TZDs、GLP-1受体激动剂、DPP-4抑制剂以及SGLT-2抑制剂单独使用时通常不会导致低血糖，在接受降糖治疗的患者中，一旦发生低血糖，应迅速补充葡萄糖或含糖食物，以使血糖水平恢复正常，并及时调整降糖治疗方案。", "ner": [[0, 2, "Disease"], [4, 8, "Anatomy"], [28, 31, "Disease"], [33, 37, "Disease"], [33, 35, "Anatomy"], [44, 47, "Disease"], [49, 50, "Disease"], [54, 56, "Disease"], [64, 65, "Disease"], [74, 78, "Disease"], [80, 83, "Disease"], [104, 106, "ADE"], [108, 110, "Drug"], [112, 117, "Drug"], [122, 124, "ADE"], [127, 129, "Drug"], [133, 138, "Drug"], [140, 142, "ADE"], [150, 153, "Drug"], [155, 162, "Drug"], [164, 167, "Drug"], [169, 178, "Drug"], [180, 187, "Drug"], [190, 198, "Drug"], [210, 212, "ADE"], [230, 232, "ADE"], [250, 251, "Test_items"], [254, 257, "Test_Value"], [239, 241, "Drug"], [52, 53, "Level"]], "rel": [[4, 8, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [33, 35, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"], [122, 124, "ADE", 108, 110, "Drug", "ADE_Drug"], [122, 124, "ADE", 112, 117, "Drug", "ADE_Drug"], [140, 142, "ADE", 127, 129, "Drug", "ADE_Drug"], [140, 142, "ADE", 133, 138, "Drug", "ADE_Drug"], [210, 212, "ADE", 150, 153, "Drug", "ADE_Drug"], [210, 212, "ADE", 155, 162, "Drug", "ADE_Drug"], [210, 212, "ADE", 164, 167, "Drug", "ADE_Drug"], [210, 212, "ADE", 169, 178, "Drug", "ADE_Drug"], [210, 212, "ADE", 180, 187, "Drug", "ADE_Drug"], [210, 212, "ADE", 190, 198, "Drug", "ADE_Drug"]]}
{"idx": 898, "sentence": "4.肾功能不全", "ner": [[2, 6, "Disease"], [2, 2, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 899, "sentence": "T2DM和ASCVD患者常合并CKD。当患者存在肾功能不全[eGFR<60ml/(min.1.73m2)]时，大多数非胰岛素降糖药物的药代动力学会发生", "ner": [[0, 3, "Disease"], [5, 9, "Disease"], [15, 17, "Disease"], [24, 28, "Disease"], [24, 24, "Anatomy"], [30, 33, "Test_items"], [34, 50, "Test_Value"], [59, 61, "Drug"]], "rel": [[24, 24, "Anatomy", 24, 28, "Disease", "Anatomy_Disease"], [30, 33, "Test_items", 24, 28, "Disease", "Test_items_Disease"]]}
{"idx": 900, "sentence": "改变。", "ner": [], "rel": []}
{"idx": 901, "sentence": "因此，对于合并CKD的患者.降糖药物的选择应基于药物的药代动力学特征和患者肾功能状态进行综合判断，以确保在有效降糖的同时不增加低血糖风险，并避免诱发乳酸性酸中毒.。", "ner": [[7, 9, "Disease"], [63, 65, "ADE"], [74, 79, "ADE"]], "rel": []}
{"idx": 902, "sentence": "瑞格列奈和利格列汀在CKD1~5期全程均可使用，且无需调整剂量。其他非胰岛素降糖药的使用均可因肾功能不全的不同程度而受到一定的影响。二甲双胍在CKD3a期[eGFR45~59ml/(min.1.73m2)]时应减量，在CKD3b期[eGFR30--45ml/(min.1.73m2)]时证据相对有限，谨慎观察下减量使用，在CKD4期[eGFR<30ml/(min.1.73m2)]时禁用。基于LEADER研究和LIRA-RENAL研究的数据.推荐利拉鲁肽可用于CKD1~3期，从CKD4期开始禁用。根据美国FDA批准的药品说明书，恩格列净可用于CKD1~3a期，从3b期开始不推荐使用。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [10, 12, "Disease"], [35, 37, "Drug"], [47, 51, "Disease"], [47, 47, "Anatomy"], [66, 69, "Drug"], [71, 73, "Disease"], [78, 81, "Test_items"], [82, 100, "Test_Value"], [109, 111, "Disease"], [116, 119, "Test_items"], [120, 139, "Test_Value"], [161, 163, "Disease"], [167, 170, "Test_items"], [171, 187, "Test_Value"], [223, 226, "Drug"], [230, 232, "Disease"], [239, 241, "Disease"], [265, 268, "Drug"], [272, 274, "Disease"]], "rel": [[0, 3, "Drug", 10, 12, "Disease", "Drug_Disease"], [5, 8, "Drug", 10, 12, "Disease", "Drug_Disease"], [47, 47, "Anatomy", 47, 51, "Disease", "Anatomy_Disease"], [66, 69, "Drug", 71, 73, "Disease", "Drug_Disease"], [78, 81, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [116, 119, "Test_items", 109, 111, "Disease", "Test_items_Disease"], [167, 170, "Test_items", 161, 163, "Disease", "Test_items_Disease"], [223, 226, "Drug", 230, 232, "Disease", "Drug_Disease"], [265, 268, "Drug", 272, 274, "Disease", "Drug_Disease"]]}
{"idx": 903, "sentence": "在CVOT中，包括肾脏不良事件在内的微血管事件通常作为研究的次要终点。在LEADER研究中，24.7%的患者基线时合并CKD3期或以上，利拉鲁肽可使肾脏事件复合终点(包括新发大量蛋白尿、Scr倍增、终末期肾病或肾病导致的死亡)的风险显著降低22%(P=0.003)。在EMPA-REGOUTCOME研究中，25.9%的患者基线时伴有CKD3期，恩格列净可使肾脏事件复合终点(Scr倍增、起始肾脏替代治疗或因肾病死亡)的风险显著降低46%(P<0.001)。", "ner": [[9, 14, "Disease"], [9, 10, "Anatomy"], [18, 22, "Disease"], [18, 20, "Anatomy"], [59, 61, "Disease"], [68, 71, "Drug"], [74, 77, "Disease"], [74, 75, "Anatomy"], [89, 91, "Disease"], [87, 88, "Level"], [93, 95, "Test_items"], [96, 97, "Test_Value"], [99, 103, "Disease"], [102, 102, "Anatomy"], [105, 106, "Disease"], [105, 105, "Anatomy"], [166, 168, "Disease"], [172, 175, "Drug"], [178, 181, "Disease"], [178, 179, "Anatomy"], [187, 189, "Test_items"], [190, 191, "Test_Value"], [193, 200, "Operation"], [203, 204, "Disease"], [203, 203, "Anatomy"]], "rel": [[9, 10, "Anatomy", 9, 14, "Disease", "Anatomy_Disease"], [18, 20, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"], [68, 71, "Drug", 59, 61, "Disease", "Drug_Disease"], [93, 95, "Test_items", 59, 61, "Disease", "Test_items_Disease"], [74, 75, "Anatomy", 74, 77, "Disease", "Anatomy_Disease"], [102, 102, "Anatomy", 99, 103, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 105, 106, "Disease", "Anatomy_Disease"], [172, 175, "Drug", 166, 168, "Disease", "Drug_Disease"], [187, 189, "Test_items", 166, 168, "Disease", "Test_items_Disease"], [178, 179, "Anatomy", 178, 181, "Disease", "Anatomy_Disease"], [203, 203, "Anatomy", 203, 204, "Disease", "Anatomy_Disease"]]}
{"idx": 904, "sentence": "2016年6月，美国FDA修改坎格列净和达格列净的药物说明书，新增急性肾损伤风险的标签警示信息，建议处方这两种药物之前全面考虑增加急性肾损伤风险的各种因素，并在服药期间监测肾功能的动态变化。", "ner": [[15, 18, "Drug"], [20, 23, "Drug"], [33, 37, "ADE"], [65, 69, "Disease"], [67, 67, "Anatomy"], [86, 88, "Test"]], "rel": [[33, 37, "ADE", 15, 18, "Drug", "ADE_Drug"], [33, 37, "ADE", 20, 23, "Drug", "ADE_Drug"], [67, 67, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"]]}
{"idx": 905, "sentence": "表4总结了T2DM合并ASCVD患者降糖药物使用应着重关注的主要安全性问题，其中包括药物的心血管效应、低血糖风险、对体重的影响、在心力衰竭或肝肾功能不全等特殊患者中应用的注意事项。", "ner": [[5, 8, "Disease"], [11, 15, "Disease"], [65, 68, "Disease"], [65, 65, "Anatomy"], [70, 75, "Disease"], [70, 70, "Anatomy"], [71, 71, "Anatomy"], [51, 53, "ADE"]], "rel": [[65, 65, "Anatomy", 65, 68, "Disease", "Anatomy_Disease"], [70, 70, "Anatomy", 70, 75, "Disease", "Anatomy_Disease"], [71, 71, "Anatomy", 70, 75, "Disease", "Anatomy_Disease"]]}
{"idx": 906, "sentence": "五、结语与展望", "ner": [], "rel": []}
{"idx": 907, "sentence": "对于T2DM合并ASCVD患者，应采取综合管理策略，全面控制高血糖、高血压、血脂异常、超重或肥胖等多重心血管危险因素。在血糖管理方面，临床医师应充分考虑降糖药物的疗效与安全性之间的平衡，并且全面了解常用降糖药物的心血管安全性，这样才能熟练掌握其应用原则。", "ner": [[2, 5, "Disease"], [8, 12, "Disease"], [30, 32, "Disease"], [34, 36, "Disease"], [38, 41, "Disease"], [43, 44, "Disease"], [46, 47, "Disease"], [51, 53, "Anatomy"], [60, 61, "Test_items"]], "rel": [[51, 53, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [51, 53, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 908, "sentence": "随着CVOT的广泛开展，其研究结果将陆续公布。最新公布的SUSTAIN-6研究显示，新型长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)同样也可显著降低心血管事件风险。因此，有理由相信未来将会出现越来越多可为T2DM患者带来心血管保护作用的降糖药物，这将推动T2DM(特别是合并ASCVD)患者的治疗策略和理念发生巨大的变革。", "ner": [[44, 80, "Drug"], [89, 93, "Disease"], [89, 91, "Anatomy"], [117, 120, "Disease"], [142, 145, "Disease"], [152, 156, "Disease"], [125, 127, "Anatomy"]], "rel": [[89, 91, "Anatomy", 89, 93, "Disease", "Anatomy_Disease"], [125, 127, "Anatomy", 117, 120, "Disease", "Anatomy_Disease"]]}
{"idx": 909, "sentence": "二甲双胍临床应用专家共识(2016年版)", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 910, "sentence": "二甲双胍应用于临床已有50多年的历史，是目前全球应用最广泛的口服降糖药之一。近年来，虽然有多个新型降糖药物上市，但二甲双胍仍是全球使用量迅速增加的经典口服降糖药物。二甲双胍有良好的单药/联合治疗的疗效和安全性证据、良好的卫生经济学效益证据，以及心血管并发症预防等方面明确的临床证据。因此，该药已经成为全球控制糖尿病的核心药物。二甲双胍在我国已经有20多年的临床应用经验。1995年，美国食品药品监督管理局(FDA)正式批准二甲双胍用于治疗T2DM。2004年，欧盟正式批准二甲双胍用于治疗10岁及上T2DM患儿。", "ner": [[0, 3, "Drug"], [57, 60, "Drug"], [82, 85, "Drug"], [122, 124, "Anatomy"], [163, 166, "Drug"], [211, 214, "Drug"], [236, 239, "Drug"], [249, 252, "Disease"], [219, 222, "Disease"], [75, 76, "Method"], [154, 156, "Disease"], [30, 31, "Method"]], "rel": [[211, 214, "Drug", 219, 222, "Disease", "Drug_Disease"], [236, 239, "Drug", 249, 252, "Disease", "Drug_Disease"]]}
{"idx": 911, "sentence": "国内外主要糖尿病指南均建议，无论对于超重还是体重正常的T2DM患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了该药在糖尿病治疗中的重要地位。", "ner": [[5, 7, "Disease"], [27, 30, "Disease"], [58, 61, "Drug"], [78, 81, "Drug"], [90, 92, "Disease"], [18, 19, "Disease"]], "rel": [[58, 61, "Drug", 27, 30, "Disease", "Drug_Disease"], [78, 81, "Drug", 90, 92, "Disease", "Drug_Disease"]]}
{"idx": 912, "sentence": "自2014年版《二甲双胍临床应用专家共识》发布以来，该共识已成为临床医生正确认识、合理使用二甲双胍的重要学术参考文献。", "ner": [[8, 11, "Drug"], [45, 48, "Drug"]], "rel": []}
{"idx": 913, "sentence": "近两年，针对二甲双胍的研究涌现出了一些新的临床证据。", "ner": [[6, 9, "Drug"]], "rel": []}
{"idx": 914, "sentence": "为此，内分泌临床专家、药学专家对2014年版《二甲双胍临床应用专家共识》进行更新。", "ner": [[23, 26, "Drug"]], "rel": []}
{"idx": 915, "sentence": "推荐意见、循证医学据分级、常见缩略语见表1~3。", "ner": [], "rel": []}
{"idx": 916, "sentence": "一、临床地位与使用时机", "ner": [], "rel": []}
{"idx": 917, "sentence": "1.二甲双胍被推荐为治疗T2DM的一线首选和全程用药：二甲双胍有可靠的短期和长期降糖疗效，单独使用能有效降低T2DM患者的FPG、PPG，可使HbA1c下降1.0%~2.0%(去除安慰剂效应后)，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的二甲双胍的降糖疗效强于其他口服降糖药。数据分析显示，二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(I级)。与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，今后需调整治疗方案的可能性也最低。二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险。另外，二甲双胍具有心血管保护作用。二甲双胍的长期治疗与新诊断T2DM患者及已经发生心血管疾病的T2DM患者的心血管疾病发生风险下降相关(I级)。二甲双胍具有良好的安全性和耐受性，低血糖发生率低，其胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症或乳酸酸中毒风险。", "ner": [[2, 5, "Drug"], [12, 15, "Disease"], [27, 30, "Drug"], [54, 57, "Disease"], [61, 63, "Test_items"], [65, 67, "Test_items"], [71, 75, "Test_items"], [76, 86, "Test_Value"], [105, 108, "Disease"], [112, 116, "Test_items"], [117, 122, "Test_Value"], [148, 152, "Test_items"], [164, 171, "Amount"], [174, 177, "Drug"], [187, 188, "Method"], [200, 203, "Drug"], [220, 221, "Method"], [234, 235, "Test_items"], [247, 248, "Method"], [268, 271, "Drug"], [286, 287, "Method"], [296, 298, "Drug"], [324, 327, "Drug"], [330, 332, "Drug"], [339, 343, "Test_items"], [353, 356, "ADE"], [358, 360, "ADE"], [347, 349, "Drug"], [367, 370, "Drug"], [373, 375, "Anatomy"], [381, 384, "Drug"], [394, 397, "Disease"], [405, 409, "Disease"], [405, 407, "Anatomy"], [411, 414, "Disease"], [418, 422, "Disease"], [418, 420, "Anatomy"], [436, 439, "Drug"], [453, 455, "ADE"], [462, 466, "ADE"], [476, 479, "Disease"], [476, 477, "Anatomy"], [488, 492, "Disease"], [494, 498, "Disease"]], "rel": [[2, 5, "Drug", 12, 15, "Disease", "Drug_Disease"], [27, 30, "Drug", 54, 57, "Disease", "Drug_Disease"], [61, 63, "Test_items", 54, 57, "Disease", "Test_items_Disease"], [65, 67, "Test_items", 54, 57, "Disease", "Test_items_Disease"], [71, 75, "Test_items", 54, 57, "Disease", "Test_items_Disease"], [112, 116, "Test_items", 105, 108, "Disease", "Test_items_Disease"], [164, 171, "Amount", 174, 177, "Drug", "Amount_Drug"], [353, 356, "ADE", 324, 327, "Drug", "ADE_Drug"], [358, 360, "ADE", 324, 327, "Drug", "ADE_Drug"], [353, 356, "ADE", 330, 332, "Drug", "ADE_Drug"], [358, 360, "ADE", 330, 332, "Drug", "ADE_Drug"], [381, 384, "Drug", 394, 397, "Disease", "Drug_Disease"], [405, 407, "Anatomy", 405, 409, "Disease", "Anatomy_Disease"], [418, 420, "Anatomy", 418, 422, "Disease", "Anatomy_Disease"], [453, 455, "ADE", 436, 439, "Drug", "ADE_Drug"], [462, 466, "ADE", 436, 439, "Drug", "ADE_Drug"], [476, 477, "Anatomy", 476, 479, "Disease", "Anatomy_Disease"]]}
{"idx": 918, "sentence": "与其他降糖药物相比，二甲双胍具有良好的成本-效益比(I级)。", "ner": [[10, 13, "Drug"]], "rel": []}
{"idx": 919, "sentence": "如无禁忌证，二甲双胍是治疗T2DM的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。", "ner": [[6, 9, "Drug"], [13, 16, "Disease"], [45, 47, "Disease"]], "rel": [[6, 9, "Drug", 13, 16, "Disease", "Drug_Disease"]]}
{"idx": 920, "sentence": "2.二甲双胍是否只是超重/肥胖T2DM患者的首选用药：回顾性和前瞻性临床研究结果均显示，二甲双胍在正常体重/超重/肥胖T2DM患者中的疗效相当(I级)。", "ner": [[2, 5, "Drug"], [10, 11, "Disease"], [13, 14, "Disease"], [15, 18, "Disease"], [44, 47, "Drug"], [54, 55, "Disease"], [57, 58, "Disease"], [59, 62, "Disease"]], "rel": [[2, 5, "Drug", 15, 18, "Disease", "Drug_Disease"], [44, 47, "Drug", 59, 62, "Disease", "Drug_Disease"]]}
{"idx": 921, "sentence": "因此，体重不是能否使用二甲双胍治疗的决定因素。", "ner": [[11, 14, "Drug"]], "rel": []}
{"idx": 922, "sentence": "无论对于超重/肥胖或体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。", "ner": [[4, 5, "Disease"], [7, 8, "Disease"], [23, 25, "Disease"], [31, 34, "Drug"], [38, 41, "Disease"]], "rel": [[31, 34, "Drug", 38, 41, "Disease", "Drug_Disease"]]}
{"idx": 923, "sentence": "3.二甲双胍能否预防糖尿病：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。", "ner": [[2, 5, "Drug"], [10, 12, "Disease"], [14, 17, "Drug"], [28, 30, "Disease"], [34, 36, "Disease"], [49, 53, "Disease"], [58, 61, "Disease"]], "rel": [[2, 5, "Drug", 10, 12, "Disease", "Drug_Disease"], [14, 17, "Drug", 28, 30, "Disease", "Drug_Disease"], [14, 17, "Drug", 34, 36, "Disease", "Drug_Disease"]]}
{"idx": 924, "sentence": "但在我国预防糖尿病尚不是二甲双胍的适应证。", "ner": [[6, 8, "Disease"], [12, 15, "Drug"]], "rel": []}
{"idx": 925, "sentence": "DPP是一项糖尿病预防计划的随机对照研究，该研究结果显示，强化生活方式干预和二甲双胍(850mg，2次/d)治疗，3年内T2DM的发生率分别降低58%和31%(I级)。DPP随访研究显示，以安慰剂为对照，二甲双胍可降低IGT人群糖尿病发生率约13%(I级)。DPP/DPPOS结果显示，与强化生活方式干预相比，二甲双胍能减少糖尿病前期发展为糖尿病的发生率，减少患者体重增加，且10年内花费更低(I级)。印度IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低糖尿病的发生风险，分别为26.4%和28.2%(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好起始生活方式干预；对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病。接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。", "ner": [[38, 41, "Drug"], [60, 63, "Disease"], [6, 8, "Disease"], [43, 47, "Amount"], [49, 52, "Frequency"], [31, 36, "Treatment"], [102, 105, "Drug"], [114, 116, "Disease"], [155, 158, "Drug"], [162, 166, "Disease"], [170, 172, "Disease"], [182, 185, "ADE"], [109, 111, "Disease"], [146, 151, "Treatment"], [212, 215, "Drug"], [222, 227, "Treatment"], [236, 238, "Disease"], [274, 277, "Disease"], [285, 287, "Disease"], [301, 303, "Disease"], [312, 313, "Disease"], [320, 323, "Drug"], [292, 297, "Treatment"], [329, 333, "Disease"], [339, 344, "Treatment"], [357, 358, "Test_items"], [365, 368, "Drug"], [374, 376, "Disease"], [380, 383, "Drug"], [395, 397, "Disease"], [428, 432, "Disease"], [422, 426, "Test"]], "rel": [[43, 47, "Amount", 38, 41, "Drug", "Amount_Drug"], [38, 41, "Drug", 60, 63, "Disease", "Drug_Disease"], [49, 52, "Frequency", 38, 41, "Drug", "Frequency_Drug"], [31, 36, "Treatment", 60, 63, "Disease", "Treatment_Disease"], [102, 105, "Drug", 109, 111, "Disease", "Drug_Disease"], [155, 158, "Drug", 162, 166, "Disease", "Drug_Disease"], [146, 151, "Treatment", 162, 166, "Disease", "Treatment_Disease"], [212, 215, "Drug", 236, 238, "Disease", "Drug_Disease"], [222, 227, "Treatment", 236, 238, "Disease", "Treatment_Disease"], [292, 297, "Treatment", 285, 287, "Disease", "Treatment_Disease"], [320, 323, "Drug", 301, 303, "Disease", "Drug_Disease"], [320, 323, "Drug", 312, 313, "Disease", "Drug_Disease"], [339, 344, "Treatment", 329, 333, "Disease", "Treatment_Disease"], [357, 358, "Test_items", 374, 376, "Disease", "Test_items_Disease"], [365, 368, "Drug", 374, 376, "Disease", "Drug_Disease"], [380, 383, "Drug", 395, 397, "Disease", "Drug_Disease"], [422, 426, "Test", 428, 432, "Disease", "Test_Disease"]]}
{"idx": 926, "sentence": "二、作用机制", "ner": [], "rel": []}
{"idx": 927, "sentence": "二甲双胍改善高血糖主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低FFA，提高IS，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高GLP-1水平。", "ner": [[0, 3, "Drug"], [6, 8, "Disease"], [67, 69, "Test_items"], [73, 74, "Test_items"], [112, 118, "Test_items"]], "rel": [[0, 3, "Drug", 6, 8, "Disease", "Drug_Disease"]]}
{"idx": 928, "sentence": "三、剂量与临床疗效", "ner": [], "rel": []}
{"idx": 929, "sentence": "1.二甲双胍的最小、最大及最佳使用剂量：临床研究显示，在500~2000mg/d的剂量范围内，二甲双胍的降糖效果与剂量呈正相关。500mg/d二甲双胍可降低HbA1c 0.6%(减去安慰剂效应后，以下同)，2000 mg/d可降低HbA1c 2.0%，且与1000mg或1500mg比较，胃肠道反应差异无统计学意义。UKPDS研究中，二甲双胍强化治疗剂量中位数达到2550 mg/d，缓释剂型推荐最大用量为2000 mg/d，普通片推荐成人可用的最大剂量为2550 mg/d。综上所述，二甲双胍起效的最小推荐剂量为500mg/d，成人可用的最大剂量为2550mg/d，最佳有效剂量为2000mg/d。", "ner": [[2, 5, "Drug"], [28, 39, "Amount"], [47, 50, "Drug"], [64, 70, "Amount"], [71, 74, "Drug"], [78, 82, "Test_items"], [84, 87, "Test_Value"], [103, 111, "Amount"], [115, 119, "Test_items"], [121, 124, "Test_Value"], [128, 133, "Amount"], [135, 140, "Amount"], [144, 148, "ADE"], [167, 170, "Drug"], [182, 190, "Amount"], [203, 211, "Amount"], [228, 236, "Amount"], [243, 246, "Drug"], [257, 263, "Amount"], [275, 282, "Amount"], [291, 298, "Amount"]], "rel": [[28, 39, "Amount", 47, 50, "Drug", "Amount_Drug"], [64, 70, "Amount", 71, 74, "Drug", "Amount_Drug"], [103, 111, "Amount", 71, 74, "Drug", "Amount_Drug"], [128, 133, "Amount", 71, 74, "Drug", "Amount_Drug"], [135, 140, "Amount", 71, 74, "Drug", "Amount_Drug"], [144, 148, "ADE", 71, 74, "Drug", "ADE_Drug"], [203, 211, "Amount", 167, 170, "Drug", "Amount_Drug"], [228, 236, "Amount", 167, 170, "Drug", "Amount_Drug"], [182, 190, "Amount", 167, 170, "Drug", "Amount_Drug"], [257, 263, "Amount", 243, 246, "Drug", "Amount_Drug"], [275, 282, "Amount", 243, 246, "Drug", "Amount_Drug"], [291, 298, "Amount", 243, 246, "Drug", "Amount_Drug"]]}
{"idx": 930, "sentence": "2.二甲双胍使用时的剂量调整：剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000 mg/d，1~2周后加量至最大有效剂量2000 mg/d或最大耐受剂量。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案，建议起始500mg，2次/d，如无明显胃肠道不良反应，随后可逐步增加至1000mg，2次/d。二甲双胍的血浆半衰期为5.1h，但其同时分布于红细胞储藏室，使得全血消除半衰期达17.6h。二甲双胍1000mg，2次/d，可维持24h有效血药浓度。可根据患者状况个体化治疗，通常剂量1500~2000mg/d，分2~3次服用。注意老年人群及肝肾功能不全的患者需调整剂量，具体方法详见“二甲双胍在特殊人群的使用”。", "ner": [[2, 5, "Drug"], [40, 46, "Amount"], [48, 57, "Amount"], [73, 81, "Amount"], [90, 93, "Drug"], [111, 114, "Frequency"], [158, 162, "Amount"], [164, 167, "Frequency"], [173, 179, "ADE"], [189, 194, "Amount"], [196, 199, "Frequency"], [201, 204, "Drug"], [247, 250, "Drug"], [251, 256, "Amount"], [258, 261, "Frequency"], [293, 305, "Amount"], [307, 311, "Frequency"], [344, 347, "Drug"], [96, 105, "Method"], [116, 125, "Method"], [271, 274, "Pathogenesis"], [322, 327, "Disease"], [322, 322, "Anatomy"], [323, 323, "Anatomy"]], "rel": [[111, 114, "Frequency", 90, 93, "Drug", "Frequency_Drug"], [96, 105, "Method", 90, 93, "Drug", "Method_Drug"], [116, 125, "Method", 90, 93, "Drug", "Method_Drug"], [251, 256, "Amount", 247, 250, "Drug", "Amount_Drug"], [258, 261, "Frequency", 247, 250, "Drug", "Frequency_Drug"], [344, 347, "Drug", 322, 327, "Disease", "Drug_Disease"], [322, 322, "Anatomy", 322, 327, "Disease", "Anatomy_Disease"], [323, 323, "Anatomy", 322, 327, "Disease", "Anatomy_Disease"]]}
{"idx": 931, "sentence": "3.二甲双胍的剂型：目前，国内外主要有单一成分的二甲双胍普通片(250 mg/片、500 mg/片或850 mg/片)、二甲双胍缓释片或胶囊(500mg/片或500 mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250 mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药，如磺脲类药物或DPP-4抑制剂组成的复方制剂。", "ner": [[2, 5, "Drug"], [120, 125, "Drug"], [132, 133, "Method"], [139, 143, "Drug"], [145, 152, "Drug"], [90, 99, "Drug"], [60, 69, "Drug"], [24, 30, "Drug"]], "rel": []}
{"idx": 932, "sentence": "4.不同剂型二甲双胍疗效的区别：(1)各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放；肠溶片从胃排空到肠道后崩解释放；缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放；肠溶胶囊在肠道内溶出、释放。", "ner": [[6, 9, "Drug"]], "rel": []}
{"idx": 933, "sentence": "(2)普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之。", "ner": [], "rel": []}
{"idx": 934, "sentence": "因而每种制剂给药后血药浓度峰值、达峰时间、表观半衰期等参数存在一定的差异，多剂量给药后的达稳时间也不一致。", "ner": [[9, 12, "Pathogenesis"]], "rel": []}
{"idx": 935, "sentence": "(3)缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性。", "ner": [[33, 37, "ADE"]], "rel": []}
{"idx": 936, "sentence": "(4)合格的药物制剂，在相同的给药剂量下，各种剂型间应具有生物等效性。", "ner": [], "rel": []}
{"idx": 937, "sentence": "(5)不同剂型的临床疗效是否一致，尚需更多的临床研究证实。", "ner": [], "rel": []}
{"idx": 938, "sentence": "5.二甲双胍单药治疗的降糖疗效：一项随机、双盲、平行对照研究结果显示，在减去安慰剂效应后二甲双胍单药治疗29周可降低FPG3.2mmol/L、PPG4.0mmol/L、HbA1c1.8%(I级)。在中国人群开展的安慰剂对照的临床研究中，1000mg/d或1700mg/d二甲双胍单药治疗可使HbA1c分别降低0.7%和1.0%(去除安慰剂效应后)(I级)。一项前瞻性、随机对照研究显示，在新诊断的曾经接受短期胰岛素治疗后的T2DM患者中，以二甲双胍(2000mg/d)为基础的口服降糖药物组疗效与甘精胰岛素组的降糖疗效相当(I级)。在中国人群中的研究显示，2000mg/d二甲双胍的疗效与1000mg/d二甲双胍联合DPP-4抑制剂的疗效相当(I级)。一项前瞻性、随机对照研究显示，在新诊断的T2DM患者中，二甲双胍(1500mg/d)的降糖疗效和阿卡波糖(300mg/d)相当。", "ner": [[2, 5, "Drug"], [44, 47, "Drug"], [58, 60, "Test_items"], [71, 73, "Test_items"], [74, 82, "Test_Value"], [84, 88, "Test_items"], [89, 92, "Test_Value"], [58, 60, "Test_items"], [118, 125, "Amount"], [127, 134, "Amount"], [135, 138, "Drug"], [145, 149, "Test_items"], [152, 162, "Test_Value"], [204, 206, "Drug"], [211, 214, "Disease"], [220, 223, "Drug"], [225, 232, "Amount"], [238, 239, "Method"], [248, 252, "Drug"], [278, 285, "Amount"], [286, 289, "Drug"], [294, 301, "Amount"], [302, 305, "Drug"], [308, 315, "Drug"], [346, 349, "Disease"], [354, 357, "Drug"], [359, 366, "Amount"], [374, 377, "Drug"], [379, 385, "Amount"], [52, 54, "Duration"], [61, 69, "Test_Value"]], "rel": [[52, 54, "Duration", 44, 47, "Drug", "Duration_Drug"], [118, 125, "Amount", 135, 138, "Drug", "Amount_Drug"], [127, 134, "Amount", 135, 138, "Drug", "Amount_Drug"], [204, 206, "Drug", 211, 214, "Disease", "Drug_Disease"], [220, 223, "Drug", 211, 214, "Disease", "Drug_Disease"], [248, 252, "Drug", 211, 214, "Disease", "Drug_Disease"], [225, 232, "Amount", 220, 223, "Drug", "Amount_Drug"], [238, 239, "Method", 220, 223, "Drug", "Method_Drug"], [278, 285, "Amount", 286, 289, "Drug", "Amount_Drug"], [294, 301, "Amount", 302, 305, "Drug", "Amount_Drug"], [354, 357, "Drug", 346, 349, "Disease", "Drug_Disease"], [374, 377, "Drug", 346, 349, "Disease", "Drug_Disease"], [359, 366, "Amount", 354, 357, "Drug", "Amount_Drug"], [379, 385, "Amount", 374, 377, "Drug", "Amount_Drug"]]}
{"idx": 939, "sentence": "6.二甲双胍联合磺脲类药物的疗效：二甲双胍可改善IR，减少肝糖输出；磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c(I级)。磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时复合制剂治疗组FPG水平控制更好(I级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降低幅度(1.7%)高于二甲双胍联合阿卡波糖治疗组(0.9%)，且两组低血糖、体重增加比较，差异无统计学意义(I级)。另有随机、双盲、双模拟、平行对照研究显示，与相同剂量的格列本脲相比，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂降糖效果相当，但低血糖发生的风险减低(I级)。", "ner": [[2, 5, "Drug"], [8, 12, "Drug"], [17, 20, "Drug"], [34, 38, "Drug"], [69, 72, "Disease"], [24, 25, "Pathogenesis"], [100, 103, "Drug"], [106, 109, "Drug"], [116, 119, "Drug"], [123, 126, "Drug"], [134, 136, "Test_items"], [138, 142, "Test_items"], [148, 152, "Drug"], [153, 154, "Test_items"], [169, 181, "Drug"], [186, 187, "Test_items"], [192, 196, "Test_items"], [215, 218, "Drug"], [231, 234, "Drug"], [263, 265, "Test_items"], [280, 283, "Disease"], [304, 307, "Drug"], [310, 313, "Drug"], [318, 322, "Test_items"], [335, 338, "Drug"], [341, 344, "Drug"], [358, 360, "ADE"], [362, 365, "ADE"], [409, 412, "Drug"], [417, 420, "Drug"], [429, 432, "Drug"], [450, 452, "ADE"], [155, 158, "Test_Value"], [164, 166, "Duration"], [197, 201, "Test_Value"]], "rel": [[17, 20, "Drug", 69, 72, "Disease", "Drug_Disease"], [34, 38, "Drug", 69, 72, "Disease", "Drug_Disease"], [24, 25, "Pathogenesis", 69, 72, "Disease", "Pathogenesis_Disease"], [164, 166, "Duration", 148, 152, "Drug", "Duration_Drug"], [304, 307, "Drug", 280, 283, "Disease", "Drug_Disease"], [310, 313, "Drug", 280, 283, "Disease", "Drug_Disease"], [318, 322, "Test_items", 280, 283, "Disease", "Test_items_Disease"], [335, 338, "Drug", 280, 283, "Disease", "Drug_Disease"], [341, 344, "Drug", 280, 283, "Disease", "Drug_Disease"], [358, 360, "ADE", 304, 307, "Drug", "ADE_Drug"], [362, 365, "ADE", 304, 307, "Drug", "ADE_Drug"], [358, 360, "ADE", 310, 313, "Drug", "ADE_Drug"], [362, 365, "ADE", 310, 313, "Drug", "ADE_Drug"], [358, 360, "ADE", 335, 338, "Drug", "ADE_Drug"], [362, 365, "ADE", 335, 338, "Drug", "ADE_Drug"], [358, 360, "ADE", 341, 344, "Drug", "ADE_Drug"], [362, 365, "ADE", 341, 344, "Drug", "ADE_Drug"], [450, 452, "ADE", 409, 412, "Drug", "ADE_Drug"], [450, 452, "ADE", 417, 420, "Drug", "ADE_Drug"], [450, 452, "ADE", 429, 432, "Drug", "ADE_Drug"]]}
{"idx": 940, "sentence": "7.二甲双胍联合TZDs的疗效：二甲双胍联合TZDs能更好地降低HbA1c，显著改善胰岛功能和IR，但联合治疗药物的不良反应(体重增加、升高LDL-C)高于单用二甲双胍；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著。故IR严重的患者可考虑二甲双胍联合TZDs药物的治疗方案(I级)。", "ner": [[2, 5, "Drug"], [8, 11, "Drug"], [16, 19, "Drug"], [22, 25, "Drug"], [32, 36, "Test_items"], [47, 48, "Pathogenesis"], [63, 66, "ADE"], [68, 74, "ADE"], [80, 83, "Drug"], [85, 98, "Drug"], [102, 105, "Drug"], [115, 119, "Test_items"], [121, 123, "Test_items"], [129, 130, "Disease"], [139, 142, "Drug"], [145, 148, "Drug"], [131, 132, "Level"]], "rel": [[63, 66, "ADE", 16, 19, "Drug", "ADE_Drug"], [68, 74, "ADE", 16, 19, "Drug", "ADE_Drug"], [63, 66, "ADE", 22, 25, "Drug", "ADE_Drug"], [68, 74, "ADE", 22, 25, "Drug", "ADE_Drug"], [63, 66, "ADE", 80, 83, "Drug", "ADE_Drug"], [68, 74, "ADE", 80, 83, "Drug", "ADE_Drug"], [139, 142, "Drug", 129, 130, "Disease", "Drug_Disease"], [145, 148, "Drug", 129, 130, "Disease", "Drug_Disease"]]}
{"idx": 941, "sentence": "8.二甲双胍联合格列奈类药物的疗效：格列奈类药物属于餐时促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中，瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生风险却未增加。那格列奈联用二甲双胍与格列齐特联用二甲双胍的降糖强度相似，但低血糖发生的风险更小(I级)。故在二甲双胍联合磺脲类药物且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。", "ner": [[2, 5, "Drug"], [8, 13, "Drug"], [18, 23, "Drug"], [28, 34, "Drug"], [37, 40, "Drug"], [55, 56, "Test_items"], [62, 66, "Test_items"], [71, 75, "Test_Value"], [78, 81, "Disease"], [86, 89, "Drug"], [91, 94, "Drug"], [100, 103, "Drug"], [110, 114, "Test_items"], [117, 119, "ADE"], [129, 132, "Drug"], [135, 138, "Drug"], [140, 143, "Drug"], [146, 149, "Drug"], [159, 161, "ADE"], [176, 179, "Drug"], [182, 186, "Drug"], [188, 190, "ADE"], [204, 207, "Drug"], [210, 215, "Drug"], [59, 60, "Test_Value"]], "rel": [[55, 56, "Test_items", 78, 81, "Disease", "Test_items_Disease"], [62, 66, "Test_items", 78, 81, "Disease", "Test_items_Disease"], [86, 89, "Drug", 78, 81, "Disease", "Drug_Disease"], [91, 94, "Drug", 78, 81, "Disease", "Drug_Disease"], [100, 103, "Drug", 78, 81, "Disease", "Drug_Disease"], [117, 119, "ADE", 86, 89, "Drug", "ADE_Drug"], [117, 119, "ADE", 91, 94, "Drug", "ADE_Drug"], [117, 119, "ADE", 100, 103, "Drug", "ADE_Drug"], [159, 161, "ADE", 129, 132, "Drug", "ADE_Drug"], [159, 161, "ADE", 135, 138, "Drug", "ADE_Drug"], [159, 161, "ADE", 140, 143, "Drug", "ADE_Drug"], [159, 161, "ADE", 146, 149, "Drug", "ADE_Drug"], [188, 190, "ADE", 176, 179, "Drug", "ADE_Drug"], [188, 190, "ADE", 182, 186, "Drug", "ADE_Drug"]]}
{"idx": 942, "sentence": "在二甲双胍的基础上加用米格列奈，可进一步降低HbA1c、FPG和PPG，并提高达标率，而不良事件的发生率比较，差异无统计学意义。", "ner": [[1, 4, "Drug"], [11, 14, "Drug"], [22, 26, "Test_items"], [28, 30, "Test_items"], [32, 34, "Test_items"]], "rel": []}
{"idx": 943, "sentence": "9.二甲双胍联合α-糖苷酶抑制剂的疗效：二甲双胍与α-糖苷酶抑制剂联合，可兼顾FPG和PPG。超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好控制HbA1c、FPG和体重。", "ner": [[2, 5, "Drug"], [8, 15, "Drug"], [20, 23, "Drug"], [25, 32, "Drug"], [39, 41, "Test_items"], [43, 45, "Test_items"], [47, 48, "Disease"], [50, 53, "Disease"], [57, 60, "Drug"], [69, 72, "Drug"], [78, 82, "Test_items"], [84, 86, "Test_items"]], "rel": [[57, 60, "Drug", 47, 48, "Disease", "Drug_Disease"], [69, 72, "Drug", 47, 48, "Disease", "Drug_Disease"], [78, 82, "Test_items", 47, 48, "Disease", "Test_items_Disease"], [84, 86, "Test_items", 47, 48, "Disease", "Test_items_Disease"], [57, 60, "Drug", 50, 53, "Disease", "Drug_Disease"], [69, 72, "Drug", 50, 53, "Disease", "Drug_Disease"], [78, 82, "Test_items", 50, 53, "Disease", "Test_items_Disease"], [84, 86, "Test_items", 50, 53, "Disease", "Test_items_Disease"]]}
{"idx": 944, "sentence": "二甲双胍和磺脲类联用的降糖疗效优于二甲双胍和阿卡波糖联用(Ⅰ级)。", "ner": [[0, 3, "Drug"], [5, 7, "Drug"], [17, 20, "Drug"], [22, 25, "Drug"]], "rel": []}
{"idx": 945, "sentence": "这两种药物都有一定的胃肠道不良反应，联合应用有可能增加胃肠不适。", "ner": [[10, 16, "ADE"], [27, 30, "ADE"]], "rel": []}
{"idx": 946, "sentence": "10.二甲双胍联合DPP-4抑制剂的疗效：二甲双胍与DPP-4抑制剂的联合治疗，可针对T2DM不同的病理生理缺陷，发挥机制互补、协同增效的降糖作用。一项随机、双盲、对照研究显示，二甲双胍单药控制不佳的T2DM患者加用DPP-4抑制剂可有效改善血糖水平，且耐受性良好(I级)。中国多中心、前瞻性、随机、对照研究显示，1000mg二甲双胍联合维格列汀与二甲双胍2000mg单药疗效和安全性相当；在新诊断T2DM患者中，1700mg/d二甲双胍单药治疗的降糖疗效非劣于1700mg二甲双胍联合西格列汀治疗(Ⅰ级)。建议遵循《中国2型糖尿病防治指南》的治疗原则，新诊断T2DM患者首选二甲双胍，可耐受的情况下加至最佳有效剂量(2000mg/d)；不达标的患者，可以联合DPP-4抑制剂。", "ner": [[3, 6, "Drug"], [9, 16, "Drug"], [21, 24, "Drug"], [26, 33, "Drug"], [43, 46, "Disease"], [89, 92, "Drug"], [100, 103, "Disease"], [108, 115, "Drug"], [121, 122, "Test_items"], [157, 162, "Amount"], [163, 166, "Drug"], [169, 172, "Drug"], [174, 177, "Drug"], [178, 183, "Amount"], [199, 202, "Disease"], [207, 214, "Amount"], [215, 218, "Drug"], [231, 236, "Amount"], [237, 240, "Drug"], [243, 246, "Drug"], [261, 265, "Disease"], [280, 283, "Disease"], [288, 291, "Drug"], [309, 316, "Amount"], [330, 337, "Drug"]], "rel": [[21, 24, "Drug", 43, 46, "Disease", "Drug_Disease"], [26, 33, "Drug", 43, 46, "Disease", "Drug_Disease"], [89, 92, "Drug", 100, 103, "Disease", "Drug_Disease"], [108, 115, "Drug", 100, 103, "Disease", "Drug_Disease"], [121, 122, "Test_items", 100, 103, "Disease", "Test_items_Disease"], [157, 162, "Amount", 163, 166, "Drug", "Amount_Drug"], [178, 183, "Amount", 174, 177, "Drug", "Amount_Drug"], [215, 218, "Drug", 199, 202, "Disease", "Drug_Disease"], [237, 240, "Drug", 199, 202, "Disease", "Drug_Disease"], [243, 246, "Drug", 199, 202, "Disease", "Drug_Disease"], [207, 214, "Amount", 215, 218, "Drug", "Amount_Drug"], [231, 236, "Amount", 237, 240, "Drug", "Amount_Drug"], [288, 291, "Drug", 280, 283, "Disease", "Drug_Disease"], [330, 337, "Drug", 280, 283, "Disease", "Drug_Disease"], [309, 316, "Amount", 288, 291, "Drug", "Amount_Drug"]]}
{"idx": 947, "sentence": "11.二甲双胍联合GLP-1受体激动剂的疗效：目前，中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG和HbA1c，提高血糖达标率，改善胰岛β细胞功能，改善IR，降低体重和SBP，且不增加严重低血糖发生的风险(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍降糖疗效相当，前者使体重和血压降低，低血糖发生风险减少。", "ner": [[3, 6, "Drug"], [9, 18, "Drug"], [33, 42, "Drug"], [47, 50, "Drug"], [52, 55, "Drug"], [58, 61, "Drug"], [69, 78, "Drug"], [86, 88, "Test_items"], [90, 94, "Test_items"], [98, 99, "Test_items"], [116, 117, "Pathogenesis"], [124, 126, "Test"], [150, 153, "Disease"], [173, 176, "Drug"], [179, 182, "Drug"], [184, 187, "Drug"], [190, 193, "Drug"], [212, 214, "ADE"], [132, 136, "ADE"], [207, 208, "Test"], [209, 210, "Test_Value"]], "rel": [[132, 136, "ADE", 58, 61, "Drug", "ADE_Drug"], [132, 136, "ADE", 69, 78, "Drug", "ADE_Drug"], [173, 176, "Drug", 150, 153, "Disease", "Drug_Disease"], [179, 182, "Drug", 150, 153, "Disease", "Drug_Disease"], [184, 187, "Drug", 150, 153, "Disease", "Drug_Disease"], [190, 193, "Drug", 150, 153, "Disease", "Drug_Disease"], [207, 208, "Test", 150, 153, "Disease", "Test_Disease"], [212, 214, "ADE", 173, 176, "Drug", "ADE_Drug"], [212, 214, "ADE", 179, 182, "Drug", "ADE_Drug"], [212, 214, "ADE", 184, 187, "Drug", "ADE_Drug"], [212, 214, "ADE", 190, 193, "Drug", "ADE_Drug"]]}
{"idx": 948, "sentence": "患者对利拉鲁肽联合二甲双胍治疗所导致的不良反应的耐受性更差。", "ner": [[3, 6, "Drug"], [9, 12, "Drug"]], "rel": []}
{"idx": 949, "sentence": "12.二甲双胍联合胰岛素的疗效：二甲双胍可以增强肝脏和肌肉组织的IS，口服降糖药联合治疗血糖控制不佳的T2DM患者启动胰岛素治疗后应保留二甲双胍。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险，联合使用还可能与心血管疾病和肿瘤风险下降相关(I级)。HOME研究是一项前瞻性、随机、双盲、安慰剂对照研究，该研究对接受胰岛素治疗的T2DM患者随访4.3年。结果显示，较单纯胰岛素治疗，二甲双胍联合胰岛素治疗能提高降糖疗效，降低胰岛素用量(胰岛素日剂量平均减少19.63U)，且体重增加更少。对该研究的次级终点的分析显示，二甲双胍的治疗与大血管事件相对风险降低40%相关(I级)。一项随机、对照研究纳入96例磺脲类继发性失效的T2DM患者，治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组均有所增加；且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大、每日胰岛素用量最少、低血糖的发生率最低。", "ner": [[3, 6, "Drug"], [9, 11, "Drug"], [16, 19, "Drug"], [44, 45, "Test_items"], [51, 54, "Disease"], [59, 61, "Drug"], [68, 71, "Drug"], [35, 36, "Method"], [74, 76, "Drug"], [84, 87, "Drug"], [90, 92, "Drug"], [99, 103, "Test_items"], [107, 109, "Drug"], [113, 116, "ADE"], [118, 120, "ADE"], [132, 136, "Disease"], [132, 134, "Anatomy"], [190, 193, "Disease"], [184, 186, "Drug"], [211, 213, "Drug"], [217, 220, "Drug"], [223, 225, "Drug"], [238, 240, "Drug"], [244, 246, "Drug"], [254, 259, "Amount"], [263, 266, "ADE"], [285, 288, "Drug"], [293, 297, "Disease"], [293, 295, "Anatomy"], [328, 330, "Drug"], [337, 340, "Disease"], [352, 354, "Drug"], [356, 359, "Drug"], [389, 391, "Drug"], [393, 396, "Drug"], [398, 402, "Test_items"], [410, 412, "Drug"], [418, 420, "ADE"], [46, 49, "Test_Value"], [198, 201, "Duration"]], "rel": [[44, 45, "Test_items", 51, 54, "Disease", "Test_items_Disease"], [59, 61, "Drug", 51, 54, "Disease", "Drug_Disease"], [68, 71, "Drug", 51, 54, "Disease", "Drug_Disease"], [113, 116, "ADE", 84, 87, "Drug", "ADE_Drug"], [118, 120, "ADE", 84, 87, "Drug", "ADE_Drug"], [113, 116, "ADE", 90, 92, "Drug", "ADE_Drug"], [118, 120, "ADE", 90, 92, "Drug", "ADE_Drug"], [113, 116, "ADE", 107, 109, "Drug", "ADE_Drug"], [118, 120, "ADE", 107, 109, "Drug", "ADE_Drug"], [132, 134, "Anatomy", 132, 136, "Disease", "Anatomy_Disease"], [184, 186, "Drug", 190, 193, "Disease", "Drug_Disease"], [198, 201, "Duration", 184, 186, "Drug", "Duration_Drug"], [263, 266, "ADE", 211, 213, "Drug", "ADE_Drug"], [263, 266, "ADE", 217, 220, "Drug", "ADE_Drug"], [263, 266, "ADE", 223, 225, "Drug", "ADE_Drug"], [254, 259, "Amount", 244, 246, "Drug", "Amount_Drug"], [293, 295, "Anatomy", 293, 297, "Disease", "Anatomy_Disease"], [352, 354, "Drug", 337, 340, "Disease", "Drug_Disease"], [356, 359, "Drug", 337, 340, "Disease", "Drug_Disease"], [398, 402, "Test_items", 337, 340, "Disease", "Test_items_Disease"], [418, 420, "ADE", 389, 391, "Drug", "ADE_Drug"], [418, 420, "ADE", 393, 396, "Drug", "ADE_Drug"]]}
{"idx": 950, "sentence": "一项回顾性队列研究采用倾向匹配法分组分析发现，与胰岛素单药治疗组相比，二甲双胍联合胰素治疗组的死亡率降低。", "ner": [[24, 26, "Drug"], [35, 38, "Drug"], [41, 42, "Drug"]], "rel": []}
{"idx": 951, "sentence": "13.新诊断T2DM患者胰岛素短期强化治疗的后续治疗：对于有明显高血糖临床症状的新诊断T2DM患者可实施短期胰岛素治疗。在高血糖得到控制和症状缓解后可根据病情调整治疗方案，如改用口服降糖药物或医学营养和运动治疗。一项中国的研究将经短期胰岛素强化治疗后的T2DM患者随机分为甘精胰岛素治疗组和以二甲双胍为基础的口服降糖药治疗组，治疗24周的结果显示，两组降糖疗效相当，且以二甲双胍为基础的口服降糖药治疗方案简单易行、依从性好，较好地控制体重，成本-效益比更佳。因此，建议接受胰岛素短期治疗的新诊断T2DM患者可在高血糖症状得到改善后可考虑改成以二甲双胍为起始的口服降糖药物治疗方案。", "ner": [[6, 9, "Disease"], [12, 14, "Drug"], [32, 34, "Disease"], [43, 46, "Disease"], [54, 56, "Drug"], [61, 63, "Disease"], [89, 90, "Method"], [96, 99, "Treatment"], [101, 104, "Treatment"], [117, 119, "Drug"], [126, 129, "Disease"], [136, 140, "Drug"], [146, 149, "Drug"], [154, 155, "Method"], [185, 188, "Drug"], [193, 194, "Method"], [236, 238, "Drug"], [247, 250, "Disease"], [255, 257, "Disease"], [271, 274, "Drug"], [279, 280, "Method"], [30, 31, "Level"]], "rel": [[12, 14, "Drug", 6, 9, "Disease", "Drug_Disease"], [54, 56, "Drug", 43, 46, "Disease", "Drug_Disease"], [117, 119, "Drug", 126, 129, "Disease", "Drug_Disease"], [136, 140, "Drug", 126, 129, "Disease", "Drug_Disease"], [146, 149, "Drug", 126, 129, "Disease", "Drug_Disease"], [154, 155, "Method", 146, 149, "Drug", "Method_Drug"], [193, 194, "Method", 185, 188, "Drug", "Method_Drug"], [236, 238, "Drug", 247, 250, "Disease", "Drug_Disease"], [271, 274, "Drug", 247, 250, "Disease", "Drug_Disease"], [279, 280, "Method", 271, 274, "Drug", "Method_Drug"]]}
{"idx": 952, "sentence": "14.二甲双胍是否应尽早足量使用以维持更长的达标时间：500~2000mg/d剂量，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本-效益比。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下(Ⅰ级)。", "ner": [[3, 6, "Drug"], [27, 38, "Amount"], [42, 45, "Drug"], [67, 70, "Drug"], [98, 101, "Disease"], [106, 109, "Drug"], [111, 118, "Amount"], [136, 140, "Test_items"], [143, 149, "Test_Value"]], "rel": [[27, 38, "Amount", 42, 45, "Drug", "Amount_Drug"], [106, 109, "Drug", 98, 101, "Disease", "Drug_Disease"], [136, 140, "Test_items", 98, 101, "Disease", "Test_items_Disease"], [111, 118, "Amount", 106, 109, "Drug", "Amount_Drug"]]}
{"idx": 953, "sentence": "在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周(I级)。", "ner": [[19, 22, "Drug"], [24, 30, "Amount"], [39, 42, "Drug"], [44, 51, "Amount"], [63, 67, "Test_items"], [70, 76, "Test_items"]], "rel": [[24, 30, "Amount", 19, 22, "Drug", "Amount_Drug"], [44, 51, "Amount", 39, 42, "Drug", "Amount_Drug"]]}
{"idx": 954, "sentence": "因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可使血糖控制尽早达标，且可使血糖得到更长时间的良好控制。", "ner": [[24, 31, "Amount"], [34, 37, "Drug"], [44, 45, "Test_items"], [56, 57, "Test_items"]], "rel": [[24, 31, "Amount", 34, 37, "Drug", "Amount_Drug"]]}
{"idx": 955, "sentence": "如果出现可以耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换为其他降糖药。", "ner": [], "rel": []}
{"idx": 956, "sentence": "15.二甲双胍可否用于胰岛素治疗的T1DM患者：T1DM患者可在胰岛素治疗基础上加用二甲双胍，尤其适用于胰岛素剂量较大、体重增加明显的患者；但DKA、糖尿病高血糖高渗综合征(HHS)、糖尿病乳酸酸中毒患者禁用。临床研究发现，二甲双胍不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C水平。对于单用胰岛素治疗血糖控制不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。荟萃分析结果显示，二甲双胍能降低T1DM患者的日常胰岛素剂量、体重及血脂水平，且不增加低血糖及DKA的发生风险。", "ner": [[3, 6, "Drug"], [11, 13, "Drug"], [17, 20, "Disease"], [24, 27, "Disease"], [32, 34, "Drug"], [42, 45, "Drug"], [52, 54, "Drug"], [71, 73, "Disease"], [92, 99, "Disease"], [112, 115, "Drug"], [121, 123, "Drug"], [142, 143, "Test_items"], [151, 155, "Test_items"], [163, 165, "Drug"], [168, 169, "Test_items"], [134, 137, "Test"], [182, 185, "Drug"], [190, 192, "Drug"], [203, 205, "Drug"], [210, 215, "ADE"], [226, 229, "Drug"], [233, 236, "Disease"], [242, 244, "Drug"], [251, 254, "Test"], [260, 262, "Disease"], [264, 266, "Disease"], [60, 65, "ADE"], [75, 90, "Disease"], [170, 173, "Test_Value"]], "rel": [[11, 13, "Drug", 17, 20, "Disease", "Drug_Disease"], [32, 34, "Drug", 24, 27, "Disease", "Drug_Disease"], [42, 45, "Drug", 24, 27, "Disease", "Drug_Disease"], [60, 65, "ADE", 52, 54, "Drug", "ADE_Drug"], [210, 215, "ADE", 203, 205, "Drug", "ADE_Drug"], [226, 229, "Drug", 233, 236, "Disease", "Drug_Disease"], [242, 244, "Drug", 233, 236, "Disease", "Drug_Disease"], [251, 254, "Test", 233, 236, "Disease", "Test_Disease"]]}
{"idx": 957, "sentence": "16.二甲双胍的减重效果：二甲双胍具有减轻体重的作用，其减轻体重的机制可能包括抑制食欲，减少热量摄入；改善高胰岛素血症，降低基础胰岛和负荷后胰岛素水平；增加瘦素敏感性。一项前瞻性、开放标签研究表明，新诊断T2DM患者经二甲双胍单药治疗16周，正常(BMI 18.5~23.9kg/m2)、超重(BMI 24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81、2.92kg，患者不同基线BMI水平不会造成二甲双胍单药对血糖控制的差异(Ⅰ级)。在中国T2DM人群中开展的另外一项研究结果提示，接受二甲双胍(最大剂量1500mg/d)治疗48周后，体重降低1.88kg(可能包含部分安慰剂效应)。磺脲类、格列酮类和胰岛素治疗伴有体重增加，联用二甲双胍可减轻上述药物对体重增加的影响；HOME研究显示，与单用胰岛素组相比，二甲双胍联合胰岛素治疗组体重少增加2.28~3.85kg(I级)。由于不同研究的入组人群及试验方法存在一定的差异，其结果可能有所不同。荟萃分析显示，体重降幅最大的常用口服降糖药为二甲双胍，可使体重降低1.1kg。", "ner": [[3, 6, "Drug"], [13, 16, "Drug"], [53, 58, "Disease"], [102, 105, "Disease"], [109, 112, "Drug"], [144, 145, "Disease"], [167, 168, "Disease"], [238, 241, "Drug"], [245, 246, "Test_items"], [260, 263, "Disease"], [283, 286, "Drug"], [292, 299, "Amount"], [332, 334, "Drug"], [336, 339, "Drug"], [341, 343, "Drug"], [355, 358, "Drug"], [367, 370, "ADE"], [387, 389, "Drug"], [394, 397, "Drug"], [400, 402, "Drug"], [477, 478, "Method"], [483, 486, "Drug"], [348, 351, "ADE"]], "rel": [[13, 16, "Drug", 53, 58, "Disease", "Drug_Disease"], [109, 112, "Drug", 102, 105, "Disease", "Drug_Disease"], [283, 286, "Drug", 260, 263, "Disease", "Drug_Disease"], [292, 299, "Amount", 283, 286, "Drug", "Amount_Drug"], [348, 351, "ADE", 332, 334, "Drug", "ADE_Drug"], [348, 351, "ADE", 336, 339, "Drug", "ADE_Drug"], [348, 351, "ADE", 341, 343, "Drug", "ADE_Drug"], [477, 478, "Method", 483, 486, "Drug", "Method_Drug"]]}
{"idx": 958, "sentence": "四、特殊人群用药", "ner": [], "rel": []}
{"idx": 959, "sentence": "1.心力衰竭是否是二甲双胍的绝对禁忌证：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证。但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。而且多项研究显示，二甲双胍的治疗可能与糖尿病患者心力衰竭和死亡发生风险的减少有关，可能与伴心力衰竭的糖尿病患者的存活率提高相关。", "ner": [[2, 5, "Disease"], [9, 12, "Drug"], [40, 43, "Disease"], [2, 2, "Anatomy"], [30, 30, "Anatomy"], [60, 63, "Drug"], [70, 73, "Disease"], [70, 70, "Anatomy"], [79, 82, "Disease"], [79, 79, "Anatomy"], [101, 104, "Drug"], [111, 113, "Disease"], [116, 119, "Disease"], [116, 116, "Anatomy"], [137, 140, "Disease"], [137, 137, "Anatomy"], [142, 144, "Disease"], [27, 38, "Disease"]], "rel": [[2, 2, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [30, 30, "Anatomy", 27, 38, "Disease", "Anatomy_Disease"], [70, 70, "Anatomy", 70, 73, "Disease", "Anatomy_Disease"], [79, 79, "Anatomy", 79, 82, "Disease", "Anatomy_Disease"], [101, 104, "Drug", 111, 113, "Disease", "Drug_Disease"], [116, 116, "Anatomy", 116, 119, "Disease", "Anatomy_Disease"], [137, 137, "Anatomy", 137, 140, "Disease", "Anatomy_Disease"]]}
{"idx": 960, "sentence": "2016年，ADA糖尿病指南指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者。", "ner": [[9, 11, "Disease"], [25, 28, "Drug"], [37, 39, "Disease"]], "rel": [[25, 28, "Drug", 37, 39, "Disease", "Drug_Disease"]]}
{"idx": 961, "sentence": "欧洲版二甲双胍说明书中已删除慢性心力衰竭的禁忌证。", "ner": [[3, 6, "Drug"], [14, 19, "Disease"], [16, 16, "Anatomy"]], "rel": [[3, 6, "Drug", 14, 19, "Disease", "Drug_Disease"], [16, 16, "Anatomy", 14, 19, "Disease", "Anatomy_Disease"]]}
{"idx": 962, "sentence": "2.针对65岁以上老年患者如何使用二甲双胍：((2013年IDF老年糖尿病指南》和《中国老糖尿病诊疗措施专家共识》都推荐二甲双胍为一线首选用药，并没有限制二甲双胍的具体使用年龄。老年糖尿病患者合理应用二甲双胍可以达到良好的降糖效果，且较少的低血糖风险对老年患者也有一定益处，但需要定期监测肾功能(3~6个月检查1次)。80岁以上患者[eGFR<45ml/(min·1.73m2)除外]如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍然可取得良好效果。因此，年龄并非二甲双胍治疗的禁忌，但需要定期监测肾功能。老年患者的eGFR 45~59ml/(min·1.73m2)者，应该减少剂量；如eGFR<45ml/(min·1.73m2)，则不能使用。适合我国CKD患者的eGFR评估公式为：eGFR=175XScr-1.234(mg/dl)×年龄-0.179(女性X0.79)。", "ner": [[17, 20, "Drug"], [34, 36, "Disease"], [45, 47, "Disease"], [60, 63, "Drug"], [77, 80, "Drug"], [91, 93, "Disease"], [100, 103, "Drug"], [120, 122, "ADE"], [167, 170, "Test_items"], [171, 187, "Test_Value"], [218, 221, "Drug"], [239, 242, "Drug"], [256, 256, "Test_items"], [256, 258, "Test"], [144, 146, "Test"], [265, 268, "Test_items"], [270, 288, "Test_Value"], [300, 303, "Test_items"], [304, 320, "Test_Value"], [333, 335, "Disease"], [339, 342, "Test_items"], [349, 352, "Test_items"]], "rel": [[60, 63, "Drug", 34, 36, "Disease", "Drug_Disease"], [60, 63, "Drug", 45, 47, "Disease", "Drug_Disease"], [100, 103, "Drug", 91, 93, "Disease", "Drug_Disease"], [144, 146, "Test", 91, 93, "Disease", "Test_Disease"], [120, 122, "ADE", 100, 103, "Drug", "ADE_Drug"], [339, 342, "Test_items", 333, 335, "Disease", "Test_items_Disease"]]}
{"idx": 963, "sentence": "3.二甲双胍可否用于儿童和青少年糖尿病患者：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，糖尿病得到诊断后可给予生活方式干预，不达标者以二甲双胍为起始治疗药物。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的患儿。", "ner": [[2, 5, "Drug"], [25, 27, "Drug"], [41, 44, "Disease"], [48, 50, "Disease"], [59, 64, "Treatment"], [71, 74, "Drug"], [83, 86, "Drug"], [97, 100, "Disease"], [117, 124, "Amount"], [16, 18, "Disease"]], "rel": [[25, 27, "Drug", 41, 44, "Disease", "Drug_Disease"], [59, 64, "Treatment", 48, 50, "Disease", "Treatment_Disease"], [71, 74, "Drug", 48, 50, "Disease", "Drug_Disease"], [83, 86, "Drug", 97, 100, "Disease", "Drug_Disease"], [117, 124, "Amount", 83, 86, "Drug", "Amount_Drug"]]}
{"idx": 964, "sentence": "4.GDM患者能否使用二甲双胍：虽然国际多个学术组织推荐二甲双胍可用于GDM患者，但基于目前国内证据缺乏，暂不推荐(V级)。二甲双胍在FDA妊娠期用药分级中为B类药物。2013年，《糖尿病和妊娠：美国内分泌学会临床实践指南》建议，在妊娠前3个月内医学营养治疗血糖控制不佳，以及拒绝和不适合使用胰岛素和格列本脲的GDM患者可使用二甲双胍治疗。2015年，NICE《妊娠糖尿病及其并发症的管理指南》建议，饮食和运动1~2周血糖未达标的GDM患者，可使用二甲双胍治疗。但我国药监部门尚未批准二甲双胍用于妊娠妇女。对于有糖尿病病史的产妇，二甲双胍干预可以有效减缓10年随访期中糖尿病的发展。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率，在控制孕妇体重和治疗IR方面有优势。在有效控制血糖的前提下，二甲双胍较胰岛素更有益于产妇健康。一项前瞻性随机对照临床试验结果显示，二甲双胍或二甲双胍联用胰岛素治疗GDM在体重、先兆子痫、新生儿死亡率等方面优于胰岛素单药治疗。", "ner": [[2, 4, "Disease"], [11, 14, "Drug"], [28, 31, "Drug"], [35, 37, "Disease"], [62, 65, "Drug"], [91, 93, "Disease"], [129, 130, "Test_items"], [146, 148, "Drug"], [150, 153, "Drug"], [155, 157, "Disease"], [163, 166, "Drug"], [181, 185, "Disease"], [200, 201, "Treatment"], [203, 204, "Treatment"], [209, 210, "Test_items"], [215, 217, "Disease"], [224, 227, "Drug"], [242, 245, "Drug"], [256, 258, "Disease"], [265, 268, "Drug"], [284, 286, "Disease"], [291, 294, "Drug"], [298, 301, "Disease"], [313, 315, "Disease"], [331, 332, "Pathogenesis"], [344, 345, "Test_items"], [351, 354, "Drug"], [356, 358, "Drug"], [386, 389, "Drug"], [391, 394, "Drug"], [397, 399, "Drug"], [402, 404, "Disease"], [409, 412, "Disease"], [425, 427, "Drug"], [131, 134, "Test_Value"], [211, 213, "Test_Value"]], "rel": [[28, 31, "Drug", 35, 37, "Disease", "Drug_Disease"], [163, 166, "Drug", 155, 157, "Disease", "Drug_Disease"], [200, 201, "Treatment", 215, 217, "Disease", "Treatment_Disease"], [203, 204, "Treatment", 215, 217, "Disease", "Treatment_Disease"], [209, 210, "Test_items", 215, 217, "Disease", "Test_items_Disease"], [224, 227, "Drug", 215, 217, "Disease", "Drug_Disease"], [265, 268, "Drug", 284, 286, "Disease", "Drug_Disease"], [291, 294, "Drug", 298, 301, "Disease", "Drug_Disease"], [291, 294, "Drug", 313, 315, "Disease", "Drug_Disease"], [331, 332, "Pathogenesis", 298, 301, "Disease", "Pathogenesis_Disease"], [331, 332, "Pathogenesis", 313, 315, "Disease", "Pathogenesis_Disease"], [386, 389, "Drug", 402, 404, "Disease", "Drug_Disease"], [391, 394, "Drug", 402, 404, "Disease", "Drug_Disease"], [397, 399, "Drug", 402, 404, "Disease", "Drug_Disease"]]}
{"idx": 965, "sentence": "5.肝功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍不经过肝脏代谢，无肝脏毒性。目前，肝功能不全患者使用二甲双胍的临床资料较少。肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者应避免使用二甲双胍。", "ner": [[2, 6, "Disease"], [2, 2, "Anatomy"], [8, 11, "Disease"], [16, 19, "Drug"], [27, 30, "Drug"], [48, 52, "Disease"], [48, 48, "Anatomy"], [57, 60, "Drug"], [69, 75, "Disease"], [69, 69, "Anatomy"], [72, 73, "Level"], [91, 95, "Test_items"], [106, 112, "Disease"], [106, 107, "Level"], [108, 108, "Anatomy"], [121, 124, "Drug"], [96, 103, "Test_Value"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [16, 19, "Drug", 2, 6, "Disease", "Drug_Disease"], [16, 19, "Drug", 8, 11, "Disease", "Drug_Disease"], [69, 69, "Anatomy", 69, 75, "Disease", "Anatomy_Disease"], [91, 95, "Test_items", 69, 75, "Disease", "Test_items_Disease"], [108, 108, "Anatomy", 106, 112, "Disease", "Anatomy_Disease"]]}
{"idx": 966, "sentence": "血清转氨酶轻度升高的患者使用时应密切监测肝功能。", "ner": [[0, 4, "Test_items"], [5, 8, "Test_Value"], [20, 22, "Test"]], "rel": []}
{"idx": 967, "sentence": "6.肾功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。建议根据患者eGFR水平调整二甲双胍剂量。eGFR≥60ml/(min·1.73m2)无需调整剂量，eGFR 45~59ml/(min·1.73m2)减量，eGFR<45ml/(min·1.73m2)禁用(V级)。2015年，ADA/EASD立场声明，建议放宽二甲双胍用于中度肾功能不全T2DM患者的限制，仅在eGFR<30ml/(min·1.73m2)患者中禁用。2016年，ADA糖尿病指南指出，已有累积观察性数据显示，二甲双胍用于eGFR在30~45ml/(min·1.73m2)的患者依然安全。", "ner": [[2, 6, "Disease"], [8, 11, "Disease"], [16, 19, "Drug"], [27, 30, "Drug"], [51, 53, "Disease"], [57, 60, "Drug"], [2, 2, "Anatomy"], [73, 76, "Test_items"], [81, 84, "Drug"], [88, 91, "Test_items"], [92, 108, "Test_Value"], [117, 120, "Test_items"], [122, 140, "Test_Value"], [145, 148, "Test_items"], [149, 165, "Test_Value"], [197, 200, "Drug"], [203, 209, "Disease"], [203, 204, "Level"], [205, 205, "Anatomy"], [210, 213, "Disease"], [222, 225, "Test_items"], [226, 242, "Test_Value"], [259, 261, "Disease"], [279, 282, "Drug"], [285, 288, "Test_items"], [290, 308, "Test_Value"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [16, 19, "Drug", 2, 6, "Disease", "Drug_Disease"], [16, 19, "Drug", 8, 11, "Disease", "Drug_Disease"], [197, 200, "Drug", 203, 209, "Disease", "Drug_Disease"], [197, 200, "Drug", 210, 213, "Disease", "Drug_Disease"], [205, 205, "Anatomy", 203, 209, "Disease", "Anatomy_Disease"], [222, 225, "Test_items", 203, 209, "Disease", "Test_items_Disease"], [222, 225, "Test_items", 210, 213, "Disease", "Test_items_Disease"], [279, 282, "Drug", 259, 261, "Disease", "Drug_Disease"], [285, 288, "Test_items", 259, 261, "Disease", "Test_items_Disease"]]}
{"idx": 968, "sentence": "同时建议，如果二甲双胍用于这个eGFR范围内的患者，应减少药物剂量并停止使用治疗恶心、呕吐及脱水的药物。", "ner": [[7, 10, "Drug"], [15, 18, "Test_items"], [40, 41, "Symptom"], [43, 44, "Symptom"], [46, 47, "Symptom"]], "rel": []}
{"idx": 969, "sentence": "7.患者造影或全身麻醉术前停用二甲双胍的时间，以及再行启用的时间：肾功能正常的糖尿病患者，造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用造影剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。", "ner": [[4, 5, "Test"], [7, 11, "Operation"], [15, 18, "Drug"], [33, 35, "Test"], [39, 41, "Disease"], [45, 46, "Test"], [52, 55, "Drug"], [83, 85, "Test"], [98, 102, "Disease"], [98, 98, "Anatomy"], [60, 62, "Drug"], [109, 111, "Drug"], [113, 117, "Operation"], [128, 131, "Drug"], [148, 150, "Test"], [36, 37, "Test_Value"], [86, 87, "Test_Value"], [153, 154, "Test_Value"]], "rel": [[33, 35, "Test", 39, 41, "Disease", "Test_Disease"], [45, 46, "Test", 39, 41, "Disease", "Test_Disease"], [52, 55, "Drug", 39, 41, "Disease", "Drug_Disease"], [60, 62, "Drug", 39, 41, "Disease", "Drug_Disease"], [83, 85, "Test", 39, 41, "Disease", "Test_Disease"], [98, 98, "Anatomy", 98, 102, "Disease", "Anatomy_Disease"], [148, 150, "Test", 98, 102, "Disease", "Test_Disease"], [109, 111, "Drug", 98, 102, "Disease", "Drug_Disease"], [113, 117, "Operation", 98, 102, "Disease", "Operation_Disease"]]}
{"idx": 970, "sentence": "五、安全性", "ner": [], "rel": []}
{"idx": 971, "sentence": "1.二甲双胍的禁忌证：(1)中度(3b级)和严重肾衰竭或肾功能不全[Cr<45ml/min或eGFR<45ml/(min·1.73m2)]；(2)可造成组织缺氧的疾病(尤其是急性疾病或慢性疾病的恶化)，如失代偿性心力衰竭、呼吸衰竭、近期发作的心肌梗死、休克；(3)严重感染和外伤、外科大手术、临床有低血压等；(4)已知对盐酸二甲双胍过敏者；(5)急性或慢性代谢性酸中毒，包括有或无昏迷的DKA(DKA需要用胰岛素治疗)；(6)酗酒者；(7)接受血管内注射碘化造影剂者，可以暂时停用本品；(8)维生素B12、叶酸缺乏未纠正者。", "ner": [[2, 5, "Drug"], [14, 26, "Disease"], [24, 24, "Anatomy"], [28, 32, "Disease"], [28, 28, "Anatomy"], [34, 35, "Test_items"], [36, 44, "Test_Value"], [46, 49, "Test_items"], [50, 66, "Test_Value"], [102, 109, "Disease"], [106, 106, "Anatomy"], [111, 114, "Disease"], [121, 124, "Disease"], [126, 127, "Disease"], [132, 135, "Disease"], [132, 133, "Level"], [137, 138, "Disease"], [149, 151, "Disease"], [160, 165, "Drug"], [173, 183, "Disease"], [197, 199, "Disease"], [203, 205, "Drug"], [227, 231, "Drug"], [121, 122, "Anatomy"], [166, 167, "ADE"], [190, 191, "Symptom"], [193, 195, "Disease"], [222, 226, "Method"], [246, 256, "Disease"]], "rel": [[24, 24, "Anatomy", 14, 26, "Disease", "Anatomy_Disease"], [28, 28, "Anatomy", 28, 32, "Disease", "Anatomy_Disease"], [34, 35, "Test_items", 28, 32, "Disease", "Test_items_Disease"], [46, 49, "Test_items", 28, 32, "Disease", "Test_items_Disease"], [106, 106, "Anatomy", 102, 109, "Disease", "Anatomy_Disease"], [121, 122, "Anatomy", 121, 124, "Disease", "Anatomy_Disease"], [166, 167, "ADE", 160, 165, "Drug", "ADE_Drug"], [203, 205, "Drug", 197, 199, "Disease", "Drug_Disease"], [222, 226, "Method", 227, 231, "Drug", "Method_Drug"], [190, 191, "Symptom", 193, 195, "Disease", "Symptom_Disease"]]}
{"idx": 972, "sentence": "2.二甲双胍的常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。", "ner": [[2, 5, "Drug"], [22, 23, "ADE"], [25, 26, "ADE"], [28, 29, "ADE"], [31, 32, "ADE"], [34, 35, "ADE"], [37, 40, "ADE"], [47, 48, "ADE"], [42, 45, "ADE"]], "rel": [[22, 23, "ADE", 2, 5, "Drug", "ADE_Drug"], [25, 26, "ADE", 2, 5, "Drug", "ADE_Drug"], [28, 29, "ADE", 2, 5, "Drug", "ADE_Drug"], [31, 32, "ADE", 2, 5, "Drug", "ADE_Drug"], [34, 35, "ADE", 2, 5, "Drug", "ADE_Drug"], [37, 40, "ADE", 2, 5, "Drug", "ADE_Drug"], [42, 45, "ADE", 2, 5, "Drug", "ADE_Drug"], [47, 48, "ADE", 2, 5, "Drug", "ADE_Drug"]]}
{"idx": 973, "sentence": "这些不良反应的发生往往见于药物治疗的早期，大多数患者可耐受。", "ner": [], "rel": []}
{"idx": 974, "sentence": "随着治疗时间的延长，上述不良反应可基本消失。", "ner": [], "rel": []}
{"idx": 975, "sentence": "小剂量开始，逐渐增加剂量是减少治疗初期不良反应发生的有效方法。", "ner": [], "rel": []}
{"idx": 976, "sentence": "3.二甲双胍的胃肠道反应与剂量的相关性，以及处理措施：二甲双胍引起的胃肠道反应多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。一项多中心、双盲、安慰剂对照研究显示，二甲双胍(1000mg/d)起始治疗，其胃肠道反应发生率为24%，增至2500mg/d时胃肠道反应发生率与1000mg/d比较，差异无统计学意义(Ⅰ级)。", "ner": [[2, 5, "Drug"], [7, 11, "ADE"], [27, 30, "Drug"], [34, 38, "ADE"], [106, 109, "Drug"], [111, 118, "Amount"], [126, 130, "ADE"], [141, 148, "Amount"], [150, 154, "ADE"], [159, 166, "Amount"]], "rel": [[7, 11, "ADE", 2, 5, "Drug", "ADE_Drug"], [34, 38, "ADE", 27, 30, "Drug", "ADE_Drug"], [111, 118, "Amount", 106, 109, "Drug", "Amount_Drug"], [141, 148, "Amount", 106, 109, "Drug", "Amount_Drug"], [159, 166, "Amount", 106, 109, "Drug", "Amount_Drug"], [126, 130, "ADE", 106, 109, "Drug", "ADE_Drug"], [150, 154, "ADE", 106, 109, "Drug", "ADE_Drug"]]}
{"idx": 977, "sentence": "国内报道二甲双胍的胃肠道反应发生率为15%，且二甲双胍的胃肠道反应与患者的体重、二甲双胍剂量没有明显的相关性。", "ner": [[4, 7, "Drug"], [9, 13, "ADE"], [23, 26, "Drug"], [28, 32, "ADE"], [40, 43, "Drug"]], "rel": [[9, 13, "ADE", 4, 7, "Drug", "ADE_Drug"], [28, 32, "ADE", 23, 26, "Drug", "ADE_Drug"]]}
{"idx": 978, "sentence": "如果增加二甲双胍剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量。", "ner": [[4, 7, "Drug"], [13, 19, "ADE"], [13, 14, "Level"]], "rel": [[13, 19, "ADE", 4, 7, "Drug", "ADE_Drug"]]}
{"idx": 979, "sentence": "缓释制剂也可以减少患者的胃肠道症状。", "ner": [[12, 16, "ADE"]], "rel": []}
{"idx": 980, "sentence": "4.二甲双胍对维生素B12的吸收是否有影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。", "ner": [[2, 5, "Drug"], [47, 50, "Drug"], [54, 59, "Test_items"], [63, 64, "Test_Value"]], "rel": []}
{"idx": 981, "sentence": "其机制可能是(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可以抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。", "ner": [[45, 50, "Test_items"], [76, 79, "Drug"], [119, 120, "Drug"]], "rel": []}
{"idx": 982, "sentence": "一项研究结果显示，虽然二甲双胍可导致血清维生素B12水平降低，但可改善细胞内维生素B12代谢。", "ner": [[11, 14, "Drug"], [18, 25, "Test_items"], [26, 29, "Test_Value"]], "rel": []}
{"idx": 983, "sentence": "二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。", "ner": [[0, 3, "Drug"], [8, 15, "Disease"], [25, 32, "Disease"]], "rel": []}
{"idx": 984, "sentence": "建议长期使用二甲双胍治疗的患者应适当补充维生素B12。", "ner": [[6, 9, "Drug"], [20, 25, "Drug"]], "rel": []}
{"idx": 985, "sentence": "不建议服用二甲双胍的患者常规监测维生素B12的水平。", "ner": [[5, 8, "Drug"], [16, 21, "Test_items"]], "rel": []}
{"idx": 986, "sentence": "5.二甲双胍是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍本身对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争肝脏P450酶，在体内也不降解，而是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此，二甲双胍无肝毒性，肝功能正常者，接受推荐剂量范围内用药，不会造成肝损害。", "ner": [[2, 5, "Drug"], [13, 16, "Drug"], [51, 54, "Drug"], [61, 65, "Test_items"], [80, 83, "Drug"], [95, 98, "Drug"], [115, 118, "Drug"], [130, 133, "Drug"], [220, 223, "Drug"], [252, 254, "Disease"], [252, 252, "Anatomy"], [55, 58, "Test_items"], [67, 70, "Test_Value"]], "rel": [[252, 252, "Anatomy", 252, 254, "Disease", "Anatomy_Disease"]]}
{"idx": 987, "sentence": "但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。", "ner": [[1, 5, "Disease"], [1, 1, "Anatomy"], [9, 12, "Drug"], [20, 24, "Disease"], [20, 20, "Anatomy"]], "rel": [[1, 1, "Anatomy", 1, 5, "Disease", "Anatomy_Disease"], [20, 20, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"]]}
{"idx": 988, "sentence": "6.二甲双胍与乳酸酸中毒：目前，尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝、肾功能正常者长期应用并不增加乳酸酸中毒风险。COSMIC研究是一项随机、开放标签、活性对照、平行分组研究，结果显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗比较，差异无统计学意义(I级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因为二甲双胍直接以原形经肾脏排泄，所以有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用二甲双胍。", "ner": [[2, 5, "Drug"], [7, 11, "Disease"], [25, 28, "Drug"], [33, 37, "Disease"], [57, 61, "Disease"], [103, 106, "Drug"], [108, 112, "Disease"], [158, 161, "Drug"], [165, 169, "Disease"], [174, 177, "Drug"], [180, 184, "Disease"], [193, 194, "Method"], [203, 206, "Drug"], [221, 225, "Disease"], [221, 221, "Anatomy"], [230, 233, "Drug"], [249, 253, "Disease"], [259, 263, "Disease"], [259, 259, "Anatomy"], [265, 268, "Test_items"], [269, 285, "Test_Value"], [289, 292, "Disease"], [300, 303, "Drug"]], "rel": [[221, 221, "Anatomy", 221, 225, "Disease", "Anatomy_Disease"], [259, 259, "Anatomy", 259, 263, "Disease", "Anatomy_Disease"], [265, 268, "Test_items", 259, 263, "Disease", "Test_items_Disease"]]}
{"idx": 989, "sentence": "7.二甲双胍与哪些非降糖药物的相互作用值得关注", "ner": [[2, 5, "Drug"]], "rel": []}
{"idx": 990, "sentence": "(1)建议密切监测血糖并调整二甲双胍和/或相互作用的药物剂量：使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯喋啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，会影响肾功能或二甲双胍分布。", "ner": [[9, 10, "Test_items"], [14, 17, "Drug"], [33, 36, "Drug"], [38, 40, "Drug"], [42, 43, "Drug"], [45, 49, "Drug"], [51, 53, "Drug"], [55, 56, "Drug"], [58, 61, "Drug"], [63, 66, "Drug"], [68, 73, "Drug"], [75, 78, "Drug"], [100, 103, "Drug"]], "rel": []}
{"idx": 991, "sentence": "(2)需密切监测血糖：同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物。而在这些药物停用后，要密切注意低血糖的发生；合并服用氯磺丙脲的患者在换用二甲双胍的最初两周要密切监测血糖，氯磺丙脲在体内有较长滞留，易发生低血糖。", "ner": [[8, 9, "Test_items"], [15, 19, "Drug"], [21, 25, "Drug"], [27, 31, "Drug"], [33, 35, "Drug"], [37, 41, "Drug"], [43, 45, "Drug"], [49, 51, "Drug"], [47, 48, "Method"], [53, 55, "Drug"], [57, 59, "Drug"], [61, 66, "Drug"], [68, 75, "Drug"], [77, 79, "Drug"], [84, 85, "Test_items"], [107, 109, "ADE"], [118, 121, "Drug"], [128, 131, "Drug"], [142, 143, "Test_items"], [145, 148, "Drug"], [161, 163, "ADE"], [86, 87, "Test_Value"]], "rel": [[47, 48, "Method", 49, 51, "Drug", "Method_Drug"], [161, 163, "ADE", 145, 148, "Drug", "ADE_Drug"]]}
{"idx": 992, "sentence": "(3)二甲双胍有增加华法林的抗凝血倾向。", "ner": [[3, 6, "Drug"], [10, 12, "Drug"]], "rel": []}
{"idx": 993, "sentence": "(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。", "ner": [[3, 7, "Drug"], [10, 12, "Drug"], [14, 15, "Drug"], [17, 18, "Drug"], [21, 24, "Drug"]], "rel": []}
{"idx": 994, "sentence": "六、对心血管系统的影响", "ner": [], "rel": []}
{"idx": 995, "sentence": "1.二甲双胍是否具有心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用。前瞻性糖尿病研究UKPDS结果显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%、心肌梗死风险下降39%(I级)；UKPDS 10年随访显示，使用二甲双胍治疗带来的大血管并发症及死亡风险的获益具有延续效应，且其降低死亡和心肌梗死的作用优于磺脲类和胰岛素(Ⅰ级)。REACH研究是一项全球、多中心、随机、双盲研究，结果提示二甲双胍治疗2年，全因死亡相对风险下降24%。HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险。意大利多中心队列研究将纳入的T2DM患者(平均67岁)按年龄及eGFR分层，结果提示，与其他降糖药物治疗相比，二甲双胍组心血管事件发生风险降低。SPREAD是一项在中国进行的多中心、随机、双盲、安慰剂对照研究，结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。", "ner": [[2, 5, "Drug"], [18, 21, "Drug"], [28, 30, "Disease"], [33, 35, "Disease"], [39, 40, "Pathogenesis"], [92, 95, "Drug"], [97, 98, "Disease"], [99, 102, "Disease"], [120, 123, "Disease"], [152, 155, "Drug"], [161, 163, "Anatomy"], [189, 192, "Disease"], [198, 200, "Drug"], [202, 204, "Drug"], [239, 242, "Drug"], [273, 276, "Drug"], [279, 281, "Drug"], [285, 287, "Drug"], [292, 296, "Disease"], [292, 294, "Anatomy"], [314, 317, "Disease"], [331, 334, "Test_items"], [355, 358, "Drug"], [360, 364, "Disease"], [360, 362, "Anatomy"], [413, 415, "Disease"], [419, 422, "Disease"], [427, 430, "Drug"], [435, 438, "Drug"], [120, 121, "Anatomy"], [189, 190, "Anatomy"]], "rel": [[18, 21, "Drug", 28, 30, "Disease", "Drug_Disease"], [18, 21, "Drug", 33, 35, "Disease", "Drug_Disease"], [39, 40, "Pathogenesis", 28, 30, "Disease", "Pathogenesis_Disease"], [39, 40, "Pathogenesis", 33, 35, "Disease", "Pathogenesis_Disease"], [92, 95, "Drug", 97, 98, "Disease", "Drug_Disease"], [92, 95, "Drug", 99, 102, "Disease", "Drug_Disease"], [120, 121, "Anatomy", 120, 123, "Disease", "Anatomy_Disease"], [189, 190, "Anatomy", 189, 192, "Disease", "Anatomy_Disease"], [292, 294, "Anatomy", 292, 296, "Disease", "Anatomy_Disease"], [331, 334, "Test_items", 314, 317, "Disease", "Test_items_Disease"], [355, 358, "Drug", 314, 317, "Disease", "Drug_Disease"], [360, 362, "Anatomy", 360, 364, "Disease", "Anatomy_Disease"], [427, 430, "Drug", 413, 415, "Disease", "Drug_Disease"], [435, 438, "Drug", 413, 415, "Disease", "Drug_Disease"], [427, 430, "Drug", 419, 422, "Disease", "Drug_Disease"], [435, 438, "Drug", 419, 422, "Disease", "Drug_Disease"]]}
{"idx": 996, "sentence": "2.二甲双胍的心血管保护作用机制：二甲双胍可能通过减少心血管疾病的风险因素而达到心血管保护作用。心血管疾病的风因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制风险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等。", "ner": [[2, 5, "Drug"], [17, 20, "Drug"], [27, 31, "Disease"], [48, 52, "Disease"], [59, 62, "Disease"], [64, 65, "Disease"], [67, 68, "Disease"], [70, 72, "Disease"], [74, 78, "Disease"], [101, 104, "Drug"], [116, 117, "Test_items"], [127, 128, "Pathogenesis"], [147, 148, "Test"], [155, 156, "Test_items"], [158, 162, "Test_items"], [164, 165, "Test_items"], [170, 174, "Test_items"], [121, 125, "Disease"], [27, 29, "Anatomy"], [48, 50, "Anatomy"], [133, 134, "Anatomy"], [136, 137, "Anatomy"]], "rel": [[27, 29, "Anatomy", 27, 31, "Disease", "Anatomy_Disease"], [48, 50, "Anatomy", 48, 52, "Disease", "Anatomy_Disease"], [101, 104, "Drug", 121, 125, "Disease", "Drug_Disease"]]}
{"idx": 997, "sentence": "此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。", "ner": [[3, 6, "Drug"]], "rel": []}
{"idx": 998, "sentence": "七、降糖外作用", "ner": [], "rel": []}
{"idx": 999, "sentence": "1.二甲双胍在改善血脂方面的作用：二甲双胍能改善脂肪的合成与代谢。多项研究显示，二甲双胍可降低T2DM患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。", "ner": [[2, 5, "Drug"], [9, 10, "Test"], [17, 20, "Drug"], [40, 43, "Drug"], [47, 50, "Disease"], [53, 56, "Test_items"], [58, 62, "Test_items"], [64, 65, "Test_items"], [71, 75, "Test_items"]], "rel": [[40, 43, "Drug", 47, 50, "Disease", "Drug_Disease"], [53, 56, "Test_items", 47, 50, "Disease", "Test_items_Disease"], [58, 62, "Test_items", 47, 50, "Disease", "Test_items_Disease"], [64, 65, "Test_items", 47, 50, "Disease", "Test_items_Disease"], [71, 75, "Test_items", 47, 50, "Disease", "Test_items_Disease"]]}
{"idx": 1000, "sentence": "2.二甲双胍在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组颁布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出，除非存在明显的肝损害(如血清转氨酶大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，NAFLD患者可安全使用二甲双胍(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况。所有研究均显示，HOMAI-IR明显改善，13项研究显示血清酶学(ALT、AST)明显下降，5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有显著改善。", "ner": [[2, 5, "Drug"], [9, 13, "Disease"], [30, 32, "Disease"], [34, 38, "Disease"], [46, 54, "Disease"], [80, 82, "Disease"], [80, 80, "Anatomy"], [85, 89, "Test_items"], [90, 98, "Test_Value"], [101, 105, "Disease"], [101, 101, "Anatomy"], [107, 113, "Disease"], [111, 111, "Anatomy"], [118, 122, "Disease"], [130, 133, "Drug"], [150, 153, "Drug"], [155, 159, "Disease"], [173, 174, "Pathogenesis"], [192, 199, "Test_items"], [217, 219, "Test_items"], [221, 223, "Test_items"], [236, 239, "Drug"], [241, 244, "Disease"], [241, 242, "Anatomy"], [246, 253, "Disease"], [32, 32, "Anatomy"], [37, 37, "Anatomy"], [53, 53, "Anatomy"], [168, 171, "Test"], [212, 215, "Test"], [77, 78, "Level"], [200, 203, "Test_Value"], [225, 228, "Test_Value"], [25, 26, "Disease"], [25, 25, "Anatomy"]], "rel": [[2, 5, "Drug", 9, 13, "Disease", "Drug_Disease"], [32, 32, "Anatomy", 30, 32, "Disease", "Anatomy_Disease"], [37, 37, "Anatomy", 34, 38, "Disease", "Anatomy_Disease"], [53, 53, "Anatomy", 46, 54, "Disease", "Anatomy_Disease"], [80, 80, "Anatomy", 80, 82, "Disease", "Anatomy_Disease"], [85, 89, "Test_items", 80, 82, "Disease", "Test_items_Disease"], [101, 101, "Anatomy", 101, 105, "Disease", "Anatomy_Disease"], [111, 111, "Anatomy", 107, 113, "Disease", "Anatomy_Disease"], [130, 133, "Drug", 118, 122, "Disease", "Drug_Disease"], [150, 153, "Drug", 155, 159, "Disease", "Drug_Disease"], [168, 171, "Test", 155, 159, "Disease", "Test_Disease"], [173, 174, "Pathogenesis", 155, 159, "Disease", "Pathogenesis_Disease"], [236, 239, "Drug", 241, 244, "Disease", "Drug_Disease"], [236, 239, "Drug", 246, 253, "Disease", "Drug_Disease"], [241, 242, "Anatomy", 241, 244, "Disease", "Anatomy_Disease"], [25, 25, "Anatomy", 25, 26, "Disease", "Anatomy_Disease"]]}
{"idx": 1001, "sentence": "3.二甲双胍在治疗PCOS方面的作用：国内外应用二甲双胍治疗PCOS已有10余年的历史。美国内分泌学会推荐，二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。AACE/ACE PCOS临床诊治指南中推荐二甲双胍可作为青少年女性PCOS单药或联合避孕药和抗雄激素药治疗的一线用药。在偏瘦的青少年女性中，最低日剂量控制在850mg可有效改善PCOS症状；在超重和肥胖的青少年女性中，二甲双胍日治疗剂量常需要增至1500~2500mg(V级)。同时，该指南中提到，二甲双胍可减轻绝经前PCOS妇女的MS相关症状。循证医学证据表明，二甲双胍可降低血浆胰岛素水平、增加IS、降低雄激素水平、提高雌二醇(E2)水平，改善PCOS患者的多毛症，使月经规律、诱导排卵。同时，二甲双胍用于PCOS患者除改善IR和高血糖症等代谢状况外，还被证明可改善PCOS患者的排卵、受孕及生产存活率。", "ner": [[2, 5, "Drug"], [9, 12, "Disease"], [24, 27, "Drug"], [30, 33, "Disease"], [54, 57, "Drug"], [61, 64, "Disease"], [67, 70, "Disease"], [72, 74, "Disease"], [78, 83, "Treatment"], [103, 105, "Drug"], [146, 149, "Drug"], [158, 161, "Disease"], [167, 169, "Drug"], [171, 175, "Drug"], [203, 207, "Amount"], [213, 216, "Disease"], [221, 222, "Disease"], [224, 225, "Disease"], [234, 237, "Drug"], [248, 258, "Amount"], [274, 277, "Drug"], [284, 287, "Disease"], [291, 292, "Disease"], [349, 352, "Disease"], [356, 358, "Symptom"], [374, 377, "Drug"], [380, 383, "Disease"], [389, 390, "Disease"], [392, 395, "Disease"], [410, 413, "Disease"], [314, 318, "Test_items"], [329, 331, "Test_items"], [337, 343, "Test_items"], [307, 310, "Drug"]], "rel": [[2, 5, "Drug", 9, 12, "Disease", "Drug_Disease"], [24, 27, "Drug", 30, 33, "Disease", "Drug_Disease"], [54, 57, "Drug", 61, 64, "Disease", "Drug_Disease"], [54, 57, "Drug", 67, 70, "Disease", "Drug_Disease"], [54, 57, "Drug", 72, 74, "Disease", "Drug_Disease"], [78, 83, "Treatment", 61, 64, "Disease", "Treatment_Disease"], [78, 83, "Treatment", 67, 70, "Disease", "Treatment_Disease"], [78, 83, "Treatment", 72, 74, "Disease", "Treatment_Disease"], [146, 149, "Drug", 158, 161, "Disease", "Drug_Disease"], [167, 169, "Drug", 158, 161, "Disease", "Drug_Disease"], [171, 175, "Drug", 158, 161, "Disease", "Drug_Disease"], [234, 237, "Drug", 221, 222, "Disease", "Drug_Disease"], [234, 237, "Drug", 224, 225, "Disease", "Drug_Disease"], [248, 258, "Amount", 234, 237, "Drug", "Amount_Drug"], [274, 277, "Drug", 284, 287, "Disease", "Drug_Disease"], [274, 277, "Drug", 291, 292, "Disease", "Drug_Disease"], [307, 310, "Drug", 349, 352, "Disease", "Drug_Disease"], [314, 318, "Test_items", 349, 352, "Disease", "Test_items_Disease"], [329, 331, "Test_items", 349, 352, "Disease", "Test_items_Disease"], [337, 343, "Test_items", 349, 352, "Disease", "Test_items_Disease"], [356, 358, "Symptom", 349, 352, "Disease", "Symptom_Disease"], [374, 377, "Drug", 380, 383, "Disease", "Drug_Disease"], [374, 377, "Drug", 389, 390, "Disease", "Drug_Disease"], [374, 377, "Drug", 392, 395, "Disease", "Drug_Disease"]]}
{"idx": 1002, "sentence": "PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分2次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。", "ner": [[0, 3, "Disease"], [8, 14, "Amount"], [22, 26, "Amount"], [30, 37, "Amount"], [39, 48, "Method"]], "rel": []}
{"idx": 1003, "sentence": "国外也有用到2500mg/d，安全性依然良好。", "ner": [[6, 13, "Amount"]], "rel": []}
{"idx": 1004, "sentence": "目前，我国药监部门未批准二甲双胍用于治疗PCOS。", "ner": [[12, 15, "Drug"], [20, 23, "Disease"]], "rel": []}
{"idx": 1005, "sentence": "4.二甲双胍是否具有抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的风险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激酶(AMPK)通路，而AMPK通路的激活除了影响代谢外，还可能抑制肿瘤的发生和发展。英国一项大型病例对照研究显示，二甲双胍治疗与癌症的发生风险下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势。多项荟萃分析结果显示，二甲双胍治疗与肺癌、前列腺癌、直肠癌等癌症风险降低相关。", "ner": [[2, 5, "Drug"], [16, 18, "Disease"], [28, 30, "Disease"], [28, 29, "Anatomy"], [32, 34, "Disease"], [32, 33, "Anatomy"], [36, 39, "Disease"], [36, 38, "Anatomy"], [41, 45, "Disease"], [41, 44, "Anatomy"], [60, 63, "Drug"], [133, 136, "Drug"], [177, 180, "Drug"], [207, 210, "Drug"], [214, 215, "Disease"], [214, 214, "Anatomy"], [217, 220, "Disease"], [217, 219, "Anatomy"], [222, 224, "Disease"], [222, 223, "Anatomy"]], "rel": [[2, 5, "Drug", 16, 18, "Disease", "Drug_Disease"], [28, 29, "Anatomy", 28, 30, "Disease", "Anatomy_Disease"], [32, 33, "Anatomy", 32, 34, "Disease", "Anatomy_Disease"], [36, 38, "Anatomy", 36, 39, "Disease", "Anatomy_Disease"], [41, 44, "Anatomy", 41, 45, "Disease", "Anatomy_Disease"], [207, 210, "Drug", 214, 215, "Disease", "Drug_Disease"], [207, 210, "Drug", 217, 220, "Disease", "Drug_Disease"], [207, 210, "Drug", 222, 224, "Disease", "Drug_Disease"], [214, 214, "Anatomy", 214, 215, "Disease", "Anatomy_Disease"], [217, 219, "Anatomy", 217, 220, "Disease", "Anatomy_Disease"], [222, 223, "Anatomy", 222, 224, "Disease", "Anatomy_Disease"]]}
{"idx": 1006, "sentence": "中国住院患者血糖管理专家共识", "ner": [[6, 7, "Test_items"]], "rel": []}
{"idx": 1007, "sentence": "一、住院患者高血糖概述", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 1008, "sentence": "院内高血糖是指血糖水平>7.8mmol/L，若血糖水平持续而明显地高于此水平则提示患者有可能需要接受治疗。造成高血糖的原因既可以是由于已知的或未诊断的糖尿病，也可以是由于急危重症所致的应激性高血糖。不论高血糖的原因如何，也不论患者是否伴有糖尿病，高血糖均会增加住院患者的并发症和死亡风险。对所有的高血糖患者在入院时均应检测血糖并应询问是否有糖尿病病史，必要时检测HbA1c水平以明确患者住院前是否已经存在糖尿病。", "ner": [[2, 4, "Disease"], [7, 10, "Test_items"], [11, 20, "Test_Value"], [23, 26, "Test_items"], [55, 57, "Disease"], [75, 77, "Disease"], [92, 97, "Disease"], [101, 103, "Disease"], [119, 121, "Disease"], [123, 125, "Disease"], [148, 150, "Disease"], [161, 162, "Test_items"], [170, 172, "Disease"], [181, 187, "Test_items"], [202, 204, "Disease"], [33, 37, "Test_Value"]], "rel": [[7, 10, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [161, 162, "Test_items", 148, 150, "Disease", "Test_items_Disease"], [181, 187, "Test_items", 202, 204, "Disease", "Test_items_Disease"]]}
{"idx": 1009, "sentence": "新诊断的糖尿病患者HbA1c≥6.5%；而应激性高血糖患者的HbA1c水平一般不高；血糖的水平通常随导致血糖升高的急危重症的出现或缓解而升高或恢复正常。", "ner": [[4, 6, "Disease"], [9, 12, "Test_items"], [13, 18, "Test_Value"], [21, 26, "Disease"], [30, 36, "Test_items"], [42, 43, "Test_items"], [52, 53, "Test_items"], [54, 55, "Test_Value"]], "rel": [[9, 12, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [30, 36, "Test_items", 21, 26, "Disease", "Test_items_Disease"]]}
{"idx": 1010, "sentence": "住院患者发生高血糖非常普通，包括入住内分泌科的成人糖尿病患者，其他内科、外科、急诊、重症监护科室的糖尿病或高血糖患者以及妊娠糖尿病或糖尿病妊娠患者等，针对不同患者的具体血糖控制目标见表1和表2。", "ner": [[6, 8, "Disease"], [25, 27, "Disease"], [49, 51, "Disease"], [53, 55, "Disease"], [60, 64, "Disease"], [66, 70, "Disease"], [84, 85, "Test_items"]], "rel": [[84, 85, "Test_items", 49, 51, "Disease", "Test_items_Disease"], [84, 85, "Test_items", 53, 55, "Disease", "Test_items_Disease"], [84, 85, "Test_items", 60, 64, "Disease", "Test_items_Disease"], [84, 85, "Test_items", 66, 70, "Disease", "Test_items_Disease"]]}
{"idx": 1011, "sentence": "另外，院内高血糖的管理主要分为危重患者和非危重患者的高血糖的管理(图1)。", "ner": [[5, 7, "Disease"], [15, 16, "Level"], [20, 22, "Level"], [26, 28, "Disease"]], "rel": []}
{"idx": 1012, "sentence": "结合患者入院的原因以及患者的疾病状况，需要对患者进行分层管理，设定不同的血糖控制目标。", "ner": [[36, 37, "Test_items"]], "rel": []}
{"idx": 1013, "sentence": "二、住院患者的血糖控制目标", "ner": [[7, 8, "Test_items"]], "rel": []}
{"idx": 1014, "sentence": "在本世纪初的住院患者血糖管理中，重点关注降低高血糖，倾向于较低的血糖控制目标，而这种治疗模式导致低血糖的风险明显增加。", "ner": [[22, 24, "Disease"], [48, 50, "Disease"], [10, 11, "Test_items"], [32, 33, "Test_items"]], "rel": [[10, 11, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [32, 33, "Test_items", 48, 50, "Disease", "Test_items_Disease"]]}
{"idx": 1015, "sentence": "近年来，随着对住院高血糖管理认识的不断深化和证据积累，血糖控制目标已由强化血糖控制发展至多样化的个体化目标。", "ner": [[9, 11, "Disease"], [27, 28, "Test_items"], [37, 38, "Test_items"]], "rel": [[27, 28, "Test_items", 9, 11, "Disease", "Test_items_Disease"]]}
{"idx": 1016, "sentence": "我们在参考多个国内外指南的基础上，结合中国的临床实际情况及特点，推荐对不同的住院患者使用不同的血糖控制目标，达到更为精细和个体化的管理推荐的血脑控制目标分层如表1所示。", "ner": [[47, 48, "Test_items"]], "rel": []}
{"idx": 1017, "sentence": "不同住院人群的控制目标如表2所示。与非妊娠的糖尿病或高血糖患者相比，妊娠患者由于涉及到母亲和胎儿两方面，其控制目标需要更为严格，具体目标见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”章节。", "ner": [[22, 24, "Disease"], [26, 28, "Disease"], [70, 74, "Disease"], [76, 80, "Disease"], [86, 87, "Test_items"]], "rel": [[86, 87, "Test_items", 70, 74, "Disease", "Test_items_Disease"], [86, 87, "Test_items", 76, 80, "Disease", "Test_items_Disease"]]}
{"idx": 1018, "sentence": "三、住院患者的血糖管理", "ner": [[7, 8, "Test_items"]], "rel": []}
{"idx": 1019, "sentence": "(一)内分泌科住院糖尿病患者的血糖管理", "ner": [[9, 11, "Disease"], [15, 16, "Test_items"]], "rel": [[15, 16, "Test_items", 9, 11, "Disease", "Test_items_Disease"]]}
{"idx": 1020, "sentence": "1.内分泌科糖尿病患者的住院标准", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 1021, "sentence": "糖尿病患者在其长期的治疗过程中涉及到“家—医院—家“的一体化管理，糖尿病患者绝大多数时间需要在家和门诊进行调整和管理血糖，但许多情况下可能需要住院进行短期血糖管理和优化治疗、并发症筛查和应激状态的控制等，尤其在需要起始胰岛素治疗的情况下。", "ner": [[0, 2, "Disease"], [33, 35, "Disease"], [58, 59, "Test_items"], [87, 91, "Treatment"], [93, 99, "Treatment"], [109, 111, "Drug"], [77, 78, "Test_items"]], "rel": [[58, 59, "Test_items", 33, 35, "Disease", "Test_items_Disease"], [77, 78, "Test_items", 33, 35, "Disease", "Test_items_Disease"], [87, 91, "Treatment", 33, 35, "Disease", "Treatment_Disease"], [93, 99, "Treatment", 33, 35, "Disease", "Treatment_Disease"], [109, 111, "Drug", 33, 35, "Disease", "Drug_Disease"]]}
{"idx": 1022, "sentence": "糖尿病患者有以下情况建议住院：", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 1023, "sentence": "·新诊断1型糖尿病；", "ner": [[4, 8, "Disease"]], "rel": []}
{"idx": 1024, "sentence": "·新诊断2型糖尿病需进行慢性并发症筛查或评估，或血糖较高需考虑胰岛素强化治疗；", "ner": [[4, 8, "Disease"], [24, 25, "Test_items"], [26, 27, "Test_Value"], [31, 33, "Drug"]], "rel": [[24, 25, "Test_items", 4, 8, "Disease", "Test_items_Disease"], [31, 33, "Drug", 4, 8, "Disease", "Drug_Disease"]]}
{"idx": 1025, "sentence": "·新诊断的糖尿病患者，不能明确分型，需入院进一步明确分型；", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 1026, "sentence": "·糖尿病妊娠或妊娠糖尿病(详见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”部分)；", "ner": [[1, 5, "Disease"], [7, 11, "Disease"], [16, 20, "Disease"], [22, 26, "Disease"], [32, 33, "Test_items"]], "rel": [[32, 33, "Test_items", 16, 20, "Disease", "Test_items_Disease"], [32, 33, "Test_items", 22, 26, "Disease", "Test_items_Disease"]]}
{"idx": 1027, "sentence": "·糖尿病合并急性并发症如糖尿病酮症或糖尿病酮症酸中毒(DKA)、高血糖高渗状态和乳酸酸中毒伴高血糖等；", "ner": [[1, 3, "Disease"], [12, 16, "Disease"], [18, 30, "Disease"], [32, 38, "Disease"], [40, 44, "Disease"], [46, 48, "Disease"]], "rel": []}
{"idx": 1028, "sentence": "·糖尿病血糖控制差或不稳定，经门诊调整治疗不达标；", "ner": [[1, 3, "Disease"], [10, 12, "Test_Value"], [4, 5, "Test_items"], [6, 8, "Test_Value"]], "rel": [[4, 5, "Test_items", 1, 3, "Disease", "Test_items_Disease"]]}
{"idx": 1029, "sentence": "·病程长的糖尿病需进行慢性并发症筛查或评估；", "ner": [[5, 7, "Disease"], [11, 20, "Test"]], "rel": [[11, 20, "Test", 5, 7, "Disease", "Test_Disease"]]}
{"idx": 1030, "sentence": "·糖尿病合并各种应激状态如心脑血管意外、创伤，感染和手术等；", "ner": [[1, 3, "Disease"], [13, 18, "Disease"], [20, 21, "Disease"], [23, 24, "Disease"]], "rel": []}
{"idx": 1031, "sentence": "·糖尿病患者围手术期血糖不达标者；", "ner": [[1, 3, "Disease"], [6, 11, "Test_items"], [12, 14, "Test_Value"]], "rel": [[6, 11, "Test_items", 1, 3, "Disease", "Test_items_Disease"]]}
{"idx": 1032, "sentence": "·糖尿病合开各种严重慢性开发症如各种神经病变、视网膜病变、肾病、糖尿病足溃疡伴或不伴感染等；", "ner": [[1, 3, "Disease"], [18, 21, "Disease"], [18, 19, "Anatomy"], [23, 27, "Disease"], [23, 25, "Anatomy"], [29, 30, "Disease"], [29, 29, "Anatomy"], [32, 37, "Disease"], [35, 35, "Anatomy"], [42, 43, "Disease"]], "rel": [[18, 19, "Anatomy", 18, 21, "Disease", "Anatomy_Disease"], [23, 25, "Anatomy", 23, 27, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 29, 30, "Disease", "Anatomy_Disease"], [35, 35, "Anatomy", 32, 37, "Disease", "Anatomy_Disease"]]}
{"idx": 1033, "sentence": "·糖尿病合并多脏器功能不全如肝肾心肺功能不全等；", "ner": [[1, 3, "Disease"], [14, 21, "Disease"], [14, 14, "Anatomy"], [15, 15, "Anatomy"], [16, 16, "Anatomy"], [17, 17, "Anatomy"]], "rel": [[14, 14, "Anatomy", 14, 21, "Disease", "Anatomy_Disease"], [15, 15, "Anatomy", 14, 21, "Disease", "Anatomy_Disease"], [16, 16, "Anatomy", 14, 21, "Disease", "Anatomy_Disease"], [17, 17, "Anatomy", 14, 21, "Disease", "Anatomy_Disease"]]}
{"idx": 1034, "sentence": "·特殊类型糖尿病；", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 1035, "sentence": "·糖尿病患者在门诊治疗过程中，出现严重低血糖或经常出现低血糖症状者；", "ner": [[1, 3, "Disease"], [17, 18, "Level"], [19, 21, "Disease"], [27, 29, "Disease"]], "rel": []}
{"idx": 1036, "sentence": "·需要安装胰岛素泵治疗的患者；", "ner": [], "rel": []}
{"idx": 1037, "sentence": "·糖尿病患者需要接受胰岛细胞移植或干细胞治疗者。", "ner": [[1, 3, "Disease"], [10, 15, "Operation"], [17, 21, "Treatment"]], "rel": [[10, 15, "Operation", 1, 3, "Disease", "Operation_Disease"], [17, 21, "Treatment", 1, 3, "Disease", "Treatment_Disease"]]}
{"idx": 1038, "sentence": "糖尿病患者在经住院短期优化血糖控制，完善相关检查和缓解应激状态和病情之后，可在出院前修改为出院可维持的方案或维持住院治疗的方案门诊治疗。", "ner": [[0, 2, "Disease"], [13, 14, "Test_items"]], "rel": [[13, 14, "Test_items", 0, 2, "Disease", "Test_items_Disease"]]}
{"idx": 1039, "sentence": "2.内分泌科住院糖尿病患者的血糖管理", "ner": [[8, 10, "Disease"], [14, 15, "Test_items"]], "rel": [[14, 15, "Test_items", 8, 10, "Disease", "Test_items_Disease"]]}
{"idx": 1040, "sentence": "为了进一步规范内分泌科住院成人糖尿病患者的血糖管理，制定本共识。", "ner": [[15, 17, "Disease"], [21, 22, "Test_items"]], "rel": [[21, 22, "Test_items", 15, 17, "Disease", "Test_items_Disease"]]}
{"idx": 1041, "sentence": "管理流程见图1，就其中血糖管理部分阐述如下。", "ner": [[11, 12, "Test_items"]], "rel": []}
{"idx": 1042, "sentence": "(1)管理对象：内分泌科住院的成人糖尿病患者。", "ner": [[17, 19, "Disease"]], "rel": []}
{"idx": 1043, "sentence": "(2)入院时病情评估：入院即刻血糖(血糖≥16.7mmol/L时，需检测血酮或尿酮、血气、血钠、血钾、血乳酸、肝肾功能、血尿粪常规)、病史(病程、已诊断的并发症和伴发疾病，目前降糖方案及治疗依从性等)、现并存的临床症状、阳性体征和重要的阴性体征(包括生命体征、意识状态、有无脱水体征等）、既往检查的病历资料。", "ner": [[11, 16, "Test_items"], [18, 19, "Test_items"], [20, 30, "Test_Value"], [36, 37, "Test_items"], [39, 40, "Test_items"], [42, 43, "Test_items"], [45, 46, "Test_items"], [48, 49, "Test_items"], [51, 53, "Test_items"], [55, 58, "Test"], [60, 64, "Test"], [137, 140, "Symptom"]], "rel": []}
{"idx": 1044, "sentence": "(3)经上述评估后分类：①合并急危重症者：(a)合并急性并发症：包括糖尿病酮症、DKA、高血糖高渗状态、乳酸酸中毒伴高血糖；(b)低血糖昏迷：(c)合并感染：包括糖尿病足或不明原因发热。", "ner": [[34, 38, "Disease"], [40, 42, "Disease"], [44, 50, "Disease"], [52, 56, "Disease"], [58, 60, "Disease"], [65, 69, "Disease"], [76, 77, "Disease"], [81, 84, "Disease"], [84, 84, "Anatomy"], [90, 91, "Disease"]], "rel": [[84, 84, "Anatomy", 81, 84, "Disease", "Anatomy_Disease"]]}
{"idx": 1045, "sentence": "②血糖控制差且非急危重症者：(a)符合下述特征的糖代谢严重絮乱状态：间断多次测定随机血糖≥16.7mmol/L；可有轻度脱水体征；血pH正常，尿酮阴性或弱阳性，或血酮≥1.0mmol/L且<3.0mmol/L；有效血浆渗透压<320.0mmol/L；(b)符合下述特征的较高血糖水平：尿酮阴性或血酮<1.0mmo/L、无明显脱水体征且满足空腹血糖(FPG)≥11.1mmol/L或随机血糖≥13.9mmol/L或近期HbA1c≥9.0%；(c)符合下述特征的高血糖水平：FPG<11.1mmol/L，或随机血糖<13.9mmo/L，或HbA1c<9.0%；伴严重慢性并发症或伴发病，或低血糖风险，或长病程，或2种以上口服降糖药或已使用胰岛素；(d)单纯的高血糖水平：FPG<11.1mmol/L，或随机血糖<13.9mmol/L，或HbA1c<9.0%；无明显慢性并发症或伴发病，或2种以因口服降糖药，或未规律饮食药物治疗。", "ner": [[24, 32, "Symptom"], [40, 43, "Test_items"], [44, 54, "Test_Value"], [60, 63, "Symptom"], [65, 67, "Test_items"], [68, 69, "Test_Value"], [71, 72, "Test_items"], [73, 74, "Test_Value"], [76, 78, "Test_Value"], [81, 82, "Test_items"], [83, 92, "Test_Value"], [94, 103, "Test_Value"], [105, 111, "Test_items"], [112, 123, "Test_Value"], [135, 140, "Symptom"], [142, 143, "Test_items"], [147, 148, "Test_items"], [169, 177, "Test_items"], [190, 193, "Test_items"], [208, 212, "Test_items"], [235, 237, "Test_items"], [251, 254, "Test_items"], [267, 271, "Test_items"], [333, 335, "Test_items"], [349, 352, "Test_items"], [366, 370, "Test_items"], [395, 396, "Method"], [144, 145, "Test_Value"], [149, 157, "Test_Value"], [178, 188, "Test_Value"], [194, 204, "Test_Value"], [213, 217, "Test_Value"], [238, 248, "Test_Value"], [255, 264, "Test_Value"], [272, 276, "Test_Value"], [336, 346, "Test_Value"], [353, 363, "Test_Value"], [371, 375, "Test_Value"], [229, 233, "Symptom"], [292, 294, "Disease"], [308, 309, "Method"], [317, 319, "Drug"], [327, 331, "Symptom"], [162, 165, "Symptom"], [1, 2, "Test_items"], [3, 5, "Test_Value"]], "rel": []}
{"idx": 1046, "sentence": "(4)血糖管理：①合并急危重症：(a)合并急性并发症：DKA、高血糖高渗状态、乳酸酸中毒伴高血糖。严重糖代谢紊乱伴水、电解质、酸碱平衡紊乱时的降糖治疗：此时患者处于急性糖代谢严重紊乱状态，合并脱水、电解质絮乱甚至酸中毒，危及生命。补液和胰岛素的应用有利于最大限度地逆转病情。在积极补液，有效改善组织灌注的同时，给予小剂量短效胰岛素静脉滴注，开始时按每小时每千克体重计算胰岛素的剂量0.1U·kg-1·h-1，每1小时监测血糖。之后根据血糖下降速度调整胰岛素剂量，血糖下降速度一般控制在每小时降低3.9~6.1mmol/L为宜。如第1个小时血糖下降不明显，且脱水已基本纠正，胰岛素剂量可加倍。当血糖降至13.9mmol/L.时，胰岛素剂量减至0.05~0.1U·kg-1·h-1，使血糖稳定在8.0~13.9mmol/L。观察病情，临床症状缓解，消化道症状基本消失，能少量进食后，需皮下注射基胰岛素(即中效胰岛素或长效胰岛素类似物)1~2h后，方可停止胰岛素静脉滴注。静脉输注胰岛素转皮下胰岛素注射时，可选择每日多次胰岛素皮下注射(MDI)或持续皮下胰岛素输注(CSH)。不能正常进食者，可仅给予基础胰岛素，或CSⅡ的基础量，每4~6h监测血糖。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg-1·h-1计算。进食主食量不足25g时，可暂时不给予餐前胰岛素，但要观察餐后血糖变化。进食量增加且能规律，或进食后血糖明显增加时，可在三顿主餐前加用短效胰岛素或速效胰岛素类似物，或CSII的餐前大剂量。使用剂量视者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。患者病情稳定，血糖控制满意后，调整为院外降糖方案，并至少监测1天的7次血糖。院外降糖方案可依据患者具体情况，选择MDI、CSII、预混胰岛素或预混胰岛素类似物2~3次皮下注射，加用或不加用二甲双胍、α-糖苷酶抑制剂。院外血糖控制目标可参照2011年《中国成人2型糖尿病HbA1c控制目标的专家共识》，血糖监测计", "ner": [[27, 29, "Disease"], [31, 37, "Disease"], [39, 43, "Disease"], [45, 47, "Disease"], [51, 55, "Disease"], [49, 50, "Level"], [57, 68, "Disease"], [82, 83, "Level"], [84, 92, "Disease"], [96, 97, "Disease"], [99, 103, "Disease"], [106, 108, "Disease"], [115, 116, "Treatment"], [118, 120, "Drug"], [140, 141, "Treatment"], [145, 150, "Treatment"], [165, 168, "Method"], [160, 164, "Drug"], [184, 186, "Drug"], [210, 211, "Test_items"], [217, 218, "Test_items"], [225, 227, "Drug"], [231, 232, "Test_items"], [269, 270, "Test_items"], [271, 275, "Test_Value"], [242, 259, "Test_Value"], [278, 279, "Symptom"], [286, 288, "Drug"], [296, 297, "Test_items"], [300, 309, "Test_Value"], [313, 315, "Drug"], [320, 337, "Amount"], [190, 202, "Amount"], [340, 341, "Test_items"], [345, 358, "Test_Value"], [390, 393, "Method"], [394, 397, "Drug"], [400, 404, "Drug"], [406, 413, "Drug"], [425, 427, "Drug"], [428, 431, "Method"], [433, 436, "Method"], [437, 439, "Drug"], [443, 445, "Drug"], [446, 447, "Method"], [470, 483, "Method"], [453, 468, "Method"], [499, 501, "Drug"], [524, 526, "Drug"], [538, 540, "Drug"], [552, 554, "Drug"], [559, 571, "Amount"], [593, 597, "Drug"], [603, 606, "Test_items"], [621, 625, "Test_items"], [626, 629, "Test_Value"], [641, 645, "Drug"], [647, 654, "Drug"], [683, 685, "Drug"], [695, 696, "Test_items"], [707, 709, "Drug"], [717, 718, "Test_items"], [723, 725, "Disease"], [768, 769, "Test_items"], [789, 791, "Method"], [793, 796, "Method"], [816, 819, "Method"], [800, 802, "Drug"], [806, 811, "Drug"], [827, 830, "Drug"], [832, 839, "Drug"], [862, 866, "Disease"], [867, 871, "Test_items"], [457, 459, "Drug"], [474, 476, "Drug"], [3, 4, "Test_items"], [843, 844, "Test_items"], [519, 520, "Test_items"], [740, 741, "Test_items"]], "rel": [[165, 168, "Method", 160, 164, "Drug", "Method_Drug"], [190, 202, "Amount", 184, 186, "Drug", "Amount_Drug"], [320, 337, "Amount", 313, 315, "Drug", "Amount_Drug"], [390, 393, "Method", 394, 397, "Drug", "Method_Drug"], [428, 431, "Method", 425, 427, "Drug", "Method_Drug"], [433, 436, "Method", 437, 439, "Drug", "Method_Drug"], [446, 447, "Method", 443, 445, "Drug", "Method_Drug"], [470, 483, "Method", 474, 476, "Drug", "Method_Drug"], [453, 468, "Method", 457, 459, "Drug", "Method_Drug"], [717, 718, "Test_items", 723, 725, "Disease", "Test_items_Disease"], [867, 871, "Test_items", 862, 866, "Disease", "Test_items_Disease"], [843, 844, "Test_items", 862, 866, "Disease", "Test_items_Disease"]]}
{"idx": 1047, "sentence": "(b)低血糖昏迷：停止全部降糖治疗药物。静脉推注50%葡萄糖液60ml，继而5%~10%葡萄糖液持续静脉滴注，至意识恢复并保持。监测血糖，至少观察3d。抢救参照《内科学》第八版，以及2013年《中国2型糖尿病防治指南》、2012年《中国糖尿病患者低血糖管理的专家共识》。通常血糖在3~7d后逐渐增高，依据血糖水平和病情及本次低血糖昏迷的诱发因素综合分析，重新选择较为安全的降糖策略。(c)合并感染：包括糖尿病足或不明原因发热。感染可导致难以控制的高血糖，高血糖不利于感染的控制，如患者存在糖尿病足或不明原因发热，严格控制血糖为首要措施，胰岛素治疗为首选，如无严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应采用CSII或MDI治疗。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg1·d1计算。三餐前餐时胰岛素或餐前大剂量视患者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。如存在严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应积极补液及静脉胰岛素治疗，具体静脉使用胰岛素的方法与前述“(a)合并急性并发症”部分相同，使血糖稳定在8.0~13.9mmol/L。", "ner": [[3, 7, "Disease"], [20, 23, "Method"], [24, 30, "Drug"], [31, 34, "Amount"], [38, 47, "Drug"], [48, 53, "Method"], [99, 103, "Disease"], [118, 120, "Disease"], [123, 125, "Disease"], [137, 138, "Test_items"], [152, 153, "Test_items"], [162, 166, "Disease"], [196, 197, "Disease"], [201, 204, "Disease"], [204, 204, "Anatomy"], [210, 211, "Disease"], [213, 214, "Reason"], [223, 225, "Disease"], [227, 229, "Disease"], [233, 234, "Disease"], [244, 247, "Disease"], [247, 247, "Anatomy"], [253, 254, "Disease"], [268, 270, "Drug"], [279, 280, "Level"], [281, 285, "Disease"], [287, 297, "Disease"], [302, 305, "Method"], [307, 309, "Method"], [315, 317, "Drug"], [329, 331, "Drug"], [343, 345, "Drug"], [350, 360, "Amount"], [369, 371, "Drug"], [390, 392, "Drug"], [402, 403, "Test_items"], [414, 416, "Drug"], [424, 425, "Test_items"], [430, 432, "Disease"], [443, 444, "Level"], [445, 449, "Disease"], [451, 461, "Disease"], [466, 467, "Treatment"], [471, 473, "Drug"], [469, 470, "Method"], [483, 485, "Drug"], [510, 511, "Test_items"], [515, 528, "Test_Value"], [66, 67, "Test_items"], [260, 261, "Test_items"]], "rel": [[20, 23, "Method", 24, 30, "Drug", "Method_Drug"], [31, 34, "Amount", 24, 30, "Drug", "Amount_Drug"], [48, 53, "Method", 38, 47, "Drug", "Method_Drug"], [152, 153, "Test_items", 162, 166, "Disease", "Test_items_Disease"], [204, 204, "Anatomy", 201, 204, "Disease", "Anatomy_Disease"], [213, 214, "Reason", 223, 225, "Disease", "Reason_Disease"], [247, 247, "Anatomy", 244, 247, "Disease", "Anatomy_Disease"], [268, 270, "Drug", 244, 247, "Disease", "Drug_Disease"], [260, 261, "Test_items", 244, 247, "Disease", "Test_items_Disease"], [268, 270, "Drug", 253, 254, "Disease", "Drug_Disease"], [260, 261, "Test_items", 253, 254, "Disease", "Test_items_Disease"], [302, 305, "Method", 268, 270, "Drug", "Method_Drug"], [307, 309, "Method", 268, 270, "Drug", "Method_Drug"], [350, 360, "Amount", 315, 317, "Drug", "Amount_Drug"], [424, 425, "Test_items", 430, 432, "Disease", "Test_items_Disease"], [466, 467, "Treatment", 445, 449, "Disease", "Treatment_Disease"], [471, 473, "Drug", 445, 449, "Disease", "Drug_Disease"], [466, 467, "Treatment", 451, 461, "Disease", "Treatment_Disease"], [471, 473, "Drug", 451, 461, "Disease", "Drug_Disease"], [469, 470, "Method", 471, 473, "Drug", "Method_Drug"]]}
{"idx": 1048, "sentence": "观察病情，临床症状缓解，过渡至皮下胰岛素注射，应避免低血糖发生。", "ner": [[15, 21, "Method"], [17, 19, "Drug"], [26, 28, "Disease"]], "rel": [[15, 21, "Method", 17, 19, "Drug", "Method_Drug"]]}
{"idx": 1049, "sentence": "存在严重感染时禁用二甲双胍治疗。", "ner": [[9, 12, "Drug"]], "rel": []}
{"idx": 1050, "sentence": "②血糖控制差且非急危重症：(a)第1类患者糖代谢紊乱严重，尚未危及生命，但持续高血糖状态可促使病情进展，应积极逆转，是胰岛素治疗的指征。降糖治疗需应用胰岛素，可相对短的时间静脉输注改善高糖毒性，缓解临床症状后改皮下注射。与前述“①合并急危重症者”中“(a)合并急性并发症“部分静脉胰岛素使用原则相同，不同的是开始时胰岛素剂量0.05U·kg-1·d-1，且静脉滴注时间相对短。患者血糖稳定在8.0~11.1mmol/L后2~4h，可改为多次胰岛素(基础一餐时)皮下注射或胰岛素泵治疗。同时改每小时监测血糖为每天检测7次血糖或4~6个监测点，必要时加测夜间血糖。依据血糖调整胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案。(b)第2、3类患者均为胰岛素治疗的指征。降糖治疗亦应用胰岛素，最好采用胰岛素强化治疗方案，包括：基础加餐时胰岛素的MDI、CSⅡ、预混胰岛素类似物每日3次皮下注射，优选前两种。胰岛素强化治疗时，胰岛素起始剂量选择可按0.4~0.5U·kg-1·d-1。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。监测7次血糖，必要时加测夜间血糖。依据血糖调整胰岛素用量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案根据病情可选择加用或不加用口服降糖药及胰升糖素样肽1(GLP-1)受体激动剂。需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，以及评估患者的估算肾小球滤过率(eGFR)。二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。因采用胰岛素强化治疗方案，原则上不联用胰岛素促泌剂。(c)第4类患者相对病情轻。对于胰岛素缺乏为主的患者仍应胰岛素治疗，可以基础胰岛素联合口服降糖药治疗，或预混胰岛素2次皮下注射，必要时也可胰岛素强化治疗。每天1次基础或预混胰岛素注射时，胰岛素起始剂量选择0.2U·kg-1·d-1。每天2次预混胰岛素注射时，胰岛素起始剂量选择可按0.2~0.4U·kg-1·d-1，按照1：1比例分配于早晚餐前。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。与前述相同，需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，要估算eGFR。", "ner": [[21, 25, "Disease"], [26, 27, "Level"], [37, 43, "Symptom"], [59, 61, "Drug"], [75, 77, "Drug"], [86, 89, "Method"], [105, 108, "Method"], [140, 142, "Drug"], [157, 159, "Drug"], [162, 175, "Amount"], [178, 181, "Method"], [190, 191, "Test_items"], [195, 208, "Test_Value"], [220, 222, "Drug"], [230, 233, "Method"], [259, 260, "Test_items"], [275, 278, "Test_items"], [282, 283, "Test_items"], [286, 288, "Drug"], [302, 304, "Disease"], [334, 336, "Drug"], [350, 352, "Drug"], [358, 360, "Drug"], [376, 378, "Drug"], [380, 382, "Method"], [384, 386, "Method"], [400, 403, "Method"], [396, 399, "Frequency"], [411, 413, "Drug"], [420, 422, "Drug"], [431, 447, "Amount"], [455, 457, "Drug"], [458, 459, "Test_items"], [460, 461, "Test_Value"], [464, 466, "Disease"], [484, 486, "Drug"], [487, 488, "Test_items"], [495, 497, "Disease"], [489, 492, "Test_Value"], [519, 520, "Test_items"], [527, 530, "Test_items"], [534, 535, "Test_items"], [538, 540, "Drug"], [554, 556, "Disease"], [586, 587, "Method"], [592, 610, "Drug"], [644, 657, "Test_items"], [659, 662, "Drug"], [664, 671, "Drug"], [673, 680, "Drug"], [690, 692, "Drug"], [697, 698, "Test_items"], [705, 706, "Disease"], [708, 710, "Drug"], [735, 744, "Drug"], [750, 752, "Drug"], [766, 771, "Drug"], [789, 793, "Pathogenesis"], [801, 803, "Drug"], [811, 813, "Drug"], [816, 817, "Method"], [830, 831, "Frequency"], [832, 835, "Method"], [842, 844, "Drug"], [850, 853, "Frequency"], [866, 868, "Drug"], [875, 887, "Amount"], [889, 892, "Frequency"], [825, 829, "Drug"], [388, 395, "Drug"], [857, 861, "Drug"], [893, 897, "Drug"], [902, 904, "Drug"], [913, 929, "Amount"], [952, 954, "Drug"], [955, 956, "Test_items"], [957, 958, "Test_Value"], [961, 963, "Disease"], [981, 983, "Drug"], [984, 985, "Test_items"], [986, 989, "Test_Value"], [992, 994, "Disease"], [1046, 1049, "Test_items"], [630, 635, "Disease"], [632, 633, "Anatomy"], [1036, 1041, "Disease"], [1038, 1039, "Anatomy"], [1, 2, "Test_items"], [3, 5, "Test_Value"], [296, 297, "Test_items"], [250, 251, "Test_items"], [548, 549, "Test_items"]], "rel": [[59, 61, "Drug", 21, 25, "Disease", "Drug_Disease"], [37, 43, "Symptom", 21, 25, "Disease", "Symptom_Disease"], [86, 89, "Method", 75, 77, "Drug", "Method_Drug"], [105, 108, "Method", 75, 77, "Drug", "Method_Drug"], [162, 175, "Amount", 157, 159, "Drug", "Amount_Drug"], [178, 181, "Method", 157, 159, "Drug", "Method_Drug"], [230, 233, "Method", 220, 222, "Drug", "Method_Drug"], [296, 297, "Test_items", 302, 304, "Disease", "Test_items_Disease"], [380, 382, "Method", 376, 378, "Drug", "Method_Drug"], [384, 386, "Method", 376, 378, "Drug", "Method_Drug"], [400, 403, "Method", 376, 378, "Drug", "Method_Drug"], [396, 399, "Frequency", 376, 378, "Drug", "Frequency_Drug"], [431, 447, "Amount", 420, 422, "Drug", "Amount_Drug"], [548, 549, "Test_items", 554, 556, "Disease", "Test_items_Disease"], [708, 710, "Drug", 705, 706, "Disease", "Drug_Disease"], [830, 831, "Frequency", 825, 829, "Drug", "Frequency_Drug"], [832, 835, "Method", 825, 829, "Drug", "Method_Drug"], [850, 853, "Frequency", 857, 861, "Drug", "Frequency_Drug"], [875, 887, "Amount", 866, 868, "Drug", "Amount_Drug"], [889, 892, "Frequency", 893, 897, "Drug", "Frequency_Drug"], [913, 929, "Amount", 902, 904, "Drug", "Amount_Drug"], [1046, 1049, "Test_items", 1036, 1041, "Disease", "Test_items_Disease"], [632, 633, "Anatomy", 630, 635, "Disease", "Anatomy_Disease"], [1038, 1039, "Anatomy", 1036, 1041, "Disease", "Anatomy_Disease"]]}
{"idx": 1051, "sentence": "二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动。", "ner": [[0, 3, "Drug"], [5, 12, "Drug"], [14, 21, "Drug"], [31, 33, "Drug"], [38, 39, "Test_items"]], "rel": []}
{"idx": 1052, "sentence": "每天2次以上胰岛素注射时原则上不联用胰岛素促泌剂(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。", "ner": [[0, 3, "Frequency"], [6, 8, "Drug"], [18, 23, "Drug"], [27, 28, "Disease"], [30, 32, "Drug"], [57, 66, "Drug"]], "rel": [[0, 3, "Frequency", 6, 8, "Drug", "Frequency_Drug"], [30, 32, "Drug", 27, 28, "Disease", "Drug_Disease"]]}
{"idx": 1053, "sentence": "监测7次血糖，或监测FPG、早餐后2h血糖、晚餐前及餐后2h血糖和睡前血糖。", "ner": [[4, 5, "Test_items"], [10, 12, "Test_items"], [14, 20, "Test_items"], [22, 31, "Test_items"], [33, 36, "Test_items"]], "rel": []}
{"idx": 1054, "sentence": "必要时加测夜间血糖。", "ner": [[5, 8, "Test_items"]], "rel": []}
{"idx": 1055, "sentence": "(d)对所有患者都应进行生活方式教育和管理及对症治疗", "ner": [[12, 20, "Treatment"]], "rel": []}
{"idx": 1056, "sentence": "(5)住院糖尿病患者控制目标：具体请见“二、住院患者的血糖控制目标”章节。", "ner": [[5, 7, "Disease"], [27, 28, "Test_items"]], "rel": [[27, 28, "Test_items", 5, 7, "Disease", "Test_items_Disease"]]}
{"idx": 1057, "sentence": "(6)住院期间：①根据院内血糖监测情况、年龄，及入院后完善的检查，包括HbA1c、胰岛功能及其相关抗体、肝肾功能、慢性并发症情况、心血管系统及其相关代谢指标等健康状态评估后确定院内血糖控制目标。2根据上述情况及糖尿病分型完善降糖及综合治疗方案。③制订并实施饮食、运动治疗方案。④全程糖尿病健康指导，包括：饮食、运动、血糖监测、胰岛素注射技术、预防低血糖和糖尿病急性并发症、足保护、体重管理等。", "ner": [[35, 39, "Test_items"], [105, 107, "Disease"], [128, 136, "Treatment"], [141, 143, "Disease"], [144, 147, "Treatment"], [163, 165, "Drug"], [173, 175, "Disease"], [177, 184, "Disease"], [186, 188, "Treatment"], [190, 193, "Treatment"], [90, 91, "Test_items"], [158, 161, "Test_items"], [13, 16, "Test_items"]], "rel": [[144, 147, "Treatment", 141, 143, "Disease", "Treatment_Disease"], [186, 188, "Treatment", 141, 143, "Disease", "Treatment_Disease"], [190, 193, "Treatment", 141, 143, "Disease", "Treatment_Disease"], [158, 161, "Test_items", 141, 143, "Disease", "Test_items_Disease"]]}
{"idx": 1058, "sentence": "(7)出院前准备：①制订院外降糖及综合治疗方案。", "ner": [[12, 22, "Treatment"]], "rel": []}
{"idx": 1059, "sentence": "院外降糖方案在住院期间逐步形成，或胰岛素强化治疗转为院外非胰岛素强化治疗方案时需要至少监测1天的7次血糖，以评估治疗方案的有效性和安全性。", "ner": [[48, 51, "Test_items"], [17, 19, "Drug"], [26, 37, "Treatment"]], "rel": []}
{"idx": 1060, "sentence": "告知血糖监测频率和控制目标。", "ner": [[2, 5, "Test_items"]], "rel": []}
{"idx": 1061, "sentence": "③制订体重管理与生活方式计划。", "ner": [[3, 6, "Treatment"], [8, 13, "Treatment"]], "rel": []}
{"idx": 1062, "sentence": "④告知随访时间和内容。", "ner": [], "rel": []}
{"idx": 1063, "sentence": "(二)非内分泌科住院的糖尿病或高血糖患者的血糖管理", "ner": [[11, 13, "Disease"], [15, 17, "Disease"], [21, 22, "Test_items"]], "rel": [[21, 22, "Test_items", 11, 13, "Disease", "Test_items_Disease"], [21, 22, "Test_items", 15, 17, "Disease", "Test_items_Disease"]]}
{"idx": 1064, "sentence": "对非内分泌科住院的糖尿病或高血糖患者的管理流程同样参见图1，如下详细阐述了其中血糖管理部分。", "ner": [[9, 11, "Disease"], [13, 15, "Disease"], [39, 40, "Test_items"]], "rel": [[39, 40, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [39, 40, "Test_items", 13, 15, "Disease", "Test_items_Disease"]]}
{"idx": 1065, "sentence": "1.管理对象", "ner": [], "rel": []}
{"idx": 1066, "sentence": "非内分泌科住院的成人糖尿病或高血糖患者。", "ner": [[10, 12, "Disease"], [14, 16, "Disease"]], "rel": []}
{"idx": 1067, "sentence": "包括既往明确诊断的糖尿病患者和既往无糖尿病史，在住院期间出现高血糖的患者。", "ner": [[9, 11, "Disease"], [18, 20, "Disease"], [30, 32, "Disease"]], "rel": []}
{"idx": 1068, "sentence": "2.入院时病情评估", "ner": [], "rel": []}
{"idx": 1069, "sentence": "(1)既往无糖尿病史患者，入院后出现血糖水平持续并显著高于7.8mmo/L，则需重新评估，制订诊治方案；HbA1c≥6.5%，提示入院前已存在高糖状态。", "ner": [[6, 8, "Disease"], [18, 21, "Test_items"], [27, 36, "Test_Value"], [52, 55, "Test_items"], [56, 61, "Test_Value"], [71, 74, "Symptom"]], "rel": []}
{"idx": 1070, "sentence": "(2)既往有糖尿病史患者，既往3个月内如未行HbA1c检测，入院后则需进行HbA1c检测；", "ner": [[6, 8, "Disease"], [22, 26, "Test_items"], [37, 41, "Test_items"]], "rel": [[37, 41, "Test_items", 6, 8, "Disease", "Test_items_Disease"]]}
{"idx": 1071, "sentence": "(3)糖尿病患者，询问既往有无低血糖事件，评判发生低血糖的风险程度。", "ner": [[3, 5, "Disease"], [15, 19, "Symptom"], [25, 27, "Disease"]], "rel": [[15, 19, "Symptom", 3, 5, "Disease", "Symptom_Disease"]]}
{"idx": 1072, "sentence": "(4)原发疾病的病情评估：年龄、预期寿命、是否存在器官功能不全、精神或智力障碍、心脑血管疾病既往史和(或)风险程度、是否需重症监护、是否需进行手术、手术的类型(急症、择期、整形等精细手术、或器官移植手术)；患者的营养状态、进食情况(禁食、正常摄食,或胃肠外营养)等。", "ner": [[95, 100, "Operation"], [80, 92, "Operation"], [40, 45, "Disease"], [32, 38, "Disease"], [40, 43, "Anatomy"]], "rel": [[40, 43, "Anatomy", 40, 45, "Disease", "Anatomy_Disease"]]}
{"idx": 1073, "sentence": "3.血糖管理目标", "ner": [[2, 3, "Test_items"]], "rel": []}
{"idx": 1074, "sentence": "经上述评估后，对血糖管理目标进行分类：", "ner": [[8, 9, "Test_items"]], "rel": []}
{"idx": 1075, "sentence": "(1)如年轻的新诊断糖尿病患者和低血糖低危人群，在接受内科治疗的同时需严格控制血糖；其他内科疾病患者，若是高龄、或无法耐受低血糖、或存在器官功能不全，或预期寿命<5年、存在精神或智力障碍、本身是心脑血管疾病患者或心脑血管疾病高危人群,仅需宽松或一般控制血糖。", "ner": [[10, 12, "Disease"], [16, 18, "Disease"], [61, 63, "Disease"], [68, 73, "Disease"], [86, 92, "Disease"], [97, 102, "Disease"], [106, 111, "Disease"], [97, 100, "Anatomy"], [106, 109, "Anatomy"], [126, 127, "Test_items"], [39, 40, "Test_items"]], "rel": [[39, 40, "Test_items", 10, 12, "Disease", "Test_items_Disease"], [39, 40, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [97, 100, "Anatomy", 97, 102, "Disease", "Anatomy_Disease"], [106, 109, "Anatomy", 106, 111, "Disease", "Anatomy_Disease"], [126, 127, "Test_items", 106, 111, "Disease", "Test_items_Disease"]]}
{"idx": 1076, "sentence": "对于重症监护患者、或拟进行急症和择期大中小手术的患者，在术前、术中和术后建议宽松控制血糖；对于精细手术(如整形手术)，血糖需严格控制;对于器官移植手术需一般控制血糖。", "ner": [[53, 56, "Operation"], [59, 60, "Test_items"], [69, 74, "Operation"], [80, 81, "Test_items"], [42, 43, "Test_items"]], "rel": []}
{"idx": 1077, "sentence": "(2)严格、一般和宽松血糖控制目标的定义详见本共识“二、住院患者的血糖控制目标“部分。", "ner": [[11, 12, "Test_items"], [33, 34, "Test_items"]], "rel": []}
{"idx": 1078, "sentence": "4.血糖管理措施", "ner": [[2, 3, "Test_items"]], "rel": []}
{"idx": 1079, "sentence": "(1)对血糖控制未达标的非内分泌科住院高血糖患者，尤其在合并有糖尿病酮症、DKA和糖尿病高渗状态等急性并发症的患者，建议邀请内分泌专科医生协同诊治。", "ner": [[19, 21, "Disease"], [31, 35, "Disease"], [37, 39, "Disease"], [41, 47, "Disease"], [4, 5, "Test_items"]], "rel": [[4, 5, "Test_items", 19, 21, "Disease", "Test_items_Disease"]]}
{"idx": 1080, "sentence": "(2)对于大多数的非内分泌科住院高血糖患者而言，胰岛素是控制血糖的首选治疗方法。", "ner": [[16, 18, "Disease"], [24, 26, "Drug"], [30, 31, "Test_items"]], "rel": [[24, 26, "Drug", 16, 18, "Disease", "Drug_Disease"], [30, 31, "Test_items", 16, 18, "Disease", "Test_items_Disease"]]}
{"idx": 1081, "sentence": "(3)对于急危重症患者，推荐采用持续静脉岛素输注，根据血糖波动情况随时调整胰岛素剂量；在打算改用胰岛素皮下注射时，需在停止胰岛素静脉输注前1~2h接受皮下注射。", "ner": [[16, 23, "Method"], [19, 21, "Drug"], [27, 28, "Test_items"], [37, 39, "Drug"], [48, 50, "Drug"], [51, 54, "Method"], [61, 63, "Drug"], [64, 67, "Method"], [75, 78, "Method"]], "rel": [[16, 23, "Method", 19, 21, "Drug", "Method_Drug"], [51, 54, "Method", 48, 50, "Drug", "Method_Drug"], [64, 67, "Method", 61, 63, "Drug", "Method_Drug"], [75, 78, "Method", 61, 63, "Drug", "Method_Drug"]]}
{"idx": 1082, "sentence": "同时，每日减少大约20%~40%的胰岛素总量。", "ner": [[17, 19, "Drug"]], "rel": []}
{"idx": 1083, "sentence": "(4)对于非急危重症患者，可考虑皮下胰岛素注射。胰岛素注射剂量根据进餐和睡眠时间进行设定；如未进食或有持续肠内或肠外营养，每4~6h皮下注射短效或速效胰岛素。", "ner": [[16, 22, "Method"], [18, 20, "Drug"], [24, 26, "Drug"], [51, 59, "Treatment"], [66, 69, "Method"], [70, 77, "Drug"]], "rel": [[16, 22, "Method", 18, 20, "Drug", "Method_Drug"], [66, 69, "Method", 70, 77, "Drug", "Method_Drug"]]}
{"idx": 1084, "sentence": "对于进食差，或无法正常进食的患者，可考虑以基础胰岛素为主，辅以临时短效或速效胰岛素注射；营养摄入充足患者，则推荐基础一餐时胰岛素治疗方案以及必要时临时补充短效或速效胰岛素，有条件的也可考虑胰岛素泵治疗。", "ner": [[23, 25, "Drug"], [33, 40, "Drug"], [41, 42, "Method"], [61, 63, "Drug"], [77, 84, "Drug"]], "rel": [[41, 42, "Method", 33, 40, "Drug", "Method_Drug"]]}
{"idx": 1085, "sentence": "推荐餐前进行床旁血糖监测。", "ner": [[8, 11, "Test_items"]], "rel": []}
{"idx": 1086, "sentence": "(5)在胰岛素制剂的选择上，有短效或速效胰岛素、预混胰岛素、中效或长效胰岛素。速效胰岛素类似物联合长效胰岛素类似物进行基础一餐时胰岛素治疗或者速效胰岛素类似物用于胰岛素泵治疗能够带来更好的血糖控制，降低低血糖的发生风险，血糖达标时间更短，有助于缩短手术前准备时间和住院时间。速效胰岛素类似物可以餐前即刻或餐后立即注射的灵活特点也使其能够更好地满足进食不规律的住院患者的治疗需求。而且，速效胰岛素类似物堵管的发生风险较低，更适合于胰岛素泵治疗。", "ner": [[4, 6, "Drug"], [15, 22, "Drug"], [24, 28, "Drug"], [30, 37, "Drug"], [39, 46, "Drug"], [49, 56, "Drug"], [64, 66, "Drug"], [71, 78, "Drug"], [101, 103, "ADE"], [137, 144, "Drug"], [156, 157, "Method"], [192, 199, "Drug"], [200, 201, "ADE"], [94, 95, "Test_items"], [110, 111, "Test_items"]], "rel": [[156, 157, "Method", 137, 144, "Drug", "Method_Drug"], [200, 201, "ADE", 192, 199, "Drug", "ADE_Drug"]]}
{"idx": 1087, "sentence": "对于入院前应用预混胰岛素且血糖控制良好的患者，入院后可考虑继续应用预混胰岛素治疗。", "ner": [[7, 11, "Drug"], [13, 14, "Test_items"], [33, 37, "Drug"]], "rel": []}
{"idx": 1088, "sentence": "(6)口服降糖药物，包括二肽基肽酶4(DPP-4)抑制剂和GLP-1受体激动剂在住院高血糖患者的使用证据较少。如果患者的临床状况比较稳定、进食规律并且没有使用这些药物的禁忌证，则在入院后可以考虑维续应用其入院前已经使用的口服降糖药物或GLP-1受体激动剂。", "ner": [[3, 4, "Method"], [12, 27, "Drug"], [29, 38, "Drug"], [42, 44, "Disease"], [110, 111, "Method"], [117, 126, "Drug"]], "rel": [[3, 4, "Method", 12, 27, "Drug", "Method_Drug"], [3, 4, "Method", 29, 38, "Drug", "Method_Drug"], [12, 27, "Drug", 42, 44, "Disease", "Drug_Disease"], [29, 38, "Drug", 42, 44, "Disease", "Drug_Disease"]]}
{"idx": 1089, "sentence": "5.特殊情况的处理", "ner": [], "rel": []}
{"idx": 1090, "sentence": "(1)肠内或肠外营养：①持续肠内营养，每日1次或2次基础胰岛素；同时，每4h给予短效或速效胰岛素皮下注射；分次肠内营养，维持原基胰岛素治疗方案；如初始治疗，给予10U基础胰岛素。", "ner": [[3, 9, "Treatment"], [12, 17, "Treatment"], [19, 25, "Frequency"], [28, 30, "Drug"], [35, 37, "Frequency"], [40, 47, "Drug"], [48, 51, "Method"], [55, 58, "Treatment"], [64, 66, "Drug"], [80, 82, "Amount"], [85, 87, "Drug"]], "rel": [[19, 25, "Frequency", 28, 30, "Drug", "Frequency_Drug"], [35, 37, "Frequency", 40, 47, "Drug", "Frequency_Drug"], [48, 51, "Method", 40, 47, "Drug", "Method_Drug"], [80, 82, "Amount", 85, 87, "Drug", "Amount_Drug"]]}
{"idx": 1091, "sentence": "同时，在每次进行肠内营养时，给予短效或速效胰岛素皮下注射；③肠外营养，全胃肠外静脉营养液中添加短效或速效胰岛素；同时，每4h给予短效或速效胰岛素皮下注射。", "ner": [[8, 11, "Treatment"], [16, 23, "Drug"], [24, 27, "Method"], [30, 33, "Treatment"], [35, 43, "Drug"], [47, 54, "Drug"], [59, 61, "Frequency"], [64, 71, "Drug"], [72, 75, "Method"]], "rel": [[24, 27, "Method", 16, 23, "Drug", "Method_Drug"], [59, 61, "Frequency", 64, 71, "Drug", "Frequency_Drug"], [72, 75, "Method", 64, 71, "Drug", "Method_Drug"]]}
{"idx": 1092, "sentence": "(2)糖皮质激素的使用：糖皮质激素在使用时需考虑其在体内作用时间对高血糖的影响。可使用中效或长效胰岛素控制血糖。同样床旁血糖监测非常重要，根据血精监测结果调整胰岛素的使用。", "ner": [[3, 7, "Drug"], [12, 16, "Drug"], [33, 35, "Disease"], [43, 50, "Drug"], [79, 81, "Drug"], [53, 54, "Test_items"], [60, 63, "Test_items"], [71, 74, "Test_items"]], "rel": [[12, 16, "Drug", 33, 35, "Disease", "Drug_Disease"]]}
{"idx": 1093, "sentence": "(3)围手术期：①围手术期血糖控制目标参见本共识“二、住院患者的血糖控制目标”部分；对于缺血性心脏病高风险患者，存在自主神经病变或肾功能衰竭患者需慎重评估围手术期低血糖风险；根据患者的血糖情况、一般状况及手术的类型决定是否需要停用之前的口服降糖药物以及是否需要胰岛素治疗。", "ner": [[44, 49, "Disease"], [47, 48, "Anatomy"], [58, 63, "Disease"], [60, 61, "Anatomy"], [65, 69, "Disease"], [65, 65, "Anatomy"], [81, 83, "Disease"], [92, 93, "Test_items"], [118, 119, "Method"], [130, 132, "Drug"], [13, 14, "Test_items"], [32, 33, "Test_items"]], "rel": [[47, 48, "Anatomy", 44, 49, "Disease", "Anatomy_Disease"], [60, 61, "Anatomy", 58, 63, "Disease", "Anatomy_Disease"], [65, 65, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"]]}
{"idx": 1094, "sentence": "对于需要禁食的手术，在进行手术当日早上，停用口服降糖药物，给予半剂量中性低精蛋白锌胰岛素(NPH)，或全剂量长效胰岛素类似物，或全剂量胰岛素泵基础量。", "ner": [[22, 23, "Method"], [31, 48, "Drug"], [51, 61, "Drug"]], "rel": []}
{"idx": 1095, "sentence": "③在禁食期间，每4~6h进行血糖检测，超过血糖控制目标时给子短效或速效胰岛素。", "ner": [[30, 37, "Drug"], [21, 22, "Test_items"], [14, 17, "Test_items"]], "rel": []}
{"idx": 1096, "sentence": "(4)DKA和糖尿病高渗状态：处理目标包括：纠正血容量、改善组织灌注、纠正高血糖、血电解质紊乱和酮症等。寻找相关诱因非常重要。小剂量胰岛素静脉、肌肉或皮下注射是治疗DKA和高渗状态的安全有效措施。具体治疗方案详见本章节“(一)内分泌科住院糖尿病患者的血糖管理“中“2.内分泌科住院糖尿病患者的血糖管理”部分。", "ner": [[3, 5, "Disease"], [7, 13, "Disease"], [66, 68, "Drug"], [69, 78, "Method"], [82, 84, "Disease"], [86, 89, "Disease"], [119, 121, "Disease"], [140, 142, "Disease"], [146, 147, "Test_items"], [125, 126, "Test_items"]], "rel": [[69, 78, "Method", 66, 68, "Drug", "Method_Drug"], [66, 68, "Drug", 82, 84, "Disease", "Drug_Disease"], [66, 68, "Drug", 86, 89, "Disease", "Drug_Disease"], [125, 126, "Test_items", 119, 121, "Disease", "Test_items_Disease"], [146, 147, "Test_items", 140, 142, "Disease", "Test_items_Disease"]]}
{"idx": 1097, "sentence": "6.低血糖的治疗和预防：参见本章节”(一)内分泌科住院糖尿病患者的血糖管理”中“2.内分泌科住院糖尿病患者的血糖管理”中对低血糖的管理。", "ner": [[2, 4, "Disease"], [27, 29, "Disease"], [48, 50, "Disease"], [61, 63, "Disease"], [33, 34, "Test_items"], [54, 55, "Test_items"]], "rel": [[33, 34, "Test_items", 27, 29, "Disease", "Test_items_Disease"], [54, 55, "Test_items", 48, 50, "Disease", "Test_items_Disease"]]}
{"idx": 1098, "sentence": "7.出院随访", "ner": [], "rel": []}
{"idx": 1099, "sentence": "(1)完整的出院小结信息有助于患者在出院后方便安全地在门诊随访或至当地或基层医疗机构就诊。", "ner": [], "rel": []}
{"idx": 1100, "sentence": "相关信息包括高血糖的病因信息(或寻找病因的方案)相关并发症与合并症，推荐的后继治疗方案等。", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 1101, "sentence": "(2)出院时向患者及家属交代清楚治疗方案，确保新处方的安全性；正确使用并处置胰岛素皮下注射针头和注射器；提供购买相关医疗设备或耗材的信息(如胰岛素笔、便携式血糖仪)；对药物的服用方法、药品的管理、血糖监测、高低血糖的识别、预防和应急处理进行宣传教育。", "ner": [[38, 40, "Drug"], [41, 44, "Method"], [103, 106, "Disease"], [98, 101, "Test_items"]], "rel": [[41, 44, "Method", 38, 40, "Drug", "Method_Drug"]]}
{"idx": 1102, "sentence": "(3)建议所有糖尿病或高血糖患者在出院1个月后接受内分泌专科医生的评估。糖尿病患者根据出院后的血糖水平，由内分泌专科医生进行降糖方案的调整并制订长期随访方案。对于住院新发现的高血糖患者更有必要在出院后重新进行糖代谢状态的评估。", "ner": [[7, 9, "Disease"], [11, 13, "Disease"], [36, 38, "Disease"], [47, 50, "Test_items"], [87, 89, "Disease"], [104, 111, "Test"]], "rel": [[47, 50, "Test_items", 36, 38, "Disease", "Test_items_Disease"], [104, 111, "Test", 87, 89, "Disease", "Test_Disease"]]}
{"idx": 1103, "sentence": "(三)糖尿病妊娠及妊娠糖尿病住院患者的管理", "ner": [[3, 7, "Disease"], [9, 13, "Disease"]], "rel": []}
{"idx": 1104, "sentence": "妊娠期间高血糖包括糖尿病妊娠与妊娠糖尿病(GDM)，不论是那种类型高血糖，均可能导致不良妊娠结局，其中需要进行住院血糖管理的患者包括：糖尿病患者计划妊娠或已妊娠时，或GDM患者，经门诊治疗血糖不达标者；合并严重急、慢性并发症者；妊娠期需启动胰岛素治疗者；另外，在产科住院的妊娠高血糖患者，依据血糖情况，必要时也应请内分泌科进行血糖管理。", "ner": [[4, 6, "Disease"], [8, 13, "Disease"], [15, 24, "Disease"], [33, 35, "Disease"], [42, 45, "Symptom"], [67, 69, "Disease"], [83, 85, "Disease"], [94, 95, "Test_items"], [96, 98, "Test_Value"], [120, 122, "Drug"], [136, 140, "Disease"], [146, 147, "Test_items"], [57, 58, "Test_items"], [163, 164, "Test_items"]], "rel": [[42, 45, "Symptom", 33, 35, "Disease", "Symptom_Disease"], [57, 58, "Test_items", 67, 69, "Disease", "Test_items_Disease"], [57, 58, "Test_items", 83, 85, "Disease", "Test_items_Disease"], [163, 164, "Test_items", 136, 140, "Disease", "Test_items_Disease"], [146, 147, "Test_items", 136, 140, "Disease", "Test_items_Disease"]]}
{"idx": 1105, "sentence": "1.计划妊娠的糖尿病患者住院血糖管理", "ner": [[7, 9, "Disease"], [14, 15, "Test_items"]], "rel": [[14, 15, "Test_items", 7, 9, "Disease", "Test_items_Disease"]]}
{"idx": 1106, "sentence": "糖尿病患者从计划妊娠至整个孕期，都应进行严格的血糖管理.以减少不良妊娠结局的发生。计划妊娠的糖尿病患者因血糖控制不良或合并严重急、慢性并发症入院时，需要进行以下管理：", "ner": [[0, 2, "Disease"], [31, 34, "Symptom"], [46, 48, "Disease"], [23, 24, "Test_items"], [52, 53, "Test_items"], [54, 57, "Test_Value"]], "rel": [[23, 24, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [31, 34, "Symptom", 0, 2, "Disease", "Symptom_Disease"], [52, 53, "Test_items", 46, 48, "Disease", "Test_items_Disease"]]}
{"idx": 1107, "sentence": "(1)糖尿病病情评估：系统评价血糖控制状况，监测全天血糖谱(三餐前后、睡前血糖)及HbA1c，必要时可进行动态血糖监测系统(CGMS)；全面评估糖尿病慢性并发症状况如糖尿病视网膜病变(DR)、糖尿病肾脏病变(DKD)及糖尿病周围神经病变等，评估可能加重或促使DR、DKD进展的危险因素；根据White分级(表3)评估糖尿病病情与妊娠风险，White分级在F级以下的患者，妊娠后胎儿存活率不到5%，因而应避免妊娠。", "ner": [[3, 5, "Disease"], [41, 45, "Test_items"], [72, 81, "Disease"], [83, 94, "Disease"], [96, 107, "Disease"], [109, 117, "Disease"], [86, 88, "Anatomy"], [99, 100, "Anatomy"], [112, 115, "Anatomy"], [129, 130, "Disease"], [132, 134, "Disease"], [158, 160, "Disease"], [201, 204, "Treatment"], [24, 28, "Test_items"], [30, 38, "Test_items"], [15, 16, "Test_items"], [53, 66, "Test_items"]], "rel": [[15, 16, "Test_items", 3, 5, "Disease", "Test_items_Disease"], [86, 88, "Anatomy", 83, 94, "Disease", "Anatomy_Disease"], [99, 100, "Anatomy", 96, 107, "Disease", "Anatomy_Disease"], [112, 115, "Anatomy", 109, 117, "Disease", "Anatomy_Disease"], [201, 204, "Treatment", 158, 160, "Disease", "Treatment_Disease"]]}
{"idx": 1108, "sentence": "(2)血糖控制目标和治疗方案：计划妊娠的糖尿病患者应严格控制血糖，餐前血糖控制在3.9-6.5mmol/L，餐后血糖<8.5mmol/L，在避免低血糖的情况下尽量控制HbA1c<6.5%，用胰岛素治疗者控制HbA1c<7.0%。目前我国口服降糖药物均未纳入妊娠期使用适应证，因此孕前正在使用口服降糖药物的2型糖尿病患者应适时停用，并转换为胰岛素控制血糖。", "ner": [[20, 22, "Disease"], [33, 36, "Test_items"], [40, 52, "Test_Value"], [54, 57, "Test_items"], [58, 67, "Test_Value"], [72, 74, "Disease"], [83, 87, "Test_items"], [88, 92, "Test_Value"], [95, 97, "Drug"], [103, 107, "Test_items"], [108, 112, "Test_Value"], [118, 119, "Method"], [145, 146, "Method"], [152, 156, "Disease"], [169, 171, "Drug"], [3, 4, "Test_items"], [30, 31, "Test_items"], [174, 175, "Test_items"]], "rel": [[30, 31, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [169, 171, "Drug", 152, 156, "Disease", "Drug_Disease"], [174, 175, "Test_items", 152, 156, "Disease", "Test_items_Disease"]]}
{"idx": 1109, "sentence": "(3)制订妊娠计划与患者教育：住院期间，应对计划妊娠的糖尿病患者及其家属进行教育，帮助患者及其家属明确糖尿病与妊娠间的相互影响，帮助患者制订以家庭为单位的妊娠计划，并制定完善的孕期随访计划。", "ner": [[3, 8, "Treatment"], [27, 29, "Disease"], [51, 53, "Disease"], [68, 80, "Treatment"], [83, 93, "Treatment"]], "rel": [[68, 80, "Treatment", 51, 53, "Disease", "Treatment_Disease"], [83, 93, "Treatment", 51, 53, "Disease", "Treatment_Disease"]]}
{"idx": 1110, "sentence": "2.妊娠期间的住院血糖管理", "ner": [[9, 10, "Test_items"]], "rel": []}
{"idx": 1111, "sentence": "对于血糖控制不良的孕妇而言，如何在较短的孕期内尽早实现良好血糖控制十分重要。", "ner": [[2, 3, "Test_items"], [4, 7, "Test_Value"], [29, 30, "Test_items"]], "rel": []}
{"idx": 1112, "sentence": "妊娠期间进行住院血糖管理内容包括：", "ner": [[8, 9, "Test_items"]], "rel": []}
{"idx": 1113, "sentence": "(1)病情监测与控制目标：血糖控制不良或不稳定时，应每日监测全天血糖谱(三餐前后、睡前血糖)，必要时可进行CGMS。当孕妇出现不明原因恶心、呕吐、乏力等不适或者血糖控制不理想时还应及时监测尿酮体，必要时行血气分析。妊娠期间血糖控制目标根据糖尿病类型不同有所不同(表4)。", "ner": [[53, 56, "Test"], [67, 68, "Symptom"], [70, 71, "Symptom"], [73, 74, "Symptom"], [94, 96, "Test_items"], [102, 105, "Test"], [119, 121, "Disease"], [13, 14, "Test_items"], [15, 22, "Test_Value"], [80, 81, "Test_items"], [111, 112, "Test_items"], [32, 34, "Test_items"], [36, 44, "Test_items"], [82, 86, "Test_Value"]], "rel": [[111, 112, "Test_items", 119, 121, "Disease", "Test_items_Disease"]]}
{"idx": 1114, "sentence": "(2)管理方案：①饮食与运动方案：饮食与运动干预是妊娠期高血糖管理的基础，在孕妇身体条件允许的情况下，住院期间也应进行合理的饮食、运动干预。饮食应控制总能量摄入，并保证营养均衡，可请营养科进行指导。②胰岛素治疗方案：糖尿病患者妊娠时，血糖水平波动较大，血糖较难控制，均需要使用胰岛素控制血糖。而通过生活方式干预血糖不能达标的GDM孕妇应首先推荐应用胰岛素控制血糖。虽然国外有研究证实了口服降糖药物二甲双胍等在GDM孕妇中应用的安全性和有效性，但我国尚缺乏相关研究，且口服降糖药在我国均无妊娠期间使用的适应证。", "ner": [[17, 23, "Treatment"], [25, 30, "Disease"], [62, 68, "Treatment"], [100, 102, "Drug"], [108, 110, "Disease"], [117, 120, "Test_items"], [121, 124, "Test_Value"], [126, 127, "Test_items"], [138, 140, "Drug"], [149, 154, "Treatment"], [162, 164, "Disease"], [155, 156, "Test_items"], [174, 176, "Drug"], [192, 193, "Method"], [198, 201, "Drug"], [233, 234, "Method"], [143, 144, "Test_items"], [179, 180, "Test_items"]], "rel": [[17, 23, "Treatment", 25, 30, "Disease", "Treatment_Disease"], [138, 140, "Drug", 108, 110, "Disease", "Drug_Disease"], [117, 120, "Test_items", 108, 110, "Disease", "Test_items_Disease"], [149, 154, "Treatment", 162, 164, "Disease", "Treatment_Disease"], [155, 156, "Test_items", 162, 164, "Disease", "Test_items_Disease"], [174, 176, "Drug", 162, 164, "Disease", "Drug_Disease"], [192, 193, "Method", 198, 201, "Drug", "Method_Drug"]]}
{"idx": 1115, "sentence": "对于孕前已使用二甲双胍的多囊卵巢综合征(PCOS)患者，应权衡药物的潜在风险和可能获益，在知情同意的基础上可以考虑妊娠期间继续使用。", "ner": [[7, 10, "Drug"], [12, 24, "Disease"]], "rel": [[7, 10, "Drug", 12, 24, "Disease", "Drug_Disease"]]}
{"idx": 1116, "sentence": "妊娠期常用的胰岛素制剂类型包括短效人胰岛素、中效人胰岛素，另外，胰岛素类似物如门冬胰岛素、地特胰岛素已获国家食品药品监督管理总局(CFDA)批准可以在妊娠期间使用(表5)。", "ner": [[6, 8, "Drug"], [15, 20, "Drug"], [22, 27, "Drug"], [32, 37, "Drug"], [39, 43, "Drug"], [45, 49, "Drug"]], "rel": []}
{"idx": 1117, "sentence": "临床上最符合生理要求的胰岛素治疗方案为基础一餐时胰岛素治疗和CSII，两种方案均可根据血糖监测情况进行灵活的个体化调整。", "ner": [[11, 13, "Drug"], [43, 46, "Test_items"], [24, 26, "Drug"]], "rel": []}
{"idx": 1118, "sentence": "需要注意的是，妊娠中、晚期对胰岛素需要量有不同程度的增加，妊娠32~36周胰岛素需要量达高峰，妊娠36周后稍下降，应根据个体血糖监测结果，不断调整胰岛素用量。", "ner": [[14, 16, "Drug"], [37, 39, "Drug"], [62, 65, "Test_items"], [73, 75, "Drug"]], "rel": []}
{"idx": 1119, "sentence": "产后一旦患者恢复正常饮食，应及时进行血糖监测，根据血糖情况决定是否需要继续胰岛素治疗，通常产后胰岛素需要量较妊娠期会明显减少。", "ner": [[18, 21, "Test_items"], [25, 26, "Test_items"], [37, 39, "Drug"], [47, 49, "Drug"]], "rel": []}
{"idx": 1120, "sentence": "(3)急、危重症的处理：①妊娠期低血糖：常见诱因包括：早孕反应(如晨起恶心)引起的摄食异常；运动量过大；胰岛素剂量过大；围产期能量清耗过大。治疗原则：迅速给予糖水或碳水化合物食物；重症者需用50%葡萄糖静脉注射；如需要，可为糖尿病孕妇提供胰升糖素；寻找诱因，及时调整药物治疗。②妊娠期DKA：孕期血糖控制不良容易并发酮症甚至DKA，常见诱因包括：妊娠期间漏诊、未及时诊断或治疗的糖尿病：胰岛素治疗不规范；饮食控制不合理；产程中和手术前后应激状态；合并感染；使用糖皮质激素等。", "ner": [[13, 18, "Disease"], [27, 44, "Reason"], [46, 50, "Reason"], [52, 58, "Reason"], [60, 68, "Reason"], [77, 88, "Treatment"], [95, 100, "Drug"], [101, 104, "Method"], [112, 114, "Disease"], [119, 122, "Drug"], [139, 144, "Disease"], [158, 159, "Disease"], [162, 164, "Disease"], [173, 191, "Reason"], [193, 200, "Reason"], [202, 208, "Reason"], [210, 221, "Reason"], [223, 226, "Reason"], [228, 234, "Reason"], [148, 149, "Test_items"]], "rel": [[27, 44, "Reason", 13, 18, "Disease", "Reason_Disease"], [46, 50, "Reason", 13, 18, "Disease", "Reason_Disease"], [52, 58, "Reason", 13, 18, "Disease", "Reason_Disease"], [60, 68, "Reason", 13, 18, "Disease", "Reason_Disease"], [101, 104, "Method", 95, 100, "Drug", "Method_Drug"], [119, 122, "Drug", 112, 114, "Disease", "Drug_Disease"], [173, 191, "Reason", 139, 144, "Disease", "Reason_Disease"], [193, 200, "Reason", 139, 144, "Disease", "Reason_Disease"], [202, 208, "Reason", 139, 144, "Disease", "Reason_Disease"], [210, 221, "Reason", 139, 144, "Disease", "Reason_Disease"], [223, 226, "Reason", 139, 144, "Disease", "Reason_Disease"], [228, 234, "Reason", 139, 144, "Disease", "Reason_Disease"], [148, 149, "Test_items", 158, 159, "Disease", "Test_items_Disease"], [148, 149, "Test_items", 162, 164, "Disease", "Test_items_Disease"]]}
{"idx": 1121, "sentence": "治疗原则：给予胰岛素降低血糖、纠正代谢和电解质紊乱、改善血液循环、去除诱因。", "ner": [[7, 9, "Drug"], [12, 13, "Test_items"]], "rel": []}
{"idx": 1122, "sentence": "(4)分娩及产料、儿料处理：住院期间如出现母儿并发症，应及时联合产科进病情评估，根据病情决定终止妊娠时机及分娩方式。新生儿出生后易发生低血糖，严密监测其血糖变化及时发现低血糖，提早喂糖水、开奶，必要时进行静脉葡萄滴注。", "ner": [[67, 69, "Disease"], [76, 77, "Test_items"], [84, 86, "Disease"], [88, 95, "Treatment"], [102, 107, "Method"]], "rel": [[76, 77, "Test_items", 84, 86, "Disease", "Test_items_Disease"], [88, 95, "Treatment", 84, 86, "Disease", "Treatment_Disease"]]}
{"idx": 1123, "sentence": "档案建立及远期随访：所有因糖尿病住院的孕妇都应常规建立随访档案，制订随访计划，定期到内分泌门诊随访血糖状况。推荐所有GDM妇女在产后6~12周进行口服葡萄糖耐量试验(OGTT)检查，明确有无糖代谢异常，以后每3年随访1次。同时，建议对糖尿病患者的子代进行生长发育状况的随访，并进行健康生活方式的指导。", "ner": [[13, 15, "Disease"], [49, 50, "Test_items"], [58, 60, "Disease"], [73, 89, "Test"], [95, 99, "Disease"], [117, 119, "Disease"], [140, 148, "Treatment"], [127, 135, "Treatment"]], "rel": [[49, 50, "Test_items", 13, 15, "Disease", "Test_items_Disease"], [73, 89, "Test", 58, 60, "Disease", "Test_Disease"], [127, 135, "Treatment", 117, 119, "Disease", "Treatment_Disease"], [140, 148, "Treatment", 117, 119, "Disease", "Treatment_Disease"]]}
{"idx": 1124, "sentence": "四、住院患者血糖管理模式介绍", "ner": [[6, 7, "Test_items"]], "rel": []}
{"idx": 1125, "sentence": "住院血糖管理模式是在管理理念指导下建构起来，由管理方法、管理制度、管理工具、管理程序组成的住院血糖管理行为体系结构。虽然我国糖尿病患病率逐年升高，但关于住院患者血糖管理模式的研究报道较少。", "ner": [[62, 64, "Disease"], [2, 3, "Test_items"], [47, 48, "Test_items"], [80, 81, "Test_items"]], "rel": [[80, 81, "Test_items", 62, 64, "Disease", "Test_items_Disease"]]}
{"idx": 1126, "sentence": "由于各国医患关系、医院体制及医保制度的不同，住院患者管理模式存在差异。", "ner": [], "rel": []}
{"idx": 1127, "sentence": "参照美国临床内分泌医师协会(AACE)住院患者血糖管理模式，结合我国住院患者及医院管理实情，对我国住院血糖管理模式进行以下推荐，以期为住院患者良好的血糖控制提供帮助。", "ner": [[23, 24, "Test_items"], [51, 52, "Test_items"], [74, 75, "Test_items"]], "rel": []}
{"idx": 1128, "sentence": "(一)住院血糖管理模式的分类", "ner": [[5, 6, "Test_items"]], "rel": []}
{"idx": 1129, "sentence": "根据我国住院患者病情轻者比例较高，新诊断糖尿病患者入院治疗较多，住院期间新发现的糖尿病患者较多，住院患者病情差异性大等特点，推荐我国住院血糖管理分为以下3种：(1)科室自我管理模式：(2)会诊专业管理模式；(3)互联网系统管理模式。", "ner": [[20, 22, "Disease"], [40, 42, "Disease"], [68, 69, "Test_items"]], "rel": [[68, 69, "Test_items", 40, 42, "Disease", "Test_items_Disease"]]}
{"idx": 1130, "sentence": "(二)科室自我管理模式", "ner": [], "rel": []}
{"idx": 1131, "sentence": "1.科室自我管理模式定义：住院患者血糖由患者所住科室医护人员、健康教育工作者、营养师、患者等共同参与的血糖管理模式。", "ner": [[17, 18, "Test_items"], [51, 52, "Test_items"]], "rel": []}
{"idx": 1132, "sentence": "2.科室自我管理模式适用患者：(1)集中收治在内分泌科的患者；(2)收治在非内分泌科病区患者：①入院前血糖控制可，住院期间可继续入院前控糖方案；②住院期间按照临床指南给予基础一餐时胰岛素注射方案，血糖容易达标；③收治重症病区患者，病区医师能够按照临床指南规范使用并合理调整胰岛素方案。", "ner": [[90, 92, "Drug"], [98, 99, "Test_items"], [136, 138, "Drug"], [51, 52, "Test_items"], [53, 55, "Test_Value"]], "rel": []}
{"idx": 1133, "sentence": "3.科室自我管理模式的优势和不足：(1)优势：患者能第一时间得到所住科室医护人员、健康教育工作者、营养师的指导及治疗。", "ner": [], "rel": []}
{"idx": 1134, "sentence": "(2)不足：由于非内分泌科医护人员糖尿病知识的非专业性及患者健康教育不到位，非内分泌科住院患者血糖达标率低。", "ner": [[17, 19, "Disease"], [47, 51, "Test_items"], [52, 52, "Test_Value"]], "rel": []}
{"idx": 1135, "sentence": "(三)会诊专业管理模式", "ner": [], "rel": []}
{"idx": 1136, "sentence": "1.会诊专业管理模式定义：非内分泌科住院患者血糖除由患者所住科室医护人员、健康教育工作者、营养师、患者等参与血糖管理外，血糖控制不良、临床状态特殊、控糖方案制定困难时，内分泌科医师通过会诊方式参与的血糖管理模式。", "ner": [[22, 23, "Test_items"], [54, 55, "Test_items"], [60, 61, "Test_items"], [99, 100, "Test_items"], [62, 65, "Test_Value"]], "rel": []}
{"idx": 1137, "sentence": "在会诊专业管理模式中，有一种由内分泌科医生及糖尿病教育护士组成核心管理团队，其他非内分泌科室的护士也参与其中共同管理住院患者血糖的会诊模式，这一模式可以称为糖尿病团队管理模式。", "ner": [[22, 24, "Disease"], [62, 63, "Test_items"], [78, 80, "Disease"]], "rel": []}
{"idx": 1138, "sentence": "如果医院情况允许，也可以在团队中加入营养师、药剂师等多学科成员。", "ner": [], "rel": []}
{"idx": 1139, "sentence": "糖尿病团队管理模式同样由内分泌科医生给出会诊治疗意见，但可以更多地发挥护士的职能，糖尿病教育护士可以协助内分泌科医生对非内分泌科的高血糖住院患者进行随访，反馈患者情况给内分泌医生并传达内分泌科医生的治疗意见。", "ner": [[0, 2, "Disease"], [41, 43, "Disease"], [65, 67, "Disease"]], "rel": []}
{"idx": 1140, "sentence": "糖尿病团队模式需要医院行政管理层的支持和(或)非内分泌科室的良好合作意愿，同时要求内分泌科具有高效的医护团队，因此需要各医院根据自身情况来决定是否实施。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 1141, "sentence": "2.会诊专业管理模式适用患者：(1)住院期间按照临床指南使用及调整胰岛素治疗方案，但血糖仍不能达标的患者；(2)合并特殊情况的患者：进食不规律、需肠内营养、应激、伴有糖尿病急性并发症、糖尿病妊娠、围手术期、合并使用糖皮质激素、免疫抑制剂等。", "ner": [[33, 35, "Drug"], [42, 43, "Test_items"], [45, 48, "Test_Value"], [73, 76, "Treatment"], [83, 90, "Disease"], [92, 96, "Disease"], [107, 111, "Drug"], [113, 117, "Drug"]], "rel": []}
{"idx": 1142, "sentence": "3.会诊专业管理模式的优势和不足：(1)优势：内分泌科医师通过院内会诊参与非内分泌科住院患者的血糖管理可以提高患者血糖达标率、缩短平均住院日及改善患者临床结局。(2)不足：医疗资源的短缺使内分泌科医护人员不可能参与每个非内分泌科住院患者的血糖管理，更多的住院糖尿病患者血糖管理实际上由所在科室医护人员完成，得到专科医师的指导有限。", "ner": [[57, 61, "Test_items"], [129, 131, "Disease"], [47, 48, "Test_items"], [119, 120, "Test_items"], [134, 135, "Test_items"]], "rel": [[134, 135, "Test_items", 129, 131, "Disease", "Test_items_Disease"]]}
{"idx": 1143, "sentence": "(四)互联网系统管理模式", "ner": [], "rel": []}
{"idx": 1144, "sentence": "随着互联网技术的发展、医疗软件的开发利用以及智能手机、平板电脑等移动终端的普及，基于互联网的系统管理模式逐渐用于糖尿病患者血糖管理，通过信息技术合理配置医疗资源，提高医疗资源的利用率。", "ner": [[56, 58, "Disease"], [61, 62, "Test_items"]], "rel": [[61, 62, "Test_items", 56, 58, "Disease", "Test_items_Disease"]]}
{"idx": 1145, "sentence": "1.互联网系统管理模式定义：利用住院患者互联网管理系统，与患者血糖监测数据管理系统相结合，使院内任一科室糖尿病患者都能及时接受糖尿病医护的远程系统管理，包括糖尿病教育、监测及治疗方案制定与调整。", "ner": [[52, 54, "Disease"], [63, 65, "Disease"], [78, 80, "Disease"], [31, 34, "Test_items"]], "rel": [[31, 34, "Test_items", 52, 54, "Disease", "Test_items_Disease"]]}
{"idx": 1146, "sentence": "2.互联网系统管理模式适用条件及患者：建立好互联网系统管理模式的医院可以开展远程糖尿病系统管理，适合该系统的患者为已纳入系统管理，且录入信息准确，能配合医护治疗方案执行的患者。", "ner": [[40, 42, "Disease"]], "rel": []}
{"idx": 1147, "sentence": "3.互联网系统管理模式的优势和不足：(1)优势：①国内外互联网系统管理模式系统有所不同，对住院患者血糖控制改善率不一.但均能提高住院患者血糖达标率，降低低血糖发生率及平均住院日，改善预后；②提高患者糖尿病知识的知晓率，提高医护人员工作效率，同时提升患者满意度；③管理系统通过对患者连续的、主动的个性化服务与管理，实现了院内“分泌科-非内分泌科“血糖管理无缝衔接。(2)不足：①护理人员的工作量繁重、交互界面操作困难、内置提醒设置不充足及对错误的关注不足是互联网系统管理模式实施的主要困难；2低血糖发生在系统中被过分关注，导致护士为避免低血糖发生而不完全执行系统推荐的胰岛素注射剂量，增加血糖达标难度：③互联网系统管理模式所有信息建立在电子病历基础上，不能完全替代面对面的内分泌医师会诊评估。", "ner": [[68, 72, "Test_items"], [76, 78, "Disease"], [99, 101, "Disease"], [245, 247, "Disease"], [267, 269, "Disease"], [283, 285, "Drug"], [293, 294, "Test_items"], [49, 50, "Test_items"], [172, 173, "Test_items"], [286, 287, "Method"]], "rel": [[68, 72, "Test_items", 76, 78, "Disease", "Test_items_Disease"], [293, 294, "Test_items", 267, 269, "Disease", "Test_items_Disease"], [286, 287, "Method", 283, 285, "Drug", "Method_Drug"]]}
{"idx": 1148, "sentence": "4.互联网系统管理模式的前景：互联网系统管理模式是未来极具前景和应用推广价值的住院血糖管理模式，但牵涉到住院患者管理系统、终端末梢血糖监测系统、血糖管理系统及网络服务器的整合，需一定财力、物力的投入及医院多部门协作。", "ner": [[65, 68, "Test_items"], [41, 42, "Test_items"], [72, 73, "Test_items"]], "rel": []}
{"idx": 1149, "sentence": "在信息技术和互联网技术的发展下，互联网系统管理模式需不断更新、改进，其安全性、有效性及性价比有待进一步提高。", "ner": [], "rel": []}
{"idx": 1150, "sentence": "盘点降糖药物的中国指南/共识(下)", "ner": [], "rel": []}
{"idx": 1151, "sentence": "近几年，国外新药进入中国市场的速度似乎逐渐加快，这些新药无疑给血糖管理增添了新的选择，基于国内外的研究证据，国内学术组织已经发布了一些针对这些新药的指南或共识，这有助于规范用临床应用，下面就让我们一起去了解这些新型降糖药。", "ner": [[31, 32, "Test_items"]], "rel": []}
{"idx": 1152, "sentence": "现在，我国临床上可供选择的降糖药物已达到九种，其中二肽基肽酶IV(DPP- 4)抑制剂、胰高血糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是最近几年刚刚进入我国，但由于作用机制不同于传统的降糖药物，迅速成为热门药物。", "ner": [[25, 42, "Drug"], [44, 63, "Drug"], [65, 86, "Drug"]], "rel": []}
{"idx": 1153, "sentence": "DPP-4抑制剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 1154, "sentence": "胃肠道是机体重要的内分泌器官，其分泌的肠促胰素所引起的胰岛素分泌约占全部胰岛素分泌量的50%~70%，而且肠促胰素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。", "ner": [[92, 94, "Disease"], [84, 85, "Test_items"]], "rel": [[84, 85, "Test_items", 92, 94, "Disease", "Test_items_Disease"]]}
{"idx": 1155, "sentence": "正因为如此，人们研发出了模拟肠促胰素的GLP-1受体激动剂和延缓肠促胰素降解的DPP- 4抑制剂。", "ner": [[19, 28, "Drug"], [39, 47, "Drug"]], "rel": []}
{"idx": 1156, "sentence": "目前国内已经上市了两种GLP-1受体激动剂(艾塞那肽和利拉鲁肽)和5种DPP-4抑制剂(西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀)(见表1)。", "ner": [[11, 20, "Drug"], [22, 25, "Drug"], [27, 30, "Drug"], [35, 42, "Drug"], [44, 47, "Drug"], [49, 52, "Drug"], [54, 57, "Drug"], [59, 62, "Drug"], [64, 67, "Drug"]], "rel": []}
{"idx": 1157, "sentence": "中华医学会糖尿病学分会(CDS)在2014年发布了《基于胰高血糖素样肽1降糖药物的临床应用共识》(简称“临床应用共识”)；中华医学会内分泌学分会与中国药学会医院药学专业委员会在2015年年底联合发布了《基于肠促胰素的药物治疗临床应用的快速建议指南》(简称“快速建议指南”)，该指南计划于2018年进行更新，届时可能会根据新的中国证据做出一些调整。", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 1158, "sentence": "DPP-4抑制剂在2017年才被纳入医保乙类药物(即需要部分自费)，所以临床上更多地是在大城市的大医院使用，或是在其他降糖药物效果不佳时才被使用，所以在我国的糖尿病指南中的治疗地位要比快速建议指南中的地位略低一些。", "ner": [[0, 7, "Drug"], [79, 81, "Disease"]], "rel": []}
{"idx": 1159, "sentence": "以下内容我们将仅仅客观分析现有证据，具体到临床应用，大家还是需要和医生共同商定。", "ner": [], "rel": []}
{"idx": 1160, "sentence": "适用人群", "ner": [], "rel": []}
{"idx": 1161, "sentence": "临床应用共识指出，DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。", "ner": [[9, 16, "Drug"], [22, 26, "Disease"], [30, 31, "Test_items"]], "rel": [[9, 16, "Drug", 22, 26, "Disease", "Drug_Disease"], [30, 31, "Test_items", 22, 26, "Disease", "Test_items_Disease"]]}
{"idx": 1162, "sentence": "目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制。", "ner": [[16, 19, "Drug"], [37, 40, "Drug"], [54, 57, "Drug"], [59, 62, "Drug"], [85, 88, "Drug"], [97, 100, "Drug"], [106, 109, "Drug"], [111, 114, "Drug"], [141, 144, "Drug"], [150, 153, "Drug"], [166, 169, "Drug"], [171, 175, "Drug"], [49, 50, "Test_items"], [89, 90, "Test_items"], [136, 137, "Test_items"], [182, 183, "Test_items"], [23, 26, "Treatment"], [28, 29, "Treatment"], [65, 66, "Treatment"], [68, 69, "Treatment"], [157, 160, "Treatment"], [162, 163, "Treatment"], [91, 94, "Test_Value"]], "rel": []}
{"idx": 1163, "sentence": "临床应用共识还强调，DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。", "ner": [[10, 17, "Drug"], [22, 26, "Disease"], [28, 35, "Disease"]], "rel": []}
{"idx": 1164, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 1165, "sentence": "(1)起始用药", "ner": [], "rel": []}
{"idx": 1166, "sentence": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的一线治疗选择之一，认为在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4抑制剂可以作为一线的替代治疗药物。在刚刚结束的2017年CDS年会上，贾伟平教授简单介绍了即将发布的《中国2型糖尿病防治指南(2017年版)》(简称2017版指南)的一些内容，在高血糖治疗流程上一个主要变化是把原来的一线、二线、三线药物改为单药、二联和三联治疗，这相当于进一步强调了二甲双胍的重要地位，因为二联和三联治疗均推荐在二甲双胍基础上加用其他药物，而且在单药治疗中，二甲双胍不耐受或存在禁忌时的备选药物给出的是α一糖苷酶抑制剂和胰岛素促泌剂。个人认为，推荐α一糖苷酶抑制剂是考虑到餐后高血糖(尤其是单纯餐后高血糖)在国内很常见，推荐胰岛素促泌剂则是因为其降糖效力和二甲双胍相当，而未推荐DPP-4抑制剂一方面可能是从经济和可获得性角度考虑，另一方面可能是其降糖效力略弱。碰巧在2017年CDS年会上，纪立农教授题为《血糖达标的策略：2型糖尿病起始治疗》的报告中，恰巧也分析了起始单药治疗时，二甲双胍与DPP-4抑制剂的对比情况。2016—2017年发表的比较二甲双胍和西格列汀、阿格列汀、利格列汀的三项中国研究均发现，无论是低剂量还是高剂量(1700或2000毫克/天)的二甲双胍治疗，其降糖疗效都要优于DPP-4抑制剂。", "ner": [[8, 15, "Drug"], [38, 41, "Drug"], [57, 64, "Drug"], [203, 206, "Drug"], [226, 229, "Drug"], [249, 252, "Drug"], [271, 278, "Drug"], [280, 285, "Drug"], [294, 301, "Drug"], [332, 337, "Drug"], [348, 351, "Drug"], [359, 366, "Drug"], [461, 464, "Drug"], [466, 473, "Drug"], [495, 498, "Drug"], [500, 503, "Drug"], [505, 508, "Drug"], [510, 513, "Drug"], [552, 555, "Drug"], [568, 575, "Drug"], [18, 22, "Disease"], [115, 119, "Disease"], [432, 436, "Disease"], [151, 153, "Disease"], [306, 310, "Disease"], [317, 321, "Disease"], [424, 425, "Test_items"], [426, 427, "Test_Value"], [537, 549, "Amount"]], "rel": [[8, 15, "Drug", 18, 22, "Disease", "Drug_Disease"], [461, 464, "Drug", 432, 436, "Disease", "Drug_Disease"], [466, 473, "Drug", 432, 436, "Disease", "Drug_Disease"], [537, 549, "Amount", 552, 555, "Drug", "Amount_Drug"], [424, 425, "Test_items", 432, 436, "Disease", "Test_items_Disease"]]}
{"idx": 1167, "sentence": "因此，纪教授的观点是，对于单药治疗患者，高剂量二甲双胍应作为常规起始治疗。", "ner": [[23, 26, "Drug"]], "rel": []}
{"idx": 1168, "sentence": "(2)联合用药", "ner": [], "rel": []}
{"idx": 1169, "sentence": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的二线和三线治疗选择之一，指出在当二甲双胍或者其他降糖药物单药治疗后，如糖化血红蛋白水平仍未达标，可联合此类药物。2017版指南也同样将DPP-4抑制剂列为与二甲双胍进行二联或三联治疗的选择之一。在这一点上，两个指南并没有分歧，然而。从最新的国内研究证据来看，在二甲双胍高剂量(2000毫克/天)单药治疗的基础上，加用DPP-4抑制剂只能使糖化血红蛋白进一步下降约0-2%，而减重作用反而更差一些，而在欧美人群中进行的研究中，糖化血红蛋白进一步下降了约0.5%，这是否是降糖药物的又一个中国特色呢(前一个中国特色是α-糖苷酶抑制剂的“西方不亮东方亮”——本刊注)?不过，DPP-4抑制剂可以带来多重获益。", "ner": [[8, 15, "Drug"], [42, 45, "Drug"], [93, 100, "Drug"], [104, 107, "Drug"], [156, 159, "Drug"], [184, 191, "Drug"], [282, 289, "Drug"], [310, 317, "Drug"], [18, 22, "Disease"], [61, 66, "Test_items"], [195, 200, "Test_items"], [238, 243, "Test_items"], [164, 171, "Amount"], [70, 72, "Test_Value"], [204, 210, "Test_Value"], [247, 254, "Test_Value"]], "rel": [[8, 15, "Drug", 18, 22, "Disease", "Drug_Disease"], [42, 45, "Drug", 18, 22, "Disease", "Drug_Disease"], [164, 171, "Amount", 156, 159, "Drug", "Amount_Drug"], [61, 66, "Test_items", 18, 22, "Disease", "Test_items_Disease"]]}
{"idx": 1170, "sentence": "我们或许不能单以降低糖化血红蛋白的能力论英雄。", "ner": [[10, 15, "Test_items"]], "rel": []}
{"idx": 1171, "sentence": "这些都还有待更多的研究来论证。", "ner": [], "rel": []}
{"idx": 1172, "sentence": "毕竟这类药物进入我国临床只有短短几年而已。", "ner": [], "rel": []}
{"idx": 1173, "sentence": "(3)用法用量", "ner": [], "rel": []}
{"idx": 1174, "sentence": "快速建议指南推荐DPP-4抑制剂的剂量为说明中规定的常规使用剂量。临床应用共识则给出了更详细的肝肾功能不全患者的用法用量：", "ner": [[8, 15, "Drug"], [47, 52, "Disease"], [47, 47, "Anatomy"], [48, 48, "Anatomy"]], "rel": [[47, 47, "Anatomy", 47, 52, "Disease", "Anatomy_Disease"], [48, 48, "Anatomy", 47, 52, "Disease", "Anatomy_Disease"]]}
{"idx": 1175, "sentence": "特殊情况", "ner": [], "rel": []}
{"idx": 1176, "sentence": "(1)与胰岛素联用", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 1177, "sentence": "(2)老年患者", "ner": [], "rel": []}
{"idx": 1178, "sentence": "快速建议指南推荐DPP-4抑制剂用于65岁以上的2型糖尿病患者的降糖治疗。其理由是，老年患者常常合并多种并发疾病，而DPP-4抑制剂具有良好的血糖控制效果和安全性，同时也指出，推荐使用常规剂量进行治疗，但如患者伴有肝或肾功能不全，则需要根据说明书进行剂量调整。", "ner": [[8, 15, "Drug"], [58, 65, "Drug"], [24, 28, "Disease"], [71, 72, "Test_items"], [107, 113, "Disease"], [107, 107, "Anatomy"], [109, 109, "Anatomy"]], "rel": [[71, 72, "Test_items", 24, 28, "Disease", "Test_items_Disease"], [107, 107, "Anatomy", 107, 113, "Disease", "Anatomy_Disease"], [109, 109, "Anatomy", 107, 113, "Disease", "Anatomy_Disease"]]}
{"idx": 1179, "sentence": "(3)超重/肥胖患者", "ner": [[3, 4, "Disease"], [6, 7, "Disease"]], "rel": []}
{"idx": 1180, "sentence": "快速建议指南认为DPP-4抑制剂可用于超重/肥胖2型糖尿病患者的降糖治疗，理由是DPP-4抑制剂并不影响患者的体重。", "ner": [[8, 15, "Drug"], [40, 47, "Drug"], [19, 20, "Disease"], [22, 23, "Disease"], [24, 28, "Disease"]], "rel": [[8, 15, "Drug", 19, 20, "Disease", "Drug_Disease"], [8, 15, "Drug", 22, 23, "Disease", "Drug_Disease"], [8, 15, "Drug", 24, 28, "Disease", "Drug_Disease"]]}
{"idx": 1181, "sentence": "然而，如前所述，最新研究显示在二甲双胍治疗基础上加上DPP-4抑制剂，患者的体重减轻幅度反而变小了，其原因还需要进一步的研究来明确。", "ner": [[15, 18, "Drug"], [26, 33, "Drug"]], "rel": []}
{"idx": 1182, "sentence": "(4)伴心血管疾病或心血管风险高的患者", "ner": [[4, 8, "Disease"], [4, 6, "Anatomy"]], "rel": [[4, 6, "Anatomy", 4, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 1183, "sentence": "快速建议指南基于证据总结和专家意见，认为DPP-4抑制剂可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗。", "ner": [[20, 27, "Drug"], [47, 51, "Disease"], [33, 37, "Disease"], [33, 35, "Anatomy"], [39, 43, "Disease"], [39, 41, "Anatomy"]], "rel": [[20, 27, "Drug", 33, 37, "Disease", "Drug_Disease"], [20, 27, "Drug", 47, 51, "Disease", "Drug_Disease"], [33, 35, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"], [39, 41, "Anatomy", 39, 43, "Disease", "Anatomy_Disease"]]}
{"idx": 1184, "sentence": "(5)复方制剂", "ner": [], "rel": []}
{"idx": 1185, "sentence": "快速建议指南推荐复方制剂(DPP-4抑制剂和二甲双胍)用于2型糖尿病患者的起始降糖治疗，指出对于糖化血红蛋白>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4抑制剂和二甲双胍)进行起始治疗。", "ner": [[13, 20, "Drug"], [22, 25, "Drug"], [76, 83, "Drug"], [85, 88, "Drug"], [29, 33, "Disease"], [48, 53, "Test_items"], [54, 58, "Test_Value"]], "rel": [[13, 20, "Drug", 29, 33, "Disease", "Drug_Disease"], [22, 25, "Drug", 29, 33, "Disease", "Drug_Disease"], [48, 53, "Test_items", 29, 33, "Disease", "Test_items_Disease"]]}
{"idx": 1186, "sentence": "不过就像前面提到的，这种用法可能还有待商榷。", "ner": [], "rel": []}
{"idx": 1187, "sentence": "(6)超敏反应", "ner": [], "rel": []}
{"idx": 1188, "sentence": "临床应用共识指出西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和剥脱性皮肤损害，如怀疑发生超敏反应时应停用；维格列汀尽管在临床中未观察到皮肤损伤发生率升高，但在合并糖尿病皮肤并发症的患者中经验有限，建议观察皮肤病变，如水疱、皮疹或溃疡等情况；阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应时应停用；沙格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)，怀疑时应停用；利格列汀在临床研究中也报告有高敏反应，如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应。", "ner": [[8, 11, "Drug"], [61, 64, "Drug"], [128, 131, "Drug"], [163, 166, "Drug"], [203, 206, "Drug"], [89, 96, "Disease"], [21, 24, "ADE"], [28, 31, "ADE"], [33, 37, "ADE"], [39, 45, "ADE"], [52, 55, "ADE"], [75, 83, "ADE"], [110, 113, "ADE"], [116, 117, "ADE"], [119, 120, "ADE"], [122, 123, "ADE"], [140, 145, "ADE"], [154, 157, "ADE"], [175, 178, "ADE"], [182, 187, "ADE"], [189, 193, "ADE"], [217, 220, "ADE"], [223, 225, "ADE"], [227, 231, "ADE"], [233, 238, "ADE"], [240, 246, "ADE"], [19, 20, "Level"], [138, 139, "Level"], [152, 153, "Level"], [173, 174, "Level"], [92, 93, "Anatomy"]], "rel": [[21, 24, "ADE", 8, 11, "Drug", "ADE_Drug"], [28, 31, "ADE", 8, 11, "Drug", "ADE_Drug"], [33, 37, "ADE", 8, 11, "Drug", "ADE_Drug"], [39, 45, "ADE", 8, 11, "Drug", "ADE_Drug"], [52, 55, "ADE", 8, 11, "Drug", "ADE_Drug"], [140, 145, "ADE", 128, 131, "Drug", "ADE_Drug"], [154, 157, "ADE", 128, 131, "Drug", "ADE_Drug"], [175, 178, "ADE", 163, 166, "Drug", "ADE_Drug"], [182, 187, "ADE", 163, 166, "Drug", "ADE_Drug"], [189, 193, "ADE", 163, 166, "Drug", "ADE_Drug"], [223, 225, "ADE", 203, 206, "Drug", "ADE_Drug"], [217, 220, "ADE", 203, 206, "Drug", "ADE_Drug"], [227, 231, "ADE", 203, 206, "Drug", "ADE_Drug"], [233, 238, "ADE", 203, 206, "Drug", "ADE_Drug"], [240, 246, "ADE", 203, 206, "Drug", "ADE_Drug"], [92, 93, "Anatomy", 89, 96, "Disease", "Anatomy_Disease"]]}
{"idx": 1189, "sentence": "(7)药物相互作用", "ner": [], "rel": []}
{"idx": 1190, "sentence": "西格列汀与磺脲类药物合用时低血糖风险增加，需适当减少磺脲类剂量；利格列汀与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类剂量；沙格列汀与酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦和泰利霉素等合用时，应将剂量限制为2.5毫克/天。", "ner": [[0, 3, "Drug"], [5, 9, "Drug"], [26, 28, "Drug"], [32, 35, "Drug"], [37, 39, "Drug"], [41, 43, "Drug"], [60, 62, "Drug"], [64, 66, "Drug"], [70, 73, "Drug"], [75, 77, "Drug"], [79, 82, "Drug"], [84, 87, "Drug"], [89, 92, "Drug"], [94, 97, "Drug"], [99, 102, "Drug"], [104, 107, "Drug"], [109, 112, "Drug"], [114, 117, "Drug"], [119, 122, "Drug"], [13, 19, "ADE"], [47, 53, "ADE"], [135, 141, "Amount"]], "rel": [[13, 19, "ADE", 0, 3, "Drug", "ADE_Drug"], [13, 19, "ADE", 5, 9, "Drug", "ADE_Drug"], [47, 53, "ADE", 32, 35, "Drug", "ADE_Drug"], [47, 53, "ADE", 37, 39, "Drug", "ADE_Drug"], [47, 53, "ADE", 41, 43, "Drug", "ADE_Drug"], [135, 141, "Amount", 70, 73, "Drug", "Amount_Drug"]]}
{"idx": 1191, "sentence": "GLP一1受体激动剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)", "ner": [[0, 9, "Drug"]], "rel": []}
{"idx": 1192, "sentence": "由于GLP一1受体广泛分布在胰岛细胞、胃肠、肺、脑、肾脏、下丘脑、心血管系统、肝脏、脂肪组织和骨骼肌，所以GLP-1除了能促进胰岛素分泌和抑制胰高血糖素分泌之外，还具有延缓胃排空和肠蠕动、抑制食欲、增加饱腹感、降压、降脂、保护肾脏等多方面的作用。", "ner": [], "rel": []}
{"idx": 1193, "sentence": "也正因为如此，GLP-1受体激动剂类药物近年来备受关注和推崇，需要注射给药这一原本的短板，也随着每周一次的超长效制剂出现而得到弥补，每半月或每月给药一次的制剂也正在研发中，这类药物目前来看简直完美。", "ner": [[7, 19, "Drug"]], "rel": []}
{"idx": 1194, "sentence": "适用人群", "ner": [], "rel": []}
{"idx": 1195, "sentence": "临床应用共识指出，GLP-1受体激动剂适用于成人2型糖尿病患者，其中艾塞那肽目前国内适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者，而在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类以及基础胰岛素联合使用等；利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用，而在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍+磺脲类或与二甲双胍+噻唑烷二酮类或与胰岛素联合应用的适应证等。", "ner": [[9, 18, "Drug"], [34, 37, "Drug"], [47, 50, "Drug"], [52, 54, "Drug"], [58, 61, "Drug"], [64, 66, "Drug"], [85, 88, "Drug"], [92, 97, "Drug"], [99, 102, "Drug"], [105, 107, "Drug"], [109, 112, "Drug"], [115, 120, "Drug"], [123, 127, "Drug"], [134, 137, "Drug"], [146, 149, "Drug"], [151, 155, "Drug"], [178, 181, "Drug"], [183, 187, "Drug"], [198, 201, "Drug"], [217, 220, "Drug"], [222, 224, "Drug"], [227, 230, "Drug"], [232, 237, "Drug"], [240, 242, "Drug"], [24, 28, "Disease"], [69, 70, "Test_items"], [166, 167, "Test_items"], [72, 75, "Test_Value"], [169, 172, "Test_Value"]], "rel": [[69, 70, "Test_items", 24, 28, "Disease", "Test_items_Disease"]]}
{"idx": 1196, "sentence": "2017版指南同样将GLP-1受体激动剂列为可与二甲双胍进行二联或三联治疗的注射类药物之一。", "ner": [[10, 19, "Drug"], [24, 27, "Drug"]], "rel": []}
{"idx": 1197, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 1198, "sentence": "临床应用共识推荐参考药品说明书使用。", "ner": [], "rel": []}
{"idx": 1199, "sentence": "目前，两种GLP-1受体激动剂不仅价格昂贵，而且尚未被纳入医保，因此尽管能够带来多重获益，但临床上仍主要被用于其他降糖药物无法有效控糖的“顽固”患者和经济条件好的患者。", "ner": [[5, 14, "Drug"]], "rel": []}
{"idx": 1200, "sentence": "我们也期待着这类药物尽快被纳入医保，让更多患者从中获益。", "ner": [], "rel": []}
{"idx": 1201, "sentence": "艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，因此临床应用共识建议医生应当告知患者急性胰腺炎的特征性症状，如怀疑发生了胰腺炎。应该立即停用。此外，GLP-1受体激动剂与磺脲类药物合用时低血糖发生率升高，建议适当减少磺脲类药物剂量以减少低血糖风险，当联合使用GLP-1受体激动剂与磺脲类药物时，医生应告知患者在驾驶或操作机械时采取必要措施以防止发生低血糖。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [75, 84, "Drug"], [86, 90, "Drug"], [109, 113, "Drug"], [130, 139, "Drug"], [141, 145, "Drug"], [15, 19, "Disease"], [43, 47, "Disease"], [61, 63, "Disease"], [17, 18, "Anatomy"], [45, 46, "Anatomy"], [61, 62, "Anatomy"], [94, 96, "ADE"], [119, 121, "ADE"], [175, 177, "ADE"]], "rel": [[0, 3, "Drug", 15, 19, "Disease", "Drug_Disease"], [5, 8, "Drug", 15, 19, "Disease", "Drug_Disease"], [94, 96, "ADE", 75, 84, "Drug", "ADE_Drug"], [94, 96, "ADE", 86, 90, "Drug", "ADE_Drug"], [119, 121, "ADE", 109, 113, "Drug", "ADE_Drug"], [175, 177, "ADE", 130, 139, "Drug", "ADE_Drug"], [175, 177, "ADE", 141, 145, "Drug", "ADE_Drug"], [17, 18, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"], [45, 46, "Anatomy", 43, 47, "Disease", "Anatomy_Disease"], [61, 62, "Anatomy", 61, 63, "Disease", "Anatomy_Disease"]]}
{"idx": 1202, "sentence": "特殊情况", "ner": [], "rel": []}
{"idx": 1203, "sentence": "(1)不适用人群", "ner": [], "rel": []}
{"idx": 1204, "sentence": "临床应用共识给出了以下几类不适宜使用GLP-1受体激动剂的患者：", "ner": [[18, 27, "Drug"]], "rel": []}
{"idx": 1205, "sentence": "·GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。", "ner": [[1, 10, "Drug"], [15, 17, "Drug"], [23, 27, "Disease"], [31, 38, "Disease"]], "rel": []}
{"idx": 1206, "sentence": "·严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。", "ner": [[3, 7, "Disease"], [3, 3, "Anatomy"], [4, 5, "Anatomy"]], "rel": [[3, 3, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"], [4, 5, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 1207, "sentence": "·艾塞那肽有罕见肾功能改变报告，不推荐用于终末期肾病或严重肾功能不全患者；利拉鲁肽由于经验有限，也不推荐用于肾脏终末期患者。", "ner": [[1, 4, "Drug"], [37, 40, "Drug"], [8, 12, "ADE"], [24, 25, "Disease"], [29, 33, "Disease"], [24, 24, "Anatomy"], [29, 29, "Anatomy"], [27, 28, "Level"]], "rel": [[8, 12, "ADE", 1, 4, "Drug", "ADE_Drug"], [24, 24, "Anatomy", 24, 25, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 29, 33, "Disease", "Anatomy_Disease"]]}
{"idx": 1208, "sentence": "·利拉鲁肽在纽约心脏病学会(NYHA)分级l-II级的充血性心力衰竭的患者中的治疗经验有限，尚无在III一IV级充血性心力衰竭患者中的应用经验。", "ner": [[1, 4, "Drug"], [27, 33, "Disease"], [56, 62, "Disease"], [30, 30, "Anatomy"], [59, 59, "Anatomy"]], "rel": [[1, 4, "Drug", 27, 33, "Disease", "Drug_Disease"], [30, 30, "Anatomy", 27, 33, "Disease", "Anatomy_Disease"], [59, 59, "Anatomy", 56, 62, "Disease", "Anatomy_Disease"]]}
{"idx": 1209, "sentence": "·利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者。", "ner": [[1, 4, "Drug"], [10, 20, "Disease"], [32, 44, "Disease"], [10, 12, "Anatomy"]], "rel": [[10, 12, "Anatomy", 10, 20, "Disease", "Anatomy_Disease"]]}
{"idx": 1210, "sentence": "·禁用于对该类产品活性成分或任何其他辅料过敏者。", "ner": [], "rel": []}
{"idx": 1211, "sentence": "(2)额外获益人群", "ner": [], "rel": []}
{"idx": 1212, "sentence": "快速建议指南指出，以下人群更加适合使用GLP-1受体激动剂：", "ner": [[19, 28, "Drug"]], "rel": []}
{"idx": 1213, "sentence": "·由于GLP-1受体激动剂可显著降低患者体重，对于超重肥胖的2型糖尿病患者，建议用于超重/肥胖患者的降糖治疗。", "ner": [[3, 12, "Drug"], [30, 34, "Disease"], [42, 43, "Disease"], [45, 46, "Disease"], [25, 26, "Disease"], [27, 28, "Disease"]], "rel": [[3, 12, "Drug", 25, 26, "Disease", "Drug_Disease"], [3, 12, "Drug", 27, 28, "Disease", "Drug_Disease"], [3, 12, "Drug", 30, 34, "Disease", "Drug_Disease"], [3, 12, "Drug", 42, 43, "Disease", "Drug_Disease"], [3, 12, "Drug", 45, 46, "Disease", "Drug_Disease"]]}
{"idx": 1214, "sentence": "·对于伴有非酒精性脂肪肝的2型糖尿病患者，GL-1受体激动剂可降低体质指数(BMl)和转氨酶ALT水平，建议使用GLP-1受体激动剂进行治疗。", "ner": [[21, 29, "Drug"], [56, 65, "Drug"], [5, 11, "Disease"], [13, 17, "Disease"], [43, 48, "Test_items"]], "rel": [[21, 29, "Drug", 5, 11, "Disease", "Drug_Disease"], [21, 29, "Drug", 13, 17, "Disease", "Drug_Disease"], [43, 48, "Test_items", 13, 17, "Disease", "Test_items_Disease"]]}
{"idx": 1215, "sentence": "钠-葡萄糖共转运蛋白2抑制剂：(《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》)", "ner": [[0, 13, "Drug"], [17, 38, "Drug"]], "rel": []}
{"idx": 1216, "sentence": "钠-葡萄糖共转运蛋白2抑制剂是一种非常特殊的口服降糖药物，说它特殊是因为，与其他降糖药物都不同的是，它并没有从胰腺、胃肠道等调节血糖的内分泌器官入手，而是作用于葡萄糖的排泄器官一肾脏，通过让更多葡萄糖经肾脏从尿液排出体外来达到降低血糖的效果。", "ner": [[0, 13, "Drug"], [22, 23, "Method"], [64, 65, "Test_items"], [115, 116, "Test_items"]], "rel": [[22, 23, "Method", 0, 13, "Drug", "Method_Drug"]]}
{"idx": 1217, "sentence": "大家都知道，只有血糖水平超过肾糖阈时，血中多余的葡萄糖才会从肾脏排泄，这也是血糖需要达到较高水平时尿糖试纸才会有反应的原因。", "ner": [[8, 9, "Test_items"], [38, 39, "Test_items"]], "rel": []}
{"idx": 1218, "sentence": "然而，随着研究的深入，人们发现，SGLT-2抑制剂并不仅仅是通过降低肾糖阈来促进葡萄糖经尿排出，它还具有明显的减重效果，并且可降低血压、尿酸水平，减少尿蛋白排泄，降低甘油三酯，同时升高高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)，但不增加LDL/HDL比值。", "ner": [[16, 24, "Drug"], [83, 86, "Test_items"], [65, 66, "Test_items"], [68, 69, "Test_items"], [92, 107, "Test_items"], [109, 124, "Test_items"], [130, 138, "Test_items"], [75, 77, "Test_items"]], "rel": []}
{"idx": 1219, "sentence": "因此，SGLT-2抑制剂这两年也成为临床研究和学术会议的热点。", "ner": [[3, 11, "Drug"]], "rel": []}
{"idx": 1220, "sentence": "目前，已经有多个SGLT-2抑制剂及其复方制剂在国外上市，并得到越来越多的临床应用。", "ner": [[8, 16, "Drug"]], "rel": []}
{"idx": 1221, "sentence": "《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》(简称中国建议)发布的时候，我国还没有SGLT-2抑制剂获批上市，但在今年，中国国家食品药品监督管理总局(CFDA)一连批准了两个SGLT-2抑制剂上市，先是在3月份批准达格列净上市，接着在9月份有批准恩格列净上市。", "ner": [[55, 63, "Drug"], [101, 109, "Drug"], [121, 124, "Drug"], [137, 140, "Drug"], [1, 22, "Drug"]], "rel": []}
{"idx": 1222, "sentence": "相信随着来自中国人群的临床应用证据越来越多，中国建议还将不断完善。", "ner": [], "rel": []}
{"idx": 1223, "sentence": "适用人群", "ner": [], "rel": []}
{"idx": 1224, "sentence": "中国建议指出，SGLT-2抑制剂可应用于成人2型糖尿病，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用，也可与其他口服降糖药物及胰岛素联合使用。", "ner": [[7, 15, "Drug"], [46, 49, "Drug"], [74, 76, "Drug"], [22, 26, "Disease"], [37, 38, "Test_items"]], "rel": [[7, 15, "Drug", 22, 26, "Disease", "Drug_Disease"], [74, 76, "Drug", 22, 26, "Disease", "Drug_Disease"], [37, 38, "Test_items", 22, 26, "Disease", "Test_items_Disease"]]}
{"idx": 1225, "sentence": "由于SGLT-2抑制剂的药理作用依赖于一定水平的肾小球滤过率，所以要求患者的估算肾小球滤过率(eGFR)>60或45mI/(min·1.73m2)。", "ner": [[2, 10, "Drug"], [24, 29, "Test_items"], [40, 51, "Test_items"], [52, 72, "Test_Value"]], "rel": []}
{"idx": 1226, "sentence": "CFDA批准的达格列净说明书上所写的适应证为“在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。", "ner": [[7, 10, "Drug"], [44, 48, "Disease"], [55, 56, "Test_items"]], "rel": [[55, 56, "Test_items", 44, 48, "Disease", "Test_items_Disease"]]}
{"idx": 1227, "sentence": "”目前，SGLT-2抑制剂未被批准用于1型糖尿病；儿童青少年及孕妇和哺乳期妇女中无使用SGLT-2抑制剂的数据，故暂不推荐在此类人群中使用。", "ner": [[4, 12, "Drug"], [43, 51, "Drug"], [19, 23, "Disease"]], "rel": []}
{"idx": 1228, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 1229, "sentence": "(1)用量", "ner": [], "rel": []}
{"idx": 1230, "sentence": "CFDA批准的达格列净剂量规格为5毫克和10毫克两种，说明书给出的用量是，推荐起始剂量为5毫克每日一次，对于需加强血糖控制且耐受5毫克每日一次的患者，可增加至10毫克每日一次。", "ner": [[7, 10, "Drug"], [44, 46, "Amount"], [64, 66, "Amount"], [79, 82, "Amount"], [57, 58, "Test_items"], [83, 86, "Frequency"], [47, 50, "Frequency"]], "rel": [[44, 46, "Amount", 7, 10, "Drug", "Amount_Drug"], [64, 66, "Amount", 7, 10, "Drug", "Amount_Drug"], [79, 82, "Amount", 7, 10, "Drug", "Amount_Drug"], [83, 86, "Frequency", 7, 10, "Drug", "Frequency_Drug"], [47, 50, "Frequency", 7, 10, "Drug", "Frequency_Drug"]]}
{"idx": 1231, "sentence": "CFDA批准的恩格列净剂量规格只有10毫克一种，所以10毫克起始，最大剂量可能为20毫克(目前尚未得到恩格列净说明书)。", "ner": [[7, 10, "Drug"], [51, 54, "Drug"], [40, 43, "Amount"], [26, 29, "Amount"]], "rel": [[26, 29, "Amount", 7, 10, "Drug", "Amount_Drug"], [40, 43, "Amount", 7, 10, "Drug", "Amount_Drug"]]}
{"idx": 1232, "sentence": "(2)用法", "ner": [], "rel": []}
{"idx": 1233, "sentence": "此类药物均只需晨服一次即可，达格列净和恩格列净餐前或餐后均可服用。", "ner": [[14, 17, "Drug"], [19, 22, "Drug"], [9, 10, "Frequency"]], "rel": [[9, 10, "Frequency", 14, 17, "Drug", "Frequency_Drug"], [9, 10, "Frequency", 19, 22, "Drug", "Frequency_Drug"]]}
{"idx": 1234, "sentence": "(3)不良反应处理", "ner": [], "rel": []}
{"idx": 1235, "sentence": "A.泌尿生殖道感染由于此类药物促进大量葡萄糖从尿液排出，这就增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT-2抑制剂治疗后生殖道感染发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效；女性较男性生殖道感染发生率稍高；有感染疾病史者感染率升高，且感染后需抗感染治疗。", "ner": [[2, 8, "Disease"], [73, 81, "Drug"], [85, 89, "Disease"], [111, 112, "Disease"], [129, 133, "Disease"], [141, 144, "Disease"], [154, 155, "Disease"], [4, 6, "Anatomy"], [85, 87, "Anatomy"], [129, 131, "Anatomy"], [107, 110, "Level"]], "rel": [[4, 6, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [85, 87, "Anatomy", 85, 89, "Disease", "Anatomy_Disease"], [129, 131, "Anatomy", 129, 133, "Disease", "Anatomy_Disease"]]}
{"idx": 1236, "sentence": "女性生殖道感染大部分发生在用药的初始4个月内，最常见的是外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎；男性生殖道感染大部分发生在用药第一年内，最常见的是念珠菌性龟头炎和阴茎包皮炎。", "ner": [[2, 6, "Disease"], [28, 35, "Disease"], [37, 42, "Disease"], [44, 48, "Disease"], [52, 56, "Disease"], [75, 81, "Disease"], [83, 87, "Disease"], [2, 4, "Anatomy"], [28, 31, "Anatomy"], [37, 38, "Anatomy"], [44, 47, "Anatomy"], [52, 54, "Anatomy"], [79, 80, "Anatomy"], [83, 86, "Anatomy"]], "rel": [[2, 4, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [28, 31, "Anatomy", 28, 35, "Disease", "Anatomy_Disease"], [37, 38, "Anatomy", 37, 42, "Disease", "Anatomy_Disease"], [44, 47, "Anatomy", 44, 48, "Disease", "Anatomy_Disease"], [52, 54, "Anatomy", 52, 56, "Disease", "Anatomy_Disease"], [79, 80, "Anatomy", 75, 81, "Disease", "Anatomy_Disease"], [83, 86, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"]]}
{"idx": 1237, "sentence": "【应对】为避免生殖道和泌尿道感染发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如发生感染并需要抗感染治疗时建议暂时停药，感染治愈后，可继续使用。使用过程中，尤其是第一个月，需要关注是否出现感染的症状和体征，如出现，应及时就医并作相关检查以明确有无感染。患者在使用此类药物过程中，还应当注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染发生。", "ner": [[7, 15, "Disease"], [36, 41, "Disease"], [61, 62, "Disease"], [113, 114, "Disease"], [142, 143, "Disease"], [185, 186, "Disease"], [7, 9, "Anatomy"], [11, 13, "Anatomy"], [36, 37, "Anatomy"], [38, 39, "Anatomy"], [161, 169, "Treatment"], [171, 174, "Treatment"], [176, 181, "Treatment"]], "rel": [[7, 9, "Anatomy", 7, 15, "Disease", "Anatomy_Disease"], [11, 13, "Anatomy", 7, 15, "Disease", "Anatomy_Disease"], [36, 37, "Anatomy", 36, 41, "Disease", "Anatomy_Disease"], [38, 39, "Anatomy", 36, 41, "Disease", "Anatomy_Disease"], [161, 169, "Treatment", 185, 186, "Disease", "Treatment_Disease"], [171, 174, "Treatment", 185, 186, "Disease", "Treatment_Disease"], [176, 181, "Treatment", 185, 186, "Disease", "Treatment_Disease"]]}
{"idx": 1238, "sentence": "B.低血糖S GLT-2抑制剂单药治疗不增加低血糖风险；与二甲双胍、DPP-4抑制剂、噻唑烷二酮类等药物联用时，低血糖风险也没有明显增加；与胰岛素或磺脲类药物联用时低血糖风险增加。", "ner": [[29, 32, "Drug"], [34, 41, "Drug"], [43, 48, "Drug"], [5, 14, "Drug"], [70, 72, "Drug"], [74, 78, "Drug"], [2, 4, "ADE"], [22, 24, "ADE"], [56, 58, "ADE"], [82, 84, "ADE"]], "rel": [[82, 84, "ADE", 5, 14, "Drug", "ADE_Drug"], [82, 84, "ADE", 70, 72, "Drug", "ADE_Drug"], [82, 84, "ADE", 74, 78, "Drug", "ADE_Drug"]]}
{"idx": 1239, "sentence": "【应对】与胰岛素或磺脲类药物联用时，要注意调整胰岛素或磺脲类药物剂量，加强血糖监测，避免低血糖发生。", "ner": [[5, 7, "Drug"], [9, 13, "Drug"], [23, 25, "Drug"], [27, 31, "Drug"], [37, 40, "Test_items"], [44, 46, "ADE"]], "rel": [[44, 46, "ADE", 5, 7, "Drug", "ADE_Drug"], [44, 46, "ADE", 9, 13, "Drug", "ADE_Drug"], [44, 46, "ADE", 23, 25, "Drug", "ADE_Drug"], [44, 46, "ADE", 27, 31, "Drug", "ADE_Drug"]]}
{"idx": 1240, "sentence": "C.DKA SGLT-2抑制剂在上市前研究和上市后应用过程中，都有过糖尿病酮症酸中毒(DKA)及酮症的病例报告，但非常少见。发生者大多存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理应激等诱因，部分联用胰岛素的患者胰岛素减量过快。使用此类药物发生DKA及酮症的患者症状不典型，血糖通常不超过13.9毫摩尔/升，被称为“血糖不高的DKA”，往往不易被诊断。", "ner": [[6, 14, "Drug"], [2, 4, "Disease"], [34, 46, "Disease"], [48, 49, "Disease"], [146, 148, "Disease"], [150, 151, "Disease"], [187, 189, "Disease"], [69, 70, "Reason"], [72, 75, "Reason"], [77, 80, "Reason"], [82, 83, "Reason"], [85, 88, "Reason"], [90, 94, "Reason"], [96, 105, "Reason"], [107, 115, "Reason"], [124, 126, "Drug"], [130, 132, "Drug"], [161, 162, "Test_items"], [165, 176, "Test_Value"], [182, 183, "Test_items"], [184, 185, "Test_Value"]], "rel": [[182, 183, "Test_items", 187, 189, "Disease", "Test_items_Disease"]]}
{"idx": 1241, "sentence": "【应对】用药期间，如出现和DKA相关的症状，如腹痛、恶心、呕吐、乏力、呼吸困难，需要考虑是否出现DKA并检测血酮和动脉血酸碱度以明确诊断。明确诊断为DKA者，应立即停用SGLT-2抑制剂，并按照传统DKA治疗程序进行治疗。为减少用药期间发生DKA的风险，建议在择期手术、剧烈体力活动(如马拉松)前24小时停用SGLT-2抑制剂，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT-2抑制剂，采用其他合适降糖措施；口服SGLT2抑制剂期间避免过多饮酒及极低碳水化合物饮食。", "ner": [[13, 15, "Disease"], [48, 50, "Disease"], [74, 76, "Disease"], [99, 101, "Disease"], [120, 122, "Disease"], [23, 24, "Symptom"], [26, 27, "Symptom"], [29, 30, "Symptom"], [32, 33, "Symptom"], [35, 38, "Symptom"], [54, 55, "Test_items"], [57, 62, "Test_items"], [84, 92, "Drug"], [154, 162, "Drug"], [181, 183, "Drug"], [209, 217, "Drug"], [232, 239, "Drug"], [230, 231, "Method"]], "rel": [[23, 24, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [26, 27, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [29, 30, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [32, 33, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [35, 38, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [54, 55, "Test_items", 48, 50, "Disease", "Test_items_Disease"], [57, 62, "Test_items", 48, 50, "Disease", "Test_items_Disease"], [230, 231, "Method", 232, 239, "Drug", "Method_Drug"]]}
{"idx": 1242, "sentence": "特殊情况", "ner": [], "rel": []}
{"idx": 1243, "sentence": "(1)老年", "ner": [], "rel": []}
{"idx": 1244, "sentence": "老年患者在原有治疗方案疗效不佳时加用SGLT-2抑制剂，可有效降低血糖、减轻体重和降低血压，且耐受性良好。", "ner": [[18, 26, "Drug"], [33, 34, "Test_items"], [43, 44, "Test"]], "rel": []}
{"idx": 1245, "sentence": "不过，老年患者需监测肾功能，肾功能正常或轻度不全时可使用。", "ner": [[8, 12, "Test"], [20, 21, "Level"]], "rel": []}
{"idx": 1246, "sentence": "SGLT-2抑制剂在中度肾功能不全患者可减量使用，起始治疗前需检测肾功能，根据肾功能确认是否可以起始，治疗中每年至少监测一次肾功能，如同时予以影响肾功能的药物，起始前也需监测肾功能，当肾功能逐渐下降并趋向于中度肾功能不全时，则需每年监测2~4次肾功能。", "ner": [[0, 8, "Drug"], [12, 16, "Disease"], [12, 12, "Anatomy"], [105, 109, "Disease"], [105, 105, "Anatomy"], [10, 11, "Level"], [103, 104, "Level"], [31, 35, "Test"], [58, 64, "Test"], [85, 89, "Test"], [116, 124, "Test"]], "rel": [[0, 8, "Drug", 12, 16, "Disease", "Drug_Disease"], [12, 12, "Anatomy", 12, 16, "Disease", "Anatomy_Disease"], [31, 35, "Test", 12, 16, "Disease", "Test_Disease"], [105, 105, "Anatomy", 105, 109, "Disease", "Anatomy_Disease"], [116, 124, "Test", 105, 109, "Disease", "Test_Disease"]]}
{"idx": 1247, "sentence": "SGLT-2抑制剂在轻中度肝功能不全时也可使用。由于在重度肝功能不全的2型糖尿病患者中使用数据有限。欧美国家的药物说明书中均不推荐用于重度肝功能不全患者。", "ner": [[0, 8, "Drug"], [13, 17, "Disease"], [13, 13, "Anatomy"], [29, 33, "Disease"], [35, 39, "Disease"], [69, 73, "Disease"], [29, 29, "Anatomy"], [69, 69, "Anatomy"], [10, 12, "Level"], [27, 28, "Level"], [67, 68, "Level"]], "rel": [[0, 8, "Drug", 13, 17, "Disease", "Drug_Disease"], [13, 13, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 29, 33, "Disease", "Anatomy_Disease"], [69, 69, "Anatomy", 69, 73, "Disease", "Anatomy_Disease"]]}
{"idx": 1248, "sentence": "(3)心血管疾病", "ner": [[3, 7, "Disease"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 1249, "sentence": "SGLT-2抑制剂除有效降糖外。", "ner": [[0, 8, "Disease"]], "rel": []}
{"idx": 1250, "sentence": "还具有减重、降压、降尿酸、减少蛋白尿等与心血管疾病相关危险因素的作用，目前也有一些研究证实此类药物确实能够降低心血管事件风险。", "ner": [[20, 24, "Disease"], [20, 22, "Anatomy"], [55, 59, "Disease"], [55, 57, "Anatomy"]], "rel": [[20, 22, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"], [55, 57, "Anatomy", 55, 59, "Disease", "Anatomy_Disease"]]}
{"idx": 1251, "sentence": "不过，由于此类药物刚刚进入中国，我们还需要更多的临床数据去了解它们。", "ner": [], "rel": []}
{"idx": 1252, "sentence": "(4)其他", "ner": [], "rel": []}
{"idx": 1253, "sentence": "目前，临床研究数据尚未证实此类药物与膀胱癌风险存在因果关系，上市后至今尚无相关肿瘤病例报告；FDA和EMA根据不良事件报告系统的数据，已加强提醒在使用SGLT-2抑制剂过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净、坎格列净)，但它们之间是否存在因果关系仍需要进一步研究。", "ner": [[18, 20, "Disease"], [18, 19, "Anatomy"], [39, 40, "Disease"], [75, 83, "Drug"], [90, 91, "Disease"], [101, 104, "Disease"], [101, 102, "Anatomy"], [114, 118, "Disease"], [116, 116, "Anatomy"], [122, 125, "Drug"], [127, 130, "Drug"], [95, 98, "Drug"], [108, 111, "Drug"]], "rel": [[18, 19, "Anatomy", 18, 20, "Disease", "Anatomy_Disease"], [75, 83, "Drug", 39, 40, "Disease", "Drug_Disease"], [101, 102, "Anatomy", 101, 104, "Disease", "Anatomy_Disease"], [116, 116, "Anatomy", 114, 118, "Disease", "Anatomy_Disease"]]}
{"idx": 1254, "sentence": "(2)肝肾功能不全", "ner": [[3, 8, "Disease"], [3, 3, "Anatomy"], [4, 4, "Anatomy"]], "rel": [[4, 4, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [3, 3, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 1255, "sentence": "由于中国建议发布时，此类药物尚未在国内上市，所以仅介绍了国外的使用情况，美国药品食品监督管理局(FDA)批准达格列净和恩格列净的起始剂量分别为5毫克和10毫克，根据血糖控制的需求和是否耐受可调整至最大剂量10毫克和25毫克，每日一次口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10毫克，对于重度肝功能不全的患者可从5毫克起始。", "ner": [[54, 57, "Drug"], [59, 62, "Drug"], [141, 144, "Drug"], [71, 73, "Amount"], [75, 78, "Amount"], [102, 105, "Amount"], [107, 110, "Amount"], [151, 154, "Amount"], [170, 172, "Amount"], [112, 115, "Frequency"], [116, 117, "Method"], [160, 164, "Disease"], [160, 160, "Anatomy"], [158, 159, "Level"], [82, 83, "Test_items"]], "rel": [[71, 73, "Amount", 54, 57, "Drug", "Amount_Drug"], [102, 105, "Amount", 54, 57, "Drug", "Amount_Drug"], [112, 115, "Frequency", 54, 57, "Drug", "Frequency_Drug"], [116, 117, "Method", 54, 57, "Drug", "Method_Drug"], [75, 78, "Amount", 59, 62, "Drug", "Amount_Drug"], [107, 110, "Amount", 59, 62, "Drug", "Amount_Drug"], [112, 115, "Frequency", 59, 62, "Drug", "Frequency_Drug"], [116, 117, "Method", 59, 62, "Drug", "Method_Drug"], [151, 154, "Amount", 141, 144, "Drug", "Amount_Drug"], [170, 172, "Amount", 141, 144, "Drug", "Amount_Drug"], [141, 144, "Drug", 160, 164, "Disease", "Drug_Disease"], [160, 160, "Anatomy", 160, 164, "Disease", "Anatomy_Disease"]]}
{"idx": 1256, "sentence": "美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT一2抑制剂可单独使用及与其他降糖药物联合使用。", "ner": [[47, 55, "Drug"]], "rel": []}
{"idx": 1257, "sentence": "快速建议指南推荐DPP-4抑制剂联合基础胰岛用于2型糖尿病患者的降糖治疗，指出当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，添加DPP-4抑制剂进行联合治疗，并根据糖化血红白水平，调整胰岛素的剂量。", "ner": [[8, 15, "Drug"], [18, 21, "Drug"], [42, 46, "Drug"], [69, 76, "Drug"], [97, 99, "Drug"], [24, 28, "Disease"], [52, 57, "Test_items"], [61, 64, "Test_Value"], [87, 91, "Test_items"]], "rel": [[8, 15, "Drug", 24, 28, "Disease", "Drug_Disease"], [18, 21, "Drug", 24, 28, "Disease", "Drug_Disease"], [52, 57, "Test_items", 24, 28, "Disease", "Test_items_Disease"], [87, 91, "Test_items", 24, 28, "Disease", "Test_items_Disease"]]}
{"idx": 1258, "sentence": "B.肝功能不全：西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整，尚无严重肝功能不全患者使用的临床经验；维格列汀不推荐用于开始给药前血清谷丙转氨酶或谷草转氨酶大于正常上限3倍的患者，罕见有肝功能障碍(包括肝炎)报告，但需要定期检测肝酶，对用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用；沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者；利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量；阿格列汀在肝功能检查结果异常的患者中应慎重使用，如患者报告发生可能提示肝损伤的症状，应迅速进行肝功能检查，出现具有临床意义的肝酶升高或肝功能检查异常结果持续或恶化时，应停用，如未发现引起肝功能检查异常的其他原因，则不要再次使用。", "ner": [[2, 6, "Disease"], [19, 23, "Disease"], [42, 46, "Disease"], [99, 103, "Disease"], [107, 108, "Disease"], [163, 167, "Disease"], [183, 187, "Disease"], [201, 205, "Disease"], [257, 259, "Disease"], [2, 2, "Anatomy"], [19, 19, "Anatomy"], [42, 42, "Anatomy"], [99, 99, "Anatomy"], [107, 107, "Anatomy"], [163, 163, "Anatomy"], [183, 183, "Anatomy"], [201, 201, "Anatomy"], [257, 257, "Anatomy"], [8, 11, "Drug"], [57, 60, "Drug"], [155, 158, "Drug"], [192, 195, "Drug"], [222, 225, "Drug"], [14, 15, "Level"], [17, 18, "Level"], [40, 41, "Level"], [161, 162, "Level"], [181, 182, "Level"], [71, 77, "Test_items"], [79, 83, "Test_items"], [120, 121, "Test_items"], [129, 130, "Test_items"], [284, 285, "Test_items"], [84, 91, "Test_Value"], [131, 132, "Test_Value"], [136, 140, "Test"], [227, 231, "Test"], [269, 273, "Test"], [289, 293, "Test"], [315, 319, "Test"], [286, 287, "Test_Value"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [8, 11, "Drug", 2, 6, "Disease", "Drug_Disease"], [19, 19, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [8, 11, "Drug", 19, 23, "Disease", "Drug_Disease"], [42, 42, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [99, 99, "Anatomy", 99, 103, "Disease", "Anatomy_Disease"], [57, 60, "Drug", 99, 103, "Disease", "Drug_Disease"], [120, 121, "Test_items", 99, 103, "Disease", "Test_items_Disease"], [129, 130, "Test_items", 99, 103, "Disease", "Test_items_Disease"], [107, 107, "Anatomy", 107, 108, "Disease", "Anatomy_Disease"], [57, 60, "Drug", 107, 108, "Disease", "Drug_Disease"], [120, 121, "Test_items", 107, 108, "Disease", "Test_items_Disease"], [129, 130, "Test_items", 107, 108, "Disease", "Test_items_Disease"], [163, 163, "Anatomy", 163, 167, "Disease", "Anatomy_Disease"], [155, 158, "Drug", 163, 167, "Disease", "Drug_Disease"], [183, 183, "Anatomy", 183, 187, "Disease", "Anatomy_Disease"], [201, 201, "Anatomy", 201, 205, "Disease", "Anatomy_Disease"], [257, 257, "Anatomy", 257, 259, "Disease", "Anatomy_Disease"], [269, 273, "Test", 257, 259, "Disease", "Test_Disease"]]}
{"idx": 1259, "sentence": "A.肾功能不全：西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病患者时需要根据肌酐清除率调整剂量；维格列汀在中度或重度肾功能不全或需要接受血液透析治疗的终末期肾病患者中的应用经验有限，因此不推荐此类患者使用；沙格列汀在轻度肾功能不全的患者中无需调整剂量，中重度肾功能不全的患者应将剂量调整为2.5毫克，每日1次，在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用；利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量；阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受损或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。", "ner": [[2, 6, "Disease"], [39, 40, "Disease"], [88, 89, "Disease"], [212, 216, "Disease"], [25, 29, "Disease"], [68, 72, "Disease"], [120, 124, "Disease"], [139, 143, "Disease"], [168, 172, "Disease"], [240, 244, "Disease"], [262, 266, "Disease"], [271, 275, "Disease"], [2, 2, "Anatomy"], [25, 25, "Anatomy"], [39, 39, "Anatomy"], [68, 68, "Anatomy"], [88, 88, "Anatomy"], [120, 120, "Anatomy"], [139, 139, "Anatomy"], [168, 168, "Anatomy"], [212, 212, "Anatomy"], [240, 240, "Anatomy"], [262, 262, "Anatomy"], [271, 271, "Anatomy"], [8, 11, "Drug"], [58, 61, "Drug"], [113, 116, "Drug"], [194, 197, "Drug"], [233, 236, "Drug"], [21, 24, "Level"], [63, 64, "Level"], [66, 67, "Level"], [118, 119, "Level"], [136, 138, "Level"], [166, 167, "Level"], [238, 239, "Level"], [260, 261, "Level"], [48, 52, "Test_items"], [33, 34, "Treatment"], [78, 81, "Treatment"], [154, 158, "Amount"], [160, 163, "Frequency"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [8, 11, "Drug", 2, 6, "Disease", "Drug_Disease"], [48, 52, "Test_items", 2, 6, "Disease", "Test_items_Disease"], [39, 39, "Anatomy", 39, 40, "Disease", "Anatomy_Disease"], [8, 11, "Drug", 39, 40, "Disease", "Drug_Disease"], [48, 52, "Test_items", 39, 40, "Disease", "Test_items_Disease"], [33, 34, "Treatment", 39, 40, "Disease", "Treatment_Disease"], [88, 88, "Anatomy", 88, 89, "Disease", "Anatomy_Disease"], [78, 81, "Treatment", 88, 89, "Disease", "Treatment_Disease"], [212, 212, "Anatomy", 212, 216, "Disease", "Anatomy_Disease"], [194, 197, "Drug", 212, 216, "Disease", "Drug_Disease"], [25, 25, "Anatomy", 25, 29, "Disease", "Anatomy_Disease"], [8, 11, "Drug", 25, 29, "Disease", "Drug_Disease"], [48, 52, "Test_items", 25, 29, "Disease", "Test_items_Disease"], [68, 68, "Anatomy", 68, 72, "Disease", "Anatomy_Disease"], [120, 120, "Anatomy", 120, 124, "Disease", "Anatomy_Disease"], [113, 116, "Drug", 120, 124, "Disease", "Drug_Disease"], [139, 139, "Anatomy", 139, 143, "Disease", "Anatomy_Disease"], [113, 116, "Drug", 139, 143, "Disease", "Drug_Disease"], [168, 168, "Anatomy", 168, 172, "Disease", "Anatomy_Disease"], [240, 240, "Anatomy", 240, 244, "Disease", "Anatomy_Disease"], [233, 236, "Drug", 240, 244, "Disease", "Drug_Disease"], [262, 262, "Anatomy", 262, 266, "Disease", "Anatomy_Disease"], [233, 236, "Drug", 262, 266, "Disease", "Drug_Disease"], [271, 271, "Anatomy", 271, 275, "Disease", "Anatomy_Disease"], [233, 236, "Drug", 271, 275, "Disease", "Drug_Disease"], [154, 158, "Amount", 113, 116, "Drug", "Amount_Drug"], [160, 163, "Frequency", 113, 116, "Drug", "Frequency_Drug"]]}
{"idx": 1260, "sentence": "在开始使用阿格列汀前应评估肾功能并定期复查。", "ner": [[5, 8, "Drug"]], "rel": []}
{"idx": 1261, "sentence": "盘点降糖药物的中国指南/共识(上)", "ner": [], "rel": []}
{"idx": 1262, "sentence": "降糖药物大多基于纠正导致血糖升高的两个主要病理生理改变，即胰岛素抵抗和胰岛素分泌受损。", "ner": [[29, 33, "Pathogenesis"], [35, 41, "Pathogenesis"], [12, 13, "Test_items"], [14, 15, "Test_Value"]], "rel": []}
{"idx": 1263, "sentence": "根据作用机制的不同，降糖药可分为：促进胰岛素分泌为主要作用的药物，包括磺脲类、格列奈类、二肽基肽酶-4(DPP-4) 抑制剂、胰高血糖素样肽-1(GLP-1) 受体激动剂或胰岛素替代药物(即外源性胰岛素制剂)；通过其他机制降低血糖的药物，包括双胍类、噻唑烷二酮类、α-糖苷酶抑制剂、钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂。", "ner": [[35, 37, "Drug"], [39, 42, "Drug"], [44, 61, "Drug"], [63, 84, "Drug"], [86, 103, "Drug"], [121, 123, "Drug"], [125, 130, "Drug"], [132, 139, "Drug"], [141, 163, "Drug"]], "rel": []}
{"idx": 1264, "sentence": "下面我们将逐类盘点近几年发布的相关指南或共识，如存在更新版，则仅讨论最新版本。", "ner": [], "rel": []}
{"idx": 1265, "sentence": " ", "ner": [], "rel": []}
{"idx": 1266, "sentence": "二甲双胍(资料来源：《二甲双胍临床应用专家共识(2016年版)》) ", "ner": [[0, 3, "Drug"], [11, 14, "Drug"]], "rel": []}
{"idx": 1267, "sentence": "二甲双胍是一个在临床上已经应用了60年的老药，曾几经沉浮，目前国内外主要糖尿病指南均认可其核心地位，建议无论超重还是体重正常的2型糖尿病患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍。", "ner": [[0, 3, "Drug"], [36, 38, "Disease"], [54, 55, "Disease"], [63, 67, "Disease"], [95, 98, "Drug"], [115, 118, "Drug"]], "rel": [[0, 3, "Drug", 36, 38, "Disease", "Drug_Disease"], [95, 98, "Drug", 54, 55, "Disease", "Drug_Disease"], [95, 98, "Drug", 63, 67, "Disease", "Drug_Disease"]]}
{"idx": 1268, "sentence": " ", "ner": [], "rel": []}
{"idx": 1269, "sentence": "作用机制 ", "ner": [], "rel": []}
{"idx": 1270, "sentence": "二甲双胍改善高血糖的主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高胰高血糖素样肽-1(GLP-1) 水平。", "ner": [[0, 3, "Drug"], [6, 8, "Disease"]], "rel": [[0, 3, "Drug", 6, 8, "Disease", "Drug_Disease"]]}
{"idx": 1271, "sentence": "近年来研究者们更是发现二甲双胍可能具有改善肠道茵群、抗癌、抗衰老等更多”神奇“的作用。", "ner": [[11, 14, "Drug"]], "rel": []}
{"idx": 1272, "sentence": "国内的多位内分泌、药学专家于2014年发布了第一版《二甲双胍临床应用专家共识》，基于这两年涌现的新证据，该共识于2016年进行了更新，从使用时机、剂量与疗效、安全性、特殊人群的使用以及降糖外作用等多个方面给出了指导建议。", "ner": [[26, 29, "Drug"]], "rel": []}
{"idx": 1273, "sentence": "适用人群 ", "ner": [], "rel": []}
{"idx": 1274, "sentence": "应该说，二甲双胍是真正的糖尿病全程治疗药物，从糖尿病预防到糖尿病前期再到糖尿病的各个阶段。", "ner": [[4, 7, "Drug"], [12, 14, "Disease"], [23, 25, "Disease"], [29, 31, "Disease"], [36, 38, "Disease"]], "rel": [[4, 7, "Drug", 12, 14, "Disease", "Drug_Disease"]]}
{"idx": 1275, "sentence": " ", "ner": [], "rel": []}
{"idx": 1276, "sentence": "(1)2型糖尿病的一线首选和全程用药：在横向对比中，最佳有效剂量(2000毫克/天)二甲双胍治疗的降糖疗效要强于其他口服降糖药；在纵向对比中，与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，以后需调整治疗方案的可能性也最低。二甲双胍减轻体重的这个“副作用”令其成为联合治疗中的“百搭药“。此外，二甲双胍还具有心血管保护作用，安全性和耐受性也很好，价格还不算贵。有这么多好处，也难怪该共识给出这样的建议，而且是最高级别的推荐——如无禁忌证，二甲双胍是治疗2型糖尿病的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。记得在2007年版的《中国2型糖尿病防治指南》中还仅建议超重或肥胖的2型糖尿病患者将二甲双胍作为一线药物，此后的研究证据显示二甲双胍在正常体重/超重/肥胖的2型糖尿病患者中的疗效相当，体重并不是能否使用二甲双胍治疗的决定因素，所以早在2010年版的《中国2型糖尿病防治指南》中就已经开始给出与该共识类似的建议。", "ner": [[3, 7, "Disease"], [42, 45, "Drug"], [33, 40, "Amount"], [58, 59, "Method"], [75, 76, "Method"], [96, 99, "Drug"], [124, 126, "Drug"], [152, 155, "Drug"], [156, 159, "ADE"], [187, 190, "Drug"], [259, 262, "Drug"], [266, 270, "Disease"], [299, 301, "Disease"], [321, 325, "Disease"], [336, 337, "Disease"], [339, 340, "Disease"], [342, 346, "Disease"], [350, 353, "Drug"], [370, 373, "Drug"], [380, 381, "Disease"], [383, 384, "Disease"], [386, 390, "Disease"], [409, 412, "Drug"], [435, 439, "Disease"], [114, 115, "Method"]], "rel": [[42, 45, "Drug", 3, 7, "Disease", "Drug_Disease"], [33, 40, "Amount", 42, 45, "Drug", "Amount_Drug"], [156, 159, "ADE", 152, 155, "Drug", "ADE_Drug"], [259, 262, "Drug", 266, 270, "Disease", "Drug_Disease"], [350, 353, "Drug", 336, 337, "Disease", "Drug_Disease"], [350, 353, "Drug", 339, 340, "Disease", "Drug_Disease"], [350, 353, "Drug", 342, 346, "Disease", "Drug_Disease"], [370, 373, "Drug", 380, 381, "Disease", "Drug_Disease"], [370, 373, "Drug", 383, 384, "Disease", "Drug_Disease"], [370, 373, "Drug", 386, 390, "Disease", "Drug_Disease"]]}
{"idx": 1277, "sentence": "\"", "ner": [], "rel": []}
{"idx": 1278, "sentence": "(2)2型糖尿病预防用药：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物，能有效降低糖尿病前期人群发生2型糖尿病的风险，且具有良好的耐受性和长期有效性。不过在我国，预防糖尿病还不是二甲双胍的适应证，所以该共识也无法给出明确建议。但是，共识中提到，基于各国的大型研究结果，国际糖尿病联盟(IDF)2012年全球2型糖尿病指南推荐，预防糖尿病最好起始生活方式干预；对于空腹血糖受损(IFG)、年龄<60岁的肥胖人群，可给予二甲双胍干预；并建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病(属于超药品说明书用药——本刊注)，接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。", "ner": [[3, 7, "Disease"], [13, 16, "Drug"], [27, 29, "Disease"], [33, 35, "Disease"], [47, 49, "Disease"], [56, 60, "Disease"], [89, 91, "Disease"], [95, 98, "Drug"], [142, 144, "Disease"], [159, 163, "Disease"], [171, 173, "Disease"], [187, 197, "Disease"], [206, 207, "Disease"], [214, 217, "Drug"], [224, 226, "Disease"], [252, 253, "Test_items"], [260, 263, "Drug"], [269, 271, "Disease"], [292, 295, "Drug"], [307, 309, "Disease"], [334, 338, "Test"], [340, 342, "Disease"], [178, 183, "Treatment"], [234, 239, "Treatment"]], "rel": [[13, 16, "Drug", 27, 29, "Disease", "Drug_Disease"], [95, 98, "Drug", 89, 91, "Disease", "Drug_Disease"], [178, 183, "Treatment", 171, 173, "Disease", "Treatment_Disease"], [214, 217, "Drug", 187, 197, "Disease", "Drug_Disease"], [214, 217, "Drug", 206, 207, "Disease", "Drug_Disease"], [234, 239, "Treatment", 224, 226, "Disease", "Treatment_Disease"], [252, 253, "Test_items", 224, 226, "Disease", "Test_items_Disease"], [260, 263, "Drug", 269, 271, "Disease", "Drug_Disease"], [292, 295, "Drug", 307, 309, "Disease", "Drug_Disease"], [334, 338, "Test", 340, 342, "Disease", "Test_Disease"]]}
{"idx": 1279, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 1280, "sentence": "(1)剂型选择：目前，国内单一成分的二甲双胍制剂包括普通片(250毫克/片、500毫克/片或850毫克/片)、缓释片或胶囊(500毫克/片或500毫克/胶囊)、肠溶片或胶囊(250毫克/片或250毫克/胶囊)等；复方制剂则包括二甲双胍与磺脲类、吡格列酮或DPP一4抑制剂组成的复方制剂。", "ner": [[113, 116, "Drug"], [118, 120, "Drug"], [122, 125, "Drug"], [127, 134, "Drug"], [18, 21, "Drug"]], "rel": []}
{"idx": 1281, "sentence": "该共识指出：①各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放，肠溶片从胃排空到肠道后崩解释放，缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放，肠溶胶囊在肠道内溶出、释放；②普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之，因而每种制剂给药后血药浓度峰值、达峰时间、半衰期等参数存在一定差异，多剂量给药后的达稳时间也不一致；③缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；④合格的药物制剂，在相同的给药剂量下，各种剂型问应具有生物等效性；⑤不同剂型的临床疗效是否一致，尚需更多的临床研究证实。", "ner": [[215, 219, "ADE"], [143, 146, "Pathogenesis"]], "rel": []}
{"idx": 1282, "sentence": "(2)使用方法：①用量临床研究显示，在500~2000毫克/天的剂量范围内，二甲双胍的降糖效果随剂量增加而增加，而当每日用量达到1000豪克后，胃肠道反应并未随剂量增加而加重。该共识推荐，二甲双胍起效的最小剂量为500毫克/天，成人可用的最大剂量为2550毫克/天，最佳有效剂量为2000毫克/天。", "ner": [[19, 30, "Amount"], [38, 41, "Drug"], [72, 76, "ADE"], [94, 97, "Drug"], [106, 112, "Amount"], [124, 131, "Amount"], [140, 147, "Amount"], [58, 69, "Amount"]], "rel": [[19, 30, "Amount", 38, 41, "Drug", "Amount_Drug"], [58, 69, "Amount", 38, 41, "Drug", "Amount_Drug"], [72, 76, "ADE", 38, 41, "Drug", "ADE_Drug"], [106, 112, "Amount", 94, 97, "Drug", "Amount_Drug"], [124, 131, "Amount", 94, 97, "Drug", "Amount_Drug"], [140, 147, "Amount", 94, 97, "Drug", "Amount_Drug"]]}
{"idx": 1283, "sentence": "大家看看是不是自己的二甲双胍用量远没有达到这个标准。", "ner": [[10, 13, "Drug"]], "rel": []}
{"idx": 1284, "sentence": "②调量剂量调整遵循“小剂量起始，逐渐加量”的原则，开始时每日用量不超1000毫克，1~2周后加量至最大有效剂量2000毫克/天或最大耐受剂量。", "ner": [[55, 62, "Amount"], [28, 39, "Amount"]], "rel": []}
{"idx": 1285, "sentence": "考虑药物的临床疗效及从患者依从性，可采用简化的剂量方案，建议起始500毫克，2次/天，如无明显胃肠道不良反应，随后可逐至1000，2次/天。", "ner": [[32, 36, "Amount"], [38, 41, "Frequency"], [47, 53, "ADE"], [60, 63, "Amount"], [65, 68, "Frequency"]], "rel": []}
{"idx": 1286, "sentence": "③服法可在进餐时或餐后立即服用，缓释剂型1次/天，晚餐时或餐后立即服用。", "ner": [[20, 23, "Frequency"]], "rel": []}
{"idx": 1287, "sentence": "根据患者状况，当每日用量达到1500毫克后，可分为2~3次服用。", "ner": [[8, 19, "Amount"]], "rel": []}
{"idx": 1288, "sentence": "(3)联合用药：将该共识的这部分内容概括一句话就是，二甲双胍可以和临床上现有的各种降糖药联用，而且还能减轻某些降糖药的副作用(α-糖苷酶抑制剂除外，两者联用有可能增加胃肠不适)，实现扬长避短的效果。", "ner": [[26, 29, "Drug"], [63, 70, "Drug"], [83, 86, "ADE"]], "rel": [[83, 86, "ADE", 26, 29, "Drug", "ADE_Drug"], [83, 86, "ADE", 63, 70, "Drug", "ADE_Drug"]]}
{"idx": 1289, "sentence": "(4)特殊情况：①尽管二甲双胍说明书上的禁忌一栏中列出了需要药物治疗的充血性心力衰竭，研究显示，二甲双胍本身并不会导致心衰，也不会对心衰患者造成不良影响，相反，甚至可能降低糖尿病患者心衰和死亡风险，提高伴心衰的糖尿病患者的存活率。所以，美国糖尿病协会(ADA)的糖尿病指南指出，如肾功能正常，二甲双胍可用于病情稳定的充血性心衰患者；欧洲版二甲双胍说明书中更是单春了慢性心衰的禁忌证。②年龄同样不是二甲双胍使用禁忌，而是要根据患者的肾功能情况而定，由于随着年龄增长，肾功能会逐渐下降，高龄患者使用二甲双胍时需定期监测肾功能。③二甲双胍可用于10岁及以上的2型糖尿病儿童青少年，且最高剂量不超过2000毫克/天，目前暂不推荐用于10岁以下的患儿④虽然国际多个学术组织推荐二甲双胍可用于妊娠糖尿病患者，但由于目前国内证据缺乏，我国药监部门尚未批准二甲双胍用于妊娠妇女。⑤尽管二甲双胍不经肝脏代谢，无肝脏毒性，但建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者避免使用二甲双胍，血清转氨酶轻度升高者使用时应密切监测肝功能。⑥二甲双胍本身不会对肾功能有影响，随着教育普及，公众对二甲双胍伤肾的错误认识已经得较普遍的纠正，近年来国内外的各大指南都将二甲双胍的使用范围放宽至轻中度肾功能不全患者，但中度肾功能不全患者应减少用量并停用治疗恶心、呕吐及脱水的药物。⑦肾功能正常者在造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72小时，复查肾功能正常后可继续用药；而肾功能异常者在使用造影剂及全身麻醉术前48小时时应暂停二甲双胍，之后还需停药48~72小时，复查肾功能正常后可继续用药。", "ner": [[11, 14, "Drug"], [35, 41, "Disease"], [48, 51, "Drug"], [59, 60, "ADE"], [66, 67, "Disease"], [66, 66, "Anatomy"], [86, 88, "Disease"], [91, 92, "Disease"], [91, 91, "Anatomy"], [102, 103, "Disease"], [102, 102, "Anatomy"], [105, 107, "Disease"], [120, 122, "Disease"], [131, 133, "Disease"], [146, 149, "Drug"], [158, 162, "Disease"], [161, 161, "Anatomy"], [169, 172, "Drug"], [182, 185, "Disease"], [198, 201, "Drug"], [247, 250, "Drug"], [255, 259, "Test"], [262, 265, "Drug"], [276, 280, "Disease"], [295, 302, "Amount"], [333, 336, "Drug"], [340, 344, "Disease"], [370, 373, "Drug"], [384, 387, "Drug"], [396, 399, "ADE"], [404, 408, "Test_items"], [409, 416, "Test_Value"], [419, 420, "Level"], [421, 425, "Disease"], [421, 421, "Anatomy"], [438, 442, "Test_items"], [443, 446, "Test_Value"], [454, 458, "Test"], [461, 464, "Drug"], [487, 490, "Drug"], [491, 492, "ADE"], [521, 524, "Drug"], [533, 535, "Level"], [536, 540, "Disease"], [536, 536, "Anatomy"], [545, 546, "Level"], [547, 551, "Disease"], [547, 547, "Anatomy"], [584, 585, "Test"], [591, 594, "Drug"], [599, 601, "Drug"], [636, 640, "Disease"], [636, 636, "Anatomy"], [645, 647, "Drug"], [649, 652, "Operation"], [663, 666, "Drug"], [682, 686, "Test"], [621, 625, "Test"], [38, 38, "Anatomy"], [184, 184, "Anatomy"]], "rel": [[38, 38, "Anatomy", 35, 41, "Disease", "Anatomy_Disease"], [66, 66, "Anatomy", 66, 67, "Disease", "Anatomy_Disease"], [91, 91, "Anatomy", 91, 92, "Disease", "Anatomy_Disease"], [102, 102, "Anatomy", 102, 103, "Disease", "Anatomy_Disease"], [146, 149, "Drug", 158, 162, "Disease", "Drug_Disease"], [184, 184, "Anatomy", 182, 185, "Disease", "Anatomy_Disease"], [262, 265, "Drug", 276, 280, "Disease", "Drug_Disease"], [295, 302, "Amount", 262, 265, "Drug", "Amount_Drug"], [333, 336, "Drug", 340, 344, "Disease", "Drug_Disease"], [421, 421, "Anatomy", 421, 425, "Disease", "Anatomy_Disease"], [521, 524, "Drug", 536, 540, "Disease", "Drug_Disease"], [536, 536, "Anatomy", 536, 540, "Disease", "Anatomy_Disease"], [547, 547, "Anatomy", 547, 551, "Disease", "Anatomy_Disease"], [636, 636, "Anatomy", 636, 640, "Disease", "Anatomy_Disease"], [645, 647, "Drug", 636, 640, "Disease", "Drug_Disease"], [649, 652, "Operation", 636, 640, "Disease", "Operation_Disease"]]}
{"idx": 1290, "sentence": "(5)药物相互作用：①氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等药物会影响肾功能或二甲双胍分布，因此建议密切监测血糖并调整二甲双胍和/或其他药物的剂量。②同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物时，也应密切监测血糖，这些药物停用后，则要密切注意低血糖。③二甲双胍有增加华法林的抗凝血倾向。", "ner": [[11, 14, "Drug"], [16, 18, "Drug"], [20, 21, "Drug"], [23, 27, "Drug"], [29, 31, "Drug"], [33, 34, "Drug"], [36, 39, "Drug"], [41, 44, "Drug"], [46, 51, "Drug"], [53, 56, "Drug"], [67, 70, "Drug"], [80, 83, "Test_items"], [87, 90, "Drug"], [107, 111, "Drug"], [115, 117, "Drug"], [119, 123, "Drug"], [125, 127, "Drug"], [129, 133, "Drug"], [135, 137, "Drug"], [139, 143, "Drug"], [139, 140, "Method"], [145, 147, "Drug"], [149, 151, "Drug"], [153, 158, "Drug"], [160, 167, "Drug"], [169, 171, "Drug"], [176, 177, "Test_items"], [178, 179, "Test_Value"], [189, 192, "Test_items"], [208, 210, "ADE"], [213, 216, "Drug"], [220, 222, "Drug"], [224, 226, "ADE"]], "rel": [[139, 140, "Method", 139, 143, "Drug", "Method_Drug"], [224, 226, "ADE", 220, 222, "Drug", "ADE_Drug"]]}
{"idx": 1291, "sentence": "④树脂类药物，如苏合香、血竭、乳香等中药与二甲双胍合用会减少其吸收。", "ner": [[8, 10, "Drug"], [12, 13, "Drug"], [15, 16, "Drug"], [21, 24, "Drug"], [1, 5, "Drug"]], "rel": []}
{"idx": 1292, "sentence": "磺脲类药物(资料来源：《磺脲类药物临床应用专家共识(2016年版)》)", "ner": [[0, 4, "Drug"], [12, 16, "Drug"]], "rel": []}
{"idx": 1293, "sentence": "磺脲类药物正式用于糖尿病临床治疗也已经快60年了，目前仍是糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病指南中占据着非常重要的治疗地位。", "ner": [[0, 4, "Drug"], [9, 11, "Disease"], [29, 31, "Disease"], [43, 44, "Method"], [58, 62, "Disease"]], "rel": [[0, 4, "Drug", 9, 11, "Disease", "Drug_Disease"], [43, 44, "Method", 0, 4, "Drug", "Method_Drug"]]}
{"idx": 1294, "sentence": "基于循证医学证据的进展，2004年版《磺脲类药物临床应用专家共识》在2016年得到更新。", "ner": [[19, 23, "Drug"]], "rel": []}
{"idx": 1295, "sentence": "作用机制", "ner": [], "rel": []}
{"idx": 1296, "sentence": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，其中格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。", "ner": [[0, 4, "Drug"], [7, 9, "Disease"], [32, 35, "Drug"]], "rel": [[0, 4, "Drug", 7, 9, "Disease", "Drug_Disease"]]}
{"idx": 1297, "sentence": "②部分胰岛素增敏作用。", "ner": [], "rel": []}
{"idx": 1298, "sentence": "试验表明，磺脲类药物可使外周葡萄糖利用率加平均增加近三分之一(29%)。", "ner": [[5, 9, "Drug"]], "rel": []}
{"idx": 1299, "sentence": "适用人群", "ner": [], "rel": []}
{"idx": 1300, "sentence": "尽管新型降糖药物不断出现，磺脲类药物以其临床应用经验丰富、疗效确切和价格低廉，无论是在国内还是国外，仍然被广泛应用，国内外的多个2型糖尿病指南也将其推荐为一线备选或二线降糖用药。", "ner": [[13, 17, "Drug"], [64, 68, "Disease"]], "rel": [[13, 17, "Drug", 64, 68, "Disease", "Drug_Disease"]]}
{"idx": 1301, "sentence": "(1)一线备选：尽管二甲双胍被作为一线用药，但当患者无法耐受二甲双胍治疗或是存在禁忌证时，可考虑将磺脲类药物作为一线用药。该共识还指出，对于新诊断的糖化血红蛋白>7.5%的2型糖尿病患者，可选择作用机制互补的两种降糖药物联合应用，结合中国国情和患者特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。", "ner": [[10, 13, "Drug"], [30, 33, "Drug"], [49, 53, "Drug"], [74, 79, "Test_items"], [80, 84, "Test_Value"], [86, 90, "Disease"], [127, 131, "Drug"], [134, 137, "Drug"]], "rel": []}
{"idx": 1302, "sentence": "(2)二线用药：当二甲双胍最佳有效剂量单药治疗仍无法控糖达标时，需增加其他类型降糖药，磺脲类药物是备选之一。需要指出的是，尽管磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。", "ner": [[9, 12, "Drug"], [43, 47, "Drug"], [63, 67, "Drug"], [73, 76, "ADE"], [79, 80, "Disease"], [82, 83, "Disease"]], "rel": [[73, 76, "ADE", 63, 67, "Drug", "ADE_Drug"]]}
{"idx": 1303, "sentence": "相比于传统磺脲类药物(如氯磺丙脲、格列本脲)，新型磺脲类药物(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小，而且通过与二甲双胍、阿卡波糖、SGLT一2抑制剂等具有减轻体重作用的药物联用，能够减少磺脲类药物的体重增加风险。", "ner": [[5, 9, "Drug"], [12, 15, "Drug"], [17, 20, "Drug"], [25, 29, "Drug"], [32, 35, "Drug"], [42, 48, "Drug"], [65, 68, "Drug"], [70, 73, "Drug"], [75, 83, "Drug"], [103, 107, "Drug"], [109, 112, "ADE"]], "rel": [[109, 112, "ADE", 103, 107, "Drug", "ADE_Drug"]]}
{"idx": 1304, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 1305, "sentence": "(1)药物选择：从磺脲类药物的降糖机制不难看出，患者需要有一定的胰岛功能才能起效，所以糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物的疗效会更好。", "ner": [[9, 13, "Drug"], [43, 45, "Disease"], [55, 61, "Treatment"], [67, 71, "Drug"]], "rel": [[55, 61, "Treatment", 43, 45, "Disease", "Treatment_Disease"], [67, 71, "Drug", 43, 45, "Disease", "Drug_Disease"]]}
{"idx": 1306, "sentence": "早期磺脲类药物甲苯磺丁脲和氯磺丙脲已基本退出临床，目前临床常用的磺脲类药物包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲等。", "ner": [[2, 6, "Drug"], [7, 11, "Drug"], [13, 16, "Drug"], [32, 36, "Drug"], [39, 42, "Drug"], [44, 47, "Drug"], [49, 52, "Drug"], [54, 57, "Drug"], [59, 62, "Drug"]], "rel": []}
{"idx": 1307, "sentence": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短，适用于餐后血糖升高为主的患者；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长，适用于以空腹血糖升高为主的患者或空腹、餐后血糖均高的患者。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [30, 33, "Test_items"], [34, 35, "Test_Value"], [42, 45, "Drug"], [47, 53, "Drug"], [55, 58, "Drug"], [60, 66, "Drug"], [68, 71, "Drug"], [91, 94, "Test_items"], [95, 96, "Test_Value"], [103, 109, "Test_items"], [110, 111, "Test_Value"]], "rel": []}
{"idx": 1308, "sentence": "(2)使用方法：磺脲类药物的降糖作用在常规剂量内呈剂量依赖性，且患者初始糖化血红蛋白水平越高，治疗后的降幅越大。由于低血糖是磺脲类药物最常见的不良反应，所以宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。", "ner": [[8, 12, "Drug"], [36, 41, "Test_items"], [58, 60, "ADE"], [62, 66, "Drug"], [88, 91, "Test_items"], [42, 45, "Test_Value"]], "rel": [[58, 60, "ADE", 62, 66, "Drug", "ADE_Drug"]]}
{"idx": 1309, "sentence": "任何一种磺脲类药物的每日用量都不应超过其最大剂量。", "ner": [[4, 8, "Drug"]], "rel": []}
{"idx": 1310, "sentence": "常用磺脲类药物的用法见表1。", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 1311, "sentence": "(3)联合用药：尽管磺脲类药物理论上可以和各种降糖药联用以获得更好的降糖效果，但正如之前提到的，考虑到磺脲类药物的低血糖和增重副作用，它更适合与二甲双胍、α一糖苷酶抑制剂等低血糖风险低且具有减重作用的药物联用。需要特别指出的是，尽管通常不推荐磺脲类药物联合胰岛素治疗，但胰岛细胞尚有部分分泌功能的2型糖尿病患者可考虑使用磺脲类药物联合基础胰岛素治疗，不过应特别注意饮食和运动量，以及体重增加和低血糖。", "ner": [[10, 14, "Drug"], [51, 55, "Drug"], [57, 59, "ADE"], [61, 62, "ADE"], [72, 75, "Drug"], [77, 84, "Drug"], [121, 125, "Drug"], [128, 130, "Drug"], [148, 152, "Disease"], [160, 164, "Drug"], [169, 171, "Drug"], [191, 194, "ADE"], [196, 198, "ADE"], [86, 88, "ADE"], [180, 187, "Treatment"], [95, 96, "ADE"]], "rel": [[57, 59, "ADE", 51, 55, "Drug", "ADE_Drug"], [61, 62, "ADE", 51, 55, "Drug", "ADE_Drug"], [160, 164, "Drug", 148, 152, "Disease", "Drug_Disease"], [169, 171, "Drug", 148, 152, "Disease", "Drug_Disease"], [180, 187, "Treatment", 148, 152, "Disease", "Treatment_Disease"], [191, 194, "ADE", 160, 164, "Drug", "ADE_Drug"], [196, 198, "ADE", 160, 164, "Drug", "ADE_Drug"]]}
{"idx": 1312, "sentence": "(4)特殊情况：①目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(ALT)>8~10倍参考值上限或ALT>3倍参考值上限且血清总胆红素(TBIL)>2倍参考值上限提示重度肝损害，应禁用磺脲类药物。②肾功能不全者禁用格列本脲，格列吡嗪、格列齐特、格列美脲可用于轻度肾功能不全患者，格列喹酮则可用于轻、中度肾功能不全患者。医生需要根据肾功能情况来确定如何调整治疗，见表2。③老年患者应重点考虑药物的低血糖风险，若既往有严重低血糖史、预期生存期较短或合并其他严重疾病，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖发生风险降至最小。", "ner": [[13, 17, "Drug"], [23, 24, "Level"], [25, 29, "Disease"], [36, 48, "Test_items"], [49, 59, "Test_Value"], [61, 63, "Test_items"], [64, 71, "Test_Value"], [73, 84, "Test_items"], [85, 92, "Test_Value"], [95, 96, "Level"], [97, 99, "Disease"], [97, 97, "Anatomy"], [104, 108, "Drug"], [111, 115, "Disease"], [111, 111, "Anatomy"], [119, 122, "Drug"], [124, 127, "Drug"], [129, 132, "Drug"], [134, 137, "Drug"], [141, 142, "Level"], [143, 147, "Disease"], [143, 143, "Anatomy"], [151, 154, "Drug"], [159, 162, "Level"], [163, 167, "Disease"], [163, 163, "Anatomy"], [209, 211, "ADE"], [221, 223, "Disease"], [219, 220, "Level"], [268, 272, "Drug"], [278, 281, "Drug"], [289, 293, "Drug"], [307, 310, "Test_items"], [316, 317, "Test_items"], [329, 331, "ADE"], [25, 25, "Anatomy"], [261, 263, "ADE"]], "rel": [[25, 25, "Anatomy", 25, 29, "Disease", "Anatomy_Disease"], [36, 48, "Test_items", 97, 99, "Disease", "Test_items_Disease"], [61, 63, "Test_items", 97, 99, "Disease", "Test_items_Disease"], [73, 84, "Test_items", 97, 99, "Disease", "Test_items_Disease"], [97, 97, "Anatomy", 97, 99, "Disease", "Anatomy_Disease"], [111, 111, "Anatomy", 111, 115, "Disease", "Anatomy_Disease"], [124, 127, "Drug", 143, 147, "Disease", "Drug_Disease"], [129, 132, "Drug", 143, 147, "Disease", "Drug_Disease"], [134, 137, "Drug", 143, 147, "Disease", "Drug_Disease"], [143, 143, "Anatomy", 143, 147, "Disease", "Anatomy_Disease"], [151, 154, "Drug", 163, 167, "Disease", "Drug_Disease"], [163, 163, "Anatomy", 163, 167, "Disease", "Anatomy_Disease"], [329, 331, "ADE", 289, 293, "Drug", "ADE_Drug"]]}
{"idx": 1313, "sentence": "④目前，所有磺脲类药物均未被中国食品药品监督管理局(CFDA)批准用于妊娠、儿童和青少年患者。", "ner": [[6, 10, "Drug"]], "rel": []}
{"idx": 1314, "sentence": "中国成人2型糖尿病HbA1c控制目标的专家共识", "ner": [[4, 8, "Disease"], [9, 13, "Test_items"]], "rel": [[9, 13, "Test_items", 4, 8, "Disease", "Test_items_Disease"]]}
{"idx": 1315, "sentence": "目前，2型糖尿病及其并发症已经成为危害公众健康的主要疾病之一，控制血糖是延缓糖尿病进展及其并发症发生的重要措施之一。虽然HbA1c是评价血糖控制水平的公认指标，但应该控制的理想水平即目标值究竟是多少还存在争议。糖尿病控制与并发症试验(DCCT，1993)、熊本(Kumamoto，1995)、英国前瞻性糖尿病研究(UKPDS，1998)等高质量临床研究已经证实，对新诊断的糖尿病患者或病情较轻的患者进行严格的血糖控制会延缓糖尿病微血管病变的发生、发展，其后续研究DCCT-EDIC(2005)、UKPDS一80(2008)还证实早期有效控制血糖对大血管也有保护作用。这些研究终点的HbA1c控制在7.5%左右，那么年龄较大、糖尿病病程较长、部分已有心血管疾病(CVD)或伴CVD极高危因素的糖尿病人群进一步降低血糖，对CVD的影响将会如何?糖尿病患者心血管风险干预研究(ACCORD)、退伍军人糖尿病研究(VADT)和糖尿病与心血管疾病行动研究(ADVANCE)等对该类人群平均5年左右的干预，结果显示强化降糖治疗使HbA1c<6.5%，患者死亡风险和大血管事件发生并无进一步减少，ACCORD甚至表明控制HbA1c水平接近正常值(<6.4%)会增加这类患者死亡率。这些与理论或预期不一致结果产生的原因尚不确定，可能与人组人群差异、低血糖、体重增加、随访时间长短及评估方法等诸多因素有关，但过分苛求血糖正常化可能是主要原因之一。ACCORD、VADT数据分析提示对病程长、有低血糖史、有CVD或合并CVD极高危的患者，盲目地进行强化达标治疗，会明显增加低血糖和心血管事件发生。各权威组织推荐的血糖控制目标HbA1c的水平也不尽相同，美国糖尿病协会(ADA)认为一般情况下血糖控制目标值HbA1c<7%；国际糖尿病联盟(IDF)、美国内分泌医师协会/美国内分泌协会(AACE/ACE)、英国健康与临床优化研究所(NICE)、全球有效管理糖尿病合作组织(GPEDM)和加拿大糖尿病协会(CDA)则建议一般情况时HbA1c<6.5%；中华医学会糖尿病分会推荐的一般HbA1c目标值为<6.5%。", "ner": [[3, 7, "Disease"], [33, 34, "Test_items"], [38, 40, "Disease"], [60, 64, "Test_items"], [68, 69, "Test_items"], [105, 107, "Disease"], [151, 153, "Disease"], [186, 188, "Disease"], [204, 205, "Test_items"], [211, 218, "Disease"], [214, 216, "Anatomy"], [270, 271, "Test_items"], [273, 275, "Anatomy"], [290, 294, "Test_items"], [298, 303, "Test_Value"], [312, 314, "Disease"], [324, 333, "Disease"], [324, 326, "Anatomy"], [336, 338, "Disease"], [345, 347, "Disease"], [355, 356, "Test_items"], [359, 361, "Disease"], [370, 372, "Disease"], [375, 377, "Anatomy"], [397, 399, "Disease"], [409, 411, "Disease"], [413, 417, "Disease"], [413, 415, "Anatomy"], [458, 462, "Test_items"], [463, 467, "Test_Value"], [476, 480, "Disease"], [476, 478, "Anatomy"], [503, 507, "Test_items"], [510, 521, "Test_Value"], [566, 568, "Disease"], [570, 573, "Symptom"], [599, 600, "Test_items"], [601, 602, "Test_Value"], [637, 639, "Disease"], [643, 645, "Disease"], [649, 651, "Disease"], [676, 678, "Disease"], [680, 684, "Disease"], [680, 682, "Anatomy"], [735, 736, "Test_items"], [742, 746, "Test_items"], [747, 749, "Test_Value"], [753, 755, "Disease"], [718, 720, "Disease"], [817, 819, "Disease"], [835, 837, "Disease"], [853, 857, "Test_items"], [858, 862, "Test_Value"], [869, 871, "Disease"], [879, 883, "Test_items"], [888, 892, "Test_Value"], [696, 697, "Test_items"], [702, 706, "Test_items"]], "rel": [[33, 34, "Test_items", 38, 40, "Disease", "Test_items_Disease"], [204, 205, "Test_items", 211, 218, "Disease", "Test_items_Disease"], [214, 216, "Anatomy", 211, 218, "Disease", "Anatomy_Disease"], [324, 326, "Anatomy", 324, 333, "Disease", "Anatomy_Disease"], [355, 356, "Test_items", 345, 347, "Disease", "Test_items_Disease"], [375, 377, "Anatomy", 370, 372, "Disease", "Anatomy_Disease"], [413, 415, "Anatomy", 413, 417, "Disease", "Anatomy_Disease"], [458, 462, "Test_items", 476, 480, "Disease", "Test_items_Disease"], [476, 478, "Anatomy", 476, 480, "Disease", "Anatomy_Disease"], [503, 507, "Test_items", 476, 480, "Disease", "Test_items_Disease"], [680, 682, "Anatomy", 680, 684, "Disease", "Anatomy_Disease"], [735, 736, "Test_items", 718, 720, "Disease", "Test_items_Disease"], [742, 746, "Test_items", 718, 720, "Disease", "Test_items_Disease"], [853, 857, "Test_items", 835, 837, "Disease", "Test_items_Disease"], [879, 883, "Test_items", 869, 871, "Disease", "Test_items_Disease"]]}
{"idx": 1316, "sentence": "糖尿病患者血糖控制目标应该遵循个体化原则，即对血糖控制的风险(risk)与获益(benefit)、成本(cost)与效益(effectiveness)和可行性(feasibility)方面进行科学评估，寻找较为合理的平衡，这一点已是专家共识。在我国，多数糖尿病患者居住在县以下及农村地区，经济、受教育程度、医疗保障及医疗水平等诸多影响血糖控制的因素差别极大，地域差别较强，因此临床医生在设定糖尿病血糖控制目标时除考虑病理生理因素即病情外，还必须考虑社会因素，社会因素的重要性在某些特定患者甚至超过病情。比如自我血糖监测(SMBG)在我国开展不普遍，因此防范严重低血糖的发生必须放在首位，HbA1c目标的制定应统筹考虑安全性、可行性和科学性。我们不主张笼统推荐成人2型糖尿病的HbA1c控制目标，而是根据病情分层和社会因素的差异建议相对合理的HbA1c值，力争做到安全达标。", "ner": [[0, 2, "Disease"], [5, 6, "Test_items"], [23, 24, "Test_items"], [127, 129, "Disease"], [167, 168, "Test_items"], [195, 197, "Disease"], [198, 199, "Test_items"], [253, 264, "Test_items"], [280, 282, "Disease"], [293, 297, "Test_items"], [331, 335, "Disease"], [337, 341, "Test_items"], [370, 374, "Test_items"]], "rel": [[5, 6, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [167, 168, "Test_items", 127, 129, "Disease", "Test_items_Disease"], [198, 199, "Test_items", 195, 197, "Disease", "Test_items_Disease"], [253, 264, "Test_items", 280, 282, "Disease", "Test_items_Disease"], [293, 297, "Test_items", 280, 282, "Disease", "Test_items_Disease"], [337, 341, "Test_items", 331, 335, "Disease", "Test_items_Disease"]]}
{"idx": 1317, "sentence": "从病情因素考虑，大致将患者分为以下6类。", "ner": [], "rel": []}
{"idx": 1318, "sentence": "一、无糖尿病并发症和严重伴发疾病的非老年(<65岁)患者", "ner": [[3, 5, "Disease"]], "rel": []}
{"idx": 1319, "sentence": "1.一般将HbA1c控制于<6.5%，若降糖治疗无低血糖或体重增加等不良反应者可使HbA1c<6%。目前，新诊断糖尿病患者的人数逐年增加，越来越年轻化，尤其是30—39岁比例增加引起了临床医生的关注。这些患者绝大多数除糖尿病外并无并发症和其他疾病，考虑对患者预期寿命和生活质量的影响，应该严格控制血糖，目标值HbA1c<6.5%，我们也同意并推荐IDF的建议，对于年轻、病程较短、治疗后无低血糖或体重增加等不良反应发生的患者，血糖控制目标值应该尽量使HbAIc<6%。", "ner": [[5, 9, "Test_items"], [13, 17, "Test_Value"], [25, 27, "ADE"], [29, 32, "ADE"], [41, 45, "Test_items"], [46, 48, "Test_Value"], [56, 58, "Disease"], [109, 111, "Disease"], [154, 158, "Test_items"], [148, 149, "Test_items"], [213, 214, "Test_items"], [225, 229, "Test_items"], [194, 196, "ADE"], [198, 201, "ADE"], [159, 163, "Test_Value"], [230, 232, "Test_Value"]], "rel": [[148, 149, "Test_items", 109, 111, "Disease", "Test_items_Disease"], [154, 158, "Test_items", 109, 111, "Disease", "Test_items_Disease"], [213, 214, "Test_items", 109, 111, "Disease", "Test_items_Disease"], [225, 229, "Test_items", 109, 111, "Disease", "Test_items_Disease"]]}
{"idx": 1320, "sentence": "研究表明，随着HbA1c水平的升高，发生CVD的危险性相对增加，而且糖尿病病史越长的患者治疗后CVD危险性减低越小；流行病学调查结果的meta分析显示，HbA1c每增加1%，2型糖尿病心血管事件的相对危险性为1.18，1型糖尿病为1.15；ACCORD亚组分析也提示，既往无CVD且HbA1c<8%的患者强化治疗后CVD的发生及其死亡率明显下降，这与总体患者(平均病程10年，35%发生过CVD)的研究结果恰恰相反。另一方面，DCCT-EDIC经过后续8年的随访证实1型糖尿病患者早期强化治疗对微血管有持久的保护作用，并延缓动脉粥样硬化的发展；UKPDS-80经过后续10年的长期随访发现对新诊断的2型糖尿病患者，强化降糖治疗不仅能减少微血管并发症的发生，还能显著降低患者的心肌梗死发生率和总死亡率。所以，观察到严格控制血糖对大血管的保护作用可能需要较长的时间。总之，不管从病理生理还是流行病学的角度，在糖尿病诊断时就严格控制血糖，同时控制体重、血脂、血压，抗血小板治疗，全面降低CVD危险因素会延缓慢性并发症的发生、发展。", "ner": [[7, 11, "Test_items"], [15, 16, "Test_Value"], [20, 22, "Disease"], [34, 36, "Disease"], [47, 49, "Disease"], [87, 91, "Disease"], [76, 80, "Test_items"], [82, 85, "Test_Value"], [92, 96, "Disease"], [92, 94, "Anatomy"], [109, 113, "Disease"], [137, 139, "Disease"], [141, 145, "Test_items"], [146, 148, "Test_Value"], [157, 159, "Disease"], [194, 196, "Disease"], [233, 237, "Disease"], [247, 249, "Anatomy"], [262, 267, "Disease"], [262, 263, "Anatomy"], [299, 303, "Disease"], [318, 320, "Anatomy"], [337, 340, "Disease"], [337, 338, "Anatomy"], [360, 361, "Test_items"], [363, 365, "Anatomy"], [402, 404, "Disease"], [413, 414, "Test_items"], [423, 424, "Test"], [426, 427, "Test"], [440, 442, "Disease"]], "rel": [[7, 11, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [76, 80, "Test_items", 87, 91, "Disease", "Test_items_Disease"], [92, 94, "Anatomy", 92, 96, "Disease", "Anatomy_Disease"], [247, 249, "Anatomy", 233, 237, "Disease", "Anatomy_Disease"], [262, 263, "Anatomy", 262, 267, "Disease", "Anatomy_Disease"], [318, 320, "Anatomy", 299, 303, "Disease", "Anatomy_Disease"], [337, 338, "Anatomy", 337, 340, "Disease", "Anatomy_Disease"], [413, 414, "Test_items", 402, 404, "Disease", "Test_items_Disease"], [423, 424, "Test", 402, 404, "Disease", "Test_Disease"], [426, 427, "Test", 402, 404, "Disease", "Test_Disease"]]}
{"idx": 1321, "sentence": "2.口服降糖药物未达标加用或改用胰岛素的患者，其血糖控制目标值可适当放宽至HbA1c<7%，以减少低血糖和体重增加这两大不良反应。Miller等对1055例2型糖尿病患者(平均年龄61岁，病程10.8年)的低血糖发生情况调查显示，在随访的7个月中有24.5%的患者至少发生过一次低血糖(有低血糖症状并且血糖<3.3mmol/L)，其中生活方式干预组(HbA1c<6%)占11.8%，口服药物治疗组(HbA1c<7%)占16.2%，胰岛素治疗组(HbA1c<8.1%)占30.5%，而且随访过程中发生的5例严重低血糖事件(0.5%)均在胰岛素治疗组。UKPDS和ACCORD均发现胰岛素使体重增加，若体重增加，可能加重胰岛素抵抗，增加CVD风险。", "ner": [[2, 3, "Method"], [16, 18, "Drug"], [24, 25, "Test_items"], [37, 41, "Test_items"], [42, 44, "Test_Value"], [49, 51, "ADE"], [53, 56, "ADE"], [78, 82, "Disease"], [103, 105, "Disease"], [139, 141, "Disease"], [144, 146, "Disease"], [151, 152, "Test_items"], [153, 162, "Test_Value"], [175, 179, "Test_items"], [180, 182, "Test_Value"], [191, 192, "Method"], [199, 203, "Test_items"], [204, 206, "Test_Value"], [252, 258, "ADE"], [267, 269, "Drug"], [289, 291, "Drug"], [293, 296, "ADE"], [299, 302, "Reason"], [308, 312, "Pathogenesis"], [316, 318, "Disease"], [215, 217, "Drug"], [222, 226, "Test_items"], [227, 231, "Test_Value"]], "rel": [[151, 152, "Test_items", 144, 146, "Disease", "Test_items_Disease"], [175, 179, "Test_items", 144, 146, "Disease", "Test_items_Disease"], [252, 258, "ADE", 267, 269, "Drug", "ADE_Drug"], [293, 296, "ADE", 289, 291, "Drug", "ADE_Drug"], [299, 302, "Reason", 316, 318, "Disease", "Reason_Disease"], [308, 312, "Pathogenesis", 316, 318, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1322, "sentence": "调查结果和临床经验提示对应用胰岛素治疗的患者适当放宽控制目标，也许患者受益更多。", "ner": [[14, 16, "Drug"]], "rel": []}
{"idx": 1323, "sentence": "3.目前不必使用降糖药物的患者，即经过一定时间的降糖治疗后已经停用降糖药物，仅使用生活方式干预血糖控制很好，其目标值应该更严格(HbA1c<6%)。", "ner": [[47, 48, "Test_items"], [64, 68, "Test_items"], [69, 71, "Test_Value"]], "rel": []}
{"idx": 1324, "sentence": "这些患者达到目标值的过程中仍存在低血糖风险，但其发生率较低，更严格的血糖控制能显著减缓慢性并发症的发生、发展，因此获益/风险比明显增加。", "ner": [[16, 18, "Disease"], [34, 35, "Test_items"]], "rel": []}
{"idx": 1325, "sentence": "二、已有CVD或CVD极高危患者", "ner": [[4, 6, "Disease"], [8, 10, "Disease"]], "rel": []}
{"idx": 1326, "sentence": "糖尿病病史长，已患CVD或处于CVD极高危，我们推荐HbA1c≤7.5%，因为他们发生或再次发生CVD风险明显增加，低血糖风险较高，目前还没有足够的证据证明HbA1c控制在7%以下对大血管的益处。大规模随机对照试验，如ACCORD、VADT和ADVANCE的结果表明，强化降糖5年内并未发现大血管受益，ACCORD甚至显示总死亡风险反而有所增加。分析ACCORD的研究资料发现对病情较重的入组患者(平均年龄62岁，病程10年，伴CVD占35%)进行强化降糖，可能是主要原因之一。对这些年龄大、病程长、并发症和伴发疾病多的患者严格控制血糖，若发生低血糖可能诱发CVD，增加患者的死亡风险。", "ner": [[0, 2, "Disease"], [9, 11, "Disease"], [15, 17, "Disease"], [26, 30, "Test_items"], [31, 35, "Test_Value"], [48, 50, "Disease"], [58, 60, "Disease"], [78, 82, "Test_items"], [83, 89, "Test_Value"], [91, 93, "Anatomy"], [214, 216, "Disease"], [266, 267, "Test_items"], [272, 274, "Reason"], [279, 281, "Disease"]], "rel": [[26, 30, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [91, 93, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [78, 82, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [26, 30, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [91, 93, "Anatomy", 9, 11, "Disease", "Anatomy_Disease"], [78, 82, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [26, 30, "Test_items", 15, 17, "Disease", "Test_items_Disease"], [91, 93, "Anatomy", 15, 17, "Disease", "Anatomy_Disease"], [78, 82, "Test_items", 15, 17, "Disease", "Test_items_Disease"], [266, 267, "Test_items", 279, 281, "Disease", "Test_items_Disease"], [272, 274, "Reason", 279, 281, "Disease", "Reason_Disease"]]}
{"idx": 1327, "sentence": "ACCORD中3或4种降糖药物同时应用力求快速达到控制目标(HbA1c<6.0%)，这明显增加低血糖的发生率和总死亡率。", "ner": [[30, 34, "Test_items"], [35, 39, "Test_Value"], [47, 49, "Disease"]], "rel": [[30, 34, "Test_items", 47, 49, "Disease", "Test_items_Disease"]]}
{"idx": 1328, "sentence": "ADVANCE与ACCORD不同，其血糖控制力求平稳，低血糖发生率较低，效果也更好，至少没有增加CVD事件和死亡率。", "ner": [[18, 19, "Test_items"], [27, 29, "Disease"], [48, 50, "Disease"]], "rel": [[18, 19, "Test_items", 27, 29, "Disease", "Test_items_Disease"]]}
{"idx": 1329, "sentence": "另外，虽然DCCT-EDIC和UKPDS-80提示，对病情较轻的患者进行早期强化降糖治疗大血管受益较多，但即使是新诊断的糖尿病人群观察到降糖对大血管的保护作用也需要10年以上。", "ner": [[60, 62, "Disease"]], "rel": []}
{"idx": 1330, "sentence": "对伴CVD或CVD极高危患者血糖控制目标要适当放宽，治疗过程中要避免血糖下降速度过快和发生低血糖；并且该组患者多同时服用其他干预CVD危险因素的药物，应慎重选择降糖药物，注意药物的禁忌证和药物间的相互作用。", "ner": [[2, 4, "Disease"], [6, 8, "Disease"], [14, 15, "Test_items"], [64, 66, "Disease"], [45, 47, "Disease"], [36, 41, "Test_Value"], [34, 35, "Test_items"]], "rel": [[14, 15, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [14, 15, "Test_items", 6, 8, "Disease", "Test_items_Disease"]]}
{"idx": 1331, "sentence": "三、老年糖尿病患者", "ner": [[2, 6, "Disease"]], "rel": []}
{"idx": 1332, "sentence": "多数指南并未单独设定老年糖尿病患者(>65岁)的血糖控制目标，这是因为老年患者的身体健康状况、脏器功能、认知功能以及预期寿命差异较大，不能一概而论；同时缺乏相关的循证医学证据指导制定个体化治疗目标。本共识专家认为应该就此特殊人群制定血糖控制目标，本共识专家认为应该就此特殊人群制定血糖控制目标，参考国外文献，建议血糖控制目标：若患者脏器功能和认知能力良好、预期生存期>15年，应严格控制HbA1c<7%；若患者合并其他疾病、预期生存期5~15年，可适当放宽HbA1c<8%；若患者既往有严重低血糖史、合并其他严重疾病、预期生存期<5年，美国退伍军人事务局推荐控制目标可放宽到HbA1c<9%。HbA1c较高者应避免发生高血糖症状、急性代谢紊乱和感染。", "ner": [[12, 14, "Disease"], [24, 25, "Test_items"], [116, 117, "Test_items"], [140, 141, "Test_items"], [156, 157, "Test_items"], [193, 197, "Test_items"], [198, 200, "Test_Value"], [228, 232, "Test_items"], [233, 235, "Test_Value"], [243, 244, "Level"], [245, 247, "Disease"], [287, 291, "Test_items"], [292, 294, "Test_Value"], [296, 300, "Test_items"], [301, 302, "Test_Value"], [309, 311, "Disease"], [315, 320, "Disease"], [322, 323, "Disease"]], "rel": [[24, 25, "Test_items", 12, 14, "Disease", "Test_items_Disease"], [287, 291, "Test_items", 245, 247, "Disease", "Test_items_Disease"], [296, 300, "Test_items", 309, 311, "Disease", "Test_items_Disease"], [296, 300, "Test_items", 315, 320, "Disease", "Test_items_Disease"], [296, 300, "Test_items", 322, 323, "Disease", "Test_items_Disease"]]}
{"idx": 1333, "sentence": "对老年尤其高龄(>80岁)患者的血糖控制目标总体放宽主要原因是，老年人的神经反应比较迟钝或存在神经病变，容易发生无感知低血糖，患者常常在没有任何征兆的情况下发生低血糖昏迷，这种情况如果发生在夜间非常危险，往往因错过抢救时机导致严重脑损伤甚至死亡；而且老年人多伴有心脑血管动脉粥样硬化，一旦发生低血糖可诱发心肌梗死及脑卒中。", "ner": [[56, 61, "Disease"], [16, 17, "Test_items"], [80, 84, "Disease"], [113, 114, "Level"], [115, 117, "Disease"], [115, 115, "Anatomy"], [131, 140, "Disease"], [131, 134, "Anatomy"], [146, 148, "Reason"], [152, 155, "Disease"], [157, 159, "Disease"], [152, 153, "Anatomy"], [157, 157, "Anatomy"]], "rel": [[16, 17, "Test_items", 56, 61, "Disease", "Test_items_Disease"], [115, 115, "Anatomy", 115, 117, "Disease", "Anatomy_Disease"], [131, 134, "Anatomy", 131, 140, "Disease", "Anatomy_Disease"], [146, 148, "Reason", 152, 155, "Disease", "Reason_Disease"], [146, 148, "Reason", 157, 159, "Disease", "Reason_Disease"], [152, 153, "Anatomy", 152, 155, "Disease", "Anatomy_Disease"], [157, 157, "Anatomy", 157, 159, "Disease", "Anatomy_Disease"]]}
{"idx": 1334, "sentence": "即使是轻微的低血糖也可能引起患者摔伤、骨折等机体损伤，导致患者入院，增加心理和经济负担。", "ner": [[3, 8, "Reason"], [16, 17, "Disease"], [19, 20, "Disease"]], "rel": [[3, 8, "Reason", 16, 17, "Disease", "Reason_Disease"], [3, 8, "Reason", 19, 20, "Disease", "Reason_Disease"]]}
{"idx": 1335, "sentence": "老年患者的预期寿命也很重要，严格的强化治疗会使生活质量下降、心理压力明显增大，如果预期生存期<5年，则获益/风险比显著下降。", "ner": [], "rel": []}
{"idx": 1336, "sentence": "因此，对老年糖尿病患者的血糖控制目标放宽程度应该因人而异，治疗措施应该简单易行，控制高血糖药物选择还需充分考虑患者脏器功能的减退程度。", "ner": [[6, 8, "Disease"], [12, 13, "Test_items"], [42, 44, "Disease"]], "rel": [[12, 13, "Test_items", 6, 8, "Disease", "Test_items_Disease"]]}
{"idx": 1337, "sentence": "糖尿病病程>15年、有无感知低血糖病史、有严重伴发病如肝肾功能不全或全天血糖波动较大并反复出现低血糖症状的患者，很难设定其HbA1c的靶目标，最重要的是避免低血糖的发生，也许HbA1c控制在7%~9%是可以接受的。因为Stratton等对4585例2型糖尿病患者10年的随访表明，HbA1c<7%患者慢性并发症的发生和死亡风险最低；HbA1c控制在7%~9%，上述风险虽然增加，但是相对增长缓慢；一旦HbA1c>9%，风险明显增加甚至翻倍。", "ner": [[0, 2, "Disease"], [14, 16, "Disease"], [27, 32, "Disease"], [27, 27, "Anatomy"], [28, 28, "Anatomy"], [36, 37, "Test_items"], [38, 41, "Test_Value"], [47, 49, "Disease"], [61, 65, "Test_items"], [78, 80, "Disease"], [87, 91, "Test_items"], [95, 99, "Test_Value"], [124, 128, "Disease"], [140, 144, "Test_items"], [145, 147, "Test_Value"], [166, 170, "Test_items"], [174, 178, "Test_Value"], [200, 204, "Test_items"], [205, 207, "Test_Value"]], "rel": [[36, 37, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [61, 65, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [87, 91, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [27, 27, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [28, 28, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [140, 144, "Test_items", 124, 128, "Disease", "Test_items_Disease"], [200, 204, "Test_items", 124, 128, "Disease", "Test_items_Disease"], [166, 170, "Test_items", 124, 128, "Disease", "Test_items_Disease"]]}
{"idx": 1338, "sentence": "四、低血糖高危险人群", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 1339, "sentence": "所有大样本随机对照研究都证实强化治疗使低血糖的发生率明显增加，虽然严重低血糖事件发生率少，但对UKPDS、前瞻性吡格列酮对大血管事件影响的临床研究(PROactive)、ADVANCE、VADT和ACCORD五大临床研究的meta分析显示强化治疗组的严重低血糖发生率为2.3%，常规治疗组为1.2%，可见，强化治疗增加低血糖发生率是不可避免的。但是，如前面所述，低血糖除了直接造成相应的严重临床后果外，频繁或严重的低血糖影响糖尿病患者的治疗。调查表明患者一旦出现频繁或严重的低血糖会明显降低患者对血糖控制达标的积极性。", "ner": [[19, 21, "Disease"], [33, 34, "Level"], [35, 37, "Disease"], [56, 59, "Drug"], [61, 65, "Disease"], [61, 63, "Anatomy"], [125, 126, "Level"], [127, 129, "Disease"], [159, 161, "Disease"], [181, 183, "Disease"], [204, 205, "Level"], [207, 209, "Disease"], [212, 214, "Disease"], [234, 235, "Level"], [237, 239, "Disease"], [248, 249, "Test_items"]], "rel": [[56, 59, "Drug", 61, 65, "Disease", "Drug_Disease"], [61, 63, "Anatomy", 61, 65, "Disease", "Anatomy_Disease"], [248, 249, "Test_items", 237, 239, "Disease", "Test_items_Disease"]]}
{"idx": 1340, "sentence": "因此低血糖高危人群的个体化血糖控制格外重要。", "ner": [[2, 4, "Disease"], [13, 14, "Test_items"]], "rel": [[13, 14, "Test_items", 2, 4, "Disease", "Test_items_Disease"]]}
{"idx": 1341, "sentence": "五、妊娠期高血糖", "ner": [[2, 7, "Disease"]], "rel": []}
{"idx": 1342, "sentence": "对于计划妊娠的糖尿病患者，应严格控制血糖目标值HbA1c<6.5%，如应用胰岛素可适当放宽HbA1c<7%以防止低血糖发生。不建议HbA1c>8%的患者妊娠，这些患者应首先应控制血糖，因为高血糖会明显增加早期流产和胎儿畸形风险。", "ner": [[7, 9, "Disease"], [18, 19, "Test_items"], [23, 27, "Test_items"], [28, 32, "Test_Value"], [45, 49, "Test_items"], [50, 52, "Test_Value"], [37, 39, "Drug"], [56, 58, "ADE"], [65, 69, "Test_items"], [70, 72, "Test_Value"], [89, 90, "Test_items"], [94, 96, "Reason"], [102, 105, "Disease"], [107, 110, "Disease"]], "rel": [[18, 19, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [23, 27, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [45, 49, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [37, 39, "Drug", 7, 9, "Disease", "Drug_Disease"], [56, 58, "ADE", 37, 39, "Drug", "ADE_Drug"], [94, 96, "Reason", 102, 105, "Disease", "Reason_Disease"], [94, 96, "Reason", 107, 110, "Disease", "Reason_Disease"]]}
{"idx": 1343, "sentence": "妊娠期高血糖包括糖尿病合并妊娠(妊娠前糖尿病)、妊娠期发现的糖尿病(overt diabetes，指妊娠期HbA1c或血糖达到糖尿病诊断标准)和妊娠糖尿病(GDM)三种情况。", "ner": [[0, 5, "Disease"], [8, 14, "Disease"], [16, 21, "Disease"], [30, 32, "Disease"], [34, 47, "Disease"], [53, 57, "Test_items"], [59, 60, "Test_items"], [63, 65, "Disease"], [72, 76, "Disease"]], "rel": [[53, 57, "Test_items", 63, 65, "Disease", "Test_items_Disease"], [59, 60, "Test_items", 63, 65, "Disease", "Test_items_Disease"]]}
{"idx": 1344, "sentence": "妊娠前糖尿病或妊娠期发现的糖尿病在不发生低血糖前提下孕期血糖控制，理想目标值为HbA1c<6%；毛细血管血糖餐前、睡前及夜间不高于5.4mmol/L，餐后峰值不高于7.1mmol/L。GDM毛细血管血糖餐前<5.3mmol/L，餐后1h<7.8mmol/L或2h<6.7mmol/L。", "ner": [[0, 5, "Disease"], [13, 15, "Disease"], [20, 22, "Disease"], [28, 29, "Test_items"], [39, 43, "Test_items"], [44, 46, "Test_Value"], [48, 61, "Test_items"], [62, 73, "Test_Value"], [75, 78, "Test_items"], [79, 90, "Test_Value"], [92, 94, "Disease"], [95, 102, "Test_items"], [103, 112, "Test_Value"], [114, 117, "Test_items"], [118, 127, "Test_Value"], [129, 130, "Test_items"], [131, 140, "Test_Value"]], "rel": [[28, 29, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [39, 43, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [48, 61, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [75, 78, "Test_items", 0, 5, "Disease", "Test_items_Disease"], [95, 102, "Test_items", 92, 94, "Disease", "Test_items_Disease"], [114, 117, "Test_items", 92, 94, "Disease", "Test_items_Disease"], [129, 130, "Test_items", 92, 94, "Disease", "Test_items_Disease"]]}
{"idx": 1345, "sentence": "临床研究显示，相对于餐前血糖而言，餐后血糖的良好控制可更好地减少并发症，尤其是巨大儿出生；相对于餐后2h血糖，控制好餐后1h血糖，产科结局更好。", "ner": [[10, 13, "Test_items"], [17, 20, "Test_items"], [39, 41, "Disease"], [48, 53, "Test_items"], [58, 63, "Test_items"]], "rel": [[10, 13, "Test_items", 39, 41, "Disease", "Test_items_Disease"], [17, 20, "Test_items", 39, 41, "Disease", "Test_items_Disease"]]}
{"idx": 1346, "sentence": "六、其他情况", "ner": [], "rel": []}
{"idx": 1347, "sentence": "与2型糖尿病并存的其他疾病比较多，这些情况下血糖控制目标目前缺乏相应的循证医学证据和共识。比如：恶性肿瘤、老年痴呆症、癫痫等。若患者预期寿命<5年者，HbA1c不应超过9%；预期寿命更长者，HbA1c可控制在7%左右。执行治疗方案较困难的情况，如精神或智力障碍者、视力障碍者、老年、高龄及独居者等，其血糖的控制目标应适当放宽，HbA1c不应超过9%，主要防止血糖过高引起的症状、急性代谢紊乱、感染和低血糖的发生。", "ner": [[1, 5, "Disease"], [22, 23, "Test_items"], [48, 51, "Disease"], [53, 57, "Disease"], [59, 60, "Disease"], [75, 79, "Test_items"], [80, 85, "Test_Value"], [95, 99, "Test_items"], [104, 107, "Test_Value"], [123, 129, "Disease"], [132, 135, "Disease"], [150, 151, "Test_items"], [163, 167, "Test_items"], [168, 173, "Test_Value"], [179, 180, "Test_items"], [181, 182, "Test_Value"], [189, 194, "Disease"], [196, 197, "Disease"], [199, 201, "Disease"]], "rel": [[22, 23, "Test_items", 1, 5, "Disease", "Test_items_Disease"], [150, 151, "Test_items", 123, 129, "Disease", "Test_items_Disease"], [163, 167, "Test_items", 123, 129, "Disease", "Test_items_Disease"], [150, 151, "Test_items", 132, 135, "Disease", "Test_items_Disease"], [163, 167, "Test_items", 132, 135, "Disease", "Test_items_Disease"]]}
{"idx": 1348, "sentence": "社会因素是决定血糖控制目标的另一个重要且必须考虑的问题，对美国不同种族的糖尿病患者在降糖治疗过程中的依从性和血糖控制情况的调查表明，那些医疗保障差的患者，治疗的依从性、血糖的自我管理能力和血糖的控制水平明显下降。", "ner": [[7, 8, "Test_items"], [36, 38, "Disease"], [54, 55, "Test_items"], [84, 85, "Test_items"], [94, 95, "Test_items"]], "rel": [[54, 55, "Test_items", 36, 38, "Disease", "Test_items_Disease"]]}
{"idx": 1349, "sentence": "但是，医疗保障差的人群总花销并不比平均水平低，这主要是因为忽视糖尿病治疗导致血糖过低或过高，引起相关疾病发生而入院诊治。", "ner": [[31, 33, "Disease"], [38, 39, "Test_items"], [40, 41, "Test_Value"], [43, 44, "Test_Value"]], "rel": [[38, 39, "Test_items", 31, 33, "Disease", "Test_items_Disease"]]}
{"idx": 1350, "sentence": "在我国，很多糖尿病患者居住在县以下及农村地区，家庭收入和受教育程度较低、医疗保障及医疗条件差，他们对糖尿病相关知识知之甚少，对糖尿病的危险性认识不够、依从性差、几乎不能进行血糖自我监测(SMBG)，这类患者的血糖控制目标应依据患者的病情综合考虑，适当放宽，尽量避免因严重的低血糖或高血糖发生，加重患者病情和经济负担。", "ner": [[50, 52, "Disease"], [63, 65, "Disease"], [86, 97, "Test_items"], [104, 105, "Test_items"], [133, 134, "Level"], [136, 138, "Disease"], [140, 142, "Disease"], [6, 8, "Disease"]], "rel": [[86, 97, "Test_items", 63, 65, "Disease", "Test_items_Disease"]]}
{"idx": 1351, "sentence": "对中国成人2型糖尿病HbA1c目标值的适用人群以HbA1c水平分层，总结于表1。", "ner": [[5, 9, "Disease"], [10, 14, "Test_items"], [24, 28, "Test_items"]], "rel": [[10, 14, "Test_items", 5, 9, "Disease", "Test_items_Disease"], [24, 28, "Test_items", 5, 9, "Disease", "Test_items_Disease"]]}
{"idx": 1352, "sentence": "总之，糖尿病患者的血糖控制目标要因人而异，像GPEDM倡导的“量体裁衣”(tailoring)式管理血糖，有些患者可适当放宽，不要因为过分强调HbA1c达标或正常化增加患者低血糖和死亡风险。HbA1c受检测方法和血红蛋白、红细胞转换、年龄等诸多因素的影响，也不能反映瞬时血糖水平及血糖波动，常规开展HbA1c测定还有困难，且目前国内尚缺乏检测方法的标准化，因此必须充分结合血糖监测才能真正了解糖代谢的控制情况。HbA1c的监测可依据病情每3~6个月进行一次。应该依据病情、治疗方案的不同结合患者的经济、文化、对治疗的依从性、医疗条件等多种因素，制定个体化的降糖策略，达到安全平稳降糖。必须强调血糖以外的CVD风险因素如血压、血脂、体重以及促凝状态等控制，戒烟及生活方式干预对防止、延缓或减少糖尿病并发症的发生同样十分重要。", "ner": [[3, 5, "Disease"], [9, 10, "Test_items"], [50, 51, "Test_items"], [71, 75, "Test_items"], [76, 77, "Test_Value"], [79, 80, "Test_Value"], [86, 88, "Disease"], [95, 99, "Test_items"], [135, 136, "Test_items"], [149, 153, "Test_items"], [186, 187, "Test_items"], [140, 141, "Test_items"], [142, 143, "Test_Value"], [205, 209, "Test_items"], [296, 297, "Test_items"], [301, 303, "Disease"], [309, 310, "Test"], [312, 313, "Test"], [327, 328, "Treatment"], [345, 347, "Disease"], [330, 335, "Treatment"]], "rel": [[9, 10, "Test_items", 3, 5, "Disease", "Test_items_Disease"], [71, 75, "Test_items", 3, 5, "Disease", "Test_items_Disease"], [296, 297, "Test_items", 301, 303, "Disease", "Test_items_Disease"], [309, 310, "Test", 301, 303, "Disease", "Test_Disease"], [312, 313, "Test", 301, 303, "Disease", "Test_Disease"], [327, 328, "Treatment", 345, 347, "Disease", "Treatment_Disease"], [330, 335, "Treatment", 345, 347, "Disease", "Treatment_Disease"]]}
{"idx": 1353, "sentence": "中国2型糖尿病自我管理处方专家共识(2017年版)", "ner": [[2, 6, "Disease"], [7, 10, "Treatment"]], "rel": [[7, 10, "Treatment", 2, 6, "Disease", "Treatment_Disease"]]}
{"idx": 1354, "sentence": "流行病学调查显示，我国成年人2型糖尿病患病率为9.7%~11.6%，已成为全球糖尿病患者最多的国家。糖尿病作为慢性终身性疾病，患者生活质量的提高有赖于自身管理。", "ner": [[14, 18, "Disease"], [39, 41, "Disease"], [50, 52, "Disease"], [75, 78, "Treatment"]], "rel": [[75, 78, "Treatment", 50, 52, "Disease", "Treatment_Disease"]]}
{"idx": 1355, "sentence": "有效的糖尿病自我管理教育和支持(diabetes self-management education/support，DSME/S)是协助糖尿病思者管理和维持自身健康行为的基础。", "ner": [[3, 65, "Treatment"], [3, 5, "Disease"], [69, 71, "Disease"]], "rel": [[3, 65, "Treatment", 3, 5, "Disease", "Treatment_Disease"]]}
{"idx": 1356, "sentence": "我国的糖尿病教育管理起步于20世纪90年代中期，最初是医护人员组织住院糖尿病患者进行授课，模式单一，患者学习比较被动。", "ner": [[3, 5, "Disease"], [6, 9, "Treatment"]], "rel": [[6, 9, "Treatment", 3, 5, "Disease", "Treatment_Disease"]]}
{"idx": 1357, "sentence": "随着国外的成功经验不断引人，以专业人员小组授课、个体化自我管理技能培训及病友同伴教育相结合的DSME模式开始出现。", "ner": [], "rel": []}
{"idx": 1358, "sentence": "但目前我国糖尿病教育存在诸多问题：如内容单调(以书本知识为主)、讲者随意性强、缺少系统评估和随访、教育与行为改变脱节、脱离患者需求、缺乏个体化的教育和饮食、运动计划以及制定的DSME计划无法很好地落实等。", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 1359, "sentence": "研究显示，DSME处万可改善治疗质量。为了指导广大医护工作者更加规范、科学地运用指南，结合个体化需求，选择合适时机，量化确定自我管理的内容、目标、预期效果，与患者一起制定实施计划，确定复诊时间，以提高患者生活质量，中华医学会糖尿病学分会糖尿病教育与管理学组组织专家编写“中国2型糖尿病自我管理处方专家共识”。", "ner": [[62, 65, "Treatment"], [112, 114, "Disease"], [118, 120, "Disease"], [137, 141, "Disease"]], "rel": []}
{"idx": 1360, "sentence": "本共识将从DSME处方的定义、理论依据、内容、形式、实践流程、应用时机、团队与技术这七个方面分别进行阐述。", "ner": [], "rel": []}
{"idx": 1361, "sentence": "一、自我管理处方的定义", "ner": [], "rel": []}
{"idx": 1362, "sentence": "自我管理处方是一种个体化的糖尿病教育管理工具，将2型糖尿病全方位自我管理的知识和技能以处方形式综合为一体，且随着处方的实施和不断改进，能将DSME/S延续并形成持续支持的糖尿病教育管理行为改变闭环。", "ner": [[13, 15, "Disease"], [24, 28, "Disease"], [85, 87, "Disease"], [69, 74, "Treatment"], [32, 35, "Treatment"]], "rel": [[32, 35, "Treatment", 24, 28, "Disease", "Treatment_Disease"]]}
{"idx": 1363, "sentence": "二、自我管理处方的理论依据", "ner": [], "rel": []}
{"idx": 1364, "sentence": "由于糖尿病是一种终身性的慢性代谢性疾病，其治疗要求患者具有高度的自我管理能力，DSME/S理论的应用对患者的临床、社会心理和行为等方面均有积极的影响。", "ner": [[2, 4, "Disease"], [39, 44, "Treatment"]], "rel": [[39, 44, "Treatment", 2, 4, "Disease", "Treatment_Disease"]]}
{"idx": 1365, "sentence": "自我管理处方的设计以DSME/S为理论基础，为了达到患者的行为改变，加入相关的健康管理与行为改变理论，如健康信念模型(health belief model)、行为分阶段转变理论模型(the transtheoretical model and stages of change)、Precede-Proceed模型(the Precede-Proceed Model)、Fogg行为模型(BJ Fogg Behavior Model)等。", "ner": [[10, 15, "Treatment"]], "rel": []}
{"idx": 1366, "sentence": "三、自我管理处方内容", "ner": [], "rel": []}
{"idx": 1367, "sentence": "糖尿病的教育管理涉及多学科知识.需要采取综合性措施，因而自我管理处方需要囊括多方面内容，包括综合评估、个性化控制目标、情绪管理、自我监测、饮食管理、运动管理、用药管理、胰岛素注射技术、糖尿病并发症筛查以及卫生资源支持。", "ner": [[0, 2, "Disease"], [4, 7, "Treatment"], [46, 49, "Treatment"], [51, 57, "Treatment"], [59, 62, "Treatment"], [64, 67, "Treatment"], [69, 72, "Treatment"], [74, 77, "Treatment"]], "rel": [[4, 7, "Treatment", 0, 2, "Disease", "Treatment_Disease"]]}
{"idx": 1368, "sentence": "处方制定以中国糖尿病领域专业指南为依据，结合患者的病程、病情和行为改变特点等，兼具科学性和个性化。", "ner": [[7, 9, "Disease"]], "rel": []}
{"idx": 1369, "sentence": "(一)综合评估", "ner": [], "rel": []}
{"idx": 1370, "sentence": "在制定个性化自我管理方案之前，需要对患者进行综合、系统的评估：", "ner": [[6, 9, "Treatment"]], "rel": []}
{"idx": 1371, "sentence": "1.患者基本信息：如年龄、性别、身高、体重、糖尿病类型、教育、职业、经济状况、病程、病史、用药情况、糖尿病家族史等。", "ner": [[22, 24, "Disease"], [50, 52, "Disease"]], "rel": []}
{"idx": 1372, "sentence": "2.糖尿病相关临床指标评估：如血糖、糖化血红蛋白、血压、血脂等。", "ner": [[2, 4, "Disease"], [15, 16, "Test_items"], [18, 23, "Test_items"], [25, 26, "Test"], [28, 29, "Test_items"]], "rel": [[15, 16, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [18, 23, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [25, 26, "Test", 2, 4, "Disease", "Test_Disease"], [28, 29, "Test_items", 2, 4, "Disease", "Test_items_Disease"]]}
{"idx": 1373, "sentence": "3.并发症评估：急性并发症，如低血糖、酮症酸中毒；慢性并发症，包括视网膜病变、心脑血管病变、糖尿病肾病、糖尿病神经病变、糖尿病足病等评估。", "ner": [[15, 17, "Disease"], [19, 23, "Disease"], [33, 37, "Disease"], [39, 44, "Disease"], [46, 50, "Disease"], [52, 58, "Disease"], [60, 64, "Disease"], [33, 35, "Anatomy"], [39, 42, "Anatomy"], [49, 49, "Anatomy"], [55, 56, "Anatomy"], [63, 63, "Anatomy"]], "rel": [[33, 35, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"], [39, 42, "Anatomy", 39, 44, "Disease", "Anatomy_Disease"], [49, 49, "Anatomy", 46, 50, "Disease", "Anatomy_Disease"], [55, 56, "Anatomy", 52, 58, "Disease", "Anatomy_Disease"], [63, 63, "Anatomy", 60, 64, "Disease", "Anatomy_Disease"]]}
{"idx": 1374, "sentence": "4.饮食习惯：包括食物摄取量、饮食种类、有无偏食、有无食物过敏及烹调习惯等。", "ner": [], "rel": []}
{"idx": 1375, "sentence": "5.运动习惯：如日常活动量、运动的种类、时间及频率等。", "ner": [], "rel": []}
{"idx": 1376, "sentence": "6.生活方式：睡眠、休闲娱乐、烟酒嗜好等。", "ner": [], "rel": []}
{"idx": 1377, "sentence": "7.心理状态：如糖尿病生命质量(diabetes quality of life)测定量表、焦虑自评量表(self-rating anxiety seale)、抑郁自评量表(self-rating depression scale)等评估。", "ner": [], "rel": []}
{"idx": 1378, "sentence": "8.依从性评估：利用相关评估工具，如Morisky用药依从性量表，服药信念量表(beliefs about medical questionnaire)等，全面了解影响患者用药依从性的因素，如患者对药物作用的认识、对自身病情了解程度、对医的理解程度、用药方案是否简单易行等。", "ner": [], "rel": []}
{"idx": 1379, "sentence": "9.注射技术评估(仅限注射治疗者)：使用药物及注射装置的种类、患者注射部位的皮肤状况、注射前的准备工作(剂量调节和检查、胰岛素摇匀方法、部位选择、装针头方式、皮肤消毒等)、注射的操作方式(捏皮方法、进针角度、推注方法、停留时长、拔针方法等)、注射部位的轮换、注射部位皮肤问题的处理、胰岛素的保存方法等。", "ner": [[60, 62, "Drug"], [141, 143, "Drug"]], "rel": []}
{"idx": 1380, "sentence": "评估人员在评估过程中需要与患者充分沟通，以免遗漏信息。", "ner": [], "rel": []}
{"idx": 1381, "sentence": "评估方式和评估内容视患者的年龄、病程、接受情况等而异，避免引起患者的抵触心理，评估的结果需要完整记录并且存档，作为下一次随访及复诊评估的参考。", "ner": [], "rel": []}
{"idx": 1382, "sentence": "(二)个性化目标", "ner": [], "rel": []}
{"idx": 1383, "sentence": "糖尿病患者常合并代谢综合征的一个或多个组分，如高血压、血脂异常、肥胖症等，因此糖尿病患者不仅要控制血糖，还要降压、调脂、控制体重，改善生活方式，只有全面达标，才能有效控制糖尿病。", "ner": [[0, 2, "Disease"], [23, 25, "Disease"], [27, 30, "Disease"], [32, 34, "Disease"], [39, 41, "Disease"], [47, 50, "Test_items"], [54, 55, "Treatment"], [57, 58, "Treatment"], [60, 63, "Treatment"], [65, 70, "Treatment"], [85, 87, "Disease"]], "rel": [[47, 50, "Test_items", 39, 41, "Disease", "Test_items_Disease"], [54, 55, "Treatment", 39, 41, "Disease", "Treatment_Disease"], [57, 58, "Treatment", 39, 41, "Disease", "Treatment_Disease"], [60, 63, "Treatment", 39, 41, "Disease", "Treatment_Disease"], [65, 70, "Treatment", 39, 41, "Disease", "Treatment_Disease"]]}
{"idx": 1384, "sentence": "目标设定注重个体化，根据患者的年龄、病程、预期寿命、并发症或合并症情况等进行综合考虑。", "ner": [], "rel": []}
{"idx": 1385, "sentence": "1.控制目标：(1)毛细血管血糖：空腹与非空腹；(2)糖化血红蛋白；(3)血压；(4)血脂：总胆固醇、高密度脂蛋白胆固醇、甘油三酯、低密度脂蛋白胆固醇；(5)体重：体质指数；(6)尿白蛋白/尿肌酐比值。", "ner": [[10, 15, "Test_items"], [27, 32, "Test_items"], [37, 38, "Test_items"], [43, 44, "Test_items"], [46, 49, "Test_items"], [51, 59, "Test_items"], [61, 64, "Test_items"], [66, 74, "Test_items"], [90, 99, "Test_items"]], "rel": []}
{"idx": 1386, "sentence": "2.行为目标：除了糖尿病综合控制目标之外同时需要设定以行为改变为导向的个性化行为目际。", "ner": [[9, 11, "Disease"]], "rel": []}
{"idx": 1387, "sentence": "行为目标由患者和自我管理处方制定者共同商定，目标需具体、可测量、可实现，避免一次设定过多目标。", "ner": [], "rel": []}
{"idx": 1388, "sentence": "例如饮食目标设定：早餐加一盒250ml的牛奶；运动目标设定：每天晚饭后半小时散步45分钟等。", "ner": [[9, 21, "Treatment"], [32, 43, "Treatment"]], "rel": []}
{"idx": 1389, "sentence": "(三)管理计划", "ner": [], "rel": []}
{"idx": 1390, "sentence": "1.情绪管理：糖尿病会为患者带来不同程度的情绪反应，如沮丧、易怒、多虑、孤独感、挫败感、内疚感等。研究显示情绪因素可能是导致并发症增多的因素之一，而通过合理的糖尿病教育及心理干预能更好地改善情绪障碍及糖代谢状态。", "ner": [[2, 5, "Treatment"], [7, 9, "Disease"], [21, 24, "Symptom"], [27, 28, "Symptom"], [30, 31, "Symptom"], [33, 34, "Symptom"], [36, 38, "Symptom"], [40, 42, "Symptom"], [44, 46, "Symptom"], [79, 81, "Disease"], [82, 88, "Treatment"], [95, 98, "Symptom"], [100, 104, "Test_items"]], "rel": [[2, 5, "Treatment", 7, 9, "Disease", "Treatment_Disease"], [21, 24, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [27, 28, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [30, 31, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [33, 34, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [36, 38, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [40, 42, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [44, 46, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [82, 88, "Treatment", 79, 81, "Disease", "Treatment_Disease"], [95, 98, "Symptom", 79, 81, "Disease", "Symptom_Disease"], [100, 104, "Test_items", 79, 81, "Disease", "Test_items_Disease"]]}
{"idx": 1391, "sentence": "心理干预计划：评估负面情绪产生的原因及临床表现，分析情绪因素在糖尿病的发生、发展与转归中的重要作用，提出改善情绪障碍的实用性建议，展开心理问题讨论，配合音乐治疗和放松认练。", "ner": [[0, 3, "Treatment"], [31, 33, "Disease"], [74, 79, "Treatment"], [81, 84, "Treatment"]], "rel": [[0, 3, "Treatment", 31, 33, "Disease", "Treatment_Disease"], [74, 79, "Treatment", 31, 33, "Disease", "Treatment_Disease"], [81, 84, "Treatment", 31, 33, "Disease", "Treatment_Disease"]]}
{"idx": 1392, "sentence": "在患者同意的情况下，可纳入其家属参与讨论。", "ner": [], "rel": []}
{"idx": 1393, "sentence": "同伴支持对于负面情绪改善的影响也不可忽视，教育者可根据患者的性格特点等组织合适的患者小组开展相关活动。", "ner": [], "rel": []}
{"idx": 1394, "sentence": "2.自我监测：对血糖等指标进行规律的自我监测.可以反映治疗效果，指导治疗方案的及时调整，减缓和预防多种并发症发生。", "ner": [[2, 5, "Treatment"], [8, 9, "Test_items"], [18, 21, "Treatment"]], "rel": []}
{"idx": 1395, "sentence": "帮助患者理解定期监测的重要性以及如何监测。", "ner": [[8, 9, "Treatment"], [18, 19, "Treatment"]], "rel": []}
{"idx": 1396, "sentence": "自我监测处方内容包括：(D监测内容：血糖、糖化血红蛋白、血压、血脂、尿数量白蛋白等。", "ner": [[18, 19, "Test_items"], [21, 26, "Test_items"], [28, 29, "Test"], [31, 32, "Test_items"], [34, 39, "Test_items"]], "rel": []}
{"idx": 1397, "sentence": "(2)监测频次：根据患者的情况个性化制定。", "ner": [], "rel": []}
{"idx": 1398, "sentence": "3.饮食管理：饮食管理旨在根据中国糖尿病患者的饮食特点，纠正患者的不良饮食习惯，帮助患者树立科学的饮食观念，学会并应用健康的饮食方法。", "ner": [[2, 5, "Treatment"], [17, 19, "Disease"], [7, 10, "Treatment"]], "rel": [[7, 10, "Treatment", 17, 19, "Disease", "Treatment_Disease"]]}
{"idx": 1399, "sentence": "饮食管理处方内容包括：(1)糖尿病饮食治疗的基本原则：概述总热量控制、合理搭配饮食结构、体重管理、合理分餐、食物多样化、烹调方式、甜味剂等。", "ner": [[14, 16, "Disease"], [17, 20, "Treatment"]], "rel": [[17, 20, "Treatment", 14, 16, "Disease", "Treatment_Disease"]]}
{"idx": 1400, "sentence": "(2)个性化食谱：需要考虑患者的饮食习惯制定个性化食谱。", "ner": [[20, 26, "Treatment"], [3, 7, "Treatment"]], "rel": []}
{"idx": 1401, "sentence": "(3)食物量的衡量和估算：利用食物交换份、手掌法则、食物模型等方法和工具，帮助患者理解食物“份”的概念，学会并应用粗略估算食物大小的方法。", "ner": [[3, 11, "Treatment"]], "rel": []}
{"idx": 1402, "sentence": "(4)饮食技巧：根据患者的饮食行为问题及饮食管理的疑惑，教给患者实用的饮食技巧，如外出就餐技巧、食物选择技巧、认识食物标签、血糖生成指数及血糖负荷指数表、碳水化合物计算等。", "ner": [[3, 6, "Treatment"]], "rel": []}
{"idx": 1403, "sentence": "4.运动管理：运动锻炼在糖尿病患者的全面管理中占重要地位。规律运动可增加胰岛素敏感性，有助于控制血糖，减少心血管危险因素.减轻体重，提升幸福感。", "ner": [[2, 5, "Treatment"], [12, 14, "Disease"], [36, 38, "Drug"], [7, 10, "Treatment"], [29, 32, "Treatment"], [48, 49, "Test_items"]], "rel": [[2, 5, "Treatment", 12, 14, "Disease", "Treatment_Disease"], [7, 10, "Treatment", 12, 14, "Disease", "Treatment_Disease"]]}
{"idx": 1404, "sentence": "如有运动禁忌证，可能需要转诊至专业运动康复师咨询并获取专业建议。", "ner": [], "rel": []}
{"idx": 1405, "sentence": "自我管理运动处方包括：(1)个性化运动方案：运动方案设定原则为在保证安全的前提下，选择适合患者运动条件的运动形式，并尽量达到降糖或降脂的效果。", "ner": [], "rel": []}
{"idx": 1406, "sentence": "设定运动目的：如增加机体糖代谢、脂代谢、增强骨骼肌力量、发展平衡能力等；确定运动时机：如餐后1小时；制定运动项目、运动时长、运动强度、运动频率(如5天/周)、运动时有效心率等计划。", "ner": [], "rel": []}
{"idx": 1407, "sentence": "提供工具帮助患者达到理想的运动效果，如不同运动能量消耗对照表、自觉疲劳程度(ratings of perceived exertion)量表等。", "ner": [], "rel": []}
{"idx": 1408, "sentence": "(2)运动注意事项：说明运动前、中、后的注意事项，确保患者运动的安全性；明确应避免参加的运动项目；运动时自我观察的指标(血糖、血压等)以及当指标出现异常时运动终止的标准(如低血糖症状)等。", "ner": [[60, 61, "Test_items"], [63, 64, "Test"], [86, 90, "Symptom"]], "rel": []}
{"idx": 1409, "sentence": "5.用药管理：主要为糖尿病患者用药依从性管理。", "ner": [[10, 12, "Disease"]], "rel": []}
{"idx": 1410, "sentence": "用药不依从可降低糖尿病治疗的达标率，对健康造成不良影响，浪费卫生资源，是糖尿病控制中的重要问题。", "ner": [[8, 10, "Disease"], [36, 38, "Disease"]], "rel": []}
{"idx": 1411, "sentence": "通过用药依从性评估和个性化的指导教育，可以有效地提高糖尿病患者的用药依从性，延缓并发症的发生，提高患者生存质量。", "ner": [[26, 28, "Disease"]], "rel": []}
{"idx": 1412, "sentence": "用药管理教育处方：制定合理的用药教育方案，如遵医嘱用药的重要性、药物的作用特点、为什么需要使用此用药方案，提醒用药的办法等。", "ner": [], "rel": []}
{"idx": 1413, "sentence": "6.胰岛素及其他注射药物管理：胰岛素是目前糖尿病治疗最有效的药物之一，但据研究显示，我国即使在已经使用胰岛素的患者中.血糖达标率也只有37%，而患者对胰岛素注射技术掌握不到位可能是重要原因之一。", "ner": [[2, 4, "Drug"], [15, 17, "Drug"], [21, 23, "Disease"], [51, 53, "Drug"], [67, 69, "Test_Value"], [75, 77, "Drug"], [8, 9, "Method"], [59, 60, "Test_items"], [78, 79, "Method"]], "rel": [[8, 9, "Method", 2, 4, "Drug", "Method_Drug"], [15, 17, "Drug", 21, 23, "Disease", "Drug_Disease"], [78, 79, "Method", 75, 77, "Drug", "Method_Drug"]]}
{"idx": 1414, "sentence": "近年来，胰高血糖素样肽1类似物也开始广泛应用于临床，其不规范注射同样影响患者血糖达标情况。", "ner": [[4, 14, "Drug"], [38, 39, "Test_items"], [30, 31, "Method"]], "rel": [[30, 31, "Method", 4, 14, "Drug", "Method_Drug"]]}
{"idx": 1415, "sentence": "注射技术自我管理处方包括：(1)注射技术教育：根据患者注射技术的问题实施个体化教育，需要考虑患者的经济能力、教育水平、年龄、影响操作的其他因素等。(2)胰岛素泵使用教育：胰岛素泵治疗是采用人工智能控制的胰岛素输入装置，通过持续皮下输注胰岛素的方式，最大程度模拟胰岛素的生理性分泌模式，从而达到更好控制血糖的一种胰岛素治疗方法。泵治疗适用于1型糖尿病患者、需要短期胰岛素强化治疗的2型糖尿病以及妊娠期糖尿病等。", "ner": [[101, 103, "Drug"], [111, 116, "Method"], [117, 119, "Drug"], [130, 132, "Drug"], [150, 151, "Test_items"], [155, 157, "Drug"], [169, 173, "Disease"], [181, 183, "Drug"], [189, 193, "Disease"], [196, 201, "Disease"]], "rel": [[111, 116, "Method", 117, 119, "Drug", "Method_Drug"]]}
{"idx": 1416, "sentence": "对于胰岛素泵治疗的教育内容包括：选择注射部位、胰岛素泵的安装、胰岛素泵报警的处理、意外血糖异常的原因排查(电池、泵故障、管路松动堵塞、储药器破裂、埋植部位硬结感染等)、胰岛素泵耗材使用及护理规范等。", "ner": [[43, 44, "Test_items"], [45, 46, "Test_Value"]], "rel": []}
{"idx": 1417, "sentence": "7.糖尿病并发症的筛查与防治(自我管理处方)：(1)预防和延缓并发症：对于尚未确诊糖尿病并发症的患者，自我管理处方需要包含预防和延缓尿病并发症的实用措施，如：糖尿病急慢性并发定的识别、糖尿病并发症筛查表(包括检查的项目、时间、频率、意义等)、并发症的预防措施等；(2)并发症的自我管理与日常保健：对于已经患有糖尿病并发症的患者，根据患者的并发症类型提供自我管里处方，包括定期复查(包括复查项目、复查频次、在哪里复查、复查前注意事项等)、自我保健(如糖尿病足的日常护理、皮肤护理、牙齿护理等)、注意事项(如糖尿病肾病患者需要注意蛋白质的摄取、糖尿病视网膜病变的患者需要注意运动的强度等。", "ner": [[41, 46, "Disease"], [2, 7, "Disease"], [79, 81, "Disease"], [92, 97, "Disease"], [138, 141, "Treatment"], [143, 146, "Treatment"], [154, 159, "Disease"], [218, 221, "Treatment"], [224, 227, "Disease"], [227, 227, "Anatomy"], [234, 237, "Treatment"], [239, 242, "Treatment"], [229, 232, "Treatment"], [252, 256, "Disease"], [255, 255, "Anatomy"], [270, 277, "Disease"], [273, 275, "Anatomy"]], "rel": [[138, 141, "Treatment", 154, 159, "Disease", "Treatment_Disease"], [143, 146, "Treatment", 154, 159, "Disease", "Treatment_Disease"], [218, 221, "Treatment", 154, 159, "Disease", "Treatment_Disease"], [227, 227, "Anatomy", 224, 227, "Disease", "Anatomy_Disease"], [229, 232, "Treatment", 224, 227, "Disease", "Treatment_Disease"], [234, 237, "Treatment", 224, 227, "Disease", "Treatment_Disease"], [239, 242, "Treatment", 224, 227, "Disease", "Treatment_Disease"], [255, 255, "Anatomy", 252, 256, "Disease", "Anatomy_Disease"], [273, 275, "Anatomy", 270, 277, "Disease", "Anatomy_Disease"]]}
{"idx": 1418, "sentence": "(四)卫生资源支持", "ner": [], "rel": []}
{"idx": 1419, "sentence": "卫生资源支持包括：", "ner": [], "rel": []}
{"idx": 1420, "sentence": "1.自我教育管理网站、应用程序(application，APP)及其他新媒体形式的学习资源推荐.如E糖书，掌控糖尿病等。", "ner": [[55, 57, "Disease"]], "rel": []}
{"idx": 1421, "sentence": "2.教育课堂，如课堂讲座或小组座读。", "ner": [], "rel": []}
{"idx": 1422, "sentence": "3.急救联系方式等。", "ner": [], "rel": []}
{"idx": 1423, "sentence": "四、自我管理处方的形式", "ner": [], "rel": []}
{"idx": 1424, "sentence": "自我管理处方的形式可根据各医疗机构的条件选择使用电子式或非电子式。", "ner": [], "rel": []}
{"idx": 1425, "sentence": "1.非电子式：将处方必须要素制成固定模板，制定时只需填写并打印。", "ner": [], "rel": []}
{"idx": 1426, "sentence": "纸质处方最好患者和医务人员各保留一份，便于处方执行的最踪和优化。", "ner": [], "rel": []}
{"idx": 1427, "sentence": "2.电子式：借助网络智能糖尿病管理平台的患者信息收集模块、数据评估与智能分析模块、医务人员制定处方方案模块来实现处方制定。", "ner": [[12, 14, "Disease"]], "rel": []}
{"idx": 1428, "sentence": "患者的信息记录和储存实现电子化，医务人员填写和制定处方的方案也能够被存储，供后期的修改和优化。", "ner": [], "rel": []}
{"idx": 1429, "sentence": "智能化设计的软件系统可以辅助医务人员分析，智能生成相应的处方方案，节省医务人员处方制定时间等。", "ner": [], "rel": []}
{"idx": 1430, "sentence": "附录提供了2型糖尿病生活方式自我管理处方和胰岛素使用自我管理处方范例。", "ner": [[5, 9, "Disease"], [21, 23, "Drug"]], "rel": []}
{"idx": 1431, "sentence": "五、自我管理处方实施流程", "ner": [], "rel": []}
{"idx": 1432, "sentence": "国内外研究证明，对患者进行糖尿病DSME，包括健康饮食、规律运动、正确服药、充足的社会支持等，能提高患者对饮食控制、血糖监测、检查足部的依从性，有效降低患者的体重、血糖、糖化血红蛋白，提高生活质量。中华医学会糖尿病学会等学术组织积极推动各级医疗机构普及糖尿病教育，有些地区糖尿病DSME/S现已被纳人到医疗门诊及社区卫生服务中心常规诊疗项目。", "ner": [[13, 15, "Disease"], [82, 83, "Test_items"], [85, 90, "Test_items"], [58, 61, "Test_items"], [16, 19, "Treatment"], [23, 26, "Treatment"], [28, 31, "Treatment"], [41, 44, "Treatment"], [65, 66, "Anatomy"], [104, 106, "Disease"], [126, 128, "Disease"], [136, 138, "Disease"], [139, 144, "Treatment"]], "rel": [[16, 19, "Treatment", 13, 15, "Disease", "Treatment_Disease"], [23, 26, "Treatment", 13, 15, "Disease", "Treatment_Disease"], [28, 31, "Treatment", 13, 15, "Disease", "Treatment_Disease"], [41, 44, "Treatment", 13, 15, "Disease", "Treatment_Disease"], [58, 61, "Test_items", 13, 15, "Disease", "Test_items_Disease"], [82, 83, "Test_items", 13, 15, "Disease", "Test_items_Disease"], [85, 90, "Test_items", 13, 15, "Disease", "Test_items_Disease"], [65, 66, "Anatomy", 13, 15, "Disease", "Anatomy_Disease"], [139, 144, "Treatment", 136, 138, "Disease", "Treatment_Disease"]]}
{"idx": 1433, "sentence": "实施自我管理处方的关键是与患者及其家属建立伙伴关系，在充分评估的基础上，帮助患者认识自身的问题，制定一份适合患者的切实可行的目标、措施和行动计划，同时为患者提供可利用资源的长期支持。", "ner": [], "rel": []}
{"idx": 1434, "sentence": "自我管理处方的实施流程如图1所示。", "ner": [], "rel": []}
{"idx": 1435, "sentence": "首先，糖尿病教育者接受由其他医务人员转诊来的患者。", "ner": [[3, 5, "Disease"]], "rel": []}
{"idx": 1436, "sentence": "其次，教育者全面评估患者相关的知识技能。", "ner": [], "rel": []}
{"idx": 1437, "sentence": "其三，为患者制定自我管理处方和行动计划[图2，为方便患者应用，本文单位均采取中文习惯用法，如分钟(不用min)，天(不用d)等]。", "ner": [], "rel": []}
{"idx": 1438, "sentence": "最后，根据个体需要进行跟踪随访，填写患者自我管理行动反馈表(图3)。", "ner": [[11, 14, "Treatment"]], "rel": []}
{"idx": 1439, "sentence": "按照每3个月访视一次，评估患者的行为改变情况。", "ner": [], "rel": []}
{"idx": 1440, "sentence": "必要时调整行动目标和计划。", "ner": [], "rel": []}
{"idx": 1441, "sentence": "六、自我管理处方的时机", "ner": [], "rel": []}
{"idx": 1442, "sentence": "DSME/S是促进糖尿病自我保健知识、技能和能力的一个持续性过程。2015年发表的联合立场声明中强调了评估、实施、调整DSME/S的4个关键时机，包括：确诊时、年度教育、出现影响自我管理新的复杂影响因素时、管理方案发生改变时。", "ner": [[0, 5, "Treatment"], [9, 11, "Disease"], [59, 64, "Treatment"]], "rel": [[0, 5, "Treatment", 9, 11, "Disease", "Treatment_Disease"]]}
{"idx": 1443, "sentence": "这4个关键时机也应该是自我管理处方的评估、制定和修改的重要标志，建议如下：", "ner": [], "rel": []}
{"idx": 1444, "sentence": "1.确诊时：为新确诊的糖尿病患者制定自我管理处方之前应进行全面的自我管理能力及其影响因素(如文化因素、健康信仰、经济状况、读写能力等)的评估，关注并解答糖尿病诊断相关问题并给予情感支持。", "ner": [[11, 13, "Disease"], [76, 78, "Disease"], [86, 91, "Treatment"]], "rel": [[86, 91, "Treatment", 76, 78, "Disease", "Treatment_Disease"]]}
{"idx": 1445, "sentence": "自我管理处方内容包括：个性化自我管理方案、治疗及自我管理的目标、突发情况的解决方法(如用药安全相关、低血糖处理等)、教育和支持的资源获取建议(如饮食指南、糖尿病学习网站、糖尿病论坛、医院的就诊和科室信息等)", "ner": [], "rel": []}
{"idx": 1446, "sentence": "2.年度评估时：对患者的自我管理、解决问题的能力进行审查与评估，关注和解决愚者所面临的问题，积极根据患者的需要调整治疗方案。", "ner": [], "rel": []}
{"idx": 1447, "sentence": "内容包括：回顾再评估糖尿病知识、技能及行为、体重的变化和管理、调整或强化自我管理的目标、增加并发症及生活质量改善相关的教育指导。", "ner": [[31, 42, "Treatment"], [44, 62, "Treatment"]], "rel": []}
{"idx": 1448, "sentence": "3.出现影响自我管理新的复杂因素时：指出现新的健康状况如肾脏疾病、卒中及需要复杂药物：出现身体机能受限如视力受损、移动受限；出现情感因素如焦虑和抑郁；出现基本生活需求如食物获取和经济能力有限时。需要及时调整自我管理处方，调整内容包括：个性化的行为改变及健康应对的策略、增加所需要的特殊自我护理技能，以延缓糖尿病并发症进展及预防新的并发症发生，必要时提供和抑郁相关的情感支持。", "ner": [[28, 31, "Disease"], [28, 29, "Anatomy"], [52, 55, "Symptom"], [57, 60, "Symptom"], [69, 70, "Symptom"], [72, 73, "Symptom"], [174, 185, "Treatment"], [152, 157, "Disease"], [134, 147, "Treatment"], [33, 34, "Disease"]], "rel": [[28, 29, "Anatomy", 28, 31, "Disease", "Anatomy_Disease"], [52, 55, "Symptom", 28, 31, "Disease", "Symptom_Disease"], [57, 60, "Symptom", 28, 31, "Disease", "Symptom_Disease"], [52, 55, "Symptom", 33, 34, "Disease", "Symptom_Disease"], [57, 60, "Symptom", 33, 34, "Disease", "Symptom_Disease"], [174, 185, "Treatment", 152, 157, "Disease", "Treatment_Disease"], [134, 147, "Treatment", 152, 157, "Disease", "Treatment_Disease"]]}
{"idx": 1449, "sentence": "4.管理方案发生改变时：生活环境改变如住院患者出院、年龄相关因素变化如出现认知功能和自我管理障碍等问题。此时在建立新的管理方案之前，自我管理处方需要包含：与糖尿病管理团队中的其他成员沟通，为患者制定糖尿病管理方案过波计划，后期再制定新的管理方案和教育支持计划。", "ner": [[37, 47, "Symptom"], [78, 80, "Disease"], [99, 101, "Disease"], [114, 128, "Treatment"]], "rel": [[114, 128, "Treatment", 99, 101, "Disease", "Treatment_Disease"]]}
{"idx": 1450, "sentence": "七、自我管理处方的多方团队与技术", "ner": [], "rel": []}
{"idx": 1451, "sentence": "糖尿病自我管理指患者为应对病情所采取的行动和选择，包括使用一系列技能、知识和应对策略。自我管理的任务包括：(1)医疗或行为管理：照顾自己的健康问题、定期服药或医学检查、改变膳食和其他高危行为、使用仪器。", "ner": [[0, 2, "Disease"], [3, 6, "Treatment"], [43, 46, "Treatment"], [64, 72, "Treatment"], [74, 82, "Treatment"], [84, 94, "Treatment"], [96, 99, "Treatment"]], "rel": [[3, 6, "Treatment", 0, 2, "Disease", "Treatment_Disease"]]}
{"idx": 1452, "sentence": "(2)角色管理：建立和保持在社会、工作、家庭和朋友中的角色，从而正常参加工作、与人相处。", "ner": [[8, 28, "Treatment"], [32, 42, "Treatment"], [3, 6, "Treatment"]], "rel": []}
{"idx": 1453, "sentence": "(3)情绪管理：处理和应对疾病带来的情绪障碍。", "ner": [[3, 6, "Treatment"], [8, 21, "Treatment"]], "rel": []}
{"idx": 1454, "sentence": "通常，教育团队由内分泌科医师、营养师、糖尿病专科护士组成，共同为患者提供DSME。不同成员的角色分工不同，美国糖尿病学会建议所有糖尿病患者都需要做以下三个方面的评估和转诊：(1)营养教育：由注册营养师提供医学营养评估与治疗；(2)糖尿病教育：在4个关键时机由糖尿病教育护士对患者进行评估、提供和调整DSME/S；(3)心理健康咨询：必要情况下转诊至专业心理医师。", "ner": [[19, 21, "Disease"], [36, 39, "Treatment"], [55, 57, "Disease"], [64, 66, "Disease"], [89, 92, "Treatment"], [115, 119, "Treatment"], [159, 164, "Treatment"], [149, 154, "Treatment"], [129, 131, "Disease"]], "rel": [[36, 39, "Treatment", 19, 21, "Disease", "Treatment_Disease"], [89, 92, "Treatment", 64, 66, "Disease", "Treatment_Disease"], [115, 119, "Treatment", 64, 66, "Disease", "Treatment_Disease"], [159, 164, "Treatment", 64, 66, "Disease", "Treatment_Disease"], [149, 154, "Treatment", 129, 131, "Disease", "Treatment_Disease"]]}
{"idx": 1455, "sentence": "此外，患者可能需要康复治疗和运动管理专家的指导。", "ner": [], "rel": []}
{"idx": 1456, "sentence": "随着信息化技术和互联网技术的发展，智能化的远程教育服务应用广泛。基于指南及专家共识构建知识库，设置健康评估提醒功能，智能化辅助识别潜在危险因素，在多学科管理患者的同时，将自我管理处方加人大数据和人工智能技术，实现线上线下、院内居家闭环管理的智能化处方系统应运而生。美国移动医疗公司WellDoc研发了首个获美国食品药品监督管理局批准的可帮助医师优化开具处方的手机应用BlueStar。在一项随机对照试验中，验证了其对糖化血红蛋白的降低效果达2.03%。So等开发了交互式虚拟网络平台[亚洲糖尿病联合评估(Joint Asia Diabetes Evaluation，JADE)].并证实亚洲不同国家和地区使用JADE平台的可行性和有效性。随着国内互联网技术的进步及大数据时代的快速发展，智能化处方系统(控糖尿病智能管理网络终端、APP端、微信端)也已在多家医院投人使用，且该系统通过与中国疾病预防控制中心等机构临床研究证实其有助于提高糖尿病患者血糖监测、有效运动及规律服药等行为的依从性.血糖控制效果明显。", "ner": [[208, 213, "Test_items"], [244, 246, "Disease"], [352, 354, "Disease"], [417, 419, "Disease"], [422, 425, "Test_items"], [444, 447, "Test_items"], [215, 216, "Test_Value"]], "rel": [[422, 425, "Test_items", 417, 419, "Disease", "Test_items_Disease"]]}
{"idx": 1457, "sentence": "目前，糖尿病自我管理处方的智能平台已经实现多种功能：储存患者健康信息、通过人工智能技术快速辅助分析患者自我管理行为问题、智能生成个性化糖尿病自我管理方案、配合远程糖尿病教育和复诊评估、评估后智能优化自我管理处方，为患者提供连续的DSME/S。", "ner": [[3, 5, "Disease"], [67, 69, "Disease"], [81, 83, "Disease"], [114, 119, "Treatment"]], "rel": [[114, 119, "Treatment", 81, 83, "Disease", "Treatment_Disease"]]}
{"idx": 1458, "sentence": "不久的将来，通过大数据和云平台，可以将智能硬件(如血糖仪和可穿戴设备)自动连接，甚至可与居民健康档案系统对接，形成区域性疾病管理云平台，最大程度地提升糖尿病教育管理的效益。", "ner": [[75, 77, "Disease"], [78, 81, "Treatment"]], "rel": [[78, 81, "Treatment", 75, 77, "Disease", "Treatment_Disease"]]}
{"idx": 1459, "sentence": "中国2型糖尿病合并肥胖综合管理专家共识", "ner": [[2, 6, "Disease"], [9, 10, "Disease"]], "rel": []}
{"idx": 1460, "sentence": "随着生活方式的改变及人口老龄化的加速，2型尿病(type 2 diabetes mellitus，T2DM)和肥胖的患病率呈快速上升趋势，并且已经成为全球性公共卫生问题。2010年中国糖尿病流行病学调查[以糖化血红蛋白(hemoglobin A1c，HbA1c)≥6.5%作为诊断标准之一]数据显示，中国成人糖尿病患病率高达11.6%，糖尿病患者人数居全球首位。肥胖和T2DM关系密切，中国超重与肥胖人群的糖尿病患病率分别为12.8%和18.5%；而在糖尿病患者中超重比例为41%、肥胖比例为24.3%、腹型肥胖[腰围≥90cm(男)或≥85cm(女)]患者高达45.4%。与白种人相比，中国人肥胖程度较轻，而体脂分布趋向于腹腔内积聚，更易形成腹型肥胖。", "ner": [[19, 53, "Disease"], [55, 56, "Disease"], [92, 94, "Disease"], [103, 130, "Test_items"], [131, 135, "Test_Value"], [154, 156, "Disease"], [168, 170, "Disease"], [181, 182, "Disease"], [184, 187, "Disease"], [195, 196, "Disease"], [198, 199, "Disease"], [203, 205, "Disease"], [226, 228, "Disease"], [232, 233, "Disease"], [241, 242, "Disease"], [252, 255, "Disease"], [297, 298, "Disease"], [299, 302, "Level"], [322, 325, "Disease"], [312, 313, "Anatomy"]], "rel": [[103, 130, "Test_items", 92, 94, "Disease", "Test_items_Disease"], [312, 313, "Anatomy", 322, 325, "Disease", "Anatomy_Disease"]]}
{"idx": 1461, "sentence": "虽然既往流行病学调查中使用的超重、肥胖的诊断标准略有不同，但仍然可在一定程度上反映其高患病率，T2DM合并肥胖的管理形势非常严峻。", "ner": [[14, 15, "Disease"], [17, 18, "Disease"], [47, 50, "Disease"], [53, 54, "Disease"]], "rel": []}
{"idx": 1462, "sentence": "因此，我国临床内分泌学专家根据当前中国T2DM和肥胖患者的流行病学特征及现有的临床证据，制订出本部中国T2DM合并肥胖综合管理专家共识。", "ner": [[19, 22, "Disease"], [24, 25, "Disease"], [51, 54, "Disease"], [57, 58, "Disease"]], "rel": []}
{"idx": 1463, "sentence": "一、T2DM合并肥胖管理的意义", "ner": [[2, 5, "Disease"], [8, 9, "Disease"]], "rel": []}
{"idx": 1464, "sentence": "肥胖与糖尿病存在的其他代谢异常协同作用可进一步加剧T2DM患者慢性并发症的发生。肥胖是糖尿病肾脏病变的独立危险因素，可导致慢性肾脏病的恶化。减轻体重有利于减少慢性肾脏病患者的蛋白尿，延缓肾功能衰退进程。T2DM合并肥胖使心脑血管疾病患病风险升高。因此，针对T2DM合并肥胖患者，在降糖的同时加强体重管理，对于预防糖尿病并发症、提高患者生活质量具有重要意义。", "ner": [[0, 1, "Disease"], [3, 5, "Disease"], [25, 28, "Disease"], [40, 41, "Reason"], [43, 49, "Disease"], [46, 47, "Anatomy"], [61, 65, "Disease"], [63, 64, "Anatomy"], [70, 73, "Treatment"], [79, 83, "Disease"], [81, 82, "Anatomy"], [93, 97, "Disease"], [93, 93, "Anatomy"], [101, 104, "Disease"], [107, 108, "Disease"], [110, 115, "Disease"], [110, 113, "Anatomy"], [128, 131, "Disease"], [134, 135, "Disease"], [140, 141, "Treatment"], [147, 150, "Treatment"], [156, 161, "Disease"]], "rel": [[40, 41, "Reason", 43, 49, "Disease", "Reason_Disease"], [46, 47, "Anatomy", 43, 49, "Disease", "Anatomy_Disease"], [63, 64, "Anatomy", 61, 65, "Disease", "Anatomy_Disease"], [70, 73, "Treatment", 79, 83, "Disease", "Treatment_Disease"], [81, 82, "Anatomy", 79, 83, "Disease", "Anatomy_Disease"], [93, 93, "Anatomy", 93, 97, "Disease", "Anatomy_Disease"], [110, 113, "Anatomy", 110, 115, "Disease", "Anatomy_Disease"], [140, 141, "Treatment", 128, 131, "Disease", "Treatment_Disease"], [147, 150, "Treatment", 128, 131, "Disease", "Treatment_Disease"], [140, 141, "Treatment", 134, 135, "Disease", "Treatment_Disease"], [147, 150, "Treatment", 134, 135, "Disease", "Treatment_Disease"]]}
{"idx": 1465, "sentence": "二、T2DM合并肥胖的诊断标准", "ner": [[2, 5, "Disease"], [8, 9, "Disease"]], "rel": []}
{"idx": 1466, "sentence": "目前T2DM的诊断标准与分型参考WHO 1999年标准；肥胖诊断标准参考《中国成人肥胖症防治专家共识》和《中国2型糖尿病防治指南(2013年)》腹型肥胖的标准。", "ner": [[2, 5, "Disease"], [28, 29, "Disease"], [41, 43, "Disease"], [55, 59, "Disease"], [72, 75, "Disease"]], "rel": []}
{"idx": 1467, "sentence": "符合两种疾病诊断的患者即可按照T2DM合并肥胖进行管理。", "ner": [[15, 18, "Disease"], [21, 22, "Disease"]], "rel": []}
{"idx": 1468, "sentence": "糖尿病和肥胖的诊断标准见表1、表2。", "ner": [[0, 2, "Disease"], [4, 5, "Disease"]], "rel": []}
{"idx": 1469, "sentence": "三、T2DM合并肥胖的管理", "ner": [[2, 5, "Disease"], [8, 9, "Disease"]], "rel": []}
{"idx": 1470, "sentence": "(一)T2DM合并肥胖患者的综合控制目标见表3", "ner": [[3, 6, "Disease"], [9, 10, "Disease"]], "rel": []}
{"idx": 1471, "sentence": "(二)T2DM合并超重或肥胖管理流程见图1", "ner": [[3, 6, "Disease"], [9, 10, "Disease"], [12, 13, "Disease"]], "rel": []}
{"idx": 1472, "sentence": "(三)饮食、运动和心理干预", "ner": [[3, 12, "Treatment"]], "rel": []}
{"idx": 1473, "sentence": "生活方式干预应当作为所有T2DM合并肥胖治疗的基础性措施并长期坚持。", "ner": [[0, 5, "Treatment"], [12, 15, "Disease"], [18, 19, "Disease"]], "rel": [[0, 5, "Treatment", 12, 15, "Disease", "Treatment_Disease"], [0, 5, "Treatment", 18, 19, "Disease", "Treatment_Disease"]]}
{"idx": 1474, "sentence": "1.医学营养治疗：", "ner": [[2, 7, "Treatment"]], "rel": []}
{"idx": 1475, "sentence": "(1)控制总能量。", "ner": [[3, 7, "Treatment"]], "rel": []}
{"idx": 1476, "sentence": "高于正常体重的T2DM患者，推荐按照25~30kcal/(kg标准体重·d)计算，再根据患者身高、体重、性别、年龄、活动量、应激状况等调整为个体化能量标准。", "ner": [[7, 10, "Disease"]], "rel": []}
{"idx": 1477, "sentence": "不推荐长期<800kcal/d的极低能量膳食。", "ner": [], "rel": []}
{"idx": 1478, "sentence": "(2)培养营养均衡的膳食习惯，蛋白质摄入量在总能量15%~20%、脂肪在总能量30%以下、碳水化合物在总能量45%~60%：①碳水化合物要注重食物品种的选择，不能单纯降低谷类主食量，以避免低血糖或酮症的发生。", "ner": [[79, 89, "Treatment"], [94, 96, "Disease"], [98, 99, "Disease"], [3, 13, "Treatment"]], "rel": []}
{"idx": 1479, "sentence": "推荐增加低升糖指数(glycemic index，GI)食物的比例。", "ner": [[2, 32, "Treatment"]], "rel": []}
{"idx": 1480, "sentence": "②不建议超重或肥胖人群长期食用高蛋白质膳食；乳清蛋白有助于促进胰岛素分泌、改善糖代谢和短期内减轻体重。", "ner": [[4, 5, "Disease"], [7, 8, "Disease"]], "rel": []}
{"idx": 1481, "sentence": "③应限制饱和脂肪酸与反式脂肪酸的摄入量，增加植物脂肪占总脂肪摄入的比例；膳食中宜增加富含ω-3多不饱和脂肪酸的植物油；每日胆固醇摄入量不宜超过300mg。", "ner": [[2, 18, "Treatment"], [20, 34, "Treatment"], [36, 57, "Treatment"], [59, 75, "Treatment"]], "rel": []}
{"idx": 1482, "sentence": "④保证丰富的维生素、矿物质和膳食纤维摄，推荐每日膳食纤维摄入量为25~30g或10~14g/1000kcal。", "ner": [[1, 18, "Treatment"], [20, 53, "Treatment"]], "rel": []}
{"idx": 1483, "sentence": "2.运动治疗：", "ner": [[2, 5, "Treatment"]], "rel": []}
{"idx": 1484, "sentence": "合理运动可改善胰岛素敏感性、骨酪肌功能、改善代谢紊乱，对改善生活质量有正反馈作用。(1)运动治疗前进行医学评估，严格把握适应证和禁忌证。(2)根据病程、严重程度、并发症等，并综合考虑年龄、家庭状况、运动习惯、文化背景等多种因素，制定个体化运动处方。运动处方应包括运动频率、运动强度、运动时间、运动类型和运动量5大要素。运动类型应以有氧运动为主。(3)注意事项：运动前、后监测血糖以预防低血糖，关键是自我监测与医师指导。如运动前血糖<4.2mmol/L或有低血糖反应，应降低降糖药物的使用剂量。T2DM合并肥胖患者，运动时应注意预防关节疼痛和不适。", "ner": [[0, 3, "Treatment"], [51, 54, "Treatment"], [159, 170, "Treatment"], [185, 188, "Test_items"], [192, 194, "Disease"], [199, 202, "Treatment"], [204, 207, "Treatment"], [210, 214, "Test_items"], [215, 224, "Test_Value"], [227, 231, "Symptom"], [246, 249, "Disease"], [252, 253, "Disease"], [265, 271, "Symptom"], [114, 122, "Treatment"]], "rel": []}
{"idx": 1485, "sentence": "3.心理干预：", "ner": [[2, 5, "Treatment"]], "rel": []}
{"idx": 1486, "sentence": "肥胖和T2DM的共存使糖尿病的治疗变得更为复杂。肥胖和糖尿病的双重压力进一步加重患者的心理负担。对于肥胖或超重的T2DM惠者应该加强心理干预，通过专业心理医生或者糖尿病专科医生的心理指导，帮助患者循序渐进地改善生活方式，建立自信。降低体重不仅会减轻T2DM患者的心理障碍，而且更容易使很多患者从减肥和运动中再次获得自信，提高生活满意度。", "ner": [[0, 1, "Disease"], [3, 6, "Disease"], [11, 13, "Disease"], [24, 25, "Disease"], [27, 29, "Disease"], [50, 51, "Disease"], [53, 54, "Disease"], [56, 59, "Disease"], [64, 69, "Treatment"], [81, 83, "Disease"], [124, 127, "Disease"], [115, 118, "Treatment"]], "rel": [[64, 69, "Treatment", 50, 51, "Disease", "Treatment_Disease"], [64, 69, "Treatment", 53, 54, "Disease", "Treatment_Disease"], [115, 118, "Treatment", 124, 127, "Disease", "Treatment_Disease"]]}
{"idx": 1487, "sentence": "4.药物治疗：", "ner": [], "rel": []}
{"idx": 1488, "sentence": "(1)总体治疗原则：①在选择降糖药物时，应优先考虑有利于减轻体重或对体重影响中性的药物；②需要胰岛素治疗的T2DM合并肥胖患者，建议联合使用至少一种其他降糖药物，如二甲双胍、胰升糖素样肽1(glucagon-like peptide-1，GLP-1)受体激动剂(GLP-1RA)、α-糖苷酶抑制剂、二肽基肽酶4(dipeptidyl peptidase 4，DPP-4)抑制剂等，从而减轻因胰岛素剂量过大而引起的体重增加。", "ner": [[53, 56, "Disease"], [59, 60, "Disease"], [47, 49, "Drug"], [82, 85, "Drug"], [87, 138, "Drug"], [140, 147, "Drug"], [149, 187, "Drug"], [195, 201, "Reason"], [206, 209, "Disease"]], "rel": [[47, 49, "Drug", 53, 56, "Disease", "Drug_Disease"], [47, 49, "Drug", 59, 60, "Disease", "Drug_Disease"], [195, 201, "Reason", 206, 209, "Disease", "Reason_Disease"]]}
{"idx": 1489, "sentence": "③体重控制仍不理想者，可短期或长期联合使用对糖代谢有改善作用且安全性良好的减肥药。", "ner": [], "rel": []}
{"idx": 1490, "sentence": "(2)常用降糖药物对血糖、体重的影响：各种降糖药物的作用机制不同，对体重的影响也存在差异。T2DM合并肥胖患者在选择降糖药物时，应兼顾血糖和体重，尽可能选择降效果肯定同时不增加体重的药物。", "ner": [[10, 11, "Test_items"], [45, 48, "Disease"], [51, 52, "Disease"], [67, 68, "Test_items"]], "rel": [[67, 68, "Test_items", 45, 48, "Disease", "Test_items_Disease"], [67, 68, "Test_items", 51, 52, "Disease", "Test_items_Disease"]]}
{"idx": 1491, "sentence": "常用降糖药物对血糖、体重及内脏脂肪的作用见表4。", "ner": [[7, 8, "Test_items"]], "rel": []}
{"idx": 1492, "sentence": "降糖同时增加体重的药物有胰岛素、噻唑烷二酮类(thiazolidinediones，TZDs)、磺脲类药物。", "ner": [[12, 14, "Drug"], [16, 46, "Drug"], [48, 52, "Drug"], [4, 7, "ADE"]], "rel": [[4, 7, "ADE", 12, 14, "Drug", "ADE_Drug"], [4, 7, "ADE", 16, 46, "Drug", "ADE_Drug"], [4, 7, "ADE", 48, 52, "Drug", "ADE_Drug"]]}
{"idx": 1493, "sentence": "胰岛素仍是迄今为止最强有效的降糖药物，胰岛素的增重效应呈剂量依赖性和个体差异性，但不同胰岛素种类在增重方面有所差异，如基础胰岛素类似物-地特胰岛素具有体重增加较少的优势。", "ner": [[0, 2, "Drug"], [19, 21, "Drug"], [23, 24, "ADE"], [43, 45, "Drug"], [49, 50, "ADE"], [61, 66, "Drug"], [68, 72, "Drug"]], "rel": [[23, 24, "ADE", 19, 21, "Drug", "ADE_Drug"], [49, 50, "ADE", 43, 45, "Drug", "ADE_Drug"]]}
{"idx": 1494, "sentence": "TZDs主要通过增加靶细胞对胰岛素作用的敏感性而降低血糖，可使HbA1c下降1.0%~1.5%，引起体重增加(主要为水钠潴留)。", "ner": [[0, 3, "Drug"], [14, 16, "Drug"], [26, 27, "Test_items"], [31, 35, "Test_items"], [36, 46, "Test_Value"], [50, 53, "ADE"], [58, 61, "Pathogenesis"]], "rel": [[50, 53, "ADE", 0, 3, "Drug", "ADE_Drug"]]}
{"idx": 1495, "sentence": "磺脲类药物通过刺激胰岛β细胞分泌胰岛素，增加体内胰岛素水平来发挥降糖作用，可使HbA1c降低1.0%~1.5%；磺脲类药物也可引起体重增加。", "ner": [[0, 4, "Drug"], [39, 43, "Test_items"], [44, 54, "Test_Value"], [56, 60, "Drug"], [65, 68, "ADE"]], "rel": [[65, 68, "ADE", 56, 60, "Drug", "ADE_Drug"]]}
{"idx": 1496, "sentence": "降糖同时减轻或不增加体重的降糖药物主要有GLP-1受体激动剂、二甲双胍、α-糖苷酶抑制剂、DPP-4抑制剂和钠-葡萄糖协同转运蛋白2(sodium-glucose cotransporter-2，SGLT-2)抑制剂。其中，GLP-1受体激动剂可显著减轻患者体重。", "ner": [[20, 29, "Drug"], [31, 34, "Drug"], [36, 43, "Drug"], [45, 52, "Drug"], [54, 107, "Drug"], [112, 121, "Drug"], [125, 130, "ADE"]], "rel": [[125, 130, "ADE", 112, 121, "Drug", "ADE_Drug"]]}
{"idx": 1497, "sentence": "GLP-1受体激动剂主要通过激活GLP-1受体发挥作用，因其降糖作用具有葡萄糖浓度依赖性，因此低血糖发生率极低。利拉鲁肽无论单药或联合治疗，均能显著降低HbA1c1.1%~1.6%，降低体重1.0-3.2kg，持久地缩小患者腰围，且基线体重、腰围值越大，降低体重、缩小腰围的效果越显著。LEAD-2研究中，利拉鲁肽1.2mg或1.8mg治疗使患者内脏脂肪分别减少17.1%和16.4%。另一种GLP-1受体激动剂艾塞那肽，与利拉鲁肽头对头比较的临床研究显示，降糖效果略差，减重效果类似。此外，利拉鲁肽(3.0mg/d)在美国、加拿大、欧盟已经被正式批准作为减肥药。", "ner": [[0, 9, "Drug"], [47, 49, "ADE"], [56, 59, "Drug"], [76, 80, "Test_items"], [81, 89, "Test_Value"], [153, 156, "Drug"], [157, 161, "Amount"], [163, 167, "Amount"], [196, 209, "Drug"], [212, 215, "Drug"], [246, 249, "Drug"], [251, 257, "Amount"]], "rel": [[47, 49, "ADE", 0, 9, "Drug", "ADE_Drug"], [157, 161, "Amount", 153, 156, "Drug", "Amount_Drug"], [163, 167, "Amount", 153, 156, "Drug", "Amount_Drug"], [251, 257, "Amount", 246, 249, "Drug", "Amount_Drug"]]}
{"idx": 1498, "sentence": "二甲双胍通过减少肝脏葡萄糖的输出和改善外周胰岛素抵抗而降低血糖，被多个国家的糖尿病诊治指南推荐为T2DM治疗一线用药。", "ner": [[0, 3, "Drug"], [19, 25, "Pathogenesis"], [29, 30, "Test_items"], [38, 40, "Disease"], [48, 51, "Disease"]], "rel": [[19, 25, "Pathogenesis", 48, 51, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1499, "sentence": "二甲双胍可降低HbA1c1.0%~1.5%，减轻体重约1.1kg。", "ner": [[0, 3, "Drug"], [7, 11, "Test_items"], [12, 20, "Test_Value"]], "rel": []}
{"idx": 1500, "sentence": "α-糖苷酶抑制剂通过减慢碳水化合物在小肠上部的吸收速度而降低餐后血糖，可以使HbA1c下降0.5%~1.1%，对体重的影响呈中性或轻度减轻体重。", "ner": [[0, 7, "Drug"], [30, 33, "Test_items"], [38, 42, "Test_items"], [43, 53, "Test_Value"]], "rel": []}
{"idx": 1501, "sentence": "DPP-4抑制剂通过抑制DPP-4活性减少GLP-1在体内的失活，使内源性GLP-1水平升高，促进葡萄糖依赖的胰岛素分泌和抑制胰升糖素分泌，可降低HbA1c0.4%~1.0%。", "ner": [[0, 7, "Drug"], [73, 77, "Test_items"], [78, 86, "Test_Value"]], "rel": []}
{"idx": 1502, "sentence": "DPP-4抑制剂对体重的影响呈中性。", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 1503, "sentence": "SGLT-2抑制剂主要通过减少肾脏对葡萄糖的重吸收、增加葡萄精排泄而降低血糖水平。SGLT-2抑制剂可使HbA1c降低0.5%~1.0%，同时减轻患者体重(平均减少1.8kg)。由于SGLT-2抑制剂增加尿糖排出，会导致代偿性的食欲旺盛，故其减重作用需要配合控制饮食或其他类似手段。", "ner": [[0, 8, "Drug"], [36, 39, "Test_items"], [41, 49, "Drug"], [52, 56, "Test_items"], [57, 67, "Test_Value"], [91, 99, "Drug"], [110, 117, "ADE"]], "rel": [[110, 117, "ADE", 91, 99, "Drug", "ADE_Drug"]]}
{"idx": 1504, "sentence": "四、手术治疗", "ner": [], "rel": []}
{"idx": 1505, "sentence": "对于采取非手术治疗后减重或血糖控制效果不理想的T2DM合并肥胖患者，可以考虑手术治疗。减重手术可以改善T2DM合并肥胖患者的血糖控制，甚至使部分患者糖尿病“缓解”。手术治疗T2DM的前提是患者尚具备足够的胰岛β细胞功能。严格选择患者及适合的手术方式，充分进行术前评估和术前准备，并加强术后随访和营养、运动指导，是提高手术治疗T2DM有效性和安全性的关键。", "ner": [[13, 16, "Test_items"], [23, 26, "Disease"], [29, 30, "Disease"], [43, 46, "Operation"], [51, 54, "Disease"], [57, 58, "Disease"], [62, 65, "Test_items"], [74, 76, "Disease"], [86, 89, "Disease"], [142, 145, "Treatment"], [147, 153, "Treatment"], [162, 165, "Disease"]], "rel": [[13, 16, "Test_items", 23, 26, "Disease", "Test_items_Disease"], [13, 16, "Test_items", 29, 30, "Disease", "Test_items_Disease"], [43, 46, "Operation", 51, 54, "Disease", "Operation_Disease"], [43, 46, "Operation", 57, 58, "Disease", "Operation_Disease"], [62, 65, "Test_items", 51, 54, "Disease", "Test_items_Disease"], [62, 65, "Test_items", 57, 58, "Disease", "Test_items_Disease"], [142, 145, "Treatment", 162, 165, "Disease", "Treatment_Disease"], [147, 153, "Treatment", 162, 165, "Disease", "Treatment_Disease"]]}
{"idx": 1506, "sentence": "(一)适应证", "ner": [], "rel": []}
{"idx": 1507, "sentence": "1.年龄在18~60岁，一般状况较好，手术风险较低，经生活方式干预和各种药物治疗难以控制的2型糖尿病患者(HbA1c>7.0%)。", "ner": [[45, 49, "Disease"], [27, 32, "Treatment"]], "rel": [[27, 32, "Treatment", 45, 49, "Disease", "Treatment_Disease"]]}
{"idx": 1508, "sentence": "2.根据患者的BMI和临床情况来判断是否行手术治疗：(1)积极手术：BMl≥32kg/m2，无论是否存在其他合并症(阻塞性睡眠呼吸暂停综合征、非酒精性脂肪性肝炎、高尿酸血症、多囊卵巢综合征、肾功能异常等)；(2)慎重手术：BMI28~32kg/m2，至少符合额外的2个代谢综合征组分，或存在合并症；(3)暂不推荐：BMI25~28kg/m2。", "ner": [[58, 69, "Disease"], [71, 79, "Disease"], [78, 78, "Anatomy"], [81, 85, "Disease"], [87, 93, "Disease"], [89, 90, "Anatomy"], [95, 99, "Disease"], [95, 95, "Anatomy"]], "rel": [[78, 78, "Anatomy", 71, 79, "Disease", "Anatomy_Disease"], [89, 90, "Anatomy", 87, 93, "Disease", "Anatomy_Disease"], [95, 95, "Anatomy", 95, 99, "Disease", "Anatomy_Disease"]]}
{"idx": 1509, "sentence": "如果患者合并腹型肥胖，且至少符合额外的2个代谢综合征组分，可酌情提高手术推荐等级。", "ner": [[6, 9, "Disease"]], "rel": []}
{"idx": 1510, "sentence": "腹腔镜袖状胃切除术(laparoscopic sleeve gastrectomy，LSG)是中重度T2DM合并肥胖的首选术式；胃旁路术(roux-en-Y gastric、bypass，RYGB)适用于T2DM病程相对较长、需要减重更多的患者。", "ner": [[0, 45, "Operation"], [50, 53, "Disease"], [56, 57, "Disease"], [47, 49, "Level"], [64, 98, "Operation"], [102, 105, "Disease"]], "rel": [[0, 45, "Operation", 50, 53, "Disease", "Operation_Disease"], [0, 45, "Operation", 56, 57, "Disease", "Operation_Disease"], [64, 98, "Operation", 102, 105, "Disease", "Operation_Disease"]]}
{"idx": 1511, "sentence": "(二)禁忌证", "ner": [], "rel": []}
{"idx": 1512, "sentence": "1.滥用药物、酒精成瘾、患有难以控制的精神疾病患者，以及对减重手术的风险、益处、预期后果缺乏理解能力的患者。", "ner": [[19, 22, "Disease"]], "rel": []}
{"idx": 1513, "sentence": "2.明确诊断为1型糖尿病的患者。", "ner": [[7, 11, "Disease"]], "rel": []}
{"idx": 1514, "sentence": "3.胰岛β细胞功能已明显衰竭的2型糖尿病患者。", "ner": [[2, 13, "Pathogenesis"], [15, 19, "Disease"]], "rel": [[2, 13, "Pathogenesis", 15, 19, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1515, "sentence": "4.外科手术禁忌者。", "ner": [], "rel": []}
{"idx": 1516, "sentence": "5.BMI<25kg/m2。", "ner": [], "rel": []}
{"idx": 1517, "sentence": "6.妊娠糖尿病及其他特殊类型的糖尿病。", "ner": [[15, 17, "Disease"], [2, 6, "Disease"]], "rel": []}
{"idx": 1518, "sentence": "五、血糖和体重监测", "ner": [[2, 3, "Test_items"]], "rel": []}
{"idx": 1519, "sentence": "(一)血糖监测", "ner": [[3, 6, "Test_items"]], "rel": []}
{"idx": 1520, "sentence": "HbA1c反映近2~3个月血糖平均水平，是评价长期血糖控制的金标准，也是指导临床调整治疗方案的重要依据。", "ner": [[0, 4, "Test_items"], [13, 18, "Test_items"], [23, 28, "Test_items"]], "rel": []}
{"idx": 1521, "sentence": "在治疗初期建议每3个月检测1次，一旦达到治疗目标可每6个月检查一次。", "ner": [], "rel": []}
{"idx": 1522, "sentence": "(二)体重监测", "ner": [], "rel": []}
{"idx": 1523, "sentence": "1.作为一种慢性疾病，为了预防体重再次增加和防治并发疾病，体重长期监测必不可少。", "ner": [], "rel": []}
{"idx": 1524, "sentence": "2.有效性评估：建议糖尿病合并肥胖患者体重降幅至少>3%。", "ner": [[10, 12, "Disease"], [15, 16, "Disease"]], "rel": []}
{"idx": 1525, "sentence": "采用药物治疗3个月后对疗效进行评价：体重下降2%~3%为不显著：体重下降3%~5%为显著：体重下降>5%为非常显著。", "ner": [], "rel": []}
{"idx": 1526, "sentence": "3.在6个月时间达到5%~15%的体重下降；重度肥胖(如BMI>35kg/m2)可能需要更多(20%或以上)的体重减轻。", "ner": [[22, 23, "Level"], [24, 25, "Disease"]], "rel": []}
{"idx": 1527, "sentence": "4.对于接受手术治疗的患者，在术后第1年至少要进行3次门诊随访，还需要更多的电话或其他方式的随访。", "ner": [], "rel": []}
{"idx": 1528, "sentence": "对于可调节胃绑带术的患者，门诊随访的次数可能需要增加，以便对绑带进行适当的调节。", "ner": [[2, 8, "Operation"]], "rel": []}
{"idx": 1529, "sentence": "六、T2DM合并肥胖心血管风险因素的控制", "ner": [[2, 5, "Disease"], [8, 9, "Disease"]], "rel": []}
{"idx": 1530, "sentence": "体重增加是T2DM发生的独立危险因素。体重或腰围增加均可加重胰岛素抵抗，增加T2DM的发生风险，以及血糖控制的难度。与单纯肥胖的患者相比，T2DM合并肥胖患者减重并维持体重更加困难。首先，肥胖患者的胰岛素水平显著增高，而胰岛素具有抑制脂肪分解、促进脂肪合成的作用。其次，肥胖本身与糖尿病患者存在的其他代谢异常协同作用可加重T2DM的胰岛素抵抗，而内脏脂肪增加可能是肥胖患者发生胰岛素抵抗的主要原因。减轻体重可以改善胰岛素抵抗、降低血糖和改善心血管疾病的危险因素，超重和肥胖T2DM患者减重3%~5%，即能产生血糖、HbA1c、血压、甘油三酯(triglyceride，TG)均显著降低等具有临床意义的健康获益，并且提高生活质量。", "ner": [[0, 3, "Reason"], [5, 8, "Disease"], [19, 25, "Reason"], [38, 41, "Disease"], [30, 34, "Pathogenesis"], [50, 53, "Test_items"], [59, 62, "Disease"], [69, 72, "Disease"], [75, 76, "Disease"], [94, 95, "Disease"], [99, 103, "Test_items"], [104, 107, "Test_Value"], [135, 136, "Disease"], [140, 142, "Disease"], [161, 164, "Disease"], [166, 170, "Pathogenesis"], [173, 178, "Reason"], [182, 183, "Disease"], [188, 192, "Pathogenesis"], [199, 202, "Treatment"], [207, 211, "Pathogenesis"], [215, 216, "Test_items"], [231, 232, "Disease"], [234, 235, "Disease"], [236, 239, "Disease"], [254, 255, "Test_items"], [257, 261, "Test_items"], [263, 264, "Test_items"], [266, 286, "Test_items"]], "rel": [[0, 3, "Reason", 5, 8, "Disease", "Reason_Disease"], [19, 25, "Reason", 38, 41, "Disease", "Reason_Disease"], [30, 34, "Pathogenesis", 38, 41, "Disease", "Pathogenesis_Disease"], [50, 53, "Test_items", 38, 41, "Disease", "Test_items_Disease"], [99, 103, "Test_items", 94, 95, "Disease", "Test_items_Disease"], [166, 170, "Pathogenesis", 161, 164, "Disease", "Pathogenesis_Disease"], [173, 178, "Reason", 182, 183, "Disease", "Reason_Disease"], [188, 192, "Pathogenesis", 182, 183, "Disease", "Pathogenesis_Disease"], [199, 202, "Treatment", 231, 232, "Disease", "Treatment_Disease"], [199, 202, "Treatment", 234, 235, "Disease", "Treatment_Disease"], [199, 202, "Treatment", 236, 239, "Disease", "Treatment_Disease"], [254, 255, "Test_items", 231, 232, "Disease", "Test_items_Disease"], [257, 261, "Test_items", 231, 232, "Disease", "Test_items_Disease"], [263, 264, "Test_items", 231, 232, "Disease", "Test_items_Disease"], [266, 286, "Test_items", 231, 232, "Disease", "Test_items_Disease"], [254, 255, "Test_items", 234, 235, "Disease", "Test_items_Disease"], [257, 261, "Test_items", 234, 235, "Disease", "Test_items_Disease"], [263, 264, "Test_items", 234, 235, "Disease", "Test_items_Disease"], [266, 286, "Test_items", 234, 235, "Disease", "Test_items_Disease"], [263, 264, "Test_items", 236, 239, "Disease", "Test_items_Disease"], [257, 261, "Test_items", 236, 239, "Disease", "Test_items_Disease"], [254, 255, "Test_items", 236, 239, "Disease", "Test_items_Disease"], [266, 286, "Test_items", 236, 239, "Disease", "Test_items_Disease"]]}
{"idx": 1531, "sentence": "在一定范围内，减重越多，获益越大。", "ner": [], "rel": []}
{"idx": 1532, "sentence": "T2DM及肥胖确诊后，至少每年评估1次心血管病变的风险因素，评估的内容包括心血管病既往史及现状、年龄、有无心血管风险因素(吸烟、血脂紊乱、高血压和家族史等)、肾脏损害(尿白蛋白排泄率增高等)、心房颤动(可导致卒中)。全面评估和控制心血管疾病风险因素，并进行合理的降压、调脂和抗血小板治疗，可显著改善糖尿病患者心脑血管病变和死亡发生的风险。联合使用其他药物时应注意：β受体阻滞剂增加体重、他汀类药物升高血糖、某些抗抑郁焦虑药物增加体重等。", "ner": [[0, 3, "Disease"], [5, 6, "Disease"], [37, 40, "Disease"], [37, 39, "Anatomy"], [53, 55, "Anatomy"], [64, 67, "Disease"], [69, 71, "Disease"], [79, 82, "Disease"], [84, 90, "Test_items"], [91, 92, "Test_Value"], [96, 99, "Reason"], [104, 105, "Disease"], [15, 28, "Treatment"], [131, 132, "Treatment"], [134, 135, "Treatment"], [137, 142, "Treatment"], [149, 151, "Disease"], [154, 159, "Disease"], [154, 157, "Anatomy"], [182, 187, "Drug"], [188, 191, "ADE"], [193, 197, "Drug"], [198, 201, "ADE"], [79, 80, "Anatomy"]], "rel": [[15, 28, "Treatment", 0, 3, "Disease", "Treatment_Disease"], [15, 28, "Treatment", 5, 6, "Disease", "Treatment_Disease"], [37, 39, "Anatomy", 37, 40, "Disease", "Anatomy_Disease"], [84, 90, "Test_items", 79, 82, "Disease", "Test_items_Disease"], [79, 80, "Anatomy", 79, 82, "Disease", "Anatomy_Disease"], [96, 99, "Reason", 104, 105, "Disease", "Reason_Disease"], [131, 132, "Treatment", 149, 151, "Disease", "Treatment_Disease"], [134, 135, "Treatment", 149, 151, "Disease", "Treatment_Disease"], [137, 142, "Treatment", 149, 151, "Disease", "Treatment_Disease"], [154, 157, "Anatomy", 154, 159, "Disease", "Anatomy_Disease"], [188, 191, "ADE", 182, 187, "Drug", "ADE_Drug"], [198, 201, "ADE", 193, 197, "Drug", "ADE_Drug"]]}
{"idx": 1533, "sentence": "《基于肠促胰素的药物治疗临床应用的快速建议指南》", "ner": [], "rel": []}
{"idx": 1534, "sentence": "肠促胰素(incretin)是一种经食物刺激后由肠细胞分泌入血、能够刺激胰岛素分泌的激素。", "ner": [], "rel": []}
{"idx": 1535, "sentence": "基于肠促胰素的治疗药物(incretin-based therapies，IBTs)通过与器官上的特异性受体结合，发挥类肠促胰素作用，从而达到降糖疗效。", "ner": [], "rel": []}
{"idx": 1536, "sentence": "由于这类药物具有低血糖风险小和改善细胞功能等多方面的优势，逐渐在临床广泛使用。", "ner": [[8, 10, "ADE"]], "rel": []}
{"idx": 1537, "sentence": "目前在国内已经上市了两种胰高血糖素样肽-1受体激动剂(Glucagon-likepeptide-1 receptoragonists，GLP-1RA)：包括艾塞那肽(Exenatide和利拉鲁肽(Liraglutide)，以及5种二肽基肽酶Ⅳ抑制剂(Dipeptidyl Peptidase- 4 inhibitor，DPP-4i)：包括西格列汀(Sitagliptin)、维格列汀(Vildagliptin)、沙格列汀(Saxagliptin)、利格列汀(Linagliptin)和阿格列汀(Alogliptin)(表1)", "ner": [[12, 74, "Drug"], [78, 91, "Drug"], [93, 109, "Drug"], [115, 165, "Drug"], [169, 185, "Drug"], [187, 204, "Drug"], [206, 222, "Drug"], [224, 240, "Drug"], [242, 257, "Drug"]], "rel": []}
{"idx": 1538, "sentence": "基于肠促胰素的治疗药物的出现为临床医生提供了更多选择，但它们的有效性、安全性和经济性究竟如何?基于肠促胰素的治疗药物在特殊人群(如老年患者)中使用有哪些注意事项?特别是这类药物在全球临床指南中地位变化迅速时，我们该如何评价、选择和应用?这些问题都有待于采用系统、科学的方法来回答。", "ner": [], "rel": []}
{"idx": 1539, "sentence": "本指南采用GRADE(the Grading of Recommendation Assessment，Development and Evaluation)证据质量评价与推荐强度系统。", "ner": [], "rel": []}
{"idx": 1540, "sentence": "证据量评价：A表示高质量，B表示中等质量，C表示低质量，D表示极低质量；推荐强度：1表示强推荐，2表示弱推荐，0表示无明确推荐意见。", "ner": [], "rel": []}
{"idx": 1541, "sentence": "(见表2、3)", "ner": [], "rel": []}
{"idx": 1542, "sentence": "临床问题1：DPP-4i是否可作为2型糖尿病患者的一线治疗选择之一?", "ner": [[6, 11, "Drug"], [17, 21, "Disease"]], "rel": [[6, 11, "Drug", 17, 21, "Disease", "Drug_Disease"]]}
{"idx": 1543, "sentence": "推荐意见 ", "ner": [], "rel": []}
{"idx": 1544, "sentence": "推荐D PP-4i作为2型糖尿病患者的一线治疗选择之一。", "ner": [[2, 8, "Drug"], [11, 15, "Disease"]], "rel": [[2, 8, "Drug", 11, 15, "Disease", "Drug_Disease"]]}
{"idx": 1545, "sentence": "推荐说明", "ner": [], "rel": []}
{"idx": 1546, "sentence": "二甲双胍被各国指南推荐作为2型糖尿病患者的一线治疗药物。", "ner": [[0, 3, "Drug"], [13, 17, "Disease"]], "rel": [[0, 3, "Drug", 13, 17, "Disease", "Drug_Disease"]]}
{"idx": 1547, "sentence": "在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4i可以作为一线的替代治疗药物。", "ner": [[1, 4, "Drug"], [20, 25, "Drug"]], "rel": []}
{"idx": 1548, "sentence": "DPP-4i的推荐剂量为说明书中规定的常规使用剂量。", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 1549, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1550, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1551, "sentence": "临床问题2：在单药治疗血糖控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的二线治疗选择之一? ", "ner": [[11, 12, "Test_items"], [21, 26, "Drug"], [32, 36, "Disease"], [13, 16, "Test_Value"]], "rel": [[11, 12, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [21, 26, "Drug", 32, 36, "Disease", "Drug_Disease"]]}
{"idx": 1552, "sentence": "推荐意见 ", "ner": [], "rel": []}
{"idx": 1553, "sentence": "推荐DPP-4i作为2型糖尿病患者的二线治疗之一。", "ner": [[2, 7, "Drug"], [10, 14, "Disease"]], "rel": [[2, 7, "Drug", 10, 14, "Disease", "Drug_Disease"]]}
{"idx": 1554, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1555, "sentence": "当二甲双胍或者其他降糖药物单药治疗后，糖化血红蛋白水平仍未达标，则需联合另外一种降糖药治疗。", "ner": [[1, 4, "Drug"], [19, 24, "Test_items"], [28, 30, "Test_Value"]], "rel": []}
{"idx": 1556, "sentence": "推荐等级：1 证据级别：B", "ner": [], "rel": []}
{"idx": 1557, "sentence": "临床问题3：在二线治疗控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的三线治疗", "ner": [[19, 24, "Drug"], [30, 34, "Disease"]], "rel": [[19, 24, "Drug", 30, 34, "Disease", "Drug_Disease"]]}
{"idx": 1558, "sentence": "选择之一?", "ner": [], "rel": []}
{"idx": 1559, "sentence": "推荐意见推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。", "ner": [[6, 11, "Drug"], [14, 18, "Disease"]], "rel": [[6, 11, "Drug", 14, 18, "Disease", "Drug_Disease"]]}
{"idx": 1560, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1561, "sentence": "由于DPP-4i具有较好的有效性和安全性，在二线治疗时仍未使用DPP-4i治疗的患者，推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。", "ner": [[2, 7, "Drug"], [31, 36, "Drug"], [45, 50, "Drug"], [53, 57, "Disease"]], "rel": [[45, 50, "Drug", 53, 57, "Disease", "Drug_Disease"]]}
{"idx": 1562, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1563, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1564, "sentence": "临床问题4：DPP-4i联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?", "ner": [[6, 11, "Drug"], [16, 18, "Drug"], [24, 28, "Disease"]], "rel": [[6, 11, "Drug", 24, 28, "Disease", "Drug_Disease"], [16, 18, "Drug", 24, 28, "Disease", "Drug_Disease"]]}
{"idx": 1565, "sentence": "推荐意见 ", "ner": [], "rel": []}
{"idx": 1566, "sentence": "推荐DPP-4i联合基础胰岛素用于2型糖尿病的降糖治疗。", "ner": [[2, 7, "Drug"], [12, 14, "Drug"], [17, 21, "Disease"]], "rel": [[2, 7, "Drug", 17, 21, "Disease", "Drug_Disease"], [12, 14, "Drug", 17, 21, "Disease", "Drug_Disease"]]}
{"idx": 1567, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1568, "sentence": "当使用基础胰岛素进行治疗，糖化血红蛋白控制不佳时，可添加DPP-4i进行联合治疗，并根据糖化血红蛋白水平，调整胰岛素的剂量。", "ner": [[5, 7, "Drug"], [13, 18, "Test_items"], [19, 22, "Test_Value"], [28, 33, "Drug"], [44, 49, "Test_items"], [55, 57, "Drug"]], "rel": []}
{"idx": 1569, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1570, "sentence": " 证据级别：B", "ner": [], "rel": []}
{"idx": 1571, "sentence": "临床问题5：DPP-4i是否可用于65岁以上的2型糖尿病患者的降糖治疗? ", "ner": [[6, 11, "Drug"], [23, 27, "Disease"]], "rel": [[6, 11, "Drug", 23, 27, "Disease", "Drug_Disease"]]}
{"idx": 1572, "sentence": "推荐意见", "ner": [], "rel": []}
{"idx": 1573, "sentence": "推荐DPP-4i用于65岁以上的2型糖尿病患者糖治疗。", "ner": [[2, 7, "Drug"], [16, 20, "Disease"]], "rel": [[2, 7, "Drug", 16, 20, "Disease", "Drug_Disease"]]}
{"idx": 1574, "sentence": "推荐说明", "ner": [], "rel": []}
{"idx": 1575, "sentence": "由于老年患者常常合并多种并发疾病，DPP-4i具有良好的血糖控制效果和安全性，推荐DPP-4i用于老年2型糖尿病患者的降糖治疗。", "ner": [[17, 22, "Drug"], [28, 29, "Test_items"], [41, 46, "Drug"], [51, 55, "Disease"]], "rel": [[28, 29, "Test_items", 51, 55, "Disease", "Test_items_Disease"], [41, 46, "Drug", 51, 55, "Disease", "Drug_Disease"]]}
{"idx": 1576, "sentence": "推荐使用常规剂量进行治疗，除非伴有肝或肾功能不全，需根据说明书进行剂量调整。", "ner": [[17, 23, "Disease"], [17, 17, "Anatomy"], [19, 19, "Anatomy"]], "rel": [[17, 17, "Anatomy", 17, 23, "Disease", "Anatomy_Disease"], [19, 19, "Anatomy", 17, 23, "Disease", "Anatomy_Disease"]]}
{"idx": 1577, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1578, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1579, "sentence": "临床问题6：DPP-4i是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ", "ner": [[6, 11, "Drug"], [17, 18, "Disease"], [20, 21, "Disease"], [22, 26, "Disease"]], "rel": [[6, 11, "Drug", 22, 26, "Disease", "Drug_Disease"]]}
{"idx": 1580, "sentence": "推荐意见DPP-4i可用于超重/肥胖2型糖尿病患者的降疗。", "ner": [[4, 9, "Drug"], [13, 14, "Disease"], [16, 17, "Disease"], [18, 22, "Disease"]], "rel": [[4, 9, "Drug", 18, 22, "Disease", "Drug_Disease"]]}
{"idx": 1581, "sentence": "推荐说明", "ner": [], "rel": []}
{"idx": 1582, "sentence": "由于DPP-4i不影响患者的体重，故建议DPP-4i用于超重/肥胖2型糖尿病患者的降糖治疗。", "ner": [[2, 7, "Drug"], [20, 25, "Drug"], [28, 29, "Disease"], [31, 32, "Disease"], [33, 37, "Disease"]], "rel": [[20, 25, "Drug", 33, 37, "Disease", "Drug_Disease"]]}
{"idx": 1583, "sentence": "推荐等级：2 ", "ner": [], "rel": []}
{"idx": 1584, "sentence": "证据级别：C", "ner": [], "rel": []}
{"idx": 1585, "sentence": "临床问题7：DPP-4i是否可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗? 推荐意见", "ner": [[6, 11, "Drug"], [33, 37, "Disease"], [19, 23, "Disease"], [25, 29, "Disease"], [19, 21, "Anatomy"], [25, 27, "Anatomy"]], "rel": [[6, 11, "Drug", 33, 37, "Disease", "Drug_Disease"], [19, 21, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [25, 27, "Anatomy", 25, 29, "Disease", "Anatomy_Disease"]]}
{"idx": 1586, "sentence": "DPP-4i可用于伴有心血管疾病或心血管事件的2型糖尿病患者的降糖治疗。", "ner": [[0, 5, "Drug"], [23, 27, "Disease"], [11, 15, "Disease"], [11, 13, "Anatomy"], [17, 21, "Disease"], [17, 19, "Anatomy"]], "rel": [[0, 5, "Drug", 23, 27, "Disease", "Drug_Disease"], [11, 13, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"], [17, 19, "Anatomy", 17, 21, "Disease", "Anatomy_Disease"]]}
{"idx": 1587, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1588, "sentence": "基于证据总结和专家意见，DPP-4i可用于血管疾病或心血管事件风险的2型糖尿病患者。", "ner": [[12, 17, "Drug"], [34, 38, "Disease"], [21, 24, "Disease"], [21, 22, "Anatomy"], [26, 30, "Disease"], [26, 28, "Anatomy"]], "rel": [[12, 17, "Drug", 34, 38, "Disease", "Drug_Disease"], [21, 22, "Anatomy", 21, 24, "Disease", "Anatomy_Disease"], [26, 28, "Anatomy", 26, 30, "Disease", "Anatomy_Disease"]]}
{"idx": 1589, "sentence": "推荐等级：2 ", "ner": [], "rel": []}
{"idx": 1590, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1591, "sentence": "临床问题8：复方制剂(DPP-4i和二甲双胍)是否可用于2型糖尿病患者的起始降糖治疗? ", "ner": [[11, 16, "Drug"], [18, 21, "Drug"], [28, 32, "Disease"]], "rel": [[11, 16, "Drug", 28, 32, "Disease", "Drug_Disease"], [18, 21, "Drug", 28, 32, "Disease", "Drug_Disease"]]}
{"idx": 1592, "sentence": "推荐意见", "ner": [], "rel": []}
{"idx": 1593, "sentence": "推荐复方制剂(DPP-4i和二甲双胍)用于2型糖病患者的起始降糖治疗。", "ner": [[7, 12, "Drug"], [14, 17, "Drug"], [21, 24, "Disease"]], "rel": [[7, 12, "Drug", 21, 24, "Disease", "Drug_Disease"], [14, 17, "Drug", 21, 24, "Disease", "Drug_Disease"]]}
{"idx": 1594, "sentence": "推荐说明", "ner": [], "rel": []}
{"idx": 1595, "sentence": "对于HbA1c>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4i和二甲双胍)进行起始治疗。", "ner": [[2, 6, "Test_items"], [7, 11, "Test_Value"], [29, 34, "Drug"], [36, 39, "Drug"]], "rel": []}
{"idx": 1596, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1597, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1598, "sentence": "临床问题9：在单药治疗血糖控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的二线治疗选择之一? ", "ner": [[11, 12, "Test_items"], [13, 16, "Test_Value"], [21, 27, "Drug"], [33, 37, "Disease"]], "rel": [[11, 12, "Test_items", 33, 37, "Disease", "Test_items_Disease"], [21, 27, "Drug", 33, 37, "Disease", "Drug_Disease"]]}
{"idx": 1599, "sentence": "推荐意见 ", "ner": [], "rel": []}
{"idx": 1600, "sentence": "推荐GLP—1RA作为2型糖尿病患者的二线治疗择之一。", "ner": [[2, 8, "Drug"], [11, 15, "Disease"]], "rel": [[2, 8, "Drug", 11, 15, "Disease", "Drug_Disease"]]}
{"idx": 1601, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1602, "sentence": "由于GLP一1RA具有较好控制血糖和降低体重的作用，在单药治疗血糖控制不佳的情况，推荐GLP—1RA作为2型糖尿病患者的治疗选择。", "ner": [[2, 8, "Drug"], [15, 16, "Test_items"], [31, 32, "Test_items"], [33, 36, "Test_Value"], [43, 49, "Drug"], [52, 56, "Disease"]], "rel": [[31, 32, "Test_items", 52, 56, "Disease", "Test_items_Disease"], [43, 49, "Drug", 52, 56, "Disease", "Drug_Disease"]]}
{"idx": 1603, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1604, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1605, "sentence": "临床问题10：在二线治疗控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的三线治疗选择之一?", "ner": [[20, 26, "Drug"], [32, 36, "Disease"]], "rel": [[20, 26, "Drug", 32, 36, "Disease", "Drug_Disease"]]}
{"idx": 1606, "sentence": "推荐意见", "ner": [], "rel": []}
{"idx": 1607, "sentence": "推荐GLP一1RA作为2型糖尿病患者的三线治疗选择之一。", "ner": [[2, 8, "Drug"], [11, 15, "Disease"]], "rel": [[2, 8, "Drug", 11, 15, "Disease", "Drug_Disease"]]}
{"idx": 1608, "sentence": "推荐说明", "ner": [], "rel": []}
{"idx": 1609, "sentence": "由于GLP—1RA具有较好的血糖控制效果，在二线治疗时血糖仍控制不佳的患者，推荐GLP-1RA作为2型糖尿病患者的三线治疗选择之一。", "ner": [[2, 8, "Drug"], [14, 15, "Test_items"], [27, 28, "Test_items"], [30, 33, "Test_Value"], [40, 46, "Drug"], [49, 53, "Disease"]], "rel": [[27, 28, "Test_items", 49, 53, "Disease", "Test_items_Disease"], [40, 46, "Drug", 49, 53, "Disease", "Drug_Disease"]]}
{"idx": 1610, "sentence": "推荐等级：1 ", "ner": [], "rel": []}
{"idx": 1611, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1612, "sentence": "临床问题11：GLP-1RA联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?", "ner": [[7, 13, "Drug"], [18, 20, "Drug"], [26, 30, "Disease"]], "rel": [[7, 13, "Drug", 26, 30, "Disease", "Drug_Disease"], [18, 20, "Drug", 26, 30, "Disease", "Drug_Disease"]]}
{"idx": 1613, "sentence": "推荐意见推荐GLP一1RA联合基础胰岛素用于2型糖尿病患者的降糖治疗。", "ner": [[6, 12, "Drug"], [17, 19, "Drug"], [22, 26, "Disease"]], "rel": [[6, 12, "Drug", 22, 26, "Disease", "Drug_Disease"], [17, 19, "Drug", 22, 26, "Disease", "Drug_Disease"]]}
{"idx": 1614, "sentence": "推荐说明", "ner": [], "rel": []}
{"idx": 1615, "sentence": "当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，可添GLP-1RA进行联合治疗并根据糖化血红蛋白水平，调整胰岛素的剂量。", "ner": [[5, 7, "Drug"], [13, 18, "Test_items"], [22, 25, "Test_Value"], [30, 36, "Drug"], [46, 51, "Test_items"], [57, 59, "Drug"]], "rel": []}
{"idx": 1616, "sentence": "推荐等级：1", "ner": [], "rel": []}
{"idx": 1617, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1618, "sentence": "临床问题12：GLP-1RA是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ", "ner": [[7, 13, "Drug"], [19, 20, "Disease"], [22, 23, "Disease"], [24, 28, "Disease"]], "rel": [[7, 13, "Drug", 24, 28, "Disease", "Drug_Disease"]]}
{"idx": 1619, "sentence": "推荐意见 ", "ner": [], "rel": []}
{"idx": 1620, "sentence": "建议GLP-1RA用于超重/fie胖2型糖尿病患者的降糖治疗。", "ner": [[2, 8, "Drug"], [11, 12, "Disease"], [18, 22, "Disease"]], "rel": [[2, 8, "Drug", 18, 22, "Disease", "Drug_Disease"]]}
{"idx": 1621, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1622, "sentence": "由于GLP-1RA可显著降低患者体重，对于超重/肥胖的2型糖尿病患者，建议GLP-1RA用于超重/肥胖患者的降糖治疗。", "ner": [[2, 8, "Drug"], [21, 22, "Disease"], [24, 25, "Disease"], [27, 31, "Disease"], [37, 43, "Drug"], [46, 47, "Disease"], [49, 50, "Disease"]], "rel": [[2, 8, "Drug", 27, 31, "Disease", "Drug_Disease"]]}
{"idx": 1623, "sentence": "推荐等级：2 ", "ner": [], "rel": []}
{"idx": 1624, "sentence": "证据级别：B", "ner": [], "rel": []}
{"idx": 1625, "sentence": "临床问题13：GLP-1RA是否可用于伴有非酒精性脂肪肝的2型糖尿病患者的降糖治疗? ", "ner": [[7, 13, "Drug"], [21, 27, "Disease"], [27, 27, "Anatomy"], [29, 33, "Disease"]], "rel": [[7, 13, "Drug", 29, 33, "Disease", "Drug_Disease"], [27, 27, "Anatomy", 21, 27, "Disease", "Anatomy_Disease"]]}
{"idx": 1626, "sentence": "推荐意见 ", "ner": [], "rel": []}
{"idx": 1627, "sentence": "建议GLP-1RA用于伴有非酒精性脂肪肝2型糖尿病患者的降糖治疗。", "ner": [[2, 8, "Drug"], [13, 19, "Disease"], [19, 19, "Anatomy"], [20, 24, "Disease"]], "rel": [[2, 8, "Drug", 20, 24, "Disease", "Drug_Disease"], [19, 19, "Anatomy", 13, 19, "Disease", "Anatomy_Disease"]]}
{"idx": 1628, "sentence": "推荐说明 ", "ner": [], "rel": []}
{"idx": 1629, "sentence": "对于伴有非酒精性脂肪肝的2型糖尿病患者GLP-1RA可降低BMI和ALT水平，建议使用GLP-1RA进行治疗。", "ner": [[4, 10, "Disease"], [10, 10, "Anatomy"], [12, 16, "Disease"], [19, 25, "Drug"], [33, 35, "Test_items"], [43, 49, "Drug"]], "rel": [[10, 10, "Anatomy", 4, 10, "Disease", "Anatomy_Disease"], [19, 25, "Drug", 12, 16, "Disease", "Drug_Disease"], [33, 35, "Test_items", 12, 16, "Disease", "Test_items_Disease"]]}
{"idx": 1630, "sentence": "推荐等级：2 ", "ner": [], "rel": []}
{"idx": 1631, "sentence": "证据级别：C", "ner": [], "rel": []}
{"idx": 1632, "sentence": "预混胰岛素临床应用专家共识(2016年版)", "ner": [[0, 4, "Drug"]], "rel": []}
{"idx": 1633, "sentence": "2007~2008年中国糖尿病流行病学调查结果显示，我国20岁以上的人群中糖尿病的患病率为9.7%，而2010年的调查数据显示，我国成人糖尿病患病率高达11.6%。中国糖尿病患者人数已经位居全球首位，并且给社会和家庭带来沉重的经济负担。中国新诊断的2型糖尿病(type 2 diabetesmellius，T2DM)患者以餐后血糖升高为主，这可能与中国患者胰岛β细胞功能的衰退更显著、饮食结构多以碳水化合物为主有关。预混胰岛素能同时提供基础和餐时胰岛素，控制餐后血糖同时兼顾整体血糖。因此，目前多数中国T2DM患者选择预混胰岛素为胰岛素起始治疗方案。", "ner": [[12, 14, "Disease"], [37, 39, "Disease"], [68, 70, "Disease"], [84, 86, "Disease"], [124, 157, "Disease"], [161, 164, "Test_items"], [165, 166, "Test_Value"], [178, 187, "Pathogenesis"], [192, 204, "Reason"], [208, 212, "Drug"], [229, 232, "Test_items"], [239, 240, "Test_items"], [251, 254, "Disease"], [259, 263, "Drug"], [265, 267, "Drug"], [223, 225, "Drug"]], "rel": [[161, 164, "Test_items", 124, 157, "Disease", "Test_items_Disease"], [178, 187, "Pathogenesis", 124, 157, "Disease", "Pathogenesis_Disease"], [192, 204, "Reason", 124, 157, "Disease", "Reason_Disease"], [259, 263, "Drug", 251, 254, "Disease", "Drug_Disease"], [265, 267, "Drug", 251, 254, "Disease", "Drug_Disease"]]}
{"idx": 1634, "sentence": "尽管接受口服药物治疗及生活方式干预，但大部分T2DM患者胰岛β细胞功能仍随病程进展逐渐恶化，故及时启动胰岛素治疗能减轻胰岛β细胞负荷，解除高糖毒性，改善胰岛素抵抗，保护残存的β细胞功能。《中国2型糖尿病防治指南(2013年版)》指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服降糖药联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素注射(基础+餐时胰岛素或每日3次预混胰岛素类似物)。", "ner": [[11, 16, "Treatment"], [22, 25, "Disease"], [28, 44, "Pathogenesis"], [51, 53, "Drug"], [59, 65, "Pathogenesis"], [76, 80, "Pathogenesis"], [96, 100, "Disease"], [117, 120, "Frequency"], [123, 125, "Drug"], [127, 132, "Frequency"], [133, 137, "Drug"], [142, 144, "Drug"], [155, 157, "Drug"], [159, 163, "Drug"], [176, 177, "Test_items"], [178, 180, "Test_Value"], [193, 195, "Drug"], [196, 197, "Method"], [204, 206, "Drug"], [208, 211, "Frequency"], [212, 219, "Drug"], [4, 5, "Method"], [165, 166, "Method"]], "rel": [[11, 16, "Treatment", 22, 25, "Disease", "Treatment_Disease"], [28, 44, "Pathogenesis", 22, 25, "Disease", "Pathogenesis_Disease"], [59, 65, "Pathogenesis", 22, 25, "Disease", "Pathogenesis_Disease"], [76, 80, "Pathogenesis", 22, 25, "Disease", "Pathogenesis_Disease"], [51, 53, "Drug", 22, 25, "Disease", "Drug_Disease"], [117, 120, "Frequency", 123, 125, "Drug", "Frequency_Drug"], [127, 132, "Frequency", 133, 137, "Drug", "Frequency_Drug"], [196, 197, "Method", 193, 195, "Drug", "Method_Drug"], [208, 211, "Frequency", 212, 219, "Drug", "Frequency_Drug"]]}
{"idx": 1635, "sentence": "为了更好地指导临床医生合理规范使用预混胰岛素，中华医学会内分泌学分会(Chinese Society of Endocrinology，CSE)于2013年发表了《预混胰岛素临床应用共识》，考虑到三年来有一些临床研究证据的更新，故基于原共识进行重新修订。", "ner": [[17, 21, "Drug"], [82, 86, "Drug"]], "rel": []}
{"idx": 1636, "sentence": "1 预混胰岛素分类", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 1637, "sentence": "预混胰岛素主要包括预混人胰岛素和预混胰素类似物(见表1)。", "ner": [[0, 4, "Drug"], [9, 14, "Drug"], [16, 22, "Drug"]], "rel": []}
{"idx": 1638, "sentence": "1.1 预混人胰岛素预混人胰岛素是指将重组人胰岛素(短效)与精蛋白锌重组人胰岛素(中效)按一定比例混合而成的胰岛素制剂，包括低预混人胰岛素和中预混人胰岛素。", "ner": [[4, 9, "Drug"], [10, 15, "Drug"], [19, 28, "Drug"], [30, 43, "Drug"], [54, 58, "Drug"], [63, 68, "Drug"], [71, 76, "Drug"]], "rel": []}
{"idx": 1639, "sentence": "低预混人胰岛素主要为70/30剂型(30%短效+70%中效)，如优泌林70/30、诺和灵30R、甘舒霖30R、重和林M30等。", "ner": [[32, 34, "Drug"], [41, 43, "Drug"], [48, 50, "Drug"], [55, 57, "Drug"], [1, 6, "Drug"]], "rel": []}
{"idx": 1640, "sentence": "中预混人胰岛素主要为50/50剂型(50%短效+50%中效)，如诺和灵50R、甘舒霖50R等。", "ner": [[1, 6, "Drug"], [32, 34, "Drug"], [39, 41, "Drug"]], "rel": []}
{"idx": 1641, "sentence": "1.2 预混胰岛素类似物预混胰岛素类似物是指将速效胰岛素类似物(赖脯胰岛素或门冬胰岛素)与精蛋白锌速效胰岛素类似物按一定比例混合而成的胰岛素制剂，包括低预混胰岛素类似物和中预混胰岛素类似物。", "ner": [[4, 11, "Drug"], [12, 19, "Drug"], [23, 30, "Drug"], [32, 36, "Drug"], [38, 42, "Drug"], [45, 56, "Drug"], [67, 71, "Drug"], [76, 83, "Drug"], [86, 93, "Drug"]], "rel": []}
{"idx": 1642, "sentence": "国内低预混胰岛素类似物主要为75/25剂型，如赖脯胰岛素25(25%赖脯胰岛素+75%精蛋白锌赖脯胰岛素)和70/30剂型，如门冬胰岛素30(30%门冬胰岛素+70%精蛋白锌门冬胰岛素)。", "ner": [[3, 10, "Drug"], [23, 27, "Drug"], [34, 38, "Drug"], [43, 51, "Drug"], [63, 67, "Drug"], [74, 78, "Drug"], [83, 91, "Drug"]], "rel": []}
{"idx": 1643, "sentence": "中预混胰岛素类似物主要为50/50剂型，如赖脯胰岛素50(50%赖脯胰岛素+50%精蛋白锌赖脯胰岛素)和门冬胰岛素50(50%门冬胰岛素+50%精蛋白锌门冬胰岛素)。", "ner": [[1, 8, "Drug"], [21, 25, "Drug"], [32, 36, "Drug"], [41, 49, "Drug"], [52, 56, "Drug"], [63, 67, "Drug"], [72, 80, "Drug"]], "rel": []}
{"idx": 1644, "sentence": "2 预混胰岛素治疗方案", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 1645, "sentence": "2.1 每日1次方案", "ner": [[4, 7, "Frequency"]], "rel": []}
{"idx": 1646, "sentence": "2.1.1 适用人群生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后HbA1c≥7.0%的患者。", "ner": [[10, 15, "Treatment"], [24, 25, "Method"], [38, 42, "Test_items"], [43, 47, "Test_Value"]], "rel": []}
{"idx": 1647, "sentence": "2.1.2 预混胰岛素选择低预混人胰岛素、低预混胰素类似物、中预混人胰岛素、中预混胰岛素类似物。", "ner": [[6, 10, "Drug"], [14, 19, "Drug"], [22, 28, "Drug"], [31, 36, "Drug"], [39, 46, "Drug"]], "rel": []}
{"idx": 1648, "sentence": "2.1.3 起始剂量每日1次起始剂量一般为0.2IU/(kg·d)，", "ner": [[10, 13, "Frequency"], [21, 32, "Amount"]], "rel": []}
{"idx": 1649, "sentence": "晚餐前注射，根据患者情况作适当调整。", "ner": [[0, 4, "Method"]], "rel": []}
{"idx": 1650, "sentence": "2.1.4 注意事项", "ner": [], "rel": []}
{"idx": 1651, "sentence": "(1)如果HbA1c或空腹血糖仍不达标，则可改为每日2次治疗方案，可参考1-2-3次方案；", "ner": [[5, 9, "Test_items"], [11, 14, "Test_items"], [16, 18, "Test_Value"], [24, 27, "Frequency"]], "rel": []}
{"idx": 1652, "sentence": "(2)预混人胰岛素应在餐前30min皮下注射，预混胰岛素类似物可在餐前即刻注射或餐后立即注射；", "ner": [[3, 8, "Drug"], [11, 21, "Method"], [23, 30, "Drug"], [33, 38, "Method"], [40, 45, "Method"]], "rel": [[11, 21, "Method", 3, 8, "Drug", "Method_Drug"], [33, 38, "Method", 23, 30, "Drug", "Method_Drug"], [40, 45, "Method", 23, 30, "Drug", "Method_Drug"]]}
{"idx": 1653, "sentence": "(3)在预混胰岛素选择方面，临床医生应注意根据患者具体情况决定，中预混胰岛素主要针对餐后血糖升高明显的患者；", "ner": [[4, 8, "Drug"], [33, 37, "Drug"], [42, 45, "Test_items"], [46, 47, "Test_Value"]], "rel": []}
{"idx": 1654, "sentence": "(4)可根据患者具体情况调整口服降糖药。", "ner": [[14, 15, "Method"]], "rel": []}
{"idx": 1655, "sentence": "2.2 每日2次方案", "ner": [[4, 7, "Frequency"]], "rel": []}
{"idx": 1656, "sentence": "2.2.1 适用人群", "ner": [], "rel": []}
{"idx": 1657, "sentence": "(1)新诊断T2DM患者，HbA1c≥9.0%同时合并明显临床症状；", "ner": [[6, 9, "Disease"], [13, 17, "Test_items"], [18, 22, "Test_Value"]], "rel": [[13, 17, "Test_items", 6, 9, "Disease", "Test_items_Disease"]]}
{"idx": 1658, "sentence": "(2)生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后HbA1c≥9.0%的患者；", "ner": [[3, 8, "Treatment"], [17, 18, "Method"], [31, 35, "Test_items"], [36, 40, "Test_Value"]], "rel": []}
{"idx": 1659, "sentence": "(3)口服降糖药物联合基础胰岛素治疗以后，HbA1c≥7%，而空腹血糖已达标的患者。", "ner": [[3, 4, "Method"], [13, 15, "Drug"], [21, 25, "Test_items"], [26, 28, "Test_Value"], [31, 34, "Test_items"], [36, 37, "Test_Value"]], "rel": []}
{"idx": 1660, "sentence": "2.2.2 预混胰岛素选择低预混人胰岛素、低预混胰岛素类似物、中预混人胰岛素、中预混胰岛素类似物。", "ner": [[6, 10, "Drug"], [14, 19, "Drug"], [22, 29, "Drug"], [32, 37, "Drug"], [40, 47, "Drug"]], "rel": []}
{"idx": 1661, "sentence": "2.2.3 起始剂量对于(1)、(2)情况，一般为0.2~0.4IU/(kg·d)或10~12IU/d，按1：1分配到早餐前和晚餐前；对于(3)情况，一般以基础胰岛素与预混胰岛素以1：1.3的比例进行剂量转换，按1：1分配到早餐前和晚餐前。", "ner": [[25, 40, "Amount"], [42, 50, "Amount"], [80, 82, "Drug"], [84, 88, "Drug"]], "rel": []}
{"idx": 1662, "sentence": "临床医生一定要根据患者具体情况决定预混胰岛素类别、日总剂量和早晚餐前剂量的分配比例。", "ner": [[17, 21, "Drug"]], "rel": []}
{"idx": 1663, "sentence": "2.2.4 注意事项", "ner": [], "rel": []}
{"idx": 1664, "sentence": "(1)采用预混胰岛素每日2次治疗方案时，不建议同时使用胰岛素促泌剂(主要不良反应与胰岛素一致，为低血糖和体重增加)；", "ner": [[5, 9, "Drug"], [10, 13, "Frequency"], [27, 32, "Drug"], [41, 43, "Drug"], [48, 50, "ADE"], [52, 55, "ADE"]], "rel": [[10, 13, "Frequency", 5, 9, "Drug", "Frequency_Drug"], [48, 50, "ADE", 27, 32, "Drug", "ADE_Drug"], [52, 55, "ADE", 27, 32, "Drug", "ADE_Drug"], [48, 50, "ADE", 41, 43, "Drug", "ADE_Drug"], [52, 55, "ADE", 41, 43, "Drug", "ADE_Drug"]]}
{"idx": 1665, "sentence": "(2)可继续使用二甲双胍或α-糖苷酶抑制剂，视患者个体情况决定是否停用TZD类药物；", "ner": [[8, 11, "Drug"], [13, 20, "Drug"], [35, 40, "Drug"]], "rel": []}
{"idx": 1666, "sentence": "(3)按时、定量进餐及规律运动，预混人胰岛素应在早、晚餐前30min皮下注射，预混胰岛素类似物", "ner": [[3, 9, "Treatment"], [11, 14, "Treatment"], [16, 21, "Drug"], [24, 37, "Method"], [39, 46, "Drug"]], "rel": [[24, 37, "Method", 16, 21, "Drug", "Method_Drug"]]}
{"idx": 1667, "sentence": "可在餐前即刻注射或餐后立即注射；", "ner": [[2, 7, "Method"], [9, 14, "Method"]], "rel": []}
{"idx": 1668, "sentence": "(4)中预混胰岛素主要针对餐后血糖升高明显或者血糖波动较大的患者(如口服降糖药失效后，早餐后血糖≥13.5mmol/L或早餐前后血糖波动≥4.4mmol/L)，以及饮食中碳水化合物比例较高的患者；", "ner": [[4, 8, "Drug"], [13, 16, "Test_items"], [17, 18, "Test_Value"], [23, 24, "Test_items"], [25, 28, "Test_Value"], [34, 35, "Method"], [43, 47, "Test_items"], [48, 58, "Test_Value"], [66, 77, "Test_Value"], [60, 65, "Test_items"]], "rel": []}
{"idx": 1669, "sentence": "(5)若低预混人胰岛素每日2次治疗的患者餐后血糖≥11.1mmol/L，临床医生可依据具体情况考虑等剂量改为低预混胰岛素类似物或中预混胰岛素类似物。", "ner": [[5, 10, "Drug"], [11, 14, "Frequency"], [20, 23, "Test_items"], [24, 34, "Test_Value"], [55, 62, "Drug"], [65, 72, "Drug"]], "rel": [[11, 14, "Frequency", 5, 10, "Drug", "Frequency_Drug"]]}
{"idx": 1670, "sentence": "2.3 每日3次方案", "ner": [[4, 7, "Frequency"]], "rel": []}
{"idx": 1671, "sentence": "2.3.1 适用人群 ", "ner": [], "rel": []}
{"idx": 1672, "sentence": "(1)预混胰岛素每日2次治疗后HbA1c≥7.0%的患者；", "ner": [[3, 7, "Drug"], [8, 11, "Frequency"], [15, 19, "Test_items"], [20, 24, "Test_Value"]], "rel": [[8, 11, "Frequency", 3, 7, "Drug", "Frequency_Drug"]]}
{"idx": 1673, "sentence": "(2)?血糖控制不达标，需要基础+餐时胰岛素强化治疗，但不愿意接受该治疗方案的患者。", "ner": [[4, 5, "Test_items"], [6, 10, "Test_Value"], [19, 21, "Drug"]], "rel": []}
{"idx": 1674, "sentence": "2.3.2 预混胰岛素选择低预混胰岛素类似物、中预混胰岛素类似物。", "ner": [[6, 10, "Drug"], [14, 21, "Drug"], [24, 31, "Drug"]], "rel": []}
{"idx": 1675, "sentence": "2.3.3 起始剂量对于(1)情况，早晚餐前等剂量转换，午餐前加2~4IU或每天胰岛素总量的10%，并可能需要减少早餐前的剂量2~4IU；对于(2)情况，临床医生根据具体情况决定。", "ner": [[32, 36, "Amount"], [63, 67, "Amount"], [40, 42, "Drug"]], "rel": [[32, 36, "Amount", 40, 42, "Drug", "Amount_Drug"], [63, 67, "Amount", 40, 42, "Drug", "Amount_Drug"]]}
{"idx": 1676, "sentence": "2.3.4 注意事项", "ner": [], "rel": []}
{"idx": 1677, "sentence": "(1)如果预混胰岛素从每日2次增加至每日3次时，建议将预混人胰岛素改为预混胰岛素类似物；", "ner": [[5, 9, "Drug"], [11, 14, "Frequency"], [18, 21, "Frequency"], [27, 32, "Drug"], [35, 42, "Drug"]], "rel": [[11, 14, "Frequency", 5, 9, "Drug", "Frequency_Drug"], [18, 21, "Frequency", 5, 9, "Drug", "Frequency_Drug"]]}
{"idx": 1678, "sentence": "(2)若低预混胰岛素每日2次治疗，HbA1c≥7.0%，早餐后血糖<10.0mmol/L，可考虑调整为低预混胰岛素类似物每日3次；若早餐后血糖≥10.0mmol/L的患者，则可考虑调整为中预混胰岛素类似物3次治疗；", "ner": [[5, 9, "Drug"], [10, 13, "Frequency"], [17, 21, "Test_items"], [22, 26, "Test_Value"], [28, 32, "Test_items"], [33, 43, "Test_Value"], [52, 59, "Drug"], [60, 63, "Frequency"], [66, 70, "Test_items"], [71, 81, "Test_Value"], [94, 101, "Drug"]], "rel": [[10, 13, "Frequency", 5, 9, "Drug", "Frequency_Drug"], [60, 63, "Frequency", 52, 59, "Drug", "Frequency_Drug"]]}
{"idx": 1679, "sentence": "(3)预混胰岛素类似物可在餐前即刻注射或餐后立即注射；", "ner": [[3, 10, "Drug"], [13, 18, "Method"], [20, 25, "Method"]], "rel": [[13, 18, "Method", 3, 10, "Drug", "Method_Drug"], [20, 25, "Method", 3, 10, "Drug", "Method_Drug"]]}
{"idx": 1680, "sentence": "(4)对于中预混胰岛素类似物每日3次治疗患者，如果餐后血糖控制好而空腹血糖>6mmol/L时，可考虑将晚餐前调整为低预混胰岛素类似物。", "ner": [[6, 13, "Drug"], [58, 65, "Drug"], [14, 17, "Frequency"], [25, 28, "Test_items"], [29, 31, "Test_Value"], [33, 36, "Test_items"], [37, 44, "Test_Value"]], "rel": [[14, 17, "Frequency", 6, 13, "Drug", "Frequency_Drug"]]}
{"idx": 1681, "sentence": "2.4.1 适用人群生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后HbA1c≥7.0%的患者。", "ner": [[10, 15, "Treatment"], [24, 25, "Method"], [38, 42, "Test_items"], [43, 47, "Test_Value"]], "rel": []}
{"idx": 1682, "sentence": "2.4.2 预混胰岛素选择低预混胰岛素类似物、中预混胰岛素类似物。", "ner": [[6, 10, "Drug"], [14, 21, "Drug"], [24, 31, "Drug"]], "rel": []}
{"idx": 1683, "sentence": "2.4.3 起始剂量预混胰岛素类似物每日1次起始剂量一般为10~12IU，晚餐前注射，根据早餐前血糖调整剂量；如果治疗后HbA1c或餐前血糖不达标，则早餐前加用预混胰岛素类似物3~6IU，根据晚餐前和空腹血糖调整早餐前和晚餐前剂量；如果治疗后HbA1c或午餐后血糖不达标，则午餐前加用预混胰岛素类似物3IU或将早餐前剂量按1：1分配到早、午餐前，根据午餐后或晚餐前血糖调整午餐前剂量。", "ner": [[10, 17, "Drug"], [80, 87, "Drug"], [142, 149, "Drug"], [18, 21, "Frequency"], [29, 35, "Amount"], [37, 41, "Method"], [45, 49, "Test_items"], [60, 64, "Test_items"], [66, 69, "Test_items"], [70, 72, "Test_Value"], [88, 92, "Amount"], [96, 103, "Test_items"], [121, 125, "Test_items"], [127, 131, "Test_items"], [132, 134, "Test_Value"], [150, 152, "Amount"], [175, 183, "Test_items"]], "rel": [[18, 21, "Frequency", 10, 17, "Drug", "Frequency_Drug"], [29, 35, "Amount", 10, 17, "Drug", "Amount_Drug"], [37, 41, "Method", 10, 17, "Drug", "Method_Drug"], [88, 92, "Amount", 80, 87, "Drug", "Amount_Drug"], [150, 152, "Amount", 142, 149, "Drug", "Amount_Drug"]]}
{"idx": 1684, "sentence": "2.4.4 注意事项", "ner": [], "rel": []}
{"idx": 1685, "sentence": "(1)一般在口服降糖药治疗的基础上加用预混胰岛素类似物每日1次治疗，临床医生也可根据患者具体情况调整口服降糖药；", "ner": [[6, 7, "Method"], [19, 26, "Drug"], [27, 30, "Frequency"], [50, 51, "Method"]], "rel": [[27, 30, "Frequency", 19, 26, "Drug", "Frequency_Drug"]]}
{"idx": 1686, "sentence": "(2)当调整为预混胰岛素类似物每日2次或每日3次治疗时，不建议同时使用胰岛素促泌剂(主要不良反应与胰岛素一致，为低血糖和体重增加)；", "ner": [[7, 14, "Drug"], [15, 18, "Frequency"], [20, 23, "Frequency"], [35, 40, "Drug"], [49, 51, "Drug"], [56, 58, "ADE"], [60, 63, "ADE"]], "rel": [[15, 18, "Frequency", 7, 14, "Drug", "Frequency_Drug"], [20, 23, "Frequency", 7, 14, "Drug", "Frequency_Drug"], [56, 58, "ADE", 35, 40, "Drug", "ADE_Drug"], [60, 63, "ADE", 35, 40, "Drug", "ADE_Drug"], [56, 58, "ADE", 49, 51, "Drug", "ADE_Drug"], [60, 63, "ADE", 49, 51, "Drug", "ADE_Drug"]]}
{"idx": 1687, "sentence": "(3)可继续使用二甲双胍或α-糖苷酶抑制剂，视患者个体情况决定是否停用TZD类药物；", "ner": [[8, 11, "Drug"], [13, 20, "Drug"], [35, 40, "Drug"]], "rel": []}
{"idx": 1688, "sentence": "(4)中预混胰岛素类似物主要针对餐后血糖升高明显的患者；", "ner": [[4, 11, "Drug"], [16, 19, "Test_items"], [20, 21, "Test_Value"]], "rel": []}
{"idx": 1689, "sentence": "(5)预混胰岛素类似物应在餐前即刻注射或餐后立即注射。", "ner": [[3, 10, "Drug"], [13, 18, "Method"], [20, 25, "Method"]], "rel": [[13, 18, "Method", 3, 10, "Drug", "Method_Drug"], [20, 25, "Method", 3, 10, "Drug", "Method_Drug"]]}
{"idx": 1690, "sentence": "3 自我血糖监测", "ner": [[2, 7, "Test_items"]], "rel": []}
{"idx": 1691, "sentence": "自我血糖监测(self-monitoring of blood glucose，SMBG)是糖尿病管理中的重要组成部分，其结果有助于评估降糖治疗的效果并指导治疗方案的调整。", "ner": [[46, 48, "Disease"], [0, 44, "Test_items"]], "rel": [[0, 44, "Test_items", 46, 48, "Disease", "Test_items_Disease"]]}
{"idx": 1692, "sentence": "可根据不同的胰岛素治疗方案制定个体化的SMBG方案。", "ner": [[6, 8, "Drug"], [19, 22, "Test_items"]], "rel": []}
{"idx": 1693, "sentence": "3.1 每日1次预混胰岛素类似物治疗的SMBG方案每日1次预混胰岛素类似物治疗的患者在血糖达标前每周监测3天空腹、晚餐后和睡前血糖，每2周复诊1次，复诊前1天加测3个时间点血糖；在血糖达标后每周监测3次血糖，即空腹、晚餐后和睡前血糖，每月复诊1次，复诊前1天加测3个时间点血糖(见表2)。", "ner": [[4, 7, "Frequency"], [8, 15, "Drug"], [19, 22, "Test_items"], [25, 28, "Frequency"], [29, 36, "Drug"], [43, 44, "Test_items"], [45, 46, "Test_Value"], [54, 64, "Test_items"], [86, 87, "Test_items"], [90, 91, "Test_items"], [92, 93, "Test_Value"], [101, 102, "Test_items"], [105, 115, "Test_items"], [136, 137, "Test_items"]], "rel": [[4, 7, "Frequency", 8, 15, "Drug", "Frequency_Drug"], [25, 28, "Frequency", 29, 36, "Drug", "Frequency_Drug"]]}
{"idx": 1694, "sentence": "3.2 每日2次预混胰岛素(包括预混人胰岛素和预混胰岛素类似物)治疗的SMBG方案每日2次预混胰岛素治疗的患者在血糖达标前每周监测3天空腹和晚餐前血糖，每2周复诊1次，复诊前1天加测5个时间点血糖；在血糖达标后每周监测3次血糖，即空腹、晚餐前和晚餐后血糖，每月复诊1次，复诊前1天加测5个时间点血糖(见表3)。", "ner": [[4, 7, "Frequency"], [8, 12, "Drug"], [16, 21, "Drug"], [23, 30, "Drug"], [35, 38, "Test_items"], [41, 44, "Frequency"], [45, 49, "Drug"], [56, 57, "Test_items"], [58, 59, "Test_Value"], [67, 74, "Test_items"], [96, 97, "Test_items"], [100, 101, "Test_items"], [102, 103, "Test_Value"], [111, 112, "Test_items"], [115, 126, "Test_items"], [147, 148, "Test_items"]], "rel": [[4, 7, "Frequency", 8, 12, "Drug", "Frequency_Drug"], [41, 44, "Frequency", 45, 49, "Drug", "Frequency_Drug"]]}
{"idx": 1695, "sentence": "3.3 每日3次预混胰岛素类似物治疗的SMBG方案每日3次预混胰岛素类似物治疗的开始阶段应每天监5~7个时间点血糖，包括空腹、三餐前后、睡前，血糖达标后每日监测2~4个时间点血糖(见表4)。3.4 注意事项在胰岛素治疗期间，如有低血糖表现时需随时监测血糖；如出现不可解释的空腹高血糖或夜间低血糖时，应监测夜间血糖(如3am血糖)。", "ner": [[4, 7, "Frequency"], [8, 15, "Drug"], [19, 22, "Test_items"], [25, 28, "Frequency"], [29, 36, "Drug"], [55, 56, "Test_items"], [71, 72, "Test_items"], [73, 74, "Test_Value"], [87, 88, "Test_items"], [104, 106, "Drug"], [114, 116, "ADE"], [123, 126, "Test_items"], [138, 140, "ADE"], [144, 146, "ADE"], [150, 155, "Test_items"], [158, 162, "Test_items"]], "rel": [[4, 7, "Frequency", 8, 15, "Drug", "Frequency_Drug"], [25, 28, "Frequency", 29, 36, "Drug", "Frequency_Drug"], [114, 116, "ADE", 104, 106, "Drug", "ADE_Drug"], [138, 140, "ADE", 104, 106, "Drug", "ADE_Drug"], [144, 146, "ADE", 104, 106, "Drug", "ADE_Drug"]]}
{"idx": 1696, "sentence": "4 预混胰岛素剂量调整方法", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 1697, "sentence": "临床医生应根据患者具体情况设定血糖控制目标。", "ner": [[15, 16, "Test_items"]], "rel": []}
{"idx": 1698, "sentence": "在胰岛素治疗期间，结合血糖监测结果，适时调整治疗方案和胰岛素剂量，以取得良好的血糖控制。对于不同的预混胰岛素治疗方案，其剂量调整方法有所不同，可参考每日2次预混胰岛素治疗方案(见表5)和1-2-3次预混胰岛素类似物治疗方案的剂量调整方法(见表6)，每3~5天调整1次，每次调整1~4IU，直至血糖达标。", "ner": [[1, 3, "Drug"], [11, 14, "Test_items"], [27, 29, "Drug"], [39, 40, "Test_items"], [49, 53, "Drug"], [74, 77, "Frequency"], [78, 82, "Drug"], [99, 106, "Drug"], [138, 142, "Amount"], [146, 147, "Test_items"], [148, 149, "Test_Value"]], "rel": [[74, 77, "Frequency", 78, 82, "Drug", "Frequency_Drug"], [138, 142, "Amount", 78, 82, "Drug", "Amount_Drug"], [138, 142, "Amount", 99, 106, "Drug", "Amount_Drug"]]}
{"idx": 1699, "sentence": "5 需要注意的情况", "ner": [], "rel": []}
{"idx": 1700, "sentence": "T2DM患者的血糖控制目标因患者的年龄、合并症、并发症等不同而异，临床医生应注意结合患者病情、经济等各方面的因素综合考虑，选择适合患者的治疗方案。对已合并心脑血管疾病或其他危险因素的T2DM患者，在胰岛素治疗治疗时，应当采取稳妥、安全的降糖治疗措施和目标值，尽量避免低血糖的发生。", "ner": [[0, 3, "Disease"], [7, 8, "Test_items"], [77, 82, "Disease"], [77, 80, "Anatomy"], [91, 94, "Disease"], [99, 101, "Drug"], [133, 135, "ADE"]], "rel": [[77, 80, "Anatomy", 77, 82, "Disease", "Anatomy_Disease"], [133, 135, "ADE", 99, 101, "Drug", "ADE_Drug"]]}
{"idx": 1701, "sentence": "6 小结", "ner": [], "rel": []}
{"idx": 1702, "sentence": "预混胰岛素能同时提供基础及餐时胰岛素，方案简便、易操作，在中国糖尿病患者中应用广泛。临床医生要根据患者的具体情况综合考虑，包括生活方式、方案的简便程度，长期依从性，血糖监测及低血糖发生等多种因素，制定个体化的胰岛素治疗方案。", "ner": [[0, 4, "Drug"], [31, 33, "Disease"], [82, 85, "Test_items"], [87, 89, "ADE"], [104, 106, "Drug"], [15, 17, "Drug"]], "rel": [[0, 4, "Drug", 31, 33, "Disease", "Drug_Disease"], [82, 85, "Test_items", 31, 33, "Disease", "Test_items_Disease"], [15, 17, "Drug", 31, 33, "Disease", "Drug_Disease"], [87, 89, "ADE", 104, 106, "Drug", "ADE_Drug"]]}
{"idx": 1703, "sentence": "预混胰岛素基本治疗路线(见图1)的制定借鉴了国内外诸多临床研究的经验，为实际应用提供指导和帮助。", "ner": [[0, 4, "Drug"]], "rel": []}
{"idx": 1704, "sentence": "2.4 1-2-3次方案1-2-3次方案是指，对于采用生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗血糖仍不达标(HbA1c≥7.0%)的患者，起始每日1次预混胰岛素类似物注射，血糖控制仍不达标时，可逐渐增加到每日2次、每日3次的方案。", "ner": [[27, 32, "Treatment"], [41, 42, "Method"], [54, 55, "Test_items"], [56, 59, "Test_Value"], [61, 65, "Test_items"], [66, 70, "Test_Value"], [78, 81, "Frequency"], [82, 89, "Drug"], [90, 91, "Method"], [93, 94, "Test_items"], [95, 100, "Test_Value"], [109, 112, "Frequency"], [114, 117, "Frequency"]], "rel": [[78, 81, "Frequency", 82, 89, "Drug", "Frequency_Drug"], [109, 112, "Frequency", 82, 89, "Drug", "Frequency_Drug"], [114, 117, "Frequency", 82, 89, "Drug", "Frequency_Drug"], [90, 91, "Method", 82, 89, "Drug", "Method_Drug"]]}
{"idx": 1705, "sentence": "中国2型糖尿病患者餐后高血糖管理专家共识", "ner": [[2, 6, "Disease"], [11, 13, "Disease"]], "rel": []}
{"idx": 1706, "sentence": "一、餐后高血糖的定义和病理生理基础", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 1707, "sentence": "二、餐后高血糖的临床意义", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 1708, "sentence": "流行病学研究显示，餐后或负荷后高血糖与多种疾病相关，但目前尚无十分充足的临床证据支持在糖尿病患者中特异性的干预餐后高血糖比干预整体血糖有更多的临床收益。", "ner": [[43, 45, "Disease"], [65, 66, "Test_items"], [15, 17, "Disease"], [57, 59, "Disease"]], "rel": [[65, 66, "Test_items", 43, 45, "Disease", "Test_items_Disease"], [65, 66, "Test_items", 57, 59, "Disease", "Test_items_Disease"]]}
{"idx": 1709, "sentence": "1.餐后高血糖与糖尿病微血管并发症发生的风险增高相关：餐后高血糖比HbA1c能更好地预测DR的发生发展。", "ner": [[8, 16, "Disease"], [33, 37, "Test_items"], [44, 45, "Disease"], [4, 6, "Disease"], [29, 31, "Disease"], [11, 13, "Anatomy"]], "rel": [[11, 13, "Anatomy", 8, 16, "Disease", "Anatomy_Disease"], [33, 37, "Test_items", 44, 45, "Disease", "Test_items_Disease"]]}
{"idx": 1710, "sentence": "可能的机制是快速升高的PPG造成血糖波动，导致视网膜血管内皮功能下降、血管反应性增加。", "ner": [[11, 13, "Test_items"], [16, 17, "Test_items"], [18, 19, "Test_Value"]], "rel": []}
{"idx": 1711, "sentence": "2.餐后高血糖与糖尿病大血管并发症发生的风险增高相关：流行病学研究显示，餐后或糖负荷后血糖与心血管风险及其结局相关。PPG预测心血管事件的作用优于FPG。多项流行病学观察性研究发现，2 hPG是全因死亡和心血管死亡的独立危险因素，也是心血管疾病和全因死亡的预测因素。餐后高血糖与心血管疾病风险增加相关的机制可能与血糖波动有关。急性血糖升高会快速抑制内皮型一氧化氮(NO)释放及内皮依赖性血管扩张，增加可溶性黏附分子水平，并可能激活血栓形成。", "ner": [[8, 16, "Disease"], [63, 67, "Disease"], [58, 60, "Test_items"], [73, 75, "Test_items"], [91, 95, "Test_items"], [102, 106, "Disease"], [97, 100, "Disease"], [102, 104, "Anatomy"], [63, 65, "Anatomy"], [117, 121, "Disease"], [123, 126, "Disease"], [117, 119, "Anatomy"], [139, 143, "Disease"], [139, 141, "Anatomy"], [156, 157, "Test_items"], [158, 159, "Test_Value"], [165, 166, "Test_items"], [167, 168, "Test_Value"], [215, 216, "Disease"], [4, 6, "Disease"], [39, 44, "Test_items"], [135, 137, "Disease"], [12, 13, "Anatomy"]], "rel": [[12, 13, "Anatomy", 8, 16, "Disease", "Anatomy_Disease"], [58, 60, "Test_items", 63, 67, "Disease", "Test_items_Disease"], [73, 75, "Test_items", 63, 67, "Disease", "Test_items_Disease"], [63, 65, "Anatomy", 63, 67, "Disease", "Anatomy_Disease"], [91, 95, "Test_items", 102, 106, "Disease", "Test_items_Disease"], [91, 95, "Test_items", 97, 100, "Disease", "Test_items_Disease"], [102, 104, "Anatomy", 102, 106, "Disease", "Anatomy_Disease"], [117, 119, "Anatomy", 117, 121, "Disease", "Anatomy_Disease"], [139, 141, "Anatomy", 139, 143, "Disease", "Anatomy_Disease"], [156, 157, "Test_items", 139, 143, "Disease", "Test_items_Disease"], [156, 157, "Test_items", 135, 137, "Disease", "Test_items_Disease"], [165, 166, "Test_items", 215, 216, "Disease", "Test_items_Disease"]]}
{"idx": 1712, "sentence": "急性血糖波动比慢性持续性高血糖更显著地促进氧化应激(OS)反应和损害内皮功能。", "ner": [[2, 3, "Test_items"], [4, 5, "Test_Value"], [12, 14, "Disease"]], "rel": []}
{"idx": 1713, "sentence": "如果能降低餐后高血糖，则可改善0S、炎症和内皮细胞功能，有可能降低血栓形成的风险。", "ner": [[33, 34, "Disease"], [7, 9, "Disease"]], "rel": []}
{"idx": 1714, "sentence": "3.餐后高血糖与多项心血管疾病的危险因素相关：餐后高血糖升高渗透压，可增加血小板反应性，激活血小板，与餐后高凝状态相关。餐后高血糖可减少心肌血容量及心肌血流。研究显示，糖尿病患者餐后心肌血容量及心肌血流较正常对照者下降。餐后高血糖及血糖波动与颈动脉内-中膜厚度(CIMT)增加相关。降低餐后高血糖、减少血糖波动有可能延缓或减轻CIMT进展。", "ner": [[10, 14, "Disease"], [10, 12, "Anatomy"], [116, 117, "Test_items"], [118, 119, "Test_Value"], [151, 152, "Test_items"], [153, 154, "Test_Value"], [84, 86, "Disease"], [4, 6, "Disease"], [25, 27, "Disease"], [62, 64, "Disease"], [112, 114, "Disease"], [145, 147, "Disease"], [121, 137, "Reason"]], "rel": [[10, 12, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [116, 117, "Test_items", 112, 114, "Disease", "Test_items_Disease"], [151, 152, "Test_items", 145, 147, "Disease", "Test_items_Disease"], [121, 137, "Reason", 112, 114, "Disease", "Reason_Disease"]]}
{"idx": 1715, "sentence": "4.餐后高血糖对机体的其他不良影响：随着病程进展，胰岛β细胞功能减退及餐后血糖逐渐升高，而增高的餐后高血糖及血糖波动可使胰岛β细胞能进一步恶化。此外，有学者发现，餐后高血糖和PPG波动与老年人整体认知、执行和注意力障碍有关。", "ner": [[25, 33, "Pathogenesis"], [35, 38, "Test_items"], [41, 42, "Test_Value"], [54, 55, "Test_items"], [56, 57, "Test_Value"], [87, 89, "Test_items"], [90, 91, "Test_Value"], [4, 6, "Disease"], [50, 52, "Disease"], [60, 70, "Pathogenesis"], [83, 85, "Disease"], [87, 89, "Test_items"], [90, 91, "Test_Value"]], "rel": [[25, 33, "Pathogenesis", 4, 6, "Disease", "Pathogenesis_Disease"], [35, 38, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [54, 55, "Test_items", 50, 52, "Disease", "Test_items_Disease"], [60, 70, "Pathogenesis", 50, 52, "Disease", "Pathogenesis_Disease"], [87, 89, "Test_items", 83, 85, "Disease", "Test_items_Disease"]]}
{"idx": 1716, "sentence": "5.PPG与HbA1c的关系：HbA1c代表2~3个月的平均血糖水平，由FPG和PPG共同促进形成。", "ner": [[2, 4, "Test_items"], [6, 10, "Test_items"], [15, 19, "Test_items"], [30, 31, "Test_Value"], [36, 38, "Test_items"], [40, 42, "Test_items"]], "rel": []}
{"idx": 1717, "sentence": "横断面流行病学研究显示，HbA1c越接近正常值，PPG对其形成的贡献就越大，当HbA1c<7.3%时，PPG的贡献占70%；HbA1c7.3%~9.2%，PPG的贡献约50%；即使HbA1c>9.3%时，PPG的贡献仍占40%。", "ner": [[12, 16, "Test_items"], [24, 26, "Test_items"], [39, 43, "Test_items"], [44, 48, "Test_Value"], [51, 53, "Test_items"], [62, 66, "Test_items"], [77, 79, "Test_items"], [90, 94, "Test_items"], [95, 99, "Test_Value"], [102, 104, "Test_items"], [67, 75, "Test_Value"], [18, 22, "Test_Value"]], "rel": []}
{"idx": 1718, "sentence": "但上述研究结果对临床治疗的指导价值尚需前瞻性临床研究验证。", "ner": [], "rel": []}
{"idx": 1719, "sentence": "(表1)", "ner": [], "rel": []}
{"idx": 1720, "sentence": "三、餐后高血糖的检测", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 1721, "sentence": "1.检测对象：对于以下临床状态的患者，可通过监测PPG评价疗效、低血糖风险和指导药物剂量调整。(1)任何HbA1c不达标的T2DM患者，尤其是FPG达标，而HbA1c不达标，如FPG<6.0mmol/L，但HbA1c>7.0%；(2)低血糖风险较高的患者，如使用促泌剂或胰岛素治疗、进餐不规律或餐后剧烈运动者；(3)使用降糖药物，尤其是降低PPG的药物时。", "ner": [[32, 34, "Disease"], [52, 56, "Test_items"], [61, 64, "Disease"], [71, 73, "Test_items"], [78, 82, "Test_items"], [88, 90, "Test_items"], [91, 100, "Test_Value"], [103, 107, "Test_items"], [108, 112, "Test_Value"], [117, 119, "Disease"], [131, 133, "Drug"], [135, 137, "Drug"], [170, 172, "Test_items"], [22, 26, "Test_items"], [83, 85, "Test_Value"], [74, 75, "Test_Value"], [57, 59, "Test_Value"]], "rel": [[22, 26, "Test_items", 32, 34, "Disease", "Test_items_Disease"], [71, 73, "Test_items", 61, 64, "Disease", "Test_items_Disease"], [78, 82, "Test_items", 61, 64, "Disease", "Test_items_Disease"]]}
{"idx": 1722, "sentence": "2.检测方法：需要监测PPG的糖尿病患者除3~6个月检测1次HbA1c外，还应通过自我血糖监测(SMBG)监测PPG。", "ner": [[15, 17, "Disease"], [30, 34, "Test_items"], [41, 52, "Test_items"], [53, 57, "Test_items"], [9, 13, "Test_items"]], "rel": [[9, 13, "Test_items", 15, 17, "Disease", "Test_items_Disease"], [30, 34, "Test_items", 15, 17, "Disease", "Test_items_Disease"], [41, 52, "Test_items", 15, 17, "Disease", "Test_items_Disease"], [53, 57, "Test_items", 15, 17, "Disease", "Test_items_Disease"]]}
{"idx": 1723, "sentence": "对于采用胰岛素强化治疗、血糖波动较大及低血糖风险较高者，可通过动态血糖监测(CGM)更好地指导治疗方案的调整。", "ner": [[4, 6, "Drug"], [12, 13, "Test_items"], [14, 15, "Test_Value"], [19, 21, "ADE"], [31, 41, "Test_items"]], "rel": []}
{"idx": 1724, "sentence": "1，5-脱水葡萄糖醇(1，5-AG)也是反映短期餐后高血及血糖波动的指标，但其与并发症的关系有待进一步探讨。", "ner": [[0, 17, "Test_items"], [29, 30, "Test_items"], [31, 32, "Test_Value"]], "rel": []}
{"idx": 1725, "sentence": "3.PPG与血糖波动：血糖波动包括日间血糖波动和日内血糖波动，需要连续监测血糖来计算波动的大小。PPG升高和低血糖构成日内血糖波动，但餐后高血糖是日内血糖波动的主要原因。进餐引起的血糖波动与饮食习惯密切相关，如饮食量、食物种类[不同升糖指数(GI)的食物]及进食次数等。T2DM患者日内血糖波动高于非糖尿病人群，主原因在于餐后高血糖。", "ner": [[2, 4, "Test_items"], [6, 7, "Test_items"], [8, 9, "Test_Value"], [11, 12, "Test_items"], [13, 14, "Test_Value"], [17, 20, "Test_items"], [21, 22, "Test_Value"], [24, 27, "Test_items"], [28, 29, "Test_Value"], [35, 38, "Test_items"], [42, 43, "Test_Value"], [48, 50, "Test_items"], [51, 52, "Test_Value"], [54, 56, "Disease"], [59, 62, "Test_items"], [63, 64, "Test_Value"], [69, 71, "Disease"], [73, 76, "Test_items"], [77, 78, "Test_Value"], [90, 91, "Test_items"], [92, 93, "Test_Value"], [135, 138, "Disease"], [141, 144, "Test_items"], [145, 146, "Test_Value"], [150, 152, "Disease"], [163, 165, "Disease"]], "rel": [[48, 50, "Test_items", 54, 56, "Disease", "Test_items_Disease"], [59, 62, "Test_items", 54, 56, "Disease", "Test_items_Disease"], [73, 76, "Test_items", 69, 71, "Disease", "Test_items_Disease"], [141, 144, "Test_items", 135, 138, "Disease", "Test_items_Disease"]]}
{"idx": 1726, "sentence": "(表2)", "ner": [], "rel": []}
{"idx": 1727, "sentence": "四、控制餐后高血糖的临床获益", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 1728, "sentence": "1.控制PPG助于HbA1c达标：单纯控制PPG可改善HbA1c。", "ner": [[4, 6, "Test_items"], [9, 13, "Test_items"], [21, 23, "Test_items"], [27, 31, "Test_items"]], "rel": []}
{"idx": 1729, "sentence": "当HbA1c接近7%，而FPG控制达标时，加强PPG的控制可进一步增加其的贡献。", "ner": [[1, 5, "Test_items"], [12, 14, "Test_items"], [23, 25, "Test_items"], [17, 18, "Test_Value"], [6, 9, "Test_Value"]], "rel": []}
{"idx": 1730, "sentence": "临床试验显示，控制FPG达标(<5.6mmol/L的患者可有64%实现HbA1c<7%，而进一步控PPG达标(<7.8mmol/L)的患者则有94%实HbA1c<7%。", "ner": [[9, 11, "Test_items"], [15, 24, "Test_Value"], [35, 39, "Test_items"], [40, 42, "Test_Value"], [49, 51, "Test_items"], [55, 64, "Test_Value"], [75, 79, "Test_items"], [80, 82, "Test_Value"], [12, 13, "Test_Value"], [52, 53, "Test_Value"]], "rel": []}
{"idx": 1731, "sentence": "由此可见，控制PPG有助于进一步提高整体血糖达标率。", "ner": [[7, 9, "Test_items"], [20, 21, "Test_items"]], "rel": []}
{"idx": 1732, "sentence": "2.控制餐后高血糖与心血管获益：针对性的控制餐后高血糖是否会使T2DM患者心血管疾病发生的风险下降尚无临床证据。HEART2D研究比较了胰岛素治疗控制空腹高血糖或餐后高血糖对急性心肌梗死后心血管终点的影响，结果显示，两组HbA1c水平比较，差异无统计学意义；FPG和PPG比较差异有统计学意义，但与降低FPG为主比较，降低餐后高血糖未能进一步降低复合心血管终点事件的风险。对该研究的亚组分析发现，在老年糖尿病患者中，控制餐后高血糖可降低心血管风险。对短期评价血糖控制的临床试验的荟萃分析(MeR-IA-7)结果显示，与安慰剂比较，降低PPG的药物，如阿卡波糖的治疗与心血管事件风险下降相关(心肌梗死的风险降低64%、任何心血管事件的风险降低35%)。", "ner": [[6, 8, "Disease"], [24, 26, "Disease"], [31, 34, "Disease"], [37, 41, "Disease"], [37, 39, "Anatomy"], [68, 70, "Drug"], [75, 79, "Disease"], [83, 85, "Disease"], [89, 92, "Disease"], [89, 90, "Anatomy"], [110, 114, "Test_items"], [129, 131, "Test_items"], [133, 135, "Test_items"], [151, 153, "Test_items"], [163, 165, "Disease"], [173, 181, "Disease"], [175, 177, "Anatomy"], [201, 203, "Disease"], [212, 214, "Disease"], [229, 230, "Test_items"], [267, 269, "Test_items"], [275, 278, "Drug"], [283, 287, "Disease"], [283, 285, "Anatomy"], [295, 298, "Disease"], [295, 296, "Anatomy"], [310, 314, "Disease"], [310, 312, "Anatomy"]], "rel": [[37, 39, "Anatomy", 37, 41, "Disease", "Anatomy_Disease"], [68, 70, "Drug", 83, 85, "Disease", "Drug_Disease"], [68, 70, "Drug", 75, 79, "Disease", "Drug_Disease"], [89, 90, "Anatomy", 89, 92, "Disease", "Anatomy_Disease"], [110, 114, "Test_items", 163, 165, "Disease", "Test_items_Disease"], [129, 131, "Test_items", 163, 165, "Disease", "Test_items_Disease"], [133, 135, "Test_items", 163, 165, "Disease", "Test_items_Disease"], [175, 177, "Anatomy", 173, 181, "Disease", "Anatomy_Disease"], [267, 269, "Test_items", 283, 287, "Disease", "Test_items_Disease"], [275, 278, "Drug", 283, 287, "Disease", "Drug_Disease"], [283, 285, "Anatomy", 283, 287, "Disease", "Anatomy_Disease"], [295, 296, "Anatomy", 295, 298, "Disease", "Anatomy_Disease"], [310, 312, "Anatomy", 310, 314, "Disease", "Anatomy_Disease"]]}
{"idx": 1733, "sentence": "3.降低PPG与改善心血管疾病危险因素相关：控制PPG与改善多种心血管疾病危险因素有关，如TC、TG、LDL-C降低和HDL-C升高；血压、高凝状态及炎症因子均降低；CIMT进展减慢等。", "ner": [[4, 6, "Test_items"], [10, 14, "Disease"], [10, 12, "Anatomy"], [24, 26, "Test_items"], [32, 36, "Disease"], [32, 34, "Anatomy"], [67, 68, "Test"], [75, 78, "Test_items"], [70, 73, "Test_items"], [80, 81, "Test_Value"], [59, 63, "Test_items"], [64, 65, "Test_Value"], [45, 46, "Test_items"], [48, 49, "Test_items"], [51, 55, "Test_items"], [56, 57, "Test_Value"], [59, 63, "Test_items"]], "rel": [[4, 6, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [10, 12, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [24, 26, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [32, 34, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"], [45, 46, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [48, 49, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [51, 55, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [59, 63, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [70, 73, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [75, 78, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [67, 68, "Test", 32, 36, "Disease", "Test_Disease"]]}
{"idx": 1734, "sentence": "五、餐后高血糖的管理", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 1735, "sentence": "1.餐后高血糖的控制目标：控制餐后血糖对HbA1c达标及减少血糖波动非常重要。设定HbA1c目标值应根据患者年龄、病程、预期寿命、并发症严重程度、低血糖发生风险等因素个体化确定，与此相对应的PPG控制目标也应遵循个体化原则。", "ner": [[4, 6, "Disease"], [15, 18, "Test_items"], [20, 24, "Test_items"], [30, 31, "Test_items"], [32, 33, "Test_Value"], [41, 45, "Test_items"], [68, 69, "Level"], [73, 75, "Disease"], [95, 97, "Test_items"], [25, 26, "Test_Value"]], "rel": [[15, 18, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [20, 24, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [30, 31, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [41, 45, "Test_items", 73, 75, "Disease", "Test_items_Disease"], [95, 97, "Test_items", 73, 75, "Disease", "Test_items_Disease"]]}
{"idx": 1736, "sentence": "(表3)", "ner": [], "rel": []}
{"idx": 1737, "sentence": "2.控制PPG的方法", "ner": [[4, 6, "Test_items"]], "rel": []}
{"idx": 1738, "sentence": "(1)生活方式干预：饮食的质和量均影响PPG。高GI饮食可导致PPG升高，且增加血糖曲线下面积(AUC)。分别摄入低GI饮食与高GI饮食可使HbA1c相差0.5%~0.7%。餐后运动可以降低T2DM患者PPG，降低幅度与运动持续时间和频率密切相关，但较少影响FPG。", "ner": [[3, 8, "Treatment"], [19, 21, "Test_items"], [31, 33, "Test_items"], [34, 35, "Test_Value"], [40, 41, "Test_items"], [70, 74, "Test_items"], [75, 85, "Test_Value"], [87, 90, "Treatment"], [95, 98, "Disease"], [101, 103, "Test_items"], [129, 131, "Test_items"]], "rel": [[87, 90, "Treatment", 95, 98, "Disease", "Treatment_Disease"], [101, 103, "Test_items", 95, 98, "Disease", "Test_items_Disease"], [129, 131, "Test_items", 95, 98, "Disease", "Test_items_Disease"]]}
{"idx": 1739, "sentence": "(2)降糖药物：各种降糖药物均能不同程度地降低FPG和PPG，以降低PPG为主的口服降糖药包括α-糖苷酶抑制剂、短效磺脲类促泌剂、格列奈类促泌剂、二肽基肽酶一4(DPP-4)抑制剂；以降低PPG为主的注射制剂包括短效胰岛素及速效胰岛素似物、短效胰升血糖素样肽-1(GLP-1)受体激动剂。", "ner": [[23, 25, "Test_items"], [27, 29, "Test_items"], [34, 36, "Test_items"], [40, 41, "Method"], [47, 54, "Drug"], [56, 63, "Drug"], [65, 71, "Drug"], [73, 89, "Drug"], [94, 96, "Test_items"], [100, 101, "Method"], [106, 110, "Drug"], [113, 118, "Drug"], [120, 142, "Drug"]], "rel": [[40, 41, "Method", 47, 54, "Drug", "Method_Drug"], [40, 41, "Method", 56, 63, "Drug", "Method_Drug"], [40, 41, "Method", 65, 71, "Drug", "Method_Drug"], [40, 41, "Method", 73, 89, "Drug", "Method_Drug"], [100, 101, "Method", 106, 110, "Drug", "Method_Drug"], [100, 101, "Method", 113, 118, "Drug", "Method_Drug"], [100, 101, "Method", 120, 142, "Drug", "Method_Drug"]]}
{"idx": 1740, "sentence": "(表4)", "ner": [], "rel": []}
{"idx": 1741, "sentence": "以降低餐后血糖为主的口服降糖药物，α-糖苷酶抑制剂能延缓碳水化合物在小肠上段的吸收，降低餐后高血糖和减少血糖波动，包括阿卡波糖、伏格列波糖和米格列醇。α-糖苷酶抑制剂可降低HbA1c约0.5%。在中国人群中开展的MARCH研究表明，新诊断T2DM患者使用阿卡波糖300mg/d，HbA1c降幅达1.1%(可能包括部分安慰剂效应)并可减低体重。荟萃分析结果显示，在二甲双胍治疗的基础上采用α-糖苷酶抑制剂，改善体重的效果与GLP-1受体激动剂相当。常见的不良反应为胃肠道反应(腹胀、腹泻、恶心、肠道排气增多等)。小剂量开始、逐渐加量可减少胃肠道不良反应。单独使用一般不发生低血糖，甚至可减少反应性低血糖，总体耐受性良好。与其他降糖药物联合使用时可进一步改善血糖并减少体重增加。与胰岛素促泌剂或胰岛素合用时，如果出现低血糖，应采取口服或静脉注射葡萄糖纠正。", "ner": [[3, 6, "Test_items"], [10, 11, "Method"], [17, 24, "Drug"], [46, 48, "Disease"], [52, 53, "Test_items"], [54, 55, "Test_Value"], [59, 62, "Drug"], [64, 68, "Drug"], [70, 73, "Drug"], [75, 82, "Drug"], [86, 90, "Test_items"], [92, 95, "Test_Value"], [119, 122, "Disease"], [127, 130, "Drug"], [131, 137, "Amount"], [139, 143, "Test_items"], [144, 150, "Test_Value"], [181, 184, "Drug"], [193, 200, "Drug"], [210, 219, "Drug"], [231, 235, "ADE"], [237, 238, "ADE"], [240, 241, "ADE"], [243, 244, "ADE"], [246, 251, "ADE"], [268, 274, "ADE"], [285, 287, "Disease"], [294, 299, "Disease"], [327, 328, "Test_items"], [332, 335, "ADE"], [338, 343, "Drug"], [345, 347, "Drug"], [356, 358, "Disease"], [363, 364, "Method"], [366, 369, "Method"], [370, 372, "Drug"]], "rel": [[3, 6, "Test_items", 46, 48, "Disease", "Test_items_Disease"], [10, 11, "Method", 17, 24, "Drug", "Method_Drug"], [17, 24, "Drug", 46, 48, "Disease", "Drug_Disease"], [52, 53, "Test_items", 46, 48, "Disease", "Test_items_Disease"], [59, 62, "Drug", 46, 48, "Disease", "Drug_Disease"], [64, 68, "Drug", 46, 48, "Disease", "Drug_Disease"], [70, 73, "Drug", 46, 48, "Disease", "Drug_Disease"], [127, 130, "Drug", 119, 122, "Disease", "Drug_Disease"], [139, 143, "Test_items", 119, 122, "Disease", "Test_items_Disease"], [131, 137, "Amount", 127, 130, "Drug", "Amount_Drug"], [338, 343, "Drug", 356, 358, "Disease", "Drug_Disease"], [345, 347, "Drug", 356, 358, "Disease", "Drug_Disease"], [370, 372, "Drug", 356, 358, "Disease", "Drug_Disease"], [363, 364, "Method", 370, 372, "Drug", "Method_Drug"], [366, 369, "Method", 370, 372, "Drug", "Method_Drug"]]}
{"idx": 1742, "sentence": "短效磺脲类促泌剂通过与胰岛β细胞膜上的磺脲类受体结合，促进胰岛素分泌，增加体内胰岛素水平而降低血糖。常用的短效磺脲类药物包括格列吡嗪和格列喹酮，降低HbA1c约1.0%。磺脲类药物可导致低血糖，更易在老年及肝、肾功能不全的患者中发生。磺脲类药物可增加体重。肾功能不全的患者可考虑选用格列喹酮。", "ner": [[0, 7, "Drug"], [47, 48, "Test_items"], [53, 59, "Drug"], [62, 65, "Drug"], [67, 70, "Drug"], [74, 78, "Test_items"], [79, 83, "Test_Value"], [85, 89, "Drug"], [93, 95, "ADE"], [103, 109, "Disease"], [103, 103, "Anatomy"], [105, 105, "Anatomy"], [117, 121, "Drug"], [123, 126, "ADE"], [128, 132, "Disease"], [128, 128, "Anatomy"], [141, 144, "Drug"]], "rel": [[93, 95, "ADE", 85, 89, "Drug", "ADE_Drug"], [103, 103, "Anatomy", 103, 109, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 103, 109, "Disease", "Anatomy_Disease"], [123, 126, "ADE", 117, 121, "Drug", "ADE_Drug"], [128, 128, "Anatomy", 128, 132, "Disease", "Anatomy_Disease"], [141, 144, "Drug", 128, 132, "Disease", "Drug_Disease"]]}
{"idx": 1743, "sentence": "格列奈类药物降糖机制类似磺脲类，但起效更快，改善胰岛素早相分泌更明显，主要降低PPG，括括瑞格列奈、那格列奈和米格列奈，降低HbA1c0.5%~1.0%。瑞格列奈的降糖作用以促进胰岛素第一时相分泌为主。荟萃分析结果显示，在降低HbA1c方面，瑞格列奈优于安慰剂及磺脲类药物。一项随机对照研究显示，单纯饮食治疗血糖控制不佳的新诊断T2DM患者，那格列奈单药治疗12周后HbA1c较基线降低0.9%(可能包括部分安慰剂效应)，2 hPG亦下降。此类药物需在餐前即刻服用，可单独或与其他非促泌剂类降糖药物联合应用。常见不良反应为低血糖和体重增加，但严重程度较磺脲类药物轻。肾功能不全的患者可选择瑞格列奈。", "ner": [[0, 5, "Drug"], [12, 14, "Drug"], [45, 48, "Drug"], [50, 53, "Drug"], [55, 58, "Drug"], [62, 66, "Test_items"], [67, 75, "Test_Value"], [77, 80, "Drug"], [113, 117, "Test_items"], [121, 124, "Drug"], [131, 135, "Drug"], [171, 174, "Drug"], [164, 167, "Disease"], [154, 155, "Test_items"], [211, 215, "Test_items"], [217, 218, "Test_Value"], [191, 196, "Test_Value"], [183, 187, "Test_items"], [179, 182, "Duration"], [240, 244, "Drug"], [261, 263, "ADE"], [265, 268, "ADE"], [271, 272, "Level"], [276, 280, "Drug"], [39, 41, "Test_items"], [148, 153, "Treatment"], [156, 159, "Test_Value"], [283, 287, "Disease"], [283, 283, "Anatomy"], [294, 297, "Drug"]], "rel": [[171, 174, "Drug", 164, 167, "Disease", "Drug_Disease"], [179, 182, "Duration", 171, 174, "Drug", "Duration_Drug"], [148, 153, "Treatment", 164, 167, "Disease", "Treatment_Disease"], [154, 155, "Test_items", 164, 167, "Disease", "Test_items_Disease"], [183, 187, "Test_items", 164, 167, "Disease", "Test_items_Disease"], [211, 215, "Test_items", 164, 167, "Disease", "Test_items_Disease"], [261, 263, "ADE", 276, 280, "Drug", "ADE_Drug"], [265, 268, "ADE", 276, 280, "Drug", "ADE_Drug"], [283, 283, "Anatomy", 283, 287, "Disease", "Anatomy_Disease"], [294, 297, "Drug", 283, 287, "Disease", "Drug_Disease"]]}
{"idx": 1744, "sentence": "3.降低PPG为主的注射制剂(表4)：胰岛素是T2DM患者降糖治疗的有效手段，短效人胰岛素和速效胰岛素类似物主要用于控制PPG。短效胰岛素一般在餐前15~30min皮下注射；速效胰岛素类似物可在餐前即刻皮下注射，个别情况，如进餐量无法估计可餐后即刻注射，注射后30~60min作用达到高峰。速效胰岛素类似物降糖能力与短效人胰岛素相当，但在模拟生理性胰岛素分泌、降低PPG幅度和低血糖风险方面优于人胰岛素，且餐前即刻注射更为方便，有助于提高治疗依从性。此外，预混胰岛素制剂包含一定比例的短效/速效胰岛素，同样可降低PPG。胰岛素治疗可引起低血糖，并增加体重。", "ner": [[4, 6, "Test_items"], [10, 11, "Method"], [19, 21, "Drug"], [23, 26, "Disease"], [39, 44, "Drug"], [46, 53, "Drug"], [60, 62, "Test_items"], [64, 68, "Drug"], [87, 94, "Drug"], [127, 128, "Method"], [130, 137, "Duration"], [145, 152, "Drug"], [158, 163, "Drug"], [182, 184, "Test_items"], [188, 190, "ADE"], [197, 200, "Drug"], [228, 234, "Drug"], [242, 249, "Drug"], [256, 258, "Test_items"], [260, 262, "Drug"], [268, 270, "ADE"], [273, 276, "ADE"], [120, 125, "Method"], [97, 104, "Method"], [72, 85, "Method"], [203, 208, "Method"]], "rel": [[4, 6, "Test_items", 23, 26, "Disease", "Test_items_Disease"], [10, 11, "Method", 19, 21, "Drug", "Method_Drug"], [19, 21, "Drug", 23, 26, "Disease", "Drug_Disease"], [39, 44, "Drug", 23, 26, "Disease", "Drug_Disease"], [46, 53, "Drug", 23, 26, "Disease", "Drug_Disease"], [72, 85, "Method", 64, 68, "Drug", "Method_Drug"], [97, 104, "Method", 87, 94, "Drug", "Method_Drug"], [130, 137, "Duration", 87, 94, "Drug", "Duration_Drug"], [188, 190, "ADE", 145, 152, "Drug", "ADE_Drug"], [203, 208, "Method", 145, 152, "Drug", "Method_Drug"], [188, 190, "ADE", 158, 163, "Drug", "ADE_Drug"], [268, 270, "ADE", 260, 262, "Drug", "ADE_Drug"], [273, 276, "ADE", 260, 262, "Drug", "ADE_Drug"]]}
{"idx": 1745, "sentence": "六、特殊人群餐后高血糖控制药物的选择", "ner": [[8, 10, "Disease"]], "rel": []}
{"idx": 1746, "sentence": "1.老年T2DM患者：已确诊的老年T2DM患者，且HbA1c>7.0%时，需考虑口服单药或联合降糖药物治疗。二甲双胍是治疗T2DM的基础用药，但以降低FPG为主；α-糖苷酶抑制剂或DPP-4抑制剂主要降低PPG，这两种药物都不增加低血糖发生，且耐受性较好。老年T2DM患者在使用胰岛素促泌剂或胰岛之前应认真考虑低血糖的风险。", "ner": [[4, 7, "Disease"], [17, 20, "Disease"], [25, 29, "Test_items"], [30, 34, "Test_Value"], [40, 41, "Method"], [54, 57, "Drug"], [61, 64, "Disease"], [75, 77, "Test_items"], [81, 88, "Drug"], [90, 97, "Drug"], [102, 104, "Test_items"], [115, 117, "ADE"], [130, 133, "Disease"], [139, 144, "Drug"], [146, 147, "Drug"], [155, 157, "ADE"]], "rel": [[25, 29, "Test_items", 17, 20, "Disease", "Test_items_Disease"], [54, 57, "Drug", 61, 64, "Disease", "Drug_Disease"], [75, 77, "Test_items", 61, 64, "Disease", "Test_items_Disease"], [139, 144, "Drug", 130, 133, "Disease", "Drug_Disease"], [146, 147, "Drug", 130, 133, "Disease", "Drug_Disease"], [155, 157, "ADE", 139, 144, "Drug", "ADE_Drug"], [155, 157, "ADE", 146, 147, "Drug", "ADE_Drug"]]}
{"idx": 1747, "sentence": "2.T2DM合并心血管系统疾病：T2DM合并心血管系统疾病患者PPG较高时可选用α-糖苷酶印制剂、DPP-4抑制剂、格列奈类或短效促泌剂。MeRIA研究证实了阿卡波糖的治疗与T2DM患者的心血管预后改善相关。", "ner": [[8, 14, "Disease"], [8, 10, "Anatomy"], [2, 5, "Disease"], [16, 19, "Disease"], [22, 28, "Disease"], [22, 24, "Anatomy"], [31, 33, "Test_items"], [34, 35, "Test_Value"], [40, 47, "Drug"], [49, 56, "Drug"], [58, 61, "Drug"], [63, 67, "Drug"], [79, 82, "Drug"], [87, 90, "Disease"]], "rel": [[8, 10, "Anatomy", 8, 14, "Disease", "Anatomy_Disease"], [31, 33, "Test_items", 16, 19, "Disease", "Test_items_Disease"], [40, 47, "Drug", 16, 19, "Disease", "Drug_Disease"], [49, 56, "Drug", 16, 19, "Disease", "Drug_Disease"], [58, 61, "Drug", 16, 19, "Disease", "Drug_Disease"], [63, 67, "Drug", 16, 19, "Disease", "Drug_Disease"], [22, 24, "Anatomy", 22, 28, "Disease", "Anatomy_Disease"], [79, 82, "Drug", 87, 90, "Disease", "Drug_Disease"]]}
{"idx": 1748, "sentence": "大型临床研究TECOS、EXAMINE和SAVOR和ELIXA结果分别证实了西格列汀、阿格列汀、沙格列汀和利司那肽与安慰剂比较，不增加心血管不良事件的风险。", "ner": [[38, 41, "Drug"], [43, 46, "Drug"], [48, 51, "Drug"], [53, 56, "Drug"], [67, 73, "ADE"]], "rel": []}
{"idx": 1749, "sentence": "当HbA1c>9.0%时，可根据患者情况选择联合用药的方案。", "ner": [[1, 5, "Test_items"], [6, 10, "Test_Value"]], "rel": []}
{"idx": 1750, "sentence": "如果两种口服降糖药物联合治疗3个月以上血糖仍不达标，可考虑起始胰岛素治疗或GLP-1受体激动剂或3种口服降糖药物联合治疗。", "ner": [[4, 5, "Method"], [14, 18, "Duration"], [19, 20, "Test_items"], [22, 24, "Test_Value"], [29, 33, "Drug"], [37, 46, "Drug"], [50, 51, "Method"]], "rel": []}
{"idx": 1751, "sentence": "餐后高血糖的定义为摄食后1~2 hPG>7.8mmol/L。", "ner": [[19, 28, "Test_Value"], [2, 4, "Disease"], [12, 18, "Test_items"]], "rel": [[12, 18, "Test_items", 2, 4, "Disease", "Test_items_Disease"]]}
{"idx": 1752, "sentence": "餐后高血糖的主要病理生理基础与第一时相/早相胰岛素分泌缺陷、外周组织IS下降、胰升血糖素分泌在进餐后不受抑制及餐后肝糖输出持续增高相关。", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 1753, "sentence": "DPP-4抑制剂通过抑制DDP-4酶对GLP-1的降解，提高周围血GLP-1水平2~3倍，进而促进胰岛β细胞分泌胰岛素，抑制胰升血糖素，降低PPG，可降低HbA1c0.4%~0.9%。此类药包括西格列汀、沙格列汀、维格列汀、利格列汀和阿格列汀。中国T2DM患者使用西格列汀单药治疗HbA1c下降0.7%，2 hPG下降2.8mmol/L；单独使用沙格列汀可使HbA1c下降0.5%，以速食面进行混合餐耐量试验(MMTT)可使2 hPG下降1.32mmol/L。同时，二甲双胍单药治疗血糖控不佳的T2DM患者，加用维格列汀后，较安慰剂组HbA1c下降0.51%；2 hPG下降1.53mmol/L。二甲双胍联合磺脲类药物治疗血糖控制不佳的T2DM患者加用利格列汀后，HbA1c较基线下降0.68%。DPP-4酶抑制剂单独使用低血糖风小，对体重的作用为中性或轻度增加。", "ner": [[0, 7, "Drug"], [70, 72, "Test_items"], [68, 69, "Test_Value"], [75, 76, "Test_Value"], [77, 81, "Test_items"], [82, 90, "Test_Value"], [97, 100, "Drug"], [102, 105, "Drug"], [107, 110, "Drug"], [112, 115, "Drug"], [117, 120, "Drug"], [124, 127, "Disease"], [132, 135, "Drug"], [140, 144, "Test_items"], [145, 150, "Test_Value"], [152, 156, "Test_items"], [157, 167, "Test_Value"], [173, 176, "Drug"], [179, 183, "Test_items"], [184, 189, "Test_Value"], [212, 216, "Test_items"], [217, 228, "Test_Value"], [233, 236, "Drug"], [241, 242, "Test_items"], [243, 245, "Test_Value"], [247, 250, "Disease"], [256, 259, "Drug"], [263, 265, "Drug"], [267, 271, "Test_items"], [272, 278, "Test_Value"], [280, 284, "Test_items"], [285, 296, "Test_Value"], [298, 301, "Drug"], [304, 308, "Drug"], [311, 312, "Test_items"], [313, 316, "Test_Value"], [318, 321, "Disease"], [326, 329, "Drug"], [332, 336, "Test_items"], [340, 346, "Test_Value"], [348, 356, "Drug"], [361, 363, "ADE"], [368, 380, "ADE"], [197, 209, "Test"]], "rel": [[132, 135, "Drug", 124, 127, "Disease", "Drug_Disease"], [173, 176, "Drug", 124, 127, "Disease", "Drug_Disease"], [140, 144, "Test_items", 124, 127, "Disease", "Test_items_Disease"], [152, 156, "Test_items", 124, 127, "Disease", "Test_items_Disease"], [233, 236, "Drug", 247, 250, "Disease", "Drug_Disease"], [241, 242, "Test_items", 247, 250, "Disease", "Test_items_Disease"], [256, 259, "Drug", 247, 250, "Disease", "Drug_Disease"], [263, 265, "Drug", 247, 250, "Disease", "Drug_Disease"], [267, 271, "Test_items", 247, 250, "Disease", "Test_items_Disease"], [280, 284, "Test_items", 247, 250, "Disease", "Test_items_Disease"], [298, 301, "Drug", 318, 321, "Disease", "Drug_Disease"], [304, 308, "Drug", 318, 321, "Disease", "Drug_Disease"], [311, 312, "Test_items", 318, 321, "Disease", "Test_items_Disease"], [326, 329, "Drug", 318, 321, "Disease", "Drug_Disease"], [368, 380, "ADE", 348, 356, "Drug", "ADE_Drug"], [361, 363, "ADE", 348, 356, "Drug", "ADE_Drug"]]}
{"idx": 1754, "sentence": "短效GLP-1受体激动剂可刺激胰岛素分泌、抑制胰升血糖素分泌、延缓胃排空、增加饱腹感和减少进食量而降低PPG。目前，我国临床使用的短效制剂艾塞那肽。在二甲双胍治疗的基础上联合短效GLP-1受体激动剂可降低HbA1c0.8%~1.5%。我国新诊断T2DM患者使用艾塞那肽治疗后，HbA1c较基线下降1.8%。其显著的特点是，在降糖同时，大部分患者可减轻体重、降低TG和SBP。常见的不良反应为胃肠道反应，如恶心、呕吐等，但随着治疗时间(约2周)延长逐渐减弱。单用低血糖发生率低，与胰岛素促泌剂合用可增加低血糖发生风险。", "ner": [[0, 11, "Drug"], [51, 53, "Test_items"], [69, 72, "Drug"], [75, 78, "Drug"], [87, 98, "Drug"], [102, 106, "Test_items"], [107, 115, "Test_Value"], [122, 125, "Disease"], [130, 133, "Drug"], [138, 142, "Test_items"], [146, 151, "Test_Value"], [180, 181, "Test_items"], [183, 185, "Test_items"], [195, 199, "ADE"], [202, 203, "ADE"], [205, 206, "ADE"], [217, 219, "Duration"], [230, 232, "ADE"], [239, 244, "Drug"], [250, 252, "ADE"]], "rel": [[130, 133, "Drug", 122, 125, "Disease", "Drug_Disease"], [138, 142, "Test_items", 122, 125, "Disease", "Test_items_Disease"], [230, 232, "ADE", 239, 244, "Drug", "ADE_Drug"]]}
{"idx": 1755, "sentence": "中国成人糖尿病患病率高达9.7%，患者人数居全球首位。糖尿病防治的关键在于积极预防、早期诊断及尽早规范化干预。糖尿病管理的最终目标是防治糖尿病慢性并发症，包括微血管并发症和动脉粥样硬化性血管病(ASVD)，以提高患者生活质量、延长寿命。研究显示，我国门诊T2DM患者血糖达标率仅32.6%；在心血管风险因素控制方面，我国T2DM患者血糖、血压、血脂达标率分别为47.7%、28.4%和36.1%，仅5.6%的患者3项指标均达标。目前，我国糖尿病患者血糖控制现状及临床合理用药情况不容乐观。大部分中国T2DM患者伴有餐后血糖(PPG)升高。流行病学筛查诊断的糖尿病患者中，单纯PPG升高患者的比例达50%，糖尿病前期中约70%为单纯性IGT。PPG增高是导致HbA1c升高的主要原因之一，PPG升高与糖尿病慢性并发症发生发展有相关性。因此，控制PPG是促使HbA1c控制达标以防治糖尿病慢性发症的重要策略。糖尿病的管理中，控制PPG的手段与控制FPG的策略和手段有明显不同。为使广大从事糖尿病防治的医务人员更全面了解餐后高血糖的病理生理特征、临床意义和更好地应用针对餐后高血糖的控制措施，国内部分专家基于国内外临床证据及临床经验，制订了《中国2型糖尿病患者餐后高血糖管理专家共识》，以期为临床医生更好地管理糖尿病提供参考。", "ner": [[4, 6, "Disease"], [27, 29, "Disease"], [55, 57, "Disease"], [79, 84, "Disease"], [86, 101, "Disease"], [133, 134, "Test_items"], [127, 130, "Disease"], [160, 163, "Disease"], [166, 167, "Test_items"], [172, 173, "Test_items"], [219, 221, "Disease"], [224, 225, "Test_items"], [249, 252, "Disease"], [257, 265, "Test_items"], [266, 267, "Test_Value"], [278, 280, "Disease"], [287, 289, "Test_items"], [290, 291, "Test_Value"], [302, 304, "Disease"], [219, 221, "Disease"], [320, 322, "Test_items"], [323, 324, "Test_Value"], [328, 332, "Test_items"], [333, 334, "Test_Value"], [343, 345, "Test_items"], [346, 347, "Test_Value"], [349, 356, "Disease"], [371, 373, "Test_items"], [377, 381, "Test_items"], [389, 395, "Disease"], [402, 404, "Disease"], [412, 414, "Test_items"], [421, 423, "Test_items"], [442, 444, "Disease"], [68, 75, "Disease"], [520, 524, "Disease"], [552, 554, "Disease"], [459, 461, "Disease"], [529, 531, "Disease"], [484, 486, "Disease"], [169, 170, "Test"]], "rel": [[133, 134, "Test_items", 127, 130, "Disease", "Test_items_Disease"], [166, 167, "Test_items", 160, 163, "Disease", "Test_items_Disease"], [172, 173, "Test_items", 160, 163, "Disease", "Test_items_Disease"], [169, 170, "Test", 160, 163, "Disease", "Test_Disease"], [224, 225, "Test_items", 219, 221, "Disease", "Test_items_Disease"], [257, 265, "Test_items", 249, 252, "Disease", "Test_items_Disease"], [287, 289, "Test_items", 278, 280, "Disease", "Test_items_Disease"], [343, 345, "Test_items", 349, 356, "Disease", "Test_items_Disease"], [371, 373, "Test_items", 389, 395, "Disease", "Test_items_Disease"], [377, 381, "Test_items", 389, 395, "Disease", "Test_items_Disease"], [412, 414, "Test_items", 402, 404, "Disease", "Test_items_Disease"], [421, 423, "Test_items", 402, 404, "Disease", "Test_items_Disease"]]}
{"idx": 1756, "sentence": "SGLT2i在不同程度肾功能不全的T2DM患者中所进行的研究提示，轻度肾功能不全，此类药物仍然发挥疗效，并具有良好的安全性。中度肾功能不全进一步下降SGLT2i的疗效，逐渐下降直至无明显疗效，但并没有明显的安全性的问题。起始SGLT2i治疗前需检测肾功能，并根据肾功能确认是否可以起始治疗，治疗过程中每年至少监测一次肾功能。治疗过程中，如果同时予以影响肾功能的药物治疗其他疾病时，起始前需监测肾功能，且定期监测肾功能，当患者的肾功能逐渐下降并趋向与中度肾功能不全时，需要每年监测2~4次肾功能同时关注泌尿道感染和血容量降低相关的不良事件。目前，在重度肝功能不全的T2DM数据有限。欧、美国家的药物说明书中不推荐在重度肝功能不全的T2DM中使用SGLT2i。", "ner": [[11, 15, "Disease"], [11, 11, "Anatomy"], [0, 5, "Drug"], [17, 20, "Disease"], [33, 34, "Level"], [35, 39, "Disease"], [35, 35, "Anatomy"], [62, 63, "Level"], [74, 79, "Drug"], [112, 117, "Drug"], [122, 126, "Test"], [194, 198, "Test"], [203, 207, "Test"], [224, 225, "Level"], [226, 230, "Disease"], [226, 226, "Anatomy"], [256, 260, "ADE"], [250, 254, "ADE"], [273, 274, "Level"], [275, 279, "Disease"], [275, 275, "Anatomy"], [281, 284, "Disease"], [306, 307, "Level"], [308, 312, "Disease"], [308, 308, "Anatomy"], [314, 317, "Disease"], [321, 326, "Drug"], [154, 160, "Test"], [237, 245, "Test"]], "rel": [[11, 11, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"], [0, 5, "Drug", 17, 20, "Disease", "Drug_Disease"], [35, 35, "Anatomy", 35, 39, "Disease", "Anatomy_Disease"], [226, 226, "Anatomy", 226, 230, "Disease", "Anatomy_Disease"], [237, 245, "Test", 226, 230, "Disease", "Test_Disease"], [275, 275, "Anatomy", 275, 279, "Disease", "Anatomy_Disease"], [308, 308, "Anatomy", 308, 312, "Disease", "Anatomy_Disease"]]}
{"idx": 1757, "sentence": "钠-葡萄糖共转运蛋白2(SGLT2) 抑制剂临床合理应用中国专家建议 ", "ner": [[0, 21, "Drug"]], "rel": []}
{"idx": 1758, "sentence": "通过控制T2DM患者多种代谢异常和高血压，预防和延缓糖尿病的大血管病变和微血管病变、提高患者生活质量，延长患者寿命是治疗T2DM的目标。当前，T2DM的控制还面临巨大的挑战，在糖尿病患者的血糖控制上仍需更有效的新型降糖药物来满足传统降糖药物未能满足的治疗需求。", "ner": [[4, 7, "Disease"], [17, 19, "Disease"], [26, 28, "Disease"], [30, 34, "Disease"], [30, 32, "Anatomy"], [36, 40, "Disease"], [36, 38, "Anatomy"], [60, 63, "Disease"], [71, 74, "Disease"], [88, 90, "Disease"], [94, 95, "Test_items"]], "rel": [[30, 32, "Anatomy", 30, 34, "Disease", "Anatomy_Disease"], [36, 38, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [94, 95, "Test_items", 88, 90, "Disease", "Test_items_Disease"]]}
{"idx": 1759, "sentence": " ", "ner": [], "rel": []}
{"idx": 1760, "sentence": "钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一种新型的口服降糖药物，该类药物在国外多个国家已经上市并得到越来越广泛的临床应用，即将在中国上市的SGLT2i主要有达格列净(dapagliflozin) 、坎格列净(canagliflozin) 和恩格列净(empagliflozin)。", "ner": [[0, 21, "Drug"], [28, 29, "Method"], [72, 77, "Drug"], [81, 99, "Drug"], [102, 120, "Drug"], [123, 141, "Drug"]], "rel": [[28, 29, "Method", 0, 21, "Drug", "Method_Drug"]]}
{"idx": 1761, "sentence": "考虑中国广大医生尚无使用该药的经验，故中国内分泌、心血管及肾脏领域的专家共同制定《SGLT2抑制剂临床合理应用中国专家建议》，以指导临床医生和患者对该类药物有更全面的了解和合理使用。", "ner": [[41, 48, "Drug"]], "rel": []}
{"idx": 1762, "sentence": "一、肾脏与葡萄糖代谢 ", "ner": [], "rel": []}
{"idx": 1763, "sentence": "正常生理情祝下，肾脏每天经过肾小球滤过近160~180g的葡萄糖到肾小管中，但滤过的葡萄糖全部被重吸收。一般情况下，当血糖浓度达到10mmol/L(肾糖阈)时葡萄糖会漏出到尿液中。血糖浓度超过肾糖阈越多，从尿中排出的葡萄糖就越多。在肾小管内的葡萄糖主要通过钠-葡萄糖共转运蛋白(SGLT)重吸收回到血液循环中。人类SGLT家族主要包括SGLT1-SGLT6，在体内广泛分布。其中，SGLT2是该家族中的重要一员，主要分布在近段肾小管的管腔侧细胞膜上，负责肾小管中90%葡萄糖的重吸收，另外，10%的葡萄糖通过分布在远肾小管的SGLT1通道重吸收，出于对肾脏过量葡萄糖排出的适应，T2DM患者肾糖阈较非糖尿病患者高、导致重吸收葡萄糖量增加。SGLT2基因突变导致的SGLT2通道重吸收葡萄糖的能力下降(肾糖阈降低)可导致在正常血糖水平情况下的尿糖排出增多，即肾性尿糖。该类患者无过高的发生低血糖、肾功能受损、电解质系乱等风险未见显著增高。", "ner": [[59, 62, "Test_items"], [65, 77, "Test_items"], [90, 93, "Test_items"], [96, 98, "Test_items"], [289, 292, "Disease"], [295, 297, "Test_items"], [300, 302, "Disease"], [350, 352, "Test_items"], [362, 363, "Test_items"], [393, 395, "Disease"], [397, 401, "Disease"], [403, 407, "Disease"], [397, 397, "Anatomy"]], "rel": [[295, 297, "Test_items", 289, 292, "Disease", "Test_items_Disease"], [397, 397, "Anatomy", 397, 401, "Disease", "Anatomy_Disease"]]}
{"idx": 1764, "sentence": "二、SGLT2i", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 1765, "sentence": "近年来，人们逐渐认识到肾脏葡萄糖重吸收在血糖调节中的作用并研发出SGLT2i，通过抑制SGLT2或SGLT1的作用抑制葡萄糖重吸收，降低肾糖阀而促进尿葡萄糖排泄，从而达到降低血液循环中葡萄糖水平的作用。", "ner": [[20, 21, "Test_items"], [32, 37, "Drug"], [68, 70, "Test_items"]], "rel": []}
{"idx": 1766, "sentence": "达格列净和思格列净主要抑制SGLT2，而坎格列净同时抑制SGLT2和SGLT1，因SGLT抑制剂药物分子结构和受体选择性的不同，各种药物药代动力学参数也不尽相同(表1)。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [20, 23, "Drug"]], "rel": []}
{"idx": 1767, "sentence": "三、SGLT2i临床有效性", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 1768, "sentence": "SGLT2i单独使用时不增加低血糖发生的风险，联合胰岛素或磺脲类药物时，可增加低血糖发生风险，SGLT2i其主要的不良反应为生殖泌尿道感染，多数为轻度到中度感染，抗感染治疗有效。", "ner": [[0, 5, "Drug"], [14, 16, "ADE"], [25, 27, "Drug"], [29, 33, "Drug"], [39, 41, "ADE"], [47, 52, "Drug"], [62, 68, "ADE"]], "rel": [[14, 16, "ADE", 0, 5, "Drug", "ADE_Drug"], [39, 41, "ADE", 25, 27, "Drug", "ADE_Drug"], [39, 41, "ADE", 29, 33, "Drug", "ADE_Drug"]]}
{"idx": 1769, "sentence": "在中国人群中开展的SGLT2i的临床研究结果与全球研究结果基本保持一致(表2)。", "ner": [[9, 14, "Drug"]], "rel": []}
{"idx": 1770, "sentence": "四、临床适用人群及用法", "ner": [], "rel": []}
{"idx": 1771, "sentence": "SGLT2i可应用于成人T2DM，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用。也可与其他口服降糖药物及胰岛素联合使用。由于SGLT2i的药理作用依赖一定水平的eGFR，故对患者eGFR的要求>60或45ml/(min·1.73m2)，在中国人群中已完成SGLT2i在新诊断成人T2DM中单药治疗、在二甲双胍单药治疗效果不佳或二甲双胍联合磺脲类药物治疗效果不佳人群中两药或三药联合治疗的3期临床研究。", "ner": [[0, 5, "Drug"], [12, 15, "Disease"], [35, 38, "Drug"], [26, 27, "Test_items"], [56, 57, "Method"], [63, 65, "Drug"], [73, 78, "Drug"], [138, 143, "Drug"], [150, 153, "Disease"], [161, 164, "Drug"], [174, 177, "Drug"], [180, 184, "Drug"]], "rel": [[0, 5, "Drug", 12, 15, "Disease", "Drug_Disease"], [26, 27, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [35, 38, "Drug", 12, 15, "Disease", "Drug_Disease"], [138, 143, "Drug", 150, 153, "Disease", "Drug_Disease"], [161, 164, "Drug", 150, 153, "Disease", "Drug_Disease"], [180, 184, "Drug", 150, 153, "Disease", "Drug_Disease"]]}
{"idx": 1772, "sentence": "美国药品食品监督管理局(FDA)批准达格列净、卡格列净和恩格列净的起始剂量分别为5mg、100mg和10mg，根据血糖控制的需求和是否耐受可调整至最大剂量10mg、300mg和25mg，每日一次口服，达格列净和思格列净餐前或餐后均可服用，坎格列净需要在第一次正餐前口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10mg，对于重度肝功能不全的患者可从5mg起始。美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT2i可单独使用及与其他降糖药物联合使用。", "ner": [[18, 21, "Drug"], [23, 26, "Drug"], [28, 31, "Drug"], [40, 42, "Amount"], [44, 48, "Amount"], [50, 53, "Amount"], [57, 58, "Test_items"], [77, 80, "Amount"], [82, 86, "Amount"], [88, 91, "Amount"], [93, 96, "Frequency"], [97, 98, "Method"], [100, 103, "Drug"], [105, 108, "Drug"], [119, 122, "Drug"], [132, 133, "Method"], [157, 160, "Drug"], [167, 170, "Amount"], [176, 180, "Disease"], [176, 176, "Anatomy"], [174, 175, "Level"], [186, 188, "Amount"], [212, 214, "Disease"], [220, 222, "Disease"], [239, 244, "Drug"]], "rel": [[40, 42, "Amount", 18, 21, "Drug", "Amount_Drug"], [77, 80, "Amount", 18, 21, "Drug", "Amount_Drug"], [93, 96, "Frequency", 18, 21, "Drug", "Frequency_Drug"], [44, 48, "Amount", 23, 26, "Drug", "Amount_Drug"], [82, 86, "Amount", 23, 26, "Drug", "Amount_Drug"], [93, 96, "Frequency", 23, 26, "Drug", "Frequency_Drug"], [50, 53, "Amount", 28, 31, "Drug", "Amount_Drug"], [88, 91, "Amount", 28, 31, "Drug", "Amount_Drug"], [93, 96, "Frequency", 28, 31, "Drug", "Frequency_Drug"], [132, 133, "Method", 119, 122, "Drug", "Method_Drug"], [186, 188, "Amount", 157, 160, "Drug", "Amount_Drug"], [167, 170, "Amount", 157, 160, "Drug", "Amount_Drug"], [176, 176, "Anatomy", 176, 180, "Disease", "Anatomy_Disease"], [239, 244, "Drug", 212, 214, "Disease", "Drug_Disease"]]}
{"idx": 1773, "sentence": "五、临床应用中安全性及处理原则", "ner": [], "rel": []}
{"idx": 1774, "sentence": "1.泌尿生殖道感染：SGLT2i促进大量葡萄糖从尿液中排出，增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT2i治疗后其生殖道感染的发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效：女性较男性生殖道感染发生率稍高，最为常见的生殖道感染疾病在女性中为外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎，在男性中为念珠菌性龟头炎和阴茎包皮炎；有感染疾病史的患者，感染率升高；且发生感染后，需抗感染治疗；女性生殖道感染大部分发生在用药的初始4个月内，而男性则在第一年内。为避免生殖道和泌尿道感染的发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如果发生感染并需要抗感染治疗时建议暂停SGLT2i。", "ner": [[2, 8, "Disease"], [10, 15, "Drug"], [73, 78, "Drug"], [106, 106, "Level"], [108, 109, "Level"], [165, 170, "Disease"], [165, 166, "Anatomy"], [172, 176, "Disease"], [172, 175, "Anatomy"], [183, 189, "Disease"], [187, 188, "Anatomy"], [191, 195, "Disease"], [191, 194, "Anatomy"], [156, 163, "Disease"], [156, 159, "Anatomy"], [144, 148, "Disease"], [144, 146, "Anatomy"], [128, 132, "Disease"], [2, 6, "Anatomy"], [83, 87, "Disease"], [83, 85, "Anatomy"], [128, 130, "Anatomy"], [229, 233, "Disease"], [229, 231, "Anatomy"], [267, 271, "Disease"], [267, 269, "Anatomy"], [293, 298, "Disease"], [334, 339, "Drug"]], "rel": [[2, 6, "Anatomy", 2, 8, "Disease", "Anatomy_Disease"], [165, 166, "Anatomy", 165, 170, "Disease", "Anatomy_Disease"], [172, 175, "Anatomy", 172, 176, "Disease", "Anatomy_Disease"], [187, 188, "Anatomy", 183, 189, "Disease", "Anatomy_Disease"], [191, 194, "Anatomy", 191, 195, "Disease", "Anatomy_Disease"], [156, 159, "Anatomy", 156, 163, "Disease", "Anatomy_Disease"], [144, 146, "Anatomy", 144, 148, "Disease", "Anatomy_Disease"], [128, 130, "Anatomy", 128, 132, "Disease", "Anatomy_Disease"], [83, 85, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [229, 231, "Anatomy", 229, 233, "Disease", "Anatomy_Disease"], [267, 269, "Anatomy", 267, 271, "Disease", "Anatomy_Disease"]]}
{"idx": 1775, "sentence": "感染治愈后，可继续使用。", "ner": [], "rel": []}
{"idx": 1776, "sentence": "使用SGLT2i过程中，尤其是使用的第一个月，需要关注患者是否出现感染的症状和体征。", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 1777, "sentence": "如果患者出现泌尿和生殖道感染的症状，应就医并作相关检查以明确有无感染。", "ner": [[9, 13, "ADE"]], "rel": []}
{"idx": 1778, "sentence": "使用SGLT2i的患者，建议注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染的发生。", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 1779, "sentence": "2.低血糖：SGLT2i单药治疗不增加低血糖发生风险。与二甲双胍、二肽基肽酶-4抑制剂(DPP-4i)、TZDs等药物联合使用时，低血糖发生的风险也没有明显增加；与胰岛素或磺脲类药物联合使用时低血糖发生风险增加。建议与胰岛素或磺类药物联合使用时，注意调整胰岛素或磺脲类药物的剂量，避免低血糖发生。", "ner": [[2, 4, "ADE"], [6, 11, "Drug"], [19, 21, "ADE"], [28, 31, "Drug"], [33, 50, "Drug"], [52, 55, "Drug"], [65, 67, "ADE"], [82, 84, "Drug"], [86, 90, "Drug"], [96, 98, "ADE"], [109, 111, "Drug"], [113, 116, "Drug"], [127, 129, "Drug"], [131, 135, "Drug"], [142, 144, "ADE"]], "rel": [[96, 98, "ADE", 82, 84, "Drug", "ADE_Drug"], [96, 98, "ADE", 86, 90, "Drug", "ADE_Drug"], [142, 144, "ADE", 127, 129, "Drug", "ADE_Drug"], [142, 144, "ADE", 131, 135, "Drug", "ADE_Drug"]]}
{"idx": 1780, "sentence": "3.DKA：在SGLT2i临床研究中及上市后临床应用中，曾发现发生DKA及酮症的病例，但非常少见。临床报道的病例中，部分病例为T1DM，多数患者存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理的压力等诱因，部分联合使用胰岛素的患者胰岛素减量过快。", "ner": [[2, 4, "Disease"], [7, 12, "Drug"], [33, 35, "Disease"], [37, 38, "Disease"], [63, 66, "Disease"], [82, 85, "Disease"], [82, 83, "Anatomy"], [87, 88, "Disease"], [90, 91, "Level"], [132, 134, "Drug"], [139, 140, "Drug"]], "rel": [[132, 134, "Drug", 63, 66, "Disease", "Drug_Disease"], [82, 83, "Anatomy", 82, 85, "Disease", "Anatomy_Disease"]]}
{"idx": 1781, "sentence": "使用SGLT2i时发生DKA及酮症的患者症状不典型，血糖通常不超13.9mmol/L，被称之为“血糖不高的DKA”，往往不易被诊断。专家建议在使用SGLT2i期间，如果患者出现和DKA相关的症状如腹痛、恶心、呕吐、乏力、呼吸困难、需要考虑患者是否出现DKA并检测血酮体和动脉血酸碱度以明确诊断。明确诊断为DKA的患者，应立即停用SGLT2i，并按照传统的DKA治疗程序进行治疗。为减少患者在使用SGLT2i期间发生DKA的风险，建议在择期手术、剧烈体力活动，如马拉松比赛前24h停用SGLT2i，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT2i，采用其他合适降糖措施；口服SGLT2i期间避免过多饮酒及极低碳水化合物饮食。目前，SGLT-2i未被批准用于T1DM。", "ner": [[2, 7, "Drug"], [11, 13, "Disease"], [15, 16, "Disease"], [26, 27, "Test_items"], [30, 41, "Test_Value"], [53, 55, "Disease"], [48, 49, "Test_items"], [73, 78, "Drug"], [89, 91, "Disease"], [98, 99, "Symptom"], [101, 102, "Symptom"], [104, 105, "Symptom"], [107, 108, "Symptom"], [110, 113, "Symptom"], [125, 127, "Disease"], [135, 140, "Test_items"], [131, 133, "Test_items"], [152, 154, "Disease"], [164, 169, "Drug"], [177, 179, "Disease"], [197, 202, "Drug"], [207, 209, "Disease"], [241, 246, "Drug"], [265, 267, "Drug"], [293, 298, "Drug"], [313, 318, "Drug"], [341, 347, "Drug"], [354, 357, "Disease"], [311, 312, "Method"]], "rel": [[98, 99, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [101, 102, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [104, 105, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [107, 108, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [110, 113, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [131, 133, "Test_items", 125, 127, "Disease", "Test_items_Disease"], [135, 140, "Test_items", 125, 127, "Disease", "Test_items_Disease"], [311, 312, "Method", 313, 318, "Drug", "Method_Drug"]]}
{"idx": 1782, "sentence": "六、SGLT2i在特殊人群的使用", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 1783, "sentence": "1.老年人群：SGLT2i可用于老年T2DM患者。老年患者中，在原有治疗方案疗效不佳的情况下加用SGLT2i，可有效降低血糖、减轻体重和降低血压，且耐受性良好。探讨影响SGLT2i在对老年患者中有效性与安全性的影响因素发现，校正eGFR影响后，年龄并不影响SGLT2i的疗效。当eGFR≥60ml/(min·1.73m2)时，SGLT2i降糖和减重疗效在老年(年龄≥65岁)和非老年(年龄<65岁)人群中相当，且总体不良事件没有增加，泌尿生殖道感染也没有增加，但是，当老年患者eGFR<60ml/(min·1.73m2)时，低血糖风险、低血容量相关事件、肾损伤或肾衰竭风险升高。", "ner": [[7, 12, "Drug"], [18, 21, "Disease"], [48, 53, "Drug"], [60, 61, "Test_items"], [70, 71, "Test"], [84, 89, "Drug"], [128, 133, "Drug"], [163, 168, "Drug"], [217, 223, "Disease"], [217, 221, "Anatomy"], [262, 264, "ADE"], [268, 271, "ADE"], [277, 279, "Disease"], [281, 283, "Disease"], [281, 281, "Anatomy"], [277, 277, "Anatomy"]], "rel": [[7, 12, "Drug", 18, 21, "Disease", "Drug_Disease"], [217, 221, "Anatomy", 217, 223, "Disease", "Anatomy_Disease"], [277, 277, "Anatomy", 277, 279, "Disease", "Anatomy_Disease"], [281, 281, "Anatomy", 281, 283, "Disease", "Anatomy_Disease"]]}
{"idx": 1784, "sentence": "因此，老年患者需监测其肾功能，肾功能正常或轻度不全时，均可使用SGLT2i。", "ner": [[21, 22, "Level"], [31, 36, "Drug"]], "rel": []}
{"idx": 1785, "sentence": "2.糖尿病合并肝肾功能不全者：SGLT2i在中度肾功能不全[45≤eGFR<60ml/(min·1.73m2)]的患者可减量使用。轻中度肝功能不全时也可使用。", "ner": [[2, 4, "Disease"], [7, 12, "Disease"], [7, 8, "Anatomy"], [15, 20, "Drug"], [22, 23, "Level"], [24, 28, "Disease"], [24, 24, "Anatomy"], [65, 67, "Level"], [68, 72, "Disease"], [68, 68, "Anatomy"]], "rel": [[15, 20, "Drug", 2, 4, "Disease", "Drug_Disease"], [7, 8, "Anatomy", 7, 12, "Disease", "Anatomy_Disease"], [24, 24, "Anatomy", 24, 28, "Disease", "Anatomy_Disease"], [68, 68, "Anatomy", 68, 72, "Disease", "Anatomy_Disease"]]}
{"idx": 1786, "sentence": "3.糖尿病合并心血管疾病者：T2DM是心血管疾病的等危症，控制糖尿病患者的各种代谢危险因素如血压、血脂等可有效降低心血管疾病的发生风险。研究表明，SGLT2i除有效降糖外，还可减轻体重，降低血压，降低血尿酸浓度，减少蛋白尿等与心血管疾病相关的危险因素。针对已经完成的达格列净和坎格列净3期临床随机对照研究中的心血管终点的汇总分析，结果显示，这两类药物均不增加心血管事件风险，然而，上述两种药物对心血管的影响需要正在进行中的心血管结局研究DE-CLARE和CANVAS、CANVAS-R和CREDENCE验证。", "ner": [[2, 4, "Disease"], [7, 11, "Disease"], [7, 9, "Anatomy"], [14, 17, "Disease"], [19, 23, "Disease"], [19, 21, "Anatomy"], [31, 33, "Disease"], [46, 47, "Test_items"], [49, 50, "Test_items"], [57, 61, "Disease"], [57, 59, "Anatomy"], [73, 78, "Drug"], [88, 91, "ADE"], [93, 96, "ADE"], [98, 104, "ADE"], [106, 110, "ADE"], [113, 117, "Disease"], [113, 115, "Anatomy"], [133, 136, "Drug"], [138, 141, "Drug"], [179, 183, "Disease"], [179, 181, "Anatomy"]], "rel": [[7, 9, "Anatomy", 7, 11, "Disease", "Anatomy_Disease"], [19, 21, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [46, 47, "Test_items", 31, 33, "Disease", "Test_items_Disease"], [49, 50, "Test_items", 31, 33, "Disease", "Test_items_Disease"], [57, 59, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"], [88, 91, "ADE", 73, 78, "Drug", "ADE_Drug"], [93, 96, "ADE", 73, 78, "Drug", "ADE_Drug"], [98, 104, "ADE", 73, 78, "Drug", "ADE_Drug"], [106, 110, "ADE", 73, 78, "Drug", "ADE_Drug"], [113, 115, "Anatomy", 113, 117, "Disease", "Anatomy_Disease"], [179, 181, "Anatomy", 179, 183, "Disease", "Anatomy_Disease"]]}
{"idx": 1787, "sentence": "恩格列净的心血管结局研究(EMPA-REGOUTCOME)已完成并发布了其研究结果。该研究中患者均为心血管疾病的高危人群。结果显示，恩格列净的治疗与全因死亡、心血管死亡、心血管病变、心力衰竭、肾功能下降和终末期肾病发生的风险下降相关。该研究提示对于糖尿病合并心血管疾病的患者，恩格列净具有心血管及肾脏保护作用。", "ner": [[0, 3, "Drug"], [50, 54, "Disease"], [50, 52, "Anatomy"], [66, 69, "Drug"], [79, 83, "Disease"], [79, 81, "Anatomy"], [85, 89, "Disease"], [85, 87, "Anatomy"], [91, 94, "Disease"], [91, 91, "Anatomy"], [105, 106, "Disease"], [105, 105, "Anatomy"], [124, 126, "Disease"], [129, 133, "Disease"], [129, 131, "Anatomy"], [138, 141, "Drug"]], "rel": [[50, 52, "Anatomy", 50, 54, "Disease", "Anatomy_Disease"], [79, 81, "Anatomy", 79, 83, "Disease", "Anatomy_Disease"], [85, 87, "Anatomy", 85, 89, "Disease", "Anatomy_Disease"], [91, 91, "Anatomy", 91, 94, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 105, 106, "Disease", "Anatomy_Disease"], [138, 141, "Drug", 124, 126, "Disease", "Drug_Disease"], [129, 131, "Anatomy", 129, 133, "Disease", "Anatomy_Disease"]]}
{"idx": 1788, "sentence": "5.其他：SGLT2i作为新型的口服降糖药物，其长期使用中的安全性也需要关注。在临床试验和药物上市后报告的一些不良事件，如膀胱癌、骨折、足趾截肢风险，以及急性肾损伤风险等需要在更多的临床研究和观察中予以进一步澄清。目前，临床研究数据尚未证实SGLT2i与膀胱癌发生风险间是否存在因果关系，上市后至今尚无相关肿瘤病例的报告.FDA和EMA根据不良事件报告系统的数据.已加强提醒在使用SGLT2i的过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净，坎格列净)。", "ner": [[5, 10, "Drug"], [16, 17, "Method"], [61, 63, "Disease"], [61, 62, "Anatomy"], [65, 66, "ADE"], [68, 71, "ADE"], [77, 81, "Disease"], [79, 79, "Anatomy"], [120, 125, "Drug"], [127, 129, "Disease"], [127, 128, "Anatomy"], [190, 195, "Drug"], [203, 204, "ADE"], [208, 211, "Drug"], [214, 217, "ADE"], [221, 224, "Drug"], [227, 231, "ADE"], [235, 238, "Drug"], [240, 243, "Drug"]], "rel": [[16, 17, "Method", 5, 10, "Drug", "Method_Drug"], [61, 62, "Anatomy", 61, 63, "Disease", "Anatomy_Disease"], [79, 79, "Anatomy", 77, 81, "Disease", "Anatomy_Disease"], [127, 128, "Anatomy", 127, 129, "Disease", "Anatomy_Disease"], [203, 204, "ADE", 208, 211, "Drug", "ADE_Drug"], [214, 217, "ADE", 221, 224, "Drug", "ADE_Drug"], [227, 231, "ADE", 240, 243, "Drug", "ADE_Drug"], [227, 231, "ADE", 235, 238, "Drug", "ADE_Drug"]]}
{"idx": 1789, "sentence": "但SGLT2i和这些风险之间是否存在因果关系，仍需要进一步研究。", "ner": [[1, 6, "Drug"]], "rel": []}
{"idx": 1790, "sentence": "七、小结", "ner": [], "rel": []}
{"idx": 1791, "sentence": "4.T1DM、儿童青少年、孕妇和哺乳期妇女：目前，SGLT2i均没有在T1DM中使用的适应证。已经完成的探索性研究证实了SGLT2i与胰岛素联合治疗T1DM的疗效与安全性。T1DM患者使用SGLT2i发生DKA的风险可能增加。", "ner": [[2, 5, "Disease"], [25, 30, "Drug"], [35, 38, "Disease"], [60, 65, "Drug"], [67, 69, "Drug"], [74, 77, "Disease"], [86, 89, "Disease"], [94, 99, "Drug"], [102, 104, "Disease"]], "rel": [[25, 30, "Drug", 35, 38, "Disease", "Drug_Disease"], [60, 65, "Drug", 74, 77, "Disease", "Drug_Disease"], [67, 69, "Drug", 74, 77, "Disease", "Drug_Disease"], [94, 99, "Drug", 86, 89, "Disease", "Drug_Disease"]]}
{"idx": 1792, "sentence": "儿童青少年及孕妇和哺乳期妇女中无使用SGLT2i的数据，暂不推荐在此类人群中使用。", "ner": [[18, 23, "Drug"]], "rel": []}
{"idx": 1793, "sentence": "在全球范围内，已完成的SGLT2i多项临床研究对该类药物的有效性与安全性进行了评价。SGLT2i降低HbA1c幅度大，约0.5%~1.0%，减轻体重1.5~3.5kg，降低SBP3~5mmHg与胰岛素联合使用时，还可减少每日胰岛素用量大约5.9~8.7U/d。", "ner": [[11, 16, "Drug"], [42, 47, "Drug"], [50, 54, "Test_items"], [59, 68, "Test_Value"], [86, 88, "Test_items"], [89, 95, "Test_Value"], [112, 114, "Drug"], [119, 128, "Amount"], [97, 99, "Drug"]], "rel": [[119, 128, "Amount", 112, 114, "Drug", "Amount_Drug"]]}
{"idx": 1794, "sentence": "SGLT2i与常用的口服降糖药物比较，其降糖疗效与二甲双胍相当，优于西格列汀和磺脲类药物；有明显的减重效果。", "ner": [[0, 5, "Drug"], [10, 11, "Method"], [25, 28, "Drug"], [34, 37, "Drug"], [39, 43, "Drug"]], "rel": []}
{"idx": 1795, "sentence": "另外，SGLT2i可降低血压、尿酸水平，减少尿蛋白排泄，降低TG，同时升高HDL-C和LDL-C，但不增加LDL/HDL比值。", "ner": [[3, 8, "Drug"], [12, 13, "Test_items"], [15, 16, "Test_items"], [37, 41, "Test_items"], [30, 31, "Test_items"], [22, 24, "Test_items"], [53, 59, "Test_items"], [43, 47, "Test_items"]], "rel": []}
{"idx": 1796, "sentence": "SGLT2i是一类全新的口服降糖药物。该类药物降糖疗效确切，无低血糖风险，减轻体重、降低血压，可能有心血管及DN保护作用，满足了当前糖尿病治疗中部分未被满足的需求。未来几年内.目前正在进行中的CANVAS、CANVAS-R、CRE-DENCE、DECLARE-TIMI等大规模长期临床研究將提供更多的数据。我们希望临床医师在使用SGLT2i治疗T2DM前充分了解该类药物的特性，在临床应用中尚需根据每个患者的情况，平衡获益与风险，遵照说明书正确使用.确保给患者带来最大程度的治疗获益。", "ner": [[0, 5, "Drug"], [12, 13, "Method"], [31, 33, "ADE"], [37, 40, "ADE"], [42, 45, "ADE"], [66, 68, "Disease"], [164, 169, "Drug"], [172, 175, "Disease"]], "rel": [[12, 13, "Method", 0, 5, "Drug", "Method_Drug"]]}
{"idx": 1797, "sentence": "格列喹酮临床应用中国专家共识(2017年版)", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 1798, "sentence": "磺脲类胰岛素促泌剂是最早发现并使用最广泛的口服降糖药物，《中国2型糖尿病防治指南(2013)》推荐该类药物为中国2型糖尿病患者降糖治疗的一线备选用药。", "ner": [[0, 8, "Drug"], [21, 22, "Method"], [31, 35, "Disease"], [56, 60, "Disease"]], "rel": [[21, 22, "Method", 0, 8, "Drug", "Method_Drug"], [0, 8, "Drug", 31, 35, "Disease", "Drug_Disease"]]}
{"idx": 1799, "sentence": "其中格列喹酮作为二代磺脲类促泌剂，具有良好的降糖作用及安全性，同时兼具肾脏保护作用，获得全球多个权威指南推荐。", "ner": [[2, 5, "Drug"], [10, 15, "Drug"]], "rel": []}
{"idx": 1800, "sentence": "为进一步指导规范格列喹酮的临床应用，中国50余位知名内分泌代谢领域专家起草、讨论、制订了此专家共识。", "ner": [[8, 11, "Drug"]], "rel": []}
{"idx": 1801, "sentence": "全文回顾了格列酮相关循证依据，并对药物安全性、有效性、使用人群及使用方法进行了总结和推荐，希望藉此为临床医生提供指导与帮助。", "ner": [[5, 7, "Drug"]], "rel": []}
{"idx": 1802, "sentence": "一、格列喹酮药代动力学及药理特点", "ner": [[2, 5, "Drug"]], "rel": []}
{"idx": 1803, "sentence": "格列喹酮口服吸收迅速完全，血药浓度2~3h达峰值，平均半衰期1.5h，降糖持续时间为5~8h；其代谢途径95%经粪便排泄，仅5%经肾脏排泄；格列喹酮在肝脏中经羟基化被代谢为大量非活性代谢产物，该代谢过程在肝功能不全患者体内仍可进行，且长期应用亦不影响肝胆疾病患者的肝功能；由于代谢产物无活性，不易产生药物蓄积作用，具有很高的安全性。", "ner": [[0, 3, "Drug"], [4, 5, "Method"], [13, 16, "Pathogenesis"], [42, 45, "Duration"], [70, 73, "Drug"], [125, 128, "Disease"], [125, 126, "Anatomy"], [102, 106, "Disease"], [102, 102, "Anatomy"]], "rel": [[4, 5, "Method", 0, 3, "Drug", "Method_Drug"], [42, 45, "Duration", 0, 3, "Drug", "Duration_Drug"], [125, 126, "Anatomy", 125, 128, "Disease", "Anatomy_Disease"], [102, 102, "Anatomy", 102, 106, "Disease", "Anatomy_Disease"]]}
{"idx": 1804, "sentence": "格列喹酮药代动力学不受血糖、年龄、肾功能的影响。", "ner": [[0, 3, "Drug"], [11, 12, "Test_items"]], "rel": []}
{"idx": 1805, "sentence": "格列喹酮通过与胰岛β细胞膜上磺脲受体结合促进胰岛素分泌，该结合作用短效可逆，避免了对细胞的持续刺激，降低了发生低血糖的风险。动物试验和床研究均证实，格列喹酮可有效控制餐后血糖(PPG)及血糖波动，促胰岛素分泌的达峰时间为30-~0min，在120~180min后逐渐下降，可见格列喹酮通过促进胰岛素早期时相分泌，较好地模拟生理胰岛素分泌模式，同时降糖作用维持时间适中，可避免下餐前低血糖。", "ner": [[0, 3, "Drug"], [55, 57, "ADE"], [74, 77, "Drug"], [83, 91, "Test_items"], [93, 94, "Test_items"], [95, 96, "Test_Value"], [138, 141, "Drug"], [190, 192, "ADE"]], "rel": [[55, 57, "ADE", 0, 3, "Drug", "ADE_Drug"], [190, 192, "ADE", 138, 141, "Drug", "ADE_Drug"]]}
{"idx": 1806, "sentence": "研究表明，格列喹酮还可有效改善β细胞功能障碍，改善胰岛素抵抗，增强胰岛素敏感性，其作用机制与增强PPAR靶基因的表达有关，另外，格列喹酮还可通过增加外周组织细胞上胰岛素受体的数目、促进肌细胞葡萄糖摄取等胰外作用协同降低血糖。", "ner": [[5, 8, "Drug"], [25, 29, "Pathogenesis"], [15, 21, "Pathogenesis"], [64, 67, "Drug"], [109, 110, "Test_items"]], "rel": []}
{"idx": 1807, "sentence": "格列酮可有效降低尿白蛋白排率泄，并能够抑制NF-κB及其下游炎症因子的激活，抑制糖基化终产物诱导的人肾系膜细胞RANTES的表达和分泌，从而减缓糖尿病肾病的发生发展.。", "ner": [[0, 2, "Drug"], [72, 74, "Disease"], [75, 76, "Disease"], [75, 75, "Anatomy"]], "rel": [[75, 75, "Anatomy", 75, 76, "Disease", "Anatomy_Disease"]]}
{"idx": 1808, "sentence": "格列喹酮对胰岛β细胞具高度选择性，对心肌细胞、血管平滑肌细胞亲和力弱，因此安全性更高。动物研究显示，格列喹酮具有抗血小板聚集的活性，抗动脉粥样硬化，改善血脂指标，对体重无影响。", "ner": [[0, 3, "Drug"], [50, 53, "Drug"], [76, 77, "Test_items"], [67, 72, "Disease"], [67, 68, "Anatomy"]], "rel": [[50, 53, "Drug", 67, 72, "Disease", "Drug_Disease"], [76, 77, "Test_items", 67, 72, "Disease", "Test_items_Disease"], [67, 68, "Anatomy", 67, 72, "Disease", "Anatomy_Disease"]]}
{"idx": 1809, "sentence": "二、格列喹酮临床有效性及安全性", "ner": [[2, 5, "Drug"]], "rel": []}
{"idx": 1810, "sentence": "1.格列喹酮单药治疗降糖有效性及安全性", "ner": [[2, 5, "Drug"]], "rel": []}
{"idx": 1811, "sentence": "我国一项使用格列哇喹4.5年的同回性分析结果显示：格列喹酮单药治疗2型糖尿病，HbA1c降幅1.31%，PPG降幅4.88mmol/L，空腹血糖(FPG)降3幅.88mmol/L。而格列喹酮早期的队列研究结果显示：服用格列哇喹的患者仅有0.13%发生轻度低血糖事件，无严重低血糖发生。", "ner": [[6, 9, "Drug"], [25, 28, "Drug"], [33, 37, "Disease"], [39, 43, "Test_items"], [44, 50, "Test_Value"], [52, 54, "Test_items"], [55, 66, "Test_Value"], [68, 76, "Test_items"], [77, 88, "Test_Value"], [91, 94, "Drug"], [109, 112, "Drug"], [127, 129, "ADE"], [136, 138, "ADE"]], "rel": [[25, 28, "Drug", 33, 37, "Disease", "Drug_Disease"], [39, 43, "Test_items", 33, 37, "Disease", "Test_items_Disease"], [52, 54, "Test_items", 33, 37, "Disease", "Test_items_Disease"], [68, 76, "Test_items", 33, 37, "Disease", "Test_items_Disease"], [127, 129, "ADE", 109, 112, "Drug", "ADE_Drug"]]}
{"idx": 1812, "sentence": "可见格列喹酮单药治疗能够全面控制患者血糖，并具有良好的安全性和耐受性。", "ner": [[2, 5, "Drug"], [18, 19, "Test_items"]], "rel": []}
{"idx": 1813, "sentence": "国内一项涉及10家医疗机构、2型糖尿病患者的多中心、自身对照临床试验对格列哇喹的量效关系研究显示，2/3的患者使用30-~20mg/d，若血糖控制不佳可增加剂量，平均剂量为112mg/dl即使剂量增加至270mg/d也无更多低血糖反应发生。", "ner": [[14, 18, "Disease"], [35, 38, "Drug"], [57, 66, "Amount"], [69, 70, "Test_items"], [71, 74, "Test_Value"], [86, 93, "Amount"], [101, 107, "Amount"], [112, 114, "ADE"]], "rel": [[35, 38, "Drug", 14, 18, "Disease", "Drug_Disease"], [69, 70, "Test_items", 14, 18, "Disease", "Test_items_Disease"], [57, 66, "Amount", 35, 38, "Drug", "Amount_Drug"], [86, 93, "Amount", 35, 38, "Drug", "Amount_Drug"], [101, 107, "Amount", 35, 38, "Drug", "Amount_Drug"], [112, 114, "ADE", 35, 38, "Drug", "ADE_Drug"]]}
{"idx": 1814, "sentence": "提示在一定剂量范围内，格列哇喹降糖作用呈剂量依赖性。", "ner": [[11, 14, "Drug"]], "rel": []}
{"idx": 1815, "sentence": "2.格列喹酮联合治疗降糖有效性及安全性", "ner": [[2, 5, "Drug"]], "rel": []}
{"idx": 1816, "sentence": "(1)格列喹酮与二甲双胍联合：一项多中心、随机、开放、平行分组对照研究显示：格列喹酮在单药和(或)联合治疗失败的2型糖尿病患者中与二甲双胍联合治疗14周后，平均HbA1c下降1.7%，HbA1c<6.5%及HbA1c<7.0%的达标率分别为25.71%及42.86%，均高于阿卡波糖联合二甲双胍组；格列喹酮组对PPG降低幅度达4.75mmol/L，是阿卡波糖组的2倍以上：对FPG降低度为1.0mmol/L。", "ner": [[3, 6, "Drug"], [8, 11, "Drug"], [38, 41, "Drug"], [56, 60, "Disease"], [65, 68, "Drug"], [73, 76, "Duration"], [80, 84, "Test_items"], [85, 90, "Test_Value"], [92, 96, "Test_items"], [97, 101, "Test_Value"], [103, 107, "Test_items"], [108, 112, "Test_Value"], [137, 140, "Drug"], [143, 146, "Drug"], [149, 152, "Drug"], [155, 157, "Test_items"], [158, 172, "Test_Value"], [175, 178, "Drug"], [187, 189, "Test_items"], [190, 202, "Test_Value"]], "rel": [[3, 6, "Drug", 56, 60, "Disease", "Drug_Disease"], [8, 11, "Drug", 56, 60, "Disease", "Drug_Disease"], [73, 76, "Duration", 38, 41, "Drug", "Duration_Drug"], [80, 84, "Test_items", 56, 60, "Disease", "Test_items_Disease"], [73, 76, "Duration", 65, 68, "Drug", "Duration_Drug"]]}
{"idx": 1817, "sentence": "此外，格列喹酮组可改善胰岛素抵抗。", "ner": [[3, 6, "Drug"], [11, 15, "Pathogenesis"]], "rel": []}
{"idx": 1818, "sentence": "(2)格列喹酮与胰岛素联合：格列喹酮与中效胰岛素联合治疗降低患者HbA1c、PPG及FPG的效果优于预混胰岛素组(P<0.05)，同时不增加低血糖发生率。", "ner": [[3, 6, "Drug"], [8, 10, "Drug"], [14, 17, "Drug"], [19, 23, "Drug"], [32, 36, "Test_items"], [38, 40, "Test_items"], [42, 44, "Test_items"], [50, 54, "Drug"], [70, 72, "ADE"]], "rel": []}
{"idx": 1819, "sentence": "中效胰岛素可以明显改善空腹血糖，但对餐后血糖控制欠佳者，联合格列喹酮治疗可以很好地克服这一问题。", "ner": [[0, 4, "Drug"], [11, 14, "Test_items"], [18, 21, "Test_items"], [22, 25, "Test_Value"], [30, 33, "Drug"]], "rel": []}
{"idx": 1820, "sentence": "(4)格列喹酮与二肽基肽酶-Ⅳ抑制剂(DPP-4i)联合：格列喹酮与西格列汀联合治疗初诊2型糖尿病患者的研究结果显示：联合用药治疗后患者平均血糖FPG6.5mmol/L、PPG7.3mmol/L、HbA1c6.2%，降糖效果优于单用西格列汀(P<0.01)，无低血糖发生，且能够改善胰岛素抵抗。", "ner": [[3, 6, "Drug"], [8, 25, "Drug"], [29, 32, "Drug"], [34, 37, "Drug"], [44, 48, "Disease"], [72, 74, "Test_items"], [75, 83, "Test_Value"], [85, 87, "Test_items"], [88, 96, "Test_Value"], [98, 102, "Test_items"], [103, 106, "Test_Value"], [116, 119, "Drug"], [130, 132, "ADE"], [141, 145, "Pathogenesis"], [68, 71, "Test_items"]], "rel": [[29, 32, "Drug", 44, 48, "Disease", "Drug_Disease"], [34, 37, "Drug", 44, 48, "Disease", "Drug_Disease"], [72, 74, "Test_items", 44, 48, "Disease", "Test_items_Disease"], [98, 102, "Test_items", 44, 48, "Disease", "Test_items_Disease"], [68, 71, "Test_items", 44, 48, "Disease", "Test_items_Disease"], [141, 145, "Pathogenesis", 44, 48, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1821, "sentence": "(5)格列喹酮与噻唑烷二酮类(TZDs)联合：格列喹酮等磺脲类药物与罗格列酮联合应用治疗2型糖尿病患者的研究结果显示，可有效降低HbA1c、PPG及FPG(P<0.05)，改善胰岛素抵抗及高胰岛素血症，且未监测到低血糖发生。", "ner": [[3, 6, "Drug"], [8, 19, "Drug"], [23, 26, "Drug"], [28, 32, "Drug"], [34, 37, "Drug"], [44, 48, "Disease"], [64, 68, "Test_items"], [70, 72, "Test_items"], [74, 76, "Test_items"], [88, 92, "Pathogenesis"], [106, 108, "ADE"], [94, 99, "Disease"]], "rel": [[23, 26, "Drug", 44, 48, "Disease", "Drug_Disease"], [28, 32, "Drug", 44, 48, "Disease", "Drug_Disease"], [34, 37, "Drug", 44, 48, "Disease", "Drug_Disease"], [64, 68, "Test_items", 44, 48, "Disease", "Test_items_Disease"], [70, 72, "Test_items", 44, 48, "Disease", "Test_items_Disease"], [74, 76, "Test_items", 44, 48, "Disease", "Test_items_Disease"], [88, 92, "Pathogenesis", 44, 48, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1822, "sentence": "建议：对于应用基础胰岛素或其他口服降糖药不能有效控制血糖的患者，格列喹酮可与多种降糖药物联合使用，通过机制互补增加降糖作用，降低不良反应。", "ner": [[9, 11, "Drug"], [15, 16, "Method"], [26, 27, "Test_items"], [32, 35, "Drug"]], "rel": []}
{"idx": 1823, "sentence": "一般不推荐与餐时胰岛素或其他促泌剂联用。", "ner": [[6, 10, "Drug"]], "rel": []}
{"idx": 1824, "sentence": "三、格列喹酮应用于特殊人群", "ner": [[2, 5, "Drug"]], "rel": []}
{"idx": 1825, "sentence": "1.老年患者", "ner": [], "rel": []}
{"idx": 1826, "sentence": "对于格列喹酮治疗平均年龄60岁老年患者、近4年半的回顾性分析中，格列喹酮单药及联合治疗1年后，HbA1c下降1.7%，PPG下降6.38mmol/L，FPG下降4.45mmo/L(P<0.01)；另一项针对老年患者的研究显示格列喹酮在降糖的同时可有效改善尿蛋白排泄率(UAE)、β细胞功能指数(HOMA-β)(P<0.001)。以上两项研究的安全性分析显示格列喹酮长期应用低血糖发生人次较少且均为轻度低血糖，进食或调整药物剂量后好转，无低血糖昏迷。", "ner": [[2, 5, "Drug"], [32, 35, "Drug"], [47, 51, "Test_items"], [52, 57, "Test_Value"], [59, 61, "Test_items"], [62, 73, "Test_Value"], [75, 77, "Test_items"], [78, 88, "Test_Value"], [112, 115, "Drug"], [178, 181, "Drug"], [186, 188, "ADE"], [198, 199, "Level"], [200, 202, "ADE"], [218, 220, "ADE"]], "rel": [[186, 188, "ADE", 178, 181, "Drug", "ADE_Drug"]]}
{"idx": 1827, "sentence": "建议：格列喹酮治疗老年2型糖尿病患者低血糖发生率较低，且调整剂量方便，推荐作为老年2型糖尿病患者磺脲类药物的优先选择之一。", "ner": [[3, 6, "Drug"], [11, 15, "Disease"], [18, 20, "ADE"], [41, 45, "Disease"], [48, 52, "Drug"]], "rel": [[3, 6, "Drug", 11, 15, "Disease", "Drug_Disease"], [18, 20, "ADE", 3, 6, "Drug", "ADE_Drug"]]}
{"idx": 1828, "sentence": "2.慢性肾病(CKD)1~5期患者", "ner": [[2, 10, "Disease"], [4, 4, "Anatomy"]], "rel": [[4, 4, "Anatomy", 2, 10, "Disease", "Anatomy_Disease"]]}
{"idx": 1829, "sentence": "老年男性2型糖尿病早期肾病患者[尿白蛋白/肌酐比值(ACR)≥30μg/mg，血肌酐(SCr)<177.8μmol/L]经格列喹酮治疗2个月后血糖各指标显著下降，研究结果显示不升高患者尿氮素(BUN)、SCr、ACR。", "ner": [[4, 8, "Disease"], [11, 12, "Disease"], [11, 11, "Anatomy"], [16, 29, "Test_items"], [30, 37, "Test_Value"], [39, 46, "Test_items"], [47, 59, "Test_Value"], [61, 64, "Drug"], [67, 70, "Duration"], [71, 72, "Test_items"], [78, 79, "Test_Value"], [92, 99, "Test_items"], [101, 103, "Test_items"], [105, 107, "Test_items"]], "rel": [[16, 29, "Test_items", 4, 8, "Disease", "Test_items_Disease"], [39, 46, "Test_items", 4, 8, "Disease", "Test_items_Disease"], [71, 72, "Test_items", 4, 8, "Disease", "Test_items_Disease"], [61, 64, "Drug", 4, 8, "Disease", "Drug_Disease"], [11, 11, "Anatomy", 11, 12, "Disease", "Anatomy_Disease"], [67, 70, "Duration", 61, 64, "Drug", "Duration_Drug"]]}
{"idx": 1830, "sentence": "甚至UAE明显降低，SCr水平呈下降趋势，内皮素(ET)、血栓因子2(TXB2)降低，一氧化氮(NO)浓度、前列腺素Flα(PGFlα)升高，意味着格列喹酮通过减少血小板聚集，改善肾血管收缩状态，纠正缺血和炎症，增加肾血流量，实现肾功能改善作用。", "ner": [[10, 12, "Test_items"], [16, 17, "Test_Value"], [7, 8, "Test_Value"], [2, 4, "Test_items"], [21, 27, "Test_items"], [29, 39, "Test_items"], [40, 41, "Test_Value"], [43, 52, "Test_items"], [54, 67, "Test_items"], [68, 69, "Test_Value"], [74, 77, "Drug"]], "rel": []}
{"idx": 1831, "sentence": "四、总结", "ner": [], "rel": []}
{"idx": 1832, "sentence": "格列喹酮是具有肾脏保护作用的胰岛素促泌剂，降糖效果明确，低血糖风险低，不影响体重。单药治疗可全面降糖，亦可与其他非胰岛素促泌剂广泛联合，剂量调整方便，利于个体化治疗，价格合理。主要适用人群为2型糖尿病患者，包括：PPG升高为主的2型糖尿病患者、老年患者和CKD各期患者。由此，格列喹酮可作为中国2型糖尿病患者降糖治疗的一线用药。", "ner": [[0, 3, "Drug"], [14, 19, "Drug"], [28, 30, "ADE"], [57, 62, "Drug"], [95, 99, "Disease"], [106, 108, "Test_items"], [109, 110, "Test_Value"], [114, 118, "Disease"], [127, 129, "Disease"], [138, 141, "Drug"], [147, 151, "Disease"]], "rel": [[28, 30, "ADE", 0, 3, "Drug", "ADE_Drug"], [106, 108, "Test_items", 95, 99, "Disease", "Test_items_Disease"], [138, 141, "Drug", 147, 151, "Disease", "Drug_Disease"]]}
{"idx": 1833, "sentence": "建议：2015年《2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识(2015)》建议格列喹酮在2型糖尿病合并CKD1~3b期(GFR≥30ml/min)患者中可用，GFR<60ml/min时只有格列喹酮是唯一无需调整剂量的口服磺脲类降糖药；2010年《美国综合临床肾脏病学》推荐格列喹酮在CKD~-5期全程均可使用；2015年欧洲肾脏最佳临床实践(European Renal Best Practice，ERBP)颁布了《糖尿病合并慢性肾脏病3b期或以上(DM-CKD3b~5)患者的诊疗指南》，建议格列喹酮用于CKD1~5期，全程均不需要剂量调整；格列喹酮可有效降低蛋白尿水平，延缓或逆转糖尿病肾病的进一步进展；格列喹酮在老年2型糖尿病合并肾病患者中降糖安全有效。", "ner": [[9, 13, "Disease"], [16, 20, "Disease"], [18, 19, "Anatomy"], [21, 22, "Method"], [45, 48, "Drug"], [50, 54, "Disease"], [57, 59, "Disease"], [100, 103, "Drug"], [114, 115, "Method"], [116, 118, "Drug"], [135, 137, "Disease"], [135, 136, "Anatomy"], [142, 145, "Drug"], [147, 149, "Disease"], [215, 217, "Disease"], [220, 224, "Disease"], [232, 233, "Disease"], [235, 237, "Disease"], [254, 257, "Drug"], [260, 262, "Disease"], [279, 282, "Drug"], [299, 303, "Disease"], [311, 314, "Drug"], [318, 322, "Disease"], [325, 326, "Disease"], [325, 325, "Anatomy"], [222, 223, "Anatomy"], [302, 302, "Anatomy"]], "rel": [[45, 48, "Drug", 50, 54, "Disease", "Drug_Disease"], [114, 115, "Method", 116, 118, "Drug", "Method_Drug"], [135, 136, "Anatomy", 135, 137, "Disease", "Anatomy_Disease"], [142, 145, "Drug", 135, 137, "Disease", "Drug_Disease"], [222, 223, "Anatomy", 220, 224, "Disease", "Anatomy_Disease"], [279, 282, "Drug", 299, 303, "Disease", "Drug_Disease"], [302, 302, "Anatomy", 299, 303, "Disease", "Anatomy_Disease"], [311, 314, "Drug", 318, 322, "Disease", "Drug_Disease"], [325, 325, "Anatomy", 325, 326, "Disease", "Anatomy_Disease"]]}
{"idx": 1834, "sentence": "(3)格列喹酮与α-糖苷酶抑制剂联合：格列喹酮与阿卡波糖联合治疗老年2型糖尿病患者的研究结果显示：联合用药对PPG及FPG的降幅均大于单用阿卡波糖，同时由于药物剂量减少，胃肠道不适等不良反应发生率明显降低，且无一例出现低血糖反应。", "ner": [[3, 6, "Drug"], [8, 15, "Drug"], [19, 22, "Drug"], [24, 27, "Drug"], [34, 38, "Disease"], [54, 56, "Test_items"], [58, 60, "Test_items"], [69, 72, "Drug"], [85, 89, "ADE"], [109, 111, "ADE"]], "rel": [[19, 22, "Drug", 34, 38, "Disease", "Drug_Disease"], [85, 89, "ADE", 19, 22, "Drug", "ADE_Drug"], [24, 27, "Drug", 34, 38, "Disease", "Drug_Disease"], [85, 89, "ADE", 24, 27, "Drug", "ADE_Drug"], [54, 56, "Test_items", 34, 38, "Disease", "Test_items_Disease"], [58, 60, "Test_items", 34, 38, "Disease", "Test_items_Disease"]]}
{"idx": 1835, "sentence": "建议：(1)格列喹酮对2型糖尿病患者各项血糖指标均有很好的控制作用，可作为2型糖尿病降糖选择的一线用药之一；对于主要以PPG升高为主的，或新发2型糖尿病患者，格列喹酮可作为磺脲类药物的优先选择。(2)格列喹酮临床处方剂量范围为15~180mg/d，根据长期临床使用经验，在综合考虑患者耐受程度及经济情况等条件的前提下，推荐使用格列喹酮单药治疗90mg/d(30mg，Tid)能够尽快使血糖达标；若患者控糖效果不理想，可综合考虑患者基本情况增加临床处方剂量，推荐最大剂量180mg/d(60mg，Tid)。", "ner": [[6, 9, "Drug"], [11, 15, "Disease"], [20, 21, "Test_items"], [37, 41, "Disease"], [59, 61, "Test_items"], [62, 63, "Test_Value"], [71, 75, "Disease"], [79, 82, "Drug"], [86, 90, "Drug"], [100, 103, "Drug"], [113, 122, "Amount"], [163, 166, "Drug"], [171, 186, "Amount"], [192, 193, "Test_items"], [194, 195, "Test_Value"], [234, 250, "Amount"]], "rel": [[6, 9, "Drug", 11, 15, "Disease", "Drug_Disease"], [20, 21, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [59, 61, "Test_items", 71, 75, "Disease", "Test_items_Disease"], [79, 82, "Drug", 71, 75, "Disease", "Drug_Disease"], [86, 90, "Drug", 71, 75, "Disease", "Drug_Disease"], [113, 122, "Amount", 100, 103, "Drug", "Amount_Drug"], [171, 186, "Amount", 163, 166, "Drug", "Amount_Drug"], [234, 250, "Amount", 163, 166, "Drug", "Amount_Drug"]]}
{"idx": 1836, "sentence": "成人2 型糖尿病基础胰岛素临床应用中国专家指导建议", "ner": [[10, 12, "Drug"], [2, 7, "Disease"]], "rel": [[10, 12, "Drug", 2, 7, "Disease", "Drug_Disease"]]}
{"idx": 1837, "sentence": "一、前言", "ner": [], "rel": []}
{"idx": 1838, "sentence": "T2DM是慢性进展性疾病，随着自然病程的进展，胰岛β细胞功能进行性减退，胰岛素补充或替代治疗成为控制T2DM患者高血糖的有效手段。基础胰岛素是常用的胰岛素治疗方案，具有低血糖风险低，使用简单方便等优点，国内外指南均推荐，口服降糖药治疗血糖控制不佳时即可起始基础胰岛素与口服药联合治疗。但临床研究显示，中国T2DM患者起始基础胰岛素治疗较晚(起始胰岛素时HbA1c已达9.6 %)，起始剂量偏低且在起始治疗后剂量调整不足，是导致起始胰岛素治疗后血糖控制不满意的重要原因。为规范基础胰岛素在临床中的合理使用，我国内分泌临床专家基于循证医学依据，共同制定了《成人2 型糖尿病基础胰岛素临床应用中国专家指导建议》，以供临床参考。", "ner": [[0, 3, "Disease"], [23, 34, "Pathogenesis"], [50, 53, "Disease"], [56, 58, "Disease"], [67, 69, "Drug"], [74, 76, "Drug"], [84, 86, "ADE"], [110, 111, "Method"], [117, 118, "Test_items"], [119, 122, "Test_Value"], [130, 132, "Drug"], [134, 135, "Method"], [152, 155, "Disease"], [162, 164, "Drug"], [172, 174, "Drug"], [176, 180, "Test_items"], [183, 187, "Test_Value"], [215, 217, "Drug"], [221, 222, "Test_items"], [239, 241, "Drug"], [278, 283, "Disease"], [286, 288, "Drug"]], "rel": [[23, 34, "Pathogenesis", 0, 3, "Disease", "Pathogenesis_Disease"], [84, 86, "ADE", 67, 69, "Drug", "ADE_Drug"], [162, 164, "Drug", 152, 155, "Disease", "Drug_Disease"], [286, 288, "Drug", 278, 283, "Disease", "Drug_Disease"]]}
{"idx": 1839, "sentence": "二、基础胰岛素种类及其特点", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 1840, "sentence": "在生理非进食状态下胰岛β细胞持续分泌的胰岛素被称为基础胰岛素，约占胰岛素全天分泌总量的50%。基础胰岛素通过抑制肝脏中肝糖原分解和糖异生作用而减少肝糖输出控制基础血糖。经皮下注射的外源性基础胰岛素药物具有和内源性基础胰岛素相似的特性，能模拟正常人体的生理性基础胰岛素作用。", "ner": [[85, 88, "Method"], [93, 97, "Drug"], [108, 110, "Drug"], [130, 132, "Drug"]], "rel": [[85, 88, "Method", 93, 97, "Drug", "Method_Drug"]]}
{"idx": 1841, "sentence": "目前，国内临床使用的基础胰岛素主要包括中效胰岛素(NPH，中性鱼精蛋白锌胰岛素)、长效胰岛素(PZI，精蛋白锌胰岛素)和长效人胰岛素类似物(甘精胰岛素，地特胰岛素等)(表1)。NPH是人胰岛素锌晶体与鱼精蛋白结合而制成的基础胰岛素，作用时间13~16h，且具有明显峰值，变异性较大，低血糖发生的风险相对高。长效人胰岛素类似物甘精胰岛素在人胰岛素的基础上经氨基酸序列修饰，能更好地模拟生理性胰岛素分泌，减少低血糖风险，是我国使用最广泛的基础胰岛素。甘精胰岛素在中性pH液中溶解度低，皮下注射后形成细微沉淀物，其中的多聚体在皮下持续缓慢释放，达到24h平稳、无峰的血药浓度。地特胰岛素是另一种长效人胰岛素类似物，在人胰岛素的基础上经分子结构修饰，皮下注射后自我聚集作用增强，同时添加的脂肪酸侧链与白蛋白可逆结合，从而可延长药物的吸收和作用时间，相对长效人胰岛素类似物，中效胰岛素的价格较低。", "ner": [[19, 23, "Drug"], [25, 27, "Drug"], [29, 38, "Drug"], [41, 45, "Drug"], [47, 49, "Drug"], [51, 57, "Drug"], [60, 68, "Drug"], [70, 74, "Drug"], [76, 80, "Drug"], [88, 90, "Drug"], [141, 143, "ADE"], [112, 114, "Drug"], [153, 161, "Drug"], [162, 166, "Drug"], [168, 171, "Drug"], [202, 204, "ADE"], [219, 221, "Drug"], [223, 227, "Drug"], [240, 243, "Method"], [280, 283, "Pathogenesis"], [285, 289, "Drug"], [294, 302, "Drug"], [305, 308, "Drug"], [321, 324, "Method"], [372, 380, "Drug"], [382, 386, "Drug"]], "rel": [[141, 143, "ADE", 88, 90, "Drug", "ADE_Drug"], [202, 204, "ADE", 219, 221, "Drug", "ADE_Drug"], [240, 243, "Method", 223, 227, "Drug", "Method_Drug"], [321, 324, "Method", 305, 308, "Drug", "Method_Drug"]]}
{"idx": 1842, "sentence": "三、基础胰岛素临床使用方案", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 1843, "sentence": "1.概述：控制高血糖与微血管、大血管病变发生的风险下降相关。临床研究证实，糖尿病患者早期进行积极有效的降糖治疗，能够显著降低血管并发症的发生风险，而在病程较长的患者中，强化降糖并未带来心血管获益。所以糖尿病患者在早期即维持良好的血糖控制至关重要。随着病情进展，T2DM患者胰岛β细胞功能逐渐减退，胰岛素补充或替代治疗成为T2DM高血糖管理的重要手段。对于使用1~2种口服药血糖控制不佳的患者，即可以考虑联合基础胰岛素注射以进一步改善血糖控制。对于口服降糖药与基础胰岛素联合使用后血糖仍无法达标的患者，可以使用基础胰岛素联合1~3次餐时胰岛素治疗进一步控制血糖。", "ner": [[7, 9, "Disease"], [11, 19, "Disease"], [11, 13, "Anatomy"], [15, 17, "Anatomy"], [37, 39, "Disease"], [62, 66, "ADE"], [100, 102, "Disease"], [114, 115, "Test_items"], [130, 133, "Disease"], [148, 150, "Drug"], [136, 146, "Pathogenesis"], [160, 163, "Disease"], [164, 166, "Disease"], [183, 184, "Method"], [186, 187, "Test_items"], [205, 207, "Drug"], [208, 209, "Method"], [216, 217, "Test_items"], [223, 224, "Method"], [231, 233, "Drug"], [239, 240, "Test_items"], [256, 258, "Drug"], [261, 264, "Frequency"], [267, 269, "Drug"], [277, 278, "Test_items"], [188, 191, "Test_Value"]], "rel": [[11, 13, "Anatomy", 11, 19, "Disease", "Anatomy_Disease"], [15, 17, "Anatomy", 11, 19, "Disease", "Anatomy_Disease"], [114, 115, "Test_items", 100, 102, "Disease", "Test_items_Disease"], [148, 150, "Drug", 130, 133, "Disease", "Drug_Disease"], [208, 209, "Method", 205, 207, "Drug", "Method_Drug"], [261, 264, "Frequency", 256, 258, "Drug", "Frequency_Drug"]]}
{"idx": 1844, "sentence": "血糖控制的目标应根据个体化原则，综合考虑患者的年龄、病程、预期寿命、伴发疾病、降糖治疗方案及患者意愿等情况制定。对于大多数非妊娠成年T2DM患者，合理的血糖控制目标为HbA1c<7%、FPG4.4~7.0mmol/L；对于病程较短、预期寿命较长、无严重并发症或低血糖风险低的患者可设定较为严格的血糖控制目标，HbA1c≤6.5%、FPG<6.1mmol/L；而对于有严重低血糖史、预期寿命较短、合并严重并发症的患者，血糖控制目标较为宽松，HbA1c<8.0%、FPG<8.0mmol/L或更高(表2)。", "ner": [[0, 1, "Test_items"], [66, 69, "Disease"], [76, 77, "Test_items"], [83, 87, "Test_items"], [88, 90, "Test_Value"], [92, 94, "Test_items"], [95, 107, "Test_Value"], [124, 125, "Level"], [130, 132, "ADE"], [147, 148, "Test_items"], [154, 158, "Test_items"], [159, 163, "Test_Value"], [165, 167, "Test_items"], [168, 177, "Test_Value"], [183, 184, "Level"], [185, 187, "Disease"], [199, 200, "Level"], [208, 209, "Test_items"], [219, 223, "Test_items"], [224, 228, "Test_Value"], [230, 232, "Test_items"], [233, 242, "Test_Value"]], "rel": [[76, 77, "Test_items", 66, 69, "Disease", "Test_items_Disease"], [83, 87, "Test_items", 66, 69, "Disease", "Test_items_Disease"], [92, 94, "Test_items", 66, 69, "Disease", "Test_items_Disease"]]}
{"idx": 1845, "sentence": "2.口服降糖药联合基础胰岛素方案", "ner": [[2, 3, "Method"], [11, 13, "Drug"]], "rel": [[2, 3, "Method", 11, 13, "Drug", "Method_Drug"]]}
{"idx": 1846, "sentence": "(1)适用人群：高血糖(FPG>11.1mmol/L，或HbA1c>9%)伴明显高血糖症状的新诊断T2DM患者；1~2种口服降糖药(超重或肥胖患者1~3种口服降糖药)规范治疗3个月以上血糖控制仍未达标者；正在接受预混胰岛素治疗(低于50U/d)的患者血糖控制不佳，频繁发作低血糖者，或对每日2次预混胰岛素注射依从性差者。", "ner": [[8, 10, "Disease"], [12, 14, "Test_items"], [15, 25, "Test_Value"], [28, 32, "Test_items"], [33, 35, "Test_Value"], [40, 42, "Disease"], [49, 52, "Disease"], [60, 61, "Method"], [77, 78, "Method"], [87, 91, "Duration"], [92, 93, "Test_items"], [97, 99, "Test_Value"], [106, 110, "Drug"], [114, 120, "Amount"], [125, 126, "Test_items"], [127, 130, "Test_Value"], [136, 138, "ADE"], [143, 146, "Frequency"], [147, 151, "Drug"], [152, 153, "Method"]], "rel": [[12, 14, "Test_items", 8, 10, "Disease", "Test_items_Disease"], [28, 32, "Test_items", 8, 10, "Disease", "Test_items_Disease"], [87, 91, "Duration", 106, 110, "Drug", "Duration_Drug"], [114, 120, "Amount", 106, 110, "Drug", "Amount_Drug"], [136, 138, "ADE", 106, 110, "Drug", "ADE_Drug"], [143, 146, "Frequency", 106, 110, "Drug", "Frequency_Drug"], [152, 153, "Method", 147, 151, "Drug", "Method_Drug"]]}
{"idx": 1847, "sentence": "早期良好的血糖控制是降低远期并发症风险的重要手段。对于血糖较高伴高血糖症状的新诊断糖尿病患者，口服降糖药很难在短期内使血糖得到满意的控制，可使用口服降糖药与基础胰岛素联合治疗，使血糖达标，并部分恢复胰岛β细胞功能。对于已使用口服降糖药治疗的患者，当1~2种较大剂量的口服降糖药规范治疗3个月以上血糖仍未达标时，也可联合使用基础胰岛素以进一步控制血糖。对15项随机对照研究进行的汇总分析也提示，使用二甲双胍和/或磺脲类药物血糖控制不佳的T2DM患者，起始基础胰岛素治疗后，能有效控制血糖，且不会增加严重低血糖发生的风险。", "ner": [[5, 6, "Test_items"], [27, 28, "Test_items"], [29, 30, "Test_Value"], [32, 34, "Disease"], [41, 43, "Disease"], [47, 48, "Method"], [59, 60, "Test_items"], [72, 73, "Method"], [80, 82, "Drug"], [89, 90, "Test_items"], [91, 92, "Test_Value"], [112, 113, "Method"], [133, 134, "Method"], [142, 146, "Duration"], [147, 148, "Test_items"], [150, 152, "Test_Value"], [163, 165, "Drug"], [172, 173, "Test_items"], [198, 201, "Drug"], [205, 209, "Drug"], [210, 211, "Test_items"], [212, 215, "Test_Value"], [217, 220, "Disease"], [228, 230, "Drug"], [240, 241, "Test_items"], [248, 249, "Level"], [250, 252, "ADE"]], "rel": [[59, 60, "Test_items", 41, 43, "Disease", "Test_items_Disease"], [198, 201, "Drug", 217, 220, "Disease", "Drug_Disease"], [205, 209, "Drug", 217, 220, "Disease", "Drug_Disease"], [250, 252, "ADE", 228, 230, "Drug", "ADE_Drug"]]}
{"idx": 1848, "sentence": "对于临床中使用口服药联合预混胰岛素治疗的患者，若其血糖控制不满意且患者病程较短，有一定残存胰岛β细胞功能，也可尝试调整为基础胰岛素与口服降糖药联合治疗。研究发现，在血糖控制不满意，病程<10年，预混胰岛素剂量<50U/d的患者中，将预混胰岛素转换为基础胰岛素联合口服药治疗方案后，能够显著改善血糖，并较继续使用并优化预混胰岛素低血糖发生的风险低。", "ner": [[7, 8, "Method"], [12, 16, "Drug"], [25, 26, "Test_items"], [62, 64, "Drug"], [66, 67, "Method"], [82, 83, "Test_items"], [97, 101, "Drug"], [104, 109, "Amount"], [116, 120, "Drug"], [126, 128, "Drug"], [131, 132, "Method"], [146, 147, "Test_items"], [158, 162, "Drug"], [163, 165, "ADE"], [27, 31, "Test_Value"], [84, 88, "Test_Value"]], "rel": [[104, 109, "Amount", 97, 101, "Drug", "Amount_Drug"], [163, 165, "ADE", 158, 162, "Drug", "ADE_Drug"]]}
{"idx": 1849, "sentence": "(2)与基础胰岛素联合使用的口服降糖药种类及注意事项：不同口服降糖药的降糖作用机制不同，临床上与基础胰岛素联合使用时，需根据药物特点，注意监测血糖及可能出现的不良反应(表3)。", "ner": [[6, 8, "Drug"], [14, 15, "Method"], [29, 30, "Method"], [50, 52, "Drug"], [69, 72, "Test_items"]], "rel": []}
{"idx": 1850, "sentence": "(3)临床使用建议", "ner": [], "rel": []}
{"idx": 1851, "sentence": "①? 基础胰岛素起始方法：血糖明显增高伴有明显高血糖症状的新诊断糖尿病患者或口服降糖药治疗血糖控制不佳的患者起始基础胰岛素时，可根据体重计算起始剂量，通常为0.1~0.3U/(kg·d)，肥胖患者或HbA1c>8.0%时，可考虑0.2~0.3U/（kg·d)起始。", "ner": [[5, 7, "Drug"], [13, 14, "Test_items"], [17, 18, "Test_Value"], [23, 25, "Disease"], [32, 34, "Disease"], [38, 39, "Method"], [45, 46, "Test_items"], [47, 50, "Test_Value"], [58, 60, "Drug"], [78, 92, "Amount"], [99, 103, "Test_items"], [104, 108, "Test_Value"], [114, 128, "Amount"]], "rel": [[5, 7, "Drug", 32, 34, "Disease", "Drug_Disease"], [13, 14, "Test_items", 23, 25, "Disease", "Test_items_Disease"], [45, 46, "Test_items", 32, 34, "Disease", "Test_items_Disease"], [99, 103, "Test_items", 32, 34, "Disease", "Test_items_Disease"], [78, 92, "Amount", 58, 60, "Drug", "Amount_Drug"], [114, 128, "Amount", 58, 60, "Drug", "Amount_Drug"]]}
{"idx": 1852, "sentence": "从预混胰岛素治疗转换为基础胰岛素时，可依据血糖水平，按照原预混胰岛素总剂量的60%~80%起始基础胰岛素。", "ner": [[1, 5, "Drug"], [13, 15, "Drug"], [21, 22, "Test_items"], [29, 33, "Drug"], [49, 51, "Drug"]], "rel": []}
{"idx": 1853, "sentence": "如HbA1c≤8.0%时，甘精胰岛素起始剂量=原预混胰岛素总量×0.6；HbA1c>8%时，甘精胰岛素推荐起始剂量=原预混胰岛素总量×0.8。", "ner": [[1, 5, "Test_items"], [6, 10, "Test_Value"], [13, 17, "Drug"], [24, 28, "Drug"], [36, 40, "Test_items"], [41, 43, "Test_Value"], [46, 50, "Drug"], [59, 63, "Drug"]], "rel": []}
{"idx": 1854, "sentence": "口服药种类和剂量根据患者个体情况酌情选择和调整。", "ner": [[0, 1, "Method"]], "rel": []}
{"idx": 1855, "sentence": "②剂量调整方案：剂量调整是胰岛素治疗中至关重要的一环，起始基础胰岛素治疗后，需根据FPG，在避免低血糖的情况下及时调整胰岛素剂量。只有通过积极的剂量调整，才能获得有效的血糖控制。多数患者长效胰岛素类似物剂量达到约0.5U/(kg·d)前，可通过继续调整剂量控制血糖，而无需调整治疗方案。在血糖未达到设定的血糖目标值前，建议患者在医生指导下，根据FPG，每周调整2~6U基础胰岛素直至FPG达标。对于能进行血糖监测、感知低血糖、进行自我管理的患者，医生可指导其进行简便易行的自我胰岛素剂量调整，每3天调整2~3U直至FPG达标(表4)。", "ner": [[13, 15, "Drug"], [31, 33, "Drug"], [41, 43, "Test_items"], [48, 50, "ADE"], [59, 61, "Drug"], [84, 85, "Test_items"], [93, 100, "Drug"], [106, 116, "Amount"], [130, 131, "Test_items"], [144, 145, "Test_items"], [152, 153, "Test_items"], [172, 174, "Test_items"], [180, 183, "Amount"], [191, 193, "Test_items"], [194, 195, "Test_Value"], [202, 205, "Test_items"], [209, 211, "ADE"], [238, 240, "Drug"], [251, 254, "Amount"], [257, 259, "Test_items"], [260, 261, "Test_Value"]], "rel": [[48, 50, "ADE", 59, 61, "Drug", "ADE_Drug"], [106, 116, "Amount", 93, 100, "Drug", "Amount_Drug"], [180, 183, "Amount", 238, 240, "Drug", "Amount_Drug"], [209, 211, "ADE", 238, 240, "Drug", "ADE_Drug"], [251, 254, "Amount", 238, 240, "Drug", "Amount_Drug"]]}
{"idx": 1856, "sentence": "3.基础胰岛素联合餐时胰岛素方案", "ner": [[4, 6, "Drug"], [11, 13, "Drug"]], "rel": []}
{"idx": 1857, "sentence": "(1)适用人群和使用方案：口服降糖药联合基础胰岛素治疗后，FPG达标，HbA1c仍不达标者，或使用较大剂量基础胰岛素后[如0.6U/(kg·d)]，血糖仍不达标者；使用多次预混胰岛素治疗，血糖控制不佳者或反复发作低血糖者；需短时间内纠正高血糖的糖尿病患者。", "ner": [[13, 14, "Method"], [22, 24, "Drug"], [29, 31, "Test_items"], [35, 39, "Test_items"], [41, 43, "Test_Value"], [55, 57, "Drug"], [61, 71, "Amount"], [74, 75, "Test_items"], [77, 79, "Test_Value"], [86, 90, "Drug"], [94, 95, "Test_items"], [96, 99, "Test_Value"], [106, 108, "ADE"], [118, 120, "Disease"], [122, 124, "Disease"]], "rel": [[61, 71, "Amount", 55, 57, "Drug", "Amount_Drug"], [86, 90, "Drug", 122, 124, "Disease", "Drug_Disease"], [106, 108, "ADE", 86, 90, "Drug", "ADE_Drug"], [94, 95, "Test_items", 122, 124, "Disease", "Test_items_Disease"]]}
{"idx": 1858, "sentence": "患者采用口服降糖药联合基础胰岛素治疗，FPG已达标，但HbA1c仍未达标时，可逐步增加1~3次餐时胰岛素注射以更好的控制血糖。如果患者在接受较高剂量基础胰岛素治疗后，血糖仍未达标，建议逐步增加餐时胰岛素进行治疗。预混胰岛素由于其短/速效胰岛素和中效胰岛素的比例固定，在提供个体化的胰岛素需求上有一定的局限性。对于每日多次预混胰岛素方案治疗，仍无法满意控制血糖或频发低血糖的患者，可以考虑使用基础联合餐时胰岛素治疗。", "ner": [[4, 5, "Method"], [13, 15, "Drug"], [19, 21, "Test_items"], [23, 24, "Test_Value"], [27, 31, "Test_items"], [33, 35, "Test_Value"], [43, 46, "Frequency"], [49, 51, "Drug"], [52, 53, "Method"], [76, 78, "Drug"], [83, 84, "Test_items"], [86, 88, "Test_Value"], [98, 100, "Drug"], [106, 110, "Drug"], [114, 120, "Drug"], [122, 126, "Drug"], [140, 142, "Drug"], [160, 164, "Drug"], [156, 159, "Frequency"], [177, 178, "Test_items"], [182, 184, "ADE"], [201, 203, "Drug"]], "rel": [[43, 46, "Frequency", 49, 51, "Drug", "Frequency_Drug"], [52, 53, "Method", 49, 51, "Drug", "Method_Drug"], [156, 159, "Frequency", 160, 164, "Drug", "Frequency_Drug"], [182, 184, "ADE", 160, 164, "Drug", "ADE_Drug"]]}
{"idx": 1859, "sentence": "4.肠内/肠外营养患者：接受肠内/肠外营养的住院糖尿病患者如血糖得不到满意控制，可增加并发症和死亡风险。无论是否诊断为糖尿病，接受人工营养的患者血糖>7.8mmol/L即可起始胰岛素治疗。已接受胰岛素治疗的大部分患者血糖控制目标推荐7.8~10.0mmol/L，更为严格的目标，如6.1~7.8mmol/L适用于某些需要严格控制血糖的重症患者。持续肠内营养采用基础联合餐时方案(每日1~2次基础胰岛素联合每4~6h一次短效/速效胰岛素)，基础胰岛素按0.15~0.25U/(kg·d)起始。接受肠外营养的糖尿病患者可根据7~10U/100g葡萄糖的比例酌情添加胰岛素，皮下胰岛素注射也可作为补充。", "ner": [[24, 26, "Disease"], [30, 31, "Test_items"], [59, 61, "Disease"], [72, 73, "Test_items"], [74, 83, "Test_Value"], [88, 90, "Drug"], [97, 99, "Drug"], [108, 109, "Test_items"], [116, 129, "Test_Value"], [140, 152, "Test_Value"], [164, 165, "Test_items"], [189, 194, "Frequency"], [197, 199, "Drug"], [202, 208, "Frequency"], [209, 216, "Drug"], [221, 223, "Drug"], [225, 241, "Amount"], [252, 254, "Disease"], [260, 269, "Amount"], [270, 272, "Drug"], [280, 282, "Drug"], [286, 288, "Drug"], [289, 290, "Method"]], "rel": [[30, 31, "Test_items", 59, 61, "Disease", "Test_items_Disease"], [88, 90, "Drug", 59, 61, "Disease", "Drug_Disease"], [189, 194, "Frequency", 197, 199, "Drug", "Frequency_Drug"], [202, 208, "Frequency", 209, 216, "Drug", "Frequency_Drug"], [280, 282, "Drug", 252, 254, "Disease", "Drug_Disease"], [289, 290, "Method", 286, 288, "Drug", "Method_Drug"]]}
{"idx": 1860, "sentence": "接受持续肠内/肠外营养的患者，推荐每4~6h进行1次血糖监测。", "ner": [[26, 29, "Test_items"]], "rel": []}
{"idx": 1861, "sentence": "对于血糖水平显著增高并伴有高血糖症状的新诊断T2DM患者；或在糖尿病治疗过程中，需短时间内纠正高血糖的患者，推荐进行基础-餐时模式的短期胰岛素强化治疗。", "ner": [[2, 3, "Test_items"], [8, 9, "Test_Value"], [13, 15, "Disease"], [22, 25, "Disease"], [31, 33, "Disease"], [47, 49, "Disease"], [66, 70, "Drug"]], "rel": [[2, 3, "Test_items", 22, 25, "Disease", "Test_items_Disease"]]}
{"idx": 1862, "sentence": "(2)临床使用建议", "ner": [], "rel": []}
{"idx": 1863, "sentence": "①基础/餐时胰岛素起始方法：对于口服降糖药联合基础胰岛素治疗的患者，基础胰岛素可维持原剂量，主餐/早餐前给予餐时胰岛素4U；对于之前使用预混胰岛素的患者，可按照原先预混胰岛素剂量的40%~50%作为基础胰岛素，剩余量作为餐时胰岛素，三餐平均分配；对于需短时间内纠正高血糖的患者，可根据0.3~0.5U/(kg·d)估算起始胰岛素总量，其中，50%为基础胰岛素，50%为餐时胰岛素，三餐平均分配。", "ner": [[6, 8, "Drug"], [16, 17, "Method"], [25, 27, "Drug"], [36, 38, "Drug"], [56, 58, "Drug"], [59, 60, "Amount"], [68, 72, "Drug"], [82, 86, "Drug"], [101, 103, "Drug"], [112, 114, "Drug"], [132, 134, "Disease"], [142, 156, "Amount"], [161, 163, "Drug"], [176, 178, "Drug"], [186, 188, "Drug"]], "rel": [[59, 60, "Amount", 56, 58, "Drug", "Amount_Drug"], [142, 156, "Amount", 161, 163, "Drug", "Amount_Drug"]]}
{"idx": 1864, "sentence": "四、基础胰岛素在特殊人群中的应用", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 1865, "sentence": "1.老年糖尿病患者：老年糖尿病患者常合并多种疾病，器官功能减退，且低血糖感知性弱、耐受性差，认知能力、自我管理能力下降。因此，老年糖尿病患者血糖控制目标一般较为宽松，HbA1c为7.5%~8.0%，对于出现糖尿病并发症或合并多种疾病的患者，血糖控制目标可进一步放宽。在使用降糖药物控制血糖，预防和减少并发症的同时，需考虑老年患者的肝、肾功能及合并用药的相互作用问题，减少低血糖发生。临床上常采用口服降糖药治疗，需胰岛素治疗情况下通常推荐使用基础胰岛素，尤其是低血糖风险较低的长效胰岛素类似物。除新诊断伴严重高血糖症状及某些特殊情况外，不推荐多次胰岛素注射的方案。", "ner": [[4, 6, "Disease"], [12, 14, "Disease"], [33, 35, "Disease"], [65, 67, "Disease"], [70, 71, "Test_items"], [83, 87, "Test_items"], [89, 97, "Test_Value"], [103, 105, "Disease"], [120, 121, "Test_items"], [142, 143, "Test_items"], [185, 187, "ADE"], [197, 198, "Method"], [206, 208, "Drug"], [222, 224, "Drug"], [229, 231, "ADE"], [237, 244, "Drug"], [251, 252, "Level"], [253, 255, "ADE"], [272, 274, "Drug"], [275, 276, "Method"]], "rel": [[70, 71, "Test_items", 65, 67, "Disease", "Test_items_Disease"], [83, 87, "Test_items", 65, 67, "Disease", "Test_items_Disease"], [229, 231, "ADE", 206, 208, "Drug", "ADE_Drug"], [275, 276, "Method", 272, 274, "Drug", "Method_Drug"]]}
{"idx": 1866, "sentence": "②胰岛素治疗方案和剂量调整：逐步增加餐时胰岛素的治疗方案中，主餐/早餐起始4~6U餐时胰岛素后，根据下一餐前血糖值，每周调整1~2次餐时胰岛素剂量，每次调整1~2U或10%~15%直至达到下次餐前血糖目标；根据每3~6个月HbA1c结果，如需要可逐渐增加至2~3次餐时胰岛素治疗。采用基础-三餐前胰岛素治疗方案时，如果血糖水平整体偏高，可先调整基础胰岛素剂量，对于需尽快解除高血糖状态的情况，则可同时调整基础和餐时的剂量。条件允许时，在起始胰岛素治疗的早期可通过住院密切监测血糖每天调整胰岛素剂量。根据FPG，调整基础胰岛素剂量1~4U或10%~20%；根据下一餐前血糖值，调整餐时胰岛素剂量1~2U或10%。如果出现空腹或夜间低血糖(<3.9mmol/L)或低血糖症状，则可减少基础胰岛素和/或晚餐前的餐时胰岛素剂量10%~20%；如果日间两餐间出现低血糖，则减少上一餐的餐时胰岛素剂量10%~20%；如出现需他人协助的严重低血糖或随机血糖<2.2mmol/L，则减少20%~40%胰岛素剂量。", "ner": [[1, 3, "Drug"], [20, 22, "Drug"], [43, 45, "Drug"], [68, 70, "Drug"], [134, 136, "Drug"], [148, 150, "Drug"], [174, 176, "Drug"], [220, 222, "Drug"], [243, 245, "Drug"], [259, 261, "Drug"], [291, 293, "Drug"], [342, 344, "Drug"], [354, 356, "Drug"], [389, 391, "Drug"], [442, 444, "Drug"], [37, 40, "Amount"], [54, 55, "Test_items"], [62, 65, "Frequency"], [78, 81, "Amount"], [96, 99, "Test_items"], [111, 115, "Test_items"], [128, 131, "Frequency"], [159, 160, "Test_items"], [165, 166, "Test_Value"], [187, 189, "Disease"], [235, 238, "Test_items"], [251, 253, "Test_items"], [264, 267, "Amount"], [281, 284, "Test_items"], [296, 299, "Amount"], [312, 316, "Test_items"], [318, 327, "Test_Value"], [330, 332, "ADE"], [376, 378, "ADE"], [411, 412, "Level"], [417, 420, "Test_items"], [421, 430, "Test_Value"], [413, 415, "ADE"]], "rel": [[37, 40, "Amount", 43, 45, "Drug", "Amount_Drug"], [62, 65, "Frequency", 68, 70, "Drug", "Frequency_Drug"], [78, 81, "Amount", 68, 70, "Drug", "Amount_Drug"], [128, 131, "Frequency", 134, 136, "Drug", "Frequency_Drug"], [264, 267, "Amount", 259, 261, "Drug", "Amount_Drug"], [296, 299, "Amount", 291, 293, "Drug", "Amount_Drug"], [330, 332, "ADE", 342, 344, "Drug", "ADE_Drug"], [413, 415, "ADE", 442, 444, "Drug", "ADE_Drug"]]}
{"idx": 1867, "sentence": "2.GDM患者与糖尿病合并妊娠(PGDM)患者：妊娠期间高血糖会增加围生期母婴发生不良临床结局的风险，故相比一般糖尿病患者血糖控制应更加严格。GDM血糖值控制在餐前≤5.3mmol/L，1hPG及2 hPG分别为≤7.8或6.7mmol/L，HbA1c<5.5%；PGDM妊娠期餐前、夜间血糖及FPG宜控制在≤5.6mmol/L，餐后峰值血糖5.6~7.1mmol/L，HbA1c<6.0%。GDM与PGDM患者，通过饮食治疗血糖不能得到满意控制时，需起始胰岛素治疗。", "ner": [[2, 4, "Disease"], [8, 10, "Disease"], [16, 19, "Disease"], [28, 30, "Disease"], [56, 58, "Disease"], [61, 62, "Test_items"], [71, 73, "Disease"], [74, 75, "Test_items"], [82, 91, "Test_Value"], [93, 96, "Test_items"], [98, 102, "Test_items"], [106, 109, "Test_Value"], [111, 119, "Test_Value"], [121, 125, "Test_items"], [126, 130, "Test_Value"], [132, 135, "Disease"], [142, 145, "Test_items"], [147, 149, "Test_items"], [154, 163, "Test_Value"], [165, 170, "Test_items"], [171, 183, "Test_Value"], [185, 189, "Test_items"], [190, 194, "Test_Value"], [196, 198, "Disease"], [200, 203, "Disease"], [213, 214, "Test_items"], [228, 230, "Drug"]], "rel": [[61, 62, "Test_items", 56, 58, "Disease", "Test_items_Disease"], [74, 75, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [93, 96, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [98, 102, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [121, 125, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [142, 145, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [147, 149, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [165, 170, "Test_items", 71, 73, "Disease", "Test_items_Disease"], [228, 230, "Drug", 196, 198, "Disease", "Drug_Disease"], [228, 230, "Drug", 200, 203, "Disease", "Drug_Disease"], [213, 214, "Test_items", 200, 203, "Disease", "Test_items_Disease"]]}
{"idx": 1868, "sentence": "由于人胰岛素不通过胎盘屏障，因此NPH在妊娠期间使用不限制。", "ner": [[2, 5, "Drug"], [16, 18, "Drug"]], "rel": []}
{"idx": 1869, "sentence": "长效人胰岛素类似物在妊娠妇女中临床对照研究证据有限，患者起始长效人胰岛素类似物治疗前，临床医生需充分考虑获益及潜在风险后选择治疗方案。", "ner": [[0, 8, "Drug"], [30, 38, "Drug"]], "rel": []}
{"idx": 1870, "sentence": "3.围手术期患者：高血糖会增加感染发生率，延迟伤口愈合，因此对于择期手术的患者，手术前血糖控制在FPG<7.8mmol/L，2hPG<10.0mmol/L。对于血糖长期升高者、特殊手术患者等需建立个体化目标。围手术期需使用胰岛素控制血糖，入院前口服降糖药的患者，接受小手术的术前当晚及手术当天应停用口服降糖药，接受大中手术则应在术前3天停用口服降糖药，均改为胰岛素治疗。术前和术后可正常饮食的高血糖患者可采用基础联合餐时胰岛素方案，大中型手术术中需要静脉使用胰岛素。对于常规(非心脏)手术患者，基础联合餐时方案相比仅使用短效或速效胰岛素的方案血糖控制更佳、围手术期并发症更少。入院前已使用胰岛素者，手术日停用早餐前短效/速效胰岛素，继续使用基础胰岛素。长效胰岛素在手术当日早晨予常规剂量的50%~100%；中效胰岛素如为晚间注射，术前1d予常规剂量的75%，手术当日早晨予常规剂量的50%~75%；预混胰岛素在手术当日早晨应更换为基础胰岛素，剂量为预混胰岛素中的中效成分的50%~75%。大中型手术术后病情稳定、恢复正常饮食者可予胰岛素皮下注射。一般起始总剂量为0.4~0.5U(kg·d)，年龄≥70岁或eGFR≤60ml/min者减量至0.2~0.3U/(kg·d)，其中，基础和餐时胰岛素各占50%。", "ner": [[9, 11, "Disease"], [43, 44, "Test_items"], [48, 50, "Test_items"], [51, 60, "Test_Value"], [62, 65, "Test_items"], [66, 76, "Test_Value"], [80, 81, "Test_items"], [84, 85, "Test_Value"], [111, 113, "Drug"], [116, 117, "Test_items"], [122, 123, "Method"], [149, 150, "Method"], [170, 171, "Method"], [179, 181, "Drug"], [196, 198, "Disease"], [210, 212, "Drug"], [225, 226, "Method"], [229, 231, "Drug"], [263, 267, "Drug"], [271, 272, "Test_items"], [294, 296, "Drug"], [307, 314, "Drug"], [322, 324, "Drug"], [326, 330, "Drug"], [353, 357, "Drug"], [360, 363, "Method"], [399, 403, "Drug"], [417, 419, "Drug"], [424, 428, "Drug"], [465, 467, "Drug"], [468, 471, "Method"], [481, 494, "Amount"], [520, 534, "Amount"], [544, 546, "Drug"]], "rel": [[43, 44, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [48, 50, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [62, 65, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [210, 212, "Drug", 196, 198, "Disease", "Drug_Disease"], [225, 226, "Method", 229, 231, "Drug", "Method_Drug"], [360, 363, "Method", 353, 357, "Drug", "Method_Drug"], [468, 471, "Method", 465, 467, "Drug", "Method_Drug"], [481, 494, "Amount", 544, 546, "Drug", "Amount_Drug"], [520, 534, "Amount", 544, 546, "Drug", "Amount_Drug"]]}
{"idx": 1871, "sentence": "五、总结及展望", "ner": [], "rel": []}
{"idx": 1872, "sentence": "基础胰岛素是T2DM管理中重要的降糖措施，基础胰岛素的及时起始和合理充分的剂量调整能改善T2DM患者的整体血糖控制，也为之后更复杂的基础联合餐时胰岛素的治疗方案奠定了基础。临床工作中我们需加强对患者的教育和管理，适时起始基础胰岛素治疗并根据血糖水平进行剂量调整，通过适当的血糖监测和随访，实现长期平稳的血糖控制，降低糖尿病并发症发生的风险，改善患者生活质量和延长寿命。", "ner": [[2, 4, "Drug"], [6, 9, "Disease"], [23, 25, "Drug"], [44, 47, "Disease"], [53, 54, "Test_items"], [72, 74, "Drug"], [112, 114, "Drug"], [120, 121, "Test_items"], [136, 139, "Test_items"], [151, 152, "Test_items"], [158, 163, "Disease"]], "rel": [[2, 4, "Drug", 6, 9, "Disease", "Drug_Disease"], [53, 54, "Test_items", 44, 47, "Disease", "Test_items_Disease"], [112, 114, "Drug", 158, 163, "Disease", "Drug_Disease"], [151, 152, "Test_items", 158, 163, "Disease", "Test_items_Disease"]]}
{"idx": 1873, "sentence": "糖尿病患者血糖波动管理专家共识 ", "ner": [[0, 2, "Disease"], [5, 6, "Test_items"], [7, 8, "Test_Value"]], "rel": [[5, 6, "Test_items", 0, 2, "Disease", "Test_items_Disease"]]}
{"idx": 1874, "sentence": "血糖波动是评价血糖控制的重要指标之一。糖化血红蛋白(hemoglobin Alc，HbA1c)虽能反映3个月内血糖的平均水平，但无法反映血糖波动的情况，HbA1c控制相似的糖尿病患者可能因血糖波动的程度不同，发生并发症的风险也不相同。糖尿病患者理想的血糖控制不仅要HbA1c达标，还应尽可能减少血糖波动的幅度。目前，针对血糖波动相关指标的评估方法较为复杂、可操作性差，不利于临床医生对血糖波动进行有效的管理，因此，中华医学会内分泌学分会组织部分临床内分泌学领域专家，通过系统性回顾分析现有循证医学证据并结合专家临床经验，制定了《糖尿病患者血糖波动管理专家共识》。", "ner": [[0, 1, "Test_items"], [2, 3, "Test_Value"], [7, 8, "Test_items"], [19, 46, "Test_items"], [55, 56, "Test_items"], [68, 69, "Test_items"], [70, 71, "Test_Value"], [76, 80, "Test_items"], [86, 88, "Disease"], [94, 95, "Test_items"], [96, 97, "Test_Value"], [117, 119, "Disease"], [125, 126, "Test_items"], [132, 136, "Test_items"], [137, 138, "Test_Value"], [147, 148, "Test_items"], [149, 150, "Test_Value"], [160, 161, "Test_items"], [162, 163, "Test_Value"], [192, 193, "Test_items"], [194, 195, "Test_Value"], [264, 266, "Disease"], [269, 270, "Test_items"], [271, 272, "Test_Value"]], "rel": [[19, 46, "Test_items", 86, 88, "Disease", "Test_items_Disease"], [55, 56, "Test_items", 86, 88, "Disease", "Test_items_Disease"], [125, 126, "Test_items", 117, 119, "Disease", "Test_items_Disease"], [132, 136, "Test_items", 117, 119, "Disease", "Test_items_Disease"], [269, 270, "Test_items", 264, 266, "Disease", "Test_items_Disease"]]}
{"idx": 1875, "sentence": "1血糖波动的定义?", "ner": [[1, 2, "Test_items"], [3, 4, "Test_Value"]], "rel": []}
{"idx": 1876, "sentence": "血糖波动指血糖水平在其高峰和低谷之间变化的不稳定状态，不仅包括短期血糖波动，即日间血糖波动和日内血糖波动，还包括长期血糖波动，即HbA1c变异性，本共识着重介绍日内血糖波动的相关危害及管理。", "ner": [[0, 1, "Test_items"], [2, 3, "Test_Value"], [5, 6, "Test_items"], [33, 34, "Test_items"], [35, 36, "Test_Value"], [39, 42, "Test_items"], [43, 44, "Test_Value"], [46, 49, "Test_items"], [50, 51, "Test_Value"], [58, 59, "Test_items"], [60, 61, "Test_Value"], [64, 68, "Test_items"], [82, 83, "Test_items"], [84, 85, "Test_Value"]], "rel": []}
{"idx": 1877, "sentence": "2.哪些因素可导致血糖波动?", "ner": [[9, 10, "Test_items"], [11, 12, "Test_Value"]], "rel": []}
{"idx": 1878, "sentence": "糖尿病患者血糖波动的主要原因包括胰岛β细胞功能状态、饮食、运动和药物等。", "ner": [[0, 2, "Disease"], [5, 6, "Test_items"], [7, 8, "Test_Value"]], "rel": [[5, 6, "Test_items", 0, 2, "Disease", "Test_items_Disease"]]}
{"idx": 1879, "sentence": "(1)胰岛β细胞功能：糖尿病患者自身β细胞功能减退甚至衰竭，导致体内胰岛素水平不足，血糖调节能力低下，导致血糖容易波动。", "ner": [[16, 24, "Pathogenesis"], [11, 13, "Disease"], [42, 43, "Test_items"], [53, 54, "Test_items"], [57, 58, "Test_Value"]], "rel": [[16, 24, "Pathogenesis", 11, 13, "Disease", "Pathogenesis_Disease"], [42, 43, "Test_items", 11, 13, "Disease", "Test_items_Disease"]]}
{"idx": 1880, "sentence": "并且β细胞功能越差，血糖波动幅度越大。", "ner": [[10, 11, "Test_items"], [12, 13, "Test_Value"], [2, 8, "Pathogenesis"]], "rel": []}
{"idx": 1881, "sentence": "(2)饮食：饮食的“质”和“量”；均可影响血糖波动，摄入高升糖指数(glycemic index，GI)食物以及食物摄入量过多均可引起餐后血糖迅速升高，导致血糖波动的幅度增加。", "ner": [[21, 22, "Test_items"], [23, 24, "Test_Value"], [67, 70, "Test_items"], [73, 74, "Test_Value"], [78, 79, "Test_items"], [80, 81, "Test_Value"]], "rel": []}
{"idx": 1882, "sentence": "(3)药物：应用降糖药物所带来的低血糖也是血糖波动增加的诱因之一。如促进胰岛素分泌的药物或者胰岛素本身等均会增加患者的低血糖风险，增加血糖波动。", "ner": [[16, 18, "ADE"], [21, 22, "Test_items"], [23, 24, "Test_Value"], [59, 61, "ADE"], [67, 68, "Test_items"], [69, 70, "Test_Value"], [46, 48, "Drug"]], "rel": [[59, 61, "ADE", 46, 48, "Drug", "ADE_Drug"]]}
{"idx": 1883, "sentence": "此外，饮食和运动不规律、治疗依从性差、情绪应激、睡眠障碍、酣酒、感染、胰岛素不规范注射等多种因素也可增加血糖波动，而应对餐后血糖的药物作用不足也是导致血波动的原因之一。", "ner": [[52, 53, "Test_items"], [54, 55, "Test_Value"], [60, 63, "Test_items"], [76, 77, "Test_Value"], [35, 37, "Drug"], [41, 42, "Method"]], "rel": [[41, 42, "Method", 35, 37, "Drug", "Method_Drug"]]}
{"idx": 1884, "sentence": "3血糖波动会带米哪些危害?", "ner": [[1, 2, "Test_items"], [3, 4, "Test_Value"]], "rel": []}
{"idx": 1885, "sentence": "血糖波动对于糖尿病慢性并发症的危害甚至比持续性高血糖更为严重，血糖波动通过激活氧化应激通路，损伤内皮细胞功能，加剧慢性炎症状态等造成血管损伤，增加糖尿病并发症的发生风险。血糖波动与糖尿病慢性并发症的发生和发展密切相关：", "ner": [[0, 1, "Test_items"], [2, 3, "Test_Value"], [6, 13, "Disease"], [23, 25, "Disease"], [28, 29, "Level"], [31, 32, "Test_items"], [33, 34, "Test_Value"], [73, 78, "Disease"], [85, 86, "Test_items"], [87, 88, "Test_Value"], [90, 97, "Disease"]], "rel": [[0, 1, "Test_items", 6, 13, "Disease", "Test_items_Disease"], [85, 86, "Test_items", 90, 97, "Disease", "Test_items_Disease"]]}
{"idx": 1886, "sentence": "(1)大血管并发症：血糖波动与糖尿病患者冠心病严重程度显著相关，其作用独立于血糖水平本身，平均血糖波动幅度(mean amplitude of glucose excursions，MAGE)与患者急性心肌梗死事件再发显著相关。荟萃分析亦提示，血糖波动与心血管疾病的发生风险显著相关。", "ner": [[3, 8, "Disease"], [10, 11, "Test_items"], [12, 13, "Test_Value"], [15, 17, "Disease"], [20, 22, "Disease"], [23, 24, "Level"], [38, 39, "Test_items"], [47, 48, "Test_items"], [49, 50, "Test_Value"], [99, 104, "Disease"], [101, 102, "Anatomy"], [122, 123, "Test_items"], [124, 125, "Test_Value"], [127, 131, "Disease"], [127, 129, "Anatomy"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [10, 11, "Test_items", 15, 17, "Disease", "Test_items_Disease"], [101, 102, "Anatomy", 99, 104, "Disease", "Anatomy_Disease"], [122, 123, "Test_items", 127, 131, "Disease", "Test_items_Disease"], [127, 129, "Anatomy", 127, 131, "Disease", "Anatomy_Disease"]]}
{"idx": 1887, "sentence": "(2)微血管并发症：动态血糖监测系统(continuous glucose monitoring system，CGMS)测得的血糖波动与尿微量白蛋白排泄率具有相关性，血糖波动也是糖尿病视网膜病变的相关危险因素。", "ner": [[3, 8, "Disease"], [3, 5, "Anatomy"], [12, 15, "Test_items"], [64, 65, "Test_items"], [66, 67, "Test_Value"], [69, 74, "Test_items"], [84, 85, "Test_items"], [86, 87, "Test_Value"], [90, 92, "Disease"], [93, 97, "Disease"], [93, 95, "Anatomy"]], "rel": [[3, 5, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [64, 65, "Test_items", 90, 92, "Disease", "Test_items_Disease"], [69, 74, "Test_items", 90, 92, "Disease", "Test_items_Disease"], [93, 95, "Anatomy", 93, 97, "Disease", "Anatomy_Disease"]]}
{"idx": 1888, "sentence": "4临床上有哪些血糖波动的监测方式?", "ner": [[7, 8, "Test_items"], [9, 10, "Test_Value"]], "rel": []}
{"idx": 1889, "sentence": "目前动态血糖监测(continuous glucose monitoring，CGM)和自我血糖监测(self-monitoring of blood glucose，SMBG)都可以有效评估血糖波动程度。CGM能够准确、全面地反映血糖波动的特征，但监测成本较高，操作相对复杂，不易在糖尿病人群中普及。SMBG灵活方便、易操作、相对经济、可行性高，通过每日7-8次SMBG值能够较为准确地估计2型糖尿病患者的日内血糖波动，且与CGM有较好的相关性。但SMBG测定的血糖结果变异性大，用以评估血糖波动时所采用的个别指标计算复杂，缺乏正常参考值。", "ner": [[2, 42, "Test_items"], [44, 88, "Test_items"], [96, 97, "Test_items"], [98, 99, "Test_Value"], [103, 105, "Test_items"], [116, 117, "Test_items"], [118, 119, "Test_Value"], [142, 144, "Disease"], [151, 154, "Test_items"], [182, 185, "Test_items"], [196, 200, "Disease"], [204, 207, "Test_items"], [208, 209, "Test_Value"], [213, 215, "Test_items"], [225, 228, "Test_items"], [232, 233, "Test_items"], [245, 246, "Test_items"], [247, 248, "Test_Value"]], "rel": [[96, 97, "Test_items", 142, 144, "Disease", "Test_items_Disease"], [103, 105, "Test_items", 142, 144, "Disease", "Test_items_Disease"], [204, 207, "Test_items", 196, 200, "Disease", "Test_items_Disease"], [225, 228, "Test_items", 196, 200, "Disease", "Test_items_Disease"], [232, 233, "Test_items", 196, 200, "Disease", "Test_items_Disease"]]}
{"idx": 1890, "sentence": "5 CGM评估血糖波动有哪些指标?", "ner": [[2, 4, "Test_items"], [7, 8, "Test_items"], [9, 10, "Test_Value"]], "rel": []}
{"idx": 1891, "sentence": "CGM已成为评估血糖波动的主要手段。", "ner": [[0, 2, "Test_items"], [8, 9, "Test_items"], [10, 11, "Test_Value"]], "rel": []}
{"idx": 1892, "sentence": "常用的CGM评估血糖波动的指标及正常参考值见表1.", "ner": [[3, 5, "Test_items"], [8, 9, "Test_items"], [10, 11, "Test_Value"]], "rel": []}
{"idx": 1893, "sentence": "6 SMBG评估血糖波动的指标有哪些?", "ner": [[2, 5, "Test_items"], [8, 9, "Test_items"], [10, 11, "Test_Value"]], "rel": []}
{"idx": 1894, "sentence": "常用的7点SMBG评估血糖波动的指标及正常参考值见表2。", "ner": [[5, 8, "Test_items"], [11, 12, "Test_items"], [13, 14, "Test_Value"]], "rel": []}
{"idx": 1895, "sentence": "7不同的降糖药物对血糖波动的影响是否不同?", "ner": [[9, 10, "Test_items"], [11, 12, "Test_Value"]], "rel": []}
{"idx": 1896, "sentence": "餐后高血糖和低血糖是引起糖尿病患者血糖波动的两个重要原因。常用降糖药对餐后高血糖和低血糖的影响见表3。", "ner": [[2, 4, "Disease"], [6, 8, "Disease"], [12, 14, "Disease"], [17, 18, "Test_items"], [19, 20, "Test_Value"], [37, 39, "Disease"], [41, 43, "Disease"]], "rel": [[17, 18, "Test_items", 12, 14, "Disease", "Test_items_Disease"]]}
{"idx": 1897, "sentence": "8哪些患者需要重点关注血糖波动?", "ner": [[11, 12, "Test_items"], [13, 14, "Test_Value"]], "rel": []}
{"idx": 1898, "sentence": "餐后血糖高、胰岛功能差、使用胰岛素/胰岛素类似物或胰岛素促泌剂、低血糖风险高、长病程、高龄的糖尿病患者一般血糖波动大，应重点关注，尤其是使用胰岛素/胰岛素类似物或磺脲类药物的患者，因为这两类药物的低血糖风险较高，故更易造成血糖波动。研究提示，在磺脲类促泌剂基础上联合α-糖苷酶抑制剂，可减少低血糖，改善血糖波动；使用胰岛素/胰岛素类似物治疗的患者联合α-糖苷酶抑制剂后MAGE显著改善。", "ner": [[25, 30, "Drug"], [14, 16, "Drug"], [18, 23, "Drug"], [46, 48, "Disease"], [53, 54, "Test_items"], [55, 56, "Test_Value"], [70, 72, "Drug"], [74, 79, "Drug"], [81, 85, "Drug"], [98, 100, "ADE"], [111, 112, "Test_items"], [113, 114, "Test_Value"], [122, 127, "Drug"], [133, 140, "Drug"], [145, 147, "ADE"], [151, 152, "Test_items"], [153, 154, "Test_Value"], [158, 160, "Drug"], [162, 167, "Drug"], [175, 182, "Drug"], [0, 3, "Test_items"], [32, 34, "ADE"]], "rel": [[32, 34, "ADE", 25, 30, "Drug", "ADE_Drug"], [25, 30, "Drug", 46, 48, "Disease", "Drug_Disease"], [32, 34, "ADE", 14, 16, "Drug", "ADE_Drug"], [14, 16, "Drug", 46, 48, "Disease", "Drug_Disease"], [32, 34, "ADE", 18, 23, "Drug", "ADE_Drug"], [18, 23, "Drug", 46, 48, "Disease", "Drug_Disease"], [53, 54, "Test_items", 46, 48, "Disease", "Test_items_Disease"], [98, 100, "ADE", 81, 85, "Drug", "ADE_Drug"], [145, 147, "ADE", 122, 127, "Drug", "ADE_Drug"], [145, 147, "ADE", 133, 140, "Drug", "ADE_Drug"], [145, 147, "ADE", 158, 160, "Drug", "ADE_Drug"], [145, 147, "ADE", 162, 167, "Drug", "ADE_Drug"]]}
{"idx": 1899, "sentence": "9特殊人群的血糖波动管理应注意哪些问题?", "ner": [[6, 7, "Test_items"], [8, 9, "Test_Value"]], "rel": []}
{"idx": 1900, "sentence": "以下患者应适当放宽血糖控制目标，并视患者的具体情况而选用降糖药物，以避免低血糖的发生，如果选择使用具有低血糖风险的药物时，应从小剂量开始，逐渐加量并注意观察患者的血糖变化及对药物的反应。", "ner": [[9, 10, "Test_items"], [36, 38, "ADE"], [51, 53, "ADE"], [81, 82, "Test_items"]], "rel": []}
{"idx": 1901, "sentence": "(1)儿童及青少年糖尿病患者：推荐理想的HbA1c控制在7%以下，强调糖尿病血糖控制应权衡利弊，实行个体化，低血糖风险较高或尚无低血糖风险意识的患儿可适当放标准。", "ner": [[9, 11, "Disease"], [20, 24, "Test_items"], [28, 31, "Test_Value"], [35, 37, "Disease"], [38, 39, "Test_items"], [54, 56, "Disease"], [64, 66, "Disease"]], "rel": [[20, 24, "Test_items", 9, 11, "Disease", "Test_items_Disease"], [38, 39, "Test_items", 9, 11, "Disease", "Test_items_Disease"]]}
{"idx": 1902, "sentence": "(2)老年糖尿病患者：老年糖尿病患者病情复杂，病程较长，对低血糖的感知和耐受性差，慢性并发症常见，尤其是心血管疾病以及认知功能障碍等，因此，应加强对多重危险因素的管理。有研究显示，老年糖尿病患者的血糖波动存在性别差异，女性高于男性，此外，糖尿病病程、HbA1c水平也是老年2型糖尿病患者血糖波动的重要影响因素。", "ner": [[5, 7, "Disease"], [13, 15, "Disease"], [29, 31, "Disease"], [52, 56, "Disease"], [52, 54, "Anatomy"], [92, 94, "Disease"], [98, 99, "Test_items"], [100, 101, "Test_Value"], [119, 121, "Disease"], [125, 129, "Test_items"], [136, 140, "Disease"], [143, 144, "Test_items"], [145, 146, "Test_Value"]], "rel": [[52, 54, "Anatomy", 52, 56, "Disease", "Anatomy_Disease"], [98, 99, "Test_items", 92, 94, "Disease", "Test_items_Disease"], [125, 129, "Test_items", 92, 94, "Disease", "Test_items_Disease"]]}
{"idx": 1903, "sentence": "国内外指南均建议在全面评估的基础上，遵循个体化的原则，根据忠者病情等综合情况，设定更具针对性和实用性的血糖控制分层管理目标.。", "ner": [[51, 52, "Test_items"]], "rel": []}
{"idx": 1904, "sentence": "(3)妊娠期的糖尿病忠者：糖尿病合并妊娠、妊娠期糖尿病患者的血糖控制目标在餐前及餐后2h分别为≤5.3mmol/L、6.7mmol/L，特殊情况下可测定餐后1h血糖，其控制目标是≤7.8mmol/L；但夜间血糖不低于3.3mmol/L。", "ner": [[7, 9, "Disease"], [13, 15, "Disease"], [21, 26, "Disease"], [30, 31, "Test_items"], [47, 56, "Test_Value"], [58, 66, "Test_Value"], [76, 81, "Test_items"], [89, 98, "Test_Value"], [101, 104, "Test_items"], [105, 116, "Test_Value"]], "rel": [[30, 31, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [76, 81, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [101, 104, "Test_items", 7, 9, "Disease", "Test_items_Disease"]]}
{"idx": 1905, "sentence": "(4)糖尿病合并慢性肾脏病患者：糖尿病合并慢性肾脏病，尤其是估算肾小球滤过率(estimated glomerular filtration rate，eGFR)<45mL·min-1(1.73m2)-2的患者，其血糖控制目标应遵循个体化原则，尽量避免低血糖的发生。", "ner": [[3, 5, "Disease"], [8, 12, "Disease"], [10, 11, "Anatomy"], [16, 18, "Disease"], [21, 25, "Disease"], [107, 108, "Test_items"], [126, 128, "Disease"], [23, 24, "Anatomy"], [32, 80, "Test_items"], [81, 101, "Test_Value"]], "rel": [[10, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [32, 80, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [107, 108, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [23, 24, "Anatomy", 21, 25, "Disease", "Anatomy_Disease"]]}
{"idx": 1906, "sentence": "(5)糖尿病合并心血管疾病患者：在合并心血管疾病的糖尿病患者中，一旦发生严重低血糖，可能诱发心肌梗死、严重心律失常、卒中、猝死等严重事件，对于这类人群，应尽量在避免低血糖的情况下使血糖控制达标。因此，本共识建议，对于老年、病程长、合并心血管疾病的糖尿病患者，为了避免低血糖带来的风险，HbA1c控制目标应适当宽松(<7.5%-8.0%)。", "ner": [[3, 5, "Disease"], [8, 12, "Disease"], [8, 10, "Anatomy"], [19, 23, "Disease"], [19, 21, "Anatomy"], [25, 27, "Disease"], [38, 40, "Disease"], [36, 37, "Level"], [46, 49, "Disease"], [46, 47, "Anatomy"], [51, 52, "Level"], [53, 56, "Disease"], [53, 53, "Anatomy"], [58, 59, "Disease"], [61, 62, "Disease"], [64, 65, "Level"], [82, 84, "Disease"], [90, 91, "Test_items"], [94, 95, "Test_Value"], [117, 121, "Disease"], [117, 119, "Anatomy"], [123, 125, "Disease"], [133, 135, "Disease"], [142, 146, "Test_items"], [157, 166, "Test_Value"]], "rel": [[8, 10, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [19, 21, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [46, 47, "Anatomy", 46, 49, "Disease", "Anatomy_Disease"], [53, 53, "Anatomy", 53, 56, "Disease", "Anatomy_Disease"], [117, 119, "Anatomy", 117, 121, "Disease", "Anatomy_Disease"], [142, 146, "Test_items", 123, 125, "Disease", "Test_items_Disease"]]}
{"idx": 1907, "sentence": "血糖波动与糖尿病慢性并发症的关系越来越受到重视，血糖波动控制的重要性将比肩于HbA1c、空腹血糖、餐后血糖控制。未来，血糖波动的评价指标仍需不断地优化、量化，以易于计算，继续寻找基于终点事件的血糖波动指标的切点及血糖波动与终点事件因果关系的证据，都将有助于优化降糖药物治疗策略，使更多的糖尿病患者受益。", "ner": [[0, 1, "Test_items"], [2, 3, "Test_Value"], [5, 12, "Disease"], [24, 25, "Test_items"], [26, 27, "Test_Value"], [38, 42, "Test_items"], [44, 47, "Test_items"], [49, 52, "Test_items"], [59, 60, "Test_items"], [61, 62, "Test_Value"], [96, 97, "Test_items"], [98, 99, "Test_Value"], [106, 107, "Test_items"], [108, 109, "Test_Value"], [143, 145, "Disease"]], "rel": [[38, 42, "Test_items", 5, 12, "Disease", "Test_items_Disease"], [44, 47, "Test_items", 5, 12, "Disease", "Test_items_Disease"], [49, 52, "Test_items", 5, 12, "Disease", "Test_items_Disease"], [59, 60, "Test_items", 5, 12, "Disease", "Test_items_Disease"], [106, 107, "Test_items", 143, 145, "Disease", "Test_items_Disease"]]}
{"idx": 1908, "sentence": "糖尿病微循环障碍临床用药专家共识", "ner": [[0, 2, "Disease"], [3, 7, "Symptom"]], "rel": [[3, 7, "Symptom", 0, 2, "Disease", "Symptom_Disease"]]}
{"idx": 1909, "sentence": "1 背景", "ner": [], "rel": []}
{"idx": 1910, "sentence": "糖尿病及其慢性并发症可导致患者肾功能衰竭、失明、截肢和心脑血管事件，致残率和致死率高，给患者的健康和生命造成了严重威胁。微障碍是糖尿病慢性并发症发生的重要病理生理基础之一，在控制血糖的同时改善微循环障碍，对于预防、延缓、治疗糖尿病各种慢性并发症具有十分重要的意义。", "ner": [[0, 2, "Disease"], [15, 19, "Disease"], [21, 22, "Disease"], [24, 25, "Operation"], [27, 32, "Disease"], [60, 62, "Symptom"], [112, 114, "Disease"], [15, 15, "Anatomy"], [27, 30, "Anatomy"], [96, 100, "Symptom"], [89, 90, "Test_items"], [64, 66, "Disease"]], "rel": [[15, 15, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"], [27, 30, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [60, 62, "Symptom", 64, 66, "Disease", "Symptom_Disease"], [89, 90, "Test_items", 112, 114, "Disease", "Test_items_Disease"]]}
{"idx": 1911, "sentence": "当前临床工作中，对于微循环障碍在糖尿病慢性并发症发生发展中的作用及机制，认识尚不充分，相关药物的选择与使用欠规范。", "ner": [[10, 14, "Symptom"], [16, 18, "Disease"]], "rel": [[10, 14, "Symptom", 16, 18, "Disease", "Symptom_Disease"]]}
{"idx": 1912, "sentence": "鉴于此，中国微循环学会糖尿病与微循环专业委员会制订此共识，以期为临床合理选择改善糖尿病微循环障碍药物提供参考。", "ner": [[11, 13, "Disease"], [40, 42, "Disease"], [43, 47, "Symptom"]], "rel": [[43, 47, "Symptom", 40, 42, "Disease", "Symptom_Disease"]]}
{"idx": 1913, "sentence": "2 糖尿病微循环障碍的定义", "ner": [[2, 4, "Disease"], [5, 9, "Symptom"]], "rel": [[5, 9, "Symptom", 2, 4, "Disease", "Symptom_Disease"]]}
{"idx": 1914, "sentence": "2.1 微循环障碍微循环由微动脉、后微动脉、毛细血管前括约肌、真毛细血管、动-静脉吻合支和微静脉及其流经其内的液体所组成，是循环系统的基础结构，也是血液与组织间实现物质交换的主要场所和功能单位。", "ner": [[4, 8, "Symptom"]], "rel": []}
{"idx": 1915, "sentence": "在炎症反应、代谢障碍等病理情况下，可发生血管细胞功能障碍，自主神经功能异常及内分泌激素分泌紊乱，导致微血管舒缩功能紊乱、血管壁通透性升高以及血液流变性变化，并可出现微血管结构和毛细血管密度的异常，影响组织的物质交换和器官功能。", "ner": [[1, 4, "Reason"], [6, 9, "Reason"]], "rel": []}
{"idx": 1916, "sentence": "这种病理情况下，微循环结构及功能的异常导致其不能与组织和器官代谢水平相适应，影响组织的物质交换和器官功能状态称之为微循环障碍。", "ner": [[57, 61, "Symptom"]], "rel": []}
{"idx": 1917, "sentence": "2.2 糖尿病微循环障碍由糖尿病相关因素导致的微循环障碍称之为糖尿病微循环障碍。它不仅在糖尿病血管并发症的发生中起着重要作用，而且参与了胰岛素抵抗及糖尿病的发生发展。目前糖尿病微循环障碍的确切发病机制尚未被完全阐明，主要涉及血管内皮受损及一氧化氮合成减少、多元醇通路激活、蛋白质非酶糖化、氧化应激、蛋白激酶C激活等多个方面的功能和代谢异常，进而出现微循环自律运动障碍，微血管血流量增加，压力增高。持续的血流动力学异常可致微血管结构损伤，通透性增加，毛细血管渗出，基底膜增厚，血管腔狭窄甚至闭塞，微血栓形成，发生微循环缺血、缺氧，进而导致器官功能障碍。微循环障碍可发生于糖尿病期及糖尿病前期，早期对其进行干预有助于糖尿病及其血管并发症的防治。", "ner": [[4, 6, "Disease"], [13, 15, "Disease"], [31, 33, "Disease"], [44, 46, "Disease"], [68, 72, "Disease"], [74, 76, "Disease"], [284, 286, "Disease"], [289, 291, "Disease"], [306, 308, "Disease"], [85, 87, "Disease"], [7, 11, "Symptom"], [23, 27, "Symptom"], [34, 38, "Symptom"], [88, 92, "Symptom"], [275, 279, "Symptom"], [112, 117, "Pathogenesis"], [119, 126, "Pathogenesis"], [128, 134, "Pathogenesis"], [136, 142, "Pathogenesis"], [144, 147, "Pathogenesis"], [149, 155, "Pathogenesis"]], "rel": [[7, 11, "Symptom", 4, 6, "Disease", "Symptom_Disease"], [23, 27, "Symptom", 13, 15, "Disease", "Symptom_Disease"], [34, 38, "Symptom", 31, 33, "Disease", "Symptom_Disease"], [275, 279, "Symptom", 284, 286, "Disease", "Symptom_Disease"], [275, 279, "Symptom", 289, 291, "Disease", "Symptom_Disease"], [88, 92, "Symptom", 85, 87, "Disease", "Symptom_Disease"], [112, 117, "Pathogenesis", 85, 87, "Disease", "Pathogenesis_Disease"], [119, 126, "Pathogenesis", 85, 87, "Disease", "Pathogenesis_Disease"], [128, 134, "Pathogenesis", 85, 87, "Disease", "Pathogenesis_Disease"], [136, 142, "Pathogenesis", 85, 87, "Disease", "Pathogenesis_Disease"], [144, 147, "Pathogenesis", 85, 87, "Disease", "Pathogenesis_Disease"], [149, 155, "Pathogenesis", 85, 87, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1918, "sentence": "3 糖尿病微循环障碍的表现", "ner": [[2, 4, "Disease"], [5, 9, "Symptom"]], "rel": [[5, 9, "Symptom", 2, 4, "Disease", "Symptom_Disease"]]}
{"idx": 1919, "sentence": "糖尿病微循环障碍在糖尿病肾病、糖尿病视网膜病变、糖尿病神经病变和糖尿病足病的发生发展中发挥着重要作用，是这些糖尿病慢性并发症共同的病因学机制之一。", "ner": [[9, 13, "Disease"], [15, 22, "Disease"], [24, 30, "Disease"], [32, 36, "Disease"], [12, 12, "Anatomy"], [18, 20, "Anatomy"], [35, 35, "Anatomy"], [0, 2, "Disease"], [3, 7, "Symptom"], [54, 56, "Disease"], [27, 28, "Anatomy"]], "rel": [[12, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [18, 20, "Anatomy", 15, 22, "Disease", "Anatomy_Disease"], [27, 28, "Anatomy", 24, 30, "Disease", "Anatomy_Disease"], [35, 35, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"], [3, 7, "Symptom", 0, 2, "Disease", "Symptom_Disease"]]}
{"idx": 1920, "sentence": "3.1 糖尿病肾病糖尿病肾病的主要病理改变表现为肾小球基底膜增厚、肾小球系膜区细胞外基质沉积，最终肾小球硬化伴或不伴肾小管间质纤维化。肾小球受累临床主要表现为进行性肾小球滤过率降低和尿白蛋白排泄增多。随着病程的进展出现严重肾小球硬化时，肾脏会逐步缩小。微量白蛋白尿是糖尿病肾病的早期临床表现，也是诊断糖尿病肾病的重要依据。糖尿病肾病自然病程分为5期：急性肾小球高滤过期、正常白蛋白尿期(尿蛋白排泄正常或间歇性白蛋白尿)、早期糖尿病肾病期(持续微量白蛋白尿)、临床糖尿病肾病期(显性白蛋白尿，部分进展为肾病综合征)、肾衰竭期。糖尿病肾病是糖尿病患者肾功能衰竭的主要原因。糖尿病肾病最新进展研究表明，肾小管损伤也应包括在糖尿病肾病概念中，其在疾病的早期即可出现，且可先于肾小球病变。", "ner": [[4, 8, "Disease"], [9, 13, "Disease"], [49, 53, "Disease"], [58, 65, "Disease"], [111, 115, "Disease"], [133, 137, "Disease"], [150, 154, "Disease"], [161, 165, "Disease"], [262, 266, "Disease"], [268, 270, "Disease"], [273, 277, "Disease"], [284, 288, "Disease"], [308, 312, "Disease"], [24, 31, "Symptom"], [33, 45, "Symptom"], [79, 89, "Symptom"], [91, 98, "Symptom"], [118, 124, "Symptom"], [126, 131, "Symptom"], [298, 302, "Symptom"], [333, 337, "Symptom"], [7, 7, "Anatomy"], [12, 12, "Anatomy"], [49, 51, "Anatomy"], [58, 60, "Anatomy"], [111, 113, "Anatomy"], [153, 153, "Anatomy"], [136, 136, "Anatomy"], [164, 164, "Anatomy"], [265, 265, "Anatomy"], [273, 273, "Anatomy"], [287, 287, "Anatomy"], [311, 311, "Anatomy"]], "rel": [[7, 7, "Anatomy", 4, 8, "Disease", "Anatomy_Disease"], [12, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [24, 31, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [33, 45, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [58, 60, "Anatomy", 58, 65, "Disease", "Anatomy_Disease"], [111, 113, "Anatomy", 111, 115, "Disease", "Anatomy_Disease"], [118, 124, "Symptom", 111, 115, "Disease", "Symptom_Disease"], [136, 136, "Anatomy", 133, 137, "Disease", "Anatomy_Disease"], [126, 131, "Symptom", 133, 137, "Disease", "Symptom_Disease"], [153, 153, "Anatomy", 150, 154, "Disease", "Anatomy_Disease"], [164, 164, "Anatomy", 161, 165, "Disease", "Anatomy_Disease"], [265, 265, "Anatomy", 262, 266, "Disease", "Anatomy_Disease"], [273, 273, "Anatomy", 273, 277, "Disease", "Anatomy_Disease"], [287, 287, "Anatomy", 284, 288, "Disease", "Anatomy_Disease"], [311, 311, "Anatomy", 308, 312, "Disease", "Anatomy_Disease"], [298, 302, "Symptom", 308, 312, "Disease", "Symptom_Disease"], [333, 337, "Symptom", 308, 312, "Disease", "Symptom_Disease"]]}
{"idx": 1921, "sentence": "3.2 糖尿病视网膜病变糖尿病视网膜病变的病理特征是周细胞丢失、视神经视网膜异常和血管新生。糖尿病视网膜病变的主要临床表现为微血管瘤、出血斑点、硬性渗出、棉绒斑、静脉串珠状、视网膜内微血管异常(intraretinal microvascular abnormality，IRMA)以及黄斑水肿等。广泛出血会引起视网膜或视盘的新生血管、视网膜前出血、玻璃体积血及牵拉性视网膜脱离，微血管瘤出现最早期。", "ner": [[4, 11, "Disease"], [12, 19, "Disease"], [46, 53, "Disease"], [156, 166, "Disease"], [168, 173, "Disease"], [175, 179, "Disease"], [181, 188, "Disease"], [190, 193, "Disease"], [7, 9, "Anatomy"], [15, 17, "Anatomy"], [49, 51, "Anatomy"], [156, 158, "Anatomy"], [160, 161, "Anatomy"], [168, 170, "Anatomy"], [175, 177, "Anatomy"], [184, 186, "Anatomy"], [26, 30, "Symptom"], [32, 39, "Symptom"], [41, 44, "Symptom"], [62, 65, "Symptom"], [67, 70, "Symptom"], [72, 75, "Symptom"], [77, 79, "Symptom"], [81, 85, "Symptom"], [87, 140, "Symptom"], [143, 146, "Symptom"]], "rel": [[7, 9, "Anatomy", 4, 11, "Disease", "Anatomy_Disease"], [15, 17, "Anatomy", 12, 19, "Disease", "Anatomy_Disease"], [26, 30, "Symptom", 12, 19, "Disease", "Symptom_Disease"], [32, 39, "Symptom", 12, 19, "Disease", "Symptom_Disease"], [41, 44, "Symptom", 12, 19, "Disease", "Symptom_Disease"], [49, 51, "Anatomy", 46, 53, "Disease", "Anatomy_Disease"], [62, 65, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [67, 70, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [72, 75, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [77, 79, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [81, 85, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [87, 140, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [143, 146, "Symptom", 46, 53, "Disease", "Symptom_Disease"], [156, 158, "Anatomy", 156, 166, "Disease", "Anatomy_Disease"], [160, 161, "Anatomy", 156, 166, "Disease", "Anatomy_Disease"], [168, 170, "Anatomy", 168, 173, "Disease", "Anatomy_Disease"], [175, 177, "Anatomy", 175, 179, "Disease", "Anatomy_Disease"], [184, 186, "Anatomy", 181, 188, "Disease", "Anatomy_Disease"]]}
{"idx": 1922, "sentence": "糖尿病视网膜病变临床表现分为6期(具体分型、分期标准参考相关指南)。", "ner": [[0, 7, "Disease"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 0, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 1923, "sentence": "糖尿病视网膜病变是导致糖尿病患者失明的主要原因。", "ner": [[0, 7, "Disease"], [11, 13, "Disease"], [16, 17, "Disease"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 0, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 1924, "sentence": "3.3 糖尿病神经病变糖尿病神经病变主要可累及周围神经、自主神经、颅神经，脑及脊髓也可受累，早期表现为神经纤维脱髓鞘和轴突变性、Schwann细胞增生。随着病程进展，表现为轴突变性和髓鞘纤维消失。周围神经病变最常见的症状，诸如麻木、疼痛等感觉异常或者感觉丧失。自主神经受累时，可表现为心血管、胃肠道、泌尿生殖系统和排汗障碍或失调。颅神经病变以动眼神经受损最常见，其次为外展神经、滑车神经、面神经和三叉神经等，常单侧受累，双侧受累少见。脊髓病变以后索损害为主，主要为变性改变。", "ner": [[4, 10, "Disease"], [11, 17, "Disease"], [7, 8, "Anatomy"], [14, 15, "Anatomy"], [23, 26, "Anatomy"], [28, 31, "Anatomy"], [33, 35, "Anatomy"], [37, 37, "Anatomy"], [39, 40, "Anatomy"], [51, 57, "Symptom"], [59, 62, "Symptom"], [64, 74, "Symptom"], [86, 89, "Symptom"], [91, 96, "Symptom"], [98, 103, "Disease"], [113, 114, "Symptom"], [116, 117, "Symptom"], [119, 122, "Symptom"], [125, 128, "Symptom"], [130, 135, "Symptom"], [142, 163, "Symptom"], [165, 169, "Disease"], [165, 167, "Anatomy"], [172, 176, "Symptom"], [184, 187, "Anatomy"], [189, 192, "Anatomy"], [194, 196, "Anatomy"], [198, 201, "Anatomy"], [217, 220, "Disease"], [217, 218, "Anatomy"], [222, 225, "Symptom"], [232, 235, "Symptom"], [98, 101, "Anatomy"]], "rel": [[7, 8, "Anatomy", 4, 10, "Disease", "Anatomy_Disease"], [14, 15, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [23, 26, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [28, 31, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [33, 35, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [37, 37, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [39, 40, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [51, 57, "Symptom", 11, 17, "Disease", "Symptom_Disease"], [59, 62, "Symptom", 11, 17, "Disease", "Symptom_Disease"], [64, 74, "Symptom", 11, 17, "Disease", "Symptom_Disease"], [98, 101, "Anatomy", 98, 103, "Disease", "Anatomy_Disease"], [113, 114, "Symptom", 98, 103, "Disease", "Symptom_Disease"], [116, 117, "Symptom", 98, 103, "Disease", "Symptom_Disease"], [119, 122, "Symptom", 98, 103, "Disease", "Symptom_Disease"], [125, 128, "Symptom", 98, 103, "Disease", "Symptom_Disease"], [165, 167, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [184, 187, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [189, 192, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [194, 196, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [198, 201, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [172, 176, "Symptom", 165, 169, "Disease", "Symptom_Disease"], [217, 218, "Anatomy", 217, 220, "Disease", "Anatomy_Disease"], [232, 235, "Symptom", 217, 220, "Disease", "Symptom_Disease"], [222, 225, "Symptom", 217, 220, "Disease", "Symptom_Disease"]]}
{"idx": 1925, "sentence": "3.4 糖尿病足糖尿病患者因周围神经病变与外周血管疾病合并过高的机械压力，可引起足部过高的机械压力，从而导致足部软组织及骨关节系统的破坏与畸形形成。", "ner": [[4, 7, "Disease"], [7, 7, "Anatomy"], [8, 10, "Disease"], [14, 19, "Disease"], [21, 26, "Disease"], [40, 41, "Anatomy"], [54, 58, "Anatomy"], [60, 62, "Anatomy"], [14, 17, "Anatomy"], [21, 24, "Anatomy"]], "rel": [[7, 7, "Anatomy", 4, 7, "Disease", "Anatomy_Disease"], [54, 58, "Anatomy", 4, 7, "Disease", "Anatomy_Disease"], [60, 62, "Anatomy", 4, 7, "Disease", "Anatomy_Disease"], [40, 41, "Anatomy", 4, 7, "Disease", "Anatomy_Disease"], [14, 17, "Anatomy", 14, 19, "Disease", "Anatomy_Disease"], [21, 24, "Anatomy", 21, 26, "Disease", "Anatomy_Disease"]]}
{"idx": 1926, "sentence": "如果合并不同程度的感染，可从轻度的表皮的浅表感染到严重的坏疽等。", "ner": [[28, 29, "Disease"]], "rel": []}
{"idx": 1927, "sentence": "如不及时治疗，甚至导致截肢。", "ner": [[11, 12, "Operation"]], "rel": []}
{"idx": 1928, "sentence": "糖尿病足是目前非创伤性截肢的主要原因。", "ner": [[7, 12, "Operation"], [0, 3, "Disease"], [3, 3, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"]]}
{"idx": 1929, "sentence": "3.5 其他糖尿病心肌病变可在代谢紊乱及微血管病变的基础上引发心肌广泛局灶性坏死，出现亚临床的心功能异常，最终进展为心力衰竭、心律失常及心源性休克，重症患者甚至猝死。", "ner": [[6, 12, "Disease"], [9, 10, "Anatomy"], [15, 18, "Disease"], [20, 24, "Disease"], [20, 22, "Anatomy"], [31, 39, "Symptom"], [47, 51, "Symptom"], [58, 61, "Disease"], [63, 66, "Disease"], [68, 72, "Disease"], [58, 58, "Anatomy"]], "rel": [[9, 10, "Anatomy", 6, 12, "Disease", "Anatomy_Disease"], [31, 39, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [47, 51, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [20, 22, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"], [58, 58, "Anatomy", 58, 61, "Disease", "Anatomy_Disease"]]}
{"idx": 1930, "sentence": "糖尿病皮肤病变的发病机理是以微血管病变为主，晚期糖基化终产物蓄积、炎性反应、生长因子改变等参与的多因素的病变过程。临床可表现为胫前色素斑、类脂质渐进性坏死、糖尿病性水疱病、硬肿病和皮肤感染。", "ner": [[0, 2, "Disease"], [3, 6, "Disease"], [3, 4, "Anatomy"], [14, 18, "Disease"], [14, 16, "Anatomy"], [63, 67, "Symptom"], [69, 76, "Symptom"], [78, 84, "Symptom"], [86, 88, "Symptom"], [90, 93, "Symptom"]], "rel": [[3, 4, "Anatomy", 3, 6, "Disease", "Anatomy_Disease"], [63, 67, "Symptom", 3, 6, "Disease", "Symptom_Disease"], [69, 76, "Symptom", 3, 6, "Disease", "Symptom_Disease"], [78, 84, "Symptom", 3, 6, "Disease", "Symptom_Disease"], [86, 88, "Symptom", 3, 6, "Disease", "Symptom_Disease"], [90, 93, "Symptom", 3, 6, "Disease", "Symptom_Disease"], [14, 16, "Anatomy", 14, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 1931, "sentence": "4 糖尿病微循环障碍的药物治疗", "ner": [[2, 4, "Disease"], [5, 9, "Symptom"]], "rel": [[5, 9, "Symptom", 2, 4, "Disease", "Symptom_Disease"]]}
{"idx": 1932, "sentence": "4.1 用药原则积极控制血糖、血压、血脂仍是糖尿病治疗的基础。微循环障碍贯穿糖尿病病程的始终，改善糖尿病微循环用药应遵循“早期、个体化、合理联合、重视安全”的原则。", "ner": [[12, 13, "Test_items"], [18, 19, "Test_items"], [31, 35, "Symptom"], [38, 40, "Disease"], [49, 51, "Disease"], [22, 24, "Disease"], [15, 16, "Test"]], "rel": [[12, 13, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [18, 19, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [31, 35, "Symptom", 38, 40, "Disease", "Symptom_Disease"], [15, 16, "Test", 22, 24, "Disease", "Test_Disease"]]}
{"idx": 1933, "sentence": "4.1.1 早期一旦诊断为糖尿病，需尽早做并发症筛查，早诊断，考虑尽早使用改善微循环的药物。", "ner": [[13, 15, "Disease"]], "rel": []}
{"idx": 1934, "sentence": "4.1.2 个体化根据不同患者的临床表现特点和药物的作用机制，针对性选择药物，并给予适当疗程(在医生指导下用药和停药)，兼顾风险与获益的平衡。", "ner": [], "rel": []}
{"idx": 1935, "sentence": "4.1.3 合理联合一般不建议联合用药；如需联合，应遵循机制互补的原则，避免作用机制相同的药物联合，同时注意药物间的相互作用，尤其需考虑患者肝肾功能、年龄等因素。", "ner": [], "rel": []}
{"idx": 1936, "sentence": "4.1.4 重视安全严格掌握药物的适应证与禁忌证，注意药物的不良反应。", "ner": [], "rel": []}
{"idx": 1937, "sentence": "4.2. 改善糖尿病微循环障碍的药物改善糖尿病微循环障碍的药物主要包括血管扩张药物、影响血液流变学的药物、保护血管内皮的药物以及部分中药制剂等(改善微循环障碍药物的临床推荐意见见表1；常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书)。", "ner": [[7, 9, "Disease"], [10, 14, "Symptom"], [20, 22, "Disease"], [23, 27, "Symptom"], [74, 78, "Symptom"], [96, 98, "Disease"], [99, 103, "Symptom"]], "rel": [[10, 14, "Symptom", 7, 9, "Disease", "Symptom_Disease"], [23, 27, "Symptom", 20, 22, "Disease", "Symptom_Disease"], [99, 103, "Symptom", 96, 98, "Disease", "Symptom_Disease"]]}
{"idx": 1938, "sentence": "4.2.1 血管扩张药物", "ner": [], "rel": []}
{"idx": 1939, "sentence": "(1)胰激肽原酶(pancreatic kzllidinogenase，PK)：PK可增加毛细血管血流量；能激活纤溶酶，降低血液黏度，改善血流变；促使肾髓质分泌前列腺素E2，改善组织灌注。临床用于治疗各种微循环障碍性疾病，如糖尿病引起的肾病、周围神经病变、视网膜病变。", "ner": [[3, 38, "Drug"], [40, 41, "Drug"], [112, 114, "Disease"], [118, 119, "Disease"], [121, 126, "Disease"], [128, 132, "Disease"], [118, 118, "Anatomy"], [121, 124, "Anatomy"], [128, 130, "Anatomy"]], "rel": [[118, 118, "Anatomy", 118, 119, "Disease", "Anatomy_Disease"], [121, 124, "Anatomy", 121, 126, "Disease", "Anatomy_Disease"], [128, 130, "Anatomy", 128, 132, "Disease", "Anatomy_Disease"]]}
{"idx": 1940, "sentence": "国外研究提示，PK可以抑制血管增生，有利于控制糖尿病患者视网膜病变。", "ner": [[28, 32, "Disease"], [28, 30, "Anatomy"], [23, 25, "Disease"]], "rel": [[28, 30, "Anatomy", 28, 32, "Disease", "Anatomy_Disease"]]}
{"idx": 1941, "sentence": "PK在国内具有多年的临床使用经验，但尚需长期大样本及高质量的随机对照研究对其疗效和安全性验证。", "ner": [], "rel": []}
{"idx": 1942, "sentence": "翟所迪等进行的系统性评价结果提示，PK对糖尿病视网膜病变和糖尿病肾病有一定的疗效。", "ner": [[20, 27, "Disease"], [23, 25, "Anatomy"], [29, 33, "Disease"], [32, 32, "Anatomy"]], "rel": [[23, 25, "Anatomy", 20, 27, "Disease", "Anatomy_Disease"], [32, 32, "Anatomy", 29, 33, "Disease", "Anatomy_Disease"]]}
{"idx": 1943, "sentence": "(2)前列地尔：即前列腺素E1(prostaglandin1，PGE1)，增加血管平滑肌细胞内环磷酸腺苷(cyclic adenosine monophosphate，cAMP)含量，舒张血管平滑肌，发挥强大的扩血管作用，尤其对阻塞部位的血管作用显著。通过降低血液黏度，改善红细胞变形能力从而改善微循环。临床上用于治疗慢性动脉闭塞症引起的四肢溃疡及微小血管循环障碍引起的四肢静息疼痛。荟萃分析显示，PGE1可以缓解疼痛，增加无痛行走距离(pain-free walking distance，PFWD)和最大行走距离(maximum walking distance，MWD)且效果持续，促进溃疡愈合，降低截肢率。对于糖尿病神经病变的患者，荟萃分析结果显示，PGE1联合甲钴胺对糖尿病周围神经病变症状和体征改善的总有效率和对平均运动神经传导速度(motor nerve conduction velocity，MNCV)的改善优于单用甲钴胺。对于糖尿病合并肾功能不全的患者，荟萃分析结果显示，PGE1联合常规治疗，可显著降低尿白蛋白排出率(urinary albumin excretion rate，UAER)。", "ner": [[3, 6, "Drug"], [9, 35, "Drug"], [159, 165, "Disease"], [169, 172, "Symptom"], [174, 181, "Symptom"], [185, 190, "Symptom"], [309, 315, "Disease"], [312, 313, "Anatomy"], [329, 332, "Drug"], [335, 337, "Drug"], [339, 347, "Disease"], [344, 345, "Anatomy"], [417, 419, "Drug"], [423, 425, "Disease"], [428, 432, "Disease"], [428, 428, "Anatomy"], [446, 449, "Drug"], [462, 505, "Test_items"]], "rel": [[169, 172, "Symptom", 159, 165, "Disease", "Symptom_Disease"], [174, 181, "Symptom", 159, 165, "Disease", "Symptom_Disease"], [185, 190, "Symptom", 159, 165, "Disease", "Symptom_Disease"], [312, 313, "Anatomy", 309, 315, "Disease", "Anatomy_Disease"], [329, 332, "Drug", 339, 347, "Disease", "Drug_Disease"], [335, 337, "Drug", 339, 347, "Disease", "Drug_Disease"], [344, 345, "Anatomy", 339, 347, "Disease", "Anatomy_Disease"], [446, 449, "Drug", 423, 425, "Disease", "Drug_Disease"], [462, 505, "Test_items", 423, 425, "Disease", "Test_items_Disease"], [428, 428, "Anatomy", 428, 432, "Disease", "Anatomy_Disease"], [446, 449, "Drug", 428, 432, "Disease", "Drug_Disease"], [462, 505, "Test_items", 428, 432, "Disease", "Test_items_Disease"]]}
{"idx": 1944, "sentence": "(3)贝前列素钠：通过作用于血小板和血管平滑肌的前列环素受体，发挥抗血小板和扩张血管作用，从而改善微循环。临床上用于改善慢性动脉闭塞性疾病引起的溃疡、间歇性跛行、疼痛和冷感等症状。一项多中心、随机、双盲、对照研究显示，贝前列素钠治疗3~6个月可以显著改善间歇性跛行患者的PFWD和MWD。另一项随机双盲对照研究证实，慢性糖尿病足溃疡患者接受6周贝前列素钠治疗后，中位创面愈合率较安慰剂组显著提高。中国一项随机对照研究结果显示，前列地尔和前列地尔-贝前列素钠序贯治疗糖尿病肾病患者，均能显著降低尿微量白蛋白及尿总蛋白水平。", "ner": [[3, 7, "Drug"], [60, 68, "Disease"], [72, 73, "Symptom"], [75, 79, "Symptom"], [81, 82, "Symptom"], [84, 85, "Symptom"], [109, 113, "Drug"], [116, 120, "Duration"], [127, 131, "Disease"], [158, 162, "Disease"], [163, 165, "Symptom"], [170, 171, "Duration"], [172, 176, "Drug"], [213, 216, "Drug"], [232, 236, "Disease"], [235, 235, "Anatomy"], [247, 251, "Test_items"], [253, 256, "Test_items"], [218, 221, "Drug"], [223, 227, "Drug"]], "rel": [[72, 73, "Symptom", 60, 68, "Disease", "Symptom_Disease"], [75, 79, "Symptom", 60, 68, "Disease", "Symptom_Disease"], [81, 82, "Symptom", 60, 68, "Disease", "Symptom_Disease"], [84, 85, "Symptom", 60, 68, "Disease", "Symptom_Disease"], [109, 113, "Drug", 127, 131, "Disease", "Drug_Disease"], [116, 120, "Duration", 109, 113, "Drug", "Duration_Drug"], [163, 165, "Symptom", 158, 162, "Disease", "Symptom_Disease"], [172, 176, "Drug", 158, 162, "Disease", "Drug_Disease"], [170, 171, "Duration", 172, 176, "Drug", "Duration_Drug"], [213, 216, "Drug", 232, 236, "Disease", "Drug_Disease"], [235, 235, "Anatomy", 232, 236, "Disease", "Anatomy_Disease"], [247, 251, "Test_items", 232, 236, "Disease", "Test_items_Disease"], [253, 256, "Test_items", 232, 236, "Disease", "Test_items_Disease"], [218, 221, "Drug", 232, 236, "Disease", "Drug_Disease"], [223, 227, "Drug", 232, 236, "Disease", "Drug_Disease"]]}
{"idx": 1945, "sentence": "其他血管扩张药，如尼莫地平、桂哌齐特等钙离子通道阻滞剂，也可改善微血管痉挛和纠正缺血。", "ner": [[9, 12, "Drug"], [14, 17, "Drug"], [19, 26, "Drug"]], "rel": []}
{"idx": 1946, "sentence": "4.2.2 影响血液流变学的药物", "ner": [], "rel": []}
{"idx": 1947, "sentence": "(1)不同类型的抗血小板药：抗血小板的药物甚多，其主要作用是抑制血小板功能。氯吡格雷和噻氯匹定等药物是一类抑制二磷酸腺苷介导的血小板活化的新型抗血小板药。盐酸沙格雷酯是5-羟色胺2(5-hydroxytryptamine 2，5-HT2)受体拮抗剂，对血小板以及对血管平滑肌的5-HT2受体具有特异性拮抗作用，从而抑制5-HT2受体介导的血小板凝聚、抑制血管收缩和平滑肌细胞增殖，改善红细胞的变形能力，改善侧支循环，升高慢性动脉闭塞症患者的经皮氧分压以皮肤表面温度，改善微循环障碍。盐酸沙格雷酯可改善包括糖尿病周围血管病变引起的疼痛、冷感、溃疡等多种症状。一项随机对照研究显示，盐酸沙格雷酯治疗能有效增加糖尿病下肢血管病变患者MWD和PFWD，部分改善足背动脉和胫后动脉的流速、阻力指数和踝肱指数(ankle brachial index，ABI)。一项纳入了9个随机对照研究的荟萃分析结果显示，盐酸沙格雷酯治疗下肢血管病变，能减小患者溃疡面积，增加ABI、足背动脉血流量和PFWD。另一项研究显示，盐酸沙雷酯可降低早期糖尿病肾病患者蛋白尿，延缓肾病发展。", "ner": [[38, 41, "Drug"], [43, 46, "Drug"], [77, 82, "Drug"], [84, 123, "Drug"], [210, 216, "Disease"], [235, 239, "Symptom"], [212, 213, "Anatomy"], [241, 246, "Drug"], [252, 259, "Disease"], [255, 258, "Anatomy"], [264, 265, "Symptom"], [267, 268, "Symptom"], [270, 271, "Symptom"], [289, 294, "Drug"], [302, 310, "Disease"], [305, 308, "Anatomy"], [398, 403, "Drug"], [406, 411, "Disease"], [406, 409, "Anatomy"], [450, 454, "Drug"], [460, 464, "Disease"], [463, 463, "Anatomy"], [467, 469, "Symptom"], [473, 474, "Disease"], [473, 473, "Anatomy"]], "rel": [[77, 82, "Drug", 210, 216, "Disease", "Drug_Disease"], [84, 123, "Drug", 210, 216, "Disease", "Drug_Disease"], [212, 213, "Anatomy", 210, 216, "Disease", "Anatomy_Disease"], [241, 246, "Drug", 252, 259, "Disease", "Drug_Disease"], [255, 258, "Anatomy", 252, 259, "Disease", "Anatomy_Disease"], [264, 265, "Symptom", 252, 259, "Disease", "Symptom_Disease"], [267, 268, "Symptom", 252, 259, "Disease", "Symptom_Disease"], [270, 271, "Symptom", 252, 259, "Disease", "Symptom_Disease"], [289, 294, "Drug", 302, 310, "Disease", "Drug_Disease"], [305, 308, "Anatomy", 302, 310, "Disease", "Anatomy_Disease"], [398, 403, "Drug", 406, 411, "Disease", "Drug_Disease"], [406, 409, "Anatomy", 406, 411, "Disease", "Anatomy_Disease"], [450, 454, "Drug", 460, 464, "Disease", "Drug_Disease"], [463, 463, "Anatomy", 460, 464, "Disease", "Anatomy_Disease"], [467, 469, "Symptom", 460, 464, "Disease", "Symptom_Disease"], [473, 473, "Anatomy", 473, 474, "Disease", "Anatomy_Disease"]]}
{"idx": 1948, "sentence": "其他抗血小板药包括阿司匹林、双嘧达莫(潘生丁)和西洛他唑等。", "ner": [[9, 12, "Drug"], [14, 22, "Drug"], [24, 27, "Drug"]], "rel": []}
{"idx": 1949, "sentence": "(2)抗凝血药：包括抗凝血因子、抗血小板因子及新型的Xa因子和Ⅱa抑制剂。抗凝血因子又分为非肠道用药及肠道用药，临床常用的肝素(多用低分子肝素)为非肠道用药。新型抗凝血药指新研发上市的口服Xa因子和Ⅱa直接抑制剂，前者包括阿哌沙班、利伐沙班、依度沙班等，后者有达比加群。", "ner": [[10, 14, "Drug"], [16, 21, "Drug"], [23, 35, "Drug"], [37, 41, "Drug"], [61, 71, "Drug"], [94, 105, "Drug"], [111, 114, "Drug"], [116, 119, "Drug"], [121, 124, "Drug"], [130, 133, "Drug"], [92, 93, "Method"]], "rel": [[92, 93, "Method", 94, 105, "Drug", "Method_Drug"]]}
{"idx": 1950, "sentence": "(3)促纤溶药：蚓激酶是从露天红赤子爱胜蚓中提取的一种含有纤维蛋白溶酶和纤维蛋白溶酶原激活剂的混合物，可用于缺血性心脑血管疾病和糖尿病性周围血管闭塞症。", "ner": [[8, 10, "Drug"], [54, 62, "Disease"], [64, 74, "Disease"], [57, 60, "Anatomy"], [68, 71, "Anatomy"]], "rel": [[57, 60, "Anatomy", 54, 62, "Disease", "Anatomy_Disease"], [68, 71, "Anatomy", 64, 74, "Disease", "Anatomy_Disease"]]}
{"idx": 1951, "sentence": "4.2.3 保护血管内皮的药物", "ner": [], "rel": []}
{"idx": 1952, "sentence": "(1)血管保护药：①羟苯磺酸钙通过抗氧化应激作用，减轻炎症改善血管内皮功能紊乱，减轻微血管渗漏，改善微循环；减少血管内皮生长因子(vascular endothelial growth factor，VEGF)与受体结合，抑制新生血管生成。临床用于治疗糖尿病视网膜病变及糖尿病肾病。一项多中心、随机双盲对照研究证实，伴有早期视网膜病变的2型糖尿病患者使用羟苯磺酸钙治疗24个月，后玻璃体穿透率(posterior vitreous penetration ratio，PVPR)较基线进行性降低(降幅13.2%)，且不同血糖控制水平的亚组中PVPR均有显著改善，微动脉瘤及出血进展平均值均显著低于安慰剂组。一项纳入221项研究的荟萃分析显示，羟苯磺酸钙可显著改善非增殖期视网膜病变患者微动脉瘤、眼底渗出和眼底出血。对于较晚期的视网膜病变患者，羟苯磺酸钙可作为激光治疗的辅助手段，进一步提高激光治疗疗效。中国一项随机临床试验也显示，较单纯视网膜激光治疗组，羟苯磺酸钙联合视网膜激光治疗组能更明显减少糖尿病患者的黄斑中心凹厚度。一项针对糖尿病肾脏病变的观察性研究显示，羟苯磺酸治疗3个月可使90%的糖尿病肾脏病患者微量蛋白尿下降至正常。", "ner": [[10, 14, "Drug"], [177, 181, "Drug"], [126, 133, "Disease"], [135, 139, "Disease"], [138, 138, "Anatomy"], [129, 131, "Anatomy"], [160, 166, "Symptom"], [168, 172, "Disease"], [190, 238, "Test_items"], [242, 255, "Test_Value"], [260, 261, "Test_items"], [281, 284, "Disease"], [321, 325, "Drug"], [335, 339, "Disease"], [335, 337, "Anatomy"], [342, 345, "Symptom"], [347, 350, "Symptom"], [352, 355, "Symptom"], [363, 367, "Disease"], [371, 375, "Drug"], [379, 382, "Treatment"], [394, 397, "Treatment"], [418, 424, "Treatment"], [427, 431, "Drug"], [434, 440, "Treatment"], [448, 450, "Disease"], [454, 460, "Test_items"], [466, 472, "Disease"], [469, 470, "Anatomy"], [482, 485, "Drug"], [497, 502, "Disease"], [500, 501, "Anatomy"], [507, 509, "Test_items"], [510, 514, "Test_Value"], [488, 490, "Duration"], [363, 365, "Anatomy"], [184, 187, "Duration"]], "rel": [[10, 14, "Drug", 126, 133, "Disease", "Drug_Disease"], [10, 14, "Drug", 135, 139, "Disease", "Drug_Disease"], [177, 181, "Drug", 168, 172, "Disease", "Drug_Disease"], [184, 187, "Duration", 177, 181, "Drug", "Duration_Drug"], [129, 131, "Anatomy", 126, 133, "Disease", "Anatomy_Disease"], [138, 138, "Anatomy", 135, 139, "Disease", "Anatomy_Disease"], [160, 166, "Symptom", 168, 172, "Disease", "Symptom_Disease"], [190, 238, "Test_items", 168, 172, "Disease", "Test_items_Disease"], [260, 261, "Test_items", 168, 172, "Disease", "Test_items_Disease"], [321, 325, "Drug", 335, 339, "Disease", "Drug_Disease"], [335, 337, "Anatomy", 335, 339, "Disease", "Anatomy_Disease"], [342, 345, "Symptom", 335, 339, "Disease", "Symptom_Disease"], [347, 350, "Symptom", 335, 339, "Disease", "Symptom_Disease"], [352, 355, "Symptom", 335, 339, "Disease", "Symptom_Disease"], [363, 365, "Anatomy", 363, 367, "Disease", "Anatomy_Disease"], [371, 375, "Drug", 363, 367, "Disease", "Drug_Disease"], [379, 382, "Treatment", 363, 367, "Disease", "Treatment_Disease"], [394, 397, "Treatment", 363, 367, "Disease", "Treatment_Disease"], [418, 424, "Treatment", 448, 450, "Disease", "Treatment_Disease"], [427, 431, "Drug", 448, 450, "Disease", "Drug_Disease"], [454, 460, "Test_items", 448, 450, "Disease", "Test_items_Disease"], [469, 470, "Anatomy", 466, 472, "Disease", "Anatomy_Disease"], [482, 485, "Drug", 466, 472, "Disease", "Drug_Disease"], [488, 490, "Duration", 482, 485, "Drug", "Duration_Drug"], [500, 501, "Anatomy", 497, 502, "Disease", "Anatomy_Disease"], [507, 509, "Test_items", 497, 502, "Disease", "Test_items_Disease"]]}
{"idx": 1953, "sentence": "②递法明主要成分为欧洲越橘的花青苷和β-胡萝卜素。", "ner": [[1, 3, "Drug"]], "rel": []}
{"idx": 1954, "sentence": "花青苷被认为具有抗氧化、抗炎、抗渗出和抗出血的作用，促进视网膜对光线强度化的敏感性，改善视力、暗适应和视网膜的血液供应，因而能够保护血管、改善微循环。", "ner": [], "rel": []}
{"idx": 1955, "sentence": "在欧洲，用于临床治疗视网膜病变已多年。", "ner": [[10, 14, "Disease"], [10, 12, "Anatomy"]], "rel": [[10, 12, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"]]}
{"idx": 1956, "sentence": "中国一项察性研究结果显示，递法明组的单纯型糖尿病网膜病变患者改善情况优于常规组(P<0.05)。", "ner": [[13, 15, "Drug"], [21, 27, "Disease"], [24, 25, "Anatomy"]], "rel": [[13, 15, "Drug", 21, 27, "Disease", "Drug_Disease"], [24, 25, "Anatomy", 21, 27, "Disease", "Anatomy_Disease"]]}
{"idx": 1957, "sentence": "(2)抗血管内皮生长因子药：①雷珠单抗，临床上用于各种原因引起的黄斑水肿、视网膜新生血管、视网膜静脉阻塞、新生血管性青光眼等疾病。随机对照研究结果显示，雷珠单抗可显著降低糖尿病黄斑水肿患者硬性渗出区域。此外，存在黄斑水肿、黄斑变性、视网膜内囊肿、玻璃体严重增厚眼病的糖尿病患者使用雷珠单抗治疗可有效减轻黄斑变性。②贝伐单抗可用于治疗视网膜新生血管性疾病。一项随机对照研究结果显示，贝伐单抗联合视网膜光凝术治疗可显著降低高风险糖尿病视网膜病变患者的视敏度恶化程度，减少黄斑中心凹厚度及黄斑体积。", "ner": [[15, 18, "Drug"], [32, 35, "Disease"], [32, 33, "Anatomy"], [37, 43, "Disease"], [37, 39, "Anatomy"], [45, 51, "Disease"], [45, 47, "Anatomy"], [53, 60, "Disease"], [60, 60, "Anatomy"], [76, 79, "Drug"], [106, 109, "Disease"], [85, 91, "Disease"], [88, 89, "Anatomy"], [111, 114, "Disease"], [116, 121, "Disease"], [123, 131, "Disease"], [133, 135, "Disease"], [140, 143, "Drug"], [151, 154, "Disease"], [106, 107, "Anatomy"], [111, 112, "Anatomy"], [116, 118, "Anatomy"], [123, 125, "Anatomy"], [151, 152, "Anatomy"], [157, 160, "Drug"], [166, 175, "Disease"], [166, 168, "Anatomy"], [190, 193, "Drug"], [196, 203, "Operation"], [212, 219, "Disease"], [215, 217, "Anatomy"]], "rel": [[15, 18, "Drug", 32, 35, "Disease", "Drug_Disease"], [15, 18, "Drug", 37, 43, "Disease", "Drug_Disease"], [15, 18, "Drug", 45, 51, "Disease", "Drug_Disease"], [15, 18, "Drug", 53, 60, "Disease", "Drug_Disease"], [32, 33, "Anatomy", 32, 35, "Disease", "Anatomy_Disease"], [37, 39, "Anatomy", 37, 43, "Disease", "Anatomy_Disease"], [45, 47, "Anatomy", 45, 51, "Disease", "Anatomy_Disease"], [60, 60, "Anatomy", 53, 60, "Disease", "Anatomy_Disease"], [76, 79, "Drug", 85, 91, "Disease", "Drug_Disease"], [140, 143, "Drug", 106, 109, "Disease", "Drug_Disease"], [106, 107, "Anatomy", 106, 109, "Disease", "Anatomy_Disease"], [88, 89, "Anatomy", 85, 91, "Disease", "Anatomy_Disease"], [140, 143, "Drug", 111, 114, "Disease", "Drug_Disease"], [111, 112, "Anatomy", 111, 114, "Disease", "Anatomy_Disease"], [140, 143, "Drug", 116, 121, "Disease", "Drug_Disease"], [116, 118, "Anatomy", 116, 121, "Disease", "Anatomy_Disease"], [140, 143, "Drug", 123, 131, "Disease", "Drug_Disease"], [123, 125, "Anatomy", 123, 131, "Disease", "Anatomy_Disease"], [140, 143, "Drug", 151, 154, "Disease", "Drug_Disease"], [151, 152, "Anatomy", 151, 154, "Disease", "Anatomy_Disease"], [157, 160, "Drug", 166, 175, "Disease", "Drug_Disease"], [166, 168, "Anatomy", 166, 175, "Disease", "Anatomy_Disease"], [190, 193, "Drug", 212, 219, "Disease", "Drug_Disease"], [196, 203, "Operation", 212, 219, "Disease", "Operation_Disease"], [215, 217, "Anatomy", 212, 219, "Disease", "Anatomy_Disease"]]}
{"idx": 1958, "sentence": "4.2.4 中药制剂一些具有活血化瘀作用的植物药及中药制剂也常被用于糖尿病微循环障碍的治疗，如银杏叶制剂、复方丹参滴丸、三七制剂等。", "ner": [[34, 36, "Disease"], [37, 41, "Symptom"], [47, 51, "Drug"], [53, 58, "Drug"], [60, 63, "Drug"]], "rel": [[47, 51, "Drug", 34, 36, "Disease", "Drug_Disease"], [53, 58, "Drug", 34, 36, "Disease", "Drug_Disease"], [60, 63, "Drug", 34, 36, "Disease", "Drug_Disease"], [37, 41, "Symptom", 34, 36, "Disease", "Symptom_Disease"]]}
{"idx": 1959, "sentence": "(1)银杏叶提取物片(EGb761)：该药的多成分之间具有协同作用，主要通过降低血液黏度来改善血液流变学，从而改善血液循环；清除自由基，抑制细胞膜发生脂质过氧化；拮抗血小板活化因子(platelet active factor，PAF)，从而抑制血小板聚集；促进突触重塑，保护神经细胞。临床上主要用于脑动脉硬化导致的脑功能障碍、糖尿病性视网病变以及周围血管病变导致的间歇性跛行。脑部、周围血流循环障碍：包括糖尿病引起的视网膜病变及神经障碍、老年黄斑变性、间歇性跛行症等。一项针对台湾地区居民的研究显示，银杏叶提取物片能够有效地改善2型糖尿病视网膜病变患者的视网膜毛细血管血流量，从而缓解糖尿病视网膜病变。系统性评价结果显示，在常规治疗基础上联合银杏叶提取物片可进一步降低糖尿病肾病患空腹血糖及尿白蛋白排泄率，改善患者血液流变学。国内的研究显示，银杏叶提取物片联合甲钴胺治疗糖尿病周围神经病变，可明显改善糖尿周围神经病变患者的临床症状及神经传导速度，总有效率(显效和有效)达到88.9%。", "ner": [[3, 17, "Drug"], [150, 154, "Disease"], [158, 162, "Disease"], [164, 171, "Disease"], [174, 179, "Disease"], [183, 187, "Disease"], [203, 205, "Disease"], [215, 218, "Disease"], [220, 225, "Disease"], [227, 232, "Disease"], [265, 274, "Disease"], [293, 300, "Disease"], [335, 339, "Disease"], [386, 394, "Disease"], [401, 408, "Disease"], [150, 152, "Anatomy"], [158, 158, "Anatomy"], [168, 169, "Anatomy"], [174, 177, "Anatomy"], [209, 213, "Disease"], [209, 211, "Anatomy"], [215, 216, "Anatomy"], [222, 223, "Anatomy"], [270, 272, "Anatomy"], [296, 298, "Anatomy"], [338, 338, "Anatomy"], [389, 392, "Anatomy"], [403, 406, "Anatomy"], [251, 257, "Drug"], [322, 328, "Drug"], [372, 378, "Drug"], [381, 383, "Drug"], [341, 344, "Test_items"], [346, 352, "Test_items"]], "rel": [[150, 152, "Anatomy", 150, 154, "Disease", "Anatomy_Disease"], [158, 158, "Anatomy", 158, 162, "Disease", "Anatomy_Disease"], [168, 169, "Anatomy", 164, 171, "Disease", "Anatomy_Disease"], [174, 177, "Anatomy", 174, 179, "Disease", "Anatomy_Disease"], [215, 216, "Anatomy", 215, 218, "Disease", "Anatomy_Disease"], [222, 223, "Anatomy", 220, 225, "Disease", "Anatomy_Disease"], [270, 272, "Anatomy", 265, 274, "Disease", "Anatomy_Disease"], [251, 257, "Drug", 265, 274, "Disease", "Drug_Disease"], [296, 298, "Anatomy", 293, 300, "Disease", "Anatomy_Disease"], [338, 338, "Anatomy", 335, 339, "Disease", "Anatomy_Disease"], [341, 344, "Test_items", 335, 339, "Disease", "Test_items_Disease"], [346, 352, "Test_items", 335, 339, "Disease", "Test_items_Disease"], [322, 328, "Drug", 335, 339, "Disease", "Drug_Disease"], [389, 392, "Anatomy", 386, 394, "Disease", "Anatomy_Disease"], [381, 383, "Drug", 386, 394, "Disease", "Drug_Disease"], [372, 378, "Drug", 386, 394, "Disease", "Drug_Disease"], [403, 406, "Anatomy", 401, 408, "Disease", "Anatomy_Disease"], [209, 211, "Anatomy", 209, 213, "Disease", "Anatomy_Disease"]]}
{"idx": 1960, "sentence": "(2)复方丹参滴丸：由丹参、三七、冰片等药物组成，其中丹参的有效成分为水溶性丹参素，可提高机体抗凝和纤溶活性，抑制血小板聚集和释放前列环素类物质，抗凝血和抑制血栓形成；阻断羟自由基的产生，阻止脂质过氧化，是一种有效的氧自由基清除剂，临床上用于糖尿病肾病、视网病变和神经病变的治疗。一项纳入19个研究的荟萃分析结果显示，在常规治疗的基础上加用复方丹参滴丸，可显著减少24h尿蛋白总量，但是对血肌肝和血糖无影响。在中国疗非增殖性糖尿病视网膜病变患者中进行的一项随机对照研究，24周时眼底荧光血管造影及眼底检查结果均显示，高剂量和中剂量复方丹参滴丸组的有效的患者比例显著高于安慰剂组，且无临床不良事件发生。此外，复方丹参滴丸可以改善血瘀型糖尿病周围神经病变的血瘀症状，提高周围神经传导速度包括尺神经、腓总神经、腓肠神经和胫后神经的运动传导速度和感觉传导速度，有治疗和延缓其发展的作用。", "ner": [[121, 125, "Disease"], [127, 130, "Disease"], [132, 135, "Disease"], [208, 219, "Disease"], [313, 324, "Disease"], [3, 8, "Drug"], [170, 175, "Drug"], [182, 189, "Test_items"], [194, 196, "Test_items"], [198, 199, "Test_items"], [235, 246, "Test"], [248, 251, "Test"], [326, 327, "Symptom"], [265, 270, "Drug"], [303, 308, "Drug"], [124, 124, "Anatomy"], [127, 128, "Anatomy"], [132, 133, "Anatomy"], [215, 217, "Anatomy"], [319, 322, "Anatomy"]], "rel": [[3, 8, "Drug", 121, 125, "Disease", "Drug_Disease"], [124, 124, "Anatomy", 121, 125, "Disease", "Anatomy_Disease"], [3, 8, "Drug", 127, 130, "Disease", "Drug_Disease"], [127, 128, "Anatomy", 127, 130, "Disease", "Anatomy_Disease"], [3, 8, "Drug", 132, 135, "Disease", "Drug_Disease"], [132, 133, "Anatomy", 132, 135, "Disease", "Anatomy_Disease"], [215, 217, "Anatomy", 208, 219, "Disease", "Anatomy_Disease"], [235, 246, "Test", 208, 219, "Disease", "Test_Disease"], [248, 251, "Test", 208, 219, "Disease", "Test_Disease"], [303, 308, "Drug", 313, 324, "Disease", "Drug_Disease"], [319, 322, "Anatomy", 313, 324, "Disease", "Anatomy_Disease"], [326, 327, "Symptom", 313, 324, "Disease", "Symptom_Disease"]]}
{"idx": 1961, "sentence": "其他中药提取物如血塞通注射液、丹红注射液和津力达颗粒等临床上也可用于治疗糖尿病微循环障碍疾病，但缺少长期大样本数据的支持。常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书。", "ner": [[8, 13, "Drug"], [15, 19, "Drug"], [21, 25, "Drug"], [36, 45, "Disease"], [65, 67, "Disease"], [68, 72, "Symptom"]], "rel": [[8, 13, "Drug", 36, 45, "Disease", "Drug_Disease"], [15, 19, "Drug", 36, 45, "Disease", "Drug_Disease"], [21, 25, "Drug", 36, 45, "Disease", "Drug_Disease"], [68, 72, "Symptom", 65, 67, "Disease", "Symptom_Disease"]]}
{"idx": 1962, "sentence": "5 总结与展望", "ner": [], "rel": []}
{"idx": 1963, "sentence": "本共识从微循环障碍在糖尿病慢性并发症发生中的机制入手，分析其临床表现及药物治疗原则，以期帮助临床医生提高对糖尿病患者微循环障碍的重视程度，在临床实践中实现早期识别、早期诊断、早期预防和治疗，改善糖尿病患者的预后。", "ner": [[4, 8, "Symptom"], [10, 12, "Disease"], [53, 55, "Disease"], [58, 62, "Symptom"], [97, 99, "Disease"]], "rel": [[4, 8, "Symptom", 10, 12, "Disease", "Symptom_Disease"], [58, 62, "Symptom", 53, 55, "Disease", "Symptom_Disease"]]}
{"idx": 1964, "sentence": "在我国，许多改善微循环障碍的药物仍缺乏足够的循证医学证据，今后仍需开展相关大型前瞻性临床研究，为糖尿病患者微循环障碍治疗的安全性、个体化用药提供更多的临床循证依据。", "ner": [[8, 12, "Symptom"], [48, 50, "Disease"], [53, 57, "Symptom"]], "rel": [[53, 57, "Symptom", 48, 50, "Disease", "Symptom_Disease"]]}
{"idx": 1965, "sentence": "成人2型糖尿病胰岛素临床应用的中国专家共识", "ner": [[2, 6, "Disease"], [7, 9, "Drug"]], "rel": [[7, 9, "Drug", 2, 6, "Disease", "Drug_Disease"]]}
{"idx": 1966, "sentence": "糖尿病已成为严重威胁国人健康的最重要的慢性非传染性疾病之一，但糖尿病控制状况在我国并不容乐观，甚至按纵向比较，血糖控制情况亦无显著改善。2011年公布现状调查显示口服药联合胰岛素治疗的患者中85%HbA1c控制未达标(≥7.o%)糖尿病相关治疗费用中约80%用于糖尿病并发症的治疗。", "ner": [[0, 2, "Disease"], [31, 33, "Disease"], [55, 56, "Test_items"], [81, 82, "Method"], [86, 88, "Drug"], [98, 102, "Test_items"], [103, 114, "Test_Value"], [115, 117, "Disease"], [131, 133, "Disease"]], "rel": [[55, 56, "Test_items", 31, 33, "Disease", "Test_items_Disease"], [86, 88, "Drug", 115, 117, "Disease", "Drug_Disease"], [98, 102, "Test_items", 115, 117, "Disease", "Test_items_Disease"]]}
{"idx": 1967, "sentence": "众所周知，2型糖尿病患者胰岛β细胞功能随病程进展逐渐恶化。由此推论，随病程进展，为取得血糖最佳控制，大部分2型糖尿病患者似乎最终均需胰岛素治疗。", "ner": [[5, 9, "Disease"], [12, 27, "Pathogenesis"], [43, 44, "Test_items"], [53, 57, "Disease"], [66, 68, "Drug"]], "rel": [[12, 27, "Pathogenesis", 5, 9, "Disease", "Pathogenesis_Disease"], [43, 44, "Test_items", 53, 57, "Disease", "Test_items_Disease"], [66, 68, "Drug", 53, 57, "Disease", "Drug_Disease"]]}
{"idx": 1968, "sentence": "然而，由于社会、经济和心理因素，胰岛素使用不足和使用过度的情况在我国同时并存。", "ner": [[16, 18, "Drug"]], "rel": []}
{"idx": 1969, "sentence": "因此，规范胰岛素治疗对于改善糖尿病管理、提高广大医护人员的临床实践水平具有重要意义。", "ner": [[5, 7, "Drug"], [14, 16, "Disease"]], "rel": [[5, 7, "Drug", 14, 16, "Disease", "Drug_Disease"]]}
{"idx": 1970, "sentence": "目前临床应用的胰岛素包括动物胰岛素、人胰岛素及胰岛素类似物。其中，人胰岛素具有免疫原性低、长期使用安全可靠、效价比高等优点，在临床中应用最为广泛，在2型糖尿病血糖管理中作用突出。", "ner": [[7, 9, "Drug"], [12, 16, "Drug"], [18, 21, "Drug"], [23, 28, "Drug"], [33, 36, "Drug"], [74, 78, "Disease"], [79, 80, "Test_items"]], "rel": [[79, 80, "Test_items", 74, 78, "Disease", "Test_items_Disease"]]}
{"idx": 1971, "sentence": "胰岛素类似物通过改变人胰岛素结构从而改变其药代动力学特性，可分为超短效胰岛素类似物和长效胰岛素类似物。", "ner": [[0, 5, "Drug"], [10, 13, "Drug"], [32, 40, "Drug"], [42, 49, "Drug"]], "rel": []}
{"idx": 1972, "sentence": "因起效和持续时间不同，胰岛素类似物有其各自的特点，但其使用和剂量调整原则与人胰岛素基本相同（表1）。", "ner": [[11, 16, "Drug"], [37, 40, "Drug"]], "rel": []}
{"idx": 1973, "sentence": "一、合理选择胰岛素治疗时机", "ner": [[6, 8, "Drug"]], "rel": []}
{"idx": 1974, "sentence": "对于2型糖尿病患者而言，尽早启动胰岛素治疗能减轻胰岛β细胞的负荷，尽快纠正高血糖状态，迅速解除高糖毒性，改善胰岛素抵抗，保护甚至逆转残存β细胞功能。", "ner": [[2, 6, "Disease"], [16, 18, "Drug"], [37, 39, "Disease"], [47, 50, "Pathogenesis"], [54, 58, "Pathogenesis"]], "rel": [[16, 18, "Drug", 2, 6, "Disease", "Drug_Disease"], [47, 50, "Pathogenesis", 2, 6, "Disease", "Pathogenesis_Disease"], [54, 58, "Pathogenesis", 2, 6, "Disease", "Pathogenesis_Disease"]]}
{"idx": 1975, "sentence": "对于胰岛素起始治疗的时机，不同学术组织的推荐有所不同(表2)。", "ner": [[2, 4, "Drug"]], "rel": []}
{"idx": 1976, "sentence": "多项研究表明，亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低，糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著。因此，中国2型糖尿病患者应适时启动胰岛素治疗。", "ner": [[7, 31, "Pathogenesis"], [33, 55, "Pathogenesis"], [62, 66, "Disease"], [74, 76, "Drug"]], "rel": [[74, 76, "Drug", 62, 66, "Disease", "Drug_Disease"]]}
{"idx": 1977, "sentence": "本共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全；(4)妊娠期间。", "ner": [[8, 12, "Disease"], [23, 25, "Drug"], [74, 79, "Disease"], [74, 74, "Anatomy"], [75, 75, "Anatomy"]], "rel": [[23, 25, "Drug", 8, 12, "Disease", "Drug_Disease"], [74, 74, "Anatomy", 74, 79, "Disease", "Anatomy_Disease"], [75, 75, "Anatomy", 74, 79, "Disease", "Anatomy_Disease"]]}
{"idx": 1978, "sentence": "以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，HbA1c≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药物次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)的患者；(3)病程中出现无明显诱因的体重下降者。", "ner": [[7, 9, "Drug"], [19, 20, "Method"], [23, 25, "Drug"], [37, 41, "Disease"], [45, 49, "Test_items"], [50, 54, "Test_Value"], [56, 58, "Disease"], [73, 78, "Treatment"], [87, 88, "Method"], [103, 104, "Test_items"], [106, 108, "Test_Value"], [110, 114, "Test_items"], [115, 119, "Test_Value"], [139, 142, "Symptom"]], "rel": [[45, 49, "Test_items", 37, 41, "Disease", "Test_items_Disease"]]}
{"idx": 1979, "sentence": "二、初始胰岛素治疗方案的制定", "ner": [[4, 6, "Drug"]], "rel": []}
{"idx": 1980, "sentence": "临床医师在制定胰岛素方案、剂量调整和设定糖尿病血糖控制目标时，除考虑病理生理因素外，还必须考虑社会经济因素，并统筹考虑安全性、可行性和科学性，制定个体化的血糖控制目标和起始治疗方案。", "ner": [[7, 9, "Drug"], [20, 22, "Disease"], [23, 24, "Test_items"], [77, 78, "Test_items"]], "rel": [[7, 9, "Drug", 20, 22, "Disease", "Drug_Disease"], [23, 24, "Test_items", 20, 22, "Disease", "Test_items_Disease"]]}
{"idx": 1981, "sentence": "同时，在治疗过程中，应及时进行临床评价，进行适当调整。", "ner": [], "rel": []}
{"idx": 1982, "sentence": "1.制定个体化的治疗目标：(1)长期血糖控制目标：一般而言，以反映最近2~3个月血糖控制情况的HbA1c为主要目标，兼顾空腹和餐后血糖达标(具体可参照《中国成人2型糖尿病Hbh1c控制目标的专家共识》，表3)。", "ner": [[18, 19, "Test_items"], [40, 41, "Test_items"], [47, 51, "Test_items"], [60, 66, "Test_items"], [67, 68, "Test_Value"], [80, 84, "Disease"], [85, 89, "Test_items"]], "rel": [[85, 89, "Test_items", 80, 84, "Disease", "Test_items_Disease"]]}
{"idx": 1983, "sentence": "(2)短期血糖控制目标：一般住院患者，降糖治疗以即时血糖达标为主要目标。", "ner": [[5, 6, "Test_items"], [26, 27, "Test_items"], [28, 29, "Test_Value"]], "rel": []}
{"idx": 1984, "sentence": "一般推荐7.8~10mmol/L(140~180mg/d1)为宜。", "ner": [[4, 29, "Test_Value"]], "rel": []}
{"idx": 1985, "sentence": "2.各种治疗方案的特点：目前临床中常见的胰岛素治疗方案有1天1次或2次基础胰岛素联合口服药、1天2次预混胰岛素方案、基础+餐时胰岛素方案。", "ner": [[20, 22, "Drug"], [28, 34, "Frequency"], [35, 39, "Drug"], [42, 43, "Method"], [46, 49, "Frequency"], [50, 54, "Drug"], [58, 65, "Drug"]], "rel": [[28, 34, "Frequency", 35, 39, "Drug", "Frequency_Drug"], [46, 49, "Frequency", 50, 54, "Drug", "Frequency_Drug"], [46, 49, "Frequency", 58, 65, "Drug", "Frequency_Drug"]]}
{"idx": 1986, "sentence": "各种方案适用于不同的临床情况(根据患者的治疗意愿、能力、生活方式和血糖状况做出选择)，具体详见表4。", "ner": [[33, 34, "Test_items"]], "rel": []}
{"idx": 1987, "sentence": "3.不同治疗方案的选择：目前尚无循证医学证据证实何种胰岛素起始治疗方案更优，各权威学术组织推荐的胰岛素启动治疗方案不尽相同。多数国家和地区[美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南]推荐起始使用基础胰岛素。若血糖控制不达标，可加用餐时胰岛素。美国临床内分泌医师协会(AACE)/美国内分泌学院(ACE)专家共识推荐基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素1日多次注射、餐时胰岛素加二甲双胍这4种胰岛素方案中任一种均可作为起始治疗。", "ner": [[26, 28, "Drug"], [48, 50, "Drug"], [72, 74, "Disease"], [85, 87, "Disease"], [107, 109, "Disease"], [143, 145, "Disease"], [166, 168, "Drug"], [171, 172, "Test_items"], [173, 177, "Test_Value"], [182, 186, "Drug"], [224, 228, "Drug"], [230, 234, "Drug"], [236, 243, "Drug"], [245, 249, "Drug"], [250, 253, "Frequency"], [254, 255, "Method"], [257, 261, "Drug"], [263, 266, "Drug"], [270, 272, "Drug"]], "rel": [[250, 253, "Frequency", 224, 228, "Drug", "Frequency_Drug"], [254, 255, "Method", 224, 228, "Drug", "Method_Drug"], [250, 253, "Frequency", 230, 234, "Drug", "Frequency_Drug"], [254, 255, "Method", 230, 234, "Drug", "Method_Drug"], [250, 253, "Frequency", 236, 243, "Drug", "Frequency_Drug"], [254, 255, "Method", 236, 243, "Drug", "Method_Drug"], [250, 253, "Frequency", 245, 249, "Drug", "Frequency_Drug"], [254, 255, "Method", 245, 249, "Drug", "Method_Drug"]]}
{"idx": 1988, "sentence": "总体而言，预混胰岛素治疗达标率更高，基础胰岛素治疗低血糖发生率相对较低。亚裔糖尿病患者中以餐后血糖增高更常见，餐后血糖在血糖控制中的作用尤为重要。中国2型糖尿病防治指南(2010年版)指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服药物联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素治疗(基础胰岛素加餐时胰岛素或每日3次预混胰岛素。", "ner": [[5, 9, "Drug"], [18, 22, "Drug"], [25, 27, "ADE"], [38, 40, "Disease"], [45, 48, "Test_items"], [49, 50, "Test_Value"], [55, 58, "Test_items"], [60, 61, "Test_items"], [75, 79, "Disease"], [95, 98, "Frequency"], [99, 103, "Drug"], [105, 110, "Frequency"], [111, 115, "Drug"], [120, 122, "Drug"], [131, 135, "Drug"], [137, 141, "Drug"], [143, 144, "Method"], [153, 154, "Test_items"], [155, 157, "Test_Value"], [170, 172, "Drug"], [176, 180, "Drug"], [182, 186, "Drug"], [188, 191, "Frequency"], [192, 196, "Drug"]], "rel": [[25, 27, "ADE", 18, 22, "Drug", "ADE_Drug"], [45, 48, "Test_items", 38, 40, "Disease", "Test_items_Disease"], [99, 103, "Drug", 75, 79, "Disease", "Drug_Disease"], [111, 115, "Drug", 75, 79, "Disease", "Drug_Disease"], [120, 122, "Drug", 75, 79, "Disease", "Drug_Disease"], [95, 98, "Frequency", 99, 103, "Drug", "Frequency_Drug"], [105, 110, "Frequency", 111, 115, "Drug", "Frequency_Drug"], [188, 191, "Frequency", 192, 196, "Drug", "Frequency_Drug"]]}
{"idx": 1989, "sentence": "图1)。", "ner": [], "rel": []}
{"idx": 1990, "sentence": "三、不同类别胰岛素的选择", "ner": [[6, 8, "Drug"]], "rel": []}
{"idx": 1991, "sentence": "药物经济学已经成为评价临床治疗方案的重要手段之一。在选择2型糖尿病治疗方案时，应综合考虑控制医疗费用、患者病情及其支付能力等多方面因素。作为发展中国家，我国医疗资源仍相对匮乏，且糖尿病患者人数众多且增长迅猛，在为2型糖尿病制定胰岛素治疗方案时需考虑以上诸多因素。", "ner": [[28, 32, "Disease"], [89, 91, "Disease"], [106, 110, "Disease"], [113, 115, "Drug"]], "rel": [[113, 115, "Drug", 106, 110, "Disease", "Drug_Disease"]]}
{"idx": 1992, "sentence": "人胰岛素经济、安全、有效，在2型糖尿病治疗中发挥重要的作用。", "ner": [[14, 18, "Disease"], [0, 3, "Drug"]], "rel": [[0, 3, "Drug", 14, 18, "Disease", "Drug_Disease"]]}
{"idx": 1993, "sentence": "正是基于成本和效益比基础上，《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》亦对胰岛素的选择做出规定(表5)。", "ner": [[48, 50, "Drug"]], "rel": []}
{"idx": 1994, "sentence": "目前用于临床的胰岛素包括动物胰岛素、人胰岛素和胰岛素类似物。由于潜在免疫原性等问题，动物胰岛素在大多数地区使用逐渐减少，人胰岛素和胰岛素类似物使用逐渐增多。人胰岛素与人体自身分泌的胰岛素结构完全相同，胰岛素类似物通过改变胰岛素结构而改变胰岛素药代动力学特性。短期研究表明，胰岛素类似物与人胰岛素相比，控制HbA1c的能力相似，但使用更方便，在减少低血糖发生的潜在危险方面胰岛素类似物优于人胰岛素，这一优势主要表现在1型糖尿病患者。目前尚缺乏胰岛素类似物对患者长期终点事件，如死亡率、糖尿病相关微血管和大血管并发症等方面的证据。多项meta分析及临床研究显示，在2型糖尿病患者中，胰岛素类似物在HbA1c达标率、胰岛素剂量、体重、日问低血糖、严重低血糖和不良反应方面与人胰岛素相当，长效胰岛素类似物对夜间低血糖的改善优于NPH。", "ner": [[7, 9, "Drug"], [12, 16, "Drug"], [18, 21, "Drug"], [23, 28, "Drug"], [42, 46, "Drug"], [60, 63, "Drug"], [65, 70, "Drug"], [78, 81, "Drug"], [100, 105, "Drug"], [118, 120, "Drug"], [136, 141, "Drug"], [143, 146, "Drug"], [152, 156, "Test_items"], [173, 175, "ADE"], [185, 190, "Drug"], [193, 196, "Drug"], [207, 211, "Disease"], [220, 225, "Drug"], [241, 243, "Disease"], [246, 248, "Anatomy"], [250, 252, "Anatomy"], [280, 284, "Disease"], [289, 294, "Drug"], [296, 300, "Test_items"], [305, 307, "Drug"], [316, 318, "Disease"], [320, 321, "Level"], [322, 324, "Disease"], [333, 336, "Drug"], [340, 347, "Drug"], [351, 353, "Disease"], [359, 361, "Drug"]], "rel": [[173, 175, "ADE", 185, 190, "Drug", "ADE_Drug"], [173, 175, "ADE", 193, 196, "Drug", "ADE_Drug"], [185, 190, "Drug", 207, 211, "Disease", "Drug_Disease"], [193, 196, "Drug", 207, 211, "Disease", "Drug_Disease"], [220, 225, "Drug", 241, 243, "Disease", "Drug_Disease"], [246, 248, "Anatomy", 241, 243, "Disease", "Anatomy_Disease"], [250, 252, "Anatomy", 241, 243, "Disease", "Anatomy_Disease"], [289, 294, "Drug", 280, 284, "Disease", "Drug_Disease"], [333, 336, "Drug", 280, 284, "Disease", "Drug_Disease"], [340, 347, "Drug", 280, 284, "Disease", "Drug_Disease"], [359, 361, "Drug", 280, 284, "Disease", "Drug_Disease"], [296, 300, "Test_items", 280, 284, "Disease", "Test_items_Disease"]]}
{"idx": 1995, "sentence": "四、胰岛素应用中应注意的问题", "ner": [[2, 4, "Drug"]], "rel": []}
{"idx": 1996, "sentence": "1.在积极使用胰岛素的同时，应合理使用胰岛素，避免过度应用。对于肥胖(体重指数>28kg/m2)的患者，应在口服药充分治疗的基础上起始胰岛素治疗。", "ner": [[7, 9, "Drug"], [19, 21, "Drug"], [32, 33, "Disease"], [54, 55, "Method"], [67, 69, "Drug"]], "rel": [[67, 69, "Drug", 32, 33, "Disease", "Drug_Disease"]]}
{"idx": 1997, "sentence": "2.合理的联合用药，避免药物不良反应的产生和叠加。单独使用胰岛素的主要不良反应是低血糖和体重增加。推荐采用胰岛素/口服药联合方案，以增加降糖疗效，同时减少低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量。α-葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，减少胰岛素使用剂量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或α糖苷酶抑制剂与胰岛素联用。", "ner": [[29, 31, "Drug"], [40, 42, "ADE"], [44, 47, "ADE"], [53, 55, "Drug"], [57, 58, "Method"], [77, 79, "ADE"], [81, 84, "ADE"], [91, 94, "Drug"], [96, 98, "Drug"], [104, 107, "ADE"], [111, 116, "Drug"], [120, 129, "Drug"], [131, 133, "Drug"], [141, 142, "Test_items"], [149, 151, "Drug"], [159, 162, "ADE"], [179, 183, "Disease"], [191, 194, "Drug"], [196, 202, "Drug"], [204, 206, "Drug"]], "rel": [[40, 42, "ADE", 29, 31, "Drug", "ADE_Drug"], [44, 47, "ADE", 29, 31, "Drug", "ADE_Drug"], [104, 107, "ADE", 91, 94, "Drug", "ADE_Drug"], [104, 107, "ADE", 96, 98, "Drug", "ADE_Drug"], [159, 162, "ADE", 149, 151, "Drug", "ADE_Drug"], [191, 194, "Drug", 179, 183, "Disease", "Drug_Disease"], [196, 202, "Drug", 179, 183, "Disease", "Drug_Disease"], [204, 206, "Drug", 179, 183, "Disease", "Drug_Disease"]]}
{"idx": 1998, "sentence": "促泌剂可发生低血糖和体重增加的不良反应，因此，除基础胰岛素外，不建议胰岛素和促泌剂联合使用。", "ner": [[0, 2, "Drug"], [6, 8, "ADE"], [10, 13, "ADE"], [24, 28, "Drug"], [34, 36, "Drug"], [38, 40, "Drug"]], "rel": [[6, 8, "ADE", 0, 2, "Drug", "ADE_Drug"], [10, 13, "ADE", 0, 2, "Drug", "ADE_Drug"]]}
{"idx": 1999, "sentence": "3.对已合并心脑血管疾病或危险因素的2型糖尿病患者，或老年糖尿病患者，过于激进的降糖治疗策略可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低，在使用胰岛素时，应采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。", "ner": [[6, 11, "Disease"], [6, 9, "Anatomy"], [18, 22, "Disease"], [29, 31, "Disease"], [85, 86, "Disease"], [90, 92, "Disease"], [103, 105, "Drug"], [129, 131, "ADE"]], "rel": [[6, 9, "Anatomy", 6, 11, "Disease", "Anatomy_Disease"], [103, 105, "Drug", 85, 86, "Disease", "Drug_Disease"], [103, 105, "Drug", 90, 92, "Disease", "Drug_Disease"], [129, 131, "ADE", 103, 105, "Drug", "ADE_Drug"]]}
{"idx": 2000, "sentence": "4.肾功能不全时肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症即血液中的尿素氮达9mmol[/L(25mg/d1)以上、肌酐达178μmol/L以上时，应根据血糖的监测及时减少和调整胰岛素的用量，使血糖维持在适当的范围内。", "ner": [[2, 6, "Disease"], [2, 2, "Anatomy"], [8, 20, "Pathogenesis"], [24, 32, "Pathogenesis"], [34, 43, "Pathogenesis"], [49, 52, "Disease"], [58, 60, "Test_items"], [82, 83, "Test_items"], [84, 95, "Test_Value"], [61, 80, "Test_Value"], [113, 115, "Drug"], [121, 122, "Test_items"], [101, 102, "Test_items"]], "rel": [[2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [8, 20, "Pathogenesis", 49, 52, "Disease", "Pathogenesis_Disease"], [24, 32, "Pathogenesis", 49, 52, "Disease", "Pathogenesis_Disease"], [34, 43, "Pathogenesis", 49, 52, "Disease", "Pathogenesis_Disease"], [58, 60, "Test_items", 49, 52, "Disease", "Test_items_Disease"], [82, 83, "Test_items", 49, 52, "Disease", "Test_items_Disease"], [101, 102, "Test_items", 49, 52, "Disease", "Test_items_Disease"]]}
{"idx": 2001, "sentence": "胰岛素应优先选择短效、速效剂型。", "ner": [[0, 2, "Drug"]], "rel": []}
{"idx": 2002, "sentence": "5.在治疗过程中，应加强患者教育，通过多学科的专业合作，提升患者的自我管理能力。", "ner": [], "rel": []}
{"idx": 2003, "sentence": "6.对于注射胰岛素的患者，必须进行自我血糖监测。监测的频率取决于治疗的目标和方式[具体可参考：中国血糖监测临床应用指南(2011年版)]。", "ner": [[6, 8, "Drug"], [4, 5, "Method"], [49, 50, "Test_items"], [17, 22, "Test_items"]], "rel": [[4, 5, "Method", 6, 8, "Drug", "Method_Drug"]]}
{"idx": 2004, "sentence": "基于以上，成人2型糖尿病胰岛素临床应用中国专家共识推荐如下：", "ner": [[7, 11, "Disease"], [12, 14, "Drug"]], "rel": [[12, 14, "Drug", 7, 11, "Disease", "Drug_Disease"]]}
{"idx": 2005, "sentence": "合理把握胰岛素启动治疗时机。新诊断2型糖尿病患者HbA1c≥9.0%同时合并明显临床症状，或合并严重并发症，2种或2种以上口服降糖药次大剂量治疗3个月后仍不达标者(HbA1c≥7.0%)，应启动胰岛素治疗。", "ner": [[4, 6, "Drug"], [17, 21, "Disease"], [24, 28, "Test_items"], [29, 33, "Test_Value"], [61, 62, "Method"], [82, 86, "Test_items"], [87, 91, "Test_Value"], [97, 99, "Drug"]], "rel": [[24, 28, "Test_items", 17, 21, "Disease", "Test_items_Disease"], [82, 86, "Test_items", 17, 21, "Disease", "Test_items_Disease"], [97, 99, "Drug", 17, 21, "Disease", "Drug_Disease"]]}
{"idx": 2006, "sentence": "基础胰岛素或预混胰岛素均可作为胰岛素起始治疗方案。", "ner": [[0, 4, "Drug"], [6, 10, "Drug"], [15, 17, "Drug"]], "rel": []}
{"idx": 2007, "sentence": "应综合考虑患者病情、经济能力等各方面的因素，对血糖控制的风险与益处、成本与效益以及可行性进行科学评估，选择合理的胰岛素。", "ner": [[23, 24, "Test_items"], [56, 58, "Drug"]], "rel": []}
{"idx": 2008, "sentence": "磺脲类药物临床应用专家共识(2016年版)", "ner": [[0, 4, "Drug"]], "rel": []}
{"idx": 2009, "sentence": "1 磺脲类药物的临床地位和使用时机", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 2010, "sentence": "1.1 国内外指南如何推荐使用磺脲类药物? ", "ner": [[15, 19, "Drug"]], "rel": []}
{"idx": 2011, "sentence": "尽管近年来新型降糖药物不断问世，但磺脲类药物因临床应用时间长、疗效确切，仍被多个国内外成人T2DM防治指南推荐为一线备选或二线降糖用药。", "ner": [[17, 21, "Drug"], [45, 48, "Disease"]], "rel": [[17, 21, "Drug", 45, 48, "Disease", "Drug_Disease"]]}
{"idx": 2012, "sentence": "1.2 哪些情况下磺脲类药物可以作为治疗T2DM的一线选择?", "ner": [[9, 13, "Drug"], [20, 23, "Disease"]], "rel": []}
{"idx": 2013, "sentence": "中国大规模横断面调查研究发现，口服降糖药治疗仍是治疗T2DM的主要降糖方案。虽然二甲双胍被多数指南推荐为治疗T2DM的一线用药，但对于二甲双胍不耐受或存在禁忌证的患者，可以考虑将磺脲类药物作为一线用药。", "ner": [[15, 16, "Method"], [67, 70, "Drug"], [40, 43, "Drug"], [89, 93, "Drug"], [26, 29, "Disease"], [54, 57, "Disease"]], "rel": [[40, 43, "Drug", 54, 57, "Disease", "Drug_Disease"]]}
{"idx": 2014, "sentence": "对于新诊断的糖化血红蛋白(hemoglobin A1c，HbA1c)>7.5%的T2DM患者，可以选择作用机制互补的两种降糖药物联合应用。结合中国国情和中国T2DM患者的特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。", "ner": [[6, 33, "Test_items"], [34, 38, "Test_Value"], [88, 92, "Drug"], [95, 98, "Drug"], [40, 43, "Disease"], [78, 81, "Disease"]], "rel": [[6, 33, "Test_items", 40, 43, "Disease", "Test_items_Disease"], [88, 92, "Drug", 78, 81, "Disease", "Drug_Disease"], [95, 98, "Drug", 78, 81, "Disease", "Drug_Disease"]]}
{"idx": 2015, "sentence": "1.3 磺脲类药物可否用于超重或肥胖的T2DM患者? ", "ner": [[4, 8, "Drug"], [13, 14, "Disease"], [16, 17, "Disease"], [19, 22, "Disease"]], "rel": [[4, 8, "Drug", 19, 22, "Disease", "Drug_Disease"]]}
{"idx": 2016, "sentence": "磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。不同磺脲类药物单药治疗对患者体重的影响存在差异，改良剂型对患者体重的影响较小。临床研究显示，传统磺脲类药物(如氯磺丙脲、格列本脲)对肥胖患者体重影响较大，治疗3年平均约增加3~5kg；新的品种(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小(平均增加0.4~0.6kg)。由于二甲双胍、阿卡波糖、钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂等具有减轻体重的作用，对于超重或肥胖患者，磺脲类药物与此类药物联合使用，可减少磺脲类药物带来的体重增加的风险。", "ner": [[0, 4, "Drug"], [34, 38, "Drug"], [78, 84, "Drug"], [87, 90, "Drug"], [92, 95, "Drug"], [130, 133, "Drug"], [140, 146, "Drug"], [175, 178, "Drug"], [180, 183, "Drug"], [185, 239, "Drug"], [261, 265, "Drug"], [279, 283, "Drug"], [16, 17, "Disease"], [19, 20, "Disease"], [98, 99, "Disease"], [253, 254, "Disease"], [256, 257, "Disease"], [10, 13, "ADE"], [243, 246, "ADE"], [287, 290, "ADE"]], "rel": [[10, 13, "ADE", 0, 4, "Drug", "ADE_Drug"], [243, 246, "ADE", 175, 178, "Drug", "ADE_Drug"], [243, 246, "ADE", 180, 183, "Drug", "ADE_Drug"], [243, 246, "ADE", 185, 239, "Drug", "ADE_Drug"], [287, 290, "ADE", 279, 283, "Drug", "ADE_Drug"]]}
{"idx": 2017, "sentence": "2 作用机制", "ner": [], "rel": []}
{"idx": 2018, "sentence": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，包括依赖KATP通道和不依赖KAT P通道刺激胰岛β细胞分泌胰岛素。", "ner": [[0, 4, "Drug"], [7, 9, "Disease"]], "rel": [[0, 4, "Drug", 7, 9, "Disease", "Drug_Disease"]]}
{"idx": 2019, "sentence": "格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 2020, "sentence": "②部分胰岛素增敏作用。", "ner": [], "rel": []}
{"idx": 2021, "sentence": "人体葡萄糖钳夹试验表明，磺脲类药物可使外周葡萄糖利用率增加10%~52%(平均29%)。", "ner": [[12, 16, "Drug"]], "rel": []}
{"idx": 2022, "sentence": "3 临床疗效", "ner": [], "rel": []}
{"idx": 2023, "sentence": "磺脲类药物单药治疗可使HbA1c下降1%~2%，降糖作用在常规剂量内呈剂量依赖性，且患者基线HbA1c越高，HbA1c降幅越大。磺脲类药物可以与多种其他降糖药物联合应用，并且可以作为治疗方案的基础用药之一长期使用。长期使用磺脲类药物治疗的患者应严密监测有无低血糖和体重增加。", "ner": [[0, 4, "Drug"], [64, 68, "Drug"], [111, 115, "Drug"], [11, 15, "Test_items"], [46, 50, "Test_items"], [54, 58, "Test_items"], [16, 22, "Test_Value"], [128, 130, "ADE"], [132, 135, "ADE"]], "rel": [[128, 130, "ADE", 111, 115, "Drug", "ADE_Drug"], [132, 135, "ADE", 111, 115, "Drug", "ADE_Drug"]]}
{"idx": 2024, "sentence": "应用磺脲类药物治疗的患者需要有一定的胰岛功能。糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物治疗可能具有更好的疗效。", "ner": [[2, 6, "Drug"], [23, 25, "Disease"], [47, 51, "Drug"], [35, 41, "Treatment"]], "rel": [[47, 51, "Drug", 23, 25, "Disease", "Drug_Disease"], [35, 41, "Treatment", 23, 25, "Disease", "Treatment_Disease"]]}
{"idx": 2025, "sentence": "3.1 目前常用的磺脲类药物有哪些?如何调整剂量? ", "ner": [[9, 13, "Drug"]], "rel": []}
{"idx": 2026, "sentence": "早期的磺脲类药物以甲苯磺丁脲和氯磺丙脲为代表，由于甲苯磺丁脲增加T2DM患者心血管事件的发生风险，氯磺丙脲作用时间过长易导致低血糖等原因，临床上已基本淘汰。新一代磺脲类药物具有降糖作用强、不良反应少等优势，包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲(易导致低血糖临床较少使用)等。", "ner": [[3, 7, "Drug"], [9, 13, "Drug"], [15, 18, "Drug"], [25, 29, "Drug"], [49, 52, "Drug"], [81, 85, "Drug"], [105, 108, "Drug"], [110, 113, "Drug"], [115, 118, "Drug"], [120, 123, "Drug"], [125, 128, "Drug"], [32, 35, "Disease"], [38, 42, "ADE"], [62, 64, "ADE"], [133, 135, "ADE"]], "rel": [[3, 7, "Drug", 32, 35, "Disease", "Drug_Disease"], [9, 13, "Drug", 32, 35, "Disease", "Drug_Disease"], [15, 18, "Drug", 32, 35, "Disease", "Drug_Disease"], [25, 29, "Drug", 32, 35, "Disease", "Drug_Disease"], [38, 42, "ADE", 25, 29, "Drug", "ADE_Drug"], [62, 64, "ADE", 49, 52, "Drug", "ADE_Drug"], [133, 135, "ADE", 105, 108, "Drug", "ADE_Drug"], [133, 135, "ADE", 110, 113, "Drug", "ADE_Drug"], [133, 135, "ADE", 115, 118, "Drug", "ADE_Drug"], [133, 135, "ADE", 120, 123, "Drug", "ADE_Drug"], [133, 135, "ADE", 125, 128, "Drug", "ADE_Drug"]]}
{"idx": 2027, "sentence": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长。短效药物需要每日3次给药，中、长效药物每日给药1~2次即可。", "ner": [[0, 3, "Drug"], [5, 12, "Drug"], [27, 30, "Drug"], [32, 38, "Drug"], [40, 43, "Drug"], [45, 51, "Drug"], [53, 56, "Drug"], [78, 81, "Frequency"], [91, 98, "Frequency"]], "rel": [[78, 81, "Frequency", 0, 3, "Drug", "Frequency_Drug"], [78, 81, "Frequency", 5, 12, "Drug", "Frequency_Drug"], [91, 98, "Frequency", 27, 30, "Drug", "Frequency_Drug"], [91, 98, "Frequency", 32, 38, "Drug", "Frequency_Drug"], [91, 98, "Frequency", 40, 43, "Drug", "Frequency_Drug"], [91, 98, "Frequency", 45, 51, "Drug", "Frequency_Drug"], [91, 98, "Frequency", 53, 56, "Drug", "Frequency_Drug"]]}
{"idx": 2028, "sentence": "以餐后血糖升高为主的患者，宜选择短效制剂，以空腹血糖升高为主的患者或空腹、餐后血糖均高者，宜选择中、长效制剂。", "ner": [[1, 4, "Test_items"], [22, 25, "Test_items"], [26, 27, "Test_Value"], [34, 40, "Test_items"], [5, 6, "Test_Value"], [41, 42, "Test_Value"]], "rel": []}
{"idx": 2029, "sentence": "低血糖是磺脲类药物治疗最常见的不良反应。为减少低血糖风险，服用磺脲类药物时宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。", "ner": [[4, 8, "Drug"], [31, 35, "Drug"], [0, 2, "ADE"], [23, 25, "ADE"], [47, 48, "Test_items"]], "rel": [[0, 2, "ADE", 4, 8, "Drug", "ADE_Drug"], [23, 25, "ADE", 31, 35, "Drug", "ADE_Drug"]]}
{"idx": 2030, "sentence": "任何一种磺脲类药物的每日用量不应超过其最大剂量。", "ner": [[4, 8, "Drug"]], "rel": []}
{"idx": 2031, "sentence": "常用磺脲类药物的用法、用量见表2。", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 2032, "sentence": "3.2 磺脲类药物单药治疗疗效如何? ", "ner": [[4, 8, "Drug"]], "rel": []}
{"idx": 2033, "sentence": "磺脲类药物单药治疗一般可降低HbA1c1%~2%，平均降低1.5%。对于新诊断T2DM患者，格列齐特缓释片单药治疗52周可使HbA1c降低1.28%，安全性良好，治疗期间无严重低血糖事件发生；格列吡嗪控释片单药治疗8周可使HbA1c降低1.12%；格列本脲单药治疗12个月可使HbA1c降低1.26%；格列美脲单药治疗16周可使HbA1c降低2.5%，稳态模型评估的β细胞功能指数(HOMA-β)显著升高，稳态模型评估的胰岛素抵抗指数(HOMA-IR)显著降低，经血糖检测≤3.9mmol/L证实的低血糖发生率为3.8%，总体安全性良好。", "ner": [[0, 4, "Drug"], [46, 52, "Drug"], [96, 102, "Drug"], [124, 127, "Drug"], [151, 154, "Drug"], [14, 18, "Test_items"], [62, 66, "Test_items"], [111, 115, "Test_items"], [138, 142, "Test_items"], [164, 168, "Test_items"], [232, 233, "Test_items"], [19, 23, "Test_Value"], [27, 32, "Test_Value"], [67, 73, "Test_Value"], [116, 122, "Test_Value"], [143, 149, "Test_Value"], [169, 174, "Test_Value"], [236, 245, "Test_Value"], [39, 42, "Disease"], [57, 59, "Duration"], [107, 108, "Duration"], [132, 135, "Duration"], [159, 161, "Duration"], [88, 90, "ADE"], [86, 87, "Level"], [183, 197, "Test_items"], [198, 201, "Test_Value"], [210, 225, "Test_items"], [226, 229, "Test_Value"]], "rel": [[46, 52, "Drug", 39, 42, "Disease", "Drug_Disease"], [88, 90, "ADE", 46, 52, "Drug", "ADE_Drug"], [57, 59, "Duration", 46, 52, "Drug", "Duration_Drug"], [107, 108, "Duration", 96, 102, "Drug", "Duration_Drug"], [132, 135, "Duration", 124, 127, "Drug", "Duration_Drug"], [159, 161, "Duration", 151, 154, "Drug", "Duration_Drug"]]}
{"idx": 2034, "sentence": "3.3 磺脲类药物联合二甲双胍疗效如何? ", "ner": [[4, 8, "Drug"], [11, 14, "Drug"]], "rel": []}
{"idx": 2035, "sentence": "磺脲类药物与二甲双胍联合治疗可同时改善胰岛素分泌不足和胰岛素抵抗，其疗效和安全性已得到长期临床验证，是推荐的联合治疗方案之一。一项系统性评价结果显示，磺脲类药物联合二甲双胍可使HbA1c降低0.47%~1.30%。与二甲双胍单药治疗相比，二甲双胍联合格列齐特或格列美脲治疗3个月均可使患者HbA1c降低1.9%。为期2年的随机对照研究结果显示，T2DM患者起始二甲双胍联合磺脲类药物治疗可降低HbA1c 1.5%；二甲双胍单药治疗血糖控制不佳的患者加用格列吡嗪治疗可使HbA1c进一步降低0.59%。", "ner": [[0, 4, "Drug"], [6, 9, "Drug"], [75, 79, "Drug"], [82, 85, "Drug"], [108, 111, "Drug"], [119, 122, "Drug"], [125, 128, "Drug"], [130, 133, "Drug"], [180, 183, "Drug"], [186, 190, "Drug"], [207, 210, "Drug"], [226, 229, "Drug"], [88, 92, "Test_items"], [144, 148, "Test_items"], [196, 200, "Test_items"], [234, 238, "Test_items"], [93, 105, "Test_Value"], [149, 154, "Test_Value"], [202, 205, "Test_Value"], [242, 248, "Test_Value"], [172, 175, "Disease"], [215, 216, "Test_items"], [217, 220, "Test_Value"], [19, 25, "Pathogenesis"], [27, 31, "Pathogenesis"], [136, 138, "Duration"]], "rel": [[136, 138, "Duration", 119, 122, "Drug", "Duration_Drug"], [136, 138, "Duration", 125, 128, "Drug", "Duration_Drug"], [136, 138, "Duration", 130, 133, "Drug", "Duration_Drug"], [180, 183, "Drug", 172, 175, "Disease", "Drug_Disease"], [186, 190, "Drug", 172, 175, "Disease", "Drug_Disease"]]}
{"idx": 2036, "sentence": "3.4 磺脲类药物联合α-糖苷酶抑制剂的疗效如何?", "ner": [[4, 8, "Drug"], [11, 18, "Drug"]], "rel": []}
{"idx": 2037, "sentence": "磺脲类药物促进胰岛素分泌，α-糖苷酶抑制剂抑制肠道碳水化合物吸收，二者联合，机制互补，可更好地控制T2DM患者的空腹血糖和餐后血糖。一项交叉设计临床对照研究，磺脲类药物联合阿卡波糖可使患者HbA1c下降2.2%，空腹血糖(fasting plasma glucose，FPG)下降2.8mmol/L，餐后血糖(postprandial plasma glucose，PPG)下降5.3mmol/L，甘油三酯下降35.7mg/dl。随机、双盲、安慰剂对照研究显示，与阿卡波糖、格列本脲单药治疗相比，格列本脲联合阿卡波糖可显著降低患者的餐后血糖，且较格列本脲单药治疗显著降低患者血清胰岛素水平。对于新诊断T2DM患者，格列吡嗪控释片联合阿卡波糖治疗8周较格列吡嗪控释片单药治疗，患者的体质指数(body mass index，BMI)、腰围及HbA1c变化无统计学差异，但前者可显著改善患者HOMA-IR，降低餐后血糖增量，且有效减少血糖波动(日间血糖变异度与日内血糖变异度)。", "ner": [[0, 4, "Drug"], [13, 20, "Drug"], [79, 83, "Drug"], [86, 89, "Drug"], [232, 235, "Drug"], [237, 240, "Drug"], [248, 251, "Drug"], [254, 257, "Drug"], [273, 276, "Drug"], [307, 313, "Drug"], [316, 319, "Drug"], [325, 331, "Drug"], [49, 52, "Disease"], [56, 59, "Test_items"], [61, 64, "Test_items"], [94, 98, "Test_items"], [106, 137, "Test_items"], [150, 186, "Test_items"], [199, 202, "Test_items"], [266, 269, "Test_items"], [287, 293, "Test_items"], [340, 364, "Test_items"], [369, 373, "Test_items"], [393, 399, "Test_items"], [403, 408, "Test_items"], [415, 416, "Test_items"], [420, 426, "Test_items"], [428, 434, "Test_items"], [99, 104, "Test_Value"], [138, 148, "Test_Value"], [187, 197, "Test_Value"], [203, 213, "Test_Value"], [322, 323, "Duration"], [300, 303, "Disease"]], "rel": [[0, 4, "Drug", 49, 52, "Disease", "Drug_Disease"], [13, 20, "Drug", 49, 52, "Disease", "Drug_Disease"], [307, 313, "Drug", 300, 303, "Disease", "Drug_Disease"], [322, 323, "Duration", 307, 313, "Drug", "Duration_Drug"], [316, 319, "Drug", 300, 303, "Disease", "Drug_Disease"], [322, 323, "Duration", 316, 319, "Drug", "Duration_Drug"], [56, 59, "Test_items", 49, 52, "Disease", "Test_items_Disease"], [61, 64, "Test_items", 49, 52, "Disease", "Test_items_Disease"], [340, 364, "Test_items", 300, 303, "Disease", "Test_items_Disease"], [369, 373, "Test_items", 300, 303, "Disease", "Test_items_Disease"], [393, 399, "Test_items", 300, 303, "Disease", "Test_items_Disease"], [403, 408, "Test_items", 300, 303, "Disease", "Test_items_Disease"], [415, 416, "Test_items", 300, 303, "Disease", "Test_items_Disease"], [420, 426, "Test_items", 300, 303, "Disease", "Test_items_Disease"], [428, 434, "Test_items", 300, 303, "Disease", "Test_items_Disease"]]}
{"idx": 2038, "sentence": "3.5 磺脲类药物联合噻唑烷二酮类药物的疗效如何? ", "ner": [[4, 8, "Drug"], [11, 18, "Drug"]], "rel": []}
{"idx": 2039, "sentence": "磺脲类药物单药治疗血糖控制不佳时，联合噻唑烷二酮类药物治疗可以进一步改善血糖，减轻胰岛素抵抗。随机、双盲、安慰剂对照研究结果显示，患者使用罗格列酮4mg联合磺脲类药物和罗格列酮8mg联合磺脲类药物治疗24周，HbA1c分别下降1.04%和1.44%，空腹血糖分别下降1.2mmol/L和2.0mmol/L，血中胰岛素水平较基线分别下降23.3pmol/L和30.4pmol/L，但患者体重增加更明显。", "ner": [[0, 4, "Drug"], [19, 26, "Drug"], [69, 72, "Drug"], [78, 82, "Drug"], [84, 87, "Drug"], [93, 97, "Drug"], [9, 10, "Test_items"], [36, 37, "Test_items"], [104, 108, "Test_items"], [125, 128, "Test_items"], [153, 159, "Test_items"], [11, 14, "Test_Value"], [109, 123, "Test_Value"], [131, 151, "Test_Value"], [165, 187, "Test_Value"], [41, 45, "Pathogenesis"], [73, 75, "Amount"], [88, 90, "Amount"], [100, 102, "Duration"], [192, 198, "ADE"]], "rel": [[73, 75, "Amount", 69, 72, "Drug", "Amount_Drug"], [100, 102, "Duration", 69, 72, "Drug", "Duration_Drug"], [192, 198, "ADE", 69, 72, "Drug", "ADE_Drug"], [100, 102, "Duration", 78, 82, "Drug", "Duration_Drug"], [192, 198, "ADE", 78, 82, "Drug", "ADE_Drug"], [88, 90, "Amount", 84, 87, "Drug", "Amount_Drug"], [100, 102, "Duration", 84, 87, "Drug", "Duration_Drug"], [192, 198, "ADE", 84, 87, "Drug", "ADE_Drug"], [100, 102, "Duration", 93, 97, "Drug", "Duration_Drug"], [192, 198, "ADE", 93, 97, "Drug", "ADE_Drug"]]}
{"idx": 2040, "sentence": "3.6 磺脲类药物联合二肽基肽酶-4抑制剂的疗效如何? ", "ner": [[4, 8, "Drug"], [11, 20, "Drug"]], "rel": []}
{"idx": 2041, "sentence": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂通过降低DPP-4酶的催化活性，抑制胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解，提升GLP-1在血液中的浓度，刺激胰岛素和抑制胰高血糖素分泌，从而达到控制血糖的目的。磺脲类药物单药治疗血糖控制不佳时，联合DPP-4抑制剂可更好地控制血糖。一项为期24周的多中心、随机、双盲、安慰剂对照研究结果显示，格列美脲联合维格列汀50mg/d或100mg/d不但有效降低患者的HbA1c水平，同时改善患者β细胞功能和餐后血糖水平，且对于年龄≥65岁的老年患者同样安全、有效。磺脲类药物联合DPP-4抑制剂会增加低血糖的发生风险。", "ner": [[0, 39, "Drug"], [144, 148, "Drug"], [163, 170, "Drug"], [210, 213, "Drug"], [216, 219, "Drug"], [138, 139, "Test_items"], [153, 154, "Test_items"], [177, 178, "Test_items"], [243, 247, "Test_items"], [263, 268, "Test_items"], [292, 296, "Drug"], [299, 306, "Drug"], [310, 312, "ADE"], [155, 158, "Test_Value"], [220, 225, "Amount"], [227, 233, "Amount"]], "rel": [[220, 225, "Amount", 216, 219, "Drug", "Amount_Drug"], [227, 233, "Amount", 216, 219, "Drug", "Amount_Drug"], [310, 312, "ADE", 292, 296, "Drug", "ADE_Drug"], [310, 312, "ADE", 299, 306, "Drug", "ADE_Drug"]]}
{"idx": 2042, "sentence": "3.7 磺脲类药物联合SGLT-2抑制剂的疗效如何? ", "ner": [[4, 8, "Drug"], [11, 19, "Drug"]], "rel": []}
{"idx": 2043, "sentence": "SGLT-2抑制剂通过抑制近端肾小管钠-葡萄糖重吸收、促进尿糖排泄降低血糖浓度。磺脲类药物联合SGLT-2抑制剂可进一步降低患者血糖，并减轻患者体重，但两者联用应注意低血糖风险。一项为期48周的随机、双盲、对照研究结果显示，格列美脲治疗血糖控制不佳的T2DM患者，联合使用达格列净(dapagliflozin)2.5mg/d、5mg/d、10mg/d后，HbA1c分别进一步下降0.41%、0.56%和0.73%，体重降幅分为1.36kg、1.54kg、2.41kg，低血糖发生率为9.7%~11.3%。一项为期24周随机双盲试验和28周开放标签延长期试验的研究结果显示，与安慰剂比较，鲁格列净(Luseogliflozin)联合磺脲类药物可进一步降低患者HbA1c0.63%，低血糖事件发生率为10.7%。", "ner": [[0, 8, "Drug"], [40, 44, "Drug"], [47, 55, "Drug"], [112, 115, "Drug"], [136, 154, "Drug"], [315, 319, "Drug"], [35, 36, "Test_items"], [64, 65, "Test_items"], [118, 119, "Test_items"], [177, 181, "Test_items"], [328, 332, "Test_items"], [68, 73, "ADE"], [83, 85, "ADE"], [234, 236, "ADE"], [293, 312, "Drug"], [339, 341, "ADE"], [125, 128, "Disease"], [155, 161, "Amount"], [163, 167, "Amount"], [169, 174, "Amount"], [187, 205, "Test_Value"], [333, 337, "Test_Value"], [120, 123, "Test_Value"]], "rel": [[68, 73, "ADE", 40, 44, "Drug", "ADE_Drug"], [83, 85, "ADE", 40, 44, "Drug", "ADE_Drug"], [68, 73, "ADE", 47, 55, "Drug", "ADE_Drug"], [83, 85, "ADE", 47, 55, "Drug", "ADE_Drug"], [234, 236, "ADE", 112, 115, "Drug", "ADE_Drug"], [112, 115, "Drug", 125, 128, "Disease", "Drug_Disease"], [155, 161, "Amount", 136, 154, "Drug", "Amount_Drug"], [163, 167, "Amount", 136, 154, "Drug", "Amount_Drug"], [169, 174, "Amount", 136, 154, "Drug", "Amount_Drug"], [234, 236, "ADE", 136, 154, "Drug", "ADE_Drug"], [136, 154, "Drug", 125, 128, "Disease", "Drug_Disease"], [339, 341, "ADE", 315, 319, "Drug", "ADE_Drug"], [118, 119, "Test_items", 125, 128, "Disease", "Test_items_Disease"], [339, 341, "ADE", 293, 312, "Drug", "ADE_Drug"]]}
{"idx": 2044, "sentence": "3.8 磺脲类药物联合GLP-1受体激动剂的疗效如何?", "ner": [[4, 8, "Drug"], [11, 20, "Drug"]], "rel": []}
{"idx": 2045, "sentence": "GLP-1受体激动剂以葡萄糖浓度依赖的方式促进β细胞分泌胰岛素、降低α细胞分泌胰血高糖素，磺脲类药物联合GLP-1受体激动剂可使HbA1c水平显著降低，且安全耐受性良好。一项为期26周的随机、双盲、对照研究结果显示，无论之前患者接受何种治疗，格列美脲联合利拉鲁肽治疗均可快速降低HbA1c达1.1%，显著优于格列美脲单药治疗或格列美脲联合罗格列酮治疗。格列美脲联合利拉鲁肽1.8mg/d治疗组患者体重降低，<10%的患者发生轻度低血糖。", "ner": [[0, 9, "Drug"], [45, 49, "Drug"], [52, 61, "Drug"], [121, 124, "Drug"], [127, 130, "Drug"], [154, 157, "Drug"], [163, 166, "Drug"], [169, 172, "Drug"], [176, 179, "Drug"], [182, 185, "Drug"], [64, 68, "Test_items"], [139, 143, "Test_items"], [145, 148, "Test_Value"], [71, 74, "Test_Value"], [186, 192, "Amount"], [214, 216, "ADE"], [198, 201, "ADE"]], "rel": [[198, 201, "ADE", 176, 179, "Drug", "ADE_Drug"], [214, 216, "ADE", 176, 179, "Drug", "ADE_Drug"], [186, 192, "Amount", 176, 179, "Drug", "Amount_Drug"], [198, 201, "ADE", 182, 185, "Drug", "ADE_Drug"], [214, 216, "ADE", 182, 185, "Drug", "ADE_Drug"], [186, 192, "Amount", 182, 185, "Drug", "Amount_Drug"]]}
{"idx": 2046, "sentence": "3.9 磺脲类药物联合胰岛素的临床疗效如何? ", "ner": [[4, 8, "Drug"], [11, 13, "Drug"]], "rel": []}
{"idx": 2047, "sentence": "一般情况下，不推荐磺脲类药物联合胰岛素治疗T2DM，但胰岛细胞尚有部分分泌功能的T2DM患者可考虑使用磺脲类药物联合基础胰岛素治疗。当单一或联合口服降糖药无法满意控制血糖时，口服降糖药物(包括磺脲类药物)联合基础胰岛素可以作为一种胰岛素起始的治疗方案。", "ner": [[9, 13, "Drug"], [16, 18, "Drug"], [51, 55, "Drug"], [58, 62, "Drug"], [96, 100, "Drug"], [104, 108, "Drug"], [87, 88, "Method"], [72, 73, "Method"], [115, 116, "Drug"], [21, 24, "Disease"], [40, 43, "Disease"], [83, 84, "Test_items"]], "rel": [[51, 55, "Drug", 40, 43, "Disease", "Drug_Disease"], [58, 62, "Drug", 40, 43, "Disease", "Drug_Disease"], [87, 88, "Method", 96, 100, "Drug", "Method_Drug"], [87, 88, "Method", 104, 108, "Drug", "Method_Drug"]]}
{"idx": 2048, "sentence": "在亚洲多个国", "ner": [], "rel": []}
{"idx": 2049, "sentence": "家进行的一项443例T2DM患者参加的多中心、随机、对照研究显示，对于既往未接受胰岛素治疗的T2DM患者，格列美脲联合甘精胰岛素可进一步降低HbA1c达0.99%，HbA1c达标率为38.1%，空腹血糖降低幅度为5.89mmol/L，与格列美脲联合重组人胰岛素(NPH)组无差异，平均日间血糖降低幅度优于NPH组(-5.22mmol/L vs -4.44mmol/L)，总体低血糖发生682/220(次数/例数)，症状性低血糖为515/220(次数/例数)，严重低血糖为5/220(次数/例数)。接受磺脲类药物联合基础胰岛素治疗的患者应特别注意饮食和运动量，以及体重增加和低血糖。", "ner": [[40, 42, "Drug"], [53, 56, "Drug"], [59, 63, "Drug"], [118, 121, "Drug"], [124, 134, "Drug"], [152, 154, "Drug"], [250, 254, "Drug"], [257, 261, "Drug"], [10, 13, "Disease"], [46, 49, "Disease"], [70, 74, "Test_items"], [82, 86, "Test_items"], [97, 100, "Test_items"], [140, 149, "Test_items"], [76, 80, "Test_Value"], [91, 95, "Test_Value"], [106, 115, "Test_Value"], [157, 182, "Test_Value"], [187, 189, "ADE"], [207, 212, "ADE"], [229, 233, "ADE"], [281, 284, "ADE"], [286, 288, "ADE"]], "rel": [[53, 56, "Drug", 46, 49, "Disease", "Drug_Disease"], [187, 189, "ADE", 53, 56, "Drug", "ADE_Drug"], [207, 212, "ADE", 53, 56, "Drug", "ADE_Drug"], [229, 233, "ADE", 53, 56, "Drug", "ADE_Drug"], [59, 63, "Drug", 46, 49, "Disease", "Drug_Disease"], [187, 189, "ADE", 59, 63, "Drug", "ADE_Drug"], [207, 212, "ADE", 59, 63, "Drug", "ADE_Drug"], [229, 233, "ADE", 59, 63, "Drug", "ADE_Drug"], [281, 284, "ADE", 250, 254, "Drug", "ADE_Drug"], [286, 288, "ADE", 250, 254, "Drug", "ADE_Drug"], [281, 284, "ADE", 257, 261, "Drug", "ADE_Drug"], [286, 288, "ADE", 257, 261, "Drug", "ADE_Drug"]]}
{"idx": 2050, "sentence": "4 特殊人群用药", "ner": [], "rel": []}
{"idx": 2051, "sentence": "4.1 肝功能不全的T2DM患者是否可以使用磺脲类药物? ", "ner": [[4, 8, "Disease"], [4, 4, "Anatomy"], [10, 13, "Disease"], [22, 26, "Drug"]], "rel": [[4, 4, "Anatomy", 4, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 2052, "sentence": "目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(alanine transaminase，ALT)>3倍参考值上限可作为肝损害的敏感而特异的指标，若ALT>8~10倍参考值上限或者ALT>3倍参考值上限且血清总胆红素(total bilirubin，TBIL)>2倍参考值上限则是预测重度肝损害的特异指标，表明肝脏实质细胞受到损害，此时应禁用磺脲类药物。在临床使用中，伴有肝性脑病、腹水或凝血障碍的失代偿肝硬化患者应禁用该类药物以防发生低血糖。", "ner": [[4, 8, "Drug"], [14, 15, "Level"], [16, 20, "Disease"], [16, 16, "Anatomy"], [27, 60, "Test_items"], [61, 62, "Test_Value"], [72, 74, "ADE"], [86, 88, "Test_items"], [89, 93, "Test_Value"], [102, 104, "Test_items"], [105, 106, "Test_Value"], [114, 141, "Test_items"], [142, 143, "Test_Value"], [154, 158, "ADE"], [183, 187, "Drug"], [198, 201, "Disease"], [203, 204, "Disease"], [211, 216, "Disease"], [206, 209, "Disease"], [230, 232, "ADE"], [198, 198, "Anatomy"], [200, 200, "Anatomy"], [203, 203, "Anatomy"], [214, 214, "Anatomy"]], "rel": [[72, 74, "ADE", 4, 8, "Drug", "ADE_Drug"], [230, 232, "ADE", 4, 8, "Drug", "ADE_Drug"], [154, 158, "ADE", 4, 8, "Drug", "ADE_Drug"], [16, 16, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [198, 198, "Anatomy", 198, 201, "Disease", "Anatomy_Disease"], [200, 200, "Anatomy", 198, 201, "Disease", "Anatomy_Disease"], [203, 203, "Anatomy", 203, 204, "Disease", "Anatomy_Disease"], [214, 214, "Anatomy", 211, 216, "Disease", "Anatomy_Disease"]]}
{"idx": 2053, "sentence": "4.2 肾功能不全的T2DM患者是否可以使用磺脲类药物? ", "ner": [[4, 8, "Disease"], [4, 4, "Anatomy"], [10, 13, "Disease"], [22, 26, "Drug"]], "rel": [[4, 4, "Anatomy", 4, 8, "Disease", "Anatomy_Disease"], [22, 26, "Drug", 10, 13, "Disease", "Drug_Disease"]]}
{"idx": 2054, "sentence": "格列本脲本身及其代谢产物均具有降糖活性，肾功能不全的T2DM患者使用格列本脲容易发生严重的低血糖事件；格列美脲的代谢产物在GFR降低的患者中没有额外蓄积风险；其他常用的磺脲类药物如格列喹酮、格列齐特及格列吡嗪，代谢产物均为非活性物质，尤其是格列喹酮，其代谢产物只有5%经肾脏排泄，受肾功能的影响很小，其可用于轻、中度肾功能不全的糖尿病患者。ADVANCE研究发现，格列齐特缓释片具有肾脏保护作用，可降低患者蛋白尿和肾脏事件风险。", "ner": [[0, 3, "Drug"], [34, 37, "Drug"], [51, 54, "Drug"], [84, 88, "Drug"], [90, 93, "Drug"], [95, 98, "Drug"], [100, 103, "Drug"], [120, 123, "Drug"], [182, 188, "Drug"], [20, 24, "Disease"], [20, 20, "Anatomy"], [26, 29, "Disease"], [45, 47, "ADE"], [158, 162, "Disease"], [158, 158, "Anatomy"], [164, 166, "Disease"], [203, 205, "ADE"], [207, 210, "ADE"], [154, 157, "Level"]], "rel": [[34, 37, "Drug", 26, 29, "Disease", "Drug_Disease"], [120, 123, "Drug", 164, 166, "Disease", "Drug_Disease"], [203, 205, "ADE", 182, 188, "Drug", "ADE_Drug"], [207, 210, "ADE", 182, 188, "Drug", "ADE_Drug"], [20, 20, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"]]}
{"idx": 2055, "sentence": "磺脲类药物在T2DM合并肾功能不全患者中的使用推荐见表3。", "ner": [[0, 4, "Drug"], [6, 9, "Disease"], [12, 16, "Disease"], [12, 12, "Anatomy"]], "rel": [[0, 4, "Drug", 6, 9, "Disease", "Drug_Disease"], [12, 12, "Anatomy", 12, 16, "Disease", "Anatomy_Disease"]]}
{"idx": 2056, "sentence": "4.3 老年患者使用磺脲类药物有哪些注意事项? ", "ner": [[10, 14, "Drug"]], "rel": []}
{"idx": 2057, "sentence": "针对老年糖尿病患者，实施个体化药物治疗方案控制血糖并避免或最小化药物相关的不良反应是必要的。老年糖尿病患者对低血糖耐受性差，易出现无症状性低血糖和严重低血糖，需要特别关注。因此，在选择降糖药物时，老年患者应着重考虑药物的低血糖风险。若患者既往有严重低血糖史、预期生存期较短、或合并其他严重疾病，如果需要联合磺脲类药物治疗，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖的发生风险降至最小。", "ner": [[4, 6, "Disease"], [23, 24, "Test_items"], [48, 50, "Disease"], [54, 56, "Disease"], [65, 71, "Disease"], [110, 112, "ADE"], [124, 126, "Disease"], [122, 123, "Level"], [153, 157, "Drug"], [179, 181, "ADE"], [186, 190, "Drug"], [196, 199, "Drug"], [207, 211, "Drug"], [227, 228, "Test_items"], [234, 235, "Test_items"], [247, 249, "ADE"], [75, 77, "Disease"], [73, 74, "Level"]], "rel": [[23, 24, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [179, 181, "ADE", 186, 190, "Drug", "ADE_Drug"], [179, 181, "ADE", 196, 199, "Drug", "ADE_Drug"], [247, 249, "ADE", 207, 211, "Drug", "ADE_Drug"]]}
{"idx": 2058, "sentence": "4.4 磺脲类药物可否用于T2DM之外的糖尿病患者? ", "ner": [[4, 8, "Drug"], [13, 16, "Disease"], [20, 22, "Disease"]], "rel": [[4, 8, "Drug", 20, 22, "Disease", "Drug_Disease"]]}
{"idx": 2059, "sentence": "目前为止，所有磺脲类药物均尚未被中国食品药品监督管理局(China Food and Drug Administration，CFDA)批准用于治疗妊娠期糖尿病、儿童和青少年T2DM以及1型糖尿病患者。", "ner": [[7, 11, "Drug"], [87, 90, "Disease"], [93, 97, "Disease"], [74, 79, "Disease"]], "rel": []}
{"idx": 2060, "sentence": "5 安全性", "ner": [], "rel": []}
{"idx": 2061, "sentence": "5.1 磺脲类药物有哪些常见不良反应? ", "ner": [[4, 8, "Drug"]], "rel": []}
{"idx": 2062, "sentence": "磺脲类药物治疗常见的不良反应有以下几种：①低血糖：临床上起始磺脲类药物剂量过大，或在肝、肾功能不全患者中的不恰当使用可导致低血糖；单药治疗或与其他降糖药物联合治疗均可能出现低血糖。②体重增加。③磺脲类药物与磺胺类药物可发生交叉过敏反应，有磺胺类药物过敏史者应禁用磺脲类药物。", "ner": [[0, 4, "Drug"], [21, 23, "ADE"], [61, 63, "ADE"], [86, 88, "ADE"], [91, 94, "ADE"], [111, 116, "ADE"], [30, 34, "Drug"], [42, 48, "Disease"], [42, 42, "Anatomy"], [44, 44, "Anatomy"], [97, 101, "Drug"], [103, 107, "Drug"], [119, 123, "Drug"], [131, 135, "Drug"]], "rel": [[21, 23, "ADE", 0, 4, "Drug", "ADE_Drug"], [61, 63, "ADE", 0, 4, "Drug", "ADE_Drug"], [86, 88, "ADE", 0, 4, "Drug", "ADE_Drug"], [91, 94, "ADE", 0, 4, "Drug", "ADE_Drug"], [111, 116, "ADE", 0, 4, "Drug", "ADE_Drug"], [42, 42, "Anatomy", 42, 48, "Disease", "Anatomy_Disease"], [44, 44, "Anatomy", 42, 48, "Disease", "Anatomy_Disease"]]}
{"idx": 2063, "sentence": "5.2 如何预防磺脲类药物治疗导致的低血糖? ", "ner": [[8, 12, "Drug"], [18, 20, "ADE"]], "rel": [[18, 20, "ADE", 8, 12, "Drug", "ADE_Drug"]]}
{"idx": 2064, "sentence": "荟萃分析结果显示，正确使用磺脲类药物单药及联合治疗的患者，轻、中度低血糖发生率为1.92例/(患者·年)，重度低血糖发生率为0.01例/(患者·年)。不同磺脲类药物的作用机制及剂型存在差异，其低血糖发生率也不同，其中格列本脲导致低血糖的发生风险最高。", "ner": [[13, 17, "Drug"], [29, 35, "ADE"], [53, 57, "ADE"], [77, 81, "Drug"], [97, 98, "Test_items"], [108, 111, "Drug"], [114, 116, "ADE"]], "rel": [[29, 35, "ADE", 13, 17, "Drug", "ADE_Drug"], [53, 57, "ADE", 13, 17, "Drug", "ADE_Drug"], [114, 116, "ADE", 108, 111, "Drug", "ADE_Drug"]]}
{"idx": 2065, "sentence": "5.3 如何看待磺脲类药物增加体重的问题? ", "ner": [[8, 12, "Drug"], [13, 16, "ADE"]], "rel": [[13, 16, "ADE", 8, 12, "Drug", "ADE_Drug"]]}
{"idx": 2066, "sentence": "5.4 磺脲类药物的心血管安全性如何? ", "ner": [[4, 8, "Drug"]], "rel": []}
{"idx": 2067, "sentence": "不同磺脲类药物的心血管安全性可能存在差异。", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 2068, "sentence": "包括UKPDS和ADVANCE等多项大型临床研究结果均证实了磺脲类药物在降糖治疗中的心血管安全性。荟萃分析结果发现，与格列本脲相比，格列齐特和格列美脲可降低T2DM患者的全因死亡风险，而格列吡嗪、甲苯磺丁脲及氯磺丙脲则无此差异。一项为期5年的大样本观察性研究发现，使用格列齐特治疗的患者总病死率和心血管事件死亡率均低于格列本脲，这可能与格列齐特能选择性激活胰岛β细胞的磺脲类受体1(sulfonylurea receptor，SUR1)，而对心肌细胞上的SUR2A和血管平滑肌细胞上的SUR2B无活化作用有关。", "ner": [[30, 34, "Drug"], [59, 62, "Drug"], [66, 69, "Drug"], [71, 74, "Drug"], [93, 96, "Drug"], [98, 102, "Drug"], [104, 107, "Drug"], [134, 137, "Drug"], [159, 162, "Drug"], [168, 171, "Drug"], [78, 81, "Disease"], [148, 152, "ADE"]], "rel": [[66, 69, "Drug", 78, 81, "Disease", "Drug_Disease"], [71, 74, "Drug", 78, 81, "Disease", "Drug_Disease"], [148, 152, "ADE", 134, 137, "Drug", "ADE_Drug"], [148, 152, "ADE", 159, 162, "Drug", "ADE_Drug"]]}
{"idx": 2069, "sentence": "另外，体外试验证实格列喹酮对胰岛β细胞同样具有高选择性，推测其同样具有较好的心血管安全性。", "ner": [[9, 12, "Drug"]], "rel": []}
{"idx": 2070, "sentence": "总之，在评价不同磺脲类药物的心血管安全性时，需要具体问题具体分析。", "ner": [[8, 12, "Drug"]], "rel": []}
{"idx": 2071, "sentence": "磺脲类药物的心血管安全性问题仍需设计优良的前瞻性随机对照研究加以解决。", "ner": [[0, 4, "Drug"]], "rel": []}
{"idx": 2072, "sentence": "5.5 磺脲类药物会加速β细胞功能衰退吗? ", "ner": [[4, 8, "Drug"], [12, 18, "ADE"]], "rel": [[12, 18, "ADE", 4, 8, "Drug", "ADE_Drug"]]}
{"idx": 2073, "sentence": "β细胞功能凋亡的机制尚未完全明确。", "ner": [], "rel": []}
{"idx": 2074, "sentence": "持续20年的UKPDS研究结果表明，磺脲类药物并未加速β细胞功能衰竭。ADOPT研究终点时，格列本脲组β细胞胰岛素分泌功能和罗格列酮组相似。中国一项多中心研究结果显示，格列齐特缓释片强化治疗3个月可使约60%的患者血糖达标，停药2日后复查口服葡萄糖耐量试验，恢复为正常糖耐量或糖耐量受损者占22.83%，这说明磺脲类药物强化治疗显著改善了早相胰岛素分泌功能。", "ner": [[18, 22, "Drug"], [27, 33, "Symptom"], [46, 49, "Drug"], [62, 65, "Drug"], [84, 90, "Drug"], [155, 159, "Drug"], [95, 97, "Duration"], [119, 127, "Test"], [107, 108, "Test_items"]], "rel": [[95, 97, "Duration", 84, 90, "Drug", "Duration_Drug"]]}
{"idx": 2075, "sentence": "因此，目前尚无直接证据表明磺脲类药物治疗与β细胞功能衰退有关。", "ner": [[13, 17, "Drug"], [21, 27, "Symptom"]], "rel": []}
{"idx": 2076, "sentence": "逆向的传导，使患者心肌细胞的自发性兴奋度下降，从而消除折返激动，放慢传导的速度，药效比较持久迅速，但与胺碘酮的治疗效果比较要低一些。", "ner": [[51, 53, "Drug"]], "rel": []}
{"idx": 2077, "sentence": "胺碘酮作为III类抗心律失常药物，能较为迅速地阻断钾离子的传导通道，从而使心肌兴奋度下降，降低窦房结的自律性，消除折返激动，具有I类和IV类抗心律失常药物的特性，有显著的治疗效果。", "ner": [[0, 2, "Drug"]], "rel": []}
{"idx": 2078, "sentence": "在本次研究中，治疗组治疗的有效率高于对照组20.93%，并且治疗组血液流变学指标改善较对照组明显，改善后的指标值优于对照组(P<0.05)；治疗组患者服用胺碘酮片后hs-CRP水平明显下降，下降水平同样优于对照组(P<0.05)；治疗组不良反应发生与对照组比较没有较大的差异性(P>0.05)。", "ner": [[77, 80, "Drug"], [82, 87, "Test_items"], [90, 93, "Test_Value"]], "rel": []}
{"idx": 2079, "sentence": "该研究说明，虽然两种药物的不良反应没有较大差异，但胺碘酮治疗的效果明显优于心律平片，研究结果与学者刘荣魁、许有凡的研究结果基本一致。", "ner": [[25, 27, "Drug"], [37, 40, "Drug"]], "rel": []}
{"idx": 2080, "sentence": "总之，采用胺碘酮治疗的效果更为显著，明显地改善了患者的血液流变学指标，使hs-CRP水平明显降低，值得临床推广应用。", "ner": [[5, 7, "Drug"], [36, 41, "Test_items"], [44, 47, "Test_Value"]], "rel": []}
{"idx": 2081, "sentence": "目前普遍认为长期使用磺脲类药物可致患者体重明显增加，但不同磺脲类药物对体重的影响存在差异。剂型改良后的磺脲类药物及格列美脲对体重影响较小。随机对照研究结果显示，2型糖尿病患者使用格列吡嗪单药治疗1年体重增加2.6kg。GUIDE研究中随机分为格列齐特缓释片组和格列美脲组治疗27周，体重增加分别为0.5kg和0.6kg。荟萃分析结果显示，磺脲类药物单药治疗平均约增加体重2kg，但磺脲类药物与二甲双胍、SGLT-2抑制剂、GLP-1受体激动剂等药物联合时，这一不良反应可能会被完全或部分抵消。ZODIAC-39队列研究显示，不同磺脲类药物联合二甲双胍治疗5年，格列本脲组体重增加3.3kg，格列齐特组体重增加3.9kg，格列美脲组体重增加0.1kg。LEAD-1研究显示，之前使用格列美脲单药治疗的T2DM患者换为格列美脲联合利拉鲁肽1.2mg/d或1.8mg/d治疗后，体重变化分别为+0.3kg和-0.2kg。", "ner": [[10, 14, "Drug"], [29, 33, "Drug"], [51, 55, "Drug"], [57, 60, "Drug"], [89, 92, "Drug"], [121, 127, "Drug"], [130, 133, "Drug"], [169, 173, "Drug"], [190, 194, "Drug"], [196, 199, "Drug"], [201, 209, "Drug"], [211, 220, "Drug"], [264, 268, "Drug"], [271, 274, "Drug"], [280, 283, "Drug"], [295, 298, "Drug"], [310, 313, "Drug"], [340, 343, "Drug"], [357, 360, "Drug"], [363, 366, "Drug"], [19, 24, "ADE"], [80, 84, "Disease"], [97, 98, "Duration"], [137, 139, "Duration"], [277, 278, "Duration"], [367, 373, "Amount"], [375, 381, "Amount"], [349, 352, "Disease"], [99, 102, "ADE"], [141, 144, "ADE"], [181, 184, "ADE"], [285, 288, "ADE"], [300, 303, "ADE"], [315, 318, "ADE"]], "rel": [[19, 24, "ADE", 10, 14, "Drug", "ADE_Drug"], [99, 102, "ADE", 89, 92, "Drug", "ADE_Drug"], [97, 98, "Duration", 89, 92, "Drug", "Duration_Drug"], [89, 92, "Drug", 80, 84, "Disease", "Drug_Disease"], [141, 144, "ADE", 121, 127, "Drug", "ADE_Drug"], [137, 139, "Duration", 121, 127, "Drug", "Duration_Drug"], [141, 144, "ADE", 130, 133, "Drug", "ADE_Drug"], [137, 139, "Duration", 130, 133, "Drug", "Duration_Drug"], [181, 184, "ADE", 169, 173, "Drug", "ADE_Drug"], [277, 278, "Duration", 264, 268, "Drug", "Duration_Drug"], [277, 278, "Duration", 271, 274, "Drug", "Duration_Drug"], [285, 288, "ADE", 280, 283, "Drug", "ADE_Drug"], [300, 303, "ADE", 295, 298, "Drug", "ADE_Drug"], [315, 318, "ADE", 310, 313, "Drug", "ADE_Drug"], [357, 360, "Drug", 349, 352, "Disease", "Drug_Disease"], [367, 373, "Amount", 363, 366, "Drug", "Amount_Drug"], [375, 381, "Amount", 363, 366, "Drug", "Amount_Drug"], [363, 366, "Drug", 349, 352, "Disease", "Drug_Disease"]]}
{"idx": 2082, "sentence": "格列美脲单药治疗血糖控制不佳的患者，加用达格列净后不仅可以进一步改善血糖，还可改善体重。", "ner": [[0, 3, "Drug"], [20, 23, "Drug"], [8, 9, "Test_items"], [34, 35, "Test_items"]], "rel": []}
{"idx": 2083, "sentence": "增加磺脲类药物发生低血糖事件的主要因素有：高龄，饮酒，合并肝、肾疾病，药物过量，药物相互作用等。糖尿病患者在使用磺脲类药物时，预防低血糖的措施包括：①年长、体弱的患者建议选用低血糖风险相对低的格列齐特缓释片、格列美脲，或者其他短效制剂；2应从小剂量开始服用，并根据血糖监测结果缓慢加量至最佳剂量；③饮食方面应定食定量，避免餐前剧烈运动。如果出现腹泻、呕吐等症状，应减少药物剂量；④每天的运动量应保持相对稳定。运动量过大也可引起低血糖，在外出旅游、登山时，应适量增加饮食。对于绝大多数可被患者察觉的、有症状的低血糖事件，可通过补充含糖食物或口服/静脉推注20g葡萄糖予以纠正，若15~20min后症状仍不能缓解或血浆葡萄糖水平仍很低可以重复给予葡萄糖。对于发生严重低血糖事件的患者，尤其格列本脲所致者，需在静脉推注葡萄糖后给予较长时间(24~72h)的葡萄糖静脉滴注以防止低血糖的再次发生，并至少观察3d，密切监测血糖水平。", "ner": [[2, 6, "Drug"], [9, 11, "ADE"], [48, 50, "Disease"], [56, 60, "Drug"], [65, 67, "ADE"], [87, 89, "ADE"], [96, 102, "Drug"], [104, 107, "Drug"], [132, 133, "Test_items"], [172, 173, "ADE"], [175, 176, "ADE"], [213, 215, "ADE"], [253, 255, "ADE"], [269, 270, "Method"], [272, 275, "Method"], [276, 278, "Amount"], [279, 281, "Drug"], [321, 323, "Drug"], [331, 333, "ADE"], [342, 345, "Drug"], [352, 355, "Method"], [356, 358, "Drug"], [375, 377, "Drug"], [378, 381, "Method"], [385, 387, "ADE"], [406, 407, "Test_items"]], "rel": [[9, 11, "ADE", 2, 6, "Drug", "ADE_Drug"], [172, 173, "ADE", 2, 6, "Drug", "ADE_Drug"], [175, 176, "ADE", 2, 6, "Drug", "ADE_Drug"], [213, 215, "ADE", 2, 6, "Drug", "ADE_Drug"], [253, 255, "ADE", 2, 6, "Drug", "ADE_Drug"], [132, 133, "Test_items", 48, 50, "Disease", "Test_items_Disease"], [65, 67, "ADE", 56, 60, "Drug", "ADE_Drug"], [87, 89, "ADE", 96, 102, "Drug", "ADE_Drug"], [87, 89, "ADE", 104, 107, "Drug", "ADE_Drug"], [269, 270, "Method", 279, 281, "Drug", "Method_Drug"], [272, 275, "Method", 279, 281, "Drug", "Method_Drug"], [276, 278, "Amount", 279, 281, "Drug", "Amount_Drug"], [331, 333, "ADE", 342, 345, "Drug", "ADE_Drug"], [385, 387, "ADE", 342, 345, "Drug", "ADE_Drug"], [352, 355, "Method", 356, 358, "Drug", "Method_Drug"], [378, 381, "Method", 375, 377, "Drug", "Method_Drug"]]}
{"idx": 2084, "sentence": "2013年版《中国2型糖尿病防治指南》推荐磺脲类药物为重要的一线备选和二线降糖药物，可作为二甲双胍不耐受或存在禁忌证者的起始治疗或二甲双胍治疗血糖控制不佳时的联合用药之一。2014年国际糖尿病联盟(International Diabetes Federation，IDF)全球T2DM指南同样将磺脲类药物作为不适合二甲双胍治疗的患者的一线备选和二线首选药物。2016年美国临床内分泌医师协会(American Association of Clinical Endocrinologists，AACE)和美国内分泌学会(American College of Endocrinology，ACE)指南将磺脲类药物列为T2DM的一线治疗药物之一，但给予谨慎使用的标识。2016年美国糖尿病学会(American Diabetes Association，ADA)指南则推荐磺脲类药物为T2DM患者二甲双胍治疗后的二线药物。因此，磺脲类药物目前仍是临床上治疗T2DM的常用口服药物之一，具有相当重要的临床地位。", "ner": [[21, 25, "Drug"], [45, 48, "Drug"], [65, 68, "Drug"], [148, 152, "Drug"], [158, 161, "Drug"], [302, 306, "Drug"], [386, 390, "Drug"], [398, 401, "Drug"], [414, 418, "Drug"], [9, 13, "Disease"], [93, 95, "Disease"], [341, 343, "Disease"], [71, 72, "Test_items"], [435, 436, "Method"], [139, 142, "Disease"], [309, 312, "Disease"], [428, 431, "Disease"], [392, 395, "Disease"]], "rel": [[21, 25, "Drug", 9, 13, "Disease", "Drug_Disease"], [45, 48, "Drug", 9, 13, "Disease", "Drug_Disease"], [65, 68, "Drug", 9, 13, "Disease", "Drug_Disease"], [148, 152, "Drug", 139, 142, "Disease", "Drug_Disease"], [302, 306, "Drug", 309, 312, "Disease", "Drug_Disease"], [386, 390, "Drug", 392, 395, "Disease", "Drug_Disease"], [398, 401, "Drug", 392, 395, "Disease", "Drug_Disease"], [414, 418, "Drug", 428, 431, "Disease", "Drug_Disease"], [435, 436, "Method", 414, 418, "Drug", "Method_Drug"], [71, 72, "Test_items", 9, 13, "Disease", "Test_items_Disease"]]}
{"idx": 2085, "sentence": "磺脲类药物仍是目前糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病(type 2 diabetes mellitus，T2DM)指南中占据着非常重要的治疗地位。长期的临床应用和大量的循证医学证据均表明，磺脲类药物不仅降糖作用强，还可减少或延缓T2DM慢性并发症的发生，特别是微血管并发症。", "ner": [[9, 11, "Disease"], [0, 4, "Drug"], [111, 115, "Drug"], [147, 152, "Disease"], [147, 149, "Anatomy"], [131, 134, "Disease"], [38, 73, "Disease"]], "rel": [[0, 4, "Drug", 9, 11, "Disease", "Drug_Disease"], [111, 115, "Drug", 131, 134, "Disease", "Drug_Disease"], [147, 149, "Anatomy", 147, 152, "Disease", "Anatomy_Disease"]]}
{"idx": 2086, "sentence": "不同磺脲类药物的分子结构、药代/药效动力学以及剂型存在差异，其疗效和安全性也有所不同。", "ner": [[2, 6, "Drug"]], "rel": []}
{"idx": 2087, "sentence": "为进一步提高临床医生对磺脲类药物的认识，更好地指导临床合理用药，内分泌专家基于循证医学证据的进展，对2004年版《磺脲类药物临床应用专家共识》进行了更新。", "ner": [[11, 15, "Drug"], [57, 61, "Drug"]], "rel": []}
{"idx": 2088, "sentence": "新版共识采用问答的形式阐明了当前磺脲类药物的临床地位、作用机制、疗效、安全性以及特殊人群用药等问题。", "ner": [[16, 20, "Drug"]], "rel": []}
{"idx": 2089, "sentence": "主要推荐意见见表1。", "ner": [], "rel": []}
{"idx": 2090, "sentence": "中国糖尿病防控专家共识", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 2091, "sentence": "为了加强糖尿病防控工作，保障人民健康，国家卫生计生委疾病预防控制局组织开展了中国糖防控策略研究，经咨询和广泛征求意见，达成了专家共识，并在国家卫生计生委疾控局主办，中国疾病预防控制中心、中华医学会、中华预防医学会、中国医师协会共同承办的2016联合国糖尿病日共同关注糖尿病”活动中向社会公开发布，意见如下：", "ner": [[4, 6, "Disease"], [125, 127, "Disease"], [133, 135, "Disease"]], "rel": []}
{"idx": 2092, "sentence": "1.我国糖尿病患病率为9.7%，患者人数近1个亿，呈快速增长趋势，导致糖尿病的危险因素广泛流行，已成为严重的公共卫生问题。", "ner": [[4, 6, "Disease"], [35, 37, "Disease"]], "rel": []}
{"idx": 2093, "sentence": "2.我国居民糖尿病知晓率、治疗率、控制率低，引发多种并发症，致残致死率高，带来沉重疾病负担，严重危害劳动力健康，影响经济社会可持续发展。", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 2094, "sentence": "3.糖尿病可防可控，关键在于早防早治。", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 2095, "sentence": "健康生活方式可有效预防糖尿病，早期发现、早期干预和规范治疗，可以减少和延缓并发症的发生，降低疾病负担，提高生命质量。", "ner": [[11, 13, "Disease"]], "rel": []}
{"idx": 2096, "sentence": "4.要全面贯彻预防为主方针，坚持综合防控，防治结合，明确政府、社会、专业机构、家庭和个人在糖尿病防控中的责任，实施全方位全周期的健康管理，降低全人群糖尿病发病风险，维护和促进全民健康。", "ner": [[45, 47, "Disease"], [74, 76, "Disease"]], "rel": []}
{"idx": 2097, "sentence": "因此，我们建议：", "ner": [], "rel": []}
{"idx": 2098, "sentence": "1.加强公共政策与立法，营造健康支持性环境。将健康融入所有政策，落实部门职责。将糖尿病等慢性病防控纳入《基本医疗卫生法》制订，推动营养改善条例、公共场所控烟条例等立法进程。制订可落实、可持续发展的国家糖尿病综合防治方案，开展全民健康生活方式行动，普及合理膳食、戒烟限酒、适量运动，开展“三减三健”专项活动，促进健康行为形成。", "ner": [[40, 42, "Disease"], [100, 102, "Disease"], [125, 128, "Treatment"], [130, 133, "Treatment"], [135, 138, "Treatment"]], "rel": [[125, 128, "Treatment", 100, 102, "Disease", "Treatment_Disease"], [130, 133, "Treatment", 100, 102, "Disease", "Treatment_Disease"], [135, 138, "Treatment", 100, 102, "Disease", "Treatment_Disease"]]}
{"idx": 2099, "sentence": "加强媒体宣传，规范传播内容，提高公众健康素养。", "ner": [], "rel": []}
{"idx": 2100, "sentence": "2.推动实施生命全周期的健康管理。开展孕期和分娩后体重管理和血糖筛查，推动母乳喂养和正确添加辅食。培养儿童、青少年的健康行为和技能，保证学生在校每天1小时运动，预防儿童青少年肥胖。", "ner": [[30, 33, "Test_items"], [87, 88, "Disease"], [72, 78, "Treatment"], [25, 28, "Treatment"]], "rel": [[72, 78, "Treatment", 87, 88, "Disease", "Treatment_Disease"]]}
{"idx": 2101, "sentence": "开展职业人群健康教育，落实工间健身制度，积极建设健康食堂，降低职业人群患病风险。", "ner": [], "rel": []}
{"idx": 2102, "sentence": "开展中老年人健康体检，及早发现高危人群和患者。", "ner": [], "rel": []}
{"idx": 2103, "sentence": "3.实施高危人群干预，推动关口前移。用好居民健康档案和各类体检信息，开展机会性筛查，发现或识别高危个体。针对糖尿病前期人群和血糖正常性高危人群开展分层干预和管理。对超重、肥胖者以减重为目标强化生活方式干预。", "ner": [[54, 56, "Disease"], [62, 63, "Test_items"], [82, 83, "Disease"], [85, 86, "Disease"], [89, 90, "Treatment"], [96, 101, "Treatment"]], "rel": [[62, 63, "Test_items", 54, 56, "Disease", "Test_items_Disease"], [89, 90, "Treatment", 82, 83, "Disease", "Treatment_Disease"], [96, 101, "Treatment", 82, 83, "Disease", "Treatment_Disease"], [89, 90, "Treatment", 85, 86, "Disease", "Treatment_Disease"], [96, 101, "Treatment", 85, 86, "Disease", "Treatment_Disease"]]}
{"idx": 2104, "sentence": "4.完善糖尿病防控体系，规范糖尿病患者治疗与管理。落实基层医疗卫生机构、医院、公共卫生机构职责，推进分级诊疗制度，建立协作共享机制，促进防治结合。强化基层卫生服务能力建设，规范基本公共卫生服务糖尿病患者健康管理，对发生并发症、血糖控制效果不佳等符合转诊条件的患者及时转诊，对病情稳定患者强化非药物治疗和自我管理支持。", "ner": [[4, 6, "Disease"], [14, 16, "Disease"], [96, 98, "Disease"], [113, 114, "Test_items"], [115, 120, "Test_Value"]], "rel": [[113, 114, "Test_items", 96, 98, "Disease", "Test_items_Disease"]]}
{"idx": 2105, "sentence": "加强医院对基层医疗卫生机构的技术指导和支持。", "ner": [], "rel": []}
{"idx": 2106, "sentence": "公共卫生机构做好信息收集、质量控制和效果评价工作。", "ner": [], "rel": []}
{"idx": 2107, "sentence": "5.发展健康管理技术、创新健康服务模式。", "ner": [], "rel": []}
{"idx": 2108, "sentence": "加强区域信息平台建设，推进互联网+移动健康服务，开展家庭医生签约服务。", "ner": [], "rel": []}
{"idx": 2109, "sentence": "政府健全投入机制，引导社会力量增加糖尿病防治服务供给，催生糖尿病健康管理服务新模式。", "ner": [[17, 19, "Disease"], [29, 31, "Disease"]], "rel": []}
{"idx": 2110, "sentence": "糖尿病防控是控制慢性病和实现“健康中国”目标不可缺少的重要内容，要以改革创新为动力，坚持预防为主，树立大卫生、大健康理念，政府、社会和个人共同行动起来，遏制糖尿病增长的势头。", "ner": [[0, 2, "Disease"], [78, 80, "Disease"]], "rel": []}
{"idx": 2111, "sentence": "中国慢性肾脏病患者合并高尿酸血症诊治专家共识", "ner": [[11, 15, "Disease"], [2, 6, "Disease"], [4, 5, "Anatomy"]], "rel": [[4, 5, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 2112, "sentence": "前言", "ner": [], "rel": []}
{"idx": 2113, "sentence": "慢性肾脏病(chronic kidney disease，CKD)已成为全球性重要公共卫生问题，中国流行病学研究显示，我国普通人群CKD的患病率为10.8%，中国南方地区普通人群为12.1%，农村地区为13.6%，高原地区藏族人群为19.1%，北方地区普通人群为16.9%。CKD持续进展至终末期肾病(end stage renal disease，ESRD)会严重影响患者的生存和生活质量。", "ner": [[0, 32, "Disease"], [65, 67, "Disease"], [137, 139, "Disease"], [145, 179, "Disease"], [2, 3, "Anatomy"], [148, 148, "Anatomy"]], "rel": [[2, 3, "Anatomy", 0, 32, "Disease", "Anatomy_Disease"], [148, 148, "Anatomy", 145, 179, "Disease", "Anatomy_Disease"]]}
{"idx": 2114, "sentence": "ESRD所需的医疗费用也对国家、社会和患者家庭造成巨大的经济负担。", "ner": [[0, 3, "Disease"]], "rel": []}
{"idx": 2115, "sentence": "寻找可控的危险因素进而采取针对性措施对于延缓CKD的持续进展非常重要。", "ner": [[22, 24, "Disease"]], "rel": []}
{"idx": 2116, "sentence": "我国CKD患者中的高尿酸血症(hyperuricemia，HUA)患病率为36.6%~50.0%，随CKD的进展其患病率明显升高。在IgA肾病患者队列中的研究显示，HUA是肾功能进展的独立危险因素，且该作用独立于患者的基线eGFR水平。维持性腹膜透析(腹透)患者的队列研究显示，血尿酸水平与腹透患者的全因死亡及心血管疾病(cardiovascular disease，CVD)死亡均独立相关。", "ner": [[2, 4, "Disease"], [9, 32, "Disease"], [50, 52, "Disease"], [66, 70, "Disease"], [82, 84, "Disease"], [111, 114, "Test_items"], [118, 128, "Treatment"], [139, 141, "Test_items"], [145, 146, "Treatment"], [155, 187, "Disease"], [155, 157, "Anatomy"], [69, 69, "Anatomy"]], "rel": [[69, 69, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"], [111, 114, "Test_items", 82, 84, "Disease", "Test_items_Disease"], [139, 141, "Test_items", 155, 187, "Disease", "Test_items_Disease"], [155, 157, "Anatomy", 155, 187, "Disease", "Anatomy_Disease"]]}
{"idx": 2117, "sentence": "然而，目前对于CKD患者中无症状HUA的治疗仍存在争议。", "ner": [[7, 9, "Disease"], [16, 18, "Disease"]], "rel": []}
{"idx": 2118, "sentence": "我们需要基于目前已有的证据和经验，制定符合中国CKD患者实际情况的专家共识，指导临床医生关注和重视CKD患者HUA的诊断和治疗，并为将来制定临床指南提供基础。", "ner": [[23, 25, "Disease"], [49, 51, "Disease"], [54, 56, "Disease"]], "rel": []}
{"idx": 2119, "sentence": "证据来源", "ner": [], "rel": []}
{"idx": 2120, "sentence": "1.证据来源：本共识以关键词检索当前关CKD合并HUA的相关研究证据，主要关键词包括：慢性肾脏病(chronic kidney disease)、高尿酸血症(hyperuricemia)、指南(guideline)、荟萃分析(met中国生物医学文献数据库(CBM)、中国期刊网全文数据库(CNKI)、万方数据资源系统和中文科技期刊全文数据库(VIP)。", "ner": [[19, 21, "Disease"], [24, 26, "Disease"], [43, 71, "Disease"], [73, 92, "Disease"], [45, 46, "Anatomy"]], "rel": [[45, 46, "Anatomy", 43, 71, "Disease", "Anatomy_Disease"]]}
{"idx": 2121, "sentence": "检索时间从建库至2016年8月底。", "ner": [], "rel": []}
{"idx": 2122, "sentence": "同时检索医脉通、Uptodate、Dynamed补充指南和相关入研究，查看纳入研究的参考文献。", "ner": [], "rel": []}
{"idx": 2123, "sentence": "若缺乏指南和系统评价证剧支持，则选用随机对照试验(RCT)，若RCT缺乏，则补充观察性研究和综述。", "ner": [], "rel": []}
{"idx": 2124, "sentence": "见图1。", "ner": [], "rel": []}
{"idx": 2125, "sentence": "a analysis)、系统评价(systemic review)、随机对照试验(randomized controlled trial)。", "ner": [], "rel": []}
{"idx": 2126, "sentence": "检索数据库包括：Embase、Medline PubMed、循证医学数据库(包括CDSR DARE、CCTR及ACP Journal Club)、OVID平台数据库、Springer—Link、Elsevier ScienceDirect电子期刊、", "ner": [], "rel": []}
{"idx": 2127, "sentence": "2.纳入、排除标准：纳入所有CKD合并HUA相关的研究，研究类型包括指南、系统评价、观察性研究、综述。", "ner": [[14, 16, "Disease"], [19, 21, "Disease"]], "rel": []}
{"idx": 2128, "sentence": "部分研究作为支撑推荐意见的相关证据，部分研究作为提供参考的背景材料。", "ner": [], "rel": []}
{"idx": 2129, "sentence": "未纳入非中、英文发表的研究和摘要。", "ner": [], "rel": []}
{"idx": 2130, "sentence": "见图1。", "ner": [], "rel": []}
{"idx": 2131, "sentence": "3.方法学质量评价：对检索到的文献进行质量评价，其中对指南使用AGREE II工具，对系统评价使用AMSTAR工具，对RCT使用Cochrane Risk of Bias工具，对观察性研究使用对应的方法学质量评价工具。", "ner": [], "rel": []}
{"idx": 2132, "sentence": "诊断标准和分型", "ner": [], "rel": []}
{"idx": 2133, "sentence": "1.CKD的诊断标准和分期：CKD的诊断标准：①肾脏损伤(肾脏结构或功能异常)≥3个月，伴或不伴肾小球滤过率(GFR)下降，肾脏病理学检查异常或肾脏损伤(血、尿成分或影像学检查异常)；②GFR<60ml·min-1·1.73m2)-1达到或超过3个月，有或无肾脏损伤证据。", "ner": [[2, 4, "Disease"], [14, 16, "Disease"], [48, 58, "Test_items"], [59, 60, "Test_Value"], [62, 68, "Test"], [77, 87, "Test"], [93, 95, "Test_items"], [96, 116, "Test_Value"], [117, 124, "Test_Value"]], "rel": [[62, 68, "Test", 2, 4, "Disease", "Test_Disease"], [77, 87, "Test", 2, 4, "Disease", "Test_Disease"], [48, 58, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [48, 58, "Test_items", 14, 16, "Disease", "Test_items_Disease"], [62, 68, "Test", 14, 16, "Disease", "Test_Disease"], [77, 87, "Test", 14, 16, "Disease", "Test_Disease"]]}
{"idx": 2134, "sentence": "CKD的分期参考改善全球肾脏病预后组织(The Kidney Disease：Improving Global Outcomes，KDIGO)的标准。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2135, "sentence": "2.HUA的诊断标准和分型：HUA的诊断标准：嘌呤饮食状态下，非同日2次空腹血尿酸(serum uric acid，SUA)水平，男性>420μmol/L，女性>357μmol/L；没有出现痛风或痛风石时为无症状HUA。HUA的分型诊断，是根据患者低嘌呤饮食5d后，留取24h尿检测尿尿酸水平的结果，分为3型，具体如下：(1)尿酸排泄不良型：尿酸排泄<0.48mg·kg-1·h-1，尿酸清除率<6.2ml/min；⑵尿酸生成过多型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率≥6.2ml/min；(3)混合型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率<6.2ml/min。", "ner": [[2, 4, "Disease"], [14, 16, "Disease"], [65, 76, "Test_Value"], [78, 89, "Test_Value"], [95, 96, "Disease"], [98, 100, "Disease"], [106, 108, "Disease"], [110, 112, "Disease"], [141, 143, "Test_items"], [171, 174, "Test_items"], [192, 196, "Test_items"], [217, 220, "Test_items"], [238, 242, "Test_items"], [261, 264, "Test_items"], [282, 286, "Test_items"], [175, 190, "Test_Value"], [197, 206, "Test_Value"], [221, 236, "Test_Value"], [243, 252, "Test_Value"], [265, 280, "Test_Value"], [287, 296, "Test_Value"], [36, 61, "Test_items"]], "rel": [[36, 61, "Test_items", 14, 16, "Disease", "Test_items_Disease"], [141, 143, "Test_items", 110, 112, "Disease", "Test_items_Disease"], [171, 174, "Test_items", 110, 112, "Disease", "Test_items_Disease"], [192, 196, "Test_items", 110, 112, "Disease", "Test_items_Disease"]]}
{"idx": 2136, "sentence": "治疗", "ner": [], "rel": []}
{"idx": 2137, "sentence": "一、患者教育和规律随访监测", "ner": [], "rel": []}
{"idx": 2138, "sentence": "积极开展患者教育，提高患者防病、治病的意识，提高治疗依从性，对于伴有HUA的CKD患者的治疗至关重要。", "ner": [[34, 36, "Disease"], [38, 40, "Disease"]], "rel": []}
{"idx": 2139, "sentence": "1.生活方式指导：对患者生活方式的指导应包括以下方面：健康饮食(详见表1)、坚持适度运动、限制体重和限制烟酒等。", "ner": [[27, 30, "Treatment"], [38, 43, "Treatment"], [45, 48, "Treatment"], [50, 53, "Treatment"]], "rel": []}
{"idx": 2140, "sentence": "建议患者根据个人情况坚持适度运动(每天30min以上中等强度的锻炼，如散步、太极拳、瑜伽、阻力训练等有氧运动)。", "ner": [[10, 54, "Treatment"]], "rel": []}
{"idx": 2141, "sentence": "患者在运动中应避免剧烈运动及突然受凉。", "ner": [], "rel": []}
{"idx": 2142, "sentence": "肥胖者应减体重，控制体重在正常范围。", "ner": [[4, 6, "Treatment"]], "rel": []}
{"idx": 2143, "sentence": "2.规律随访监测：对伴有HUA的CKD患者，建议治疗前全面评估肾功能和合并症、并发症情况，并在治疗过程中向患者强调规律随访监测的重要性。", "ner": [[12, 14, "Disease"], [16, 18, "Disease"]], "rel": []}
{"idx": 2144, "sentence": "建议患者在监测估算肾小球滤过率(eGFR)、尿蛋白水平的同时，至少每3~6个月检测1次血尿酸水平。", "ner": [[9, 20, "Test_items"], [22, 24, "Test_items"], [43, 45, "Test_items"]], "rel": []}
{"idx": 2145, "sentence": "二、饮食治疗", "ner": [[2, 5, "Treatment"]], "rel": []}
{"idx": 2146, "sentence": "1.健康饮食：饮食治疗在伴有HUA的CKD患者治疗中占有非常重要的地位，研究显示饮食治疗可以降低10%~18%的血尿酸水平或使血尿酸降低70~90μmol/L。推荐患者的饮食应以低嘌呤食物为主，具体建议详见表1。对于患者正在接受非透析治疗的CKD患者，应结合低蛋白饮食营养方案。", "ner": [[2, 5, "Treatment"], [7, 10, "Treatment"], [14, 16, "Disease"], [18, 20, "Disease"], [40, 43, "Treatment"], [56, 58, "Test_items"], [63, 65, "Test_items"], [120, 122, "Disease"], [129, 133, "Treatment"], [66, 78, "Test_Value"]], "rel": [[2, 5, "Treatment", 14, 16, "Disease", "Treatment_Disease"], [2, 5, "Treatment", 18, 20, "Disease", "Treatment_Disease"], [7, 10, "Treatment", 14, 16, "Disease", "Treatment_Disease"], [7, 10, "Treatment", 18, 20, "Disease", "Treatment_Disease"], [40, 43, "Treatment", 14, 16, "Disease", "Treatment_Disease"], [56, 58, "Test_items", 14, 16, "Disease", "Test_items_Disease"], [63, 65, "Test_items", 14, 16, "Disease", "Test_items_Disease"], [40, 43, "Treatment", 18, 20, "Disease", "Treatment_Disease"], [56, 58, "Test_items", 18, 20, "Disease", "Test_items_Disease"], [63, 65, "Test_items", 18, 20, "Disease", "Test_items_Disease"], [129, 133, "Treatment", 120, 122, "Disease", "Treatment_Disease"]]}
{"idx": 2147, "sentence": "避免高蛋白饮食、海鲜、动物内脏、大量乳制品的食用。", "ner": [[0, 23, "Treatment"]], "rel": []}
{"idx": 2148, "sentence": "避免啤酒、白酒，也应减少富含果糖的饮料摄入。", "ner": [[0, 20, "Treatment"]], "rel": []}
{"idx": 2149, "sentence": "2.多饮水：建议患者每日饮水量2000ml以上，可促进尿酸排泄并预防尿路结石。", "ner": [[2, 4, "Treatment"], [27, 28, "Test_items"], [34, 37, "Disease"]], "rel": [[2, 4, "Treatment", 34, 37, "Disease", "Treatment_Disease"], [27, 28, "Test_items", 34, 37, "Disease", "Test_items_Disease"]]}
{"idx": 2150, "sentence": "结合患者肾功能及血压情况，从患者尿量的角度，建议保证每日的尿量在1500ml以上，最好2000ml。", "ner": [], "rel": []}
{"idx": 2151, "sentence": "3.适当碱化尿液：建议碱化尿液，尿pH在6.2~6.9范围间内最有利于尿酸盐结晶溶解和从尿液排出，但尿pH>7.0易形成草酸钙及其他类结石。", "ner": [[16, 18, "Test_items"], [50, 52, "Test_items"], [53, 56, "Test_Value"], [20, 26, "Test_Value"]], "rel": []}
{"idx": 2152, "sentence": "因此，碱化尿液过程中要注意检测患者的尿pH值。", "ner": [[18, 21, "Test_items"]], "rel": []}
{"idx": 2153, "sentence": "建议碱化尿液的方法：碳酸氢钠或枸橼酸合剂。", "ner": [[15, 19, "Drug"], [10, 13, "Drug"]], "rel": []}
{"idx": 2154, "sentence": "碳酸氢钠(小苏打)口服：每次0.5~1g，每日3次。在CKD患者中碳酸氢钠可同时改善代谢性酸中毒，因此具有双重功效。但也需要注意钠负荷诱发患者充血性心力衰竭和水肿的可能。枸橼酸合剂口服时应注意监测CKD患者的血钾水平，避免发生高钾血症。", "ner": [[0, 8, "Drug"], [9, 10, "Method"], [12, 19, "Amount"], [21, 24, "Frequency"], [27, 29, "Disease"], [33, 36, "Drug"], [71, 77, "Disease"], [79, 80, "Disease"], [85, 89, "Drug"], [90, 91, "Method"], [98, 100, "Disease"], [104, 105, "Test_items"], [113, 116, "ADE"]], "rel": [[9, 10, "Method", 0, 8, "Drug", "Method_Drug"], [12, 19, "Amount", 0, 8, "Drug", "Amount_Drug"], [21, 24, "Frequency", 0, 8, "Drug", "Frequency_Drug"], [33, 36, "Drug", 27, 29, "Disease", "Drug_Disease"], [90, 91, "Method", 85, 89, "Drug", "Method_Drug"], [113, 116, "ADE", 85, 89, "Drug", "ADE_Drug"], [104, 105, "Test_items", 98, 100, "Disease", "Test_items_Disease"]]}
{"idx": 2155, "sentence": "三、药物治疗", "ner": [], "rel": []}
{"idx": 2156, "sentence": "(一)急性痛风发作治疗", "ner": [[3, 6, "Disease"]], "rel": []}
{"idx": 2157, "sentence": "痛风关节炎急性发作期的治疗建议：及早(应在24h内)给予抗炎止痛治疗，推荐的用药包括：非甾体抗炎药(NSAIDs)、糖皮质激素和秋水仙碱。建议使用选择性环氧化酶2(COX-2)抑制剂，该药可针对性地抑制COX-2，减少对CKD患者胃肠道损伤的不良作用。研究显示，依托考昔治疗急性痛风疗效优于吲哚美辛、双氯芬酸、塞来昔布。但CKD患者在使用NSAIDs时应警惕引起急性肾损伤，更应充分水化，密切注意肾功能情况。NSAIDs不耐受或禁忌的患者可考虑用糖皮质激素(如泼尼松30~35mg/d，共3~5d)或秋水仙碱。秋水仙碱最好在症状出现的12~24h内开始使用，但其不能用于重度肾功能或肝功能损害的患者。", "ner": [[0, 4, "Disease"], [43, 56, "Drug"], [58, 62, "Drug"], [64, 67, "Drug"], [73, 90, "Drug"], [110, 112, "Disease"], [131, 134, "Drug"], [139, 140, "Disease"], [145, 148, "Drug"], [150, 153, "Drug"], [155, 158, "Drug"], [161, 163, "Disease"], [169, 174, "Drug"], [181, 185, "ADE"], [204, 209, "Drug"], [223, 227, "Drug"], [230, 232, "Drug"], [250, 253, "Drug"], [233, 241, "Amount"], [243, 247, "Duration"], [255, 258, "Drug"], [115, 119, "ADE"], [285, 286, "Level"], [287, 295, "Disease"], [287, 287, "Anatomy"], [291, 291, "Anatomy"]], "rel": [[43, 56, "Drug", 0, 4, "Disease", "Drug_Disease"], [58, 62, "Drug", 0, 4, "Disease", "Drug_Disease"], [64, 67, "Drug", 0, 4, "Disease", "Drug_Disease"], [73, 90, "Drug", 110, 112, "Disease", "Drug_Disease"], [131, 134, "Drug", 139, 140, "Disease", "Drug_Disease"], [145, 148, "Drug", 139, 140, "Disease", "Drug_Disease"], [150, 153, "Drug", 139, 140, "Disease", "Drug_Disease"], [155, 158, "Drug", 139, 140, "Disease", "Drug_Disease"], [169, 174, "Drug", 161, 163, "Disease", "Drug_Disease"], [181, 185, "ADE", 169, 174, "Drug", "ADE_Drug"], [243, 247, "Duration", 230, 232, "Drug", "Duration_Drug"], [233, 241, "Amount", 230, 232, "Drug", "Amount_Drug"], [287, 287, "Anatomy", 287, 295, "Disease", "Anatomy_Disease"], [291, 291, "Anatomy", 287, 295, "Disease", "Anatomy_Disease"]]}
{"idx": 2158, "sentence": "急性期不宜积极降尿酸治疗，除非一直在服用降尿酸药物。", "ner": [[8, 9, "Test_items"], [21, 22, "Test_items"]], "rel": []}
{"idx": 2159, "sentence": "CKD患者痛风急性发作时应特别重视水化和碱化尿液，并在上述治疗的同时辅以局部NSAIDs药物的使用，改善患者的症状，最大限度减少全身用药的毒副作用。", "ner": [[0, 2, "Disease"], [5, 6, "Disease"], [38, 45, "Drug"], [17, 23, "Symptom"]], "rel": [[38, 45, "Drug", 0, 2, "Disease", "Drug_Disease"], [38, 45, "Drug", 5, 6, "Disease", "Drug_Disease"], [17, 23, "Symptom", 5, 6, "Disease", "Symptom_Disease"]]}
{"idx": 2160, "sentence": "(二)降尿酸治疗", "ner": [[4, 5, "Test_items"]], "rel": []}
{"idx": 2161, "sentence": "1.抑制尿酸生成药物：", "ner": [], "rel": []}
{"idx": 2162, "sentence": "(1)别嘌醇：适应证：①慢性原发性或继发性痛风的治疗；②伴或不伴痛风症状的高尿酸血症的CKD患者；③反复发作性尿酸结石患者；④预防白血病、淋巴瘤或其他肿瘤在化疗或放疗后继发的组织内尿酸盐沉积、肾结石等。", "ner": [[3, 5, "Drug"], [18, 22, "Disease"], [32, 33, "Disease"], [37, 41, "Disease"], [43, 45, "Disease"], [55, 58, "Disease"], [65, 67, "Disease"], [69, 71, "Disease"], [75, 76, "Disease"], [96, 98, "Disease"], [96, 96, "Anatomy"], [78, 79, "Treatment"], [81, 82, "Treatment"], [90, 94, "Disease"]], "rel": [[3, 5, "Drug", 18, 22, "Disease", "Drug_Disease"], [78, 79, "Treatment", 75, 76, "Disease", "Treatment_Disease"], [81, 82, "Treatment", 75, 76, "Disease", "Treatment_Disease"], [96, 96, "Anatomy", 96, 98, "Disease", "Anatomy_Disease"]]}
{"idx": 2163, "sentence": "用法及用量：从小剂量起始，逐渐加量。", "ner": [], "rel": []}
{"idx": 2164, "sentence": "初始剂量：每次50~100mg，每日1~3次。2~3周后增至每日300mg，分2~3次服用。肾功能下降时，如eGFR<60ml/min时别嘌醇应减量，推荐剂量为50~100mg/d，eGFR<15ml/min时应禁用。", "ner": [[5, 14, "Amount"], [30, 36, "Amount"], [38, 42, "Frequency"], [54, 57, "Test_items"], [58, 66, "Test_Value"], [68, 70, "Drug"], [80, 89, "Amount"], [91, 94, "Test_items"], [95, 103, "Test_Value"], [16, 21, "Frequency"]], "rel": [[80, 89, "Amount", 68, 70, "Drug", "Amount_Drug"]]}
{"idx": 2165, "sentence": "注意事项：①别嘌醇的严重不良反应与所用剂量相关，当使用最小有效剂量能够使血尿酸达标时，尽量不增加剂量。②控制急性痛风发作时，建议同时应用秋水仙碱或其他消炎药，尤其是在治疗的早期。", "ner": [[6, 8, "Drug"], [36, 38, "Test_items"], [56, 57, "Disease"], [68, 71, "Drug"]], "rel": [[68, 71, "Drug", 56, 57, "Disease", "Drug_Disease"]]}
{"idx": 2166, "sentence": "不良反应：包括胃肠道症状、皮疹、肝功能损害、骨髓抑制等，应密切监测。", "ner": [[7, 11, "ADE"], [13, 14, "ADE"], [16, 20, "ADE"], [22, 25, "ADE"]], "rel": []}
{"idx": 2167, "sentence": "偶有发生严重的“别嘌醇超敏反应综合征”，应予以重视和积极处理。", "ner": [[8, 17, "ADE"]], "rel": []}
{"idx": 2168, "sentence": "禁忌证：对别嘌醇过敏、严重肝肾功能不全和明显血细胞低下者、孕妇、有可能怀孕妇女以及哺乳期妇女。", "ner": [[13, 18, "Disease"], [13, 13, "Anatomy"], [14, 14, "Anatomy"], [5, 9, "Disease"], [11, 12, "Level"]], "rel": [[13, 13, "Anatomy", 13, 18, "Disease", "Anatomy_Disease"], [14, 14, "Anatomy", 13, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 2169, "sentence": "禁用于正在接受硫唑嘌呤治疗的患者。", "ner": [[7, 10, "Drug"]], "rel": []}
{"idx": 2170, "sentence": "密切监测别嘌醇的超敏反应。别嘌醇的超敏反应主要发生在最初使用的几个月内，最常见的是剥脱性皮炎。使用噻嗪类利尿剂及肾功能不全是发生超敏反应的危险因素。", "ner": [[4, 6, "Drug"], [13, 15, "Drug"], [41, 45, "ADE"], [49, 54, "Drug"], [56, 60, "Disease"], [56, 56, "Anatomy"], [8, 11, "ADE"], [17, 20, "ADE"], [64, 67, "ADE"]], "rel": [[8, 11, "ADE", 4, 6, "Drug", "ADE_Drug"], [41, 45, "ADE", 13, 15, "Drug", "ADE_Drug"], [17, 20, "ADE", 13, 15, "Drug", "ADE_Drug"], [64, 67, "ADE", 49, 54, "Drug", "ADE_Drug"], [56, 56, "Anatomy", 56, 60, "Disease", "Anatomy_Disease"]]}
{"idx": 2171, "sentence": "对于特定人群(3期或3期以上CKD的朝鲜人、所有中国汉族和泰国人)，其HLA-B*5801等位基因频率较高，HLA-B*5801阳性个体发生严重别嘌醇超敏反应危险性极高。", "ner": [[14, 16, "Disease"], [54, 63, "Test_items"], [64, 65, "Test_Value"], [72, 74, "Drug"], [75, 78, "ADE"]], "rel": [[75, 78, "ADE", 72, 74, "Drug", "ADE_Drug"]]}
{"idx": 2172, "sentence": "因此，HLA-B*5801阳性的患者忌用。", "ner": [[3, 12, "Test_items"], [13, 14, "Test_Value"]], "rel": []}
{"idx": 2173, "sentence": "(2)非布司他：适用于痛风患者HUA的长期治疗。", "ner": [[3, 6, "Drug"], [11, 12, "Disease"], [15, 17, "Disease"]], "rel": [[3, 6, "Drug", 11, 12, "Disease", "Drug_Disease"], [3, 6, "Drug", 15, 17, "Disease", "Drug_Disease"]]}
{"idx": 2174, "sentence": "用法及用量：①口服推荐剂量为40mg或80mg，每日1次。", "ner": [[7, 8, "Method"], [14, 22, "Amount"], [24, 27, "Frequency"]], "rel": []}
{"idx": 2175, "sentence": "推荐起始剂量为40mg，每日1次。若2周后，血尿酸水平仍不低于360μmol/L，建议剂量增至80mg，每日1次。②给药时，无需考虑食物和抗酸剂的影响。③轻、中度肾功能不全(eGFR30~89ml/min)的患者无需调整剂量。④对于CKD4期及以上患者，已有多项研究示非布司他的有效性及安全性，建议起始剂量为20mg，每日1次。", "ner": [[2, 10, "Amount"], [12, 15, "Frequency"], [22, 24, "Test_items"], [28, 39, "Test_Value"], [47, 50, "Amount"], [52, 55, "Frequency"], [81, 85, "Disease"], [81, 81, "Anatomy"], [87, 90, "Test_items"], [91, 101, "Test_Value"], [116, 118, "Disease"], [134, 137, "Drug"], [149, 157, "Amount"], [159, 162, "Frequency"]], "rel": [[81, 81, "Anatomy", 81, 85, "Disease", "Anatomy_Disease"], [87, 90, "Test_items", 81, 85, "Disease", "Test_items_Disease"], [134, 137, "Drug", 116, 118, "Disease", "Drug_Disease"], [159, 162, "Frequency", 134, 137, "Drug", "Frequency_Drug"], [149, 157, "Amount", 134, 137, "Drug", "Amount_Drug"]]}
{"idx": 2176, "sentence": "不良反应：主要有肝功能异常、恶心、关节痛、皮疹。", "ner": [[8, 12, "ADE"], [14, 15, "ADE"], [17, 19, "ADE"], [21, 22, "ADE"]], "rel": []}
{"idx": 2177, "sentence": "数项研究显示非布司他的不良反应发生率低于别嘌醇。", "ner": [[6, 9, "Drug"], [20, 22, "Drug"]], "rel": []}
{"idx": 2178, "sentence": "禁忌证：本品禁用于正在接受硫唑嘌呤、巯嘌呤治疗的患者。", "ner": [[13, 16, "Drug"], [18, 20, "Drug"]], "rel": []}
{"idx": 2179, "sentence": "注意事项：在服用非布司他的初期，可见痛风发作频率增加。源于血尿酸浓度降低，导致组织中沉积的尿酸盐动员。为预防治疗初期的痛风发作，建议同时服用非甾体类抗炎药或秋水仙碱。在非布司他治疗期间，若痛风发作，无需中止非布司他治疗。", "ner": [[8, 11, "Drug"], [18, 25, "ADE"], [59, 60, "Disease"], [70, 76, "Drug"], [78, 81, "Drug"], [84, 87, "Drug"], [94, 95, "Disease"], [103, 106, "Drug"], [29, 33, "Test_items"], [34, 35, "Test_Value"]], "rel": [[18, 25, "ADE", 8, 11, "Drug", "ADE_Drug"], [78, 81, "Drug", 59, 60, "Disease", "Drug_Disease"], [70, 76, "Drug", 59, 60, "Disease", "Drug_Disease"], [103, 106, "Drug", 94, 95, "Disease", "Drug_Disease"]]}
{"idx": 2180, "sentence": "应根据患者的具体情况进行适当调整。", "ner": [], "rel": []}
{"idx": 2181, "sentence": "针对高尿酸血症不同治疗方法的有效性和安全性比较的研究分析显示，与其他药物相比，非布司他具有更好的疗效和安全性。", "ner": [[2, 6, "Disease"], [39, 42, "Drug"]], "rel": [[39, 42, "Drug", 2, 6, "Disease", "Drug_Disease"]]}
{"idx": 2182, "sentence": "2.促进尿酸排泄药物：若使用促排尿酸药物(包括苯溴马隆、丙磺舒)降低患者血尿酸水平，在治疗开始前和治疗过程中，要特别注意多饮水和使用碱化尿液的药物。若患者24h尿尿酸的排出量已经增加(>3.54mmol)或有泌尿系尿酸结石则应禁用此类药物，在溃疡病或肾功能不全者慎用。", "ner": [[23, 26, "Drug"], [28, 30, "Drug"], [36, 38, "Test_items"], [60, 62, "Treatment"], [77, 82, "Test_items"], [89, 90, "Test_Value"], [92, 100, "Test_Value"], [104, 110, "Disease"], [121, 123, "Disease"], [125, 129, "Disease"], [125, 125, "Anatomy"], [104, 106, "Anatomy"]], "rel": [[104, 106, "Anatomy", 104, 110, "Disease", "Anatomy_Disease"], [125, 125, "Anatomy", 125, 129, "Disease", "Anatomy_Disease"]]}
{"idx": 2183, "sentence": "(1)苯溴马隆：适用于原发性和继发性高尿酸血症。", "ner": [[3, 6, "Drug"], [15, 22, "Disease"]], "rel": [[3, 6, "Drug", 15, 22, "Disease", "Drug_Disease"]]}
{"idx": 2184, "sentence": "用法及用量：成人起始剂量为每次口服50mg，每日1次，早餐后服用。成人及14岁以上患者每日50~100mg。轻、中度肾功能不全患者(eGFR>60ml/min)无须调整剂量。", "ner": [[15, 16, "Method"], [17, 20, "Amount"], [22, 25, "Frequency"], [43, 52, "Amount"], [58, 62, "Disease"], [58, 58, "Anatomy"], [66, 69, "Test_items"], [70, 78, "Test_Value"], [54, 57, "Level"]], "rel": [[66, 69, "Test_items", 58, 62, "Disease", "Test_items_Disease"], [58, 58, "Anatomy", 58, 62, "Disease", "Anatomy_Disease"]]}
{"idx": 2185, "sentence": "不良反应：可能出现肝损、胃肠不适、腹泻、皮疹、阳痿等，但较为少见。", "ner": [[9, 10, "ADE"], [12, 15, "ADE"], [17, 18, "ADE"], [20, 21, "ADE"], [23, 24, "ADE"]], "rel": []}
{"idx": 2186, "sentence": "禁忌证：对本品中任何成分过敏者。", "ner": [], "rel": []}
{"idx": 2187, "sentence": "严重肾功能损害者(eGFR<30ml/min)及有肾结石的患者，孕妇、有可能怀孕妇女以及哺乳期妇女。", "ner": [[2, 6, "Disease"], [2, 2, "Anatomy"], [9, 12, "Test_items"], [13, 21, "Test_Value"], [25, 27, "Disease"], [25, 25, "Anatomy"], [0, 1, "Level"]], "rel": [[9, 12, "Test_items", 2, 6, "Disease", "Test_items_Disease"], [2, 2, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [25, 25, "Anatomy", 25, 27, "Disease", "Anatomy_Disease"]]}
{"idx": 2188, "sentence": "注意事项：①治疗期间需大量饮水以增加尿量(治疗初期饮水量不得少于1500~2000ml/d)，避免排泄尿酸过多而在泌尿系统形成尿酸结石；2监测肝肾功能；③开始用药期间，建议给予碳酸氢钠或枸橼酸合剂，使患者的pH控制在6.2~6.9。", "ner": [[11, 14, "Treatment"], [51, 52, "Test_items"], [63, 66, "Disease"], [69, 74, "Test"], [88, 91, "Drug"], [93, 97, "Drug"]], "rel": []}
{"idx": 2189, "sentence": "(2)丙磺舒：促排降尿酸治疗中，可选择丙磺舒作为单药疗法促排尿酸。", "ner": [[3, 5, "Drug"], [10, 11, "Test_items"], [19, 21, "Drug"], [30, 31, "Test_items"]], "rel": []}
{"idx": 2190, "sentence": "用法及用量：成人起始剂量为每次口服0.25g，1日2次，1周后可增至每次0.5g，1日2次。根据临床表现及血和尿尿酸水平调整药物用量，原则上以最小有效量维持。丙磺舒的不良反应为肠胃不适、食欲下降、皮肤出疹，泌尿系尿酸结石等；当eGFR<30ml/min时无效，应避免使用。", "ner": [[15, 16, "Method"], [17, 21, "Amount"], [23, 26, "Frequency"], [34, 39, "Amount"], [41, 44, "Frequency"], [53, 57, "Test_items"], [79, 81, "Drug"], [88, 91, "ADE"], [93, 96, "ADE"], [98, 101, "ADE"], [103, 109, "ADE"], [113, 116, "Test_items"], [117, 125, "Test_Value"], [28, 29, "Duration"]], "rel": [[88, 91, "ADE", 79, 81, "Drug", "ADE_Drug"], [93, 96, "ADE", 79, 81, "Drug", "ADE_Drug"], [98, 101, "ADE", 79, 81, "Drug", "ADE_Drug"], [103, 109, "ADE", 79, 81, "Drug", "ADE_Drug"]]}
{"idx": 2191, "sentence": "丙磺舒目前已较少临床使用，注意事项与苯溴马隆相似。", "ner": [[0, 2, "Drug"], [18, 21, "Drug"]], "rel": []}
{"idx": 2192, "sentence": "3.兼有降尿酸作用的其他药物：氯沙坦不但能降血压，同时能促进尿酸排泄。高血压患者，可考虑使用氯沙坦，但单独使用的降尿酸作用较弱。", "ner": [[15, 17, "Drug"], [35, 37, "Disease"], [46, 48, "Drug"]], "rel": [[46, 48, "Drug", 35, 37, "Disease", "Drug_Disease"]]}
{"idx": 2193, "sentence": "有研究显示，非诺贝特与他汀类药物(尤其是阿托伐他汀)具有促进尿酸排泄作用。伴有高脂血症的患者，可考虑使用非诺贝特或他汀类药物，但两者的降尿酸作用都较弱。", "ner": [[6, 9, "Drug"], [11, 15, "Drug"], [20, 24, "Drug"], [39, 42, "Disease"], [52, 55, "Drug"], [57, 61, "Drug"]], "rel": [[52, 55, "Drug", 39, 42, "Disease", "Drug_Disease"], [57, 61, "Drug", 39, 42, "Disease", "Drug_Disease"]]}
{"idx": 2194, "sentence": "4.降尿酸药物的使用推荐意见：CKD患者HUA建议治疗流程见图2，各期CKD患者HUA的推荐治疗方案见表2。", "ner": [[15, 17, "Disease"], [20, 22, "Disease"], [35, 37, "Disease"], [40, 42, "Disease"]], "rel": []}
{"idx": 2195, "sentence": "(三)药物相互作用", "ner": [], "rel": []}
{"idx": 2196, "sentence": "在应用降尿酸药物治疗CKD患者HUA时，应注意各药物之间的相互作用，详见表3。", "ner": [[10, 12, "Disease"], [15, 17, "Disease"]], "rel": []}
{"idx": 2197, "sentence": "综上，HUA是CKD发生、发展和预后的危险因素。", "ner": [[3, 5, "Disease"], [7, 9, "Disease"]], "rel": []}
{"idx": 2198, "sentence": "充分重视和积极干预HUA将有利于CKD患者的预后。", "ner": [[9, 11, "Disease"], [16, 18, "Disease"]], "rel": []}
{"idx": 2199, "sentence": "在临床实践工作中，应参考指南共识，并根据患者的具体情况实施个体化治疗，提高疗效，减少和防范药物的不良反应，改善患者的长期预后。", "ner": [], "rel": []}
{"idx": 2200, "sentence": "我们期待在该领域有更多大样本、长随访的RCT研究为将来的临床指南的制定提供更多循证医学依据。", "ner": [], "rel": []}
{"idx": 2201, "sentence": "CKD患者HUA的降尿酸治疗，建议根据患者的伴随症状、合并症、并发症、肾功能情况和尿酸水平合理实施。对于伴有痛风的CKD患者，应在早期积极给予非药物治疗及降尿酸治疗。对于无症状的伴有HUA的CKD患者，男性血尿酸>420μmoI/L，女性血尿酸>360μmol/L，建议降尿酸治疗。降尿酸一线药物包括抑制尿酸生成药物(别嘌醇和非布司他)，促进尿酸排泄药物(苯溴马隆和丙磺舒)可为备选药物，治疗的血尿酸水平最低控制目标应<360μmol/L，在伴有严重痛风时建议控制目标<300μmol/L。不推荐长期维持血尿酸水平<180μmol/L。目前，对于无症状的伴有HUA的CKD患者，降尿酸的起始治疗阈值仍有争议，需要未来的进一步研究来确定。", "ner": [[0, 2, "Disease"], [5, 7, "Disease"], [10, 11, "Test_items"], [41, 42, "Test_items"], [54, 55, "Disease"], [57, 59, "Disease"], [78, 79, "Test_items"], [91, 93, "Disease"], [95, 97, "Disease"], [101, 105, "Test_items"], [106, 115, "Test_Value"], [117, 121, "Test_items"], [122, 131, "Test_Value"], [136, 137, "Test_items"], [159, 161, "Drug"], [163, 166, "Drug"], [150, 157, "Drug"], [169, 176, "Drug"], [178, 181, "Drug"], [183, 185, "Drug"], [197, 199, "Test_items"], [209, 218, "Test_Value"], [225, 226, "Disease"], [234, 243, "Test_Value"], [252, 254, "Test_items"], [257, 266, "Test_Value"], [279, 281, "Disease"], [283, 285, "Disease"], [290, 291, "Test_items"], [223, 224, "Level"]], "rel": [[10, 11, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [41, 42, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [10, 11, "Test_items", 5, 7, "Disease", "Test_items_Disease"], [41, 42, "Test_items", 5, 7, "Disease", "Test_items_Disease"], [78, 79, "Test_items", 54, 55, "Disease", "Test_items_Disease"], [78, 79, "Test_items", 57, 59, "Disease", "Test_items_Disease"], [101, 105, "Test_items", 91, 93, "Disease", "Test_items_Disease"], [117, 121, "Test_items", 91, 93, "Disease", "Test_items_Disease"], [136, 137, "Test_items", 91, 93, "Disease", "Test_items_Disease"], [101, 105, "Test_items", 95, 97, "Disease", "Test_items_Disease"], [117, 121, "Test_items", 95, 97, "Disease", "Test_items_Disease"], [136, 137, "Test_items", 95, 97, "Disease", "Test_items_Disease"], [159, 161, "Drug", 225, 226, "Disease", "Drug_Disease"], [163, 166, "Drug", 225, 226, "Disease", "Drug_Disease"], [150, 157, "Drug", 225, 226, "Disease", "Drug_Disease"], [169, 176, "Drug", 225, 226, "Disease", "Drug_Disease"], [178, 181, "Drug", 225, 226, "Disease", "Drug_Disease"], [183, 185, "Drug", 225, 226, "Disease", "Drug_Disease"], [197, 199, "Test_items", 225, 226, "Disease", "Test_items_Disease"], [290, 291, "Test_items", 279, 281, "Disease", "Test_items_Disease"], [290, 291, "Test_items", 283, 285, "Disease", "Test_items_Disease"]]}
{"idx": 2202, "sentence": "对于降尿酸治疗对肾脏的益处也需要更多高质、大样本的RCT来证实。", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 2203, "sentence": "对于噻唑烷二酮类与α-葡萄糖苷酶抑制剂这两类口服降糖药物，目前国内糖尿病相关专业组织尚未发布专门的临床指南或共识，不过据悉，吡格列酮临床应用的专家共识很快将会发布，届时我们再进行介绍。", "ner": [[2, 7, "Drug"], [9, 18, "Drug"], [33, 35, "Disease"], [62, 65, "Drug"], [22, 23, "Method"]], "rel": [[2, 7, "Drug", 33, 35, "Disease", "Drug_Disease"], [22, 23, "Method", 2, 7, "Drug", "Method_Drug"], [9, 18, "Drug", 33, 35, "Disease", "Drug_Disease"], [22, 23, "Method", 9, 18, "Drug", "Method_Drug"], [62, 65, "Drug", 33, 35, "Disease", "Drug_Disease"]]}
{"idx": 2204, "sentence": "本期我们先来看看胰岛素方面的中国指南/共识，下期再对近几年出现的几类新型降糖药进行总结，作为年底的“温故知新”。", "ner": [[8, 10, "Drug"]], "rel": []}
{"idx": 2205, "sentence": "相比于其他降糖药物类别，胰岛素的成员最多，临床应用也各不相同，所以需要分开介绍。在这里我们将分为1型糖尿病与2型糖尿病、餐时/基础/预混胰岛素来看看相应的指南/共识是怎么说的。", "ner": [[12, 14, "Drug"], [48, 52, "Disease"], [54, 58, "Disease"], [66, 70, "Drug"]], "rel": [[66, 70, "Drug", 48, 52, "Disease", "Drug_Disease"], [66, 70, "Drug", 54, 58, "Disease", "Drug_Disease"]]}
{"idx": 2206, "sentence": "1型糖尿病：(《中国1型糖尿病胰岛素治疗指南》)", "ner": [[0, 4, "Disease"], [10, 14, "Disease"], [15, 17, "Drug"]], "rel": [[15, 17, "Drug", 10, 14, "Disease", "Drug_Disease"]]}
{"idx": 2207, "sentence": "与发达国家的1型糖尿病人群相比，我国的1型糖尿病人群存在血糖达标率低、急慢性并发症发生率高、寿命短等明显不足。尽管国际上倡导“基础+餐时”胰岛素强化治疗方案，但该方案在我国1型糖尿病人群中的应用率很低，而以每日2次方案者居多。为此，中华医学会糖尿病学分会在2016年发布了《中国1型糖尿病胰岛素治疗指南》，以期规范我国的1型糖尿病胰岛素治疗。", "ner": [[6, 10, "Disease"], [19, 23, "Disease"], [28, 29, "Test_items"], [69, 71, "Drug"], [86, 90, "Disease"], [121, 123, "Disease"], [139, 143, "Disease"], [144, 146, "Drug"], [160, 164, "Disease"], [165, 167, "Drug"], [103, 106, "Frequency"], [30, 33, "Test_Value"]], "rel": [[28, 29, "Test_items", 19, 23, "Disease", "Test_items_Disease"], [69, 71, "Drug", 86, 90, "Disease", "Drug_Disease"], [103, 106, "Frequency", 69, 71, "Drug", "Frequency_Drug"], [144, 146, "Drug", 139, 143, "Disease", "Drug_Disease"], [165, 167, "Drug", 160, 164, "Disease", "Drug_Disease"]]}
{"idx": 2208, "sentence": "基本原则", "ner": [], "rel": []}
{"idx": 2209, "sentence": "(1)1型糖尿病患者因自身胰岛素分泌绝对缺乏，完全或部分需要外源性胰岛素替代以维持体内糖代谢平衡和生存，基础加餐时胰岛素治疗是其首选的胰岛素治疗方案。", "ner": [[3, 7, "Disease"], [13, 21, "Pathogenesis"], [57, 59, "Drug"], [67, 69, "Drug"], [33, 35, "Drug"]], "rel": [[13, 21, "Pathogenesis", 3, 7, "Disease", "Pathogenesis_Disease"], [33, 35, "Drug", 3, 7, "Disease", "Drug_Disease"]]}
{"idx": 2210, "sentence": "(2)应尽可能在避免低血糖的前提下使血糖达标，以降低远期并发症的发生风险，因此建议胰岛治疗方案必须个体化，制订方案时要兼顾胰岛功能血糖控制目标、血糖波动幅度、低血糖发生风险等。", "ner": [[10, 12, "Disease"], [18, 19, "Test_items"], [65, 66, "Test_items"], [72, 73, "Test_items"], [79, 81, "ADE"], [74, 75, "Test_Value"]], "rel": [[18, 19, "Test_items", 10, 12, "Disease", "Test_items_Disease"]]}
{"idx": 2211, "sentence": "(3)基础加餐时胰岛素替代治疗方法包括每日多次胰岛素注射和持续皮下胰岛素输注。", "ner": [[8, 10, "Drug"], [23, 25, "Drug"], [26, 27, "Method"], [31, 32, "Method"], [33, 35, "Drug"], [19, 22, "Frequency"]], "rel": [[26, 27, "Method", 23, 25, "Drug", "Method_Drug"], [19, 22, "Frequency", 23, 25, "Drug", "Frequency_Drug"], [31, 32, "Method", 33, 35, "Drug", "Method_Drug"], [19, 22, "Frequency", 33, 35, "Drug", "Frequency_Drug"]]}
{"idx": 2212, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 2213, "sentence": "(1)每日多次胰岛素注射方案", "ner": [[7, 9, "Drug"], [10, 11, "Method"], [3, 6, "Frequency"]], "rel": [[10, 11, "Method", 7, 9, "Drug", "Method_Drug"], [3, 6, "Frequency", 7, 9, "Drug", "Frequency_Drug"]]}
{"idx": 2214, "sentence": "基础胰岛素可通过中效胰岛素、长效胰岛素或长效胰岛素类似物给予，餐时胰岛素可通过短效胰岛或速效胰岛素类似物给予，详见表1。该指南指出与中效胰岛素相比，长效胰岛素类似物空腹血糖控制更好，夜间低血糖发生风险更低。具体用法：①体重在理想体重正负20%以内的成年患者，若无特殊情况每日胰岛素需要总量0.4~0.8单位/千克体重，每日总量也可以最小剂量12~18单位起始；儿童则需根据年龄、体重及血糖情况酌情处理。2每日胰岛素基础=全天胰岛素总量X(40%~60%)，长效胰岛素一般1次注射，中效胰岛素可每日1次或2次注射。", "ner": [[2, 4, "Drug"], [8, 12, "Drug"], [14, 18, "Drug"], [20, 27, "Drug"], [33, 35, "Drug"], [39, 42, "Drug"], [44, 53, "Drug"], [66, 70, "Drug"], [74, 81, "Drug"], [82, 85, "Test_items"], [86, 89, "Level"], [93, 95, "ADE"], [137, 139, "Drug"], [144, 157, "Amount"], [192, 193, "Test_items"], [204, 206, "Drug"], [228, 232, "Drug"], [237, 238, "Method"], [235, 236, "Frequency"], [240, 244, "Drug"], [246, 252, "Frequency"], [253, 254, "Method"], [170, 176, "Amount"]], "rel": [[144, 157, "Amount", 137, 139, "Drug", "Amount_Drug"], [237, 238, "Method", 228, 232, "Drug", "Method_Drug"], [235, 236, "Frequency", 228, 232, "Drug", "Frequency_Drug"], [246, 252, "Frequency", 240, 244, "Drug", "Frequency_Drug"], [253, 254, "Method", 240, 244, "Drug", "Method_Drug"]]}
{"idx": 2215, "sentence": "③每日餐时量一般按餐时总量的35%、30%、35%分配在早中晚餐前。", "ner": [], "rel": []}
{"idx": 2216, "sentence": "(2)持续皮下胰岛素输注", "ner": [[7, 9, "Drug"], [5, 6, "Method"]], "rel": [[5, 6, "Method", 7, 9, "Drug", "Method_Drug"]]}
{"idx": 2217, "sentence": "无论是直接起始胰岛素泵还是每日多次胰岛素注射方案与胰岛素泵方案的相互转换，都建议住医生指导下完成。具体用法：①初始胰岛素泵方每日胰岛素总量可按0.4~0.5单位/千克体重计算；2每日基础量=全天胰岛素总量X(40%~60%)，常规分为6或更多个时间段，以尽量减少或避免低血糖事件，或根据血糖情况分段设置基础输注率；③餐食追加量=全天胰岛素总量X(40%~60%)，根据早中晚三餐比例一般按1/3、1/3、1/3或1/5、2/5、2/5分配，之后根据血糖监测结果调整。", "ner": [[13, 16, "Frequency"], [17, 19, "Drug"], [20, 21, "Method"], [71, 84, "Amount"], [134, 136, "ADE"], [224, 227, "Test_items"], [64, 66, "Drug"], [143, 144, "Test_items"], [166, 168, "Drug"], [97, 99, "Drug"]], "rel": [[13, 16, "Frequency", 17, 19, "Drug", "Frequency_Drug"], [20, 21, "Method", 17, 19, "Drug", "Method_Drug"], [71, 84, "Amount", 64, 66, "Drug", "Amount_Drug"]]}
{"idx": 2218, "sentence": "(3)特殊情况", "ner": [], "rel": []}
{"idx": 2219, "sentence": "①蜜月期：初诊1型糖尿病患者经胰岛素规范治疗后可短期停用胰岛素或每日使用很少量胰岛素治疗，血糖水平就能维持在接近正常或正常的范围内，即1型糖尿病蜜月期。在此阶段根据血糖监测情况，可每日≤3次小剂量胰岛素(包括预混胰岛素)注射，但应以维持血糖达标为准；如出现血糖波动大、血糖不易控制，需频繁调整胰岛素用量等情况，建议及时评估胰岛功能并及时改用胰岛素强化治疗方案。", "ner": [[7, 11, "Disease"], [15, 17, "Drug"], [28, 30, "Drug"], [39, 41, "Drug"], [45, 46, "Test_items"], [67, 71, "Disease"], [82, 85, "Test_items"], [90, 94, "Frequency"], [98, 100, "Drug"], [104, 108, "Drug"], [110, 111, "Method"], [118, 119, "Test_items"], [128, 129, "Test_items"], [130, 132, "Test_Value"], [134, 135, "Test_items"], [136, 139, "Test_Value"], [146, 148, "Drug"], [170, 172, "Drug"]], "rel": [[15, 17, "Drug", 7, 11, "Disease", "Drug_Disease"], [45, 46, "Test_items", 7, 11, "Disease", "Test_items_Disease"], [90, 94, "Frequency", 98, 100, "Drug", "Frequency_Drug"], [90, 94, "Frequency", 104, 108, "Drug", "Frequency_Drug"], [110, 111, "Method", 98, 100, "Drug", "Method_Drug"], [110, 111, "Method", 104, 108, "Drug", "Method_Drug"]]}
{"idx": 2220, "sentence": "②脆性糖尿病：1型糖尿病患病一段时间后由于胰岛功能完全衰竭，出现血糖巨幅波动，高血低与低血糖交替出现，频发不可预知的严重低血糖，即脆性糖尿病。少数进展迅速的患者在确诊时即可进入脆性糖尿病阶段。此类患者建议使用胰岛素泵或速效胰岛素类似物联合长效胰岛素类似物方案。", "ner": [[1, 5, "Disease"], [7, 11, "Disease"], [21, 28, "Reason"], [32, 33, "Test_items"], [34, 37, "Level"], [43, 45, "Disease"], [60, 62, "Disease"], [65, 69, "Disease"], [88, 92, "Disease"], [109, 116, "Drug"], [119, 126, "Drug"], [39, 41, "Disease"], [58, 59, "Level"]], "rel": [[21, 28, "Reason", 1, 5, "Disease", "Reason_Disease"], [32, 33, "Test_items", 1, 5, "Disease", "Test_items_Disease"], [21, 28, "Reason", 7, 11, "Disease", "Reason_Disease"], [32, 33, "Test_items", 7, 11, "Disease", "Test_items_Disease"], [109, 116, "Drug", 88, 92, "Disease", "Drug_Disease"], [119, 126, "Drug", 88, 92, "Disease", "Drug_Disease"]]}
{"idx": 2221, "sentence": "③儿童青少年患者：因特殊情况无法坚持基础加餐时胰岛素治疗方案时，如短期使用预混胰岛素治疗，必须加强血糖监测，及时根据血糖情况重新调整胰岛素治疗方案，以避免长期血糖不达标带来的各种急慢性并发症。", "ner": [[23, 25, "Drug"], [37, 41, "Drug"], [49, 52, "Test_items"], [58, 59, "Test_items"], [66, 68, "Drug"], [79, 80, "Test_items"], [81, 83, "Test_Value"]], "rel": []}
{"idx": 2222, "sentence": "进入青春期后，一方面维持正常生长发育而不可过度严格控制饮食，另一方面体内性激素、生长激素等胰岛素拮抗激素分泌增多，因此胰岛素需要量会增加，而且患者的血糖水平会比青春期前明显升高且波动较大，需要加强血糖监测，适时调整胰岛素治疗方案。", "ner": [[59, 61, "Drug"], [74, 75, "Test_items"], [84, 87, "Test_Value"], [89, 92, "Test_Value"], [98, 101, "Test_items"], [107, 109, "Test_items"], [25, 28, "Treatment"]], "rel": []}
{"idx": 2223, "sentence": "④妊娠患者：合并妊娠时可采用短效胰岛素、中效胰岛素或长效胰岛素进行方案组合，或使用胰岛泵治疗。目前经国家食品药品监督管理总局(CFDA)批准可用于妊娠糖尿病和糖尿病合并妊娠患者的胰岛素类似物制剂是门冬胰岛素和地特胰岛素。与2型糖尿病患者妊娠期间的情况类似，由于激素水平的变化，妊娠中后期胰岛素需要量，尤其是日间胰岛素需要量会增加，而随着胎盘娩出，拮抗胰岛素的激素及破坏胰岛素的酶急剧减少或消失，胰岛素需要量会快速减少，一般分娩后2~3天胰岛素可减量至原量的1/3~1/2。", "ner": [[14, 18, "Drug"], [20, 24, "Drug"], [26, 30, "Drug"], [73, 77, "Disease"], [79, 81, "Disease"], [89, 96, "Drug"], [98, 102, "Drug"], [104, 108, "Drug"], [111, 115, "Disease"], [143, 145, "Drug"], [155, 157, "Drug"], [197, 199, "Drug"], [218, 220, "Drug"]], "rel": [[89, 96, "Drug", 73, 77, "Disease", "Drug_Disease"], [98, 102, "Drug", 73, 77, "Disease", "Drug_Disease"], [104, 108, "Drug", 73, 77, "Disease", "Drug_Disease"], [89, 96, "Drug", 79, 81, "Disease", "Drug_Disease"], [98, 102, "Drug", 79, 81, "Disease", "Drug_Disease"], [104, 108, "Drug", 79, 81, "Disease", "Drug_Disease"], [143, 145, "Drug", 111, 115, "Disease", "Drug_Disease"]]}
{"idx": 2224, "sentence": "⑤超重或肥胖患者：胰岛素抵抗会导致胰岛素需要量增加，必要时可联合二甲双胍(10岁以下儿童禁用)。", "ner": [[1, 2, "Disease"], [4, 5, "Disease"], [9, 13, "Pathogenesis"], [17, 19, "Drug"], [32, 35, "Drug"]], "rel": [[17, 19, "Drug", 1, 2, "Disease", "Drug_Disease"], [32, 35, "Drug", 1, 2, "Disease", "Drug_Disease"], [17, 19, "Drug", 4, 5, "Disease", "Drug_Disease"], [32, 35, "Drug", 4, 5, "Disease", "Drug_Disease"]]}
{"idx": 2225, "sentence": "2型糖尿病：(《成人2型糖尿病胰岛素临床应用的中国专家共识(2013年版)》)", "ner": [[0, 4, "Disease"], [10, 14, "Disease"], [15, 17, "Drug"]], "rel": [[15, 17, "Drug", 10, 14, "Disease", "Drug_Disease"]]}
{"idx": 2226, "sentence": "中国特色", "ner": [], "rel": []}
{"idx": 2227, "sentence": "首先来说，东西方2型糖尿病人群的病生理特点及血糖特点有所不同：西方白种人的日常饮食中脂肪含量较高，胰岛素抵抗和腹型肥胖尤为突出，空腹血糖升高更为明显；而中国人群的饮食以碳水化合物为主，β细胞功能缺陷相对更为明显，胰岛素分泌和储备能力低，尤其是胰岛素早相分泌减退更严重，餐后血糖升高显著，不仅如此，体质指数(BMI)虽然相对较低但腹部脂肪蓄积较多，高糖高脂毒性及氧化应激等对β细胞的伤害更明显。", "ner": [[8, 12, "Disease"], [22, 23, "Test_items"], [49, 53, "Pathogenesis"], [55, 58, "Disease"], [64, 67, "Test_items"], [68, 69, "Level"], [92, 98, "Pathogenesis"], [106, 116, "Pathogenesis"], [121, 129, "Pathogenesis"], [134, 137, "Test_items"], [138, 141, "Test_Value"], [39, 47, "Reason"]], "rel": [[22, 23, "Test_items", 8, 12, "Disease", "Test_items_Disease"], [49, 53, "Pathogenesis", 8, 12, "Disease", "Pathogenesis_Disease"], [64, 67, "Test_items", 8, 12, "Disease", "Test_items_Disease"], [39, 47, "Reason", 8, 12, "Disease", "Reason_Disease"]]}
{"idx": 2228, "sentence": "由此所带来的就是东西方2型糖尿病人群的胰岛素治疗理念也应有所不同：西方2型糖尿病的治疗主要是以改善胰岛素抵抗和补充基础胰岛素为主的起始治疗，例如，多数国家和地区的指南均推荐起始使用基础胰岛素，像美国糖尿病协会(ADA)/欧洲糖尿究学会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南；而美国内分泌医师协会/美国内分泌学会(AACE/ACE)专家共识则指出基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素一日多次注射、餐时胰岛素加二甲双胍这四种胰岛素方案中任一种均可作为起始治疗。《成人2糖尿病胰岛素临床应用的中国专家共识》的一个主要特点就是提出，中国2型糖尿病患者更需要适时启胰岛素治疗，而且基于餐后血糖更为常见，在干预策略上，应同时针对β细胞功能缺陷和胰岛素作用障碍两个方面，兼顾基础和餐时胰岛素；同时考虑我国2型糖尿病患者的疾病特点和现实社会因素，推荐基础胰岛素和预混胰岛素均可作为口服药失效或血糖较高的新诊断2型糖尿病患者的一线治疗方案。", "ner": [[11, 15, "Disease"], [19, 21, "Drug"], [35, 39, "Disease"], [49, 53, "Pathogenesis"], [59, 61, "Drug"], [92, 94, "Drug"], [132, 134, "Disease"], [168, 170, "Disease"], [220, 222, "Drug"], [224, 228, "Drug"], [230, 237, "Drug"], [244, 247, "Frequency"], [248, 249, "Method"], [239, 243, "Drug"], [251, 255, "Drug"], [257, 260, "Drug"], [264, 266, "Drug"], [285, 288, "Disease"], [289, 291, "Drug"], [318, 322, "Disease"], [331, 333, "Drug"], [341, 344, "Test_items"], [362, 368, "Pathogenesis"], [370, 376, "Pathogenesis"], [387, 391, "Drug"], [399, 403, "Disease"], [423, 425, "Drug"], [427, 431, "Drug"], [442, 443, "Test_items"], [444, 445, "Test_Value"], [450, 454, "Disease"], [99, 101, "Disease"]], "rel": [[19, 21, "Drug", 11, 15, "Disease", "Drug_Disease"], [49, 53, "Pathogenesis", 35, 39, "Disease", "Pathogenesis_Disease"], [59, 61, "Drug", 35, 39, "Disease", "Drug_Disease"], [244, 247, "Frequency", 220, 222, "Drug", "Frequency_Drug"], [248, 249, "Method", 220, 222, "Drug", "Method_Drug"], [244, 247, "Frequency", 224, 228, "Drug", "Frequency_Drug"], [248, 249, "Method", 224, 228, "Drug", "Method_Drug"], [244, 247, "Frequency", 230, 237, "Drug", "Frequency_Drug"], [248, 249, "Method", 230, 237, "Drug", "Method_Drug"], [244, 247, "Frequency", 239, 243, "Drug", "Frequency_Drug"], [248, 249, "Method", 239, 243, "Drug", "Method_Drug"], [289, 291, "Drug", 285, 288, "Disease", "Drug_Disease"], [331, 333, "Drug", 318, 322, "Disease", "Drug_Disease"], [341, 344, "Test_items", 318, 322, "Disease", "Test_items_Disease"], [362, 368, "Pathogenesis", 318, 322, "Disease", "Pathogenesis_Disease"], [370, 376, "Pathogenesis", 318, 322, "Disease", "Pathogenesis_Disease"], [387, 391, "Drug", 318, 322, "Disease", "Drug_Disease"], [423, 425, "Drug", 399, 403, "Disease", "Drug_Disease"], [427, 431, "Drug", 399, 403, "Disease", "Drug_Disease"], [442, 443, "Test_items", 399, 403, "Disease", "Test_items_Disease"]]}
{"idx": 2229, "sentence": "适用人群", "ner": [], "rel": []}
{"idx": 2230, "sentence": "该共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗(暂不考虑口服降糖药治疗)：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全； (4)妊娠期间。而以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，糖化血红蛋白(HbA1c)≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)患者；(3)病程中出现无确切诱因的体重下降者。", "ner": [[8, 12, "Disease"], [23, 25, "Drug"], [111, 113, "Drug"], [127, 129, "Drug"], [141, 145, "Disease"], [149, 161, "Test_items"], [162, 166, "Test_Value"], [168, 170, "Disease"], [185, 190, "Treatment"], [214, 215, "Test_items"], [217, 219, "Test_Value"], [221, 225, "Test_items"], [226, 230, "Test_Value"], [33, 34, "Method"], [87, 92, "Disease"], [87, 87, "Anatomy"], [88, 88, "Anatomy"]], "rel": [[23, 25, "Drug", 8, 12, "Disease", "Drug_Disease"], [127, 129, "Drug", 141, 145, "Disease", "Drug_Disease"], [149, 161, "Test_items", 141, 145, "Disease", "Test_items_Disease"], [87, 87, "Anatomy", 87, 92, "Disease", "Anatomy_Disease"], [88, 88, "Anatomy", 87, 92, "Disease", "Anatomy_Disease"]]}
{"idx": 2231, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 2232, "sentence": "(1)基本原则", "ner": [], "rel": []}
{"idx": 2233, "sentence": "该共识的另一个显著特点就是强调要综合考虑疗效与安全性、患者病情与能力、支付能力(经济水平和医疗保障)等多种因素，选择适宜的治疗方案，详见表2和图1。", "ner": [], "rel": []}
{"idx": 2234, "sentence": "(2)联合用药", "ner": [], "rel": []}
{"idx": 2235, "sentence": "药物的合理联用可以避免或减少药物不良反应产生。", "ner": [], "rel": []}
{"idx": 2236, "sentence": "该共识推荐采用胰岛素/口服药联合方案以增加降糖疗效，同时减少胰岛素治疗潜在的低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量；葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，可减少胰岛素用量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或糖苷酶抑制剂与胰岛素联用。", "ner": [[7, 9, "Drug"], [30, 32, "Drug"], [38, 40, "ADE"], [42, 45, "ADE"], [52, 55, "Drug"], [57, 59, "Drug"], [65, 68, "ADE"], [75, 77, "Drug"], [81, 88, "Drug"], [90, 92, "Drug"], [100, 101, "Test_items"], [109, 111, "Drug"], [117, 120, "ADE"], [137, 141, "Disease"], [149, 152, "Drug"], [154, 159, "Drug"], [161, 163, "Drug"], [11, 12, "Method"]], "rel": [[38, 40, "ADE", 30, 32, "Drug", "ADE_Drug"], [42, 45, "ADE", 30, 32, "Drug", "ADE_Drug"], [149, 152, "Drug", 137, 141, "Disease", "Drug_Disease"], [154, 159, "Drug", 137, 141, "Disease", "Drug_Disease"], [161, 163, "Drug", 137, 141, "Disease", "Drug_Disease"]]}
{"idx": 2237, "sentence": "而胰岛素促泌剂也潜在有低血糖和体重增加的不良反应，所以除基础胰岛素外，不建议其与胰岛素联用。", "ner": [[1, 6, "Drug"], [11, 13, "ADE"], [15, 18, "ADE"], [30, 32, "Drug"], [40, 42, "Drug"]], "rel": [[11, 13, "ADE", 1, 6, "Drug", "ADE_Drug"], [15, 18, "ADE", 1, 6, "Drug", "ADE_Drug"]]}
{"idx": 2238, "sentence": "(3)特殊情况", "ner": [], "rel": []}
{"idx": 2239, "sentence": "①肥胖患者：共识指出，在积极使用胰岛素同时，还应注意合理使用以避免过度应用，对于肥胖(BMl>28千克/米2)的患者，应在口服药充分治疗的基础上再考虑起始胰岛素治疗。2低血糖风险：对已合并心脑血管疾病或危险因素的2型糖尿病患者，或是老年糖尿病患者，过于激进的降糖治疗可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低。然而脑血管疾病在我国发病率显著高于西方国家，因此在使用胰岛素时，更加需要注意采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。", "ner": [[1, 2, "Disease"], [16, 18, "Drug"], [40, 41, "Disease"], [77, 79, "Drug"], [84, 86, "Disease"], [94, 99, "Disease"], [94, 97, "Anatomy"], [106, 110, "Disease"], [118, 120, "Disease"], [172, 173, "Disease"], [177, 179, "Disease"], [189, 193, "Disease"], [189, 191, "Anatomy"], [214, 216, "Drug"], [245, 247, "ADE"]], "rel": [[94, 97, "Anatomy", 94, 99, "Disease", "Anatomy_Disease"], [189, 191, "Anatomy", 189, 193, "Disease", "Anatomy_Disease"], [245, 247, "ADE", 214, 216, "Drug", "ADE_Drug"]]}
{"idx": 2240, "sentence": "③肾功能不全患者：这类患者的肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症时[血液中尿素氮超过9毫摩尔/升(mmol/L)、肌酐超过178微摩尔/升(μmol/L)]应根据血糖监测情况及时减少和调整胰岛素用量，使血糖维持在适当范围内，并且优先选择短效或速效胰岛素剂型。", "ner": [[1, 5, "Disease"], [1, 1, "Anatomy"], [17, 19, "Drug"], [30, 32, "Drug"], [55, 58, "Disease"], [64, 66, "Test_items"], [67, 81, "Test_Value"], [84, 85, "Test_items"], [86, 102, "Test_Value"], [108, 111, "Test_items"], [121, 123, "Drug"], [128, 129, "Test_items"], [148, 152, "Drug"]], "rel": [[1, 1, "Anatomy", 1, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2241, "sentence": "餐时胰岛素：《速效胰岛素类似物临床应用专家指导意见》", "ner": [[7, 14, "Drug"], [2, 4, "Drug"]], "rel": []}
{"idx": 2242, "sentence": "临床上应用的胰岛素制剂历经两次换代，即动物胰岛素-人胰岛素-胰岛素类似物，更新换代的目的就是希望能够更好地模拟生理性胰岛素分泌，以速效胰岛素类似物为例，其与短效人胰岛素同为模拟餐时胰岛素分泌，但在控制血糖和减少低血糖风险等方面均优于后者，而且可以餐前即刻注射更为方便，能够提高患者的治疗依从性。", "ner": [[6, 8, "Drug"], [19, 23, "Drug"], [25, 28, "Drug"], [30, 35, "Drug"], [58, 60, "Drug"], [65, 72, "Drug"], [78, 83, "Drug"], [90, 92, "Drug"], [100, 101, "Test_items"], [105, 107, "ADE"], [123, 128, "Method"]], "rel": [[123, 128, "Method", 78, 83, "Drug", "Method_Drug"], [105, 107, "ADE", 90, 92, "Drug", "ADE_Drug"]]}
{"idx": 2243, "sentence": "2016年，多位国内内分泌专家联合发布了《速效胰岛素类似物临床应用专家指导意见》，旨在指导速效胰岛素类似物的合理使用。", "ner": [[21, 28, "Drug"], [45, 52, "Drug"]], "rel": []}
{"idx": 2244, "sentence": "作用特点", "ner": [], "rel": []}
{"idx": 2245, "sentence": "正常人的胰岛素分泌包括基础性的持续分泌和外源性刺激后(主要是进餐)的餐时分泌两部分，两者大约各占全天总量的一半。前者的主要作用是调节空腹和餐前血糖，后者的主要作用是控制餐后血糖。餐时胰岛素又可以细分为早相(第一时相)和晚相(第二时相)分泌，其中早相分泌的速度和分泌量是决定餐后血糖升高幅度和持续时间的主要因素。2型糖尿病早期阶段主要是早相分泌减少，同时伴有晚相分泌代偿性增加且分泌高峰后移；随着病情进展，早相分泌进减少甚至消失，而晚相分泌峰值也逐渐下降，最后发展至基础分泌也逐渐减少。", "ner": [[69, 72, "Test_items"], [84, 87, "Test_items"], [136, 139, "Test_items"], [140, 141, "Test_Value"], [155, 159, "Disease"]], "rel": []}
{"idx": 2246, "sentence": "由此可见，胰岛素早相分泌异常不仅是2型糖病的早期表现，并将持续整个病程，同时也是餐后高血糖的主要原因。《中国2型糖尿病患者餐后高血糖管理专家共识》建议，短效人胰岛素和速效胰岛素类似物均可用于补充餐时胰岛素的不足以控制餐后高血糖。", "ner": [[42, 44, "Disease"], [5, 13, "Pathogenesis"], [54, 58, "Disease"], [63, 65, "Disease"], [76, 81, "Drug"], [83, 90, "Drug"], [110, 112, "Disease"], [17, 20, "Disease"]], "rel": [[5, 13, "Pathogenesis", 17, 20, "Disease", "Pathogenesis_Disease"], [76, 81, "Drug", 110, 112, "Disease", "Drug_Disease"], [83, 90, "Drug", 110, 112, "Disease", "Drug_Disease"]]}
{"idx": 2247, "sentence": "不过如前所述，速效胰岛素类似物由于起效、达峰和峰效时间更为合理，所以具有更大的治疗优势。", "ner": [[7, 14, "Drug"]], "rel": []}
{"idx": 2248, "sentence": "目前国内临床上应用的速效胰岛素类似物主要有门冬胰岛素、赖脯胰岛素和谷赖胰岛素，详见见表3。", "ner": [[10, 17, "Drug"], [21, 25, "Drug"], [27, 31, "Drug"], [33, 37, "Drug"]], "rel": []}
{"idx": 2249, "sentence": "临床用法", "ner": [], "rel": []}
{"idx": 2250, "sentence": "(1)制剂选择", "ner": [], "rel": []}
{"idx": 2251, "sentence": "速效胰岛素类似物常与基础胰岛素联合使用，较少单独三餐前皮下注射，除非患者空腹血糖不高而餐后血糖明显升高，而且必须使用胰岛素治疗，如妊娠糖尿病患者或严重肝肾功能异常的糖尿病患者。此外，胰岛素泵只能采用速效胰岛素类似物或短效人胰岛素；速效胰岛素类似物静脉使用没有优势，故不推荐。三种速效胰岛素类似物尽管在药代动力学和药效学方面有一定的差别，但在对餐后血糖的总体控制、严重低血糖发生率等方面并没有显著差别，三种速效胰岛素类似物在胰岛素泵中的应用优势也类似。", "ner": [[0, 7, "Drug"], [12, 14, "Drug"], [27, 30, "Method"], [36, 39, "Test_items"], [40, 41, "Test_Value"], [43, 46, "Test_items"], [47, 50, "Test_Value"], [58, 60, "Drug"], [65, 69, "Disease"], [82, 84, "Disease"], [99, 106, "Drug"], [108, 113, "Drug"], [115, 122, "Drug"], [123, 124, "Method"], [139, 146, "Drug"], [171, 174, "Test_items"], [183, 185, "ADE"], [202, 209, "Drug"], [73, 74, "Level"], [75, 80, "Disease"], [75, 75, "Anatomy"], [76, 76, "Anatomy"]], "rel": [[27, 30, "Method", 0, 7, "Drug", "Method_Drug"], [27, 30, "Method", 12, 14, "Drug", "Method_Drug"], [58, 60, "Drug", 65, 69, "Disease", "Drug_Disease"], [58, 60, "Drug", 82, 84, "Disease", "Drug_Disease"], [123, 124, "Method", 115, 122, "Drug", "Method_Drug"], [183, 185, "ADE", 139, 146, "Drug", "ADE_Drug"], [183, 185, "ADE", 202, 209, "Drug", "ADE_Drug"], [75, 75, "Anatomy", 75, 80, "Disease", "Anatomy_Disease"], [76, 76, "Anatomy", 75, 80, "Disease", "Anatomy_Disease"]]}
{"idx": 2252, "sentence": "(2)使用方法", "ner": [], "rel": []}
{"idx": 2253, "sentence": "首先要估算初始的胰岛素每日总剂量：在保持相对恒定的饮食及活动量的情况下，需要根据患者的体重、病情、生理需要量等进行估算，一般情况下，1型糖尿病患者可按0.4~0.5单位仟克体重计算，2型糖尿病病患者可按0.5~1.0单位/千克体重计算。然后根据治疗方案的不同计算出餐时胰岛素的用量并合理分配至三餐：采用基础-餐时方案时，餐时胰岛素约占每日总量的40%~60%，再按1/3、1/3、1/3或1/5、2/5、2/5的比例分配至早午晚三餐前注射；采用胰岛素泵治疗时，餐时胰岛素约占每日总量的50%，按1/3、1/3、1/3的比例分配至三餐前大剂量。", "ner": [[8, 10, "Drug"], [66, 70, "Disease"], [91, 95, "Disease"], [75, 87, "Amount"], [101, 112, "Amount"], [134, 136, "Drug"], [162, 164, "Drug"], [217, 218, "Method"], [232, 234, "Drug"]], "rel": [[75, 87, "Amount", 8, 10, "Drug", "Amount_Drug"], [101, 112, "Amount", 8, 10, "Drug", "Amount_Drug"], [217, 218, "Method", 134, 136, "Drug", "Method_Drug"], [217, 218, "Method", 162, 164, "Drug", "Method_Drug"]]}
{"idx": 2254, "sentence": "最后再根据次餐前或睡前血糖的水平调整餐时胰岛素用量：一般先对最高的餐前血糖值进行调整，每3~5天调整1次，每次调整1~2个注射时间点，每次调整胰岛素剂量为1~4个单位，直至血糖达标，调量方法见表4。", "ner": [[9, 12, "Test_items"], [20, 22, "Drug"], [33, 36, "Test_items"], [71, 73, "Drug"], [86, 87, "Test_items"]], "rel": []}
{"idx": 2255, "sentence": "(3)特殊情况", "ner": [], "rel": []}
{"idx": 2256, "sentence": "①妊娠期：目前，CFDA仅批准门冬胰岛素在妊娠期间使用。", "ner": [[15, 19, "Drug"]], "rel": []}
{"idx": 2257, "sentence": "研究显示，相比于短效人胰岛素，门冬胰岛素在改善母婴预后方面更具优势。②儿童和青少年：门冬胰岛素已被CFDA批准用于2岁以上儿童及青少年糖尿病患者；我国的《儿童及青少年糖尿病患者的胰岛素治疗指南》建议赖脯胰岛素的使用年龄为12 岁以上。③肝、肾功能不全：糖尿病合并肾功能不全患者的胰岛素治疗应优先选择短效胰岛素威速效胰岛素类似物。", "ner": [[8, 13, "Drug"], [15, 19, "Drug"], [42, 46, "Drug"], [67, 69, "Disease"], [83, 85, "Disease"], [89, 91, "Drug"], [99, 103, "Drug"], [120, 124, "Disease"], [120, 120, "Anatomy"], [126, 128, "Disease"], [131, 135, "Disease"], [139, 141, "Drug"], [149, 153, "Drug"], [155, 162, "Drug"], [131, 131, "Anatomy"]], "rel": [[42, 46, "Drug", 67, 69, "Disease", "Drug_Disease"], [99, 103, "Drug", 83, 85, "Disease", "Drug_Disease"], [89, 91, "Drug", 83, 85, "Disease", "Drug_Disease"], [120, 120, "Anatomy", 120, 124, "Disease", "Anatomy_Disease"], [139, 141, "Drug", 126, 128, "Disease", "Drug_Disease"], [149, 153, "Drug", 126, 128, "Disease", "Drug_Disease"], [155, 162, "Drug", 126, 128, "Disease", "Drug_Disease"], [131, 131, "Anatomy", 131, 135, "Disease", "Anatomy_Disease"]]}
{"idx": 2258, "sentence": " ", "ner": [], "rel": []}
{"idx": 2259, "sentence": "基础胰岛素： 《成人2型糖尿病基础胰岛素临床应用中国专家指导建议》 ", "ner": [[2, 4, "Drug"], [10, 14, "Disease"], [17, 19, "Drug"]], "rel": [[17, 19, "Drug", 10, 14, "Disease", "Drug_Disease"]]}
{"idx": 2260, "sentence": "基础胰岛素是胰岛素治疗方案中常用的胰岛素类型，具有低血糖风险低，使用简单方便等优点，既可与口服降糖药物联用作为起始方案，又可与餐时胰岛素组成强化治疗方案。然而，临床研究显示，中国2型糖尿病患者起始基础胰岛素治疗较晚，起始剂量偏低且在起始治疗后剂量调整不足，是导致起始胰岛素治疗后血糖控制不满意的重要原因。为此，国内多位内分泌学专家在2017年初联合发布了《成人2型糖尿病基础胰岛素临床应用中国专家指导建议》，以规范基础胰岛素在临床上的合理使用。", "ner": [[2, 4, "Drug"], [6, 8, "Drug"], [17, 19, "Drug"], [25, 27, "ADE"], [65, 67, "Drug"], [89, 93, "Disease"], [100, 102, "Drug"], [133, 135, "Drug"], [139, 142, "Test_items"], [143, 145, "Test_Value"], [180, 184, "Disease"], [187, 189, "Drug"], [209, 211, "Drug"], [45, 46, "Method"]], "rel": [[100, 102, "Drug", 89, 93, "Disease", "Drug_Disease"], [139, 142, "Test_items", 89, 93, "Disease", "Test_items_Disease"], [187, 189, "Drug", 180, 184, "Disease", "Drug_Disease"], [209, 211, "Drug", 180, 184, "Disease", "Drug_Disease"]]}
{"idx": 2261, "sentence": " ", "ner": [], "rel": []}
{"idx": 2262, "sentence": "作用特点 ", "ner": [], "rel": []}
{"idx": 2263, "sentence": "目前，国内临床使用的基础胰岛素主要包括中效胰岛素(NPH，中性鱼精蛋白锌胰岛素) 、长效胰岛素(PZI，精蛋白锌胰岛素) 和长效人胰岛素类似物 (甘精胰岛素，地特胰岛素等) ，详见表5。NPH具有明显峰值，变异性较大，低血糖发生风险相对高，但价格较低。", "ner": [[12, 14, "Drug"], [19, 23, "Drug"], [25, 27, "Drug"], [29, 38, "Drug"], [42, 46, "Drug"], [52, 58, "Drug"], [48, 50, "Drug"], [62, 70, "Drug"], [73, 77, "Drug"], [79, 83, "Drug"], [93, 95, "Drug"], [109, 111, "ADE"]], "rel": [[109, 111, "ADE", 93, 95, "Drug", "ADE_Drug"]]}
{"idx": 2264, "sentence": "长效胰岛素目前临床上已经很少使用。", "ner": [[0, 4, "Drug"]], "rel": []}
{"idx": 2265, "sentence": "长效人胰岛素类似物平稳无峰，能更好地模拟生理性胰岛素分泌，减少低血糖风险，但价格较高。", "ner": [[1, 8, "Drug"], [31, 33, "ADE"]], "rel": []}
{"idx": 2266, "sentence": " ", "ner": [], "rel": []}
{"idx": 2267, "sentence": "临床用法 ", "ner": [], "rel": []}
{"idx": 2268, "sentence": "(1)适用人群 ", "ner": [], "rel": []}
{"idx": 2269, "sentence": "①口服降糖药联合基础胰岛素方案：高血糖 (FPG>11.1毫摩尔/升，或HbA1c>9%) 伴明显高血糖症状的新诊2型糖尿病患者；1~2种口服降糖药 (超重或肥胖患者1~3种口服降糖药)规范治疗3个月以上血糖控制仍未达标者；正在接受预混胰岛素治疗(低于50单位/天)的患者血糖控制不佳，频繁发作低血糖者，或对每日2次预混胰岛素注射依从性差者。", "ner": [[16, 18, "Disease"], [24, 33, "Test_Value"], [36, 40, "Test_items"], [41, 43, "Test_Value"], [49, 51, "Disease"], [57, 61, "Disease"], [76, 77, "Disease"], [79, 80, "Disease"], [102, 103, "Test_items"], [116, 120, "Drug"], [124, 131, "Amount"], [136, 137, "Test_items"], [138, 141, "Test_Value"], [147, 149, "Disease"], [158, 162, "Drug"], [154, 157, "Frequency"], [163, 164, "Method"], [107, 109, "Test_Value"], [1, 2, "Method"], [10, 12, "Drug"], [21, 23, "Test_items"], [47, 48, "Level"], [87, 88, "Method"], [69, 70, "Method"]], "rel": [[21, 23, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [36, 40, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [124, 131, "Amount", 116, 120, "Drug", "Amount_Drug"], [163, 164, "Method", 158, 162, "Drug", "Method_Drug"], [154, 157, "Frequency", 158, 162, "Drug", "Frequency_Drug"]]}
{"idx": 2270, "sentence": " ", "ner": [], "rel": []}
{"idx": 2271, "sentence": "②基础胰岛素联合餐时胰岛素方案：口服降糖药联合基础胰岛素治疗后，空腹血糖达标，HbA1c仍不达标者，或使用较大剂量基础胰岛素后[如0.6单位/ (千克·天)]，血糖仍不达标者；使用多次预混胰岛素治疗，血糖控制不佳者或反复发作低血糖者；需短时间内纠正高血糖的糖尿病患者。", "ner": [[3, 5, "Drug"], [10, 12, "Drug"], [25, 27, "Drug"], [32, 35, "Test_items"], [39, 43, "Test_items"], [59, 61, "Drug"], [65, 76, "Amount"], [80, 81, "Test_items"], [92, 96, "Drug"], [100, 101, "Test_items"], [102, 105, "Test_Value"], [112, 114, "Disease"], [124, 126, "Disease"], [128, 130, "Disease"], [45, 47, "Test_Value"], [83, 85, "Test_Value"], [16, 17, "Method"]], "rel": [[65, 76, "Amount", 59, 61, "Drug", "Amount_Drug"]]}
{"idx": 2272, "sentence": " ", "ner": [], "rel": []}
{"idx": 2273, "sentence": "(2)使用方法 ", "ner": [], "rel": []}
{"idx": 2274, "sentence": "①口服降糖药联合基础胰岛素方案：血糖明显增高伴有明显高血糖症状的新诊断糖尿病患者或口服降糖药治疗血糖控制不佳的患者起始基础胰岛素时，可根据体重计算每日起始剂量，通常为0.1~0.3单位/千克体重，肥胖患者或HbA1c>8.0%时，可考虑0.2~0.3单位/千克体重起始。从预混缺岛素治疗转换为基础胰岛素时，可依据血糖水平，按照原预混胰岛素总剂量的60%-80%起始基础胰岛素；如HbA1c≦8.0%，基础胰岛素起始剂量=原预混胰岛素总量x 0.6，HbA1c>8%时，推荐起始剂量=原预混胰岛素总量x0.8。口服药种类和剂量根据患者个体情况酌情选择和调整。此后，根据空腹血糖水平，在避免低血糖的情况下及时调整胰岛素剂量。多数患者长效胰岛素类似物每日剂量达到约0.5单位/千克体重前，可通过继续调整剂量控制血糖，而无需调整治疗方案。", "ner": [[10, 12, "Drug"], [16, 17, "Test_items"], [18, 21, "Test_Value"], [26, 28, "Disease"], [35, 37, "Disease"], [48, 49, "Test_items"], [50, 53, "Test_Value"], [61, 63, "Drug"], [83, 96, "Amount"], [98, 99, "Disease"], [103, 107, "Test_items"], [108, 112, "Test_Value"], [118, 131, "Amount"], [136, 140, "Drug"], [148, 150, "Drug"], [156, 157, "Test_items"], [164, 168, "Drug"], [184, 186, "Drug"], [189, 193, "Test_items"], [194, 198, "Test_Value"], [202, 204, "Drug"], [211, 215, "Drug"], [224, 228, "Test_items"], [229, 231, "Test_Value"], [242, 246, "Drug"], [283, 286, "Test_items"], [293, 295, "Disease"], [304, 306, "Drug"], [314, 321, "Drug"], [329, 338, "Amount"], [352, 353, "Test_items"], [1, 2, "Method"], [41, 42, "Method"]], "rel": [[16, 17, "Test_items", 26, 28, "Disease", "Test_items_Disease"], [16, 17, "Test_items", 35, 37, "Disease", "Test_items_Disease"], [83, 96, "Amount", 61, 63, "Drug", "Amount_Drug"], [118, 131, "Amount", 61, 63, "Drug", "Amount_Drug"], [329, 338, "Amount", 314, 321, "Drug", "Amount_Drug"]]}
{"idx": 2275, "sentence": "在血糖未达到设定的血糖目标值前，建议患者在医生指导下，根据空腹血糖，每周调整2~6单位直至空腹血糖达标；对于能进行血糖测、感知低血糖、进行自我管理的患者，医生可指导其进行简使易行的自我胰岛素剂量调整，每3天调整2~3单位直至空腹血糖达标，详见表6。", "ner": [[1, 2, "Test_items"], [9, 10, "Test_items"], [29, 32, "Test_items"], [45, 48, "Test_items"], [57, 58, "Test_items"], [63, 65, "Disease"], [92, 94, "Drug"], [112, 115, "Test_items"]], "rel": []}
{"idx": 2276, "sentence": " ", "ner": [], "rel": []}
{"idx": 2277, "sentence": "②基础胰岛素联合餐时胰岛素方案：对于口服降糖药联合基础胰岛素治疗的患者，基础胰岛素可维持原剂量，开始时可在主餐/早餐前给予餐时胰岛素4-6单位，然后逐步增加餐时胰岛素，根据下一餐前血糖值，每周调整1~2次餐时胰岛素剂量，每次调整1-2单位或10%~15%直至达到下次餐前血糖目标，根据每3~6个月的HbA1c结果，如需要可逐渐增加至每日2~3次餐时胰岛素注射。对于之前使用预混胰岛素的患者，可按照原先预混胰岛素剂量的40%~50% 作为基础胰岛素，剩余量作为餐时胰岛素，三餐平均分配；对于需短时间内纠正高血糖的患者，可根据0.3~0.5单位/千克体重来估算起始胰岛素总量，其中，50%为基础胰岛素，50%为餐时胰岛素，三餐平均分配。", "ner": [[3, 5, "Drug"], [27, 29, "Drug"], [38, 40, "Drug"], [8, 12, "Drug"], [61, 65, "Drug"], [78, 82, "Drug"], [88, 91, "Test_items"], [102, 106, "Drug"], [133, 136, "Test_items"], [149, 153, "Test_items"], [172, 176, "Drug"], [177, 178, "Method"], [186, 190, "Drug"], [200, 204, "Drug"], [220, 222, "Drug"], [229, 233, "Drug"], [251, 253, "Disease"], [280, 282, "Drug"], [295, 297, "Drug"], [303, 307, "Drug"], [261, 274, "Amount"], [18, 19, "Method"], [166, 171, "Frequency"], [66, 70, "Amount"]], "rel": [[66, 70, "Amount", 61, 65, "Drug", "Amount_Drug"], [177, 178, "Method", 172, 176, "Drug", "Method_Drug"], [166, 171, "Frequency", 172, 176, "Drug", "Frequency_Drug"], [280, 282, "Drug", 251, 253, "Disease", "Drug_Disease"], [261, 274, "Amount", 280, 282, "Drug", "Amount_Drug"]]}
{"idx": 2278, "sentence": "采用基础+三餐前胰岛素治疗方案时，如果血糖水平整体偏高，可先调整基础胰岛素剂量，对于需尽快解除高血糖状态的情况，则可同时调整基础和餐时的剂量。", "ner": [[8, 10, "Drug"], [19, 20, "Test_items"], [23, 26, "Test_Value"], [34, 36, "Drug"], [47, 49, "Disease"]], "rel": []}
{"idx": 2279, "sentence": " ", "ner": [], "rel": []}
{"idx": 2280, "sentence": "条件允许时，在起始胰岛素治疗的早期可通过住院密切监测血糖来每天调整胰岛素剂量：根据空腹血糖，调整基础胰岛素剂量1~4单位或10%~20%；根据下一餐前血糖值，调整餐时胰岛素剂量1-2单位或10%。如果出现空腹或夜间低血糖(<3.9毫摩尔/升)或低血糖症状，则应减少基础胰岛素和/或晚餐前的餐时胰岛素剂量10%~20%；如果日间两餐间出低血糖，则减少上一餐的餐时胰岛素剂量10%~20%；如出现需他人协助的严重低血糖或随机血糖<2.2毫摩尔/升，则减少20%~40%胰岛素剂量。", "ner": [[9, 11, "Drug"], [24, 27, "Test_items"], [33, 35, "Drug"], [41, 44, "Test_items"], [73, 76, "Test_items"], [50, 52, "Drug"], [81, 85, "Drug"], [108, 109, "Test_items"], [111, 119, "Test_Value"], [122, 124, "ADE"], [134, 136, "Drug"], [144, 148, "Drug"], [167, 169, "ADE"], [178, 182, "Drug"], [204, 206, "ADE"], [208, 211, "Test_items"], [212, 220, "Test_Value"], [232, 234, "Drug"], [55, 59, "Amount"], [88, 92, "Amount"]], "rel": [[55, 59, "Amount", 50, 52, "Drug", "Amount_Drug"], [88, 92, "Amount", 81, 85, "Drug", "Amount_Drug"], [122, 124, "ADE", 134, 136, "Drug", "ADE_Drug"], [167, 169, "ADE", 178, 182, "Drug", "ADE_Drug"], [204, 206, "ADE", 232, 234, "Drug", "ADE_Drug"]]}
{"idx": 2281, "sentence": " ", "ner": [], "rel": []}
{"idx": 2282, "sentence": "(3)特殊情况 ", "ner": [], "rel": []}
{"idx": 2283, "sentence": "①老年患者：老年糖尿病患者常合并多种疾病，器官功能减退，且低血糖感知性弱、耐受性差，认知能力、自我管理能力下降。因此，老年糖尿病患者血糖控制目标一般较为宽松，在选择降糖药物时，除了控糖达标以预防和减少并发症，更应当考虑其肝、肾功能及合并用药的相互作用，减少低血糖发生。临床上常采用口服降糖药治疗，需胰岛素治疗时通常推荐使用基础胰岛素，尤其是低血糖风险较低的长效胰岛素类似物。除新诊断伴严重高血糖症状及某些特殊情况外，不推荐多次胰岛素注射的方案。", "ner": [[8, 10, "Disease"], [29, 31, "Disease"], [61, 63, "Disease"], [66, 69, "Test_items"], [128, 130, "Disease"], [149, 151, "Drug"], [163, 165, "Drug"], [170, 172, "ADE"], [178, 185, "Drug"], [194, 196, "Disease"], [213, 215, "Drug"], [216, 217, "Method"], [140, 141, "Method"], [192, 193, "Level"]], "rel": [[216, 217, "Method", 213, 215, "Drug", "Method_Drug"]]}
{"idx": 2284, "sentence": " ", "ner": [], "rel": []}
{"idx": 2285, "sentence": "②妊娠期：无论是妊娠期糖尿病还是糖尿病合并妊娠，当通过饮食治疗血糖不能得到满意控制时，均需起始胰岛素治疗。由于人胰岛素不通过胎盘屏障，因此NPH在妊娠期间使用不受限制。", "ner": [[8, 13, "Disease"], [16, 18, "Disease"], [27, 30, "Treatment"], [31, 32, "Test_items"], [47, 49, "Drug"], [55, 58, "Drug"], [69, 71, "Drug"]], "rel": [[27, 30, "Treatment", 8, 13, "Disease", "Treatment_Disease"], [31, 32, "Test_items", 8, 13, "Disease", "Test_items_Disease"]]}
{"idx": 2286, "sentence": "但由于长效胰岛素类似物在妊娠妇女中临床证据有限，临床医生需充分考虑获益及潜在风险后确定是否使用。", "ner": [[3, 10, "Drug"]], "rel": []}
{"idx": 2287, "sentence": " ", "ner": [], "rel": []}
{"idx": 2288, "sentence": "③围手术期：围手术期需使用胰岛素控制血糖，入院前口服降糖药的患者，接受小手术的术前当晚及手术当天应停用口服降糖药，接受大中手术则应在术前3天停用口服降糖药，均改为胰岛素治疗。术前和术后可正常饮食的高血糖患者可采用基础联合餐时胰岛素方案，大中型手术术中需要静脉使用胰岛素。", "ner": [[13, 15, "Drug"], [18, 19, "Test_items"], [81, 83, "Drug"], [98, 100, "Disease"], [112, 114, "Drug"], [127, 128, "Method"], [131, 133, "Drug"], [24, 25, "Method"], [51, 52, "Method"], [72, 73, "Method"]], "rel": [[112, 114, "Drug", 98, 100, "Disease", "Drug_Disease"], [127, 128, "Method", 131, 133, "Drug", "Method_Drug"]]}
{"idx": 2289, "sentence": "对于常规(非心脏)手术患者，基础联合餐时方案相比仅使用短效或速效胰岛素的方案血糖控制更佳、围手术期并发症更少。", "ner": [[30, 34, "Drug"], [38, 39, "Test_items"]], "rel": []}
{"idx": 2290, "sentence": "入院前已使用胰岛素者，手术日停用早餐前短效/速效胰岛素，继续使用基础胰岛素。", "ner": [[6, 8, "Drug"], [22, 26, "Drug"], [34, 36, "Drug"]], "rel": []}
{"idx": 2291, "sentence": "长效胰岛素类似物在手术当日早晨予常规剂量的5 0%~100%；中效胰岛素如为晚间注射，术前1天予常规剂量的75%，手术当日早晨予常规剂量的50%~75%；预混胰岛素在手术当日早晨应更换为基础胰岛素，剂量为预混胰岛素中的中效成分的50%~75%。", "ner": [[0, 7, "Drug"], [31, 35, "Drug"], [40, 41, "Method"], [77, 81, "Drug"], [95, 97, "Drug"], [102, 106, "Drug"]], "rel": [[40, 41, "Method", 31, 35, "Drug", "Method_Drug"]]}
{"idx": 2292, "sentence": " ", "ner": [], "rel": []}
{"idx": 2293, "sentence": "预混胰岛素：《预混胰岛素床应用专家共识(2016年版 )》 ", "ner": [[0, 4, "Drug"], [7, 11, "Drug"]], "rel": []}
{"idx": 2294, "sentence": "《中国2型糖尿病防治指南 (2013年版)》指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服降糖药联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素注射(基础+餐时岛素或每日3次预混胰岛素类似物)。", "ner": [[3, 7, "Disease"], [31, 33, "Drug"], [25, 28, "Frequency"], [35, 40, "Frequency"], [41, 45, "Drug"], [50, 52, "Drug"], [63, 65, "Drug"], [67, 71, "Drug"], [84, 85, "Test_items"], [86, 88, "Test_Value"], [101, 103, "Drug"], [104, 105, "Method"], [115, 118, "Frequency"], [119, 126, "Drug"], [112, 113, "Drug"]], "rel": [[25, 28, "Frequency", 31, 33, "Drug", "Frequency_Drug"], [35, 40, "Frequency", 41, 45, "Drug", "Frequency_Drug"], [104, 105, "Method", 101, 103, "Drug", "Method_Drug"], [115, 118, "Frequency", 119, 126, "Drug", "Frequency_Drug"]]}
{"idx": 2295, "sentence": "《预混胰岛素临床应用专家共识(2016年版)》是对2013年版的更新。", "ner": [[1, 5, "Drug"]], "rel": []}
{"idx": 2296, "sentence": " ", "ner": [], "rel": []}
{"idx": 2297, "sentence": "作用特点 ", "ner": [], "rel": []}
{"idx": 2298, "sentence": "目前国内临床应用的预混胰岛素包括预混人胰岛素和预混胰岛素类似物，详见表7。", "ner": [[9, 13, "Drug"], [16, 21, "Drug"], [23, 30, "Drug"]], "rel": []}
{"idx": 2299, "sentence": " ", "ner": [], "rel": []}
{"idx": 2300, "sentence": "临床用法 ", "ner": [], "rel": []}
{"idx": 2301, "sentence": "(1)适用人群 ", "ner": [], "rel": []}
{"idx": 2302, "sentence": "①每日1次方案：生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后H bA1c≥7.0%的患者。", "ner": [[8, 13, "Treatment"], [36, 41, "Test_items"], [42, 46, "Test_Value"], [1, 4, "Frequency"], [22, 23, "Method"]], "rel": []}
{"idx": 2303, "sentence": " ", "ner": [], "rel": []}
{"idx": 2304, "sentence": "②每日2次方案：新诊2型糖尿病患者，HbA1c≥9.0%同时合并明显临床症状；生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后HbA1c≥9.0% 的患者；口服降糖药物联合基础胰岛素治疗以后，HbA1c≥7%，而空腹血糖已达标的患者。", "ner": [[1, 4, "Frequency"], [10, 16, "Disease"], [18, 22, "Test_items"], [23, 27, "Test_Value"], [39, 44, "Treatment"], [67, 71, "Test_items"], [72, 76, "Test_Value"], [92, 94, "Drug"], [100, 104, "Test_items"], [105, 107, "Test_Value"], [110, 113, "Test_items"], [53, 54, "Method"], [82, 83, "Method"], [114, 116, "Test_Value"]], "rel": [[18, 22, "Test_items", 10, 16, "Disease", "Test_items_Disease"]]}
{"idx": 2305, "sentence": " ", "ner": [], "rel": []}
{"idx": 2306, "sentence": "③每日3次方案：预混胰岛素每日2次治疗后HbA1c≥7.0%的患者；血糖控制不达标，需要基础 +餐时胰岛素强化治疗，但不愿意接受该治疗方案的患者。", "ner": [[1, 4, "Frequency"], [8, 12, "Drug"], [13, 16, "Frequency"], [20, 24, "Test_items"], [25, 29, "Test_Value"], [34, 35, "Test_items"], [36, 40, "Test_Value"], [50, 52, "Drug"]], "rel": [[13, 16, "Frequency", 8, 12, "Drug", "Frequency_Drug"]]}
{"idx": 2307, "sentence": " ", "ner": [], "rel": []}
{"idx": 2308, "sentence": "④1-2-3次方案：生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后HbA1c ≥7.0%的患者。", "ner": [[10, 15, "Treatment"], [38, 42, "Test_items"], [44, 48, "Test_Value"], [24, 25, "Method"]], "rel": []}
{"idx": 2309, "sentence": " ", "ner": [], "rel": []}
{"idx": 2310, "sentence": "(2)使用方法 ", "ner": [], "rel": []}
{"idx": 2311, "sentence": "①每日1次方案：起始剂量一般为0.2单位/千克体重，晚餐前注射，根据个人情况作适当调整。", "ner": [[15, 24, "Amount"], [1, 4, "Frequency"], [29, 30, "Method"]], "rel": []}
{"idx": 2312, "sentence": "根据血糖监测情况调整用量，如H bA1c或空腹血糖仍不达标，可改为每日2次治疗方案。", "ner": [[2, 5, "Test_items"], [14, 19, "Test_items"], [21, 24, "Test_items"], [26, 28, "Test_Value"], [33, 36, "Frequency"]], "rel": []}
{"idx": 2313, "sentence": " ", "ner": [], "rel": []}
{"idx": 2314, "sentence": "②每日2次方案：对于新诊患者或预混胰岛素起始的患者，一般起始用量为0.2~0.4单位/千克体重或10~12单位/天，按1：1分配到早餐前和晚餐前；对于基础胰岛素联合口服药方案转预混胰岛素方案者，一般以基础胰岛素与预混胰岛素以1：1.3的比例进行剂量转换，按1：1分配到早餐前和晚餐前。", "ner": [[1, 4, "Frequency"], [15, 19, "Drug"], [33, 46, "Amount"], [48, 56, "Amount"], [77, 79, "Drug"], [88, 92, "Drug"], [102, 104, "Drug"], [106, 110, "Drug"], [82, 83, "Method"]], "rel": [[1, 4, "Frequency", 15, 19, "Drug", "Frequency_Drug"], [33, 46, "Amount", 15, 19, "Drug", "Amount_Drug"], [48, 56, "Amount", 15, 19, "Drug", "Amount_Drug"]]}
{"idx": 2315, "sentence": "临床医生应对根据患者具体情况决定预混胰岛素类别、日总剂量和早晚餐前剂量的分配比例。", "ner": [[16, 20, "Drug"]], "rel": []}
{"idx": 2316, "sentence": "不建议同时使用胰岛素促泌剂，但可继续使用二甲双胍或α-糖苷酶抑制剂，需视患者个体情况决定是否停用噻唑烷二酮类药物。", "ner": [[7, 12, "Drug"], [20, 23, "Drug"], [25, 32, "Drug"], [48, 55, "Drug"]], "rel": []}
{"idx": 2317, "sentence": "中预混胰岛素(赖朋胰岛素50、门冬胰岛素50)主要针对餐后血糖升高明显或者血糖波动较大的患者(如口服降糖药失效后，早餐后血糖≥13.5毫摩尔/升或早餐前后血糖波动≥4.4毫摩尔/升，以及饮食中碳水化合物比例较高的患者；若低预混人胰岛素每日2次治疗的患者餐后血糖≥11.1毫摩尔/升，临床医生可依据具体情况考虑等剂量改为低预混胰岛素类似物(赖脯胰岛素7 5/25、门冬胰岛素30)或中预混胰岛素类似物。", "ner": [[1, 5, "Drug"], [7, 11, "Drug"], [15, 19, "Drug"], [27, 30, "Test_items"], [37, 38, "Test_items"], [31, 34, "Test_Value"], [39, 42, "Test_Value"], [60, 61, "Test_items"], [77, 78, "Test_items"], [62, 71, "Test_Value"], [79, 80, "Test_Value"], [81, 89, "Test_Value"], [111, 116, "Drug"], [117, 120, "Frequency"], [126, 129, "Test_items"], [130, 139, "Test_Value"], [160, 167, "Drug"], [169, 173, "Drug"], [181, 185, "Drug"], [191, 198, "Drug"], [48, 49, "Method"]], "rel": [[117, 120, "Frequency", 111, 116, "Drug", "Frequency_Drug"]]}
{"idx": 2318, "sentence": " ", "ner": [], "rel": []}
{"idx": 2319, "sentence": "④1-2-3次方案：使用预混胰岛素类似物，餐后血糖升高明显者选择中预混制剂。每日1次起始剂量一般为10~12单位，晚餐前注射，根据早餐前血糖调整剂量；如HbA1c或餐前血糖不达标，则早餐前增加3~6单位，根据晚餐前和空腹血糖调整早餐前和晚餐前剂量；如HbA1c或午餐后血糖仍不达标，则午餐前加用3位或将早餐前剂量按1：1分配到早、午餐前，根据午餐后或晚餐血糖调整午餐前剂量。预混胰岛素类做物每日1次治疗时可根据具体情况调整口服降糖药；当调整为每日2次或3次时，不建议同时使用胰岛素促泌剂，可继续使用二甲双胍或α-糖苷酶抑制剂，视患者个体情况决定是否停用噻唑烷二酮类药物。", "ner": [[12, 19, "Drug"], [21, 24, "Test_items"], [25, 28, "Test_Value"], [38, 41, "Frequency"], [49, 55, "Amount"], [60, 61, "Method"], [68, 69, "Test_items"], [76, 80, "Test_items"], [82, 85, "Test_items"], [86, 88, "Test_Value"], [108, 111, "Test_items"], [125, 129, "Test_items"], [132, 135, "Test_items"], [137, 139, "Test_Value"], [177, 178, "Test_items"], [221, 227, "Frequency"], [237, 242, "Drug"], [249, 252, "Drug"], [254, 261, "Drug"], [276, 283, "Drug"], [195, 198, "Frequency"], [187, 194, "Drug"]], "rel": [[195, 198, "Frequency", 187, 194, "Drug", "Frequency_Drug"]]}
{"idx": 2320, "sentence": " ", "ner": [], "rel": []}
{"idx": 2321, "sentence": "③每日3次方案：建议使用预混胰岛素类似物。当预混胰岛素每日2次转为3次时，早晚餐前可等剂量转换，午餐前加2-4单位或每天胰岛素总量的10%，并可能需要减少早餐前的剂量2~4单位；当替代基础+餐时方案进行强化治疗时，医生需要根据具体情况制定方案。", "ner": [[12, 19, "Drug"], [1, 4, "Frequency"], [22, 26, "Drug"], [27, 30, "Frequency"], [60, 62, "Drug"], [52, 56, "Amount"], [83, 87, "Amount"]], "rel": [[1, 4, "Frequency", 12, 19, "Drug", "Frequency_Drug"], [27, 30, "Frequency", 22, 26, "Drug", "Frequency_Drug"], [52, 56, "Amount", 60, 62, "Drug", "Amount_Drug"], [83, 87, "Amount", 60, 62, "Drug", "Amount_Drug"]]}
{"idx": 2322, "sentence": "若低预混胰岛素每2次治疗，HbA1c≥7.0%，早餐后血糖<10.0毫摩尔/升，可考虑调整为低预混胰岛素类似物每日3次；若早餐后血糖≥10.0毫摩尔/升，则可考虑调整为中预混胰岛素类似物每日3次治疗；中预混胰岛素类物每日3次治疗者，如餐后血糖控制好而空腹血糖>6毫摩尔/升，可考虑将晚餐前调整为低预混胰岛素类似物。", "ner": [[2, 6, "Drug"], [13, 17, "Test_items"], [18, 22, "Test_Value"], [25, 28, "Test_items"], [29, 38, "Test_Value"], [47, 54, "Drug"], [55, 58, "Frequency"], [62, 65, "Test_items"], [66, 75, "Test_Value"], [85, 92, "Drug"], [93, 96, "Frequency"], [101, 107, "Drug"], [108, 111, "Frequency"], [117, 120, "Test_items"], [125, 128, "Test_items"], [129, 135, "Test_Value"], [148, 155, "Drug"]], "rel": [[55, 58, "Frequency", 47, 54, "Drug", "Frequency_Drug"], [93, 96, "Frequency", 85, 92, "Drug", "Frequency_Drug"], [108, 111, "Frequency", 101, 107, "Drug", "Frequency_Drug"]]}
{"idx": 2323, "sentence": " ", "ner": [], "rel": []}
{"idx": 2324, "sentence": "儿童青少年2型糖尿病诊治中国专家共识 ", "ner": [[5, 9, "Disease"]], "rel": []}
{"idx": 2325, "sentence": "前言  ", "ner": [], "rel": []}
{"idx": 2326, "sentence": "儿童青少年肥胖已成为全球性的严重公共卫生问题，随之而来的是儿童青少年2型糖尿病(type 2 diabetes mellitus)发病率的急剧上升。", "ner": [[0, 6, "Disease"], [34, 64, "Disease"]], "rel": []}
{"idx": 2327, "sentence": "据2015年国际糖尿病联盟报道，全球糖尿病总数及经济支出逐年攀升，发展中国家尤甚，而中国上升速度则位居全球第一。", "ner": [[8, 10, "Disease"], [18, 20, "Disease"]], "rel": []}
{"idx": 2328, "sentence": "儿童青少年2型糖尿病既不同于成人2型糖尿病，也不同于儿童青少年1型糖尿病(type 1 diubetes mellitus)，有其特征：胰岛β细胞功能快速衰竭，快速出现并发症并发展迅速。", "ner": [[5, 9, "Disease"], [16, 20, "Disease"], [31, 61, "Disease"], [68, 78, "Pathogenesis"]], "rel": [[68, 78, "Pathogenesis", 31, 61, "Disease", "Pathogenesis_Disease"]]}
{"idx": 2329, "sentence": "由于儿童青少年肥胖日益增多，临床表现的重叠，区分1型糖尿病或2型糖尿病变得越来越困难，同时全国各地儿童青少年2型糖尿病的发病特征、诊疗经验及统计数据各有不同，儿童青少年2型糖尿病诊治、管理面临众多挑战。", "ner": [[24, 28, "Disease"], [30, 34, "Disease"], [54, 58, "Disease"], [84, 88, "Disease"], [2, 8, "Disease"]], "rel": []}
{"idx": 2330, "sentence": "为进一步规范中国儿童青少年2型糖尿病的诊断、分型，治疗、随访，并发症和合并症的评估及治疗，由中华医学会儿科学分会内分泌遗传代谢学组组织专家讨论，并参考国内外的最新指南，包括美国糖尿病协会(American Diabetes Association)指南，美国儿科协会(American Academy of Pediatries)指南，国际儿童青少年糖尿病协会(International Society for Pediatric and Adolescent Diabetes)指南，美国临床内分泌协会(American Association of Clinical Endocrinolo gists) 指南，加拿大糖尿病协会(Canadian Diabetes Association)指南，中华医学会糖尿病学分会指南等，同时结合国内外流行病学调查、临床研究成果，制订如下共识。", "ner": [[13, 17, "Disease"], [88, 90, "Disease"], [175, 177, "Disease"], [312, 314, "Disease"], [356, 358, "Disease"]], "rel": []}
{"idx": 2331, "sentence": " ", "ner": [], "rel": []}
{"idx": 2332, "sentence": "【2型糖尿病定义和诊断】 ", "ner": [[1, 5, "Disease"]], "rel": []}
{"idx": 2333, "sentence": "2型糖尿病是由于胰岛素抵抗，引起胰岛素分泌相对不足导致血糖升高，往往合并其他代谢异常，由于后期β细胞功能衰竭，最终也可导致胰岛素分泌绝对不足。除了高血糖外，还可表现出脂代谢异常，高血压，多囊卵巢综合征(PCOS)，脂肪肝等。2型糖尿病的胰岛素分泌随着疾病状态和病程的不同差异较大，可以是糖负荷高峰延迟，也可以是处于完全的低分泌状态。", "ner": [[0, 4, "Disease"], [112, 116, "Disease"], [73, 75, "Disease"], [83, 87, "Disease"], [89, 91, "Disease"], [93, 105, "Disease"], [107, 109, "Disease"], [8, 12, "Pathogenesis"], [16, 24, "Pathogenesis"], [38, 41, "Symptom"], [45, 53, "Pathogenesis"], [61, 69, "Pathogenesis"], [143, 149, "Symptom"], [157, 164, "Symptom"], [95, 96, "Anatomy"], [109, 109, "Anatomy"], [27, 28, "Test_items"], [29, 30, "Test_Value"]], "rel": [[8, 12, "Pathogenesis", 0, 4, "Disease", "Pathogenesis_Disease"], [16, 24, "Pathogenesis", 0, 4, "Disease", "Pathogenesis_Disease"], [45, 53, "Pathogenesis", 0, 4, "Disease", "Pathogenesis_Disease"], [61, 69, "Pathogenesis", 0, 4, "Disease", "Pathogenesis_Disease"], [38, 41, "Symptom", 0, 4, "Disease", "Symptom_Disease"], [27, 28, "Test_items", 0, 4, "Disease", "Test_items_Disease"], [143, 149, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [157, 164, "Symptom", 112, 116, "Disease", "Symptom_Disease"], [95, 96, "Anatomy", 93, 105, "Disease", "Anatomy_Disease"], [109, 109, "Anatomy", 107, 109, "Disease", "Anatomy_Disease"]]}
{"idx": 2334, "sentence": "有症状的成年患者在诊断时胰岛素分泌量已经缩减50%左右，而青少年患者胰岛素分泌功能的丧失可能更为迅速。", "ner": [[34, 43, "Pathogenesis"]], "rel": []}
{"idx": 2335, "sentence": " ", "ner": [], "rel": []}
{"idx": 2336, "sentence": "2型糖尿病的诊断分2步。首先确定是否符合糖尿病的诊断标准，然后再分型。", "ner": [[0, 4, "Disease"], [20, 22, "Disease"]], "rel": []}
{"idx": 2337, "sentence": " ", "ner": [], "rel": []}
{"idx": 2338, "sentence": "第一步：糖尿病的诊断。糖尿病的诊断基于症状和血浆葡萄糖检测。目前我们仍然依据美国糖尿病协会和国际儿童青少年糖尿病协会共同制定的诊断标准，符合该标准以下4条中的1条即可诊断糖尿病。(1)空腹血糖≥7.0mmol/L(126mg/dl)，(2)糖耐量试验(用1.75g/kg无水葡萄糖溶于水作为糖负荷，最大不超过75g)2h血糖≥11.1mmol/L(200mg/dl)，(3)有糖尿病的三多一少症状且随机血糖≥11.1mmol/L(200mg/dl)，(4)糖化血红蛋白(HbA1c) >6.5%。", "ner": [[4, 6, "Disease"], [11, 13, "Disease"], [40, 42, "Disease"], [53, 55, "Disease"], [85, 87, "Disease"], [22, 28, "Test_items"], [92, 95, "Test_items"], [120, 122, "Test_items"], [158, 161, "Test_items"], [199, 202, "Test_items"], [228, 240, "Test_items"], [96, 105, "Test_Value"], [107, 114, "Test_Value"], [162, 172, "Test_Value"], [174, 181, "Test_Value"], [203, 213, "Test_Value"], [215, 222, "Test_Value"], [242, 246, "Test_Value"], [188, 190, "Disease"]], "rel": [[22, 28, "Test_items", 11, 13, "Disease", "Test_items_Disease"], [199, 202, "Test_items", 188, 190, "Disease", "Test_items_Disease"], [228, 240, "Test_items", 188, 190, "Disease", "Test_items_Disease"]]}
{"idx": 2339, "sentence": "必须注意：作为诊断的HbA1c检测应该采用美国HbA1c标准化计划组织(NGSP)或糖尿病控制和并发症研究(DCCT)认证的方法进行。", "ner": [[10, 14, "Test_items"], [23, 27, "Test_items"], [42, 44, "Disease"]], "rel": [[10, 14, "Test_items", 42, 44, "Disease", "Test_items_Disease"], [23, 27, "Test_items", 42, 44, "Disease", "Test_items_Disease"]]}
{"idx": 2340, "sentence": "后者使用的高压液相离子层析法(HPLC)是国际公认的金标法。", "ner": [], "rel": []}
{"idx": 2341, "sentence": "单纯以HbA1c诊断的人群和以空腹血糖或糖耐量诊断的人群并不完全重叠，在儿童中应用该标准也仍有争议，因此，单独以HbA1c诊断仍需慎重。", "ner": [[3, 7, "Test_items"], [56, 60, "Test_items"], [15, 18, "Test_items"], [20, 22, "Test_items"]], "rel": []}
{"idx": 2342, "sentence": "以上任何一种检测方法，如果没有糖尿病典型症状，必须于次日再加以复查才能确诊。", "ner": [[15, 17, "Disease"]], "rel": []}
{"idx": 2343, "sentence": "此外，急性感染、创伤或其他应激情况下可出现暂时性血糖增高，若没有明确的糖尿病症状，也不能以此血糖值诊断，应在应激消除后复查。", "ner": [[24, 25, "Test_items"], [46, 48, "Test_items"], [35, 37, "Disease"], [26, 27, "Test_Value"], [3, 6, "Disease"], [8, 9, "Disease"]], "rel": []}
{"idx": 2344, "sentence": "空腹血糖受损和糖耐量受损为糖尿病前期。", "ner": [[0, 3, "Test_items"], [7, 9, "Test_items"], [4, 5, "Test_Value"], [10, 11, "Test_Value"], [13, 15, "Disease"]], "rel": [[0, 3, "Test_items", 13, 15, "Disease", "Test_items_Disease"], [7, 9, "Test_items", 13, 15, "Disease", "Test_items_Disease"]]}
{"idx": 2345, "sentence": "糖尿病诊断路径见图1。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2346, "sentence": " ", "ner": [], "rel": []}
{"idx": 2347, "sentence": "第二步：糖尿病分型。儿童糖尿病中1型糖尿病占89.6%，2型糖尿病仅占7.4%，因此，儿童在糖尿病分型时，首先考虑为1型糖尿病，有如下线索者提示为2型糖尿病：明确的2型糖尿病家族史、肥胖、起病缓慢、症状不明显、发病年龄较大、无需使用胰岛素治疗，或存在和胰岛素抵抗相关的表现，如黑棘皮病、高血压、血脂异常、PCOS等。", "ner": [[4, 6, "Disease"], [12, 14, "Disease"], [16, 20, "Disease"], [28, 32, "Disease"], [46, 48, "Disease"], [58, 62, "Disease"], [73, 77, "Disease"], [82, 86, "Disease"], [91, 92, "Disease"], [138, 141, "Disease"], [152, 155, "Disease"], [116, 118, "Drug"], [126, 130, "Pathogenesis"], [143, 145, "Disease"], [147, 148, "Test_items"], [149, 150, "Test_Value"]], "rel": [[126, 130, "Pathogenesis", 73, 77, "Disease", "Pathogenesis_Disease"], [147, 148, "Test_items", 73, 77, "Disease", "Test_items_Disease"]]}
{"idx": 2348, "sentence": "1型糖尿病和2型糖尿病间的鉴别可参考表1。", "ner": [[0, 4, "Disease"], [6, 10, "Disease"]], "rel": []}
{"idx": 2349, "sentence": " ", "ner": [], "rel": []}
{"idx": 2350, "sentence": "随着基因检测技术的提高，单基因糖尿病的诊断率日益增加。典型的单基因糖尿病有：青少年发病的成年型糖尿病(maturity-onset diabetes of the young，MODY)，线粒体基因突变糖尿病(maternally inherited diabetes and deafness，母系遗传的线粒体基因突变伴有多系统的异常)，新生儿糖尿病(neonatal diabetes mellitus)，A型胰岛素抵抗综合征等等。基因检测有助于明确诊断。所有6月龄前发病的糖尿病均应行基因检测。儿童或青年期诊断者，如果不具备1型糖尿病或2型糖尿病的特点，且连续多代有糖尿病(提示常染色体显性遗传模式)，则应考虑MODY基因检测。", "ner": [[12, 17, "Disease"], [30, 35, "Disease"], [44, 92, "Disease"], [94, 146, "Disease"], [170, 203, "Disease"], [205, 214, "Disease"], [239, 241, "Disease"], [265, 269, "Disease"], [271, 275, "Disease"], [286, 288, "Disease"], [308, 315, "Test"], [218, 221, "Test"], [245, 248, "Test"]], "rel": [[245, 248, "Test", 239, 241, "Disease", "Test_Disease"], [308, 315, "Test", 286, 288, "Disease", "Test_Disease"]]}
{"idx": 2351, "sentence": "如青少年无肥胖而出现严重胰岛素抵抗，要考虑胰岛素受体基因检测。", "ner": [[5, 6, "Disease"], [21, 29, "Test"], [12, 16, "Pathogenesis"]], "rel": []}
{"idx": 2352, "sentence": " ", "ner": [], "rel": []}
{"idx": 2353, "sentence": "值得注意的是，部分患儿刚开始诊断时可能难以明确分型，此时要引导家长和患儿把重点放在控制血糖上，暂时不要对分型过于焦虑，而后可通过治疗反应和追踪观察重新评估分型。", "ner": [[43, 44, "Test_items"]], "rel": []}
{"idx": 2354, "sentence": "【2型糖尿病的治疗】 ", "ner": [[1, 5, "Disease"]], "rel": []}
{"idx": 2355, "sentence": "一、治疗目的 ", "ner": [], "rel": []}
{"idx": 2356, "sentence": "1.保持血糖在目标范围。", "ner": [[4, 5, "Test_items"]], "rel": []}
{"idx": 2357, "sentence": " ", "ner": [], "rel": []}
{"idx": 2358, "sentence": "2.保证患儿正常生长发育。", "ner": [], "rel": []}
{"idx": 2359, "sentence": " ", "ner": [], "rel": []}
{"idx": 2360, "sentence": "3.预防及控制各种合并症。", "ner": [], "rel": []}
{"idx": 2361, "sentence": " ", "ner": [], "rel": []}
{"idx": 2362, "sentence": "二、治疗策略 ", "ner": [], "rel": []}
{"idx": 2363, "sentence": "1.生活方式的干预：生活方式干预是2型糖尿病的首要治疗手段，要注重全家的参与，同时还应包括营养师，心理医生，社会工作者和运动生理学家等在内的多学科教育和管理。有效的自我管理教育和自我管理支持是近年来糖尿病教育的重点，可以延缓和预防糖尿病并发症的发生。包括参与各种培训计划，心理咨询等，应作为评估、监测和治疗的一部分。患儿对疾病的态度、对治疗和预后的期望值、情感/情绪状态、与糖尿病相关的生活质量、资源(经济、社会和情感方面)以及精神病史等均与糖尿病预后密切相关。对于糖尿病前期和高危患儿，更应强调生活方式干预以有效降低发病率。", "ner": [[17, 21, "Disease"], [99, 101, "Disease"], [115, 120, "Disease"], [187, 189, "Disease"], [214, 216, "Disease"], [221, 223, "Disease"], [233, 235, "Disease"], [2, 8, "Treatment"], [10, 15, "Treatment"], [79, 87, "Treatment"], [89, 94, "Treatment"], [127, 134, "Treatment"], [136, 139, "Treatment"], [248, 253, "Treatment"]], "rel": [[2, 8, "Treatment", 17, 21, "Disease", "Treatment_Disease"], [10, 15, "Treatment", 17, 21, "Disease", "Treatment_Disease"], [79, 87, "Treatment", 99, 101, "Disease", "Treatment_Disease"], [89, 94, "Treatment", 99, 101, "Disease", "Treatment_Disease"], [79, 87, "Treatment", 115, 120, "Disease", "Treatment_Disease"], [89, 94, "Treatment", 115, 120, "Disease", "Treatment_Disease"], [248, 253, "Treatment", 233, 235, "Disease", "Treatment_Disease"]]}
{"idx": 2364, "sentence": "2.饮食疗法：糖尿病前期及糖尿病患者应接受个体化的医学营养治疗(MNT)以达到治疗目标。MNT包括对患者进行个体化营养评估诊断，制定相应的营养干预计划，以便在保证儿童青少年正常生长发育的前提下，纠正已发生的代谢紊乱，减轻胰岛β细胞负荷，从而延缓并减轻糖尿病及并发症的发生和发展。", "ner": [[7, 9, "Disease"], [13, 15, "Disease"], [125, 127, "Disease"], [2, 5, "Treatment"], [25, 35, "Treatment"], [44, 46, "Treatment"], [110, 116, "Pathogenesis"]], "rel": [[2, 5, "Treatment", 7, 9, "Disease", "Treatment_Disease"], [25, 35, "Treatment", 7, 9, "Disease", "Treatment_Disease"], [2, 5, "Treatment", 13, 15, "Disease", "Treatment_Disease"], [25, 35, "Treatment", 13, 15, "Disease", "Treatment_Disease"], [110, 116, "Pathogenesis", 125, 127, "Disease", "Pathogenesis_Disease"]]}
{"idx": 2365, "sentence": "MNT最好能由熟悉糖尿病MNT的注册营养师指导，制定个体化能量平衡计划。", "ner": [[0, 2, "Treatment"], [9, 14, "Treatment"]], "rel": []}
{"idx": 2366, "sentence": " ", "ner": [], "rel": []}
{"idx": 2367, "sentence": "据美国儿科协会2型糖尿病的指南，6~12岁儿童每日热量需控制在3765.6-5020.8kJ(900-1200kcal)为宜，13~18岁则需要每日5020.8kJ(1200kal)以上。目前糖尿病患者并没有一个完全相同、理想的碳水化合物、蛋白质和脂肪的热量比例；所以宏量营养素的分配应根据总热量摄入和代谢控制目标进行个体化评估。许多饮食方式利于管理2型糖尿病和糖尿病前期，包括地中海饮食、高血压控制饮食(dietary approaches to stop hypertension)和素食。", "ner": [[7, 11, "Disease"], [96, 98, "Disease"], [175, 179, "Disease"], [181, 183, "Disease"], [189, 193, "Treatment"], [195, 242, "Treatment"], [244, 245, "Treatment"]], "rel": [[189, 193, "Treatment", 175, 179, "Disease", "Treatment_Disease"], [195, 242, "Treatment", 175, 179, "Disease", "Treatment_Disease"], [244, 245, "Treatment", 175, 179, "Disease", "Treatment_Disease"], [189, 193, "Treatment", 181, 183, "Disease", "Treatment_Disease"], [195, 242, "Treatment", 181, 183, "Disease", "Treatment_Disease"], [244, 245, "Treatment", 181, 183, "Disease", "Treatment_Disease"]]}
{"idx": 2368, "sentence": "血糖控制达标的关键仍然是监测碳水化合物的摄入量。推荐每日碳水化合物供能比45%~60%，如碳水化合物的来源为低血糖生成指数(GI)食物，其供能比可达60%。建议碳水化合物来自于低GI，富含膳食纤维的食物，如全麦(全谷)粉、荞麦、粉丝、黑米、粟米等，以及蔬菜、水果、豆类和奶制品。整体应符合中国居民膳食推荐摄入量，应避免含糖饮料的摄入，减少含蔗糖食物。同时，很多研究引入血糖负荷(GL)这一指标。GL是食物GI与其碳水化合物含量的乘积，克服了单纯使用血糖指数或碳水化合物含量评估的不足。研究表明高GL饮食明显增加了2型糖尿病的发病率，同时肥胖成人中，GL与HbA1c呈正相关。", "ner": [[0, 1, "Test_items"], [2, 5, "Test_Value"], [157, 165, "Treatment"], [167, 173, "Treatment"], [256, 260, "Disease"], [268, 269, "Disease"], [277, 281, "Test_items"]], "rel": [[277, 281, "Test_items", 268, 269, "Disease", "Test_items_Disease"]]}
{"idx": 2369, "sentence": "膳食总脂肪的摄入以每天占总能量的25%-30%为宜。", "ner": [], "rel": []}
{"idx": 2370, "sentence": "同时应增加植物脂肪占总脂肪摄入的比例，限制饱和脂肪酸与反式脂肪酸的摄入量，饱和脂肪酸的摄入量不应超过供能比的10%。", "ner": [], "rel": []}
{"idx": 2371, "sentence": "富含单不饱和脂肪酸的地中海式饮食结构可能对血糖控制和降低心血管危险因素有益，推荐富含长链ω-3脂肪酸的食物(如富含脂肪的鱼类、坚果、种子)，但目前证据并不支持补充ω-3制剂。", "ner": [[0, 17, "Treatment"], [21, 22, "Test_items"], [40, 68, "Treatment"]], "rel": []}
{"idx": 2372, "sentence": "肾功能正常的糖尿病患者，推荐蛋白质摄入量占总能量的15%~20%。植物来源蛋白质，尤其是大豆蛋白更有助于降低血脂水平。高蛋白膳食在短期内有助于减轻体重，但不建议超重或肥胖人群长期食用。乳清蛋白有助胰岛素分泌，改善糖代谢，并在短期内减轻体重。2型糖尿病患者摄入蛋白质能增加胰岛素应答，但不升高血糖浓度。", "ner": [[6, 8, "Disease"], [120, 124, "Disease"], [80, 81, "Disease"], [83, 84, "Disease"], [145, 146, "Test_items"]], "rel": []}
{"idx": 2373, "sentence": "所以低血时不应用含蛋白质较高的碳水化合物。", "ner": [], "rel": []}
{"idx": 2374, "sentence": "膳食纤维可改善餐后血糖代谢和长期糖尿病控制，谷物膳食纤维还可增强胰岛素敏感性。", "ner": [[16, 18, "Disease"], [7, 10, "Test_items"], [0, 3, "Treatment"]], "rel": [[7, 10, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [0, 3, "Treatment", 16, 18, "Disease", "Treatment_Disease"]]}
{"idx": 2375, "sentence": "推荐糖尿病患者的膳食纤维摄入量为10-14g/4184kJ(1000kcal)。", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 2376, "sentence": "糖尿病患者如无维生素缺乏，常规大量补充维生素并无益处，因此不作推荐。", "ner": [[0, 2, "Disease"], [7, 9, "Test_items"], [10, 11, "Test_Value"]], "rel": []}
{"idx": 2377, "sentence": "3.运动：运动也是一个重要治疗手段。", "ner": [[2, 3, "Treatment"], [5, 6, "Treatment"]], "rel": []}
{"idx": 2378, "sentence": "要注意调动儿童的兴趣和积极性，循序渐进，更要长期坚持。需注意若有心肺功能异常或严重高血压者或严重高血糖代谢不稳定者需根据病情在专家指导下运动，或避免剧烈运动。", "ner": [[68, 69, "Treatment"], [32, 37, "Disease"], [41, 43, "Disease"], [48, 55, "Disease"], [39, 40, "Level"], [46, 47, "Level"], [32, 32, "Anatomy"], [33, 33, "Anatomy"]], "rel": [[32, 32, "Anatomy", 32, 37, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 32, 37, "Disease", "Anatomy_Disease"]]}
{"idx": 2379, "sentence": "运动方式：多采用一些既增加能量消耗又容易坚持的有氧运动项目，也可采用力量运动和柔韧性训练相互结合。", "ner": [[0, 1, "Treatment"], [23, 26, "Treatment"], [34, 37, "Treatment"], [39, 43, "Treatment"]], "rel": []}
{"idx": 2380, "sentence": "有氧运动如快走、慢跑、上下楼梯、跳绳、打球、游泳、骑自行车、登山等。", "ner": [[0, 3, "Treatment"]], "rel": []}
{"idx": 2381, "sentence": "力量运动可采用哑铃、杠铃以及其他的沙袋、器械等进行；柔韧性训练包括各种伸展性活动。", "ner": [[0, 3, "Treatment"], [26, 30, "Treatment"]], "rel": []}
{"idx": 2382, "sentence": "运动强度：可以用脉搏来衡量。", "ner": [], "rel": []}
{"idx": 2383, "sentence": "有氧运动时脉博应达到最大心率的60%-75%，可参照公式：脉搏=(220-年龄)x(60%~75%)。", "ner": [], "rel": []}
{"idx": 2384, "sentence": " ", "ner": [], "rel": []}
{"idx": 2385, "sentence": "运动时间：坚持每天锻炼至少30min，最好达到每天60min的中等强度运动。", "ner": [[5, 17, "Treatment"], [23, 36, "Treatment"]], "rel": []}
{"idx": 2386, "sentence": "每周至少完成中等强度运动5d才可起到控制体重的作用。", "ner": [[6, 13, "Treatment"]], "rel": []}
{"idx": 2387, "sentence": " ", "ner": [], "rel": []}
{"idx": 2388, "sentence": "4.药物治疗：尽管成人2型糖尿病有多种药物可供选择，但在儿童青少年，世界上大部分地区仅批准二甲双胍和胰岛素应用。", "ner": [[11, 15, "Disease"], [45, 48, "Drug"], [50, 52, "Drug"]], "rel": [[45, 48, "Drug", 11, 15, "Disease", "Drug_Disease"], [50, 52, "Drug", 11, 15, "Disease", "Drug_Disease"]]}
{"idx": 2389, "sentence": "(1)二甲双胍。", "ner": [[3, 6, "Drug"]], "rel": []}
{"idx": 2390, "sentence": "指征：如果患儿代谢尚稳定(HbA1c<9%及随机血糖<13.9mmol/L且无症状)，应以二甲双胍开始治疗。剂量：初始剂量500mg/d，x7d，接下的3-4周内每周增加500mg/d，最大不超过2000mg/d。疗效：现认为长期应用二甲双胍后，HbA1c可有1%~2%的降低，也可一定程度上降低体重。但TODAY(treatment options for type 2 diabeles in adolescents and youth)研究表明，仅一半的2型糖尿病患儿通过二甲双胍单药治疗达到持久血糖控制，且其有效性可持续<18个月。注意事项：二甲双胍单用基本无低血糖的风险，产生乳酸酸中毒的风险也极低。可有胃肠道副作用，包括一过性的腹痛，腹泻，恶心等，基本上都可耐受，如严重可暂时停药，采用缓释制剂也可减少胃肠道反应。但在肝肾功能不全，如肝酶升高3倍以上，严重感染，重大手术，或放射检查使用碘化造影剂时禁用。此外长期使用二甲双胍可能与维生素B12缺乏有关。", "ner": [[45, 48, "Drug"], [117, 120, "Drug"], [239, 242, "Drug"], [275, 278, "Drug"], [414, 417, "Drug"], [13, 17, "Test_items"], [22, 25, "Test_items"], [123, 127, "Test_items"], [251, 252, "Test_items"], [373, 374, "Test_items"], [18, 20, "Test_Value"], [26, 36, "Test_Value"], [61, 67, "Amount"], [83, 91, "Amount"], [95, 105, "Amount"], [69, 71, "Duration"], [76, 80, "Duration"], [130, 137, "Test_Value"], [375, 380, "Test_Value"], [230, 234, "Disease"], [284, 286, "ADE"], [293, 297, "ADE"], [307, 312, "ADE"], [316, 321, "ADE"], [323, 324, "ADE"], [326, 327, "ADE"], [357, 361, "ADE"], [365, 370, "Disease"], [365, 365, "Anatomy"], [366, 366, "Anatomy"], [384, 385, "Disease"], [382, 383, "Level"], [393, 396, "Test"], [421, 428, "ADE"]], "rel": [[239, 242, "Drug", 230, 234, "Disease", "Drug_Disease"], [293, 297, "ADE", 275, 278, "Drug", "ADE_Drug"], [307, 312, "ADE", 275, 278, "Drug", "ADE_Drug"], [316, 321, "ADE", 275, 278, "Drug", "ADE_Drug"], [323, 324, "ADE", 275, 278, "Drug", "ADE_Drug"], [326, 327, "ADE", 275, 278, "Drug", "ADE_Drug"], [357, 361, "ADE", 275, 278, "Drug", "ADE_Drug"], [421, 428, "ADE", 414, 417, "Drug", "ADE_Drug"], [251, 252, "Test_items", 230, 234, "Disease", "Test_items_Disease"], [373, 374, "Test_items", 365, 370, "Disease", "Test_items_Disease"], [365, 365, "Anatomy", 365, 370, "Disease", "Anatomy_Disease"], [366, 366, "Anatomy", 365, 370, "Disease", "Anatomy_Disease"]]}
{"idx": 2391, "sentence": "在用二甲双胍治疗的患者，尤其伴有贫血或周围神经病变的患者，应该考虑定期监测维生素B12的水平。", "ner": [[2, 5, "Drug"], [37, 42, "Test_items"], [16, 17, "Disease"], [19, 24, "Disease"]], "rel": []}
{"idx": 2392, "sentence": "(2)胰岛素。", "ner": [[3, 5, "Drug"]], "rel": []}
{"idx": 2393, "sentence": "胰岛素可快速改善代谢异常并能保护胰岛β细胞功能。用于随机血糖>13.9mmol/L和(或) bA1c>9%，糖尿病酮症酸中毒或代谢不稳定的患儿。剂量：1天1次中性鱼精蛋白锌胰岛素或基础胰岛素(0.25~0.5U/kg起)往往已能有效控制代谢异常。如果患儿代谢不稳定但无酸中毒，可联用二甲双胍。如果二甲双胍和基础量胰岛素(最高至1.2U/kg)联用仍不能达到目标，需要逐渐加用餐前胰岛素，直到血糖正常。病情稳定后胰岛素每次减量30%-50%，过渡到单用二甲双胍，过渡期往往需要2~6周。疗效：胰岛素控制血糖起效快，疗效肯定。但据统计，90%的青少年2型糖尿病患儿在起始治疗时单用二甲双胍即可控制病情。注意事项：如果经过以上治疗，血糖仍然不能控制，要重新考虑2型糖尿病的诊断或者加强生活方式的改变。胰岛素的不良反应主要是低血糖，也要注意体重增加的风险。", "ner": [[0, 2, "Drug"], [79, 88, "Drug"], [90, 94, "Drug"], [141, 144, "Drug"], [148, 151, "Drug"], [153, 158, "Drug"], [187, 191, "Drug"], [205, 207, "Drug"], [225, 228, "Drug"], [245, 247, "Drug"], [288, 291, "Drug"], [347, 349, "Drug"], [8, 11, "Disease"], [26, 29, "Test_items"], [46, 49, "Test_items"], [195, 196, "Test_items"], [250, 251, "Test_items"], [313, 314, "Test_items"], [30, 40, "Test_Value"], [50, 52, "Test_Value"], [197, 198, "Test_Value"], [317, 320, "Test_Value"], [54, 61, "Disease"], [63, 67, "Disease"], [118, 121, "Disease"], [134, 136, "Disease"], [273, 277, "Disease"], [327, 331, "Disease"], [75, 78, "Frequency"], [96, 108, "Amount"], [160, 169, "Amount"], [210, 218, "Amount"], [339, 345, "Treatment"], [358, 360, "ADE"], [366, 369, "ADE"]], "rel": [[0, 2, "Drug", 8, 11, "Disease", "Drug_Disease"], [79, 88, "Drug", 118, 121, "Disease", "Drug_Disease"], [75, 78, "Frequency", 79, 88, "Drug", "Frequency_Drug"], [90, 94, "Drug", 118, 121, "Disease", "Drug_Disease"], [96, 108, "Amount", 90, 94, "Drug", "Amount_Drug"], [160, 169, "Amount", 153, 158, "Drug", "Amount_Drug"], [210, 218, "Amount", 205, 207, "Drug", "Amount_Drug"], [288, 291, "Drug", 273, 277, "Disease", "Drug_Disease"], [358, 360, "ADE", 347, 349, "Drug", "ADE_Drug"], [366, 369, "ADE", 347, 349, "Drug", "ADE_Drug"], [26, 29, "Test_items", 54, 61, "Disease", "Test_items_Disease"], [26, 29, "Test_items", 63, 67, "Disease", "Test_items_Disease"], [46, 49, "Test_items", 54, 61, "Disease", "Test_items_Disease"], [46, 49, "Test_items", 63, 67, "Disease", "Test_items_Disease"], [313, 314, "Test_items", 327, 331, "Disease", "Test_items_Disease"], [339, 345, "Treatment", 327, 331, "Disease", "Treatment_Disease"]]}
{"idx": 2394, "sentence": "值得注意的是，由于2型糖尿病是一种进行性疾病，大多数患者最终仍需要胰岛素治疗。", "ner": [[33, 35, "Drug"], [9, 13, "Disease"]], "rel": [[33, 35, "Drug", 9, 13, "Disease", "Drug_Disease"]]}
{"idx": 2395, "sentence": "除此以外，其他药物包括DPP-4抑制剂，GLP-受体激动剂和SGLT2抑制剂等尽管已用于成人，但尚未被FDA批准用于儿童，暂时不推荐应用。", "ner": [[11, 18, "Drug"], [20, 28, "Drug"], [30, 37, "Drug"]], "rel": []}
{"idx": 2396, "sentence": "5.血糖监测及控制目标：2型糖尿病自身血糖监测频次对血糖控制的影响虽弱于1型糖尿病，但是仍不可缺少。自身血糖监测的频次应基于血糖控制情况和自身条件个体化，血糖控制理想时，1周数次餐前餐后血糖测量即可，而控制不理想时，应增加测量频次，如每日三餐前后加凌晨的血糖。如果使用胰岛素，一定要注意无症状低血糖的检测。糖化血红蛋白一般每3个月测1次，如未达标则需要强化治疗。美国糖尿病协会建议对于所有儿童糖尿病患者，推荐HbA1c目标<7.5%。", "ner": [[2, 5, "Test_items"], [19, 22, "Test_items"], [52, 55, "Test_items"], [89, 96, "Test_items"], [12, 16, "Disease"], [36, 40, "Disease"], [62, 63, "Test_items"], [77, 78, "Test_items"], [153, 158, "Test_items"], [134, 136, "Drug"], [183, 185, "Disease"], [196, 198, "Disease"], [204, 208, "Test_items"], [211, 215, "Test_Value"], [79, 82, "Test_Value"], [117, 128, "Test_items"], [143, 148, "ADE"]], "rel": [[19, 22, "Test_items", 12, 16, "Disease", "Test_items_Disease"], [19, 22, "Test_items", 36, 40, "Disease", "Test_items_Disease"], [204, 208, "Test_items", 196, 198, "Disease", "Test_items_Disease"]]}
{"idx": 2397, "sentence": "6.代谢手术：儿童患者代谢手术的研究相对有限。", "ner": [[2, 5, "Operation"], [11, 14, "Operation"]], "rel": []}
{"idx": 2398, "sentence": "根据国际儿科内分泌手术协会(International Pediatric Endo surgery Group)指南，对于接近成人身高的青少年，体质指数(BMI) >40kg/m或BMI>35kg/m并有严重并发症者方考虑手术干预。一项针对严重肥胖青少年的代谢手术指南指出，代谢手术应在发育阶段Tanner 4-5期，接近成人身高，男孩>15岁，女孩>13岁方可进行。新西兰一项研究报告，18岁以下肥胖青少年两种术式的代谢手术后，BMI分别降低11.6kg/m2和16.6kg/m2。美国5家儿童中心联合研究(Teen- LABS study)表明，242例平均BMI为53kg/m2的2型糖尿病患儿手术后，95%2型糖尿病及合并症病情都有好转，同时也能更快达到HbA1c控制目标.传统的Roux-en-Y胃旁路术安全性较差，胃束带和袖管胃切除术等较新的手术较为安全，但对儿童患者，还是不推荐常规应用。代谢手术应该在具有多学科团队的有治疗糖尿病和胃肠外科验的大医院进行，手术后仍要坚持生活方式的干预。", "ner": [[332, 336, "Test_items"], [123, 124, "Disease"], [129, 132, "Operation"], [121, 122, "Level"], [138, 141, "Operation"], [200, 201, "Disease"], [210, 213, "Operation"], [294, 298, "Disease"], [308, 312, "Disease"], [345, 357, "Operation"], [364, 373, "Operation"], [402, 405, "Operation"], [420, 422, "Disease"], [443, 449, "Treatment"]], "rel": [[332, 336, "Test_items", 308, 312, "Disease", "Test_items_Disease"], [129, 132, "Operation", 123, 124, "Disease", "Operation_Disease"], [210, 213, "Operation", 200, 201, "Disease", "Operation_Disease"], [402, 405, "Operation", 420, 422, "Disease", "Operation_Disease"], [443, 449, "Treatment", 420, 422, "Disease", "Treatment_Disease"]]}
{"idx": 2399, "sentence": "【2型糖尿病并发症和合并症的评估与治疗】 ", "ner": [[1, 5, "Disease"]], "rel": []}
{"idx": 2400, "sentence": "与1型糖尿病不同，2型糖尿病一经诊断，就要进行相关并发症、合并症的评估。", "ner": [[1, 5, "Disease"], [9, 13, "Disease"]], "rel": []}
{"idx": 2401, "sentence": "一、常见并发症 ", "ner": [], "rel": []}
{"idx": 2402, "sentence": "2.高血压：高血压的定义为平均收缩压或舒张压大于同年龄、性别和身高血压值的第95百分位数[若第95百分位数高于130/80mmHg(17.3/10.6kPa，1mmHg=0.133kPa) ，则标准为>130/80 mmHg(17.3/10.6kPa) ]。高血压应该非同日复测3次血压证实。如为90~95百分位数则为正常高限血压。TODAY研究发现，在633例平均病程7个月的2型糖尿病青少年患者中13.6%存在高血压，当随访至3.9年时，这一比例上升到33.8%*。高血压的起始治疗包括减轻体重，低盐饮食，加强锻炼。", "ner": [[2, 4, "Disease"], [6, 8, "Disease"], [129, 131, "Disease"], [189, 193, "Disease"], [207, 209, "Disease"], [235, 237, "Disease"], [137, 142, "Test"], [245, 248, "Treatment"], [250, 253, "Treatment"], [255, 258, "Treatment"]], "rel": [[137, 142, "Test", 129, 131, "Disease", "Test_Disease"], [250, 253, "Treatment", 235, 237, "Disease", "Treatment_Disease"], [255, 258, "Treatment", 235, 237, "Disease", "Treatment_Disease"], [245, 248, "Treatment", 235, 237, "Disease", "Treatment_Disease"]]}
{"idx": 2403, "sentence": "如果6个月后血压仍大于第95百分位数，应开始使用ACEI，渐加量至血压小于第90百分位数，控制目标值是血压持续<130/80mmHg(17.3/10.6 kPa)，或低于同年龄、性别、身高组血压的第90百位数。", "ner": [[6, 7, "Test"], [33, 34, "Test"], [51, 52, "Test"], [95, 96, "Test"], [9, 17, "Test_Value"], [35, 43, "Test_Value"], [53, 65, "Test_Value"], [67, 79, "Test_Value"]], "rel": []}
{"idx": 2404, "sentence": "如果因不良反应而不能耐受ACEI，可使用血管紧张素受体阻断剂、钙通道阻滞剂及利尿剂。", "ner": [[12, 15, "Drug"], [20, 29, "Drug"], [31, 36, "Drug"], [38, 40, "Drug"]], "rel": []}
{"idx": 2405, "sentence": "如果单药应用不能维持血压正常，可能需要联合用药。", "ner": [[10, 11, "Test"], [12, 13, "Test_Value"]], "rel": []}
{"idx": 2406, "sentence": " ", "ner": [], "rel": []}
{"idx": 2407, "sentence": "3.脂代谢异常：TODAY研究发现诊断数月后的2型糖尿病青少年患者中，79.8%存在低高密度脂蛋白血症，10.2%存在高甘油三酯血症。所有大于2岁的儿童在诊断糖尿病后，如有高胆固醇血症家族史、家族在55岁前出现心血管事件或家族史不明，应考虑检查空腹血脂谱(在血糖得到控制后)。", "ner": [[2, 6, "Disease"], [23, 27, "Disease"], [42, 50, "Disease"], [59, 65, "Disease"], [79, 81, "Disease"], [86, 91, "Disease"], [105, 109, "Disease"], [105, 107, "Anatomy"], [122, 126, "Test_items"], [129, 130, "Test_items"]], "rel": [[122, 126, "Test_items", 79, 81, "Disease", "Test_items_Disease"], [129, 130, "Test_items", 79, 81, "Disease", "Test_items_Disease"], [105, 107, "Anatomy", 105, 109, "Disease", "Anatomy_Disease"]]}
{"idx": 2408, "sentence": "如果无上述家族史，应在青春期(≥10岁)开始首次血脂筛查。", "ner": [[24, 27, "Test"]], "rel": []}
{"idx": 2409, "sentence": "脂代谢异常诊断后，一般每年复查1次。", "ner": [[0, 4, "Disease"]], "rel": []}
{"idx": 2410, "sentence": "糖尿病患者血脂目标水平为低密度脂蛋白<2.6mmol/L(100mg/dl)，高密度脂蛋白>0.91 mmol/L.(35mg/dl) 甘油三酯<1.7mmol/L(150 mg/dl)。如果LDL水平过高，应尽可能控制血糖并进行饮食控制(饮食胆固醇<200mg/d，饱和脂肪占总热卡<7%，脂肪占总热卡<30%)，6个月内进行空腹血脂复查。10岁以上患者，如在医学营养治疗和生活方式改变后，低密度脂蛋白>4.1 mmol/L(160mg/dl)，或>3.4mmol/L(130mg/dl)伴1个或多个心血管病危险因素时可加用他汀类药物理想状态应低于2.6mmol/L(100mg/dl)。甘油三酯：如空腹>4.5mmol/L(400mg/dl)或非空腹>11.3mmol/L(1000mg/dl)即可开始药物治疗，以达到空腹<4.5mmol/L(400mg/dl)的目标。苯氧芳酸类为治疗高甘油三酯血症的首选药物，目前显示是安全有效的，但对儿童患者仍需谨慎使用。", "ner": [[5, 6, "Test_items"], [12, 17, "Test_items"], [39, 44, "Test_items"], [68, 71, "Test_items"], [96, 98, "Test_items"], [110, 111, "Test_items"], [120, 124, "Test_items"], [134, 141, "Test_items"], [146, 151, "Test_items"], [164, 167, "Test_items"], [196, 201, "Test_items"], [295, 298, "Test_items"], [301, 302, "Test_items"], [324, 326, "Test_items"], [361, 362, "Test_items"], [0, 2, "Disease"], [18, 27, "Test_Value"], [29, 36, "Test_Value"], [45, 56, "Test_Value"], [59, 65, "Test_Value"], [72, 81, "Test_Value"], [83, 91, "Test_Value"], [125, 132, "Test_Value"], [142, 144, "Test_Value"], [152, 155, "Test_Value"], [99, 102, "Test_Value"], [202, 212, "Test_Value"], [214, 221, "Test_Value"], [225, 234, "Test_Value"], [236, 243, "Test_Value"], [273, 283, "Test_Value"], [285, 292, "Test_Value"], [303, 312, "Test_Value"], [314, 321, "Test_Value"], [327, 337, "Test_Value"], [339, 347, "Test_Value"], [363, 372, "Test_Value"], [374, 381, "Test_Value"], [181, 186, "Treatment"], [188, 193, "Treatment"], [263, 267, "Drug"], [387, 391, "Drug"], [395, 401, "Disease"]], "rel": [[5, 6, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [12, 17, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [39, 44, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [68, 71, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [387, 391, "Drug", 395, 401, "Disease", "Drug_Disease"]]}
{"idx": 2411, "sentence": "4.视网膜病变：儿童青春期开始或≥10岁，一旦糖尿病病程3~5年，应该考虑进行首次扩瞳后综合性眼科检查。", "ner": [[2, 6, "Disease"], [23, 25, "Disease"], [2, 4, "Anatomy"], [44, 48, "Test"]], "rel": [[2, 4, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 2412, "sentence": "此后，推荐每年进行常规随访。", "ner": [], "rel": []}
{"idx": 2413, "sentence": "虽然视网膜照片可以作为视网膜病变的一个筛查工具，但不能替代综合性眼科检查。", "ner": [[11, 15, "Disease"], [11, 13, "Anatomy"], [29, 35, "Test"]], "rel": [[11, 13, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"]]}
{"idx": 2414, "sentence": "随访频次应该在进行一次全面的眼科检查后，由眼科专家推荐。", "ner": [[14, 17, "Test"]], "rel": []}
{"idx": 2415, "sentence": "5.神经病变：2型糖尿病确诊时应该筛查远端对称性多发性神经病变，可使用简单的临床检查手段进行筛查，以后至少每年筛查1次。如果临床特征典型，一般不需要进行电生理学检查或转诊给神经科专家。严格控制糖尿病病情有助于改善神经病变，疼痛明显时可以采用镇痛剂对症治疗。同时应该筛查心血管自主神经病变的症状和体征，但由于不影响治疗或预后，一般不需特殊辅助检查。", "ner": [[2, 5, "Disease"], [7, 11, "Disease"], [19, 30, "Disease"], [96, 98, "Disease"], [134, 142, "Disease"], [134, 136, "Anatomy"], [106, 109, "Disease"], [76, 81, "Test"], [111, 112, "Symptom"], [120, 122, "Drug"]], "rel": [[111, 112, "Symptom", 96, 98, "Disease", "Symptom_Disease"], [120, 122, "Drug", 96, 98, "Disease", "Drug_Disease"], [134, 136, "Anatomy", 134, 142, "Disease", "Anatomy_Disease"], [111, 112, "Symptom", 106, 109, "Disease", "Symptom_Disease"], [120, 122, "Drug", 106, 109, "Disease", "Drug_Disease"]]}
{"idx": 2416, "sentence": " ", "ner": [], "rel": []}
{"idx": 2417, "sentence": "6.非酒精性脂肪肝病(NAFLD)：2型糖尿病患儿25%~50%合并有NAFLD，故糖尿病一经诊断即需对此相应评估，包括肝脏B超或磁共振肝脏脂肪定量等，以后每年1次。对于有胰岛素抵抗的患儿，控制体重及口服二甲双胍均能降低肝酶，改善NAFLD。护肝药虽可用于肝功能损伤，但对于2型糖尿病合并NAFLD的青少年，最佳方法还是改善胰岛素抵抗。", "ner": [[2, 16, "Disease"], [18, 22, "Disease"], [35, 39, "Disease"], [42, 44, "Disease"], [115, 119, "Disease"], [137, 141, "Disease"], [144, 148, "Disease"], [8, 8, "Anatomy"], [60, 63, "Test"], [65, 73, "Test"], [86, 90, "Pathogenesis"], [162, 166, "Pathogenesis"], [102, 105, "Drug"], [100, 101, "Method"], [110, 111, "Test_items"], [128, 132, "Disease"], [128, 128, "Anatomy"]], "rel": [[8, 8, "Anatomy", 2, 16, "Disease", "Anatomy_Disease"], [60, 63, "Test", 42, 44, "Disease", "Test_Disease"], [65, 73, "Test", 42, 44, "Disease", "Test_Disease"], [110, 111, "Test_items", 115, 119, "Disease", "Test_items_Disease"], [162, 166, "Pathogenesis", 137, 141, "Disease", "Pathogenesis_Disease"], [100, 101, "Method", 102, 105, "Drug", "Method_Drug"], [128, 128, "Anatomy", 128, 132, "Disease", "Anatomy_Disease"]]}
{"idx": 2418, "sentence": "如果在控制体重和糖尿病治疗下肝酶仍持续升高，则需考虑肝脏活检。", "ner": [[8, 10, "Disease"], [14, 15, "Test_items"], [17, 20, "Test_Value"], [26, 29, "Test"]], "rel": [[14, 15, "Test_items", 8, 10, "Disease", "Test_items_Disease"]]}
{"idx": 2419, "sentence": "7.PCOS：目前倾向于认为PCOS也是胰岛素抵抗综合征的一部分。", "ner": [[2, 5, "Disease"], [14, 17, "Disease"], [20, 27, "Disease"]], "rel": []}
{"idx": 2420, "sentence": "2型糖尿病的女孩自诊断起每次随访中都应详细询问月经史，如果存在原发性或继发性闭经，多毛及严重痤疮，需考虑PCOS的存在。PCOS的诊断需基于月经稀少或停经同时有高雄激素血症的临床或生化表现，可以合并或不合并多囊卵巢。控制体重，改善胰岛素抵抗，体育锻炼，口服二甲双胍均能改善卵巢功能，提高日后生育率。", "ner": [[0, 4, "Disease"], [31, 39, "Disease"], [41, 42, "Disease"], [46, 47, "Disease"], [52, 55, "Disease"], [60, 63, "Disease"], [103, 106, "Disease"], [44, 45, "Level"], [70, 73, "Symptom"], [75, 76, "Symptom"], [80, 85, "Disease"], [105, 106, "Anatomy"], [108, 111, "Treatment"], [121, 124, "Treatment"], [115, 119, "Pathogenesis"], [126, 127, "Method"], [128, 131, "Drug"]], "rel": [[70, 73, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [75, 76, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [105, 106, "Anatomy", 103, 106, "Disease", "Anatomy_Disease"], [126, 127, "Method", 128, 131, "Drug", "Method_Drug"]]}
{"idx": 2421, "sentence": " ", "ner": [], "rel": []}
{"idx": 2422, "sentence": "二、需要注意的情况 ", "ner": [], "rel": []}
{"idx": 2423, "sentence": "还需在患儿初诊和随访中筛查阻塞性睡眠呼吸暂停、吸烟和饮酒情况等。", "ner": [[13, 21, "Disease"]], "rel": []}
{"idx": 2424, "sentence": " ", "ner": [], "rel": []}
{"idx": 2425, "sentence": "【高危青少年和糖尿病前期的筛查】 ", "ner": [[7, 9, "Disease"]], "rel": []}
{"idx": 2426, "sentence": "【从儿科到成人治疗的过渡】 ", "ner": [], "rel": []}
{"idx": 2427, "sentence": "2型糖尿病青少年过渡到成人期间，医疗卫生人员和家人必须结合他们的特点，从青少年早中期即开始，至少在过渡前1年做好转诊准备。", "ner": [[0, 4, "Disease"]], "rel": []}
{"idx": 2428, "sentence": "儿科医师和成人医疗卫生人员应为青少年和刚成年的患者提供支持和相关的资源。", "ner": [], "rel": []}
{"idx": 2429, "sentence": "综上所述，2型糖尿病的诊断包括糖尿病的诊断和分型。在分型上，糖尿病家族史，自身抗体，胰岛素和C肽释放试验等均可帮助诊断。治疗首先要改变生活方式，包括饮食，运动等。药物治疗包括二甲双胍和胰岛素的单用或联用，治疗要根据高血糖的严重程度，有无酮症和(或)酮症酸中毒来选择。不同于1型糖尿病的是，2型糖尿病在诊断伊始就要进行并发症和合并症的评估，包括肾病，高血压，脂代谢异常，视网膜病变，NAFLD，PCOS，神经病变，阻塞性睡眠呼吸暂停等。", "ner": [[5, 9, "Disease"], [15, 17, "Disease"], [30, 32, "Disease"], [136, 140, "Disease"], [144, 148, "Disease"], [171, 172, "Disease"], [174, 176, "Disease"], [178, 182, "Disease"], [184, 188, "Disease"], [190, 194, "Disease"], [196, 199, "Disease"], [201, 204, "Disease"], [206, 214, "Disease"], [171, 171, "Anatomy"], [184, 186, "Anatomy"], [37, 40, "Test_items"], [42, 44, "Test_items"], [46, 47, "Test_items"], [65, 70, "Treatment"], [74, 75, "Treatment"], [77, 78, "Treatment"], [87, 90, "Drug"], [92, 94, "Drug"], [107, 109, "Disease"], [118, 119, "Disease"], [124, 128, "Disease"]], "rel": [[37, 40, "Test_items", 30, 32, "Disease", "Test_items_Disease"], [42, 44, "Test_items", 30, 32, "Disease", "Test_items_Disease"], [46, 47, "Test_items", 30, 32, "Disease", "Test_items_Disease"], [171, 171, "Anatomy", 171, 172, "Disease", "Anatomy_Disease"], [184, 186, "Anatomy", 184, 188, "Disease", "Anatomy_Disease"]]}
{"idx": 2430, "sentence": "诊断之后要定期复查血脂，肝酶，尿白蛋白/肌酐比值，监测血压，眼底检查等。", "ner": [[9, 10, "Test_items"], [12, 13, "Test_items"], [15, 23, "Test_items"], [25, 28, "Test"], [30, 33, "Test"]], "rel": []}
{"idx": 2431, "sentence": "儿童青少年2型糖尿病诊治专家共识尚需在我国更多的临床实践中不断完善，并逐步建立指南。", "ner": [[5, 9, "Disease"]], "rel": []}
{"idx": 2432, "sentence": "在应用表1指标时要注意，临床上1型糖尿病和2型糖尿病有时仍然较难鉴别，究其原因包括：(1)肥胖多为2型糖尿病的特点，但儿童肥胖发病率增加，导致新诊断的1型糖尿病也有30%合并肥胖。(2)2型糖尿病诊断时如在急性期，不少也可合并代谢紊乱包括酮症或酮症酸中毒。(3)在一些地区和人群中，糖尿病发病率可高达15%，导致阳性家族史常见。(4)胰岛素及C肽释放试验的局限性。由于各种原因，在1型糖尿病和2型糖尿病特定病程中胰岛素和C肽水平可有部分重叠。如蜜月期时，1型糖尿病的C肽水平可处于正常范围之内，而急性高血糖时，由于高血糖对胰岛细胞的毒性作用，也可导致2型糖尿病的C肽水平相对较低，如果临床病情稳定后数月C肽水平仍然低下，则倾向于诊断1型糖尿病。", "ner": [[15, 19, "Disease"], [21, 25, "Disease"], [45, 46, "Disease"], [49, 53, "Disease"], [59, 62, "Disease"], [75, 79, "Disease"], [87, 88, "Disease"], [93, 97, "Disease"], [113, 116, "Disease"], [119, 120, "Disease"], [122, 126, "Disease"], [141, 143, "Disease"], [190, 194, "Disease"], [196, 200, "Disease"], [227, 231, "Disease"], [275, 279, "Disease"], [316, 320, "Disease"], [167, 169, "Test_items"], [171, 172, "Test_items"], [206, 208, "Test_items"], [210, 211, "Test_items"], [233, 234, "Test_items"], [250, 252, "Disease"], [257, 259, "Disease"], [281, 282, "Test_items"], [301, 302, "Test_items"]], "rel": [[206, 208, "Test_items", 190, 194, "Disease", "Test_items_Disease"], [210, 211, "Test_items", 190, 194, "Disease", "Test_items_Disease"], [206, 208, "Test_items", 196, 200, "Disease", "Test_items_Disease"], [210, 211, "Test_items", 196, 200, "Disease", "Test_items_Disease"], [233, 234, "Test_items", 227, 231, "Disease", "Test_items_Disease"], [281, 282, "Test_items", 275, 279, "Disease", "Test_items_Disease"], [301, 302, "Test_items", 275, 279, "Disease", "Test_items_Disease"]]}
{"idx": 2433, "sentence": "(5)自身抗体检测的不足。", "ner": [[3, 6, "Test_items"]], "rel": []}
{"idx": 2434, "sentence": "自身抗体是区分1型糖尿病和2型糖尿病较为准确的方法，但由于检测方法不一，不同人群抗体谱不一，不能检测到所有参与自身免疫的抗体等因素，使其临床价值受限。", "ner": [[7, 11, "Disease"], [13, 17, "Disease"], [0, 3, "Test_items"]], "rel": [[0, 3, "Test_items", 7, 11, "Disease", "Test_items_Disease"], [0, 3, "Test_items", 13, 17, "Disease", "Test_items_Disease"]]}
{"idx": 2435, "sentence": "同时亚洲人群1型糖尿病患儿抗体阳性率往往比较低，所以自身抗体阴性不能排除胰腺自身免疫的存在。", "ner": [[6, 10, "Disease"], [13, 17, "Test_items"], [26, 29, "Test_items"], [30, 31, "Test_Value"], [22, 22, "Test_Value"]], "rel": [[13, 17, "Test_items", 6, 10, "Disease", "Test_items_Disease"], [26, 29, "Test_items", 6, 10, "Disease", "Test_items_Disease"]]}
{"idx": 2436, "sentence": "另一方面，即使是很典型的2型糖尿病，也有可能存在胰岛细胞的自身免疫，在美国和欧洲国家，临床诊断为2型糖尿病的患者，也可有15%~40%出现自身抗体阳性。", "ner": [[12, 16, "Disease"], [48, 52, "Disease"], [69, 72, "Test_items"], [73, 74, "Test_Value"]], "rel": [[69, 72, "Test_items", 48, 52, "Disease", "Test_items_Disease"]]}
{"idx": 2437, "sentence": "因此，对于临床诊断为2型糖尿病的所有患儿，也应考虑糖尿病自身抗体检测。", "ner": [[10, 14, "Disease"], [25, 27, "Disease"], [28, 31, "Test_items"]], "rel": [[28, 31, "Test_items", 10, 14, "Disease", "Test_items_Disease"]]}
{"idx": 2438, "sentence": "抗体阳性的患儿或合并有Grave病，重症肌无力等自身免疫性疾病者，相对来说更支持1型糖尿病，同时或考虑是否存在自身免疫性多腺体病。", "ner": [[11, 16, "Disease"], [18, 22, "Disease"], [40, 44, "Disease"], [55, 63, "Disease"], [0, 1, "Test_items"], [2, 3, "Test_Value"]], "rel": [[0, 1, "Test_items", 40, 44, "Disease", "Test_items_Disease"], [0, 1, "Test_items", 55, 63, "Disease", "Test_items_Disease"]]}
{"idx": 2439, "sentence": "1.肾病：白蛋白尿是评估糖尿病肾病的重要指标。TODAY研究发现在633例平均病程7个月的2型糖尿病青少年患者中，6.3%存在微量白蛋白尿，而到病程36个月时，这一比例上升到16.6%。尿白蛋白/肌酐比值在诊断之初检测后，每年应检测1次。糖尿病病程超过5年的患儿，应考虑至少每年筛查尿白蛋白，取随机尿样检测白蛋白/肌酐比值。", "ner": [[2, 3, "Disease"], [12, 16, "Disease"], [45, 49, "Disease"], [119, 121, "Disease"], [2, 2, "Anatomy"], [15, 15, "Anatomy"], [5, 8, "Test_items"], [93, 101, "Test_items"], [141, 144, "Test_items"], [153, 160, "Test_items"], [63, 68, "Symptom"]], "rel": [[2, 2, "Anatomy", 2, 3, "Disease", "Anatomy_Disease"], [15, 15, "Anatomy", 12, 16, "Disease", "Anatomy_Disease"], [63, 68, "Symptom", 45, 49, "Disease", "Symptom_Disease"], [141, 144, "Test_items", 119, 121, "Disease", "Test_items_Disease"], [153, 160, "Test_items", 119, 121, "Disease", "Test_items_Disease"]]}
{"idx": 2440, "sentence": "微量白蛋白尿标准为白蛋白/肌酐比值≥30mg/g，但<300mg/g。", "ner": [[9, 16, "Test_items"], [0, 5, "Symptom"], [17, 23, "Test_Value"], [26, 33, "Test_Value"]], "rel": []}
{"idx": 2441, "sentence": "当3次尿标本至少2次白蛋白/肌酐比值升高(>30mg/g)，应该考虑应用血管紧张素转化酶抑制剂(ACEI)治疗，并逐渐加量直到比值正常。", "ner": [[10, 17, "Test_items"], [18, 19, "Test_Value"], [21, 27, "Test_Value"], [36, 52, "Drug"]], "rel": []}
{"idx": 2442, "sentence": "通过更好地控制血糖和血压，争取尿蛋白在6个月内达标。", "ner": [[7, 8, "Test_items"], [10, 11, "Test"], [15, 17, "Test_items"]], "rel": []}
{"idx": 2443, "sentence": "一般来说，由于成本较高，不需对青少年开展普遍筛查。", "ner": [], "rel": []}
{"idx": 2444, "sentence": "但在日本和我国台湾中小学生开展大样本尿糖筛查已有多年，结果表明其仍有一定效益。目前认为在超重并有2项或2项以上其他糖尿病危险因素(一级或二级亲属中有2型糖尿病病史，胰岛素抵抗相关临床状态，母亲妊娠期糖尿病史)的儿童和青少年，应考虑筛查2型糖尿病和糖尿病前期。可使用空腹血糖、糖耐量试验2h血糖或HbA1c筛查糖尿病前期。应该通过饮食控制和运动降低糖尿病前期的糖尿病发生风险，同时每年进行检测。对于糖尿病前期的人群，需同时筛查并治疗可改变的心血管疾病危险因素，包括血脂，血压的检测和控制。", "ner": [[18, 21, "Test"], [44, 45, "Reason"], [57, 59, "Disease"], [57, 59, "Disease"], [74, 78, "Disease"], [117, 121, "Disease"], [123, 125, "Disease"], [154, 156, "Disease"], [173, 175, "Disease"], [179, 181, "Disease"], [198, 200, "Disease"], [219, 223, "Disease"], [82, 86, "Symptom"], [132, 135, "Test_items"], [137, 141, "Test_items"], [142, 145, "Test_items"], [147, 151, "Test_items"], [96, 101, "Disease"], [164, 167, "Treatment"], [169, 170, "Treatment"], [231, 232, "Test"], [234, 238, "Test"], [219, 221, "Anatomy"]], "rel": [[44, 45, "Reason", 57, 59, "Disease", "Reason_Disease"], [82, 86, "Symptom", 74, 78, "Disease", "Symptom_Disease"], [132, 135, "Test_items", 154, 156, "Disease", "Test_items_Disease"], [137, 141, "Test_items", 154, 156, "Disease", "Test_items_Disease"], [142, 145, "Test_items", 154, 156, "Disease", "Test_items_Disease"], [147, 151, "Test_items", 154, 156, "Disease", "Test_items_Disease"], [164, 167, "Treatment", 173, 175, "Disease", "Treatment_Disease"], [169, 170, "Treatment", 173, 175, "Disease", "Treatment_Disease"], [231, 232, "Test", 198, 200, "Disease", "Test_Disease"], [234, 238, "Test", 198, 200, "Disease", "Test_Disease"], [219, 221, "Anatomy", 219, 223, "Disease", "Anatomy_Disease"]]}
{"idx": 2445, "sentence": " ", "ner": [], "rel": []}
{"idx": 2446, "sentence": "评中国成人2型糖尿病胰岛素促泌剂应用专家共识 ", "ner": [[5, 9, "Disease"], [10, 15, "Drug"]], "rel": [[10, 15, "Drug", 5, 9, "Disease", "Drug_Disease"]]}
{"idx": 2447, "sentence": "胰岛素促泌剂是临床应用最早、最广泛的口服降糖药之一，降糖疗效肯定、安全性高、价格低廉、可与其他口服降糖药联用，在2型糖尿病(T2DM)治疗中占有重要地位，是多数国际权威人T2DM防治指南中的一线降糖药物。为了强调其重要性及正确认识和评价这一大类降糖药、中华医学会内分泌学分会于2011年讨论通过了《中国成人2型糖尿病胰岛素促泌剂应用的专家共识》，并于2012年正式表发。", "ner": [[0, 5, "Drug"], [18, 19, "Method"], [47, 48, "Method"], [56, 66, "Disease"], [85, 88, "Disease"], [153, 157, "Disease"], [158, 163, "Drug"]], "rel": [[18, 19, "Method", 0, 5, "Drug", "Method_Drug"], [158, 163, "Drug", 153, 157, "Disease", "Drug_Disease"]]}
{"idx": 2448, "sentence": " ", "ner": [], "rel": []}
{"idx": 2449, "sentence": "1 胰岛素促泌剂的作用机制及特点 ", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 2450, "sentence": "目前国内使用的胰岛素促泌剂包括磺脲类和格列奈类。", "ner": [[7, 12, "Drug"], [15, 17, "Drug"], [19, 22, "Drug"]], "rel": []}
{"idx": 2451, "sentence": "磺脲类促泌剂包括半衰期较短的短效促泌剂(如格列吡嗪和格列喹酮)和半衰期较长的中长效促泌剂(如普通剂型的格列美脲、格列苯脲和格列齐特，以及通过特殊的胃肠道治疗系统(GITS)技术实现控释的格列吡嗪控释片和采用以亲水性羟丙甲纤维素为基质的缓释技术格列齐特缓释片)。", "ner": [[0, 5, "Drug"], [21, 24, "Drug"], [26, 29, "Drug"], [51, 54, "Drug"], [56, 59, "Drug"], [61, 64, "Drug"], [93, 99, "Drug"], [121, 127, "Drug"]], "rel": []}
{"idx": 2452, "sentence": "格列奈类半衰期较短，属短效促剂，包括瑞格列奈和那格列奈。", "ner": [[0, 3, "Drug"], [18, 21, "Drug"], [23, 26, "Drug"]], "rel": []}
{"idx": 2453, "sentence": " ", "ner": [], "rel": []}
{"idx": 2454, "sentence": "磺脲类促泌剂通过与β细胞膜三磷酸腺苷(ATP)敏感的钾通道(KATP)的磺脲类药物受体(SUR)结合，ATP/ADP比值升高，KATP通道关闭，细胞内的K+外流受阻，胞内K+升高、细胞膜去极化，触发L2型电压依赖的Ca2+通道开放，细胞外Ca2+内流增加，胞质内Ca2+浓度升高，从而刺激胰岛素分泌颗粒向细胞外分泌。", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 2455, "sentence": "KATP通道也存在于大脑、心肌和血管平滑肌等组织。", "ner": [], "rel": []}
{"idx": 2456, "sentence": "不同组织的SUR存在差异，不同胰岛素促泌剂会与β细胞不同分子量的SUR受体结合，且亲和力和解离速度也各不相同，这些是其产生药效学差异的原因。", "ner": [[15, 20, "Drug"]], "rel": []}
{"idx": 2457, "sentence": "格列本脲可作用于SUR1和SUR2A，而格列齐特仅作用于SUR1。", "ner": [[0, 3, "Drug"], [20, 23, "Drug"]], "rel": []}
{"idx": 2458, "sentence": "格列本脲和格列美脲各自与SUR1不同亚单位特异性结合，格列美脲与SUR的亲和力更强、结合和解离速度也更快。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [27, 30, "Drug"]], "rel": []}
{"idx": 2459, "sentence": "格列本脲与两个SUR1位点相结合，不易与受体脱离，且作用时间相对较长。", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 2460, "sentence": "近年来，通过对β细胞的电压钳研究证实，磺脲类药物可不作用于KATP而直接加强Ca2+依赖的胰岛素分泌作用。", "ner": [[19, 23, "Drug"]], "rel": []}
{"idx": 2461, "sentence": "通过葡萄糖钳夹技术研究发现，磺脲类药物可使人体外周葡萄糖利用增加10%~52%(平均29%)。", "ner": [[14, 18, "Drug"]], "rel": []}
{"idx": 2462, "sentence": "但促泌剂改善胰岛素敏感性的作用主要继发于葡萄糖毒性作用的改善。", "ner": [], "rel": []}
{"idx": 2463, "sentence": "不同的促泌剂对胰岛素敏感性的影响可能存在差异，如格列美脲在离体培养的脂肪细胞和肌肉组织中具有直接的拟胰岛素和胰岛素增敏作用。", "ner": [[24, 27, "Drug"]], "rel": []}
{"idx": 2464, "sentence": "有研究表明，磺脲类促泌剂还可以通过其他机制降低血糖，其降低空腹血糖的作用与其抑制基础肝糖的生成密切相关。", "ner": [[6, 11, "Drug"], [23, 24, "Test_items"], [29, 32, "Test_items"]], "rel": []}
{"idx": 2465, "sentence": " ", "ner": [], "rel": []}
{"idx": 2466, "sentence": "格列奈类药物也与胰岛β细胞膜SUR结合，与磺脲类药物相比，促胰岛素分泌作用起效快、作用持续时间短，有效降低餐后血糖，同时不增加胰岛素分泌总量，不加重β细胞负荷，低血糖的发生率低。", "ner": [[0, 5, "Drug"], [21, 25, "Drug"], [53, 56, "Test_items"], [80, 82, "ADE"]], "rel": [[80, 82, "ADE", 0, 5, "Drug", "ADE_Drug"]]}
{"idx": 2467, "sentence": "胰岛素促泌剂降糖主要与对β细胞的作用有关，胰外作用不如对β细胞的作用重要。", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 2468, "sentence": "2 对胰岛素促泌剂认识的误区 ", "ner": [[3, 8, "Drug"]], "rel": []}
{"idx": 2469, "sentence": "2.1 低血糖风险高", "ner": [[4, 6, "ADE"]], "rel": []}
{"idx": 2470, "sentence": "低血糖是磺脲类药物最常见的不良反度。但剂型改良后的格列吡嗪控释片、格列齐特缓释片和格列美脲等中长效制剂及餐时血糖调节药格列奈类，因其较低的血药浓度和依赖葡萄糖的降糖作用，低血糖的发生率低。GUIDE结果显示，在血糖水平控制相似的情况下，不同磺脲类促泌剂所致低血糖发生风险不同。糖尿病和心血管疾病行动研究(ADVANCE)以格列齐特缓释片为基瑞的降糖治疗严重低血糖年发生率仅为英国前瞻性糖尿病研究(UKPDS)采用格列本脲和氯磺丙脲为基碗的降糖治疗的1/4。英国一般实践研究数据库表明，磺脲类药物使用者年低血糖的发生半为1.8%，其中2.0%为年龄>65岁。在磺脲类药物中，格列苯脲的低血糖发生率最高，格列齐特和格列吡嗪的低血糖发生风险比格列苯脲低25%和40%。UKPDS对使用氯磺丙脲、格列苯脲和胰岛素的T2DM患者进行10年的随访表明，其年低血糖的发生率分别为11.0%、17.7%和36.5%。", "ner": [[4, 8, "Drug"], [25, 31, "Drug"], [33, 39, "Drug"], [41, 44, "Drug"], [59, 62, "Drug"], [120, 125, "Drug"], [161, 167, "Drug"], [206, 209, "Drug"], [211, 214, "Drug"], [242, 246, "Drug"], [279, 283, "Drug"], [286, 289, "Drug"], [300, 303, "Drug"], [305, 308, "Drug"], [318, 321, "Drug"], [339, 342, "Drug"], [344, 347, "Drug"], [349, 351, "Drug"], [0, 2, "ADE"], [85, 87, "ADE"], [128, 130, "ADE"], [178, 180, "ADE"], [251, 253, "ADE"], [291, 293, "ADE"], [310, 312, "ADE"], [372, 374, "ADE"], [69, 72, "Pathogenesis"], [52, 55, "Test_items"], [105, 106, "Test_items"], [138, 140, "Disease"], [142, 146, "Disease"], [142, 144, "Anatomy"], [192, 194, "Disease"], [353, 356, "Disease"]], "rel": [[0, 2, "ADE", 4, 8, "Drug", "ADE_Drug"], [85, 87, "ADE", 25, 31, "Drug", "ADE_Drug"], [85, 87, "ADE", 33, 39, "Drug", "ADE_Drug"], [85, 87, "ADE", 41, 44, "Drug", "ADE_Drug"], [85, 87, "ADE", 59, 62, "Drug", "ADE_Drug"], [128, 130, "ADE", 120, 125, "Drug", "ADE_Drug"], [178, 180, "ADE", 161, 167, "Drug", "ADE_Drug"], [161, 167, "Drug", 138, 140, "Disease", "Drug_Disease"], [178, 180, "ADE", 206, 209, "Drug", "ADE_Drug"], [206, 209, "Drug", 192, 194, "Disease", "Drug_Disease"], [178, 180, "ADE", 211, 214, "Drug", "ADE_Drug"], [211, 214, "Drug", 192, 194, "Disease", "Drug_Disease"], [251, 253, "ADE", 242, 246, "Drug", "ADE_Drug"], [291, 293, "ADE", 286, 289, "Drug", "ADE_Drug"], [310, 312, "ADE", 300, 303, "Drug", "ADE_Drug"], [310, 312, "ADE", 305, 308, "Drug", "ADE_Drug"], [310, 312, "ADE", 318, 321, "Drug", "ADE_Drug"], [372, 374, "ADE", 339, 342, "Drug", "ADE_Drug"], [339, 342, "Drug", 353, 356, "Disease", "Drug_Disease"], [372, 374, "ADE", 344, 347, "Drug", "ADE_Drug"], [344, 347, "Drug", 353, 356, "Disease", "Drug_Disease"], [372, 374, "ADE", 349, 351, "Drug", "ADE_Drug"], [349, 351, "Drug", 353, 356, "Disease", "Drug_Disease"], [142, 144, "Anatomy", 142, 146, "Disease", "Anatomy_Disease"]]}
{"idx": 2471, "sentence": "公认的低血糖发生少的甘精胰岛素的大型研究最新结果显示，甘精胰岛素低血糖发生的风险明显高于口服药。", "ner": [[10, 14, "Drug"], [27, 31, "Drug"], [3, 5, "ADE"], [32, 34, "ADE"], [44, 45, "Method"]], "rel": [[3, 5, "ADE", 10, 14, "Drug", "ADE_Drug"], [32, 34, "ADE", 27, 31, "Drug", "ADE_Drug"]]}
{"idx": 2472, "sentence": "由此可见，胰岛素促泌剂肯定存在低血糖风险，但是胰岛素的低血糖风险更大。", "ner": [[5, 10, "Drug"], [23, 25, "Drug"], [15, 17, "ADE"], [27, 29, "ADE"]], "rel": [[15, 17, "ADE", 5, 10, "Drug", "ADE_Drug"], [27, 29, "ADE", 23, 25, "Drug", "ADE_Drug"]]}
{"idx": 2473, "sentence": "因此需要时一般情况下应优先选择胰岛素促泌剂而不是胰岛素。", "ner": [[15, 20, "Drug"], [24, 26, "Drug"]], "rel": []}
{"idx": 2474, "sentence": " ", "ner": [], "rel": []}
{"idx": 2475, "sentence": "2.2 体重增加明显 ", "ner": [[4, 7, "ADE"]], "rel": []}
{"idx": 2476, "sentence": "目前一般认为磺脲类药物治疗可引起患者体重增加。UKPDS表明，以格列本脲为基础的降糖治疗，患者体重增加1.7kg。Schernthaner等对使用格列齐特和格列美脲治疗的患者行27周的随访发现，其体重增加分别为0.5kg和0.6kg。", "ner": [[6, 10, "Drug"], [32, 35, "Drug"], [73, 76, "Drug"], [78, 81, "Drug"], [18, 21, "ADE"], [47, 50, "ADE"], [98, 101, "ADE"]], "rel": [[18, 21, "ADE", 6, 10, "Drug", "ADE_Drug"], [47, 50, "ADE", 32, 35, "Drug", "ADE_Drug"], [98, 101, "ADE", 73, 76, "Drug", "ADE_Drug"], [98, 101, "ADE", 78, 81, "Drug", "ADE_Drug"]]}
{"idx": 2477, "sentence": "而ADVANCE5年的观察分析并未发现以格列齐特缓释片为基础的降糖治疗增加患者体重。", "ner": [[20, 26, "Drug"]], "rel": []}
{"idx": 2478, "sentence": "很多大型研究表明胰岛素增加体重更明显，比如ADVANCE新近的分析发现用胰岛素体重增加3.3kg，而磺脲服类为0.7kg。", "ner": [[50, 53, "Drug"], [11, 14, "ADE"], [39, 42, "ADE"], [8, 10, "Drug"], [36, 38, "Drug"]], "rel": [[11, 14, "ADE", 8, 10, "Drug", "ADE_Drug"], [39, 42, "ADE", 36, 38, "Drug", "ADE_Drug"]]}
{"idx": 2479, "sentence": "不难看出，胰岛素促泌剂增加体重，但胰岛素体重增加更明显。表明超重和肥胖的糖尿病患者选用降药时一般也应是胰岛素促泌剂优于胰岛素。", "ner": [[5, 10, "Drug"], [17, 19, "Drug"], [30, 31, "Drug"], [33, 34, "Drug"], [36, 38, "Drug"], [51, 56, "Drug"], [59, 61, "Drug"], [11, 14, "ADE"], [20, 23, "ADE"]], "rel": [[11, 14, "ADE", 5, 10, "Drug", "ADE_Drug"], [20, 23, "ADE", 17, 19, "Drug", "ADE_Drug"]]}
{"idx": 2480, "sentence": " ", "ner": [], "rel": []}
{"idx": 2481, "sentence": "2.3加重β细胞功能衰竭", "ner": [[5, 11, "Pathogenesis"]], "rel": []}
{"idx": 2482, "sentence": "有研究认为胰岛素促泌剂可以引起胰岛β细胞凋亡，且促凋亡作用呈时间-剂量依赖性增加。UKPDS的结果显示，无论使用何种降糖治疗，胰岛β细胞功能每年以约7%的速度丧失，使用格列本脲和氯磺丙脲治疗的患者β细胞胰岛素分泌功能有下降趋势，但与采用二甲双胍治疗和单纯饮食控制相似。糖尿病进展试验(ADOPT)对比了3种不同类型降糖药物(罗格列酮、格列本脲和二甲双胍)在新诊断T2DM患者中的疗效，发现格列本脲改善β细胞胰岛素分泌功能明显优于罗格列酮和二甲双胍，并非发现磺脲类药物加重或加速了β细胞的衰竭。", "ner": [[5, 10, "Drug"], [84, 87, "Drug"], [89, 92, "Drug"], [118, 121, "Drug"], [162, 165, "Drug"], [167, 170, "Drug"], [172, 175, "Drug"], [194, 197, "Drug"], [214, 217, "Drug"], [219, 222, "Drug"], [228, 232, "Drug"], [15, 21, "Pathogenesis"], [239, 244, "Pathogenesis"], [125, 130, "Treatment"], [134, 136, "Disease"], [181, 184, "Disease"]], "rel": [[162, 165, "Drug", 134, 136, "Disease", "Drug_Disease"], [167, 170, "Drug", 134, 136, "Disease", "Drug_Disease"], [172, 175, "Drug", 134, 136, "Disease", "Drug_Disease"]]}
{"idx": 2483, "sentence": "迄今的循证医学证据没有发现映岛素促泌剂加重或加速β细胞衰竭。", "ner": [[13, 18, "Drug"], [24, 28, "Pathogenesis"]], "rel": []}
{"idx": 2484, "sentence": " ", "ner": [], "rel": []}
{"idx": 2485, "sentence": "2.4 心血管风险 ", "ner": [[4, 8, "Disease"], [4, 6, "Anatomy"]], "rel": [[4, 6, "Anatomy", 4, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 2486, "sentence": "美国大学组糖尿病研究项目(UGDP)研究提出，甲苯磺丁脲可能增加T2DM患者心血管死亡风险。UKPDS随机给予新发T2DM患者胰岛素注射或口服降糖药治疗，以了解不同治疗方式对心血管并发症的影响。结果显示，磺脲类药物未增加心血管并发症发生；相反，其后续研究发现磺脲类可减少心血管事件发生。ADVANCE对病程较长，合并心血管高危因素的T2DM患者采用以格列齐特缓释片为基础的降糖治疗，主要微血管事件减少14%。Meta分析结果显示，以氯磺丙脲、格列本脲和格列齐特缓释片为基础的降糖治疗可使T2DM患者非致死性心肌梗死风险降低17%、冠心病风险降低15%。", "ner": [[5, 7, "Disease"], [32, 35, "Disease"], [57, 60, "Disease"], [166, 169, "Disease"], [243, 248, "Disease"], [253, 256, "Disease"], [265, 267, "Disease"], [23, 27, "Drug"], [63, 65, "Drug"], [102, 106, "Drug"], [129, 131, "Drug"], [175, 181, "Drug"], [216, 219, "Drug"], [221, 224, "Drug"], [226, 232, "Drug"], [87, 92, "ADE"], [38, 42, "ADE"], [110, 115, "ADE"], [135, 139, "ADE"], [193, 197, "ADE"]], "rel": [[23, 27, "Drug", 32, 35, "Disease", "Drug_Disease"], [63, 65, "Drug", 57, 60, "Disease", "Drug_Disease"], [175, 181, "Drug", 166, 169, "Disease", "Drug_Disease"], [216, 219, "Drug", 243, 248, "Disease", "Drug_Disease"], [221, 224, "Drug", 243, 248, "Disease", "Drug_Disease"], [226, 232, "Drug", 243, 248, "Disease", "Drug_Disease"], [38, 42, "ADE", 23, 27, "Drug", "ADE_Drug"], [87, 92, "ADE", 63, 65, "Drug", "ADE_Drug"]]}
{"idx": 2487, "sentence": "现有的证据表明，胰岛素促泌剂中的磺脲类药物有利于保护T2DM的心血管，没有随机双盲前瞻性长时间研究发现它增加心血管风险。", "ner": [[8, 13, "Drug"], [16, 20, "Drug"], [26, 29, "Disease"], [54, 58, "ADE"]], "rel": []}
{"idx": 2488, "sentence": " ", "ner": [], "rel": []}
{"idx": 2489, "sentence": "2.5 肿瘤风险 ", "ner": [[4, 5, "Disease"]], "rel": []}
{"idx": 2490, "sentence": "有研究表明T2DM患者的肿瘤风险增加，甚至某些回顾性的资料分析发现磺脲类药物可能增加肿瘤的风险，但高水平高级别的证据如从UKPDS到近期发表的ADVANCE亚组分析均未发现磺脲类药物增加患者肿瘤风险。", "ner": [[5, 8, "Disease"], [95, 96, "Disease"], [42, 43, "Disease"], [12, 13, "Disease"], [33, 37, "Drug"], [86, 90, "Drug"]], "rel": []}
{"idx": 2491, "sentence": "3 胰岛素促泌剂的临床应用 ", "ner": [[2, 7, "Drug"]], "rel": []}
{"idx": 2492, "sentence": "共识强调胰岛素促泌剂仍是治疗T2DM的一线药，对于有一定β细胞功能、无胰岛素促泌剂应用禁忌的T2DM患者均可考虑选用胰岛素促泌剂。对无超重和肥胖或二甲双胍不耐受者或其他口服降糖药物治疗血糖控制不佳的T2DM患者促泌剂可作为首选或联合药物。应根据患者血糖谱选择不同类型的胰岛素促泌剂：以餐后血糖(PPG)升高为主者宜选择格列奈类及短效磺脲类促泌剂；以空腹血糖(FPG)升高为主PPG和FPG均升高者宜选择依从性好、低血糖风险低的中长效磺脲类促泌剂。", "ner": [[4, 9, "Drug"], [58, 63, "Drug"], [73, 76, "Drug"], [134, 139, "Drug"], [159, 162, "Drug"], [164, 171, "Drug"], [213, 221, "Drug"], [14, 17, "Disease"], [46, 49, "Disease"], [67, 68, "Disease"], [70, 71, "Disease"], [99, 102, "Disease"], [35, 40, "Drug"], [84, 85, "Method"], [92, 93, "Test_items"], [124, 126, "Test_items"], [142, 150, "Test_items"], [174, 182, "Test_items"], [187, 189, "Test_items"], [191, 193, "Test_items"], [94, 97, "Test_Value"], [151, 152, "Test_Value"], [183, 184, "Test_Value"], [194, 196, "Test_Value"], [206, 208, "ADE"]], "rel": [[4, 9, "Drug", 14, 17, "Disease", "Drug_Disease"], [58, 63, "Drug", 46, 49, "Disease", "Drug_Disease"], [134, 139, "Drug", 99, 102, "Disease", "Drug_Disease"], [206, 208, "ADE", 213, 221, "Drug", "ADE_Drug"], [92, 93, "Test_items", 99, 102, "Disease", "Test_items_Disease"]]}
{"idx": 2493, "sentence": "若单药治疗血糖控制不达标，应与其他口服降糖药联用，一般联合两种药物，最多可联用3种药物。", "ner": [[17, 18, "Method"], [5, 6, "Test_items"], [7, 11, "Test_Value"]], "rel": []}
{"idx": 2494, "sentence": "胰岛素促泌剂可与基础胰岛素合用，但不主张与格列奈类合用。", "ner": [[0, 5, "Drug"], [8, 12, "Drug"], [21, 24, "Drug"]], "rel": []}
{"idx": 2495, "sentence": "胰岛素促泌剂与其他药物联合使用时应选择作用机制互补的降糖药物，这样既增强药物降糖效果又减少了各自的剂量及体重增加、严重低血糖等不良反应的发生率，同时要评估联合用药的成本-效益因素，充分考虑患者的经济承受能力和用药的依从性，特别是经济欠发达和农村地区患者。", "ner": [[0, 5, "Drug"], [52, 55, "ADE"], [59, 61, "ADE"], [57, 58, "Level"]], "rel": []}
{"idx": 2496, "sentence": " ", "ner": [], "rel": []}
{"idx": 2497, "sentence": "胰岛素促泌剂的降糖作用在常规剂量内呈剂量依赖性，可平均将糖化血红蛋白(HbA1c)水平降低2%左右，且患者的基线HbA1c水平越高，服用胰鸟素促泌剂治疗后HbA1c的降幅越大。", "ner": [[0, 5, "Drug"], [68, 73, "Drug"], [28, 40, "Test_items"], [54, 60, "Test_items"], [77, 81, "Test_items"], [43, 48, "Test_Value"], [64, 64, "Test_Value"], [83, 86, "Test_Value"]], "rel": []}
{"idx": 2498, "sentence": "剂量应从小量开始，以减少低血糖发生。", "ner": [[12, 14, "ADE"]], "rel": []}
{"idx": 2499, "sentence": " ", "ner": [], "rel": []}
{"idx": 2500, "sentence": "中或重度肝肾功能不全者不宜使用胰岛素促泌剂。轻中度肾功能不全者若不用胰岛素，需要用胰岛素促泌剂时可考虑瑞格列奈和格列喹酮。", "ner": [[4, 9, "Disease"], [4, 4, "Anatomy"], [5, 5, "Anatomy"], [0, 3, "Level"], [15, 20, "Drug"], [25, 29, "Disease"], [25, 25, "Anatomy"], [34, 36, "Drug"], [41, 46, "Drug"], [51, 54, "Drug"], [56, 59, "Drug"], [22, 24, "Level"]], "rel": [[4, 4, "Anatomy", 4, 9, "Disease", "Anatomy_Disease"], [5, 5, "Anatomy", 4, 9, "Disease", "Anatomy_Disease"], [25, 25, "Anatomy", 25, 29, "Disease", "Anatomy_Disease"], [41, 46, "Drug", 25, 29, "Disease", "Drug_Disease"], [51, 54, "Drug", 25, 29, "Disease", "Drug_Disease"], [56, 59, "Drug", 25, 29, "Disease", "Drug_Disease"]]}
{"idx": 2501, "sentence": "总之，胰岛素促泌剂符合中国2型糖尿病的特点，是多数权威指南推荐的治疗2型糖尿病的一线药物。", "ner": [[3, 8, "Drug"], [13, 17, "Disease"], [34, 38, "Disease"]], "rel": []}
{"idx": 2502, "sentence": "磺脲类药物应用时间长、降糖效果强、安全性高、价格低廉，早期使用可减少大血管、微血管、并发症和全因死亡的发生。", "ner": [[0, 4, "Drug"]], "rel": []}
{"idx": 2503, "sentence": "格列奈类有效降低餐后血糖，在中国也广泛使用。", "ner": [[0, 3, "Drug"], [8, 11, "Test_items"]], "rel": []}
{"idx": 2504, "sentence": "临床医生应以循证医学研究的证据来科学评价胰岛素促泌剂，同时应充分了解各种药物的特点，结合患者的血糖谱、年龄、病程、肝肾功能、胰岛功能、依从性、经济条件等情况综合考虑，制定个体化的用药方案，使患者血糖安全达标的同时减少不良反应的发生，延缓疾病进程，减少并发症，提高患者的生活质量。", "ner": [[20, 25, "Drug"], [47, 49, "Test_items"], [97, 98, "Test_items"], [99, 102, "Test_Value"]], "rel": []}
{"idx": 2505, "sentence": " ", "ner": [], "rel": []}
{"idx": 2506, "sentence": "基层糖尿病微血管病变筛查与防治专家共识 ", "ner": [[2, 9, "Disease"], [5, 7, "Anatomy"]], "rel": [[5, 7, "Anatomy", 2, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 2507, "sentence": "随着人们生活方式的改变和社会人口老龄化进程的加剧，糖尿病正成为一种全球范围内的慢性流行性疾病。据国际糖尿病联盟估计，至2030年，世界范围内2型糖尿病患者数量将达到5.92亿。糖尿病的管理不仅要实现理想的血糖控制，更要通过良好的代谢控制达到预防慢性并发症、提高患者生活质量及延长患者寿命的目的。", "ner": [[25, 27, "Disease"], [50, 52, "Disease"], [70, 74, "Disease"], [88, 90, "Disease"], [102, 103, "Test_items"]], "rel": [[102, 103, "Test_items", 88, 90, "Disease", "Test_items_Disease"]]}
{"idx": 2508, "sentence": "在糖尿病慢性并发症中，视网膜、肾脏及外周神经的微血管并发症是各类型糖尿病的特异性表现，对患者生活质量的影响非常严重，是糖尿病患者致死、致残的重要原因，严重降低了患者的生活质量，加重了家庭和社会的经济负担。", "ner": [[1, 8, "Disease"], [11, 28, "Disease"], [33, 35, "Disease"], [59, 61, "Disease"], [11, 13, "Anatomy"], [15, 16, "Anatomy"], [18, 21, "Anatomy"], [23, 25, "Anatomy"]], "rel": []}
{"idx": 2509, "sentence": " ", "ner": [], "rel": []}
{"idx": 2510, "sentence": "1 我国糖尿病微血管并发症的流行病学现状及卫生经济负担 ", "ner": [[4, 12, "Disease"], [7, 9, "Anatomy"]], "rel": [[7, 9, "Anatomy", 4, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 2511, "sentence": "糖尿病微血管并发症最主要的危险因素是糖尿病病程和高血糖。资料显示，我国糖尿病视网膜病变(diabetic retinopathy，DR)的患病率为24.7%~37.5%，病程<5年者眼底病变患病率为38.0% ~39.0%；病程5~10年者眼底病变患病率为5 0.0%~56.7%；病程>10年者眼底病变患病率增至69.0%~90.0%。目前我国尚缺乏全国性的糖尿病肾脏疾病(diabetic kidney disease，DKD)流行病学调查资料，但就基层而言，2009-2013年的资料提示，我国社区2型糖尿病患者DKD患病率已高达40%左右，我国16.4%的终末期肾病患者由DKD所致。", "ner": [[0, 8, "Disease"], [35, 67, "Disease"], [91, 94, "Disease"], [120, 123, "Disease"], [148, 151, "Disease"], [180, 215, "Disease"], [252, 256, "Disease"], [259, 261, "Disease"], [285, 286, "Disease"], [290, 292, "Disease"], [3, 5, "Anatomy"], [38, 40, "Anatomy"], [91, 92, "Anatomy"], [120, 121, "Anatomy"], [183, 183, "Anatomy"], [285, 285, "Anatomy"], [18, 22, "Reason"], [24, 26, "Reason"]], "rel": [[3, 5, "Anatomy", 0, 8, "Disease", "Anatomy_Disease"], [18, 22, "Reason", 0, 8, "Disease", "Reason_Disease"], [24, 26, "Reason", 0, 8, "Disease", "Reason_Disease"], [38, 40, "Anatomy", 35, 67, "Disease", "Anatomy_Disease"], [91, 92, "Anatomy", 91, 94, "Disease", "Anatomy_Disease"], [120, 121, "Anatomy", 120, 123, "Disease", "Anatomy_Disease"], [183, 183, "Anatomy", 180, 215, "Disease", "Anatomy_Disease"], [285, 285, "Anatomy", 285, 286, "Disease", "Anatomy_Disease"]]}
{"idx": 2512, "sentence": "糖尿病诊断后，病程3年、 10年、15年、20年、25年的DKD累计患病率分别为3%、6%、10%、28%、56%。", "ner": [[0, 2, "Disease"], [29, 31, "Disease"]], "rel": []}
{"idx": 2513, "sentence": "最近关于新诊断2型糖尿病患者的全国多中心研究显示，平均病程为8.1年的2型糖尿病患者神经病变的患病率为15.2%。", "ner": [[7, 11, "Disease"], [35, 39, "Disease"], [42, 45, "Disease"], [42, 43, "Anatomy"]], "rel": [[42, 43, "Anatomy", 42, 45, "Disease", "Anatomy_Disease"]]}
{"idx": 2514, "sentence": "本共识主要描述糖尿病周围神经病变 (diabetic peripheral neuropathy，DPN)。", "ner": [[7, 52, "Disease"], [10, 13, "Anatomy"]], "rel": [[10, 13, "Anatomy", 7, 52, "Disease", "Anatomy_Disease"]]}
{"idx": 2515, "sentence": " ", "ner": [], "rel": []}
{"idx": 2516, "sentence": "数据显示，伴微血管并发症的糖尿病患者年直接医疗费用是无并发症患者的3.18倍，因此，微血管并发症的防治是2型糖尿病管理中非常重要的环节。", "ner": [[6, 11, "Disease"], [13, 15, "Disease"], [42, 47, "Disease"], [52, 56, "Disease"], [6, 8, "Anatomy"], [42, 44, "Anatomy"]], "rel": [[6, 8, "Anatomy", 6, 11, "Disease", "Anatomy_Disease"], [42, 44, "Anatomy", 42, 47, "Disease", "Anatomy_Disease"]]}
{"idx": 2517, "sentence": " ", "ner": [], "rel": []}
{"idx": 2518, "sentence": "2 基层医疗卫生机构糖尿病微血管并发症管理现状 ", "ner": [[10, 18, "Disease"], [13, 15, "Anatomy"]], "rel": [[13, 15, "Anatomy", 10, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 2519, "sentence": "基层医疗卫生机构在糖尿病及其并发症的防控中担任重要角色。我国87%的糖尿病患者就诊于县级及以下医疗机构，而农村人群糖尿病的知晓率、治疗率及控制率均低于城市人群(24.6%vs38.7%，21.5%vs32.7%，38.6%vs40.8%)。然而，基层医疗卫生机构尚缺乏完整和规范的糖尿病微血管并发症筛查、防治及管理流程。以DR为例，50%以上就诊于基层医疗卫生机构的糖尿病患者未被告知应定期接受眼底检查，近70%的糖尿病患者未接受规范的眼科治疗，90%具有激光治疗指征的DR患者未接受激光治疗。", "ner": [[9, 11, "Disease"], [34, 36, "Disease"], [57, 59, "Disease"], [140, 148, "Disease"], [183, 185, "Disease"], [207, 209, "Disease"], [235, 236, "Disease"], [161, 162, "Disease"], [143, 145, "Anatomy"], [197, 200, "Test"], [242, 245, "Treatment"]], "rel": [[143, 145, "Anatomy", 140, 148, "Disease", "Anatomy_Disease"], [197, 200, "Test", 183, 185, "Disease", "Test_Disease"], [242, 245, "Treatment", 235, 236, "Disease", "Treatment_Disease"]]}
{"idx": 2520, "sentence": " ", "ner": [], "rel": []}
{"idx": 2521, "sentence": "3 基层医疗卫生机构糖尿病微血管并发症的筛查、诊断、随访教育及分级诊疗建议 ", "ner": [[10, 18, "Disease"], [13, 15, "Anatomy"]], "rel": [[13, 15, "Anatomy", 10, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 2522, "sentence": "3.1 基本配置建议(参考附录1)我国2017年发布的《中国糖尿病视网膜病变防治指南(基层版)》和同年美国糖尿病学会(American Diabetes Assoc- iation，ADA) 发布的DR指南中都强调了2型糖尿病患者应在诊断后进行眼底筛查，并明确了眼底照相在DR筛查和诊断中的地位与意义。", "ner": [[30, 37, "Disease"], [53, 55, "Disease"], [99, 100, "Disease"], [108, 112, "Disease"], [136, 137, "Disease"], [33, 35, "Anatomy"], [122, 125, "Test"], [131, 134, "Test"]], "rel": [[33, 35, "Anatomy", 30, 37, "Disease", "Anatomy_Disease"], [122, 125, "Test", 108, 112, "Disease", "Test_Disease"], [131, 134, "Test", 136, 137, "Disease", "Test_Disease"]]}
{"idx": 2523, "sentence": "在当地医院缺乏有资质的眼科医师时，免散瞳眼底照相可以作为DR筛查的有效措施；但应由有经验的眼科医师或经过认证的智能远程系统辅助读片。", "ner": [[28, 29, "Disease"], [17, 23, "Test"]], "rel": [[17, 23, "Test", 28, 29, "Disease", "Test_Disease"]]}
{"idx": 2524, "sentence": "同时，眼底照相操作简便，应在患者初诊时进行。", "ner": [[3, 6, "Test"]], "rel": []}
{"idx": 2525, "sentence": "因此，本共识建议将免散瞳眼底照相机作为基层医疗卫生机构筛查DR的首选设备进行配置，在无相关技术及设备的情况下，建议转诊至上一级医院进行检查。", "ner": [[29, 30, "Disease"], [9, 16, "Test"]], "rel": [[9, 16, "Test", 29, 30, "Disease", "Test_Disease"]]}
{"idx": 2526, "sentence": " ", "ner": [], "rel": []}
{"idx": 2527, "sentence": "尿微量白蛋白排泄的检测方法包括尿白蛋白/尿肌酐比值(ACR)及尿白蛋白定量等，检测技术已较为成熟，ACR与尿白蛋白定量比较，具有快速、简便、精确等特点。这些检测方法在多数基层医疗卫生机构均能开展或可外送第三方检测机构，因此本项共识建议将尿ACR作为基层医疗卫生机构DKD筛查的首选方法。", "ner": [[0, 5, "Test_items"], [15, 29, "Test_items"], [31, 34, "Test_items"], [49, 51, "Test_items"], [53, 56, "Test_items"], [118, 121, "Test_items"], [132, 134, "Disease"]], "rel": [[118, 121, "Test_items", 132, 134, "Disease", "Test_items_Disease"]]}
{"idx": 2528, "sentence": " ", "ner": [], "rel": []}
{"idx": 2529, "sentence": "近年来，随着检查技术的进步，DPN的诊断率有所提高。目前的评估主要依据患者临床症状和体征。5项检查(踝反射、针刺痛觉、震动觉、压力觉、温度觉)等方法半定量评估患者的神经病变程度。本共识建议基层医疗卫生机构配置神经病变筛查工具，条件允许的情况下可考虑配备感觉阈值测定仪，用以评估DPN。", "ner": [[14, 16, "Disease"], [138, 140, "Disease"], [104, 107, "Disease"], [82, 85, "Disease"], [104, 105, "Anatomy"], [82, 83, "Anatomy"], [50, 52, "Test"], [54, 57, "Test"], [59, 61, "Test"], [63, 65, "Test"], [67, 69, "Test"]], "rel": [[104, 105, "Anatomy", 104, 107, "Disease", "Anatomy_Disease"], [82, 83, "Anatomy", 82, 85, "Disease", "Anatomy_Disease"], [50, 52, "Test", 82, 85, "Disease", "Test_Disease"], [54, 57, "Test", 82, 85, "Disease", "Test_Disease"], [59, 61, "Test", 82, 85, "Disease", "Test_Disease"], [63, 65, "Test", 82, 85, "Disease", "Test_Disease"], [67, 69, "Test", 82, 85, "Disease", "Test_Disease"]]}
{"idx": 2530, "sentence": "3.2 筛查与随访筛查项目与随访频率推荐见表1。", "ner": [], "rel": []}
{"idx": 2531, "sentence": " ", "ner": [], "rel": []}
{"idx": 2532, "sentence": "3.3糖尿病微血管并发症的诊断DR的诊断参考2 017年《中国糖尿病视网膜病变防治指南(基层版)》，依据散瞳后眼底镜检查或眼底照相结果进行诊断与分级。DKD的诊断标准参考《美国肾脏基金会肾脏病预后质量倡议(NKF-K/DOQI)指南标准》。DPN的诊断参考《中国2型糖尿病防治指南(2017年版)》的诊断标准(详见附录2 )。如要确诊是否为DKD或糖尿病合并肾脏疾病，需行肾穿刺活检。", "ner": [[3, 11, "Disease"], [15, 16, "Disease"], [31, 38, "Disease"], [75, 77, "Disease"], [93, 95, "Disease"], [120, 122, "Disease"], [131, 135, "Disease"], [170, 172, "Disease"], [174, 176, "Disease"], [179, 182, "Disease"], [6, 8, "Anatomy"], [34, 36, "Anatomy"], [93, 94, "Anatomy"], [179, 180, "Anatomy"], [52, 59, "Test"], [61, 64, "Test"], [186, 190, "Test"]], "rel": [[6, 8, "Anatomy", 3, 11, "Disease", "Anatomy_Disease"], [52, 59, "Test", 15, 16, "Disease", "Test_Disease"], [61, 64, "Test", 15, 16, "Disease", "Test_Disease"], [34, 36, "Anatomy", 31, 38, "Disease", "Anatomy_Disease"], [93, 94, "Anatomy", 93, 95, "Disease", "Anatomy_Disease"], [186, 190, "Test", 170, 172, "Disease", "Test_Disease"], [186, 190, "Test", 174, 176, "Disease", "Test_Disease"], [179, 180, "Anatomy", 179, 182, "Disease", "Anatomy_Disease"], [186, 190, "Test", 179, 182, "Disease", "Test_Disease"]]}
{"idx": 2533, "sentence": " ", "ner": [], "rel": []}
{"idx": 2534, "sentence": "3.4 分级诊疗服务目标与转诊机制 ", "ner": [], "rel": []}
{"idx": 2535, "sentence": "(1)国家分级诊疗制度中关于不同等级医院的分工：2015年9月，国务院办公厅印发《国务院办公厅关于推进分级诊疗制度建设的指导意见(国办发(2015)70号)》，部署加快推进分级诊疗制度建设，形成科学有序的就医秩序，全面提高人民卫生服务水平，进一步保障和改善民生。分级诊疗模式可概括为16个字：基层首诊、双向转诊、急慢分治、上下联动。基层医疗卫生机构具备常见慢性病的诊疗能力，是实施分级诊疗的重要基础。在糖尿病患者的长期管理中，加强基层医疗卫生机构医师和护士糖尿病专业知识的规范化培训，以患者的需求为中心，充当糖尿病首诊、知识宣教、长期随访的主力军。二级医院组建糖尿病专业管理团队，全面管理糖尿病患者的血糖、血压、血脂，着力于糖尿病的诊断、并发症的筛查及慢性并发症的诊治，发挥承上启下作用。", "ner": [[201, 203, "Disease"], [228, 230, "Disease"], [254, 256, "Disease"], [280, 282, "Disease"], [294, 296, "Disease"], [312, 314, "Disease"], [300, 301, "Test_items"], [303, 304, "Test"], [306, 307, "Test_items"]], "rel": [[300, 301, "Test_items", 294, 296, "Disease", "Test_items_Disease"], [303, 304, "Test", 294, 296, "Disease", "Test_Disease"], [306, 307, "Test_items", 294, 296, "Disease", "Test_items_Disease"]]}
{"idx": 2536, "sentence": "三级医院积极将诊断明确、病情稳定的患者转诊至基层医疗卫生机构是实施分级诊疗的关键。", "ner": [], "rel": []}
{"idx": 2537, "sentence": "由不同等级医院实现有效的临床交流和互动，构建专科联盟，达到迅速、便捷、规范化的双向转诊，真正做到上下联动。", "ner": [], "rel": []}
{"idx": 2538, "sentence": " ", "ner": [], "rel": []}
{"idx": 2539, "sentence": "(2)基层医疗卫生机构糖尿病微血管并发症分级诊疗和双向转诊建议：糖尿病患者适时地双向转诊是为了确保患者得到早期筛查和安全有效的治疗，最大限度地发挥基层医疗卫生机构和专科医疗机构各自的优势；同时也是应对在糖尿病微血管病变筛查中所面临的我国基层医疗卫生机构资源配置不平衡、尤其是筛查设备配备不足问题的有效解决方法之一。", "ner": [[11, 19, "Disease"], [32, 34, "Disease"], [101, 107, "Disease"], [14, 16, "Anatomy"], [104, 106, "Anatomy"]], "rel": [[14, 16, "Anatomy", 11, 19, "Disease", "Anatomy_Disease"], [104, 106, "Anatomy", 101, 107, "Disease", "Anatomy_Disease"]]}
{"idx": 2540, "sentence": "转诊对象的纳入标准(以糖尿病微血管并发症患者为对象)如下，满足下列任一条件者需进行双向转诊。", "ner": [[11, 19, "Disease"], [14, 16, "Anatomy"]], "rel": [[14, 16, "Anatomy", 11, 19, "Disease", "Anatomy_Disease"]]}
{"idx": 2541, "sentence": "转往上级医院：①基层医疗卫生机构缺乏糖尿病微血管并发症筛查设备；②糖尿病微血管并发症患者需调整治疗方案；③糖尿病患者出现严重微血管并发症或病情进一步恶化，基层医疗卫生机构缺乏进一步改善微血管并发症的治疗手段，医患双方均同意转往上级医院就诊。", "ner": [[18, 26, "Disease"], [33, 41, "Disease"], [53, 55, "Disease"], [62, 67, "Disease"], [92, 97, "Disease"], [21, 23, "Anatomy"], [36, 38, "Anatomy"], [62, 64, "Anatomy"], [92, 94, "Anatomy"], [60, 61, "Level"]], "rel": [[21, 23, "Anatomy", 18, 26, "Disease", "Anatomy_Disease"], [36, 38, "Anatomy", 33, 41, "Disease", "Anatomy_Disease"], [62, 64, "Anatomy", 62, 67, "Disease", "Anatomy_Disease"], [92, 94, "Anatomy", 92, 97, "Disease", "Anatomy_Disease"]]}
{"idx": 2542, "sentence": "转往基层医疗卫生机构：①患者在当地中心医院或三级甲等医院完成糖尿病微血管并发症的筛查项目；②治疗方案确定且血糖基本控制稳定；③糖尿病微血管并发症患者的症状和体征得到控制或改善，医患双方均同意转回基层医疗卫生机构。", "ner": [[30, 38, "Disease"], [63, 71, "Disease"], [33, 35, "Anatomy"], [66, 68, "Anatomy"], [53, 54, "Test_items"], [59, 60, "Test_Value"]], "rel": [[33, 35, "Anatomy", 30, 38, "Disease", "Anatomy_Disease"], [66, 68, "Anatomy", 63, 71, "Disease", "Anatomy_Disease"]]}
{"idx": 2543, "sentence": " ", "ner": [], "rel": []}
{"idx": 2544, "sentence": "糖尿病微血管病变筛查与防治双向转诊流程见图1，具体并发症筛查与防治双向转诊流程见图2一4。", "ner": [[0, 7, "Disease"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 0, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 2545, "sentence": " ", "ner": [], "rel": []}
{"idx": 2546, "sentence": "3.5 患者管理与教育基层医疗卫生机构医师需要为患者建立糖尿病及其并发症相关档案，主要包括患者的基本信息、一般资料、DR、DKD、DPN、自主神经病变筛查记录，具体筛查记录表格见附录1。", "ner": [[28, 30, "Disease"], [58, 59, "Disease"], [61, 63, "Disease"], [65, 67, "Disease"], [69, 74, "Disease"], [69, 72, "Anatomy"]], "rel": [[69, 72, "Anatomy", 69, 74, "Disease", "Anatomy_Disease"]]}
{"idx": 2547, "sentence": " ", "ner": [], "rel": []}
{"idx": 2548, "sentence": "4 基层医疗卫生机构糖尿病微血管并发症的预防和治疗 ", "ner": [[10, 18, "Disease"], [13, 15, "Anatomy"]], "rel": [[13, 15, "Anatomy", 10, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 2549, "sentence": "4.1 糖尿病微血管并发症的筛查与预防 ", "ner": [[4, 12, "Disease"], [7, 9, "Anatomy"]], "rel": [[7, 9, "Anatomy", 4, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 2550, "sentence": "积极控制血糖、血压、血脂等危险因素是预防和延缓糖尿病微血管并发症的基础，基本原则包括纠正高血糖、高血压及血脂异常。", "ner": [[23, 31, "Disease"], [26, 28, "Anatomy"], [4, 5, "Test_items"], [7, 8, "Test"], [10, 11, "Test_items"], [44, 46, "Disease"], [48, 50, "Disease"], [52, 55, "Disease"]], "rel": [[26, 28, "Anatomy", 23, 31, "Disease", "Anatomy_Disease"], [4, 5, "Test_items", 23, 31, "Disease", "Test_items_Disease"], [10, 11, "Test_items", 23, 31, "Disease", "Test_items_Disease"], [7, 8, "Test", 23, 31, "Disease", "Test_Disease"]]}
{"idx": 2551, "sentence": "(1)血糖控制：DCCT、UKPDS、VADT等多项临床研究结果均显示强化血糖控制可以降低糖尿病微血管并发症的发生风险。大多数成人2型糖尿病患者合理的糖化血红蛋白(HbA1c)目标是<7%。研究证明，严格控制血糖，使HbA1c<6.5%，可以更好地预防糖尿病微血管并发症的发生。对于经过生活方式干预和规范口服降糖药治疗3个月血糖仍不能达标的2型糖尿病患者，需及时使用胰岛素治疗。此外，具有降糖之外微血管病变防治效应的降糖药应优先选择。基层医疗卫生机构在使用胰岛素时可优先考虑使用方便、低血糖风险小的胰岛素产品，如基础胰岛素等。目前，国内外指南对糖尿病微血管并发症防治的降糖药物并无特别推荐，但有研究显示，及时开始胰岛素治疗可以延缓糖尿病患者微血管瘤和DR的进展。ORIGIN研究亦显示，甘精胰岛素可延缓糖尿病患者DKD和微量白蛋白尿的进展。", "ner": [[45, 53, "Disease"], [65, 69, "Disease"], [126, 134, "Disease"], [170, 174, "Disease"], [198, 202, "Disease"], [272, 280, "Disease"], [315, 317, "Disease"], [320, 323, "Disease"], [325, 326, "Disease"], [315, 317, "Disease"], [351, 353, "Disease"], [356, 358, "Disease"], [48, 50, "Anatomy"], [129, 131, "Anatomy"], [198, 200, "Anatomy"], [275, 277, "Anatomy"], [320, 322, "Anatomy"], [37, 38, "Test_items"], [75, 87, "Test_items"], [104, 105, "Test_items"], [108, 112, "Test_items"], [162, 163, "Test_items"], [343, 347, "Drug"], [360, 365, "Test_items"], [91, 93, "Test_Value"], [113, 117, "Test_Value"], [165, 168, "Test_Value"], [152, 153, "Method"], [183, 185, "Drug"], [228, 230, "Drug"], [249, 251, "Drug"], [256, 260, "Drug"], [306, 308, "Drug"], [143, 148, "Treatment"], [159, 161, "Duration"], [242, 244, "ADE"]], "rel": [[48, 50, "Anatomy", 45, 53, "Disease", "Anatomy_Disease"], [37, 38, "Test_items", 45, 53, "Disease", "Test_items_Disease"], [75, 87, "Test_items", 65, 69, "Disease", "Test_items_Disease"], [129, 131, "Anatomy", 126, 134, "Disease", "Anatomy_Disease"], [162, 163, "Test_items", 170, 174, "Disease", "Test_items_Disease"], [183, 185, "Drug", 170, 174, "Disease", "Drug_Disease"], [143, 148, "Treatment", 170, 174, "Disease", "Treatment_Disease"], [198, 200, "Anatomy", 198, 202, "Disease", "Anatomy_Disease"], [275, 277, "Anatomy", 272, 280, "Disease", "Anatomy_Disease"], [320, 322, "Anatomy", 320, 323, "Disease", "Anatomy_Disease"], [306, 308, "Drug", 320, 323, "Disease", "Drug_Disease"], [306, 308, "Drug", 325, 326, "Disease", "Drug_Disease"], [306, 308, "Drug", 315, 317, "Disease", "Drug_Disease"], [343, 347, "Drug", 351, 353, "Disease", "Drug_Disease"], [343, 347, "Drug", 356, 358, "Disease", "Drug_Disease"], [242, 244, "ADE", 228, 230, "Drug", "ADE_Drug"]]}
{"idx": 2552, "sentence": " ", "ner": [], "rel": []}
{"idx": 2553, "sentence": "(2)血压控制：2型糖尿病患者每次随访均需监测血压。对于糖尿病合并高血压的患者，除接受生活方式干预外，需立即行药物治疗，以及时达到血压控制目标，无DKD的糖尿病患者血压控制目标为≤140/90mmHg，有DR、DKD或脑血管损伤患者的血压控制目标为≤130/80mmHg。降压药物的选择如下：血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂(ACEI/ARB)、噻嗪类利尿剂或钙通道阻滞剂(CCB)，通常需联用多种降压药物。对于微量白蛋白/肌酐比值(UACR)≥300mg/g肌酐或30~299mg/g肌酐的糖尿病患者，推荐采用最大可耐受剂量ACEI或ARB作为高血压治疗的一线用药。", "ner": [[8, 12, "Disease"], [73, 75, "Disease"], [77, 79, "Disease"], [102, 103, "Disease"], [105, 107, "Disease"], [109, 113, "Disease"], [280, 282, "Disease"], [28, 30, "Disease"], [33, 35, "Disease"], [109, 111, "Anatomy"], [23, 24, "Test"], [65, 66, "Test"], [82, 83, "Test"], [117, 118, "Test"], [213, 228, "Test_items"], [253, 255, "Disease"], [89, 99, "Test_Value"], [124, 134, "Test_Value"], [229, 238, "Test_Value"], [240, 251, "Test_Value"], [146, 178, "Drug"], [180, 185, "Drug"], [187, 197, "Drug"], [270, 273, "Drug"], [275, 277, "Drug"]], "rel": [[23, 24, "Test", 8, 12, "Disease", "Test_Disease"], [82, 83, "Test", 77, 79, "Disease", "Test_Disease"], [117, 118, "Test", 102, 103, "Disease", "Test_Disease"], [117, 118, "Test", 105, 107, "Disease", "Test_Disease"], [109, 111, "Anatomy", 109, 113, "Disease", "Anatomy_Disease"], [117, 118, "Test", 109, 113, "Disease", "Test_Disease"], [270, 273, "Drug", 280, 282, "Disease", "Drug_Disease"], [275, 277, "Drug", 280, 282, "Disease", "Drug_Disease"], [65, 66, "Test", 28, 30, "Disease", "Test_Disease"], [65, 66, "Test", 33, 35, "Disease", "Test_Disease"], [213, 228, "Test_items", 253, 255, "Disease", "Test_items_Disease"]]}
{"idx": 2554, "sentence": "不建议ACEI和ARB联用。", "ner": [[3, 6, "Test_items"], [8, 10, "Test_items"]], "rel": []}
{"idx": 2555, "sentence": "使用ACEI、ARB或利尿剂时，需注意检测患者血肌酐、估算肾小球滤过率(eGFR)及血钾水平。", "ner": [[23, 25, "Test_items"], [29, 40, "Test_items"], [42, 43, "Test_items"], [2, 5, "Drug"], [7, 9, "Drug"], [11, 13, "Drug"]], "rel": []}
{"idx": 2556, "sentence": " ", "ner": [], "rel": []}
{"idx": 2557, "sentence": "(3)血脂控制：2型糖尿病患者每年应至少进行1次血脂检查。接受调脂药物治疗者，根据评估疗效的需要可增加检查次数。目前常用的降脂药物主要包括：他汀类、贝特类、烟酸类、胆酸螯合剂、依折麦布、n-3脂肪酸制剂。在进行降脂药物治疗时，应将降低低密度脂蛋白胆固醇(LDL-C)作为首要目标。未合并冠心病患者的LDL-C<2.6mmol/L，合并冠心病患者的LDL-C<1.8mmol/L。若甘油三酯>5.7mmol/L，可在生活方式干预的基础上使用降低甘油三酯的药物，以降低急性胰腺炎的发生风险。FIELD研究显示，非诺贝特可减缓DR进展，减少激光治疗需求。", "ner": [[3, 4, "Test_items"], [8, 12, "Disease"], [24, 27, "Test"], [70, 72, "Drug"], [74, 76, "Drug"], [78, 80, "Drug"], [82, 86, "Drug"], [88, 91, "Drug"], [93, 100, "Drug"], [253, 256, "Drug"], [117, 132, "Test_items"], [149, 153, "Test_items"], [173, 177, "Test_items"], [190, 193, "Test_items"], [178, 187, "Test_Value"], [194, 203, "Test_Value"], [154, 163, "Test_Value"], [221, 224, "Test_items"], [143, 145, "Disease"], [207, 212, "Treatment"], [167, 169, "Disease"], [232, 236, "Disease"], [234, 235, "Anatomy"], [260, 261, "Disease"], [267, 270, "Treatment"]], "rel": [[24, 27, "Test", 8, 12, "Disease", "Test_Disease"], [253, 256, "Drug", 260, 261, "Disease", "Drug_Disease"], [149, 153, "Test_items", 143, 145, "Disease", "Test_items_Disease"], [173, 177, "Test_items", 167, 169, "Disease", "Test_items_Disease"], [207, 212, "Treatment", 167, 169, "Disease", "Treatment_Disease"], [234, 235, "Anatomy", 232, 236, "Disease", "Anatomy_Disease"], [267, 270, "Treatment", 260, 261, "Disease", "Treatment_Disease"]]}
{"idx": 2558, "sentence": " ", "ner": [], "rel": []}
{"idx": 2559, "sentence": "糖尿病微血管并发症预防的推荐意见见表2。", "ner": [[0, 8, "Disease"], [3, 5, "Anatomy"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 0, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 2560, "sentence": "4.2 糖尿病微血管并发症的治疗对于己合并DR、DKD或DPN的糖尿病患者，延缓并发症进展、及时给予针对性治疗可最大限度地保护靶器官，减少失明、终末期肾病及糖尿病足等事件的发生。积极控制血糖、血压、血脂仍是糖尿病治疗的基础。改善微循环治疗是针对糖尿病微血管病变重要的临床治疗方法，改善糖尿病微循环用药应遵循“早期、个体化、合理联合、重视安全”的原则。", "ner": [[4, 12, "Disease"], [21, 22, "Disease"], [24, 26, "Disease"], [28, 30, "Disease"], [32, 34, "Disease"], [69, 70, "Disease"], [75, 76, "Disease"], [78, 81, "Disease"], [103, 105, "Disease"], [122, 129, "Disease"], [142, 144, "Disease"], [7, 9, "Anatomy"], [75, 75, "Anatomy"], [125, 127, "Anatomy"], [93, 94, "Test_items"], [96, 97, "Test"], [99, 100, "Test_items"], [112, 118, "Treatment"]], "rel": [[7, 9, "Anatomy", 4, 12, "Disease", "Anatomy_Disease"], [75, 75, "Anatomy", 75, 76, "Disease", "Anatomy_Disease"], [93, 94, "Test_items", 103, 105, "Disease", "Test_items_Disease"], [96, 97, "Test", 103, 105, "Disease", "Test_Disease"], [99, 100, "Test_items", 103, 105, "Disease", "Test_items_Disease"], [125, 127, "Anatomy", 122, 129, "Disease", "Anatomy_Disease"], [112, 118, "Treatment", 122, 129, "Disease", "Treatment_Disease"]]}
{"idx": 2561, "sentence": " ", "ner": [], "rel": []}
{"idx": 2562, "sentence": "(1)DR：改善微循环治疗可能延缓DR的进展。①胰激肽原酶，可增加毛细血管血流量，激活纤溶酶，降低血液黏度，改善血流变；②羟苯磺酸钙，可抗氧化应激和炎症，维护视网膜屏障完整性，抑制新生血管生成，延缓DR进展；③抗血管内皮生长因子药物，包括雷珠单抗和贝伐单抗，可用于各种原因引起的黄斑水肿、视网膜新生血管等。", "ner": [[3, 4, "Disease"], [17, 18, "Disease"], [99, 100, "Disease"], [139, 142, "Disease"], [144, 150, "Disease"], [139, 140, "Anatomy"], [144, 146, "Anatomy"], [6, 12, "Treatment"], [24, 28, "Drug"], [61, 65, "Drug"], [105, 115, "Drug"], [119, 122, "Drug"], [124, 127, "Drug"]], "rel": [[6, 12, "Treatment", 17, 18, "Disease", "Treatment_Disease"], [61, 65, "Drug", 99, 100, "Disease", "Drug_Disease"], [139, 140, "Anatomy", 139, 142, "Disease", "Anatomy_Disease"], [105, 115, "Drug", 139, 142, "Disease", "Drug_Disease"], [119, 122, "Drug", 139, 142, "Disease", "Drug_Disease"], [124, 127, "Drug", 139, 142, "Disease", "Drug_Disease"], [144, 146, "Anatomy", 144, 150, "Disease", "Anatomy_Disease"], [105, 115, "Drug", 144, 150, "Disease", "Drug_Disease"], [119, 122, "Drug", 144, 150, "Disease", "Drug_Disease"], [124, 127, "Drug", 144, 150, "Disease", "Drug_Disease"]]}
{"idx": 2563, "sentence": " ", "ner": [], "rel": []}
{"idx": 2564, "sentence": "对于重度非增殖型糖尿病视网膜病变(non-proli- ferative diabetic retinopathy，NPDR) 及增殖型糖尿病视网膜病变(proliferative diabetic retinopathy，PDR) 的糖尿病患者需请眼科医师会诊。高危PDR和部分严重NPDR患者可行激光光凝术。", "ner": [[65, 115, "Disease"], [4, 62, "Disease"], [118, 120, "Disease"], [134, 136, "Disease"], [142, 145, "Disease"], [2, 3, "Level"], [132, 133, "Level"], [140, 141, "Level"], [150, 154, "Treatment"]], "rel": [[150, 154, "Treatment", 134, 136, "Disease", "Treatment_Disease"], [150, 154, "Treatment", 142, 145, "Disease", "Treatment_Disease"]]}
{"idx": 2565, "sentence": " ", "ner": [], "rel": []}
{"idx": 2566, "sentence": "对于eGFR<30ml/(min·1.73m2) 的DKD患者应请肾脏专科医师治疗；若eGFR<15ml/(min·1.73m2) ，需考虑替代治疗，如进行血液透析治疗等。", "ner": [[26, 28, "Disease"], [2, 5, "Test_items"], [43, 46, "Test_items"], [6, 23, "Test_Value"], [47, 64, "Test_Value"], [78, 83, "Treatment"]], "rel": [[2, 5, "Test_items", 26, 28, "Disease", "Test_items_Disease"]]}
{"idx": 2567, "sentence": " ", "ner": [], "rel": []}
{"idx": 2568, "sentence": "(3)DPN：积极严格地控制高血糖并保持血糖稳定是预防和治疗DPN最重要的措施，", "ner": [[3, 5, "Disease"], [30, 32, "Disease"], [14, 16, "Disease"], [20, 21, "Test_items"], [22, 23, "Test_Value"]], "rel": [[20, 21, "Test_items", 30, 32, "Disease", "Test_items_Disease"]]}
{"idx": 2569, "sentence": "针对神经病变发病机制的治疗包括：①神经修复，常用药物有甲钴胺、神经生长因子等；②神经营养因子、肌醇、神经节苷酯及亚麻酸等。针对神经病变发病机制的治疗包括：①抗氧化应激：通过抑制脂质过氧化，增加神经营养血管的血流量，提高神经Na+-K+-ATP酶活性，保护血管内皮功能，常用药物为硫辛酸；②改善代谢素乱：醛糖还原酶抑制剂，常用依帕司他等；③改善微循环：周围神经血流减少是导致DPN发生的重要因素，通过扩张血管，改善血液高凝状态和微循环，提高神经细胞的血氧供应，可有效改善DPN患者的临床症状，常用药物包括前列地尔、贝前列素钠、西洛他唑、己酮可可碱、胰激肽原酶、CCB及活血化瘀类中药等。", "ner": [[2, 5, "Disease"], [234, 236, "Disease"], [186, 188, "Disease"], [63, 66, "Disease"], [2, 3, "Anatomy"], [63, 64, "Anatomy"], [175, 182, "Reason"], [27, 29, "Drug"], [31, 36, "Drug"], [40, 45, "Drug"], [47, 48, "Drug"], [50, 54, "Drug"], [56, 58, "Drug"], [139, 141, "Drug"], [151, 158, "Drug"], [162, 165, "Drug"], [251, 254, "Drug"], [256, 260, "Drug"], [262, 265, "Drug"], [267, 271, "Drug"], [273, 277, "Drug"], [279, 281, "Drug"]], "rel": [[2, 3, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [27, 29, "Drug", 2, 5, "Disease", "Drug_Disease"], [31, 36, "Drug", 2, 5, "Disease", "Drug_Disease"], [251, 254, "Drug", 234, 236, "Disease", "Drug_Disease"], [256, 260, "Drug", 234, 236, "Disease", "Drug_Disease"], [262, 265, "Drug", 234, 236, "Disease", "Drug_Disease"], [267, 271, "Drug", 234, 236, "Disease", "Drug_Disease"], [273, 277, "Drug", 234, 236, "Disease", "Drug_Disease"], [279, 281, "Drug", 234, 236, "Disease", "Drug_Disease"], [175, 182, "Reason", 186, 188, "Disease", "Reason_Disease"], [63, 64, "Anatomy", 63, 66, "Disease", "Anatomy_Disease"]]}
{"idx": 2570, "sentence": " ", "ner": [], "rel": []}
{"idx": 2571, "sentence": "糖尿病微血管并发症治疗的推荐意见见表3。", "ner": [[0, 8, "Disease"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 0, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 2572, "sentence": "5 总结与展望 ", "ner": [], "rel": []}
{"idx": 2573, "sentence": "衷心希望《基层糖尿病微血管病变筛查与防治专家共识》的发布能够为推动我国基层糖尿病防控的发展贡献力量，希望基层医疗卫生机构能在微血管并发症筛查和管理方面多方联动，逐步完善，真正有效地预防和控制糖尿病微血管并发症的发生发展，改善患者生存质量，减轻患者家庭和社会卫生经济负担。", "ner": [[7, 14, "Disease"], [10, 12, "Anatomy"], [37, 39, "Disease"], [62, 67, "Disease"], [62, 64, "Anatomy"], [95, 103, "Disease"], [98, 100, "Anatomy"]], "rel": [[10, 12, "Anatomy", 7, 14, "Disease", "Anatomy_Disease"], [62, 64, "Anatomy", 62, 67, "Disease", "Anatomy_Disease"], [98, 100, "Anatomy", 95, 103, "Disease", "Anatomy_Disease"]]}
{"idx": 2574, "sentence": " ", "ner": [], "rel": []}
{"idx": 2575, "sentence": "附录2：糖尿病微血管并发症诊断", "ner": [[4, 12, "Disease"], [7, 9, "Anatomy"]], "rel": [[7, 9, "Anatomy", 4, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 2576, "sentence": "(1)糖尿病视网膜病变(DR)的诊断：DR依据散瞳后眼底镜检查或眼底照相结果进行诊断与分级诊断与分级标准参照目前全球统一的“糖黄斑水肿疾病严重程度分级标准。", "ner": [[3, 14, "Disease"], [6, 8, "Anatomy"], [19, 20, "Disease"], [23, 30, "Test"], [32, 35, "Test"], [62, 66, "Disease"], [63, 64, "Anatomy"]], "rel": [[6, 8, "Anatomy", 3, 14, "Disease", "Anatomy_Disease"], [23, 30, "Test", 19, 20, "Disease", "Test_Disease"], [32, 35, "Test", 19, 20, "Disease", "Test_Disease"], [63, 64, "Anatomy", 62, 66, "Disease", "Anatomy_Disease"]]}
{"idx": 2577, "sentence": "(3)糖尿病周围神经病变(DPN)的诊断：DPN是指在排除其他原因的情况下，糖尿病患者出现周障碍相关的症状或体征，其中最常见及最具代尿病远端对称性多发性神经病变(DSPN)。", "ner": [[3, 16, "Disease"], [21, 23, "Disease"], [38, 40, "Disease"], [66, 85, "Disease"], [6, 9, "Anatomy"], [76, 77, "Anatomy"]], "rel": [[6, 9, "Anatomy", 3, 16, "Disease", "Anatomy_Disease"], [76, 77, "Anatomy", 66, 85, "Disease", "Anatomy_Disease"]]}
{"idx": 2578, "sentence": "DSPN诊断标准如下：", "ner": [[0, 3, "Disease"]], "rel": []}
{"idx": 2579, "sentence": "附录3 各项糖尿病微血管并发症检查方法DR：眼底检查或眼底照相。DKD：指导患者留取血、尿标本。", "ner": [[6, 14, "Disease"], [9, 11, "Anatomy"], [19, 20, "Disease"], [32, 34, "Disease"], [22, 25, "Test"], [27, 30, "Test"]], "rel": [[9, 11, "Anatomy", 6, 14, "Disease", "Anatomy_Disease"], [22, 25, "Test", 19, 20, "Disease", "Test_Disease"], [27, 30, "Test", 19, 20, "Disease", "Test_Disease"]]}
{"idx": 2580, "sentence": "DPN：", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2581, "sentence": "(1)音叉：深感觉评估，初步评估粗将振动的128Hz音叉末端置于双足趾背面的骨测试3次，在患者闭眼的状况下，询问患叉的振动，3次中2次以上回答错误判为振动中2次以上回答正确则判为振动觉存在。", "ner": [[3, 4, "Test"]], "rel": []}
{"idx": 2582, "sentence": "(2)尼龙单丝：深感觉评估。", "ner": [[3, 6, "Test"], [8, 12, "Test"]], "rel": []}
{"idx": 2583, "sentence": "初步评估粗感觉能。", "ner": [[2, 7, "Test"]], "rel": []}
{"idx": 2584, "sentence": "以双足趾及第I、第V跖骨头的掌面为检查部位胼胝及溃疡部位)，将单丝置于检察部位压弯，1~2，在患者闭眼的情况下，回答是否感觉到单丝的每个部位各测试3次，3次中2次以上回答错误则判为力觉缺失，3次中2次以上回答正确则判为压力觉存在。", "ner": [[24, 25, "Disease"]], "rel": []}
{"idx": 2585, "sentence": "(3)温觉：浅感觉评估，初步评估细录患者温度觉正常或异常。", "ner": [[3, 4, "Test"], [6, 10, "Test"]], "rel": []}
{"idx": 2586, "sentence": "任意一侧温阳性；双侧温度觉正常，则判为阴性。", "ner": [], "rel": []}
{"idx": 2587, "sentence": "(4)痛觉：浅感觉评估，初步评估细感觉纤意一侧针刺痛觉缺失，即判为阳性；双侧针刺判为阴性。", "ner": [[3, 4, "Test"], [6, 10, "Test"]], "rel": []}
{"idx": 2588, "sentence": "(5)踝反射：深反射检查，针对胫神经的传侧踝反射同时出现减弱或消失时判为阳性；反射减弱、消失、亢进及正常时均判为阴性。", "ner": [[3, 5, "Test"], [7, 11, "Test"]], "rel": []}
{"idx": 2589, "sentence": "(2)DKD：DKD患者需优质低蛋白饮食，戒烟，严格控制血压、血糖、血脂及尿酸水平。肾功能不全患者可优先选择经肾脏排泄较少的降糖药，严重肾功能不全患者应采用胰岛素治疗。", "ner": [[3, 5, "Disease"], [7, 9, "Disease"], [42, 46, "Disease"], [68, 72, "Disease"], [42, 42, "Anatomy"], [68, 68, "Anatomy"], [13, 19, "Treatment"], [21, 22, "Treatment"], [28, 29, "Test"], [31, 32, "Test_items"], [34, 35, "Test_items"], [37, 38, "Test_items"], [78, 80, "Drug"], [66, 67, "Level"]], "rel": [[13, 19, "Treatment", 7, 9, "Disease", "Treatment_Disease"], [21, 22, "Treatment", 7, 9, "Disease", "Treatment_Disease"], [28, 29, "Test", 7, 9, "Disease", "Test_Disease"], [31, 32, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [34, 35, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [37, 38, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [42, 42, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [68, 68, "Anatomy", 68, 72, "Disease", "Anatomy_Disease"], [78, 80, "Drug", 68, 72, "Disease", "Drug_Disease"]]}
{"idx": 2590, "sentence": "使用过程中应加强血糖监测，及时调整胰岛素的用量。", "ner": [[8, 9, "Test_items"], [17, 19, "Drug"]], "rel": []}
{"idx": 2591, "sentence": "降压药首选ACEI/ARB，在降低血压的同时可有效减少蛋白尿。", "ner": [[17, 18, "Test"], [5, 12, "Drug"], [27, 29, "Symptom"]], "rel": []}
{"idx": 2592, "sentence": " ", "ner": [], "rel": []}
{"idx": 2593, "sentence": "此外，改善微循环治疗可能延缓DKD进展；①胰激肽原酶对DKD具有一定疗效，但同样需要高质量的随机对照研究进一步证实；②前列地尔与贝前列素钠可舒张血管平滑肌，发挥扩血管作用，同时通过降低血液黏度、改善红细胞变形能力，从而改善微循环；③文献报道，银杏叶提取物、丹参提取物、黄芪制剂等中药制剂可能发挥一定的肾脏保护作用，但总体上仍缺乏高质量和大型研究数据的支持。", "ner": [[3, 9, "Treatment"], [14, 16, "Disease"], [27, 29, "Disease"], [21, 25, "Drug"], [59, 62, "Drug"], [64, 68, "Drug"], [121, 126, "Drug"], [128, 132, "Drug"], [134, 137, "Drug"]], "rel": [[3, 9, "Treatment", 14, 16, "Disease", "Treatment_Disease"], [21, 25, "Drug", 27, 29, "Disease", "Drug_Disease"]]}
{"idx": 2594, "sentence": " ", "ner": [], "rel": []}
{"idx": 2595, "sentence": "(6)感觉阈值测定：一般选用振动感觉阈值(VPT)检测仪进行测定，对平仰卧的糖尿病患者肢体进行感觉检查，可选择内踝及第一足趾部位进行测定，对两侧分别检测，首先用低档的初始电压，随时间慢慢增加电压，直至患者四肢有较明显的感觉为止，记录测定的感觉阈值。", "ner": [[3, 8, "Test"], [38, 40, "Disease"]], "rel": []}
{"idx": 2596, "sentence": "中国糖尿病足诊治指南 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2597, "sentence": "糖尿病足是导致我国糖尿病患者致残、致死的严重慢性并发症之一，其发病率高，治疗困难，花费巨大目前我国主要是参考国际足病工作者与美国糖尿病足病学组制定的指南。", "ner": [[0, 3, "Disease"], [3, 3, "Anatomy"], [9, 11, "Disease"], [56, 57, "Disease"], [56, 56, "Anatomy"], [64, 68, "Disease"], [67, 67, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [56, 56, "Anatomy", 56, 57, "Disease", "Anatomy_Disease"], [67, 67, "Anatomy", 64, 68, "Disease", "Anatomy_Disease"]]}
{"idx": 2598, "sentence": "但是，由于我国糖尿病足具有自身的特点，因此，中国医疗保健国际交流促进会组织全国足病相关专家起草了糖尿病足诊治指南。", "ner": [[7, 10, "Disease"], [10, 10, "Anatomy"], [39, 40, "Disease"], [39, 39, "Anatomy"], [48, 51, "Disease"], [51, 51, "Anatomy"]], "rel": [[10, 10, "Anatomy", 7, 10, "Disease", "Anatomy_Disease"], [39, 39, "Anatomy", 39, 40, "Disease", "Anatomy_Disease"], [51, 51, "Anatomy", 48, 51, "Disease", "Anatomy_Disease"]]}
{"idx": 2599, "sentence": " ", "ner": [], "rel": []}
{"idx": 2600, "sentence": "一、糖尿病足及高危足的概念 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"], [7, 9, "Disease"], [9, 9, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [9, 9, "Anatomy", 7, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 2601, "sentence": "糖尿病足：糖尿病患者因下肢远端神经异常和不同程度的血管病变导致的足部感染、溃疡和(或) 深层组织破坏。", "ner": [[0, 3, "Disease"], [3, 3, "Anatomy"], [5, 7, "Disease"], [11, 18, "Reason"], [20, 28, "Reason"], [32, 35, "Symptom"], [37, 38, "Symptom"], [44, 49, "Symptom"], [11, 16, "Anatomy"], [32, 33, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [11, 18, "Reason", 0, 3, "Disease", "Reason_Disease"], [20, 28, "Reason", 0, 3, "Disease", "Reason_Disease"], [11, 16, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [32, 33, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"]]}
{"idx": 2602, "sentence": " ", "ner": [], "rel": []}
{"idx": 2603, "sentence": "糖尿病高危足糖尿病患者未出现足溃疡但存在周围神经病变，不管是否存在足畸形或周围动脉病变或足溃疡史或截肢(趾)史。", "ner": [[6, 8, "Disease"], [14, 16, "Symptom"], [20, 25, "Disease"], [20, 23, "Anatomy"], [33, 35, "Disease"], [37, 42, "Disease"], [33, 33, "Anatomy"], [37, 40, "Anatomy"], [44, 46, "Disease"], [44, 44, "Anatomy"], [0, 5, "Disease"], [5, 5, "Anatomy"], [49, 53, "Operation"]], "rel": [[14, 16, "Symptom", 6, 8, "Disease", "Symptom_Disease"], [20, 23, "Anatomy", 20, 25, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 33, 35, "Disease", "Anatomy_Disease"], [37, 40, "Anatomy", 37, 42, "Disease", "Anatomy_Disease"], [44, 44, "Anatomy", 44, 46, "Disease", "Anatomy_Disease"], [5, 5, "Anatomy", 0, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2604, "sentence": " ", "ner": [], "rel": []}
{"idx": 2605, "sentence": "二、糖尿病足与下肢动脉病变的流行病学 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"], [7, 12, "Disease"], [7, 10, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [7, 10, "Anatomy", 7, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 2606, "sentence": "国外资料显示在所有的非外伤性低位截肢手术中，糖尿病患者占40%~60%，在糖尿病相关的低位远端截肢中，有85%是发生在足部溃疡后。", "ner": [[22, 24, "Disease"], [37, 39, "Disease"], [59, 62, "Disease"], [59, 60, "Anatomy"], [10, 19, "Operation"], [43, 48, "Operation"]], "rel": [[10, 19, "Operation", 22, 24, "Disease", "Operation_Disease"], [43, 48, "Operation", 22, 24, "Disease", "Operation_Disease"], [59, 60, "Anatomy", 59, 62, "Disease", "Anatomy_Disease"]]}
{"idx": 2607, "sentence": "糖尿病患者中足部溃疡的患病率为4%~10%。", "ner": [[0, 2, "Disease"], [6, 9, "Disease"], [6, 7, "Anatomy"]], "rel": [[6, 7, "Anatomy", 6, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 2608, "sentence": "国内多中心研究资料显示我国50岁以上糖尿病患者下肢动脉病变的比例为19.5%。", "ner": [[18, 20, "Disease"], [23, 28, "Disease"], [23, 26, "Anatomy"]], "rel": [[23, 26, "Anatomy", 23, 28, "Disease", "Anatomy_Disease"]]}
{"idx": 2609, "sentence": "单中心研究显示60岁以上糖尿病患者下肢动脉病变的比例为3 5.4%。", "ner": [[12, 14, "Disease"], [17, 22, "Disease"], [17, 20, "Anatomy"]], "rel": [[17, 20, "Anatomy", 17, 22, "Disease", "Anatomy_Disease"]]}
{"idx": 2610, "sentence": "我国糖尿病患者1年内新发溃疡发生率为8.1%，糖尿病足溃疡患者1年内新发溃疡发生率为31.6%", "ner": [[2, 4, "Disease"], [12, 13, "Disease"], [23, 25, "Disease"], [26, 28, "Disease"], [26, 26, "Anatomy"], [36, 37, "Disease"]], "rel": [[26, 26, "Anatomy", 26, 28, "Disease", "Anatomy_Disease"]]}
{"idx": 2611, "sentence": "三、糖尿病足的临床表现 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2612, "sentence": "神经病变表现：患肢皮肤干而无汗，肢端刺痛、灼痛、麻木、感觉减退或缺失，呈袜套样改变，行走时脚踩棉絮感", "ner": [[0, 3, "Disease"], [0, 1, "Anatomy"], [9, 11, "Symptom"], [13, 14, "Symptom"], [16, 19, "Symptom"], [21, 22, "Symptom"], [24, 25, "Symptom"], [27, 33, "Symptom"], [35, 40, "Symptom"], [42, 49, "Symptom"]], "rel": [[0, 1, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [9, 11, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [13, 14, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [16, 19, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [21, 22, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [24, 25, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [27, 33, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [35, 40, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [42, 49, "Symptom", 0, 3, "Disease", "Symptom_Disease"]]}
{"idx": 2613, "sentence": "下肢缺血表现：皮肤营养不良、肌肉萎缩，皮肤干燥弹性差，皮温下降，色素沉着，肢端动脉搏动减弱或消失，患者可合并有下肢间歇跛行症状。", "ner": [[0, 3, "Disease"], [0, 1, "Anatomy"], [7, 12, "Symptom"], [14, 17, "Symptom"], [19, 25, "Symptom"], [27, 30, "Symptom"], [32, 35, "Symptom"], [37, 47, "Symptom"], [55, 60, "Disease"], [55, 56, "Anatomy"]], "rel": [[0, 1, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [7, 12, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [14, 17, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [19, 25, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [27, 30, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [32, 35, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [37, 47, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [55, 56, "Anatomy", 55, 60, "Disease", "Anatomy_Disease"]]}
{"idx": 2614, "sentence": "随着病变进展，可出现静息痛，趾端出现坏疽，足跟或跖趾关节受压部位出现溃疡，部分患者可肢体感染。", "ner": [[10, 12, "Symptom"], [14, 19, "Symptom"], [42, 45, "Symptom"], [21, 35, "Symptom"]], "rel": []}
{"idx": 2615, "sentence": " ", "ner": [], "rel": []}
{"idx": 2616, "sentence": "四、糖尿病足的辅助检查 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2617, "sentence": "(一)神经系统检查 ", "ner": [], "rel": []}
{"idx": 2618, "sentence": "糖尿病周围神经病变(diabetic peripheral neuropathy，DPN）可以通过以下几种方法得到诊断。", "ner": [[0, 44, "Disease"], [3, 6, "Anatomy"]], "rel": [[3, 6, "Anatomy", 0, 44, "Disease", "Anatomy_Disease"]]}
{"idx": 2619, "sentence": " ", "ner": [], "rel": []}
{"idx": 2620, "sentence": "1.10g尼龙丝检查法：该方法是较为简便的感觉神经检测方法，要具备一根特制的尼龙丝(其弯曲45°能够产生10g的压力)。", "ner": [[2, 9, "Test"]], "rel": []}
{"idx": 2621, "sentence": "检查开始前，通常在患者手掌或前臂试用该尼龙丝2~3次，让患者感受1 0g尼龙丝产生压力的正常感觉。", "ner": [], "rel": []}
{"idx": 2622, "sentence": "测试应对双侧足部进行检查；每个检查点施压时间约2-3s，时间不宜过长；检查部位应避开胼胝、水疱和溃疡面等；建议检测点为第1、3、5趾腹，第1、3、5跖骨头处，足心，足掌外侧，足跟及足背第1、2跖骨间共10个点，患者有2个或2个以上感觉异常点则视为异常。", "ner": [[42, 43, "Symptom"], [45, 46, "Symptom"], [48, 50, "Symptom"]], "rel": []}
{"idx": 2623, "sentence": " ", "ner": [], "rel": []}
{"idx": 2624, "sentence": "2.震动觉：该检查是对深部组织感觉的半定量检查。", "ner": [[2, 4, "Test"]], "rel": []}
{"idx": 2625, "sentence": "在进行前，首先将振动的音叉柄置于患者乳突处让其感受音叉的振动，然后分别置于双足的骨性凸起部位进行比较检查(第1跖趾关节内侧，内外踝)。", "ner": [], "rel": []}
{"idx": 2626, "sentence": " ", "ner": [], "rel": []}
{"idx": 2627, "sentence": "3.踝反射、痛觉、温度觉：这3种检查方法，也可以应用于糖尿病周围神经病变的诊断。", "ner": [[2, 4, "Test"], [6, 7, "Test"], [9, 11, "Test"], [27, 35, "Disease"], [30, 33, "Anatomy"]], "rel": [[2, 4, "Test", 27, 35, "Disease", "Test_Disease"], [6, 7, "Test", 27, 35, "Disease", "Test_Disease"], [9, 11, "Test", 27, 35, "Disease", "Test_Disease"], [30, 33, "Anatomy", 27, 35, "Disease", "Anatomy_Disease"]]}
{"idx": 2628, "sentence": " ", "ner": [], "rel": []}
{"idx": 2629, "sentence": "4.神经传导速度(nerve conduction velocity，NCV) ：过去被认为是DPN诊断的“金标准”，通常认为有两项或以上NCV减慢者结合其他症状体征及辅助检查可考虑存在DPN。", "ner": [[2, 38, "Test"], [47, 49, "Disease"], [69, 71, "Test"], [93, 95, "Disease"]], "rel": [[2, 38, "Test", 47, 49, "Disease", "Test_Disease"], [69, 71, "Test", 47, 49, "Disease", "Test_Disease"]]}
{"idx": 2630, "sentence": " ", "ner": [], "rel": []}
{"idx": 2631, "sentence": "(二)血管病变检查 ", "ner": [[3, 6, "Disease"], [3, 4, "Anatomy"]], "rel": [[3, 4, "Anatomy", 3, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 2632, "sentence": "1.体检：通过触诊，扪及股、腘、足背动脉和 (或) 胫后动脉搏动了解下肢血管病变；通过Buerger 试验了解下肢缺血情况。", "ner": [[2, 3, "Test"], [7, 8, "Test"], [34, 39, "Disease"], [34, 37, "Anatomy"], [43, 52, "Test"], [55, 58, "Disease"], [55, 56, "Anatomy"]], "rel": [[2, 3, "Test", 34, 39, "Disease", "Test_Disease"], [7, 8, "Test", 34, 39, "Disease", "Test_Disease"], [34, 37, "Anatomy", 34, 39, "Disease", "Anatomy_Disease"], [43, 52, "Test", 55, 58, "Disease", "Test_Disease"], [55, 56, "Anatomy", 55, 58, "Disease", "Anatomy_Disease"]]}
{"idx": 2633, "sentence": " ", "ner": [], "rel": []}
{"idx": 2634, "sentence": "2.皮肤温度检查：红外线皮肤温度检查是一种简单、实用的评估局部血供的方法，最好采用温度差判断肢体血供。", "ner": [[2, 7, "Test"], [9, 17, "Test"]], "rel": []}
{"idx": 2635, "sentence": " ", "ner": [], "rel": []}
{"idx": 2636, "sentence": "3.踝动脉-肱动脉血压比值，又称踝肱指数(ankle brachial index，ABI) ：ABI反映的是肢体的血运状况，正常值为0.9~1.3，0.71~0.89为轻度缺血，0.5-0.7为中度缺血，<0.5为重度缺血，重度缺血的患者容易发生下肢(趾)坏疽。如果踝动脉收缩压过高，如高于200mmHg(1mmHg= 0.133kPa) 或ABI>1.3，则应高度怀疑患者有下肢动脉钙化，部分ABI正常患者，可能存在假阴性，可采用平板运动试验或趾臂指数(TBI）测定来纠正。", "ner": [[87, 88, "Disease"], [85, 86, "Level"], [98, 99, "Level"], [100, 101, "Disease"], [108, 109, "Level"], [110, 111, "Disease"], [113, 114, "Level"], [115, 116, "Disease"], [124, 130, "Symptom"], [124, 128, "Anatomy"], [134, 139, "Test_items"], [140, 141, "Test_Value"], [144, 169, "Test_Value"], [172, 174, "Test"], [189, 194, "Disease"], [189, 192, "Anatomy"], [217, 222, "Test"], [175, 178, "Test_Value"]], "rel": [[124, 130, "Symptom", 87, 88, "Disease", "Symptom_Disease"], [134, 139, "Test_items", 189, 194, "Disease", "Test_items_Disease"], [172, 174, "Test", 189, 194, "Disease", "Test_Disease"], [189, 192, "Anatomy", 189, 194, "Disease", "Anatomy_Disease"], [217, 222, "Test", 189, 194, "Disease", "Test_Disease"]]}
{"idx": 2637, "sentence": " ", "ner": [], "rel": []}
{"idx": 2638, "sentence": "4.经皮氧分压(transcutaneous oxygenpressure，TcPO2)：正常人足背TcPO2>40 mmHg；如<30mmHg提示周围血液供应不足，足部易发生溃疡，或已有的溃疡难以愈合；如TcPO2<20mmHg，足溃疡几乎没有愈合的可能。", "ner": [[2, 43, "Test"], [50, 54, "Test"], [74, 81, "Disease"], [88, 89, "Symptom"], [83, 84, "Anatomy"], [95, 100, "Symptom"], [116, 118, "Symptom"], [116, 116, "Anatomy"], [103, 107, "Test"], [65, 71, "Test_Value"], [108, 114, "Test_Value"], [55, 62, "Test_Value"]], "rel": [[88, 89, "Symptom", 74, 81, "Disease", "Symptom_Disease"], [95, 100, "Symptom", 74, 81, "Disease", "Symptom_Disease"]]}
{"idx": 2639, "sentence": "五、糖尿病足的诊断 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2640, "sentence": "(一)? 糖尿病下肢血管病变的诊断", "ner": [[5, 7, "Disease"], [8, 13, "Disease"], [8, 11, "Anatomy"]], "rel": [[8, 11, "Anatomy", 8, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 2641, "sentence": "诊断依据：(1)符合糖尿病诊断；(2)具有下肢缺血的临床表现；(3)辅助检查提示下肢血管病变。", "ner": [[10, 12, "Disease"], [21, 24, "Symptom"], [40, 45, "Disease"], [40, 43, "Anatomy"]], "rel": [[40, 43, "Anatomy", 40, 45, "Disease", "Anatomy_Disease"]]}
{"idx": 2642, "sentence": "静息时ABI<0.9，或静息时ABI>0.9，但运动时出现下肢不适症状，行踏车平板试验后ABI降低1 5%-20%或影像学提示血管存在狭窄。", "ner": [[24, 25, "Reason"], [29, 32, "Symptom"], [37, 42, "Test"], [58, 60, "Test"], [63, 68, "Symptom"]], "rel": []}
{"idx": 2643, "sentence": " ", "ner": [], "rel": []}
{"idx": 2644, "sentence": "(二)糖尿病周围神经病变的诊断 ", "ner": [[6, 11, "Disease"], [6, 9, "Anatomy"], [3, 5, "Disease"]], "rel": [[6, 9, "Anatomy", 6, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 2645, "sentence": "明确的糖尿病病史；在诊断糖尿病时或之后出现的神经病变；临床症状和体征与DPN的表现相符；以下5项检查中如果有2项或2项以上异常则诊断为DPN：(1) 温度觉异常； (2) 尼龙丝检查，足部感觉减退或消失；(3)振动觉异常；(4)踝反射消失； (5) NCV有2项或2项以上减慢。", "ner": [[3, 5, "Disease"], [12, 14, "Disease"], [22, 25, "Disease"], [22, 23, "Anatomy"], [35, 37, "Disease"], [67, 69, "Disease"], [75, 77, "Test"], [78, 79, "Test_Value"], [86, 90, "Test"], [92, 100, "Symptom"], [105, 107, "Test"], [108, 109, "Test_Value"], [114, 116, "Test"], [117, 118, "Test_Value"], [125, 127, "Test"], [129, 137, "Test_Value"]], "rel": [[22, 23, "Anatomy", 22, 25, "Disease", "Anatomy_Disease"]]}
{"idx": 2646, "sentence": " ", "ner": [], "rel": []}
{"idx": 2647, "sentence": "排除其他病变如颈腰椎病变(神经根压迫、椎管狭窄、颈腰椎退行性变)、脑梗死、格林-巴利综合征、严重动静脉血管性病变(静脉栓塞、淋巴管炎)等，尚需鉴别药物尤其是化疗药物引起的神经毒性作用以及肾功能不全引起的代谢毒物对神经的损伤。", "ner": [[7, 11, "Disease"], [7, 9, "Anatomy"], [13, 17, "Disease"], [13, 15, "Anatomy"], [19, 22, "Disease"], [19, 20, "Anatomy"], [24, 30, "Disease"], [24, 26, "Anatomy"], [33, 35, "Disease"], [33, 33, "Anatomy"], [37, 44, "Disease"], [46, 47, "Level"], [48, 55, "Disease"], [48, 50, "Anatomy"], [57, 60, "Disease"], [57, 58, "Anatomy"], [62, 65, "Disease"], [62, 64, "Anatomy"], [93, 97, "Disease"], [93, 93, "Anatomy"]], "rel": [[13, 15, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"], [19, 20, "Anatomy", 19, 22, "Disease", "Anatomy_Disease"], [24, 26, "Anatomy", 24, 30, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 33, 35, "Disease", "Anatomy_Disease"], [48, 50, "Anatomy", 48, 55, "Disease", "Anatomy_Disease"], [57, 58, "Anatomy", 57, 60, "Disease", "Anatomy_Disease"], [62, 64, "Anatomy", 62, 65, "Disease", "Anatomy_Disease"], [93, 93, "Anatomy", 93, 97, "Disease", "Anatomy_Disease"]]}
{"idx": 2648, "sentence": " ", "ner": [], "rel": []}
{"idx": 2649, "sentence": "个别学者对DPN诊断进行分层，第1层指有DPN的症状或体征(踝反射、压力觉、振动觉、针刺觉、温度觉任意1项体征为阳性)，同时存在神经传导功能异常，可确诊；第2层指有DPN的症状及1项体征为阳性，或无症状但有2项及以上体征为阳性，可临床诊断；第3层指有DPN的症状但无体征或无症状但有1项体征阳性，为疑似诊断；第4层指无症状和体征，仅存在神经传导功能异常，为亚临床诊断。", "ner": [[5, 7, "Disease"], [20, 22, "Disease"], [30, 32, "Test"], [34, 36, "Test"], [38, 40, "Test"], [42, 44, "Test"], [46, 48, "Test"], [64, 71, "Symptom"], [64, 65, "Anatomy"], [82, 84, "Disease"], [125, 127, "Disease"], [168, 175, "Symptom"], [168, 169, "Anatomy"]], "rel": [[30, 32, "Test", 5, 7, "Disease", "Test_Disease"], [34, 36, "Test", 5, 7, "Disease", "Test_Disease"], [38, 40, "Test", 5, 7, "Disease", "Test_Disease"], [42, 44, "Test", 5, 7, "Disease", "Test_Disease"], [46, 48, "Test", 5, 7, "Disease", "Test_Disease"], [64, 71, "Symptom", 5, 7, "Disease", "Symptom_Disease"]]}
{"idx": 2650, "sentence": " ", "ner": [], "rel": []}
{"idx": 2651, "sentence": "(三)糖尿病足感染 ", "ner": [[3, 8, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 2652, "sentence": "糖尿病患者足踝以下部位的感染，糖尿病足感染依据感染范围和症状分为轻中重度(表1)。", "ner": [[0, 2, "Disease"], [5, 13, "Symptom"], [5, 10, "Anatomy"], [15, 20, "Disease"], [18, 18, "Anatomy"], [32, 35, "Level"]], "rel": [[5, 13, "Symptom", 0, 2, "Disease", "Symptom_Disease"], [18, 18, "Anatomy", 15, 20, "Disease", "Anatomy_Disease"]]}
{"idx": 2653, "sentence": " ", "ner": [], "rel": []}
{"idx": 2654, "sentence": "(四)糖尿病足的分类、分级 ", "ner": [[3, 6, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 2655, "sentence": "糖尿病足的表现为感染、溃疡和坏疽。溃疡依据病因可分为神经性、缺血性和混合性溃疡；坏疽的性质可分为湿性坏疽、干性坏疽和混合性坏疽3种类型。", "ner": [[0, 3, "Disease"], [3, 3, "Anatomy"], [8, 9, "Symptom"], [11, 12, "Symptom"], [14, 15, "Symptom"], [17, 18, "Disease"], [40, 41, "Disease"], [48, 51, "Disease"], [53, 56, "Disease"], [58, 62, "Disease"], [34, 38, "Disease"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [8, 9, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [11, 12, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [14, 15, "Symptom", 0, 3, "Disease", "Symptom_Disease"]]}
{"idx": 2656, "sentence": "治疗前对糖尿病足患者进行正确的分类和分级，有助于选择合理的治疗方案和判断预后。", "ner": [[4, 7, "Disease"], [7, 7, "Anatomy"]], "rel": [[7, 7, "Anatomy", 4, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 2657, "sentence": " ", "ner": [], "rel": []}
{"idx": 2658, "sentence": "1.依据溃疡的病因进行分类", "ner": [[4, 5, "Disease"]], "rel": []}
{"idx": 2659, "sentence": "(1)神经性溃疡：神经性溃疡患者通常有患足麻木、感觉异常、皮肤干燥，但皮温正常，足背动脉搏动良好。病情严重者可发展为神经性关节病 (Charcot关节病)。", "ner": [[3, 7, "Disease"], [9, 13, "Disease"], [19, 22, "Symptom"], [24, 27, "Symptom"], [29, 32, "Symptom"], [20, 20, "Anatomy"], [29, 30, "Anatomy"], [51, 52, "Level"], [58, 76, "Disease"], [61, 62, "Anatomy"]], "rel": [[19, 22, "Symptom", 3, 7, "Disease", "Symptom_Disease"], [24, 27, "Symptom", 3, 7, "Disease", "Symptom_Disease"], [29, 32, "Symptom", 3, 7, "Disease", "Symptom_Disease"], [61, 62, "Anatomy", 58, 76, "Disease", "Anatomy_Disease"]]}
{"idx": 2660, "sentence": " ", "ner": [], "rel": []}
{"idx": 2661, "sentence": "(2)神经-缺血性溃疡：同时具有周围神经病变和周围血管病变，糖尿病足患者以此类居多。患者除了有神经性溃疡症状外还有下肢发凉感、间敏性跛行、静息痛等，足背动脉搏动减弱或消失，足部温减低，在进行清创换药时创面渗血少。", "ner": [[3, 10, "Disease"], [16, 21, "Disease"], [16, 19, "Anatomy"], [23, 28, "Disease"], [23, 26, "Anatomy"], [30, 33, "Disease"], [33, 33, "Anatomy"], [47, 51, "Disease"], [57, 61, "Symptom"], [63, 67, "Symptom"], [69, 71, "Symptom"], [74, 84, "Symptom"], [86, 90, "Symptom"], [100, 104, "Symptom"]], "rel": [[16, 19, "Anatomy", 16, 21, "Disease", "Anatomy_Disease"], [23, 26, "Anatomy", 23, 28, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 30, 33, "Disease", "Anatomy_Disease"], [57, 61, "Symptom", 47, 51, "Disease", "Symptom_Disease"], [63, 67, "Symptom", 47, 51, "Disease", "Symptom_Disease"], [69, 71, "Symptom", 47, 51, "Disease", "Symptom_Disease"], [74, 84, "Symptom", 47, 51, "Disease", "Symptom_Disease"], [86, 90, "Symptom", 47, 51, "Disease", "Symptom_Disease"], [100, 104, "Symptom", 47, 51, "Disease", "Symptom_Disease"]]}
{"idx": 2662, "sentence": " ", "ner": [], "rel": []}
{"idx": 2663, "sentence": "(3)单纯缺血性溃疡：此类患者无周围神经病变，以缺血性改变为主，较少见，需根据症状、体征及相关检查排除周围神经病变后方可诊断。", "ner": [[3, 9, "Disease"], [16, 21, "Disease"], [16, 19, "Anatomy"], [24, 30, "Symptom"], [51, 56, "Disease"], [51, 54, "Anatomy"]], "rel": [[24, 30, "Symptom", 3, 9, "Disease", "Symptom_Disease"], [16, 19, "Anatomy", 16, 21, "Disease", "Anatomy_Disease"], [51, 54, "Anatomy", 51, 56, "Disease", "Anatomy_Disease"]]}
{"idx": 2664, "sentence": " ", "ner": [], "rel": []}
{"idx": 2665, "sentence": "2.依据坏疽的性质分类 ", "ner": [[4, 5, "Disease"]], "rel": []}
{"idx": 2666, "sentence": "(1)湿性坏疽：糖尿病湿性坏疽发病人数较多。", "ner": [[3, 6, "Disease"], [8, 10, "Disease"], [11, 14, "Disease"]], "rel": []}
{"idx": 2667, "sentence": "多因肢端循环及微循环障碍，常伴周围神经病变和患足感染。", "ner": [[2, 11, "Reason"], [15, 20, "Disease"], [15, 18, "Anatomy"], [22, 25, "Disease"], [23, 23, "Anatomy"]], "rel": [[15, 18, "Anatomy", 15, 20, "Disease", "Anatomy_Disease"], [23, 23, "Anatomy", 22, 25, "Disease", "Anatomy_Disease"]]}
{"idx": 2668, "sentence": "局部常有红、肿、热、痛、功能障碍等，严重者常伴有毒血症或败血症等临床表现。", "ner": [[0, 15, "Symptom"], [18, 19, "Level"], [24, 26, "Disease"], [28, 30, "Disease"]], "rel": []}
{"idx": 2669, "sentence": " ", "ner": [], "rel": []}
{"idx": 2670, "sentence": "(2)干性坏疽：糖尿病干性坏疽发病人数较少，占糖尿病足坏疽的5.0%。多发生在糖尿病患者肢端动脉及小动脉粥样硬化，致管腔狭窄或闭塞，局部血供障碍，最终导致缺血组织发生干性坏疽。", "ner": [[3, 6, "Disease"], [8, 10, "Disease"], [11, 14, "Disease"], [23, 25, "Disease"], [26, 28, "Disease"], [26, 26, "Anatomy"], [39, 41, "Disease"], [44, 47, "Anatomy"], [49, 55, "Symptom"], [49, 51, "Anatomy"], [58, 64, "Symptom"], [58, 59, "Anatomy"], [66, 71, "Reason"], [83, 86, "Disease"], [77, 80, "Anatomy"]], "rel": [[26, 26, "Anatomy", 26, 28, "Disease", "Anatomy_Disease"], [44, 47, "Anatomy", 39, 41, "Disease", "Anatomy_Disease"], [58, 64, "Symptom", 39, 41, "Disease", "Symptom_Disease"], [49, 55, "Symptom", 39, 41, "Disease", "Symptom_Disease"], [66, 71, "Reason", 83, 86, "Disease", "Reason_Disease"], [77, 80, "Anatomy", 83, 86, "Disease", "Anatomy_Disease"]]}
{"idx": 2671, "sentence": " ", "ner": [], "rel": []}
{"idx": 2672, "sentence": "(3)混合性坏疽：混合性坏疽较干性坏疽稍多见，占糖尿病足坏疽的15.2%。肢端局部血供障碍引起干性坏疽，而病变另一部分合并感染。", "ner": [[3, 7, "Disease"], [9, 13, "Disease"], [15, 18, "Disease"], [24, 26, "Disease"], [27, 29, "Disease"], [27, 27, "Anatomy"], [37, 44, "Reason"], [47, 50, "Disease"], [61, 62, "Disease"]], "rel": [[27, 27, "Anatomy", 27, 29, "Disease", "Anatomy_Disease"], [37, 44, "Reason", 47, 50, "Disease", "Reason_Disease"]]}
{"idx": 2673, "sentence": " ", "ner": [], "rel": []}
{"idx": 2674, "sentence": "3.糖尿病足的分级 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2675, "sentence": "依据不同的病变程度需要对糖尿病足进行分级，目前临床上广为接受的分级方法主要有Wagner 分级、Texas分级，但因为糖尿病足病情复杂，血管病变、神经病变、感染的程度、软组织及骨质破坏情况等差异大，所以任何一种分级方法都不可能做到十全十美。", "ner": [[12, 15, "Disease"], [15, 15, "Anatomy"], [59, 62, "Disease"], [62, 62, "Anatomy"], [68, 71, "Disease"], [68, 69, "Anatomy"], [73, 76, "Disease"], [73, 74, "Anatomy"], [78, 79, "Disease"], [84, 91, "Disease"], [84, 86, "Anatomy"]], "rel": [[15, 15, "Anatomy", 12, 15, "Disease", "Anatomy_Disease"], [62, 62, "Anatomy", 59, 62, "Disease", "Anatomy_Disease"], [68, 69, "Anatomy", 68, 71, "Disease", "Anatomy_Disease"], [73, 74, "Anatomy", 73, 76, "Disease", "Anatomy_Disease"], [84, 86, "Anatomy", 84, 91, "Disease", "Anatomy_Disease"]]}
{"idx": 2676, "sentence": " ", "ner": [], "rel": []}
{"idx": 2677, "sentence": "(1) Wagner分级：此分级方法首先由Meggitt于1976年提出，Wagner后来加以推广，是目前临床及科研中应用最为广泛的分级方法(表2)。", "ner": [], "rel": []}
{"idx": 2678, "sentence": " ", "ner": [], "rel": []}
{"idx": 2679, "sentence": "(2) Texas分级法：Texas分级法是由美国Texas San Antonio大学Lavery等提出的(表3) ，此分级方法从病变程度和病因两个方面对糖尿病足溃疡及坏疽进行评估，更好地体现了创面感染和缺血的情况，相对于Wagner分级在评价创面的严重性和预测肢体预后情况上更好。", "ner": [[78, 80, "Disease"], [81, 83, "Disease"], [81, 81, "Anatomy"], [85, 86, "Disease"], [98, 101, "Symptom"], [103, 104, "Symptom"], [123, 124, "Symptom"]], "rel": [[98, 101, "Symptom", 78, 80, "Disease", "Symptom_Disease"], [103, 104, "Symptom", 78, 80, "Disease", "Symptom_Disease"], [123, 124, "Symptom", 78, 80, "Disease", "Symptom_Disease"], [81, 81, "Anatomy", 81, 83, "Disease", "Anatomy_Disease"], [98, 101, "Symptom", 81, 83, "Disease", "Symptom_Disease"], [103, 104, "Symptom", 81, 83, "Disease", "Symptom_Disease"], [123, 124, "Symptom", 81, 83, "Disease", "Symptom_Disease"], [98, 101, "Symptom", 85, 86, "Disease", "Symptom_Disease"], [103, 104, "Symptom", 85, 86, "Disease", "Symptom_Disease"], [123, 124, "Symptom", 85, 86, "Disease", "Symptom_Disease"]]}
{"idx": 2680, "sentence": " ", "ner": [], "rel": []}
{"idx": 2681, "sentence": "(3)空军总医院分级法：空军总医院内分泌科李仕明主任依据机体组织抗感染能力及坏疽病变的性质、范围、深度作为分级的依据和说明感染严重程度的依据，结合国内外分级标准，将糖尿病足按病变程度划分为0~5级，提出了空军总医院糖尿病足分级方法。", "ner": [[38, 41, "Disease"], [61, 62, "Disease"], [82, 85, "Disease"], [85, 85, "Anatomy"], [94, 97, "Level"], [107, 110, "Disease"], [110, 110, "Anatomy"]], "rel": [[85, 85, "Anatomy", 82, 85, "Disease", "Anatomy_Disease"], [110, 110, "Anatomy", 107, 110, "Disease", "Anatomy_Disease"]]}
{"idx": 2682, "sentence": " ", "ner": [], "rel": []}
{"idx": 2683, "sentence": "0级：皮肤无开放性病灶。", "ner": [[0, 1, "Level"]], "rel": []}
{"idx": 2684, "sentence": "常表现为肢端供血不足、皮温凉、颜色紫绀或苍白、麻木、感觉迟钝或丧失。", "ner": [[4, 9, "Symptom"], [11, 13, "Symptom"], [15, 21, "Symptom"], [23, 24, "Symptom"], [26, 32, "Symptom"]], "rel": []}
{"idx": 2685, "sentence": "肢端刺痛或灼痛，常兼有足趾或足的畸形等高危足表现。", "ner": [[0, 6, "Symptom"], [11, 17, "Symptom"], [19, 21, "Symptom"]], "rel": []}
{"idx": 2686, "sentence": " ", "ner": [], "rel": []}
{"idx": 2687, "sentence": "1级：肢端皮肤有开放性病灶。", "ner": [[0, 1, "Level"], [3, 12, "Symptom"], [3, 6, "Anatomy"]], "rel": []}
{"idx": 2688, "sentence": "水疱、血泡、鸡眼或胼胝、冻伤或烫伤及其他皮肤损伤所引起的浅表溃疡，但病灶尚未波及深部组织。", "ner": [[0, 1, "Symptom"], [3, 4, "Symptom"], [6, 7, "Symptom"], [9, 10, "Symptom"], [28, 31, "Symptom"], [12, 13, "Symptom"], [15, 16, "Symptom"], [20, 23, "Symptom"]], "rel": []}
{"idx": 2689, "sentence": " ", "ner": [], "rel": []}
{"idx": 2690, "sentence": "2级：感染病灶已侵犯深部肌肉组织。", "ner": [[0, 1, "Level"], [3, 15, "Symptom"]], "rel": []}
{"idx": 2691, "sentence": "常有轻度蜂窝织炎，多发性脓灶及窦道形成，或感染延肌间隙扩大，造成足底、足背贯通性溃疡或坏疽，脓性分泌物较多。", "ner": [[4, 7, "Symptom"], [9, 13, "Symptom"], [15, 16, "Symptom"], [21, 28, "Symptom"], [32, 41, "Symptom"], [43, 44, "Symptom"], [46, 52, "Symptom"]], "rel": []}
{"idx": 2692, "sentence": "足或趾皮肤灶性干性坏疽，但肌腱韧带尚无破坏。", "ner": [[0, 10, "Symptom"]], "rel": []}
{"idx": 2693, "sentence": " ", "ner": [], "rel": []}
{"idx": 2694, "sentence": "3级：肌健韧带组织破坏。", "ner": [[0, 1, "Level"], [3, 10, "Symptom"], [3, 8, "Anatomy"]], "rel": []}
{"idx": 2695, "sentence": "蜂窝织炎融合形成大脓腔，脓性分泌物及坏死组织增多，足或少数趾干性坏疽，但骨质破坏尚不明显。", "ner": [[0, 3, "Disease"], [8, 10, "Symptom"], [12, 23, "Symptom"], [25, 33, "Disease"], [25, 25, "Anatomy"], [29, 29, "Anatomy"], [36, 39, "Symptom"]], "rel": [[8, 10, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [12, 23, "Symptom", 0, 3, "Disease", "Symptom_Disease"], [25, 25, "Anatomy", 25, 33, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 25, 33, "Disease", "Anatomy_Disease"]]}
{"idx": 2696, "sentence": " ", "ner": [], "rel": []}
{"idx": 2697, "sentence": "4级：严重感染已造成骨质破坏，骨髓炎，骨关节破坏或已形成假关节，Charcot关节病，部分足或趾发生湿性或干性严重坏疽或坏死。", "ner": [[0, 1, "Level"], [3, 4, "Level"], [5, 6, "Reason"], [10, 13, "Disease"], [15, 17, "Disease"], [15, 16, "Anatomy"], [19, 23, "Disease"], [19, 21, "Anatomy"], [28, 30, "Disease"], [29, 30, "Anatomy"], [32, 41, "Disease"], [39, 40, "Anatomy"], [45, 61, "Disease"], [45, 45, "Anatomy"], [47, 47, "Anatomy"], [55, 56, "Level"]], "rel": [[5, 6, "Reason", 10, 13, "Disease", "Reason_Disease"], [5, 6, "Reason", 15, 17, "Disease", "Reason_Disease"], [5, 6, "Reason", 19, 23, "Disease", "Reason_Disease"], [5, 6, "Reason", 28, 30, "Disease", "Reason_Disease"], [5, 6, "Reason", 32, 41, "Disease", "Reason_Disease"], [5, 6, "Reason", 45, 61, "Disease", "Reason_Disease"], [15, 16, "Anatomy", 15, 17, "Disease", "Anatomy_Disease"], [19, 21, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [29, 30, "Anatomy", 28, 30, "Disease", "Anatomy_Disease"], [39, 40, "Anatomy", 32, 41, "Disease", "Anatomy_Disease"], [45, 45, "Anatomy", 45, 61, "Disease", "Anatomy_Disease"], [47, 47, "Anatomy", 45, 61, "Disease", "Anatomy_Disease"]]}
{"idx": 2698, "sentence": " ", "ner": [], "rel": []}
{"idx": 2699, "sentence": "5级：足的大部分或足的全部感染或缺血，导致严重的湿性或干性坏疽，肢端变黑，尸干，常波及踝关节及小腿。一般多采取大截肢。", "ner": [[0, 1, "Level"], [21, 22, "Level"], [24, 30, "Disease"], [3, 17, "Reason"], [3, 3, "Anatomy"], [9, 9, "Anatomy"], [32, 35, "Symptom"], [32, 33, "Anatomy"], [37, 38, "Symptom"], [43, 45, "Anatomy"], [47, 48, "Anatomy"], [55, 57, "Operation"]], "rel": [[3, 17, "Reason", 24, 30, "Disease", "Reason_Disease"], [32, 35, "Symptom", 24, 30, "Disease", "Symptom_Disease"], [37, 38, "Symptom", 24, 30, "Disease", "Symptom_Disease"], [43, 45, "Anatomy", 24, 30, "Disease", "Anatomy_Disease"], [47, 48, "Anatomy", 24, 30, "Disease", "Anatomy_Disease"]]}
{"idx": 2700, "sentence": " ", "ner": [], "rel": []}
{"idx": 2701, "sentence": "六、糖尿病足预后 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2702, "sentence": "糖尿病足的最终结局是：溃疡愈合、截肢和死亡。 ", "ner": [[0, 3, "Disease"], [3, 3, "Anatomy"], [11, 12, "Symptom"], [16, 17, "Operation"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [16, 17, "Operation", 0, 3, "Disease", "Operation_Disease"], [11, 12, "Symptom", 0, 3, "Disease", "Symptom_Disease"]]}
{"idx": 2703, "sentence": "七、糖尿病足的治疗 ", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"]]}
{"idx": 2704, "sentence": "(一)? 糖尿病足的治疗目标及治疗策略 ", "ner": [[5, 8, "Disease"], [8, 8, "Anatomy"]], "rel": [[8, 8, "Anatomy", 5, 8, "Disease", "Anatomy_Disease"]]}
{"idx": 2705, "sentence": "糖尿病足的治疗目标：预防全身动脉粥样硬化疾病的进展，预防心、脑血管事件的发生，降低糖尿病足患者死亡率；预防缺血导致的溃疡和肢端坏疽，预防截肢或降低截肢平面，改善间歇性跛行患者的下肢肤体功能状态。", "ner": [[0, 3, "Disease"], [3, 3, "Anatomy"], [12, 21, "Disease"], [12, 15, "Anatomy"], [28, 34, "Disease"], [28, 32, "Anatomy"], [41, 44, "Disease"], [44, 44, "Anatomy"], [53, 54, "Reason"], [58, 59, "Disease"], [61, 64, "Disease"], [61, 62, "Anatomy"], [68, 69, "Operation"], [80, 84, "Disease"], [88, 91, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [12, 15, "Anatomy", 12, 21, "Disease", "Anatomy_Disease"], [28, 32, "Anatomy", 28, 34, "Disease", "Anatomy_Disease"], [44, 44, "Anatomy", 41, 44, "Disease", "Anatomy_Disease"], [53, 54, "Reason", 58, 59, "Disease", "Reason_Disease"], [53, 54, "Reason", 61, 64, "Disease", "Reason_Disease"], [68, 69, "Operation", 58, 59, "Disease", "Operation_Disease"], [61, 62, "Anatomy", 61, 64, "Disease", "Anatomy_Disease"], [68, 69, "Operation", 61, 64, "Disease", "Operation_Disease"], [88, 91, "Anatomy", 80, 84, "Disease", "Anatomy_Disease"]]}
{"idx": 2706, "sentence": " ", "ner": [], "rel": []}
{"idx": 2707, "sentence": "糖尿病足的治疗策略：一级预防——防止或延缓神经病变、周围血管病变的发生；二级预防——缓解症状，延缓神经病变、周围血管病变的进展；三级预防——血运重建，溃疡综合治疗，降低截肢率和心血管事件发生率。", "ner": [[0, 3, "Disease"], [3, 3, "Anatomy"], [21, 24, "Disease"], [21, 22, "Anatomy"], [26, 31, "Disease"], [26, 29, "Anatomy"], [49, 52, "Disease"], [49, 50, "Anatomy"], [54, 59, "Disease"], [54, 57, "Anatomy"], [75, 76, "Disease"], [88, 92, "Disease"], [88, 90, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 3, "Disease", "Anatomy_Disease"], [21, 22, "Anatomy", 21, 24, "Disease", "Anatomy_Disease"], [26, 29, "Anatomy", 26, 31, "Disease", "Anatomy_Disease"], [49, 50, "Anatomy", 49, 52, "Disease", "Anatomy_Disease"], [54, 57, "Anatomy", 54, 59, "Disease", "Anatomy_Disease"], [88, 90, "Anatomy", 88, 92, "Disease", "Anatomy_Disease"]]}
{"idx": 2708, "sentence": " ", "ner": [], "rel": []}
{"idx": 2709, "sentence": "(二)糖尿病足的内科治疗 ", "ner": [[3, 6, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 2710, "sentence": "在糖尿病足的药物治疗中，要重视综合治疗。糖尿病足常分为3种类型，即神经型、缺血型和神经缺血型(也叫混合型)。研究发现，我国糖尿病足以混合型为主，其次为缺血型，而单纯神经型比较少见。", "ner": [[1, 4, "Disease"], [4, 4, "Anatomy"], [20, 23, "Disease"], [23, 23, "Anatomy"], [61, 64, "Disease"], [64, 64, "Anatomy"]], "rel": [[4, 4, "Anatomy", 1, 4, "Disease", "Anatomy_Disease"], [23, 23, "Anatomy", 20, 23, "Disease", "Anatomy_Disease"], [64, 64, "Anatomy", 61, 64, "Disease", "Anatomy_Disease"]]}
{"idx": 2711, "sentence": "对于神经病变型，目前除治疗神经病变外，重要的是患肢减压，局部清创可促进溃疡愈合；而对于缺血型病变则可以通过药物治疗，运动锻炼和重建下肢血流的方法，取得一定疗效；即使混合型病变，如果血流得到改善，其神经病变也可得到部分缓解。", "ner": [[13, 16, "Disease"], [13, 14, "Anatomy"], [28, 31, "Treatment"], [35, 36, "Symptom"], [58, 61, "Treatment"], [63, 68, "Operation"], [98, 101, "Disease"], [98, 99, "Anatomy"]], "rel": [[13, 14, "Anatomy", 13, 16, "Disease", "Anatomy_Disease"], [98, 99, "Anatomy", 98, 101, "Disease", "Anatomy_Disease"]]}
{"idx": 2712, "sentence": " ", "ner": [], "rel": []}
{"idx": 2713, "sentence": "1.良好的代谢管理：对于糖尿病足患者，应积极进行血糖控制，首选胰岛素控制血糖，同时对患者进行充分地血糖控制[糖化血红蛋白 (HbA1c)<7%] ，同时尽可能减少低血糖的发生以降低足溃疡和感染的发生率，继而降低患者的截肢风险。但由于糖尿病足患者常常年龄较大，合并症及并发症较多，因此不能一味地强调将患者的H bA1c控制在7%以下，此时应该参照中华医学会内分泌学分会制定的《中国成人2型糖尿病HbA1c控制目标的专家共识》推荐的个体化控制目标. ", "ner": [[12, 15, "Disease"], [15, 15, "Anatomy"], [24, 25, "Test_items"], [31, 33, "Drug"], [36, 37, "Test_items"], [49, 50, "Test_items"], [54, 67, "Test_items"], [68, 70, "Test_Value"], [81, 83, "Disease"], [90, 92, "Disease"], [90, 90, "Anatomy"], [94, 95, "Disease"], [116, 119, "Disease"], [119, 119, "Anatomy"], [152, 157, "Test_items"], [161, 164, "Test_Value"], [191, 195, "Disease"], [196, 200, "Test_items"], [108, 109, "Operation"]], "rel": [[15, 15, "Anatomy", 12, 15, "Disease", "Anatomy_Disease"], [36, 37, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [54, 67, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [90, 90, "Anatomy", 90, 92, "Disease", "Anatomy_Disease"], [119, 119, "Anatomy", 116, 119, "Disease", "Anatomy_Disease"], [152, 157, "Test_items", 116, 119, "Disease", "Test_items_Disease"], [196, 200, "Test_items", 191, 195, "Disease", "Test_items_Disease"]]}
{"idx": 2714, "sentence": "对于糖尿病足合并高血压者，应将血压控制在140/85mmHg以下；糖尿病足合并脂代谢患者，应给予他汀类药物治疗，将低密度脂蛋白胆固醇水平控制在2.1mmol/L以下，若患者同时合并下肢动脉病变，则应将低密度脂蛋白胆固醇水平控制在1 .7mmol/L以下；若无临床禁忌，应该给予小剂量阿司匹林(75~150mg/d)。", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"], [8, 10, "Disease"], [33, 36, "Disease"], [36, 36, "Anatomy"], [48, 52, "Drug"], [90, 95, "Disease"], [90, 93, "Anatomy"], [141, 144, "Drug"], [146, 155, "Frequency"], [15, 16, "Test"], [20, 31, "Test_Value"], [57, 65, "Test_items"], [71, 81, "Test_Value"], [100, 110, "Test_items"], [114, 125, "Test_Value"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [15, 16, "Test", 8, 10, "Disease", "Test_Disease"], [36, 36, "Anatomy", 33, 36, "Disease", "Anatomy_Disease"], [48, 52, "Drug", 33, 36, "Disease", "Drug_Disease"], [90, 93, "Anatomy", 90, 95, "Disease", "Anatomy_Disease"], [141, 144, "Drug", 90, 95, "Disease", "Drug_Disease"], [100, 110, "Test_items", 90, 95, "Disease", "Test_items_Disease"], [146, 155, "Frequency", 141, 144, "Drug", "Frequency_Drug"]]}
{"idx": 2715, "sentence": " ", "ner": [], "rel": []}
{"idx": 2716, "sentence": "2.下肢运动康复治疗：对于足部皮肤完整的缺血型或神经缺血型患者，运动锻炼能改善间歇性跛行患者的步行距离及行走时间。与安慰剂或常规护理相比较，监督下的运动康复锻炼可显著提高下肢动脉病变患者的最大步行距离[加权均数差 (WMD) =218.01m，95%CI：161.54~274.48m，P<0.00001] 、无痛行走距离(WMD=174.19m，95%CI：130.25~218.13m，P<0.00001) 、6min 步行距离(WMD=42.91m，95%CI：25.41~ 59.41m，P<0.00001)。", "ner": [[32, 35, "Treatment"], [39, 43, "Disease"], [74, 79, "Treatment"], [85, 90, "Disease"], [85, 88, "Anatomy"], [2, 9, "Treatment"]], "rel": [[32, 35, "Treatment", 39, 43, "Disease", "Treatment_Disease"], [74, 79, "Treatment", 85, 90, "Disease", "Treatment_Disease"], [85, 88, "Anatomy", 85, 90, "Disease", "Anatomy_Disease"]]}
{"idx": 2717, "sentence": "同时还可以显著提高下肢动脉病变患者的运动功能指标，如行走受损问卷(WIQ) 距离评分、WIQ速度评分、WIQ爬梯评分。", "ner": [[9, 14, "Disease"], [9, 12, "Anatomy"]], "rel": [[9, 12, "Anatomy", 9, 14, "Disease", "Anatomy_Disease"]]}
{"idx": 2718, "sentence": "提示强化步行运动可以提高足部皮肤完整的缺血型或神经缺血型患者的运动耐受性，改善运动功能，且不增加不良事件的发生，是一种安全有效的治疗方式。", "ner": [[2, 7, "Treatment"]], "rel": []}
{"idx": 2719, "sentence": " ", "ner": [], "rel": []}
{"idx": 2720, "sentence": "3.  药物治疗 ", "ner": [], "rel": []}
{"idx": 2721, "sentence": "(1)扩张血管药物治疗：目前临床所用的血管扩张药包括脂微球前列地尔注射液、贝前列素钠、西洛他唑、盐酸沙格雷酯、萘呋胺、丁咯地尔和己酮可可碱等。", "ner": [[26, 35, "Drug"], [37, 41, "Drug"], [43, 46, "Drug"], [48, 53, "Drug"], [55, 57, "Drug"], [59, 62, "Drug"], [64, 68, "Drug"]], "rel": []}
{"idx": 2722, "sentence": " ", "ner": [], "rel": []}
{"idx": 2723, "sentence": "盐酸沙格雷酯是一种多靶点循环改善剂，对血小板以及血管平滑肌的5-羟色胺(5-HT)2受体具有特异性拮抗作用，从而抑制5-HT2导致的血小板凝聚，抑制血管收缩和平滑肌细胞增殖；改善红细胞的变形能力，改善侧支循环及微循环障碍。", "ner": [[0, 5, "Drug"], [9, 16, "Drug"]], "rel": []}
{"idx": 2724, "sentence": " ", "ner": [], "rel": []}
{"idx": 2725, "sentence": "一项系统评价纳入了9个RCT研究，荟萃分析结果显示，盐酸沙格雷酯治疗下肢血管病变，能减小患者溃疡面积，增加ABI、足背动脉血流量，无痛行走距离增加200.87m。一项RCT研究显示，盐酸沙格雷酯治疗糖尿病下肢血管病变，能有效增加患者最大行走距离和无痛行走距离，部分改善足背动脉和胫后动脉的流速、阻力指数和ABI指标。因此，盐酸沙格雷酯被推荐治疗慢性动脉闭塞症所引起的溃疡、疼痛以及冷感等缺血性诸症状，尤其对静息痛的疗效显著。盐酸沙格雷酯的推荐剂量为100mg/次，2次/d。", "ner": [[26, 31, "Drug"], [34, 39, "Disease"], [34, 37, "Anatomy"], [91, 96, "Drug"], [99, 101, "Disease"], [102, 107, "Disease"], [102, 105, "Anatomy"], [161, 166, "Drug"], [172, 178, "Disease"], [183, 184, "Symptom"], [186, 187, "Symptom"], [174, 175, "Anatomy"], [190, 191, "Symptom"], [203, 205, "Symptom"], [212, 217, "Drug"], [224, 230, "Amount"], [232, 235, "Frequency"], [46, 47, "Symptom"], [57, 63, "Test_items"]], "rel": [[26, 31, "Drug", 34, 39, "Disease", "Drug_Disease"], [34, 37, "Anatomy", 34, 39, "Disease", "Anatomy_Disease"], [46, 47, "Symptom", 34, 39, "Disease", "Symptom_Disease"], [57, 63, "Test_items", 34, 39, "Disease", "Test_items_Disease"], [91, 96, "Drug", 99, 101, "Disease", "Drug_Disease"], [91, 96, "Drug", 102, 107, "Disease", "Drug_Disease"], [102, 105, "Anatomy", 102, 107, "Disease", "Anatomy_Disease"], [161, 166, "Drug", 172, 178, "Disease", "Drug_Disease"], [174, 175, "Anatomy", 172, 178, "Disease", "Anatomy_Disease"], [183, 184, "Symptom", 172, 178, "Disease", "Symptom_Disease"], [186, 187, "Symptom", 172, 178, "Disease", "Symptom_Disease"], [190, 191, "Symptom", 172, 178, "Disease", "Symptom_Disease"], [203, 205, "Symptom", 172, 178, "Disease", "Symptom_Disease"], [224, 230, "Amount", 212, 217, "Drug", "Amount_Drug"], [232, 235, "Frequency", 212, 217, "Drug", "Frequency_Drug"]]}
{"idx": 2726, "sentence": " ", "ner": [], "rel": []}
{"idx": 2727, "sentence": "在前列腺素类药物中，脂微球前列地尔注射液的疗效和耐受性最好。", "ner": [[1, 7, "Drug"], [10, 19, "Drug"]], "rel": []}
{"idx": 2728, "sentence": "荟萃分析表明，与安慰剂相比，前列腺素El(PGE I) 能够显著增加步行距离，即使停止治疗后其步行能力仍然保持增加。脂微球前列地尔注射液的剂量根据患者病变程度推荐为10μg/次，1~2次/d，静脉推注或滴注，疗程14~ 21d。贝前列素钠治疗能改善糖尿病性周围血管病变患者下肢的主观症状，如烧灼样感觉、冷感觉、水肿、劳力性疼痛、针刺样疼痛及感觉异常。与安慰剂相比，每日口服贝前列素钠40μg，3次/d，治疗6个月，无痛性行走距离改善超过50%的LEAD患者在两组分别为43.5%与33.3%，两组间无痛性行走距离分别增加81.5%和52.5%，最大步行距离分别增加60.1%和35.0%，严重心血管事件的发生率分别为4.8%和8.9%。", "ner": [[14, 26, "Drug"], [58, 67, "Drug"], [82, 87, "Amount"], [89, 94, "Frequency"], [96, 102, "Method"], [106, 112, "Duration"], [114, 118, "Drug"], [124, 133, "Disease"], [128, 131, "Anatomy"], [145, 149, "Symptom"], [151, 153, "Symptom"], [155, 156, "Symptom"], [158, 162, "Symptom"], [164, 168, "Symptom"], [170, 173, "Symptom"], [184, 185, "Method"], [186, 190, "Drug"], [191, 194, "Amount"], [196, 199, "Frequency"], [203, 205, "Duration"], [222, 225, "Disease"], [234, 238, "Test_Value"], [240, 244, "Test_Value"], [258, 270, "Test_Value"], [280, 292, "Test_Value"], [294, 295, "Level"], [296, 300, "ADE"]], "rel": [[89, 94, "Frequency", 58, 67, "Drug", "Frequency_Drug"], [106, 112, "Duration", 58, 67, "Drug", "Duration_Drug"], [82, 87, "Amount", 58, 67, "Drug", "Amount_Drug"], [96, 102, "Method", 58, 67, "Drug", "Method_Drug"], [128, 131, "Anatomy", 124, 133, "Disease", "Anatomy_Disease"], [145, 149, "Symptom", 124, 133, "Disease", "Symptom_Disease"], [151, 153, "Symptom", 124, 133, "Disease", "Symptom_Disease"], [155, 156, "Symptom", 124, 133, "Disease", "Symptom_Disease"], [158, 162, "Symptom", 124, 133, "Disease", "Symptom_Disease"], [164, 168, "Symptom", 124, 133, "Disease", "Symptom_Disease"], [170, 173, "Symptom", 124, 133, "Disease", "Symptom_Disease"], [184, 185, "Method", 186, 190, "Drug", "Method_Drug"], [186, 190, "Drug", 222, 225, "Disease", "Drug_Disease"], [296, 300, "ADE", 186, 190, "Drug", "ADE_Drug"], [203, 205, "Duration", 186, 190, "Drug", "Duration_Drug"], [196, 199, "Frequency", 186, 190, "Drug", "Frequency_Drug"], [191, 194, "Amount", 186, 190, "Drug", "Amount_Drug"]]}
{"idx": 2729, "sentence": "因此，贝前列素钠能有效地改善间歇性行患者的症状。", "ner": [[3, 7, "Drug"], [14, 17, "Disease"]], "rel": [[3, 7, "Drug", 14, 17, "Disease", "Drug_Disease"]]}
{"idx": 2730, "sentence": "贝前列腺素钠的剂量根据患者病变程度推荐为20~40μg/次，2~ 3次/d。", "ner": [[0, 5, "Drug"], [20, 28, "Amount"], [30, 36, "Frequency"]], "rel": [[30, 36, "Frequency", 0, 5, "Drug", "Frequency_Drug"]]}
{"idx": 2731, "sentence": " ", "ner": [], "rel": []}
{"idx": 2732, "sentence": "目前临床应用较多还有其他一些扩张血管药物，比如己酮可可碱，中药通塞脉片等。", "ner": [[23, 27, "Drug"], [31, 34, "Drug"]], "rel": []}
{"idx": 2733, "sentence": "(2)抗血小板药物治疗：在糖尿病足患者，氯吡格雷是有适应证的抗血小板药物，与阿司匹林相比，氯吡格雷联合阿司匹林的抗血小板治疗能显著降低其全因死亡率(RR=0.73，95%CI：0.58~0.93)和心血管事件(RR=0.81，95%CI：0.67~0.98)发生，但严重出血的风险轻度增加。", "ner": [[13, 16, "Disease"], [16, 16, "Anatomy"], [20, 23, "Drug"], [38, 41, "Drug"], [45, 48, "Drug"], [51, 54, "Drug"], [99, 103, "ADE"], [135, 136, "ADE"]], "rel": [[16, 16, "Anatomy", 13, 16, "Disease", "Anatomy_Disease"], [20, 23, "Drug", 13, 16, "Disease", "Drug_Disease"], [38, 41, "Drug", 13, 16, "Disease", "Drug_Disease"], [99, 103, "ADE", 20, 23, "Drug", "ADE_Drug"], [135, 136, "ADE", 20, 23, "Drug", "ADE_Drug"], [99, 103, "ADE", 38, 41, "Drug", "ADE_Drug"], [135, 136, "ADE", 38, 41, "Drug", "ADE_Drug"]]}
{"idx": 2734, "sentence": "此外，氯吡格雷联合阿司匹林的双联抗血小板治疗能显著降低下肢血管重建术后的大截肢事件[与单纯的阿司匹林治疗相比，RR=0.68，95%CI：0.46~0.99，需治疗人数(NNT)=94]。", "ner": [[3, 6, "Drug"], [9, 12, "Drug"], [27, 32, "Operation"], [36, 38, "Operation"], [46, 49, "Drug"]], "rel": []}
{"idx": 2735, "sentence": "因此，目前推荐氯吡格雷为对阿司匹林不耐受或对阿司匹林过敏的患者的另一种治疗选择。", "ner": [[7, 10, "Drug"], [13, 16, "Drug"], [22, 25, "Drug"]], "rel": []}
{"idx": 2736, "sentence": "此外，在行血管旁路手术的糖尿病足患者，阿司匹林或阿司匹林联合双密达莫(ASA/DIP)治疗能显著改善移植人工血管的血管通畅率(OR=0.42，95%C：0.22~0.83，P=0.01)。但在自体静脉移植血管中任何时间点均未发现这种效果，而在人造血管移植中的各个时间点都能发现这种益处，包括在移植12个月后(OR=0.19，95%CI：0.10~0.36，P<0.00001)。阿司匹林联合氯毗格雷与阿司匹林比较，所有血管移植物的通畅率在24个月时均无明显差异，组间的截肢或死亡发生率差异无统计学意义，而阿司匹林联合氯吡格雷虽然不增加大出血或致死性出血风险，但增加总的出血风险(OR=2.65，95%CI：1.69~4.15)，包括轻度出血(OR=2.34，95%CI：1.37~4.00)和中度出血(OR=4.13，95%CI：1.37~12.45)。", "ner": [[4, 10, "Operation"], [12, 15, "Disease"], [15, 15, "Anatomy"], [19, 22, "Drug"], [24, 27, "Drug"], [30, 33, "Drug"], [57, 61, "Test_items"], [96, 101, "Operation"], [121, 126, "Operation"], [189, 192, "Drug"], [195, 198, "Drug"], [200, 203, "Drug"], [234, 235, "Operation"], [252, 255, "Drug"], [258, 261, "Drug"], [267, 269, "ADE"], [271, 275, "ADE"], [284, 285, "ADE"], [318, 319, "ADE"], [316, 317, "Level"], [346, 347, "Level"], [348, 349, "ADE"]], "rel": [[4, 10, "Operation", 12, 15, "Disease", "Operation_Disease"], [15, 15, "Anatomy", 12, 15, "Disease", "Anatomy_Disease"], [57, 61, "Test_items", 12, 15, "Disease", "Test_items_Disease"], [19, 22, "Drug", 12, 15, "Disease", "Drug_Disease"], [30, 33, "Drug", 12, 15, "Disease", "Drug_Disease"], [284, 285, "ADE", 252, 255, "Drug", "ADE_Drug"], [284, 285, "ADE", 258, 261, "Drug", "ADE_Drug"]]}
{"idx": 2737, "sentence": "(3)抗凝血药物(肝素、低分子肝素及口服抗凝血药物)：月前没有明确的证据支持在糖尿病足前期的间歇性跛行阶段应用抗凝血治疗。与单用阿司匹林相比，在严重肢体缺血患者，低分子肝素联合阿司匹林能显著降低血管腔内微创治疗(球囊扩张及支架植入)的糖尿病足患者的血管闭塞/再狭窄(高达85%)(OR=0.15，95%CI：0.06~0.42，P=0.0003)；而巴曲酶联合阿司匹林显著降低糖尿病患者的再狭窄(OR=0.28，95%Cl：0.13~0.60)，不伴出血和其他消化道不良事件的显著增加。", "ner": [[9, 10, "Drug"], [12, 16, "Drug"], [18, 19, "Method"], [39, 42, "Disease"], [42, 42, "Anatomy"], [46, 50, "Symptom"], [64, 67, "Drug"], [72, 73, "Level"], [74, 77, "Disease"], [74, 75, "Anatomy"], [81, 85, "Drug"], [88, 91, "Drug"], [97, 115, "Operation"], [117, 120, "Disease"], [120, 120, "Anatomy"], [124, 131, "Symptom"], [175, 177, "Drug"], [180, 183, "Drug"], [188, 190, "Disease"], [194, 196, "Symptom"], [225, 226, "ADE"], [230, 236, "ADE"], [230, 232, "Anatomy"]], "rel": [[9, 10, "Drug", 39, 42, "Disease", "Drug_Disease"], [12, 16, "Drug", 39, 42, "Disease", "Drug_Disease"], [42, 42, "Anatomy", 39, 42, "Disease", "Anatomy_Disease"], [46, 50, "Symptom", 39, 42, "Disease", "Symptom_Disease"], [64, 67, "Drug", 74, 77, "Disease", "Drug_Disease"], [74, 75, "Anatomy", 74, 77, "Disease", "Anatomy_Disease"], [81, 85, "Drug", 74, 77, "Disease", "Drug_Disease"], [97, 115, "Operation", 117, 120, "Disease", "Operation_Disease"], [124, 131, "Symptom", 117, 120, "Disease", "Symptom_Disease"], [175, 177, "Drug", 188, 190, "Disease", "Drug_Disease"], [225, 226, "ADE", 175, 177, "Drug", "ADE_Drug"], [230, 236, "ADE", 175, 177, "Drug", "ADE_Drug"], [180, 183, "Drug", 188, 190, "Disease", "Drug_Disease"], [225, 226, "ADE", 180, 183, "Drug", "ADE_Drug"], [230, 236, "ADE", 180, 183, "Drug", "ADE_Drug"], [194, 196, "Symptom", 188, 190, "Disease", "Symptom_Disease"]]}
{"idx": 2738, "sentence": "在急性肢体缺血的初期治疗中，起始手术或者溶栓治疗对于30d、6个月或1年的保肢或死亡发生，两者差异无统计学意义；但起始溶栓治疗组(1.3%)30d的卒中发生率较起始手术治疗组(0%)显著增加(OR=6.41，95%CI：1.57~26.22)；30d的大出血发生率分别为8.8%与3.3%(OR=2.80，95%CI：1.70~4.60)，病灶远端的栓塞发生率分别为12.4%与0%(OR=8.35，95%CI：4.47~15.58)；因此，在急性肢体缺血患者，起始手术治疗或者溶栓治疗对于保肢或死亡均无明显差异，但起始溶栓治疗会使肢体缺血与出血并发症风险增加。", "ner": [[1, 6, "Disease"], [3, 4, "Anatomy"], [74, 75, "ADE"], [126, 128, "ADE"], [170, 176, "ADE"], [222, 227, "Disease"], [224, 225, "Anatomy"], [266, 269, "ADE"], [271, 272, "ADE"]], "rel": [[3, 4, "Anatomy", 1, 6, "Disease", "Anatomy_Disease"], [224, 225, "Anatomy", 222, 227, "Disease", "Anatomy_Disease"]]}
{"idx": 2739, "sentence": "从某种程度上讲，上述药物治疗方法仅仅是对于轻至中度的下肢动脉缺血性病变的患者延缓其病变的发展，是糖尿病足治疗的基础；但对于严重下肢缺血(CLI)患者多数并不能达到改善症状、保肢的目的。", "ner": [[21, 24, "Level"], [26, 34, "Disease"], [26, 29, "Anatomy"], [48, 51, "Disease"], [51, 51, "Anatomy"], [61, 62, "Level"], [63, 71, "Disease"], [63, 64, "Anatomy"]], "rel": [[26, 29, "Anatomy", 26, 34, "Disease", "Anatomy_Disease"], [51, 51, "Anatomy", 48, 51, "Disease", "Anatomy_Disease"], [63, 64, "Anatomy", 63, 71, "Disease", "Anatomy_Disease"]]}
{"idx": 2740, "sentence": "因此，对于缺血严重而内科常规治疗无效者，需行经皮介入治疗或外科手术治疗。", "ner": [[5, 6, "Symptom"], [7, 8, "Level"], [22, 27, "Operation"]], "rel": []}
{"idx": 2741, "sentence": "(二)? 手术干预治疗 ", "ner": [], "rel": []}
{"idx": 2742, "sentence": "对于缺血严重，系统药物治疗效果不理想的患者，手术血流重建则是必要的措施。", "ner": [[2, 3, "Symptom"], [4, 5, "Level"], [24, 27, "Operation"]], "rel": []}
{"idx": 2743, "sentence": "手术血流重建的方法，有以下几种：", "ner": [[2, 5, "Operation"]], "rel": []}
{"idx": 2744, "sentence": "1.下肢动脉腔内介人治疗：主要具体方法包括经皮穿刺动脉内成形(主要指普通/药物涂层球囊扩张术)和在球囊扩张的基础上支架成形术或直接的动脉腔内支架成形术以及目前常用的各种减容手术。", "ner": [[2, 11, "Operation"], [21, 46, "Operation"], [49, 52, "Operation"], [57, 61, "Operation"], [66, 74, "Operation"]], "rel": []}
{"idx": 2745, "sentence": "作为一种微创手段，可以作为首选，尤其是当患者年老体弱或伴有其他疾病无法耐受动脉旁路手术时。", "ner": [[37, 42, "Operation"]], "rel": []}
{"idx": 2746, "sentence": "(1)下肢动脉腔内介人治疗适应证：Rutherford分级3级以上，Fontaine分级Ⅱb以上。", "ner": [[3, 12, "Operation"]], "rel": []}
{"idx": 2747, "sentence": "(2)疗效评价：目前的评估指标包括主观指标和客观指标。", "ner": [], "rel": []}
{"idx": 2748, "sentence": "前者包括主观症状的改善，如疼痛缓解或减轻程度，肢体发冷感觉改善情况等；后者包括ABI，溃疡面愈合情况，截肢平面的降低等。对于糖尿病下肢缺血患者，只要有一项指标得到改善就视为临床成功。", "ner": [[23, 28, "Symptom"], [13, 14, "Symptom"], [62, 64, "Disease"], [65, 68, "Disease"], [65, 66, "Anatomy"]], "rel": [[65, 66, "Anatomy", 65, 68, "Disease", "Anatomy_Disease"]]}
{"idx": 2749, "sentence": "腔内介人治疗术后，靶血管血流恢复即视为技术成功。", "ner": [[0, 7, "Disease"]], "rel": []}
{"idx": 2750, "sentence": "2.下肢动脉旁路移植：常用方法有膝上旁路和膝下旁路等，具体手术方式根据术者经验及患者血管条件而定。", "ner": [[2, 9, "Operation"]], "rel": []}
{"idx": 2751, "sentence": "(1)动脉旁路移植的适应证：①下肢远端有比较好的动脉流出道；②患者体质较好，能够耐受手术。", "ner": [[3, 8, "Operation"]], "rel": []}
{"idx": 2752, "sentence": "(2)疗效评价：评价指标基本同下肢动脉腔内介入治疗的评价；吻合口远端血运得到改善视为技术成功。", "ner": [[15, 24, "Operation"]], "rel": []}
{"idx": 2753, "sentence": "3.干细胞移植：干细胞目前尚不能作为治疗糖尿病下肢血管病变的常规手段，国内外研究报道干细胞移植治疗下肢血管病变有一定疗效。目前干细胞移植包括自体和异体移植，是最近十多年发展起来的新技术。自体干细胞移植在国内得到一定程度的普及，取得了良好的效果。目前干细胞的来源有骨髓、外周血和改良的骨髓3种方法。自体干细胞至少有2个优点：(1)不存在免疫排斥；(2)没有胚胎干细胞的伦理问题。异体干细胞主要包括脐血、间充质和胚胎干细胞，前两者在临床上已经有比较好的结果。但是限于国家政策，异体干细胞移植需要有一定的资质，目前处于临床研究阶段，有条件的单位可根据情况决定是否选择。此外，干细胞联合凝胶可以修复糖尿病足的创面，临床上技术尚不完全成熟，建议有条件单位要谨慎开展。", "ner": [[2, 6, "Operation"], [20, 22, "Disease"], [23, 28, "Disease"], [23, 26, "Anatomy"], [42, 46, "Operation"], [49, 54, "Disease"], [49, 52, "Anatomy"], [63, 67, "Operation"], [70, 76, "Operation"], [93, 99, "Operation"], [236, 242, "Operation"], [295, 298, "Disease"], [298, 298, "Anatomy"], [300, 301, "Symptom"], [167, 170, "ADE"]], "rel": [[2, 6, "Operation", 20, 22, "Disease", "Operation_Disease"], [2, 6, "Operation", 23, 28, "Disease", "Operation_Disease"], [23, 26, "Anatomy", 23, 28, "Disease", "Anatomy_Disease"], [49, 52, "Anatomy", 49, 54, "Disease", "Anatomy_Disease"], [298, 298, "Anatomy", 295, 298, "Disease", "Anatomy_Disease"], [300, 301, "Symptom", 295, 298, "Disease", "Symptom_Disease"]]}
{"idx": 2754, "sentence": "4.围手术期的处理：无论采用哪种治疗方法，均要重视围手术期的处理。", "ner": [], "rel": []}
{"idx": 2755, "sentence": "除内科药物治疗外，主要有以下几种措施：", "ner": [], "rel": []}
{"idx": 2756, "sentence": "(1)抗凝治疗：糖尿病下肢缺血患者，多为血液高凝状态，可以采用抗凝措施防止血栓形成，尤其是在膝下动脉血运重建后。", "ner": [[8, 10, "Disease"], [11, 14, "Symptom"], [21, 25, "Symptom"], [29, 34, "Treatment"], [37, 38, "Disease"]], "rel": [[11, 14, "Symptom", 8, 10, "Disease", "Symptom_Disease"]]}
{"idx": 2757, "sentence": "(2)抗血小板治疗：常规应用。", "ner": [], "rel": []}
{"idx": 2758, "sentence": "(3)扩血管药物：常规应用", "ner": [], "rel": []}
{"idx": 2759, "sentence": "(4)降纤治疗：糖尿病足患者的纤维蛋白原高于正常者，可给予降纤治疗。", "ner": [[8, 11, "Disease"], [15, 19, "Test_items"], [20, 20, "Test_Value"], [11, 11, "Anatomy"]], "rel": [[11, 11, "Anatomy", 8, 11, "Disease", "Anatomy_Disease"], [15, 19, "Test_items", 8, 11, "Disease", "Test_items_Disease"]]}
{"idx": 2760, "sentence": "(四)糖尿病足创面处理", "ner": [[3, 6, "Disease"], [6, 6, "Anatomy"], [7, 8, "Symptom"]], "rel": [[6, 6, "Anatomy", 3, 6, "Disease", "Anatomy_Disease"], [7, 8, "Symptom", 3, 6, "Disease", "Symptom_Disease"]]}
{"idx": 2761, "sentence": "1.促进创面愈合的前提条件：在创面处理的同时，需积极进行全身情况的治疗，包括控制血糖、抗感染、代谢调节、下肢血运重建等。", "ner": [[4, 5, "Symptom"], [15, 16, "Symptom"], [52, 57, "Operation"]], "rel": []}
{"idx": 2762, "sentence": "2.非手术治疗", "ner": [], "rel": []}
{"idx": 2763, "sentence": "(1)姑息性清创：换药时，在避免活动性出血和过度损失健康组织的前提下，可用组织剪去除明确坏死组织，以缩短自溶性清创时间，减少感染机会，改善深部组织引流，但须注意保留间生态组织。", "ner": [[16, 20, "Symptom"], [22, 29, "Symptom"], [44, 47, "Symptom"], [62, 63, "Symptom"]], "rel": []}
{"idx": 2764, "sentence": "(2)创面换药：创面换药可门诊进行，根据创面感染程度和渗出量决定换药频次。", "ner": [[20, 21, "Symptom"], [22, 23, "Symptom"], [27, 28, "Symptom"], [3, 4, "Symptom"], [8, 9, "Symptom"]], "rel": []}
{"idx": 2765, "sentence": "(3)创面用药：根据创面不同阶段选择创面用药，如创面以感染表现为主，可单独应用碘伏等消毒剂，加强换药频次；如创面坏死组织已溶脱，基底肉芽组织开始增生，可选择消毒杀菌类药物和促进生长类药物复合使用。", "ner": [[18, 19, "Symptom"], [24, 25, "Symptom"], [27, 28, "Symptom"], [39, 40, "Drug"], [54, 62, "Symptom"], [64, 73, "Symptom"]], "rel": []}
{"idx": 2766, "sentence": "(4)敷料选择：优先选择具有杀菌、吸附渗液保持创面适度湿性、防粘连等具有复合功能且高性价比的伤口敷料，也可根据创面情况选择多种单一功能敷料逐层覆盖使用。", "ner": [[23, 24, "Symptom"], [55, 56, "Symptom"]], "rel": []}
{"idx": 2767, "sentence": "(5)持续封闭式负压吸引：可有效改善创面引流，加速坏死组织溶脱和肉芽组织增生，但需住院接受治疗。对糖尿病足创面应注意避免压力设置过高、避免因覆盖不当导致相邻足趾压迫缺血。", "ner": [[49, 52, "Disease"], [52, 52, "Anatomy"], [53, 54, "Symptom"], [78, 83, "Symptom"], [78, 79, "Anatomy"], [3, 11, "Treatment"]], "rel": [[53, 54, "Symptom", 49, 52, "Disease", "Symptom_Disease"], [78, 83, "Symptom", 49, 52, "Disease", "Symptom_Disease"], [52, 52, "Anatomy", 49, 52, "Disease", "Anatomy_Disease"]]}
{"idx": 2768, "sentence": "(6)生物治疗：①干细胞疗法：可选择自体骨髓干细胞或外周血干细胞，小腿肌肉多点注射后有助于促进缺血肢体的侧支循环建立，改善远端缺血状况。", "ner": [[9, 13, "Treatment"], [3, 6, "Treatment"]], "rel": []}
{"idx": 2769, "sentence": "②自体富血小板血浆凝腔外用疗法：可有效改善缺血性创面的局部肉芽组织增生能力，但需应用于清创后相对无菌创面。", "ner": [[1, 14, "Treatment"]], "rel": []}
{"idx": 2770, "sentence": "③蛆虫疗法：可用于加速去除创面坏死组织，缩短疗程，但需采用医用级蛆虫。", "ner": [[1, 4, "Treatment"], [13, 18, "Symptom"]], "rel": []}
{"idx": 2771, "sentence": "(7)减压支具应用：在治疗和愈后预防复发过程中，应根据创面部位，适时选择减压鞋垫，糖尿病足鞋等专业支县，有助于避免创面加深和复发。", "ner": [[57, 63, "Symptom"]], "rel": []}
{"idx": 2772, "sentence": "(8)物理治疗：理疗和创面高压氧治疗，有助于改善创面的炎症和微循环状况，促进创面愈合。", "ner": [[8, 9, "Treatment"], [11, 17, "Treatment"], [3, 6, "Treatment"]], "rel": []}
{"idx": 2773, "sentence": "3.手术治疗：应根据创面情况、患者全身状况，适时进行清创术或植皮术等手术治疗，可有效去除坏死组织，尽早封闭创面，显著缩短疗程，避免因长期换药导致下肢废用性肌萎缩、骨质疏松、深静脉血栓及心肺功能下降等并发症。", "ner": [[26, 28, "Operation"], [30, 32, "Operation"], [44, 47, "Symptom"], [66, 69, "Reason"], [72, 79, "Disease"], [72, 73, "Anatomy"], [81, 84, "Disease"], [86, 90, "Disease"], [86, 88, "Anatomy"], [92, 97, "Disease"], [92, 92, "Anatomy"], [93, 93, "Anatomy"], [10, 11, "Symptom"], [53, 54, "Symptom"]], "rel": [[66, 69, "Reason", 72, 79, "Disease", "Reason_Disease"], [66, 69, "Reason", 81, 84, "Disease", "Reason_Disease"], [66, 69, "Reason", 86, 90, "Disease", "Reason_Disease"], [66, 69, "Reason", 92, 97, "Disease", "Reason_Disease"], [72, 73, "Anatomy", 72, 79, "Disease", "Anatomy_Disease"], [86, 88, "Anatomy", 86, 90, "Disease", "Anatomy_Disease"], [92, 92, "Anatomy", 92, 97, "Disease", "Anatomy_Disease"], [93, 93, "Anatomy", 92, 97, "Disease", "Anatomy_Disease"]]}
{"idx": 2774, "sentence": "(1)手术时机：在全身状况许可的前提下，应尽早进行清创术去除创面坏死组织；在创面肉芽组织增生已覆盖骨骼、肌腱等深部组织，具备条件时应及时进行植皮术以避免创面肉芽组织水肿老化、疗程过长等问题。", "ner": [[25, 27, "Operation"], [30, 35, "Symptom"], [70, 72, "Operation"], [38, 58, "Symptom"], [76, 85, "Symptom"]], "rel": []}
{"idx": 2775, "sentence": "(2)创面清创手术的适应证：①已发生明确的足趾、足掌、肢体坏疽创面；②坏死性筋膜炎急性炎症期的创面；③形成足底筋膜、肌膜间隙脓肿的创面：④形成感染性窦道的创面；⑤肌腱、骨骼等深部组织外露失活，换药难以去除的创面；⑥残存大量坏死组织的创面；⑦创面基底肉芽组织增生，无深部组织外露，达到植皮条件而通过换药1个月内难以愈合的创面。", "ner": [[3, 8, "Operation"], [21, 32, "Symptom"], [21, 22, "Anatomy"], [24, 25, "Anatomy"], [27, 28, "Anatomy"], [35, 40, "Disease"], [38, 39, "Anatomy"], [53, 66, "Symptom"], [53, 56, "Anatomy"], [58, 61, "Anatomy"], [71, 78, "Symptom"], [81, 94, "Symptom"], [96, 104, "Symptom"], [81, 82, "Anatomy"], [84, 85, "Anatomy"], [107, 117, "Symptom"], [120, 129, "Symptom"], [141, 142, "Operation"], [154, 160, "Symptom"], [47, 48, "Symptom"]], "rel": [[38, 39, "Anatomy", 35, 40, "Disease", "Anatomy_Disease"], [47, 48, "Symptom", 35, 40, "Disease", "Symptom_Disease"]]}
{"idx": 2776, "sentence": "(3)手术方式的选择：尽可能优先选择简单、维发损伤小的手术方案，争取以简单方法解决复杂问题。①止血带：疑似血运障碍者，建议慎用止血带。②清创术：注意探查深层组织损伤情况，避免肌肉组织夹心样坏死和骨筋膜间室综合征，术后能够通畅引流；建议通过多次清创的手术方式，避免损伤过多健康组织，对无明确坏死表现的骨质应尽可能保全。③缝合术：不推荐清创后一期缝合。④植皮术：创面基底达到植皮条件，应尽早手术封闭创面。建议优先选择刃厚皮植皮，能够选择游离皮片移植的不需选择皮瓣移植。⑤皮瓣移植术：因糖尿病足患者多双下肢同步发生血管缺血性病变，故不推荐皮瓣转移移植手术，以避免出现皮瓣修复失败甚至供瓣区愈合不良。需在术前对术区血管详细检查评估的前提下，制定手术方案，选择皮瓣的优先顺序为邻位、远位、带蒂、游离。⑥截肢/趾术：对坏死肢体感染危及生命、血供无法重建、创面难以愈合、因疼痛难以忍受，患者家庭经济状况难以坚持长期非手术治疗而强烈要求者，可进行截肢治疗。", "ner": [[53, 56, "Disease"], [68, 70, "Operation"], [76, 81, "Symptom"], [87, 95, "Disease"], [87, 90, "Anatomy"], [97, 104, "Disease"], [97, 101, "Anatomy"], [121, 122, "Operation"], [159, 161, "Operation"], [166, 167, "Operation"], [175, 177, "Operation"], [185, 186, "Operation"], [179, 180, "Symptom"], [197, 198, "Symptom"], [206, 210, "Operation"], [216, 221, "Operation"], [227, 230, "Operation"], [233, 237, "Operation"], [240, 243, "Disease"], [243, 243, "Anatomy"], [247, 260, "Disease"], [247, 249, "Anatomy"], [266, 273, "Operation"], [280, 285, "ADE"], [288, 294, "ADE"], [346, 350, "Operation"], [353, 358, "Disease"], [355, 356, "Anatomy"], [359, 362, "Symptom"], [364, 369, "Symptom"], [371, 376, "Symptom"], [379, 384, "Symptom"], [415, 416, "Operation"]], "rel": [[76, 81, "Symptom", 87, 95, "Disease", "Symptom_Disease"], [76, 81, "Symptom", 97, 104, "Disease", "Symptom_Disease"], [87, 90, "Anatomy", 87, 95, "Disease", "Anatomy_Disease"], [97, 101, "Anatomy", 97, 104, "Disease", "Anatomy_Disease"], [233, 237, "Operation", 240, 243, "Disease", "Operation_Disease"], [243, 243, "Anatomy", 240, 243, "Disease", "Anatomy_Disease"], [247, 249, "Anatomy", 247, 260, "Disease", "Anatomy_Disease"], [346, 350, "Operation", 353, 358, "Disease", "Operation_Disease"], [355, 356, "Anatomy", 353, 358, "Disease", "Anatomy_Disease"], [415, 416, "Operation", 353, 358, "Disease", "Operation_Disease"], [359, 362, "Symptom", 353, 358, "Disease", "Symptom_Disease"], [364, 369, "Symptom", 353, 358, "Disease", "Symptom_Disease"], [371, 376, "Symptom", 353, 358, "Disease", "Symptom_Disease"], [379, 384, "Symptom", 353, 358, "Disease", "Symptom_Disease"]]}
{"idx": 2777, "sentence": "⑦截肢平面选择：一般可根据患者全身状况、局部供血和损伤情况决定截胶平面，争取达到残端一期愈合的情况下保留患肢功能。", "ner": [[1, 2, "Operation"]], "rel": []}
{"idx": 2778, "sentence": "目前临床上使用比较广泛的是采用经皮氧分压测定(也可结合血管影像学检查)，一般来讲，组织的经皮氧分压<20mmHg时，预示着截肢残端无法愈合；经皮氧分压>40mmHg时，预示着戴肢残端可以愈合；介于二者之间有愈合的可能，可能需要采用增加血流的方法。", "ner": [[15, 21, "Test"], [27, 33, "Test"], [41, 48, "Test"], [61, 68, "Symptom"], [70, 74, "Test"], [75, 81, "Test_Value"], [49, 55, "Test_Value"]], "rel": []}
{"idx": 2779, "sentence": "西洛他唑是一种强效磷酸二酯Ⅲ抑制剂，2007年被泛大西洋协作组织(TASC) Ⅱ指南推荐作为治疗间歇性跛行的一线药物。在糖尿病足的治疗中，西洛他唑既可以抑制血小板的聚集，防止血栓形成；另一方面，也能够通过扩张血管的作用，增加狭窄动脉的血流量，改善患肢取血状态。西洛他唑的应用可以大幅延迟糖尿病患者截肢的发生，并且改善糖尿病足患者下肢动脉缺血的情况。一般来讲，24周的西洛他唑(100mg，2次/d)治疗可以有效预防糖尿病足者发生溃疡；经8周的西洛他唑(100mg，2次/d)治疗，2型糖尿病下肢缺血患者的经皮氧分压、间歇性跛行、肢体冷感以及疼痛感等显著改善且优于阿司匹林，给予西洛他唑100mg与50mg，2次/d，其无痛性跛行距离均有较好的改善(WMD=31.4lm，95%CI：22.38~40.45m，P<0.00001； WMD=19.89m，95%CI：9.44~30.34m，P=0.0002)，最大跛行距离也有明显改善(WMD=43.12m，95% CI：18.28~67.96m，P=0.0007；WMD=32.00m，95%CI：14.17~49.83m，P=0.0004)，提示西洛他唑能够改善下肢动脉粥样硬化性病变(LEAD) 患者的步行距离，但目前没有足够的证据证明服用西洛他唑能够降低全因病死率和心血管事件或者改善患者的生活质量。此外，经血管腔内微创治疗(球囊扩张及支架植入) 的LEAD患者，西洛他唑治疗较噻氯匹啶有更少的再闭塞发生(OR=0.32，95%CI：0.13~0.76，P=0.01)，且西洛他唑治疗是预防血管再狭窄的独立预测因子。西洛他唑的不良反应主要有头痛、腹泻、大便异常、头晕以及心悸，但症状轻微可以忍受，严重不良事件包括心血管事件及死亡率与安慰剂相比并没有增加，但长期有效性尚不明确。", "ner": [[0, 3, "Drug"], [7, 16, "Drug"], [48, 52, "Disease"], [60, 63, "Disease"], [63, 63, "Anatomy"], [69, 72, "Drug"], [78, 83, "Pathogenesis"], [87, 88, "Symptom"], [130, 133, "Drug"], [143, 145, "Disease"], [148, 149, "Operation"], [158, 161, "Disease"], [161, 161, "Anatomy"], [164, 169, "Disease"], [164, 167, "Anatomy"], [179, 181, "Duration"], [183, 186, "Drug"], [188, 192, "Amount"], [194, 197, "Frequency"], [207, 210, "Disease"], [210, 210, "Anatomy"], [214, 215, "Symptom"], [218, 219, "Duration"], [221, 224, "Drug"], [226, 230, "Amount"], [232, 235, "Frequency"], [240, 244, "Disease"], [245, 248, "Disease"], [245, 246, "Anatomy"], [252, 256, "Test"], [258, 262, "Symptom"], [264, 267, "Symptom"], [264, 265, "Anatomy"], [270, 272, "Symptom"], [281, 284, "Drug"], [288, 291, "Drug"], [292, 296, "Amount"], [298, 301, "Amount"], [303, 306, "Frequency"], [499, 502, "Drug"], [507, 523, "Disease"], [507, 510, "Anatomy"], [547, 550, "Drug"], [561, 565, "Disease"], [561, 563, "Anatomy"], [581, 600, "Operation"], [603, 606, "Disease"], [610, 613, "Drug"], [617, 620, "Drug"], [625, 627, "ADE"], [664, 667, "Drug"], [673, 677, "Symptom"], [686, 689, "Drug"], [698, 699, "ADE"], [701, 702, "ADE"], [704, 707, "ADE"], [709, 710, "ADE"], [713, 714, "ADE"], [719, 720, "Level"], [726, 727, "Level"], [734, 738, "ADE"], [734, 736, "Anatomy"]], "rel": [[0, 3, "Drug", 48, 52, "Disease", "Drug_Disease"], [63, 63, "Anatomy", 60, 63, "Disease", "Anatomy_Disease"], [69, 72, "Drug", 60, 63, "Disease", "Drug_Disease"], [87, 88, "Symptom", 60, 63, "Disease", "Symptom_Disease"], [78, 83, "Pathogenesis", 60, 63, "Disease", "Pathogenesis_Disease"], [130, 133, "Drug", 143, 145, "Disease", "Drug_Disease"], [130, 133, "Drug", 158, 161, "Disease", "Drug_Disease"], [130, 133, "Drug", 164, 169, "Disease", "Drug_Disease"], [148, 149, "Operation", 143, 145, "Disease", "Operation_Disease"], [161, 161, "Anatomy", 158, 161, "Disease", "Anatomy_Disease"], [164, 167, "Anatomy", 164, 169, "Disease", "Anatomy_Disease"], [179, 181, "Duration", 183, 186, "Drug", "Duration_Drug"], [183, 186, "Drug", 207, 210, "Disease", "Drug_Disease"], [194, 197, "Frequency", 183, 186, "Drug", "Frequency_Drug"], [188, 192, "Amount", 183, 186, "Drug", "Amount_Drug"], [218, 219, "Duration", 221, 224, "Drug", "Duration_Drug"], [221, 224, "Drug", 240, 244, "Disease", "Drug_Disease"], [221, 224, "Drug", 245, 248, "Disease", "Drug_Disease"], [221, 224, "Drug", 507, 523, "Disease", "Drug_Disease"], [221, 224, "Drug", 561, 565, "Disease", "Drug_Disease"], [226, 230, "Amount", 221, 224, "Drug", "Amount_Drug"], [298, 301, "Amount", 221, 224, "Drug", "Amount_Drug"], [232, 235, "Frequency", 221, 224, "Drug", "Frequency_Drug"], [281, 284, "Drug", 240, 244, "Disease", "Drug_Disease"], [258, 262, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [264, 267, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [270, 272, "Symptom", 240, 244, "Disease", "Symptom_Disease"], [252, 256, "Test", 240, 244, "Disease", "Test_Disease"], [245, 246, "Anatomy", 245, 248, "Disease", "Anatomy_Disease"], [281, 284, "Drug", 245, 248, "Disease", "Drug_Disease"], [252, 256, "Test", 245, 248, "Disease", "Test_Disease"], [507, 510, "Anatomy", 507, 523, "Disease", "Anatomy_Disease"], [561, 563, "Anatomy", 561, 565, "Disease", "Anatomy_Disease"], [581, 600, "Operation", 603, 606, "Disease", "Operation_Disease"], [610, 613, "Drug", 603, 606, "Disease", "Drug_Disease"], [617, 620, "Drug", 603, 606, "Disease", "Drug_Disease"], [673, 677, "Symptom", 603, 606, "Disease", "Symptom_Disease"], [625, 627, "ADE", 610, 613, "Drug", "ADE_Drug"], [625, 627, "ADE", 617, 620, "Drug", "ADE_Drug"], [698, 699, "ADE", 686, 689, "Drug", "ADE_Drug"], [701, 702, "ADE", 686, 689, "Drug", "ADE_Drug"], [704, 707, "ADE", 686, 689, "Drug", "ADE_Drug"], [709, 710, "ADE", 686, 689, "Drug", "ADE_Drug"], [713, 714, "ADE", 686, 689, "Drug", "ADE_Drug"], [734, 738, "ADE", 686, 689, "Drug", "ADE_Drug"]]}
{"idx": 2780, "sentence": "西洛他唑的推荐剂量为50~100mg/次，2次/d。", "ner": [[0, 3, "Drug"], [10, 19, "Amount"], [21, 24, "Frequency"]], "rel": [[21, 24, "Frequency", 0, 3, "Drug", "Frequency_Drug"], [10, 19, "Amount", 0, 3, "Drug", "Amount_Drug"]]}
{"idx": 2781, "sentence": " ", "ner": [], "rel": []}
{"idx": 2782, "sentence": "5.血管影像检查：包括动脉彩色多普勒超声检查、CT血管造影(CTA) 、磁共振血管造影(MRA) 和数字减影血管造影(DSA)血管彩色多普勒检查具有无创、简便的特点，可以了解动脉硬化斑块状况及有无动脉狭窄或闭塞，适用于血管病变大范围筛查。 CTA和MR A具有成像清晰的特点，可以显示血管有无狭窄或闭塞，但准确率低于DSA。对于肾功能正常者，CTA目前可作为糖尿病足下肢血管病变的首选影像学检查手段。DSA仍是诊断下肢血管病变的金标准，可以准确显示动脉堵塞状况及侧支循环建立情况，对外科治疗方案的选择有重要作用。", "ner": [[2, 7, "Test"], [11, 21, "Test"], [23, 33, "Test"], [36, 47, "Test"], [50, 62, "Test"], [63, 71, "Test"], [87, 92, "Disease"], [87, 88, "Anatomy"], [98, 104, "Symptom"], [98, 99, "Anatomy"], [109, 112, "Disease"], [109, 110, "Anatomy"], [120, 122, "Test"], [124, 127, "Test"], [158, 160, "Test"], [171, 173, "Test"], [179, 182, "Disease"], [182, 182, "Anatomy"], [183, 188, "Disease"], [183, 186, "Anatomy"], [192, 196, "Test"], [200, 202, "Test"], [207, 212, "Disease"], [207, 210, "Anatomy"], [224, 227, "Symptom"], [224, 225, "Anatomy"]], "rel": [[2, 7, "Test", 109, 112, "Disease", "Test_Disease"], [2, 7, "Test", 87, 92, "Disease", "Test_Disease"], [11, 21, "Test", 109, 112, "Disease", "Test_Disease"], [11, 21, "Test", 87, 92, "Disease", "Test_Disease"], [23, 33, "Test", 109, 112, "Disease", "Test_Disease"], [23, 33, "Test", 87, 92, "Disease", "Test_Disease"], [36, 47, "Test", 109, 112, "Disease", "Test_Disease"], [36, 47, "Test", 87, 92, "Disease", "Test_Disease"], [50, 62, "Test", 109, 112, "Disease", "Test_Disease"], [50, 62, "Test", 87, 92, "Disease", "Test_Disease"], [63, 71, "Test", 109, 112, "Disease", "Test_Disease"], [63, 71, "Test", 87, 92, "Disease", "Test_Disease"], [87, 88, "Anatomy", 87, 92, "Disease", "Anatomy_Disease"], [98, 104, "Symptom", 109, 112, "Disease", "Symptom_Disease"], [109, 110, "Anatomy", 109, 112, "Disease", "Anatomy_Disease"], [171, 173, "Test", 179, 182, "Disease", "Test_Disease"], [171, 173, "Test", 183, 188, "Disease", "Test_Disease"], [182, 182, "Anatomy", 179, 182, "Disease", "Anatomy_Disease"], [192, 196, "Test", 179, 182, "Disease", "Test_Disease"], [183, 186, "Anatomy", 183, 188, "Disease", "Anatomy_Disease"], [192, 196, "Test", 183, 188, "Disease", "Test_Disease"], [200, 202, "Test", 207, 212, "Disease", "Test_Disease"], [207, 210, "Anatomy", 207, 212, "Disease", "Anatomy_Disease"], [224, 227, "Symptom", 207, 212, "Disease", "Symptom_Disease"]]}
{"idx": 2783, "sentence": " ", "ner": [], "rel": []}
{"idx": 2784, "sentence": "《中国高尿酸血症相关疾病诊疗多学科专家共识》解读", "ner": [[3, 7, "Disease"]], "rel": []}
{"idx": 2785, "sentence": "高尿酸血症(HUA)的流行总体呈现逐年升高的趋势，常与高血压、高脂血症、2型糖尿病、肥胖、胰岛素抵抗等传统的代谢性心血管危险因素伴发，因此长期以来HUA仅仅被认为是代谢异常的一种标志。但近年来多个前瞻性大规模临床结果显示，HUA是心血管疾病、糖尿病的独立危险因素，也是全因死亡、总心血管事件和缺血性卒中的独立危险因素。HUA可增加糖尿病肾病的风险，是急慢性肾衰竭的强有力的预测因素。", "ner": [[0, 9, "Disease"], [27, 29, "Disease"], [31, 34, "Disease"], [36, 40, "Disease"], [45, 49, "Disease"], [42, 43, "Disease"], [73, 75, "Disease"], [111, 113, "Disease"], [115, 119, "Disease"], [146, 150, "Disease"], [159, 161, "Disease"], [175, 180, "Disease"], [178, 178, "Anatomy"], [168, 168, "Anatomy"], [121, 123, "Disease"], [0, 9, "Disease"], [115, 117, "Anatomy"], [165, 169, "Disease"], [134, 137, "Disease"], [140, 144, "Disease"], [140, 142, "Anatomy"]], "rel": [[115, 117, "Anatomy", 115, 119, "Disease", "Anatomy_Disease"], [178, 178, "Anatomy", 175, 180, "Disease", "Anatomy_Disease"], [168, 168, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [140, 142, "Anatomy", 140, 144, "Disease", "Anatomy_Disease"]]}
{"idx": 2786, "sentence": "在此背景下，风湿免疫、肾脏、内分泌代谢、心血管、神经、泌尿和中医科等学科专家组成的HUA相关疾病诊疗多学科共识专家组，经过充分讨论制定出《中国高尿酸血症相关疾病诊疗多学科专家共识》，并于发布在《中华内科杂志》2017年第3期上，该专家共识旨在推动多学科协作，指导和规范HUA相关疾病的临床实践。", "ner": [[41, 43, "Disease"], [71, 75, "Disease"], [134, 136, "Disease"]], "rel": []}
{"idx": 2787, "sentence": "HUA的定义", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2788, "sentence": "HUA的流行病学特征", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2789, "sentence": "血尿酸水平受年龄、性别、种族、遗传、饮食习惯、药物、环境等多种因素影响，我国目前尚缺乏全国范围的HUA流行病学调查资料。来自不同时间、地区的资料显示，目前我国HUA呈现高流行、年轻化、男性高于女性、沿海高于内陆的流行趋势，原因可能与人群饮食结构、平均寿命的延长和医疗保健水平的不断提高有关。", "ner": [[0, 2, "Test_items"], [48, 50, "Disease"], [79, 81, "Disease"], [116, 121, "Reason"], [123, 129, "Reason"], [131, 141, "Reason"]], "rel": [[0, 2, "Test_items", 48, 50, "Disease", "Test_items_Disease"], [116, 121, "Reason", 79, 81, "Disease", "Reason_Disease"], [123, 129, "Reason", 79, 81, "Disease", "Reason_Disease"], [131, 141, "Reason", 79, 81, "Disease", "Reason_Disease"]]}
{"idx": 2790, "sentence": "HUA及痛风的诊断", "ner": [[0, 2, "Disease"], [4, 5, "Disease"]], "rel": []}
{"idx": 2791, "sentence": "共识明确提出，正常饮食下，非同日两次空腹血尿酸水平>420μmol/L即可诊断为HUA。同时指出，年龄<25岁、具有痛风家族史的HUA患者需排查遗传性嘌呤代谢异常疾病。关于痛风的诊断既往多采用1977年美国风湿病学会(ACR)痛风分类标准。近年来，关节B超检查和双能CT检查逐渐普及，共识建议采用2015年ACR/欧洲抗风湿病联盟(EULAR)提出的ACR/EULAR痛风分类标准，新标准不仅可用于痛风急性发作期的诊断分类，同时也可应用于间歇期痛风患者的分类，能够真正有效地将痛风从其他疾病中区分出来，从而更好地进行临床研究和药物临床试验。新的标准将影像学诊断纳入评分体系中，体现了对新的影像技术的肯定，但由于关节超声检查易受操作者技术水平影响，超声及双能CT的迅速推广也给痛风的诊断带来新的挑战。", "ner": [[18, 22, "Test_items"], [25, 34, "Test_Value"], [40, 42, "Disease"], [58, 59, "Disease"], [64, 66, "Disease"], [72, 80, "Disease"], [86, 87, "Disease"], [103, 105, "Disease"], [113, 114, "Disease"], [126, 127, "Test"], [160, 162, "Disease"], [184, 185, "Disease"], [199, 200, "Disease"], [222, 223, "Disease"], [238, 239, "Disease"], [305, 308, "Test"], [323, 324, "Test"], [326, 329, "Test"], [337, 338, "Disease"], [131, 134, "Test"]], "rel": [[18, 22, "Test_items", 40, 42, "Disease", "Test_items_Disease"], [126, 127, "Test", 184, 185, "Disease", "Test_Disease"], [131, 134, "Test", 184, 185, "Disease", "Test_Disease"], [305, 308, "Test", 337, 338, "Disease", "Test_Disease"], [323, 324, "Test", 337, 338, "Disease", "Test_Disease"], [326, 329, "Test", 337, 338, "Disease", "Test_Disease"]]}
{"idx": 2792, "sentence": "因此，规范、可靠的影像学诊断十分必要。", "ner": [], "rel": []}
{"idx": 2793, "sentence": "HUA的危害性", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2794, "sentence": "尿酸来源部分由人体摄入，部分由体内分解代谢的嘌呤化合物在肝脏中产生，三分之二通过肾脏排泄，其余由消化道、皮肤汗腺等排泄。正常情况下，体内尿酸产生和排泄保持动态平衡，凡导致尿酸生成过多和/或排泄减少的因素均可导致HUA。", "ner": [[0, 1, "Test_items"], [68, 69, "Test_items"], [85, 90, "Reason"], [94, 97, "Reason"], [105, 107, "Disease"]], "rel": [[68, 69, "Test_items", 105, 107, "Disease", "Test_items_Disease"], [85, 90, "Reason", 105, 107, "Disease", "Reason_Disease"], [94, 97, "Reason", 105, 107, "Disease", "Reason_Disease"]]}
{"idx": 2795, "sentence": "HUA的危害性越来越受到重视。当血尿酸超过饱和浓度，尿酸盐晶体析出可直接黏附、沉积于关节及周围软组织、肾小管和血管等部位，趋化中性粒细胞和巨噬细胞；细胞与晶体相互作用后释放致炎因子、金属蛋白酶9、水解酶等，导致关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤，故普遍认为HUA是多种心血管危险因素及相关疾病(代谢综合征、2型糖尿病、高血压、心血管事件及死亡、慢性肾病等)的独立危险因素。共识明确指出，HUA是痛风发生的最重要生化基础和最直接的病因，痛风性关节炎患者首先遵循HUA管理原则。", "ner": [[0, 2, "Disease"], [16, 18, "Test_items"], [86, 89, "Reason"], [91, 96, "Reason"], [98, 100, "Reason"], [105, 128, "Disease"], [105, 108, "Anatomy"], [110, 111, "Anatomy"], [113, 114, "Anatomy"], [117, 120, "Anatomy"], [135, 137, "Reason"], [154, 158, "Disease"], [160, 164, "Disease"], [166, 168, "Disease"], [170, 174, "Disease"], [170, 172, "Anatomy"], [179, 182, "Disease"], [181, 181, "Anatomy"], [200, 202, "Reason"], [204, 205, "Disease"], [224, 229, "Disease"], [236, 238, "Disease"], [227, 228, "Anatomy"], [19, 24, "Test_Value"]], "rel": [[16, 18, "Test_items", 105, 128, "Disease", "Test_items_Disease"], [86, 89, "Reason", 105, 128, "Disease", "Reason_Disease"], [91, 96, "Reason", 105, 128, "Disease", "Reason_Disease"], [98, 100, "Reason", 105, 128, "Disease", "Reason_Disease"], [105, 108, "Anatomy", 105, 128, "Disease", "Anatomy_Disease"], [110, 111, "Anatomy", 105, 128, "Disease", "Anatomy_Disease"], [113, 114, "Anatomy", 105, 128, "Disease", "Anatomy_Disease"], [117, 120, "Anatomy", 105, 128, "Disease", "Anatomy_Disease"], [135, 137, "Reason", 154, 158, "Disease", "Reason_Disease"], [135, 137, "Reason", 160, 164, "Disease", "Reason_Disease"], [135, 137, "Reason", 166, 168, "Disease", "Reason_Disease"], [135, 137, "Reason", 170, 174, "Disease", "Reason_Disease"], [135, 137, "Reason", 179, 182, "Disease", "Reason_Disease"], [170, 172, "Anatomy", 170, 174, "Disease", "Anatomy_Disease"], [200, 202, "Reason", 204, 205, "Disease", "Reason_Disease"], [227, 228, "Anatomy", 224, 229, "Disease", "Anatomy_Disease"]]}
{"idx": 2796, "sentence": "HUA和痛风的多学科联合诊治", "ner": [[0, 2, "Disease"], [4, 5, "Disease"]], "rel": []}
{"idx": 2797, "sentence": "本共识特别强调在HUA以及痛风患者治疗过程中必须做到多学科联合治疗。(1)应关注高危人群：高龄男性、肥胖、一级亲属中有痛风史者、患有心血管疾病、肾脏疾病人群，应定期监测血清血尿酸(SUA)浓度。同时尽量避免各种危险因素因素；饮食因素、其他疾病治疗过程中的药物因素如小剂量阿司匹林、利尿剂，环孢素A、麦考酚酯、吡嗪酰胺、乙胺丁醇均可抑制尿酸在肾小管的排泄导致HUA。同时在高危人群中强调非药物治疗，包括正确生活方式指导。共时指出，健康饮食、戒烟限酒、坚持运动和控制体质量、大量饮水适当碱化尿液等生活方式改变可预防HUA，这些需要专科医师体验中心、营养师、慢病管理团队等多学科联合进行。(2)确诊的HUA或痛风患者应积极筛查并发症或合并症，及时制定多学科联合治疗方案：肾病患者须避免使用损害肾脏药物并定期监测肾功能；肾石症患者须碱化尿液，必要时给予溶石或手术治疗；合并高血糖、血脂紊乱、高血压者须同时积极降糖、调脂、降压治疗，尽量选择有利于尿酸排泄的药物，如对于高胆固醇血症或动脉粥样硬化合并HUA的患者，优先考虑阿托伐他汀；对于高甘油三酯血症合并HUA的患者，优先选用非诺贝特；高血压合并HUA患者降压药物优选氯沙坦、二氢吡啶类钙通道阻滞剂等。", "ner": [[8, 10, "Disease"], [13, 14, "Disease"], [50, 51, "Disease"], [72, 75, "Disease"], [84, 93, "Test_items"], [112, 115, "Reason"], [127, 162, "Reason"], [165, 175, "Pathogenesis"], [178, 180, "Disease"], [214, 217, "Treatment"], [219, 222, "Treatment"], [224, 227, "Treatment"], [229, 233, "Treatment"], [235, 238, "Treatment"], [255, 257, "Disease"], [297, 299, "Disease"], [301, 302, "Disease"], [332, 333, "Disease"], [332, 332, "Anatomy"], [356, 357, "Disease"], [356, 356, "Anatomy"], [382, 384, "Disease"], [386, 389, "Disease"], [391, 393, "Disease"], [200, 207, "Treatment"], [372, 373, "Treatment"], [429, 434, "Disease"], [436, 441, "Disease"], [455, 459, "Drug"], [463, 469, "Disease"], [472, 474, "Disease"], [483, 486, "Drug"], [488, 490, "Disease"], [493, 495, "Disease"], [59, 60, "Disease"], [66, 70, "Disease"], [66, 68, "Anatomy"], [72, 73, "Anatomy"], [350, 354, "Test"], [504, 506, "Drug"], [508, 518, "Drug"]], "rel": [[72, 73, "Anatomy", 72, 75, "Disease", "Anatomy_Disease"], [112, 115, "Reason", 178, 180, "Disease", "Reason_Disease"], [127, 162, "Reason", 178, 180, "Disease", "Reason_Disease"], [165, 175, "Pathogenesis", 178, 180, "Disease", "Pathogenesis_Disease"], [214, 217, "Treatment", 255, 257, "Disease", "Treatment_Disease"], [219, 222, "Treatment", 255, 257, "Disease", "Treatment_Disease"], [224, 227, "Treatment", 255, 257, "Disease", "Treatment_Disease"], [229, 233, "Treatment", 255, 257, "Disease", "Treatment_Disease"], [235, 238, "Treatment", 255, 257, "Disease", "Treatment_Disease"], [332, 332, "Anatomy", 332, 333, "Disease", "Anatomy_Disease"], [350, 354, "Test", 332, 333, "Disease", "Test_Disease"], [356, 356, "Anatomy", 356, 357, "Disease", "Anatomy_Disease"], [372, 373, "Treatment", 356, 357, "Disease", "Treatment_Disease"], [455, 459, "Drug", 429, 434, "Disease", "Drug_Disease"], [455, 459, "Drug", 436, 441, "Disease", "Drug_Disease"], [483, 486, "Drug", 463, 469, "Disease", "Drug_Disease"], [483, 486, "Drug", 472, 474, "Disease", "Drug_Disease"], [504, 506, "Drug", 488, 490, "Disease", "Drug_Disease"], [508, 518, "Drug", 488, 490, "Disease", "Drug_Disease"], [504, 506, "Drug", 493, 495, "Disease", "Drug_Disease"], [508, 518, "Drug", 493, 495, "Disease", "Drug_Disease"], [66, 68, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"]]}
{"idx": 2798, "sentence": "降尿酸治疗的起点和目标值", "ner": [], "rel": []}
{"idx": 2799, "sentence": "共识在总结国内外痛风治疗指南和大量痛风及HUA治疗临床研究的基础上，对降尿酸药物治疗的指征、SUA控制的目标以及药物的选择给出了清晰的建议。并强调了痛风治疗的长期性和SUA定期复查的重要性。", "ner": [[8, 9, "Disease"], [17, 18, "Disease"], [20, 22, "Disease"], [74, 75, "Disease"], [46, 48, "Test_items"], [83, 85, "Test_items"]], "rel": [[46, 48, "Test_items", 8, 9, "Disease", "Test_items_Disease"], [46, 48, "Test_items", 20, 22, "Disease", "Test_items_Disease"], [83, 85, "Test_items", 74, 75, "Disease", "Test_items_Disease"]]}
{"idx": 2800, "sentence": "HUA的治疗应根据不同的危险因素进行分层管理。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 2801, "sentence": "共识指出对HUA和痛风患者，在尿酸测定之后，必须要针对患者的具体情况进行评估，不同的尿酸水平在不同的人群对器官的损害水平是不同的。在治疗上遵循个体化、分层、达标、长程管理的原则，逐步调整剂量以避免短期内血尿酸水平波动过大诱发痛风急性发作。共识指出应该根据患者SUA水平的不同和是否合并心血管危险因素或心血管及代谢性疾病的状态给予积极的分层治疗；在今后的临床实践中灵活应用，可有效预防和降低HUA对机体各脏器的危害。", "ner": [[5, 7, "Disease"], [9, 10, "Disease"], [15, 16, "Test_items"], [42, 43, "Test_items"], [101, 103, "Test_items"], [112, 113, "Disease"], [129, 131, "Test_items"], [150, 158, "Disease"], [194, 196, "Disease"], [150, 152, "Anatomy"]], "rel": [[15, 16, "Test_items", 5, 7, "Disease", "Test_items_Disease"], [15, 16, "Test_items", 9, 10, "Disease", "Test_items_Disease"], [101, 103, "Test_items", 112, 113, "Disease", "Test_items_Disease"], [129, 131, "Test_items", 150, 158, "Disease", "Test_items_Disease"], [150, 152, "Anatomy", 150, 158, "Disease", "Anatomy_Disease"]]}
{"idx": 2802, "sentence": "降尿酸药物的选择", "ner": [], "rel": []}
{"idx": 2803, "sentence": "共识分别对目前临床上使用的两类降尿酸药物：抑制尿酸合成的药物和促进尿酸排泄的药物进行了详细的介绍，包括起始剂量、最大剂量以及在肾功能不全患者中的使用情况。", "ner": [[63, 67, "Disease"], [63, 63, "Anatomy"]], "rel": [[63, 63, "Anatomy", 63, 67, "Disease", "Anatomy_Disease"]]}
{"idx": 2804, "sentence": "特别提到使用过程中需注意药物不良反应，强调亚裔人群使用别嘌呤醇时发生严重超敏反应的风险明显高于白种人。", "ner": [[28, 30, "Drug"], [36, 39, "ADE"]], "rel": [[36, 39, "ADE", 28, 30, "Drug", "ADE_Drug"]]}
{"idx": 2805, "sentence": "共识还对近年来国外上市的尿酸酶以及降尿酸药物的联合使用等做了简要述评，给出适用情况及可能的不良反应。", "ner": [[12, 14, "Drug"]], "rel": []}
{"idx": 2806, "sentence": "HUA在中国呈现高流行、年轻化趋势，同时HUA也是多种心血管事件危险因素及相关疾病的独立危险因素，本共识是我国首个HUA相关疾病的多学科专家共识，强调从系统医学角度全面认识该疾病，结合中国国情和国内诊疗实践特点，多学科协作、内外兼治，连续、全程、系统地管控HUA及其相关疾病，对HUA的诊断标准、药物选择、控制目标及预防的核心策略均给予明确阐述，对中国HUA的规范化管理具有积极的推动意义。", "ner": [[0, 2, "Disease"], [20, 22, "Disease"], [27, 31, "Disease"], [27, 29, "Anatomy"], [57, 59, "Disease"], [128, 130, "Disease"], [139, 141, "Disease"], [176, 178, "Disease"]], "rel": [[27, 29, "Anatomy", 27, 31, "Disease", "Anatomy_Disease"]]}
{"idx": 2807, "sentence": "共识根据痛风是否发作、危险因素、SUA浓度等分为三种情况：第一种情况是当有痛风发作且发作频繁时(≥2次)或者痛风性关节炎只发作1次，但合并有其他相关危险因素(年龄<40岁、有痛风石或关节腔尿酸盐沉积证据、尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、肥胖、卒中、冠心病、心力衰竭)中的—项，不论尿酸水平如何，都需要进行降尿酸治疗，尿酸控制目标值应<360μmol/L，如果出现痛风石、慢性痛风性关节炎、痛风性关节炎发作频繁，患者尿酸控制目标值应<300μmol/L；第二种情况是痛风性关节炎只发作1次，或者没有急性发作但合并有其他相关危险因素(尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、卒中、冠心病、肥胖、心力衰竭)，当尿酸浓度超过480μmol/L，应启动降尿酸治疗，尿酸控制目标值同第一种况；第三种情况是如果没有危险因素，也没有痛风发作，但尿酸>540μmol/L，也建议启动降尿酸治疗，尿酸控制目标值应<420μmol/L。", "ner": [[4, 5, "Disease"], [37, 38, "Disease"], [16, 18, "Test_items"], [54, 59, "Disease"], [57, 58, "Anatomy"], [102, 107, "Disease"], [105, 105, "Anatomy"], [109, 117, "Disease"], [109, 109, "Anatomy"], [119, 121, "Disease"], [123, 125, "Disease"], [127, 130, "Disease"], [132, 133, "Disease"], [135, 136, "Disease"], [138, 140, "Disease"], [139, 139, "Anatomy"], [142, 145, "Disease"], [142, 142, "Anatomy"], [154, 155, "Test_items"], [172, 173, "Test_items"], [180, 189, "Test_Value"], [195, 197, "Disease"], [199, 206, "Disease"], [204, 205, "Anatomy"], [208, 213, "Disease"], [211, 212, "Anatomy"], [221, 222, "Test_items"], [229, 238, "Test_Value"], [246, 251, "Disease"], [249, 250, "Anatomy"], [279, 284, "Disease"], [282, 282, "Anatomy"], [286, 294, "Disease"], [286, 286, "Anatomy"], [296, 298, "Disease"], [300, 302, "Disease"], [304, 307, "Disease"], [309, 310, "Disease"], [312, 314, "Disease"], [313, 313, "Anatomy"], [316, 317, "Disease"], [319, 322, "Disease"], [326, 327, "Test_items"], [330, 340, "Test_Value"], [351, 352, "Test_items"], [382, 383, "Disease"], [388, 389, "Test_items"], [390, 399, "Test_Value"], [412, 413, "Test_items"], [420, 429, "Test_Value"], [319, 319, "Anatomy"], [87, 89, "Disease"], [91, 98, "Disease"], [91, 93, "Anatomy"]], "rel": [[16, 18, "Test_items", 4, 5, "Disease", "Test_items_Disease"], [154, 155, "Test_items", 4, 5, "Disease", "Test_items_Disease"], [57, 58, "Anatomy", 54, 59, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 102, 107, "Disease", "Anatomy_Disease"], [109, 109, "Anatomy", 109, 117, "Disease", "Anatomy_Disease"], [139, 139, "Anatomy", 138, 140, "Disease", "Anatomy_Disease"], [142, 142, "Anatomy", 142, 145, "Disease", "Anatomy_Disease"], [204, 205, "Anatomy", 199, 206, "Disease", "Anatomy_Disease"], [211, 212, "Anatomy", 208, 213, "Disease", "Anatomy_Disease"], [249, 250, "Anatomy", 246, 251, "Disease", "Anatomy_Disease"], [326, 327, "Test_items", 246, 251, "Disease", "Test_items_Disease"], [282, 282, "Anatomy", 279, 284, "Disease", "Anatomy_Disease"], [326, 327, "Test_items", 279, 284, "Disease", "Test_items_Disease"], [286, 286, "Anatomy", 286, 294, "Disease", "Anatomy_Disease"], [326, 327, "Test_items", 286, 294, "Disease", "Test_items_Disease"], [326, 327, "Test_items", 300, 302, "Disease", "Test_items_Disease"], [326, 327, "Test_items", 304, 307, "Disease", "Test_items_Disease"], [326, 327, "Test_items", 309, 310, "Disease", "Test_items_Disease"], [313, 313, "Anatomy", 312, 314, "Disease", "Anatomy_Disease"], [326, 327, "Test_items", 312, 314, "Disease", "Test_items_Disease"], [326, 327, "Test_items", 316, 317, "Disease", "Test_items_Disease"], [319, 319, "Anatomy", 319, 322, "Disease", "Anatomy_Disease"], [326, 327, "Test_items", 319, 322, "Disease", "Test_items_Disease"], [388, 389, "Test_items", 382, 383, "Disease", "Test_items_Disease"], [91, 93, "Anatomy", 91, 98, "Disease", "Anatomy_Disease"]]}
{"idx": 2808, "sentence": "共识指出，这三种情况都不应将血尿酸降至180μmol/L以下。", "ner": [[14, 16, "Test_items"], [19, 27, "Test_Value"]], "rel": []}
{"idx": 2809, "sentence": "HUA具有两层含义，一种是理化性质上的定义，另一种流行病学上的定义。既往HUA定义的依据是流行病学数据，即正常嘌呤饮食下，非同日两次空腹血尿酸水平男性>420μmol/L，女性>360μmol/L。而理化性质上的定义，也称为绝对HUA，正常人体血液pH值为7.35~7.45，处于微碱性，而尿酸在这样的酸碱环境下，浓度—H超过420 μmol/L(不分男女)，便会析出尿酸钠结晶而沉积在关节腔和其他组织中，继而引起痛风性关节炎和/或其他相关组织损伤。", "ner": [[0, 2, "Disease"], [36, 38, "Disease"], [66, 70, "Test_items"], [75, 84, "Test_Value"], [88, 97, "Test_Value"], [114, 116, "Disease"], [122, 125, "Test_items"], [128, 136, "Test_Value"], [145, 146, "Test_items"], [207, 212, "Disease"], [114, 116, "Disease"], [184, 201, "Reason"], [163, 172, "Test_Value"], [210, 211, "Anatomy"]], "rel": [[66, 70, "Test_items", 36, 38, "Disease", "Test_items_Disease"], [122, 125, "Test_items", 114, 116, "Disease", "Test_items_Disease"], [145, 146, "Test_items", 114, 116, "Disease", "Test_items_Disease"], [184, 201, "Reason", 207, 212, "Disease", "Reason_Disease"], [210, 211, "Anatomy", 207, 212, "Disease", "Anatomy_Disease"]]}
{"idx": 2810, "sentence": "因此，本共识将血尿酸水平>420μmol/L定义为HUA，更具有临床意义。", "ner": [[7, 9, "Test_items"], [12, 21, "Test_Value"], [25, 27, "Disease"]], "rel": [[7, 9, "Test_items", 25, 27, "Disease", "Test_items_Disease"]]}
{"idx": 2811, "sentence": "老年糖尿病诊疗措施专家共识(2013年版)", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 2812, "sentence": "我国与营养代谢相关的慢性疾病发展迅速，糖尿病患病人群快速增加，其中老年(按我国标准≥60岁)患者是糖尿病的主流人群。", "ner": [[19, 21, "Disease"], [49, 51, "Disease"]], "rel": []}
{"idx": 2813, "sentence": "由于多种因素，国内外研究对老年糖尿病患者的诊治措施缺乏足以借鉴的证据，多个学术团体有关老年糖尿病诊治的指南缺少具体实施措施，老年糖尿病诊疗中存在诸多误区，影响整体糖尿病防治水平的提高。", "ner": [[81, 83, "Disease"], [15, 17, "Disease"], [45, 47, "Disease"], [64, 66, "Disease"]], "rel": []}
{"idx": 2814, "sentence": "借鉴近年来国内外内分泌代谢专业学术组织相关指南和共识，集本学会各位内分泌专家的临床研究和实践总结，并汇总国内本专业知名专家的意见，编写了“老年糖尿病诊疗措施专家共识”，以促进老年糖尿病防治水平的提高。", "ner": [[71, 73, "Disease"], [89, 91, "Disease"]], "rel": []}
{"idx": 2815, "sentence": "一、老年糖尿病的临床特点和存在的问题", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 2816, "sentence": "回顾近30年我国多次全国糖尿病流行病学调查数据，在糖尿病总患病率增加的同时，老年人群患病率也明显增加(表1)。", "ner": [[12, 14, "Disease"], [25, 27, "Disease"]], "rel": []}
{"idx": 2817, "sentence": "2007—2008年全国糖尿病调查报告数据显示，60岁以上老年人中糖尿病患病率为20.4%，估算约为3538万，占总患病人数的38.1%。", "ner": [[33, 35, "Disease"], [12, 14, "Disease"]], "rel": []}
{"idx": 2818, "sentence": "按我国老龄化发展趋势，在老龄人口增加的同时糖尿病患病率也增长，预示老年糖尿病人数将大幅度增加。", "ner": [[21, 23, "Disease"], [35, 37, "Disease"]], "rel": []}
{"idx": 2819, "sentence": "国内多项研究显示，60岁以后糖尿病发病率仍有随龄增加而增加的趋势，70岁以后趋于平缓，但总患病率仍在增加。", "ner": [[14, 16, "Disease"]], "rel": []}
{"idx": 2820, "sentence": "与中青年人群相似，老年人群糖尿病患病率有城市略高于农村、女性略高于男性的趋势。", "ner": [[13, 15, "Disease"]], "rel": []}
{"idx": 2821, "sentence": "据国际糖尿病联盟(IDF)2013年公布的数据，全球有510万人死于糖尿病相关疾病，占总死亡人数的8.39%。我国近年来研究报道糖尿病的病死率明显增加，10、20、30年间分别增长1.12倍(北京1991—2000年)、4.15倍(上海市徐汇区1986—2005年)和11.61倍(武汉1975—2006年)，糖尿病可致早亡，人均死亡损失寿命年为5.4~6.8人年，均为女性高于男性，60岁以上人群明显增加。主要死亡原因在欧美国家是心血管疾病，国内报道是心、脑血管疾病，其次为恶性肿瘤、肺部感染、肾衰竭。", "ner": [[34, 36, "Disease"], [64, 66, "Disease"], [155, 157, "Disease"], [216, 220, "Disease"], [216, 218, "Anatomy"], [227, 233, "Disease"], [227, 231, "Anatomy"], [238, 241, "Disease"], [243, 246, "Disease"], [243, 244, "Anatomy"], [248, 250, "Disease"], [248, 248, "Anatomy"], [3, 5, "Disease"]], "rel": [[216, 218, "Anatomy", 216, 220, "Disease", "Anatomy_Disease"], [227, 231, "Anatomy", 227, 233, "Disease", "Anatomy_Disease"], [243, 244, "Anatomy", 243, 246, "Disease", "Anatomy_Disease"], [248, 248, "Anatomy", 248, 250, "Disease", "Anatomy_Disease"]]}
{"idx": 2822, "sentence": "60~70岁以恶性肿瘤排位最前，80~90岁心血管病、肺部感染升至最高。", "ner": [[7, 10, "Disease"], [22, 25, "Disease"], [22, 24, "Anatomy"], [27, 30, "Disease"], [27, 28, "Anatomy"]], "rel": [[22, 24, "Anatomy", 22, 25, "Disease", "Anatomy_Disease"], [27, 28, "Anatomy", 27, 30, "Disease", "Anatomy_Disease"]]}
{"idx": 2823, "sentence": "高血压和血脂紊乱是老年人心脑血管死亡最主要的危害因素，糖尿病合并高血压和血脂紊乱将增加心脑血管死亡风险3倍。", "ner": [[0, 2, "Disease"], [4, 7, "Disease"], [27, 29, "Disease"], [32, 34, "Disease"], [36, 39, "Disease"]], "rel": []}
{"idx": 2824, "sentence": "老年糖尿病患者可分为老年前患糖尿病和老年后新发糖尿病两种情况。两者在自身状况、糖尿病临床特点、罹患其他疾病和已存在的脏器功能损伤等方面均有所不同。在环境因素相似的情况下，患病越晚提示胰岛β细胞代偿能力越好。与进入老年前已患病者比较，老年后患糖尿病者更多表现为明显胰岛素抵抗和胰岛素代偿性高分泌。", "ner": [[2, 4, "Disease"], [39, 41, "Disease"], [58, 63, "Disease"], [58, 59, "Anatomy"], [137, 145, "Pathogenesis"], [131, 135, "Pathogenesis"], [14, 16, "Disease"], [23, 25, "Disease"], [120, 122, "Disease"]], "rel": [[58, 59, "Anatomy", 58, 63, "Disease", "Anatomy_Disease"], [137, 145, "Pathogenesis", 120, 122, "Disease", "Pathogenesis_Disease"], [131, 135, "Pathogenesis", 120, 122, "Disease", "Pathogenesis_Disease"]]}
{"idx": 2825, "sentence": "老年人群中40%~70%患有高血压病，30%~50%患有血脂紊乱，均高于糖尿病的患病率，腹型肥胖比单纯BMI增高在老年患者中更常见。同时合并糖代谢紊乱、高血压、向心性肥胖、高甘油三酯血症(代谢综合征)的老年人高达30%~40%，而无上述各项者不到10%。老年综合征是老年人群中常见的与年龄相关的疾病组合，包括智能和体能的缺陷、自伤和他伤防护能力的下降、跌倒和骨折风险的增加、认知障碍和抑郁、尿失禁、疼痛、用药过多等。", "ner": [[14, 17, "Disease"], [28, 31, "Disease"], [36, 38, "Disease"], [44, 47, "Disease"], [70, 74, "Disease"], [76, 78, "Disease"], [80, 84, "Disease"], [86, 99, "Disease"], [127, 131, "Disease"], [154, 161, "Symptom"], [163, 174, "Symptom"], [176, 185, "Symptom"], [187, 190, "Symptom"], [192, 193, "Symptom"], [195, 197, "Symptom"], [199, 200, "Symptom"], [202, 205, "Symptom"]], "rel": [[154, 161, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [163, 174, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [176, 185, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [187, 190, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [192, 193, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [195, 197, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [199, 200, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [202, 205, "Symptom", 127, 131, "Disease", "Symptom_Disease"]]}
{"idx": 2826, "sentence": "这些对老年糖尿病患者的自我管理也会带来负面影响。", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 2827, "sentence": "老年糖尿病患者的知晓率、诊断率、治疗率均不高，老年糖尿病以餐后血糖升高为多见，尤其是新诊断的患者，即使是联合空腹血糖和糖化血红蛋白(HbA1c)做筛查时，仍有1/3比例的餐后高血糖患者漏诊。", "ner": [[2, 4, "Disease"], [25, 27, "Disease"], [29, 32, "Test_items"], [33, 34, "Test_Value"], [54, 57, "Test_items"], [59, 71, "Test_items"], [87, 89, "Disease"]], "rel": [[29, 32, "Test_items", 25, 27, "Disease", "Test_items_Disease"], [54, 57, "Test_items", 25, 27, "Disease", "Test_items_Disease"], [59, 71, "Test_items", 25, 27, "Disease", "Test_items_Disease"]]}
{"idx": 2828, "sentence": "这种状况在医疗条件相对差的农村更明显，涉及到我国约65%的老年人群。", "ner": [], "rel": []}
{"idx": 2829, "sentence": "老年人群中糖尿病前期的患病人数远远高于中青年人群，在控制糖尿病快速发展的策略中是应该被关注的群体。", "ner": [[5, 7, "Disease"], [28, 30, "Disease"]], "rel": []}
{"idx": 2830, "sentence": "随着国民寿命的延长，老年期会涉及每个人的20~30个生命年。按现有资料估计，糖代谢异常约影响我国1亿老年人的晚年生活，高龄老人也是多种慢性病的高风险人群，如缺少科学的防病治病行为，糖尿病所致危害不仅减少生存年，还会因失明、致残、智能障碍等使相当一部分老年患者的生活质量大大下降。", "ner": [[38, 42, "Pathogenesis"], [90, 92, "Disease"], [108, 109, "Symptom"], [111, 112, "Symptom"], [114, 117, "Symptom"]], "rel": [[38, 42, "Pathogenesis", 90, 92, "Disease", "Pathogenesis_Disease"], [108, 109, "Symptom", 90, 92, "Disease", "Symptom_Disease"], [111, 112, "Symptom", 90, 92, "Disease", "Symptom_Disease"], [114, 117, "Symptom", 90, 92, "Disease", "Symptom_Disease"]]}
{"idx": 2831, "sentence": "我国糖尿病患者血糖总体控制水平不理想，在中老年(年龄>45岁)人群的2项全国多省市糖尿病患者调查中，以HbA1c<6.5%为标准，达标率分别为20.3%(2009年)和16.8%(2010年)(C)。", "ner": [[2, 4, "Disease"], [7, 8, "Test_items"], [41, 43, "Disease"], [51, 55, "Test_items"], [56, 60, "Test_Value"]], "rel": [[7, 8, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [51, 55, "Test_items", 41, 43, "Disease", "Test_items_Disease"]]}
{"idx": 2832, "sentence": "医疗保健条件好的干部人群HbA1c控制达标率(63.5%)高于北京社区老年患者(46.5%)。", "ner": [[12, 16, "Test_items"], [17, 28, "Test_Value"]], "rel": []}
{"idx": 2833, "sentence": "可见良好的医疗保健条件对老年患者血糖控制有积极地促进作用(D)。", "ner": [[16, 17, "Test_items"]], "rel": []}
{"idx": 2834, "sentence": "在老年糖尿病的治疗中，加强糖尿病教育和管理是重要的理念工程。英国前瞻性糖尿病研究(UKPDS)和糖尿病控制与并发症试验(DCCT)的后续研究给了我们强化血糖控制获得‘代谢记忆’的启示，多个研究显示在糖尿病早期给予的良好血糖控制是患者后期获益的基石(B)。丹麦干预多重危险因素对2型糖尿病微血管病、心血管病、病死率的效果(Steno-2研究)和日本2型糖尿病长期理想血糖控制对糖尿病大血管病变的影响(Kumamoto研究)显示，对糖尿病综合治疗可获得良好结局(B)。由此而言，“早防早治、良好血糖控制、综合控制多项代谢异常”是糖尿病患者的理想治疗原则。", "ner": [[3, 5, "Disease"], [13, 15, "Disease"], [99, 101, "Disease"], [109, 110, "Test_items"], [138, 142, "Disease"], [173, 177, "Disease"], [182, 183, "Test_items"], [187, 189, "Disease"], [190, 194, "Disease"], [190, 192, "Anatomy"], [214, 216, "Disease"], [245, 246, "Test_items"], [256, 259, "Symptom"], [262, 264, "Disease"], [35, 37, "Disease"], [48, 50, "Disease"], [76, 77, "Test_items"], [143, 146, "Disease"], [143, 145, "Anatomy"], [148, 151, "Disease"], [148, 150, "Anatomy"]], "rel": [[109, 110, "Test_items", 99, 101, "Disease", "Test_items_Disease"], [182, 183, "Test_items", 173, 177, "Disease", "Test_items_Disease"], [190, 192, "Anatomy", 190, 194, "Disease", "Anatomy_Disease"], [245, 246, "Test_items", 262, 264, "Disease", "Test_items_Disease"], [256, 259, "Symptom", 262, 264, "Disease", "Symptom_Disease"], [76, 77, "Test_items", 48, 50, "Disease", "Test_items_Disease"], [143, 145, "Anatomy", 143, 146, "Disease", "Anatomy_Disease"], [148, 150, "Anatomy", 148, 151, "Disease", "Anatomy_Disease"]]}
{"idx": 2835, "sentence": "但在现实中大多数患者未能遵循这个原则，原因之一是缺乏糖尿病筛查意识或条件，半数左右糖尿病患者不能早发现异常、早被诊断、早开始治疗。", "ner": [[26, 28, "Disease"], [41, 43, "Disease"]], "rel": []}
{"idx": 2836, "sentence": "其二，已诊断的患者中约有2/5为老年人，是被多数指南认为有风险而放宽管理的人群。", "ner": [], "rel": []}
{"idx": 2837, "sentence": "另1/5已有严重并发症或合并脏器功能异常或是患有其他病变、恶性疾病不宜严格控制血糖者。", "ner": [[39, 40, "Test_items"], [14, 19, "Disease"], [14, 15, "Anatomy"]], "rel": [[39, 40, "Test_items", 14, 19, "Disease", "Test_items_Disease"], [14, 15, "Anatomy", 14, 19, "Disease", "Anatomy_Disease"]]}
{"idx": 2838, "sentence": "剩余的患者还会受到不同原因未能达到良好治疗目标。", "ner": [], "rel": []}
{"idx": 2839, "sentence": "以致全国调查中糖尿病的控制达标率始终不能提升。", "ner": [[7, 9, "Disease"]], "rel": []}
{"idx": 2840, "sentence": "我国老年人有防病治病的一些优势条件，绝大多数已无工作压力，在掌握防病知识后，治疗的依从性高于中青年患者。", "ner": [], "rel": []}
{"idx": 2841, "sentence": "近年来城市、乡村新农合基本医疗保险覆盖率达到95%以上，绝大多数的老年糖尿病患者基本用药可以得到保证。", "ner": [[35, 37, "Disease"]], "rel": []}
{"idx": 2842, "sentence": "关键是提高患者的自我管理能力，促进不同层次医疗保健机构改变管理理念，争取安全有益地控制多项代谢异常所致的损害，总体改善老年糖尿病的生活质量。", "ner": [[61, 63, "Disease"]], "rel": []}
{"idx": 2843, "sentence": "二、老年糖尿病治疗策略的优化", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 2844, "sentence": "(一)综合评估的策略", "ner": [], "rel": []}
{"idx": 2845, "sentence": "老年糖尿病个性化治疗方案的制定应该有对患者情况综合评估的基础。", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 2846, "sentence": "需要提高对患者的了解度。", "ner": [], "rel": []}
{"idx": 2847, "sentence": "可从5个方面进行分析：", "ner": [], "rel": []}
{"idx": 2848, "sentence": "1.了解患者的血糖控制水平：包括总体水平(HbA1c是最好的证据)、实际血糖波动情况(幅度大小和影响因素)、血糖变化的特点(空腹抑或餐后血糖升高为主，短期还是长期高血糖)；影响血糖控制的因素，包括饮食和运动情况、现有降糖药应用(剂量、方法)、低血糖发生的风险等。", "ner": [[7, 8, "Test_items"], [21, 25, "Test_items"], [36, 37, "Test_items"], [38, 39, "Test_Value"], [54, 55, "Test_items"], [62, 69, "Test_items"], [70, 71, "Test_Value"], [81, 83, "Disease"], [88, 89, "Test_items"], [121, 123, "ADE"]], "rel": [[7, 8, "Test_items", 81, 83, "Disease", "Test_items_Disease"], [21, 25, "Test_items", 81, 83, "Disease", "Test_items_Disease"], [62, 69, "Test_items", 81, 83, "Disease", "Test_items_Disease"]]}
{"idx": 2849, "sentence": "要求和督促患者自测血糖，首先推荐监测早、晚餐前血糖(最基本观测点)，根据需要测定三餐前和三餐后2h加晚睡前血糖(全天血糖观测)，获知患者血糖变化的类型，为调整降糖治疗打好基础(IV)。", "ner": [[9, 10, "Test_items"], [18, 24, "Test_items"], [40, 62, "Test_items"], [68, 69, "Test_items"]], "rel": []}
{"idx": 2850, "sentence": "2.了解患者自身糖调节能力：对新就诊的老年糖尿病患者，有条件时可与血糖检测同步测定患者的血浆胰岛素和/或C肽浓度，结合病程、血糖变化情况了解患者胰岛β细胞分泌水平，有助于选择合适的降糖药(IV)。", "ner": [[21, 23, "Disease"], [33, 34, "Test_items"], [44, 48, "Test_items"], [52, 55, "Test_items"], [62, 63, "Test_items"]], "rel": [[33, 34, "Test_items", 21, 23, "Disease", "Test_items_Disease"], [44, 48, "Test_items", 21, 23, "Disease", "Test_items_Disease"], [52, 55, "Test_items", 21, 23, "Disease", "Test_items_Disease"], [62, 63, "Test_items", 21, 23, "Disease", "Test_items_Disease"]]}
{"idx": 2851, "sentence": "3.评估患者是否合并高血压、血脂异常、高尿酸和肥胖：同时测定血液中肝酶和肾功能指标，有条件测定血蛋白质、电解质、同型半胱氨酸水平，有助于评定患者的心血管疾病风险和确定饮食食谱，为患者制定综合治疗方案(IV)。", "ner": [[10, 12, "Disease"], [14, 17, "Disease"], [19, 21, "Disease"], [23, 24, "Disease"], [33, 34, "Test_items"], [36, 38, "Test_items"], [47, 50, "Test_items"], [52, 54, "Test_items"], [56, 63, "Test_items"], [73, 77, "Disease"], [73, 75, "Anatomy"]], "rel": [[33, 34, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [36, 38, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [47, 50, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [52, 54, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [56, 63, "Test_items", 73, 77, "Disease", "Test_items_Disease"], [73, 75, "Anatomy", 73, 77, "Disease", "Anatomy_Disease"]]}
{"idx": 2852, "sentence": "4.通过眼底检查、尿液白蛋白/肌酐比值测定、颈动脉B超检查等进行糖尿病合并症的早期筛查：了解是否存在糖尿病的血管并发症，评估心脑血管病变风险。", "ner": [[4, 7, "Test"], [9, 18, "Test_items"], [22, 26, "Test"], [32, 34, "Disease"], [50, 52, "Disease"], [54, 58, "Disease"], [62, 67, "Disease"], [54, 55, "Anatomy"], [62, 65, "Anatomy"]], "rel": [[4, 7, "Test", 32, 34, "Disease", "Test_Disease"], [9, 18, "Test_items", 32, 34, "Disease", "Test_items_Disease"], [22, 26, "Test", 32, 34, "Disease", "Test_Disease"], [54, 55, "Anatomy", 54, 58, "Disease", "Anatomy_Disease"], [62, 65, "Anatomy", 62, 67, "Disease", "Anatomy_Disease"]]}
{"idx": 2853, "sentence": "根据既往病史、体征、相关检查了解主要脏器功能是否存在异常或潜在的功能不全。", "ner": [], "rel": []}
{"idx": 2854, "sentence": "有否其他伴存影响寿命的恶性肿瘤、严重疾病，营养状况如何(可借助营养筛查表)，评估预期寿命(IV)。", "ner": [[11, 14, "Disease"]], "rel": []}
{"idx": 2855, "sentence": "5.评估患者的自我管理水平：从智能(文化水平、理解能力和智力测评)和体能(肢体运动的灵活度和耐力)方面判断患者的个人能力，包括认知功能(借助Folstein精神状态检查表，蒙特利尔认知评估表)、体能损害、跌倒和骨折风险、精神(老年抑郁量表)、视力和听力损害程度；从糖尿病知识获取程度和自我健康需求判断患者的自我约束力；从患者实际医疗需求和医疗经费是否充足了解患者治病的财力(个人、家庭和社会支持的总和)(IV)。", "ner": [[132, 134, "Disease"]], "rel": []}
{"idx": 2856, "sentence": "糖尿病专科医师或专科护士应该充分了解上述5个方面的内容，对患者进行完善的评估，也可根据实际条件进行项目选择。第1、2条是合理选用降糖药的基础，规避滥用药；第3、4条是综合治疗、全面控制心血管风险、保护脏器功能的基础，第5条有助于评估患者的自我管理能力，综合考虑为患者制定量身打造的治疗方案。", "ner": [[92, 96, "Disease"], [92, 94, "Anatomy"], [0, 2, "Disease"]], "rel": [[92, 94, "Anatomy", 92, 96, "Disease", "Anatomy_Disease"]]}
{"idx": 2857, "sentence": "基层医疗单位可根据实际条件进行评估，尽可能做到对患者有全面了解，方能实施个性化治疗和管理。", "ner": [], "rel": []}
{"idx": 2858, "sentence": "(二)“四早”原则", "ner": [], "rel": []}
{"idx": 2859, "sentence": "1.早预防：观念的转变很重要。", "ner": [], "rel": []}
{"idx": 2860, "sentence": "慢性病的预防则需遵从“治未病”理念，积极进行糖尿病防治知识的学习和宣教，提倡健康生活方式，增加运动。", "ner": [[22, 24, "Disease"], [38, 43, "Treatment"], [45, 48, "Treatment"]], "rel": [[38, 43, "Treatment", 22, 24, "Disease", "Treatment_Disease"], [45, 48, "Treatment", 22, 24, "Disease", "Treatment_Disease"]]}
{"idx": 2861, "sentence": "特别是糖尿病的高危人群(有家族史者、腹型肥胖者、高血压患者、高甘油三酯血症患者、高胰岛素血症患者)应列为重点防治对象，做好糖尿病的一级预防(防发病)(B)。", "ner": [[3, 5, "Disease"], [18, 21, "Disease"], [24, 26, "Disease"], [30, 36, "Disease"], [40, 45, "Disease"], [61, 63, "Disease"]], "rel": []}
{"idx": 2862, "sentence": "2.早诊断：2型糖尿病的发生有较长的前期过程，包括高胰岛素-正常血糖的代偿期、血糖轻度异常的糖尿病前期[以空腹血糖(FPG)升高为主的空腹血糖受损和以糖负荷后2h血糖(2hPG)升高为主的糖耐量减低，也可两者并存]，直到糖尿病的早期阶段(血糖轻中度升高)。在不能改变遗传现状的情况下，鼓励高危患者定期体检和进行糖尿病筛查，以便早发现潜在的糖尿病威胁，早开始保护自身β细胞功能。联合空腹血糖(FPG)、随机或2hPG和HbA1c(检测方法需经国际化标准认定)，或采用口服葡萄糖(75g)耐量试验(OGTT)进行糖尿病筛查，有助于减少漏诊率(B)。在确定糖尿病诊断时，标准可适当放宽；切勿放松处于糖代谢水平异常人群的前期管理。", "ner": [[6, 10, "Disease"], [39, 40, "Test_items"], [41, 44, "Test_Value"], [46, 48, "Disease"], [53, 61, "Test_items"], [62, 63, "Test_Value"], [75, 88, "Test_items"], [89, 90, "Test_Value"], [67, 72, "Symptom"], [94, 98, "Symptom"], [110, 112, "Disease"], [119, 120, "Test_items"], [121, 126, "Test_Value"], [155, 157, "Disease"], [169, 171, "Disease"], [190, 198, "Test_items"], [232, 251, "Test"], [275, 277, "Disease"], [296, 302, "Symptom"], [200, 206, "Test_items"], [208, 212, "Test_items"]], "rel": [[39, 40, "Test_items", 6, 10, "Disease", "Test_items_Disease"], [53, 61, "Test_items", 6, 10, "Disease", "Test_items_Disease"], [75, 88, "Test_items", 6, 10, "Disease", "Test_items_Disease"], [67, 72, "Symptom", 6, 10, "Disease", "Symptom_Disease"], [94, 98, "Symptom", 6, 10, "Disease", "Symptom_Disease"], [190, 198, "Test_items", 155, 157, "Disease", "Test_items_Disease"], [200, 206, "Test_items", 155, 157, "Disease", "Test_items_Disease"], [208, 212, "Test_items", 155, 157, "Disease", "Test_items_Disease"], [232, 251, "Test", 155, 157, "Disease", "Test_Disease"], [296, 302, "Symptom", 275, 277, "Disease", "Symptom_Disease"]]}
{"idx": 2863, "sentence": "3.早治疗：包括早开始治疗性生活方式干预(TLC)、及时开始降血糖药物治疗和适时开始胰岛素治疗。检查发现FPG>5.6mmol/L、2hPG或随机血糖>7.8mmol/L或HbA1c>6.0%，是开始通过TLC防治糖尿病的警示点(IV)。如经过3个月TLC，HbA1c仍>6.5%需考虑开始非胰岛素促泌剂类口服降糖药物干预(IV)。我国的大庆研究、芬兰糖尿病预防研究(DPS)和美国的糖尿病预防研究(DPP)显示，单纯TLC可以使糖尿病的发病率减少50%~58%，阿卡波糖和二甲双胍药物干预研究分别降低糖尿病发病率88%和77%，疗效优于单纯TLC(A)。老年糖尿病患者在饮食和运动治疗的基础上HbA1c>7.0%，需要考虑单药或联合口服降糖药物治疗，根据患者胰岛素水平、肥胖程度及血糖波动的特点，将HbA1c控制到7.0%以内(B)。", "ner": [[11, 24, "Treatment"], [42, 44, "Drug"], [52, 54, "Test_items"], [55, 64, "Test_Value"], [66, 74, "Test_items"], [75, 84, "Test_Value"], [86, 89, "Test_items"], [90, 95, "Test_Value"], [102, 104, "Treatment"], [107, 109, "Disease"], [125, 127, "Treatment"], [129, 133, "Test_items"], [135, 139, "Test_Value"], [145, 158, "Drug"], [176, 178, "Disease"], [192, 194, "Disease"], [209, 211, "Treatment"], [215, 217, "Disease"], [232, 235, "Drug"], [237, 240, "Drug"], [251, 253, "Disease"], [317, 318, "Method"], [341, 342, "Test_items"], [343, 344, "Test_Value"], [350, 354, "Test_items"], [358, 363, "Test_Value"], [153, 154, "Method"], [280, 282, "Disease"], [286, 292, "Treatment"], [297, 301, "Test_items"], [302, 306, "Test_Value"], [271, 273, "Treatment"]], "rel": [[52, 54, "Test_items", 107, 109, "Disease", "Test_items_Disease"], [66, 74, "Test_items", 107, 109, "Disease", "Test_items_Disease"], [86, 89, "Test_items", 107, 109, "Disease", "Test_items_Disease"], [102, 104, "Treatment", 107, 109, "Disease", "Treatment_Disease"], [153, 154, "Method", 145, 158, "Drug", "Method_Drug"], [232, 235, "Drug", 176, 178, "Disease", "Drug_Disease"], [237, 240, "Drug", 176, 178, "Disease", "Drug_Disease"], [209, 211, "Treatment", 176, 178, "Disease", "Treatment_Disease"], [271, 273, "Treatment", 251, 253, "Disease", "Treatment_Disease"], [341, 342, "Test_items", 280, 282, "Disease", "Test_items_Disease"], [350, 354, "Test_items", 280, 282, "Disease", "Test_items_Disease"], [286, 292, "Treatment", 280, 282, "Disease", "Treatment_Disease"], [297, 301, "Test_items", 280, 282, "Disease", "Test_items_Disease"]]}
{"idx": 2864, "sentence": "联合2种以上口服降糖药治疗后HbA1c仍>7.0%，可以起始胰岛素治疗(A)，一般首选基础胰岛素治疗(IV)。", "ner": [[6, 7, "Method"], [14, 18, "Test_items"], [20, 24, "Test_Value"], [30, 32, "Drug"], [45, 47, "Drug"]], "rel": []}
{"idx": 2865, "sentence": "但对饮食控制差、肥胖、自身胰岛素分泌水平不低的患者不宜过早应用胰岛素，需先严格生活方式管理并减轻体重(IV)。", "ner": [[8, 9, "Disease"], [31, 33, "Drug"]], "rel": []}
{"idx": 2866, "sentence": "4.早达标：老年糖尿病患者的个性化控制目标包括血糖和非血糖的其他代谢相关指标。已有研究显示，对存在多项心血管危险因素的老年糖尿病患者单纯控制血糖可能得不到心血管获益，而综合防治心血管多危险因素则可能获益(B)。", "ner": [[8, 10, "Disease"], [23, 24, "Test_items"], [61, 63, "Disease"], [70, 71, "Test_items"], [27, 28, "Test_items"]], "rel": [[23, 24, "Test_items", 8, 10, "Disease", "Test_items_Disease"], [70, 71, "Test_items", 61, 63, "Disease", "Test_items_Disease"]]}
{"idx": 2867, "sentence": "(三)个性化控制目标的制定", "ner": [], "rel": []}
{"idx": 2868, "sentence": "制定个性化控制目标的目的是在治疗中使患者的生存获得最大利益和最小风险，落实过程中需兼顾来自医生角度的判断与患者自身承受能力的协调。", "ner": [], "rel": []}
{"idx": 2869, "sentence": "1.血糖相关指标：在选择HbA1c控制标准的诸多研究中，仅UKPDS和DCCT有长于10年的研究数据，选择HbA1c<7.0%为强化控制目标有远期获益的结果(A)。冠心病和糖尿病等危症的研究经10年观察才得到糖尿病心血管危害的确切数据，提示一般情况下慢性高血糖引起的损害有一定时间效应(A)。HbA1c≥6.5%时已存在高血糖对人体损害，可作为诊断标准的研究结论确实(A)，HbA1c≥6.5%的诊断特异性高，在中老年人群中相同(IV)。", "ner": [[2, 3, "Test_items"], [12, 16, "Test_items"], [53, 57, "Test_items"], [58, 62, "Test_Value"], [82, 84, "Disease"], [86, 88, "Disease"], [104, 106, "Disease"], [107, 111, "Disease"], [107, 109, "Anatomy"], [125, 129, "Disease"], [146, 150, "Test_items"], [151, 155, "Test_Value"], [160, 162, "Disease"], [187, 191, "Test_items"], [192, 196, "Test_Value"]], "rel": [[107, 109, "Anatomy", 107, 111, "Disease", "Anatomy_Disease"], [146, 150, "Test_items", 160, 162, "Disease", "Test_items_Disease"], [187, 191, "Test_items", 160, 162, "Disease", "Test_items_Disease"]]}
{"idx": 2870, "sentence": "提示血糖在此水平10年以上危害较大，需要管控。", "ner": [[2, 3, "Test_items"]], "rel": []}
{"idx": 2871, "sentence": "借鉴最新“美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)立场声明”中推荐在制定个性化HbA1c控制标准时需对患者的预期寿命、降糖药治疗风险(β细胞功能、低血糖发生、体重增加)、治疗获益程度(已有合并症、脏器功能异常程度)、患者承受治疗能力(自我管理水平、医疗条件)等进行综合评估(A)。根据现有研究结果，权衡利弊，预期寿命长于10年、低血糖风险小、预计治疗获益大、有较好医疗支持的老年糖尿病患者HbA1c控制标准以<7.0%为佳，相应FPG<7.0mmol/L和2hPG<10.0mmol/L，且减少血糖波动，并长期保持上述血糖水平(C)。", "ner": [[7, 9, "Disease"], [20, 22, "Disease"], [47, 51, "Test_items"], [75, 79, "ADE"], [81, 85, "ADE"], [87, 90, "ADE"], [197, 199, "Disease"], [202, 206, "Test_items"], [212, 216, "Test_Value"], [222, 224, "Test_items"], [225, 234, "Test_Value"], [236, 239, "Test_items"], [240, 250, "Test_Value"], [255, 256, "Test_items"], [257, 258, "Test_Value"], [267, 268, "Test_items"], [172, 176, "ADE"]], "rel": [[47, 51, "Test_items", 7, 9, "Disease", "Test_items_Disease"], [202, 206, "Test_items", 197, 199, "Disease", "Test_items_Disease"], [222, 224, "Test_items", 197, 199, "Disease", "Test_items_Disease"], [236, 239, "Test_items", 197, 199, "Disease", "Test_items_Disease"], [255, 256, "Test_items", 197, 199, "Disease", "Test_items_Disease"]]}
{"idx": 2872, "sentence": "对新诊断、相对年轻、预期生存期>10年、无并发症及伴发疾病，降糖治疗无低血糖风险，不需要降糖药物或仅用单种非胰岛素促分泌剂降糖药、治疗依从性好的患者可考虑将HbA1c控制到接近正常人水平(IV)。", "ner": [[53, 63, "Drug"], [78, 82, "Test_items"], [35, 37, "Disease"]], "rel": []}
{"idx": 2873, "sentence": "尽管ADA进一步提升了老年人HbA1c控制水平，但还缺乏老年糖尿病患者优化血糖管理是否能获益的研究证据。", "ner": [[14, 18, "Test_items"], [30, 32, "Disease"], [37, 38, "Test_items"]], "rel": [[14, 18, "Test_items", 30, 32, "Disease", "Test_items_Disease"], [37, 38, "Test_items", 30, 32, "Disease", "Test_items_Disease"]]}
{"idx": 2874, "sentence": "老年患者实际情况差异很大，应在全面评估的基础上，遵循个体化的原则，选择不同的控制标准，可参考如下分层：", "ner": [], "rel": []}
{"idx": 2875, "sentence": "(1)HbA1c<7.5%：适用于预期生存期>10年、较轻并发症及伴发疾病，有一定低血糖风险，应用胰岛素促泌剂类降糖药物或以胰岛素治疗为主的2型和1型糖尿病患者。", "ner": [[3, 7, "Test_items"], [8, 12, "Test_Value"], [41, 43, "Disease"], [49, 59, "Drug"], [62, 64, "Drug"], [70, 77, "Disease"]], "rel": [[3, 7, "Test_items", 70, 77, "Disease", "Test_items_Disease"], [49, 59, "Drug", 70, 77, "Disease", "Drug_Disease"], [62, 64, "Drug", 70, 77, "Disease", "Drug_Disease"]]}
{"idx": 2876, "sentence": "(2)HbA1c<8.0%：适用于预期生存期>5年、中等程度并发症及伴发疾病，有低血糖风险，应用胰岛素促泌剂类降糖药物或以多次胰岛素注射治疗为主的老年糖尿病患者。", "ner": [[3, 7, "Test_items"], [75, 77, "Disease"], [40, 42, "Disease"], [8, 12, "Test_Value"], [48, 58, "Drug"], [63, 65, "Drug"], [66, 67, "Method"]], "rel": [[3, 7, "Test_items", 40, 42, "Disease", "Test_items_Disease"], [3, 7, "Test_items", 75, 77, "Disease", "Test_items_Disease"], [48, 58, "Drug", 75, 77, "Disease", "Drug_Disease"], [63, 65, "Drug", 75, 77, "Disease", "Drug_Disease"], [66, 67, "Method", 63, 65, "Drug", "Method_Drug"]]}
{"idx": 2877, "sentence": "(3)HbA1c<8.5%：如有预期寿命<5年、完全丧失自我管理能力等情况，HbA1c的控制标准可放宽至<8.5%，尚需避免严重高血糖(>16.7mmol/L)引发的糖尿病急性并发症和难治性感染等情况发生。消除糖尿(血糖水平<11.1mmol/L)是老年糖尿病患者治疗的一个重要目标，有利于改善高血糖渗透性利尿(引起血容量减少，夜尿多等)和营养负平衡(尿糖排出)。", "ner": [[3, 7, "Test_items"], [8, 12, "Test_Value"], [38, 42, "Test_items"], [52, 56, "Test_Value"], [62, 78, "Reason"], [83, 90, "Disease"], [92, 96, "Disease"], [105, 106, "Symptom"], [108, 111, "Test_items"], [112, 122, "Test_Value"], [127, 129, "Disease"], [147, 154, "Symptom"], [158, 162, "Symptom"], [164, 166, "Symptom"], [170, 174, "Symptom"], [176, 177, "Symptom"]], "rel": [[3, 7, "Test_items", 83, 90, "Disease", "Test_items_Disease"], [3, 7, "Test_items", 92, 96, "Disease", "Test_items_Disease"], [62, 78, "Reason", 92, 96, "Disease", "Reason_Disease"], [62, 78, "Reason", 83, 90, "Disease", "Reason_Disease"], [105, 106, "Symptom", 127, 129, "Disease", "Symptom_Disease"], [108, 111, "Test_items", 127, 129, "Disease", "Test_items_Disease"], [147, 154, "Symptom", 127, 129, "Disease", "Symptom_Disease"], [158, 162, "Symptom", 127, 129, "Disease", "Symptom_Disease"], [164, 166, "Symptom", 127, 129, "Disease", "Symptom_Disease"], [170, 174, "Symptom", 127, 129, "Disease", "Symptom_Disease"], [176, 177, "Symptom", 127, 129, "Disease", "Symptom_Disease"]]}
{"idx": 2878, "sentence": "2.非血糖的其他代谢相关指标(参见后节)。", "ner": [[3, 4, "Test_items"]], "rel": []}
{"idx": 2879, "sentence": "三、老年糖尿病降糖治疗的措施", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 2880, "sentence": "降糖治疗需要掌握患者各类血糖变化的特点，为其提供针对性强、合适、便于操作的降糖药物治疗方案，方能达到理想的血糖控制效果。", "ner": [[12, 13, "Test_items"], [53, 54, "Test_items"]], "rel": []}
{"idx": 2881, "sentence": "(一)重视基础治疗", "ner": [], "rel": []}
{"idx": 2882, "sentence": "糖尿病的基础治疗包括教育和管理、饮食和运动两方面。缺乏糖尿病防治知识是血糖控制差的最主要原因。重视老年患者的教育和管理是提高糖尿病治疗水平的重要举措。", "ner": [[0, 2, "Disease"], [4, 7, "Treatment"], [10, 14, "Treatment"], [16, 20, "Treatment"], [27, 29, "Disease"], [62, 64, "Disease"], [54, 58, "Treatment"], [35, 36, "Test_items"], [37, 39, "Test_Value"]], "rel": [[4, 7, "Treatment", 0, 2, "Disease", "Treatment_Disease"], [10, 14, "Treatment", 0, 2, "Disease", "Treatment_Disease"], [16, 20, "Treatment", 0, 2, "Disease", "Treatment_Disease"], [35, 36, "Test_items", 27, 29, "Disease", "Test_items_Disease"], [54, 58, "Treatment", 62, 64, "Disease", "Treatment_Disease"]]}
{"idx": 2883, "sentence": "对任何年龄段的患者来说，营养管理都是糖尿病治疗中的一个重要组成部分(A)。", "ner": [[18, 20, "Disease"]], "rel": []}
{"idx": 2884, "sentence": "老年糖尿病的预防已经明确了饮食与运动干预的有效性。但对于老年患者而言，尚需注意一些特殊问题。人体进入老年阶段后，代谢水平随着年龄的增长而逐渐下降，同时运动机能也逐渐降低，导致瘦体质量逐年减少。一部分老年患者存在长期能量摄入超标的现象，表现为内脏脂肪存储过多、肌肉存量衰减型肥胖；另有部分老年患者因多种原因合并食欲减退、味觉或嗅觉异常、吞咽困难、口腔或牙齿等问题以及各种可能影响消化食物过程的功能障碍，导致体重过低和/或少肌症的发生。不良的饮食习惯(饮食结构单一、进食方式欠合理)是促成血糖波动大的重要影响因素，而不恰当的限制饮食也会给老年糖尿病患者带来额外的风险。", "ner": [[2, 4, "Disease"], [13, 17, "Treatment"], [105, 112, "Reason"], [120, 127, "Disease"], [129, 137, "Disease"], [120, 121, "Anatomy"], [154, 157, "Reason"], [159, 165, "Reason"], [167, 170, "Reason"], [202, 205, "Disease"], [209, 211, "Disease"], [216, 238, "Reason"], [242, 243, "Test_items"], [244, 245, "Test_Value"], [256, 263, "Reason"], [269, 271, "Disease"], [172, 179, "Reason"], [182, 198, "Reason"]], "rel": [[13, 17, "Treatment", 2, 4, "Disease", "Treatment_Disease"], [105, 112, "Reason", 120, 127, "Disease", "Reason_Disease"], [105, 112, "Reason", 129, 137, "Disease", "Reason_Disease"], [120, 121, "Anatomy", 120, 127, "Disease", "Anatomy_Disease"], [154, 157, "Reason", 202, 205, "Disease", "Reason_Disease"], [154, 157, "Reason", 209, 211, "Disease", "Reason_Disease"], [159, 165, "Reason", 202, 205, "Disease", "Reason_Disease"], [159, 165, "Reason", 209, 211, "Disease", "Reason_Disease"], [167, 170, "Reason", 202, 205, "Disease", "Reason_Disease"], [167, 170, "Reason", 209, 211, "Disease", "Reason_Disease"], [172, 179, "Reason", 202, 205, "Disease", "Reason_Disease"], [182, 198, "Reason", 202, 205, "Disease", "Reason_Disease"], [172, 179, "Reason", 209, 211, "Disease", "Reason_Disease"], [182, 198, "Reason", 209, 211, "Disease", "Reason_Disease"], [216, 238, "Reason", 269, 271, "Disease", "Reason_Disease"], [242, 243, "Test_items", 269, 271, "Disease", "Test_items_Disease"], [256, 263, "Reason", 269, 271, "Disease", "Reason_Disease"]]}
{"idx": 2885, "sentence": "老年糖尿病患者的饮食管理应当保证所需热量供给、合理调配饮食结构(适当限制甜食，多进食能量密度高且富含膳食纤维、升血糖指数低的食物)和进餐模式(少吃多餐、慢吃、后吃主食)，以保持良好的营养状况、改善生活质量。老年糖尿病患者的饮食结构中，碳水化合物供能应占50%~60%，没有肾脏病限制时，蛋白质的摄入量应为1.0~1.3g·kg-1·d-1，推荐以蛋、奶制品、动物肉类和大豆蛋白等优质蛋白为主。", "ner": [[2, 4, "Disease"], [105, 107, "Disease"], [136, 138, "Disease"], [136, 137, "Anatomy"]], "rel": [[136, 137, "Anatomy", 136, 138, "Disease", "Anatomy_Disease"]]}
{"idx": 2886, "sentence": "ADA推荐膳食纤维的摄入量为14g·1000kcal-1·d-1(1kcal=4.184kJ)(II)。", "ner": [], "rel": []}
{"idx": 2887, "sentence": "具体的配置需要因人而异，适合老年人个体差异大的需求。", "ner": [], "rel": []}
{"idx": 2888, "sentence": "老年患者的运动管理更需要个体化。", "ner": [], "rel": []}
{"idx": 2889, "sentence": "正常体能者、老龄体弱者、肢体残障者、智能障碍者分别选择能进行、容易坚持的全身或肢体运动方式。运动前需进行运动安全性评估。结合轻度、中度运动消耗量安排时间，提倡餐后的适量室内活动与每周3~4次的体能锻炼相结合，有利于缓解餐后高血糖，并保持或增强体质。结合有计划的抗阻力运动，如举重物、抬腿保持等可以帮助老年患者延缓肌肉的减少。肥胖者可通过适当增加有氧运动量消耗脂肪储存(B)。", "ner": [[12, 15, "Disease"], [18, 21, "Disease"], [111, 113, "Disease"], [162, 163, "Disease"], [170, 176, "Treatment"], [79, 87, "Treatment"], [89, 99, "Treatment"], [130, 134, "Treatment"], [137, 139, "Treatment"], [141, 142, "Treatment"]], "rel": [[79, 87, "Treatment", 111, 113, "Disease", "Treatment_Disease"], [89, 99, "Treatment", 111, 113, "Disease", "Treatment_Disease"], [170, 176, "Treatment", 162, 163, "Disease", "Treatment_Disease"]]}
{"idx": 2890, "sentence": "(二)合理应用降糖药", "ner": [], "rel": []}
{"idx": 2891, "sentence": "1.降糖药的选用原则：从病理改变的过程看，2型糖尿病的发展包括早期正常血糖-胰岛素代偿性高分泌阶段、糖尿病前期(血糖轻度升高)、糖尿病胰岛素分泌不足阶段、糖尿病胰岛素分泌缺乏4个代表性阶段(IV)。在选择降糖药的策略上需有所区别。如能在正常血糖-胰岛素高分泌代偿阶段开始TLC干预，消除引起胰岛素抵抗的原因，可预防糖尿病。糖尿病前期的病理特点表现为胰岛素抵抗+相对分泌不足，保护胰岛β细胞、减轻胰岛素抵抗，必要时辅用非胰岛素促泌剂和肠促胰素类药物，可以延缓糖尿病发生(A)。", "ner": [[21, 25, "Disease"], [50, 52, "Disease"], [56, 57, "Test_items"], [58, 61, "Test_Value"], [64, 66, "Disease"], [67, 73, "Pathogenesis"], [77, 79, "Disease"], [80, 86, "Pathogenesis"], [135, 137, "Treatment"], [145, 149, "Pathogenesis"], [157, 159, "Disease"], [161, 163, "Disease"], [174, 185, "Pathogenesis"], [208, 214, "Drug"], [216, 222, "Drug"], [228, 230, "Disease"], [197, 201, "Pathogenesis"], [35, 36, "Test_items"]], "rel": [[56, 57, "Test_items", 21, 25, "Disease", "Test_items_Disease"], [67, 73, "Pathogenesis", 21, 25, "Disease", "Pathogenesis_Disease"], [80, 86, "Pathogenesis", 21, 25, "Disease", "Pathogenesis_Disease"], [135, 137, "Treatment", 157, 159, "Disease", "Treatment_Disease"], [145, 149, "Pathogenesis", 157, 159, "Disease", "Pathogenesis_Disease"], [174, 185, "Pathogenesis", 161, 163, "Disease", "Pathogenesis_Disease"], [197, 201, "Pathogenesis", 161, 163, "Disease", "Pathogenesis_Disease"], [208, 214, "Drug", 161, 163, "Disease", "Drug_Disease"], [216, 222, "Drug", 161, 163, "Disease", "Drug_Disease"]]}
{"idx": 2892, "sentence": "糖尿病发展至胰岛素分泌不足阶段，需要联合胰岛素促分泌剂、必要时联合基础胰岛素，多重机制降血糖(A)。", "ner": [[0, 2, "Disease"], [6, 12, "Pathogenesis"], [20, 26, "Drug"], [33, 37, "Drug"]], "rel": [[20, 26, "Drug", 0, 2, "Disease", "Drug_Disease"], [33, 37, "Drug", 0, 2, "Disease", "Drug_Disease"], [6, 12, "Pathogenesis", 0, 2, "Disease", "Pathogenesis_Disease"]]}
{"idx": 2893, "sentence": "发展至胰岛素缺乏为主时，需要满足机体对胰岛素的需求，以胰岛素治疗为主(可采用多种治疗模式)，辅用口服降糖药(B)。", "ner": [[3, 7, "Pathogenesis"], [19, 21, "Drug"], [27, 29, "Drug"], [48, 49, "Method"]], "rel": []}
{"idx": 2894, "sentence": "一般情况下老年2型糖尿病降糖药物选用路径见图1。", "ner": [[7, 11, "Disease"]], "rel": []}
{"idx": 2895, "sentence": "多次胰岛素注射(强化治疗)：遇到新诊断老年糖尿病伴存高血糖(HbA1c>9.0%)、合并感染或急性并发症、处于手术或应激状态、应用拮抗胰岛素作用的药物(如糖皮质激素)等特殊情况时，因存在明显的胰岛素抵抗、高糖毒性、高脂毒性等加重胰岛β细胞损伤的因素，需积极采用短期一天多次胰岛素强化治疗模式，解除β细胞毒性，尽早纠正高血糖(C)。", "ner": [[2, 4, "Drug"], [5, 6, "Method"], [30, 34, "Test_items"], [35, 39, "Test_Value"], [44, 45, "Disease"], [77, 81, "Drug"], [136, 138, "Drug"], [158, 160, "Disease"], [21, 23, "Disease"], [26, 28, "Disease"], [96, 100, "ADE"], [102, 105, "ADE"], [107, 110, "ADE"], [112, 120, "ADE"], [132, 135, "Frequency"]], "rel": [[5, 6, "Method", 2, 4, "Drug", "Method_Drug"], [2, 4, "Drug", 21, 23, "Disease", "Drug_Disease"], [2, 4, "Drug", 26, 28, "Disease", "Drug_Disease"], [30, 34, "Test_items", 21, 23, "Disease", "Test_items_Disease"], [30, 34, "Test_items", 26, 28, "Disease", "Test_items_Disease"], [77, 81, "Drug", 21, 23, "Disease", "Drug_Disease"], [77, 81, "Drug", 26, 28, "Disease", "Drug_Disease"], [96, 100, "ADE", 77, 81, "Drug", "ADE_Drug"], [102, 105, "ADE", 77, 81, "Drug", "ADE_Drug"], [107, 110, "ADE", 77, 81, "Drug", "ADE_Drug"], [112, 120, "ADE", 77, 81, "Drug", "ADE_Drug"], [136, 138, "Drug", 158, 160, "Disease", "Drug_Disease"], [132, 135, "Frequency", 136, 138, "Drug", "Frequency_Drug"]]}
{"idx": 2896, "sentence": "病情稳定后重新评估，调整治疗模式。", "ner": [], "rel": []}
{"idx": 2897, "sentence": "一般不推荐老年患者常规降糖治疗中采用操作难度大的多次胰岛素治疗模式。", "ner": [[26, 28, "Drug"]], "rel": []}
{"idx": 2898, "sentence": "目前所有降糖药的作用机制均较局限，当单药治疗血糖不能达标时，联合机制互补的药物具有更大的优势(A)。", "ner": [[22, 23, "Test_items"], [24, 27, "Test_Value"]], "rel": []}
{"idx": 2899, "sentence": "除了胰岛素泵能因需调整胰岛素用量外，其他胰岛素制剂往往难顾及患者三餐血糖变化的需求，合用口服降糖药弥补欠缺是非常实际、有效的治疗模式(A)。", "ner": [[11, 13, "Drug"], [20, 24, "Drug"], [32, 35, "Test_items"], [44, 45, "Method"]], "rel": []}
{"idx": 2900, "sentence": "老年前患糖尿病的患者合并大血管、微血管病变的比例远高于老年后患糖尿病者，这部分患者胰岛β细胞功能多很差，平常血糖波动幅度大，如长期未能得到良好管理和治疗，会存在不同程度的脏器功能损害，在治疗选择上要充分考虑到可能对降糖药应用的影响(C)。", "ner": [[4, 6, "Disease"], [12, 20, "Disease"], [12, 14, "Anatomy"], [16, 18, "Anatomy"], [31, 33, "Disease"], [41, 50, "Pathogenesis"], [54, 55, "Test_items"], [56, 60, "Test_Value"], [85, 90, "Disease"], [85, 86, "Anatomy"]], "rel": [[41, 50, "Pathogenesis", 4, 6, "Disease", "Pathogenesis_Disease"], [54, 55, "Test_items", 4, 6, "Disease", "Test_items_Disease"], [12, 14, "Anatomy", 12, 20, "Disease", "Anatomy_Disease"], [16, 18, "Anatomy", 12, 20, "Disease", "Anatomy_Disease"], [41, 50, "Pathogenesis", 12, 20, "Disease", "Pathogenesis_Disease"], [54, 55, "Test_items", 12, 20, "Disease", "Test_items_Disease"], [85, 86, "Anatomy", 85, 90, "Disease", "Anatomy_Disease"]]}
{"idx": 2901, "sentence": "特别是防止严重低血糖的发生(A)。", "ner": [[7, 9, "Disease"], [5, 6, "Level"]], "rel": []}
{"idx": 2902, "sentence": "老年人低血糖症状多不典型，较多见的是非特异性神经、精神症状，尤其是眩晕、定向障碍、跌倒或突发行为改变。对于存在认知功能障碍的老年人，不能及时识别低血糖，有时会带来严重后果，其危害远高于轻中度高血糖。在老年人出现跌倒、突发行为异常，应该想到低血糖的可能。对用胰岛素促泌剂或胰岛素治疗的老年患者和/或家属，需要在第一时间告知其低血糖的防治措施，有严重低血糖发生经历的老年患者，如不能彻底阻断发生原因，血糖的控制目标需大步放松，以不发生低血糖、又无严重高血糖为目标(C)。", "ner": [[3, 5, "Disease"], [33, 34, "Symptom"], [36, 39, "Symptom"], [41, 42, "Symptom"], [44, 49, "Symptom"], [55, 60, "Disease"], [72, 74, "Disease"], [95, 97, "Disease"], [105, 106, "Symptom"], [108, 113, "Symptom"], [119, 121, "Disease"], [128, 133, "Drug"], [135, 137, "Drug"], [161, 163, "ADE"], [173, 175, "Disease"], [198, 199, "Test_items"], [215, 217, "Disease"], [223, 225, "Disease"], [221, 222, "Level"], [171, 172, "Level"]], "rel": [[33, 34, "Symptom", 3, 5, "Disease", "Symptom_Disease"], [36, 39, "Symptom", 3, 5, "Disease", "Symptom_Disease"], [41, 42, "Symptom", 3, 5, "Disease", "Symptom_Disease"], [44, 49, "Symptom", 3, 5, "Disease", "Symptom_Disease"], [105, 106, "Symptom", 119, 121, "Disease", "Symptom_Disease"], [108, 113, "Symptom", 119, 121, "Disease", "Symptom_Disease"], [161, 163, "ADE", 128, 133, "Drug", "ADE_Drug"], [161, 163, "ADE", 135, 137, "Drug", "ADE_Drug"], [198, 199, "Test_items", 173, 175, "Disease", "Test_items_Disease"], [198, 199, "Test_items", 223, 225, "Disease", "Test_items_Disease"]]}
{"idx": 2903, "sentence": "2.各类降糖药物应用注意点：", "ner": [], "rel": []}
{"idx": 2904, "sentence": "【非胰岛素促泌剂】", "ner": [[1, 7, "Drug"]], "rel": []}
{"idx": 2905, "sentence": "二甲双胍：现有国内外糖尿病指南中均推荐二甲双胍作为2型糖尿病患者控制高血糖的首选或一线用药。它较少的低血糖风险对于老年人有一定的益处，但是药物带来的胃肠道反应与体重减轻对于瘦弱的老年患者可能不利。双胍类药物本身没有肾毒性，因以原型从肾脏排出，如果估算的肾小球滤过率(eGFR)在45~60ml/min之间，则二甲双胍应该减量，如果eGFR<45ml/min二甲双胍则不能使用(A)。双胍类药物禁用于肝功能不全、心力衰竭、缺氧或接受大手术的患者，以避免乳酸性酸中毒的发生。", "ner": [[0, 3, "Drug"], [10, 12, "Disease"], [19, 22, "Drug"], [25, 29, "Disease"], [34, 36, "Disease"], [50, 52, "ADE"], [74, 78, "ADE"], [80, 83, "ADE"], [98, 102, "Drug"], [107, 109, "ADE"], [126, 137, "Test_items"], [139, 149, "Test_Value"], [154, 157, "Drug"], [165, 168, "Test_items"], [169, 177, "Test_Value"], [178, 181, "Drug"], [191, 195, "Drug"], [199, 203, "Disease"], [199, 199, "Anatomy"], [205, 208, "Disease"], [205, 205, "Anatomy"], [210, 211, "Disease"], [225, 230, "ADE"]], "rel": [[0, 3, "Drug", 10, 12, "Disease", "Drug_Disease"], [0, 3, "Drug", 25, 29, "Disease", "Drug_Disease"], [0, 3, "Drug", 34, 36, "Disease", "Drug_Disease"], [225, 230, "ADE", 191, 195, "Drug", "ADE_Drug"], [191, 195, "Drug", 199, 203, "Disease", "Drug_Disease"], [191, 195, "Drug", 205, 208, "Disease", "Drug_Disease"], [191, 195, "Drug", 210, 211, "Disease", "Drug_Disease"], [199, 199, "Anatomy", 199, 203, "Disease", "Anatomy_Disease"], [205, 205, "Anatomy", 205, 208, "Disease", "Anatomy_Disease"]]}
{"idx": 2906, "sentence": "影像学检查使用碘化造影剂时，应暂时停用二甲双胍。", "ner": [[19, 22, "Drug"], [0, 4, "Test"], [7, 11, "Drug"]], "rel": []}
{"idx": 2907, "sentence": "α-糖苷酶抑制剂：α-糖苷酶抑制剂包括阿卡波糖、伏格列波糖和米格列醇。", "ner": [[0, 7, "Drug"], [9, 16, "Drug"], [19, 22, "Drug"], [24, 28, "Drug"], [30, 33, "Drug"]], "rel": []}
{"idx": 2908, "sentence": "主要降低餐后血糖并且低血糖的风险较低，对于以碳水化合物为主要能量来源的老年糖尿病患者更为适合(B)。目前阿卡波糖是国内唯一说明书中标明有糖尿病前期服用适应证的降糖药物(A)。服药后的胃肠道反应可能会影响这类药物的使用，采用从小剂量开始，逐渐加量可以有效减少不良反应。单独服用本类药物通常不会发生低血糖。合用α-糖苷酶抑制剂的患者如果出现低血糖，治疗时需使用葡萄糖制剂，食用蔗糖或淀粉类食物纠正低血糖的效果差。", "ner": [[4, 7, "Test_items"], [10, 12, "ADE"], [37, 39, "Disease"], [52, 55, "Drug"], [68, 70, "Disease"], [91, 95, "ADE"], [147, 149, "ADE"], [153, 160, "Drug"], [168, 170, "ADE"], [178, 182, "Drug"], [196, 198, "ADE"]], "rel": [[4, 7, "Test_items", 37, 39, "Disease", "Test_items_Disease"], [52, 55, "Drug", 68, 70, "Disease", "Drug_Disease"], [168, 170, "ADE", 153, 160, "Drug", "ADE_Drug"]]}
{"idx": 2909, "sentence": "该类药物95%以上在肠道水解后排出，不增加肝肾代谢负担。", "ner": [], "rel": []}
{"idx": 2910, "sentence": "格列酮类：包括罗格列酮和吡格列酮，增加胰岛素敏感性作用明确，有延缓糖尿病进程和较长时间稳定血糖的临床疗效。但有增加体重、水肿、加重心力衰竭、骨折的风险，在老年人中的应用还存在一定的负面影响(A)。", "ner": [[0, 3, "Drug"], [7, 10, "Drug"], [12, 15, "Drug"], [33, 35, "Disease"], [45, 46, "Test_items"], [55, 58, "ADE"], [60, 61, "ADE"], [65, 68, "ADE"], [70, 71, "ADE"]], "rel": [[0, 3, "Drug", 33, 35, "Disease", "Drug_Disease"], [7, 10, "Drug", 33, 35, "Disease", "Drug_Disease"], [12, 15, "Drug", 33, 35, "Disease", "Drug_Disease"], [45, 46, "Test_items", 33, 35, "Disease", "Test_items_Disease"]]}
{"idx": 2911, "sentence": "除老年早期或有特殊需求者外，一般不推荐在老年糖尿病患者中使用(IV)。", "ner": [[22, 24, "Disease"]], "rel": []}
{"idx": 2912, "sentence": "【肠促胰素类】", "ner": [[1, 5, "Drug"]], "rel": []}
{"idx": 2913, "sentence": "二肽基肽酶-4(DPP-4)抑制剂：通过延长体内自身胰高糖素样肽-1(GLP-1)的作用改善糖代谢。", "ner": [[0, 16, "Drug"]], "rel": []}
{"idx": 2914, "sentence": "主要降低餐后血糖，低血糖风险很小，耐受性和安全性比较好，不增加体重，对于老年患者有较多获益(A)。", "ner": [[4, 7, "Test_items"], [9, 11, "ADE"]], "rel": []}
{"idx": 2915, "sentence": "GLP-1受体激动剂：GLP-1受体激动剂以降低餐后血糖为主，低血糖风险较低，经其他降糖药治疗血糖控制不佳、肥胖或贪食者可考虑本药。但是这类药物可能导致恶心等胃肠道不良反应及体重减轻，对于比较瘦弱的老年患者不适合。肾功能不全时药物需要减量。有胰腺炎病史者须慎用。", "ner": [[0, 9, "Drug"], [11, 20, "Drug"], [24, 27, "Test_items"], [31, 33, "ADE"], [47, 48, "Test_items"], [49, 52, "Test_Value"], [54, 55, "Disease"], [76, 77, "ADE"], [79, 85, "ADE"], [87, 90, "ADE"], [107, 111, "Disease"], [121, 123, "Disease"], [121, 122, "Anatomy"], [107, 107, "Anatomy"]], "rel": [[31, 33, "ADE", 0, 9, "Drug", "ADE_Drug"], [107, 107, "Anatomy", 107, 111, "Disease", "Anatomy_Disease"], [121, 122, "Anatomy", 121, 123, "Disease", "Anatomy_Disease"]]}
{"idx": 2916, "sentence": "目前尚缺少老年人应用的经验。", "ner": [], "rel": []}
{"idx": 2917, "sentence": "【胰岛素促泌剂】", "ner": [[1, 6, "Drug"]], "rel": []}
{"idx": 2918, "sentence": "磺脲类：是胰岛素促泌剂类中临床应用经验多、价格相对便宜的降糖药物。", "ner": [[0, 2, "Drug"], [5, 11, "Drug"]], "rel": []}
{"idx": 2919, "sentence": "对老年患者来说这类药物的低血糖风险相对较大，格列本脲的低血糖风险最大，不宜用于老年患者(A)。对于肝肾功能正常的老年糖尿病患者可考虑选择每日1次的磺脲类药物，或根据血糖谱的特点选择中短效的磺脲类药物。缓释(格列齐特)和控释(格列吡嗪)的包装剂型，每天服用1次，且体内药物浓度平缓，低血糖发生少，推荐老年患者选用(A)。有轻中度肾功能不全的患者，可考虑选择格列喹酮。", "ner": [[12, 14, "ADE"], [22, 25, "Drug"], [27, 29, "ADE"], [58, 60, "Disease"], [73, 77, "Drug"], [68, 71, "Frequency"], [94, 98, "Drug"], [100, 107, "Drug"], [109, 116, "Drug"], [123, 128, "Frequency"], [140, 142, "ADE"], [163, 167, "Disease"], [163, 163, "Anatomy"], [177, 180, "Drug"], [160, 162, "Level"]], "rel": [[12, 14, "ADE", 22, 25, "Drug", "ADE_Drug"], [73, 77, "Drug", 58, 60, "Disease", "Drug_Disease"], [68, 71, "Frequency", 73, 77, "Drug", "Frequency_Drug"], [140, 142, "ADE", 100, 107, "Drug", "ADE_Drug"], [123, 128, "Frequency", 100, 107, "Drug", "Frequency_Drug"], [140, 142, "ADE", 109, 116, "Drug", "ADE_Drug"], [123, 128, "Frequency", 109, 116, "Drug", "Frequency_Drug"], [177, 180, "Drug", 163, 167, "Disease", "Drug_Disease"], [163, 163, "Anatomy", 163, 167, "Disease", "Anatomy_Disease"]]}
{"idx": 2920, "sentence": "格列奈类：为非磺脲类短效胰岛素促泌剂，以降低餐后血糖为主，需餐前服用，起效快、半衰期较短。在相同降糖效力的前提下，格列奈类药物低血糖的风险较磺脲类药物低(A)。", "ner": [[0, 3, "Drug"], [6, 17, "Drug"], [22, 25, "Test_items"], [30, 33, "Method"], [57, 62, "Drug"], [63, 65, "ADE"], [70, 74, "Drug"]], "rel": [[30, 33, "Method", 0, 3, "Drug", "Method_Drug"], [63, 65, "ADE", 57, 62, "Drug", "ADE_Drug"]]}
{"idx": 2921, "sentence": "瑞格列奈(从胆汁排出)较那格列奈受肾功能影响更小。", "ner": [[0, 3, "Drug"], [12, 15, "Drug"]], "rel": []}
{"idx": 2922, "sentence": "【胰岛素制剂】", "ner": [[1, 5, "Drug"]], "rel": []}
{"idx": 2923, "sentence": "现有胰岛素制剂品种较多，包括动物来源、基因合成人胰岛素或胰岛素类似物。", "ner": [[2, 6, "Drug"], [28, 33, "Drug"], [19, 26, "Drug"]], "rel": []}
{"idx": 2924, "sentence": "按皮下注射后起效时间分为速效、短效、中效、长效和超长效，及根据需求配置的不同比例短(速)中效预混制剂。", "ner": [[1, 4, "Method"]], "rel": []}
{"idx": 2925, "sentence": "可根据老年患者具体血糖变化情况选用。", "ner": [[9, 10, "Test_items"]], "rel": []}
{"idx": 2926, "sentence": "由于老年人群的特殊性，在使用胰岛素进行降糖治疗前应该认真考虑低血糖的风险。一项在身体状况良好的健康老年人(平均年龄66岁)中进行的研究结果显示，无论是胰岛素泵还是一天多次皮下注射的方法使HbA1c维持在7%的水平达12个月的时间，低血糖发生率很低(A)。在一系列临床试验中与年轻患者(平均年龄53岁)相比，老年2型糖尿病患者(平均年龄69岁)加用长效胰岛素对于达到HbA1c目标同样有效，并且没有增加低血糖的发生率(A)。年龄超过75岁或者存在多种合并症的老年人中相关的研究数据还比较少。与人胰岛素相比，胰岛素类似物发生低血糖的风险性相对低(A)，但价格也更高。胰岛素的使用会导致体重增加(A)，尤其在每日用量40u以上者，可考虑联合口服降糖药(二甲双胍、糖苷酶抑制剂)。", "ner": [[14, 16, "Drug"], [30, 32, "ADE"], [85, 88, "Method"], [93, 97, "Test_items"], [101, 102, "Test_Value"], [115, 117, "ADE"], [155, 159, "Disease"], [173, 177, "Drug"], [182, 186, "Test_items"], [200, 202, "ADE"], [245, 248, "Drug"], [252, 257, "Drug"], [260, 262, "ADE"], [281, 283, "Drug"], [290, 293, "ADE"], [317, 318, "Method"], [323, 326, "Drug"], [328, 333, "Drug"], [305, 309, "Amount"], [301, 302, "Frequency"]], "rel": [[30, 32, "ADE", 14, 16, "Drug", "ADE_Drug"], [182, 186, "Test_items", 155, 159, "Disease", "Test_items_Disease"], [173, 177, "Drug", 155, 159, "Disease", "Drug_Disease"], [200, 202, "ADE", 173, 177, "Drug", "ADE_Drug"], [260, 262, "ADE", 245, 248, "Drug", "ADE_Drug"], [260, 262, "ADE", 252, 257, "Drug", "ADE_Drug"], [290, 293, "ADE", 281, 283, "Drug", "ADE_Drug"], [301, 302, "Frequency", 281, 283, "Drug", "Frequency_Drug"], [305, 309, "Amount", 281, 283, "Drug", "Amount_Drug"], [317, 318, "Method", 323, 326, "Drug", "Method_Drug"], [317, 318, "Method", 328, 333, "Drug", "Method_Drug"]]}
{"idx": 2927, "sentence": "视力或者手部灵活性问题可能是一些老年人使用胰岛素治疗的障碍。", "ner": [[21, 23, "Drug"]], "rel": []}
{"idx": 2928, "sentence": "胰岛素笔虽然使用比较方便，但是与药瓶和注射器相比价格较高。", "ner": [], "rel": []}
{"idx": 2929, "sentence": "使用胰岛素治疗的患者通常需要更多的血糖监测，也会增加一部分治疗负担。", "ner": [[2, 4, "Drug"], [17, 20, "Test_items"]], "rel": []}
{"idx": 2930, "sentence": "3.药物应用后的疗效评估和剂量调整：为患者选择治疗模式后，疗效观察和后续的治疗调整是重要的环节。", "ner": [], "rel": []}
{"idx": 2931, "sentence": "安排进一步的随诊、观察计划，注重患者的实效教育、改进与患者和/或家属沟通方式、根据病情变化及时调整治疗，是提高总体血糖控制达标率的有效措施(A)。", "ner": [[57, 58, "Test_items"]], "rel": []}
{"idx": 2932, "sentence": "降糖治疗中血糖波动是不可避免的现象，过度的血糖波动是加重血管损伤和发生低血糖的危险因素(B)。告诫患者在日常生活中注意调整降糖药与进食量和运动量的三点平衡，有利于促进有效、平稳降糖。", "ner": [[5, 6, "Test_items"], [7, 8, "Test_Value"], [28, 31, "Disease"], [21, 22, "Test_items"], [23, 24, "Test_Value"], [35, 37, "Disease"], [28, 29, "Anatomy"]], "rel": [[5, 6, "Test_items", 28, 31, "Disease", "Test_items_Disease"], [5, 6, "Test_items", 35, 37, "Disease", "Test_items_Disease"], [28, 29, "Anatomy", 28, 31, "Disease", "Anatomy_Disease"]]}
{"idx": 2933, "sentence": "(三)其他降血糖治疗", "ner": [], "rel": []}
{"idx": 2934, "sentence": "干细胞治疗和胃肠道手术治疗是近年来在糖尿病治疗领域发展迅速的降血糖治疗方法，目前尚没有在老年糖尿病患者应用的适应证。", "ner": [[0, 4, "Operation"], [6, 10, "Operation"], [18, 20, "Disease"], [46, 48, "Disease"]], "rel": [[0, 4, "Operation", 18, 20, "Disease", "Operation_Disease"], [6, 10, "Operation", 18, 20, "Disease", "Operation_Disease"]]}
{"idx": 2935, "sentence": "四、老年糖尿病合并多种代谢异常的综合治疗", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 2936, "sentence": "老年糖尿病患者常合并其他代谢异常，在综合评估治疗风险的基础上，应根据老年糖尿病的特点，选择合适的血压、血脂、血尿酸及体重的控制目标。老年糖尿病患者常为多病共存，需要服用多种治疗药物。", "ner": [[2, 4, "Disease"], [36, 38, "Disease"], [54, 56, "Test_items"], [68, 70, "Disease"], [51, 52, "Test_items"], [48, 49, "Test"]], "rel": [[54, 56, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [48, 49, "Test", 2, 4, "Disease", "Test_Disease"], [51, 52, "Test_items", 2, 4, "Disease", "Test_items_Disease"]]}
{"idx": 2937, "sentence": "治疗时需要关注和了解药物间的相互作用和影响，并监测相应指标，及时调整治疗。", "ner": [], "rel": []}
{"idx": 2938, "sentence": "1.控制高血压：根据目前多个国内外心血管专业指南推荐，老年糖尿病合并高血压者血压控制目标＜140／80mmHg(1mmHg=0．133kPa)(B)。可根据患者糖尿病病程、一般健康状况、有无心脑血管病变及尿蛋白情况设置不同血压控制目标。糖尿病患者降压治疗应积极，掌握“越早越好”的原则，血压处于130~140／80～90mmHg水平，经3个月以上生活方式干预无效时可开始药物治疗。血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)类降压药是老年糖尿病患者首选和基用药(Ⅱ)，次选为长效钙离子拮抗剂(CCB)和／或选择性β受体阻断剂，慎用利尿剂，尤其是合并高尿酸血症者。", "ner": [[4, 6, "Disease"], [29, 31, "Disease"], [44, 54, "Test_Value"], [34, 36, "Disease"], [38, 39, "Test_items"], [44, 54, "Test"], [80, 82, "Disease"], [95, 100, "Disease"], [95, 98, "Anatomy"], [102, 104, "Test_items"], [111, 112, "Test_items"], [118, 120, "Disease"], [143, 144, "Test_items"], [147, 163, "Test_Value"], [190, 206, "Drug"], [208, 227, "Drug"], [231, 233, "Disease"], [249, 261, "Drug"], [265, 273, "Drug"], [277, 279, "Drug"], [286, 290, "Disease"]], "rel": [[38, 39, "Test_items", 29, 31, "Disease", "Test_items_Disease"], [38, 39, "Test_items", 34, 36, "Disease", "Test_items_Disease"], [102, 104, "Test_items", 80, 82, "Disease", "Test_items_Disease"], [111, 112, "Test_items", 80, 82, "Disease", "Test_items_Disease"], [95, 98, "Anatomy", 95, 100, "Disease", "Anatomy_Disease"], [102, 104, "Test_items", 95, 100, "Disease", "Test_items_Disease"], [111, 112, "Test_items", 95, 100, "Disease", "Test_items_Disease"], [143, 144, "Test_items", 118, 120, "Disease", "Test_items_Disease"], [190, 206, "Drug", 231, 233, "Disease", "Drug_Disease"], [190, 206, "Drug", 286, 290, "Disease", "Drug_Disease"], [208, 227, "Drug", 231, 233, "Disease", "Drug_Disease"], [208, 227, "Drug", 286, 290, "Disease", "Drug_Disease"], [249, 261, "Drug", 231, 233, "Disease", "Drug_Disease"], [265, 273, "Drug", 231, 233, "Disease", "Drug_Disease"], [277, 279, "Drug", 231, 233, "Disease", "Drug_Disease"], [249, 261, "Drug", 286, 290, "Disease", "Drug_Disease"], [265, 273, "Drug", 286, 290, "Disease", "Drug_Disease"], [277, 279, "Drug", 286, 290, "Disease", "Drug_Disease"]]}
{"idx": 2939, "sentence": "提倡联合治疗，效益互补(I)。", "ner": [], "rel": []}
{"idx": 2940, "sentence": "2.控制血脂异常：血清LDL-C是老年糖尿病患者必须关注的指标。对仅有大血管粥样硬化相关检测指标异常者，LDL-C也需要降低至<2.6mmol/L，有其他心脑血管病变风险因素存在者LDL-C<1.8mmol/L(II)，未能达此标准者在除外肾脏病和甲状腺功能减退症的影响后，应该长期服用他汀类药物。有对他汀类药物不耐受者(出现肝酶、肌酶异常)需酌情调整治疗。如他汀类单药不能使LDL-C达标时，推荐联合服用胆固醇吸收抑制剂(II)。合并单纯高甘油三酯血症者(LDL-C正常)，首先控制脂肪的摄入量，如血清TG≥3.5mmol/L可加用贝特类降脂药，无高尿酸血症者可选用烟酸制剂(II)。", "ner": [[4, 7, "Disease"], [9, 15, "Test_items"], [19, 21, "Disease"], [35, 41, "Disease"], [35, 37, "Anatomy"], [52, 56, "Test_items"], [63, 72, "Test_Value"], [90, 94, "Test_items"], [120, 122, "Disease"], [120, 121, "Anatomy"], [124, 131, "Disease"], [124, 126, "Anatomy"], [143, 147, "Drug"], [163, 164, "Test_items"], [166, 167, "Test_items"], [168, 169, "Test_Value"], [151, 158, "Symptom"], [151, 155, "Drug"], [180, 184, "Drug"], [188, 192, "Test_items"], [193, 194, "Test_Value"], [218, 226, "Disease"], [229, 233, "Test_items"], [234, 235, "Test_Value"], [267, 272, "Drug"], [250, 253, "Test_items"], [254, 263, "Test_Value"], [275, 279, "Disease"], [95, 104, "Test_Value"], [203, 210, "Drug"], [284, 287, "Drug"], [77, 82, "Disease"], [77, 80, "Anatomy"]], "rel": [[9, 15, "Test_items", 4, 7, "Disease", "Test_items_Disease"], [9, 15, "Test_items", 19, 21, "Disease", "Test_items_Disease"], [35, 37, "Anatomy", 35, 41, "Disease", "Anatomy_Disease"], [52, 56, "Test_items", 35, 41, "Disease", "Test_items_Disease"], [143, 147, "Drug", 35, 41, "Disease", "Drug_Disease"], [52, 56, "Test_items", 77, 82, "Disease", "Test_items_Disease"], [52, 56, "Test_items", 120, 122, "Disease", "Test_items_Disease"], [52, 56, "Test_items", 124, 131, "Disease", "Test_items_Disease"], [120, 121, "Anatomy", 120, 122, "Disease", "Anatomy_Disease"], [143, 147, "Drug", 120, 122, "Disease", "Drug_Disease"], [124, 126, "Anatomy", 124, 131, "Disease", "Anatomy_Disease"], [143, 147, "Drug", 124, 131, "Disease", "Drug_Disease"], [143, 147, "Drug", 77, 82, "Disease", "Drug_Disease"], [229, 233, "Test_items", 218, 226, "Disease", "Test_items_Disease"], [250, 253, "Test_items", 218, 226, "Disease", "Test_items_Disease"], [267, 272, "Drug", 218, 226, "Disease", "Drug_Disease"], [284, 287, "Drug", 218, 226, "Disease", "Drug_Disease"], [229, 233, "Test_items", 275, 279, "Disease", "Test_items_Disease"], [267, 272, "Drug", 275, 279, "Disease", "Drug_Disease"], [250, 253, "Test_items", 275, 279, "Disease", "Test_items_Disease"], [284, 287, "Drug", 275, 279, "Disease", "Drug_Disease"], [77, 80, "Anatomy", 77, 82, "Disease", "Anatomy_Disease"]]}
{"idx": 2941, "sentence": "3.体重管理：老年人体重的管理以适中为好(BMI20~<25kg/m2) (II)，不建议单纯以体重变化衡量是否管理达标。建议以就诊时的状态为参照，肥胖者适度控制热量的摄入，体瘦者增加热量供给，两种情况均需进行饮食结构的调整，鼓励适度增加运动(IV)。", "ner": [[74, 75, "Disease"], [103, 111, "Treatment"], [2, 5, "Treatment"], [117, 120, "Treatment"]], "rel": [[103, 111, "Treatment", 74, 75, "Disease", "Treatment_Disease"], [117, 120, "Treatment", 74, 75, "Disease", "Treatment_Disease"]]}
{"idx": 2942, "sentence": "4.控制高尿酸血症：老年人以高尿酸血症为主，痛风发作和痛风石少于中青年(B)。", "ner": [[4, 8, "Disease"], [14, 18, "Disease"], [22, 23, "Disease"], [27, 29, "Disease"]], "rel": []}
{"idx": 2943, "sentence": "目前推荐的控制目标：血尿酸(SUA)≤360μmol/L(对于有痛风发作的患者，SUA<300μmol/L)(I)。SUA干预治疗切点：男性>420μmol/L，女性>360μmol/L(I)。生活方式(低嘌呤饮食，多饮水)未能控制达标者，应该服用降尿酸药物(D)。老年人推荐服用抑制嘌呤合成类药物(别嘌呤醇，非布司他)，逐步降低血尿酸水平至目标值(II)。如用促尿酸排出的药物苯溴马隆，需注意关注肾功能[肌酐清除率(Ccr)<60ml/min，苯溴马隆≤50mg/d]的变化和碱化尿液，可辅用碳酸氢钠(小量多次)维持尿pH在6.5左右(6.2~6.9)(c)。", "ner": [[10, 17, "Test_items"], [18, 27, "Test_Value"], [32, 33, "Disease"], [40, 42, "Test_items"], [58, 60, "Test_items"], [70, 79, "Test_Value"], [83, 92, "Test_Value"], [140, 148, "Drug"], [150, 153, "Drug"], [155, 158, "Drug"], [165, 167, "Test_items"], [189, 192, "Drug"], [199, 201, "Test"], [203, 212, "Test_items"], [213, 221, "Test_Value"], [223, 226, "Drug"], [227, 233, "Amount"], [247, 250, "Drug"], [252, 253, "Amount"], [102, 106, "Treatment"], [108, 110, "Treatment"], [259, 261, "Test_items"], [263, 276, "Test_Value"], [43, 53, "Test_Value"]], "rel": [[10, 17, "Test_items", 32, 33, "Disease", "Test_items_Disease"], [40, 42, "Test_items", 32, 33, "Disease", "Test_items_Disease"], [227, 233, "Amount", 223, 226, "Drug", "Amount_Drug"], [252, 253, "Amount", 247, 250, "Drug", "Amount_Drug"]]}
{"idx": 2944, "sentence": "5.血管活性药物：半数以上的老年糖尿病患者合并动脉粥样硬化症，阿司匹林是首选，为公认对心血管有保护作用的抗血小板制剂，使用方便，每日100(75~150)mg(I)，避免空腹服用。如有纤维蛋白原增高、存在高凝状态者，或对阿司匹林不耐受者，可用硫酸氢氯吡格雷(50~75mg，1次/d)或西洛他唑(50~100mg，2次/d，下肢病变者优选)(II)。", "ner": [[16, 18, "Disease"], [23, 29, "Disease"], [23, 24, "Anatomy"], [31, 34, "Drug"], [110, 113, "Drug"], [121, 127, "Drug"], [129, 135, "Amount"], [137, 140, "Frequency"], [143, 146, "Drug"], [148, 155, "Amount"], [157, 160, "Frequency"], [162, 165, "Disease"], [162, 163, "Anatomy"], [64, 78, "Amount"]], "rel": [[31, 34, "Drug", 16, 18, "Disease", "Drug_Disease"], [23, 24, "Anatomy", 23, 29, "Disease", "Anatomy_Disease"], [31, 34, "Drug", 23, 29, "Disease", "Drug_Disease"], [64, 78, "Amount", 31, 34, "Drug", "Amount_Drug"], [110, 113, "Drug", 162, 165, "Disease", "Drug_Disease"], [121, 127, "Drug", 162, 165, "Disease", "Drug_Disease"], [129, 135, "Amount", 121, 127, "Drug", "Amount_Drug"], [137, 140, "Frequency", 121, 127, "Drug", "Frequency_Drug"], [143, 146, "Drug", 162, 165, "Disease", "Drug_Disease"], [148, 155, "Amount", 143, 146, "Drug", "Amount_Drug"], [157, 160, "Frequency", 143, 146, "Drug", "Frequency_Drug"], [162, 163, "Anatomy", 162, 165, "Disease", "Anatomy_Disease"]]}
{"idx": 2945, "sentence": "有明确大血管粥样硬化斑块形成的患者，尤其是有下肢动脉闭塞症者，可酌情定期静脉输注具有扩张血管、改善微循环、抑制血小板凝聚的药物前列腺素E1制剂(10~40μg/d，连续10~20d为1个疗程)，也可长期口服贝前列腺素钠片(III)。", "ner": [[3, 11, "Disease"], [3, 5, "Anatomy"], [22, 28, "Disease"], [22, 25, "Anatomy"], [36, 39, "Method"], [63, 70, "Drug"], [84, 89, "Duration"], [99, 100, "Duration"], [101, 102, "Method"], [103, 109, "Drug"], [72, 80, "Amount"]], "rel": [[3, 5, "Anatomy", 3, 11, "Disease", "Anatomy_Disease"], [63, 70, "Drug", 3, 11, "Disease", "Drug_Disease"], [103, 109, "Drug", 3, 11, "Disease", "Drug_Disease"], [22, 25, "Anatomy", 22, 28, "Disease", "Anatomy_Disease"], [63, 70, "Drug", 22, 28, "Disease", "Drug_Disease"], [103, 109, "Drug", 22, 28, "Disease", "Drug_Disease"], [36, 39, "Method", 63, 70, "Drug", "Method_Drug"], [84, 89, "Duration", 63, 70, "Drug", "Duration_Drug"], [72, 80, "Amount", 63, 70, "Drug", "Amount_Drug"], [99, 100, "Duration", 103, 109, "Drug", "Duration_Drug"], [101, 102, "Method", 103, 109, "Drug", "Method_Drug"]]}
{"idx": 2946, "sentence": "6.其他心血管危险因素的控制：包括戒烟及纠正高同型半胱氨酸血症等(A)。", "ner": [[22, 30, "Disease"]], "rel": []}
{"idx": 2947, "sentence": "五、老年糖尿病合并症的防治及需要兼顾的问题", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 2948, "sentence": "老年糖尿病患者不仅会有与糖尿病相关的合并症，也有其他心血管危险因素所致脏器损害，治疗原则为早期评估、综合分析、因人施治、权衡效益风险，全面控制危险因素。", "ner": [[2, 4, "Disease"], [12, 14, "Disease"], [35, 38, "Disease"], [35, 36, "Anatomy"]], "rel": [[35, 36, "Anatomy", 35, 38, "Disease", "Anatomy_Disease"]]}
{"idx": 2949, "sentence": "1.心血管病变(冠心病、心律失常、心力衰竭)：对于老年糖尿病患者应早期开始干预和治疗心血管病变的危险因素，包括在糖尿病及高血压前期即开始管理、生活方式干预、及时启动降LDL-C治疗等综合心血管危险因素管理措施(A)。对糖尿病合并高血压和/或高LDL-C血症者应关注血管病变的筛查，颈动脉彩色多普勒超声检查为简便易行、特异性好的筛查方法(III)。有异常症状者适时行冠状动脉CT血管造影(CTA)可较早发现病变及时处置(III)。老年糖尿病患者因伴存心脏自主神经病变，可发生乏力、心悸、水肿等不典型症状或无症状心肌梗死，易合并心律失常或心力衰竭，可导致心源性猝死(C)。", "ner": [[2, 6, "Disease"], [2, 4, "Anatomy"], [8, 10, "Disease"], [12, 15, "Disease"], [12, 12, "Anatomy"], [17, 20, "Disease"], [17, 17, "Anatomy"], [27, 29, "Disease"], [42, 46, "Disease"], [42, 44, "Anatomy"], [56, 58, "Disease"], [60, 62, "Disease"], [109, 111, "Disease"], [114, 116, "Disease"], [120, 127, "Disease"], [132, 135, "Disease"], [132, 133, "Anatomy"], [140, 151, "Test"], [182, 196, "Test"], [216, 218, "Disease"], [224, 231, "Disease"], [224, 230, "Anatomy"], [236, 237, "Symptom"], [239, 240, "Symptom"], [242, 243, "Symptom"], [251, 257, "Symptom"], [262, 265, "Disease"], [262, 262, "Anatomy"], [267, 270, "Disease"], [267, 267, "Anatomy"], [275, 279, "Disease"], [9, 9, "Anatomy"]], "rel": [[2, 4, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [9, 9, "Anatomy", 8, 10, "Disease", "Anatomy_Disease"], [12, 12, "Anatomy", 12, 15, "Disease", "Anatomy_Disease"], [17, 17, "Anatomy", 17, 20, "Disease", "Anatomy_Disease"], [42, 44, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"], [140, 151, "Test", 109, 111, "Disease", "Test_Disease"], [140, 151, "Test", 114, 116, "Disease", "Test_Disease"], [140, 151, "Test", 120, 127, "Disease", "Test_Disease"], [140, 151, "Test", 132, 135, "Disease", "Test_Disease"], [236, 237, "Symptom", 216, 218, "Disease", "Symptom_Disease"], [239, 240, "Symptom", 216, 218, "Disease", "Symptom_Disease"], [242, 243, "Symptom", 216, 218, "Disease", "Symptom_Disease"], [251, 257, "Symptom", 216, 218, "Disease", "Symptom_Disease"], [224, 230, "Anatomy", 224, 231, "Disease", "Anatomy_Disease"], [236, 237, "Symptom", 224, 231, "Disease", "Symptom_Disease"], [239, 240, "Symptom", 224, 231, "Disease", "Symptom_Disease"], [242, 243, "Symptom", 224, 231, "Disease", "Symptom_Disease"], [251, 257, "Symptom", 224, 231, "Disease", "Symptom_Disease"], [262, 262, "Anatomy", 262, 265, "Disease", "Anatomy_Disease"], [267, 267, "Anatomy", 267, 270, "Disease", "Anatomy_Disease"]]}
{"idx": 2950, "sentence": "需要经心电图和血肌酶的动态监测确定诊断，及时治疗(D)。", "ner": [[3, 5, "Test"], [7, 9, "Test_items"]], "rel": []}
{"idx": 2951, "sentence": "2.缺血性脑梗死：糖尿病合并的脑血管病变90％以上是缺血性脑梗死(A)，近1／3卒中患者的病因与颈动脉狭窄有关。老年糖尿病患者脑梗死的一级预防包括积极控制血压、血糖、LDL-C在理想水平，并戒烟(I)。对心脑血管高危患者，应该定期检测颈动脉B超，如发现小斑块形成或颅脑CT或MRI发现小缺血灶，即要开始抗血小板药物治疗(I)。已发生脑梗死者，重在防止再发(D)。LDL-C控制在<2.0mmol／L，HbA1c<7.0％，血压不宜控制过严，<150/85mmHg即可(I)。", "ner": [[2, 7, "Disease"], [5, 5, "Anatomy"], [9, 11, "Disease"], [15, 19, "Disease"], [15, 17, "Anatomy"], [26, 31, "Disease"], [29, 29, "Anatomy"], [40, 41, "Disease"], [48, 52, "Reason"], [58, 60, "Disease"], [63, 65, "Disease"], [63, 63, "Anatomy"], [117, 121, "Test"], [132, 135, "Test"], [137, 139, "Test"], [142, 145, "Test_Value"], [166, 168, "Disease"], [166, 166, "Anatomy"], [200, 204, "Test_items"], [205, 209, "Test_Value"], [211, 212, "Test"], [220, 230, "Test_Value"], [77, 78, "Test"], [80, 81, "Test_items"], [83, 87, "Test_items"], [181, 185, "Test_items"], [189, 198, "Test_Value"]], "rel": [[5, 5, "Anatomy", 2, 7, "Disease", "Anatomy_Disease"], [15, 17, "Anatomy", 15, 19, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 26, 31, "Disease", "Anatomy_Disease"], [48, 52, "Reason", 40, 41, "Disease", "Reason_Disease"], [63, 63, "Anatomy", 63, 65, "Disease", "Anatomy_Disease"], [80, 81, "Test_items", 63, 65, "Disease", "Test_items_Disease"], [83, 87, "Test_items", 63, 65, "Disease", "Test_items_Disease"], [77, 78, "Test", 63, 65, "Disease", "Test_Disease"], [166, 166, "Anatomy", 166, 168, "Disease", "Anatomy_Disease"], [200, 204, "Test_items", 166, 168, "Disease", "Test_items_Disease"]]}
{"idx": 2952, "sentence": "3.下肢动脉闭塞：外周动脉疾病(PAD)是糖尿病常见的大血管并发症，老年患者中多发，下肢动脉闭塞最常见(C)。糖尿病合并高血压将增加PAD的发生及靶器官损伤(A)。应用彩色多普勒超声技术筛查下肢动脉病变，可以更早及准确检测血管损伤，并进行危险分层(C)。对出现下肢疼痛症状者，临床上按疼痛程度分级(表2)。治疗上按照病变不同阶段各有侧重，单纯动脉管壁增厚伴散在斑块者，需要加用抗血小板药物，下肢动脉管腔狭窄>50%、足背动脉搏动缺失或有运动后下肢无力等症状，可联合西洛他唑(50~100mg，2次/d)长期服用，下肢动脉管腔狭窄>75%、中重度间歇性跛行伴静息痛患者，有条件需行介入治疗(D)。", "ner": [[2, 7, "Disease"], [2, 5, "Anatomy"], [9, 19, "Disease"], [9, 12, "Anatomy"], [21, 23, "Disease"], [27, 32, "Disease"], [27, 29, "Anatomy"], [42, 47, "Disease"], [42, 45, "Anatomy"], [55, 57, "Disease"], [60, 62, "Disease"], [66, 68, "Disease"], [73, 77, "Disease"], [73, 75, "Anatomy"], [84, 90, "Test"], [95, 100, "Disease"], [95, 98, "Anatomy"], [111, 114, "Disease"], [111, 112, "Anatomy"], [130, 133, "Symptom"], [208, 215, "Disease"], [221, 224, "Symptom"], [232, 235, "Drug"], [237, 244, "Amount"], [246, 249, "Frequency"], [251, 252, "Duration"], [195, 202, "Disease"], [208, 211, "Anatomy"], [256, 263, "Disease"], [256, 260, "Anatomy"], [195, 198, "Anatomy"], [269, 271, "Level"], [272, 280, "Disease"]], "rel": [[2, 5, "Anatomy", 2, 7, "Disease", "Anatomy_Disease"], [9, 12, "Anatomy", 9, 19, "Disease", "Anatomy_Disease"], [27, 29, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [42, 45, "Anatomy", 42, 47, "Disease", "Anatomy_Disease"], [73, 75, "Anatomy", 73, 77, "Disease", "Anatomy_Disease"], [84, 90, "Test", 95, 100, "Disease", "Test_Disease"], [84, 90, "Test", 111, 114, "Disease", "Test_Disease"], [95, 98, "Anatomy", 95, 100, "Disease", "Anatomy_Disease"], [111, 112, "Anatomy", 111, 114, "Disease", "Anatomy_Disease"], [208, 211, "Anatomy", 208, 215, "Disease", "Anatomy_Disease"], [246, 249, "Frequency", 232, 235, "Drug", "Frequency_Drug"], [237, 244, "Amount", 232, 235, "Drug", "Amount_Drug"], [251, 252, "Duration", 232, 235, "Drug", "Duration_Drug"], [195, 198, "Anatomy", 195, 202, "Disease", "Anatomy_Disease"], [256, 260, "Anatomy", 256, 263, "Disease", "Anatomy_Disease"]]}
{"idx": 2953, "sentence": "4.糖尿病足：发生糖尿病足病意味着同时存在全身动脉粥样硬化性改变，是发生心脑血管严重病变的高风险信号，需要对患者进行全面评估，综合治疗(II)。病程长的糖尿病患者，均须注意预防足部皮肤破损，认真处置足癣和甲癣(B)。", "ner": [[2, 5, "Disease"], [5, 5, "Anatomy"], [9, 13, "Disease"], [12, 12, "Anatomy"], [21, 31, "Symptom"], [36, 43, "Disease"], [40, 41, "Level"], [76, 78, "Disease"], [88, 93, "Symptom"], [99, 100, "Symptom"], [102, 103, "Symptom"], [36, 39, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [12, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [21, 31, "Symptom", 9, 13, "Disease", "Symptom_Disease"], [36, 39, "Anatomy", 36, 43, "Disease", "Anatomy_Disease"], [88, 93, "Symptom", 76, 78, "Disease", "Symptom_Disease"], [99, 100, "Symptom", 76, 78, "Disease", "Symptom_Disease"], [102, 103, "Symptom", 76, 78, "Disease", "Symptom_Disease"]]}
{"idx": 2954, "sentence": "一旦发生足部皮肤溃烂，应尽快到足病专科就诊，接受多学科综合治疗，早期控制感染及损伤，降低截肢风险(B)。", "ner": [[4, 9, "Symptom"], [36, 37, "Disease"]], "rel": [[4, 9, "Symptom", 36, 37, "Disease", "Symptom_Disease"]]}
{"idx": 2955, "sentence": "5.糖尿病肾病与慢性肾衰竭：老年糖尿病肾损伤常为多因素致病。遗传因素、高血压、高血糖、肥胖、高尿酸及肾毒性药物是老年慢性肾病进展的主要影响因素，糖尿病所致肾损伤仅占1/3(D)。糖尿病肾病治疗原则：严格饮食管理(摄入优质蛋白，<0.6g·kg-1·d-1)，减轻肾脏负担(I)。治疗措施包括尽早应用肾素血管紧张素系统(RAS)抑制剂、严格控制血糖、肥胖者减轻体重、控制血压(<130/80mmHg)、控制高尿酸血症及改善肾脏微循环等。", "ner": [[2, 6, "Disease"], [8, 12, "Disease"], [10, 10, "Anatomy"], [5, 5, "Anatomy"], [16, 21, "Disease"], [19, 19, "Anatomy"], [30, 33, "Reason"], [35, 37, "Reason"], [39, 41, "Reason"], [43, 44, "Reason"], [46, 48, "Reason"], [50, 54, "Reason"], [72, 74, "Reason"], [77, 79, "Disease"], [77, 77, "Anatomy"], [58, 61, "Disease"], [60, 60, "Anatomy"], [89, 93, "Disease"], [92, 92, "Anatomy"], [149, 165, "Drug"], [202, 206, "Disease"], [171, 172, "Test_items"], [174, 175, "Disease"]], "rel": [[5, 5, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [10, 10, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [19, 19, "Anatomy", 16, 21, "Disease", "Anatomy_Disease"], [30, 33, "Reason", 58, 61, "Disease", "Reason_Disease"], [35, 37, "Reason", 58, 61, "Disease", "Reason_Disease"], [39, 41, "Reason", 58, 61, "Disease", "Reason_Disease"], [43, 44, "Reason", 58, 61, "Disease", "Reason_Disease"], [46, 48, "Reason", 58, 61, "Disease", "Reason_Disease"], [50, 54, "Reason", 58, 61, "Disease", "Reason_Disease"], [72, 74, "Reason", 77, 79, "Disease", "Reason_Disease"], [77, 77, "Anatomy", 77, 79, "Disease", "Anatomy_Disease"], [60, 60, "Anatomy", 58, 61, "Disease", "Anatomy_Disease"], [92, 92, "Anatomy", 89, 93, "Disease", "Anatomy_Disease"], [149, 165, "Drug", 202, 206, "Disease", "Drug_Disease"], [171, 172, "Test_items", 202, 206, "Disease", "Test_items_Disease"]]}
{"idx": 2956, "sentence": "如疾病进展为肾病综合征或尿毒症，还需配合肾病科医生的专科治疗(I)。", "ner": [[12, 14, "Disease"], [6, 10, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 6, 10, "Disease", "Anatomy_Disease"]]}
{"idx": 2957, "sentence": "6.糖尿病视网膜病变与失明：老年患者需要定期进行眼底检查。及时发现病变，及早开始治疗获益最大(I)。抗炎、抗血管生成及改善微循环是目前正在使用的治疗方法，激光光凝治疗是预防失明的有效措施(B)。", "ner": [[2, 9, "Disease"], [5, 7, "Anatomy"], [11, 12, "Disease"], [24, 27, "Test"], [77, 82, "Treatment"], [86, 87, "Disease"]], "rel": [[5, 7, "Anatomy", 2, 9, "Disease", "Anatomy_Disease"], [24, 27, "Test", 2, 9, "Disease", "Test_Disease"], [24, 27, "Test", 11, 12, "Disease", "Test_Disease"], [77, 82, "Treatment", 86, 87, "Disease", "Treatment_Disease"]]}
{"idx": 2958, "sentence": "7.糖尿病外周神经病变：老年糖尿病患者约半数以上合并外周神经病变(DPN)(C)。以感觉神经、自主神经受损最为常见，临床表现多样(C)。由于老年患者伴存的骨关节病变、精神异常、认知障碍等病变在一些症状的发生中相互影响，诊断DPN时需要综合分析。α-硫辛酸、前列地尔和甲基维生素B12在改善DPN引起的感觉异常、肢体麻木和疼痛方面有一定效果，非麻醉性镇痛药和辣椒辣素对减轻痛性神经病变症状有一定作用(II)。", "ner": [[2, 10, "Disease"], [5, 8, "Anatomy"], [14, 16, "Disease"], [26, 36, "Disease"], [26, 29, "Anatomy"], [42, 52, "Symptom"], [77, 81, "Disease"], [83, 86, "Disease"], [77, 79, "Anatomy"], [88, 91, "Disease"], [111, 113, "Disease"], [122, 126, "Drug"], [128, 131, "Drug"], [133, 140, "Drug"], [144, 146, "Disease"], [150, 153, "Symptom"], [155, 158, "Symptom"], [160, 161, "Symptom"], [178, 181, "Drug"], [185, 190, "Disease"], [187, 188, "Anatomy"], [170, 176, "Drug"]], "rel": [[5, 8, "Anatomy", 2, 10, "Disease", "Anatomy_Disease"], [26, 29, "Anatomy", 26, 36, "Disease", "Anatomy_Disease"], [77, 79, "Anatomy", 77, 81, "Disease", "Anatomy_Disease"], [122, 126, "Drug", 144, 146, "Disease", "Drug_Disease"], [128, 131, "Drug", 144, 146, "Disease", "Drug_Disease"], [133, 140, "Drug", 144, 146, "Disease", "Drug_Disease"], [150, 153, "Symptom", 144, 146, "Disease", "Symptom_Disease"], [155, 158, "Symptom", 144, 146, "Disease", "Symptom_Disease"], [160, 161, "Symptom", 144, 146, "Disease", "Symptom_Disease"], [178, 181, "Drug", 185, 190, "Disease", "Drug_Disease"], [187, 188, "Anatomy", 185, 190, "Disease", "Anatomy_Disease"], [170, 176, "Drug", 185, 190, "Disease", "Drug_Disease"]]}
{"idx": 2959, "sentence": "8.老年骨质疏松症与关节病变：骨质疏松症好发于绝经后妇女及老年人，适量补充维生素D3和钙剂、及时启用二膦酸盐制剂等抗骨质疏松药物是常规治疗措施(I)，预防跌倒、骨折是目标。老年糖尿病患者伴存的多种疾病均可导致跌倒及骨折的风险增高，对老年人定期进行跌倒风险及身体功能评估非常必要，同时应避免严重高血糖及低血糖导致跌倒风险的增加(B)。", "ner": [[10, 13, "Disease"], [10, 11, "Anatomy"], [15, 19, "Disease"], [37, 41, "Drug"], [43, 44, "Drug"], [50, 55, "Drug"], [77, 78, "Symptom"], [80, 81, "Disease"], [93, 99, "Reason"], [88, 90, "Disease"], [104, 105, "Symptom"], [107, 108, "Disease"], [146, 148, "Disease"], [150, 152, "Disease"], [4, 8, "Disease"], [155, 156, "Symptom"], [144, 145, "Level"]], "rel": [[10, 11, "Anatomy", 10, 13, "Disease", "Anatomy_Disease"], [37, 41, "Drug", 15, 19, "Disease", "Drug_Disease"], [43, 44, "Drug", 15, 19, "Disease", "Drug_Disease"], [50, 55, "Drug", 15, 19, "Disease", "Drug_Disease"], [77, 78, "Symptom", 15, 19, "Disease", "Symptom_Disease"], [93, 99, "Reason", 107, 108, "Disease", "Reason_Disease"], [104, 105, "Symptom", 88, 90, "Disease", "Symptom_Disease"], [155, 156, "Symptom", 146, 148, "Disease", "Symptom_Disease"], [155, 156, "Symptom", 150, 152, "Disease", "Symptom_Disease"]]}
{"idx": 2960, "sentence": "9.联合用药需注意药物间的相互作用：老年糖尿病患者常为多病共存，需要服用多种治疗药物，需注意药物间的相互作用(II)。", "ner": [[20, 22, "Disease"]], "rel": []}
{"idx": 2961, "sentence": "可升高血糖的药物包括：降压药CCB、抗结核药物利福平、喹诺酮类药物(加替沙星，莫西沙星)、淀粉酶及胰酶制剂等。", "ner": [[14, 16, "Drug"], [23, 25, "Drug"], [27, 32, "Drug"], [34, 37, "Drug"], [39, 42, "Drug"], [45, 47, "Drug"], [49, 52, "Drug"]], "rel": []}
{"idx": 2962, "sentence": "降低血糖的药物包括：别嘌呤醇、喹诺酮类药物(加替沙星、莫西沙星)、质子泵抑制剂(西咪替丁、雷尼替丁)。", "ner": [[10, 13, "Drug"], [15, 20, "Drug"], [22, 25, "Drug"], [27, 30, "Drug"], [33, 38, "Drug"], [40, 43, "Drug"], [45, 48, "Drug"]], "rel": []}
{"idx": 2963, "sentence": "升高血尿酸的药物：噻嗪类利尿剂；阿司匹林、烟酸类降脂药物。", "ner": [[9, 14, "Drug"], [16, 19, "Drug"], [21, 27, "Drug"]], "rel": []}
{"idx": 2964, "sentence": "降低血尿酸的药物：氯沙坦(B)。", "ner": [[9, 11, "Drug"]], "rel": []}
{"idx": 2965, "sentence": "10.老年糖尿病存在的其他问题：老年糖尿病患者发生认知功能障碍的风险高于正常人(B)。", "ner": [[5, 7, "Disease"], [18, 20, "Disease"], [25, 30, "Disease"]], "rel": []}
{"idx": 2966, "sentence": "需要借助简单的评估工具表(Folstein精神状态检查表)对高龄、病程较长的患者进行筛查(II)。", "ner": [], "rel": []}
{"idx": 2967, "sentence": "糖尿病与抑郁症的发病率升高也有关，未治疗的抑郁症可能会增加发生死亡及痴呆的风险，需使用老年抑郁量表对患者进行早期筛查(II)。", "ner": [[0, 2, "Disease"], [4, 6, "Disease"], [21, 23, "Disease"], [34, 35, "Disease"]], "rel": []}
{"idx": 2968, "sentence": "伴有腹型肥胖的老年患者睡眠呼吸暂停综合征(OSAS)的发病率增高，可伴有空腹高血糖、高胰岛素血症和清晨高血压，有增加晨时猝死的高风险，需及时检查、及时治疗，通过改善患者通气情况改善总体预后(II)。", "ner": [[2, 5, "Disease"], [11, 25, "Disease"], [38, 40, "Disease"], [42, 47, "Disease"], [51, 53, "Disease"], [60, 61, "Disease"]], "rel": []}
{"idx": 2969, "sentence": "11.老年糖尿病控制不好而导致的合并症：这已成为重要的社会和经济负担。", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 2970, "sentence": "与中青年糖尿病患者不同，老年糖尿病患者对社会帮助的需求相对更多(C)。", "ner": [[4, 6, "Disease"], [14, 16, "Disease"]], "rel": []}
{"idx": 2971, "sentence": "故对老年患者除要求自我管理外还需关注社会支持。", "ner": [], "rel": []}
{"idx": 2972, "sentence": "社会支持的来源涉及医院外患者参与社会活动和生活的各个方面，除了家庭(亲人和朋友)支持外，社区、邻里乡亲的支持也十分重要，尤其是存在明显认知障碍、运动受限的患者(III)。", "ner": [[67, 70, "Disease"], [65, 66, "Level"], [72, 75, "Disease"]], "rel": []}
{"idx": 2973, "sentence": "老年人得到社会支持程度越高，生活质量越好，糖尿病管理效果越佳(B)。", "ner": [[21, 23, "Disease"]], "rel": []}
{"idx": 2974, "sentence": "如有来自政府的行政(政策及舆论宣传)和经济支持(医疗保障)将会提升老年糖尿病及相关代谢异常疾病的总体管理水平，为社会和人民健康谋福利(C)。", "ner": [[35, 37, "Disease"], [41, 46, "Disease"]], "rel": []}
{"idx": 2975, "sentence": "2型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识", "ner": [[0, 4, "Disease"], [7, 11, "Disease"], [9, 10, "Anatomy"], [14, 15, "Method"]], "rel": [[9, 10, "Anatomy", 7, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 2976, "sentence": "慢性肾脏病(CKD)是严重威胁人类健康的常见慢性病，病因多种多样，由糖尿病所引发的肾脏病称为糖尿病肾脏病(DKD)。T2DM常合并CKD，高血糖是CKD发展的主要原因之一，降糖治疗至关重要。", "ner": [[0, 9, "Disease"], [2, 3, "Anatomy"], [34, 36, "Reason"], [46, 56, "Disease"], [41, 43, "Disease"], [41, 42, "Anatomy"], [49, 50, "Anatomy"], [58, 61, "Disease"], [65, 67, "Disease"], [69, 71, "Reason"], [73, 75, "Disease"]], "rel": [[2, 3, "Anatomy", 0, 9, "Disease", "Anatomy_Disease"], [34, 36, "Reason", 41, 43, "Disease", "Reason_Disease"], [49, 50, "Anatomy", 46, 56, "Disease", "Anatomy_Disease"], [41, 42, "Anatomy", 41, 43, "Disease", "Anatomy_Disease"], [69, 71, "Reason", 73, 75, "Disease", "Reason_Disease"]]}
{"idx": 2977, "sentence": "口服降糖药作为临床最常用的降糖手段，对于血糖控制具有重要意义。", "ner": [[0, 1, "Method"], [20, 21, "Test_items"]], "rel": []}
{"idx": 2978, "sentence": "近年来，T2DM合并CKD患者中口服降糖药治疗证据不断丰富，国外糖尿病及肾脏病权威指南规范了口服降糖药的应用，但我国尚缺乏T2DM合并CKD用药指南或共识。", "ner": [[4, 7, "Disease"], [10, 12, "Disease"], [16, 17, "Method"], [32, 34, "Disease"], [36, 38, "Disease"], [36, 37, "Anatomy"], [46, 47, "Method"], [61, 64, "Disease"], [67, 69, "Disease"]], "rel": [[36, 37, "Anatomy", 36, 38, "Disease", "Anatomy_Disease"]]}
{"idx": 2979, "sentence": "为规范临床用药，中国医师协会内分泌代谢科医师分会组织国内的内分泌科和肾内科领域专家共同制定了本共识。", "ner": [], "rel": []}
{"idx": 2980, "sentence": "对于口服降糖药在T2DM合并CKD患者的应用，参考药品说明书、近期国际指南及经典专著，如“The Kidney”，若缺乏用药经验，则依据从严原则，以保护医患利益。", "ner": [[2, 3, "Method"], [8, 11, "Disease"], [14, 16, "Disease"]], "rel": []}
{"idx": 2981, "sentence": "一、T2DM合并CKD的流行病学", "ner": [[2, 5, "Disease"], [8, 10, "Disease"]], "rel": []}
{"idx": 2982, "sentence": "我国糖尿病患病率逐年升高，目前糖尿病患者约9240万，其中T2DM占90%以上。糖尿病与CKD关系密切。糖尿病患者CKD发生风险较非糖尿病者增加2.6倍。近年，各地CKD流行病学调查成年人CKD的患病率存在一定差异，为9%~14%。近期全国CKD流行病学调查显示，我国成年人中CKD患病率为10.8%，据此估算18岁以上人群CKD患者人数约1.195亿。在发达国家，糖尿病已是导致CKD的主要病因，而且在发展中国家，糖尿病正逐渐成为CKD的主要致病原因。美国流行病学调查显示，年龄≥20岁的T2DM患者有39.7%合并CKD。对我国住院糖尿病患者的回顾性研究表明，33.6%的糖尿病患者合并肾脏并发症。", "ner": [[2, 4, "Disease"], [15, 17, "Disease"], [29, 32, "Disease"], [40, 42, "Disease"], [44, 46, "Disease"], [52, 54, "Disease"], [57, 59, "Disease"], [66, 68, "Disease"], [82, 84, "Disease"], [120, 122, "Disease"], [94, 96, "Disease"], [138, 140, "Disease"], [162, 164, "Disease"], [190, 192, "Disease"], [183, 185, "Reason"], [259, 261, "Disease"], [208, 210, "Reason"], [216, 218, "Disease"], [288, 290, "Disease"], [295, 296, "Anatomy"], [268, 270, "Disease"], [245, 248, "Disease"]], "rel": [[183, 185, "Reason", 190, 192, "Disease", "Reason_Disease"], [208, 210, "Reason", 216, 218, "Disease", "Reason_Disease"], [295, 296, "Anatomy", 288, 290, "Disease", "Anatomy_Disease"]]}
{"idx": 2983, "sentence": "上海市区30岁以上T2DM患者CKD患病率可达63.9%。", "ner": [[9, 12, "Disease"], [15, 17, "Disease"]], "rel": []}
{"idx": 2984, "sentence": "二、T2DM合并CKD的诊断与分期", "ner": [[2, 5, "Disease"], [8, 10, "Disease"]], "rel": []}
{"idx": 2985, "sentence": "CKD是指肾脏结构或功能异常持续超过3个月，其诊断标准见表1。目前国内外大部分指南是根据GFR来进行CKD的肾功能分期。", "ner": [[0, 2, "Disease"], [5, 13, "Disease"], [44, 46, "Test_items"], [50, 52, "Disease"], [54, 56, "Test_items"]], "rel": [[44, 46, "Test_items", 50, 52, "Disease", "Test_items_Disease"], [54, 56, "Test_items", 50, 52, "Disease", "Test_items_Disease"]]}
{"idx": 2986, "sentence": "(表2)", "ner": [], "rel": []}
{"idx": 2987, "sentence": "GFR是评价肾脏功能的重要指标之一，我国估算肾小球滤过率(eGFR)课题协作组改良简化MDRD方程，制定了适合我国CKD患者的eGFR的评估公式：eGFR[ml/(min·1.73m2)]=175×Scr-1.234(mg/dL)×年龄-0.179(女性×0.79)。", "ner": [[57, 59, "Disease"], [63, 66, "Test_items"], [0, 2, "Test_items"], [22, 33, "Test_items"], [73, 76, "Test_items"]], "rel": [[0, 2, "Test_items", 57, 59, "Disease", "Test_items_Disease"], [22, 33, "Test_items", 57, 59, "Disease", "Test_items_Disease"], [63, 66, "Test_items", 57, 59, "Disease", "Test_items_Disease"], [73, 76, "Test_items", 57, 59, "Disease", "Test_items_Disease"]]}
{"idx": 2988, "sentence": "三、T2DM合并CKD的口服降糖药选择", "ner": [[2, 5, "Disease"], [8, 10, "Disease"], [12, 13, "Method"]], "rel": []}
{"idx": 2989, "sentence": "1.选药原则：T2DM合并CKD的理想降糖治疗策略是在有效降糖的同时，不增加低血糖发生的风险，也应避免诱发乳酸性酸中毒或增加心力衰竭风险。", "ner": [[7, 10, "Disease"], [13, 15, "Disease"], [38, 40, "ADE"], [53, 58, "ADE"], [62, 65, "ADE"]], "rel": []}
{"idx": 2990, "sentence": "口服降糖药的选择应基于药物的药代动力学特征以及患者的肾功能水平综合判断。", "ner": [[0, 1, "Method"]], "rel": []}
{"idx": 2991, "sentence": "在使用某些低血糖风险较大的口服降糖药时需严格监测血糖，确保随机血糖>5mmol/L以避免低血糖的发生。", "ner": [[5, 7, "ADE"], [13, 14, "Method"], [24, 25, "Test_items"], [31, 32, "Test_items"], [33, 40, "Test_Value"], [44, 46, "ADE"]], "rel": []}
{"idx": 2992, "sentence": "2.血糖控制目标值：对T2DM合并CKD患者的血糖控制目标应遵循个体化原则，尽量避免低血糖的发生。《中国成人2型糖尿病HbA1c控制目标的专家共识》建议对T2DM合并CKD患者的HbA1c可适当放宽控制在7%~9%，一方面避免血糖水平控制过低而出现低血糖，另一方面避免血糖水平过高而出现代谢异常及感染。当CKD导致红细胞寿命缩短时，HbA1c检测结果可能被低估。在晚期CKD患者，使用糖化血清蛋白反映血糖控制水平可能更可靠。", "ner": [[2, 3, "Test_items"], [11, 14, "Disease"], [17, 19, "Disease"], [23, 24, "Test_items"], [42, 44, "Disease"], [54, 58, "Disease"], [59, 63, "Test_items"], [77, 80, "Disease"], [83, 85, "Disease"], [89, 93, "Test_items"], [102, 106, "Test_Value"], [113, 114, "Test_items"], [119, 120, "Test_Value"], [124, 126, "Disease"], [134, 135, "Test_items"], [138, 139, "Test_Value"], [143, 146, "Disease"], [148, 149, "Disease"], [152, 154, "Disease"], [157, 163, "Pathogenesis"], [166, 170, "Test_items"], [182, 186, "Disease"], [192, 197, "Test_items"], [200, 201, "Test_items"]], "rel": [[23, 24, "Test_items", 11, 14, "Disease", "Test_items_Disease"], [23, 24, "Test_items", 17, 19, "Disease", "Test_items_Disease"], [59, 63, "Test_items", 54, 58, "Disease", "Test_items_Disease"], [89, 93, "Test_items", 77, 80, "Disease", "Test_items_Disease"], [113, 114, "Test_items", 77, 80, "Disease", "Test_items_Disease"], [134, 135, "Test_items", 77, 80, "Disease", "Test_items_Disease"], [89, 93, "Test_items", 83, 85, "Disease", "Test_items_Disease"], [113, 114, "Test_items", 83, 85, "Disease", "Test_items_Disease"], [134, 135, "Test_items", 83, 85, "Disease", "Test_items_Disease"], [166, 170, "Test_items", 152, 154, "Disease", "Test_items_Disease"], [157, 163, "Pathogenesis", 152, 154, "Disease", "Pathogenesis_Disease"], [192, 197, "Test_items", 182, 186, "Disease", "Test_items_Disease"], [200, 201, "Test_items", 182, 186, "Disease", "Test_items_Disease"]]}
{"idx": 2993, "sentence": "应监测空腹及餐后血糖以更好地了解血糖控制情况。", "ner": [[3, 9, "Test_items"], [16, 17, "Test_items"]], "rel": []}
{"idx": 2994, "sentence": "3.口服降糖药的选择：口服降糖药作为临床最常用的降糖手段，对于T2DM合并CKD患者的血糖控制具有重要意义。", "ner": [[2, 3, "Method"], [11, 12, "Method"], [31, 34, "Disease"], [37, 39, "Disease"], [43, 44, "Test_items"]], "rel": [[43, 44, "Test_items", 31, 34, "Disease", "Test_items_Disease"], [43, 44, "Test_items", 37, 39, "Disease", "Test_items_Disease"]]}
{"idx": 2995, "sentence": "但口服降糖药种类繁多，各类药物的药代动力学差异显著，某些CKD患者对经肾排泄药物或其活性代谢产物的清除减少，因而伴随着不同程度的低血糖风险。", "ner": [[1, 2, "Method"], [28, 30, "Disease"], [64, 66, "ADE"]], "rel": []}
{"idx": 2996, "sentence": "因此，必须充分了解各种药物的药代动力学特点，结合患者肾功能情况进行个体化选择，确保在有效降糖的同时不增加低血糖风险。", "ner": [[52, 54, "ADE"]], "rel": []}
{"idx": 2997, "sentence": "对于大多数药物，当GFR低于60ml/(min·1.73m2)时需酌情减量或停药。", "ner": [[9, 11, "Test_items"], [12, 30, "Test_Value"]], "rel": []}
{"idx": 2998, "sentence": "常用口服降糖药的药代动力学特征及其在T2DM合并CKD人群中应用的临床证据以及适用人群见图1及表3。", "ner": [[2, 3, "Method"], [18, 21, "Disease"], [24, 26, "Disease"]], "rel": []}
{"idx": 2999, "sentence": "(1)双胍类：目前，国内外指南均一致推荐二甲双胍作为T2DM控制血糖的一线用药，其主要药理作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖。二甲双胍可使HbA1c降低1%~2%，并可减轻体重且不增加低血糖风险。英国前瞻性糖尿病研究(UKPDS)显示，二甲双胍可降低肥胖T2DM患者心血管事件和死亡风险。二甲双胍直接以原形经肾脏排泄，当肾功能损害时易发生二甲双胍与乳酸在体内蓄积，从而增加乳酸性酸中毒风险。二甲双胍用于CKD3a期患者时减量，当GFR<45ml/(min·1.73m2)停用。", "ner": [[3, 5, "Drug"], [20, 23, "Drug"], [26, 29, "Disease"], [32, 33, "Test_items"], [69, 70, "Test_items"], [72, 75, "Drug"], [78, 82, "Test_items"], [83, 89, "Test_Value"], [101, 103, "ADE"], [112, 114, "Disease"], [127, 130, "Drug"], [134, 135, "Disease"], [136, 139, "Disease"], [142, 146, "Disease"], [142, 144, "Anatomy"], [153, 156, "Drug"], [169, 173, "Disease"], [169, 169, "Anatomy"], [178, 181, "Drug"], [195, 200, "ADE"], [204, 207, "Drug"], [210, 215, "Disease"], [223, 225, "Test_items"], [226, 243, "Test_Value"]], "rel": [[20, 23, "Drug", 26, 29, "Disease", "Drug_Disease"], [32, 33, "Test_items", 26, 29, "Disease", "Test_items_Disease"], [69, 70, "Test_items", 26, 29, "Disease", "Test_items_Disease"], [101, 103, "ADE", 72, 75, "Drug", "ADE_Drug"], [127, 130, "Drug", 134, 135, "Disease", "Drug_Disease"], [127, 130, "Drug", 136, 139, "Disease", "Drug_Disease"], [127, 130, "Drug", 142, 146, "Disease", "Drug_Disease"], [142, 144, "Anatomy", 142, 146, "Disease", "Anatomy_Disease"], [153, 156, "Drug", 169, 173, "Disease", "Drug_Disease"], [195, 200, "ADE", 153, 156, "Drug", "ADE_Drug"], [169, 169, "Anatomy", 169, 173, "Disease", "Anatomy_Disease"], [178, 181, "Drug", 169, 173, "Disease", "Drug_Disease"], [204, 207, "Drug", 210, 215, "Disease", "Drug_Disease"], [223, 225, "Test_items", 210, 215, "Disease", "Test_items_Disease"]]}
{"idx": 3000, "sentence": "(2)磺脲类：为胰岛素促泌剂，主要药理作用是通过刺激胰岛β细胞释放胰岛素，增加体内的胰岛素水平而降低血糖。磺脲类药物可降低HbA1c1%~2%，是目前国内外指南中推荐的控制T2DM患者高血糖的主要用药。", "ner": [[3, 5, "Drug"], [8, 13, "Drug"], [50, 51, "Test_items"], [53, 57, "Drug"], [61, 65, "Test_items"], [86, 89, "Disease"], [92, 94, "Disease"]], "rel": [[53, 57, "Drug", 86, 89, "Disease", "Drug_Disease"], [53, 57, "Drug", 92, 94, "Disease", "Drug_Disease"], [61, 65, "Test_items", 86, 89, "Disease", "Test_items_Disease"], [61, 65, "Test_items", 92, 94, "Disease", "Test_items_Disease"]]}
{"idx": 3001, "sentence": "第一代磺脲类药物(如氯磺丙脲、妥拉磺脲、甲苯磺丁脲)的药物原型及其活性代谢产物主要依赖肾脏排泄，在CKD患者应用时半衰期延长，低血糖风险明显增加，因此禁用于该类患者，目前此类药物在临床上已基本被淘汰。在第二代磺脲类药物中，格列本脲的半衰期较长，其活性代谢产物约50%经肾脏排泄，可在CKD患者体内积聚，可能引起严重的低血糖，且持续时间超过24h。格列本脲仅可用于CKD1~2期的患者；3~5期禁用。", "ner": [[0, 7, "Drug"], [10, 13, "Drug"], [15, 18, "Drug"], [20, 24, "Drug"], [49, 51, "Disease"], [63, 65, "ADE"], [101, 108, "Drug"], [111, 114, "Drug"], [155, 160, "ADE"], [173, 176, "Drug"], [181, 187, "Disease"], [141, 143, "Disease"]], "rel": [[0, 7, "Drug", 49, 51, "Disease", "Drug_Disease"], [63, 65, "ADE", 0, 7, "Drug", "ADE_Drug"], [10, 13, "Drug", 49, 51, "Disease", "Drug_Disease"], [63, 65, "ADE", 10, 13, "Drug", "ADE_Drug"], [15, 18, "Drug", 49, 51, "Disease", "Drug_Disease"], [63, 65, "ADE", 15, 18, "Drug", "ADE_Drug"], [20, 24, "Drug", 49, 51, "Disease", "Drug_Disease"], [63, 65, "ADE", 20, 24, "Drug", "ADE_Drug"], [101, 108, "Drug", 141, 143, "Disease", "Drug_Disease"], [155, 160, "ADE", 101, 108, "Drug", "ADE_Drug"], [111, 114, "Drug", 141, 143, "Disease", "Drug_Disease"], [155, 160, "ADE", 111, 114, "Drug", "ADE_Drug"], [173, 176, "Drug", 181, 187, "Disease", "Drug_Disease"]]}
{"idx": 3002, "sentence": "格列美脲的代谢产物仍有降糖活性，其代谢产物及原型的60%经肾脏排泄。格列美脲用于CKD1~2期患者无需调整剂量；3a期减量；3b~5期禁用。", "ner": [[0, 3, "Drug"], [34, 37, "Drug"], [40, 46, "Disease"]], "rel": [[34, 37, "Drug", 40, 46, "Disease", "Drug_Disease"]]}
{"idx": 3003, "sentence": "格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于格列本脲和格列美脲。格列吡嗪用于CKD1~2期患者无需调整剂量；3期减量，4~5期禁用。格列齐特用于CKD1~2期患者无需调整剂量；在3a期减量，3b期用药经验有限，需谨慎用药；4~5期禁用。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [32, 34, "ADE"], [39, 42, "Drug"], [44, 47, "Drug"], [49, 52, "Drug"], [55, 61, "Disease"], [89, 95, "Disease"], [83, 86, "Drug"]], "rel": [[32, 34, "ADE", 0, 3, "Drug", "ADE_Drug"], [32, 34, "ADE", 5, 8, "Drug", "ADE_Drug"], [32, 34, "ADE", 39, 42, "Drug", "ADE_Drug"], [32, 34, "ADE", 44, 47, "Drug", "ADE_Drug"], [49, 52, "Drug", 55, 61, "Disease", "Drug_Disease"], [83, 86, "Drug", 89, 95, "Disease", "Drug_Disease"]]}
{"idx": 3004, "sentence": "格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5%经肾脏排泄，受肾功能影响较小，但用于CKD患者的临床证据有限，格列喹酮曾用于GFR10~50ml/(min·1.73m2)患者，但试验设计不尽完善。格列喹酮可用于CKD1~3期的患者且无需调整剂量；4期用药经验有限，需谨慎用药；5期禁用。", "ner": [[0, 3, "Drug"], [45, 47, "Disease"], [58, 61, "Drug"], [65, 67, "Test_items"], [68, 87, "Test_Value"], [101, 104, "Drug"], [108, 114, "Disease"]], "rel": [[0, 3, "Drug", 45, 47, "Disease", "Drug_Disease"], [58, 61, "Drug", 45, 47, "Disease", "Drug_Disease"], [65, 67, "Test_items", 45, 47, "Disease", "Test_items_Disease"], [101, 104, "Drug", 108, 114, "Disease", "Drug_Disease"]]}
{"idx": 3005, "sentence": "(3)格列奈类：格列奈类降糖药为非磺脲类胰岛素促泌剂，主要通过刺激早相胰岛素分泌而降低餐后血糖，具有吸收快、起效快和作用时间短的特点，可降低HbA1c0.5%~2.0%，其低血糖的风险和程度较磺脲类药物轻。格列奈类主要代表药物为那格列奈和瑞格列奈。那格列奈及其代谢产物83%经肾脏排泄，随着肾功能的降低，那格列奈的活性代谢产物水平增加，而瑞格列奈却未发现此现象。瑞格列奈及其代谢产物仅8%经肾脏排泄。瑞格列奈Ⅰ期临床试验表明，使用瑞格列奈7d后，肾功能正常患者与不同程度CKD患者相比，血药浓度没有明显差别，提示瑞格列奈在CKD患者体内无蓄积。一项入选281例伴或不伴肾功能不全T2DM患者的多中心研究提示，使用瑞格列奈替换原有降糖治疗，不同程度肾功能不全亚组患者(正常、轻、中、重、极重肾功能损害)低血糖发生率均低于2%，且瑞格列奈治疗期低血糖发生率与肾功能损害程度无关。瑞格列奈用于CKD1~5期的患者无需调整剂量；如起始用药，应0.5mg起始。那格列奈用于CKD1~3a期患者时，无需调整剂量；3b~4期减量；5期禁用。", "ner": [[3, 6, "Drug"], [8, 14, "Drug"], [16, 25, "Drug"], [43, 46, "Test_items"], [70, 74, "Test_items"], [75, 83, "Test_Value"], [86, 88, "ADE"], [96, 100, "Drug"], [103, 106, "Drug"], [114, 117, "Drug"], [119, 122, "Drug"], [124, 127, "Drug"], [152, 155, "Drug"], [169, 172, "Drug"], [181, 184, "Drug"], [200, 203, "Drug"], [215, 218, "Drug"], [235, 237, "Disease"], [256, 259, "Drug"], [261, 263, "Disease"], [284, 288, "Disease"], [284, 284, "Anatomy"], [289, 292, "Disease"], [306, 309, "Drug"], [323, 327, "Disease"], [323, 323, "Anatomy"], [333, 348, "Disease"], [333, 343, "Level"], [344, 344, "Anatomy"], [350, 352, "ADE"], [363, 366, "Drug"], [370, 372, "ADE"], [377, 381, "Disease"], [377, 377, "Anatomy"], [387, 390, "Drug"], [393, 399, "Disease"], [417, 421, "Amount"], [425, 428, "Drug"], [431, 438, "Disease"]], "rel": [[86, 88, "ADE", 3, 6, "Drug", "ADE_Drug"], [86, 88, "ADE", 8, 14, "Drug", "ADE_Drug"], [86, 88, "ADE", 16, 25, "Drug", "ADE_Drug"], [86, 88, "ADE", 96, 100, "Drug", "ADE_Drug"], [215, 218, "Drug", 235, 237, "Disease", "Drug_Disease"], [256, 259, "Drug", 261, 263, "Disease", "Drug_Disease"], [306, 309, "Drug", 284, 288, "Disease", "Drug_Disease"], [284, 284, "Anatomy", 284, 288, "Disease", "Anatomy_Disease"], [306, 309, "Drug", 289, 292, "Disease", "Drug_Disease"], [306, 309, "Drug", 333, 348, "Disease", "Drug_Disease"], [306, 309, "Drug", 323, 327, "Disease", "Drug_Disease"], [350, 352, "ADE", 306, 309, "Drug", "ADE_Drug"], [323, 323, "Anatomy", 323, 327, "Disease", "Anatomy_Disease"], [344, 344, "Anatomy", 333, 348, "Disease", "Anatomy_Disease"], [370, 372, "ADE", 363, 366, "Drug", "ADE_Drug"], [363, 366, "Drug", 377, 381, "Disease", "Drug_Disease"], [377, 377, "Anatomy", 377, 381, "Disease", "Anatomy_Disease"], [387, 390, "Drug", 393, 399, "Disease", "Drug_Disease"], [417, 421, "Amount", 387, 390, "Drug", "Amount_Drug"], [425, 428, "Drug", 431, 438, "Disease", "Drug_Disease"]]}
{"idx": 3006, "sentence": "(4)噻唑烷二酮类：噻唑烷二酮类为胰岛素增敏剂，主要通过增加靶细胞对IS而降低血糖，可降低HbA1c1.0%~1.5%。主要代表药物为吡格列酮和罗格列酮，均经肝脏代谢，不增加低血糖风险。该类药物的常见不良反应是液体潴留，因而对于重度心力衰竭患者应慎用。此外，绝经后妇女服用该类药物发生骨折及骨质疏松的风险增加，因此慎用于潜在骨疾病的患者(如肾性骨营养不良)。吡格列酮用于CKD1~3a期患者时，无需调整剂量；3b~5期患者用药经验有限，需谨慎用药。罗格列酮因增加心血管风险的安全性问题引起了国内外的警惕，目前美国食品药品监督管理局(FDA)已严格限制其使用。", "ner": [[3, 8, "Drug"], [10, 15, "Drug"], [17, 22, "Drug"], [39, 40, "Test_items"], [45, 49, "Test_items"], [50, 58, "Test_Value"], [67, 70, "Drug"], [72, 75, "Drug"], [87, 89, "ADE"], [105, 108, "ADE"], [114, 115, "Level"], [116, 119, "Disease"], [116, 116, "Anatomy"], [142, 143, "ADE"], [145, 148, "ADE"], [170, 176, "Disease"], [172, 172, "Anatomy"], [179, 182, "Drug"], [185, 192, "Disease"], [224, 227, "Drug"], [229, 235, "ADE"]], "rel": [[87, 89, "ADE", 67, 70, "Drug", "ADE_Drug"], [87, 89, "ADE", 72, 75, "Drug", "ADE_Drug"], [116, 116, "Anatomy", 116, 119, "Disease", "Anatomy_Disease"], [172, 172, "Anatomy", 170, 176, "Disease", "Anatomy_Disease"], [179, 182, "Drug", 185, 192, "Disease", "Drug_Disease"], [229, 235, "ADE", 224, 227, "Drug", "ADE_Drug"]]}
{"idx": 3007, "sentence": "(5)α-糖苷酶抑制剂：α-糖苷酶抑制剂通过延缓碳水化合物在小肠上段的吸收而降低餐后血糖，适用于饮食结构以碳水化合物为主且餐后血糖升高的患者，可降低HbA1c0.5%~0.8%，不增加体重且有减轻体重的趋势。主要代表药物有阿卡波糖、伏格列波糖等。阿卡波糖口服后很少部分被吸收，随着肾功能的降低，阿卡波糖及其代谢产物的血药浓度显著增加。阿卡波糖可用于CKD1~3期患者；4~5期禁用。", "ner": [[3, 10, "Drug"], [12, 19, "Drug"], [40, 43, "Test_items"], [61, 64, "Test_items"], [65, 66, "Test_Value"], [74, 78, "Test_items"], [79, 87, "Test_Value"], [111, 114, "Drug"], [116, 120, "Drug"], [123, 126, "Drug"], [127, 128, "Method"], [147, 150, "Drug"], [167, 170, "Drug"], [174, 180, "Disease"]], "rel": [[127, 128, "Method", 123, 126, "Drug", "Method_Drug"], [167, 170, "Drug", 174, 180, "Disease", "Drug_Disease"]]}
{"idx": 3008, "sentence": "伏格列波糖可用于CKD1~3期患者；4~5期禁用。", "ner": [[0, 4, "Drug"], [8, 14, "Disease"]], "rel": [[0, 4, "Drug", 8, 14, "Disease", "Drug_Disease"]]}
{"idx": 3009, "sentence": "(6)二肽基肽酶-4(DPP-4)抑制剂：DPP-4抑制剂通过抑制DPP-4而减少胰升糖素样肽-1(GLP-1)在体内的失活，从而增加体内GLP-1的水平。", "ner": [[3, 19, "Drug"], [21, 28, "Drug"]], "rel": []}
{"idx": 3010, "sentence": "GLP-1以葡萄糖浓度依赖的方式增强胰岛素分泌，抑制胰升血糖素分泌，并能延缓胃排空，通过中枢性食欲抑制来减少进食量。", "ner": [], "rel": []}
{"idx": 3011, "sentence": "这一类降糖药由于上市较晚，缺乏临床用药经验，因此用于合并CKD的患者时应酌情减量。", "ner": [[28, 30, "Disease"]], "rel": []}
{"idx": 3012, "sentence": "DPP-4抑制剂降低HbA1c弱于其他胰岛素促泌剂。", "ner": [[19, 24, "Drug"], [0, 7, "Drug"], [10, 14, "Test_items"], [19, 24, "Drug"]], "rel": []}
{"idx": 3013, "sentence": "目前在国内上市的DPP-4抑制剂为西格列汀、沙格列汀、维格列汀和利格列汀。", "ner": [[32, 35, "Drug"], [27, 30, "Drug"], [22, 25, "Drug"], [17, 20, "Drug"], [8, 15, "Drug"]], "rel": []}
{"idx": 3014, "sentence": "西格列汀用于GFR≥50ml/(min·1.73m2)的CKD患者时无需调整剂量；GFR在30~50ml/(min·1.73m2)时减量至50mg，qd；GFR<30ml/(min·1.73m2)时用药经验有限，减量至25mg，qd。", "ner": [[0, 3, "Drug"], [6, 8, "Test_items"], [9, 26, "Test_Value"], [28, 30, "Disease"], [41, 43, "Test_items"], [45, 64, "Test_Value"], [69, 72, "Amount"], [74, 75, "Frequency"], [114, 115, "Frequency"], [109, 112, "Amount"], [80, 97, "Test_Value"], [77, 79, "Test_items"]], "rel": [[0, 3, "Drug", 28, 30, "Disease", "Drug_Disease"], [74, 75, "Frequency", 0, 3, "Drug", "Frequency_Drug"], [69, 72, "Amount", 0, 3, "Drug", "Amount_Drug"], [109, 112, "Amount", 0, 3, "Drug", "Amount_Drug"], [114, 115, "Frequency", 0, 3, "Drug", "Frequency_Drug"], [6, 8, "Test_items", 28, 30, "Disease", "Test_items_Disease"], [41, 43, "Test_items", 28, 30, "Disease", "Test_items_Disease"], [77, 79, "Test_items", 28, 30, "Disease", "Test_items_Disease"]]}
{"idx": 3015, "sentence": "沙格列汀用于GFR≥50ml/(min·1.73m2)的CKD患者时无需调整剂量，当GFR在30~49ml/(min·1.73m2)时减量；CKD4~5期患者禁用。", "ner": [[0, 3, "Drug"], [6, 8, "Test_items"], [9, 25, "Test_Value"], [28, 30, "Disease"], [42, 44, "Test_items"], [46, 65, "Test_Value"], [70, 72, "Disease"]], "rel": [[0, 3, "Drug", 28, 30, "Disease", "Drug_Disease"], [6, 8, "Test_items", 28, 30, "Disease", "Test_items_Disease"], [42, 44, "Test_items", 28, 30, "Disease", "Test_items_Disease"]]}
{"idx": 3016, "sentence": "维格列汀用于GFR≥50ml/(min·1.73m2)的CKD患者时无需调整剂量，当GFR<50ml/(min·1.73m2)时禁用。", "ner": [[0, 3, "Drug"], [6, 8, "Test_items"], [9, 26, "Test_Value"], [28, 30, "Disease"], [42, 44, "Test_items"], [45, 62, "Test_Value"]], "rel": [[0, 3, "Drug", 28, 30, "Disease", "Drug_Disease"], [6, 8, "Test_items", 28, 30, "Disease", "Test_items_Disease"], [42, 44, "Test_items", 28, 30, "Disease", "Test_items_Disease"]]}
{"idx": 3017, "sentence": "一项为期52周的随机、双盲试验评估了利格列汀的疗效及安全性。受试者为既往接受其他降糖药治疗的T2DM患者，GFR<30ml/(min·1.73m2)，分别给予利格列汀或安慰剂，结果显示与安慰剂组相比，利格列汀降低HbA1c达0.6%，但利格列汀组低血糖发生率高于安慰剂组。", "ner": [[18, 21, "Drug"], [46, 49, "Disease"], [53, 55, "Test_items"], [56, 73, "Test_Value"], [79, 82, "Drug"], [100, 103, "Drug"], [106, 110, "Test_items"], [111, 115, "Test_Value"], [118, 121, "Drug"], [123, 125, "ADE"]], "rel": [[53, 55, "Test_items", 46, 49, "Disease", "Test_items_Disease"], [79, 82, "Drug", 46, 49, "Disease", "Drug_Disease"], [100, 103, "Drug", 46, 49, "Disease", "Drug_Disease"], [106, 110, "Test_items", 46, 49, "Disease", "Test_items_Disease"], [123, 125, "ADE", 118, 121, "Drug", "ADE_Drug"]]}
{"idx": 3018, "sentence": "利格列汀用于CKD1~4期患者时无需调整剂量，5期患者用药经验有限。", "ner": [[0, 3, "Drug"], [6, 12, "Disease"]], "rel": [[0, 3, "Drug", 6, 12, "Disease", "Drug_Disease"]]}
{"idx": 3019, "sentence": "需谨慎用药。", "ner": [], "rel": []}
{"idx": 3020, "sentence": "4.特殊人群的治疗：", "ner": [], "rel": []}
{"idx": 3021, "sentence": "(1)儿童和青少年T2DM合并CKD患者：在儿童和青少年T2DM合并CKD患者中，缺乏对高血糖、高血压和血脂异常治疗的相关数据。但是生活方式的改变(饮食、锻炼、减肥)对减少以上危险因素有益，因此对高血糖的起始干预应从改变生活方式开始。若生活方式干预不能控制血糖，应考虑降糖药治疗。尽管ADA推荐口服降糖药作为儿童和青少年T2DM患者的一线治疗，但其中仅二甲双胍被FDA批准用于10岁以上的儿童，其使用注意事项与成人相同。", "ner": [[9, 12, "Disease"], [15, 17, "Disease"], [28, 31, "Disease"], [34, 36, "Disease"], [44, 46, "Disease"], [48, 50, "Disease"], [52, 55, "Disease"], [66, 72, "Treatment"], [74, 75, "Treatment"], [77, 78, "Treatment"], [80, 81, "Treatment"], [98, 100, "Disease"], [108, 113, "Treatment"], [118, 123, "Treatment"], [128, 129, "Test_items"], [147, 148, "Method"], [160, 163, "Disease"], [176, 179, "Drug"]], "rel": [[66, 72, "Treatment", 98, 100, "Disease", "Treatment_Disease"], [74, 75, "Treatment", 98, 100, "Disease", "Treatment_Disease"], [77, 78, "Treatment", 98, 100, "Disease", "Treatment_Disease"], [80, 81, "Treatment", 98, 100, "Disease", "Treatment_Disease"], [108, 113, "Treatment", 98, 100, "Disease", "Treatment_Disease"], [176, 179, "Drug", 160, 163, "Disease", "Drug_Disease"]]}
{"idx": 3022, "sentence": "(2)老年T2DM合并CKD患者：老年T2DM合并CKD患者通常有多种合并症，尤其是心血管疾病以及认知功能障碍，因此应加强对多种危险因素的管理。", "ner": [[5, 8, "Disease"], [11, 13, "Disease"], [19, 22, "Disease"], [25, 27, "Disease"], [42, 46, "Disease"], [42, 44, "Anatomy"], [49, 54, "Disease"]], "rel": [[42, 44, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"]]}
{"idx": 3023, "sentence": "对该类患者尤其应注意避免低血糖的发生，适当调整降糖目标，并视患者的具体情况而选用口服降糖药；应从小剂量开始逐渐增加剂量并注意观察患者的反应和可能的不良反应。", "ner": [[12, 14, "Disease"], [40, 41, "Method"]], "rel": []}
{"idx": 3024, "sentence": "四、小结", "ner": [], "rel": []}
{"idx": 3025, "sentence": "我国T2DM合并CKD患者是一个数量庞大且不容忽视的人群，患者预后较仅有T2DM或仅有CKD患者更差。在临床实践中，应重视T2DM合并CKD患者口服降糖药的正确选择和规范使用。一旦GFR<60ml/(min·1.73m2)，大多数口服降糖药的药代动力学特征将会改变，低血糖及其他不良反应风险显著增加。遵循指南可使降糖达标率显著升高，低血糖风险显著降低，且入院率和治疗费用均显著下降。因而，对于T2DM合并CKD患者的口服降糖药治疗，尤应重视指南推荐和规范应用。在临床实践中，T2DM合并CKD患者应监测血糖，依据患者的肾功能分期选择合适降糖药并调整剂量，以保证有效控制血糖的同时能够最大程度减少低血糖风险。", "ner": [[2, 5, "Disease"], [8, 10, "Disease"], [36, 39, "Disease"], [43, 45, "Disease"], [67, 69, "Disease"], [61, 64, "Disease"], [72, 73, "Method"], [90, 92, "Test_items"], [93, 110, "Test_Value"], [115, 116, "Method"], [133, 135, "ADE"], [166, 168, "ADE"], [196, 199, "Disease"], [202, 204, "Disease"], [208, 209, "Method"], [237, 240, "Disease"], [243, 245, "Disease"], [251, 252, "Test_items"], [284, 285, "Test_items"], [297, 299, "ADE"]], "rel": [[251, 252, "Test_items", 237, 240, "Disease", "Test_items_Disease"]]}
{"idx": 3026, "sentence": "中国超重/肥胖医学营养治疗专家共识(2016年版) ", "ner": [[2, 3, "Disease"], [5, 6, "Disease"]], "rel": []}
{"idx": 3027, "sentence": "一、背景", "ner": [], "rel": []}
{"idx": 3028, "sentence": "近二十年来，我国超重/肥胖的患病率逐年增长，呈流行态势。中国健康营养调查(China Health and Nutrition Survey，CHNS)的数据显示，从1993年至2009年的17年间，成年人超重/肥胖的患病率从13.4%增加至26.4%，总体呈线性增长；成年人腹型肥胖的患病率从18.6%增长至37.4%，平均年增长1.1%，显著高于超重/肥胖的增长速度。肥胖是糖尿病、心血管疾病及其他代谢性疾病和肿瘤的潜在危险因素。减重治疗包括生活方式(膳食和体育运动)调整、内科药物及外科手术治疗等多种手段。科学合理的营养治疗联合运动干预仍是目前最有效、最安全的基础治疗。近年来，国际上对肥胖/超重的营养管理已经形成了一些共识。然而，以营养和生活方式干预为核心的肥胖/超重管理必须与特定的地域性饮食习惯及社会文化相适应。为更好地发挥医学营养治疗在肥胖防治中的作用，结合国内外发表的诸多证据和专家的集体智慧，特制定本共识，以便使医学减重更加科学、规范和易于实施。", "ner": [[8, 9, "Disease"], [11, 12, "Disease"], [103, 104, "Disease"], [106, 107, "Disease"], [138, 141, "Disease"], [175, 176, "Disease"], [178, 179, "Disease"], [186, 187, "Disease"], [189, 191, "Disease"], [193, 197, "Disease"], [207, 208, "Disease"], [193, 195, "Anatomy"], [217, 220, "Treatment"], [267, 270, "Treatment"], [296, 297, "Disease"], [299, 300, "Disease"], [323, 328, "Treatment"], [333, 334, "Disease"], [336, 337, "Disease"], [375, 376, "Disease"], [417, 418, "Treatment"], [261, 264, "Treatment"], [370, 373, "Treatment"], [223, 237, "Treatment"]], "rel": [[193, 195, "Anatomy", 207, 208, "Disease", "Anatomy_Disease"], [323, 328, "Treatment", 333, 334, "Disease", "Treatment_Disease"], [323, 328, "Treatment", 336, 337, "Disease", "Treatment_Disease"], [370, 373, "Treatment", 375, 376, "Disease", "Treatment_Disease"], [417, 418, "Treatment", 375, 376, "Disease", "Treatment_Disease"]]}
{"idx": 3029, "sentence": "二、证据分级与推荐意见的形成", "ner": [], "rel": []}
{"idx": 3030, "sentence": "在制定本共识的过程中，首先参照世界卫生组织(World Health Organization，WHO)出版的《WHO指南编写手册》和AGREE(Appraisal of Guideline Research and Evaluation) 协作网发表的临床指南编写的方法学原则(表1)，结合中国现况，建立制定本共识的方法学，将2009年更新后的AGREEⅡ协作网推出的指南方法学质量评价标准作为质控标准。", "ner": [], "rel": []}
{"idx": 3031, "sentence": "2015年9月，成立了超重/肥胖医学营养治疗专家共识(2016)(以下简称“共识”)撰写证据方法学小组，负责起草方法学工作方案，并协助编委会进行证据评价的相关工作。", "ner": [[11, 12, "Disease"], [14, 15, "Disease"]], "rel": []}
{"idx": 3032, "sentence": "证据级别与推荐意见分级标准的制定见表2。", "ner": [], "rel": []}
{"idx": 3033, "sentence": "三、共识编写委员会组织机构", "ner": [], "rel": []}
{"idx": 3034, "sentence": "由中国医疗保健国际交流促进会营养与代谢管理分会以及中国医师协会营养医师专业委员会、中国营养学会的67位专家组成了本共识编写委员会。", "ner": [], "rel": []}
{"idx": 3035, "sentence": "所有参与指南编写的人员均基于志愿工作。", "ner": [], "rel": []}
{"idx": 3036, "sentence": "四、目标及愿景 ", "ner": [], "rel": []}
{"idx": 3037, "sentence": "通过“共识”的撰写与发布，期望能提高社会及专业人士对营养干预在代谢性疾病治疗中的重要性认识。", "ner": [[26, 29, "Treatment"]], "rel": []}
{"idx": 3038, "sentence": "并能进一步规范医学营养减重的原则和路径，设立标准化医学营养治疗减重管理工作流程，以便临床营养专业人员及医疗保健人员掌握和使用，更好地为减重者服务。", "ner": [[9, 12, "Treatment"], [27, 32, "Treatment"]], "rel": []}
{"idx": 3039, "sentence": "五、本共识常用名词 ", "ner": [], "rel": []}
{"idx": 3040, "sentence": "1.体质指数(body mass index，BMI)：结合身高和体重用于判断人体超重/肥胖与否和程度的指数，计算公式为体重/身高2(kg/m2)。", "ner": [[41, 42, "Disease"], [44, 45, "Disease"]], "rel": []}
{"idx": 3041, "sentence": "目前我国成人BMI的切点为：18.5≤BMI<24kg/m2为正常体重范围，24≤BMI<28kg/m2为超重，BMI≥28kg/m2为肥胖。", "ner": [[53, 54, "Disease"], [68, 69, "Disease"]], "rel": []}
{"idx": 3042, "sentence": "2.肥胖(obesity)：由于体内脂肪的体积和(或）脂肪细胞数量的增加导致的体重增加，或体脂占体重的百分比异常增高，并在某些局部过多沉积脂肪，通常用BMI进行判定。", "ner": [[2, 12, "Disease"]], "rel": []}
{"idx": 3043, "sentence": "在本共识中，肥胖的主要定义即基于BMI做出，在一些情况下(如代谢综合征) ，也酌情采纳权威国际学术组织(如WHO、美国糖尿病学会等)推荐的相关诊断指标(如腰围，腰臀比)。", "ner": [[6, 7, "Disease"], [59, 61, "Disease"]], "rel": []}
{"idx": 3044, "sentence": " ", "ner": [], "rel": []}
{"idx": 3045, "sentence": "3.超重(overweight)：介于正常和肥胖间的身体状态。", "ner": [[2, 15, "Disease"], [22, 23, "Disease"]], "rel": []}
{"idx": 3046, "sentence": "通常以24≤BMI<28kg/m2作为判断标准。", "ner": [], "rel": []}
{"idx": 3047, "sentence": "4.儿童肥胖(childhood obesity)：WHO推荐以身高标准体重法对儿童肥胖进行判定，同等身高、营养良好的儿童体重为标准体重(100%)，±10%标准体重的范围为正常。", "ner": [[2, 24, "Disease"], [40, 43, "Disease"]], "rel": []}
{"idx": 3048, "sentence": ">I5%为超重，>20%为轻度肥胖，>30%为中度肥胖，>50%为重度肥胖。", "ner": [[5, 6, "Disease"], [15, 16, "Disease"], [25, 26, "Disease"], [35, 36, "Disease"], [13, 14, "Level"], [23, 24, "Level"], [33, 34, "Level"]], "rel": []}
{"idx": 3049, "sentence": "5.限能量平衡膳食(calorie-restricted diet. CRD)：一类在限制能量摄入的同时保证基本营养需求的膳食模式，其宏量营养素的供能比例应符合平衡膳食的要求。", "ner": [[2, 38, "Treatment"]], "rel": []}
{"idx": 3050, "sentence": " ", "ner": [], "rel": []}
{"idx": 3051, "sentence": "6.低能量膳食(low calorie diet.LCD)：一类在满足蛋白质、维生素、矿物质、膳食纤维和水这五大营养素的基础上，适量减少脂肪和碳水化合物的摄取，将正常自由进食的能量减去30%~50%的膳食模式。", "ner": [[2, 28, "Treatment"]], "rel": []}
{"idx": 3052, "sentence": "通常需要在医生监督下进行。", "ner": [], "rel": []}
{"idx": 3053, "sentence": "7.极低能量膳食(very-low calorie diet，VLCD)：通常指每日只摄入400-800kcal(1kcal=4.2kJ)能量，主要来自于蛋白质，而脂肪和碳水化合物的摄入受到严格限制。", "ner": [[2, 35, "Treatment"]], "rel": []}
{"idx": 3054, "sentence": "机体处于饥饿状态，因其能引起瘦体重减少、痛风发生风险增加以及电解质平衡紊乱等不良反应并不作推荐。", "ner": [[20, 21, "Disease"], [30, 36, "ADE"]], "rel": []}
{"idx": 3055, "sentence": "该方法必须在医生严格指导下进行，预防并发症的发生。", "ner": [], "rel": []}
{"idx": 3056, "sentence": "8.高蛋白质膳食(high protein diet，HPD)：高蛋白质膳食是一类每日蛋白质摄入量超过每日总能量的20%或1.5g·kg-1·d-1，但一般不超过每日总能量的30%(或2.0g·kg-1·d-1)的膳食模式。", "ner": [[2, 30, "Treatment"]], "rel": []}
{"idx": 3057, "sentence": "9.轻断食模式(intermittent fasting)：也称间歇式断食，一类采用5+2模式，即1周中5天相对正常进食，其他2天(非连续)则摄取平常的1/4能量(约女性500kcal/d，男性600kcal/d)的膳食模式。", "ner": [[2, 28, "Treatment"], [32, 36, "Treatment"]], "rel": []}
{"idx": 3058, "sentence": "10.血糖指数(glycemic index，GI)：进食恒量的食物(含50g碳水化合物)后，2~3h内的血糖曲线下面积相比空腹时的增幅除以进食50g葡萄糖后的相应增幅。", "ner": [[3, 25, "Test_items"], [53, 59, "Test_items"]], "rel": []}
{"idx": 3059, "sentence": "通常定义GI≤55%为低GI食物，55%~ 70%为中GI食物，CI≥70%为高GI食物。", "ner": [[4, 5, "Test_items"], [6, 9, "Test_Value"], [12, 13, "Test_items"], [27, 28, "Test_items"], [32, 33, "Test_items"], [34, 37, "Test_Value"], [40, 41, "Test_items"]], "rel": []}
{"idx": 3060, "sentence": "总论 ", "ner": [], "rel": []}
{"idx": 3061, "sentence": "一、肥胖的病理生理 ", "ner": [[2, 3, "Disease"]], "rel": []}
{"idx": 3062, "sentence": "众所周知，肥胖的发生常常是由遗传、少动以及摄入过多能量共同导致的结果。从代谢研究角度看则是基于代谢紊乱(metabolic disorders) ，代谢紊乱是肥胖从基因到临床表现的中心环节。肥胖者多存在脂类代谢紊乱，脂肪合成过多，而脂肪水解和脂肪分解氧化无明显异常。血浆甘油三酯、游离脂肪酸和胆固醇一般高于正常水平。应用低能量饮食治疗肥胖症时，血浆酮体增加或酮血症倾向往往低于正常人。", "ner": [[5, 6, "Disease"], [47, 71, "Reason"], [74, 77, "Reason"], [79, 80, "Disease"], [95, 96, "Disease"], [101, 106, "Reason"], [108, 113, "Reason"], [135, 138, "Test_items"], [140, 144, "Test_items"], [146, 148, "Test_items"], [160, 164, "Treatment"], [167, 169, "Disease"], [174, 175, "Test_items"], [179, 181, "Disease"], [14, 15, "Reason"], [17, 18, "Reason"], [21, 26, "Reason"], [151, 156, "Test_Value"]], "rel": [[14, 15, "Reason", 5, 6, "Disease", "Reason_Disease"], [17, 18, "Reason", 5, 6, "Disease", "Reason_Disease"], [21, 26, "Reason", 5, 6, "Disease", "Reason_Disease"], [47, 71, "Reason", 79, 80, "Disease", "Reason_Disease"], [74, 77, "Reason", 79, 80, "Disease", "Reason_Disease"], [108, 113, "Reason", 95, 96, "Disease", "Reason_Disease"], [101, 106, "Reason", 95, 96, "Disease", "Reason_Disease"], [160, 164, "Treatment", 167, 169, "Disease", "Treatment_Disease"], [174, 175, "Test_items", 179, 181, "Disease", "Test_items_Disease"]]}
{"idx": 3063, "sentence": "随着基因组学研究的快速进展，人们发现在基因多态性上的差异，使得在各年龄层次的人群都有对肥胖更易感者。", "ner": [[43, 44, "Disease"]], "rel": []}
{"idx": 3064, "sentence": "在上述背景下，加之膳食结构变化后肠道菌群结构发生的适应性变化，使得这类具有遗传易感性者对三大宏量营养素(碳水化合物、蛋白质、脂肪)的应答出现显著差异，进面造成肥胖的发生。", "ner": [[79, 80, "Disease"], [9, 29, "Reason"], [37, 41, "Reason"], [44, 73, "Reason"]], "rel": [[9, 29, "Reason", 79, 80, "Disease", "Reason_Disease"], [37, 41, "Reason", 79, 80, "Disease", "Reason_Disease"], [44, 73, "Reason", 79, 80, "Disease", "Reason_Disease"]]}
{"idx": 3065, "sentence": "二、限制能量平衡膳食(calorie restrict dict，CRD) ", "ner": [[2, 36, "Treatment"]], "rel": []}
{"idx": 3066, "sentence": "(一)背景 ", "ner": [], "rel": []}
{"idx": 3067, "sentence": "CRD对于延长寿命、延迟衰老相关疾病的发生具有明确干预作用。", "ner": [[0, 2, "Treatment"]], "rel": []}
{"idx": 3068, "sentence": "CRD目前主要有三种类型：(1)在目标摄入量基础上按一定比例递减(减少30%-50%)；(2)在目标摄入量基础上每日减少500kcal左右：(3)每日供能1000-1500kcal", "ner": [[0, 2, "Treatment"]], "rel": []}
{"idx": 3069, "sentence": "(二)证据", "ner": [], "rel": []}
{"idx": 3070, "sentence": "Huffman等对超重者进行了6个月CRD干预(能量摄入减少25%)，发现与非CRD相比，CRD组的胰岛素敏感性有明显改善，并认为这是降低体重的原因。Yoshimura等对内脏脂肪面积≥100cm2的成人进行12周CRD(CRD目标：25kcal/kg，基线能量摄入约为30kcal/kg)干预后，有效降低了体重、脂肪组织重量、内脏脂肪面积以及动脉粥样硬化的发生风险。", "ner": [[9, 10, "Disease"], [18, 22, "Treatment"], [39, 41, "Treatment"], [45, 47, "Treatment"], [107, 109, "Treatment"], [111, 113, "Treatment"], [172, 177, "Disease"], [172, 173, "Anatomy"]], "rel": [[18, 22, "Treatment", 9, 10, "Disease", "Treatment_Disease"], [172, 173, "Anatomy", 172, 177, "Disease", "Anatomy_Disease"]]}
{"idx": 3071, "sentence": "1.脂肪：多项研究证实CRD的脂肪供能比例应与正常膳食(20%~30%)一致，过低或过高都会导致膳食模式的不平衡。在CRD中补充海鱼或鱼油制剂的研究均报道n-3多不饱和脂肪酸(polyunsaturated fatty acids，n-3PUFA)对肥胖者动脉弹性、收缩压、心率、血甘油三酯及炎症指标等均有明显改善，可增强CRD的减重效果。", "ner": [[11, 13, "Treatment"], [58, 60, "Treatment"], [125, 126, "Disease"], [133, 135, "Test_items"], [137, 138, "Test_items"], [140, 144, "Test_items"], [161, 163, "Treatment"]], "rel": [[58, 60, "Treatment", 125, 126, "Disease", "Treatment_Disease"], [133, 135, "Test_items", 125, 126, "Disease", "Test_items_Disease"], [137, 138, "Test_items", 125, 126, "Disease", "Test_items_Disease"], [140, 144, "Test_items", 125, 126, "Disease", "Test_items_Disease"]]}
{"idx": 3072, "sentence": "2.蛋白质：由于CRD降低了摄入的总能量，必然导致产热的宏量营养素摄入降低，应适当提高蛋白质供给量比例(1.2~1.5g/kg，或15%~20%)，这样就能在减重过程中维持氮平衡，同时具有降低心血管疾病风险、增加骨矿物质含量等作用。", "ner": [[8, 10, "Treatment"], [96, 100, "Disease"], [96, 98, "Anatomy"]], "rel": [[96, 98, "Anatomy", 96, 100, "Disease", "Anatomy_Disease"]]}
{"idx": 3073, "sentence": "不同来源蛋白质的减重效果可能不同，有研究发现大豆蛋白的减脂作用优于酪蛋白，且其降低血液中总胆固醇和低密度脂蛋白胆固醇的作用也更明显。", "ner": [[44, 47, "Test_items"], [49, 57, "Test_items"]], "rel": []}
{"idx": 3074, "sentence": "3.碳水化合物：根据蛋白质、脂肪的摄入量来确定碳水化合物的供给量(40%~55%)。", "ner": [], "rel": []}
{"idx": 3075, "sentence": "过高或过低都将导致膳食模式不平衡。", "ner": [], "rel": []}
{"idx": 3076, "sentence": "碳水化合物的来源应参照《中国居民膳食指南》，以淀粉类复杂碳水化合物为主，保证膳食纤维的摄入量25~30g/d。", "ner": [], "rel": []}
{"idx": 3077, "sentence": "严格限制简单糖(单糖、双糖)食物或饮料的摄入", "ner": [], "rel": []}
{"idx": 3078, "sentence": "4.微量营养素：肥胖与某些微量营养素的代谢异常相关，尤其是钙、铁、锌、维生素A、维生素D及叶酸的缺乏。", "ner": [[8, 9, "Disease"], [13, 22, "Pathogenesis"], [40, 49, "Reason"]], "rel": [[13, 22, "Pathogenesis", 8, 9, "Disease", "Pathogenesis_Disease"], [40, 49, "Reason", 8, 9, "Disease", "Reason_Disease"]]}
{"idx": 3079, "sentence": "肥胖和膳食减重也可引起骨量丢失。", "ner": [[0, 1, "Disease"]], "rel": []}
{"idx": 3080, "sentence": "一项Meta分析显示肥胖群体患维生素D缺乏的风险比正常人群高35%，比超重人群高24%。", "ner": [[10, 11, "Disease"], [35, 36, "Disease"]], "rel": []}
{"idx": 3081, "sentence": "在减重干预的同时补充维生素D和钙可以增强减重效果。", "ner": [[1, 4, "Treatment"], [8, 15, "Treatment"]], "rel": []}
{"idx": 3082, "sentence": "CRD除能量摄入限制之外，也对营养均衡提出推荐。", "ner": [[0, 2, "Treatment"]], "rel": []}
{"idx": 3083, "sentence": "近年研究认为采用营养代餐方法能兼顾体重减轻和营养均衡。Wadden等对Look AHEAD研究(纳入5145例肥胖合并糖尿病的患者)进行了后续分析，该后续分析考察了接受食支持和教育以及强化生活方式干预的减重情况。", "ner": [[55, 56, "Disease"], [59, 61, "Disease"], [94, 99, "Treatment"], [8, 11, "Treatment"], [82, 89, "Treatment"]], "rel": [[94, 99, "Treatment", 55, 56, "Disease", "Treatment_Disease"], [82, 89, "Treatment", 55, 56, "Disease", "Treatment_Disease"], [94, 99, "Treatment", 59, 61, "Disease", "Treatment_Disease"], [82, 89, "Treatment", 59, 61, "Disease", "Treatment_Disease"]]}
{"idx": 3084, "sentence": "强化生活方式干预，在对患者进行均衡营养模式教育的同时也给以营养代餐作为一种支持措施。", "ner": [[2, 7, "Treatment"], [15, 22, "Treatment"], [29, 32, "Treatment"]], "rel": []}
{"idx": 3085, "sentence": "总的来说，配合营养代餐的强化生活方式干预比单纯的膳食支持和教育能更有效地降低患者的体重(强化生活方式干预组中37.7%的惠者在干预第一年结束时达到了减重10%的目标，而膳食支持和教育组只有3.3%的患者达到此目标)。", "ner": [[7, 10, "Treatment"], [14, 19, "Treatment"], [24, 30, "Treatment"], [46, 51, "Treatment"], [84, 90, "Treatment"]], "rel": []}
{"idx": 3086, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3087, "sentence": "三、高蛋白膳食模式 ", "ner": [[2, 8, "Treatment"]], "rel": []}
{"idx": 3088, "sentence": "(一)背景", "ner": [], "rel": []}
{"idx": 3089, "sentence": "高蛋白膳食中，蛋白质的供给量一般为占供热比的20%以上，或至少在1.5g/kg体重以上。", "ner": [[0, 4, "Treatment"]], "rel": []}
{"idx": 3090, "sentence": "(二)证据 ", "ner": [], "rel": []}
{"idx": 3091, "sentence": "研究表明，接受高蛋白膳食6个月的肥胖者比接受正常蛋白质饮食者体重下降更明显，1年随诊后高蛋白膳食仍较对照组多降低了10%腹部脂肪。Noakes等证实，采用高蛋白膳食比高碳水化合物膳食的肥胖人群体重下降更多(6.4kg比3.4kg，P=0.035)。当受试者每日允许能量摄入为20kcal/kg时，其蛋白质占总能量的30%，碳水化合物占45%，脂肪占25%，同时补充维生素和钾，12周后体重明显减轻(4.72±4.09)kg，BMI、腰围和腰臀比(WHR)也分别下降(1.87±1.57)kg/m2、(3.73±2.91)cm和(0.017±0.029)。Layman等将健康成年肥胖个体随机分为高蛋白低碳水化合物组(PRO组)和低蛋白高碳水化合物饮食组(CHO组)，4个月后，两组体重减少量虽无明显差别，但是PRO组的机体脂肪(体脂)含量减少更明显；相对于CHO组，PRO组对肥胖者血清中的甘油三酯、高密度脂蛋白胆固醇的改善更明显，并且依从性更高。一项为期2年的实验比较了高蛋白和高碳水化合物饮食在糖尿病超重者的减重效果，结果提示高蛋白膳食可能对存在糖尿病、心血管疾病和代谢综合征风险的患者有帮助。113例中度肥胖患者经过4周的极低能量饮食的减重治疗后，体重降低了5%~10%，而随后6个月采用高蛋白膳食(18%)及正常蛋白饮食(15%)进行体重维持，结果显示高蛋白膳食体重反弹率更低。", "ner": [[16, 17, "Disease"], [7, 11, "Treatment"], [43, 47, "Treatment"], [77, 81, "Treatment"], [92, 93, "Disease"], [289, 290, "Disease"], [388, 389, "Disease"], [395, 398, "Test_items"], [400, 408, "Test_items"], [449, 451, "Disease"], [452, 453, "Disease"], [465, 469, "Treatment"], [475, 477, "Disease"], [479, 483, "Disease"], [485, 489, "Disease"], [479, 481, "Anatomy"], [505, 506, "Disease"], [514, 519, "Treatment"], [547, 551, "Treatment"], [558, 563, "Treatment"], [580, 584, "Treatment"], [83, 90, "Treatment"], [180, 186, "Treatment"]], "rel": [[7, 11, "Treatment", 16, 17, "Disease", "Treatment_Disease"], [77, 81, "Treatment", 92, 93, "Disease", "Treatment_Disease"], [395, 398, "Test_items", 388, 389, "Disease", "Test_items_Disease"], [400, 408, "Test_items", 388, 389, "Disease", "Test_items_Disease"], [465, 469, "Treatment", 475, 477, "Disease", "Treatment_Disease"], [465, 469, "Treatment", 479, 483, "Disease", "Treatment_Disease"], [465, 469, "Treatment", 485, 489, "Disease", "Treatment_Disease"], [479, 481, "Anatomy", 479, 483, "Disease", "Anatomy_Disease"], [514, 519, "Treatment", 505, 506, "Disease", "Treatment_Disease"], [547, 551, "Treatment", 505, 506, "Disease", "Treatment_Disease"], [558, 563, "Treatment", 505, 506, "Disease", "Treatment_Disease"]]}
{"idx": 3092, "sentence": "由于慢性肾病患者可能因高蛋白饮食而增加肾脏血流负荷，建议合并慢性肾病患者应慎重选择高蛋白饮食。", "ner": [[2, 5, "Disease"], [4, 4, "Anatomy"], [11, 15, "Treatment"], [30, 33, "Disease"], [32, 32, "Anatomy"], [41, 45, "Treatment"]], "rel": [[4, 4, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [11, 15, "Treatment", 2, 5, "Disease", "Treatment_Disease"], [32, 32, "Anatomy", 30, 33, "Disease", "Anatomy_Disease"]]}
{"idx": 3093, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3094, "sentence": "具体推荐见表4。", "ner": [], "rel": []}
{"idx": 3095, "sentence": "四、轻断食膳食模式", "ner": [[2, 8, "Treatment"]], "rel": []}
{"idx": 3096, "sentence": "(一)背景", "ner": [], "rel": []}
{"idx": 3097, "sentence": "轻断食模式也称间歇式断食(intermittent fasting)5：2模式，即1周内5d正常进食，其他2d(非连续)则摄取平常的1/4能量(女性约500kcal/d，男性600kcal/d)的饮食模式。", "ner": [[0, 4, "Treatment"], [7, 33, "Treatment"]], "rel": []}
{"idx": 3098, "sentence": " ", "ner": [], "rel": []}
{"idx": 3099, "sentence": "(二）证据", "ner": [], "rel": []}
{"idx": 3100, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3101, "sentence": "具体推荐见表5。", "ner": [], "rel": []}
{"idx": 3102, "sentence": "五、运动治疗", "ner": [[2, 5, "Treatment"]], "rel": []}
{"idx": 3103, "sentence": "(一)背景", "ner": [], "rel": []}
{"idx": 3104, "sentence": "运动对减肥的影响取决于运动方式、强度、时间、频率和总量。", "ner": [], "rel": []}
{"idx": 3105, "sentence": "2013年美国关于成年人肥胖管理指南推荐，增加有氧运动(如快走)至每周150min以上(每天30min以上，每周的大多数天)；推荐更高水平的身体活动(每周200-300min)，以维持体重下降及防止减重后的体重反弹(长期，1年以上)", "ner": [[12, 13, "Disease"], [21, 31, "Treatment"], [70, 87, "Treatment"]], "rel": [[21, 31, "Treatment", 12, 13, "Disease", "Treatment_Disease"], [70, 87, "Treatment", 12, 13, "Disease", "Treatment_Disease"]]}
{"idx": 3106, "sentence": "(二)证据", "ner": [], "rel": []}
{"idx": 3107, "sentence": "1.运动与成年人减肥：一项纳入35个随机对照试验的Meta分析发现，有氧运动对降低内脏脂肪有显著效果(干预时间4周~2年，每次运动20~75min)，而渐进性抗阻运动和有氧结合抗阻运动均无显著效果，建议有氧运动作为降低内脏脂肪的核心运动。", "ner": [[34, 37, "Treatment"], [76, 82, "Treatment"], [84, 91, "Treatment"], [101, 104, "Treatment"]], "rel": []}
{"idx": 3108, "sentence": "另一项Meta分析纳人了741例受试者，其BMI在27.8~33.8kg/m2，运动干预时间为2.5~6.0个月，结果显示有氧运动的减肥效果更明显：抗阻运动对提高瘦体重更有效，与抗阻运动比较，有氧结合抗阻减肥效果更明显。", "ner": [[40, 43, "Treatment"], [61, 64, "Treatment"], [74, 77, "Treatment"], [89, 92, "Treatment"], [96, 101, "Treatment"]], "rel": []}
{"idx": 3109, "sentence": "在一项单中心、平行随机对照试验中，比较了4种不同的运动量和运动强度，结果显示与对照组相比，各运动组体重和腰围均显著减少，各组间差异无统计学意义。", "ner": [], "rel": []}
{"idx": 3110, "sentence": "这项研究表明不同运动量和运动强度对腹型肥胖可能均具有减肥效果。", "ner": [[17, 20, "Disease"]], "rel": []}
{"idx": 3111, "sentence": "2.运动结合营养干预与减重：一项纳入了3521名受试者的Mela分析，干预时间12-72个月，营养干预方式为降低能量摄入，主要为低脂(≤总能量的30%)、低饱和脂肪酸、增加水果蔬菜和膳食纤维的摄入。", "ner": [[2, 9, "Treatment"], [47, 50, "Treatment"]], "rel": []}
{"idx": 3112, "sentence": "运动干预主要是在监督下进行有氧运动和抗阻训练，强度为50%~85%最大心率。", "ner": [[0, 3, "Treatment"], [13, 16, "Treatment"], [18, 21, "Treatment"]], "rel": []}
{"idx": 3113, "sentence": "结果发现与单纯饮食组或运动组相比，饮食结合运动的减重效果更加显著，同时可以看到在改善人体测量指标方面，营养干预优于运动治疗。", "ner": [[51, 54, "Treatment"], [57, 60, "Treatment"]], "rel": []}
{"idx": 3114, "sentence": "Stephens等在2014年对60项Meta分析和23个系统性综述进行了再评价，认为多种干预措施都可以帮助受试者达到减重目标，但其中营养干预研究得出的结论较为一致，即对于减重效果最为明确。", "ner": [[67, 70, "Treatment"]], "rel": []}
{"idx": 3115, "sentence": "而运动干预研究在不同的作者所做的Meta分析中得出的结论则有较大差异。", "ner": [[1, 4, "Treatment"]], "rel": []}
{"idx": 3116, "sentence": "这种结果的异质性与研究者选定的结局评价指标、研究设计存在很大关联。", "ner": [], "rel": []}
{"idx": 3117, "sentence": "3.运动治疗与儿童减肥：一筒纳入了2项Meta分析的系统性综述，均显示体脂率有显著性降低。而其他肥胖指标(BMI、体重、中心性肥胖)则没有显著性差异。一篇纳入40项研究的系统性综述和Meta分析，评价了抗阻训练对肥胖儿童力量、体成分等的影响，显示抗阻运动对体成分有极小影响，且亚组分析显示运动量越大、年龄越小、随机对照设计产生更显著效果。一项纳入15个随机对照试验的系统性综述和Meta分析，比较仅饮食干预与饮食结合运动或仅运动干预对超重儿童减重和降低代谢风险的效果，结果显示，短期干预中仅饮食和饮食结合运动均产生了减重和代谢指标改善的效果，而长期干预显示饮食结合运动干预可以显著改善高密度脂蛋白胆固醇和空腹血糖、空腹胰岛素水平。", "ner": [[2, 5, "Treatment"], [60, 64, "Disease"], [101, 104, "Treatment"], [106, 107, "Disease"], [123, 126, "Treatment"], [199, 202, "Treatment"], [212, 215, "Treatment"], [217, 218, "Disease"], [292, 300, "Test_items"], [302, 305, "Test_items"], [307, 311, "Test_items"], [204, 209, "Treatment"], [278, 285, "Treatment"]], "rel": [[101, 104, "Treatment", 106, 107, "Disease", "Treatment_Disease"], [199, 202, "Treatment", 217, 218, "Disease", "Treatment_Disease"], [212, 215, "Treatment", 217, 218, "Disease", "Treatment_Disease"], [292, 300, "Test_items", 217, 218, "Disease", "Test_items_Disease"], [302, 305, "Test_items", 217, 218, "Disease", "Test_items_Disease"], [307, 311, "Test_items", 217, 218, "Disease", "Test_items_Disease"], [204, 209, "Treatment", 217, 218, "Disease", "Treatment_Disease"]]}
{"idx": 3118, "sentence": "4.运动治疗与孕期体重管理：一项纳人910名产后女性的系统性综述发现，单纯坚持有氧运动(步行)者与对照组相比体重变化没有显著差异。", "ner": [[2, 5, "Treatment"], [35, 46, "Treatment"]], "rel": []}
{"idx": 3119, "sentence": "而饮食干预或饮食结合运动干预者与对照组相比体重显著降低，干预措施对哺乳行为并无消极影响。", "ner": [[1, 4, "Treatment"], [6, 13, "Treatment"]], "rel": []}
{"idx": 3120, "sentence": "另一项合并了11个随机对照试验的Meta分析纳入769名产后女性，干预10-52周，结果显示最有效的减重方式是设定客观目标的运动干预，如心率监测或计步器的使用，表明生活方式干预对产后女性的减重是有益的，运动结合强化饮食干预并设定客观目标是最有效的干预方式。", "ner": [[62, 65, "Treatment"], [82, 87, "Treatment"], [101, 110, "Treatment"]], "rel": []}
{"idx": 3121, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3122, "sentence": "具体推荐见表6。", "ner": [], "rel": []}
{"idx": 3123, "sentence": "六、认知-行为及心理干预 ", "ner": [[2, 11, "Treatment"]], "rel": []}
{"idx": 3124, "sentence": "(一)背景 ", "ner": [], "rel": []}
{"idx": 3125, "sentence": "生活方式干预作为基础治疗，是一种囊括营养、运动、认知-行为及心理多方面的综合干预模式。认知-行为及心理干预是通过调整超重和肥胖患者的生活环境及心理状态，帮助患者理解和认识体重管理、肥胖及其危害，从而做出行为改变。", "ner": [[0, 5, "Treatment"], [43, 52, "Treatment"], [58, 59, "Disease"], [61, 62, "Disease"], [90, 91, "Disease"]], "rel": [[43, 52, "Treatment", 58, 59, "Disease", "Treatment_Disease"], [43, 52, "Treatment", 61, 62, "Disease", "Treatment_Disease"]]}
{"idx": 3126, "sentence": "其中包括自我监控、控制进食、刺激控制、认知重建和放松技巧等。", "ner": [[4, 7, "Treatment"], [9, 12, "Treatment"], [14, 17, "Treatment"], [19, 22, "Treatment"], [24, 27, "Treatment"]], "rel": []}
{"idx": 3127, "sentence": "(二)证据", "ner": [], "rel": []}
{"idx": 3128, "sentence": "1.认知-行为干预：认知-行为干预配合体力活动和饮食调整，能够明显降低体重，且超过6个月的行为干预比低于6个月的效果更明显。", "ner": [[2, 8, "Treatment"], [10, 16, "Treatment"], [19, 22, "Treatment"], [24, 27, "Treatment"], [45, 48, "Treatment"]], "rel": []}
{"idx": 3129, "sentence": "美国女性健康研究发现进行6-54个月的干预后，干预组的体重和腰围较对照组明显下降。", "ner": [], "rel": []}
{"idx": 3130, "sentence": "行为干预对减重后体重的维持也有明显作用。", "ner": [[0, 3, "Treatment"]], "rel": []}
{"idx": 3131, "sentence": "研究证明行为干预提升了患者的理论认识，包括对其激励、支持，指导自我监控(饮食、运动和情绪管理)，从而更有利于保持减重效果。", "ner": [[4, 7, "Treatment"]], "rel": []}
{"idx": 3132, "sentence": "通过小组和面对面个人辅导的干预可以从不同方式进行指导，以维持远期减重效果。", "ner": [], "rel": []}
{"idx": 3133, "sentence": "2.精神-心理支持：肥胖者常见的心理因素如压力、沮丧、抑郁容易导致过度进食，并引发罪恶感面陷人恶性循环中。精神-心理支持中需要医务人员能识别干扰减重管理成功的心理或精神疾患，并请专科医师进行治疗。", "ner": [[2, 8, "Treatment"], [10, 11, "Disease"], [53, 59, "Treatment"]], "rel": [[2, 8, "Treatment", 10, 11, "Disease", "Treatment_Disease"]]}
{"idx": 3134, "sentence": "在医疗活动中，肥胖患者可能会因为各种心理社会原因而拒绝寻求减重帮助。", "ner": [[7, 8, "Disease"]], "rel": []}
{"idx": 3135, "sentence": "应对患者表达充分尊重，仔细倾听并建立信任，通过健康教育提高其对肥胖加重疾病危险性的认识，不应忽略任何细微进步，给予及时、适当的奖励和称赞，这对于肥胖儿童的管理尤其重要。", "ner": [[31, 32, "Disease"], [72, 73, "Disease"], [23, 26, "Treatment"]], "rel": [[23, 26, "Treatment", 31, 32, "Disease", "Treatment_Disease"]]}
{"idx": 3136, "sentence": "(三)推荐意见 ", "ner": [], "rel": []}
{"idx": 3137, "sentence": "具体推荐见表7。", "ner": [], "rel": []}
{"idx": 3138, "sentence": " ", "ner": [], "rel": []}
{"idx": 3139, "sentence": "七、减重治疗后的维持 ", "ner": [[2, 5, "Treatment"]], "rel": []}
{"idx": 3140, "sentence": "(一)背景 ", "ner": [], "rel": []}
{"idx": 3141, "sentence": "治疗后减重的维持非常重要。", "ner": [], "rel": []}
{"idx": 3142, "sentence": "机体存在多种机制调控能量平衡以维持自身体重相对稳定，通常减重计划结束后一年，大部分人会恢复已减掉体重(复重)的30%~35%，4年内基本恢复到减重前水平。发表于新英格兰医学杂志和美国医学会杂志的2项随机对照试验表明，适当的干预措施可在一定程度上延长减重后体重的维持时间。世界胃肠病学会对肥胖管理制定的全球指南(WGO)强调，为了维持减重效果，医务人员和营养医师应向患者提供面对面或电话随访的减重维持计划，保持与患者的规律接触(每月或更加频繁)，帮助其进行高强度体力活动(如200~300min/周)，规律监测体重变化(如每周或更加频繁)，并保持低能量饮食(维持更低体重所必需)。", "ner": [[143, 144, "Disease"], [230, 248, "Treatment"], [272, 276, "Treatment"]], "rel": [[230, 248, "Treatment", 143, 144, "Disease", "Treatment_Disease"], [272, 276, "Treatment", 143, 144, "Disease", "Treatment_Disease"]]}
{"idx": 3143, "sentence": " ", "ner": [], "rel": []}
{"idx": 3144, "sentence": "(二)证据 ", "ner": [], "rel": []}
{"idx": 3145, "sentence": "1.饮食控制和体育锻炼：一篇纳入了从1984年至2007年间42项随机对照试验的系统性综述认为，生活方式和行为干预措施[包括饮食控制和(或)代餐、体育锻炼、保持减重小组间人员交流等]配合一定的药物治疗，对减少减重后复重有效型。Dombrowski等对非手术干预成人肥胖者减重后的长期维持进行了系统回顾和Mela分析，包含45项研究的7788例患者，结果显示包括食物摄取和体力活动在内的行为干预可以使患者较对照组复重减少1.56kg。", "ner": [[2, 5, "Treatment"], [7, 10, "Treatment"], [48, 51, "Treatment"], [53, 56, "Treatment"], [62, 65, "Treatment"], [70, 71, "Treatment"], [73, 76, "Treatment"], [78, 88, "Treatment"], [132, 133, "Disease"], [180, 183, "Treatment"], [185, 188, "Treatment"], [192, 195, "Treatment"]], "rel": [[180, 183, "Treatment", 132, 133, "Disease", "Treatment_Disease"], [185, 188, "Treatment", 132, 133, "Disease", "Treatment_Disease"], [192, 195, "Treatment", 132, 133, "Disease", "Treatment_Disease"]]}
{"idx": 3146, "sentence": "2.心理因素：减重所引起的能量负平衡和能量储备的降低会促使关键中枢和外周调节因素发生改变，从而导致减重者食欲的增加和能量消耗的减少，而导致减重成功后的复重。", "ner": [[2, 5, "Treatment"]], "rel": []}
{"idx": 3147, "sentence": "这种调节作用不会在新的体重稳态形成后消退，这会促使减重成功者在心理和身体诱因的驱动下恢复减掉的体重。", "ner": [], "rel": []}
{"idx": 3148, "sentence": "3.网络干预：随着互联网时代对健康产生的深远影响，越来越多的研究表明网络干预对维持减重(尤其在2年以内)有效。", "ner": [[2, 5, "Treatment"], [34, 37, "Treatment"]], "rel": []}
{"idx": 3149, "sentence": "2项设计良好的大样本随机对照试验结果均显示，在短期随访(24个月内)利用相互帮扶技术干预组的体重回升明显低于自我控制组。", "ner": [], "rel": []}
{"idx": 3150, "sentence": "一个纳入5项研究的Meta分析发现，网络干预与面对面干预效果相同，高网站利用率与减重维持正相关。", "ner": [[18, 21, "Treatment"], [23, 27, "Treatment"]], "rel": []}
{"idx": 3151, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3152, "sentence": "具体推荐见表8。", "ner": [], "rel": []}
{"idx": 3153, "sentence": " ", "ner": [], "rel": []}
{"idx": 3154, "sentence": "分论  ", "ner": [], "rel": []}
{"idx": 3155, "sentence": "一、儿童/青少年肥胖体重管理 ", "ner": [[8, 9, "Disease"]], "rel": []}
{"idx": 3156, "sentence": "(一)背景 ", "ner": [], "rel": []}
{"idx": 3157, "sentence": "儿童期肥胖容易伴随焦虑、自卑等心理问题，同时也是成人肥胖、糖尿病、心血管疾病及其他代谢性疾病和肿病的潜在危险因素。医学营养治疗主要通过培养良好的生活习惯而达到控制体重的目的。", "ner": [[3, 4, "Disease"], [26, 27, "Disease"], [29, 31, "Disease"], [33, 37, "Disease"], [33, 35, "Anatomy"]], "rel": [[33, 35, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"]]}
{"idx": 3158, "sentence": " ", "ner": [], "rel": []}
{"idx": 3159, "sentence": "(二)证据 ", "ner": [], "rel": []}
{"idx": 3160, "sentence": "1.母乳喂养与肥胖：一篇纳入25项研究的Meta分析发现，相对于未母乳喂养过的新生儿，母乳喂养者发生儿童期肥胖的比率降低22%，且母乳喂养时间与肥胖发生率有剂量-效应关系。", "ner": [[7, 8, "Disease"], [53, 54, "Disease"], [72, 73, "Disease"]], "rel": []}
{"idx": 3161, "sentence": "这与配方喂养提供了较高的脂肪和蛋白质，以及缺乏母乳中含有较多的活性物质可能有关。", "ner": [], "rel": []}
{"idx": 3162, "sentence": " ", "ner": [], "rel": []}
{"idx": 3163, "sentence": "2.规律早餐与BMI：横断面研究表明，不爱吃早餐的群体发生超重和肥胖的比例更大。芬兰一项出生队列研究发现，相对于规律进食早餐的青少年，很少吃早餐的群体更容易吸烟、喝酒、咖啡以及含有咖啡因的碳酸饮料，并且很少锻炼，BMI值更高。", "ner": [[29, 30, "Disease"], [32, 33, "Disease"], [2, 5, "Treatment"]], "rel": [[2, 5, "Treatment", 29, 30, "Disease", "Treatment_Disease"], [2, 5, "Treatment", 32, 33, "Disease", "Treatment_Disease"]]}
{"idx": 3164, "sentence": "3.零食摄入与肥胖：一项队列研究表明，高能量零食的摄入频率及进食时间与青少年肥胖有紧密联系。", "ner": [[7, 8, "Disease"], [38, 39, "Disease"]], "rel": []}
{"idx": 3165, "sentence": "每日2次以上零食的青少年其肥胖风险比(risk ratio，RR) 高于很少吃零食的青少年；以在早晨吃高能量零食的青少年为对照组，夜间进食零食的受试者发生肥胖和超重的RR为3.12。", "ner": [[13, 14, "Disease"], [77, 78, "Disease"], [80, 81, "Disease"]], "rel": []}
{"idx": 3166, "sentence": "一项长达19个月的队列研究表明，每天多喝12盎司(ounce，I盎司=28.4ml，12盎司约合340ml)的含糖饮料，将会导致BMI升高0.24kg/m2。", "ner": [], "rel": []}
{"idx": 3167, "sentence": "横断面研究发现，碳酸饮料与儿童期的肥胖有着密切关系，每周多摄入碳酸饮料240ml的青少年发生肥胖的危险增加29%。", "ner": [[17, 18, "Disease"], [46, 47, "Disease"]], "rel": []}
{"idx": 3168, "sentence": " ", "ner": [], "rel": []}
{"idx": 3169, "sentence": "4.碳水化合物与肥胖：一项队列研究表明.青少年女性膳食中血糖指数(glycemic-index)每升高1SD，BMI和腰围分别增加0.77kg/m2和1.45cm；而膳食纤维摄入最每增加1SD，会导致青少年女性BMI值降低0.44kg/m2和青少年男性腰降低1.45cm。", "ner": [[8, 9, "Disease"], [28, 47, "Test_items"]], "rel": [[28, 47, "Test_items", 8, 9, "Disease", "Test_items_Disease"]]}
{"idx": 3170, "sentence": "5.微量营养素摄入与肥胖：研究表明血清维生素B12和叶酸的浓度与青少年BMI值、躯干脂肪面积以及总脂肪面积呈负相关。一项病例对照研究表明，肥胖儿童血清中维生素B12水平为400ng/L，明显低于正常体重的儿童血清中维生素B12的水平(530ng/L)；相对于正常体重儿童，在调整性别和年龄等混杂因素的影响后，肥胖儿童血清中维生素B12偏低的风险比(odds ratio，OR)高达4.33。也有研究发现，肥胖儿童血清中含有更低水平的Zn、Se和Fe，但血清Cu的水平较高；血清Zn的水平和血清中总胆固醇水平有呈明显负相关，而与血清中HDL-C水平正相关。", "ner": [[10, 11, "Disease"], [17, 24, "Test_items"], [26, 27, "Test_items"], [69, 70, "Disease"], [76, 81, "Test_items"], [85, 91, "Test_Value"], [107, 112, "Test_items"], [117, 123, "Test_Value"], [154, 155, "Disease"], [161, 166, "Test_items"], [202, 203, "Disease"], [216, 217, "Test_items"], [219, 220, "Test_items"], [222, 223, "Test_items"], [226, 229, "Test_items"], [236, 239, "Test_items"], [247, 250, "Test_items"], [266, 270, "Test_items"]], "rel": [[17, 24, "Test_items", 10, 11, "Disease", "Test_items_Disease"], [26, 27, "Test_items", 10, 11, "Disease", "Test_items_Disease"], [76, 81, "Test_items", 69, 70, "Disease", "Test_items_Disease"], [161, 166, "Test_items", 154, 155, "Disease", "Test_items_Disease"], [216, 217, "Test_items", 202, 203, "Disease", "Test_items_Disease"], [219, 220, "Test_items", 202, 203, "Disease", "Test_items_Disease"], [222, 223, "Test_items", 202, 203, "Disease", "Test_items_Disease"], [226, 229, "Test_items", 202, 203, "Disease", "Test_items_Disease"]]}
{"idx": 3171, "sentence": "维生素D的水平与儿童肥胖的负相关也得到了进一步的证实。", "ner": [[0, 3, "Test_items"], [10, 11, "Disease"]], "rel": [[0, 3, "Test_items", 10, 11, "Disease", "Test_items_Disease"]]}
{"idx": 3172, "sentence": " ", "ner": [], "rel": []}
{"idx": 3173, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3174, "sentence": "具体推荐见表9。", "ner": [], "rel": []}
{"idx": 3175, "sentence": " ", "ner": [], "rel": []}
{"idx": 3176, "sentence": "二、围孕期体重管理 ", "ner": [], "rel": []}
{"idx": 3177, "sentence": "(一)背景 ", "ner": [], "rel": []}
{"idx": 3178, "sentence": "大量研究显示，母体孕前及孕期的肥胖均与孕期合并症及不良妊娠结局相关，包括妊娠期糖尿病、妊娠高血压、子痫、早产、死胎、巨大儿、过期产、剖宫产、先天畸形等；远期不良影响包括产后母体及子代肥胖，增加母婴罹患2型糖尿病、高血压及其他代谢综合征的风险。", "ner": [[15, 16, "Disease"], [36, 41, "Disease"], [43, 47, "Disease"], [49, 50, "Disease"], [52, 53, "Disease"], [91, 92, "Disease"], [100, 104, "Disease"], [106, 108, "Disease"]], "rel": []}
{"idx": 3179, "sentence": "(二)证据", "ner": [], "rel": []}
{"idx": 3180, "sentence": "1.肥胖与生育能力：一项前瞻性研究发现，超重女性生育能力下降8%，肥胖者下降达18%。", "ner": [[2, 3, "Disease"], [20, 21, "Disease"], [33, 34, "Disease"]], "rel": []}
{"idx": 3181, "sentence": "肥胖不仅影响自然受孕，同样影响辅助生殖的成功，增加自然流产及孕期并发症的风险。", "ner": [[0, 1, "Disease"]], "rel": []}
{"idx": 3182, "sentence": "应强调在辅助生殖实施前进行减重。", "ner": [], "rel": []}
{"idx": 3183, "sentence": "同时也有研究证实减重5%~10%就可以成功减掉30%的内脏脂肪，更有利于排卵发生。", "ner": [], "rel": []}
{"idx": 3184, "sentence": "2.肥胖女性孕期体重：2009年美国医学研究所推荐建议孕早期增重0.5~2.0kg，超重女性孕期增重7.0~11.5kg，肥胖女性孕期增重5.0~9.0kg。", "ner": [[2, 3, "Disease"], [42, 43, "Disease"], [61, 62, "Disease"]], "rel": []}
{"idx": 3185, "sentence": "相对于孕期增重超过7.0kg的肥胖女性，孕期增重低于7.0kg的肥胖女性发生子痫前期、剖宫产及巨大儿的几率明显降低。", "ner": [[32, 33, "Disease"], [38, 39, "Disease"]], "rel": []}
{"idx": 3186, "sentence": "美国一项涉及113019例新生儿研究中，肥胖孕妇过低的体重增加加重孕妇早产的风险。", "ner": [[20, 21, "Disease"], [35, 36, "Disease"]], "rel": []}
{"idx": 3187, "sentence": "3.肥胖女性妊娠期体重管理：在一项1777例妊娠妇女队列研究中，用替代健康饮食指数(the alternative healthy eating index，AHEI)进行膳食评价，发现肥胖孕妇AHEI分数更低。另一项2247例妊娠妇女队列研究也发现，高能量、低营养素含量的食物(如碳酸饮料、果汁饮料、精制面粉)也是过高能量摄入的主要贡献者，同时此类膳食富含饱和脂肪酸。小样本研究显示：当肥胖合并妊娠期糖尿病的孕妇能量限制在1800kcal左右时，孕妇体重能够得到控制且不出现酮症，也能够改善孕妇血糖水平并对新生儿出生体重无不良影响。", "ner": [[2, 3, "Disease"], [93, 94, "Disease"], [194, 195, "Disease"], [198, 203, "Disease"], [238, 239, "Disease"], [248, 249, "Test_items"]], "rel": [[248, 249, "Test_items", 194, 195, "Disease", "Test_items_Disease"], [248, 249, "Test_items", 198, 203, "Disease", "Test_items_Disease"]]}
{"idx": 3188, "sentence": "建议根据肥胖孕妇的身高、体重、年龄、活动水平等因素制定个体化的膳食能量计划。", "ner": [[4, 5, "Disease"]], "rel": []}
{"idx": 3189, "sentence": "相对于BMI正常的孕妇，肥胖孕妇的新生儿神经管畸形发病率更高。", "ner": [[12, 13, "Disease"], [20, 24, "Disease"]], "rel": []}
{"idx": 3190, "sentence": "4.超重/肥胖女性产后体重的恢复：相对于正常BMI的女性，孕期增重过多的肥胖女性产后可能储备更多的体重。", "ner": [[2, 3, "Disease"], [5, 6, "Disease"], [36, 37, "Disease"]], "rel": []}
{"idx": 3191, "sentence": "哺乳期进行膳食及运动干预可以帮助其产后恢复到孕前体重，产后哺乳至少6个月后可以降低产后体重。", "ner": [[5, 11, "Treatment"]], "rel": []}
{"idx": 3192, "sentence": "有研究显示，产后哺乳更有利于体重恢复。", "ner": [], "rel": []}
{"idx": 3193, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3194, "sentence": "具体推荐见表10。", "ner": [], "rel": []}
{"idx": 3195, "sentence": "三、多囊卵巢综合征(polyeystic ovary syndrome，PCOS)的体重管理", "ner": [[2, 40, "Disease"]], "rel": []}
{"idx": 3196, "sentence": "(一)背景", "ner": [], "rel": []}
{"idx": 3197, "sentence": "在我国19~45岁的女性中PCOS的发病率约为5.6%。", "ner": [[13, 16, "Disease"]], "rel": []}
{"idx": 3198, "sentence": "不同国家的研究显示PCOS患者肥胖的发生率在30%~70%。系统性综述表明，与正常体重的PCOS女性相比，肥胖PCOS患者所有代谢和生殖的指标(除多毛症外)，包括性激素结合球蛋白(sex hormone-binding globulin)下降，总睾酮、空腹血糖、空腹胰岛素增加和血脂升高。", "ner": [[9, 12, "Disease"], [15, 16, "Disease"], [44, 47, "Disease"], [53, 54, "Disease"], [55, 58, "Disease"], [73, 75, "Disease"], [81, 118, "Test_items"], [122, 124, "Test_items"], [126, 129, "Test_items"], [131, 135, "Test_items"], [139, 140, "Test_items"]], "rel": [[81, 118, "Test_items", 55, 58, "Disease", "Test_items_Disease"], [122, 124, "Test_items", 55, 58, "Disease", "Test_items_Disease"], [126, 129, "Test_items", 55, 58, "Disease", "Test_items_Disease"], [131, 135, "Test_items", 55, 58, "Disease", "Test_items_Disease"], [139, 140, "Test_items", 55, 58, "Disease", "Test_items_Disease"]]}
{"idx": 3199, "sentence": "(二)证据", "ner": [], "rel": []}
{"idx": 3200, "sentence": "1.生活方式干预与PCOS：临床研究显示，PCOS患者对富含碳水化合物、高血糖指数食物以及高饱和脂肪的食物摄入均显著增加；同时具有总能量摄入过高以及久坐的特点。一项系统性综述表明，对于PCOS患者，在减轻体重、改善胰岛素抵抗及高雄激素血症等方面，生活方式干预(饮食、运动和行为干预)比药物治疗更有效。研究表明，超重或肥胖的PCOS患者轻度体重减轻(减少5%~10%)即可使血清睾酮浓度下降，也可恢复正常的排卵周期，并提高妊娠成功率。因此，对于超重和肥胖的PCOS患者，建议首先进行生活方式干预(饮食和运动)以减轻体重。", "ner": [[2, 7, "Treatment"], [9, 12, "Disease"], [21, 24, "Disease"], [36, 38, "Disease"], [92, 95, "Disease"], [113, 118, "Disease"], [107, 111, "Disease"], [123, 128, "Treatment"], [130, 131, "Treatment"], [133, 134, "Treatment"], [136, 139, "Treatment"], [155, 156, "Disease"], [158, 159, "Disease"], [161, 164, "Disease"], [186, 189, "Test_items"], [221, 222, "Disease"], [224, 225, "Disease"], [227, 230, "Disease"], [240, 245, "Treatment"], [247, 248, "Treatment"], [250, 251, "Treatment"]], "rel": [[2, 7, "Treatment", 9, 12, "Disease", "Treatment_Disease"], [123, 128, "Treatment", 92, 95, "Disease", "Treatment_Disease"], [130, 131, "Treatment", 92, 95, "Disease", "Treatment_Disease"], [133, 134, "Treatment", 92, 95, "Disease", "Treatment_Disease"], [136, 139, "Treatment", 92, 95, "Disease", "Treatment_Disease"], [186, 189, "Test_items", 161, 164, "Disease", "Test_items_Disease"], [240, 245, "Treatment", 227, 230, "Disease", "Treatment_Disease"], [247, 248, "Treatment", 227, 230, "Disease", "Treatment_Disease"], [250, 251, "Treatment", 227, 230, "Disease", "Treatment_Disease"]]}
{"idx": 3201, "sentence": "2.饮食干预与PCOS：(1)限制总能量摄入：超重和肥胖的PCOS患者在减重时应以CRD为首选治疗。随机对照试验表明，CRD可改善肥胖PCOS女性的代谢及激素水平，每日饮食总能量中减少500~1000kcal，即在6~12个月减少7%~10%的原体重。(2)宏量营养素和血糖指数的选择：国内外研究显示，在限制总能量的基础上，高蛋白/低碳水化合物饮食(蛋白质30%、碳水化合物40%、脂肪30%，MHCD)和低蛋白/高碳水化合物饮食(蛋白质15%、碳水化合物55%、脂肪30%，CHCD)相比，均可降低体重和雄激素水平，MHCD明显增加胰岛素敏感性、减轻高胰岛素血症继而减轻胰岛素抵抗；低血糖指数饮食亦可通过降低PCOS患者(无论是否肥胖)胰岛素、睾酮水平，改善多毛和痤疮。", "ner": [[2, 5, "Treatment"], [7, 10, "Disease"], [23, 24, "Disease"], [26, 27, "Disease"], [29, 32, "Disease"], [41, 43, "Treatment"], [59, 61, "Treatment"], [65, 66, "Disease"], [67, 70, "Disease"], [135, 136, "Test_items"], [276, 281, "Disease"], [286, 290, "Disease"], [305, 308, "Disease"], [319, 321, "Test_items"], [323, 324, "Test_items"], [293, 294, "Test_items"], [316, 317, "Disease"]], "rel": [[2, 5, "Treatment", 7, 10, "Disease", "Treatment_Disease"], [41, 43, "Treatment", 29, 32, "Disease", "Treatment_Disease"], [59, 61, "Treatment", 67, 70, "Disease", "Treatment_Disease"], [319, 321, "Test_items", 305, 308, "Disease", "Test_items_Disease"], [323, 324, "Test_items", 305, 308, "Disease", "Test_items_Disease"], [293, 294, "Test_items", 305, 308, "Disease", "Test_items_Disease"]]}
{"idx": 3202, "sentence": "因此，在限制总能量基础上，无论宏量营养素如何配比，均可实现体重减轻及改善临床结局的目的。", "ner": [], "rel": []}
{"idx": 3203, "sentence": "在限制总能量、减轻体重的前提下，宏量营养素比例和质量选择对PCOS患者的生育、代谢、心理的影响存在着细微差别。低碳水化合物或低血糖指数饮食可更明显降低胰岛素抵抗、纤维蛋白原、总胆固醇和高密度脂蛋白胆固醇，低血糖指数饮食明显改善月经周期和生活质量，高蛋白膳食可明显改善抑郁和增强自尊；反之，高碳水化合物饮食明显增加游离睾酮指数。有研究显示，肥胖PCOS患者使用限能量代餐可降低患者BMI，改善代谢及激素指标，增加受孕几率。", "ner": [[29, 32, "Disease"], [62, 68, "Treatment"], [81, 85, "Test_items"], [87, 90, "Test_items"], [92, 100, "Test_items"], [102, 108, "Treatment"], [123, 127, "Treatment"], [156, 161, "Test_items"], [169, 170, "Disease"], [171, 174, "Disease"], [179, 183, "Treatment"], [75, 79, "Pathogenesis"]], "rel": [[179, 183, "Treatment", 171, 174, "Disease", "Treatment_Disease"]]}
{"idx": 3204, "sentence": "3.综合管理：超重/肥胖PCOS的综合管理应包括持续的社会、家庭支持和教育，个体化方案、密切随访、医师监督以及医师、家庭、配偶和同事的支持都会促进体重达标与维持。PCOS患者记录饮食运动日记有利于长期坚持，以减轻体重并维持长期疗效。强化运动管理可降低并维持体重、改善心血管危险因素，且可改善排卵及胰岛素感性。国内研究显示，超重及肥胖的PCOS患者采用饮食联合运动治疗，可改善其内分泌激素及糖脂代谢紊乱。", "ner": [[7, 8, "Disease"], [10, 11, "Disease"], [12, 15, "Disease"], [81, 84, "Disease"], [116, 121, "Treatment"], [161, 162, "Disease"], [164, 165, "Disease"], [167, 170, "Disease"], [175, 182, "Treatment"]], "rel": [[175, 182, "Treatment", 167, 170, "Disease", "Treatment_Disease"]]}
{"idx": 3205, "sentence": "(三)推荐意见", "ner": [], "rel": []}
{"idx": 3206, "sentence": "PCOS体重管理推荐见表11。", "ner": [[0, 3, "Disease"]], "rel": []}
{"idx": 3207, "sentence": "四、超重/肥胖者合并代谢综合征的体重管理", "ner": [[2, 3, "Disease"], [5, 6, "Disease"], [10, 14, "Disease"]], "rel": []}
{"idx": 3208, "sentence": "（一）背景", "ner": [], "rel": []}
{"idx": 3209, "sentence": "代谢综合征是以超重/肥胖为中心并伴有一系列代谢紊乱的病症。", "ner": [[0, 4, "Disease"], [7, 8, "Disease"], [10, 11, "Disease"]], "rel": []}
{"idx": 3210, "sentence": "随着社会生活水平的提高，以及国人膳食模式的变化，代谢综合征的流行呈现快速上升趋势，2000年至2001年的全国性横断面调查显示，男性和女性代谢综合征的惠病车分别为10.0%和23.3%。2011年美国Joslin糖尿病中心发布了合并糖尿病的肥胖患者临床营养指南，整部指南的目标人群实际是代谢综合征患者，其将体重管理置于营养管理的首要目标。与此同时，该指南还提出将膳食管理与胰岛素治疗相配合，同时需要考虑与营养有关的代谢并发症的控制。", "ner": [[24, 28, "Disease"], [69, 73, "Disease"], [106, 108, "Disease"], [116, 118, "Disease"], [120, 121, "Disease"], [143, 147, "Disease"], [181, 184, "Treatment"], [186, 188, "Drug"], [207, 211, "Disease"]], "rel": [[181, 184, "Treatment", 207, 211, "Disease", "Treatment_Disease"], [186, 188, "Drug", 207, 211, "Disease", "Drug_Disease"]]}
{"idx": 3211, "sentence": "(二)证据", "ner": [], "rel": []}
{"idx": 3212, "sentence": "20世纪80年代，Vertes等对519例门诊患者进行断食治疗，78%的患者体重下降超过18.2kg，总体减重为每周1.5kg，女性平均每周减重1.3kg，男性每周减重2.1kg，大多数均能接受该方案而无任何严重副作用。一项基于16例肥胖患者的研究显示，在隔日断食法干预8周后，患者体重平均下降(5.6±1.0)kg，腰围平均缩小4.0cm，体脂含量从原来的(45±2)%降到(42±2)%，收缩压由(124±5)mmHg(1mmHg=0.133kPa)降到(116±3)mmHg，总胆固醇、低密度脂蛋白胆固醇和甘油三酯浓度也分别下降(21±4)%、(25±10)%和(32±6)%，而高密度脂蛋白胆固醇水平无变化。Johnson等的研究也发现，在隔日断食法干预8周后，肥胖患者的BMI较基线值下降8%，而低密度脂蛋白胆固醇和甘油三酯分别下降10%和40%。2013年发表的一项基于115例肥胖女性的研究显示，干预3个月后，两日断食法的肥胖患者体重平均下降4kg，而传统能量限制的肥胖患者体重平均下降2.4kg，且前者胰岛素抵抗改善更明显。2014年一项关于2型糖尿病预防的Meta分析发现轻断食可有效减重及预防2型糖尿病，对超重和肥胖患者的血糖、胰岛素及低密度脂蛋白胆固醇、高密度脂蛋白胆固醇等代谢标记物均有改善。", "ner": [[117, 118, "Disease"], [128, 134, "Treatment"], [196, 198, "Test"], [200, 226, "Test_Value"], [229, 239, "Test_Value"], [241, 244, "Test_items"], [246, 254, "Test_items"], [256, 259, "Test_items"], [293, 301, "Test_items"], [324, 330, "Treatment"], [335, 336, "Disease"], [353, 361, "Test_items"], [363, 366, "Test_items"], [369, 373, "Test_Value"], [395, 396, "Disease"], [412, 416, "Treatment"], [418, 419, "Disease"], [440, 441, "Disease"], [459, 463, "Pathogenesis"], [479, 483, "Disease"], [495, 497, "Treatment"], [506, 510, "Disease"], [513, 514, "Disease"], [516, 517, "Disease"], [521, 522, "Test_items"], [524, 526, "Test_items"], [528, 536, "Test_items"], [538, 546, "Test_items"]], "rel": [[324, 330, "Treatment", 335, 336, "Disease", "Treatment_Disease"], [353, 361, "Test_items", 335, 336, "Disease", "Test_items_Disease"], [363, 366, "Test_items", 335, 336, "Disease", "Test_items_Disease"], [412, 416, "Treatment", 418, 419, "Disease", "Treatment_Disease"], [459, 463, "Pathogenesis", 440, 441, "Disease", "Pathogenesis_Disease"], [495, 497, "Treatment", 506, 510, "Disease", "Treatment_Disease"], [521, 522, "Test_items", 513, 514, "Disease", "Test_items_Disease"], [524, 526, "Test_items", 513, 514, "Disease", "Test_items_Disease"], [528, 536, "Test_items", 513, 514, "Disease", "Test_items_Disease"], [538, 546, "Test_items", 513, 514, "Disease", "Test_items_Disease"], [521, 522, "Test_items", 516, 517, "Disease", "Test_items_Disease"], [524, 526, "Test_items", 516, 517, "Disease", "Test_items_Disease"], [528, 536, "Test_items", 516, 517, "Disease", "Test_items_Disease"], [538, 546, "Test_items", 516, 517, "Disease", "Test_items_Disease"]]}
{"idx": 3213, "sentence": "对于合并代谢综合征的肥胖患者，临床证据中较为一致的将生活行为方式干预作为减重和改善代谢紊乱的基础治疗措施。同时，对于各种膳食模式的比较发现，在控制总能量摄入的前提下，它们的总体效果相似。需要指出的是，目前的研究样本量均不大，且干预时间较短(12~24周)，尚欠缺长时间干预的研究证据。", "ner": [[4, 8, "Disease"], [10, 11, "Disease"], [26, 33, "Treatment"]], "rel": [[26, 33, "Treatment", 4, 8, "Disease", "Treatment_Disease"], [26, 33, "Treatment", 10, 11, "Disease", "Treatment_Disease"]]}
{"idx": 3214, "sentence": "2015年，澳大利亚启动了一项针对中老年(50~69岁)MS患者的大样本(500例)减重干预研究，旨在检验综合性行为、营养和心理干预的影响，或将在未来几年得出一些有指导意义的结论。", "ner": [[59, 65, "Treatment"]], "rel": []}
{"idx": 3215, "sentence": "英国国家卫生与临床优化研究所(NICE)指南认为肥胖管理包括节食、运动、行为改变，且需要长期随访并推荐低脂、高纤维饮食，增加体力活动，避免久坐，规律监测体重和腰围变化。", "ner": [[24, 25, "Disease"], [30, 31, "Treatment"], [33, 34, "Treatment"], [36, 39, "Treatment"], [51, 52, "Treatment"], [54, 58, "Treatment"], [62, 65, "Treatment"], [67, 70, "Treatment"]], "rel": [[30, 31, "Treatment", 24, 25, "Disease", "Treatment_Disease"], [33, 34, "Treatment", 24, 25, "Disease", "Treatment_Disease"], [36, 39, "Treatment", 24, 25, "Disease", "Treatment_Disease"], [51, 52, "Treatment", 24, 25, "Disease", "Treatment_Disease"], [54, 58, "Treatment", 24, 25, "Disease", "Treatment_Disease"], [62, 65, "Treatment", 24, 25, "Disease", "Treatment_Disease"], [67, 70, "Treatment", 24, 25, "Disease", "Treatment_Disease"]]}
{"idx": 3216, "sentence": " ", "ner": [], "rel": []}
{"idx": 3217, "sentence": "中国高尿酸血症相关疾病诊疗多学科专家共识", "ner": [[2, 6, "Disease"]], "rel": []}
{"idx": 3218, "sentence": "随着社会经济发展，人们生活方式及饮食结国高尿酸血症(hyperuricemia，HUA)的患病率逐年增高，并呈年轻化趋势，已成为仅次于糖尿病的第二大代谢疾病。血尿酸升高除可引起痛风之外，还与肾脏、内分泌代谢，心脑血管等系统疾病的发生和发展有关。", "ner": [[20, 43, "Disease"], [67, 69, "Disease"], [79, 81, "Test_items"], [82, 83, "Test_Value"], [88, 89, "Disease"], [104, 112, "Disease"], [104, 107, "Anatomy"]], "rel": [[79, 81, "Test_items", 88, 89, "Disease", "Test_items_Disease"], [104, 107, "Anatomy", 104, 112, "Disease", "Anatomy_Disease"]]}
{"idx": 3219, "sentence": "既往部分学科已从本专业出发制定了相关临床指南或专家共识，各有侧重。", "ner": [], "rel": []}
{"idx": 3220, "sentence": "本共识参照系统医学模式，邀请风湿免疫、肾脏、血管、神经、泌尿和中医科等学科专家共同讨论、制定而成，是我国HUA相关疾病的首个多学科专家共识，学科协作，指导和规范HUA相关疾病的临床实践。", "ner": [[52, 54, "Disease"], [80, 82, "Disease"]], "rel": []}
{"idx": 3221, "sentence": "一、HUA定义", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 3222, "sentence": "根据流行病学资料，既往HUA定义为正常嘌呤饮食下，非同日两次空腹血尿酸水平男性>420μmol／L，女性>360 μmol／L。", "ner": [[11, 13, "Disease"], [30, 36, "Test_items"], [39, 48, "Test_Value"], [52, 62, "Test_Value"]], "rel": [[30, 36, "Test_items", 11, 13, "Disease", "Test_items_Disease"]]}
{"idx": 3223, "sentence": "因尿酸盐在血液中的饱和浓度为420μmol／L不分性别)，超过此值可引起尿酸盐结晶析出，在组织中沉积。", "ner": [[1, 3, "Test_items"], [14, 22, "Test_Value"], [36, 49, "Reason"]], "rel": []}
{"idx": 3224, "sentence": "因此，本共识将血尿酸水平>420μmol／L(7mg／dl)定义为HUA", "ner": [[7, 11, "Test_items"], [12, 29, "Test_Value"], [33, 35, "Disease"]], "rel": [[7, 11, "Test_items", 33, 35, "Disease", "Test_items_Disease"]]}
{"idx": 3225, "sentence": "二、HUA流行病学", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 3226, "sentence": "血尿酸水平受年龄、性别、种族、遗传、饮食习惯、药物、环境等多种因素影响。", "ner": [[0, 4, "Test_items"]], "rel": []}
{"idx": 3227, "sentence": "我国目前尚缺乏全国范围的HUA流行行病学调查资料。", "ner": [[12, 14, "Disease"]], "rel": []}
{"idx": 3228, "sentence": "来自不同时间、地区的资料显HUA患病率总体呈现增长趋势，近10年的流行病学研究显示，我国不同地区HUA患病率存在较大的差别，为5..46％～19.30％，其中男性为9.2％～26.0.7％～10.5％。", "ner": [[48, 50, "Disease"], [13, 15, "Disease"]], "rel": []}
{"idx": 3229, "sentence": "痛风的患病率各地报道0.86%~2.20％不等，其中男性为1.42％～3.58％，女性为0.28%~0.90％。", "ner": [[0, 1, "Disease"]], "rel": []}
{"idx": 3230, "sentence": "HUA及痛风的患病率随年龄增长而增高，男性高于女性，城市高于农村，沿海高于内陆。", "ner": [[0, 2, "Disease"], [4, 5, "Disease"]], "rel": []}
{"idx": 3231, "sentence": "三、HUA系统性损害的病理生理", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 3232, "sentence": "尿酸由饮食摄入和体内分解的嘌呤化合物在肝脏中产生，约2／3尿酸通过肾脏排泄。其余由消化道排泄。尿酸经肾小球滤过、近端肾小管重吸收、分泌后再吸收，未吸收部分从尿液中排出(图2)。正常情况下，体内尿酸产生和排泄保持平衡，凡导致尿酸生成过多和或排泄减少的因素均可导致HUA(附件1)。", "ner": [[111, 122, "Reason"], [130, 132, "Disease"]], "rel": [[111, 122, "Reason", 130, 132, "Disease", "Reason_Disease"]]}
{"idx": 3233, "sentence": "当血尿酸超过饱和浓度，尿酸盐晶体析出可直接黏附、沉积于关节及周围软组织、肾小管和血管等部位，趋化中性粒细胞、巨噬细胞；细胞与晶体相互作用后释放致炎症因子(如IL-1β、IL-6等)以及金属蛋白酶9、水解酶等，引起关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤。", "ner": [[1, 3, "Test_items"], [4, 9, "Test_Value"], [11, 17, "Reason"], [27, 28, "Anatomy"], [30, 34, "Anatomy"], [36, 38, "Anatomy"], [40, 41, "Anatomy"], [48, 52, "Anatomy"], [54, 57, "Anatomy"], [59, 67, "Reason"], [71, 75, "Test_items"], [78, 82, "Test_items"], [84, 87, "Test_items"], [92, 97, "Test_items"], [99, 101, "Test_items"], [106, 109, "Anatomy"], [111, 112, "Anatomy"], [114, 115, "Anatomy"], [118, 121, "Anatomy"], [123, 129, "Disease"]], "rel": [[59, 67, "Reason", 123, 129, "Disease", "Reason_Disease"], [106, 109, "Anatomy", 123, 129, "Disease", "Anatomy_Disease"], [111, 112, "Anatomy", 123, 129, "Disease", "Anatomy_Disease"], [114, 115, "Anatomy", 123, 129, "Disease", "Anatomy_Disease"], [118, 121, "Anatomy", 123, 129, "Disease", "Anatomy_Disease"]]}
{"idx": 3234, "sentence": "HUA引起心、脑、肾等多器官损害的机制包括促进氧自由基生成、损伤血管内皮细胞、上调内皮素并下调一氧化氮合酶的表达，导致血管舒缩功能失调；引起LDL-C氧化修饰，导致动脉粥样硬化；损害线粒体、溶酶体功能，引起肾小管上皮细胞和心肌细胞凋亡等；激活肾素-血管紧张素-醛固酮系统，导致血管重构、器官受损；促进炎性反应，导致血小板聚集黏附。", "ner": [[21, 28, "Pathogenesis"], [30, 37, "Pathogenesis"], [39, 55, "Pathogenesis"], [57, 66, "Pathogenesis"], [68, 78, "Pathogenesis"], [119, 134, "Pathogenesis"], [0, 2, "Disease"], [82, 87, "Disease"], [138, 146, "Symptom"], [5, 5, "Anatomy"], [7, 7, "Anatomy"], [9, 9, "Anatomy"], [89, 116, "Pathogenesis"], [82, 83, "Anatomy"]], "rel": [[21, 28, "Pathogenesis", 82, 87, "Disease", "Pathogenesis_Disease"], [30, 37, "Pathogenesis", 82, 87, "Disease", "Pathogenesis_Disease"], [39, 55, "Pathogenesis", 82, 87, "Disease", "Pathogenesis_Disease"], [57, 66, "Pathogenesis", 82, 87, "Disease", "Pathogenesis_Disease"], [5, 5, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [7, 7, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [9, 9, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [82, 83, "Anatomy", 82, 87, "Disease", "Anatomy_Disease"]]}
{"idx": 3235, "sentence": " ", "ner": [], "rel": []}
{"idx": 3236, "sentence": "四、HUA和痛风诊断 ", "ner": [[2, 4, "Disease"], [6, 7, "Disease"]], "rel": []}
{"idx": 3237, "sentence": "(一) HUA ", "ner": [[4, 6, "Disease"]], "rel": []}
{"idx": 3238, "sentence": "日常饮食下，非同日两次空腹血尿酸水平＞420μmol/L即可诊断HUA。血液系统肿瘤、慢性肾功能不全、先天性代谢异常、中毒、药物等因素可引起血尿酸水平升高(附件1，2)。", "ner": [[11, 17, "Test_items"], [18, 27, "Test_Value"], [32, 34, "Disease"], [36, 41, "Disease"], [43, 49, "Disease"], [51, 57, "Disease"], [70, 74, "Test_items"], [75, 76, "Test_Value"], [45, 45, "Anatomy"]], "rel": [[11, 17, "Test_items", 32, 34, "Disease", "Test_items_Disease"], [45, 45, "Anatomy", 43, 49, "Disease", "Anatomy_Disease"]]}
{"idx": 3239, "sentence": "年龄＜25岁、具有痛风家族史的HUA患者需排查遗传性嘌呤代谢异常疾病。", "ner": [[9, 10, "Disease"], [15, 17, "Disease"], [23, 33, "Disease"]], "rel": []}
{"idx": 3240, "sentence": " ", "ner": [], "rel": []}
{"idx": 3241, "sentence": "(二)痛风 ", "ner": [[3, 4, "Disease"]], "rel": []}
{"idx": 3242, "sentence": "HUA患者出现尿酸盐结晶沉积，导致关节炎(痛风性关节炎)、尿酸性肾病和肾结石称为痛风，也有学者仅将痛风性关节炎称为痛风。", "ner": [[0, 2, "Disease"], [17, 19, "Disease"], [21, 26, "Disease"], [29, 33, "Disease"], [35, 37, "Disease"], [40, 41, "Disease"], [49, 54, "Disease"], [57, 58, "Disease"], [7, 13, "Symptom"], [17, 18, "Anatomy"], [24, 25, "Anatomy"], [32, 32, "Anatomy"], [35, 35, "Anatomy"], [52, 53, "Anatomy"]], "rel": [[7, 13, "Symptom", 0, 2, "Disease", "Symptom_Disease"], [17, 18, "Anatomy", 17, 19, "Disease", "Anatomy_Disease"], [24, 25, "Anatomy", 21, 26, "Disease", "Anatomy_Disease"], [32, 32, "Anatomy", 29, 33, "Disease", "Anatomy_Disease"], [35, 35, "Anatomy", 35, 37, "Disease", "Anatomy_Disease"], [52, 53, "Anatomy", 49, 54, "Disease", "Anatomy_Disease"]]}
{"idx": 3243, "sentence": " ", "ner": [], "rel": []}
{"idx": 3244, "sentence": "HUA患者突发足第一跖趾、踝、膝等单关节红、肿、热、痛，即应考虑痛风可能，长期反复发作的患者可逐渐累及上肢关节，伴有痛风石形成。根据病程，痛风可分为4期：(1) 无症状HUA期；(2) 痛风性关节炎急性发作期；(3)痛风性关节炎发作间歇期；(4)慢性痛风性关节炎期。", "ner": [[0, 2, "Disease"], [7, 26, "Symptom"], [32, 33, "Disease"], [51, 54, "Anatomy"], [58, 60, "Disease"], [69, 70, "Disease"], [7, 11, "Anatomy"], [13, 13, "Anatomy"], [15, 15, "Anatomy"], [17, 19, "Anatomy"]], "rel": [[7, 26, "Symptom", 0, 2, "Disease", "Symptom_Disease"], [7, 11, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [13, 13, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [15, 15, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [17, 19, "Anatomy", 0, 2, "Disease", "Anatomy_Disease"], [51, 54, "Anatomy", 32, 33, "Disease", "Anatomy_Disease"]]}
{"idx": 3245, "sentence": " ", "ner": [], "rel": []}
{"idx": 3246, "sentence": "痛风诊断要点如下： ", "ner": [[0, 1, "Disease"]], "rel": []}
{"idx": 3247, "sentence": "1. 痛风性关节炎：中青年男性多见，常首发于第一跖趾关节，或踝、膝等关节。起病急骤，24h内发展至高峰。初次发病常累及单个关节，持续数天至数周可完全自然缓解，反复发作则受累关节逐渐增多，症状持续时间延长，两次关节炎发作间歇期缩短。", "ner": [[3, 8, "Disease"], [6, 7, "Anatomy"], [22, 27, "Anatomy"], [30, 30, "Anatomy"], [32, 32, "Anatomy"], [34, 35, "Anatomy"], [61, 62, "Anatomy"], [86, 87, "Anatomy"], [104, 106, "Disease"], [104, 105, "Anatomy"], [66, 67, "Duration"], [69, 70, "Duration"]], "rel": [[6, 7, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [22, 27, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [30, 30, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [32, 32, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [34, 35, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [104, 105, "Anatomy", 104, 106, "Disease", "Anatomy_Disease"]]}
{"idx": 3248, "sentence": " ", "ner": [], "rel": []}
{"idx": 3249, "sentence": "2. 痛风石：未经治疗的患者首发症状20年后约70%可出现痛风石，常出现于第一跖趾、耳郭、前臂伸面、指关节、肘关节等部位。痛风石可小如芝麻，大如鸡蛋或更大，受挤压后可破溃或形成瘘管，有白色豆腐渣样排出物。", "ner": [[3, 5, "Disease"], [29, 31, "Disease"], [61, 63, "Disease"], [37, 40, "Anatomy"], [42, 43, "Anatomy"], [45, 48, "Anatomy"], [50, 52, "Anatomy"], [54, 56, "Anatomy"], [83, 84, "Symptom"], [88, 89, "Symptom"], [92, 100, "Symptom"]], "rel": [[37, 40, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"], [42, 43, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"], [45, 48, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"], [50, 52, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"], [54, 56, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"], [83, 84, "Symptom", 61, 63, "Disease", "Symptom_Disease"], [88, 89, "Symptom", 61, 63, "Disease", "Symptom_Disease"], [92, 100, "Symptom", 61, 63, "Disease", "Symptom_Disease"]]}
{"idx": 3250, "sentence": " ", "ner": [], "rel": []}
{"idx": 3251, "sentence": "3. 关节液检查：急性期关节滑囊液偏振光显微镜下可见双折光的针形尿酸纳晶体，具有确诊价值。", "ner": [[3, 7, "Test"]], "rel": []}
{"idx": 3252, "sentence": " ", "ner": [], "rel": []}
{"idx": 3253, "sentence": "4. 关节B超检查：关节腔内可见典型的“暴雪征“和“双轨征”，具有诊断价值。关节内点状强回声及强回声团伴声影是痛风石常见表现。", "ner": [[3, 8, "Test"], [55, 57, "Disease"], [38, 53, "Symptom"]], "rel": [[38, 53, "Symptom", 55, 57, "Disease", "Symptom_Disease"]]}
{"idx": 3254, "sentence": " ", "ner": [], "rel": []}
{"idx": 3255, "sentence": "5. 双能(源)CT：特异性区分组织与关节周围尿酸盐结晶，具有诊断价值。", "ner": [[3, 9, "Test"], [23, 27, "Symptom"]], "rel": []}
{"idx": 3256, "sentence": " ", "ner": [], "rel": []}
{"idx": 3257, "sentence": "6. X线：早期急性关节炎可见软组织肿胀，反复发作后可出现关节软骨缘破坏、关节面不规则、关节间隙狭窄；痛风石沉积者可见骨质呈凿孔样缺损，边缘锐利，缺损呈半圆形或连续弧形，骨质边缘可有骨质增生反应。", "ner": [[3, 4, "Test"], [6, 12, "Disease"], [10, 11, "Anatomy"], [15, 19, "Symptom"], [29, 35, "Symptom"], [37, 42, "Symptom"], [44, 49, "Symptom"], [51, 55, "Disease"], [59, 71, "Symptom"], [73, 83, "Symptom"], [85, 96, "Symptom"], [29, 33, "Anatomy"], [37, 39, "Anatomy"], [44, 45, "Anatomy"], [15, 17, "Anatomy"]], "rel": [[10, 11, "Anatomy", 6, 12, "Disease", "Anatomy_Disease"], [15, 17, "Anatomy", 6, 12, "Disease", "Anatomy_Disease"], [29, 33, "Anatomy", 6, 12, "Disease", "Anatomy_Disease"], [37, 39, "Anatomy", 6, 12, "Disease", "Anatomy_Disease"], [44, 45, "Anatomy", 6, 12, "Disease", "Anatomy_Disease"], [15, 19, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [29, 35, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [37, 42, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [44, 49, "Symptom", 6, 12, "Disease", "Symptom_Disease"], [85, 96, "Symptom", 51, 55, "Disease", "Symptom_Disease"], [73, 83, "Symptom", 51, 55, "Disease", "Symptom_Disease"], [59, 71, "Symptom", 51, 55, "Disease", "Symptom_Disease"]]}
{"idx": 3258, "sentence": " ", "ner": [], "rel": []}
{"idx": 3259, "sentence": "诊断痛风既往多采用1977年美国风湿病学会(ACR) 痛风分类标准(附件3)，符合3项中任意1项即可分类为痛风。", "ner": [[2, 3, "Disease"], [16, 18, "Disease"], [27, 28, "Disease"], [53, 54, "Disease"]], "rel": []}
{"idx": 3260, "sentence": "近年关节B超检查和双能CT检查逐渐普及，建议采用2015年ACR/欧洲抗风湿病联盟(EULAR) 提出的ACR/ EULAR痛风分类标准(附件4)，当表中分值相加≥8分即分类为痛风。", "ner": [[36, 38, "Disease"], [62, 63, "Disease"], [88, 89, "Disease"], [2, 7, "Test"], [9, 14, "Test"]], "rel": []}
{"idx": 3261, "sentence": "目前研究显示，2015年分类标准更科学、全面、系统，诊断痛风的敏感性显著提高。", "ner": [[28, 29, "Disease"]], "rel": []}
{"idx": 3262, "sentence": " ", "ner": [], "rel": []}
{"idx": 3263, "sentence": "(三)并发症 ", "ner": [], "rel": []}
{"idx": 3264, "sentence": "痛风患者最常见表现为痛风性关节炎，但长期HUA可引起和／或加重其他多器官损伤，并发肾脏肾病变（急性尿酸性肾病、慢性尿酸盐肾病、肾石症)、高血糖、血脂紊乱，高血压、冠心病、心功能不全及卒中等。", "ner": [[0, 1, "Disease"], [10, 15, "Disease"], [20, 22, "Disease"], [41, 45, "Disease"], [47, 53, "Disease"], [55, 61, "Disease"], [63, 65, "Disease"], [68, 70, "Disease"], [72, 75, "Disease"], [77, 79, "Disease"], [81, 83, "Disease"], [85, 89, "Disease"], [91, 92, "Disease"], [13, 14, "Anatomy"], [41, 42, "Anatomy"], [43, 43, "Anatomy"], [52, 52, "Anatomy"], [60, 60, "Anatomy"], [63, 63, "Anatomy"], [85, 85, "Anatomy"]], "rel": [[13, 14, "Anatomy", 10, 15, "Disease", "Anatomy_Disease"], [41, 42, "Anatomy", 41, 45, "Disease", "Anatomy_Disease"], [43, 43, "Anatomy", 41, 45, "Disease", "Anatomy_Disease"], [52, 52, "Anatomy", 47, 53, "Disease", "Anatomy_Disease"], [60, 60, "Anatomy", 55, 61, "Disease", "Anatomy_Disease"], [63, 63, "Anatomy", 63, 65, "Disease", "Anatomy_Disease"], [85, 85, "Anatomy", 85, 89, "Disease", "Anatomy_Disease"]]}
{"idx": 3265, "sentence": "五、HUA防治", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 3266, "sentence": "HUA及痛风一经确诊，应立即对患者进行宣教及生活方式干预。", "ner": [[0, 2, "Disease"], [4, 5, "Disease"], [19, 20, "Treatment"], [22, 27, "Treatment"]], "rel": []}
{"idx": 3267, "sentence": "HUA患者需要综合和长期的全程管理，按照血尿酸水平及合并的临床症状／体征，决定药物并制定相应的治疗目标，进行分层管理。", "ner": [[0, 2, "Disease"], [20, 24, "Test_items"], [7, 16, "Treatment"]], "rel": []}
{"idx": 3268, "sentence": "(一)患者管理", "ner": [], "rel": []}
{"idx": 3269, "sentence": "患者管理患者管理是HUA及痛风防治的基础，科学的防治方法是患者在医师的帮助下对疾病及自身情况充分了解后，与医师共同制定并执行治疗方案，注重长程管理。", "ner": [[9, 11, "Disease"], [13, 14, "Disease"]], "rel": []}
{"idx": 3270, "sentence": "出现严重并发症或合并症、治疗效果不佳时建议及时转诊上一级医疗机构。", "ner": [], "rel": []}
{"idx": 3271, "sentence": "1. HUA患者管理：(1)普及HUA相关常识；(2）给予饮食、运动等方面的健康指导，制定个体化的生活方式干预(3)筛查并预防痛风及并发症；(4)与专科医师合作，多学科共同制定共患病治疗方案，尽量避免使用引起血尿酸升高的药物(附件2)；(5)药物治疗须长程控制，血尿酸持续达标，接受药物治疗的患者必须同时接受健康的生活方式干预。", "ner": [[14, 22, "Treatment"], [27, 41, "Treatment"], [43, 54, "Treatment"], [58, 68, "Treatment"], [73, 94, "Treatment"], [96, 111, "Treatment"], [3, 5, "Disease"], [131, 133, "Test_items"], [134, 137, "Test_Value"], [154, 162, "Treatment"]], "rel": []}
{"idx": 3272, "sentence": "2. 痛风患者管理：(1)痛风性关节炎患者首先遵循HUA管理原则；(2)医师须告知患者生活中避免可能的诱发因素，提出正确的预防措施，并制定个体化的急性发作时紧急处理方案；(3)痛风急性发作缓解后再考虑开始药物降尿酸治疗，已接受降尿酸药物治疗者急性期无需停药，初始药物降尿酸治疗者应给予预防痛风急性发作的药物。", "ner": [[3, 4, "Disease"], [13, 18, "Disease"], [25, 27, "Disease"], [88, 89, "Disease"], [144, 145, "Disease"], [39, 54, "Treatment"], [56, 64, "Treatment"], [67, 83, "Treatment"], [16, 17, "Anatomy"]], "rel": [[16, 17, "Anatomy", 13, 18, "Disease", "Anatomy_Disease"]]}
{"idx": 3273, "sentence": "3. 出现并发症患者管理：(1)一经确诊的HUA患者应积极筛查并发症或合并症，及时制定多学科联合方案；(2)急、慢性尿酸(盐)肾病患者须避免使用损害肾脏损伤药物，监测肾功能并指导药物选择，中重度肾功能不全者痛风急性期治疗首选糖皮质激素；(3)肾石症患者碱化尿液，必要时给予溶石或手术治疗；(4)合并高血糖、血脂紊乱、高血压者须同时积极降糖、调脂、降压治疗，尽量选择有利于尿酸排泄的药物；(5)心肌梗死、心功能不全者痛风急性发作期避免使用环氧化酶2(COX-2)抑制剂。", "ner": [[21, 23, "Disease"], [54, 64, "Disease"], [63, 63, "Anatomy"], [94, 101, "Disease"], [94, 96, "Level"], [97, 97, "Anatomy"], [103, 104, "Disease"], [112, 116, "Drug"], [121, 123, "Disease"], [121, 121, "Anatomy"], [149, 151, "Disease"], [153, 156, "Disease"], [158, 160, "Disease"], [196, 199, "Disease"], [201, 206, "Disease"], [201, 201, "Anatomy"], [207, 208, "Disease"], [218, 232, "Drug"], [196, 197, "Anatomy"], [136, 137, "Treatment"], [167, 168, "Treatment"], [170, 171, "Treatment"], [173, 174, "Treatment"], [81, 85, "Test"]], "rel": [[63, 63, "Anatomy", 54, 64, "Disease", "Anatomy_Disease"], [81, 85, "Test", 54, 64, "Disease", "Test_Disease"], [97, 97, "Anatomy", 94, 101, "Disease", "Anatomy_Disease"], [112, 116, "Drug", 103, 104, "Disease", "Drug_Disease"], [121, 121, "Anatomy", 121, 123, "Disease", "Anatomy_Disease"], [136, 137, "Treatment", 121, 123, "Disease", "Treatment_Disease"], [196, 197, "Anatomy", 196, 199, "Disease", "Anatomy_Disease"], [201, 201, "Anatomy", 201, 206, "Disease", "Anatomy_Disease"]]}
{"idx": 3274, "sentence": "4. 高危人群管理：一级亲属中有HUA或痛风患者、久坐、高嘌呤高脂饮食等不良生活方式者，存在性疾病(如糖代谢异常、血脂紊乱、非酒精性脂肪肝等）、脑血管疾病(如高血压、冠心病、心力衰竭、卒中等）以及慢性肾脏病(定义及分期见附件5)等高危人群建立定期筛查方案，普及HUA和痛风医学知识，提高人群防治意识，定期监测血尿酸水平，尽早发现并诊治HUA或痛风。", "ner": [[16, 18, "Disease"], [20, 21, "Disease"], [51, 55, "Disease"], [57, 60, "Disease"], [62, 68, "Disease"], [72, 76, "Disease"], [79, 81, "Disease"], [83, 85, "Disease"], [87, 90, "Disease"], [92, 93, "Disease"], [98, 102, "Disease"], [167, 169, "Disease"], [171, 172, "Disease"], [68, 68, "Anatomy"], [72, 74, "Anatomy"], [100, 101, "Anatomy"], [154, 158, "Test_items"], [119, 126, "Treatment"], [128, 139, "Treatment"], [141, 148, "Treatment"]], "rel": [[68, 68, "Anatomy", 62, 68, "Disease", "Anatomy_Disease"], [72, 74, "Anatomy", 72, 76, "Disease", "Anatomy_Disease"], [100, 101, "Anatomy", 98, 102, "Disease", "Anatomy_Disease"], [154, 158, "Test_items", 167, 169, "Disease", "Test_items_Disease"], [154, 158, "Test_items", 171, 172, "Disease", "Test_items_Disease"]]}
{"idx": 3275, "sentence": "(二)非药物治疗", "ner": [], "rel": []}
{"idx": 3276, "sentence": "1.提倡均衡饮食，限制每日总热量摄入，控制饮食中嘌呤含量。", "ner": [[2, 7, "Treatment"], [9, 17, "Treatment"], [19, 27, "Treatment"]], "rel": []}
{"idx": 3277, "sentence": "以低嘌呤饮食为主(表1)，严格限制动物内脏产品，海产品和肉类等高嘌呤食物的摄入。富含嘌呤的蔬菜(莴苣、菠菜、蘑菇、菜花等)、豆类及豆制品与HUA及痛风发作无明显相关性，鼓励患者多食用新鲜蔬菜，适量食用豆类及豆制品(肾功能不全者须在专科医生指导下食用）。", "ner": [[0, 7, "Treatment"], [13, 38, "Treatment"], [88, 94, "Treatment"], [96, 105, "Treatment"], [69, 71, "Disease"], [73, 74, "Disease"], [107, 111, "Disease"], [107, 107, "Anatomy"]], "rel": [[107, 107, "Anatomy", 107, 111, "Disease", "Anatomy_Disease"]]}
{"idx": 3278, "sentence": "2.大量饮水可缩短痛风发作的持续时间，心肾功能正常者需维持适当的体内水分，多饮水，维持每日尿量2000～3000ml。", "ner": [[2, 5, "Treatment"], [27, 35, "Treatment"], [37, 39, "Treatment"], [41, 57, "Treatment"], [9, 10, "Disease"]], "rel": [[2, 5, "Treatment", 9, 10, "Disease", "Treatment_Disease"]]}
{"idx": 3279, "sentence": "可饮用牛奶及乳制品(尤其是脱脂奶和低热量酸奶)，避免饮用可乐、橙汁、苹果汁或含糖软饮料。", "ner": [[1, 22, "Treatment"], [24, 42, "Treatment"]], "rel": []}
{"idx": 3280, "sentence": "咖啡与HUA及痛风的关系尚无定论，有研究显示饮用咖啡不增加HUA的风险，并可能降低发生痛风的风险。", "ner": [[3, 5, "Disease"], [7, 8, "Disease"], [29, 31, "Disease"], [43, 44, "Disease"]], "rel": []}
{"idx": 3281, "sentence": "3.水果因富含钾元素及维生素C，可降低痛风发作的风险。", "ner": [[19, 20, "Disease"]], "rel": []}
{"idx": 3282, "sentence": "HUA患者可食用含果糖较少的水果，如樱桃，草莓，菠萝、西瓜、桃子等。", "ner": [[0, 2, "Disease"], [6, 32, "Treatment"]], "rel": [[6, 32, "Treatment", 0, 2, "Disease", "Treatment_Disease"]]}
{"idx": 3283, "sentence": "4.酒精摄入可增加HUA患者痛风发作风险，酒精摄入量与痛风的发病风险呈剂量效应关系。HUA患者当限制酒精摄入，禁饮黄酒、啤酒和白酒。", "ner": [[2, 5, "Reason"], [9, 11, "Disease"], [14, 15, "Disease"], [27, 28, "Disease"], [42, 44, "Disease"], [48, 53, "Treatment"], [55, 64, "Treatment"]], "rel": [[2, 5, "Reason", 14, 15, "Disease", "Reason_Disease"], [48, 53, "Treatment", 42, 44, "Disease", "Treatment_Disease"], [55, 64, "Treatment", 42, 44, "Disease", "Treatment_Disease"]]}
{"idx": 3284, "sentence": "红酒是否增加血尿酸水平存在争议。", "ner": [[6, 10, "Test_items"]], "rel": []}
{"idx": 3285, "sentence": "5.肥胖增加HUA患者发生痛风的风险、减轻体重可有效降低血尿酸水平。建议HUA患者将体重控制正常范围(BMI18.5—23.9kg／m2)。", "ner": [[2, 3, "Reason"], [6, 8, "Disease"], [13, 14, "Disease"], [28, 32, "Test_items"], [36, 38, "Disease"], [42, 68, "Treatment"], [19, 22, "Treatment"]], "rel": [[2, 3, "Reason", 13, 14, "Disease", "Reason_Disease"], [42, 68, "Treatment", 36, 38, "Disease", "Treatment_Disease"]]}
{"idx": 3286, "sentence": "6.规律运动可降低痛风发作次数，减少HUA相关死亡。鼓励HUA患者坚持适量运动。建议每周150min(30min／d×5d／周)中等强度[运动时心率在(220-年龄)×(50％～70％)范围内]的有氧运动。运动中应当避免剧烈运动或突然受凉诱发痛风发作。", "ner": [[2, 5, "Treatment"], [9, 10, "Disease"], [18, 20, "Disease"], [28, 30, "Disease"], [33, 38, "Treatment"], [40, 101, "Treatment"], [110, 113, "Reason"], [115, 118, "Reason"], [121, 122, "Disease"]], "rel": [[2, 5, "Treatment", 9, 10, "Disease", "Treatment_Disease"], [33, 38, "Treatment", 28, 30, "Disease", "Treatment_Disease"], [110, 113, "Reason", 121, 122, "Disease", "Reason_Disease"], [115, 118, "Reason", 121, 122, "Disease", "Reason_Disease"]]}
{"idx": 3287, "sentence": "7. 吸烟或被动吸烟增加HUA和痛风的发病风险，应当戒烟、避免被动吸烟。", "ner": [[3, 4, "Reason"], [6, 9, "Reason"], [12, 14, "Disease"], [16, 17, "Disease"], [26, 27, "Treatment"], [29, 34, "Treatment"]], "rel": [[3, 4, "Reason", 12, 14, "Disease", "Reason_Disease"], [3, 4, "Reason", 16, 17, "Disease", "Reason_Disease"], [6, 9, "Reason", 12, 14, "Disease", "Reason_Disease"], [6, 9, "Reason", 16, 17, "Disease", "Reason_Disease"], [26, 27, "Treatment", 12, 14, "Disease", "Treatment_Disease"], [29, 34, "Treatment", 12, 14, "Disease", "Treatment_Disease"], [26, 27, "Treatment", 16, 17, "Disease", "Treatment_Disease"], [29, 34, "Treatment", 16, 17, "Disease", "Treatment_Disease"]]}
{"idx": 3288, "sentence": "（三)药物治疗", "ner": [], "rel": []}
{"idx": 3289, "sentence": "HUA经非药物干预疗效不佳时采用药物治疗。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 3290, "sentence": "治疗方案需个体化、分层、达标、长程管理，逐步调整剂量，避免短期内血尿酸水平波动过大诱发痛风急性发作。", "ner": [[43, 44, "Disease"], [29, 40, "Reason"]], "rel": [[29, 40, "Reason", 43, 44, "Disease", "Reason_Disease"]]}
{"idx": 3291, "sentence": "1.降尿酸治疗：临床上常用的降尿酸药物包括抑制尿酸合成和促进尿酸排泄两类，需根据病因、合并症及肝，肾功能选择药物。", "ner": [], "rel": []}
{"idx": 3292, "sentence": "药物治疗原则见表2。", "ner": [], "rel": []}
{"idx": 3293, "sentence": "(1)抑制尿酸生成药物：该类药物通过抑制黄嘌呤氧化酶活性，减少尿酸合成。", "ner": [], "rel": []}
{"idx": 3294, "sentence": "常用药物包括别嘌醇和非布司他等。", "ner": [[6, 8, "Drug"], [10, 13, "Drug"]], "rel": []}
{"idx": 3295, "sentence": "别嘌醇：成人初始剂量50～100mg／d，每2～5周测血尿酸水平1次，未达标患者每次可递增50～100mg，最大剂量600mg／d。肾功能不全患者起始剂量每日不超过1.5mg／eGFR(估算的肾小球滤过率)。G3—4期患者推荐剂量为50～100mg／d；G5期患者禁用。别嘌醇可引皮呋过敏反应及肝肾功能损伤，严重者可发生致死性剥脱性皮炎等超敏反应综合征。", "ner": [[0, 2, "Drug"], [10, 19, "Amount"], [27, 31, "Test_items"], [35, 37, "Test_Value"], [45, 52, "Amount"], [58, 64, "Amount"], [66, 70, "Disease"], [66, 66, "Anatomy"], [79, 91, "Amount"], [96, 101, "Test_items"], [116, 125, "Amount"], [135, 137, "Drug"], [140, 145, "ADE"], [147, 152, "ADE"], [160, 167, "ADE"], [169, 175, "ADE"]], "rel": [[10, 19, "Amount", 0, 2, "Drug", "Amount_Drug"], [45, 52, "Amount", 0, 2, "Drug", "Amount_Drug"], [58, 64, "Amount", 0, 2, "Drug", "Amount_Drug"], [66, 66, "Anatomy", 66, 70, "Disease", "Anatomy_Disease"], [140, 145, "ADE", 135, 137, "Drug", "ADE_Drug"], [147, 152, "ADE", 135, 137, "Drug", "ADE_Drug"], [160, 167, "ADE", 135, 137, "Drug", "ADE_Drug"], [169, 175, "ADE", 135, 137, "Drug", "ADE_Drug"]]}
{"idx": 3296, "sentence": "HLA-B*5801基因阳性，应用噻嗪类利尿剂和肾功能不全是别嘌醇发生不良反应的危险因素。", "ner": [[17, 22, "Drug"], [24, 28, "Disease"], [24, 24, "Anatomy"], [30, 32, "Drug"], [0, 11, "Test_items"], [12, 13, "Test_Value"]], "rel": [[24, 24, "Anatomy", 24, 28, "Disease", "Anatomy_Disease"]]}
{"idx": 3297, "sentence": "HLA-B*5801基因在中国(汉族)、韩国、泰国人中阳性率显著高于白种人，推荐在服用别嘌醇治疗前进行基因筛查，阳性者禁用。", "ner": [[43, 45, "Drug"], [0, 11, "Test_items"], [51, 54, "Test"], [56, 57, "Test_Value"]], "rel": []}
{"idx": 3298, "sentence": "非布司他：新型选择性黄嘌呤氧化酶抑制剂。", "ner": [[0, 3, "Drug"], [5, 18, "Drug"]], "rel": []}
{"idx": 3299, "sentence": "初始剂量20～40mg／d，2～5周后血尿酸不达标者，逐渐加量，最大剂量80mg／d。因其主要通过肝脏清除，在肾功能不全和肾移植患者中具有较高的安全性，轻中度肾功能不全（G1~3期）患者无需调整剂量，重度肾功能不全(G4~5期)患者慎用。", "ner": [[4, 12, "Amount"], [19, 21, "Test_items"], [22, 24, "Test_Value"], [36, 41, "Amount"], [55, 59, "Disease"], [55, 55, "Anatomy"], [61, 63, "Operation"], [76, 83, "Disease"], [76, 78, "Level"], [79, 79, "Anatomy"], [100, 106, "Disease"], [100, 101, "Level"], [102, 102, "Anatomy"]], "rel": [[55, 55, "Anatomy", 55, 59, "Disease", "Anatomy_Disease"], [79, 79, "Anatomy", 76, 83, "Disease", "Anatomy_Disease"], [102, 102, "Anatomy", 100, 106, "Disease", "Anatomy_Disease"]]}
{"idx": 3300, "sentence": "不良反应包括肝功能损害、恶心、皮疹等。", "ner": [[6, 10, "ADE"], [12, 13, "ADE"], [15, 16, "ADE"]], "rel": []}
{"idx": 3301, "sentence": "(2)促尿酸排泄药物：苯溴马隆通过抑制肾小管尿酸转运蛋白-1(URAT1)，抑制肾小管尿酸重吸收而促泄，降低血尿酸水平。", "ner": [[11, 14, "Drug"], [54, 58, "Test_items"]], "rel": []}
{"idx": 3302, "sentence": "苯溴马隆：成人起始剂量25～50mg／d，2～5周后根据血尿酸水平调整剂量至75mg／d或100mg／d，早餐后服用；可用于轻中度肾功能异常或肾移植患者，eGFR20～60ml·min-1·1.73m-2患者推荐50mg／d；eGFR<20~60ml·min-1·1.73m-2或尿酸性肾石症患者禁用。", "ner": [[0, 3, "Drug"], [11, 19, "Amount"], [28, 32, "Test_items"], [38, 43, "Amount"], [45, 51, "Amount"], [62, 69, "Disease"], [65, 65, "Anatomy"], [71, 73, "Operation"], [77, 80, "Test_items"], [81, 101, "Test_Value"], [106, 111, "Amount"], [113, 116, "Test_items"], [117, 138, "Test_Value"], [140, 145, "Disease"], [143, 143, "Anatomy"]], "rel": [[11, 19, "Amount", 0, 3, "Drug", "Amount_Drug"], [38, 43, "Amount", 0, 3, "Drug", "Amount_Drug"], [45, 51, "Amount", 0, 3, "Drug", "Amount_Drug"], [65, 65, "Anatomy", 62, 69, "Disease", "Anatomy_Disease"], [143, 143, "Anatomy", 140, 145, "Disease", "Anatomy_Disease"]]}
{"idx": 3303, "sentence": "服用时须碱化尿液，将尿液pH值调整至6.2～6.9，心肾功能正常者维持尿量2000ml以上。", "ner": [], "rel": []}
{"idx": 3304, "sentence": "不良反应有胃肠不适、腹泄，皮疹和肝功能损害等。", "ner": [[5, 8, "ADE"], [10, 11, "ADE"], [13, 14, "ADE"], [16, 20, "ADE"]], "rel": []}
{"idx": 3305, "sentence": "(3)新型降尿酸药物：包括尿酸酶和选择性尿酸重吸收抑制剂。", "ner": [[13, 15, "Drug"], [17, 27, "Drug"]], "rel": []}
{"idx": 3306, "sentence": "尿酸酶：将尿酸分解为可溶性产物排出。", "ner": [[0, 2, "Drug"]], "rel": []}
{"idx": 3307, "sentence": "包括拉布立酶(rasburicase)和普瑞凯希(pegloticase)。拉布立酶时一种重组尿酸氧化酶，主要用于预防和治疗血液系统恶性肿瘤患者的急性HUA，尤其适用于放化疗所致的HUA。使用拉布立酶可诱发抗体生成而使疗效下降。普瑞凯希是一种聚乙二醇重组尿酸氧化酶，适用于大部分难治性痛风，可用于其他药物疗效不佳或存在禁忌证的成年难治性痛风患者。普瑞凯希主要不良反应包括严重心血管事件、输液反应和免疫原性反应。", "ner": [[2, 18, "Drug"], [20, 36, "Drug"], [38, 41, "Drug"], [96, 99, "Drug"], [114, 117, "Drug"], [121, 131, "Drug"], [173, 176, "Drug"], [62, 69, "Disease"], [73, 77, "Disease"], [90, 92, "Disease"], [84, 86, "Reason"], [139, 143, "Disease"], [163, 169, "Disease"], [185, 191, "ADE"], [193, 196, "ADE"], [198, 203, "ADE"], [45, 51, "Drug"]], "rel": [[38, 41, "Drug", 73, 77, "Disease", "Drug_Disease"], [114, 117, "Drug", 139, 143, "Disease", "Drug_Disease"], [114, 117, "Drug", 163, 169, "Disease", "Drug_Disease"], [185, 191, "ADE", 173, 176, "Drug", "ADE_Drug"], [193, 196, "ADE", 173, 176, "Drug", "ADE_Drug"], [198, 203, "ADE", 173, 176, "Drug", "ADE_Drug"], [84, 86, "Reason", 90, 92, "Disease", "Reason_Disease"]]}
{"idx": 3308, "sentence": "选择性尿酸重吸收抑制剂：RDEA594(lesinurad）通过抑制URAT1和有机酸转运子4(OAT4)发挥疗效，用于单一足量使用黄嘌呤氧化酶抑制剂仍不能达标的痛风患者，可与黄嘌呤氧化酶抑制剂联合使用。", "ner": [[0, 10, "Drug"], [12, 29, "Drug"], [66, 74, "Drug"], [88, 96, "Drug"], [81, 82, "Disease"]], "rel": []}
{"idx": 3309, "sentence": "服药的同时加强水化，服药前须评估肾功能，G3b～5期患者不建议使用。", "ner": [], "rel": []}
{"idx": 3310, "sentence": "2.碱化尿液治疗：接受降尿酸药物，尤其是促尿酸排泄药物治疗的患者及尿酸性肾石症患者，推荐将尿PH值维持在6.2—6.9，以增加尿中尿酸溶解度。尿pH值过高增加磷酸钙和碳酸钙等结石形成风险。", "ner": [[33, 38, "Disease"], [36, 36, "Anatomy"], [71, 76, "Reason"], [87, 90, "Disease"]], "rel": [[36, 36, "Anatomy", 33, 38, "Disease", "Anatomy_Disease"], [71, 76, "Reason", 87, 90, "Disease", "Reason_Disease"]]}
{"idx": 3311, "sentence": "(1)碳酸氢钠：适用于慢性肾功能不全合并HUA和/或痛风患者。起始剂量0.5～1.0g口服，3次／d，与其他药物相隔1～2h服用。", "ner": [[3, 6, "Drug"], [11, 17, "Disease"], [13, 13, "Anatomy"], [20, 22, "Disease"], [26, 27, "Disease"], [35, 42, "Amount"], [43, 44, "Method"], [46, 49, "Frequency"]], "rel": [[3, 6, "Drug", 20, 22, "Disease", "Drug_Disease"], [3, 6, "Drug", 26, 27, "Disease", "Drug_Disease"], [13, 13, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"]]}
{"idx": 3312, "sentence": "主要不良反应为胀气、胃肠道不适，长期应用需警惕钠负荷过重及高血压。", "ner": [[7, 8, "ADE"], [10, 14, "ADE"], [23, 27, "ADE"], [29, 31, "ADE"]], "rel": []}
{"idx": 3313, "sentence": "(2)枸橼酸盐制剂：包括枸橼酸氢钾钠、枸橼酸钾和枸橼酸钠，以前者最为常用。", "ner": [[3, 8, "Drug"], [12, 17, "Drug"], [19, 22, "Drug"], [24, 27, "Drug"]], "rel": []}
{"idx": 3314, "sentence": "枸橼酸盐是尿中最强的内源性结石形成抑制物，同时可碱化尿液，增加尿尿酸溶解度，溶解尿酸结石并防止新结石的形成。枸橼酸氢钾钠起始剂量2.5～5.0g／d，服用期间需监测尿pH值以调整剂量。急性肾损伤或慢性肾衰竭(G4~5期)、严重酸-碱平衡功能失调及肝功能不全患者禁用。", "ner": [[54, 59, "Drug"], [47, 49, "Symptom"], [64, 73, "Amount"], [0, 3, "Drug"], [92, 96, "Disease"], [98, 102, "Disease"], [113, 121, "Disease"], [94, 94, "Anatomy"], [100, 100, "Anatomy"], [123, 127, "Disease"], [123, 123, "Anatomy"], [111, 112, "Level"]], "rel": [[64, 73, "Amount", 54, 59, "Drug", "Amount_Drug"], [94, 94, "Anatomy", 92, 96, "Disease", "Anatomy_Disease"], [100, 100, "Anatomy", 98, 102, "Disease", "Anatomy_Disease"], [123, 123, "Anatomy", 123, 127, "Disease", "Anatomy_Disease"]]}
{"idx": 3315, "sentence": "3.痛风急性发作期的药物治疗：急性发作期治疗目的是迅速控制关节炎症状。急性期应卧床休息，抬高患肢，局部冷敷。尽早给予药物控制急性发作，越早治疗效果越佳。秋水仙碱或非甾体类消炎药(NSAIDs)是急性关节发作的一线治疗药物，上述药物有禁忌或效果不佳时可选择糖皮质激素控制炎症。急性发作累及1～2个大关节，全身治疗效果不佳者，可考虑关节内注射短效糖皮质激素，避免短期内重复使用。", "ner": [[2, 3, "Disease"], [29, 31, "Disease"], [29, 30, "Anatomy"], [39, 42, "Treatment"], [44, 47, "Treatment"], [49, 52, "Treatment"], [76, 79, "Drug"], [81, 95, "Drug"], [127, 131, "Drug"], [147, 149, "Anatomy"], [169, 175, "Drug"], [164, 168, "Method"]], "rel": [[29, 30, "Anatomy", 29, 31, "Disease", "Anatomy_Disease"], [164, 168, "Method", 169, 175, "Drug", "Method_Drug"]]}
{"idx": 3316, "sentence": "(1)秋水仙碱：通过抑制白细胞趋化、吞噬作用及减轻炎性反应发挥止痛作用。", "ner": [[3, 6, "Drug"]], "rel": []}
{"idx": 3317, "sentence": "推荐在痛风发作12h内尽早使用，超过36h后疗效显著降低。起始负荷剂量为1.0mg口服，1h后追加0.5mg，12h后按照0.5mg，1～3次／d。使用细胞色素P4503A4酶或磷酸化糖蛋白抑制剂者(如环孢素A、克拉霉素、维拉帕米、酮康唑等)避免使用秋水仙碱。秋水仙碱不良反应随剂量增加而增加，常见有恶心、呕吐，腹泻、腹痛等胃肠道反应，症状出现时应立即停药；少数患者可出现肝功能异常，转氨酶升高，超过正常值2倍时须停药，肾脏损害可见血尿、少尿、肾功能异常，肾功能损减量。eGFR35~49ml·min-1·1.73m-2时每日最大剂0.5mg；eGFR10~34ml·min-1·1.73m-2时每次最大剂0.5mg，隔日1次；eGFR<10ml·min-1·1.73m-2或透析患者禁用。秋水仙碱可引起骨髓抑制，使用时注意监测血常规。", "ner": [[76, 87, "Drug"], [89, 98, "Drug"], [101, 104, "Drug"], [106, 109, "Drug"], [111, 114, "Drug"], [116, 118, "Drug"], [125, 128, "Drug"], [130, 133, "Drug"], [345, 348, "Drug"], [3, 4, "Disease"], [36, 40, "Amount"], [41, 42, "Method"], [49, 53, "Amount"], [61, 65, "Amount"], [67, 72, "Frequency"], [150, 151, "ADE"], [153, 154, "ADE"], [156, 157, "ADE"], [159, 160, "ADE"], [162, 166, "ADE"], [186, 190, "ADE"], [192, 194, "Test_items"], [195, 196, "Test_Value"], [198, 204, "Test_Value"], [210, 213, "ADE"], [216, 217, "ADE"], [219, 220, "ADE"], [222, 226, "ADE"], [228, 233, "ADE"], [235, 238, "Test_items"], [239, 259, "Test_Value"], [266, 270, "Amount"], [272, 275, "Test_items"], [276, 296, "Test_Value"], [303, 307, "Amount"], [309, 312, "Frequency"], [314, 317, "Test_items"], [318, 336, "Test_Value"], [338, 339, "Treatment"], [352, 355, "ADE"], [364, 366, "Test"]], "rel": [[150, 151, "ADE", 130, 133, "Drug", "ADE_Drug"], [153, 154, "ADE", 130, 133, "Drug", "ADE_Drug"], [156, 157, "ADE", 130, 133, "Drug", "ADE_Drug"], [159, 160, "ADE", 130, 133, "Drug", "ADE_Drug"], [162, 166, "ADE", 130, 133, "Drug", "ADE_Drug"], [352, 355, "ADE", 345, 348, "Drug", "ADE_Drug"]]}
{"idx": 3318, "sentence": "(2)NSAIDs：包括非选择性环氧化酶(COX)抑制剂COX-2抑制剂两种，若无禁忌推荐早期足量使用NSAIDs速效制剂。非选择性COX抑制剂主要存在消化道溃道溃疡，胃肠道穿孔、上消化道出血等胃肠道不良反应，对于不耐受非选择性COX抑制剂的患者可选用COX-2抑制剂，其胃肠道不良反应可降低50％；活动性消化道溃疡／出血，或既往有复发性消化道溃疡／出血病史者为所有NSAIDs使用禁忌症。COX-2抑制剂可能引起心血管事件的危险性增加，合并心肌梗死、心功能不全者避免使用。NSAIDs中使用过程中需监测肾功能，严重慢性肾脏病(G4～5期)未透析患者不建议使用。", "ner": [[3, 8, "Drug"], [12, 27, "Drug"], [28, 34, "Drug"], [51, 60, "Drug"], [62, 71, "Drug"], [110, 119, "Drug"], [126, 133, "Drug"], [183, 188, "Drug"], [195, 202, "Drug"], [237, 242, "Drug"], [76, 82, "ADE"], [84, 88, "ADE"], [90, 95, "ADE"], [97, 103, "ADE"], [136, 142, "ADE"], [207, 211, "ADE"], [150, 160, "Disease"], [153, 155, "Anatomy"], [166, 176, "Disease"], [169, 171, "Anatomy"], [221, 224, "Disease"], [221, 222, "Anatomy"], [226, 230, "Disease"], [226, 226, "Anatomy"], [256, 257, "Level"], [258, 262, "Disease"], [260, 261, "Anatomy"], [271, 272, "Treatment"]], "rel": [[76, 82, "ADE", 62, 71, "Drug", "ADE_Drug"], [84, 88, "ADE", 62, 71, "Drug", "ADE_Drug"], [90, 95, "ADE", 62, 71, "Drug", "ADE_Drug"], [97, 103, "ADE", 62, 71, "Drug", "ADE_Drug"], [207, 211, "ADE", 195, 202, "Drug", "ADE_Drug"], [153, 155, "Anatomy", 150, 160, "Disease", "Anatomy_Disease"], [169, 171, "Anatomy", 166, 176, "Disease", "Anatomy_Disease"], [221, 222, "Anatomy", 221, 224, "Disease", "Anatomy_Disease"], [226, 226, "Anatomy", 226, 230, "Disease", "Anatomy_Disease"], [260, 261, "Anatomy", 258, 262, "Disease", "Anatomy_Disease"]]}
{"idx": 3319, "sentence": "(3)糖皮质激素：主要用于严重急性痛风发作伴有较重全身症状，秋水仙碱、NSAIDs治疗无效或使用受限的患者以及肾功能不全患者。全身给药时，口服泼尼松0.5mg·kg-1.d-1连续用药5～10d停药，或者0.5mg·kg-1d-1用药2～5d后逐渐减量，总疗程7～10d。不宜口服用药时，可考虑静脉使用糖皮质激素。使用糖皮质激素应注意预防和治疗高血压、糖尿病、水钠潴留、感染等不良反应，避免使用长效制剂。", "ner": [[3, 7, "Drug"], [30, 33, "Drug"], [35, 40, "Drug"], [71, 73, "Drug"], [151, 155, "Drug"], [159, 163, "Drug"], [15, 18, "Disease"], [13, 14, "Level"], [55, 59, "Disease"], [55, 55, "Anatomy"], [69, 70, "Method"], [74, 87, "Amount"], [92, 96, "Duration"], [102, 114, "Amount"], [117, 120, "Duration"], [130, 134, "Duration"], [138, 139, "Method"], [147, 148, "Method"], [172, 174, "ADE"], [176, 178, "ADE"], [180, 183, "ADE"], [185, 186, "ADE"]], "rel": [[3, 7, "Drug", 15, 18, "Disease", "Drug_Disease"], [3, 7, "Drug", 55, 59, "Disease", "Drug_Disease"], [74, 87, "Amount", 71, 73, "Drug", "Amount_Drug"], [102, 114, "Amount", 71, 73, "Drug", "Amount_Drug"], [92, 96, "Duration", 71, 73, "Drug", "Duration_Drug"], [117, 120, "Duration", 71, 73, "Drug", "Duration_Drug"], [130, 134, "Duration", 71, 73, "Drug", "Duration_Drug"], [69, 70, "Method", 71, 73, "Drug", "Method_Drug"], [147, 148, "Method", 151, 155, "Drug", "Method_Drug"], [172, 174, "ADE", 159, 163, "Drug", "ADE_Drug"], [176, 178, "ADE", 159, 163, "Drug", "ADE_Drug"], [180, 183, "ADE", 159, 163, "Drug", "ADE_Drug"], [185, 186, "ADE", 159, 163, "Drug", "ADE_Drug"], [55, 55, "Anatomy", 55, 59, "Disease", "Anatomy_Disease"]]}
{"idx": 3320, "sentence": "急性发作仅累及1～2个大关节，全身治疗效果不佳者，可考虑关节腔内注射短效糖皮质激素，避免短期内重复使用。", "ner": [[34, 40, "Drug"], [11, 13, "Anatomy"], [28, 33, "Method"]], "rel": [[28, 33, "Method", 34, 40, "Drug", "Method_Drug"]]}
{"idx": 3321, "sentence": "(4)新药治疗：NSAIDs、秋水仙碱或糖皮质激素治疗无效的难治性急性痛风，或者当患者使用上述药物有禁忌时，可以考虑IL-1受体拮抗剂治疗。", "ner": [[8, 13, "Drug"], [15, 18, "Drug"], [20, 24, "Drug"], [58, 66, "Drug"], [30, 36, "Disease"]], "rel": [[58, 66, "Drug", 30, 36, "Disease", "Drug_Disease"]]}
{"idx": 3322, "sentence": "4.降尿酸治疗初期痛风急性发作的预防：由于血尿酸水平波动易诱发痛风急性发作，痛风患者初始降尿酸治疗时应使用药物预防痛风发作。首选口服小剂量秋水仙碱，推荐剂量0.5～1.01.0mg／d，轻度肾功能不全无需调整剂量，定期监测肾功能；中度肾功能不全患者剂量减半，0.5mg隔日1次口服或酌情递减；重度肾功能不全或透析患者避免使用。秋水仙碱无效时采用NSAIDs，使用时关注胃肠道、心血管、肾损伤等不良反应。对于有冠心病等慢性心血管疾病者，应权衡利弊，慎重选用NSAIDs。秋水仙碱和NSAIDs疗效不佳或存在使用禁忌时改用小剂量泼尼松或泼尼松龙(≤10mg／d)，同时注意监测和预防骨质疏松等不良反应。", "ner": [[9, 10, "Disease"], [31, 32, "Disease"], [38, 39, "Disease"], [57, 58, "Disease"], [95, 99, "Disease"], [117, 121, "Disease"], [148, 152, "Disease"], [204, 206, "Disease"], [208, 214, "Disease"], [64, 65, "Method"], [69, 72, "Drug"], [78, 91, "Amount"], [93, 94, "Level"], [95, 95, "Anatomy"], [115, 116, "Level"], [117, 117, "Anatomy"], [129, 133, "Amount"], [134, 137, "Frequency"], [138, 139, "Method"], [146, 147, "Level"], [154, 155, "Treatment"], [163, 166, "Drug"], [172, 177, "Drug"], [184, 194, "ADE"], [210, 212, "Anatomy"], [227, 232, "Drug"], [234, 237, "Drug"], [239, 244, "Drug"], [262, 264, "Drug"], [266, 269, "Drug"], [271, 277, "Amount"], [289, 292, "ADE"], [148, 148, "Anatomy"], [21, 27, "Reason"]], "rel": [[117, 117, "Anatomy", 117, 121, "Disease", "Anatomy_Disease"], [148, 148, "Anatomy", 148, 152, "Disease", "Anatomy_Disease"], [210, 212, "Anatomy", 208, 214, "Disease", "Anatomy_Disease"], [64, 65, "Method", 69, 72, "Drug", "Method_Drug"], [78, 91, "Amount", 69, 72, "Drug", "Amount_Drug"], [184, 194, "ADE", 172, 177, "Drug", "ADE_Drug"], [289, 292, "ADE", 262, 264, "Drug", "ADE_Drug"], [271, 277, "Amount", 262, 264, "Drug", "Amount_Drug"], [289, 292, "ADE", 266, 269, "Drug", "ADE_Drug"], [271, 277, "Amount", 266, 269, "Drug", "Amount_Drug"]]}
{"idx": 3323, "sentence": "预防治疗维持3~6个月，根据患者痛风性关节发作情况酌情调整。", "ner": [[6, 10, "Duration"], [16, 20, "Disease"]], "rel": []}
{"idx": 3324, "sentence": "无痛风发作病史的HUA患者接受降尿酸治疗时不推荐使用预防痛风发作药物，但应告知有诱发痛风发作的风险。一旦发生急性痛风性关节炎，应及时治疗，并考虑后续预防用药的必要性。", "ner": [[1, 2, "Disease"], [8, 10, "Disease"], [28, 29, "Disease"], [42, 43, "Disease"], [54, 61, "Disease"], [59, 60, "Anatomy"]], "rel": [[59, 60, "Anatomy", 54, 61, "Disease", "Anatomy_Disease"]]}
{"idx": 3325, "sentence": "5.痛风石治疗：痛风石患者经积极治疗，血尿酸降至300 μmol／L以下维持6个月以上，痛风石可逐渐溶解、缩小。", "ner": [[2, 4, "Disease"], [8, 10, "Disease"], [44, 46, "Disease"], [19, 21, "Test_items"], [24, 35, "Test_Value"]], "rel": []}
{"idx": 3326, "sentence": "对于痛风石较大，压迫神经或痛风石破溃，经久不愈者可考虑手术治疗，但患者术后仍须接受规范化综合治疗。", "ner": [[2, 4, "Disease"], [13, 15, "Disease"]], "rel": []}
{"idx": 3327, "sentence": "(四)中医中药", "ner": [], "rel": []}
{"idx": 3328, "sentence": "中医药干预本病强调养治并举、病证结合、分期而论的原则。", "ner": [], "rel": []}
{"idx": 3329, "sentence": "患者平素宜慎口节欲，避免饮酒或过食肥甘厚腻，可长期服用能纠正体质偏颇的食疗如薏苡仁、芡实，山药等，同时通过运动，增强体质、调摄精神，起到防病治病作用。HUA无论有无临床症状，健脾泄浊化淤为基本治法，贯穿治疗始终，常用药物有薏苡仁、土茯苓、菝葜，萆薢，虎杖等。", "ner": [[5, 8, "Treatment"], [10, 20, "Treatment"], [23, 46, "Treatment"], [53, 54, "Treatment"], [56, 59, "Treatment"], [61, 64, "Treatment"], [75, 77, "Disease"], [111, 113, "Drug"], [115, 117, "Drug"], [119, 120, "Drug"], [122, 123, "Drug"], [125, 126, "Drug"]], "rel": [[111, 113, "Drug", 75, 77, "Disease", "Drug_Disease"], [115, 117, "Drug", 75, 77, "Disease", "Drug_Disease"], [119, 120, "Drug", 75, 77, "Disease", "Drug_Disease"], [122, 123, "Drug", 75, 77, "Disease", "Drug_Disease"], [125, 126, "Drug", 75, 77, "Disease", "Drug_Disease"]]}
{"idx": 3330, "sentence": "症情累及关节，突发红肿灼痛者，为痛风急性期，以邪实为主，多采用清热利湿、通络止痛之法，方选四妙散或当归拈痛汤，常用药物有黄柏、苍术、车前子、茵陈、羌活，蚕砂等。", "ner": [], "rel": []}
{"idx": 3331, "sentence": "若肿痛迁延反复、关节畸形，或伴皮下结节和／或破溃者，为痛风慢性期，属虚实夹杂，多采用化痰祛淤、蠲痹通络之法，兼以健脾、补肾、养肝等，方选上中下通用痛风方，常用药物有威灵仙、天南星、姜黄、桂枝等。", "ner": [], "rel": []}
{"idx": 3332, "sentence": "症情内舍肾府，出现尿中伴砂石或尿少身肿者，为痛风性肾病，治疗仍守健脾补肾、泄浊通络之法，另视其虚实寒热辩证论治。", "ner": [], "rel": []}
{"idx": 3333, "sentence": "实证除浊淤外，多因湿热、石阻为患。", "ner": [], "rel": []}
{"idx": 3334, "sentence": "湿热者排尿频数、淋漓灼痛，治当清热利湿，方选八正汤或萆薢化毒汤，常用药物如车前草、篇蓄、蒲公英、木瓜、秦艽等，石阻者排尿艰涩，或突然中断，或尿中夹有砂石，治当排石通淋，方选石韦散，常用药物如石韦、滑石、海金砂等。", "ner": [], "rel": []}
{"idx": 3335, "sentence": "虚证多责于脾肾，阳虚为主者治宜温阳化饮，推荐方如温脾汤合济生肾气丸，常用药物如黄芪、党参、杜仲、狗脊、川断、附片等；阴虚为主者治宜滋阴固本，推荐方如左归丸或六味地黄丸常用药如熟地、黄精、杞子、山萸肉等。", "ner": [], "rel": []}
{"idx": 3336, "sentence": "在辨证论治的基础上，选方用药还可参考现究成果酌情使用。", "ner": [], "rel": []}
{"idx": 3337, "sentence": "研究表明，土茯苓、虎杖、菝葜、姜黄能抑制黄嘌呤氧化酶的活性，降低血尿酸水平。", "ner": [[5, 7, "Drug"], [9, 10, "Drug"], [12, 13, "Drug"], [15, 16, "Drug"], [32, 34, "Test_items"]], "rel": []}
{"idx": 3338, "sentence": "萆薢、栀子、车前草等可调控尿酸转运蛋白的表达，减少尿酸的重吸收，促进尿酸排泄。", "ner": [[0, 1, "Drug"], [3, 4, "Drug"], [6, 8, "Drug"]], "rel": []}
{"idx": 3339, "sentence": "此外，中药外敷、熏洗等局部治疗能使药效直达病所，有助于消肿止痛；中药保留灌肠既可通腑排毒，又可通过肠道吸收，使药效布散全身；针灸采用局部和循经取穴相结合，发挥标本同治的作用。", "ner": [[3, 6, "Treatment"], [8, 9, "Treatment"], [32, 37, "Treatment"], [62, 63, "Treatment"]], "rel": []}
{"idx": 3340, "sentence": "(五)多学科联合诊疗", "ner": [], "rel": []}
{"idx": 3341, "sentence": "HUA常伴随其他系统疾病，如其他代谢性疾病、肾脏疾病、心脑血管疾病等。治疗合并这些疾病的HUA时应遵循多学科联合治疗原则。", "ner": [[0, 2, "Disease"], [22, 25, "Disease"], [27, 32, "Disease"], [44, 46, "Disease"], [22, 23, "Anatomy"], [27, 30, "Anatomy"]], "rel": [[22, 23, "Anatomy", 22, 25, "Disease", "Anatomy_Disease"], [27, 30, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"]]}
{"idx": 3342, "sentence": "1.HUA与肾脏疾病：HUA时尿酸盐沉积在肾脏导致慢性尿酸盐肾病、急性尿酸性肾病和尿酸性肾石症；另一方面，肾脏疾病影响尿酸的排泄，发生继发性HUA，HUA又可导致／加重肾脏疾病。", "ner": [[2, 4, "Disease"], [6, 9, "Disease"], [11, 13, "Disease"], [25, 31, "Disease"], [33, 39, "Disease"], [41, 46, "Disease"], [67, 72, "Disease"], [84, 87, "Disease"], [6, 7, "Anatomy"], [30, 30, "Anatomy"], [38, 38, "Anatomy"], [44, 44, "Anatomy"], [84, 85, "Anatomy"], [15, 22, "Pathogenesis"], [53, 56, "Reason"], [57, 63, "Pathogenesis"], [74, 76, "Reason"]], "rel": [[6, 7, "Anatomy", 6, 9, "Disease", "Anatomy_Disease"], [30, 30, "Anatomy", 25, 31, "Disease", "Anatomy_Disease"], [15, 22, "Pathogenesis", 25, 31, "Disease", "Pathogenesis_Disease"], [38, 38, "Anatomy", 33, 39, "Disease", "Anatomy_Disease"], [44, 44, "Anatomy", 41, 46, "Disease", "Anatomy_Disease"], [53, 56, "Reason", 67, 72, "Disease", "Reason_Disease"], [57, 63, "Pathogenesis", 67, 72, "Disease", "Pathogenesis_Disease"], [84, 85, "Anatomy", 84, 87, "Disease", "Anatomy_Disease"], [74, 76, "Reason", 84, 87, "Disease", "Reason_Disease"]]}
{"idx": 3343, "sentence": "HUA已证实是慢性肾脏的独立危险因素。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 3344, "sentence": "(1)慢性尿酸盐肾病：慢性尿酸盐肾病发病机制是持续HUA尿酸钠结晶沉积在肾髓质间质组织，激活局部肾素-血管紧张素一醛固酮系统，损伤内皮细胞，引起肾小球高压力、慢性炎症反应、间质纤维化等病理改变。HUA患者出现肾小管功能障碍，如夜尿增多、低比重尿、小分子蛋白等，提示存在慢性尿酸盐肾病。尿酸升高水平与肾功能损伤程度可不匹配，排除其他慢性肾脏病后可考虑诊断，但通常很难与合并HUA的其他慢性肾脏病鉴别，确诊往往需要肾活检证实肾组织中有尿酸盐结晶沉积。晚期慢性尿酸盐肾病可导致肾小球滤过率下降和慢性肾衰竭。", "ner": [[3, 9, "Disease"], [11, 17, "Disease"], [23, 42, "Pathogenesis"], [44, 61, "Pathogenesis"], [63, 68, "Pathogenesis"], [70, 95, "Pathogenesis"], [97, 99, "Disease"], [113, 116, "Symptom"], [118, 121, "Symptom"], [123, 127, "Symptom"], [134, 140, "Disease"], [142, 143, "Test_items"], [144, 145, "Test_Value"], [149, 153, "Disease"], [149, 149, "Anatomy"], [165, 169, "Disease"], [167, 168, "Anatomy"], [185, 187, "Disease"], [191, 195, "Disease"], [193, 194, "Anatomy"], [205, 207, "Test"], [235, 240, "Test_items"], [241, 242, "Test_Value"], [244, 248, "Disease"], [246, 246, "Anatomy"], [8, 8, "Anatomy"], [16, 16, "Anatomy"], [139, 139, "Anatomy"], [223, 231, "Reason"]], "rel": [[8, 8, "Anatomy", 3, 9, "Disease", "Anatomy_Disease"], [16, 16, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [23, 42, "Pathogenesis", 11, 17, "Disease", "Pathogenesis_Disease"], [44, 61, "Pathogenesis", 11, 17, "Disease", "Pathogenesis_Disease"], [63, 68, "Pathogenesis", 11, 17, "Disease", "Pathogenesis_Disease"], [70, 95, "Pathogenesis", 11, 17, "Disease", "Pathogenesis_Disease"], [113, 116, "Symptom", 97, 99, "Disease", "Symptom_Disease"], [118, 121, "Symptom", 97, 99, "Disease", "Symptom_Disease"], [123, 127, "Symptom", 97, 99, "Disease", "Symptom_Disease"], [139, 139, "Anatomy", 134, 140, "Disease", "Anatomy_Disease"], [149, 149, "Anatomy", 149, 153, "Disease", "Anatomy_Disease"], [167, 168, "Anatomy", 165, 169, "Disease", "Anatomy_Disease"], [193, 194, "Anatomy", 191, 195, "Disease", "Anatomy_Disease"], [246, 246, "Anatomy", 244, 248, "Disease", "Anatomy_Disease"], [223, 231, "Reason", 244, 248, "Disease", "Reason_Disease"]]}
{"idx": 3345, "sentence": "慢性尿酸盐肾病一旦确诊即开始非药物治疗者，疗效不佳者根据尿酸水平及合并症开始药物治疗。出现肾功能损害(G2期及以上）、尿酸性肾石症患者血尿酸超过480μmol即开始降尿酸治疗，治疗目标值<360μmol／L。", "ner": [[0, 6, "Disease"], [45, 49, "Disease"], [59, 64, "Disease"], [5, 5, "Anatomy"], [45, 45, "Anatomy"], [62, 62, "Anatomy"], [28, 31, "Test_items"], [67, 69, "Test_items"], [70, 78, "Test_Value"], [93, 102, "Test_Value"]], "rel": [[5, 5, "Anatomy", 0, 6, "Disease", "Anatomy_Disease"], [45, 45, "Anatomy", 45, 49, "Disease", "Anatomy_Disease"], [62, 62, "Anatomy", 59, 64, "Disease", "Anatomy_Disease"]]}
{"idx": 3346, "sentence": "如合并严重痛风(如痛风石、慢性关节炎、痛风频繁发作)患者应严格控制血尿酸水平，治疗目标值<300μmol／L，但不建议180μmol／L以下。", "ner": [[5, 6, "Disease"], [3, 4, "Level"], [9, 11, "Disease"], [13, 17, "Disease"], [19, 20, "Disease"], [33, 37, "Test_items"], [44, 53, "Test_Value"], [59, 69, "Test_Value"], [15, 16, "Anatomy"]], "rel": [[15, 16, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"]]}
{"idx": 3347, "sentence": "(2)急性尿酸性肾病：急性尿酸性肾病是严重的HUA导致过量尿酸沉积并阻塞肾小管引起的少尿或无尿性急性肾损伤，多见于肿瘤溶解综合征。急性发生尿路梗阻，出现腰痛、少尿或无尿。急性肾血尿酸显著升高(>900μmol／L)应考虑急性尿酸性肾病，确诊常需肾活检，排除小管间质性肾炎等。", "ner": [[3, 9, "Disease"], [11, 17, "Disease"], [19, 20, "Level"], [22, 24, "Disease"], [27, 38, "Reason"], [48, 52, "Disease"], [57, 63, "Disease"], [69, 72, "Disease"], [76, 77, "Symptom"], [79, 80, "Symptom"], [82, 83, "Symptom"], [88, 90, "Test_items"], [91, 94, "Test_Value"], [96, 105, "Test_Value"], [110, 116, "Disease"], [122, 124, "Test"], [128, 134, "Disease"], [8, 8, "Anatomy"], [16, 16, "Anatomy"], [50, 50, "Anatomy"], [69, 70, "Anatomy"], [115, 115, "Anatomy"], [133, 133, "Anatomy"]], "rel": [[8, 8, "Anatomy", 3, 9, "Disease", "Anatomy_Disease"], [16, 16, "Anatomy", 11, 17, "Disease", "Anatomy_Disease"], [50, 50, "Anatomy", 48, 52, "Disease", "Anatomy_Disease"], [69, 70, "Anatomy", 69, 72, "Disease", "Anatomy_Disease"], [76, 77, "Symptom", 69, 72, "Disease", "Symptom_Disease"], [79, 80, "Symptom", 69, 72, "Disease", "Symptom_Disease"], [82, 83, "Symptom", 69, 72, "Disease", "Symptom_Disease"], [88, 90, "Test_items", 110, 116, "Disease", "Test_items_Disease"], [115, 115, "Anatomy", 110, 116, "Disease", "Anatomy_Disease"], [122, 124, "Test", 110, 116, "Disease", "Test_Disease"], [133, 133, "Anatomy", 128, 134, "Disease", "Anatomy_Disease"]]}
{"idx": 3348, "sentence": "肾脏病理可见肾小管不同程度变性、坏死，伴有部分肾小管萎缩和肾间质纤维化。", "ner": [], "rel": []}
{"idx": 3349, "sentence": "肾小球无明显病变或毛细血管襻缺血皱缩。", "ner": [], "rel": []}
{"idx": 3350, "sentence": "偏振光显微镜可见到肾小管腔内尿酸结晶沉积。", "ner": [], "rel": []}
{"idx": 3351, "sentence": "急性尿酸性肾病通常可逆，重在预防。高风险患者积极静脉补液，心肾功能允许情况下将尿量维持在80~100ml·m-2·h-1。首选重组尿酸酶，或黄嘌呤氧化酶抑制剂将血尿酸控制在300μmol／L以下；确诊急性尿酸者肾病患者需要紧急处理，及时有效的治疗下肾功能有望恢复正常。", "ner": [[0, 6, "Disease"], [5, 5, "Anatomy"], [24, 25, "Method"], [63, 67, "Drug"], [70, 78, "Drug"], [80, 82, "Test_items"], [86, 96, "Test_Value"], [100, 106, "Disease"], [105, 105, "Anatomy"]], "rel": [[5, 5, "Anatomy", 0, 6, "Disease", "Anatomy_Disease"], [105, 105, "Anatomy", 100, 106, "Disease", "Anatomy_Disease"]]}
{"idx": 3352, "sentence": "治疗措施包括：①严格低嘌呤饮食。", "ner": [[8, 14, "Treatment"]], "rel": []}
{"idx": 3353, "sentence": "②水化治疗：在没有禁忌情况下，每日液体摄入量应达到3000ml，保持尿量到80~100ml·m-2·h-1。", "ner": [[1, 4, "Treatment"]], "rel": []}
{"idx": 3354, "sentence": "③降尿酸药物：根据治疗前尿酸水平和／或发生肿瘤溶解综合征的风险选用。", "ner": [[12, 15, "Test_items"], [21, 27, "Disease"]], "rel": []}
{"idx": 3355, "sentence": "治疗前血尿酸<480μmol／L、肾功能无严重受损且发生肿瘤溶解综合征风险仅为中低度的患者可采用别嘌醇治疗，而治疗前血酸尿水平已经升高的患者建议选用尿酸酶治疗。", "ner": [[3, 5, "Test_items"], [6, 15, "Test_Value"], [28, 34, "Disease"], [48, 50, "Drug"], [58, 62, "Test_items"], [65, 66, "Test_Value"], [74, 76, "Drug"]], "rel": []}
{"idx": 3356, "sentence": "非布司他临床资料较少，仅在不宜或不能使用尿酸酶、别嘌醇的患者中谨慎使用。", "ner": [[0, 3, "Treatment"], [20, 22, "Treatment"], [24, 26, "Treatment"]], "rel": []}
{"idx": 3357, "sentence": "④必要时血液透析治疗。", "ner": [[4, 7, "Treatment"]], "rel": []}
{"idx": 3358, "sentence": "(3)尿酸性肾石症：随着生活水平的提高和饮食结构改变，尿酸性肾石症发病率呈上升趋势。美国尿酸结石占泌尿系结石8％～14％，我国占5.1％，仅次于草酸钙结石。尿液中尿酸溶解度下降和过饱和是尿酸结石形成的前提。尿酸性肾石症常表现为腰痛和血尿；急性梗阻时可引起急性肾损伤，表现为发热、少尿、无尿、肾积水，血肌酐升高等；慢性梗阻可引起肾积水和肾实质萎缩，甚至发展为终末期肾病。", "ner": [[3, 8, "Disease"], [6, 6, "Anatomy"], [27, 32, "Disease"], [30, 30, "Anatomy"], [44, 47, "Disease"], [49, 53, "Disease"], [72, 76, "Disease"], [78, 91, "Reason"], [93, 96, "Disease"], [103, 108, "Disease"], [106, 106, "Anatomy"], [113, 114, "Symptom"], [116, 117, "Symptom"], [119, 122, "Reason"], [127, 131, "Disease"], [129, 129, "Anatomy"], [136, 137, "Symptom"], [139, 140, "Symptom"], [142, 143, "Symptom"], [145, 147, "Symptom"], [149, 151, "Test_items"], [152, 153, "Test_Value"], [156, 159, "Reason"], [163, 165, "Disease"], [167, 171, "Disease"], [163, 163, "Anatomy"], [167, 169, "Anatomy"], [178, 182, "Disease"], [181, 181, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [30, 30, "Anatomy", 27, 32, "Disease", "Anatomy_Disease"], [78, 91, "Reason", 93, 96, "Disease", "Reason_Disease"], [106, 106, "Anatomy", 103, 108, "Disease", "Anatomy_Disease"], [113, 114, "Symptom", 103, 108, "Disease", "Symptom_Disease"], [116, 117, "Symptom", 103, 108, "Disease", "Symptom_Disease"], [119, 122, "Reason", 127, 131, "Disease", "Reason_Disease"], [129, 129, "Anatomy", 127, 131, "Disease", "Anatomy_Disease"], [136, 137, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [139, 140, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [142, 143, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [145, 147, "Symptom", 127, 131, "Disease", "Symptom_Disease"], [156, 159, "Reason", 163, 165, "Disease", "Reason_Disease"], [156, 159, "Reason", 167, 171, "Disease", "Reason_Disease"], [163, 163, "Anatomy", 163, 165, "Disease", "Anatomy_Disease"], [167, 169, "Anatomy", 167, 171, "Disease", "Anatomy_Disease"], [181, 181, "Anatomy", 178, 182, "Disease", "Anatomy_Disease"]]}
{"idx": 3359, "sentence": "尿酸性肾石症患者尿液pH值常低于6.0，尿沉渣检查可见尿酸盐结晶。肾脏B超可见高回声区伴声影。尿酸性结石X线摄片不显影(阴性结石)，阴性结石需与肾脏黄嘌呤、次黄嘌呤结石鉴别，后两者在碱性环境中不能溶解。", "ner": [[0, 5, "Disease"], [3, 3, "Anatomy"], [33, 36, "Test"], [39, 45, "Test_Value"], [20, 24, "Test"], [47, 55, "Test"], [56, 58, "Test_Value"], [60, 63, "Disease"], [66, 69, "Disease"], [72, 83, "Disease"], [72, 73, "Anatomy"]], "rel": [[33, 36, "Test", 0, 5, "Disease", "Test_Disease"], [72, 73, "Anatomy", 72, 83, "Disease", "Anatomy_Disease"]]}
{"idx": 3360, "sentence": "若混有草酸钙、磷酸钙等成分，则表现为密度不一的结石影。", "ner": [[18, 25, "Test_Value"]], "rel": []}
{"idx": 3361, "sentence": "静脉肾盂造影表现为充盈缺损。", "ner": [[0, 5, "Test"], [9, 12, "Test_Value"]], "rel": []}
{"idx": 3362, "sentence": "CT对尿酸性肾石症的诊断很有帮助，尿酸结石CT值为300～400HU，低于胱氨酸结石，但高于血块、肿瘤等病变。", "ner": [[0, 1, "Test"], [3, 8, "Disease"], [6, 6, "Anatomy"], [17, 20, "Disease"], [21, 23, "Test"], [25, 33, "Test_Value"], [37, 41, "Disease"], [46, 47, "Disease"], [49, 50, "Disease"]], "rel": [[0, 1, "Test", 3, 8, "Disease", "Test_Disease"], [6, 6, "Anatomy", 3, 8, "Disease", "Anatomy_Disease"], [21, 23, "Test", 17, 20, "Disease", "Test_Disease"]]}
{"idx": 3363, "sentence": "建议对已排出的结石石成分分析以明确诊断。", "ner": [], "rel": []}
{"idx": 3364, "sentence": "尿酸性肾石症治疗可采用排石疗法、体外冲击波碎石和／或手术治疗。", "ner": [[0, 5, "Disease"], [3, 3, "Anatomy"], [11, 14, "Treatment"], [16, 22, "Treatment"]], "rel": [[3, 3, "Anatomy", 0, 5, "Disease", "Anatomy_Disease"], [11, 14, "Treatment", 0, 5, "Disease", "Treatment_Disease"], [16, 22, "Treatment", 0, 5, "Disease", "Treatment_Disease"]]}
{"idx": 3365, "sentence": "排石疗法：适于结石直径0.5～1.0cm，且未导致尿路梗阻、感染或疼痛等症状的患者，包括一般疗法、中医中药和溶石疗法。一般疗法包括增加液体摄入、限制高嘌呤饮食及适当运动；中药治疗常采用排石颗粒、尿石通等药物；溶石疗法临床上常采用枸橼酸氢钾钠颗粒口服。", "ner": [[0, 3, "Treatment"], [7, 8, "Disease"], [25, 28, "Disease"], [25, 26, "Anatomy"], [30, 31, "Disease"], [33, 34, "Symptom"], [44, 47, "Treatment"], [54, 57, "Treatment"], [65, 70, "Treatment"], [72, 78, "Treatment"], [80, 83, "Treatment"], [92, 95, "Drug"], [97, 99, "Drug"], [104, 107, "Treatment"], [114, 121, "Drug"], [122, 123, "Method"]], "rel": [[25, 26, "Anatomy", 25, 28, "Disease", "Anatomy_Disease"], [122, 123, "Method", 114, 121, "Drug", "Method_Drug"]]}
{"idx": 3366, "sentence": "冲击波碎石：排石疗法治疗1～2个月后如效果不佳采用，适用于：①直径<2.0cm的肾盂结石、肾上盏或肾中盏结石；②直径<1.0cm的肾下盏结石，1.0～2.0cm下盏结石根据是否存在不利因素决定；③直径2.0～3.0cm或表面积<500mm2的部分鹿角形结石。", "ner": [[40, 43, "Disease"], [45, 53, "Disease"], [65, 69, "Disease"], [80, 83, "Disease"], [123, 127, "Disease"], [0, 4, "Treatment"], [6, 9, "Treatment"], [40, 41, "Anatomy"], [45, 47, "Anatomy"], [49, 51, "Anatomy"], [65, 67, "Anatomy"], [80, 81, "Anatomy"]], "rel": [[40, 41, "Anatomy", 40, 43, "Disease", "Anatomy_Disease"], [45, 47, "Anatomy", 45, 53, "Disease", "Anatomy_Disease"], [49, 51, "Anatomy", 45, 53, "Disease", "Anatomy_Disease"], [65, 67, "Anatomy", 65, 69, "Disease", "Anatomy_Disease"], [80, 81, "Anatomy", 80, 83, "Disease", "Anatomy_Disease"]]}
{"idx": 3367, "sentence": "冲击波碎石禁用于结石远端器质性梗阻、肾功能不全、未获控制的尿路感染。", "ner": [[8, 16, "Disease"], [18, 22, "Disease"], [29, 32, "Disease"], [0, 4, "Treatment"], [18, 18, "Anatomy"], [29, 30, "Anatomy"]], "rel": [[18, 18, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"], [29, 30, "Anatomy", 29, 32, "Disease", "Anatomy_Disease"]]}
{"idx": 3368, "sentence": "手术治疗：如尿酸结石造成尿路梗阻、严重感染或肾功能受损时采用手术治疗，包括开放手术、经皮肾镜手术及输尿管软镜手术。大于2.0cm肾结石、复杂性肾结石建议采用经皮肾镜。躯体严重畸形、过度肥胖等难以建立经皮肾痛道者为手术禁忌；输尿管软镜手术可用于体外冲击波效果不佳，直径小于2.0cm的结石。", "ner": [[6, 9, "Reason"], [12, 15, "Disease"], [12, 13, "Anatomy"], [19, 20, "Disease"], [17, 18, "Level"], [22, 26, "Disease"], [22, 22, "Anatomy"], [37, 40, "Operation"], [42, 47, "Operation"], [49, 55, "Operation"], [64, 66, "Disease"], [64, 64, "Anatomy"], [68, 73, "Disease"], [71, 71, "Anatomy"], [87, 88, "Disease"], [85, 86, "Level"], [90, 91, "Level"], [92, 93, "Disease"], [111, 117, "Operation"], [121, 125, "Treatment"], [141, 142, "Disease"]], "rel": [[6, 9, "Reason", 12, 15, "Disease", "Reason_Disease"], [6, 9, "Reason", 19, 20, "Disease", "Reason_Disease"], [6, 9, "Reason", 22, 26, "Disease", "Reason_Disease"], [12, 13, "Anatomy", 12, 15, "Disease", "Anatomy_Disease"], [22, 22, "Anatomy", 22, 26, "Disease", "Anatomy_Disease"], [64, 64, "Anatomy", 64, 66, "Disease", "Anatomy_Disease"], [71, 71, "Anatomy", 68, 73, "Disease", "Anatomy_Disease"], [111, 117, "Operation", 141, 142, "Disease", "Operation_Disease"]]}
{"idx": 3369, "sentence": "特殊类型的尿酸性结石如鹿角形结石可考虑溶石疗法、体外冲击波碎石及经皮肾镜取石等多种方法的联合治疗。", "ner": [[5, 9, "Disease"], [11, 15, "Disease"], [19, 22, "Treatment"], [24, 30, "Treatment"], [32, 37, "Treatment"]], "rel": []}
{"idx": 3370, "sentence": "(4)慢性肾脏病合并HUA：治疗时机及靶目标值同慢性尿酸盐肾病。慢性肾脏病患者的HUA治疗药物根据原发病、并发症及肾功能情况进行选择。", "ner": [[3, 7, "Disease"], [10, 12, "Disease"], [24, 30, "Disease"], [32, 36, "Disease"], [40, 42, "Disease"], [5, 6, "Anatomy"], [29, 29, "Anatomy"], [34, 35, "Anatomy"]], "rel": [[5, 6, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"], [29, 29, "Anatomy", 24, 30, "Disease", "Anatomy_Disease"], [34, 35, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"]]}
{"idx": 3371, "sentence": "慢性肾脏病(G4～5期)患者的痛风急性发作时不宜用NSAIDs，可给予糖皮质激素短期口服或关节内注射。也可根据eGFR酌情采用低剂量秋水仙碱治疗(见痛风急性发作期治疗)。", "ner": [[0, 4, "Disease"], [15, 16, "Disease"], [25, 30, "Drug"], [35, 39, "Drug"], [42, 43, "Method"], [45, 49, "Method"], [55, 58, "Test_items"], [2, 3, "Anatomy"], [66, 69, "Drug"], [74, 75, "Disease"]], "rel": [[2, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [42, 43, "Method", 35, 39, "Drug", "Method_Drug"], [45, 49, "Method", 35, 39, "Drug", "Method_Drug"]]}
{"idx": 3372, "sentence": "慢性肾脏病患者的降尿酸治疗可以降低肾小球尿酸荷，延缓慢性肾脏病进展，依据个体化治疗原则选择抑制尿酸生成药物和／或促尿酸排泄药物。肾功能受损可能增加别嘌醇的毒性，治疗需要从低剂量起始并小心滴定(详见药物治疗部分)。非布司他在轻中度肾功能不全患者(G1～3期)和轻中度肝损伤患者(Child—Pugh分级A／B）中应用无需调整剂量，G4～5期患者谨慎使用。非布司他超敏反应综合征发生率低于别嘌醇；促尿酸排泄药物苯溴马隆可用于轻中度肾功能不全(eGFR20～60ml·min-1·1.73m-2。", "ner": [[0, 4, "Disease"], [2, 3, "Anatomy"], [26, 30, "Disease"], [28, 29, "Anatomy"], [64, 68, "Disease"], [64, 64, "Anatomy"], [73, 75, "Drug"], [106, 109, "Drug"], [111, 113, "Level"], [114, 118, "Disease"], [114, 114, "Anatomy"], [129, 131, "Level"], [132, 134, "Disease"], [132, 132, "Anatomy"], [176, 179, "Drug"], [192, 194, "Drug"], [203, 206, "Drug"], [210, 212, "Level"], [213, 217, "Disease"], [213, 213, "Anatomy"], [219, 222, "Test_items"], [223, 243, "Test_Value"]], "rel": [[2, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [28, 29, "Anatomy", 26, 30, "Disease", "Anatomy_Disease"], [64, 64, "Anatomy", 64, 68, "Disease", "Anatomy_Disease"], [106, 109, "Drug", 114, 118, "Disease", "Drug_Disease"], [106, 109, "Drug", 132, 134, "Disease", "Drug_Disease"], [132, 132, "Anatomy", 132, 134, "Disease", "Anatomy_Disease"], [203, 206, "Drug", 213, 217, "Disease", "Drug_Disease"], [213, 213, "Anatomy", 213, 217, "Disease", "Anatomy_Disease"]]}
{"idx": 3373, "sentence": ")患者，推荐50mg／d，尿酸性肾石症和重度肾功不全(eGFR<20ml.min-1·1.73m-2)患者禁用。", "ner": [[6, 11, "Amount"], [13, 18, "Disease"], [16, 16, "Anatomy"], [20, 21, "Level"], [22, 25, "Disease"], [22, 22, "Anatomy"], [27, 30, "Test_items"], [31, 49, "Test_Value"]], "rel": [[16, 16, "Anatomy", 13, 18, "Disease", "Anatomy_Disease"], [22, 22, "Anatomy", 22, 25, "Disease", "Anatomy_Disease"]]}
{"idx": 3374, "sentence": "为防止慢性肾脏病患者降尿酸治疗时诱发痛风发作，治疗同时需预防性使用秋水仙碱。eGFR<10ml·min-1.73m-2或透析患者禁用，可考虑短期应用小剂量糖皮激素。", "ner": [[3, 7, "Disease"], [18, 19, "Disease"], [33, 36, "Drug"], [38, 41, "Test_items"], [42, 58, "Test_Value"], [60, 61, "Treatment"], [77, 80, "Drug"], [5, 6, "Anatomy"]], "rel": [[5, 6, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"], [33, 36, "Drug", 18, 19, "Disease", "Drug_Disease"]]}
{"idx": 3375, "sentence": "2.HUA与代谢综合征：代谢综合征是以肥胖高血压，高血糖、血脂异常等多种心血管疾病的危险因素同时存在于一个体的临床症候群，是一组在代谢上相互关险因素的组合，这些因素直接促进了动脉粥样硬化性血管疾病的发生，也增加了发生2型糖尿病的风险。多项研究显示，HUA与代谢综合征存在密切的联系，亦有学者将HUA作为代谢综合征的组分之一。胰岛素抵抗是代谢综合征的共同病理生理基础。", "ner": [[2, 4, "Disease"], [6, 10, "Disease"], [12, 16, "Disease"], [87, 97, "Disease"], [36, 40, "Disease"], [108, 112, "Disease"], [124, 126, "Disease"], [128, 132, "Disease"], [146, 148, "Disease"], [151, 155, "Disease"], [168, 172, "Disease"], [36, 38, "Anatomy"], [87, 88, "Anatomy"], [19, 23, "Disease"], [25, 27, "Disease"], [29, 32, "Disease"], [162, 166, "Pathogenesis"]], "rel": [[87, 88, "Anatomy", 87, 97, "Disease", "Anatomy_Disease"], [36, 38, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [162, 166, "Pathogenesis", 168, 172, "Disease", "Pathogenesis_Disease"]]}
{"idx": 3376, "sentence": "(1)肥胖：尤其是腹型肥胖与HUA关系密切一相关的轻度慢性炎症和胰岛素抵抗状态增加HUA和痛风的风险。减轻体重特别是减小腹围是非药物治疗降低尿酸水平的有效方法。", "ner": [[3, 4, "Disease"], [9, 12, "Disease"], [14, 16, "Disease"], [27, 30, "Reason"], [41, 43, "Disease"], [45, 46, "Disease"], [32, 36, "Pathogenesis"], [51, 54, "Treatment"], [58, 61, "Treatment"], [70, 73, "Test_items"], [9, 9, "Anatomy"], [25, 26, "Level"]], "rel": [[9, 9, "Anatomy", 9, 12, "Disease", "Anatomy_Disease"], [27, 30, "Reason", 41, 43, "Disease", "Reason_Disease"], [27, 30, "Reason", 45, 46, "Disease", "Reason_Disease"], [32, 36, "Pathogenesis", 41, 43, "Disease", "Pathogenesis_Disease"], [32, 36, "Pathogenesis", 45, 46, "Disease", "Pathogenesis_Disease"]]}
{"idx": 3377, "sentence": "(2)高血压：大量研究显示HUA是高血压的独立的危险因素。对于HUA合并高血压患者，优先考虑利尿剂以外的降压药物。氯沙坦钾具有促尿酸排泄的作用，并通过降低血尿酸水平使心血管事件减少13％～29％。氨氯地平是具有促尿酸排泄作用的二氢吡啶类钙拮抗剂，推荐用于合并缺血性卒中的高血压患者。", "ner": [[3, 5, "Disease"], [17, 19, "Disease"], [31, 33, "Disease"], [36, 38, "Disease"], [129, 133, "Disease"], [135, 137, "Disease"], [13, 15, "Reason"], [46, 48, "Drug"], [57, 60, "Drug"], [83, 87, "Disease"], [83, 85, "Anatomy"], [98, 101, "Drug"], [113, 121, "Drug"]], "rel": [[13, 15, "Reason", 17, 19, "Disease", "Reason_Disease"], [98, 101, "Drug", 135, 137, "Disease", "Drug_Disease"], [83, 85, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"]]}
{"idx": 3378, "sentence": "(3)高血糖：有研究显示糖尿病患者HUA检出率增高。", "ner": [[3, 5, "Disease"], [12, 14, "Disease"], [17, 19, "Disease"]], "rel": []}
{"idx": 3379, "sentence": "血尿酸水平增高不仅增加2型糖尿病的患病风险，而且是非糖尿病人群未来发生2型糖尿病的独立危险因素。HUA还是糖尿病肾病进展和恶化的重要预测因子。", "ner": [[11, 15, "Disease"], [26, 28, "Disease"], [35, 39, "Disease"], [48, 50, "Disease"], [53, 57, "Disease"], [56, 56, "Anatomy"], [0, 4, "Test_items"], [5, 6, "Test_Value"]], "rel": [[56, 56, "Anatomy", 53, 57, "Disease", "Anatomy_Disease"]]}
{"idx": 3380, "sentence": "糖代谢异常患者血尿酸>480μmol／L应立即起始降尿酸药物治疗。现有的临床资料没有显示降糖药物水平具有不良影响。磺脲类药物可促进尿酸的排出。α糖苷酶抑制剂阿卡波糖可减轻因蔗糖分解导致的血尿酸水平的升高，噻唑烷二酮类药物可能通过减轻胰岛素抵抗而降低血尿酸水平，达格列净、卡格列净等钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂能降低血尿酸水平。", "ner": [[0, 4, "Disease"], [7, 9, "Test_items"], [10, 19, "Test_Value"], [57, 61, "Drug"], [93, 97, "Test_items"], [99, 100, "Test_Value"], [102, 109, "Drug"], [116, 120, "Pathogenesis"], [124, 128, "Test_items"], [130, 133, "Drug"], [135, 138, "Drug"], [140, 162, "Drug"], [166, 170, "Test_items"], [71, 77, "Drug"], [78, 81, "Drug"]], "rel": [[7, 9, "Test_items", 0, 4, "Disease", "Test_items_Disease"]]}
{"idx": 3381, "sentence": "(4)血脂紊乱：血脂紊乱是HUA和痛风常见的合并症，高甘油三酯血症是发生HUA的独立预测因素。对于高胆固醇血症或动脉粥样硬化合并HUA患者，优先考虑阿托伐他汀；对于高甘油三酯血症合并HUA的患者，优先考虑非诺贝特。", "ner": [[3, 6, "Disease"], [8, 11, "Disease"], [13, 15, "Disease"], [17, 18, "Disease"], [26, 32, "Disease"], [36, 38, "Disease"], [49, 54, "Disease"], [56, 61, "Disease"], [64, 66, "Disease"], [82, 88, "Disease"], [91, 93, "Disease"], [56, 57, "Anatomy"], [74, 78, "Drug"], [102, 105, "Drug"]], "rel": [[56, 57, "Anatomy", 56, 61, "Disease", "Anatomy_Disease"], [74, 78, "Drug", 64, 66, "Disease", "Drug_Disease"], [102, 105, "Drug", 91, 93, "Disease", "Drug_Disease"]]}
{"idx": 3382, "sentence": "上述两种药物均具有促尿酸排泄作用。", "ner": [], "rel": []}
{"idx": 3383, "sentence": "3.HUA与心血管疾病：HUA是心血管疾病的独立危险因素，同时与许多传统的心血管危险因素相互作用参与心血管疾病的发生、发展及转归。对于HUA合并高血压、冠心病、心力衰竭(心衰)等患者，若血尿酸>480μmol／L，应起始药物降尿酸治疗，可有效防治与其相关的心血降低心血管疾病，降低心血管事件发生率。", "ner": [[2, 4, "Disease"], [6, 10, "Disease"], [50, 54, "Disease"], [67, 69, "Disease"], [72, 74, "Disease"], [76, 78, "Disease"], [80, 83, "Disease"], [85, 86, "Disease"], [132, 136, "Disease"], [140, 144, "Disease"], [6, 8, "Anatomy"], [50, 52, "Anatomy"], [85, 85, "Anatomy"], [132, 134, "Anatomy"], [140, 142, "Anatomy"], [93, 95, "Test_items"], [96, 105, "Test_Value"], [12, 14, "Reason"], [16, 20, "Disease"], [16, 18, "Anatomy"]], "rel": [[6, 8, "Anatomy", 6, 10, "Disease", "Anatomy_Disease"], [50, 52, "Anatomy", 50, 54, "Disease", "Anatomy_Disease"], [93, 95, "Test_items", 67, 69, "Disease", "Test_items_Disease"], [85, 85, "Anatomy", 85, 86, "Disease", "Anatomy_Disease"], [132, 134, "Anatomy", 132, 136, "Disease", "Anatomy_Disease"], [140, 142, "Anatomy", 140, 144, "Disease", "Anatomy_Disease"], [12, 14, "Reason", 16, 20, "Disease", "Reason_Disease"], [16, 18, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"]]}
{"idx": 3384, "sentence": "黄嘌呤氧化酶抑制剂在降低血尿酸之外，改善内皮功能、减少氧化应激、调节心肌能量代谢，从而进一管事件的发生率。NSAIDs类药物可导致水钠潴留及肾功能损伤，增加心衰恶化与心衰住院风险，因而在急、慢性心衰患者中应尽量避免使用该类药物。", "ner": [[0, 8, "Drug"], [53, 61, "Drug"], [65, 68, "ADE"], [70, 74, "ADE"], [76, 88, "ADE"], [93, 98, "Disease"], [97, 97, "Anatomy"]], "rel": [[65, 68, "ADE", 53, 61, "Drug", "ADE_Drug"], [70, 74, "ADE", 53, 61, "Drug", "ADE_Drug"], [76, 88, "ADE", 53, 61, "Drug", "ADE_Drug"], [97, 97, "Anatomy", 93, 98, "Disease", "Anatomy_Disease"]]}
{"idx": 3385, "sentence": "(1)HUA与高血压：HUA与高血压之间存在独立的相互关系，血尿酸水平是高血压发病、长期血压变化及预后的独立预测因子。血尿酸水平每增加60μmol／L，高血压发生的风险增加15％～23％。对于高尿酸合并高血压患者降压药物的选择详见HUA与代谢综合征部分。", "ner": [[3, 5, "Disease"], [7, 9, "Disease"], [11, 13, "Disease"], [15, 17, "Disease"], [36, 38, "Disease"], [76, 78, "Disease"], [96, 98, "Disease"], [101, 103, "Disease"], [115, 117, "Disease"], [119, 123, "Disease"], [30, 34, "Test_items"], [59, 63, "Test_items"], [65, 74, "Test_Value"]], "rel": [[30, 34, "Test_items", 36, 38, "Disease", "Test_items_Disease"]]}
{"idx": 3386, "sentence": "(2)HUA与冠心病：血尿酸水平每升高60μmol／L，女性心血管病病死率和缺血性心脏病病死率增加26％和30%;男性增加9％和17％，女性冠心病增加48%。HUA是女性全因死亡和冠心病死亡的独立危险因素，HUA对男性和女性冠心病的发生和预后影响不同，可能与雌激素水平的影响有关。", "ner": [[3, 5, "Disease"], [7, 9, "Disease"], [30, 33, "Disease"], [38, 43, "Disease"], [70, 72, "Disease"], [79, 81, "Reason"], [90, 92, "Disease"], [103, 105, "Reason"], [112, 114, "Disease"], [11, 15, "Test_items"], [17, 26, "Test_Value"], [129, 133, "Test_items"], [30, 32, "Anatomy"], [41, 42, "Anatomy"]], "rel": [[30, 32, "Anatomy", 30, 33, "Disease", "Anatomy_Disease"], [41, 42, "Anatomy", 38, 43, "Disease", "Anatomy_Disease"], [103, 105, "Reason", 112, 114, "Disease", "Reason_Disease"]]}
{"idx": 3387, "sentence": "在冠心病一级、二级预防的药物治疗方面，应考虑阿司匹林和阿托伐他汀等药物对血尿酸的影响。阿司匹林对于尿酸代谢的影响具有剂量特异性：大剂量阿司匹林(>3g/d)可明显抑制肾小管对尿酸的重吸收，促进尿酸排泄；中等剂量阿司匹林(<1～2g／d)抑制肾小管对尿酸的排泄，从而引起血尿酸水平升高。小剂量阿司匹林（75~325mg／d)轻度升高血尿酸，但考虑到75～325mg／d阿司匹林抗血小板作用相关的心、脑血管获益，对合并HUA的患者不建议停用，建议碱化尿液、多饮水，同时监测血尿酸水平。", "ner": [[22, 25, "Drug"], [27, 31, "Drug"], [43, 46, "Drug"], [67, 70, "Drug"], [105, 108, "Drug"], [145, 148, "Drug"], [183, 186, "Drug"], [72, 76, "Amount"], [110, 116, "Amount"], [150, 159, "Amount"], [173, 182, "Amount"], [1, 3, "Disease"], [36, 38, "Test_items"], [134, 138, "Test_items"], [139, 140, "Test_Value"], [165, 167, "Test_items"], [221, 224, "Treatment"], [226, 228, "Treatment"], [207, 209, "Disease"], [232, 238, "Treatment"]], "rel": [[22, 25, "Drug", 1, 3, "Disease", "Drug_Disease"], [27, 31, "Drug", 1, 3, "Disease", "Drug_Disease"], [72, 76, "Amount", 67, 70, "Drug", "Amount_Drug"], [110, 116, "Amount", 105, 108, "Drug", "Amount_Drug"], [150, 159, "Amount", 145, 148, "Drug", "Amount_Drug"], [173, 182, "Amount", 183, 186, "Drug", "Amount_Drug"], [36, 38, "Test_items", 1, 3, "Disease", "Test_items_Disease"], [221, 224, "Treatment", 207, 209, "Disease", "Treatment_Disease"], [226, 228, "Treatment", 207, 209, "Disease", "Treatment_Disease"], [232, 238, "Treatment", 207, 209, "Disease", "Treatment_Disease"]]}
{"idx": 3388, "sentence": "阿托伐他汀具有较弱的降尿酸作用，并HUA冠心病二级预防可优先使用。", "ner": [[0, 4, "Drug"], [17, 19, "Disease"], [20, 22, "Disease"]], "rel": [[0, 4, "Drug", 17, 19, "Disease", "Drug_Disease"], [0, 4, "Drug", 20, 22, "Disease", "Drug_Disease"]]}
{"idx": 3389, "sentence": "HUA是造影剂相关急性肾损伤的独立危险因素。HUA患者接受冠状动脉CT成像或冠状动脉造影前建议检血尿酸，并进行危险分层，加强水化，避免使用高渗性对比剂，并减少对比剂剂量。", "ner": [[0, 2, "Reason"], [4, 13, "Disease"], [11, 11, "Anatomy"], [22, 24, "Disease"], [29, 36, "Test"], [38, 43, "Test"], [48, 50, "Test_items"]], "rel": [[0, 2, "Reason", 4, 13, "Disease", "Reason_Disease"], [11, 11, "Anatomy", 4, 13, "Disease", "Anatomy_Disease"], [29, 36, "Test", 22, 24, "Disease", "Test_Disease"], [38, 43, "Test", 22, 24, "Disease", "Test_Disease"], [48, 50, "Test_items", 22, 24, "Disease", "Test_items_Disease"]]}
{"idx": 3390, "sentence": "(3)HUA与心衰：血尿酸水平增高与慢性心衰严重程度相关，并随纽约心脏病学会心功能分级(NYHA分级)加重而增加，血尿酸水平增高是慢性心衰患者预后不佳的独立预测因子。", "ner": [[3, 5, "Disease"], [7, 8, "Disease"], [7, 7, "Anatomy"], [10, 14, "Test_items"], [15, 16, "Test_Value"], [18, 21, "Disease"], [20, 20, "Anatomy"], [33, 35, "Disease"], [33, 34, "Anatomy"], [57, 61, "Test_items"], [62, 63, "Test_Value"], [65, 68, "Disease"], [67, 67, "Anatomy"]], "rel": [[7, 7, "Anatomy", 7, 8, "Disease", "Anatomy_Disease"], [10, 14, "Test_items", 18, 21, "Disease", "Test_items_Disease"], [20, 20, "Anatomy", 18, 21, "Disease", "Anatomy_Disease"], [57, 61, "Test_items", 65, 68, "Disease", "Test_items_Disease"], [67, 67, "Anatomy", 65, 68, "Disease", "Anatomy_Disease"]]}
{"idx": 3391, "sentence": "急性失代偿性心衰患者使用襻利尿剂或合并慢性肾衰竭等都可能引起血尿酸升高，导致不良预后，去除这些混杂因素后，高尿酸仍与短期预后不良(院内死亡)和长期预后不良(心源性死亡和心衰再次入院)相关。", "ner": [[0, 7, "Disease"], [6, 6, "Anatomy"], [12, 15, "Drug"], [19, 23, "Disease"], [21, 21, "Anatomy"], [30, 32, "Test_items"], [33, 34, "Test_Value"], [53, 55, "Disease"], [84, 85, "Disease"], [84, 84, "Anatomy"]], "rel": [[6, 6, "Anatomy", 0, 7, "Disease", "Anatomy_Disease"], [12, 15, "Drug", 0, 7, "Disease", "Drug_Disease"], [21, 21, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [84, 84, "Anatomy", 84, 85, "Disease", "Anatomy_Disease"]]}
{"idx": 3392, "sentence": "长期使用排钾利尿剂(尤其是噻嗪类利尿剂)降低肾脏尿酸清除率，可诱发或加重HUA。", "ner": [[4, 8, "Drug"], [13, 18, "Drug"], [22, 28, "Test_items"], [36, 38, "Disease"]], "rel": []}
{"idx": 3393, "sentence": "对于合并HUA的心衰患者，首选非噻嗪类利尿剂，同时摄取适量的水分并碱化尿液；另外，因噻嗪类利尿剂可能增加别嘌醇发生超敏反应的风险，尽量避免二者同时使用。", "ner": [[15, 21, "Drug"], [42, 47, "Drug"], [4, 6, "Disease"], [8, 9, "Disease"], [8, 8, "Anatomy"], [52, 54, "Drug"], [57, 60, "ADE"]], "rel": [[15, 21, "Drug", 8, 9, "Disease", "Drug_Disease"], [8, 8, "Anatomy", 8, 9, "Disease", "Anatomy_Disease"], [57, 60, "ADE", 52, 54, "Drug", "ADE_Drug"]]}
{"idx": 3394, "sentence": "4.HUA与神经系统疾病：HUA与多种神经系统疾病相关。", "ner": [[2, 4, "Disease"], [6, 11, "Disease"], [13, 15, "Disease"], [19, 24, "Disease"]], "rel": []}
{"idx": 3395, "sentence": "HUA促进缺血性卒中的发生及不良预后，而在神经退化行性疾病如阿尔茨海默病和帕金森病等疾病中，观察到血尿酸升高具有保护作用。尿酸与神经系统疾病间的内再联系有待进一步探索。", "ner": [[0, 2, "Disease"], [5, 9, "Disease"], [21, 28, "Disease"], [30, 35, "Disease"], [37, 40, "Disease"], [64, 69, "Disease"], [49, 51, "Test_items"], [52, 53, "Test_Value"], [61, 62, "Test_items"]], "rel": [[49, 51, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [61, 62, "Test_items", 64, 69, "Disease", "Test_items_Disease"]]}
{"idx": 3396, "sentence": "(1)HUA与缺血性卒中：血尿酸水平升高，尤其>420μmol／L是卒中的独立危险因素。HUA促进卒中发生，是我国人群缺血性卒中的独立危险因素。此外对非卒中患者的长期随访发现，血尿酸水平的增高可能时女性患者无症状性脑梗死及预期卒中的重要血清学指标，提示控制血尿酸水平对女性HUA患者预防卒中发生可能更重要的意义。", "ner": [[3, 5, "Disease"], [7, 11, "Disease"], [34, 35, "Disease"], [44, 46, "Reason"], [49, 50, "Disease"], [59, 63, "Disease"], [76, 77, "Disease"], [103, 109, "Disease"], [113, 114, "Disease"], [136, 138, "Disease"], [143, 144, "Disease"], [107, 107, "Anatomy"], [13, 17, "Test_items"], [18, 19, "Test_Value"], [23, 32, "Test_Value"], [88, 92, "Test_items"], [94, 95, "Test_Value"], [128, 132, "Test_items"]], "rel": [[44, 46, "Reason", 49, 50, "Disease", "Reason_Disease"], [107, 107, "Anatomy", 103, 109, "Disease", "Anatomy_Disease"], [88, 92, "Test_items", 103, 109, "Disease", "Test_items_Disease"], [88, 92, "Test_items", 113, 114, "Disease", "Test_items_Disease"], [128, 132, "Test_items", 143, 144, "Disease", "Test_items_Disease"]]}
{"idx": 3397, "sentence": "高血尿酸水平与卒中后早期死亡风险呈正相关，血尿酸水平增高可提示患者卒中后90d预后不良。急性卒患者血尿酸增高是卒中复发的独立危险因素。血尿酸水平可作为急性缺血性卒中患者预后评估的一项指标，预测卒中后死亡及复发的风险。", "ner": [[0, 5, "Symptom"], [7, 8, "Disease"], [21, 25, "Test_items"], [26, 27, "Test_Value"], [33, 34, "Disease"], [49, 51, "Test_items"], [52, 53, "Test_Value"], [55, 56, "Disease"], [67, 71, "Test_items"], [75, 81, "Disease"], [96, 97, "Disease"]], "rel": [[0, 5, "Symptom", 7, 8, "Disease", "Symptom_Disease"], [21, 25, "Test_items", 33, 34, "Disease", "Test_items_Disease"], [49, 51, "Test_items", 55, 56, "Disease", "Test_items_Disease"], [67, 71, "Test_items", 75, 81, "Disease", "Test_items_Disease"]]}
{"idx": 3398, "sentence": "而对脑梗死溶栓患者而言，高血尿酸水平与脑梗死容积以及预后良好(改良Rankin量表评分小于2分)相关，较低血尿酸水平与恶性大脑中动脉梗死以及出血转化相关。溶栓患者高血尿酸水平与临床症状改善呈正相关，阿替普酶溶栓同时静脉输注尿酸治疗能够改善女性患者预后，而对于男性患者不明显，可能与女性基础血尿酸水平低于男性有关。", "ner": [[2, 4, "Disease"], [2, 2, "Anatomy"], [12, 17, "Symptom"], [19, 21, "Disease"], [19, 19, "Anatomy"], [51, 57, "Symptom"], [59, 67, "Disease"], [61, 65, "Anatomy"], [70, 71, "Symptom"], [81, 86, "Symptom"], [99, 102, "Drug"], [107, 110, "Method"], [111, 112, "Drug"], [144, 148, "Test_items"]], "rel": [[2, 2, "Anatomy", 2, 4, "Disease", "Anatomy_Disease"], [19, 19, "Anatomy", 19, 21, "Disease", "Anatomy_Disease"], [61, 65, "Anatomy", 59, 67, "Disease", "Anatomy_Disease"], [107, 110, "Method", 111, 112, "Drug", "Method_Drug"]]}
{"idx": 3399, "sentence": "HUA促进缺血性卒中发生，增加卒中后早期死亡及复发，对HUA进行长期管理，有效降低血尿酸水平可以减少缺血性卒中的发生及不良预后，其治疗起始目标和最终目标参照相关章节。仅对急性缺血性卒中溶栓患者建议短期内将血尿酸保持在较高水平有助于改善临床症状及预后。", "ner": [[5, 9, "Disease"], [15, 16, "Disease"], [27, 29, "Disease"], [50, 54, "Disease"], [85, 91, "Disease"], [41, 45, "Test_items"], [102, 104, "Test_items"], [0, 2, "Reason"]], "rel": [[0, 2, "Reason", 5, 9, "Disease", "Reason_Disease"], [41, 45, "Test_items", 50, 54, "Disease", "Test_items_Disease"], [102, 104, "Test_items", 85, 91, "Disease", "Test_items_Disease"]]}
{"idx": 3400, "sentence": "HUA患者合并卒中或经评估具有卒中高危因素，需要考虑药物治疗。", "ner": [[0, 2, "Disease"], [7, 8, "Disease"], [15, 16, "Disease"]], "rel": []}
{"idx": 3401, "sentence": "用药时应充分考虑阿司匹林和阿托伐他汀等药物对血尿酸的影响。", "ner": [[8, 11, "Drug"], [13, 17, "Drug"], [22, 24, "Test_items"]], "rel": []}
{"idx": 3402, "sentence": "具体参见相关冠心病用药。", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 3403, "sentence": "(2)HUA与神经退行性疾病：阿尔茨海默病是最常见的痴呆类型，轻度认知功能障碍和阿尔茨海默病患者血尿酸水平较正常人群低，高尿酸饮食可延缓轻度认知功能障碍患者转变为阿尔茨海默病的进程。血尿酸水平升高有助于减少阿尔茨海默病的发生，保护阿尔茨海默病患者的认知功能损伤。", "ner": [[3, 5, "Disease"], [7, 13, "Disease"], [15, 20, "Disease"], [26, 27, "Disease"], [31, 38, "Disease"], [40, 45, "Disease"], [68, 75, "Disease"], [81, 86, "Disease"], [103, 108, "Disease"], [115, 120, "Disease"], [48, 52, "Test_items"], [58, 58, "Test_Value"], [60, 64, "Treatment"], [91, 95, "Test_items"], [96, 97, "Test_Value"], [124, 129, "Symptom"]], "rel": [[48, 52, "Test_items", 31, 38, "Disease", "Test_items_Disease"], [48, 52, "Test_items", 40, 45, "Disease", "Test_items_Disease"], [60, 64, "Treatment", 68, 75, "Disease", "Treatment_Disease"], [91, 95, "Test_items", 103, 108, "Disease", "Test_items_Disease"], [124, 129, "Symptom", 115, 120, "Disease", "Symptom_Disease"]]}
{"idx": 3404, "sentence": "血尿酸水平过低增加轻度认知功能障碍患者认知功能下降的风险。", "ner": [[9, 16, "Disease"], [0, 4, "Test_items"]], "rel": [[0, 4, "Test_items", 9, 16, "Disease", "Test_items_Disease"]]}
{"idx": 3405, "sentence": "帕金森病是好发于中老年人的一种常见中枢神经系统退行性疾病，血尿酸水平高的人群发生帕金森病风险较低。血尿酸水平升高有助于减少帕金森病率和延缓其进展。伴血尿酸水平高或痛风的男性患者发生帕金森病的风险相对较低，女性则无明显相关性。", "ner": [[0, 3, "Disease"], [17, 27, "Disease"], [40, 43, "Disease"], [61, 64, "Disease"], [81, 82, "Disease"], [90, 93, "Disease"], [29, 33, "Test_items"], [34, 34, "Test_Value"], [49, 53, "Test_items"], [54, 55, "Test_Value"], [74, 78, "Test_items"], [79, 79, "Test_Value"]], "rel": [[29, 33, "Test_items", 40, 43, "Disease", "Test_items_Disease"], [49, 53, "Test_items", 61, 64, "Disease", "Test_items_Disease"], [74, 78, "Test_items", 90, 93, "Disease", "Test_items_Disease"]]}
{"idx": 3406, "sentence": "血尿酸水平和神经系统疾病的关系复杂，HUA血性卒中的发生及预后不良，生理浓度的血尿酸水平对神经系统有一定的保护作用，血尿酸水平过低有可能增加神经退行性疾病发生的风险，故将血尿酸水平控制在合理范围内有助于整体健康。", "ner": [[0, 4, "Test_items"], [6, 11, "Disease"], [18, 24, "Disease"], [70, 76, "Disease"], [39, 43, "Test_items"], [58, 62, "Test_items"], [63, 64, "Test_Value"], [85, 89, "Test_items"]], "rel": [[0, 4, "Test_items", 6, 11, "Disease", "Test_items_Disease"], [58, 62, "Test_items", 70, 76, "Disease", "Test_items_Disease"]]}
{"idx": 3407, "sentence": "本共识是首个HUA相关疾病的多学科专家共识。", "ner": [[6, 8, "Disease"]], "rel": []}
{"idx": 3408, "sentence": "共识从系统医学角度全面认识疾病，参考国内外研究的最新成果，结合中国国情和国内诊疗实践特点，多学科协作、中西医结合、内外兼治，连续、全程、系统地管控HUA及其相关疾病，旨在推动国内各学科对HUA相关疾病的认识，规范和指导其临床实践，改善患者预后。", "ner": [[73, 75, "Disease"], [93, 95, "Disease"]], "rel": []}
{"idx": 3409, "sentence": "本共识采用统一的HUA诊断标准，提出个体化、分层、达标治疗，长程管理，同时考虑尿酸本身的生理作用，设定降尿酸治疗目标的下限，重点强调患者管理及非药物治疗的重要性。", "ner": [[8, 10, "Disease"]], "rel": []}
{"idx": 3410, "sentence": "鉴于中国人群的相关研究数据相对缺乏、临床研究质量有待提高等现状，本共识建议今后开展多学科联合研究，尤其是开展我国不同区域HUA及其影响因素的流行病学研究，降尿酸治疗对相应系统损害结局的前瞻性研究，单一和联合降尿酸药物治疗的安全性及有效性研究等，为下一步制定中国人HUA相关疾病临床指南提供依据。", "ner": [[60, 62, "Disease"], [131, 133, "Disease"]], "rel": []}
{"idx": 3411, "sentence": "附件1导致血尿酸升高的因素", "ner": [[5, 7, "Test_items"], [8, 9, "Test_Value"]], "rel": []}
{"idx": 3412, "sentence": "尿酸生成过多：特发性、富含嘌呤饮食，次黄嘌呤-鸟嘌呤磷酸核糖基转移酶(HPRT)缺乏症、5-磷酸核糖-1-焦磷酸(PRPP)合成酶亢进症、溶血、淋巴增生性疾病、骨髓增生性疾病、真红细胞增多症、银屑病、Paget’s病、糖员贮积症（III、IV、VII型)、横纹肌溶解、运动、饮酒、肥胖。", "ner": [[18, 42, "Disease"], [44, 67, "Disease"], [69, 70, "Disease"], [72, 78, "Disease"], [80, 86, "Disease"], [88, 94, "Disease"], [96, 98, "Disease"], [100, 107, "Disease"], [109, 113, "Disease"], [128, 132, "Disease"], [7, 16, "Reason"], [134, 135, "Reason"], [137, 138, "Reason"], [140, 141, "Reason"], [80, 81, "Anatomy"]], "rel": [[80, 81, "Anatomy", 80, 86, "Disease", "Anatomy_Disease"]]}
{"idx": 3413, "sentence": "尿酸排泄减少：特发性、肾功能不全、多囊肾病、糖尿病、尿崩症、高血压、饥饿性酮症、酸中毒(乳酸酸中毒、糖尿病酮症酸中毒)、铅中毒、铍中毒、甲状腺功能减退，甲状腺功能亢进、妊娠中毒症、巴特综合征、唐氏综合征，肉状瘤病。", "ner": [[7, 15, "Disease"], [17, 20, "Disease"], [22, 24, "Disease"], [26, 28, "Disease"], [30, 32, "Disease"], [34, 38, "Disease"], [40, 42, "Disease"], [44, 48, "Disease"], [50, 57, "Disease"], [60, 62, "Disease"], [64, 66, "Disease"], [68, 74, "Disease"], [76, 82, "Disease"], [84, 88, "Disease"], [90, 94, "Disease"], [96, 100, "Disease"], [102, 105, "Disease"], [11, 11, "Anatomy"], [19, 19, "Anatomy"], [68, 70, "Anatomy"], [76, 78, "Anatomy"]], "rel": [[11, 11, "Anatomy", 7, 15, "Disease", "Anatomy_Disease"], [19, 19, "Anatomy", 17, 20, "Disease", "Anatomy_Disease"], [68, 70, "Anatomy", 68, 74, "Disease", "Anatomy_Disease"], [76, 78, "Anatomy", 76, 82, "Disease", "Anatomy_Disease"]]}
{"idx": 3414, "sentence": "混合性机制：葡萄糖-6-磷酸酶缺乏、果糖-1-磷酸醛缩酶缺乏、饮酒、休克。", "ner": [[6, 16, "Reason"], [18, 29, "Reason"], [31, 32, "Reason"], [34, 35, "Reason"]], "rel": []}
{"idx": 3415, "sentence": "附件2影响尿酸代谢的药物", "ner": [], "rel": []}
{"idx": 3416, "sentence": "导致尿酸升高的药物：阿司匹林(<2g／d)、噻嗪类利尿剂、吡嗪酰胺、环孢素A、细胞毒药物、左旋多巴、果糖，襻利尿剂、乙胺丁醇、他克莫司、烟酸、甲氧氟烷。", "ner": [[10, 13, "Drug"], [22, 27, "Drug"], [29, 32, "Drug"], [34, 37, "Drug"], [39, 43, "Drug"], [45, 48, "Drug"], [50, 51, "Drug"], [53, 56, "Drug"], [58, 61, "Drug"], [63, 66, "Drug"], [68, 69, "Drug"], [71, 74, "Drug"], [15, 19, "Amount"]], "rel": [[15, 19, "Amount", 10, 13, "Drug", "Amount_Drug"]]}
{"idx": 3417, "sentence": "促进尿酸排泄的药物：醋酸己脲、促肾上腺皮质激素、维生素C、尿苷、甲氯芬那酸、酚红、苯基丁氮酮、丙磺舒，射线造影剂、阿司匹林(>2g／d)、磺吡酮、糖皮质激素、愈创木酚甘油醚、格隆溴铵、降脂酰胺、氯沙坦、降钙素、利血平、枸襻酸、双香豆素、二氟尼柳、雌激素、非诺贝特、氯苯锉胺。", "ner": [[10, 13, "Drug"], [15, 22, "Drug"], [24, 27, "Drug"], [29, 30, "Drug"], [32, 36, "Drug"], [38, 39, "Drug"], [41, 45, "Drug"], [47, 49, "Drug"], [51, 55, "Drug"], [57, 60, "Drug"], [69, 71, "Drug"], [73, 77, "Drug"], [79, 85, "Drug"], [87, 90, "Drug"], [92, 95, "Drug"], [97, 99, "Drug"], [101, 103, "Drug"], [105, 107, "Drug"], [109, 111, "Drug"], [113, 116, "Drug"], [118, 121, "Drug"], [123, 125, "Drug"], [127, 130, "Drug"], [132, 135, "Drug"], [62, 66, "Amount"]], "rel": [[62, 66, "Amount", 57, 60, "Drug", "Amount_Drug"]]}
{"idx": 3418, "sentence": "附件3 1977年美国风湿病学会(ACR)急性痛风性关节炎分类标准", "ner": [[11, 13, "Disease"], [21, 28, "Disease"], [26, 27, "Anatomy"]], "rel": [[26, 27, "Anatomy", 21, 28, "Disease", "Anatomy_Disease"]]}
{"idx": 3419, "sentence": "1.关节液中有特异性尿酸盐结晶。", "ner": [[2, 14, "Symptom"]], "rel": []}
{"idx": 3420, "sentence": "2.用化学方法或偏振光显微镜证实痛风石中含尿酸盐结晶。3，具备以下12项(临床、实验室、X线表现)中6项(1)急性关节炎发作>1次；(2)炎症反应在1d内达高峰；(3)单膝关节炎发作；(4)可见关节发红；(5)第一跖趾关节疼痛或肿胀；(6)单侧第一跖趾关节受累；(7)单侧跗骨关节受累；(8)可疑痛风石；(9)高尿酸血症；(10)不对称关节内肿胀(X线证实)；(11)无骨侵蚀的骨皮质下囊肿(X线证实)；(12)关节炎发作时关节液微生物培养阴性。", "ner": [[3, 25, "Symptom"], [97, 100, "Symptom"], [105, 115, "Symptom"], [120, 129, "Symptom"], [134, 141, "Symptom"], [165, 172, "Symptom"], [184, 194, "Symptom"], [55, 59, "Disease"], [57, 58, "Anatomy"], [84, 88, "Disease"], [86, 87, "Anatomy"], [148, 150, "Disease"], [155, 159, "Disease"], [174, 175, "Test"], [196, 197, "Test"], [212, 219, "Test"], [220, 221, "Test_Value"], [206, 208, "Disease"], [206, 207, "Anatomy"]], "rel": [[57, 58, "Anatomy", 55, 59, "Disease", "Anatomy_Disease"], [86, 87, "Anatomy", 84, 88, "Disease", "Anatomy_Disease"], [212, 219, "Test", 206, 208, "Disease", "Test_Disease"], [206, 207, "Anatomy", 206, 208, "Disease", "Anatomy_Disease"]]}
{"idx": 3421, "sentence": "符合以上3项中的任何1项即可分类为痛风。", "ner": [[17, 18, "Disease"]], "rel": []}
{"idx": 3422, "sentence": "附件5慢性肾脏病(CKD)定义及分期", "ner": [[3, 12, "Disease"], [5, 6, "Anatomy"]], "rel": [[5, 6, "Anatomy", 3, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 3423, "sentence": "2012年改善全球肾脏病预后组织(KDIGO)把CKD定义为肾脏出现影响健康的结构或功能异常超过3个月。", "ner": [[9, 11, "Disease"], [9, 10, "Anatomy"], [24, 26, "Disease"], [30, 31, "Anatomy"]], "rel": [[9, 10, "Anatomy", 9, 11, "Disease", "Anatomy_Disease"], [30, 31, "Anatomy", 24, 26, "Disease", "Anatomy_Disease"]]}
{"idx": 3424, "sentence": "CKD诊断标准：1.以下任意一项指标持续超过3个月；且至少满足1项。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 3425, "sentence": "(1)肾损伤标志：白蛋白尿[尿白蛋白排泄率(AER)≥30mg／24h；尿白蛋白肌酐比值(ACR)≥3mg／mmol]；尿沉渣异常；肾小管相关病变；组织学异常；影像学所见结构异常；肾移植病史。", "ner": [[3, 5, "Disease"], [3, 3, "Anatomy"], [66, 72, "Disease"], [66, 68, "Anatomy"], [9, 12, "Symptom"], [14, 25, "Test_items"], [26, 34, "Test_Value"], [36, 48, "Test_items"], [49, 57, "Test_Value"], [60, 64, "Symptom"], [90, 92, "Operation"]], "rel": [[3, 3, "Anatomy", 3, 5, "Disease", "Anatomy_Disease"], [66, 68, "Anatomy", 66, 72, "Disease", "Anatomy_Disease"]]}
{"idx": 3426, "sentence": "(2)肾小球滤过率下降：eGFR≤60ml·min-1·1.73m-2 ", "ner": [[3, 8, "Test_items"], [9, 10, "Test_Value"], [12, 15, "Test_items"], [16, 34, "Test_Value"]], "rel": []}
{"idx": 3427, "sentence": "CKD的GFR分期：可用血清肌酐估算公式或其他指标(如胱抑素C或清除率测定)对GFR进行初步评估进行分期。", "ner": [[0, 2, "Disease"], [4, 6, "Test_items"], [12, 15, "Test_items"], [27, 30, "Test_items"], [32, 36, "Test_items"], [39, 41, "Test_items"]], "rel": [[4, 6, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [12, 15, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [27, 30, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [32, 36, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [39, 41, "Test_items", 0, 2, "Disease", "Test_items_Disease"]]}
{"idx": 3428, "sentence": "针对中国肥胖与糖尿病外科手术规范的立场声明", "ner": [[4, 5, "Disease"], [7, 9, "Disease"]], "rel": []}
{"idx": 3429, "sentence": "我国肥胖与糖尿病外科(减重代谢外科)事业起源于2000年郑成竹教授开展的第一例腹腔镜垂直胃绑带术，经过近20年的发展，国内开展手术的医院已经超过200家，手术例数近年也呈现快速增长，这是令人可喜也值得欣慰的事。为了指导及规范该学科的健康发展，经过一定的临床实践，中华医学会外科学分会内分泌外科学组联合腹腔镜与内镜外科学组、胃肠外科学组及外科手术学学组分别于2007年和2010年先后制订和颁布了《中国肥胖病外科治疗指南(2007)》及《中国糖尿病外科治疗专家指导意见(2010)》。2012年中国医师协会外科医师分会肥胖和糖尿病外科医师委员会(Chinese Society for Metabolic and Bariatric Surgery，CSMBS)组建成立，2014年11月CSMBS发表了《中国肥胖和2型糖尿病外科治疗指南(2014)》，2014年12月人民卫生出版社出版了《肥胖与代谢病外科学》，旨在规范该学科的发展及应用。", "ner": [[2, 3, "Disease"], [5, 7, "Disease"], [39, 47, "Operation"], [220, 222, "Disease"], [200, 202, "Disease"], [258, 259, "Disease"], [261, 263, "Disease"], [354, 355, "Disease"], [357, 361, "Disease"], [395, 396, "Disease"], [398, 400, "Disease"]], "rel": []}
{"idx": 3430, "sentence": "但是在学科蓬勃发展的同时，少部分医生缺乏学科专业培训，特别是在少部分基层医院，存在一些不规范的问题，如：不注意手术适用证范围，超手术指征盲目追求手术量的增加；夸大手术治疗效果，不应用创伤小并发症少的腹腔镜手术而仍然采用传统的开腹手术方法；手术方式不规范如将胃旁路的胃囊体积加大，将一些探索性的实验性手术作为治疗性手术；围手术期管理及术后随访不规范不重视，甚至缺失等情况，导致术后效果不佳或者出现一些营养问题。", "ner": [[99, 103, "Operation"], [112, 115, "Operation"]], "rel": []}
{"idx": 3431, "sentence": "本声明旨在从开展手术医院及术者资质、手术指征、手术方式及术后随访管理等方面对减重代谢手术的应用做出规范。", "ner": [[38, 43, "Operation"]], "rel": []}
{"idx": 3432, "sentence": "一、医院及术者资质", "ner": [], "rel": []}
{"idx": 3433, "sentence": "肥胖与糖尿病外科手术的开展必须得到多学科协作的支持，可参考《上海市2型糖尿病外科手术管理规范》，即“手术应在三级综合性医疗单位开展，二级医院原则上不能开展，具备条件的二级医院可向省级医师协会申请并接受审核。", "ner": [[0, 1, "Disease"], [3, 5, "Disease"], [33, 37, "Disease"]], "rel": []}
{"idx": 3434, "sentence": "术者应具备中级及中级以上技术职称，并具有普外科执业资质，须了解各种术式的治疗原理和操作准则，并须登记成为全国或者省级医师协会会员，经系统指导、培训获得资质后方可施行手术。", "ner": [], "rel": []}
{"idx": 3435, "sentence": "”我们认为该要求对肥胖与糖尿病外科的安全和质量提供了保障，且切实可行，故建议当地医师协会根据此要求审核开展肥胖与糖尿病外科手术的医院及术者资质。", "ner": [[9, 10, "Disease"], [12, 14, "Disease"], [53, 54, "Disease"], [56, 58, "Disease"]], "rel": []}
{"idx": 3436, "sentence": "二、手术指征", "ner": [], "rel": []}
{"idx": 3437, "sentence": "肥胖与糖尿病外科手术开展的适应证及禁忌证均应参照《中国肥胖和2型糖尿病外科治疗指南(2014)》。针对肥胖伴有2型糖尿病的治疗，该版指南强调了胰岛功能储备，即T2DM病程小于15年，且空腹血清C肽水平高于正常值下限的二分之一。对于体质量指数(body mass index，BMI)介于25.0~27.5kg/m2的患者，即使合并T2DM及其他肥胖相关疾病，也应慎重开展手术。", "ner": [[0, 1, "Disease"], [3, 5, "Disease"], [27, 28, "Disease"], [30, 34, "Disease"], [51, 52, "Disease"], [55, 59, "Disease"], [79, 82, "Disease"], [92, 99, "Test_items"], [100, 111, "Test_Value"], [165, 168, "Disease"], [172, 173, "Disease"]], "rel": [[92, 99, "Test_items", 79, 82, "Disease", "Test_items_Disease"]]}
{"idx": 3438, "sentence": "建议此类病人应先选择内科治疗，若内科治疗效果不佳或不能耐受，且病人强烈要求手术治疗，可在充分告知后，依据临床试验的路径行手术治疗。", "ner": [], "rel": []}
{"idx": 3439, "sentence": "《中国肥胖和2型糖尿病外科治疗指南(2014)》中将建议手术年龄定为16~65岁。", "ner": [[3, 4, "Disease"], [6, 10, "Disease"]], "rel": []}
{"idx": 3440, "sentence": "然而根据循证医学证据，手术对于肥胖及相关代谢综合征的治疗效果，年龄并不是一个显著的影响因素，且对于青少年而言，生理、心理发育程度与生物学年龄不一定相符。", "ner": [[15, 16, "Disease"], [20, 24, "Disease"]], "rel": []}
{"idx": 3441, "sentence": "故我们认为对于年龄的建议可根据临床评估结果适当放宽，特别是对于青少年，在经过对肥胖程度及代谢性疾病严重程度的评估、患者及家庭成员心理评估、术后管理依从性评估之后可慎重考虑手术。", "ner": [[39, 40, "Disease"], [44, 48, "Disease"]], "rel": []}
{"idx": 3442, "sentence": "三、手术方式", "ner": [], "rel": []}
{"idx": 3443, "sentence": "目前推荐的手术方式包括：(1)腹腔镜Roux-en-Y胃旁路术(laparoscopic Roux-en-Y gastric bypass，LRYGB)；(2)腹腔镜胃袖状切除术(laparoscopic sleeve gastrectomy，LSG)；(3)胆胰分流并十二指肠转位术(biliopancreatic diversion with duodenal switch，BPD-DS)，其中BPD-DS虽然效果最好，但其并发症发生率有所增加，术后常见维生素和微量元素的缺乏，术后随访和维生素微量元素补充要求严格且长期，故需慎重选择。", "ner": [[15, 75, "Operation"], [80, 125, "Operation"], [130, 196, "Operation"], [200, 205, "Operation"], [230, 240, "ADE"]], "rel": []}
{"idx": 3444, "sentence": "另外，目前国内外报道多种新术式，包括在胃旁路术基础上发展的mini-bypass、袖状胃切除术基础上发展的“SG+X术”、以及胃折叠术、空回肠侧侧吻合术等，这些指南推荐之外的术式均尚缺乏中长期疗效数据，不建议临床推广，仅限于临床研究。", "ner": [[19, 22, "Operation"], [29, 39, "Operation"], [41, 46, "Operation"], [54, 58, "Operation"], [63, 66, "Operation"], [68, 75, "Operation"]], "rel": []}
{"idx": 3445, "sentence": "四、术后随访", "ner": [], "rel": []}
{"idx": 3446, "sentence": "接受肥胖与糖尿病外科手术患者均需终身随访，临床实践中不少医疗机构对接受减重代谢手术的病人缺少规律的随访，致使手术的安全性和有效性缺乏保障。指南确定术后1年内应至少进行4次随访，建议门诊随访，另需更多次的电话或其他方式随访，术后1个月起应对糖尿病改善进行较为完善的评估，包括血糖、糖化血红蛋白、胰岛素、C肽等，术后6个月起应对血生化、营养状况及心理、精神评估进行完善，内容应包括骨密度、维生素及微量元素水平，同时监测是否有手术并发症，进行必要的干预。", "ner": [[2, 3, "Disease"], [5, 7, "Disease"], [35, 40, "Operation"], [136, 137, "Test_items"], [139, 144, "Test_items"], [146, 148, "Test_items"], [150, 151, "Test_items"], [162, 164, "Test"], [188, 190, "Test"], [192, 194, "Test"], [196, 201, "Test"], [119, 121, "Disease"]], "rel": [[35, 40, "Operation", 2, 3, "Disease", "Operation_Disease"], [35, 40, "Operation", 5, 7, "Disease", "Operation_Disease"], [136, 137, "Test_items", 119, 121, "Disease", "Test_items_Disease"], [139, 144, "Test_items", 119, 121, "Disease", "Test_items_Disease"], [146, 148, "Test_items", 119, 121, "Disease", "Test_items_Disease"], [150, 151, "Test_items", 119, 121, "Disease", "Test_items_Disease"]]}
{"idx": 3447, "sentence": "五、总结", "ner": [], "rel": []}
{"idx": 3448, "sentence": "综上所述，肥胖与糖尿病外科手术的开展必须遵循指南，以确保医疗质量和安全，各地医师协会对肥胖与糖尿病外科的发展应起到监管作用，规范肥胖与糖尿病外科手术的管理。", "ner": [[5, 6, "Disease"], [8, 10, "Disease"], [43, 44, "Disease"], [46, 48, "Disease"], [64, 65, "Disease"], [67, 69, "Disease"]], "rel": []}
{"idx": 3449, "sentence": "糖尿病肾病防治专家共识(2014年版)", "ner": [[0, 4, "Disease"], [3, 3, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 3450, "sentence": "糖尿病肾病是糖尿病最主要的微血管并发症之一，是目前引起终末期肾病(end-stage renal disease，ESRD)的首要原因。国外研究资料显示，20年以上病程的糖尿病肾病患者发展为ESRD的发生率为40.8/1000人年，需要进行透析或移植等肾脏替代治疗。我国糖尿病肾病的患病率亦呈快速增长趋势，2009至2012年我国2型糖尿病患者的糖尿病肾病患病率在社区患者中为30%~50%，在住院患者中为40%左右。糖尿病肾病起病隐匿，一旦进入大量蛋白尿期后，进展至ESRD的速度大约为其他肾脏病变的14倍，因此早期诊断、预防与延缓糖尿病肾病的发生发展对提高糖尿病患者存活率，改善其生活质量具有重要意义。为规范糖尿病肾病的诊断和治疗，中华医学会糖尿病学分会微血管并发症学组组织国内的内分泌和肾内科领域专家共同制定本共识。", "ner": [[0, 4, "Disease"], [3, 3, "Anatomy"], [6, 8, "Disease"], [13, 15, "Anatomy"], [27, 61, "Disease"], [30, 30, "Anatomy"], [85, 89, "Disease"], [88, 88, "Anatomy"], [95, 98, "Disease"], [120, 121, "Treatment"], [123, 124, "Operation"], [135, 139, "Disease"], [138, 138, "Anatomy"], [165, 169, "Disease"], [173, 177, "Disease"], [176, 176, "Anatomy"], [209, 213, "Disease"], [212, 212, "Anatomy"], [234, 237, "Disease"], [246, 249, "Disease"], [246, 247, "Anatomy"], [267, 271, "Disease"], [270, 270, "Anatomy"], [280, 282, "Disease"], [306, 310, "Disease"], [309, 309, "Anatomy"], [323, 325, "Disease"], [329, 331, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [13, 15, "Anatomy", 6, 8, "Disease", "Anatomy_Disease"], [30, 30, "Anatomy", 27, 61, "Disease", "Anatomy_Disease"], [88, 88, "Anatomy", 85, 89, "Disease", "Anatomy_Disease"], [120, 121, "Treatment", 95, 98, "Disease", "Treatment_Disease"], [123, 124, "Operation", 95, 98, "Disease", "Operation_Disease"], [138, 138, "Anatomy", 135, 139, "Disease", "Anatomy_Disease"], [176, 176, "Anatomy", 173, 177, "Disease", "Anatomy_Disease"], [212, 212, "Anatomy", 209, 213, "Disease", "Anatomy_Disease"], [246, 247, "Anatomy", 246, 249, "Disease", "Anatomy_Disease"], [270, 270, "Anatomy", 267, 271, "Disease", "Anatomy_Disease"], [309, 309, "Anatomy", 306, 310, "Disease", "Anatomy_Disease"], [329, 331, "Anatomy", 323, 325, "Disease", "Anatomy_Disease"]]}
{"idx": 3451, "sentence": "一、糖尿病肾病的定义与诊断", "ner": [[2, 6, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 3452, "sentence": "糖尿病肾病是由糖尿病引起的肾脏损伤，以往用DN(diabetic nephropathy)表示，2007年美国肾脏病基金会(NKF)制定了肾脏病生存质量指导指南，简称NKF/KDOQI。该指南建议用DKD(diabetic kidney disease)取代DN。2014年美国糖尿病协会(ADA)与NKF达成共识，认为DKD是指由糖尿病引起的慢性肾病，主要包括肾小球滤过率(GFR)低于60ml·min-1·1.73m-2或尿白蛋白/肌酐比值(ACR)高于30mg/g持续超过3个月。糖尿病性肾小球肾病(diabetic glomerulopathy)专指经肾脏活检证实的由糖尿病引起的肾小球病变。", "ner": [[0, 4, "Disease"], [3, 3, "Anatomy"], [7, 9, "Disease"], [13, 16, "Disease"], [13, 14, "Anatomy"], [21, 44, "Disease"], [69, 71, "Disease"], [69, 70, "Anatomy"], [99, 126, "Disease"], [129, 130, "Disease"], [139, 141, "Disease"], [160, 162, "Disease"], [166, 168, "Reason"], [172, 175, "Disease"], [174, 174, "Anatomy"], [181, 191, "Test_items"], [192, 211, "Test_Value"], [213, 226, "Test_items"], [227, 234, "Test_Value"], [243, 276, "Disease"], [247, 249, "Anatomy"], [250, 250, "Anatomy"], [288, 290, "Reason"], [294, 298, "Disease"], [294, 296, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [13, 14, "Anatomy", 13, 16, "Disease", "Anatomy_Disease"], [69, 70, "Anatomy", 69, 71, "Disease", "Anatomy_Disease"], [166, 168, "Reason", 172, 175, "Disease", "Reason_Disease"], [181, 191, "Test_items", 172, 175, "Disease", "Test_items_Disease"], [213, 226, "Test_items", 172, 175, "Disease", "Test_items_Disease"], [174, 174, "Anatomy", 172, 175, "Disease", "Anatomy_Disease"], [247, 249, "Anatomy", 243, 276, "Disease", "Anatomy_Disease"], [250, 250, "Anatomy", 243, 276, "Disease", "Anatomy_Disease"], [288, 290, "Reason", 294, 298, "Disease", "Reason_Disease"], [294, 296, "Anatomy", 294, 298, "Disease", "Anatomy_Disease"]]}
{"idx": 3453, "sentence": "糖尿病肾病的诊断分为病理诊断和临床诊断。肾脏病理被认为是诊断金标准。糖尿病主要引起肾小球病变，表现为肾小球系膜增生、基底膜增厚和K-W(Kimmelstiel-Wilson)结节等，是病理诊断的主要依据。糖尿病还可引起肾小管间质、肾微血管病变，如肾间质纤维化、肾小管萎缩、出球动脉透明变性或肾微血管硬化等，这些改变亦可由其他病因引起，在诊断时仅作为辅助指标。目前糖尿病肾病临床诊断的依据有尿白蛋白和糖尿病视网膜病变。糖尿病肾病早期可表现为尿白蛋白阴性，症状不明显，易被忽略，但目前仍缺乏比尿微量白蛋白更可靠敏感的糖尿病肾病早期检测指标。", "ner": [[0, 4, "Disease"], [3, 3, "Anatomy"], [34, 36, "Disease"], [41, 45, "Disease"], [41, 43, "Anatomy"], [50, 56, "Pathogenesis"], [58, 62, "Pathogenesis"], [64, 88, "Pathogenesis"], [181, 185, "Disease"], [184, 184, "Anatomy"], [194, 197, "Test_items"], [199, 206, "Disease"], [202, 204, "Anatomy"], [208, 212, "Disease"], [211, 211, "Anatomy"], [219, 222, "Test_items"], [223, 224, "Test_Value"], [244, 249, "Test_items"], [256, 260, "Disease"], [259, 259, "Anatomy"], [102, 104, "Reason"], [109, 120, "Disease"], [115, 118, "Anatomy"], [123, 128, "Disease"], [130, 134, "Disease"], [130, 132, "Anatomy"], [123, 125, "Anatomy"], [109, 113, "Anatomy"], [136, 143, "Disease"], [145, 150, "Disease"], [145, 148, "Anatomy"]], "rel": [[3, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [41, 43, "Anatomy", 41, 45, "Disease", "Anatomy_Disease"], [50, 56, "Pathogenesis", 41, 45, "Disease", "Pathogenesis_Disease"], [58, 62, "Pathogenesis", 41, 45, "Disease", "Pathogenesis_Disease"], [64, 88, "Pathogenesis", 41, 45, "Disease", "Pathogenesis_Disease"], [184, 184, "Anatomy", 181, 185, "Disease", "Anatomy_Disease"], [194, 197, "Test_items", 181, 185, "Disease", "Test_items_Disease"], [202, 204, "Anatomy", 199, 206, "Disease", "Anatomy_Disease"], [211, 211, "Anatomy", 208, 212, "Disease", "Anatomy_Disease"], [219, 222, "Test_items", 208, 212, "Disease", "Test_items_Disease"], [244, 249, "Test_items", 208, 212, "Disease", "Test_items_Disease"], [259, 259, "Anatomy", 256, 260, "Disease", "Anatomy_Disease"], [102, 104, "Reason", 109, 120, "Disease", "Reason_Disease"], [102, 104, "Reason", 123, 128, "Disease", "Reason_Disease"], [102, 104, "Reason", 136, 143, "Disease", "Reason_Disease"], [102, 104, "Reason", 145, 150, "Disease", "Reason_Disease"], [102, 104, "Reason", 130, 134, "Disease", "Reason_Disease"], [109, 113, "Anatomy", 109, 120, "Disease", "Anatomy_Disease"], [115, 118, "Anatomy", 109, 120, "Disease", "Anatomy_Disease"], [123, 125, "Anatomy", 123, 128, "Disease", "Anatomy_Disease"], [130, 132, "Anatomy", 130, 134, "Disease", "Anatomy_Disease"], [145, 148, "Anatomy", 145, 150, "Disease", "Anatomy_Disease"]]}
{"idx": 3454, "sentence": "(一)糖尿病肾病临床诊断依据", "ner": [[3, 7, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 3455, "sentence": "1.尿白蛋白：微量白蛋白尿是糖尿病肾病早期的临床表现，也是诊断糖尿病肾病的主要依据。其评价指标为尿白蛋白排泄率(UAE/AER)或ACR。个体间UAE的差异系数接近40%，与之相比ACR更加稳定且检测方法方便，只需要检测单次随机晨尿即可，故推荐使用ACR。尿白蛋白排泄异常的定义见表1，因尿白蛋白排泄受影响因素较多，需在3-6个月内复查，3次结果中至少2次超过临界值，并且排除影响因素如24h内剧烈运动、感染、发热、充血性心力衰竭、明显高血糖、怀孕、明显高血压、尿路感染，可作出诊断。然而，尿白蛋白对诊断2型糖尿病肾病的特异性不足，对预测病情的转归也存在局限性。", "ner": [[2, 5, "Test_items"], [7, 8, "Level"], [9, 12, "Symptom"], [14, 18, "Disease"], [17, 17, "Anatomy"], [31, 35, "Disease"], [34, 34, "Anatomy"], [48, 63, "Test_items"], [65, 67, "Test_items"], [72, 74, "Test_items"], [90, 92, "Test_items"], [124, 126, "Test_items"], [128, 135, "Symptom"], [144, 147, "Test_items"], [178, 182, "Test_Value"], [202, 203, "Disease"], [205, 206, "Disease"], [208, 214, "Disease"], [211, 211, "Anatomy"], [218, 220, "Disease"], [227, 229, "Disease"], [231, 234, "Disease"], [245, 248, "Test_items"], [252, 258, "Disease"], [257, 257, "Anatomy"]], "rel": [[9, 12, "Symptom", 14, 18, "Disease", "Symptom_Disease"], [17, 17, "Anatomy", 14, 18, "Disease", "Anatomy_Disease"], [34, 34, "Anatomy", 31, 35, "Disease", "Anatomy_Disease"], [48, 63, "Test_items", 31, 35, "Disease", "Test_items_Disease"], [65, 67, "Test_items", 31, 35, "Disease", "Test_items_Disease"], [211, 211, "Anatomy", 208, 214, "Disease", "Anatomy_Disease"], [245, 248, "Test_items", 252, 258, "Disease", "Test_items_Disease"], [257, 257, "Anatomy", 252, 258, "Disease", "Anatomy_Disease"]]}
{"idx": 3456, "sentence": "长期观察结果发现，微量白蛋白尿的患者在10年中仅有30%~45%转变为大量白蛋白尿，有30%转变为尿白蛋白阴性，该现象在2型糖尿病患者中更为显著。", "ner": [[9, 10, "Level"], [11, 14, "Symptom"], [37, 40, "Symptom"], [35, 36, "Level"], [49, 52, "Test_items"], [53, 54, "Test_Value"], [60, 64, "Disease"]], "rel": [[49, 52, "Test_items", 60, 64, "Disease", "Test_items_Disease"]]}
{"idx": 3457, "sentence": "因此，尿白蛋白作为诊断依据时需进行长期随访、多次检测，结果重复时方可做出判定，且需排除其他可引起白蛋白尿的病因。", "ner": [[3, 6, "Test_items"], [48, 51, "Disease"]], "rel": [[3, 6, "Test_items", 48, 51, "Disease", "Test_items_Disease"]]}
{"idx": 3458, "sentence": "2.糖尿病视网膜病变：糖尿病视网膜病变常早于糖尿病肾病发生，大部分糖尿病肾病患者患有糖尿病视网膜病变，但在透析的糖尿病肾病患者中，糖尿病视网膜病变的发病率反而减少，糖尿病视网膜病变被NKF/KDOQI指南作为2型糖尿病患者糖尿病肾病的诊断依据之一。", "ner": [[2, 9, "Disease"], [5, 7, "Anatomy"], [14, 16, "Anatomy"], [22, 26, "Disease"], [25, 25, "Anatomy"], [33, 37, "Disease"], [36, 36, "Anatomy"], [42, 49, "Disease"], [45, 47, "Anatomy"], [53, 54, "Treatment"], [56, 60, "Disease"], [59, 59, "Anatomy"], [65, 72, "Disease"], [68, 70, "Anatomy"], [82, 89, "Disease"], [85, 87, "Anatomy"], [104, 108, "Disease"], [111, 115, "Disease"], [114, 114, "Anatomy"], [11, 18, "Disease"]], "rel": [[5, 7, "Anatomy", 2, 9, "Disease", "Anatomy_Disease"], [14, 16, "Anatomy", 11, 18, "Disease", "Anatomy_Disease"], [25, 25, "Anatomy", 22, 26, "Disease", "Anatomy_Disease"], [36, 36, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"], [45, 47, "Anatomy", 42, 49, "Disease", "Anatomy_Disease"], [53, 54, "Treatment", 56, 60, "Disease", "Treatment_Disease"], [59, 59, "Anatomy", 56, 60, "Disease", "Anatomy_Disease"], [68, 70, "Anatomy", 65, 72, "Disease", "Anatomy_Disease"], [85, 87, "Anatomy", 82, 89, "Disease", "Anatomy_Disease"], [114, 114, "Anatomy", 111, 115, "Disease", "Anatomy_Disease"]]}
{"idx": 3459, "sentence": "2007年NKF指南荟萃大量研究后指出，在大量白蛋白尿者中，糖尿病视网膜病变对糖尿病性肾小球肾病的阳性预测值为67%~100%，阴性预测值为20%~84%，灵敏度为26%~85%，特异度为13%~100%；在微量白蛋白尿者中，阳性预测值为45%左右，但阴性预测值接近100%，灵敏度为100%，特异度为46%~62%。Meta分析结果表明糖尿病视网膜病变预测2型糖尿病肾病的灵敏度为0.65(95%CI：0.62~0.68)，特异度为0.75(95%CI：0.73~0.78)，阳性为0.72(95%CI：0.68~0.75)，阴性预测值为0.69(95%CI：0.67~0.72)，提示糖尿病视网膜病变是2型糖尿病肾病诊断和筛查的有用指标。", "ner": [[21, 22, "Level"], [23, 26, "Symptom"], [30, 37, "Disease"], [33, 35, "Anatomy"], [39, 47, "Disease"], [43, 45, "Anatomy"], [46, 46, "Anatomy"], [104, 105, "Level"], [106, 109, "Symptom"], [169, 176, "Disease"], [172, 174, "Anatomy"], [179, 185, "Disease"], [184, 184, "Anatomy"], [294, 301, "Disease"], [297, 299, "Anatomy"], [303, 309, "Disease"], [308, 308, "Anatomy"]], "rel": [[33, 35, "Anatomy", 30, 37, "Disease", "Anatomy_Disease"], [43, 45, "Anatomy", 39, 47, "Disease", "Anatomy_Disease"], [46, 46, "Anatomy", 39, 47, "Disease", "Anatomy_Disease"], [172, 174, "Anatomy", 169, 176, "Disease", "Anatomy_Disease"], [184, 184, "Anatomy", 179, 185, "Disease", "Anatomy_Disease"], [297, 299, "Anatomy", 294, 301, "Disease", "Anatomy_Disease"], [308, 308, "Anatomy", 303, 309, "Disease", "Anatomy_Disease"]]}
{"idx": 3460, "sentence": "近来，发现一些因子对糖尿病肾病的诊断有价值，如转化生长因子β1(TGF-β1)、免疫球蛋白G(IgG)、转铁蛋白(TRF)、细胞外基质(ECM)、肾损伤分子1(Kim-1)及中性粒细胞明胶酶相关脂质运载蛋白(NGAL)。利用糖尿病肾病的患者血清蛋白质指纹图谱的比较中筛选到22个上调、24个下调的蛋白质或多肽，并建立诊断决策树模型，盲法验证模型的敏感性90.9%，特异性89.3%。", "ner": [[10, 14, "Disease"], [13, 13, "Anatomy"], [23, 38, "Test_items"], [40, 50, "Test_items"], [52, 60, "Test_items"], [62, 71, "Test_items"], [73, 85, "Test_items"], [87, 94, "Test_items"], [97, 108, "Test_items"], [112, 116, "Disease"], [115, 115, "Anatomy"], [120, 124, "Test_items"]], "rel": [[13, 13, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [23, 38, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [40, 50, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [52, 60, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [62, 71, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [73, 85, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [87, 94, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [97, 108, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [120, 124, "Test_items", 112, 116, "Disease", "Test_items_Disease"], [115, 115, "Anatomy", 112, 116, "Disease", "Anatomy_Disease"]]}
{"idx": 3461, "sentence": "上述检测方法被认为比微量白蛋白尿能更早地发现糖尿病肾病，可能作为糖尿病肾病早期诊断的工具，但其可靠性、特异性、敏感性仍需更多研究证实，目前尚未作为诊断依据。", "ner": [[10, 11, "Level"], [12, 15, "Disease"], [22, 26, "Disease"], [25, 25, "Anatomy"], [32, 36, "Disease"], [35, 35, "Anatomy"]], "rel": [[25, 25, "Anatomy", 22, 26, "Disease", "Anatomy_Disease"], [35, 35, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"]]}
{"idx": 3462, "sentence": "(二)糖尿病肾病的筛查和肾功能评价", "ner": [[3, 7, "Disease"], [6, 6, "Anatomy"], [12, 14, "Test"]], "rel": [[6, 6, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"], [12, 14, "Test", 3, 7, "Disease", "Test_Disease"]]}
{"idx": 3463, "sentence": "肾功能改变是糖尿病肾病的重要表现，反映肾功能的主要指标是GFR，根据GFR和其他肾脏损伤证据可进行慢性肾病(CKD)的分期(表2)。横断面调查结果显示，部分糖尿病患者无尿白蛋白排泄异常，但已经存在GFR下降，提示尿白蛋白阴性者也可能存在肾病，GFR可作为糖尿病肾病的诊断依据之一。", "ner": [[0, 2, "Test"], [3, 4, "Test_Value"], [6, 10, "Disease"], [9, 9, "Anatomy"], [19, 21, "Test"], [28, 30, "Test_items"], [34, 36, "Test_items"], [40, 41, "Anatomy"], [49, 57, "Disease"], [51, 51, "Anatomy"], [78, 80, "Disease"], [84, 87, "Test_items"], [98, 100, "Test_items"], [101, 102, "Test_Value"], [106, 109, "Test_items"], [110, 111, "Test_Value"], [118, 119, "Disease"], [118, 118, "Anatomy"], [121, 123, "Test_items"], [127, 131, "Disease"], [130, 130, "Anatomy"]], "rel": [[0, 2, "Test", 6, 10, "Disease", "Test_Disease"], [19, 21, "Test", 6, 10, "Disease", "Test_Disease"], [9, 9, "Anatomy", 6, 10, "Disease", "Anatomy_Disease"], [28, 30, "Test_items", 6, 10, "Disease", "Test_items_Disease"], [34, 36, "Test_items", 49, 57, "Disease", "Test_items_Disease"], [40, 41, "Anatomy", 49, 57, "Disease", "Anatomy_Disease"], [51, 51, "Anatomy", 49, 57, "Disease", "Anatomy_Disease"], [84, 87, "Test_items", 78, 80, "Disease", "Test_items_Disease"], [98, 100, "Test_items", 78, 80, "Disease", "Test_items_Disease"], [106, 109, "Test_items", 118, 119, "Disease", "Test_items_Disease"], [118, 118, "Anatomy", 118, 119, "Disease", "Anatomy_Disease"], [121, 123, "Test_items", 127, 131, "Disease", "Test_items_Disease"], [130, 130, "Anatomy", 127, 131, "Disease", "Anatomy_Disease"]]}
{"idx": 3464, "sentence": "GFR的评估方法分为外源性标志物的肾清除率测定法(如同位素稀释质谱法)和内源性标志物估算法。", "ner": [[0, 2, "Test_items"], [17, 20, "Test_items"]], "rel": []}
{"idx": 3465, "sentence": "后者更经济实用，更适合于临床应用。", "ner": [], "rel": []}
{"idx": 3466, "sentence": "估算GFR最常用的指标是血清肌酐，基于血清肌酐的肾小球滤过率的常用计算公式有CG(Cockcrofl-Gauh)公式和肾脏饮食修正公式(MDRD)，2009年又提出了CKD-EPI公式，被认为比CG公式和MDRD公式能更准确地估算2型糖尿病患者的GFR，但存在争议。", "ner": [[2, 4, "Test_items"], [12, 15, "Test_items"], [19, 22, "Test_items"], [24, 29, "Test_items"], [115, 119, "Disease"], [123, 125, "Test_items"]], "rel": [[123, 125, "Test_items", 115, 119, "Disease", "Test_items_Disease"]]}
{"idx": 3467, "sentence": "本共识推荐使用2006年我国预估肾小球滤过率(eGFR)协作组制定的适用于中国人的改良MDRD公式：eGFR(ml·min-1·1.73m-2)=175x血清肌酐(SCr)·1.234×年龄-0.179(如果是女性×0.79)。", "ner": [[16, 27, "Test_items"], [77, 85, "Test_items"], [50, 53, "Test_items"]], "rel": []}
{"idx": 3468, "sentence": "血清肌本酐在估算GFR中存在灵敏度不足，受个体肌肉量、蛋白质摄入、体内代谢水平、溶血、脂血等因素干扰等局限性。近年来，胱抑素C(CysC)被认为在预测2型糖尿病肾病进展为ESRD的作用上比血清肌酐更好，CysC是由有核细胞以恒速产生的，可自由滤过，被肾小管上皮细胞重吸收和细胞内降解，但不会被肾小管上皮细胞分泌，可更准确地反映肾功能，但其检测的准确性尚未得到保障。一些学者提出了基于CysC的eGFR计算公式和CKD分期。", "ner": [[0, 4, "Test_items"], [8, 10, "Test_items"], [40, 41, "Disease"], [59, 68, "Test_items"], [75, 81, "Disease"], [80, 80, "Anatomy"], [85, 88, "Disease"], [94, 97, "Test_items"], [101, 104, "Test_items"], [163, 165, "Test"], [191, 194, "Test_items"], [196, 199, "Test_items"], [205, 207, "Disease"]], "rel": [[0, 4, "Test_items", 40, 41, "Disease", "Test_items_Disease"], [8, 10, "Test_items", 40, 41, "Disease", "Test_items_Disease"], [59, 68, "Test_items", 75, 81, "Disease", "Test_items_Disease"], [80, 80, "Anatomy", 75, 81, "Disease", "Anatomy_Disease"], [94, 97, "Test_items", 85, 88, "Disease", "Test_items_Disease"], [101, 104, "Test_items", 85, 88, "Disease", "Test_items_Disease"], [191, 194, "Test_items", 205, 207, "Disease", "Test_items_Disease"], [196, 199, "Test_items", 205, 207, "Disease", "Test_items_Disease"]]}
{"idx": 3469, "sentence": "目前有研究提出，联合使用血清肌酐与CysC公式比单独使用基于其中一项指标的公式更好。", "ner": [[12, 15, "Test_items"], [17, 20, "Test_items"]], "rel": []}
{"idx": 3470, "sentence": "由于尿白蛋白和GFR对糖尿病肾病的重要性，对这两项的检测是目前糖尿病肾病的筛检项目，一旦确诊糖尿病，应每年都进行筛检：(1)所有2型糖尿病患者应从确诊时和1型糖尿病患者病程超过5年时每年检查1次以评估UAE/AER。(2)所有成人糖尿病患者，不管UAE/AER如何，每年应至少检查1次血清肌酐，并用血清肌酐估计GFR。", "ner": [[2, 5, "Test_items"], [7, 9, "Test_items"], [11, 15, "Disease"], [14, 14, "Anatomy"], [31, 35, "Disease"], [34, 34, "Anatomy"], [46, 48, "Disease"], [64, 68, "Disease"], [77, 81, "Disease"], [100, 106, "Test_items"], [115, 117, "Disease"], [123, 129, "Test_items"], [142, 145, "Test_items"], [149, 152, "Test_items"], [155, 157, "Test_items"]], "rel": [[2, 5, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [7, 9, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [14, 14, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"], [34, 34, "Anatomy", 31, 35, "Disease", "Anatomy_Disease"], [100, 106, "Test_items", 77, 81, "Disease", "Test_items_Disease"], [123, 129, "Test_items", 115, 117, "Disease", "Test_items_Disease"], [142, 145, "Test_items", 115, 117, "Disease", "Test_items_Disease"], [149, 152, "Test_items", 115, 117, "Disease", "Test_items_Disease"], [155, 157, "Test_items", 115, 117, "Disease", "Test_items_Disease"]]}
{"idx": 3471, "sentence": "如果有CKD，需进行分期。", "ner": [[3, 5, "Disease"]], "rel": []}
{"idx": 3472, "sentence": "(三)糖尿病肾病临床诊断标准", "ner": [[3, 7, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 3473, "sentence": "糖尿病肾病的国外诊断标准有美国肾脏基金会(NKF)肾脏病预后质量倡议(K/DOQI)指南标准(2007年)和英国国民医疗服务(NHS)标准(2010年)。我国目前仍无统一的糖尿病肾病诊断标准，本共识推荐采用表3诊断标准，符合任何一项者可考虑为糖尿病肾脏病变(适用于1型及2型糖尿病)：", "ner": [[0, 4, "Disease"], [3, 3, "Anatomy"], [25, 27, "Disease"], [25, 26, "Anatomy"], [86, 90, "Disease"], [89, 89, "Anatomy"], [121, 127, "Disease"], [124, 125, "Anatomy"], [135, 139, "Disease"]], "rel": [[3, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [25, 26, "Anatomy", 25, 27, "Disease", "Anatomy_Disease"], [89, 89, "Anatomy", 86, 90, "Disease", "Anatomy_Disease"]]}
{"idx": 3474, "sentence": "诊断时，出现以下情况之一的应考虑其CKD是由其他原因引起的：(1)无糖尿病视网膜病变；(2)GFR较低或迅速下降；(3)蛋白尿急剧增多或有肾病综合征；(4)顽固性高血压；(5)尿沉渣活动表现；(6)其他系统性疾病的症状或体征；(7)血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体拮抗剂(ARB)类药物开始治疗后2~3个月内肾小球滤过率下降超过30%。", "ner": [[17, 19, "Disease"], [34, 41, "Disease"], [37, 39, "Anatomy"], [46, 48, "Test_items"], [49, 50, "Test_Value"], [52, 55, "Test_Value"], [60, 62, "Disease"], [69, 73, "Disease"], [78, 83, "Disease"], [88, 90, "Test_items"], [116, 132, "Drug"], [134, 153, "Drug"], [159, 163, "Duration"], [165, 170, "Test_items"], [171, 177, "Test_Value"], [69, 69, "Anatomy"]], "rel": [[37, 39, "Anatomy", 34, 41, "Disease", "Anatomy_Disease"], [69, 69, "Anatomy", 69, 73, "Disease", "Anatomy_Disease"], [159, 163, "Duration", 116, 132, "Drug", "Duration_Drug"], [159, 163, "Duration", 134, 153, "Drug", "Duration_Drug"]]}
{"idx": 3475, "sentence": "根据NKF-K/DOQI指南、NHS等标准，强调白蛋白尿是2型糖尿病肾脏病变诊断的必要依据，但不能涵盖正常白蛋白尿的糖尿病肾病，忽略了GFR的诊断价值。考虑到ADA指南建议每年检测CKD，本共识提出糖尿病视网膜病变并CKD任何一期的诊断标准，避免遗漏那些白蛋白尿正常但eGFR下降的糖尿病肾病。", "ner": [[24, 27, "Disease"], [29, 36, "Disease"], [34, 35, "Anatomy"], [53, 56, "Disease"], [58, 62, "Disease"], [61, 61, "Anatomy"], [67, 69, "Test_items"], [90, 92, "Disease"], [99, 106, "Disease"], [102, 104, "Anatomy"], [108, 110, "Disease"], [127, 130, "Disease"], [134, 137, "Test_items"], [138, 139, "Test_Value"], [141, 145, "Disease"], [144, 144, "Anatomy"]], "rel": [[34, 35, "Anatomy", 29, 36, "Disease", "Anatomy_Disease"], [61, 61, "Anatomy", 58, 62, "Disease", "Anatomy_Disease"], [67, 69, "Test_items", 58, 62, "Disease", "Test_items_Disease"], [102, 104, "Anatomy", 99, 106, "Disease", "Anatomy_Disease"], [134, 137, "Test_items", 127, 130, "Disease", "Test_items_Disease"], [134, 137, "Test_items", 141, 145, "Disease", "Test_items_Disease"], [144, 144, "Anatomy", 141, 145, "Disease", "Anatomy_Disease"]]}
{"idx": 3476, "sentence": "(四)糖尿病肾病的临床分期和病理分级", "ner": [[3, 7, "Disease"], [6, 6, "Anatomy"]], "rel": [[6, 6, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 3477, "sentence": "1987年Mogensen建议，根据糖尿病肾病的病理生理特点和演变过程，将1型糖尿病患者的糖尿病肾病分为5期。I期：急性肾小球高滤过期，肾小球入球小动脉扩张，肾小球内压增加，GFR升高，伴或不伴肾体积增大；II期：正常白蛋白尿期，UAE正常(<20μg/min或<30mg/24h)(如休息时)，或呈间歇性微量白蛋白尿(如运动后、应激状态)，病理检查可发现肾小球基底膜轻度增厚；Ⅲ期：早期糖尿病肾病期(UAE 20~200μg/min或30~300mg/24h)，以持续性微量白蛋白尿为标志，病理检查肾小球基底膜(GBM)增厚及系膜进一步增宽；IV期：临床(显性)糖尿病肾病期，进展性显性白蛋白尿，部分可进展为肾病综合征，病理检查肾小球病变更重，如肾小球硬化，灶性肾小管萎缩及间质纤维化；V期：肾衰竭期。", "ner": [[18, 22, "Disease"], [21, 21, "Anatomy"], [37, 41, "Disease"], [45, 49, "Disease"], [48, 48, "Anatomy"], [68, 77, "Pathogenesis"], [79, 85, "Pathogenesis"], [87, 89, "Test_items"], [90, 91, "Test_Value"], [97, 101, "Pathogenesis"], [109, 112, "Disease"], [115, 117, "Test_items"], [118, 140, "Test_Value"], [153, 154, "Level"], [155, 158, "Disease"], [178, 187, "Pathogenesis"], [201, 203, "Test_items"], [205, 216, "Test_Value"], [218, 229, "Test_Value"], [236, 237, "Level"], [238, 241, "Disease"], [250, 262, "Pathogenesis"], [264, 270, "Pathogenesis"], [282, 286, "Disease"], [285, 285, "Anatomy"], [294, 297, "Disease"], [305, 309, "Disease"], [305, 305, "Anatomy"], [315, 319, "Disease"], [315, 317, "Anatomy"], [324, 328, "Pathogenesis"], [330, 336, "Pathogenesis"], [338, 342, "Pathogenesis"], [347, 349, "Disease"], [347, 347, "Anatomy"], [194, 198, "Disease"], [197, 197, "Anatomy"]], "rel": [[21, 21, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"], [48, 48, "Anatomy", 45, 49, "Disease", "Anatomy_Disease"], [115, 117, "Test_items", 109, 112, "Disease", "Test_items_Disease"], [201, 203, "Test_items", 194, 198, "Disease", "Test_items_Disease"], [285, 285, "Anatomy", 282, 286, "Disease", "Anatomy_Disease"], [305, 305, "Anatomy", 305, 309, "Disease", "Anatomy_Disease"], [315, 317, "Anatomy", 315, 319, "Disease", "Anatomy_Disease"], [324, 328, "Pathogenesis", 315, 319, "Disease", "Pathogenesis_Disease"], [330, 336, "Pathogenesis", 315, 319, "Disease", "Pathogenesis_Disease"], [338, 342, "Pathogenesis", 315, 319, "Disease", "Pathogenesis_Disease"], [347, 347, "Anatomy", 347, 349, "Disease", "Anatomy_Disease"], [197, 197, "Anatomy", 194, 198, "Disease", "Anatomy_Disease"]]}
{"idx": 3478, "sentence": "2型糖尿病患者的糖尿病肾病可参考以上标准分期。", "ner": [[0, 4, "Disease"], [8, 12, "Disease"], [11, 11, "Anatomy"]], "rel": [[11, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 3479, "sentence": "病理活检被认为是糖尿病肾病诊断的金标准，不能依据临床病史排除其他肾脏疾病时，需考虑进行肾穿刺以确诊。2010年，肾脏病理学会研究委员会首次提出了糖尿病肾病病理分级标准，在1型和2型糖尿病患者中均适用。根据肾脏组织光镜、电镜及免疫荧光染色的改变对肾小球损害和肾小管/肾血管损伤分别进行分级、分度。肾小球损伤分为4级：Ⅰ级：GBM增厚；Ⅱa级：轻度系膜增生；Ⅱb级：重度系膜增生；Ⅲ级：一个以上结节性硬化(K-W结节)；Ⅳ级：晚期糖尿病肾小球硬化。肾小管间质用间质纤维化和肾小管萎缩、间质炎症的程度评分，肾血管损伤按血管透明变性和大血管硬化的程度评分。", "ner": [[8, 12, "Disease"], [11, 11, "Anatomy"], [32, 35, "Disease"], [32, 33, "Anatomy"], [43, 45, "Test"], [72, 76, "Disease"], [75, 75, "Anatomy"], [85, 92, "Disease"], [102, 107, "Test"], [109, 117, "Test"], [122, 126, "Disease"], [122, 124, "Anatomy"], [128, 136, "Disease"], [128, 130, "Anatomy"], [132, 134, "Anatomy"], [147, 151, "Disease"], [147, 149, "Anatomy"], [160, 164, "Pathogenesis"], [170, 175, "Pathogenesis"], [181, 186, "Pathogenesis"], [191, 206, "Pathogenesis"], [211, 220, "Pathogenesis"], [222, 226, "Anatomy"], [228, 232, "Pathogenesis"], [234, 238, "Pathogenesis"], [240, 243, "Pathogenesis"], [250, 254, "Disease"], [250, 252, "Anatomy"], [256, 261, "Pathogenesis"], [263, 267, "Pathogenesis"]], "rel": [[11, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [43, 45, "Test", 8, 12, "Disease", "Test_Disease"], [32, 33, "Anatomy", 32, 35, "Disease", "Anatomy_Disease"], [43, 45, "Test", 32, 35, "Disease", "Test_Disease"], [75, 75, "Anatomy", 72, 76, "Disease", "Anatomy_Disease"], [102, 107, "Test", 122, 126, "Disease", "Test_Disease"], [102, 107, "Test", 128, 136, "Disease", "Test_Disease"], [109, 117, "Test", 122, 126, "Disease", "Test_Disease"], [109, 117, "Test", 128, 136, "Disease", "Test_Disease"], [122, 124, "Anatomy", 122, 126, "Disease", "Anatomy_Disease"], [128, 130, "Anatomy", 128, 136, "Disease", "Anatomy_Disease"], [132, 134, "Anatomy", 128, 136, "Disease", "Anatomy_Disease"], [160, 164, "Pathogenesis", 147, 151, "Disease", "Pathogenesis_Disease"], [170, 175, "Pathogenesis", 147, 151, "Disease", "Pathogenesis_Disease"], [181, 186, "Pathogenesis", 147, 151, "Disease", "Pathogenesis_Disease"], [191, 206, "Pathogenesis", 147, 151, "Disease", "Pathogenesis_Disease"], [211, 220, "Pathogenesis", 147, 151, "Disease", "Pathogenesis_Disease"], [147, 149, "Anatomy", 147, 151, "Disease", "Anatomy_Disease"], [250, 252, "Anatomy", 250, 254, "Disease", "Anatomy_Disease"], [256, 261, "Pathogenesis", 250, 254, "Disease", "Pathogenesis_Disease"], [263, 267, "Pathogenesis", 250, 254, "Disease", "Pathogenesis_Disease"]]}
{"idx": 3480, "sentence": "二、糖尿病肾病的防治", "ner": [[2, 6, "Disease"], [5, 5, "Anatomy"]], "rel": [[5, 5, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 3481, "sentence": "糖尿病肾病的防治分为三个阶段。第一阶段为糖尿病肾病的预防，对重点人群进行糖尿病筛查，发现糖耐量受损或空腹血糖受损的患者，采取改变生活方式、控制血糖等措施，预防糖尿病及糖尿病肾病的发生。第二阶段为糖尿病肾病早期治疗，出现微量白蛋白尿的糖尿病患者，予以糖尿病肾病治疗，减少或延缓大量蛋白尿的发生。第三阶段为预防或延缓肾功能不全的发生或进展，治疗并发症，出现肾功能不全者考虑肾脏替代治疗。糖尿病肾病的治疗以控制血糖、控制血压、减少尿蛋白为主，还包括生活方式干预、纠正脂质代谢紊乱、治疗肾功能不全的并发症、透析治疗等。", "ner": [[0, 4, "Disease"], [3, 3, "Anatomy"], [20, 24, "Disease"], [23, 23, "Anatomy"], [36, 38, "Disease"], [44, 48, "Pathogenesis"], [50, 55, "Pathogenesis"], [62, 67, "Treatment"], [71, 72, "Test_items"], [79, 81, "Disease"], [83, 87, "Disease"], [86, 86, "Anatomy"], [97, 101, "Disease"], [100, 100, "Anatomy"], [109, 110, "Level"], [111, 114, "Symptom"], [116, 118, "Disease"], [124, 128, "Disease"], [127, 127, "Anatomy"], [137, 138, "Level"], [139, 141, "Symptom"], [156, 160, "Disease"], [156, 156, "Anatomy"], [176, 180, "Disease"], [176, 176, "Anatomy"], [184, 189, "Treatment"], [191, 195, "Disease"], [194, 194, "Anatomy"], [207, 208, "Test"], [202, 203, "Test_items"], [212, 214, "Test_items"], [221, 226, "Treatment"], [230, 235, "Disease"], [239, 243, "Disease"], [239, 239, "Anatomy"], [249, 252, "Treatment"]], "rel": [[3, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [23, 23, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"], [44, 48, "Pathogenesis", 36, 38, "Disease", "Pathogenesis_Disease"], [50, 55, "Pathogenesis", 36, 38, "Disease", "Pathogenesis_Disease"], [62, 67, "Treatment", 36, 38, "Disease", "Treatment_Disease"], [71, 72, "Test_items", 36, 38, "Disease", "Test_items_Disease"], [86, 86, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [100, 100, "Anatomy", 97, 101, "Disease", "Anatomy_Disease"], [127, 127, "Anatomy", 124, 128, "Disease", "Anatomy_Disease"], [156, 156, "Anatomy", 156, 160, "Disease", "Anatomy_Disease"], [176, 176, "Anatomy", 176, 180, "Disease", "Anatomy_Disease"], [184, 189, "Treatment", 176, 180, "Disease", "Treatment_Disease"], [194, 194, "Anatomy", 191, 195, "Disease", "Anatomy_Disease"], [202, 203, "Test_items", 191, 195, "Disease", "Test_items_Disease"], [212, 214, "Test_items", 191, 195, "Disease", "Test_items_Disease"], [207, 208, "Test", 191, 195, "Disease", "Test_Disease"], [221, 226, "Treatment", 191, 195, "Disease", "Treatment_Disease"], [249, 252, "Treatment", 191, 195, "Disease", "Treatment_Disease"], [239, 239, "Anatomy", 239, 243, "Disease", "Anatomy_Disease"]]}
{"idx": 3482, "sentence": "(一)生活方式指导", "ner": [[3, 8, "Treatment"]], "rel": []}
{"idx": 3483, "sentence": "改变生活方式包括饮食治疗、运动、戒酒、戒烟、控制体重，有利于减缓糖尿病肾病进展，保护肾功能。近期研究证明控制多种危险因素(降糖、降脂、降压并注意生活干预后)糖尿病肾病发展至肾功能衰竭的比例明显下降，生存率明显增加。", "ner": [[0, 5, "Treatment"], [8, 11, "Treatment"], [13, 14, "Treatment"], [16, 17, "Treatment"], [19, 20, "Treatment"], [22, 25, "Treatment"], [32, 36, "Disease"], [35, 35, "Anatomy"], [72, 75, "Treatment"], [78, 82, "Disease"], [81, 81, "Anatomy"], [86, 90, "Disease"], [86, 86, "Anatomy"]], "rel": [[0, 5, "Treatment", 32, 36, "Disease", "Treatment_Disease"], [8, 11, "Treatment", 32, 36, "Disease", "Treatment_Disease"], [13, 14, "Treatment", 32, 36, "Disease", "Treatment_Disease"], [16, 17, "Treatment", 32, 36, "Disease", "Treatment_Disease"], [19, 20, "Treatment", 32, 36, "Disease", "Treatment_Disease"], [22, 25, "Treatment", 32, 36, "Disease", "Treatment_Disease"], [35, 35, "Anatomy", 32, 36, "Disease", "Anatomy_Disease"], [72, 75, "Treatment", 78, 82, "Disease", "Treatment_Disease"], [81, 81, "Anatomy", 78, 82, "Disease", "Anatomy_Disease"], [86, 86, "Anatomy", 86, 90, "Disease", "Anatomy_Disease"]]}
{"idx": 3484, "sentence": "1.医学营养治疗：医学营养治疗应强调饮食结构合理，包括对碳水化合物、蛋白质、脂肪、钠、钾、磷等营养素的管理。每日摄入的总热量应使患者维持接近理想体重，肥胖者可适当减少热量，消瘦者可适当增加热量。高蛋白摄入(超过总热量20%)与轻度肾损伤糖尿病患者中肾功能的下降、糖尿病合并高血压患者中微量白蛋白尿的发展相关联。因此糖尿病肾病患者应避免高蛋白饮食，严格控制蛋白质每日摄入量，不超过总热量的15%，微量白蛋白尿者每千克体重应控制在0.8~1.0g，显性蛋白尿者及肾功能损害者应控制在0.6~0.8g。有随机对照试验的meta分析表明，低蛋白饮食治疗对蛋白尿的控制有益，但对GFR或内生肌酐清除率(Ccr)的改善无显著作用。由于蛋白质的摄入减少，摄入的蛋白质应以生物学效价高的优质蛋白质为主，可从家禽、鱼、大豆及植物蛋白等中获得。有研究表明，ARB/ACEI类药物在低钠饮食下对糖尿病。肾病及心血管疾病的改善作用更明显，但在高钠饮食下则可能存在危害，此应限制钠盐摄入，每日摄入量控制在2000~2400mg，高血压者可配合降压药物治疗。", "ner": [[2, 7, "Treatment"], [9, 14, "Treatment"], [75, 76, "Disease"], [86, 87, "Disease"], [97, 101, "Treatment"], [115, 117, "Disease"], [115, 115, "Anatomy"], [118, 120, "Disease"], [124, 126, "Test"], [128, 129, "Test_Value"], [131, 133, "Disease"], [136, 138, "Disease"], [142, 143, "Level"], [144, 147, "Disease"], [157, 161, "Disease"], [160, 160, "Anatomy"], [197, 198, "Level"], [199, 202, "Disease"], [224, 226, "Disease"], [229, 233, "Disease"], [229, 229, "Anatomy"], [265, 271, "Treatment"], [284, 286, "Test_items"], [288, 299, "Test_items"], [273, 275, "Disease"], [368, 378, "Drug"], [386, 388, "Disease"], [390, 391, "Disease"], [390, 390, "Anatomy"], [393, 397, "Disease"], [393, 395, "Anatomy"], [424, 429, "Treatment"], [451, 453, "Disease"]], "rel": [[97, 101, "Treatment", 115, 117, "Disease", "Treatment_Disease"], [97, 101, "Treatment", 118, 120, "Disease", "Treatment_Disease"], [97, 101, "Treatment", 131, 133, "Disease", "Treatment_Disease"], [97, 101, "Treatment", 136, 138, "Disease", "Treatment_Disease"], [97, 101, "Treatment", 144, 147, "Disease", "Treatment_Disease"], [124, 126, "Test", 115, 117, "Disease", "Test_Disease"], [124, 126, "Test", 118, 120, "Disease", "Test_Disease"], [160, 160, "Anatomy", 157, 161, "Disease", "Anatomy_Disease"], [229, 229, "Anatomy", 229, 233, "Disease", "Anatomy_Disease"], [265, 271, "Treatment", 273, 275, "Disease", "Treatment_Disease"], [284, 286, "Test_items", 273, 275, "Disease", "Test_items_Disease"], [288, 299, "Test_items", 273, 275, "Disease", "Test_items_Disease"], [368, 378, "Drug", 386, 388, "Disease", "Drug_Disease"], [390, 390, "Anatomy", 390, 391, "Disease", "Anatomy_Disease"], [424, 429, "Treatment", 390, 391, "Disease", "Treatment_Disease"], [393, 395, "Anatomy", 393, 397, "Disease", "Anatomy_Disease"], [424, 429, "Treatment", 393, 397, "Disease", "Treatment_Disease"]]}
{"idx": 3485, "sentence": "尚无明确证据表明富含纤维的蔬菜的摄入对糖尿病肾病有益。", "ner": [[19, 23, "Disease"], [22, 22, "Anatomy"]], "rel": [[22, 22, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"]]}
{"idx": 3486, "sentence": "与执业营养师一起完成营养控制目标，可改善糖尿病肾病患者的预后。", "ner": [[20, 24, "Disease"], [23, 23, "Anatomy"]], "rel": [[23, 23, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"]]}
{"idx": 3487, "sentence": "2.运动：体力活动可诱导糖尿病肾病早期的尿蛋白暂时升高，长期规律的运动可通过提高胰岛素敏感性、改善糖耐量，减轻体重，改善脂质代谢，改善内皮功能，控制血糖、血压，，减缓糖尿病及糖尿病肾病的发生发展。糖尿病控制和并发症防治试验(DCCT)的回顾分析却表明运动对1型糖尿病微血管病变的预后无改善作用，但无证据表明运动带来危害，故仍建议1型糖尿病患者运动。FinnDiane研究结果显示，低频率低强度体育锻炼的1型糖尿病患者发生糖尿病肾病的比例更高。因此糖尿病肾病患者运动的频率强度应达到一定的要求。患者每周应至少进行150min以上中等强度的有氧运动(运动时心率达到最高值的50%~70%)，每周至少运动3d，每周至少安排2次对抗性训练。不适当的运动可因胰岛素水平不足诱发酮症，也可因过度耗能诱发低血糖，因而运动强度、持续时间、频率、项目的选择都要个体化，建议糖尿病肾病患者在专业人士的指导下制定合理的运动方案，或参加运动计划，提高依从性，减少运动不良后果的发生。对于进展至ESRD的糖尿病肾病患者，每周2~3次以上的有氧运动、对抗性运动有利于控制血压、减轻炎症、改善生活质量，但证据大多来自小样本试验。", "ner": [[2, 3, "Treatment"], [12, 16, "Disease"], [15, 15, "Anatomy"], [20, 22, "Test_items"], [23, 26, "Test_Value"], [28, 34, "Treatment"], [49, 51, "Test_items"], [74, 75, "Test_items"], [77, 78, "Test"], [83, 85, "Disease"], [87, 91, "Disease"], [90, 90, "Anatomy"], [333, 334, "Disease"], [324, 330, "Pathogenesis"], [316, 321, "Reason"], [345, 347, "Disease"], [377, 381, "Disease"], [380, 380, "Anatomy"], [434, 437, "Disease"], [439, 443, "Disease"], [442, 442, "Anatomy"], [447, 465, "Treatment"], [471, 472, "Test"], [98, 100, "Disease"], [128, 137, "Disease"], [125, 126, "Treatment"], [133, 135, "Anatomy"], [164, 168, "Disease"], [201, 205, "Disease"], [210, 214, "Disease"], [213, 213, "Anatomy"], [153, 154, "Treatment"], [171, 172, "Treatment"], [223, 227, "Disease"], [226, 226, "Anatomy"], [248, 271, "Treatment"], [293, 300, "Treatment"], [302, 314, "Treatment"]], "rel": [[15, 15, "Anatomy", 12, 16, "Disease", "Anatomy_Disease"], [20, 22, "Test_items", 12, 16, "Disease", "Test_items_Disease"], [49, 51, "Test_items", 12, 16, "Disease", "Test_items_Disease"], [74, 75, "Test_items", 12, 16, "Disease", "Test_items_Disease"], [28, 34, "Treatment", 12, 16, "Disease", "Treatment_Disease"], [77, 78, "Test", 12, 16, "Disease", "Test_Disease"], [316, 321, "Reason", 333, 334, "Disease", "Reason_Disease"], [324, 330, "Pathogenesis", 333, 334, "Disease", "Pathogenesis_Disease"], [316, 321, "Reason", 345, 347, "Disease", "Reason_Disease"], [380, 380, "Anatomy", 377, 381, "Disease", "Anatomy_Disease"], [447, 465, "Treatment", 434, 437, "Disease", "Treatment_Disease"], [471, 472, "Test", 434, 437, "Disease", "Test_Disease"], [447, 465, "Treatment", 439, 443, "Disease", "Treatment_Disease"], [442, 442, "Anatomy", 439, 443, "Disease", "Anatomy_Disease"], [471, 472, "Test", 439, 443, "Disease", "Test_Disease"], [125, 126, "Treatment", 128, 137, "Disease", "Treatment_Disease"], [133, 135, "Anatomy", 128, 137, "Disease", "Anatomy_Disease"], [171, 172, "Treatment", 164, 168, "Disease", "Treatment_Disease"], [213, 213, "Anatomy", 210, 214, "Disease", "Anatomy_Disease"], [226, 226, "Anatomy", 223, 227, "Disease", "Anatomy_Disease"]]}
{"idx": 3488, "sentence": "3.戒烟：吸烟是糖尿病肾病患者蛋白尿及肾功能进展的危险因素，戒烟或减少吸烟是糖尿病患者预防或控制糖尿病肾病进展的重要措施。", "ner": [[2, 3, "Treatment"], [8, 12, "Disease"], [11, 11, "Anatomy"], [15, 17, "Disease"], [19, 21, "Test"], [30, 36, "Treatment"], [38, 40, "Disease"], [48, 52, "Disease"], [51, 51, "Anatomy"]], "rel": [[2, 3, "Treatment", 8, 12, "Disease", "Treatment_Disease"], [11, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [19, 21, "Test", 8, 12, "Disease", "Test_Disease"], [30, 36, "Treatment", 38, 40, "Disease", "Treatment_Disease"], [51, 51, "Anatomy", 48, 52, "Disease", "Anatomy_Disease"]]}
{"idx": 3489, "sentence": "(二)控制血糖", "ner": [[5, 6, "Test_items"]], "rel": []}
{"idx": 3490, "sentence": "DCCT及其后续的糖尿病干预和并发症流行病学研究(EDIC)、英国2型糖尿病前瞻性研究(UKPDS)及美国退伍军人合作研究(VAC)分别验证了在1型糖尿病和2型糖尿病患者中，严格控制血糖可减少糖尿病肾病的发生或延缓其病程进展。", "ner": [[9, 11, "Disease"], [33, 37, "Disease"], [72, 76, "Disease"], [78, 82, "Disease"], [91, 92, "Test_items"], [96, 100, "Disease"], [99, 99, "Anatomy"]], "rel": [[91, 92, "Test_items", 96, 100, "Disease", "Test_items_Disease"], [99, 99, "Anatomy", 96, 100, "Disease", "Anatomy_Disease"]]}
{"idx": 3491, "sentence": "1.血糖控制目标：糖尿病肾病患者的血糖控制应遵循个体化原则。血糖控制目标：糖化血红蛋白(HbA1c)不超过7%。对中老年患者，HbA1c控制目标适当放宽至不超过7%~9%。由于CKD患者的红细胞寿命缩短，HbA1c可能被低估。在CKD4~5期的患者中，用果糖胺或糖化血清白蛋白反映血糖控制水平更可靠一。", "ner": [[2, 3, "Test_items"], [9, 13, "Disease"], [12, 12, "Anatomy"], [17, 18, "Test_items"], [30, 31, "Test_items"], [37, 49, "Test_items"], [50, 54, "Test_Value"], [63, 67, "Test_items"], [77, 84, "Test_Value"], [88, 90, "Disease"], [94, 100, "Pathogenesis"], [102, 106, "Test_items"], [114, 120, "Disease"], [127, 129, "Test_items"], [131, 137, "Test_items"], [140, 141, "Test_items"]], "rel": [[2, 3, "Test_items", 9, 13, "Disease", "Test_items_Disease"], [17, 18, "Test_items", 9, 13, "Disease", "Test_items_Disease"], [12, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [94, 100, "Pathogenesis", 88, 90, "Disease", "Pathogenesis_Disease"], [102, 106, "Test_items", 88, 90, "Disease", "Test_items_Disease"], [127, 129, "Test_items", 114, 120, "Disease", "Test_items_Disease"], [131, 137, "Test_items", 114, 120, "Disease", "Test_items_Disease"], [140, 141, "Test_items", 114, 120, "Disease", "Test_items_Disease"]]}
{"idx": 3492, "sentence": "2.抗高血糖药物的选择：包括双胍类、磺脲类、格列奈类、噻唑烷二酮类、α-糖苷酶抑制剂、二肽基肽酶IV(DPP-4)抑制剂、胰高血糖素样肽1(GLP-1)类似物及胰岛素。某些在肾脏代谢或排泄的药物，在糖尿病肾病尤其是肾功能不全的患者中，经肾排泄减少或其活性代谢产物的清除减少，可引起低血糖等不良反应，这些药物在GFR低于60ml·min·-1·1.73m-2时需酌情减量或停药(图1)。", "ner": [[3, 5, "Disease"], [14, 16, "Drug"], [18, 20, "Drug"], [22, 25, "Drug"], [27, 32, "Drug"], [34, 41, "Drug"], [43, 59, "Drug"], [61, 78, "Drug"], [80, 82, "Drug"], [99, 103, "Disease"], [102, 102, "Anatomy"], [107, 111, "Disease"], [107, 107, "Anatomy"], [140, 142, "ADE"], [154, 156, "Test_items"], [157, 177, "Test_Value"]], "rel": [[102, 102, "Anatomy", 99, 103, "Disease", "Anatomy_Disease"], [140, 142, "ADE", 99, 103, "Disease", "ADE_Disease"], [107, 107, "Anatomy", 107, 111, "Disease", "Anatomy_Disease"]]}
{"idx": 3493, "sentence": "(1)双胍类：目前，二甲双胍被推荐作为2型糖尿病控制血糖的一线用药，首选用于单纯饮食控制或体育锻炼无效的2型糖尿病，尤其适用于肥胖患者，也与胰岛素联合用于1型和2型糖尿病。其主要药理作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖，二甲双胍可以使HbA1c降低1%~2%，并可减轻体重且不增加低血糖风险。UKPDS研究显示，二甲双胍可降低伴有肥胖的2型糖尿病患者的心血管事件和死亡风险。糖尿病结果预防试验(ADOPT)研究显示，二甲双胍可延缓糖尿病患者微量白蛋白尿的进展。二甲双胍不经肝脏代谢，直接以原形经肾脏排泄，当肾功能受损时，易发生二甲双胍和乳酸在体内堆积，增加乳酸性酸中毒风险。因此二甲双胍用于CKD3a期以上的患者时应减少剂量，eGFR<45ml·min-1·1.73m-2时停用。肾功能受损的患者应用二甲双胍时应注意肾功能变化，每年至少检查一次肾功能。", "ner": [[3, 5, "Drug"], [10, 13, "Drug"], [19, 23, "Disease"], [26, 27, "Test_items"], [38, 43, "Treatment"], [45, 48, "Treatment"], [52, 56, "Disease"], [63, 64, "Disease"], [70, 72, "Drug"], [77, 84, "Disease"], [107, 111, "Pathogenesis"], [115, 116, "Test_items"], [118, 121, "Drug"], [125, 129, "Test_items"], [130, 136, "Test_Value"], [148, 150, "ADE"], [164, 167, "Drug"], [173, 174, "Disease"], [176, 180, "Disease"], [184, 188, "Disease"], [184, 186, "Anatomy"], [195, 197, "Disease"], [216, 219, "Drug"], [223, 225, "Disease"], [228, 229, "Level"], [230, 233, "Disease"], [238, 241, "Drug"], [271, 274, "Drug"], [286, 291, "ADE"], [297, 300, "Drug"], [303, 308, "Disease"], [321, 324, "Test_items"], [326, 343, "Test_Value"], [348, 352, "Disease"], [348, 348, "Anatomy"], [358, 361, "Drug"], [380, 382, "Test"], [366, 368, "Test"], [261, 265, "Disease"], [261, 261, "Anatomy"]], "rel": [[10, 13, "Drug", 19, 23, "Disease", "Drug_Disease"], [10, 13, "Drug", 63, 64, "Disease", "Drug_Disease"], [10, 13, "Drug", 77, 84, "Disease", "Drug_Disease"], [26, 27, "Test_items", 19, 23, "Disease", "Test_items_Disease"], [38, 43, "Treatment", 52, 56, "Disease", "Treatment_Disease"], [45, 48, "Treatment", 52, 56, "Disease", "Treatment_Disease"], [70, 72, "Drug", 77, 84, "Disease", "Drug_Disease"], [164, 167, "Drug", 173, 174, "Disease", "Drug_Disease"], [164, 167, "Drug", 176, 180, "Disease", "Drug_Disease"], [184, 186, "Anatomy", 184, 188, "Disease", "Anatomy_Disease"], [216, 219, "Drug", 223, 225, "Disease", "Drug_Disease"], [238, 241, "Drug", 261, 265, "Disease", "Drug_Disease"], [286, 291, "ADE", 238, 241, "Drug", "ADE_Drug"], [297, 300, "Drug", 303, 308, "Disease", "Drug_Disease"], [321, 324, "Test_items", 303, 308, "Disease", "Test_items_Disease"], [348, 348, "Anatomy", 348, 352, "Disease", "Anatomy_Disease"], [358, 361, "Drug", 348, 352, "Disease", "Drug_Disease"], [366, 368, "Test", 348, 352, "Disease", "Test_Disease"], [380, 382, "Test", 348, 352, "Disease", "Test_Disease"], [261, 261, "Anatomy", 261, 265, "Disease", "Anatomy_Disease"]]}
{"idx": 3494, "sentence": "(2)磺脲类：第一代磺脲类药物(如氯磺丙脲、妥拉磺脲、甲苯磺丁脲)的药物原型及其活性代谢产物主要依赖肾脏排泄，应用于CKD患者时半衰期延长，低血糖风险明显增加，因此禁用于该类患者，目前此类药物在临床上已基本被淘汰。第二代磺脲类药物包括格列本脲、格列吡嗪、格列奇特、格列喹酮和格列美脲等。格列本脲和格列美脲的代谢产物仍有降糖活性，尤其是格列本脲的半衰期较长，其活性代谢产物可在CKD患者体内积聚，可能引起严重的低血糖反应，且持续时间可超过24h。因而格列本脲仅可用于CKD1~2期的患者；格列美脲用于CKD3~4期的患者时，应从小剂量开始用药，即起始剂量为每日1mg；由于还未积累关于透析患者的用药经验，在透析患者禁用。格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于前两者。格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5%由肾脏排泄，受肾功能影响较小。因而格列吡嗪、格列齐特和格列喹酮于CKD1~3期患者无需调整剂量。", "ner": [[3, 5, "Drug"], [7, 14, "Drug"], [17, 20, "Drug"], [22, 25, "Drug"], [27, 31, "Drug"], [58, 60, "Disease"], [70, 72, "ADE"], [107, 114, "Drug"], [117, 120, "Drug"], [122, 125, "Drug"], [127, 130, "Drug"], [132, 135, "Drug"], [137, 140, "Drug"], [143, 146, "Drug"], [148, 151, "Drug"], [167, 170, "Drug"], [187, 189, "Disease"], [204, 206, "ADE"], [224, 227, "Drug"], [232, 238, "Disease"], [243, 246, "Drug"], [249, 255, "Disease"], [277, 281, "Amount"], [291, 292, "Treatment"], [302, 303, "Treatment"], [309, 312, "Drug"], [314, 317, "Drug"], [341, 343, "ADE"], [352, 355, "Drug"], [396, 399, "Drug"], [401, 404, "Drug"], [406, 409, "Drug"], [411, 417, "Disease"]], "rel": [[7, 14, "Drug", 58, 60, "Disease", "Drug_Disease"], [70, 72, "ADE", 7, 14, "Drug", "ADE_Drug"], [17, 20, "Drug", 58, 60, "Disease", "Drug_Disease"], [70, 72, "ADE", 17, 20, "Drug", "ADE_Drug"], [22, 25, "Drug", 58, 60, "Disease", "Drug_Disease"], [70, 72, "ADE", 22, 25, "Drug", "ADE_Drug"], [27, 31, "Drug", 58, 60, "Disease", "Drug_Disease"], [70, 72, "ADE", 27, 31, "Drug", "ADE_Drug"], [143, 146, "Drug", 187, 189, "Disease", "Drug_Disease"], [148, 151, "Drug", 187, 189, "Disease", "Drug_Disease"], [167, 170, "Drug", 187, 189, "Disease", "Drug_Disease"], [204, 206, "ADE", 167, 170, "Drug", "ADE_Drug"], [224, 227, "Drug", 232, 238, "Disease", "Drug_Disease"], [243, 246, "Drug", 249, 255, "Disease", "Drug_Disease"], [277, 281, "Amount", 243, 246, "Drug", "Amount_Drug"], [291, 292, "Treatment", 249, 255, "Disease", "Treatment_Disease"], [302, 303, "Treatment", 249, 255, "Disease", "Treatment_Disease"], [341, 343, "ADE", 309, 312, "Drug", "ADE_Drug"], [341, 343, "ADE", 314, 317, "Drug", "ADE_Drug"], [396, 399, "Drug", 411, 417, "Disease", "Drug_Disease"], [401, 404, "Drug", 411, 417, "Disease", "Drug_Disease"], [406, 409, "Drug", 411, 417, "Disease", "Drug_Disease"]]}
{"idx": 3495, "sentence": "(3)格列奈类：格列奈类药物是非磺脲类胰岛素促泌剂，其具有葡萄糖依赖性，需餐前服用。由于其对基础胰岛素分泌物无明显刺激作用，其引起低血糖的风险和程度较磺脲类药物轻。其他不良反应有过敏反应、胃肠道不适、眼睛异常、肝功能损害等，均较罕见。格列奈类的主要代表药物有那格列奈和瑞格列奈。瑞格列奈及其代谢产物主要经肝脏代谢，仅<8%经肾排泄。瑞格列奈I期临床试验表明，使用瑞格列奈7d后，肾功能正常患者与不同程度的CKD患者相比，血药浓度没有明显差异，提示瑞格列奈在CKD患者体内无蓄积。一项入选281例伴或不伴肾功能不全2型糖尿病患者的多中心研究提示，使用瑞格列奈替换原有降糖治疗，不同程度肾功能不全亚组患者(正常、轻、中、重、极重肾功能损伤)低血糖发生率均低于2%，且瑞格列奈治疗期低血糖发生率与肾功能损伤程度无关。因此瑞格列奈应用于CKD3、4期或肾脏移植、透析者，均无需调整剂量。在Ccr15~50ml·min-1·1.73m-2的糖尿病患者中，那格列奈的生物利用度和半衰期与健康人相比其差别未达到具有临床意义的程度，但随着肾功能的下降，那格列奈的活性代谢产物水平增加。有观点认为那格列奈应用于肾功能不全的糖尿病患者时无需调整剂量，但ADA仍建议CKD4期应从小剂量每次餐前60mg开始。", "ner": [[3, 6, "Drug"], [8, 13, "Drug"], [15, 24, "Drug"], [65, 67, "ADE"], [75, 78, "Drug"], [89, 92, "ADE"], [94, 98, "ADE"], [100, 103, "ADE"], [105, 109, "ADE"], [117, 120, "Drug"], [129, 132, "Drug"], [134, 137, "Drug"], [139, 142, "Drug"], [166, 169, "Drug"], [181, 184, "Drug"], [185, 186, "Duration"], [189, 191, "Test"], [202, 204, "Disease"], [223, 226, "Drug"], [228, 230, "Disease"], [210, 213, "Pathogenesis"], [251, 255, "Disease"], [251, 251, "Anatomy"], [256, 260, "Disease"], [274, 277, "Drug"], [291, 295, "Disease"], [291, 291, "Anatomy"], [301, 311, "Level"], [312, 316, "Disease"], [312, 312, "Anatomy"], [318, 320, "ADE"], [331, 334, "Drug"], [338, 340, "ADE"], [345, 349, "Disease"], [345, 345, "Anatomy"], [357, 360, "Drug"], [364, 370, "Disease"], [372, 375, "Operation"], [377, 378, "Treatment"], [390, 392, "Test_items"], [393, 413, "Test_Value"], [415, 417, "Disease"], [422, 425, "Drug"], [461, 463, "Test"], [468, 471, "Drug"], [489, 492, "Drug"], [496, 500, "Disease"], [496, 496, "Anatomy"], [502, 504, "Disease"], [522, 526, "Disease"], [534, 539, "Amount"]], "rel": [[65, 67, "ADE", 75, 78, "Drug", "ADE_Drug"], [185, 186, "Duration", 181, 184, "Drug", "Duration_Drug"], [181, 184, "Drug", 202, 204, "Disease", "Drug_Disease"], [210, 213, "Pathogenesis", 202, 204, "Disease", "Pathogenesis_Disease"], [223, 226, "Drug", 228, 230, "Disease", "Drug_Disease"], [251, 251, "Anatomy", 251, 255, "Disease", "Anatomy_Disease"], [274, 277, "Drug", 251, 255, "Disease", "Drug_Disease"], [274, 277, "Drug", 256, 260, "Disease", "Drug_Disease"], [318, 320, "ADE", 274, 277, "Drug", "ADE_Drug"], [291, 291, "Anatomy", 291, 295, "Disease", "Anatomy_Disease"], [318, 320, "ADE", 291, 295, "Disease", "ADE_Disease"], [312, 312, "Anatomy", 312, 316, "Disease", "Anatomy_Disease"], [338, 340, "ADE", 331, 334, "Drug", "ADE_Drug"], [345, 345, "Anatomy", 345, 349, "Disease", "Anatomy_Disease"], [357, 360, "Drug", 364, 370, "Disease", "Drug_Disease"], [372, 375, "Operation", 364, 370, "Disease", "Operation_Disease"], [377, 378, "Treatment", 364, 370, "Disease", "Treatment_Disease"], [390, 392, "Test_items", 415, 417, "Disease", "Test_items_Disease"], [422, 425, "Drug", 415, 417, "Disease", "Drug_Disease"], [461, 463, "Test", 415, 417, "Disease", "Test_Disease"], [489, 492, "Drug", 496, 500, "Disease", "Drug_Disease"], [489, 492, "Drug", 502, 504, "Disease", "Drug_Disease"], [489, 492, "Drug", 522, 526, "Disease", "Drug_Disease"], [534, 539, "Amount", 489, 492, "Drug", "Amount_Drug"], [496, 496, "Anatomy", 496, 500, "Disease", "Anatomy_Disease"]]}
{"idx": 3496, "sentence": "(4)噻唑烷二酮类：该类药物的常见不良反应是液体潴留，因而对于重度心衰患者应慎用。使用该类药物发生骨折及骨质疏松的风险增加，需慎用于潜在骨疾病的患者(如肾性骨营养不良)，尤其是绝经后女性；其他不良反应包括肝酶升高、体重增加等。该类药物不刺激内源性胰岛素分泌，单独使用低血糖风险低(1%~2%)。该类药物主要代表为吡格列酮和罗格列酮。由于其经过肝脏代谢，吡格列酮用于肾功能不全无需调整剂量；罗格列酮因增加心血管风险的安全性问题引起了国内外的警惕，美国食品药品监督管理局(FDA)和欧洲药品管理局建议在心功能不全和严重骨质疏松患者慎用已限制其使用(图1)。", "ner": [[31, 34, "Disease"], [33, 33, "Anatomy"], [49, 50, "Disease"], [52, 55, "Disease"], [68, 70, "Disease"], [68, 68, "Anatomy"], [76, 82, "Disease"], [78, 78, "Anatomy"], [102, 105, "ADE"], [107, 110, "ADE"], [133, 135, "ADE"], [156, 159, "Drug"], [161, 164, "Drug"], [176, 179, "Drug"], [182, 186, "Disease"], [182, 182, "Anatomy"], [194, 197, "Drug"], [201, 205, "Disease"], [201, 203, "Anatomy"], [249, 253, "Disease"], [249, 249, "Anatomy"], [255, 256, "Level"], [257, 260, "Disease"], [3, 8, "Drug"], [22, 25, "ADE"]], "rel": [[3, 8, "Drug", 31, 34, "Disease", "Drug_Disease"], [33, 33, "Anatomy", 31, 34, "Disease", "Anatomy_Disease"], [68, 68, "Anatomy", 68, 70, "Disease", "Anatomy_Disease"], [78, 78, "Anatomy", 76, 82, "Disease", "Anatomy_Disease"], [176, 179, "Drug", 182, 186, "Disease", "Drug_Disease"], [182, 182, "Anatomy", 182, 186, "Disease", "Anatomy_Disease"], [194, 197, "Drug", 201, 205, "Disease", "Drug_Disease"], [249, 249, "Anatomy", 249, 253, "Disease", "Anatomy_Disease"], [22, 25, "ADE", 3, 8, "Drug", "ADE_Drug"]]}
{"idx": 3497, "sentence": "(5)α-糖苷酶抑制剂：α-糖苷酶抑制剂适用于饮食结构以碳水化合物为主且餐后血糖升高的患者，可将HbA1c降低0.5%~0.8%，其主要药理作用是抑制碳水化合物在小肠上段的吸收而降低餐后血糖，不增加体重且有减轻体重的趋势。该类药物口服后被胃肠道吸收不到1%，故全身性不良反应不多见，主要不良反应是胃肠道不适，表现为腹胀、腹泻等，其主要代表药物有阿卡波糖、伏格列波糖等。随肾功能的降低，阿卡波糖及其代谢产物的血药浓度显著增加，Ccr低于25ml·min-1·1.73m-2者禁用。伏格列波糖仅微量被吸收，分布于肠黏膜和肾脏，可用于CKD 1~3期患者，慎用于CKD4~5期患者，不必调整剂量。", "ner": [[3, 10, "Drug"], [12, 19, "Drug"], [36, 39, "Test_items"], [40, 41, "Test_Value"], [48, 52, "Test_items"], [53, 63, "Test_Value"], [91, 94, "Test_items"], [115, 116, "Method"], [148, 152, "ADE"], [157, 158, "ADE"], [160, 161, "ADE"], [172, 175, "Drug"], [177, 181, "Drug"], [192, 195, "Drug"], [203, 206, "Pathogenesis"], [212, 214, "Test_items"], [215, 234, "Test_Value"], [239, 243, "Drug"], [264, 271, "Disease"], [278, 284, "Disease"]], "rel": [[148, 152, "ADE", 172, 175, "Drug", "ADE_Drug"], [148, 152, "ADE", 177, 181, "Drug", "ADE_Drug"], [157, 158, "ADE", 172, 175, "Drug", "ADE_Drug"], [157, 158, "ADE", 177, 181, "Drug", "ADE_Drug"], [160, 161, "ADE", 172, 175, "Drug", "ADE_Drug"], [160, 161, "ADE", 177, 181, "Drug", "ADE_Drug"], [239, 243, "Drug", 264, 271, "Disease", "Drug_Disease"]]}
{"idx": 3498, "sentence": "(6)GLP-1：GLP-1半衰期短，GLP-1类似物的半衰期延长，其代表药物有艾塞那肽、利拉鲁肽等。艾塞那肽经肾排泄，GFR低于45ml·min-1·1.73m-2时，其清除率下降36%，GFR低于30ml·min-1·1.73m-2时，其清除率下降64%且透析患者不能耐受胃肠道不良反应，因此艾塞那肽不推荐用于CKD4~5期的患者。利拉鲁肽也仅可用于CKD1~2期患者，在中度肾功能损害患者中的治疗经验有限，不推荐用于包括ESRD患者在内的重度肾功能损害患者。", "ner": [[3, 7, "Drug"], [9, 13, "Drug"], [19, 23, "Drug"], [40, 43, "Drug"], [45, 48, "Drug"], [51, 54, "Drug"], [60, 62, "Test_items"], [63, 82, "Test_Value"], [95, 97, "Test_items"], [98, 117, "Test_Value"], [130, 131, "Treatment"], [138, 144, "ADE"], [148, 151, "Drug"], [157, 163, "Disease"], [168, 171, "Drug"], [177, 183, "Disease"], [188, 189, "Level"], [190, 194, "Disease"], [190, 190, "Anatomy"], [213, 216, "Disease"], [222, 223, "Level"], [224, 228, "Disease"], [224, 224, "Anatomy"]], "rel": [[138, 144, "ADE", 51, 54, "Drug", "ADE_Drug"], [51, 54, "Drug", 157, 163, "Disease", "Drug_Disease"], [60, 62, "Test_items", 157, 163, "Disease", "Test_items_Disease"], [95, 97, "Test_items", 157, 163, "Disease", "Test_items_Disease"], [130, 131, "Treatment", 157, 163, "Disease", "Treatment_Disease"], [168, 171, "Drug", 177, 183, "Disease", "Drug_Disease"], [190, 190, "Anatomy", 190, 194, "Disease", "Anatomy_Disease"], [224, 224, "Anatomy", 224, 228, "Disease", "Anatomy_Disease"]]}
{"idx": 3499, "sentence": "包括ESRD患者在内的重度肾功能损害患者。", "ner": [[2, 5, "Disease"], [11, 12, "Level"], [13, 17, "Disease"], [13, 13, "Anatomy"]], "rel": [[13, 13, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"]]}
{"idx": 3500, "sentence": "(7)DPP-4抑制剂：DPP-4是GLP-1降解酶，DDP-4抑剂通过减少GLP-1在体内的降解，增加体内GLP-1的水平。这一类降糖药由于上市较晚，缺乏临床用药经验，因此用于糖尿病肾病患者时应酌情减量。DPP-4抑制剂降低HbA1c弱于其他胰岛素促泌剂。目前在国内上市的DPP-4抑制剂为西格列汀、沙格列汀、维格列汀和利格列汀。西格列汀用于GFR>50ml·min-1·1.73m-2的CKD患者时无需调整剂量，当GFR在30~50ml·min-1·1.73m-2时减量至50mg每日1次，GFR<30ml·min-1·1.73m-2或透析的患者可减量至每日25mg，但相关的临床经验尚不丰富。沙格列汀和维格列汀可用于CKD 1~2期患者，用于中重度肾功能不全患者的临床试验数据有限，不推荐用于3~5期患者，仅有利格列汀在CKD 4~5期时无需减量。", "ner": [[3, 10, "Drug"], [27, 33, "Drug"], [54, 58, "Test_items"], [89, 93, "Disease"], [92, 92, "Anatomy"], [103, 110, "Drug"], [113, 117, "Test_items"], [122, 127, "Drug"], [137, 144, "Drug"], [146, 149, "Drug"], [151, 154, "Drug"], [156, 159, "Drug"], [161, 164, "Drug"], [166, 169, "Drug"], [172, 174, "Test_items"], [175, 193, "Test_Value"], [195, 197, "Disease"], [209, 211, "Test_items"], [213, 233, "Test_Value"], [238, 241, "Amount"], [242, 245, "Frequency"], [247, 249, "Test_items"], [250, 268, "Test_Value"], [270, 271, "Treatment"], [281, 284, "Amount"], [299, 302, "Drug"], [304, 307, "Drug"], [311, 318, "Disease"], [324, 326, "Level"], [327, 331, "Disease"], [327, 327, "Anatomy"], [358, 361, "Drug"], [363, 370, "Disease"]], "rel": [[92, 92, "Anatomy", 89, 93, "Disease", "Anatomy_Disease"], [166, 169, "Drug", 195, 197, "Disease", "Drug_Disease"], [238, 241, "Amount", 166, 169, "Drug", "Amount_Drug"], [281, 284, "Amount", 166, 169, "Drug", "Amount_Drug"], [242, 245, "Frequency", 166, 169, "Drug", "Frequency_Drug"], [172, 174, "Test_items", 195, 197, "Disease", "Test_items_Disease"], [209, 211, "Test_items", 195, 197, "Disease", "Test_items_Disease"], [247, 249, "Test_items", 195, 197, "Disease", "Test_items_Disease"], [270, 271, "Treatment", 195, 197, "Disease", "Treatment_Disease"], [299, 302, "Drug", 311, 318, "Disease", "Drug_Disease"], [304, 307, "Drug", 311, 318, "Disease", "Drug_Disease"], [327, 327, "Anatomy", 327, 331, "Disease", "Anatomy_Disease"], [358, 361, "Drug", 363, 370, "Disease", "Drug_Disease"]]}
{"idx": 3501, "sentence": "(8)胰岛素：胰岛素是糖尿病的基础用药，适用于1型糖尿病、有急性并发症或严重合并症或处于应激状态或口服降糖药物疗效不佳或有口服降糖药禁忌的2型糖尿病、妊娠糖尿病、继发于严重胰腺疾病的糖尿病、严重营养不良等。不良反应主要有低血糖发作、体重增加、治疗初期的外周组织水肿、过敏反应等。肾功能受损者胰岛素的排泄减少，故CKD3期以上的患者胰岛素用量需减少。", "ner": [[3, 5, "Drug"], [7, 9, "Drug"], [11, 13, "Disease"], [23, 27, "Disease"], [49, 50, "Method"], [61, 62, "Method"], [69, 73, "Disease"], [75, 79, "Disease"], [84, 89, "Reason"], [91, 93, "Disease"], [95, 96, "Level"], [97, 100, "Disease"], [110, 112, "ADE"], [116, 119, "ADE"], [121, 131, "ADE"], [133, 136, "ADE"], [139, 152, "Pathogenesis"], [155, 159, "Disease"], [165, 167, "Drug"]], "rel": [[7, 9, "Drug", 11, 13, "Disease", "Drug_Disease"], [84, 89, "Reason", 91, 93, "Disease", "Reason_Disease"], [139, 152, "Pathogenesis", 155, 159, "Disease", "Pathogenesis_Disease"]]}
{"idx": 3502, "sentence": "(三)控制血压", "ner": [[5, 6, "Test"]], "rel": []}
{"idx": 3503, "sentence": "血压升高不仅是加速糖尿病肾病进展的重要因素，也是决定患者心血管病预后的主要风险因素。在2型糖尿病肾病患者中，血压对肾功能的影响更加突出，收缩压超过140mmHg(1mmHg=0.133kPa)的患者，其肾功能下降速度为每年13.5%，而收缩压<140mmHg者每年肾功能下降的速度是1%。UKPDS研究显示，在处于糖尿病早期的糖尿病患者中采用强化的血压控制，不但可以显著减少糖尿病大血管病变发生的风险，还显著减少了微血管病变发生的风险。大量临床观察也证实，严格控制高血压能明显减少糖尿病肾病患者尿蛋白水平，延缓肾功能损害的进展。", "ner": [[0, 1, "Test"], [2, 3, "Test_Value"], [9, 13, "Disease"], [12, 12, "Anatomy"], [43, 49, "Disease"], [48, 48, "Anatomy"], [54, 55, "Test"], [57, 59, "Test"], [68, 70, "Test_items"], [71, 95, "Test_Value"], [101, 103, "Test"], [118, 120, "Test_items"], [121, 128, "Test_Value"], [132, 134, "Test"], [135, 142, "Test_Value"], [157, 159, "Disease"], [163, 165, "Disease"], [174, 175, "Test"], [187, 194, "Disease"], [190, 192, "Anatomy"], [207, 211, "Disease"], [207, 209, "Anatomy"], [232, 234, "Disease"], [240, 244, "Disease"], [243, 243, "Anatomy"], [247, 249, "Test_items"], [255, 259, "Disease"], [255, 255, "Anatomy"], [28, 31, "Disease"], [28, 30, "Anatomy"]], "rel": [[0, 1, "Test", 9, 13, "Disease", "Test_Disease"], [0, 1, "Test", 28, 31, "Disease", "Test_Disease"], [12, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"], [48, 48, "Anatomy", 43, 49, "Disease", "Anatomy_Disease"], [54, 55, "Test", 43, 49, "Disease", "Test_Disease"], [57, 59, "Test", 43, 49, "Disease", "Test_Disease"], [101, 103, "Test", 43, 49, "Disease", "Test_Disease"], [132, 134, "Test", 43, 49, "Disease", "Test_Disease"], [68, 70, "Test_items", 43, 49, "Disease", "Test_items_Disease"], [118, 120, "Test_items", 43, 49, "Disease", "Test_items_Disease"], [174, 175, "Test", 163, 165, "Disease", "Test_Disease"], [190, 192, "Anatomy", 187, 194, "Disease", "Anatomy_Disease"], [207, 209, "Anatomy", 207, 211, "Disease", "Anatomy_Disease"], [243, 243, "Anatomy", 240, 244, "Disease", "Anatomy_Disease"], [247, 249, "Test_items", 240, 244, "Disease", "Test_items_Disease"], [255, 255, "Anatomy", 255, 259, "Disease", "Anatomy_Disease"], [28, 30, "Anatomy", 28, 31, "Disease", "Anatomy_Disease"]]}
{"idx": 3504, "sentence": "强化血压控制还可使心血管病终点事件的风险下降20%~30%。", "ner": [[2, 3, "Test"], [9, 12, "Disease"], [9, 11, "Anatomy"]], "rel": [[2, 3, "Test", 9, 12, "Disease", "Test_Disease"], [9, 11, "Anatomy", 9, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 3505, "sentence": "1.血压控制目标：糖尿病患者的血压控制目标为140/90mmHg，对年轻患者或合并肾病者的血压控制目标为130/80mmHg。", "ner": [[2, 3, "Test"], [9, 11, "Disease"], [15, 16, "Test"], [22, 31, "Test_Value"], [41, 42, "Disease"], [41, 41, "Anatomy"], [45, 46, "Test"], [52, 61, "Test_Value"]], "rel": [[2, 3, "Test", 9, 11, "Disease", "Test_Disease"], [15, 16, "Test", 9, 11, "Disease", "Test_Disease"], [41, 41, "Anatomy", 41, 42, "Disease", "Anatomy_Disease"], [45, 46, "Test", 41, 42, "Disease", "Test_Disease"]]}
{"idx": 3506, "sentence": "2.降压药物的选择：ACEI或ARB在糖尿病肾病中有控制血压、减少蛋白尿、延缓肾功能进展的作用，是目前治疗糖尿病肾病的药物中临床证据最多的，被推荐作为治疗糖尿病肾病的一线药物。糖尿病肾病或糖尿病合并高血压的患者首选使用其中一种，不能耐受时以另一种替代，使用期间应监测血清肌酐及血钾水平。", "ner": [[10, 13, "Drug"], [15, 17, "Drug"], [19, 23, "Disease"], [22, 22, "Anatomy"], [28, 29, "Test"], [33, 35, "Disease"], [53, 57, "Disease"], [56, 56, "Anatomy"], [77, 81, "Disease"], [80, 80, "Anatomy"], [88, 92, "Disease"], [91, 91, "Anatomy"], [94, 96, "Disease"], [99, 101, "Disease"], [133, 136, "Test_items"], [138, 141, "Test_items"]], "rel": [[10, 13, "Drug", 19, 23, "Disease", "Drug_Disease"], [15, 17, "Drug", 19, 23, "Disease", "Drug_Disease"], [22, 22, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [28, 29, "Test", 19, 23, "Disease", "Test_Disease"], [56, 56, "Anatomy", 53, 57, "Disease", "Anatomy_Disease"], [80, 80, "Anatomy", 77, 81, "Disease", "Anatomy_Disease"], [133, 136, "Test_items", 88, 92, "Disease", "Test_items_Disease"], [138, 141, "Test_items", 88, 92, "Disease", "Test_items_Disease"], [91, 91, "Anatomy", 88, 92, "Disease", "Anatomy_Disease"], [133, 136, "Test_items", 94, 96, "Disease", "Test_items_Disease"], [138, 141, "Test_items", 94, 96, "Disease", "Test_items_Disease"], [133, 136, "Test_items", 99, 101, "Disease", "Test_items_Disease"], [138, 141, "Test_items", 99, 101, "Disease", "Test_items_Disease"]]}
{"idx": 3507, "sentence": "ACEI或ARB降压效果不理想时，可联合使用钙通道阻滞剂(CCB)、噻嗪类或袢利尿剂、β受体阻滞剂等降压药物。", "ner": [[0, 3, "Drug"], [5, 7, "Drug"], [22, 32, "Drug"], [34, 36, "Drug"], [38, 41, "Drug"], [43, 48, "Drug"]], "rel": []}
{"idx": 3508, "sentence": "ACEI及ARB应用于糖尿病肾病的一级预防治疗存在争议。一项临床试验研究将伴有高血压的2型DM患者分为群多普利组、维拉帕米组、群多普利联合维拉帕米组及安慰剂组，发现群多普利组及群多普利+维拉帕米组两组患者微量白蛋白尿的出现明显延迟，提示ARB对2型糖尿病患者微量白蛋白尿的发生可能具有一级预防作用。糖尿病视网膜坎地沙坦临床试验-肾脏研究(DIRECT-Renal)和肾素-血管紧张素系统研究(RASS)的结果却表明ACEI或ARB改善微量白蛋白尿、保护肾脏的作用并不明显。", "ner": [[0, 3, "Drug"], [5, 7, "Drug"], [11, 15, "Disease"], [39, 41, "Disease"], [43, 46, "Disease"], [63, 66, "Drug"], [69, 72, "Drug"], [51, 54, "Drug"], [57, 60, "Drug"], [82, 85, "Drug"], [88, 91, "Drug"], [93, 96, "Drug"], [104, 107, "Symptom"], [118, 120, "Drug"], [122, 126, "Disease"], [131, 134, "Symptom"], [149, 151, "Disease"], [152, 154, "Anatomy"], [155, 158, "Drug"], [207, 210, "Drug"], [212, 214, "Drug"], [217, 218, "Level"], [219, 222, "Disease"], [14, 14, "Anatomy"]], "rel": [[0, 3, "Drug", 11, 15, "Disease", "Drug_Disease"], [5, 7, "Drug", 11, 15, "Disease", "Drug_Disease"], [14, 14, "Anatomy", 11, 15, "Disease", "Anatomy_Disease"], [51, 54, "Drug", 39, 41, "Disease", "Drug_Disease"], [57, 60, "Drug", 39, 41, "Disease", "Drug_Disease"], [63, 66, "Drug", 39, 41, "Disease", "Drug_Disease"], [69, 72, "Drug", 39, 41, "Disease", "Drug_Disease"], [51, 54, "Drug", 43, 46, "Disease", "Drug_Disease"], [57, 60, "Drug", 43, 46, "Disease", "Drug_Disease"], [63, 66, "Drug", 43, 46, "Disease", "Drug_Disease"], [69, 72, "Drug", 43, 46, "Disease", "Drug_Disease"], [118, 120, "Drug", 122, 126, "Disease", "Drug_Disease"], [152, 154, "Anatomy", 149, 151, "Disease", "Anatomy_Disease"], [155, 158, "Drug", 149, 151, "Disease", "Drug_Disease"], [207, 210, "Drug", 219, 222, "Disease", "Drug_Disease"], [212, 214, "Drug", 219, 222, "Disease", "Drug_Disease"]]}
{"idx": 3509, "sentence": "因此，本共识暂不推荐应用该类药物作为糖尿病肾病的一级预防。", "ner": [[18, 22, "Disease"], [21, 21, "Anatomy"]], "rel": [[21, 21, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"]]}
{"idx": 3510, "sentence": "(1)ACEI：ACEI主要药理作用是抑制血浆及组织中的血管紧张素转换酶，减少血管紧张素II的生成，减少血管收缩和醛固酮的分泌。在用药过程中需要注意观察患者肾功能及血钾的变化，对伴有肾动脉狭窄的患者要慎用或禁用。有报道显示该药物在妊娠早期可能对胎儿有害(新生儿急性肾损伤、肺毒性作用、先天心血管系统畸形、中枢神经系统畸形、肾脏畸形、头颅发育不全等)。培哚普利在糖尿病及肾功能减退患者中无不良代谢作用，但在透析中可被清除，中重度肾功能损害患者应根据肾小球滤过率变化调整剂量，起始剂量2mg/d，最大剂量不超过8mg/d，在透析患者中培哚普利清除率同肾功能正常患者。卡托普利在肾功能严重减退患者中应谨慎使用。", "ner": [[3, 6, "Drug"], [8, 11, "Drug"], [39, 45, "Test_items"], [57, 59, "Test_items"], [78, 80, "Test"], [82, 83, "Test_items"], [91, 95, "Disease"], [91, 93, "Anatomy"], [127, 134, "ADE"], [136, 140, "ADE"], [142, 150, "ADE"], [152, 159, "ADE"], [161, 164, "ADE"], [166, 171, "ADE"], [175, 178, "Drug"], [180, 182, "Disease"], [184, 188, "Disease"], [184, 184, "Anatomy"], [202, 203, "Treatment"], [210, 212, "Level"], [213, 217, "Disease"], [213, 213, "Anatomy"], [223, 228, "Test_items"], [240, 244, "Amount"], [253, 257, "Amount"], [260, 261, "Treatment"], [265, 268, "Drug"], [273, 275, "Test"], [276, 277, "Test_Value"], [281, 284, "Drug"], [286, 292, "Disease"], [286, 286, "Anatomy"]], "rel": [[91, 93, "Anatomy", 91, 95, "Disease", "Anatomy_Disease"], [175, 178, "Drug", 180, 182, "Disease", "Drug_Disease"], [175, 178, "Drug", 184, 188, "Disease", "Drug_Disease"], [184, 184, "Anatomy", 184, 188, "Disease", "Anatomy_Disease"], [223, 228, "Test_items", 213, 217, "Disease", "Test_items_Disease"], [213, 213, "Anatomy", 213, 217, "Disease", "Anatomy_Disease"], [281, 284, "Drug", 286, 292, "Disease", "Drug_Disease"], [286, 286, "Anatomy", 286, 292, "Disease", "Anatomy_Disease"]]}
{"idx": 3511, "sentence": "贝那普利的药代动力学和生物利用度在轻中度肾功能不全中不受影响，重度肾功能不全患者需减量，透析对贝那普利的浓度无影响，透析后无需补充药物。", "ner": [[0, 3, "Drug"], [17, 19, "Level"], [20, 24, "Disease"], [20, 20, "Anatomy"], [31, 32, "Level"], [33, 37, "Disease"], [33, 33, "Anatomy"], [44, 45, "Treatment"], [47, 50, "Drug"], [58, 59, "Drug"]], "rel": [[0, 3, "Drug", 20, 24, "Disease", "Drug_Disease"], [20, 20, "Anatomy", 20, 24, "Disease", "Anatomy_Disease"], [33, 33, "Anatomy", 33, 37, "Disease", "Anatomy_Disease"], [47, 50, "Drug", 33, 37, "Disease", "Drug_Disease"]]}
{"idx": 3512, "sentence": "雷米普利在中度肾功能不全患者中需减量，且不能应用于聚丙烯腈或甲基烯丙基硫化钠高通量滤膜或血液透析。", "ner": [[0, 3, "Drug"], [5, 6, "Level"], [7, 11, "Disease"], [7, 7, "Anatomy"], [25, 28, "Drug"], [30, 37, "Drug"], [44, 47, "Treatment"]], "rel": [[0, 3, "Drug", 7, 11, "Disease", "Drug_Disease"], [7, 7, "Anatomy", 7, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 3513, "sentence": "福辛普利在肾功能不全患者中应减量或停药，它在透析中不可清除，但在高流量透析膜进行血液透析时较易引起类过敏反应。", "ner": [[0, 3, "Drug"], [5, 9, "Disease"], [5, 5, "Anatomy"], [22, 23, "Treatment"], [40, 43, "Treatment"], [50, 53, "ADE"]], "rel": [[0, 3, "Drug", 5, 9, "Disease", "Drug_Disease"], [5, 5, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 3514, "sentence": "赖诺普利在严重的肾功能不全患者中半衰期可达40h以上，可在体内发生蓄积，蓄积的原药可在透析中去除。", "ner": [[0, 3, "Drug"], [5, 6, "Level"], [8, 12, "Disease"], [8, 8, "Anatomy"]], "rel": [[0, 3, "Drug", 8, 12, "Disease", "Drug_Disease"], [8, 8, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"]]}
{"idx": 3515, "sentence": "(2)ARB：ARB通过双重方式降低血压：其一是阻断血管紧张素Ⅱ(AngⅡ)与血管紧张素II 1型受体(AT1R)结合，从而直接或间接抑制血管收缩，减少血管加压素和醛固酮释放，减少肾脏水钠重吸收；其二是促使AngⅡ与AT2R结合，使血管舒张，抑制细胞分化生长，抑制钠水重吸收和交感神经活性。氯沙坦在肾功能不全患者中无需调整剂量，缬沙坦在肾功能减退的大部分患者中都无需调整用药，但在严重肾功能不全患者中用药经验不足，应谨慎用药。替米沙坦及坎地沙坦在轻中度。肾功能不全患者中无需调整用量，重度肾功能不全患者禁用。厄贝沙坦在肾功能不全及血液透析的患者中可能需要调整剂量。", "ner": [[3, 5, "Drug"], [7, 9, "Drug"], [18, 19, "Test"], [26, 37, "Test_items"], [82, 84, "Test_items"], [145, 147, "Drug"], [149, 153, "Disease"], [149, 149, "Anatomy"], [164, 166, "Drug"], [168, 172, "Disease"], [168, 168, "Anatomy"], [190, 191, "Level"], [192, 196, "Disease"], [192, 192, "Anatomy"], [213, 216, "Drug"], [218, 221, "Drug"], [223, 225, "Level"], [227, 231, "Disease"], [227, 227, "Anatomy"], [242, 243, "Level"], [244, 248, "Disease"], [244, 244, "Anatomy"], [254, 257, "Drug"], [259, 263, "Disease"], [259, 259, "Anatomy"], [265, 268, "Treatment"]], "rel": [[145, 147, "Drug", 149, 153, "Disease", "Drug_Disease"], [149, 149, "Anatomy", 149, 153, "Disease", "Anatomy_Disease"], [164, 166, "Drug", 168, 172, "Disease", "Drug_Disease"], [168, 168, "Anatomy", 168, 172, "Disease", "Anatomy_Disease"], [192, 192, "Anatomy", 192, 196, "Disease", "Anatomy_Disease"], [227, 227, "Anatomy", 227, 231, "Disease", "Anatomy_Disease"], [244, 244, "Anatomy", 244, 248, "Disease", "Anatomy_Disease"], [254, 257, "Drug", 259, 263, "Disease", "Drug_Disease"], [259, 259, "Anatomy", 259, 263, "Disease", "Anatomy_Disease"], [265, 268, "Treatment", 259, 263, "Disease", "Treatment_Disease"]]}
{"idx": 3516, "sentence": "(3)CCB：非二氢吡啶类钙拮抗剂地尔硫?和维拉帕米能够减少蛋白尿；二氢吡啶类钙拮抗剂能维持和增加肾血流量，改善Ccr和GFR；可以抑制内皮素对肾脏的影响以及预防肾脏肥大。国际拜新同抗高血压干预研究(INSIGHT)证明，与利尿剂相比，硝苯地平胃肠控释系统能显著提高肾小球滤过率，保护肾功能。一般认为，CCB延缓高血压患者的肾功能进展的机制，主要是通过降低血压减轻了体循环对肾小球内压力的传导，从而改善肾小球内高滤过、高灌注状态。在肾功能受损时，长效钙通道阻滞剂无需减低剂量，尤其适用于合并冠心病、肾动脉狭窄、重度肾功能不全、存在ACEI或ARB使用禁忌的患者。CCB是治疗CKD合并高血压最常用的选择之一，但若尿蛋白持续增多，需加用ACEI或ARB药物才能达到保护肾功能的作用。有临床研究表明，二氢吡啶类CCB氨氯地平联合贝那普利在降低糖尿病患者心血管事件及延缓肾病进展方面优于贝那普利与噻嗪类利尿剂组合，非二氢吡啶CCB类药物在降低糖尿病肾病患者尿蛋白水平，延缓肾病进程方面明显优于ACEI及β受体阻滞剂，且不受血压控制的影响。", "ner": [[3, 5, "Drug"], [7, 16, "Drug"], [17, 20, "Drug"], [22, 25, "Drug"], [30, 32, "Disease"], [34, 42, "Drug"], [56, 58, "Test_items"], [60, 62, "Test_items"], [81, 84, "Disease"], [81, 82, "Anatomy"], [88, 90, "Drug"], [112, 114, "Drug"], [118, 121, "Drug"], [133, 138, "Test_items"], [92, 94, "Disease"], [151, 153, "Drug"], [156, 158, "Disease"], [178, 179, "Test"], [216, 220, "Disease"], [216, 216, "Anatomy"], [223, 230, "Drug"], [245, 247, "Disease"], [246, 246, "Anatomy"], [249, 253, "Disease"], [255, 256, "Level"], [257, 261, "Disease"], [257, 257, "Anatomy"], [265, 268, "Drug"], [270, 272, "Drug"], [249, 251, "Anatomy"], [281, 283, "Drug"], [287, 289, "Disease"], [292, 294, "Disease"], [306, 308, "Test_items"], [309, 312, "Test_Value"], [317, 320, "Drug"], [322, 324, "Drug"], [348, 352, "Drug"], [353, 355, "Drug"], [356, 359, "Drug"], [362, 365, "Drug"], [369, 371, "Disease"], [374, 378, "Disease"], [374, 376, "Anatomy"], [390, 393, "Drug"], [395, 400, "Drug"], [418, 422, "Disease"], [421, 421, "Anatomy"], [425, 427, "Test_items"], [404, 414, "Drug"], [443, 446, "Drug"], [448, 453, "Drug"], [458, 459, "Test"], [433, 434, "Disease"], [433, 433, "Anatomy"]], "rel": [[7, 16, "Drug", 30, 32, "Disease", "Drug_Disease"], [17, 20, "Drug", 30, 32, "Disease", "Drug_Disease"], [22, 25, "Drug", 30, 32, "Disease", "Drug_Disease"], [34, 42, "Drug", 81, 84, "Disease", "Drug_Disease"], [81, 82, "Anatomy", 81, 84, "Disease", "Anatomy_Disease"], [88, 90, "Drug", 92, 94, "Disease", "Drug_Disease"], [112, 114, "Drug", 92, 94, "Disease", "Drug_Disease"], [118, 121, "Drug", 92, 94, "Disease", "Drug_Disease"], [133, 138, "Test_items", 92, 94, "Disease", "Test_items_Disease"], [151, 153, "Drug", 156, 158, "Disease", "Drug_Disease"], [178, 179, "Test", 156, 158, "Disease", "Test_Disease"], [223, 230, "Drug", 216, 220, "Disease", "Drug_Disease"], [216, 216, "Anatomy", 216, 220, "Disease", "Anatomy_Disease"], [223, 230, "Drug", 245, 247, "Disease", "Drug_Disease"], [223, 230, "Drug", 249, 253, "Disease", "Drug_Disease"], [223, 230, "Drug", 257, 261, "Disease", "Drug_Disease"], [246, 246, "Anatomy", 245, 247, "Disease", "Anatomy_Disease"], [249, 251, "Anatomy", 249, 253, "Disease", "Anatomy_Disease"], [257, 257, "Anatomy", 257, 261, "Disease", "Anatomy_Disease"], [281, 283, "Drug", 287, 289, "Disease", "Drug_Disease"], [281, 283, "Drug", 292, 294, "Disease", "Drug_Disease"], [317, 320, "Drug", 287, 289, "Disease", "Drug_Disease"], [322, 324, "Drug", 287, 289, "Disease", "Drug_Disease"], [306, 308, "Test_items", 287, 289, "Disease", "Test_items_Disease"], [317, 320, "Drug", 292, 294, "Disease", "Drug_Disease"], [322, 324, "Drug", 292, 294, "Disease", "Drug_Disease"], [306, 308, "Test_items", 292, 294, "Disease", "Test_items_Disease"], [348, 352, "Drug", 369, 371, "Disease", "Drug_Disease"], [353, 355, "Drug", 369, 371, "Disease", "Drug_Disease"], [356, 359, "Drug", 369, 371, "Disease", "Drug_Disease"], [362, 365, "Drug", 369, 371, "Disease", "Drug_Disease"], [390, 393, "Drug", 369, 371, "Disease", "Drug_Disease"], [395, 400, "Drug", 369, 371, "Disease", "Drug_Disease"], [374, 376, "Anatomy", 374, 378, "Disease", "Anatomy_Disease"], [404, 414, "Drug", 418, 422, "Disease", "Drug_Disease"], [443, 446, "Drug", 418, 422, "Disease", "Drug_Disease"], [448, 453, "Drug", 418, 422, "Disease", "Drug_Disease"], [421, 421, "Anatomy", 418, 422, "Disease", "Anatomy_Disease"], [425, 427, "Test_items", 418, 422, "Disease", "Test_items_Disease"], [458, 459, "Test", 418, 422, "Disease", "Test_Disease"], [433, 433, "Anatomy", 433, 434, "Disease", "Anatomy_Disease"]]}
{"idx": 3517, "sentence": "(4)利尿剂：60%~90%糖尿病肾病合并高血压的患者使用噻嗪类或袢利尿剂。GUARD临床研究表明ACEI与氢氯噻嗪联合用药在降低患者尿蛋白水平方面优于ACEI与CCB组合。对收缩期高血压患者应用联合治疗以预防心血管事件(ACCOMPLISH)临床研究的结果却表明，在糖尿病高血压高危患者中，ACEI与氢氯噻嗪联合用药对减缓患者肾小球滤过率下降的作用不及ACEI与CCB组合。虽然噻嗪类或袢利尿剂作为联合用药是否强于CCB存在争议，多数糖尿病肾病合并高血压的患者，尤其血压高于130/80mmHg者需要一种以上药物控制血压，故推荐噻嗪类或袢利尿剂作为联合用药。氢氯噻嗪促进钾钠排泄，造成低钠血症时可引起反射性肾素和醛固酮分泌，在无尿或肾功能损害患者的效果差，大剂量使用易导致药物蓄积，增加毒性，故其慎用于该类患者，应从小剂量每日25mg开始。", "ner": [[3, 5, "Drug"], [14, 18, "Disease"], [17, 17, "Anatomy"], [21, 23, "Disease"], [29, 31, "Drug"], [33, 36, "Drug"], [49, 52, "Drug"], [54, 57, "Drug"], [76, 79, "Drug"], [81, 83, "Drug"], [88, 93, "Disease"], [105, 109, "Disease"], [105, 107, "Anatomy"], [134, 136, "Disease"], [137, 139, "Disease"], [146, 149, "Drug"], [151, 154, "Drug"], [164, 169, "Test_items"], [170, 171, "Test_Value"], [177, 180, "Drug"], [182, 184, "Drug"], [190, 192, "Drug"], [194, 197, "Drug"], [208, 210, "Drug"], [218, 222, "Disease"], [221, 221, "Anatomy"], [225, 227, "Disease"], [234, 235, "Test"], [236, 247, "Test_Value"], [259, 260, "Test"], [265, 267, "Drug"], [269, 272, "Drug"], [314, 315, "Symptom"], [280, 283, "Drug"], [293, 296, "ADE"], [364, 367, "Amount"], [317, 321, "Disease"], [317, 317, "Anatomy"]], "rel": [[17, 17, "Anatomy", 14, 18, "Disease", "Anatomy_Disease"], [29, 31, "Drug", 14, 18, "Disease", "Drug_Disease"], [33, 36, "Drug", 14, 18, "Disease", "Drug_Disease"], [29, 31, "Drug", 21, 23, "Disease", "Drug_Disease"], [33, 36, "Drug", 21, 23, "Disease", "Drug_Disease"], [105, 107, "Anatomy", 105, 109, "Disease", "Anatomy_Disease"], [146, 149, "Drug", 134, 136, "Disease", "Drug_Disease"], [151, 154, "Drug", 134, 136, "Disease", "Drug_Disease"], [177, 180, "Drug", 134, 136, "Disease", "Drug_Disease"], [182, 184, "Drug", 134, 136, "Disease", "Drug_Disease"], [164, 169, "Test_items", 134, 136, "Disease", "Test_items_Disease"], [146, 149, "Drug", 137, 139, "Disease", "Drug_Disease"], [151, 154, "Drug", 137, 139, "Disease", "Drug_Disease"], [177, 180, "Drug", 137, 139, "Disease", "Drug_Disease"], [182, 184, "Drug", 137, 139, "Disease", "Drug_Disease"], [164, 169, "Test_items", 137, 139, "Disease", "Test_items_Disease"], [221, 221, "Anatomy", 218, 222, "Disease", "Anatomy_Disease"], [234, 235, "Test", 218, 222, "Disease", "Test_Disease"], [265, 267, "Drug", 218, 222, "Disease", "Drug_Disease"], [269, 272, "Drug", 218, 222, "Disease", "Drug_Disease"], [259, 260, "Test", 218, 222, "Disease", "Test_Disease"], [234, 235, "Test", 225, 227, "Disease", "Test_Disease"], [259, 260, "Test", 225, 227, "Disease", "Test_Disease"], [265, 267, "Drug", 225, 227, "Disease", "Drug_Disease"], [269, 272, "Drug", 225, 227, "Disease", "Drug_Disease"], [293, 296, "ADE", 280, 283, "Drug", "ADE_Drug"], [364, 367, "Amount", 280, 283, "Drug", "Amount_Drug"], [280, 283, "Drug", 317, 321, "Disease", "Drug_Disease"], [317, 317, "Anatomy", 317, 321, "Disease", "Anatomy_Disease"]]}
{"idx": 3518, "sentence": "(5)β受体阻滞剂：尽管ACEI在降低糖尿病患者蛋白尿方面较β受体阻滞剂更有优势，但两种药物均可延缓患者肾功能的衰退。UKPDS研究亦认为ACEI与β受体阻滞剂在降低2型糖尿病患者微血管和大血管并发症方面临床价值相当。β受体阻滞剂可作为降压治疗的联合用药。第一类为非选择性β受体阻滞剂，主要代表药物是普萘洛尔，目前已较少使用。第二类主要作用于β1受体，代表药物有美托洛尔、比索洛尔。美托洛尔主要经肝脏代谢，5%以原型经肾排泄，用于肾功能损害者剂量无需调整。比索洛尔50%通过肝脏代谢为无活性的代谢产物然后从肾脏排出，剩余50%以原形药的形式从肾脏排出，轻中度肾功能不全患者剂量不需调整，当GFR<20ml·min-1·1.73m-2时每日剂量不超过10mg，肾透析患者使用经验较少。第三类主要作用于β和α1受体，代表药物有卡维地洛、拉贝洛尔。拉贝洛尔55%~60%的原形药物和代谢产物由尿排f也，血液透析和腹膜透析均不易清除，应慎用于肾功能不全者。", "ner": [[3, 8, "Drug"], [12, 15, "Drug"], [19, 21, "Disease"], [24, 26, "Disease"], [30, 35, "Drug"], [69, 72, "Drug"], [74, 79, "Drug"], [83, 87, "Disease"], [90, 92, "Anatomy"], [94, 96, "Anatomy"], [109, 114, "Drug"], [132, 141, "Drug"], [150, 153, "Drug"], [181, 184, "Drug"], [186, 189, "Drug"], [191, 194, "Drug"], [215, 219, "Disease"], [215, 215, "Anatomy"], [228, 231, "Drug"], [279, 283, "Disease"], [276, 278, "Level"], [279, 279, "Anatomy"], [294, 296, "Test_items"], [297, 315, "Test_Value"], [321, 327, "Amount"], [329, 331, "Treatment"], [361, 364, "Drug"], [366, 369, "Drug"], [371, 374, "Drug"], [398, 401, "Treatment"], [403, 406, "Treatment"], [417, 421, "Disease"], [417, 417, "Anatomy"]], "rel": [[12, 15, "Drug", 19, 21, "Disease", "Drug_Disease"], [30, 35, "Drug", 19, 21, "Disease", "Drug_Disease"], [69, 72, "Drug", 83, 87, "Disease", "Drug_Disease"], [74, 79, "Drug", 83, 87, "Disease", "Drug_Disease"], [90, 92, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [94, 96, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [191, 194, "Drug", 215, 219, "Disease", "Drug_Disease"], [215, 215, "Anatomy", 215, 219, "Disease", "Anatomy_Disease"], [228, 231, "Drug", 279, 283, "Disease", "Drug_Disease"], [321, 327, "Amount", 228, 231, "Drug", "Amount_Drug"], [279, 279, "Anatomy", 279, 283, "Disease", "Anatomy_Disease"], [294, 296, "Test_items", 279, 283, "Disease", "Test_items_Disease"], [329, 331, "Treatment", 279, 283, "Disease", "Treatment_Disease"], [371, 374, "Drug", 417, 421, "Disease", "Drug_Disease"], [398, 401, "Treatment", 417, 421, "Disease", "Treatment_Disease"], [403, 406, "Treatment", 417, 421, "Disease", "Treatment_Disease"], [417, 417, "Anatomy", 417, 421, "Disease", "Anatomy_Disease"]]}
{"idx": 3519, "sentence": "(6)其他肾素-血管紧张素系统(RAS)阻断剂：ACEI或ARB类药物可以降低患者血浆醛固酮水平，但有研究发现有40%服用上述药物的患者其血浆醛固酮水平并未下降，反而升高到了其治疗前的浓度水平，称之为“醛固酮逃避”现象，这可能与肾病进展过程有关，具体机制尚不明确。早期一些短期临床研究表明，ACEI/ARB与醛固酮受体拮抗剂(MRA)联合治疗在降低1型DN患者尿白蛋白水平方面的益处，但是需要更多临床研究证实。赖诺普利联合螺内酯组与赖诺普利+安慰剂组患者相比，其尿白蛋白水平明显降低。因螺内酯可使血钾升高的风险增高，应用时需监测血钾。", "ner": [[5, 22, "Drug"], [24, 27, "Drug"], [29, 34, "Drug"], [41, 45, "Test_items"], [69, 75, "Test_items"], [77, 79, "Test_Value"], [83, 84, "Test_Value"], [114, 115, "Disease"], [114, 114, "Anatomy"], [145, 152, "Drug"], [154, 166, "Drug"], [174, 177, "Disease"], [180, 183, "Test_items"], [205, 208, "Drug"], [211, 213, "Drug"], [216, 219, "Drug"], [231, 236, "Test_items"], [237, 240, "Test_Value"], [243, 245, "Drug"], [248, 251, "ADE"], [264, 265, "Test_items"]], "rel": [[24, 27, "Drug", 114, 115, "Disease", "Drug_Disease"], [29, 34, "Drug", 114, 115, "Disease", "Drug_Disease"], [41, 45, "Test_items", 114, 115, "Disease", "Test_items_Disease"], [69, 75, "Test_items", 114, 115, "Disease", "Test_items_Disease"], [114, 114, "Anatomy", 114, 115, "Disease", "Anatomy_Disease"], [145, 152, "Drug", 174, 177, "Disease", "Drug_Disease"], [154, 166, "Drug", 174, 177, "Disease", "Drug_Disease"], [180, 183, "Test_items", 174, 177, "Disease", "Test_items_Disease"], [248, 251, "ADE", 243, 245, "Drug", "ADE_Drug"]]}
{"idx": 3520, "sentence": "抑制糖尿病肾病患者体内的肾素活性，可显著降低其血压和蛋白尿水平。2型糖尿病患者中，肾素抑制剂阿利吉仑联合氯沙坦与单用氯沙坦相比，尿蛋白更低。然而，近期一项在2型糖尿病患者中进行的阿利吉仑临床试验却因阿利吉仑与ACEI/ARB的联合应用所导致的严重不良事件所终止，不良反应包括肾功能衰竭、高血钾及低血压等。", "ner": [[137, 141, "ADE"], [143, 145, "ADE"], [147, 149, "ADE"], [2, 6, "Disease"], [5, 5, "Anatomy"], [23, 24, "Test"], [26, 28, "Test_items"], [32, 36, "Disease"], [41, 45, "Drug"], [46, 49, "Drug"], [52, 54, "Drug"], [58, 60, "Drug"], [64, 66, "Test_items"], [67, 68, "Test_Value"], [78, 82, "Disease"], [89, 92, "Drug"], [99, 102, "Drug"], [104, 107, "Drug"], [109, 111, "Drug"]], "rel": [[137, 141, "ADE", 99, 102, "Drug", "ADE_Drug"], [137, 141, "ADE", 104, 107, "Drug", "ADE_Drug"], [137, 141, "ADE", 109, 111, "Drug", "ADE_Drug"], [143, 145, "ADE", 99, 102, "Drug", "ADE_Drug"], [143, 145, "ADE", 104, 107, "Drug", "ADE_Drug"], [143, 145, "ADE", 109, 111, "Drug", "ADE_Drug"], [147, 149, "ADE", 99, 102, "Drug", "ADE_Drug"], [147, 149, "ADE", 104, 107, "Drug", "ADE_Drug"], [147, 149, "ADE", 109, 111, "Drug", "ADE_Drug"], [5, 5, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [23, 24, "Test", 2, 6, "Disease", "Test_Disease"], [26, 28, "Test_items", 2, 6, "Disease", "Test_items_Disease"], [41, 45, "Drug", 32, 36, "Disease", "Drug_Disease"], [46, 49, "Drug", 32, 36, "Disease", "Drug_Disease"], [52, 54, "Drug", 32, 36, "Disease", "Drug_Disease"], [58, 60, "Drug", 32, 36, "Disease", "Drug_Disease"], [64, 66, "Test_items", 32, 36, "Disease", "Test_items_Disease"], [89, 92, "Drug", 78, 82, "Disease", "Drug_Disease"], [99, 102, "Drug", 78, 82, "Disease", "Drug_Disease"], [104, 107, "Drug", 78, 82, "Disease", "Drug_Disease"], [109, 111, "Drug", 78, 82, "Disease", "Drug_Disease"]]}
{"idx": 3521, "sentence": "因此FDA仍将阿利吉仑禁用于已使用ACEI/ARB的糖尿病患者。", "ner": [[7, 10, "Drug"], [17, 20, "Drug"], [22, 24, "Drug"], [26, 28, "Disease"]], "rel": []}
{"idx": 3522, "sentence": "(7)联合用药：糖尿病肾病患者在血压控制不佳时，可在ACEI/ARB的基础上选择其他降压药物联合使用。一些早期小型临床研究结果表明，ACEI联合ARB在糖尿病肾病患者中具有较高的耐受性和有效率，可使糖尿病患者的尿蛋白水平显著降低，有效降低了患者舒张压。然而，较新的研究表明ACEI与ARB联合治疗疗效并不优于单药治疗，联合ARB及ACEI后，糖尿病患者血清肌酐水平、ESRD发生及死亡率方面并无明显差异。", "ner": [[8, 12, "Disease"], [11, 11, "Anatomy"], [16, 17, "Test"], [18, 21, "Test_Value"], [26, 29, "Drug"], [31, 33, "Drug"], [66, 69, "Drug"], [72, 74, "Drug"], [76, 80, "Disease"], [79, 79, "Anatomy"], [99, 101, "Disease"], [105, 107, "Test_items"], [110, 113, "Test_Value"], [122, 124, "Test"], [136, 139, "Drug"], [141, 143, "Drug"], [161, 163, "Drug"], [165, 168, "Drug"], [171, 173, "Disease"], [176, 179, "Test_items"], [183, 186, "Disease"]], "rel": [[11, 11, "Anatomy", 8, 12, "Disease", "Anatomy_Disease"], [16, 17, "Test", 8, 12, "Disease", "Test_Disease"], [26, 29, "Drug", 8, 12, "Disease", "Drug_Disease"], [31, 33, "Drug", 8, 12, "Disease", "Drug_Disease"], [66, 69, "Drug", 76, 80, "Disease", "Drug_Disease"], [72, 74, "Drug", 76, 80, "Disease", "Drug_Disease"], [79, 79, "Anatomy", 76, 80, "Disease", "Anatomy_Disease"], [105, 107, "Test_items", 99, 101, "Disease", "Test_items_Disease"], [122, 124, "Test", 99, 101, "Disease", "Test_Disease"], [136, 139, "Drug", 171, 173, "Disease", "Drug_Disease"], [141, 143, "Drug", 171, 173, "Disease", "Drug_Disease"], [161, 163, "Drug", 171, 173, "Disease", "Drug_Disease"], [165, 168, "Drug", 171, 173, "Disease", "Drug_Disease"], [176, 179, "Test_items", 171, 173, "Disease", "Test_items_Disease"]]}
{"idx": 3523, "sentence": "本共识不推荐联合使用ACEI和ARB。", "ner": [[10, 13, "Drug"], [15, 17, "Drug"]], "rel": []}
{"idx": 3524, "sentence": "如果已在联合使用ACEI和ARB，则需要检测和随访血钾和肾功能。", "ner": [[8, 11, "Drug"], [13, 15, "Drug"], [25, 26, "Test_items"], [28, 30, "Test"]], "rel": []}
{"idx": 3525, "sentence": "(四)纠正脂质代谢紊乱", "ner": [[5, 10, "Disease"]], "rel": []}
{"idx": 3526, "sentence": "高脂血症不仅直接参与糖尿病胰岛素抵抗和心血管并发症的发生，低密度脂蛋白胆固醇(LDL-C)还可以通过作用于肾小球系膜细胞上的LDL受体，导致系膜细胞和足细胞的损伤，加重蛋白尿和肾小球及肾小管间质纤维化的进展。糖尿病患者出现肾病综合征和肾功能不全，又会进一步加重高脂血症。因此，积极纠正糖尿病肾病患者体内脂代谢紊乱，亦对糖尿病肾病具有重要意义。", "ner": [[0, 3, "Disease"], [10, 12, "Disease"], [13, 17, "Pathogenesis"], [19, 24, "Disease"], [19, 21, "Anatomy"], [29, 66, "Pathogenesis"], [70, 80, "Pathogenesis"], [82, 102, "Pathogenesis"], [104, 106, "Disease"], [111, 115, "Disease"], [111, 111, "Anatomy"], [117, 121, "Disease"], [117, 117, "Anatomy"], [130, 133, "Disease"], [142, 146, "Disease"], [145, 145, "Anatomy"], [151, 155, "Disease"], [159, 163, "Disease"], [162, 162, "Anatomy"]], "rel": [[29, 66, "Pathogenesis", 0, 3, "Disease", "Pathogenesis_Disease"], [70, 80, "Pathogenesis", 0, 3, "Disease", "Pathogenesis_Disease"], [82, 102, "Pathogenesis", 0, 3, "Disease", "Pathogenesis_Disease"], [13, 17, "Pathogenesis", 10, 12, "Disease", "Pathogenesis_Disease"], [19, 21, "Anatomy", 19, 24, "Disease", "Anatomy_Disease"], [111, 111, "Anatomy", 111, 115, "Disease", "Anatomy_Disease"], [117, 117, "Anatomy", 117, 121, "Disease", "Anatomy_Disease"], [145, 145, "Anatomy", 142, 146, "Disease", "Anatomy_Disease"], [162, 162, "Anatomy", 159, 163, "Disease", "Anatomy_Disease"]]}
{"idx": 3527, "sentence": "1.血脂控制目标值：糖尿病肾病患者血脂干预治疗切点：血LDL-C>3.38mmol/L(130mg/d1)，甘油三酯(TG)>2.26(200mg/d1)。治疗目标：LDL-C水平降至2.6mmol/L以下(并发冠心病将至1.86mmol/L以下)，TG降至1.5mmol/L以下。", "ner": [[1, 3, "Test"], [10, 14, "Disease"], [13, 13, "Anatomy"], [17, 18, "Test"], [26, 31, "Test_items"], [32, 52, "Test_Value"], [54, 61, "Test_items"], [62, 76, "Test_Value"], [83, 87, "Test_items"], [90, 102, "Test_Value"], [106, 108, "Disease"], [109, 122, "Test_Value"], [125, 126, "Test_items"], [127, 139, "Test_Value"]], "rel": [[13, 13, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [17, 18, "Test", 10, 14, "Disease", "Test_Disease"], [26, 31, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [54, 61, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [83, 87, "Test_items", 106, 108, "Disease", "Test_items_Disease"], [125, 126, "Test_items", 106, 108, "Disease", "Test_items_Disease"]]}
{"idx": 3528, "sentence": "2.降脂药物的选择：研究表明他汀类药物可减少糖尿病血管疾病的发生率和肾功能减退，建议所有糖尿病患者均应首选口服他汀类药物，以TG升高为主时可首选贝特类降脂药。2型糖尿病患者常见混合性高脂血症。单一降脂药大剂量时不良反应增加，为了提高调脂治疗的达标率，往往需不同类别调脂药联合应用。他汀类和贝特类联用：混合性高脂血症经单用他汀类或贝特类未达标者，可考虑两药联合治疗。尽管目前有证据表明两药合理联用是安全的(ACCORD已经证明是安全的)，但除非特别严重的混合性血脂异常，一般应单药治疗；必要时谨慎联合，但剂量应小；两药分开时间服用；他汀类和贝特类联用时，首选非诺贝特。有以下特殊情况者慎用，包括老年、严重肝肾疾病、甲状腺功能减退等，并严密监测和随访，一旦发现异常，及时停药。他汀类和依折麦布联用：单用他汀类调脂药治疗后LDL-C仍未达标者，可考虑他汀类和依折麦布联用。现有证据表明依折麦布和小剂量他汀类联合应用比单独增加他汀类剂量能更好地改善血脂紊乱，且安全性好。", "ner": [[14, 18, "Drug"], [22, 28, "Disease"], [25, 26, "Anatomy"], [34, 38, "Disease"], [34, 34, "Anatomy"], [44, 46, "Disease"], [53, 54, "Method"], [55, 59, "Drug"], [62, 63, "Test_items"], [64, 65, "Test_Value"], [72, 77, "Drug"], [79, 83, "Disease"], [88, 94, "Disease"], [140, 142, "Drug"], [144, 146, "Drug"], [150, 156, "Disease"], [160, 162, "Drug"], [164, 166, "Drug"], [223, 224, "Level"], [226, 232, "Disease"], [265, 267, "Drug"], [269, 271, "Drug"], [278, 281, "Drug"], [299, 300, "Level"], [301, 304, "Disease"], [301, 301, "Anatomy"], [302, 302, "Anatomy"], [306, 312, "Disease"], [306, 308, "Anatomy"], [336, 338, "Drug"], [340, 343, "Drug"], [349, 354, "Drug"], [358, 362, "Test_items"], [364, 366, "Test_Value"], [372, 374, "Drug"], [376, 379, "Drug"], [389, 392, "Drug"], [397, 399, "Drug"], [409, 411, "Drug"], [420, 423, "Disease"]], "rel": [[14, 18, "Drug", 22, 28, "Disease", "Drug_Disease"], [25, 26, "Anatomy", 22, 28, "Disease", "Anatomy_Disease"], [34, 34, "Anatomy", 34, 38, "Disease", "Anatomy_Disease"], [55, 59, "Drug", 44, 46, "Disease", "Drug_Disease"], [62, 63, "Test_items", 44, 46, "Disease", "Test_items_Disease"], [72, 77, "Drug", 44, 46, "Disease", "Drug_Disease"], [160, 162, "Drug", 150, 156, "Disease", "Drug_Disease"], [164, 166, "Drug", 150, 156, "Disease", "Drug_Disease"], [265, 267, "Drug", 226, 232, "Disease", "Drug_Disease"], [269, 271, "Drug", 226, 232, "Disease", "Drug_Disease"], [278, 281, "Drug", 226, 232, "Disease", "Drug_Disease"], [301, 301, "Anatomy", 301, 304, "Disease", "Anatomy_Disease"], [302, 302, "Anatomy", 301, 304, "Disease", "Anatomy_Disease"], [306, 308, "Anatomy", 306, 312, "Disease", "Anatomy_Disease"], [389, 392, "Drug", 420, 423, "Disease", "Drug_Disease"], [397, 399, "Drug", 420, 423, "Disease", "Drug_Disease"], [409, 411, "Drug", 420, 423, "Disease", "Drug_Disease"]]}
{"idx": 3529, "sentence": "(1)三羟基三甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类)：抑制细胞内胆固醇合成早期阶段的限速酶即HMG-CoA还原酶，造成细胞内游离胆固醇减少，并通过反馈性上调细胞表面LDL受体的表达，因而使细胞LDL-C受体数目增多及活性增强，加速了循环极低密度脂蛋白(VLDL)残粒[或中间密度脂蛋白(IDL)]和LDL-C的清除。轻至中度肾功能患者无需调整辛伐他汀、氟伐他汀等他汀类的药物用量，但在重度肾功能不全(如Ccr<30ml/min)时需减量或禁用。肾脏疾病不影响阿托伐他汀的血浆浓度和其降低LDL-C的效果，故肾功能不全患者均无需调整其用药剂量，同时，由于阿托伐他汀与血浆蛋白的广泛结合，血液透析并不能显著提高其清除率，但目前由于缺乏其在透析患者中的用药经验，故仍需谨慎用药。", "ner": [[262, 266, "Disease"], [262, 262, "Anatomy"], [285, 289, "Drug"], [291, 294, "Test_items"], [301, 304, "Treatment"], [326, 327, "Treatment"], [3, 23, "Drug"], [24, 34, "Drug"], [71, 75, "Test_items"], [76, 77, "Test_Value"], [127, 139, "Test_items"], [144, 155, "Test_items"], [158, 162, "Test_items"], [167, 170, "Test_Value"], [171, 173, "Test"], [180, 183, "Drug"], [185, 188, "Drug"], [190, 192, "Drug"], [203, 207, "Disease"], [203, 203, "Anatomy"], [201, 202, "Level"], [210, 212, "Test_items"], [213, 221, "Test_Value"], [231, 234, "Disease"], [231, 232, "Anatomy"], [238, 242, "Drug"], [244, 247, "Test_items"], [252, 256, "Test_items"]], "rel": [[262, 262, "Anatomy", 262, 266, "Disease", "Anatomy_Disease"], [285, 289, "Drug", 262, 266, "Disease", "Drug_Disease"], [291, 294, "Test_items", 262, 266, "Disease", "Test_items_Disease"], [301, 304, "Treatment", 262, 266, "Disease", "Treatment_Disease"], [326, 327, "Treatment", 262, 266, "Disease", "Treatment_Disease"], [171, 173, "Test", 203, 207, "Disease", "Test_Disease"], [180, 183, "Drug", 203, 207, "Disease", "Drug_Disease"], [185, 188, "Drug", 203, 207, "Disease", "Drug_Disease"], [190, 192, "Drug", 203, 207, "Disease", "Drug_Disease"], [210, 212, "Test_items", 203, 207, "Disease", "Test_items_Disease"], [203, 203, "Anatomy", 203, 207, "Disease", "Anatomy_Disease"], [231, 232, "Anatomy", 231, 234, "Disease", "Anatomy_Disease"], [238, 242, "Drug", 231, 234, "Disease", "Drug_Disease"], [244, 247, "Test_items", 231, 234, "Disease", "Test_items_Disease"], [252, 256, "Test_items", 231, 234, "Disease", "Test_items_Disease"]]}
{"idx": 3530, "sentence": "(2)胆汁酸螯合剂：包括考来烯胺、考来替泊，主要为碱性阴离子交换树脂，在肠道内能与胆酸呈不可逆结合，因而阻断胆酸的肠肝循环，促进胆酸随大便排出体外，阻断胆汁酸中胆固醇的重吸收，能降低血总胆固醇(TC)及LDL-C水平，但对TG无降低作用。", "ner": [[3, 8, "Drug"], [12, 15, "Drug"], [17, 20, "Drug"], [92, 99, "Test_items"], [101, 105, "Test_items"], [111, 112, "Test_items"]], "rel": []}
{"idx": 3531, "sentence": "胆汁酸螯合剂在此肠道内不吸收，不参与肾脏代谢。", "ner": [[0, 5, "Drug"]], "rel": []}
{"idx": 3532, "sentence": "(3)烟酸：烟酸的降脂作用机制尚不明确，可能与抑制脂肪组织中的脂解和减少肝脏中VLDL合成和分泌有关，此外，烟酸还具有促进脂蛋白酶的活性，加速脂蛋白中TG的水解的作用，因而其降低TG的作用明显。但烟酸可导致糖代谢异常或糖耐量恶化，一般不推荐在糖尿病患者中使用，若必须使用，应该定期监测血糖水平。烟酸和阿昔莫司在。肾功能减退患者中应用证据有限，应谨慎或减量使用。", "ner": [[3, 4, "Drug"], [6, 7, "Drug"], [39, 42, "Test_items"], [54, 55, "Drug"], [75, 76, "Test_items"], [89, 90, "Test_items"], [98, 99, "Drug"], [103, 107, "ADE"], [109, 113, "ADE"], [121, 123, "Disease"], [142, 143, "Test_items"], [147, 148, "Drug"], [150, 154, "Drug"], [156, 160, "Disease"], [156, 156, "Anatomy"]], "rel": [[98, 99, "Drug", 121, 123, "Disease", "Drug_Disease"], [103, 107, "ADE", 98, 99, "Drug", "ADE_Drug"], [109, 113, "ADE", 98, 99, "Drug", "ADE_Drug"], [142, 143, "Test_items", 121, 123, "Disease", "Test_items_Disease"], [156, 156, "Anatomy", 156, 160, "Disease", "Anatomy_Disease"]]}
{"idx": 3533, "sentence": "(4)苯氧芳酸类：能增强脂蛋白酯酶的活性，加速VLDL分解代谢，并能抑制肝脏中VLDL的合成与分泌，可降低TG22%~43%、TC6%~15%，并有不同程度升高高密度脂蛋白胆固醇(HDL-C)的作用。有证据显示贝特类药物将会升高增加心血管事件风险的血清肌酐和同源半胱氨酸(Hcy)水平。肾功能减退的糖尿病患者应根据其GFR水平减少非诺贝特、吉非贝齐及苯扎贝特等贝特类药物，并在严重的肾功能不全患者中禁用。", "ner": [[3, 7, "Drug"], [23, 26, "Test_items"], [39, 42, "Test_items"], [53, 54, "Test_items"], [55, 61, "Test_Value"], [63, 64, "Test_items"], [65, 70, "Test_Value"], [80, 95, "Test_items"], [105, 109, "Drug"], [116, 120, "Disease"], [116, 118, "Anatomy"], [124, 127, "Test_items"], [129, 139, "Test_items"], [143, 145, "Test"], [146, 147, "Test_Value"], [149, 151, "Disease"], [158, 160, "Test_items"], [165, 168, "Drug"], [170, 173, "Drug"], [175, 178, "Drug"], [180, 184, "Drug"], [188, 189, "Level"], [191, 195, "Disease"], [191, 191, "Anatomy"]], "rel": [[105, 109, "Drug", 116, 120, "Disease", "Drug_Disease"], [116, 118, "Anatomy", 116, 120, "Disease", "Anatomy_Disease"], [124, 127, "Test_items", 116, 120, "Disease", "Test_items_Disease"], [129, 139, "Test_items", 116, 120, "Disease", "Test_items_Disease"], [143, 145, "Test", 149, 151, "Disease", "Test_Disease"], [158, 160, "Test_items", 149, 151, "Disease", "Test_items_Disease"], [165, 168, "Drug", 149, 151, "Disease", "Drug_Disease"], [170, 173, "Drug", 149, 151, "Disease", "Drug_Disease"], [175, 178, "Drug", 149, 151, "Disease", "Drug_Disease"], [180, 184, "Drug", 149, 151, "Disease", "Drug_Disease"], [191, 191, "Anatomy", 191, 195, "Disease", "Anatomy_Disease"]]}
{"idx": 3534, "sentence": "如非诺贝特不能用于透析，且当GFR<50ml·min-1·1.73m-2时禁用。", "ner": [[1, 4, "Drug"], [9, 10, "Treatment"], [14, 16, "Test_items"], [17, 35, "Test_Value"]], "rel": []}
{"idx": 3535, "sentence": "当患者的GFR<60ml·min-1·1.73m-2时应将吉非贝齐的用量减至600mg/d，GFR<15ml·min-1·1.73m-2时禁用吉非贝齐。", "ner": [[4, 6, "Test_items"], [7, 25, "Test_Value"], [29, 32, "Drug"], [38, 44, "Amount"], [46, 48, "Test_items"], [49, 67, "Test_Value"], [71, 74, "Drug"]], "rel": []}
{"idx": 3536, "sentence": "(5)胆固醇吸收抑制剂：依折麦布附着于小肠绒毛刷状缘，抑制胆固醇的吸收，从而降低小肠中的胆固醇向肝脏中的转运，使得肝脏胆固醇贮量降低从而增加血液中胆固醇的清除。", "ner": [[4, 10, "Drug"], [12, 15, "Drug"]], "rel": []}
{"idx": 3537, "sentence": "本品不增加胆汁分泌(如胆酸螯合剂)，也不抑制胆固醇在肝脏中的合成(如他汀类)。", "ner": [[11, 15, "Drug"], [34, 36, "Drug"]], "rel": []}
{"idx": 3538, "sentence": "依折麦布在不同肾功能水平下均无需调整剂量。", "ner": [[0, 3, "Drug"], [7, 9, "Test"]], "rel": []}
{"idx": 3539, "sentence": "(五)肾脏替代治疗", "ner": [], "rel": []}
{"idx": 3540, "sentence": "GFR低于15ml·min-1·1.73m-2的糖尿病肾病患者在条件允许的情况下可选择肾脏替代治疗，包括血液透析、腹膜透析和肾脏移植等。", "ner": [[0, 2, "Test_items"], [3, 22, "Test_Value"], [24, 28, "Disease"], [27, 27, "Anatomy"], [52, 55, "Treatment"], [57, 60, "Treatment"], [62, 65, "Operation"]], "rel": [[0, 2, "Test_items", 24, 28, "Disease", "Test_items_Disease"], [27, 27, "Anatomy", 24, 28, "Disease", "Anatomy_Disease"], [52, 55, "Treatment", 24, 28, "Disease", "Treatment_Disease"], [57, 60, "Treatment", 24, 28, "Disease", "Treatment_Disease"], [62, 65, "Operation", 24, 28, "Disease", "Operation_Disease"]]}
{"idx": 3541, "sentence": "(六)其他治疗药物应用、研制及展望", "ner": [], "rel": []}
{"idx": 3542, "sentence": "1.微循环扩张剂：(1)胰激肽原酶肠溶片(怡开)：有改善微循环作用。主要用于微循环障碍性疾病，如糖尿病引起的肾病、周围神经病、视网膜病。脑出血及其他出血性疾病的急性期禁用。(2)羟苯磺酸钙(导升明)可用于糖尿病性微血管病变：视网膜病及肾小球硬化症(基·威氏综合征)，严重肾功能不全需透析的患者应减量。", "ner": [[2, 7, "Drug"], [12, 23, "Drug"], [38, 45, "Disease"], [48, 50, "Disease"], [54, 55, "Disease"], [54, 54, "Anatomy"], [57, 61, "Disease"], [57, 60, "Anatomy"], [63, 66, "Disease"], [63, 65, "Anatomy"], [68, 70, "Disease"], [68, 68, "Anatomy"], [74, 78, "Disease"], [89, 98, "Drug"], [102, 110, "Disease"], [106, 108, "Anatomy"], [112, 115, "Disease"], [112, 114, "Anatomy"], [117, 131, "Disease"], [117, 119, "Anatomy"], [135, 139, "Disease"], [133, 134, "Level"], [135, 135, "Anatomy"], [141, 142, "Treatment"]], "rel": [[54, 54, "Anatomy", 54, 55, "Disease", "Anatomy_Disease"], [57, 60, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"], [63, 65, "Anatomy", 63, 66, "Disease", "Anatomy_Disease"], [68, 68, "Anatomy", 68, 70, "Disease", "Anatomy_Disease"], [89, 98, "Drug", 102, 110, "Disease", "Drug_Disease"], [106, 108, "Anatomy", 102, 110, "Disease", "Anatomy_Disease"], [112, 114, "Anatomy", 112, 115, "Disease", "Anatomy_Disease"], [117, 119, "Anatomy", 117, 131, "Disease", "Anatomy_Disease"], [135, 135, "Anatomy", 135, 139, "Disease", "Anatomy_Disease"], [141, 142, "Treatment", 135, 139, "Disease", "Treatment_Disease"]]}
{"idx": 3543, "sentence": "2.探索中药和中西医结合治疗糖尿病肾病：中药抽提物(如大黄酸、雷公藤甲素等)及中成药(如复方血栓通胶囊、金水宝等)对降低尿白蛋白及改善肾功能有一定的疗效，目前正在积累更多循证医学的依据。", "ner": [[14, 18, "Disease"], [17, 17, "Anatomy"], [27, 29, "Drug"], [31, 35, "Drug"], [44, 50, "Drug"], [52, 54, "Drug"], [60, 63, "Test_items"]], "rel": [[17, 17, "Anatomy", 14, 18, "Disease", "Anatomy_Disease"], [31, 35, "Drug", 14, 18, "Disease", "Drug_Disease"], [27, 29, "Drug", 14, 18, "Disease", "Drug_Disease"], [44, 50, "Drug", 14, 18, "Disease", "Drug_Disease"], [60, 63, "Test_items", 14, 18, "Disease", "Test_items_Disease"], [52, 54, "Drug", 14, 18, "Disease", "Drug_Disease"]]}
{"idx": 3544, "sentence": "3.开发针对糖尿病肾病发病机制的药物：如抗AGE药物Pyridorin、抗纤维化类药物舒洛地昔，内皮受体拮抗剂阿曲生坦进入临床试验，但其应用尚缺乏经验。", "ner": [[6, 10, "Disease"], [9, 9, "Anatomy"], [20, 25, "Drug"], [26, 34, "Drug"], [36, 42, "Drug"], [43, 46, "Drug"], [48, 54, "Drug"], [55, 58, "Drug"]], "rel": [[20, 25, "Drug", 6, 10, "Disease", "Drug_Disease"], [26, 34, "Drug", 6, 10, "Disease", "Drug_Disease"], [36, 42, "Drug", 6, 10, "Disease", "Drug_Disease"], [43, 46, "Drug", 6, 10, "Disease", "Drug_Disease"], [48, 54, "Drug", 6, 10, "Disease", "Drug_Disease"], [55, 58, "Drug", 6, 10, "Disease", "Drug_Disease"]]}
{"idx": 3545, "sentence": "心血管疾病合并糖尿病口服降糖药物应用专家共识", "ner": [[0, 4, "Disease"], [0, 2, "Anatomy"], [10, 11, "Method"], [7, 9, "Disease"]], "rel": [[0, 2, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 3546, "sentence": "2008年中国糖尿病流行病学调查显示，中国20岁及以上人群2型糖尿病患病率为9.7%。", "ner": [[7, 9, "Disease"], [29, 33, "Disease"]], "rel": []}
{"idx": 3547, "sentence": "2010年调查的全国成年人糖尿病患病率为11.6%。", "ner": [[13, 15, "Disease"]], "rel": []}
{"idx": 3548, "sentence": "2013年国际糖尿病联盟发布的第6版“糖尿病地图”公布，中国糖尿病的患病人数为9840万，居全球首位，而全球成年人糖尿病患病率为8.3%。", "ner": [[7, 9, "Disease"], [19, 21, "Disease"], [30, 32, "Disease"], [57, 59, "Disease"]], "rel": []}
{"idx": 3549, "sentence": "心血管疾病与糖尿病关系密切。2006年的”中国心脏调查”发现，慢性稳定性心绞痛和急性冠状动脉综合征(ACS)的住院患者中，约80%存在不同程度的糖代谢异常，其中糖尿病占52.9%，糖尿病前期占26.4%。中国医院门诊高血压患者中，糖尿病患病率为24.3%。中华医学会糖尿病学分会慢性并发症调查组报告，1991—2000年部分三级甲等医院住院的2型糖尿病患者合并高血压者占34.2%，合并其他心血管疾病者占17.1%。荟萃分析表明，糖化血红蛋白(HbA1c)在5%以上的患者，HbA1c每增加1%，心血管事件风险增加21%。", "ner": [[0, 4, "Disease"], [0, 2, "Anatomy"], [6, 8, "Disease"], [31, 38, "Disease"], [36, 36, "Anatomy"], [40, 53, "Disease"], [42, 45, "Anatomy"], [72, 76, "Disease"], [80, 82, "Disease"], [90, 94, "Disease"], [108, 110, "Disease"], [115, 117, "Disease"], [133, 135, "Disease"], [171, 175, "Disease"], [180, 182, "Disease"], [195, 199, "Disease"], [195, 197, "Anatomy"], [215, 227, "Test_items"], [229, 232, "Test_Value"], [237, 241, "Test_items"], [248, 252, "Disease"], [248, 250, "Anatomy"], [243, 246, "Test_Value"]], "rel": [[0, 2, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [36, 36, "Anatomy", 31, 38, "Disease", "Anatomy_Disease"], [42, 45, "Anatomy", 40, 53, "Disease", "Anatomy_Disease"], [195, 197, "Anatomy", 195, 199, "Disease", "Anatomy_Disease"], [215, 227, "Test_items", 248, 252, "Disease", "Test_items_Disease"], [237, 241, "Test_items", 248, 252, "Disease", "Test_items_Disease"], [248, 250, "Anatomy", 248, 252, "Disease", "Anatomy_Disease"]]}
{"idx": 3550, "sentence": "血糖控制情况影响心血管疾病(CVD)患者预后。英国前瞻性糖尿病研究(UKPDS)提示，早期严格血糖控制对降低大血管并发症非常重要；但目前还没有足够的临床研究证明，更加严格的血糖控制(如HbA1c<6.5%)可使所有CVD合并糖尿病患者有更进一步的心血管获益。对随机对照研究如退伍军人糖尿病事件研究(VADT)、控制糖尿病患者心血管危险行动(ACCORD)、糖尿病治疗和血管保护行动：百普乐与达美康缓释片对照评估研究(ADVANCE)进行的荟萃分析，也未发现口服降糖药强化治疗可降低心血管事件风险。同时，强化血糖控制会增加低血糖事件发生率，低血糖可诱发合并CVD的糖尿病患者发生心肌梗死及卒中等。因此，重视低血糖的危害、预防低血糖的发生，对心血管疾病合并糖尿病患者尤为重要。", "ner": [[0, 1, "Test_items"], [8, 17, "Disease"], [8, 10, "Anatomy"], [28, 30, "Disease"], [47, 48, "Test_items"], [54, 56, "Anatomy"], [86, 87, "Test_items"], [92, 96, "Test_items"], [97, 101, "Test_Value"], [107, 109, "Disease"], [112, 114, "Disease"], [123, 125, "Anatomy"], [141, 143, "Disease"], [157, 159, "Disease"], [162, 164, "Anatomy"], [178, 180, "Disease"], [184, 185, "Anatomy"], [191, 193, "Drug"], [195, 200, "Drug"], [228, 229, "Method"], [240, 244, "Disease"], [240, 242, "Anatomy"], [253, 254, "Test_items"], [260, 262, "ADE"], [269, 271, "Reason"], [277, 279, "Disease"], [281, 283, "Disease"], [288, 291, "Disease"], [288, 289, "Anatomy"], [293, 294, "Disease"], [302, 304, "ADE"], [311, 313, "ADE"], [319, 323, "Disease"], [319, 321, "Anatomy"], [326, 328, "Disease"]], "rel": [[0, 1, "Test_items", 8, 17, "Disease", "Test_items_Disease"], [8, 10, "Anatomy", 8, 17, "Disease", "Anatomy_Disease"], [54, 56, "Anatomy", 28, 30, "Disease", "Anatomy_Disease"], [47, 48, "Test_items", 28, 30, "Disease", "Test_items_Disease"], [86, 87, "Test_items", 107, 109, "Disease", "Test_items_Disease"], [86, 87, "Test_items", 112, 114, "Disease", "Test_items_Disease"], [92, 96, "Test_items", 107, 109, "Disease", "Test_items_Disease"], [92, 96, "Test_items", 112, 114, "Disease", "Test_items_Disease"], [123, 125, "Anatomy", 107, 109, "Disease", "Anatomy_Disease"], [123, 125, "Anatomy", 112, 114, "Disease", "Anatomy_Disease"], [162, 164, "Anatomy", 157, 159, "Disease", "Anatomy_Disease"], [184, 185, "Anatomy", 178, 180, "Disease", "Anatomy_Disease"], [240, 242, "Anatomy", 240, 244, "Disease", "Anatomy_Disease"], [269, 271, "Reason", 288, 291, "Disease", "Reason_Disease"], [269, 271, "Reason", 293, 294, "Disease", "Reason_Disease"], [288, 289, "Anatomy", 288, 291, "Disease", "Anatomy_Disease"], [319, 321, "Anatomy", 319, 323, "Disease", "Anatomy_Disease"]]}
{"idx": 3551, "sentence": "为进一步提高我国心血管专科医师对心血管疾病合并糖尿病患者的综合防治能力与水平，让工作在一线的临床医师能够充分了解心血管疾病患者的糖尿病筛查流程和诊断标准、常用口服降糖药物选择以及血糖控制目标值，中国医师协会心血管内科医师分会组织心内科、内分泌科以及肾内科等领域专家，共同制订此共识。", "ner": [[16, 20, "Disease"], [16, 18, "Anatomy"], [23, 25, "Disease"], [56, 60, "Disease"], [56, 58, "Anatomy"], [64, 66, "Disease"], [79, 80, "Method"], [89, 90, "Test_items"]], "rel": [[16, 18, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [56, 58, "Anatomy", 56, 60, "Disease", "Anatomy_Disease"], [89, 90, "Test_items", 56, 60, "Disease", "Test_items_Disease"], [89, 90, "Test_items", 64, 66, "Disease", "Test_items_Disease"]]}
{"idx": 3552, "sentence": "一、心血管疾病患者糖尿病筛查流程及诊断标准", "ner": [[2, 6, "Disease"], [2, 4, "Anatomy"], [9, 11, "Disease"]], "rel": [[2, 4, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 3553, "sentence": "(一)筛查对象", "ner": [], "rel": []}
{"idx": 3554, "sentence": "成年人具有下列任何一个及以上危险因素，可被定义为糖尿病高危人群，应进行糖尿病的筛查。(1)有糖调节受损史(定义见诊断标准)；(2)年龄≥40岁；(3)超重(BMI≥24kg/m2)或肥胖(BMI≥28kg/m2)和/或中心性肥胖(男性腰围≥90cm，女性腰围≥85cm)；(4)2型糖尿病患者的一级亲属；(5)高血压(血压≥140/90mmHg，1mmHg=0.133kPa)，或正在接受降压治疗；(6)血脂异常[HDL-C≤0.91mmol/L(35mg/dI)或TG≥2.26mmol/L(200mg/dI)]，或正在接受调脂治疗；(7)动脉粥样硬化性心脑血管疾病患者；(8)其他：①静坐生活方式；2有巨大儿(出生体重≥4kg)生产史，妊娠期糖尿病史；③有一过性类固醇诱导性糖尿病病史者；④多囊卵巢综合征患者；⑤严重精神病和/或长期接受抗抑郁症药物治疗的患者。", "ner": [[24, 26, "Disease"], [27, 28, "Level"], [35, 37, "Disease"], [46, 50, "Disease"], [75, 76, "Disease"], [91, 92, "Disease"], [109, 113, "Disease"], [139, 143, "Disease"], [155, 157, "Disease"], [159, 160, "Test"], [161, 171, "Test_Value"], [202, 205, "Disease"], [207, 211, "Test_items"], [212, 231, "Test_Value"], [233, 234, "Test_items"], [235, 255, "Test_Value"], [271, 283, "Disease"], [271, 272, "Anatomy"], [278, 281, "Anatomy"], [303, 305, "Disease"], [320, 325, "Disease"], [330, 341, "Disease"], [347, 353, "Disease"], [349, 350, "Anatomy"], [360, 362, "Disease"], [358, 359, "Level"], [371, 373, "Disease"]], "rel": [[159, 160, "Test", 155, 157, "Disease", "Test_Disease"], [207, 211, "Test_items", 202, 205, "Disease", "Test_items_Disease"], [233, 234, "Test_items", 202, 205, "Disease", "Test_items_Disease"], [271, 272, "Anatomy", 271, 283, "Disease", "Anatomy_Disease"], [278, 281, "Anatomy", 271, 283, "Disease", "Anatomy_Disease"], [349, 350, "Anatomy", 347, 353, "Disease", "Anatomy_Disease"]]}
{"idx": 3555, "sentence": "(二)筛查方法", "ner": [], "rel": []}
{"idx": 3556, "sentence": "1.空腹静脉血浆血糖(FPG)：FPG是评价糖代谢状态和血糖控制水平最常用的指标，要求受试者至少空腹8h后，在次日上午取血。仅通过FPG筛查糖尿病的优点是简便、易行，但存在漏诊的可能性。", "ner": [[2, 13, "Test_items"], [16, 18, "Test_items"], [28, 29, "Test_items"], [65, 67, "Test_items"], [70, 72, "Disease"]], "rel": [[65, 67, "Test_items", 70, 72, "Disease", "Test_items_Disease"]]}
{"idx": 3557, "sentence": "如不能确诊，且病情允许时可行口服葡萄糖耐量试验(OGTT)。", "ner": [[14, 28, "Test"]], "rel": []}
{"idx": 3558, "sentence": "2.OGTT：如果FPG无法确诊糖尿病，推荐采用OGTT进行糖尿病筛查：依据FPG和糖负荷后2h血糖(2hPG)水平进行诊断。", "ner": [[2, 5, "Test"], [9, 11, "Test_items"], [16, 18, "Disease"], [24, 27, "Test"], [30, 32, "Disease"], [38, 40, "Test_items"], [42, 55, "Test_items"]], "rel": [[9, 11, "Test_items", 16, 18, "Disease", "Test_items_Disease"], [24, 27, "Test", 30, 32, "Disease", "Test_Disease"], [38, 40, "Test_items", 30, 32, "Disease", "Test_items_Disease"], [42, 55, "Test_items", 30, 32, "Disease", "Test_items_Disease"]]}
{"idx": 3559, "sentence": "OGTT方法：(1)空腹至少8h，在次日上午检查前，配制口服葡萄糖溶液(无水葡萄糖粉75g，或国内常用的含1分子结晶水的葡萄糖粉82.5g，溶于300ml水内)备用；(2)第1次抽血应在服糖前，前臂采血标本测定血糖。", "ner": [[0, 3, "Test"], [28, 29, "Method"], [30, 34, "Drug"], [105, 106, "Test_items"]], "rel": [[28, 29, "Method", 30, 34, "Drug", "Method_Drug"]]}
{"idx": 3560, "sentence": "抽血时间最好是7：00—9：00。", "ner": [], "rel": []}
{"idx": 3561, "sentence": "随后，应在5min内顺利喝完备好的葡萄糖溶液。", "ner": [[17, 21, "Drug"]], "rel": []}
{"idx": 3562, "sentence": "第2次抽血应在服糖后2h整，前臂采血标本测定血糖(从服糖第一口开始计时，到2h整，为2hPG)。", "ner": [[22, 23, "Test_items"], [42, 45, "Test_items"]], "rel": []}
{"idx": 3563, "sentence": "注意事项：(1)试验过程中，受试者不喝茶及咖啡，不吸烟，不做剧烈运动，安静休息，但也无须绝对卧床；(2)血标本采集后尽早送检；(3)试验前3天内，每日碳水化合物摄入量不少于150g；(4)试验前3~7天停用可能影响血糖水平的药物，如避孕药、利尿剂或苯妥英钠等。", "ner": [[107, 108, "Test_items"], [116, 118, "Drug"], [120, 122, "Drug"], [124, 127, "Drug"]], "rel": []}
{"idx": 3564, "sentence": "3.HbA1c：HbA1c测定值可以反映近3个月内平均血糖水平，结果稳定、可靠、变异性小。", "ner": [[2, 6, "Test_items"], [8, 12, "Test_items"], [27, 28, "Test_items"]], "rel": []}
{"idx": 3565, "sentence": "不受进食时间、应激状态及短期生活方式改变的影响，是糖尿病监测和疗效评估的重要指标。", "ner": [[25, 27, "Disease"]], "rel": []}
{"idx": 3566, "sentence": "糖尿病患者应每3~6个月监测1次。", "ner": [[0, 2, "Disease"]], "rel": []}
{"idx": 3567, "sentence": "2009年国际专家委员会和2010年美国糖尿病学会(ADA)指南均提出，将HbA1c作为糖尿病的诊断标准之一，诊断糖尿病的切点为≥6.5%，糖尿病高危状态的切点介于5.7%~6.4%。目前美国和欧洲已认可HbA1c在糖尿病诊断和监测中的作用。由于HbA1c检测在我国尚未实现全国标准化，并且部分医院HbA1c的检测方法未通过美国国家糖化血红蛋白标准化计划(NGSP)标准体系的认证，故HbA1c目前在我国主要用于血糖监测。WHO的意见是，如果HbA1c检测方法通过NGSP认证，可将HbA1c作为糖尿病的诊断指标之一，以6.5%做为糖尿病的诊断切点。", "ner": [[20, 22, "Disease"], [37, 41, "Test_items"], [44, 46, "Disease"], [57, 59, "Disease"], [64, 68, "Test_Value"], [70, 72, "Disease"], [73, 74, "Level"], [102, 106, "Test_items"], [108, 110, "Disease"], [123, 127, "Test_items"], [149, 153, "Test_items"], [166, 171, "Test_items"], [192, 196, "Test_items"], [206, 207, "Test_items"], [221, 225, "Test_items"], [241, 245, "Test_items"], [248, 250, "Disease"], [260, 263, "Test_Value"], [266, 268, "Disease"], [82, 90, "Test_Value"]], "rel": [[37, 41, "Test_items", 44, 46, "Disease", "Test_items_Disease"], [102, 106, "Test_items", 108, 110, "Disease", "Test_items_Disease"], [241, 245, "Test_items", 248, 250, "Disease", "Test_items_Disease"]]}
{"idx": 3568, "sentence": "考虑到我国目前存在的上述实际状况，以及中国人群中HbA1c诊断糖尿病的切点需要进一步的研究，《中国2型糖尿病防治指南》尚未推荐在我国采用HbA1c诊断糖尿病。", "ner": [[24, 28, "Test_items"], [31, 33, "Disease"], [49, 53, "Disease"], [68, 72, "Test_items"], [75, 77, "Disease"]], "rel": [[24, 28, "Test_items", 31, 33, "Disease", "Test_items_Disease"], [68, 72, "Test_items", 75, 77, "Disease", "Test_items_Disease"]]}
{"idx": 3569, "sentence": "(三)糖尿病和糖代谢异常的诊断标准", "ner": [[3, 5, "Disease"], [7, 11, "Disease"]], "rel": []}
{"idx": 3570, "sentence": "1.糖尿病：若有代谢紊乱症状(包括多饮、多尿、多食和不明原因的体重下降)，一次FPG≥7.0mmol/L或2hPG≥11.1mmol/L或随机血糖≥11.1mmol/L，即可诊断糖尿病。无糖尿病症状者，需两次血糖值达到上述诊断标准(表1)。", "ner": [[2, 4, "Disease"], [8, 11, "Pathogenesis"], [17, 18, "Symptom"], [20, 21, "Symptom"], [23, 24, "Symptom"], [31, 34, "Symptom"], [39, 41, "Test_items"], [42, 51, "Test_Value"], [53, 56, "Test_items"], [57, 67, "Test_Value"], [69, 72, "Test_items"], [73, 83, "Test_Value"], [89, 91, "Disease"], [94, 96, "Disease"], [104, 105, "Test_items"]], "rel": [[8, 11, "Pathogenesis", 89, 91, "Disease", "Pathogenesis_Disease"], [17, 18, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [20, 21, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [23, 24, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [31, 34, "Symptom", 89, 91, "Disease", "Symptom_Disease"], [39, 41, "Test_items", 89, 91, "Disease", "Test_items_Disease"], [53, 56, "Test_items", 89, 91, "Disease", "Test_items_Disease"], [69, 72, "Test_items", 89, 91, "Disease", "Test_items_Disease"], [104, 105, "Test_items", 94, 96, "Disease", "Test_items_Disease"]]}
{"idx": 3571, "sentence": "2.糖尿病前期：空腹血糖受损(IFG)或糖耐量受损(IGT)统称为糖调节受损(IGR，即糖尿病前期)。若FPG6.1~<7.0mmoL/L，2hPG<7.8mmol/L诊断为IFG；FPG<7.0mmoL/L，2hPG7.8~<11.1mmol/L诊断为IGT(表1)。", "ner": [[2, 6, "Disease"], [8, 18, "Disease"], [20, 29, "Disease"], [33, 49, "Disease"], [52, 54, "Test_items"], [55, 68, "Test_Value"], [70, 73, "Test_items"], [74, 83, "Test_Value"], [87, 89, "Disease"], [91, 93, "Test_items"], [94, 103, "Test_Value"], [105, 108, "Test_items"], [109, 123, "Test_Value"], [127, 129, "Disease"]], "rel": [[52, 54, "Test_items", 87, 89, "Disease", "Test_items_Disease"], [70, 73, "Test_items", 87, 89, "Disease", "Test_items_Disease"], [91, 93, "Test_items", 127, 129, "Disease", "Test_items_Disease"], [105, 108, "Test_items", 127, 129, "Disease", "Test_items_Disease"]]}
{"idx": 3572, "sentence": "(四)筛查流程(图1)", "ner": [], "rel": []}
{"idx": 3573, "sentence": "二、心血管疾病合并糖尿病患者口服降糖药物选择", "ner": [[2, 6, "Disease"], [2, 4, "Anatomy"], [9, 11, "Disease"], [14, 15, "Method"]], "rel": [[2, 4, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"]]}
{"idx": 3574, "sentence": "(一)常用口服降糖药物", "ner": [[5, 6, "Method"]], "rel": []}
{"idx": 3575, "sentence": "1.双胍类：常用药物为二甲双胍，起始剂量500mg/d，随餐服用，逐渐加量，最大剂量2000mg/d。主要通过减少肝脏葡萄糖的输出和改善肝脏、肌肉胰岛素抵抗而降低血糖。二甲双胍可以使HbA1c下降1%~2%，并可减轻体重。单独使用二甲双胍极少发生低血糖。常见的副作用为胃肠道反应，绝大多数患者均能耐受；严重的副作用是乳酸性酸中毒。因此，禁用于肾功能不全[血肌酐水平男性>132.6μmol/L(1.5mg/dI)，女性>123.8μmol/L(1.4mg/dI)；或肾小球滤过率<45ml·min-1·1.73m-2]、肝功能不全、严重感染、缺氧或接受大手术的患者。", "ner": [[2, 4, "Drug"], [11, 14, "Drug"], [20, 26, "Amount"], [42, 49, "Amount"], [81, 82, "Test_items"], [84, 87, "Drug"], [91, 95, "Test_items"], [96, 102, "Test_Value"], [115, 118, "Drug"], [123, 125, "ADE"], [134, 138, "ADE"], [158, 163, "ADE"], [151, 152, "Level"], [171, 175, "Disease"], [171, 171, "Anatomy"], [177, 181, "Test_items"], [233, 238, "Test_items"], [239, 257, "Test_Value"], [260, 264, "Disease"], [260, 260, "Anatomy"], [266, 267, "Level"], [268, 269, "Disease"], [68, 69, "Anatomy"], [71, 72, "Anatomy"], [73, 77, "Pathogenesis"], [182, 205, "Test_Value"], [207, 230, "Test_Value"]], "rel": [[20, 26, "Amount", 11, 14, "Drug", "Amount_Drug"], [42, 49, "Amount", 11, 14, "Drug", "Amount_Drug"], [123, 125, "ADE", 115, 118, "Drug", "ADE_Drug"], [171, 171, "Anatomy", 171, 175, "Disease", "Anatomy_Disease"], [177, 181, "Test_items", 171, 175, "Disease", "Test_items_Disease"], [233, 238, "Test_items", 171, 175, "Disease", "Test_items_Disease"], [260, 260, "Anatomy", 260, 264, "Disease", "Anatomy_Disease"]]}
{"idx": 3576, "sentence": "以往使用对比剂之前停用二甲双胍的建议缺乏足够的循征医学证据。", "ner": [[11, 14, "Drug"]], "rel": []}
{"idx": 3577, "sentence": "因此，使用对比剂前可不停用，但需密切监测肾功能，若肾功能恶化，应立即停用二甲双胍。", "ner": [[20, 22, "Test"], [25, 27, "Test"], [28, 29, "Test_Value"], [36, 39, "Drug"]], "rel": []}
{"idx": 3578, "sentence": "2.胰岛素促分泌剂：(1)磺脲类：常用药物有格列吡嗪、格列齐特、格列喹酮及格列美脲。多从小剂量开始应用，而后根据血糖监测结果进行剂量调整。主要通过刺激胰岛β细胞分泌胰岛素，增加体内的胰岛素水平而降低血糖。磺脲类药物可以使HbA1c降低1%~2%。磺脲类药物如果使用不当可以导致低血糖，特别是老年患者和肝、肾功能不全者。磺脲类会增加体重。轻度、中度肾功能不全的患者，宜选择格列喹酮。(2)格列奈类：常用药物有瑞格列奈和那格列奈。多从小剂量开始应用，而后根据血糖监测结果进行剂量调整。主要通过刺激胰岛素的早时相分泌而降低餐后血糖，具有吸收快、起效快和作用时间短的特点，可降低HbA1c0.3%~1.5%。常见副作用是低血糖和体重增加，但与磺脲类药物相比，发生频率较低、程度较轻。", "ner": [[2, 8, "Drug"], [13, 15, "Drug"], [22, 25, "Drug"], [27, 30, "Drug"], [32, 35, "Drug"], [37, 40, "Drug"], [56, 57, "Test_items"], [99, 100, "Test_items"], [97, 98, "Test_Value"], [102, 104, "Drug"], [110, 114, "Test_items"], [115, 121, "Test_Value"], [123, 125, "Drug"], [138, 140, "ADE"], [150, 157, "Disease"], [150, 150, "Anatomy"], [152, 152, "Anatomy"], [159, 161, "Drug"], [163, 166, "ADE"], [173, 177, "Disease"], [173, 173, "Anatomy"], [168, 169, "Level"], [171, 172, "Level"], [185, 188, "Drug"], [193, 196, "Drug"], [203, 206, "Drug"], [208, 211, "Drug"], [227, 228, "Test_items"], [258, 261, "Test_items"], [285, 289, "Test_items"], [290, 298, "Test_Value"], [306, 308, "ADE"], [310, 313, "ADE"], [317, 319, "Drug"]], "rel": [[138, 140, "ADE", 123, 125, "Drug", "ADE_Drug"], [123, 125, "Drug", 150, 157, "Disease", "Drug_Disease"], [150, 150, "Anatomy", 150, 157, "Disease", "Anatomy_Disease"], [152, 152, "Anatomy", 150, 157, "Disease", "Anatomy_Disease"], [163, 166, "ADE", 159, 161, "Drug", "ADE_Drug"], [173, 173, "Anatomy", 173, 177, "Disease", "Anatomy_Disease"], [185, 188, "Drug", 173, 177, "Disease", "Drug_Disease"], [306, 308, "ADE", 317, 319, "Drug", "ADE_Drug"], [310, 313, "ADE", 317, 319, "Drug", "ADE_Drug"]]}
{"idx": 3579, "sentence": "3.α-糖苷酶抑制剂：常用药物有阿卡波糖和伏格列波糖，多从小剂量开始应用，而后根据血糖监测结果进行剂量调整。通过抑制碳水化合物在小肠上部的消化和吸收而降低餐后血糖，适用于以碳水化合物为主要食物和餐后血糖升高的患者。α-糖苷酶抑制剂可使HbA1c下降0.5%~0.8%，不增加体重。单独使用时不导致低血糖，但与胰岛素促泌剂或胰岛素合用时需要注意低血糖的防治，纠正低血糖只能使用葡萄糖制剂。", "ner": [[2, 9, "Drug"], [16, 19, "Drug"], [21, 25, "Drug"], [107, 114, "Drug"], [41, 42, "Test_items"], [77, 80, "Test_items"], [75, 76, "Test_Value"], [97, 100, "Test_items"], [101, 102, "Test_Value"], [117, 121, "Test_items"], [122, 132, "Test_Value"], [148, 150, "ADE"], [154, 159, "Drug"], [161, 163, "Drug"], [171, 173, "ADE"], [180, 182, "Disease"], [187, 191, "Drug"], [135, 138, "ADE"]], "rel": [[171, 173, "ADE", 154, 159, "Drug", "ADE_Drug"], [171, 173, "ADE", 161, 163, "Drug", "ADE_Drug"], [187, 191, "Drug", 180, 182, "Disease", "Drug_Disease"]]}
{"idx": 3580, "sentence": "常见不良反应为胃肠道反应，如有疝气或曾行胃肠道外科手术应禁用。", "ner": [[7, 11, "ADE"], [15, 16, "Disease"], [20, 26, "Operation"]], "rel": []}
{"idx": 3581, "sentence": "4.噻唑烷二酮类：常用药物有罗格列酮和吡格列酮。每日早餐前1次服用。主要通过改善外周组织胰岛素抵抗而降低血糖。噻唑烷二酮类药物可以使HbA1c下降1.0%~1.5%。噻唑烷二酮类药物单独使用时不导致低血糖。但体重增加和水肿是其常见副作用。临床研究发现噻唑烷二酮类药物与骨折和心力衰竭风险增加相关。有心力衰竭[纽约心脏病协会(NYHA)心功能Ⅱ级以上]的患者、活动性肝病或转氨酶增高超过正常上限2.5倍的患者，以及有严重骨质疏松和骨折病史的患者，应禁用本类药物。", "ner": [[2, 7, "Drug"], [14, 17, "Drug"], [19, 22, "Drug"], [24, 30, "Frequency"], [52, 53, "Test_items"], [55, 60, "Drug"], [66, 70, "Test_items"], [71, 81, "Test_Value"], [83, 88, "Drug"], [99, 101, "ADE"], [104, 107, "ADE"], [109, 110, "ADE"], [125, 130, "Drug"], [149, 152, "Disease"], [149, 149, "Anatomy"], [134, 135, "ADE"], [137, 144, "ADE"], [179, 183, "Disease"], [182, 182, "Anatomy"], [185, 187, "Test_items"], [188, 199, "Test_Value"], [207, 208, "Level"], [209, 212, "Disease"], [209, 210, "Anatomy"], [214, 215, "Disease"], [44, 48, "Pathogenesis"], [154, 173, "Disease"]], "rel": [[134, 135, "ADE", 125, 130, "Drug", "ADE_Drug"], [137, 144, "ADE", 125, 130, "Drug", "ADE_Drug"], [149, 149, "Anatomy", 149, 152, "Disease", "Anatomy_Disease"], [182, 182, "Anatomy", 179, 183, "Disease", "Anatomy_Disease"], [209, 210, "Anatomy", 209, 212, "Disease", "Anatomy_Disease"]]}
{"idx": 3582, "sentence": "5.二肽基肽酶4(DPP-4)抑制剂：目前我国上市的药物有西格列汀、维格列汀、沙格列汀、阿格列汀和利格列汀。", "ner": [[2, 17, "Drug"], [29, 32, "Drug"], [34, 37, "Drug"], [39, 42, "Drug"], [44, 47, "Drug"], [49, 52, "Drug"]], "rel": []}
{"idx": 3583, "sentence": "多每日1次服用，通过抑制DPP-4而减少胰高血糖素样肽-1(GLP-1)在体内的失活，增加内源性GLP-1水平。", "ner": [[1, 4, "Frequency"]], "rel": []}
{"idx": 3584, "sentence": "GLP-1以葡萄糖浓度依赖的方式增强胰岛素分泌，抑制胰高血糖素分泌。", "ner": [], "rel": []}
{"idx": 3585, "sentence": "临床试验显示，DPP-4抑制剂可降低HbA1c0.5%~1.0%。", "ner": [[7, 14, "Drug"], [18, 22, "Test_items"], [23, 31, "Test_Value"]], "rel": []}
{"idx": 3586, "sentence": "DPP-4抑制剂单独使用不增加低血糖发生的风险，不增加体重。", "ner": [[0, 7, "Drug"], [15, 17, "ADE"], [25, 28, "ADE"]], "rel": []}
{"idx": 3587, "sentence": "表2总结了各种口服降糖药物的作用机制、使用方法、疗效、安全性、注意事项等主要信息。", "ner": [[7, 8, "Method"]], "rel": []}
{"idx": 3588, "sentence": "(二)口服降糖药物用药原则", "ner": [[3, 4, "Method"]], "rel": []}
{"idx": 3589, "sentence": "1.一线药物治疗：许多国家和国际组织制定的糖尿病指南推荐：若无禁忌且能耐受，二甲双胍是2型糖尿病患者的基础用药。UKPDS还显示二甲双胍可减少超重或肥胖2型糖尿病患者的心血管事件和死亡。", "ner": [[21, 23, "Disease"], [38, 41, "Drug"], [43, 47, "Disease"], [64, 67, "Drug"], [71, 72, "Disease"], [74, 75, "Disease"], [76, 80, "Disease"], [84, 88, "Disease"], [84, 86, "Anatomy"]], "rel": [[38, 41, "Drug", 43, 47, "Disease", "Drug_Disease"], [64, 67, "Drug", 76, 80, "Disease", "Drug_Disease"], [64, 67, "Drug", 71, 72, "Disease", "Drug_Disease"], [64, 67, "Drug", 74, 75, "Disease", "Drug_Disease"], [84, 86, "Anatomy", 84, 88, "Disease", "Anatomy_Disease"]]}
{"idx": 3590, "sentence": "若存在禁忌或不能耐受，可考虑应用胰岛素促分泌剂或α-糖苷酶抑制剂。", "ner": [[24, 31, "Drug"], [16, 22, "Drug"]], "rel": []}
{"idx": 3591, "sentence": "如果HbA1c在10.0%~12.0%，或血糖>16.7~19.4mmoL/L，需应用胰岛素治疗。", "ner": [[2, 6, "Test_items"], [8, 18, "Test_Value"], [21, 22, "Test_items"], [23, 38, "Test_Value"], [43, 45, "Drug"]], "rel": []}
{"idx": 3592, "sentence": "2.联合用药：若起始HbA1c≥9.0%，单药治疗很难使血糖达标，需联合口服降糖药物治疗；若生活方式干预联合一线口服降糖药物单药治疗3个月不能使血糖达标，需考虑联合用药。", "ner": [[10, 14, "Test_items"], [15, 19, "Test_Value"], [28, 29, "Test_items"], [30, 31, "Test_Value"], [36, 37, "Method"], [46, 51, "Treatment"], [56, 57, "Method"], [72, 73, "Test_items"], [74, 75, "Test_Value"]], "rel": []}
{"idx": 3593, "sentence": "根据患者的情况选择联合用药方案，如胰岛素促分泌剂或α-糖苷酶抑制剂或DPP-4抑制剂或噻唑烷二酮类药物。", "ner": [[17, 23, "Drug"], [25, 32, "Drug"], [34, 41, "Drug"], [43, 50, "Drug"]], "rel": []}
{"idx": 3594, "sentence": "餐后血糖升高为主者，可优先选用格列奈类降糖药、α-糖苷酶抑制剂或DPP-4抑制剂。", "ner": [[0, 3, "Test_items"], [4, 5, "Test_Value"], [23, 30, "Drug"], [32, 39, "Drug"], [15, 21, "Drug"]], "rel": []}
{"idx": 3595, "sentence": "若两种口服降糖药物联合治疗3个月不能使患者血糖达标，可考虑联合第三种口服降糖药物，或者联合胰岛素或GLP-1受体激动剂治疗。", "ner": [[3, 4, "Method"], [21, 22, "Test_items"], [23, 24, "Test_Value"], [34, 35, "Method"], [45, 47, "Drug"], [49, 58, "Drug"]], "rel": []}
{"idx": 3596, "sentence": "三、心血管疾病合并糖尿病患者的血糖控制目标", "ner": [[2, 6, "Disease"], [2, 4, "Anatomy"], [9, 11, "Disease"], [15, 16, "Test_items"]], "rel": [[2, 4, "Anatomy", 2, 6, "Disease", "Anatomy_Disease"], [15, 16, "Test_items", 2, 6, "Disease", "Test_items_Disease"], [15, 16, "Test_items", 9, 11, "Disease", "Test_items_Disease"]]}
{"idx": 3597, "sentence": "随机对照临床试验已证实，严格的血糖控制可降低糖尿病的微血管并发症，但对大血管并发症的直接获益存在不同观点，有待进一步证实。早期临床研究如UKPDS报道，严格血糖控制可明显降低微血管并发症，心肌梗死风险降低16%(P=0.052)；在延长观察阶段，心肌梗死和全因性死亡的风险减少13%。近年，对于2型糖尿病患者的口服降糖药物强化血糖控制的随机对照研究，如VADT、ACCORD、ADVANCE，均未发现口服降糖药物强化降糖治疗可降低心血管事件风险，但对VADT、ACCORD和ADVANCE的心血管终点事件的综合荟萃分析后，HbA1c每下降1%，非致命性心梗相对风险降低15%，但未降低卒中或全因死亡风险。", "ner": [[15, 16, "Test_items"], [22, 24, "Disease"], [26, 28, "Anatomy"], [35, 37, "Anatomy"], [78, 79, "Test_items"], [94, 97, "Disease"], [94, 95, "Anatomy"], [87, 89, "Anatomy"], [123, 126, "Disease"], [123, 124, "Anatomy"], [147, 151, "Disease"], [155, 156, "Method"], [163, 164, "Test_items"], [200, 201, "Method"], [215, 219, "Disease"], [215, 217, "Anatomy"], [245, 247, "Anatomy"], [261, 265, "Test_items"], [267, 270, "Test_Value"], [272, 277, "Disease"], [276, 276, "Anatomy"], [292, 293, "Disease"]], "rel": [[15, 16, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [26, 28, "Anatomy", 22, 24, "Disease", "Anatomy_Disease"], [35, 37, "Anatomy", 22, 24, "Disease", "Anatomy_Disease"], [94, 95, "Anatomy", 94, 97, "Disease", "Anatomy_Disease"], [123, 124, "Anatomy", 123, 126, "Disease", "Anatomy_Disease"], [163, 164, "Test_items", 147, 151, "Disease", "Test_items_Disease"], [215, 217, "Anatomy", 215, 219, "Disease", "Anatomy_Disease"], [276, 276, "Anatomy", 272, 277, "Disease", "Anatomy_Disease"]]}
{"idx": 3598, "sentence": "UKPDS研究中患者糖尿病史较短，血糖控制尤其早期控制更为重要；而VADT、ACCORD和ADVANCE研究中患者病史相对较长。所以对于糖尿病病程较短，无并发症的患者，强化血糖控制可带来更多的血管并发症获益；而对于病史较长，合并症较多的患者，强化血糖控制并不能带来更多的心血管获益。糖尿病治疗的目的要兼顾用心血管获益和用药安全，合并CVD的糖尿病患者，一旦发生低血糖可诱发心肌梗死及卒中等，因而对于这类人群应尽量在避免低血糖的情况下使血糖控制达标。综合循证医学研究结果，并充分平衡风险和血管获益，结合患者的年龄、糖尿病病程以及CVD病史等，将血糖控制目标个体化。", "ner": [[10, 12, "Disease"], [17, 18, "Test_items"], [68, 70, "Disease"], [86, 87, "Test_items"], [96, 97, "Anatomy"], [123, 124, "Test_items"], [135, 137, "Anatomy"], [141, 143, "Disease"], [153, 155, "Anatomy"], [166, 168, "Disease"], [170, 172, "Disease"], [180, 182, "Reason"], [186, 189, "Disease"], [186, 187, "Anatomy"], [191, 192, "Disease"], [209, 211, "ADE"], [217, 218, "Test_items"], [243, 244, "Anatomy"], [256, 258, "Disease"], [263, 265, "Disease"], [271, 272, "Test_items"]], "rel": [[17, 18, "Test_items", 10, 12, "Disease", "Test_items_Disease"], [86, 87, "Test_items", 68, 70, "Disease", "Test_items_Disease"], [96, 97, "Anatomy", 68, 70, "Disease", "Anatomy_Disease"], [123, 124, "Test_items", 68, 70, "Disease", "Test_items_Disease"], [135, 137, "Anatomy", 68, 70, "Disease", "Anatomy_Disease"], [153, 155, "Anatomy", 141, 143, "Disease", "Anatomy_Disease"], [217, 218, "Test_items", 166, 168, "Disease", "Test_items_Disease"], [217, 218, "Test_items", 170, 172, "Disease", "Test_items_Disease"], [180, 182, "Reason", 186, 189, "Disease", "Reason_Disease"], [180, 182, "Reason", 191, 192, "Disease", "Reason_Disease"], [186, 187, "Anatomy", 186, 189, "Disease", "Anatomy_Disease"], [243, 244, "Anatomy", 256, 258, "Disease", "Anatomy_Disease"], [271, 272, "Test_items", 256, 258, "Disease", "Test_items_Disease"]]}
{"idx": 3599, "sentence": "糖尿病患者的血糖控制可根据自我血糖监测(SMBG)的结果和HbA1c水平综合判断。", "ner": [[0, 2, "Disease"], [6, 7, "Test_items"], [13, 24, "Test_items"], [29, 33, "Test_items"]], "rel": [[6, 7, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [13, 24, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [29, 33, "Test_items", 0, 2, "Disease", "Test_items_Disease"]]}
{"idx": 3600, "sentence": "在治疗之初或血糖未达标时，应每3个月进行1次HbA1c的测定，血糖控制达标者至少每半年进行1次HbA1c测定。", "ner": [[6, 7, "Test_items"], [8, 10, "Test_Value"], [22, 26, "Test_items"], [31, 32, "Test_items"], [47, 51, "Test_items"], [35, 36, "Test_Value"]], "rel": []}
{"idx": 3601, "sentence": "1.已证实HbA1c<7.0%可减少糖尿病患者微血管并发症，故推荐血糖控制目标：HbA1c<7.0%，FPG<7.0mmol/L，2hPG<10.0mmol/L。", "ner": [[5, 9, "Test_items"], [10, 14, "Test_Value"], [18, 20, "Disease"], [23, 25, "Anatomy"], [33, 34, "Test_items"], [40, 44, "Test_items"], [45, 49, "Test_Value"], [51, 53, "Test_items"], [54, 63, "Test_Value"], [65, 68, "Test_items"], [69, 79, "Test_Value"]], "rel": [[5, 9, "Test_items", 18, 20, "Disease", "Test_items_Disease"], [23, 25, "Anatomy", 18, 20, "Disease", "Anatomy_Disease"], [33, 34, "Test_items", 18, 20, "Disease", "Test_items_Disease"], [40, 44, "Test_items", 18, 20, "Disease", "Test_items_Disease"], [51, 53, "Test_items", 18, 20, "Disease", "Test_items_Disease"], [65, 68, "Test_items", 18, 20, "Disease", "Test_items_Disease"]]}
{"idx": 3602, "sentence": "2.糖尿病病史较短、预期寿命较长、没有并发症的患者，在不发生低血糖的情况下可考虑将HbA1c控制在6.5%以下。", "ner": [[2, 4, "Disease"], [30, 32, "Disease"], [41, 45, "Test_items"], [49, 54, "Test_Value"]], "rel": [[41, 45, "Test_items", 2, 4, "Disease", "Test_items_Disease"]]}
{"idx": 3603, "sentence": "3.有严重低血糖病史，或预期寿命较短，或有显著微血管或大血管并发症的患者，可放宽血糖目标值：HbA1c<7.5%~8.0%。", "ner": [[5, 7, "Disease"], [3, 4, "Level"], [23, 25, "Anatomy"], [27, 29, "Anatomy"], [40, 41, "Test_items"], [46, 50, "Test_items"], [51, 60, "Test_Value"]], "rel": [[23, 25, "Anatomy", 5, 7, "Disease", "Anatomy_Disease"], [27, 29, "Anatomy", 5, 7, "Disease", "Anatomy_Disease"], [40, 41, "Test_items", 5, 7, "Disease", "Test_items_Disease"], [46, 50, "Test_items", 5, 7, "Disease", "Test_items_Disease"]]}
{"idx": 3604, "sentence": "4.慢性疾病终末期(如心功能NYHA Ⅲ-Ⅳ级、慢性肾功能不全、恶性肿瘤伴转移、中重度认知功能障碍等)患者的HbA1c可放宽至<8.5%。", "ner": [[11, 22, "Disease"], [11, 11, "Anatomy"], [24, 30, "Disease"], [26, 26, "Anatomy"], [32, 35, "Disease"], [43, 48, "Disease"], [40, 42, "Level"], [54, 58, "Test_items"], [63, 67, "Test_Value"]], "rel": [[11, 11, "Anatomy", 11, 22, "Disease", "Anatomy_Disease"], [54, 58, "Test_items", 11, 22, "Disease", "Test_items_Disease"], [26, 26, "Anatomy", 24, 30, "Disease", "Anatomy_Disease"], [54, 58, "Test_items", 24, 30, "Disease", "Test_items_Disease"], [54, 58, "Test_items", 32, 35, "Disease", "Test_items_Disease"], [54, 58, "Test_items", 43, 48, "Disease", "Test_items_Disease"]]}
{"idx": 3605, "sentence": "四、特殊情况说明", "ner": [], "rel": []}
{"idx": 3606, "sentence": "(一)心血管疾病", "ner": [[3, 7, "Disease"], [3, 5, "Anatomy"]], "rel": [[3, 5, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 3607, "sentence": "1.ACS：若血糖>10.0mmol/L，可使用以胰岛素为基础的治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免低血糖发生。", "ner": [[2, 4, "Disease"], [7, 8, "Test_items"], [9, 19, "Test_Value"], [25, 27, "Drug"], [38, 39, "Test_items"], [45, 58, "Test_Value"], [66, 68, "ADE"]], "rel": [[7, 8, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [25, 27, "Drug", 2, 4, "Disease", "Drug_Disease"], [38, 39, "Test_items", 2, 4, "Disease", "Test_items_Disease"], [66, 68, "ADE", 25, 27, "Drug", "ADE_Drug"]]}
{"idx": 3608, "sentence": "应激情况下可出现暂时性血糖升高，对于既往没有糖尿病病史(特别是HbA1c在正常范围者)，不能以此血糖值诊断糖尿病，须在应激消除后复查，必要时行OGTT明确。", "ner": [[11, 12, "Test_items"], [13, 14, "Test_Value"], [22, 24, "Disease"], [31, 35, "Test_items"], [36, 40, "Test_Value"], [48, 49, "Test_items"], [53, 55, "Disease"], [71, 74, "Test"]], "rel": [[11, 12, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [31, 35, "Test_items", 22, 24, "Disease", "Test_items_Disease"], [48, 49, "Test_items", 53, 55, "Disease", "Test_items_Disease"], [71, 74, "Test", 53, 55, "Disease", "Test_Disease"]]}
{"idx": 3609, "sentence": "2.经皮冠状动脉介入治疗(PCI)：接受PCI的患者使用对比剂前可不停用二甲双胍，但应密切监测肾功能，若48h内肾功能恶化，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可恢复使用。", "ner": [[2, 16, "Operation"], [20, 22, "Operation"], [36, 39, "Drug"], [47, 49, "Test"], [56, 58, "Test"], [59, 60, "Test_Value"], [67, 70, "Drug"], [74, 76, "Test"], [77, 83, "Test_Value"]], "rel": []}
{"idx": 3610, "sentence": "3.冠状动脉旁路移植术(CABG)：围手术期不推荐口服降糖药，应使用胰岛素治疗。", "ner": [[2, 16, "Operation"], [25, 26, "Method"], [34, 36, "Drug"]], "rel": []}
{"idx": 3611, "sentence": "4.心力衰竭：急性心力衰竭伴有缺氧情况，禁用双胍类药物、噻唑烷二酮类药物。对于慢性心力衰竭患者，需根据肾功能、血氧状态以及基础心功能等情况，选择应用口服降糖药物，还应注意监测血清乳酸水平和血气分析指标。心功能NYHAII~IV级的患者，应避免使用噻唑烷二酮类药物。DPP-4抑制剂在心功能NYHAⅡ~Ⅲ级临床经验有限，III~IV级无临床经验，故心力衰竭时应慎用或禁用。目前缺乏其他药物在心力衰竭患者中的用药证据。", "ner": [[2, 5, "Disease"], [2, 2, "Anatomy"], [7, 12, "Disease"], [9, 9, "Anatomy"], [15, 16, "Symptom"], [22, 24, "Drug"], [28, 33, "Drug"], [39, 44, "Disease"], [41, 41, "Anatomy"], [51, 53, "Test"], [55, 56, "Test_items"], [61, 65, "Test"], [74, 75, "Method"], [87, 90, "Test_items"], [94, 97, "Test"], [101, 113, "Disease"], [101, 101, "Anatomy"], [123, 128, "Drug"], [132, 139, "Drug"], [141, 151, "Disease"], [141, 141, "Anatomy"], [173, 176, "Disease"], [173, 173, "Anatomy"], [194, 197, "Disease"], [194, 194, "Anatomy"]], "rel": [[2, 2, "Anatomy", 2, 5, "Disease", "Anatomy_Disease"], [9, 9, "Anatomy", 7, 12, "Disease", "Anatomy_Disease"], [15, 16, "Symptom", 7, 12, "Disease", "Symptom_Disease"], [41, 41, "Anatomy", 39, 44, "Disease", "Anatomy_Disease"], [51, 53, "Test", 39, 44, "Disease", "Test_Disease"], [55, 56, "Test_items", 39, 44, "Disease", "Test_items_Disease"], [61, 65, "Test", 39, 44, "Disease", "Test_Disease"], [87, 90, "Test_items", 39, 44, "Disease", "Test_items_Disease"], [94, 97, "Test", 39, 44, "Disease", "Test_Disease"], [101, 101, "Anatomy", 101, 113, "Disease", "Anatomy_Disease"], [141, 141, "Anatomy", 141, 151, "Disease", "Anatomy_Disease"], [173, 173, "Anatomy", 173, 176, "Disease", "Anatomy_Disease"], [194, 194, "Anatomy", 194, 197, "Disease", "Anatomy_Disease"]]}
{"idx": 3612, "sentence": "(二)肾功能不全", "ner": [[3, 7, "Disease"], [3, 3, "Anatomy"]], "rel": [[3, 3, "Anatomy", 3, 7, "Disease", "Anatomy_Disease"]]}
{"idx": 3613, "sentence": "心血管疾病和糖尿病患者常合并慢性肾脏病(CKD)，而CKD患者应基于药物的药代动力学特征和患者的肾功能水平综合判断，选择合适的降糖药物，并适当调整剂量，确保在有效降糖的同时不增加低血糖风险。", "ner": [[0, 4, "Disease"], [0, 2, "Anatomy"], [6, 8, "Disease"], [14, 23, "Disease"], [16, 17, "Anatomy"], [26, 28, "Disease"], [48, 50, "Test"], [89, 91, "ADE"]], "rel": [[0, 2, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [16, 17, "Anatomy", 14, 23, "Disease", "Anatomy_Disease"], [48, 50, "Test", 26, 28, "Disease", "Test_Disease"]]}
{"idx": 3614, "sentence": "瑞格列奈、利格列汀在肾功能不全时无需调整剂量；二甲双胍在GFR45~59ml·min-1·1.73m-2时应减量，GFR<45ml·min-1·1.73m-2禁用；α-糖苷酶抑制剂在GFR<30ml·min-1·1.73m-2时禁用。其他药物在肾功能不全中的应用详见图2。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [10, 14, "Disease"], [10, 10, "Anatomy"], [23, 26, "Drug"], [28, 30, "Test_items"], [31, 51, "Test_Value"], [57, 59, "Test_items"], [60, 78, "Test_Value"], [82, 89, "Drug"], [91, 93, "Test_items"], [94, 112, "Test_Value"], [122, 126, "Disease"], [122, 122, "Anatomy"]], "rel": [[0, 3, "Drug", 10, 14, "Disease", "Drug_Disease"], [5, 8, "Drug", 10, 14, "Disease", "Drug_Disease"], [10, 10, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [23, 26, "Drug", 10, 14, "Disease", "Drug_Disease"], [28, 30, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [57, 59, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [82, 89, "Drug", 10, 14, "Disease", "Drug_Disease"], [91, 93, "Test_items", 10, 14, "Disease", "Test_items_Disease"], [122, 122, "Anatomy", 122, 126, "Disease", "Anatomy_Disease"]]}
{"idx": 3615, "sentence": "(三)阻塞性睡眠呼吸暂停综合征(OSAHS)", "ner": [[3, 21, "Disease"]], "rel": []}
{"idx": 3616, "sentence": "对于OSAHS伴发2型糖尿病的患者，常用降糖药均可选用，但应尽可能使用不增加体重的药物。由于OSAHS易发生夜间缺氧，对于低氧血症严重者慎用或禁用双胍类药物。", "ner": [[2, 6, "Disease"], [9, 13, "Disease"], [46, 50, "Disease"], [54, 57, "Symptom"], [61, 64, "Disease"], [65, 66, "Level"], [73, 77, "Drug"]], "rel": [[54, 57, "Symptom", 46, 50, "Disease", "Symptom_Disease"]]}
{"idx": 3617, "sentence": "(四)老年糖尿病患者", "ner": [[5, 7, "Disease"]], "rel": []}
{"idx": 3618, "sentence": "老年患者降糖目标应个体化，考虑个人功能状态、共患或伴发疾病，尤其应考虑是否发生过心血管疾血、低血糖、微血管并发症等。", "ner": [[40, 43, "Disease"], [40, 42, "Anatomy"], [46, 48, "Disease"], [50, 52, "Anatomy"]], "rel": [[40, 42, "Anatomy", 40, 43, "Disease", "Anatomy_Disease"]]}
{"idx": 3619, "sentence": "生活自理的老人，HbA1c为7.0%~7.5%；生活无法自理者，以≤8.0%为宜；对于虚弱患者，可放宽至≤8.5%。", "ner": [[8, 12, "Test_items"], [14, 22, "Test_Value"], [33, 37, "Test_Value"], [52, 56, "Test_Value"]], "rel": []}
{"idx": 3620, "sentence": "老年糖尿病患者病情复杂、发生并发症或合并症的风险高、器官功能逐渐衰退。", "ner": [[2, 4, "Disease"]], "rel": []}
{"idx": 3621, "sentence": "因此，对于老年糖尿病患者而言，治疗方案需更有针对性、更符合个体情况、更重视安全性。", "ner": [[7, 9, "Disease"]], "rel": []}
{"idx": 3622, "sentence": "(五)低血糖", "ner": [[3, 5, "Disease"]], "rel": []}
{"idx": 3623, "sentence": "糖尿病患者血糖水平低于3.9mmol/L(70mg/dI)时，定义为低血糖。", "ner": [[0, 2, "Disease"], [5, 6, "Test_items"], [9, 28, "Test_Value"], [34, 36, "Disease"]], "rel": [[5, 6, "Test_items", 0, 2, "Disease", "Test_items_Disease"], [5, 6, "Test_items", 34, 36, "Disease", "Test_items_Disease"]]}
{"idx": 3624, "sentence": "在口服降糖药物中，胰岛素促泌剂均可引起低血糖，其中磺脲类药物尤为常见，格列奈类药物因其药理作用时间短，相对较少见。", "ner": [[1, 2, "Method"], [9, 14, "Drug"], [19, 21, "ADE"], [25, 27, "Drug"], [35, 38, "Drug"]], "rel": [[1, 2, "Method", 9, 14, "Drug", "Method_Drug"], [1, 2, "Method", 25, 27, "Drug", "Method_Drug"], [1, 2, "Method", 35, 38, "Drug", "Method_Drug"], [19, 21, "ADE", 9, 14, "Drug", "ADE_Drug"], [19, 21, "ADE", 25, 27, "Drug", "ADE_Drug"], [19, 21, "ADE", 35, 38, "Drug", "ADE_Drug"]]}
{"idx": 3625, "sentence": "常见原因包括：药物剂量、剂型或给药时间，甚至治疗方案需要调整，均可能与低血糖相关；过强的身体运动时肌肉等外周组织对葡萄糖摄取和利用增加，而消耗血糖；未正常进食，或隔夜禁食时间偏长等，导致食物来源的外源性葡萄糖摄入减少或延迟所致；因肾功能不全等疾病，使体内胰岛素或胰岛素促泌剂清除能力下降，血中胰岛素或胰岛素促泌剂浓度过高，血糖被过度降低。", "ner": [[35, 37, "ADE"], [115, 119, "Disease"], [115, 115, "Anatomy"], [161, 162, "Test_items"], [164, 167, "Test_Value"], [131, 136, "Drug"], [150, 155, "Drug"]], "rel": [[115, 115, "Anatomy", 115, 119, "Disease", "Anatomy_Disease"], [161, 162, "Test_items", 115, 119, "Disease", "Test_items_Disease"], [131, 136, "Drug", 115, 119, "Disease", "Drug_Disease"], [150, 155, "Drug", 115, 119, "Disease", "Drug_Disease"]]}
{"idx": 3626, "sentence": "二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类及DPP-4抑制剂单独使用时一般不会导致低血糖。", "ner": [[0, 3, "Drug"], [5, 12, "Drug"], [14, 19, "Drug"], [21, 28, "Drug"], [40, 42, "ADE"]], "rel": []}
{"idx": 3627, "sentence": "五、结语", "ner": [], "rel": []}
{"idx": 3628, "sentence": "糖尿病与心血管疾病关系密切，糖尿病是心血管疾病的主要危险因素之一。血糖管理是心血管疾病综合防控的重要内容之一。心血管专科医师应熟练掌握心血管疾病合并糖尿病患者常用口服降糖药物的应用原则。", "ner": [[0, 2, "Disease"], [4, 8, "Disease"], [4, 6, "Anatomy"], [14, 16, "Reason"], [18, 22, "Disease"], [18, 20, "Anatomy"], [33, 34, "Test_items"], [38, 42, "Disease"], [38, 40, "Anatomy"], [67, 71, "Disease"], [67, 69, "Anatomy"], [74, 76, "Disease"], [81, 82, "Method"]], "rel": [[4, 6, "Anatomy", 4, 8, "Disease", "Anatomy_Disease"], [14, 16, "Reason", 18, 22, "Disease", "Reason_Disease"], [18, 20, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"], [33, 34, "Test_items", 38, 42, "Disease", "Test_items_Disease"], [38, 40, "Anatomy", 38, 42, "Disease", "Anatomy_Disease"], [67, 69, "Anatomy", 67, 71, "Disease", "Anatomy_Disease"]]}
{"idx": 3629, "sentence": "DPP-4抑制剂超药物说明书用法专家共识", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 3630, "sentence": "中国20岁以上人口的2型糖尿病的患病率已经达到9.7%。传统降糖药物在2型糖尿病的防治中发挥了重要作用，但仍存在低血糖、体重增加、增加心血管风险以及药物继发失效使血糖控制进行性恶化等局限性。二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂是近年研发的口服降糖药，因作用机制独特、疗效确定、低血糖发生率少、对体重中性作用或轻度降低、心血管安全性良好等特点受到普遍关注，临床应用越来越广泛。", "ner": [[10, 14, "Disease"], [35, 39, "Disease"], [56, 58, "ADE"], [60, 63, "ADE"], [65, 71, "ADE"], [74, 79, "ADE"], [81, 82, "Test_items"], [95, 134, "Drug"], [160, 162, "ADE"], [141, 142, "Method"]], "rel": [[81, 82, "Test_items", 35, 39, "Disease", "Test_items_Disease"], [141, 142, "Method", 95, 134, "Drug", "Method_Drug"], [160, 162, "ADE", 95, 134, "Drug", "ADE_Drug"]]}
{"idx": 3631, "sentence": "DPP-4抑制剂减少体内胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解而增加循环GLP-1浓度2~3倍，GLP-1通过血糖依赖性刺激胰岛β细胞分泌胰岛素，抑制胰岛α细胞分泌胰高血糖素而发挥降低血糖的作用。", "ner": [[0, 7, "Drug"], [115, 116, "Test_items"]], "rel": []}
{"idx": 3632, "sentence": "国内批准临床应用的DPP-4抑制剂有5种，包括西格列汀(sitagliptin)、沙格列汀(saxagliptin)、维格列汀(vildagliptin)、阿格列汀(alogliptin)、利格列汀(linagliptin)。", "ner": [[9, 16, "Drug"], [23, 39, "Drug"], [41, 57, "Drug"], [59, 76, "Drug"], [78, 93, "Drug"], [95, 111, "Drug"]], "rel": []}
{"idx": 3633, "sentence": "虽然不同的DPP-4抑制剂在结构和药物代谢动力学上存在明显差异，但是所有DPP-4抑制剂均显示出相近的降糖效果(降低HbA1c0.5%~1.0%)和良好的安全性。", "ner": [[5, 12, "Drug"], [36, 43, "Drug"], [58, 62, "Test_items"], [63, 71, "Test_Value"]], "rel": []}
{"idx": 3634, "sentence": "由于各种药物说明书批准的适应证存在一定差异，而且中国大多数医生目前还缺乏实际应用经验，所以为了更好、更合理地应用这类药物，消除可能的误解，造福糖尿病患者，本共识基于国内外药物说明书、临床研究证据、以及国内外2型糖尿病防治指南，对可能出现的超药物说明书用药(药品说明书之外用法)提供参考意见。", "ner": [[71, 73, "Disease"], [103, 107, "Disease"]], "rel": []}
{"idx": 3635, "sentence": "超药物说明书用法，又称为“药品未注册用法”或“药品说明书之外的用法”(unlabeled uses，off-label uses，out-of label usage or outside of labeling）是指药品使用的适应证、给药方法、剂量或给药途径不在药品监督管理部门批准的说明书之内的用法。", "ner": [], "rel": []}
{"idx": 3636, "sentence": "美国等国家的药品管理机构同意在一定条件下，允许医师进行超药物说明书用法。", "ner": [], "rel": []}
{"idx": 3637, "sentence": "我国对此没有相应的管理法规。", "ner": [], "rel": []}
{"idx": 3638, "sentence": "存在超药物说明书用法的主要原因是药品说明书用法往往滞后于科学知识和文献的更新和发展。", "ner": [], "rel": []}
{"idx": 3639, "sentence": "药物说明书依然是临床安全使用药物的基础，药物说明书用法不是“试验性用法(experimental uses)或试验性用药”，是建立在充分循证证据和权威指南推荐的基础上，完全是为了患者的利益使用。", "ner": [], "rel": []}
{"idx": 3640, "sentence": "在具体使用前应该获得所在执业单位的药事管理委员会和伦理委员会批准备案，并签署患者知情同意书。", "ner": [], "rel": []}
{"idx": 3641, "sentence": "DPP-4抑制剂的适应证和超药物说明书用法", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 3642, "sentence": "中国批准的各种DPP-4抑制剂的说明书的适应证为2型糖尿病患者饮食运动不能控制血糖的单药、联合二甲双胍以及联合二甲双胍和磺脲类药物治疗。", "ner": [[7, 14, "Drug"], [39, 40, "Test_items"], [55, 58, "Drug"], [47, 50, "Drug"], [24, 28, "Disease"], [60, 64, "Drug"], [31, 34, "Treatment"]], "rel": [[7, 14, "Drug", 24, 28, "Disease", "Drug_Disease"], [39, 40, "Test_items", 24, 28, "Disease", "Test_items_Disease"], [55, 58, "Drug", 24, 28, "Disease", "Drug_Disease"], [47, 50, "Drug", 24, 28, "Disease", "Drug_Disease"], [31, 34, "Treatment", 24, 28, "Disease", "Treatment_Disease"], [60, 64, "Drug", 24, 28, "Disease", "Drug_Disease"]]}
{"idx": 3643, "sentence": "大多为单药或与二甲双胍联用，只有利格列汀与二甲双胍和磺脲类药物联合使用。", "ner": [[16, 19, "Drug"], [21, 24, "Drug"], [26, 30, "Drug"], [7, 10, "Drug"]], "rel": []}
{"idx": 3644, "sentence": "西格列汀的适应证单药治疗：本品配合饮食控制和运动，用于改善2型糖尿病患者的血糖控制；联合治疗：当单独使用盐酸二甲双胍血糖控制不佳时，可与盐酸二甲双胍联合使用，在饮食和运动基础上改善2型糖尿病患者的血糖控制。", "ner": [[0, 3, "Drug"], [17, 20, "Treatment"], [22, 23, "Treatment"], [29, 33, "Disease"], [37, 38, "Test_items"], [52, 57, "Drug"], [58, 59, "Test_items"], [60, 63, "Test_Value"], [68, 73, "Drug"], [80, 81, "Treatment"], [83, 84, "Treatment"], [90, 94, "Disease"], [98, 99, "Test_items"]], "rel": [[0, 3, "Drug", 29, 33, "Disease", "Drug_Disease"], [0, 3, "Drug", 90, 94, "Disease", "Drug_Disease"], [17, 20, "Treatment", 29, 33, "Disease", "Treatment_Disease"], [22, 23, "Treatment", 29, 33, "Disease", "Treatment_Disease"], [37, 38, "Test_items", 29, 33, "Disease", "Test_items_Disease"], [68, 73, "Drug", 90, 94, "Disease", "Drug_Disease"], [80, 81, "Treatment", 90, 94, "Disease", "Treatment_Disease"], [83, 84, "Treatment", 90, 94, "Disease", "Treatment_Disease"], [98, 99, "Test_items", 90, 94, "Disease", "Test_items_Disease"]]}
{"idx": 3645, "sentence": "维格列汀的适应证适用于治疗2型糖尿病。单药治疗：本品配合饮食控制和运动，用于改善2型糖尿病患者的血糖控制；当二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，本品可与二甲双胍联合使用。", "ner": [[0, 3, "Drug"], [13, 17, "Disease"], [40, 44, "Disease"], [54, 57, "Drug"], [48, 49, "Test_items"], [79, 80, "Test_items"], [87, 90, "Drug"], [28, 31, "Treatment"], [33, 34, "Treatment"]], "rel": [[0, 3, "Drug", 13, 17, "Disease", "Drug_Disease"], [33, 34, "Treatment", 40, 44, "Disease", "Treatment_Disease"], [28, 31, "Treatment", 40, 44, "Disease", "Treatment_Disease"], [48, 49, "Test_items", 40, 44, "Disease", "Test_items_Disease"]]}
{"idx": 3646, "sentence": "沙格列汀的适应证用于2型糖尿病。单药治疗：可作为单药治疗，在饮食和运动基础上改善血糖控制；联合治疗：当单独使用盐酸二甲双胍血糖控制不佳时，可与盐酸二甲双胍联合使用，在饮食和运动基础上改善血糖控制。", "ner": [[83, 84, "Treatment"], [86, 87, "Treatment"], [93, 94, "Test_items"], [71, 76, "Drug"], [40, 41, "Test_items"], [55, 60, "Drug"], [61, 62, "Test_items"], [63, 66, "Test_Value"], [33, 34, "Treatment"], [30, 31, "Treatment"], [40, 41, "Test_items"], [10, 14, "Disease"], [0, 3, "Drug"]], "rel": [[0, 3, "Drug", 10, 14, "Disease", "Drug_Disease"]]}
{"idx": 3647, "sentence": "利格列汀的适应证利格列汀与二甲双胍和磺脲类药物联合使用，配合饮食控制和运动，可用于成年2型糖尿病患者的血糖控制。", "ner": [[0, 3, "Drug"], [8, 11, "Drug"], [13, 16, "Drug"], [18, 22, "Drug"], [30, 33, "Treatment"], [35, 36, "Treatment"], [43, 47, "Disease"], [51, 52, "Test_items"]], "rel": [[0, 3, "Drug", 43, 47, "Disease", "Drug_Disease"], [8, 11, "Drug", 43, 47, "Disease", "Drug_Disease"], [13, 16, "Drug", 43, 47, "Disease", "Drug_Disease"], [18, 22, "Drug", 43, 47, "Disease", "Drug_Disease"], [30, 33, "Treatment", 43, 47, "Disease", "Treatment_Disease"], [35, 36, "Treatment", 43, 47, "Disease", "Treatment_Disease"], [51, 52, "Test_items", 43, 47, "Disease", "Test_items_Disease"]]}
{"idx": 3648, "sentence": "阿格列汀的适应证适用于治疗2型糖尿病：单药或联合二甲双胍用于成人2型糖尿病患者的血糖控制。", "ner": [[0, 3, "Drug"], [13, 17, "Disease"], [24, 27, "Drug"], [32, 36, "Disease"], [40, 41, "Test_items"]], "rel": [[0, 3, "Drug", 13, 17, "Disease", "Drug_Disease"], [24, 27, "Drug", 32, 36, "Disease", "Drug_Disease"], [40, 41, "Test_items", 32, 36, "Disease", "Test_items_Disease"]]}
{"idx": 3649, "sentence": "超出说明书范围，如与其他2种及以上的不同类别降糖药物联合使用；或在1型糖尿病患者中使用即属超药物说明书使用。", "ner": [[33, 37, "Disease"]], "rel": []}
{"idx": 3650, "sentence": "除维格列汀未在美国上市外，美国FDA批准上述药物的适应证均为饮食运动不能控制血糖的2型糖尿病患者，药物说明书提供单药以及多种联合治疗方案的详细资料。", "ner": [[1, 4, "Drug"], [30, 33, "Treatment"], [38, 39, "Test_items"], [41, 45, "Disease"]], "rel": [[1, 4, "Drug", 41, 45, "Disease", "Drug_Disease"], [30, 33, "Treatment", 41, 45, "Disease", "Treatment_Disease"], [38, 39, "Test_items", 41, 45, "Disease", "Test_items_Disease"]]}
{"idx": 3651, "sentence": "我国药物说明书的形式与欧盟更接近，需要分别批准单药或与其他降糖药的不同联合，详见表1。", "ner": [], "rel": []}
{"idx": 3652, "sentence": "诊断早期或病情较轻的2型糖尿病患者可能1种降糖药即可控制血糖，但由于2型糖尿病是进展性疾病，随病程延长需要2种以上不同种类的降糖药联用。", "ner": [[28, 29, "Test_items"], [10, 14, "Disease"], [34, 38, "Disease"]], "rel": [[28, 29, "Test_items", 10, 14, "Disease", "Test_items_Disease"]]}
{"idx": 3653, "sentence": "如果药物说明书只是批准单药或与部分药物联用，而改变说明书适应证需要严格的审批，并花费大量时间和费用，往往滞后于严格的临床研究数据；如果局限于说明书可能使其临床应用受到严重限制。", "ner": [], "rel": []}
{"idx": 3654, "sentence": "故国内外的2型糖尿病防治指南均按药物的作用机制和循证证据等进行推荐临床应用。", "ner": [], "rel": []}
{"idx": 3655, "sentence": "DPP-4抑制剂在国内外指南中的地位", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 3656, "sentence": "2011年国际糖尿病联盟(IDF)的2型糖尿病治疗路径、2013年中华医学会糖尿病分会的中国2型糖尿病防治指南、美国糖尿病协会(ADA)/欧洲糖尿病研究协会(EASD)和美国临床内分泌协会(AACE)制定的2型糖尿病治疗流程均认可DPP-4抑制剂可与多种传统降糖药物联合或单药治疗，即在二甲双胍或其他药物联合治疗不能达标加用(联用)，或不能耐受二甲双胍时选择(单药)。IDF指南和中国2型糖尿病防治指南建议在选择二甲双胍、磺脲类药物、α-糖苷酶抑制剂控制不佳后加用；AACE 治疗流程和ADA/EASD专家共识认为二甲双胍治疗不能达标或不能耐受时即可选用，也可与多种降糖药联合使用，包括胰岛素。", "ner": [[7, 9, "Disease"], [18, 22, "Disease"], [38, 40, "Disease"], [46, 50, "Disease"], [58, 60, "Disease"], [71, 73, "Disease"], [103, 107, "Disease"], [115, 122, "Drug"], [143, 146, "Drug"], [172, 175, "Drug"], [192, 196, "Disease"], [206, 209, "Drug"], [211, 215, "Drug"], [217, 224, "Drug"], [257, 260, "Drug"], [293, 295, "Drug"]], "rel": [[115, 122, "Drug", 103, 107, "Disease", "Drug_Disease"], [143, 146, "Drug", 103, 107, "Disease", "Drug_Disease"], [172, 175, "Drug", 103, 107, "Disease", "Drug_Disease"], [206, 209, "Drug", 192, 196, "Disease", "Drug_Disease"], [211, 215, "Drug", 192, 196, "Disease", "Drug_Disease"], [217, 224, "Drug", 192, 196, "Disease", "Drug_Disease"], [257, 260, "Drug", 192, 196, "Disease", "Drug_Disease"], [293, 295, "Drug", 192, 196, "Disease", "Drug_Disease"]]}
{"idx": 3657, "sentence": "指南均未推荐在1型糖尿病患者中使用。", "ner": [[7, 11, "Disease"]], "rel": []}
{"idx": 3658, "sentence": "DPP-4抑制剂的安全性及有效性的临床研究证据", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 3659, "sentence": "1. 单药治疗", "ner": [], "rel": []}
{"idx": 3660, "sentence": "目前在中国，西格列汀、维格列汀、阿格列汀和沙格列汀已获批了单药治疗的适应证，可用于饮食和运动治疗基础上不能良好控制血糖的2型糖尿病患者。国外研究也显示利格列汀对绝大多数2型糖尿病患者有明显降低血糖的效果。", "ner": [[6, 9, "Drug"], [11, 14, "Drug"], [16, 19, "Drug"], [21, 24, "Drug"], [41, 42, "Treatment"], [44, 47, "Treatment"], [57, 58, "Test_items"], [60, 64, "Disease"], [75, 78, "Drug"], [84, 88, "Disease"], [96, 97, "Test_items"]], "rel": [[6, 9, "Drug", 60, 64, "Disease", "Drug_Disease"], [11, 14, "Drug", 60, 64, "Disease", "Drug_Disease"], [16, 19, "Drug", 60, 64, "Disease", "Drug_Disease"], [21, 24, "Drug", 60, 64, "Disease", "Drug_Disease"], [41, 42, "Treatment", 60, 64, "Disease", "Treatment_Disease"], [44, 47, "Treatment", 60, 64, "Disease", "Treatment_Disease"], [57, 58, "Test_items", 60, 64, "Disease", "Test_items_Disease"], [75, 78, "Drug", 84, 88, "Disease", "Drug_Disease"], [96, 97, "Test_items", 84, 88, "Disease", "Test_items_Disease"]]}
{"idx": 3661, "sentence": "多项安慰剂对照、双盲、为期24周以上的研究显示DPP-4抑制剂降低HbA1c0.5%~1.0%，均显著优于对照组。", "ner": [[23, 30, "Drug"], [33, 37, "Test_items"], [38, 46, "Test_Value"]], "rel": []}
{"idx": 3662, "sentence": "由于不同的研究所选择的入组人群、基线HbA1c水平和研究方案的不同，不同DPP-4抑制剂在降低HbA1c方面可能存在微小差异。", "ner": [[18, 22, "Test_items"], [36, 43, "Drug"], [47, 51, "Test_items"]], "rel": []}
{"idx": 3663, "sentence": "对于那些基线HbA1c较高的患者，DPP-4抑制剂的降糖幅度较大。", "ner": [[6, 10, "Test_items"], [11, 12, "Test_Value"], [17, 24, "Drug"]], "rel": []}
{"idx": 3664, "sentence": "目前认为DPP-4抑制剂中并无某一特定药物在降糖方面比其他药物更具优势。", "ner": [[4, 11, "Drug"]], "rel": []}
{"idx": 3665, "sentence": "2. 联合应用", "ner": [], "rel": []}
{"idx": 3666, "sentence": "2.1 DPP-4抑制剂联合二甲双胍大多数DPP-4抑制剂最常见的联合用药指征是用于二甲双胍不能取得良好血糖控制的患者，主要原因在于二甲双胍是国内外指南推荐治疗2型糖尿病的一线用药。此外，这2种药物联合使用可优势互补，针对了2型糖尿病最重要的病理生理基础，即DPP-4抑制剂改善β细胞功能，二甲双胍改善胰岛素抵抗。众多的研究已经证实这种联治疗的有效性和安全性。DPP-4抑制剂联合二甲双胍可以进一步降低患者HbA1c0.5%~1.1%。DPP-4抑制剂联合二甲双胍的低血糖发生率与安慰剂组相似，胃肠道反应与二甲双胍单药治疗相比无显著差异。目在中国获批与二甲双胍联合应用的DPP-4抑制剂有沙格列汀、维格列汀、阿格列汀、西格列汀。利格列汀获得了FDA和EMA的批准用于与二甲双胍的联合治疗。目前国外已有DPP-4抑制剂与二甲双胍的复合制剂，可直接用于需要二者联合使用的患者。对于二甲双胍单药治疗不满意的患者联合DPP-4抑制剂的低血糖发生率明显低于联合磺脲类药物，且具有体重控制方面的优势。", "ner": [[4, 11, "Drug"], [14, 17, "Drug"], [21, 28, "Drug"], [42, 45, "Drug"], [52, 53, "Test_items"], [66, 69, "Drug"], [80, 84, "Disease"], [404, 411, "Drug"], [388, 391, "Drug"], [425, 429, "Drug"], [413, 415, "ADE"], [112, 116, "Disease"], [129, 136, "Drug"], [145, 148, "Drug"], [180, 187, "Drug"], [190, 193, "Drug"], [203, 207, "Test_items"], [208, 216, "Test_Value"], [218, 225, "Drug"], [228, 231, "Drug"], [233, 235, "ADE"], [247, 251, "ADE"], [253, 256, "Drug"], [276, 279, "Drug"], [285, 292, "Drug"], [294, 297, "Drug"], [299, 302, "Drug"], [304, 307, "Drug"], [309, 312, "Drug"], [314, 317, "Drug"], [350, 357, "Drug"], [359, 362, "Drug"], [334, 337, "Drug"], [151, 155, "Pathogenesis"]], "rel": [[4, 11, "Drug", 80, 84, "Disease", "Drug_Disease"], [14, 17, "Drug", 80, 84, "Disease", "Drug_Disease"], [21, 28, "Drug", 80, 84, "Disease", "Drug_Disease"], [42, 45, "Drug", 80, 84, "Disease", "Drug_Disease"], [52, 53, "Test_items", 80, 84, "Disease", "Test_items_Disease"], [66, 69, "Drug", 80, 84, "Disease", "Drug_Disease"], [413, 415, "ADE", 404, 411, "Drug", "ADE_Drug"], [413, 415, "ADE", 388, 391, "Drug", "ADE_Drug"], [413, 415, "ADE", 425, 429, "Drug", "ADE_Drug"], [129, 136, "Drug", 112, 116, "Disease", "Drug_Disease"], [145, 148, "Drug", 112, 116, "Disease", "Drug_Disease"], [151, 155, "Pathogenesis", 112, 116, "Disease", "Pathogenesis_Disease"], [233, 235, "ADE", 218, 225, "Drug", "ADE_Drug"], [247, 251, "ADE", 218, 225, "Drug", "ADE_Drug"], [233, 235, "ADE", 228, 231, "Drug", "ADE_Drug"], [247, 251, "ADE", 228, 231, "Drug", "ADE_Drug"], [247, 251, "ADE", 253, 256, "Drug", "ADE_Drug"]]}
{"idx": 3667, "sentence": "2.2 DPP-4抑制剂联合噻唑烷二酮类噻唑烷二酮类是选择性PPAR-γ(peroxisome proliferator-activated receptor-gamma)受体激动剂，主要通过增加糖尿病患者外周组织对胰岛素的敏感性来改善胰岛素抵抗。DPP-4抑制剂与噻唑烷二酮类药物联合直接针对2型糖尿病最重要的两个发病因素，部分基础研究显示两者联合治疗能够增加胰岛β细胞再生，联合治疗可能会提供更好和更持久的血糖控制和β细胞功能的保护。研究显示不同的DPP-4抑制剂与TZD类药物的联用均可降低空腹和餐后血糖，24周联合治疗HbA1c水平与对照组相比可降低约1.0%，HbA1c达标率更高。FDA已经批准了西格列汀、利格列汀、阿格列汀以及沙格列汀与TZD类药物联合应用，但是目前中国尚未批准任何DPP-4抑制剂与TZD类药物的联用。对于二甲双胍不能耐受或严重胰岛素抵抗的患者，TZD和DPP-4抑制剂的联合治疗也是一种可能的选择。", "ner": [[4, 11, "Drug"], [14, 19, "Drug"], [20, 25, "Drug"], [27, 90, "Drug"], [98, 100, "Disease"], [118, 122, "Pathogenesis"], [124, 131, "Drug"], [133, 140, "Drug"], [147, 151, "Disease"], [205, 206, "Test_items"], [226, 233, "Drug"], [235, 240, "Drug"], [248, 254, "Test_items"], [263, 267, "Test_items"], [285, 289, "Test_items"], [290, 294, "Test_Value"], [277, 283, "Test_Value"], [304, 307, "Drug"], [309, 312, "Drug"], [314, 317, "Drug"], [320, 323, "Drug"], [325, 330, "Drug"], [348, 355, "Drug"], [357, 362, "Drug"], [369, 372, "Drug"], [373, 376, "ADE"], [378, 379, "Level"], [380, 384, "Disease"], [389, 391, "Drug"], [393, 400, "Drug"]], "rel": [[4, 11, "Drug", 98, 100, "Disease", "Drug_Disease"], [14, 19, "Drug", 98, 100, "Disease", "Drug_Disease"], [20, 25, "Drug", 98, 100, "Disease", "Drug_Disease"], [27, 90, "Drug", 98, 100, "Disease", "Drug_Disease"], [118, 122, "Pathogenesis", 98, 100, "Disease", "Pathogenesis_Disease"], [124, 131, "Drug", 147, 151, "Disease", "Drug_Disease"], [133, 140, "Drug", 147, 151, "Disease", "Drug_Disease"], [205, 206, "Test_items", 147, 151, "Disease", "Test_items_Disease"], [369, 372, "Drug", 380, 384, "Disease", "Drug_Disease"], [373, 376, "ADE", 369, 372, "Drug", "ADE_Drug"], [389, 391, "Drug", 380, 384, "Disease", "Drug_Disease"], [393, 400, "Drug", 380, 384, "Disease", "Drug_Disease"]]}
{"idx": 3668, "sentence": "国内外指南的治疗流程也推荐两者合用。", "ner": [], "rel": []}
{"idx": 3669, "sentence": "2.3 DPP-4抑制剂与磺脲类药物的联合应用磺脲类药物是我国使用最广泛的口服降糖药物之一，通过刺激内源性胰岛素分泌从而降低血糖。许多患者需要在磺脲类药物治疗效果不满意或药物继发失效的基础上添加其他口服药物。众多临床研究均显示在使用磺脲类单药治疗血糖控制不良的患者中加用DPP-4抑制剂可进一步改善血糖，提高HbA1c的达标率。但需要注意的是DPP-4抑制剂自身单独使用并不引起低血糖，但与磺脲类药物联合使用时发生低血糖的风险增加。FDA已经批准西格列汀、利格列汀和沙格列汀与磺脲类药联合使用，但是上述药物尚未在中国申请与磺脲类的联合使用。从血糖控制以及低血糖风险等综合因素来看，目前的临床证据支持DPP-4抑制剂与磺脲类药物联用，指南也推荐二甲双胍不能耐受时两者的联用。", "ner": [[4, 11, "Drug"], [13, 17, "Drug"], [23, 27, "Drug"], [37, 38, "Method"], [62, 63, "Test_items"], [72, 76, "Drug"], [99, 100, "Method"], [116, 118, "Drug"], [123, 124, "Test_items"], [125, 128, "Test_Value"], [135, 142, "Drug"], [149, 150, "Test_items"], [154, 158, "Test_items"], [171, 178, "Drug"], [189, 191, "ADE"], [195, 199, "Drug"], [207, 209, "ADE"], [223, 226, "Drug"], [228, 231, "Drug"], [233, 236, "Drug"], [238, 241, "Drug"], [261, 263, "Drug"], [271, 272, "Test_items"], [277, 279, "ADE"], [299, 306, "Drug"], [308, 312, "Drug"], [321, 324, "Drug"], [325, 328, "ADE"]], "rel": [[207, 209, "ADE", 171, 178, "Drug", "ADE_Drug"], [207, 209, "ADE", 195, 199, "Drug", "ADE_Drug"], [325, 328, "ADE", 321, 324, "Drug", "ADE_Drug"]]}
{"idx": 3670, "sentence": "2.4 DPP-4抑制剂与胰岛素的联合应用DPP-4抑制剂另一个潜在的应用方法是与胰岛素联合，这种联合可以改善血糖控制，减少血糖波动而不增加低血糖的发生，并且可减少胰岛素的用量。在使用稳定剂量胰岛素治疗的患者中加用DPP-4抑制剂可进一步降低血糖，但不增加低血糖发生风险和体重，甚至降低低血糖发生率和严重程度。目前西格列汀、利格列汀和格列汀在美国FDA和欧洲EMA均获批了与胰岛素的联用适应证。中国尚未批准上述药物与胰岛素的联用。国内外指南推荐在口服药疗效不佳时可联合胰素使用。", "ner": [[4, 11, "Drug"], [13, 15, "Drug"], [21, 28, "Drug"], [55, 56, "Test_items"], [62, 63, "Test_items"], [70, 72, "ADE"], [82, 84, "Drug"], [96, 98, "Drug"], [107, 114, "Drug"], [121, 122, "Test_items"], [128, 130, "ADE"], [143, 145, "ADE"], [157, 160, "Drug"], [162, 165, "Drug"], [167, 169, "Drug"], [187, 189, "Drug"], [208, 210, "Drug"], [234, 235, "Drug"], [223, 224, "Method"], [41, 43, "Drug"]], "rel": [[70, 72, "ADE", 21, 28, "Drug", "ADE_Drug"], [70, 72, "ADE", 41, 43, "Drug", "ADE_Drug"], [128, 130, "ADE", 96, 98, "Drug", "ADE_Drug"], [128, 130, "ADE", 107, 114, "Drug", "ADE_Drug"], [223, 224, "Method", 234, 235, "Drug", "Method_Drug"]]}
{"idx": 3671, "sentence": "2.5 DPP-4抑制剂多药联合应用由于胰岛β细胞功能逐年减退，导致血糖难以持续达标，常常需要2种以上的药物联合使用以增加疗效。", "ner": [[4, 11, "Drug"], [34, 35, "Test_items"], [36, 41, "Test_Value"]], "rel": []}
{"idx": 3672, "sentence": "既往药物相互作用的研究数据未显示2种以上降糖药物联用时，在进一步降糖的同时会出现特殊的安全性问题。", "ner": [], "rel": []}
{"idx": 3673, "sentence": "有研究显示2种药物联合使用基础上加用DPP-4抑制剂可获得更好的血糖控制，而药物相关的不良反应与对照组相当。", "ner": [[18, 25, "Drug"], [32, 33, "Test_items"]], "rel": []}
{"idx": 3674, "sentence": "由于大部分DPP-4抑制剂通过肾脏排泄(利格列汀由胆汁及肠道排出)，药代动力学数据提示药物和药物之间干扰作用较小，联合应用的时候不需要调整剂量。", "ner": [[5, 12, "Drug"], [20, 23, "Drug"]], "rel": []}
{"idx": 3675, "sentence": "总之，现有的临床证据提示DPP-4抑制剂与其他多种降糖药物的多重联合有进一步疗效和安全性良好。", "ner": [[12, 19, "Drug"]], "rel": []}
{"idx": 3676, "sentence": "利格列汀、西格列汀和沙格列汀在FDA和EMA均获得了与胰岛素和二甲双胍的联合使用适应证。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [10, 13, "Drug"], [31, 34, "Drug"], [27, 29, "Drug"]], "rel": []}
{"idx": 3677, "sentence": "在中国利格列汀获得和二甲双胍与磺脲类药物联合治疗的适应证。", "ner": [[3, 6, "Drug"], [10, 13, "Drug"], [15, 19, "Drug"]], "rel": []}
{"idx": 3678, "sentence": "指南也推荐必要时3种药物联用。", "ner": [], "rel": []}
{"idx": 3679, "sentence": "DPP-4抑制剂的安全性", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 3680, "sentence": "DPP-4抑制剂是一类耐受性良好的降糖药物，单独使用基本无低血糖风险。临床试验显示其不良事件总体水平与安慰剂相当。通常DPP-4抑制剂增加内源性GLP-1 2~3倍，胃肠道反应也较少。既往曾有该类药物在临床使用后发生胰腺炎的病例报道，但大样本的回顾性分析以及新近发布的大型前瞻性研究结果均未显示DPP-4抑制剂增加胰腺炎发生风险。", "ner": [[0, 7, "Drug"], [29, 31, "ADE"], [59, 66, "Drug"], [83, 87, "ADE"], [108, 110, "Disease"], [108, 109, "Anatomy"], [147, 154, "Drug"], [157, 159, "Disease"], [157, 158, "Anatomy"]], "rel": [[83, 87, "ADE", 59, 66, "Drug", "ADE_Drug"], [108, 109, "Anatomy", 108, 110, "Disease", "Anatomy_Disease"], [157, 158, "Anatomy", 157, 159, "Disease", "Anatomy_Disease"]]}
{"idx": 3681, "sentence": "虽然DPP-4酶也存在于T淋巴细胞膜上(CD26)，但尚无证据表明DPP-4抑制剂会导致人类免疫功能异常。", "ner": [[33, 40, "Drug"]], "rel": []}
{"idx": 3682, "sentence": "但需要指出，由于DPP-4抑制剂在临床的使用时间较短，需要更多的上市后研究来发现其潜在的不良反应。", "ner": [[8, 15, "Drug"]], "rel": []}
{"idx": 3683, "sentence": "DPP-4抑制剂在特殊人群中的应用", "ner": [[0, 7, "Drug"]], "rel": []}
{"idx": 3684, "sentence": "1. 1 型糖尿病患者", "ner": [[3, 8, "Disease"]], "rel": []}
{"idx": 3685, "sentence": "GLP-1除葡萄糖依赖性刺激胰岛素分泌、抑制胰高血糖素分泌外，还具有延缓胃肠排空以及保护β细胞的作用。胰高糖素分泌相对增多也是1型糖尿病血糖升高的主要机制之一。虽然有研究提示1型糖尿病患者使用DPP-4抑制剂可降低患者HbA1c水平，并减少胰岛素的用量，但现有数据并没有显示DPP-4抑制剂具有延缓1型糖尿病进展的作用。", "ner": [[51, 60, "Pathogenesis"], [63, 67, "Disease"], [68, 69, "Test_items"], [70, 71, "Test_Value"], [87, 91, "Disease"], [96, 103, "Drug"], [109, 113, "Test_items"], [120, 122, "Drug"], [137, 144, "Drug"], [149, 153, "Disease"]], "rel": [[51, 60, "Pathogenesis", 63, 67, "Disease", "Pathogenesis_Disease"], [68, 69, "Test_items", 63, 67, "Disease", "Test_items_Disease"], [96, 103, "Drug", 87, 91, "Disease", "Drug_Disease"], [120, 122, "Drug", 87, 91, "Disease", "Drug_Disease"], [109, 113, "Test_items", 87, 91, "Disease", "Test_items_Disease"], [137, 144, "Drug", 149, 153, "Disease", "Drug_Disease"]]}
{"idx": 3686, "sentence": "因此，DPP-4抑制剂是否能够用于1型糖尿病的治疗尚需要更多的临床研究证实，也没有相应的适应证，国内外指南也未推荐使用。", "ner": [[3, 10, "Drug"], [17, 21, "Disease"]], "rel": [[3, 10, "Drug", 17, 21, "Disease", "Drug_Disease"]]}
{"idx": 3687, "sentence": "本共识不主张在临床使用DPP-4抑制剂治疗1型糖尿病患者。", "ner": [[11, 18, "Drug"], [21, 25, "Disease"]], "rel": [[11, 18, "Drug", 21, 25, "Disease", "Drug_Disease"]]}
{"idx": 3688, "sentence": "2.2 型糖尿病合并肾功能不全患者", "ner": [[10, 14, "Disease"], [10, 10, "Anatomy"], [2, 7, "Disease"]], "rel": [[10, 10, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"]]}
{"idx": 3689, "sentence": "大部分DPP-4抑制通过肾脏排泄，因此DPP-4抑制剂的暴露浓度会随着肾功能下降而相应的增加。药物说明书和国内外指南认为西格列汀、沙格列汀、维格列汀以及阿格列汀在轻度肾功能不全的患者中不需要调整剂量，但对于中到重度肾功能不全的患者需要减少剂量，利格列汀不需要调整剂量。", "ner": [[3, 9, "Drug"], [19, 26, "Drug"], [70, 73, "Drug"], [76, 79, "Drug"], [65, 68, "Drug"], [60, 63, "Drug"], [83, 87, "Disease"], [81, 82, "Level"], [83, 83, "Anatomy"], [107, 111, "Disease"], [103, 106, "Level"], [107, 107, "Anatomy"], [122, 125, "Drug"]], "rel": [[70, 73, "Drug", 83, 87, "Disease", "Drug_Disease"], [76, 79, "Drug", 83, 87, "Disease", "Drug_Disease"], [65, 68, "Drug", 83, 87, "Disease", "Drug_Disease"], [60, 63, "Drug", 83, 87, "Disease", "Drug_Disease"], [83, 83, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [107, 107, "Anatomy", 107, 111, "Disease", "Anatomy_Disease"], [122, 125, "Drug", 107, 111, "Disease", "Drug_Disease"]]}
{"idx": 3690, "sentence": " ", "ner": [], "rel": []}
{"idx": 3691, "sentence": "3.2型糖尿病合并肝功能不全患者", "ner": [[2, 6, "Disease"], [9, 13, "Disease"], [9, 9, "Anatomy"]], "rel": [[9, 9, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 3692, "sentence": "肝功能受损的患者对DPP-4抑制剂具有良好的耐受性。肝功能受损基本不会对DPP-4抑制剂产生有临床意义的药代动力学影响，对于大部分DPP-4抑制剂，在轻到中度肝功能受损的患者中均无需调整剂量。", "ner": [[0, 4, "Disease"], [0, 0, "Anatomy"], [9, 16, "Drug"], [26, 30, "Disease"], [26, 26, "Anatomy"], [36, 43, "Drug"], [65, 72, "Drug"], [75, 83, "Disease"], [79, 79, "Anatomy"]], "rel": [[0, 0, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [9, 16, "Drug", 0, 4, "Disease", "Drug_Disease"], [26, 26, "Anatomy", 26, 30, "Disease", "Anatomy_Disease"], [36, 43, "Drug", 26, 30, "Disease", "Drug_Disease"], [65, 72, "Drug", 75, 83, "Disease", "Drug_Disease"], [79, 79, "Anatomy", 75, 83, "Disease", "Anatomy_Disease"]]}
{"idx": 3693, "sentence": "但是在针对维格列汀的临床试验中发现肝酶的暂时性升高，因此对丙氨酸氨基转移酶和(下转第17页)(上接第13页)天门冬氨酸氨基转移酶高于正常上限3倍的患者不能使用。", "ner": [[5, 8, "Drug"], [17, 18, "Test"], [20, 24, "Test_Value"], [29, 36, "Test"], [54, 63, "Test"], [64, 71, "Test_Value"]], "rel": []}
{"idx": 3694, "sentence": "利格列汀在肝功能不全患者中无需调整剂量。", "ner": [[0, 3, "Drug"], [5, 9, "Disease"], [5, 5, "Anatomy"]], "rel": [[0, 3, "Drug", 5, 9, "Disease", "Drug_Disease"], [5, 5, "Anatomy", 5, 9, "Disease", "Anatomy_Disease"]]}
{"idx": 3695, "sentence": "相当，达标率相当。阿卡波糖降低餐后2h血糖的作用显著优于二甲双胍，其降低餐后胰岛素、减轻体重和降低三酰甘油的作用也优于二甲双胍。二甲双胍是新诊断2型糖尿病患者药物治疗的一线选择，但如果患者以餐后血糖升高为主要特点时，可考虑首选阿卡波糖。", "ner": [[9, 12, "Drug"], [15, 20, "Test_items"], [28, 31, "Drug"], [36, 40, "Test_items"], [49, 52, "Test_items"], [59, 62, "Drug"], [64, 67, "Drug"], [72, 76, "Disease"], [95, 98, "Test_items"], [99, 100, "Test_Value"], [113, 116, "Drug"]], "rel": [[64, 67, "Drug", 72, 76, "Disease", "Drug_Disease"], [95, 98, "Test_items", 72, 76, "Disease", "Test_items_Disease"], [113, 116, "Drug", 72, 76, "Disease", "Drug_Disease"]]}
{"idx": 3696, "sentence": "MARCH研究为比较阿卡波糖和二甲双胍的疗效和获益提供了非常有价值的信息，为指南的制定提供了循证医学证据参考，并跨出了历史性的一步。", "ner": [[10, 13, "Drug"], [15, 18, "Drug"]], "rel": []}
{"idx": 3697, "sentence": "MARCH研究以坚实的临床数据赢得了世界的尊重，在探索中国糖尿病治疗的长征路上迈出了坚实的一步。", "ner": [[29, 31, "Disease"]], "rel": []}
{"idx": 3698, "sentence": "4.老年2型糖尿病患者", "ner": [[4, 8, "Disease"]], "rel": []}
{"idx": 3699, "sentence": "老年糖尿病患者是高度差异化的人群，常常合并多种疾病，需要服用多种药物。低血糖以及整体安全性考虑在老年人群药物的选择中占有越来越重的地位。DPP-4抑制剂单独或联合使用低血糖风险较低，而且对体重的影响中性，适于在这类人群中使用。临床研究显示DPP-4抑制剂在老年人群中具有良好的有效性及安全性，甚至有荟萃分析提示DPP-4抑制剂在老年患者中的血糖控制效果优于年轻患者。总体而言，这类药物良好的安全性使其适合应用于老年2型糖尿病患者。", "ner": [[2, 4, "Disease"], [35, 37, "ADE"], [68, 75, "Drug"], [83, 85, "ADE"], [119, 126, "Drug"], [155, 162, "Drug"], [170, 171, "Test_items"], [207, 211, "Disease"]], "rel": [[83, 85, "ADE", 68, 75, "Drug", "ADE_Drug"]]}
{"idx": 3700, "sentence": "5.糖尿病合并心血管高危因素患者", "ner": [[2, 4, "Disease"], [7, 9, "Anatomy"]], "rel": [[7, 9, "Anatomy", 2, 4, "Disease", "Anatomy_Disease"]]}
{"idx": 3701, "sentence": "心血管并发症是导致糖尿病患者死亡的最主要原因，因此，在选择糖尿病治疗药物的过程中，药物的心血管安全性是非常重要的考量因素。临床研究的数据汇集分析(pooled analysis)显示，DPP-4抑制剂不增加心血管事件。最新发表的SAVOR-TIMI53研究和EXAMINE研究为评估沙格列汀和阿格列汀心血管安全性的多中心、随机、双盲、对照的前瞻性临床研究。研究纳入未接受过肠促胰素类降糖药物的2型糖尿病(HbA1c≥6.5%)合并心血管高危风险患者，随机分为安慰剂组和治疗组。研究结果显示主要复合终点事件(包括心血管疾病导致的死亡、非致死性心肌梗死、非致死性缺血性脑卒中)发生率与安慰剂组相似，进一步明确了沙格列汀和阿格列汀心血管安全性良好。其他关注DPP-4抑制剂心血管安全性的诸多大型前瞻性临床研究正在进行中，如西格列汀的TECOS研究、利格列汀的CAROLINA，CARMELINA研究等。但现有的研究数据显示DPP-4抑制剂不增加2型糖尿病患者的心血管风险。", "ner": [[0, 2, "Anatomy"], [9, 11, "Disease"], [29, 31, "Disease"], [92, 99, "Drug"], [103, 107, "Disease"], [103, 105, "Anatomy"], [141, 144, "Drug"], [146, 149, "Drug"], [186, 194, "Drug"], [196, 200, "Disease"], [202, 206, "Test_items"], [207, 211, "Test_Value"], [215, 217, "Anatomy"], [255, 259, "Disease"], [255, 257, "Anatomy"], [266, 273, "Disease"], [270, 271, "Anatomy"], [275, 284, "Disease"], [282, 282, "Anatomy"], [303, 306, "Drug"], [308, 311, "Drug"], [325, 332, "Drug"], [358, 361, "Drug"], [371, 374, "Drug"], [419, 423, "Disease"], [408, 415, "Drug"]], "rel": [[0, 2, "Anatomy", 9, 11, "Disease", "Anatomy_Disease"], [103, 105, "Anatomy", 103, 107, "Disease", "Anatomy_Disease"], [215, 217, "Anatomy", 196, 200, "Disease", "Anatomy_Disease"], [202, 206, "Test_items", 196, 200, "Disease", "Test_items_Disease"], [255, 257, "Anatomy", 255, 259, "Disease", "Anatomy_Disease"], [270, 271, "Anatomy", 266, 273, "Disease", "Anatomy_Disease"], [282, 282, "Anatomy", 275, 284, "Disease", "Anatomy_Disease"], [408, 415, "Drug", 419, 423, "Disease", "Drug_Disease"]]}
{"idx": 3702, "sentence": "总结 ", "ner": [], "rel": []}
{"idx": 3703, "sentence": "DPP-4抑制剂是一种新型的口服降糖药，疗效确切，安全性良好。中国FDA批准的适应证主要为单药或与二甲双胍联用，或与二甲双胍和磺脲类药物联用。临床应用应该以药物说明书为基础，但临床证据和国内外权威指南支持与多种传统降糖药双药以上的联合使用。暂不主张在1型糖尿病患者中应用DPP-4抑制剂，因为需要更充分的临床证据。", "ner": [[0, 7, "Drug"], [14, 15, "Method"], [49, 52, "Drug"], [58, 61, "Drug"], [63, 67, "Drug"], [125, 129, "Disease"], [135, 142, "Drug"]], "rel": [[14, 15, "Method", 0, 7, "Drug", "Method_Drug"], [135, 142, "Drug", 125, 129, "Disease", "Drug_Disease"]]}
{"idx": 3704, "sentence": "2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识(2015年更新版)", "ner": [[0, 4, "Disease"], [7, 11, "Disease"], [12, 13, "Method"], [9, 10, "Anatomy"]], "rel": [[9, 10, "Anatomy", 7, 11, "Disease", "Anatomy_Disease"]]}
{"idx": 3705, "sentence": "慢性肾脏病是严重威胁人类健康的常见慢性病，病因多种多样，由糖尿病所引发的慢性肾脏病称为糖尿病肾脏病变。2型糖尿病常合并慢性肾脏病，高血糖是慢性肾脏病发生和发展的主要原因之一.因此良好控制血糖至关重要。", "ner": [[0, 4, "Disease"], [29, 31, "Reason"], [36, 40, "Disease"], [38, 39, "Anatomy"], [43, 49, "Disease"], [46, 47, "Anatomy"], [51, 55, "Disease"], [59, 63, "Disease"], [61, 62, "Anatomy"], [65, 67, "Reason"], [69, 73, "Disease"], [71, 72, "Anatomy"], [93, 94, "Test_items"], [2, 3, "Anatomy"]], "rel": [[2, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [29, 31, "Reason", 43, 49, "Disease", "Reason_Disease"], [29, 31, "Reason", 36, 40, "Disease", "Reason_Disease"], [38, 39, "Anatomy", 36, 40, "Disease", "Anatomy_Disease"], [46, 47, "Anatomy", 43, 49, "Disease", "Anatomy_Disease"], [61, 62, "Anatomy", 59, 63, "Disease", "Anatomy_Disease"], [65, 67, "Reason", 69, 73, "Disease", "Reason_Disease"], [71, 72, "Anatomy", 69, 73, "Disease", "Anatomy_Disease"]]}
{"idx": 3706, "sentence": "口服降糖药是良好控制血糖最常用的降糖药物。", "ner": [[0, 1, "Method"], [10, 11, "Test_items"]], "rel": []}
{"idx": 3707, "sentence": "中国医师协会内分泌代谢科医师分会于2013年组织国内的内分泌科和肾内科领域专家,共同制定了“2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识”。", "ner": [[46, 50, "Disease"], [53, 57, "Disease"], [55, 56, "Anatomy"], [58, 59, "Method"]], "rel": [[55, 56, "Anatomy", 53, 57, "Disease", "Anatomy_Disease"]]}
{"idx": 3708, "sentence": "近年来2型糖尿病合并慢性肾脏病患者中口服降糖药治疗证据不断丰富,国内外糖尿病及肾脏病权威指南对2型糖尿病合并慢性肾脏病的口服降糖药应用规范也进行了相应更新,加之同时陆续有新的口服降糖药上市。", "ner": [[3, 7, "Disease"], [10, 14, "Disease"], [12, 13, "Anatomy"], [18, 19, "Method"], [35, 37, "Disease"], [39, 41, "Disease"], [47, 51, "Disease"], [54, 58, "Disease"], [56, 57, "Anatomy"], [60, 61, "Method"], [87, 88, "Method"], [39, 40, "Anatomy"]], "rel": [[12, 13, "Anatomy", 10, 14, "Disease", "Anatomy_Disease"], [39, 40, "Anatomy", 39, 41, "Disease", "Anatomy_Disease"], [56, 57, "Anatomy", 54, 58, "Disease", "Anatomy_Disease"]]}
{"idx": 3709, "sentence": "因此,本分会再次组织相关专家对原有共识进行了更新完善。", "ner": [], "rel": []}
{"idx": 3710, "sentence": "一、2型糖尿病合并慢性肾脏病的流行病学", "ner": [[2, 6, "Disease"], [9, 13, "Disease"], [11, 12, "Anatomy"]], "rel": [[11, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 3711, "sentence": "流行病学调查显示各地成年人慢性肾脏病的患病率存在差异,为9.0%~14.0%。近期中国慢性肾脏病流行病学调查显示，我国成年人中慢性肾脏病患病率为10.8%，据此估算18岁以上人群慢性肾脏病患者人数约1.195亿。一项中国健康与养老追踪调查研究表明，45岁以上中年及老年人群中，慢性肾脏病患病率达到11.5%，且城市患病率高于农村。另一方面，糖尿病的患病率也很高。2010年中国糖尿病流行病学调查显示成人糖尿病患病率已达11.6%，据此估计我国糖尿病患者人数约1.139亿。糖尿病与慢性肾脏病关系密切，糖尿病患者慢性肾脏病发生风险较非糖尿病患者增加2.6倍。在发达国家,糖尿病已是导致慢性肾脏病的主要病因,美国流行病学调查显示,年龄≥20岁的2型糖尿病患者有39.7%合并慢性肾脏病。而且在发展中国家,糖尿病正逐渐成为慢性肾脏病的主要致病原因。我国住院糖尿病患者的回顾性研究表明，52.25%的糖尿病患者合并肾脏并发症,上海市区30岁以上2型糖尿病患者慢性肾脏病患病率可达63.9%，提示糖尿病合并慢性肾脏病也是我国糖尿病研究和治疗领域面临的重大问题。", "ner": [[13, 17, "Disease"], [15, 16, "Anatomy"], [43, 47, "Disease"], [45, 46, "Anatomy"], [63, 67, "Disease"], [65, 66, "Anatomy"], [89, 93, "Disease"], [91, 92, "Anatomy"], [138, 142, "Disease"], [140, 141, "Anatomy"], [170, 172, "Disease"], [188, 190, "Disease"], [201, 203, "Disease"], [221, 223, "Disease"], [250, 252, "Disease"], [255, 259, "Disease"], [257, 258, "Anatomy"], [266, 268, "Disease"], [236, 238, "Disease"], [240, 244, "Disease"], [242, 243, "Anatomy"], [284, 286, "Reason"], [291, 295, "Disease"], [293, 294, "Anatomy"], [320, 324, "Disease"], [335, 339, "Disease"], [337, 338, "Anatomy"], [350, 352, "Reason"], [358, 362, "Disease"], [360, 361, "Anatomy"], [375, 377, "Disease"], [396, 398, "Disease"], [403, 404, "Anatomy"], [418, 422, "Disease"], [425, 429, "Disease"], [427, 428, "Anatomy"], [443, 445, "Disease"], [448, 452, "Disease"], [450, 451, "Anatomy"], [457, 459, "Disease"]], "rel": [[15, 16, "Anatomy", 13, 17, "Disease", "Anatomy_Disease"], [45, 46, "Anatomy", 43, 47, "Disease", "Anatomy_Disease"], [65, 66, "Anatomy", 63, 67, "Disease", "Anatomy_Disease"], [91, 92, "Anatomy", 89, 93, "Disease", "Anatomy_Disease"], [140, 141, "Anatomy", 138, 142, "Disease", "Anatomy_Disease"], [257, 258, "Anatomy", 255, 259, "Disease", "Anatomy_Disease"], [242, 243, "Anatomy", 240, 244, "Disease", "Anatomy_Disease"], [284, 286, "Reason", 291, 295, "Disease", "Reason_Disease"], [293, 294, "Anatomy", 291, 295, "Disease", "Anatomy_Disease"], [337, 338, "Anatomy", 335, 339, "Disease", "Anatomy_Disease"], [350, 352, "Reason", 358, 362, "Disease", "Reason_Disease"], [360, 361, "Anatomy", 358, 362, "Disease", "Anatomy_Disease"], [427, 428, "Anatomy", 425, 429, "Disease", "Anatomy_Disease"], [450, 451, "Anatomy", 448, 452, "Disease", "Anatomy_Disease"]]}
{"idx": 3712, "sentence": "二、2型糖尿病合并慢性肾脏病的诊断与分期", "ner": [[2, 6, "Disease"], [9, 13, "Disease"], [11, 12, "Anatomy"]], "rel": [[11, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 3713, "sentence": "慢性肾脏病是指肾脏结构或功能异常持续超过3个月,其诊断标准见表1。肾小球滤过率(GFR)是评价肾脏功能的重要指标之一，我国估算肾小球滤过率(eGFR)课题协作组改良简化肾脏病饮食改良 (modification of diet in renal disease，MDRD)方程，制定了适合我国慢性肾脏病患者的eGFR的评估公式。目前国内外大部分指南根据GFR来进行慢性肾脏病的肾功能分期(表2)。", "ner": [[0, 4, "Disease"], [2, 3, "Anatomy"], [7, 8, "Anatomy"], [33, 43, "Test_items"], [63, 74, "Test_items"], [84, 86, "Disease"], [84, 85, "Anatomy"], [146, 150, "Disease"], [148, 149, "Anatomy"], [154, 157, "Test_items"], [176, 178, "Test_items"], [182, 186, "Disease"], [184, 185, "Anatomy"]], "rel": [[2, 3, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [7, 8, "Anatomy", 0, 4, "Disease", "Anatomy_Disease"], [84, 85, "Anatomy", 84, 86, "Disease", "Anatomy_Disease"], [148, 149, "Anatomy", 146, 150, "Disease", "Anatomy_Disease"], [154, 157, "Test_items", 146, 150, "Disease", "Test_items_Disease"], [176, 178, "Test_items", 182, 186, "Disease", "Test_items_Disease"], [184, 185, "Anatomy", 182, 186, "Disease", "Anatomy_Disease"]]}
{"idx": 3714, "sentence": "三、2型糖尿病合并慢性肾脏病的口服降糖药选择", "ner": [[2, 6, "Disease"], [9, 13, "Disease"], [11, 12, "Anatomy"], [15, 16, "Method"]], "rel": [[11, 12, "Anatomy", 9, 13, "Disease", "Anatomy_Disease"]]}
{"idx": 3715, "sentence": "1.选药原则：治疗2型糖尿病合并慢性肾脏病的理想降糖策略是在有效降糖的同时，不增加低血糖发生的风险，同时避免诱发乳酸性酸中毒或增加心力衰竭风险。", "ner": [[9, 13, "Disease"], [16, 20, "Disease"], [18, 19, "Anatomy"], [41, 43, "ADE"], [56, 61, "Disease"], [65, 68, "Disease"], [65, 65, "Anatomy"]], "rel": [[18, 19, "Anatomy", 16, 20, "Disease", "Anatomy_Disease"], [65, 65, "Anatomy", 65, 68, "Disease", "Anatomy_Disease"]]}
{"idx": 3716, "sentence": "口服降糖药的选择应基于药物的药代和药效动力学特征以及患者的肾功能水平综合判断。", "ner": [[0, 1, "Method"], [29, 31, "Test"]], "rel": []}
{"idx": 3717, "sentence": "在", "ner": [], "rel": []}
{"idx": 3718, "sentence": "使用某些低血糖风险较大的口服降糖药时需严格监测血糖,确保随机血糖>5.0mmol/L以避免低血糖的发生。", "ner": [[4, 6, "ADE"], [12, 13, "Method"], [23, 24, "Test_items"], [32, 41, "Test_Value"], [45, 47, "ADE"], [28, 31, "Test_items"]], "rel": []}
{"idx": 3719, "sentence": "2.血糖控制目标值：对2型糖尿病合并慢性肾脏病患者的血糖控制目标应遵循个体化原则，尽量避免低血糖的发生。《中国成人2型糖尿病HbA1c控制目标的专家共识)建议对2型糖尿病合并中重度慢性肾脏病患者的HbA1c可适当放宽控制在7.0%~9.0%，以此一方面避免血糖水平控制过低而出现低血糖，另一方面避免血糖水平过高而出现代谢异常及感染。当慢性肾脏病导致红细胞寿命缩短时,HbA1c检测结果可能被低估。在晚期慢性肾脏病患者，使用糖化白蛋白可更可靠地反映血糖控制水平，同时应监测空腹及餐后血糖以更全面地了解血糖控制情况。", "ner": [[2, 3, "Test_items"], [11, 15, "Disease"], [18, 22, "Disease"], [20, 21, "Anatomy"], [26, 27, "Test_items"], [45, 47, "Disease"], [57, 61, "Disease"], [62, 66, "Test_items"], [80, 84, "Disease"], [87, 94, "Disease"], [92, 93, "Anatomy"], [98, 102, "Test_items"], [111, 119, "Test_Value"], [128, 129, "Test_items"], [134, 135, "Test_Value"], [139, 141, "Disease"], [149, 154, "Pathogenesis"], [158, 161, "Disease"], [163, 164, "Disease"], [167, 171, "Disease"], [169, 170, "Anatomy"], [183, 187, "Test_items"], [235, 241, "Test_items"], [249, 250, "Test_items"], [199, 205, "Disease"], [203, 204, "Anatomy"], [211, 215, "Test_items"], [223, 224, "Test_items"]], "rel": [[26, 27, "Test_items", 11, 15, "Disease", "Test_items_Disease"], [26, 27, "Test_items", 18, 22, "Disease", "Test_items_Disease"], [26, 27, "Test_items", 45, 47, "Disease", "Test_items_Disease"], [62, 66, "Test_items", 57, 61, "Disease", "Test_items_Disease"], [98, 102, "Test_items", 80, 84, "Disease", "Test_items_Disease"], [92, 93, "Anatomy", 87, 94, "Disease", "Anatomy_Disease"], [98, 102, "Test_items", 87, 94, "Disease", "Test_items_Disease"], [128, 129, "Test_items", 139, 141, "Disease", "Test_items_Disease"], [149, 154, "Pathogenesis", 158, 161, "Disease", "Pathogenesis_Disease"], [149, 154, "Pathogenesis", 163, 164, "Disease", "Pathogenesis_Disease"], [169, 170, "Anatomy", 167, 171, "Disease", "Anatomy_Disease"], [183, 187, "Test_items", 167, 171, "Disease", "Test_items_Disease"], [203, 204, "Anatomy", 199, 205, "Disease", "Anatomy_Disease"], [211, 215, "Test_items", 199, 205, "Disease", "Test_items_Disease"], [223, 224, "Test_items", 199, 205, "Disease", "Test_items_Disease"]]}
{"idx": 3720, "sentence": "3.口服降糖药的选择：口服降糖药是临床最常用的降糖手段，对于2型糖尿病合并慢性肾脏病患者的血糖控制不可或缺。然而,口服降糖药种类繁多，各类药物的药代动力学差异显著，加之慢性肾脏病患者对经肾排泄的药物或其活性代谢产物的清除能力下降，这使得对口服降糖药物使用不当将不同程度地增加低血糖以及其它不良事件的风险。因此临床工作中，必须充分了解各种降糖药物的药代和药效动力学特点，结合患者肾功能情况进行个体化选择，确保有效降糖的同时不增加低血糖风险。一般而言，当GFR低于60ml.min-1.(1.73m2)-1时大多数口服降糖药物需酌情减量或停药。常用口服降糖药的药代动力学特征、其在2型糖尿病合并慢性肾脏病人群中应用的临床证据以及适用人群见图1及表3。", "ner": [[2, 3, "Method"], [11, 12, "Method"], [30, 34, "Disease"], [37, 41, "Disease"], [39, 40, "Anatomy"], [45, 46, "Test_items"], [57, 58, "Method"], [84, 88, "Disease"], [86, 87, "Anatomy"], [93, 93, "Anatomy"], [119, 120, "Method"], [137, 139, "ADE"], [188, 190, "Test"], [213, 215, "ADE"], [225, 227, "Test_items"], [228, 250, "Test_Value"], [255, 256, "Method"], [272, 273, "Method"], [288, 292, "Disease"], [295, 299, "Disease"], [297, 298, "Anatomy"]], "rel": [[45, 46, "Test_items", 30, 34, "Disease", "Test_items_Disease"], [39, 40, "Anatomy", 37, 41, "Disease", "Anatomy_Disease"], [45, 46, "Test_items", 37, 41, "Disease", "Test_items_Disease"], [86, 87, "Anatomy", 84, 88, "Disease", "Anatomy_Disease"], [93, 93, "Anatomy", 84, 88, "Disease", "Anatomy_Disease"], [297, 298, "Anatomy", 295, 299, "Disease", "Anatomy_Disease"]]}
{"idx": 3721, "sentence": "◆双胍类：此药的主要作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖，可使HbA1c降低1.0%-2.0%，同时减轻体重且不增加低血糖风险。英国前瞻性糖尿病研究(UKPDS)显示，二甲双胍可降低肥胖2型糖尿病患者心血管事件和死亡风险，目前国内外指南均推荐二甲双胍作为2型糖尿病控制血糖的一线用药。研究显示，二甲双胍以原形经肾脏直接排泄，当肾功能严重损害时二甲双胍与乳酸易在体内蓄积,从而增加乳酸性酸中毒的风险。因此,二甲双胍用于慢性肾脏病3a期患者时减量，当GFR<45ml.min-1(1.73m2)-1不推荐使用，当GFR<30ml.min-1.(1.73m2)-1禁用。", "ner": [[1, 3, "Drug"], [34, 35, "Test_items"], [39, 43, "Test_items"], [44, 54, "Test_Value"], [66, 68, "ADE"], [77, 79, "Disease"], [92, 95, "Drug"], [99, 100, "Disease"], [101, 105, "Disease"], [108, 112, "Disease"], [108, 110, "Anatomy"], [129, 132, "Drug"], [135, 139, "Disease"], [142, 143, "Test_items"], [155, 158, "Drug"], [171, 173, "Test"], [174, 177, "Test_Value"], [179, 182, "Drug"], [197, 202, "Disease"], [210, 213, "Drug"], [216, 223, "Disease"], [218, 219, "Anatomy"], [231, 233, "Test_items"], [234, 254, "Test_Value"], [262, 264, "Test_items"], [265, 286, "Test_Value"]], "rel": [[66, 68, "ADE", 1, 3, "Drug", "ADE_Drug"], [92, 95, "Drug", 99, 100, "Disease", "Drug_Disease"], [92, 95, "Drug", 101, 105, "Disease", "Drug_Disease"], [108, 110, "Anatomy", 108, 112, "Disease", "Anatomy_Disease"], [129, 132, "Drug", 135, 139, "Disease", "Drug_Disease"], [142, 143, "Test_items", 135, 139, "Disease", "Test_items_Disease"], [171, 173, "Test", 197, 202, "Disease", "Test_Disease"], [179, 182, "Drug", 197, 202, "Disease", "Drug_Disease"], [210, 213, "Drug", 216, 223, "Disease", "Drug_Disease"], [218, 219, "Anatomy", 216, 223, "Disease", "Anatomy_Disease"], [231, 233, "Test_items", 216, 223, "Disease", "Test_items_Disease"], [262, 264, "Test_items", 216, 223, "Disease", "Test_items_Disease"]]}
{"idx": 3722, "sentence": "◆磺脲类：为胰岛素促泌剂，可降低HbA1c1.0%-2.0%，是目前国内外指南中推荐的控制2型糖尿病患者高血糖的主要用药之一。", "ner": [[1, 3, "Drug"], [6, 11, "Drug"], [16, 20, "Test_items"], [45, 49, "Disease"], [52, 54, "Disease"], [21, 29, "Test_Value"]], "rel": [[1, 3, "Drug", 45, 49, "Disease", "Drug_Disease"], [6, 11, "Drug", 45, 49, "Disease", "Drug_Disease"], [16, 20, "Test_items", 45, 49, "Disease", "Test_items_Disease"]]}
{"idx": 3723, "sentence": "第一代磺脲类药物(如甲苯磺丁脲等)目前临床上已基本被淘汰。第二代磺脲类药物中，格列本脲的半衰期较长，其活性代谢产物约50.0%经肾脏排泄，故其易在慢性肾脏病患者体内积聚，从而可能引起严重的低血糖，且低血糖的持续时间可超过24h。故仅推荐格列本脲用于慢性肾脏病1~2期的患者；3~5期禁用。", "ner": [[0, 7, "Drug"], [10, 14, "Drug"], [29, 36, "Drug"], [39, 42, "Drug"], [73, 77, "Disease"], [75, 76, "Anatomy"], [94, 96, "ADE"], [99, 101, "ADE"], [118, 121, "Drug"], [124, 128, "Disease"], [126, 127, "Anatomy"]], "rel": [[94, 96, "ADE", 39, 42, "Drug", "ADE_Drug"], [99, 101, "ADE", 39, 42, "Drug", "ADE_Drug"], [39, 42, "Drug", 73, 77, "Disease", "Drug_Disease"], [75, 76, "Anatomy", 73, 77, "Disease", "Anatomy_Disease"], [118, 121, "Drug", 124, 128, "Disease", "Drug_Disease"], [126, 127, "Anatomy", 124, 128, "Disease", "Anatomy_Disease"]]}
{"idx": 3724, "sentence": "格列美脲的代谢产物仍有降糖活性，其代谢产物及原型的60.0%经肾脏排泄。格列美脲用于慢性肾脏病1~2期患者无需调整剂量；3a期减量；3b~5期禁用。", "ner": [[0, 3, "Drug"], [36, 39, "Drug"], [42, 46, "Disease"], [44, 45, "Anatomy"]], "rel": [[36, 39, "Drug", 42, 46, "Disease", "Drug_Disease"], [44, 45, "Anatomy", 42, 46, "Disease", "Anatomy_Disease"]]}
{"idx": 3725, "sentence": "格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于格列本脲和格列美脲。推荐格列吡嗪用于慢性肾脏病1~2期患者无需调整剂量；3期减量，4~5期禁用。格列齐特用于慢性肾脏病1~2期患者无需调整剂量；在3a期减量，3b期需谨慎用药；4~5期禁用。", "ner": [[0, 3, "Drug"], [5, 8, "Drug"], [32, 34, "ADE"], [39, 42, "Drug"], [44, 47, "Drug"], [51, 54, "Drug"], [57, 61, "Disease"], [59, 60, "Anatomy"], [87, 90, "Drug"], [93, 97, "Disease"], [95, 96, "Anatomy"]], "rel": [[32, 34, "ADE", 0, 3, "Drug", "ADE_Drug"], [32, 34, "ADE", 5, 8, "Drug", "ADE_Drug"], [32, 34, "ADE", 39, 42, "Drug", "ADE_Drug"], [32, 34, "ADE", 44, 47, "Drug", "ADE_Drug"], [51, 54, "Drug", 57, 61, "Disease", "Drug_Disease"], [59, 60, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"], [87, 90, "Drug", 93, 97, "Disease", "Drug_Disease"], [95, 96, "Anatomy", 93, 97, "Disease", "Anatomy_Disease"]]}
{"idx": 3726, "sentence": "格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5.0%经肾脏排泄，受肾功能影响较小，但用于慢性肾脏病患者的大型临床研究有限。曾有研究观察格列喹酮用于GFR10~50mlmin-1.(1.73m2)-1患者，但试验设计不尽完善。格列喹酮可用于慢性肾脏病1~3期的患者且无需调整剂量；4期需谨慎用药；5期禁用。", "ner": [[0, 3, "Drug"], [47, 51, "Disease"], [49, 50, "Anatomy"], [70, 73, "Drug"], [76, 78, "Test_items"], [79, 101, "Test_Value"], [115, 118, "Drug"], [122, 126, "Disease"], [124, 125, "Anatomy"]], "rel": [[49, 50, "Anatomy", 47, 51, "Disease", "Anatomy_Disease"], [115, 118, "Drug", 122, 126, "Disease", "Drug_Disease"], [124, 125, "Anatomy", 122, 126, "Disease", "Anatomy_Disease"]]}
{"idx": 3727, "sentence": "◆格列奈类：格列奈类降糖药为非磺脲类胰岛素促泌剂，可降低HbA1c0.5%~2.0%，其导致低血的风险和程度低于磺脲类。", "ner": [[1, 4, "Drug"], [6, 9, "Drug"], [14, 23, "Drug"], [28, 32, "Test_items"], [33, 41, "Test_Value"], [46, 47, "ADE"], [56, 58, "Drug"]], "rel": [[46, 47, "ADE", 1, 4, "Drug", "ADE_Drug"], [46, 47, "ADE", 6, 9, "Drug", "ADE_Drug"], [46, 47, "ADE", 14, 23, "Drug", "ADE_Drug"], [46, 47, "ADE", 56, 58, "Drug", "ADE_Drug"]]}
{"idx": 3728, "sentence": "格列奈类的主要代表药物为那格列奈和瑞格列奈，近期有米格列奈用于临床。", "ner": [[0, 3, "Drug"], [12, 15, "Drug"], [17, 20, "Drug"], [25, 28, "Drug"]], "rel": []}
{"idx": 3729, "sentence": "那格列奈83.0%在尿中排泄，所服药物的6.0%~16.0%以原型在尿中排泄。药代动力学研究显示，中度及重度肾功能损害的糖尿病患者中，包括在血液透析患者，那格列奈暴露无显著变化。有研究显示那格列奈的活性代谢产物在肾功能不全患者中仅少量增加，但降糖效力仅为原药1/5。一项纳人1170例老年糖尿病患者的回顾性研究显示，在合并肾功能不全的老年糖尿病患者中，那格列奈可降低HbA1c1.1%，低血糖发生率仅3.0%。基于以上资料，推荐那格列奈在肾功能损害患者中无需调整剂量：对于起始用药的GFR<30ml.min-1.(1.73m2)-1患者，应从每餐60mg开始。", "ner": [[0, 3, "Drug"], [54, 58, "Disease"], [54, 54, "Anatomy"], [60, 62, "Disease"], [77, 80, "Drug"], [94, 97, "Drug"], [106, 110, "Disease"], [106, 106, "Anatomy"], [144, 146, "Disease"], [161, 165, "Disease"], [161, 161, "Anatomy"], [169, 171, "Disease"], [176, 179, "Drug"], [183, 187, "Test_items"], [188, 191, "Test_Value"], [193, 195, "ADE"], [214, 217, "Drug"], [219, 223, "Disease"], [219, 219, "Anatomy"], [241, 243, "Test_items"], [244, 265, "Test_Value"], [271, 276, "Amount"]], "rel": [[54, 54, "Anatomy", 54, 58, "Disease", "Anatomy_Disease"], [77, 80, "Drug", 54, 58, "Disease", "Drug_Disease"], [77, 80, "Drug", 60, 62, "Disease", "Drug_Disease"], [94, 97, "Drug", 106, 110, "Disease", "Drug_Disease"], [106, 106, "Anatomy", 106, 110, "Disease", "Anatomy_Disease"], [183, 187, "Test_items", 144, 146, "Disease", "Test_items_Disease"], [176, 179, "Drug", 144, 146, "Disease", "Drug_Disease"], [161, 161, "Anatomy", 161, 165, "Disease", "Anatomy_Disease"], [176, 179, "Drug", 161, 165, "Disease", "Drug_Disease"], [183, 187, "Test_items", 161, 165, "Disease", "Test_items_Disease"], [176, 179, "Drug", 169, 171, "Disease", "Drug_Disease"], [183, 187, "Test_items", 169, 171, "Disease", "Test_items_Disease"], [193, 195, "ADE", 176, 179, "Drug", "ADE_Drug"], [214, 217, "Drug", 219, 223, "Disease", "Drug_Disease"], [271, 276, "Amount", 214, 217, "Drug", "Amount_Drug"], [219, 219, "Anatomy", 219, 223, "Disease", "Anatomy_Disease"], [241, 243, "Test_items", 219, 223, "Disease", "Test_items_Disease"]]}
{"idx": 3730, "sentence": "瑞格列奈及其代谢产物的8.0%经肾脏排泄此药的I期临床试验表明，使用瑞格列奈7d后，与肾功能正常患者相比，不同程度慢性肾脏病患者的血药浓度没有明显差别，提示瑞格列奈在慢性肾脏病患者体内无蓄积。一项以瑞格列奈替换原有降糖治疗、共人组281例伴或不伴肾功能不全2型糖尿病患者的多中心研究显示，不同程度肾功能不全亚组患者(正常、轻、中、重、极重育功能损害)的低血糖发生率均低于2.0%，且瑞格列奈治疗期低血糖发生率与肾功能损害程度无关。推荐瑞格列奈用于慢性肾脏病1~5期的患者无需调整剂量；如系起始用药患者，应0.5mg起始。", "ner": [[0, 3, "Drug"], [16, 17, "Anatomy"], [34, 37, "Drug"], [38, 39, "Duration"], [43, 45, "Test"], [46, 47, "Test_Value"], [57, 61, "Disease"], [59, 60, "Anatomy"], [65, 68, "Pathogenesis"], [78, 81, "Drug"], [83, 87, "Disease"], [85, 86, "Anatomy"], [99, 102, "Drug"], [123, 127, "Disease"], [123, 123, "Anatomy"], [128, 132, "Disease"], [148, 152, "Disease"], [148, 148, "Anatomy"], [158, 159, "Level"], [161, 161, "Level"], [163, 163, "Level"], [165, 165, "Level"], [167, 168, "Level"], [198, 200, "ADE"], [176, 178, "ADE"], [191, 194, "Drug"], [217, 220, "Drug"], [223, 227, "Disease"], [225, 226, "Anatomy"], [252, 256, "Amount"]], "rel": [[0, 3, "Drug", 57, 61, "Disease", "Drug_Disease"], [16, 17, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"], [34, 37, "Drug", 57, 61, "Disease", "Drug_Disease"], [38, 39, "Duration", 34, 37, "Drug", "Duration_Drug"], [43, 45, "Test", 57, 61, "Disease", "Test_Disease"], [59, 60, "Anatomy", 57, 61, "Disease", "Anatomy_Disease"], [78, 81, "Drug", 83, 87, "Disease", "Drug_Disease"], [85, 86, "Anatomy", 83, 87, "Disease", "Anatomy_Disease"], [99, 102, "Drug", 123, 127, "Disease", "Drug_Disease"], [99, 102, "Drug", 128, 132, "Disease", "Drug_Disease"], [99, 102, "Drug", 148, 152, "Disease", "Drug_Disease"], [176, 178, "ADE", 99, 102, "Drug", "ADE_Drug"], [123, 123, "Anatomy", 123, 127, "Disease", "Anatomy_Disease"], [148, 148, "Anatomy", 148, 152, "Disease", "Anatomy_Disease"], [198, 200, "ADE", 191, 194, "Drug", "ADE_Drug"], [217, 220, "Drug", 223, 227, "Disease", "Drug_Disease"], [252, 256, "Amount", 217, 220, "Drug", "Amount_Drug"], [225, 226, "Anatomy", 223, 227, "Disease", "Anatomy_Disease"]]}
{"idx": 3731, "sentence": "米格列奈临床应用时间短且不够广泛.其用药方法及特点见表3。", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 3732, "sentence": "◆噻唑烷二酮类：此药为胰岛素增敏剂，可降低HbA1c1.0%~1.5%。此类药物包括毗格列酮和罗格列酮；二者均经肝脏代谢，不增加低血糖风险。此类药物的常见不良反应是体重增加、水钠潴留和心力衰竭[纽约心脏学会(NYHA)功能分级2级以上]患者禁用。此外，绝经后妇女服用该类药物增加骨折和骨质疏松风险，因此慎用于潜在骨疾病的患者(如肾性骨营养不良)。吡格列酮用于慢性肾脏病1~3a期患者时，无需调整剂量；3b~5期患者用药经验有限，需谨慎用药。肾功能损伤的患者可以单用罗格列酮，无需调整剂量。", "ner": [[1, 6, "Drug"], [11, 16, "Drug"], [42, 45, "Drug"], [47, 50, "Drug"], [21, 25, "Test_items"], [26, 34, "Test_Value"], [64, 66, "ADE"], [82, 85, "ADE"], [87, 90, "ADE"], [92, 95, "ADE"], [97, 116, "ADE"], [139, 140, "ADE"], [142, 145, "ADE"], [164, 170, "Disease"], [166, 166, "Anatomy"], [173, 176, "Drug"], [179, 183, "Disease"], [181, 182, "Anatomy"], [220, 224, "Disease"], [220, 220, "Anatomy"], [232, 235, "Drug"]], "rel": [[166, 166, "Anatomy", 164, 170, "Disease", "Anatomy_Disease"], [173, 176, "Drug", 179, 183, "Disease", "Drug_Disease"], [181, 182, "Anatomy", 179, 183, "Disease", "Anatomy_Disease"], [220, 220, "Anatomy", 220, 224, "Disease", "Anatomy_Disease"], [232, 235, "Drug", 220, 224, "Disease", "Drug_Disease"]]}
{"idx": 3733, "sentence": "◆糖苷醇抑制剂：此类药物可降低HbA1c，0.5%~0.8%。同时，此类药物不增加体重且有减轻体重的趋势。主要代表药物有阿卡波糖、伏格列波糖和米格列醇。阿卡波糖口服后很少部分被吸收，随着肾功能的降低，药物本身及其代谢产物的血药浓度增加显著。阿卡波糖可用于慢性肾脏病1~3期患者：4~5期禁用。伏格列波糖可用于慢性肾脏病1~3期患者；4~5期慎用。", "ner": [[1, 6, "Drug"], [15, 19, "Test_items"], [21, 29, "Test_Value"], [60, 63, "Drug"], [65, 69, "Drug"], [71, 74, "Drug"], [76, 79, "Drug"], [80, 81, "Method"], [93, 95, "Test"], [97, 98, "Test_Value"], [111, 114, "Pathogenesis"], [120, 123, "Drug"], [127, 131, "Disease"], [129, 130, "Anatomy"], [146, 150, "Drug"], [154, 158, "Disease"], [156, 157, "Anatomy"]], "rel": [[80, 81, "Method", 76, 79, "Drug", "Method_Drug"], [120, 123, "Drug", 127, 131, "Disease", "Drug_Disease"], [129, 130, "Anatomy", 127, 131, "Disease", "Anatomy_Disease"], [146, 150, "Drug", 154, 158, "Disease", "Drug_Disease"], [156, 157, "Anatomy", 154, 158, "Disease", "Anatomy_Disease"]]}
{"idx": 3734, "sentence": "米格列醇临床应用时间短且不够广泛，其用药方法及特点见表3", "ner": [[0, 3, "Drug"]], "rel": []}
{"idx": 3735, "sentence": "◆二肽基肽酶-IV(DPP-4)抑制剂：此类药物通过抑制DPP-4活性而减少胰升糖素样肽1(GLP-1)在体内的灭活，从而增加内源性GLP-1的水平达到降糖目的。", "ner": [[1, 18, "Drug"]], "rel": []}
{"idx": 3736, "sentence": "在以二甲双胍为基础治疗，多个联用DPP-4抑制剂或包括磺脲类、噻唑烷二酮类在内的其他多种降糖药物对比研究中，显示DPP-4抑制剂在降低HbA1c方面与阳性对照药的疗效相当。", "ner": [[2, 5, "Drug"], [16, 23, "Drug"], [27, 29, "Drug"], [31, 36, "Drug"], [56, 63, "Drug"], [67, 71, "Test_items"]], "rel": []}
{"idx": 3737, "sentence": "目前在国内上市的DPP-4抑制剂为西格列汀、沙格列汀、维格列汀、利格列汀和阿格列汀。", "ner": [[8, 15, "Drug"], [17, 20, "Drug"], [22, 25, "Drug"], [27, 30, "Drug"], [32, 35, "Drug"], [37, 40, "Drug"]], "rel": []}
{"idx": 3738, "sentence": "西格列汀大约79.0%从尿中排泄，中度肾功能不全的患者使用西格列汀后其血浆曲线下面积(AUC)约增加2倍，重度肾功能不全和终末期肾病的患者大约增加4倍：同时西格列汀可以少量被透析清除，因此为了达到与正常肾功能患者相似的血浆浓度，中、重度和终末期肾病患者需要减少药物剂量。推荐西格列汀用于GFR≥50ml.min-1.(1.73m2)-1的慢性肾脏病患者时无需调整剂量；GFR在30~50ml.min-1.(1.73m2)-1时减量至50mg，每日1次(qd)；GFR<30ml.min-1.(1.73m2)-1时减量至25mg，qd。", "ner": [[0, 3, "Drug"], [19, 23, "Disease"], [19, 19, "Anatomy"], [29, 32, "Drug"], [55, 59, "Disease"], [55, 55, "Anatomy"], [61, 65, "Disease"], [64, 64, "Anatomy"], [78, 81, "Drug"], [101, 103, "Test"], [114, 117, "Level"], [119, 123, "Disease"], [122, 122, "Anatomy"], [137, 140, "Drug"], [143, 145, "Test_items"], [147, 167, "Test_Value"], [169, 173, "Disease"], [171, 172, "Anatomy"], [184, 186, "Test_items"], [188, 211, "Test_Value"], [216, 219, "Amount"], [221, 228, "Frequency"], [230, 232, "Test_items"], [233, 254, "Test_Value"], [259, 262, "Amount"], [264, 265, "Frequency"], [87, 88, "Treatment"]], "rel": [[19, 19, "Anatomy", 19, 23, "Disease", "Anatomy_Disease"], [29, 32, "Drug", 19, 23, "Disease", "Drug_Disease"], [55, 55, "Anatomy", 55, 59, "Disease", "Anatomy_Disease"], [64, 64, "Anatomy", 61, 65, "Disease", "Anatomy_Disease"], [78, 81, "Drug", 119, 123, "Disease", "Drug_Disease"], [101, 103, "Test", 119, 123, "Disease", "Test_Disease"], [87, 88, "Treatment", 119, 123, "Disease", "Treatment_Disease"], [122, 122, "Anatomy", 119, 123, "Disease", "Anatomy_Disease"], [216, 219, "Amount", 137, 140, "Drug", "Amount_Drug"], [259, 262, "Amount", 137, 140, "Drug", "Amount_Drug"], [221, 228, "Frequency", 137, 140, "Drug", "Frequency_Drug"], [264, 265, "Frequency", 137, 140, "Drug", "Frequency_Drug"], [137, 140, "Drug", 169, 173, "Disease", "Drug_Disease"], [143, 145, "Test_items", 169, 173, "Disease", "Test_items_Disease"], [171, 172, "Anatomy", 169, 173, "Disease", "Anatomy_Disease"], [184, 186, "Test_items", 169, 173, "Disease", "Test_items_Disease"], [230, 232, "Test_items", 169, 173, "Disease", "Test_items_Disease"]]}
{"idx": 3739, "sentence": "沙格列汀通过肾和肝排泄，此药用于轻度肾功能不全患者时无需调整剂量；中或重度肾功能不全的患者应将剂量调整为2.5mg，qd；在重度肾功能不全的患者中用药经验非常有限，使用应谨慎。", "ner": [[0, 3, "Drug"], [18, 22, "Disease"], [16, 17, "Level"], [18, 18, "Anatomy"], [33, 36, "Level"], [37, 41, "Disease"], [37, 37, "Anatomy"], [52, 56, "Amount"], [58, 59, "Frequency"], [62, 63, "Level"], [64, 68, "Disease"], [64, 64, "Anatomy"]], "rel": [[0, 3, "Drug", 18, 22, "Disease", "Drug_Disease"], [0, 3, "Drug", 37, 41, "Disease", "Drug_Disease"], [0, 3, "Drug", 64, 68, "Disease", "Drug_Disease"], [52, 56, "Amount", 0, 3, "Drug", "Amount_Drug"], [58, 59, "Frequency", 0, 3, "Drug", "Frequency_Drug"], [18, 18, "Anatomy", 18, 22, "Disease", "Anatomy_Disease"], [37, 37, "Anatomy", 37, 41, "Disease", "Anatomy_Disease"], [64, 64, "Anatomy", 64, 68, "Disease", "Anatomy_Disease"]]}
{"idx": 3740, "sentence": "被代谢消除是维格列汀在人体内的主要清除途径，约占给药剂量的69.0%；其主要代谢产物(LAY151)没有药理活性，约有23.0%的维格列汀原形药物从肾脏中排泄。与正常健康受试者相比，维格列汀在轻度、中度和重度肾功能不全患者中的AUC均值分别增加1.4、1.7和2倍。对于中度或重度肾功能不全患者，维格列汀的峰浓度无明显增加，由于半衰期(TI/2)延长致使暴露水平增加约2倍，因此，对于中、重度肾功能不全患者，维格列汀50mgqd就可以维持24h对DPP-4的抑制作用。", "ner": [[6, 9, "Drug"], [91, 94, "Drug"], [96, 97, "Level"], [99, 100, "Level"], [102, 103, "Level"], [104, 108, "Disease"], [104, 104, "Anatomy"], [135, 136, "Level"], [138, 139, "Level"], [140, 144, "Disease"], [140, 140, "Anatomy"], [148, 151, "Drug"], [192, 195, "Level"], [196, 200, "Disease"], [196, 196, "Anatomy"], [204, 207, "Drug"], [208, 211, "Amount"], [212, 213, "Frequency"]], "rel": [[91, 94, "Drug", 104, 108, "Disease", "Drug_Disease"], [104, 104, "Anatomy", 104, 108, "Disease", "Anatomy_Disease"], [140, 140, "Anatomy", 140, 144, "Disease", "Anatomy_Disease"], [148, 151, "Drug", 140, 144, "Disease", "Drug_Disease"], [196, 196, "Anatomy", 196, 200, "Disease", "Anatomy_Disease"], [204, 207, "Drug", 196, 200, "Disease", "Drug_Disease"], [208, 211, "Amount", 204, 207, "Drug", "Amount_Drug"], [212, 213, "Frequency", 204, 207, "Drug", "Frequency_Drug"]]}
{"idx": 3741, "sentence": "60.0%-71.0%的阿格列汀以原型通过尿液排泄。轻度肾功能受损患者中，阿格列汀的血浆AUC升高程度不具有临床相关性。中度肾功能受损患者中阿格列汀的血浆AUC约升高2倍。重度肾功能受损和终末期肾病患者中，阿格列汀的血浆AUC分别约升高3倍和4倍，透析3h可清除体内7.0%的药物。因此中重度糖尿病合并慢性肾脏病患者应谨慎用药。大部分(约90.0%)的利格列汀以原型排泄，肾排泄低于给药剂量的5.0%，因此此药的使用不受肾功能降低的影响。利格列汀用于慢性肾脏病1~5期的患者时无需调整剂量。", "ner": [[12, 15, "Drug"], [28, 32, "Disease"], [26, 27, "Level"], [28, 28, "Anatomy"], [37, 40, "Drug"], [60, 61, "Level"], [62, 66, "Disease"], [62, 62, "Anatomy"], [70, 73, "Drug"], [86, 87, "Level"], [88, 92, "Disease"], [88, 88, "Anatomy"], [94, 98, "Disease"], [97, 97, "Anatomy"], [103, 106, "Drug"], [143, 145, "Level"], [146, 148, "Disease"], [151, 155, "Disease"], [153, 154, "Anatomy"], [176, 179, "Drug"], [219, 222, "Drug"], [225, 229, "Disease"], [227, 228, "Anatomy"]], "rel": [[28, 28, "Anatomy", 28, 32, "Disease", "Anatomy_Disease"], [37, 40, "Drug", 28, 32, "Disease", "Drug_Disease"], [70, 73, "Drug", 62, 66, "Disease", "Drug_Disease"], [62, 62, "Anatomy", 62, 66, "Disease", "Anatomy_Disease"], [88, 88, "Anatomy", 88, 92, "Disease", "Anatomy_Disease"], [103, 106, "Drug", 88, 92, "Disease", "Drug_Disease"], [97, 97, "Anatomy", 94, 98, "Disease", "Anatomy_Disease"], [103, 106, "Drug", 94, 98, "Disease", "Drug_Disease"], [153, 154, "Anatomy", 151, 155, "Disease", "Anatomy_Disease"], [219, 222, "Drug", 225, 229, "Disease", "Drug_Disease"], [227, 228, "Anatomy", 225, 229, "Disease", "Anatomy_Disease"]]}
{"idx": 3742, "sentence": "4.特殊人群的治疗：(1)儿童和青少年2型糖尿病合并慢性肾脏病患者中，缺乏高血糖、高血压和血脂异常治疗方面的相关数据；但是生活方式干预(饮食、锻炼、减肥)是各种治疗的基础，因此对高血糖的控制应从改善生活方式开始。若生活方式干预不能控制血糖，应考虑降糖药治疗。尽管美国糖尿病协会(ADA)推荐口服降糖药作为儿童和青少年2型糖尿病患者的一线治疗，但其中仅二甲双胍被美国食品药品监督管理局(FDA)批准用于10岁以上的儿童，其使用注意事项与成人相同。(2)老年2型糖尿病合并慢性肾脏病患者：老年2型糖尿病患者除合并慢性肾脏病之外，还通常合并其他多种并发症和伴随症，尤其是心血管疾病以及认知功能障碍；因此应加强对多种危险因素的管理。", "ner": [[19, 23, "Disease"], [26, 30, "Disease"], [28, 29, "Anatomy"], [37, 39, "Disease"], [41, 43, "Disease"], [45, 46, "Test"], [47, 48, "Test_Value"], [61, 66, "Treatment"], [68, 69, "Treatment"], [71, 72, "Treatment"], [74, 75, "Treatment"], [89, 91, "Disease"], [107, 112, "Treatment"], [117, 118, "Test_items"], [133, 135, "Disease"], [145, 146, "Method"], [158, 162, "Disease"], [175, 178, "Drug"], [227, 231, "Disease"], [234, 238, "Disease"], [236, 237, "Anatomy"], [244, 248, "Disease"], [254, 258, "Disease"], [256, 257, "Anatomy"], [282, 286, "Disease"], [282, 284, "Anatomy"], [289, 294, "Disease"], [97, 102, "Treatment"]], "rel": [[45, 46, "Test", 19, 23, "Disease", "Test_Disease"], [28, 29, "Anatomy", 26, 30, "Disease", "Anatomy_Disease"], [45, 46, "Test", 26, 30, "Disease", "Test_Disease"], [61, 66, "Treatment", 89, 91, "Disease", "Treatment_Disease"], [68, 69, "Treatment", 89, 91, "Disease", "Treatment_Disease"], [71, 72, "Treatment", 89, 91, "Disease", "Treatment_Disease"], [74, 75, "Treatment", 89, 91, "Disease", "Treatment_Disease"], [97, 102, "Treatment", 89, 91, "Disease", "Treatment_Disease"], [175, 178, "Drug", 158, 162, "Disease", "Drug_Disease"], [236, 237, "Anatomy", 234, 238, "Disease", "Anatomy_Disease"], [256, 257, "Anatomy", 254, 258, "Disease", "Anatomy_Disease"], [282, 284, "Anatomy", 282, 286, "Disease", "Anatomy_Disease"]]}
{"idx": 3743, "sentence": "对此类患者尤其应注意避免低血糖的发生，适当放宽降糖目标，并视患者的具体情况而选用口服降糖药；如选择使用具有低血糖风险的药物时，应从小剂量开始，逐渐加量并注意观察患者的降糖疗效和不良反应。", "ner": [[12, 14, "ADE"], [40, 41, "Method"], [53, 55, "ADE"]], "rel": []}
{"idx": 3744, "sentence": "四.结束语", "ner": [], "rel": []}
{"idx": 3745, "sentence": "2型糖尿病合并慢性肾脏病患者的预后较单纯2型糖尿病或单纯慢性肾脏病患者更差。临床实践中，应重视2型糖尿病合并慢性肾脏病患者口服降糖药的正确选择和规范使用。一旦GFR<60ml.min-1(1.73m2)-1，大多数口服降糖药的药代和药效动力学特征将发生改变，低血糖及其他不良反应风险显著增加。研究显示遵循指南可显著提高降糖达标率，显著降低低血糖风险，且入院率和治疗费用均显著下降。因而，对于2型糖尿病合并慢性肾脏病患者的口服降糖药治疗，尤应重视指南推荐和规范应用。临床实践中，应密切监测2型糖尿病合并慢性肾脏病患者的血糖，依据患者的肾功能分期合理选择降糖药物的种类并积极调整剂量，以便有效控制血糖，同时减少低血糖等多种不良风险。", "ner": [[0, 4, "Disease"], [7, 11, "Disease"], [9, 10, "Anatomy"], [20, 24, "Disease"], [28, 32, "Disease"], [30, 31, "Anatomy"], [47, 51, "Disease"], [54, 58, "Disease"], [56, 57, "Anatomy"], [61, 62, "Method"], [79, 81, "Test_items"], [82, 102, "Test_Value"], [107, 108, "Method"], [129, 131, "ADE"], [169, 171, "ADE"], [195, 199, "Disease"], [202, 206, "Disease"], [204, 205, "Anatomy"], [210, 211, "Method"], [243, 247, "Disease"], [250, 254, "Disease"], [252, 253, "Anatomy"], [258, 259, "Test_items"], [266, 268, "Test"], [296, 297, "Test_items"], [303, 305, "ADE"]], "rel": [[9, 10, "Anatomy", 7, 11, "Disease", "Anatomy_Disease"], [30, 31, "Anatomy", 28, 32, "Disease", "Anatomy_Disease"], [204, 205, "Anatomy", 202, 206, "Disease", "Anatomy_Disease"], [258, 259, "Test_items", 243, 247, "Disease", "Test_items_Disease"], [266, 268, "Test", 243, 247, "Disease", "Test_Disease"], [296, 297, "Test_items", 243, 247, "Disease", "Test_items_Disease"], [252, 253, "Anatomy", 250, 254, "Disease", "Anatomy_Disease"], [258, 259, "Test_items", 250, 254, "Disease", "Test_items_Disease"], [266, 268, "Test", 250, 254, "Disease", "Test_Disease"], [296, 297, "Test_items", 250, 254, "Disease", "Test_items_Disease"]]}